ss_d,ss_sbclllr_frctn,tss_d,ss_tx_d,crtd_b,ss_rgnsm,dc_d,chmbl_d,td,ss_strn,cll_d,ss_tss,dscrptn,vrnt_d,ss_tp,src_d,rltnshp_tp,cnfdnc_scr,src_ss_d,b_frmt
1,,,,Autocuration,,11087,CHEMBL615117,12052,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,B,1,H,8,,BAO_0000019
2,,,,Autocuration,,684,CHEMBL615118,22226,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,F,1,U,0,,BAO_0000219
3,,,,Autocuration,,15453,CHEMBL615119,22226,,,,,,B,1,U,0,,BAO_0000019
4,,,9913.0,Autocuration,Bos taurus,17841,CHEMBL615120,104729,,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,B,1,H,4,,BAO_0000249
5,,,9606.0,Intermediate,Homo sapiens,17430,CHEMBL615121,80001,,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,F,1,N,1,,BAO_0000219
6,,,9606.0,Intermediate,Homo sapiens,17430,CHEMBL615122,80001,,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,F,1,N,1,,BAO_0000219
7,,,10090.0,Intermediate,Mus musculus,13799,CHEMBL615123,80001,,163.0,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,F,1,N,1,,BAO_0000219
8,,,9606.0,Expert,Homo sapiens,17774,CHEMBL615124,80001,,163.0,,In vitro cell cytotoxicity was determined against 143B cell line,,F,1,N,1,,BAO_0000219
9,,,9606.0,Intermediate,Homo sapiens,3801,CHEMBL615125,80001,,163.0,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,F,1,N,1,,BAO_0000219
10,,,9606.0,Intermediate,Homo sapiens,17430,CHEMBL615126,80001,,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,F,1,N,1,,BAO_0000219
11,,,9606.0,Intermediate,Homo sapiens,17430,CHEMBL615127,80001,,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,F,1,N,1,,BAO_0000219
12,,,9606.0,Expert,Homo sapiens,17774,CHEMBL615128,80001,,163.0,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,F,1,N,1,,BAO_0000219
13,,,1280.0,Intermediate,Staphylococcus aureus,11324,CHEMBL857900,50185,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,F,1,N,1,,BAO_0000218
14,,,1280.0,Intermediate,Staphylococcus aureus,11324,CHEMBL615129,50185,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,F,1,N,1,,BAO_0000218
15,,,1280.0,Intermediate,Staphylococcus aureus,11324,CHEMBL615130,50185,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,F,1,N,1,,BAO_0000218
16,,,1280.0,Intermediate,Staphylococcus aureus,11324,CHEMBL615131,50185,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,F,1,N,1,,BAO_0000218
17,,,10116.0,Expert,Rattus norvegicus,11347,CHEMBL884521,100122,,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,A,1,D,9,,BAO_0000357
18,,,,Autocuration,,16474,CHEMBL615132,12054,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,B,1,H,8,,BAO_0000357
19,,,,Autocuration,,10091,CHEMBL615133,12054,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,B,1,H,8,,BAO_0000019
20,,,,Autocuration,,16474,CHEMBL615134,12054,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,B,1,H,8,,BAO_0000357
21,,,,Autocuration,,16474,CHEMBL615135,12054,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,B,1,H,8,,BAO_0000357
22,,,,Autocuration,,16474,CHEMBL615136,12054,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,B,1,H,8,,BAO_0000357
23,,,,Autocuration,,16474,CHEMBL615137,12054,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,B,1,H,8,,BAO_0000357
24,,,,Autocuration,,16474,CHEMBL615138,12054,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,B,1,H,8,,BAO_0000357
25,,,,Autocuration,,14352,CHEMBL836324,22226,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,B,1,U,0,,BAO_0000219
26,,,9986.0,Autocuration,Oryctolagus cuniculus,5646,CHEMBL615139,12054,,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,B,1,H,8,,BAO_0000357
27,,,9986.0,Autocuration,Oryctolagus cuniculus,5646,CHEMBL615140,12054,,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,B,1,H,8,,BAO_0000357
28,,,,Autocuration,,10997,CHEMBL615141,12426,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,B,1,H,8,,BAO_0000219
29,,,3847.0,Autocuration,soya bean,6309,CHEMBL615142,12054,,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,B,1,H,8,,BAO_0000357
30,,,3847.0,Autocuration,Glycine max,167,CHEMBL615143,12054,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,B,1,H,8,,BAO_0000357
31,,,3847.0,Autocuration,Glycine max,167,CHEMBL615144,12054,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,B,1,H,8,,BAO_0000357
32,,,3847.0,Autocuration,Glycine max,11087,CHEMBL872867,12054,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,B,1,H,8,,BAO_0000357
33,,,3847.0,Autocuration,Glycine max,11087,CHEMBL615145,12054,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,B,1,H,8,,BAO_0000357
34,,,3847.0,Autocuration,Glycine max,13622,CHEMBL615146,12054,,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,B,1,H,8,,BAO_0000357
35,,,3847.0,Autocuration,Glycine max,13622,CHEMBL615147,12054,,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,B,1,H,8,,BAO_0000357
36,,,10116.0,Autocuration,Rattus norvegicus,11347,CHEMBL615148,22226,,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,A,1,U,0,,BAO_0000019
37,,,562.0,Autocuration,Escherichia coli,5926,CHEMBL615149,22226,,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,B,1,U,0,,BAO_0000019
38,,,,Autocuration,,4567,CHEMBL615150,22226,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,,B,1,U,0,,BAO_0000019
39,,,,Intermediate,,3782,CHEMBL615151,22222,,,,Dissociation constant towards 16S rRNA construct A,,B,1,M,3,,BAO_0000225
40,,,,Intermediate,,3782,CHEMBL615152,22222,,,,Dissociation constant towards 16S rRNA construct B,,B,1,M,3,,BAO_0000225
41,,,562.0,Expert,Escherichia coli,4466,CHEMBL615153,100263,,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,B,1,M,3,,BAO_0000225
42,,,562.0,Expert,Escherichia coli,6592,CHEMBL615154,100263,,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,B,1,M,3,,BAO_0000225
43,,,,Autocuration,,898,CHEMBL615155,13053,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,B,1,H,8,,BAO_0000019
44,,,,Autocuration,,898,CHEMBL615156,13053,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,B,1,H,8,,BAO_0000019
45,,,9606.0,Autocuration,Homo sapiens,13163,CHEMBL615157,20001,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,B,1,H,8,,BAO_0000019
46,,,9606.0,Autocuration,Homo sapiens,13163,CHEMBL615158,20001,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,B,1,H,8,,BAO_0000019
47,,,10116.0,Expert,Rattus norvegicus,10691,CHEMBL615159,12971,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,B,1,D,9,,BAO_0000019
48,,,10116.0,Expert,Rattus norvegicus,10691,CHEMBL615172,12971,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,B,1,D,9,,BAO_0000019
49,,,10116.0,Expert,Rattus norvegicus,10691,CHEMBL615173,12971,,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,B,1,D,9,,BAO_0000019
50,,,10116.0,Expert,Rattus norvegicus,10691,CHEMBL615174,12971,,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,B,1,D,9,,BAO_0000019
51,,,,Autocuration,,898,CHEMBL884518,13053,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,B,1,H,8,,BAO_0000019
52,,,,Autocuration,,912,CHEMBL615175,11512,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,B,1,H,8,,BAO_0000357
53,,,,Autocuration,,912,CHEMBL615176,11512,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,B,1,H,8,,BAO_0000357
54,,,,Autocuration,,912,CHEMBL615177,11512,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,B,1,H,8,,BAO_0000357
55,Membranes,,10116.0,Autocuration,Rattus norvegicus,15103,CHEMBL615178,104740,,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,B,1,D,5,,BAO_0000249
56,,,9606.0,Intermediate,Homo sapiens,5116,CHEMBL615179,80002,,506.0,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,F,1,N,1,,BAO_0000219
57,,,10116.0,Autocuration,Rattus norvegicus,14578,CHEMBL615180,104835,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,F,1,D,7,,BAO_0000219
58,,,10116.0,Autocuration,Rattus norvegicus,14578,CHEMBL615181,104821,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,F,1,D,7,,BAO_0000219
59,,,10116.0,Autocuration,Rattus norvegicus,14578,CHEMBL615182,104848,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,F,1,D,7,,BAO_0000219
60,,,9606.0,Expert,Homo sapiens,4787,CHEMBL615183,80002,,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,F,1,N,1,,BAO_0000219
61,,,9606.0,Intermediate,Homo sapiens,4787,CHEMBL615184,80002,,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,F,1,N,1,,BAO_0000219
62,,,9606.0,Intermediate,Homo sapiens,3547,CHEMBL615185,80002,,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,F,1,N,1,,BAO_0000219
63,,,9606.0,Intermediate,Homo sapiens,3547,CHEMBL615186,80002,,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,F,1,N,1,,BAO_0000219
64,,,9606.0,Intermediate,Homo sapiens,6726,CHEMBL615187,80002,,506.0,,Effective dose of compound against replication of 1A9 cell line was evaluated,,F,1,N,1,,BAO_0000219
65,,,9606.0,Expert,Homo sapiens,3455,CHEMBL885343,80002,,506.0,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,F,1,N,1,,BAO_0000219
66,,,9606.0,Intermediate,Homo sapiens,5726,CHEMBL615188,80002,,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,F,1,N,1,,BAO_0000219
67,,,9606.0,Intermediate,Homo sapiens,5726,CHEMBL615189,80002,,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,F,1,N,1,,BAO_0000219
68,,,9606.0,Intermediate,Homo sapiens,5726,CHEMBL615190,80002,,506.0,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,F,1,N,1,,BAO_0000219
69,,,9606.0,Intermediate,Homo sapiens,3395,CHEMBL615191,80002,,506.0,,Inhibitory activity against Taxol resistant 1A9 cell lines,,F,1,N,1,,BAO_0000219
70,,,9606.0,Expert,Homo sapiens,3415,CHEMBL615192,80002,,506.0,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,F,1,N,1,,BAO_0000219
71,,,9606.0,Expert,Homo sapiens,3415,CHEMBL827083,80002,,506.0,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,F,1,N,1,,BAO_0000219
72,,,9606.0,Expert,Homo sapiens,17099,CHEMBL615193,80002,,506.0,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,F,1,N,1,,BAO_0000219
73,,,9606.0,Intermediate,Homo sapiens,17099,CHEMBL615194,80002,,506.0,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,F,1,N,1,,BAO_0000219
74,,,9606.0,Intermediate,Homo sapiens,17099,CHEMBL615195,80002,,506.0,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,F,1,N,1,,BAO_0000219
75,,,9606.0,Intermediate,Homo sapiens,17099,CHEMBL615196,80002,,506.0,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,F,1,N,1,,BAO_0000219
76,,,9606.0,Intermediate,Homo sapiens,17721,CHEMBL615197,81072,,503.0,,Inhibitory concentration against Jurkat cells,,F,1,N,1,,BAO_0000219
77,,,,Intermediate,,1229,CHEMBL615198,22226,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,F,1,U,0,,BAO_0000019
78,,,10116.0,Expert,Rattus norvegicus,11347,CHEMBL615199,100121,,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,A,1,D,9,,BAO_0000357
79,,,,Expert,,17117,CHEMBL615200,11231,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,B,1,H,8,,BAO_0000357
80,,,,Expert,,17117,CHEMBL615201,11231,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,B,1,H,8,,BAO_0000357
81,,,,Expert,,17117,CHEMBL615202,11231,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,B,1,H,8,,BAO_0000357
82,Microsomes,,5476.0,Autocuration,Candida albicans,11375,CHEMBL615203,11231,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,B,1,H,8,,BAO_0000251
83,Microsomes,,5476.0,Autocuration,Candida albicans,11375,CHEMBL615204,11231,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,B,1,H,8,,BAO_0000251
84,Microsomes,,4932.0,Autocuration,Saccharomyces cerevisiae,11375,CHEMBL615205,11231,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,B,1,H,8,,BAO_0000251
85,Microsomes,,4932.0,Autocuration,Saccharomyces cerevisiae,11375,CHEMBL615206,11231,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,B,1,H,8,,BAO_0000251
86,Microsomes,2107.0,9823.0,Autocuration,Sus scrofa,11375,CHEMBL615207,12083,,,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,B,1,H,8,,BAO_0000251
87,,,10116.0,Autocuration,Rattus norvegicus,791,CHEMBL827084,11231,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,B,1,H,8,,BAO_0000019
88,,,10116.0,Autocuration,Rattus norvegicus,791,CHEMBL615208,11231,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,B,1,H,8,,BAO_0000019
89,,,10116.0,Autocuration,Rattus norvegicus,791,CHEMBL615209,11231,,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,B,1,H,8,,BAO_0000019
90,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,11375,CHEMBL615210,12083,,,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,B,1,D,9,,BAO_0000251
91,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,11375,CHEMBL615211,12083,,,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,B,1,D,9,,BAO_0000251
92,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,153,CHEMBL615212,12083,,,Liver,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,B,1,D,9,,BAO_0000251
93,,,,Expert,,8269,CHEMBL615213,11377,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,B,1,H,8,,BAO_0000357
94,,,,Expert,,8269,CHEMBL615273,11377,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,B,1,H,8,,BAO_0000357
95,,,9606.0,Expert,Homo sapiens,17653,CHEMBL615274,81020,,726.0,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,F,1,N,1,,BAO_0000219
96,,,9606.0,Intermediate,Homo sapiens,14277,CHEMBL615275,81020,,726.0,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,F,1,N,1,,BAO_0000219
97,,,9606.0,Intermediate,Homo sapiens,1717,CHEMBL615276,81020,,726.0,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,F,1,N,1,,BAO_0000219
98,,,9606.0,Intermediate,Homo sapiens,14091,CHEMBL615277,81020,,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,F,1,N,1,,BAO_0000219
99,,,9606.0,Intermediate,Homo sapiens,14091,CHEMBL615326,81020,,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,F,1,N,1,,BAO_0000219
100,,,10407.0,Expert,Hepatitis B virus,17653,CHEMBL883130,50606,,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,F,1,N,1,,BAO_0000218
101,,,9606.0,Intermediate,Homo sapiens,13105,CHEMBL884519,81020,,726.0,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,F,1,N,1,,BAO_0000219
102,,,9606.0,Intermediate,Homo sapiens,1717,CHEMBL615327,81020,,726.0,,Concentration required to inhibit 50% of 2.2.15 cell line,,F,1,N,1,,BAO_0000219
103,,,9606.0,Intermediate,Homo sapiens,13105,CHEMBL615328,81020,,726.0,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,A,1,N,1,,BAO_0000219
104,,,9606.0,Intermediate,Homo sapiens,13600,CHEMBL615329,50587,,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,F,1,N,1,,BAO_0000218
105,,,9606.0,Intermediate,Homo sapiens,13467,CHEMBL615330,50587,,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,F,1,N,1,,BAO_0000218
106,,,10407.0,Expert,Hepatitis B virus,17477,CHEMBL615331,50606,,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,F,1,N,1,,BAO_0000218
107,,,9606.0,Intermediate,Homo sapiens,1593,CHEMBL615332,50587,,,,In vitro anti-HBV activity in 2.2.15 cells,,F,1,N,1,,BAO_0000218
108,,,9606.0,Intermediate,Homo sapiens,1593,CHEMBL615333,50587,,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,F,1,N,1,,BAO_0000218
109,,,9606.0,Intermediate,Homo sapiens,15089,CHEMBL615334,50587,,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,F,1,N,1,,BAO_0000218
110,,,9606.0,Intermediate,Homo sapiens,15089,CHEMBL615335,50587,,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,F,1,N,1,,BAO_0000218
111,,,9606.0,Intermediate,Homo sapiens,1593,CHEMBL615336,50587,,,,Cytotoxicity in 2.2.15 cells,,F,1,N,1,,BAO_0000218
112,,,9606.0,Intermediate,Homo sapiens,1593,CHEMBL615337,50587,,,,Cytotoxicity in 2.2.15 cells; Not determined,,F,1,N,1,,BAO_0000218
113,,,9606.0,Intermediate,Homo sapiens,13600,CHEMBL615338,50587,,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,F,1,N,1,,BAO_0000218
114,,,9606.0,Intermediate,Homo sapiens,13467,CHEMBL615339,50587,,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,F,1,N,1,,BAO_0000218
115,,,9606.0,Intermediate,Homo sapiens,13467,CHEMBL615340,50587,,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,F,1,N,1,,BAO_0000218
116,,,9606.0,Intermediate,Homo sapiens,14764,CHEMBL615341,81020,,726.0,,Antiviral activity against HBV was determined in 2.215 cell line,,F,1,N,1,,BAO_0000219
117,Microsomes,,9606.0,Autocuration,Homo sapiens,6531,CHEMBL615342,22226,,,,Inhibition of 20-HETE synthesis in human renal microsomes,,B,1,U,0,,BAO_0000251
118,,,,Autocuration,,17322,CHEMBL615343,22226,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,B,1,U,0,,BAO_0000019
119,,,9606.0,Intermediate,Homo sapiens,17072,CHEMBL615344,80612,,388.0,,Inhibitory concentration against 2008 (ovarian) cells,,F,1,N,1,,BAO_0000219
120,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL615345,80612,,388.0,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,F,1,N,1,,BAO_0000219
121,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL615346,80612,,388.0,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,F,1,N,1,,BAO_0000219
122,,,9606.0,Intermediate,Homo sapiens,17146,CHEMBL615347,80612,,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,F,1,N,1,,BAO_0000219
123,,,9606.0,Intermediate,Homo sapiens,17146,CHEMBL615348,80612,,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,F,1,N,1,,BAO_0000219
124,,,9606.0,Intermediate,Homo sapiens,10797,CHEMBL827085,80613,,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line,,F,1,N,1,,BAO_0000219
125,,,9606.0,Intermediate,Homo sapiens,10797,CHEMBL615349,80613,,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,F,1,N,1,,BAO_0000219
126,,,9606.0,Intermediate,Homo sapiens,10797,CHEMBL615350,80614,,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line,,F,1,N,1,,BAO_0000219
127,,,9606.0,Intermediate,Homo sapiens,10797,CHEMBL615351,80614,,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,F,1,N,1,,BAO_0000219
128,,,9606.0,Expert,Homo sapiens,4823,CHEMBL615352,100256,,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,B,1,S,2,,BAO_0000220
129,,,9606.0,Intermediate,Homo sapiens,12912,CHEMBL615353,100256,,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,B,1,S,2,,BAO_0000220
130,,,,Expert,,2957,CHEMBL615354,100256,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,,B,1,S,2,,BAO_0000220
131,,,,Expert,,2957,CHEMBL615355,100256,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,B,1,S,2,,BAO_0000220
132,,,,Intermediate,,3260,CHEMBL615356,100256,,,,Inhibitory activity against 20S proteosome,,B,1,S,2,,BAO_0000220
133,,,9606.0,Autocuration,Homo sapiens,3451,CHEMBL615357,22226,,,,Compound was tested for inhibitory activity against tryptase,,B,1,U,0,,BAO_0000019
134,,,9606.0,Intermediate,Homo sapiens,13885,CHEMBL615358,81020,,726.0,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,F,1,N,1,,BAO_0000219
135,,,9606.0,Intermediate,Homo sapiens,13885,CHEMBL827086,81020,,726.0,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,F,1,N,1,,BAO_0000219
136,,,,Autocuration,,3676,CHEMBL615359,22226,,,,Compound was tested for the inhibition of Alpha-glucosidase,,B,1,U,0,,BAO_0000019
137,,,,Autocuration,,6043,CHEMBL615360,235,,,,Inhibitory concentration against human neutrophil elastase (HNE),,B,1,H,8,,BAO_0000357
138,,948.0,10116.0,Autocuration,Rattus norvegicus,11140,CHEMBL615361,22226,,,Heart,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,F,1,U,0,,BAO_0000218
139,,,,Autocuration,,10543,CHEMBL615362,19640,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,F,1,H,8,,BAO_0000019
140,,,,Expert,,10543,CHEMBL615363,19640,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,F,1,H,8,,BAO_0000019
141,,,,Autocuration,,10543,CHEMBL615364,19640,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,B,1,H,8,,BAO_0000357
142,,,,Expert,,10543,CHEMBL615365,19640,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,F,1,H,8,,BAO_0000019
143,,,10090.0,Intermediate,Mus musculus,11365,CHEMBL615366,80360,,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,F,1,N,1,,BAO_0000219
144,,,10090.0,Intermediate,Mus musculus,11365,CHEMBL615367,80360,,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,F,1,N,1,,BAO_0000219
145,,,9606.0,Intermediate,Homo sapiens,11803,CHEMBL615368,80384,,554.0,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,F,1,N,1,,BAO_0000219
146,,,9940.0,Autocuration,Ovis aries,11803,CHEMBL615369,22226,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,F,1,U,0,,BAO_0000019
147,,,9940.0,Autocuration,Ovis aries,11803,CHEMBL615370,22226,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,F,1,U,0,,BAO_0000019
148,,,,Autocuration,,12278,CHEMBL615673,191,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,B,1,H,8,,BAO_0000357
149,,,9606.0,Autocuration,Homo sapiens,8249,CHEMBL615674,22226,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,F,1,U,0,,BAO_0000019
150,,,9606.0,Autocuration,Homo sapiens,8249,CHEMBL615675,22226,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,F,1,U,0,,BAO_0000019
151,,,9606.0,Autocuration,Homo sapiens,8249,CHEMBL615676,22226,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,F,1,U,0,,BAO_0000219
152,,,9606.0,Autocuration,Homo sapiens,8249,CHEMBL615677,22226,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,F,1,U,0,,BAO_0000219
153,,,9606.0,Autocuration,Homo sapiens,8249,CHEMBL615678,22226,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,F,1,U,0,,BAO_0000219
154,,,9606.0,Autocuration,Homo sapiens,8249,CHEMBL615679,22226,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,F,1,U,0,,BAO_0000219
155,,,9606.0,Autocuration,Homo sapiens,8249,CHEMBL615680,22226,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,F,1,U,0,,BAO_0000019
156,,,9606.0,Autocuration,Homo sapiens,8249,CHEMBL615681,22226,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,F,1,U,0,,BAO_0000019
157,,,,Autocuration,,16992,CHEMBL857972,104290,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,B,1,H,6,,BAO_0000249
158,,,1314.0,Intermediate,Streptococcus pyogenes,10543,CHEMBL857899,50264,,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,F,1,N,1,,BAO_0000218
159,,,10335.0,Intermediate,Human herpesvirus 3,17833,CHEMBL615371,50527,,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,F,1,N,1,,BAO_0000218
160,,,10335.0,Expert,vericilla zoster virus,17290,CHEMBL615372,50527,,468.0,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,F,1,N,1,,BAO_0000218
161,,,10335.0,Intermediate,vericilla zoster virus,17290,CHEMBL615373,50527,,,,Antiviral activity against 07/1 strain of VZV; ND: No data,,F,1,N,1,,BAO_0000218
162,,,10335.0,Intermediate,vericilla zoster virus,17290,CHEMBL615374,50527,,,,Antiviral activity against 07/1 strain of VZV; ND=No data,,F,1,N,1,,BAO_0000218
163,,,561.0,Intermediate,escherichia cloac,10932,CHEMBL615375,50145,,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,F,1,N,1,,BAO_0000218
164,,,,Autocuration,,9707,CHEMBL615376,22226,,,,Ratio of Ki at A2 to Ki at A1 receptors,,B,1,U,0,,BAO_0000019
165,,,5476.0,Expert,Candida albicans,2346,CHEMBL615377,11143,,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,B,1,H,8,,BAO_0000249
166,,,284593.0,Expert,Candida glabrata CBS 138,2205,CHEMBL615378,18077,,,,"Inhibition of 1,3-beta-glucan synthase",,B,1,H,8,,BAO_0000357
167,,,9606.0,Intermediate,Homo sapiens,11900,CHEMBL615379,80609,,832.0,,Inhibition of growth of 1-87 human tumor cell line,,F,1,N,1,,BAO_0000219
168,,,10116.0,Expert,Rattus norvegicus,14864,CHEMBL615380,12166,,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,B,1,D,9,,BAO_0000219
169,,,3847.0,Autocuration,Glycine max,16474,CHEMBL615381,100171,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,B,1,D,9,,BAO_0000357
170,,,3847.0,Autocuration,Glycine max,16474,CHEMBL615382,100171,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,B,1,D,9,,BAO_0000357
171,,,3847.0,Autocuration,Glycine max,16474,CHEMBL615383,100171,,,,% inhibition against soybean 1-lipoxygenase (SLO),,B,1,D,9,,BAO_0000357
172,,,3847.0,Autocuration,Glycine max,16474,CHEMBL615384,100171,,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,B,1,D,9,,BAO_0000357
173,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615385,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,B,1,D,9,,BAO_0000357
174,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615386,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,B,1,D,9,,BAO_0000357
175,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615387,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,B,1,D,9,,BAO_0000357
176,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615388,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,B,1,D,9,,BAO_0000357
177,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615214,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,B,1,D,9,,BAO_0000357
178,,,3847.0,Autocuration,Glycine max,3094,CHEMBL827087,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,B,1,D,9,,BAO_0000357
179,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615215,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,B,1,D,9,,BAO_0000357
180,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615216,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,B,1,D,9,,BAO_0000357
181,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615217,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,B,1,D,9,,BAO_0000357
182,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615218,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,B,1,D,9,,BAO_0000357
183,,,3847.0,Autocuration,Glycine max,3094,CHEMBL615219,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,B,1,D,9,,BAO_0000357
184,,,10090.0,Autocuration,Mus musculus,10413,CHEMBL615220,22226,,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,B,1,U,0,,BAO_0000019
185,,,10090.0,Intermediate,Mus musculus,16929,CHEMBL615221,80049,,294.0,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,F,1,N,1,,BAO_0000219
186,,,,Intermediate,,1229,CHEMBL615222,22226,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,F,1,U,0,,BAO_0000019
187,,,,Autocuration,,16587,CHEMBL615223,11489,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,B,1,H,8,,BAO_0000357
188,,,,Autocuration,,16587,CHEMBL615224,11862,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,B,1,H,8,,BAO_0000357
189,,,,Autocuration,,16587,CHEMBL615225,11862,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,B,1,H,8,,BAO_0000357
190,,,,Autocuration,,16587,CHEMBL615226,11489,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,B,1,H,8,,BAO_0000357
191,,,,Autocuration,,16587,CHEMBL615227,11862,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,B,1,H,8,,BAO_0000357
192,,,9913.0,Expert,Bos taurus,8058,CHEMBL615228,12347,,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,F,1,D,9,,BAO_0000019
193,,,10116.0,Expert,Rattus norvegicus,9065,CHEMBL615229,100120,,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,B,1,D,9,,BAO_0000357
194,,2369.0,10116.0,Expert,Rattus norvegicus,8865,CHEMBL615230,100120,,,Adrenal gland,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,B,1,D,9,,BAO_0000357
195,,,10116.0,Expert,Rattus norvegicus,9066,CHEMBL615231,100120,,,,Inhibition of rat adrenal 11-beta-hydroxylase,,B,1,D,9,,BAO_0000357
196,,,10116.0,Expert,Rattus norvegicus,8394,CHEMBL884520,100120,,,,Inhibition of rat adrenal 11-beta-hydroxylase,,B,1,D,9,,BAO_0000357
197,,,10116.0,Expert,Rattus norvegicus,8394,CHEMBL615232,100120,,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,B,1,D,9,,BAO_0000357
198,,,,Autocuration,,6431,CHEMBL615233,10328,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,B,1,H,8,,BAO_0000019
199,,,,Autocuration,,6431,CHEMBL827088,11490,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,B,1,H,8,,BAO_0000357
200,,,,Autocuration,,6431,CHEMBL615234,11490,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,B,1,H,8,,BAO_0000357
201,,,,Autocuration,,9295,CHEMBL615235,11134,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,F,1,H,8,,BAO_0000019
202,,,,Autocuration,,10193,CHEMBL615236,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,B,1,H,8,,BAO_0000019
203,,,,Autocuration,,13622,CHEMBL615237,11134,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,,B,1,H,8,,BAO_0000019
204,,,,Autocuration,,12079,CHEMBL615238,11134,,,,Inhibitory concentration against human platelet 12-lipoxygenase,,F,1,H,8,,BAO_0000019
205,,,,Autocuration,,13622,CHEMBL615239,11134,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,B,1,H,8,,BAO_0000019
206,,,9606.0,Autocuration,Homo sapiens,12079,CHEMBL615240,11134,,,,Inhibitory concentration against human platelet 12-lipoxygenase,,F,1,D,9,,BAO_0000019
207,,,,Expert,,13500,CHEMBL615241,11835,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,B,1,H,8,,BAO_0000019
208,,,,Expert,,13723,CHEMBL615242,11601,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,B,1,H,8,,BAO_0000357
209,,,,Autocuration,,16474,CHEMBL615243,11134,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,B,1,H,8,,BAO_0000019
210,,,,Autocuration,,1630,CHEMBL615244,11134,,,,Inhibitory activity against human platelet 12-lipoxygenase,,B,1,H,8,,BAO_0000019
211,,,,Autocuration,,167,CHEMBL615245,11134,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,B,1,H,8,,BAO_0000019
212,,,,Autocuration,,16474,CHEMBL615246,11134,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,B,1,H,8,,BAO_0000019
213,,,,Autocuration,,167,CHEMBL615247,11134,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,B,1,H,8,,BAO_0000019
214,,,,Autocuration,,16474,CHEMBL615248,11134,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,B,1,H,8,,BAO_0000019
215,,,,Autocuration,,10091,CHEMBL615249,11601,,,,Inhibitory activity towards porcine 12-lipoxygenase,,B,1,H,8,,BAO_0000357
216,,,,Autocuration,,11966,CHEMBL615250,11601,,,,Tested for inhibition against porcine 12-LO,,B,1,H,8,,BAO_0000357
217,,,,Autocuration,,951,CHEMBL615251,12052,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,B,1,H,8,,BAO_0000019
218,,,,Autocuration,,10997,CHEMBL615252,12052,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,B,1,H,8,,BAO_0000019
219,,,,Expert,,10193,CHEMBL828340,12052,,,,In vitro inhibition of rat platelet 12-lipoxygenase,,B,1,H,8,,BAO_0000019
220,,,,Autocuration,,10193,CHEMBL615253,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,B,1,H,8,,BAO_0000019
221,,,,Autocuration,,10193,CHEMBL615254,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,B,1,H,8,,BAO_0000019
222,,,,Autocuration,,10193,CHEMBL615255,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,B,1,H,8,,BAO_0000019
223,,,,Autocuration,,10193,CHEMBL615256,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,B,1,H,8,,BAO_0000019
224,,,,Autocuration,,10193,CHEMBL615257,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,B,1,H,8,,BAO_0000019
225,,,,Autocuration,,11087,CHEMBL615258,12052,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,B,1,H,8,,BAO_0000019
226,,,9606.0,Intermediate,Homo sapiens,15569,CHEMBL615259,80007,,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,F,1,N,1,,BAO_0000219
227,,,9606.0,Expert,Homo sapiens,12989,CHEMBL615260,80007,,621.0,,In vitro antitumor activity against 41M cell line.,,F,1,N,1,,BAO_0000219
228,,,9606.0,Intermediate,Homo sapiens,16745,CHEMBL615261,80007,,621.0,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,F,1,N,1,,BAO_0000219
229,,,9606.0,Intermediate,Homo sapiens,15569,CHEMBL615262,80007,,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,F,1,N,1,,BAO_0000219
230,,,9606.0,Expert,Homo sapiens,12989,CHEMBL615263,80007,,621.0,,In vitro antitumor activity against 41McisR cell line.,,F,1,N,1,,BAO_0000219
231,,,9606.0,Expert,Homo sapiens,12989,CHEMBL838393,80007,,621.0,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,F,1,N,1,,BAO_0000219
232,,,9606.0,Intermediate,Homo sapiens,16745,CHEMBL615264,80007,,621.0,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,F,1,N,1,,BAO_0000219
233,,,9606.0,Expert,Homo sapiens,6210,CHEMBL615265,84,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,B,1,D,9,,BAO_0000357
234,,,9606.0,Expert,Homo sapiens,6210,CHEMBL615266,68,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,B,1,D,9,,BAO_0000357
235,,,,Expert,,6226,CHEMBL615267,68,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,B,1,H,8,,BAO_0000357
236,,,,Expert,,17855,CHEMBL615268,10201,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,B,1,H,8,,BAO_0000357
237,,,,Expert,,17855,CHEMBL615269,10201,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,B,1,H,8,,BAO_0000357
238,,,,Expert,,17855,CHEMBL615270,10201,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,B,1,H,8,,BAO_0000357
239,,,,Autocuration,,10413,CHEMBL615271,12220,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,B,1,H,8,,BAO_0000357
240,,,562.0,Autocuration,Escherichia coli,10413,CHEMBL615272,11303,,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,B,1,H,8,,BAO_0000357
241,,,562.0,Autocuration,Escherichia coli,10413,CHEMBL615103,11303,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,B,1,H,8,,BAO_0000357
242,,,562.0,Autocuration,Escherichia coli,10413,CHEMBL615104,11303,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,B,1,H,8,,BAO_0000357
243,,,,Autocuration,,10413,CHEMBL615105,12220,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,B,1,H,8,,BAO_0000357
244,,,,Autocuration,,10413,CHEMBL872866,12220,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,B,1,H,8,,BAO_0000357
245,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615106,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,B,1,H,8,,BAO_0000357
246,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615107,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,B,1,H,8,,BAO_0000019
247,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615108,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,B,1,H,8,,BAO_0000357
248,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615109,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,B,1,H,8,,BAO_0000357
249,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615110,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,B,1,H,8,,BAO_0000357
250,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL840105,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,B,1,H,8,,BAO_0000019
251,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615111,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,B,1,H,8,,BAO_0000019
252,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615112,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,B,1,H,8,,BAO_0000019
253,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615113,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,B,1,H,8,,BAO_0000019
254,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615114,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,B,1,H,8,,BAO_0000019
255,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615115,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,B,1,H,8,,BAO_0000357
256,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615116,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,B,1,H,8,,BAO_0000019
257,,,,Autocuration,,7323,CHEMBL615698,11303,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,B,1,H,8,,BAO_0000357
258,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615699,22226,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,B,1,U,0,,BAO_0000019
259,,,9823.0,Autocuration,Sus scrofa,7587,CHEMBL615700,22226,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,B,1,U,0,,BAO_0000019
260,,,4932.0,Expert,Saccharomyces cerevisiae,13750,CHEMBL615701,100249,,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,B,1,H,8,,BAO_0000357
261,,,10116.0,Autocuration,Rattus norvegicus,7662,CHEMBL615702,22226,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,B,1,U,0,,BAO_0000019
262,,,10116.0,Autocuration,Rattus norvegicus,7662,CHEMBL615703,22226,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,B,1,U,0,,BAO_0000019
263,,,10116.0,Autocuration,Rattus norvegicus,7662,CHEMBL615704,22226,,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,B,1,U,0,,BAO_0000019
264,,,,Autocuration,,12211,CHEMBL615705,104698,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,F,1,H,6,,BAO_0000019
265,,,,Autocuration,,12211,CHEMBL615706,104698,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,F,1,H,6,,BAO_0000019
266,,2116.0,10141.0,Intermediate,Cavia porcellus,12211,CHEMBL615707,20033,,,Ileum,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,F,1,D,9,,BAO_0000221
267,,,,Expert,,12211,CHEMBL615708,10623,,,,Stimulatory activity of intragastric pressure was tested in the rat,,F,1,H,8,,BAO_0000019
268,,,,Autocuration,,15453,CHEMBL615709,121,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,B,1,H,8,,BAO_0000357
269,,,10116.0,Autocuration,Rattus norvegicus,11884,CHEMBL615710,22226,,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,F,1,U,0,,BAO_0000218
270,,,,Autocuration,,7185,CHEMBL615711,12688,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,F,1,H,8,,BAO_0000019
271,,,9606.0,Expert,Homo sapiens,6876,CHEMBL615712,121,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,B,1,D,9,,BAO_0000357
272,,,9606.0,Expert,Homo sapiens,6876,CHEMBL836325,121,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,B,1,D,9,,BAO_0000357
273,,,,Autocuration,,11863,CHEMBL615713,12198,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,F,1,H,8,,BAO_0000019
274,,,,Autocuration,,11863,CHEMBL615714,12198,,,,Inhibition constant of high-affinity 5-HT uptake,,B,1,H,8,,BAO_0000357
275,,,,Autocuration,,11863,CHEMBL615715,12198,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,F,1,H,8,,BAO_0000019
276,,,,Autocuration,,11863,CHEMBL615716,12198,,,,Maximum rate was determined for high affinity transport of 5-HT,,F,1,H,8,,BAO_0000019
277,,,,Autocuration,,4639,CHEMBL615717,104714,,,,Compound was tested for agonistic activity against 5-HT uptake,,F,1,H,4,,BAO_0000019
278,,,,Expert,,15796,CHEMBL881818,10577,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,B,1,H,8,,BAO_0000019
279,,,9913.0,Expert,Bos taurus,15796,CHEMBL884540,105,,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,B,1,H,8,,BAO_0000357
280,,,10116.0,Autocuration,Rattus norvegicus,12801,CHEMBL615718,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,B,1,D,5,,BAO_0000224
281,,,,Autocuration,,12801,CHEMBL615719,104744,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,B,1,H,4,,BAO_0000224
282,Membranes,,,Autocuration,,12120,CHEMBL615720,104744,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,B,1,H,4,,BAO_0000249
283,Membranes,,,Autocuration,,12120,CHEMBL615721,104744,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,B,1,H,4,,BAO_0000249
284,,,,Autocuration,,11963,CHEMBL615722,104744,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,B,1,H,4,,BAO_0000019
285,,,,Autocuration,,11701,CHEMBL615723,51,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,F,1,H,8,,BAO_0000019
286,,10000000.0,,Autocuration,,9995,CHEMBL615724,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
287,,10000000.0,,Autocuration,,9995,CHEMBL615725,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
288,,10000000.0,,Autocuration,,9995,CHEMBL615726,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
289,,,,Autocuration,,16394,CHEMBL615727,10576,,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,F,1,H,8,,BAO_0000218
290,,,10141.0,Intermediate,Cavia porcellus,11574,CHEMBL615728,105570,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,F,1,D,9,,BAO_0000019
291,,,,Autocuration,,15779,CHEMBL857971,279,,449.0,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000219
292,,,,Autocuration,,15363,CHEMBL615729,107,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
293,,,10116.0,Expert,Rattus norvegicus,15363,CHEMBL615730,12687,,,,Efficacy against 5-hydroxytryptamine 2A receptor,,F,1,D,9,,BAO_0000019
294,,,,Expert,,15329,CHEMBL615731,12687,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,F,1,H,8,,BAO_0000019
295,,,,Expert,,15329,CHEMBL615732,12687,,,,Relative potency towards 5-HT2A receptor of rat tail artery,,F,1,H,8,,BAO_0000019
296,,,,Expert,,15329,CHEMBL615733,12687,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,F,1,H,8,,BAO_0000019
297,,,,Expert,,15329,CHEMBL615734,12687,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,F,1,H,8,,BAO_0000019
298,,,,Autocuration,,15329,CHEMBL615735,12687,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,F,1,H,8,,BAO_0000019
299,,,,Expert,,15329,CHEMBL615736,12687,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,F,1,H,8,,BAO_0000019
300,,2116.0,10141.0,Intermediate,Cavia porcellus,273,CHEMBL615737,20033,,,Ileum,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,F,1,D,9,,BAO_0000221
301,,2116.0,10141.0,Intermediate,Cavia porcellus,273,CHEMBL615738,20033,,,Ileum,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,F,1,D,9,,BAO_0000221
302,,2116.0,10141.0,Intermediate,Cavia porcellus,273,CHEMBL615739,20033,,,Ileum,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,F,1,D,9,,BAO_0000221
303,,,,Autocuration,,12092,CHEMBL615278,10623,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,B,1,H,8,,BAO_0000357
304,,,10116.0,Expert,Rattus norvegicus,1317,CHEMBL615279,10623,,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,F,1,D,9,,BAO_0000019
305,,,,Expert,,12409,CHEMBL615280,168,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
306,,,9031.0,Autocuration,Gallus gallus,11126,CHEMBL615281,22226,,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,B,1,U,0,,BAO_0000019
307,,,9606.0,Autocuration,Homo sapiens,11126,CHEMBL615282,22226,,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,F,1,U,0,,BAO_0000019
308,,,9606.0,Autocuration,Homo sapiens,11126,CHEMBL615283,22226,,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,F,1,U,0,,BAO_0000019
309,,,9606.0,Autocuration,Homo sapiens,11126,CHEMBL615284,80156,,649.0,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,B,1,N,1,,BAO_0000219
310,,,9606.0,Autocuration,Homo sapiens,11126,CHEMBL615285,22226,,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,B,1,U,0,,BAO_0000019
311,,,9606.0,Autocuration,Homo sapiens,11126,CHEMBL615286,22226,,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,B,1,U,0,,BAO_0000019
312,,,9606.0,Autocuration,Homo sapiens,17807,CHEMBL615287,104703,,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,B,1,D,7,,BAO_0000219
313,,,,Intermediate,,16575,CHEMBL615288,100256,,,,Chymotryptic inhibitory activity against 26S proteasome,,F,1,S,2,,BAO_0000220
314,,,,Intermediate,,15407,CHEMBL615289,100256,,,,Inhibitory activity against 26S proteasome degradation of IkB,,B,1,S,2,,BAO_0000220
315,,,9606.0,Intermediate,Homo sapiens,10797,CHEMBL615290,81034,,478.0,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,F,1,N,1,,BAO_0000219
316,,,9606.0,Intermediate,Homo sapiens,10797,CHEMBL884522,81034,,478.0,,In vitro inhibition of 2780/S ovarian cancer cell line,,F,1,N,1,,BAO_0000219
317,,,9606.0,Autocuration,Homo sapiens,3469,CHEMBL615291,22226,,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,F,1,U,0,,BAO_0000019
318,,,,Intermediate,,16037,CHEMBL615292,22222,,,,Association constant for binding to AATT 28-mer AATT hairpin,,B,1,M,3,,BAO_0000225
319,,,,Intermediate,,16037,CHEMBL615293,22222,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,B,1,M,3,,BAO_0000225
320,,,,Intermediate,,16037,CHEMBL615294,22222,,,,Reaction Rate Parameter for 28-mer AATT hairpin,,B,1,M,3,,BAO_0000225
321,,,,Intermediate,,16037,CHEMBL615295,22222,,,,Reaction Rate Parameter for 28-mer AATT hairpin,,B,1,M,3,,BAO_0000225
322,,,9606.0,Autocuration,Homo sapiens,16524,CHEMBL825021,22226,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,F,1,U,0,,BAO_0000019
323,,,9606.0,Autocuration,Homo sapiens,16524,CHEMBL615296,22226,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,F,1,U,0,,BAO_0000019
324,,,9606.0,Autocuration,Homo sapiens,16524,CHEMBL615297,22226,,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,F,1,U,0,,BAO_0000019
325,,,10029.0,Autocuration,Cricetulus griseus,16758,CHEMBL615298,22226,,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,F,1,U,0,,BAO_0000019
326,,,10029.0,Autocuration,Cricetulus griseus,16758,CHEMBL615299,22226,,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,F,1,U,0,,BAO_0000019
327,,,10029.0,Autocuration,Cricetulus griseus,16758,CHEMBL615300,22226,,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,F,1,U,0,,BAO_0000019
328,,,,Autocuration,,14360,CHEMBL615301,241,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,B,1,H,8,,BAO_0000357
329,,,9606.0,Expert,Homo sapiens,14360,CHEMBL615302,241,,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,B,1,D,9,,BAO_0000357
330,,,10116.0,Autocuration,Rattus norvegicus,9964,CHEMBL615303,22226,,,,Selectivity ratio of ID50 in liver and heart,,B,1,U,0,,BAO_0000019
331,,,,Autocuration,,9964,CHEMBL615304,12132,,,,"Selectivity, ratio of relative ID50 in liver and heart",,B,1,H,8,,BAO_0000019
332,,,,Autocuration,,9964,CHEMBL615305,12132,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,B,1,H,8,,BAO_0000019
333,,,,Autocuration,,9964,CHEMBL615306,12132,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,B,1,H,8,,BAO_0000218
334,,,,Autocuration,,9964,CHEMBL615307,12132,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,B,1,H,8,,BAO_0000218
335,,,,Autocuration,,9964,CHEMBL615308,12132,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,B,1,H,8,,BAO_0000218
336,,,,Autocuration,,9964,CHEMBL615309,12132,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,F,1,H,8,,BAO_0000218
337,,,,Autocuration,,9964,CHEMBL615310,22226,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,B,1,U,0,,BAO_0000019
338,,,,Autocuration,,9964,CHEMBL615311,12132,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,B,1,H,8,,BAO_0000019
339,,,9606.0,Autocuration,Homo sapiens,9964,CHEMBL615312,22226,,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,B,1,U,0,,BAO_0000019
340,,,,Autocuration,,9964,CHEMBL615313,12132,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,B,1,H,8,,BAO_0000019
341,,,,Autocuration,,9964,CHEMBL615314,12132,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,F,1,H,8,,BAO_0000019
342,,,,Autocuration,,9964,CHEMBL615315,12132,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,B,1,H,8,,BAO_0000019
343,,,10116.0,Autocuration,Rattus norvegicus,9964,CHEMBL615316,22226,,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,B,1,U,0,,BAO_0000218
344,,,,Autocuration,,9964,CHEMBL615317,12132,,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,B,1,H,8,,BAO_0000218
345,,,,Autocuration,,9964,CHEMBL615318,12132,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,B,1,H,8,,BAO_0000218
346,,,10116.0,Autocuration,Rattus norvegicus,9964,CHEMBL615319,22226,,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,B,1,U,0,,BAO_0000218
347,,,,Autocuration,,9964,CHEMBL615320,12132,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,B,1,H,8,,BAO_0000019
348,,,,Autocuration,,9964,CHEMBL615321,12132,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,F,1,H,8,,BAO_0000019
349,,,10116.0,Autocuration,Rattus norvegicus,3796,CHEMBL615322,22226,,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,B,1,U,0,,BAO_0000019
350,,,562.0,Autocuration,Escherichia coli,4251,CHEMBL615323,19690,,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,B,1,H,8,,BAO_0000357
351,,,562.0,Autocuration,Escherichia coli,4251,CHEMBL615407,19690,,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,B,1,H,8,,BAO_0000357
352,,,562.0,Autocuration,Escherichia coli,4251,CHEMBL857267,19690,,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,B,1,H,8,,BAO_0000357
353,,,562.0,Autocuration,Escherichia coli,4251,CHEMBL615408,19690,,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,B,1,H,8,,BAO_0000357
354,,,,Autocuration,,166,CHEMBL615409,19690,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,B,1,H,8,,BAO_0000357
355,,,,Autocuration,,17861,CHEMBL615410,19690,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,B,1,H,8,,BAO_0000357
356,,,,Autocuration,,166,CHEMBL615411,19690,,,,Inhibition constant against 3-dehydroquinate synthase,,B,1,H,8,,BAO_0000357
357,,,,Autocuration,,166,CHEMBL615412,19690,,,,Association rate constant against 3-dehydroquinate synthase,,B,1,H,8,,BAO_0000357
358,,,,Autocuration,,166,CHEMBL615413,19690,,,,Rate constant against 3-dehydroquinate synthase,,B,1,H,8,,BAO_0000357
359,,,,Autocuration,,3548,CHEMBL615414,22226,,,,Inhibitory activity against fuc-TVII,,B,1,U,0,,BAO_0000019
360,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615415,12236,,,Liver,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,B,1,D,9,,BAO_0000251
361,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615416,12236,,,Liver,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,B,1,D,9,,BAO_0000251
362,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615417,12236,,,Liver,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,B,1,D,9,,BAO_0000251
363,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615418,12236,,,Liver,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,B,1,D,9,,BAO_0000251
364,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615419,12236,,,Liver,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,B,1,D,9,,BAO_0000251
365,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615420,12236,,,Liver,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,B,1,D,9,,BAO_0000251
366,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615421,12236,,,Liver,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,B,1,D,9,,BAO_0000251
367,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615422,12236,,,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,B,1,D,9,,BAO_0000251
368,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615423,12236,,,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,B,1,D,9,,BAO_0000251
369,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL872868,12236,,,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,B,1,D,9,,BAO_0000251
370,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,9877,CHEMBL615424,12236,,,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,B,1,D,9,,BAO_0000251
371,,,,Autocuration,,3003,CHEMBL825022,104832,,,,Inhibitory activity against 3-phosphoglycerate kinase.,,B,1,H,4,,BAO_0000224
372,,,,Autocuration,,3003,CHEMBL615425,104832,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,B,1,H,4,,BAO_0000224
373,,,,Autocuration,,3003,CHEMBL615426,104832,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,B,1,H,4,,BAO_0000224
374,,,9606.0,Expert,Homo sapiens,17185,CHEMBL615427,10612,,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,B,1,D,9,,BAO_0000357
375,,,9606.0,Intermediate,Homo sapiens,6072,CHEMBL615428,80616,,844.0,,Cytotoxicity on 3677 melanoma cells,,F,1,N,1,,BAO_0000219
376,,,9606.0,Intermediate,Homo sapiens,6072,CHEMBL615429,80616,,844.0,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,F,1,N,1,,BAO_0000219
377,,,10090.0,Intermediate,Mus musculus,5018,CHEMBL615430,80617,,700.0,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,F,1,N,1,,BAO_0000219
378,,,9606.0,Intermediate,Homo sapiens,2852,CHEMBL615431,22226,,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,F,1,U,0,,BAO_0000019
379,,,,Autocuration,,8663,CHEMBL615432,22226,,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,F,1,U,0,,BAO_0000218
380,,,,Autocuration,,8663,CHEMBL615433,22226,,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,F,1,U,0,,BAO_0000218
381,,,12131.0,Expert,Human rhinovirus 14,3245,CHEMBL615434,12464,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,F,1,D,9,,BAO_0000019
382,,,169066.0,Intermediate,Human rhinovirus sp.,3245,CHEMBL615435,50085,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,F,1,N,1,,BAO_0000218
383,,,169066.0,Intermediate,human rhinovirus type 14,3877,CHEMBL615436,50679,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,F,1,N,1,,BAO_0000218
384,,,169066.0,Intermediate,human rhinovirus type 14,3877,CHEMBL615437,50679,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,F,1,N,1,,BAO_0000218
385,,,12131.0,Expert,Human rhinovirus 14,5861,CHEMBL615438,12464,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,F,1,D,9,,BAO_0000019
386,,,12131.0,Expert,Human rhinovirus 14,5861,CHEMBL615439,12464,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,F,1,D,9,,BAO_0000019
387,,,12131.0,Expert,Human rhinovirus 14,5861,CHEMBL615440,12464,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,F,1,D,9,,BAO_0000019
388,,,12131.0,Expert,Human rhinovirus 14,5861,CHEMBL615441,12464,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,F,1,D,9,,BAO_0000019
389,,,12059.0,Intermediate,Enterovirus,13748,CHEMBL615641,50665,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,F,1,N,1,,BAO_0000218
390,,,12059.0,Intermediate,Enterovirus,13748,CHEMBL872065,50665,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,F,1,N,1,,BAO_0000218
391,,,12059.0,Intermediate,Enterovirus,13748,CHEMBL825023,50665,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,F,1,N,1,,BAO_0000218
392,,,12059.0,Intermediate,Enterovirus,13748,CHEMBL615642,50665,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,F,1,N,1,,BAO_0000218
393,,,147712.0,Expert,Human rhinovirus B,13748,CHEMBL615643,12464,,,,Inhibition of human rhinovirus 3C protease,,B,1,H,8,,BAO_0000357
394,,,9606.0,Autocuration,Homo sapiens,17699,CHEMBL615644,22226,,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,B,1,U,0,,BAO_0000019
395,,,10090.0,Intermediate,Mus musculus,7145,CHEMBL615645,80619,,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,F,1,N,1,,BAO_0000218
396,,,10090.0,Intermediate,Mus musculus,7145,CHEMBL615646,80619,,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,F,1,N,1,,BAO_0000218
397,,,10090.0,Intermediate,Mus musculus,7145,CHEMBL615647,80619,,833.0,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,F,1,N,1,,BAO_0000218
398,,,10090.0,Intermediate,Mus musculus,7145,CHEMBL615648,80619,,833.0,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,F,1,N,1,,BAO_0000218
399,,,10090.0,Intermediate,Mus musculus,7145,CHEMBL615649,80619,,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,F,1,N,1,,BAO_0000218
400,,,10090.0,Intermediate,Mus musculus,7145,CHEMBL615650,80619,,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,F,1,N,1,,BAO_0000218
401,,,10090.0,Intermediate,Mus musculus,5325,CHEMBL615651,80620,,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,F,1,N,1,,BAO_0000218
402,,,10090.0,Intermediate,Mus musculus,5325,CHEMBL615652,80620,,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,F,1,N,1,,BAO_0000218
403,,,10090.0,Expert,Mus musculus,5325,CHEMBL615653,80620,,847.0,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,F,1,N,1,,BAO_0000218
404,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615654,80620,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,F,1,N,1,,BAO_0000219
405,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615655,80620,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,F,1,N,1,,BAO_0000219
406,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL825024,80620,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,F,1,N,1,,BAO_0000219
407,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615656,80620,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,F,1,N,1,,BAO_0000219
408,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615657,80620,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,F,1,N,1,,BAO_0000219
409,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615658,80620,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,F,1,N,1,,BAO_0000219
410,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615659,80620,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,F,1,N,1,,BAO_0000219
411,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615660,80620,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,F,1,N,1,,BAO_0000219
412,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615661,80620,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,F,1,N,1,,BAO_0000219
413,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615662,80620,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,F,1,N,1,,BAO_0000219
414,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615663,80620,,847.0,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,F,1,N,1,,BAO_0000219
415,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615664,80620,,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,F,1,N,1,,BAO_0000219
416,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615665,80620,,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,F,1,N,1,,BAO_0000219
417,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615666,80620,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,F,1,N,1,,BAO_0000219
418,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615667,80620,,847.0,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,F,1,N,1,,BAO_0000219
419,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615668,80620,,847.0,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,F,1,N,1,,BAO_0000219
420,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615669,80620,,847.0,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,F,1,N,1,,BAO_0000219
421,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615670,80620,,847.0,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,F,1,N,1,,BAO_0000219
422,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL836739,80620,,847.0,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,F,1,N,1,,BAO_0000219
423,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615671,80620,,847.0,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,F,1,N,1,,BAO_0000219
424,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615672,80620,,847.0,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,F,1,N,1,,BAO_0000219
425,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615791,80620,,847.0,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,F,1,N,1,,BAO_0000219
426,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615792,80620,,847.0,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,F,1,N,1,,BAO_0000219
427,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615793,80620,,847.0,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,F,1,N,1,,BAO_0000219
428,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615794,80620,,847.0,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,F,1,N,1,,BAO_0000219
429,,,10090.0,Intermediate,Mus musculus,16169,CHEMBL615795,80620,,847.0,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,F,1,N,1,,BAO_0000219
430,,,9606.0,Intermediate,Homo sapiens,15547,CHEMBL615590,80621,,971.0,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,F,1,N,1,,BAO_0000219
431,,,,Autocuration,,8663,CHEMBL615591,22226,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,F,1,U,0,,BAO_0000218
432,,,,Autocuration,,8663,CHEMBL615592,22226,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,F,1,U,0,,BAO_0000218
433,,,,Autocuration,,8663,CHEMBL615593,22226,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,F,1,U,0,,BAO_0000218
434,,,,Autocuration,,8663,CHEMBL615594,22226,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,F,1,U,0,,BAO_0000218
435,,,10090.0,Intermediate,Mus musculus,4504,CHEMBL615595,80951,,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,F,1,N,1,,BAO_0000219
436,,,10090.0,Intermediate,Mus musculus,4504,CHEMBL615596,80951,,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,F,1,N,1,,BAO_0000219
437,,,,Expert,,12695,CHEMBL615597,11169,,723.0,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,F,1,H,8,,BAO_0000219
438,,,10090.0,Intermediate,Mus musculus,12695,CHEMBL615598,80951,,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,F,1,N,1,,BAO_0000219
439,,,10090.0,Intermediate,Mus musculus,12695,CHEMBL615599,80951,,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,F,1,N,1,,BAO_0000219
440,,,10090.0,Expert,Mus musculus,17642,CHEMBL615600,80951,,723.0,,Effective dose against murine 3T3 fibroblasts cells,,F,1,N,1,,BAO_0000219
441,,,10090.0,Expert,Mus musculus,17642,CHEMBL615601,80951,,723.0,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,F,1,N,1,,BAO_0000219
442,,,10090.0,Expert,Mus musculus,12340,CHEMBL615602,80951,,723.0,,Cytotoxic effect on 3T3 cells,,F,1,N,1,,BAO_0000219
443,,,10090.0,Expert,Mus musculus,12340,CHEMBL615603,80951,,723.0,,Cytotoxic effect on 3T3 cells,,F,1,N,1,,BAO_0000219
444,,,10090.0,Intermediate,Mus musculus,12716,CHEMBL615604,80951,,723.0,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,F,1,N,1,,BAO_0000219
445,,,10090.0,Intermediate,Mus musculus,6277,CHEMBL615605,80951,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,F,1,N,1,,BAO_0000219
446,,,10090.0,Intermediate,Mus musculus,6277,CHEMBL615606,80951,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,F,1,N,1,,BAO_0000219
447,,,10090.0,Expert,Mus musculus,6277,CHEMBL884526,80951,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,F,1,N,1,,BAO_0000219
448,,,10090.0,Expert,Mus musculus,6277,CHEMBL615607,80951,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,F,1,N,1,,BAO_0000219
449,,,10090.0,Intermediate,Mus musculus,6277,CHEMBL615608,80951,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,F,1,N,1,,BAO_0000219
450,,,10090.0,Expert,Mus musculus,6277,CHEMBL615609,80951,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,F,1,N,1,,BAO_0000219
451,,,10090.0,Expert,Mus musculus,6277,CHEMBL615682,80951,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,F,1,N,1,,BAO_0000219
452,,,10090.0,Intermediate,Mus musculus,6277,CHEMBL615683,80951,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,F,1,N,1,,BAO_0000219
453,,,10090.0,Expert,Mus musculus,17780,CHEMBL615684,80951,,723.0,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,F,1,N,1,,BAO_0000218
454,,,10090.0,Autocuration,Mus musculus,12751,CHEMBL615685,104860,,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,F,1,D,7,,BAO_0000219
455,,,10090.0,Expert,Mus musculus,12380,CHEMBL615686,80951,,723.0,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,F,1,N,1,,BAO_0000219
456,,,10090.0,Intermediate,Mus musculus,14892,CHEMBL615687,80951,,723.0,,Inhibitory activity against 3T3 cell line,,F,1,N,1,,BAO_0000219
457,,,10090.0,Intermediate,Mus musculus,12695,CHEMBL884523,80951,,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,F,1,N,1,,BAO_0000219
458,,,,Expert,,12695,CHEMBL615688,11169,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,F,1,H,8,,BAO_0000019
459,,,10090.0,Intermediate,Mus musculus,12695,CHEMBL615689,80951,,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,F,1,N,1,,BAO_0000219
460,,,10090.0,Intermediate,Mus musculus,12695,CHEMBL615690,80951,,723.0,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,F,1,N,1,,BAO_0000219
461,,,,Expert,,12695,CHEMBL615691,11169,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,F,1,H,8,,BAO_0000019
462,,,,Expert,,12695,CHEMBL615692,11169,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,F,1,H,8,,BAO_0000019
463,,,10090.0,Intermediate,Mus musculus,6277,CHEMBL615693,80951,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,F,1,N,1,,BAO_0000219
464,,,10090.0,Expert,Mus musculus,6277,CHEMBL615324,80951,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,F,1,N,1,,BAO_0000219
465,,,9606.0,Expert,Homo sapiens,4959,CHEMBL615325,9,,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,F,1,D,9,,BAO_0000219
466,,,9606.0,Expert,Homo sapiens,4959,CHEMBL615490,9,,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,F,1,D,9,,BAO_0000219
467,,,9606.0,Expert,Homo sapiens,4959,CHEMBL615491,188,,723.0,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,F,1,D,9,,BAO_0000219
468,,,9606.0,Expert,Homo sapiens,4959,CHEMBL615492,188,,723.0,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,F,1,D,9,,BAO_0000219
469,,,10090.0,Intermediate,Mus musculus,12082,CHEMBL615493,80951,,723.0,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,F,1,N,1,,BAO_0000219
470,,,10090.0,Intermediate,Mus musculus,12082,CHEMBL615494,80951,,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,F,1,N,1,,BAO_0000219
471,,,10090.0,Intermediate,Mus musculus,12082,CHEMBL615495,80951,,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,F,1,N,1,,BAO_0000219
472,,,10090.0,Intermediate,Mus musculus,12082,CHEMBL615496,80951,,723.0,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,F,1,N,1,,BAO_0000219
473,,,10090.0,Intermediate,Mus musculus,2643,CHEMBL615497,80951,,723.0,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,F,1,N,1,,BAO_0000219
474,,,10090.0,Expert,Mus musculus,11926,CHEMBL615498,80951,,723.0,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,F,1,N,1,,BAO_0000219
475,,,10090.0,Intermediate,Mus musculus,15204,CHEMBL615499,80951,,723.0,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,A,1,N,1,,BAO_0000219
476,,,10090.0,Expert,Mus musculus,15992,CHEMBL835522,80951,,723.0,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,F,1,N,1,,BAO_0000219
477,,,10090.0,Intermediate,Mus musculus,16279,CHEMBL615500,80951,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,F,1,N,1,,BAO_0000219
478,,,10090.0,Intermediate,Mus musculus,16279,CHEMBL615501,80951,,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,F,1,N,1,,BAO_0000219
479,,,10090.0,Intermediate,Mus musculus,16279,CHEMBL615502,80951,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,F,1,N,1,,BAO_0000219
480,,,10090.0,Intermediate,Mus musculus,16279,CHEMBL615503,80951,,723.0,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,F,1,N,1,,BAO_0000219
481,,,10090.0,Intermediate,Mus musculus,16279,CHEMBL615504,80951,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,F,1,N,1,,BAO_0000219
482,,,10090.0,Intermediate,Mus musculus,16279,CHEMBL615505,80951,,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,F,1,N,1,,BAO_0000219
483,,,10090.0,Expert,Mus musculus,12831,CHEMBL615506,80951,,723.0,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,F,1,N,1,,BAO_0000219
484,,,10090.0,Intermediate,Mus musculus,13497,CHEMBL615507,80951,,723.0,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,F,1,N,1,,BAO_0000219
485,,,,Intermediate,,13715,CHEMBL615508,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,F,1,N,1,,BAO_0000218
486,,,10090.0,Intermediate,Mus musculus,13618,CHEMBL615509,80006,,620.0,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,F,1,N,1,,BAO_0000219
487,,,10090.0,Intermediate,Mus musculus,11902,CHEMBL615510,80006,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,F,1,N,1,,BAO_0000219
488,,,10090.0,Intermediate,Mus musculus,11902,CHEMBL615511,80006,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,F,1,N,1,,BAO_0000219
489,,,10090.0,Intermediate,Mus musculus,11902,CHEMBL615512,80006,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,F,1,N,1,,BAO_0000219
490,,,10090.0,Intermediate,Mus musculus,14840,CHEMBL615513,80006,,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,F,1,N,1,,BAO_0000218
491,,,10090.0,Intermediate,Mus musculus,14840,CHEMBL615514,80006,,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,F,1,N,1,,BAO_0000218
492,,,,Intermediate,,13715,CHEMBL615515,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,F,1,N,1,,BAO_0000219
493,,,,Intermediate,,13715,CHEMBL615516,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,F,1,N,1,,BAO_0000219
494,,,,Intermediate,,13715,CHEMBL615517,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,F,1,N,1,,BAO_0000219
495,,,,Intermediate,,13715,CHEMBL615518,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,F,1,N,1,,BAO_0000219
496,,,,Intermediate,,13715,CHEMBL615519,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,F,1,N,1,,BAO_0000219
497,,,,Intermediate,,13715,CHEMBL615520,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,F,1,N,1,,BAO_0000218
498,,,,Intermediate,,13715,CHEMBL615521,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,F,1,N,1,,BAO_0000218
499,,,,Intermediate,,13715,CHEMBL615522,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,F,1,N,1,,BAO_0000218
500,,,,Intermediate,,13715,CHEMBL615523,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,F,1,N,1,,BAO_0000218
501,,,,Expert,,13715,CHEMBL615524,80006,,620.0,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,F,1,N,1,,BAO_0000218
502,,,,Expert,,13715,CHEMBL615525,80006,,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,F,1,N,1,,BAO_0000218
503,,,,Intermediate,,13715,CHEMBL615526,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,F,1,N,1,,BAO_0000218
504,,,,Intermediate,,13715,CHEMBL615527,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,F,1,N,1,,BAO_0000218
505,,,,Intermediate,,13715,CHEMBL615528,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,F,1,N,1,,BAO_0000218
506,,,,Expert,,13715,CHEMBL615529,80006,,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,F,1,N,1,,BAO_0000218
507,,,,Expert,,13715,CHEMBL615530,80006,,620.0,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,F,1,N,1,,BAO_0000218
508,,,,Expert,,13715,CHEMBL615531,80006,,620.0,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,F,1,N,1,,BAO_0000218
509,,,,Intermediate,,13715,CHEMBL615532,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,F,1,N,1,,BAO_0000219
510,,,,Intermediate,,13715,CHEMBL615533,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,F,1,N,1,,BAO_0000219
511,,,,Intermediate,,13715,CHEMBL615534,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,F,1,N,1,,BAO_0000219
512,,,,Intermediate,,13715,CHEMBL615535,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,F,1,N,1,,BAO_0000218
513,,,,Intermediate,,13715,CHEMBL615536,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,F,1,N,1,,BAO_0000218
514,,,,Intermediate,,13715,CHEMBL615537,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,F,1,N,1,,BAO_0000218
515,,,,Intermediate,,13715,CHEMBL615538,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,F,1,N,1,,BAO_0000218
516,,,,Intermediate,,13715,CHEMBL836166,80006,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,F,1,N,1,,BAO_0000218
517,,,,Expert,,6411,CHEMBL615539,11214,,620.0,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,F,1,H,8,,BAO_0000219
518,,,10090.0,Intermediate,Mus musculus,6411,CHEMBL615540,80006,,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,F,1,N,1,,BAO_0000219
519,,,,Expert,,6411,CHEMBL615541,11214,,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,F,1,H,8,,BAO_0000219
520,,,10090.0,Expert,Mus musculus,3966,CHEMBL615542,80006,,620.0,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,F,1,N,1,,BAO_0000219
521,,,10090.0,Intermediate,Mus musculus,3966,CHEMBL615543,80006,,620.0,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,F,1,N,1,,BAO_0000219
522,,,10090.0,Expert,Mus musculus,15556,CHEMBL615544,80006,,620.0,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,F,1,N,1,,BAO_0000219
523,,,10090.0,Expert,Mus musculus,5845,CHEMBL615545,80006,,620.0,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,F,1,N,1,,BAO_0000219
524,,,10090.0,Expert,Mus musculus,14422,CHEMBL615546,80006,,620.0,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,F,1,N,1,,BAO_0000219
525,,,10090.0,Expert,Mus musculus,5845,CHEMBL615547,80006,,620.0,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,F,1,N,1,,BAO_0000219
526,,,10090.0,Expert,Mus musculus,14508,CHEMBL615548,80006,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,F,1,N,1,,BAO_0000219
527,,,10090.0,Expert,Mus musculus,14508,CHEMBL615549,80006,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,F,1,N,1,,BAO_0000219
528,,,10090.0,Expert,Mus musculus,14508,CHEMBL615550,80006,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,F,1,N,1,,BAO_0000219
529,,,10116.0,Intermediate,Rattus norvegicus,6349,CHEMBL615551,80622,,1118.0,,Inhibitory activity against rat fibroblast (3Y1) cell line,,F,1,N,1,,BAO_0000219
530,,,10116.0,Expert,Rattus norvegicus,15899,CHEMBL615552,80622,,1118.0,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,F,1,N,1,,BAO_0000219
531,,,10116.0,Expert,Rattus norvegicus,15899,CHEMBL615553,80622,,1118.0,,Cytotoxicity in 3Y1 cells.,,F,1,N,1,,BAO_0000219
532,,,10116.0,Expert,Rattus norvegicus,15899,CHEMBL615554,80622,,1118.0,,Cytostatic effect in 3Y1 cells.,,F,1,N,1,,BAO_0000219
533,,,10116.0,Intermediate,Rattus norvegicus,15899,CHEMBL615555,80622,,1118.0,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,F,1,N,1,,BAO_0000219
534,,,10116.0,Expert,Rattus norvegicus,17038,CHEMBL615556,80622,,1118.0,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,F,1,N,1,,BAO_0000219
535,,,,Autocuration,,12421,CHEMBL615557,22226,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,B,1,U,0,,BAO_0000019
536,,,,Autocuration,,12947,CHEMBL615558,22226,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,B,1,U,0,,BAO_0000019
537,,,,Autocuration,,12947,CHEMBL872066,22226,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,B,1,U,0,,BAO_0000019
538,,,9823.0,Expert,Sus scrofa,4896,CHEMBL615559,11607,,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,B,1,D,9,,BAO_0000019
539,,,,Autocuration,,6148,CHEMBL615560,11607,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,B,1,H,8,,BAO_0000019
540,,,,Autocuration,,16432,CHEMBL615561,11607,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,B,1,H,8,,BAO_0000019
541,,,,Expert,,4978,CHEMBL857062,11607,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,B,1,H,8,,BAO_0000019
542,,,,Expert,,4978,CHEMBL615562,11607,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,B,1,H,8,,BAO_0000019
543,,,,Autocuration,,3723,CHEMBL615563,11607,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,B,1,H,8,,BAO_0000019
544,,,,Autocuration,,3518,CHEMBL615564,11607,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,B,1,H,8,,BAO_0000357
545,,,,Autocuration,,4164,CHEMBL615565,11607,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,B,1,H,8,,BAO_0000019
546,,,,Autocuration,,3518,CHEMBL615566,11607,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,B,1,H,8,,BAO_0000019
547,,,9823.0,Expert,Sus scrofa,4164,CHEMBL615567,11607,,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,B,1,D,9,,BAO_0000019
548,,,,Autocuration,,3518,CHEMBL615568,11607,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,B,1,H,8,,BAO_0000019
549,,,,Autocuration,,3518,CHEMBL615569,11607,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,B,1,H,8,,BAO_0000357
550,,,,Autocuration,,4978,CHEMBL615570,11607,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,B,1,H,8,,BAO_0000019
551,,,,Autocuration,,4978,CHEMBL615571,11607,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,B,1,H,8,,BAO_0000019
552,,,,Autocuration,,6455,CHEMBL615572,104733,,,,Binding affinity against melatonin (MT1) receptor (pC1),,B,1,H,4,,BAO_0000224
553,,,,Autocuration,,2222,CHEMBL615573,22226,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,B,1,U,0,,BAO_0000019
554,,,,Autocuration,,13020,CHEMBL615574,22226,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,B,1,U,0,,BAO_0000019
555,,,,Autocuration,,13021,CHEMBL615575,22226,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,B,1,U,0,,BAO_0000019
556,,,,Autocuration,,14532,CHEMBL615576,10619,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,B,1,H,8,,BAO_0000357
557,,,,Autocuration,,14118,CHEMBL615577,10619,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
558,,10000000.0,,Autocuration,,11884,CHEMBL615578,51,,,Hippocampus,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000221
559,,,,Expert,,13969,CHEMBL615579,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
560,,,,Expert,,13392,CHEMBL615580,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
561,,,,Expert,,14430,CHEMBL615581,51,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,B,1,H,8,,BAO_0000019
562,,10000000.0,,Autocuration,,12248,CHEMBL615582,51,,,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,B,1,H,8,,BAO_0000221
563,,10000000.0,,Autocuration,,12249,CHEMBL615583,51,,,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,B,1,H,8,,BAO_0000221
564,,10000000.0,,Autocuration,,9995,CHEMBL615584,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
565,,10000000.0,,Autocuration,,9995,CHEMBL833691,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
566,,10000000.0,,Autocuration,,9995,CHEMBL615585,51,,,Hippocampus,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
567,,10000000.0,,Autocuration,,9995,CHEMBL615586,51,,,Hippocampus,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
568,,10000000.0,,Autocuration,,9995,CHEMBL884524,51,,,Hippocampus,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
569,,10000000.0,,Autocuration,,12249,CHEMBL615587,51,,,Hippocampus,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,B,1,H,8,,BAO_0000221
570,,10000000.0,,Autocuration,,11799,CHEMBL615588,51,,,Hippocampus,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,B,1,H,8,,BAO_0000221
571,Membranes,,10116.0,Expert,Rattus norvegicus,14331,CHEMBL615589,10576,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,B,1,D,9,,BAO_0000249
572,,10000000.0,9913.0,Expert,Bos taurus,11884,CHEMBL615442,51,,,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,B,1,H,8,,BAO_0000221
573,,10000000.0,,Autocuration,,14331,CHEMBL615443,51,,,Hippocampus,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,B,1,H,8,,BAO_0000221
574,,10000000.0,,Autocuration,,11701,CHEMBL615444,51,,,Hippocampus,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,B,1,H,8,,BAO_0000221
575,,10000000.0,,Expert,,11701,CHEMBL615445,51,,,Hippocampus,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,B,1,H,8,,BAO_0000221
576,,10000000.0,,Autocuration,,12248,CHEMBL615446,51,,,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,B,1,H,8,,BAO_0000221
577,,,,Autocuration,,12248,CHEMBL615447,51,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,B,1,H,8,,BAO_0000219
578,,10000000.0,,Expert,,12248,CHEMBL615448,51,,,Hippocampus,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,B,1,H,8,,BAO_0000221
579,,10000000.0,,Expert,,12249,CHEMBL615449,51,,,Hippocampus,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,B,1,H,8,,BAO_0000221
580,,,,Autocuration,,12248,CHEMBL615450,51,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,B,1,H,8,,BAO_0000219
581,,10000000.0,,Expert,,11799,CHEMBL615451,51,,,Hippocampus,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,B,1,H,8,,BAO_0000221
582,,,,Autocuration,,634,CHEMBL615452,51,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,B,1,H,8,,BAO_0000357
583,,10000000.0,,Autocuration,,9995,CHEMBL615453,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
584,,10000000.0,,Autocuration,,9995,CHEMBL615454,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
585,,10000000.0,,Autocuration,,9995,CHEMBL615455,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
586,,10000000.0,,Autocuration,,9995,CHEMBL615456,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
587,,10000000.0,,Autocuration,,9995,CHEMBL615457,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
588,,10000000.0,,Expert,,12210,CHEMBL615458,51,,,Hippocampus,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,B,1,H,8,,BAO_0000218
589,,10000000.0,,Expert,,13311,CHEMBL615459,51,,,Hippocampus,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
590,,,9606.0,Expert,Homo sapiens,2331,CHEMBL615460,51,,449.0,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,B,1,D,9,,BAO_0000219
591,,,10141.0,Autocuration,Cavia porcellus,1375,CHEMBL615461,51,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,F,1,H,8,,BAO_0000019
592,,,10141.0,Autocuration,Cavia porcellus,1375,CHEMBL615462,51,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,F,1,H,8,,BAO_0000019
593,,10000000.0,10141.0,Autocuration,Cavia porcellus,11574,CHEMBL615463,51,,,Hippocampus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,F,1,H,8,,BAO_0000221
594,,2116.0,10141.0,Autocuration,Cavia porcellus,12867,CHEMBL615464,51,,,Ileum,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,B,1,H,8,,BAO_0000221
595,,2116.0,10141.0,Autocuration,Cavia porcellus,12867,CHEMBL615465,51,,,Ileum,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,B,1,H,8,,BAO_0000221
596,,2116.0,10141.0,Autocuration,Cavia porcellus,12867,CHEMBL615466,51,,,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,B,1,H,8,,BAO_0000221
597,,2116.0,10141.0,Autocuration,Cavia porcellus,12867,CHEMBL615467,51,,,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,B,1,H,8,,BAO_0000221
598,,2116.0,10141.0,Autocuration,Cavia porcellus,12867,CHEMBL615468,51,,,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,B,1,H,8,,BAO_0000221
599,,2116.0,10141.0,Autocuration,Cavia porcellus,12867,CHEMBL615469,51,,,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,B,1,H,8,,BAO_0000221
600,,,10141.0,Autocuration,Cavia porcellus,11574,CHEMBL615470,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
601,,,10141.0,Autocuration,Cavia porcellus,13114,CHEMBL615471,51,,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
602,,,10141.0,Autocuration,Cavia porcellus,13181,CHEMBL615472,51,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
603,,10000000.0,10141.0,Autocuration,Cavia porcellus,10639,CHEMBL883242,106,,,Hippocampus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,B,1,H,8,,BAO_0000221
604,,10000000.0,10141.0,Autocuration,Cavia porcellus,10639,CHEMBL615473,106,,,Hippocampus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,F,1,H,8,,BAO_0000221
605,,,10029.0,Autocuration,Cricetulus griseus,11883,CHEMBL615474,11863,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,B,1,H,8,,BAO_0000218
606,,,,Autocuration,,17785,CHEMBL615475,51,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
607,,,,Autocuration,,1558,CHEMBL615476,51,,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,F,1,H,8,,BAO_0000219
608,,,,Autocuration,,1558,CHEMBL615477,51,,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,F,1,H,8,,BAO_0000219
609,,,,Autocuration,,15740,CHEMBL615478,51,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000019
610,,,,Autocuration,,17624,CHEMBL615160,51,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000219
611,,,,Expert,,17624,CHEMBL615161,51,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000219
612,,,,Autocuration,,17624,CHEMBL615162,51,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,F,1,H,8,,BAO_0000219
613,,,,Autocuration,,17624,CHEMBL615163,51,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,F,1,H,8,,BAO_0000219
614,,,,Expert,,17624,CHEMBL615164,51,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,B,1,H,8,,BAO_0000219
615,,,,Expert,,17624,CHEMBL615165,51,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,B,1,H,8,,BAO_0000219
616,,,,Autocuration,,17624,CHEMBL615166,51,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,B,1,H,8,,BAO_0000219
617,,,,Autocuration,,14256,CHEMBL615167,51,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,F,1,H,8,,BAO_0000219
618,,,9606.0,Expert,Homo sapiens,3445,CHEMBL615168,51,,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,B,1,D,9,,BAO_0000219
619,,,9606.0,Expert,Homo sapiens,3445,CHEMBL615169,51,,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,B,1,D,9,,BAO_0000219
620,,,9606.0,Expert,Homo sapiens,17200,CHEMBL615170,51,,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000219
621,,,9606.0,Expert,Homo sapiens,17200,CHEMBL615171,51,,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,B,1,D,9,,BAO_0000219
622,,,,Autocuration,,15180,CHEMBL615694,51,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000019
623,,,,Autocuration,,15180,CHEMBL615695,51,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000019
624,,,,Autocuration,,16026,CHEMBL615696,51,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,F,1,H,8,,BAO_0000019
625,,,,Autocuration,,2759,CHEMBL615697,51,,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,F,1,H,8,,BAO_0000219
626,,,9606.0,Expert,Homo sapiens,2759,CHEMBL859410,51,,449.0,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,F,1,D,9,,BAO_0000219
627,,,,Autocuration,,2759,CHEMBL615841,51,,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,F,1,H,8,,BAO_0000219
628,,,9606.0,Expert,Homo sapiens,2759,CHEMBL615842,51,,449.0,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,F,1,D,9,,BAO_0000219
629,,,,Autocuration,,2759,CHEMBL835003,51,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,F,1,H,8,,BAO_0000219
630,,,,Autocuration,,2759,CHEMBL615843,51,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,F,1,H,8,,BAO_0000219
631,,,9606.0,Expert,Homo sapiens,2759,CHEMBL615979,51,,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,F,1,D,9,,BAO_0000219
632,,,,Autocuration,,2759,CHEMBL615980,51,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,F,1,H,8,,BAO_0000219
633,,,9606.0,Expert,Homo sapiens,2759,CHEMBL615981,51,,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,F,1,D,9,,BAO_0000219
634,,,9606.0,Expert,Homo sapiens,3445,CHEMBL615982,51,,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,F,1,D,9,,BAO_0000019
635,,,9606.0,Expert,Homo sapiens,5272,CHEMBL615983,51,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,F,1,D,9,,BAO_0000019
636,,,9606.0,Expert,Homo sapiens,5272,CHEMBL615984,51,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,F,1,D,9,,BAO_0000019
637,,,9606.0,Expert,Homo sapiens,5272,CHEMBL615985,51,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,F,1,D,9,,BAO_0000019
638,,,,Autocuration,,17624,CHEMBL615986,51,,449.0,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,F,1,H,8,,BAO_0000219
639,,,,Autocuration,,17624,CHEMBL615987,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,F,1,H,8,,BAO_0000219
640,,,,Autocuration,,17624,CHEMBL615988,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,F,1,H,8,,BAO_0000219
641,,,,Expert,,17624,CHEMBL615989,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,F,1,H,8,,BAO_0000219
642,,,,Autocuration,,17624,CHEMBL615990,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,F,1,H,8,,BAO_0000219
643,,,,Autocuration,,17624,CHEMBL615991,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,F,1,H,8,,BAO_0000219
644,,,,Autocuration,,17624,CHEMBL615992,51,,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,F,1,H,8,,BAO_0000219
645,,,,Autocuration,,17624,CHEMBL615993,51,,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,F,1,H,8,,BAO_0000219
646,,,,Expert,,17624,CHEMBL615994,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,F,1,H,8,,BAO_0000219
647,,,,Autocuration,,17624,CHEMBL615995,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,F,1,H,8,,BAO_0000219
648,,,,Autocuration,,17624,CHEMBL615996,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,F,1,H,8,,BAO_0000219
649,,,,Autocuration,,17624,CHEMBL615997,51,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,F,1,H,8,,BAO_0000219
650,,,,Autocuration,,6563,CHEMBL615998,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,F,1,H,8,,BAO_0000019
651,,,,Autocuration,,6563,CHEMBL615999,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,F,1,H,8,,BAO_0000019
652,,,,Autocuration,,6563,CHEMBL616000,51,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,F,1,H,8,,BAO_0000019
653,,,,Autocuration,,17296,CHEMBL616001,51,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,F,1,H,8,,BAO_0000219
654,,,9606.0,Expert,Homo sapiens,6876,CHEMBL616002,51,,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,F,1,D,9,,BAO_0000019
655,,,,Expert,,6876,CHEMBL616003,51,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,F,1,H,8,,BAO_0000019
656,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616004,51,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,F,1,D,9,,BAO_0000019
657,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616005,51,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,F,1,D,9,,BAO_0000019
658,,,,Autocuration,,5548,CHEMBL616006,51,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,F,1,H,8,,BAO_0000019
659,,,,Expert,,5548,CHEMBL616007,51,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,F,1,H,8,,BAO_0000019
660,,,,Autocuration,,5548,CHEMBL616008,51,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,F,1,H,8,,BAO_0000019
661,,,,Autocuration,,5548,CHEMBL616009,51,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,F,1,H,8,,BAO_0000019
662,,,,Expert,,5929,CHEMBL616010,51,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,F,1,H,8,,BAO_0000019
663,,,9606.0,Expert,Homo sapiens,5929,CHEMBL616011,51,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,F,1,D,9,,BAO_0000019
664,,,9606.0,Expert,Homo sapiens,5929,CHEMBL615740,51,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,F,1,D,9,,BAO_0000019
665,,,,Autocuration,,16245,CHEMBL615741,51,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,F,1,H,8,,BAO_0000019
666,,,,Expert,,5640,CHEMBL615742,51,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,F,1,H,8,,BAO_0000019
667,,,,Autocuration,,5640,CHEMBL615743,51,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,F,1,H,8,,BAO_0000019
668,,,,Autocuration,,14509,CHEMBL615744,51,,449.0,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,F,1,H,8,,BAO_0000219
669,,,,Expert,,14509,CHEMBL615745,51,,449.0,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,F,1,H,8,,BAO_0000219
670,,,,Autocuration,,15331,CHEMBL615746,51,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,B,1,H,8,,BAO_0000357
671,,,,Autocuration,,15331,CHEMBL615747,51,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,B,1,H,8,,BAO_0000357
672,,,,Autocuration,,6563,CHEMBL615748,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,F,1,H,8,,BAO_0000019
673,,,,Autocuration,,6563,CHEMBL615749,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,F,1,H,8,,BAO_0000019
674,,,,Autocuration,,6563,CHEMBL615750,51,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,F,1,H,8,,BAO_0000019
675,,,9606.0,Expert,Homo sapiens,6563,CHEMBL616259,51,,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,F,1,D,9,,BAO_0000019
676,,,,Autocuration,,6563,CHEMBL616260,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,F,1,H,8,,BAO_0000019
677,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616261,51,,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,F,1,D,9,,BAO_0000019
678,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616262,51,,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,F,1,D,9,,BAO_0000019
679,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616263,51,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,F,1,D,9,,BAO_0000019
680,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616264,51,,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,F,1,D,9,,BAO_0000019
681,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616265,51,,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,F,1,D,9,,BAO_0000019
682,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616266,51,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,F,1,D,9,,BAO_0000019
683,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616267,51,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,F,1,D,9,,BAO_0000019
684,,,9606.0,Expert,Homo sapiens,5272,CHEMBL616268,51,,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,F,1,D,9,,BAO_0000019
685,,,9606.0,Expert,Homo sapiens,16146,CHEMBL616269,51,,,,Inhibition of human 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
686,,,,Autocuration,,17624,CHEMBL884528,51,,449.0,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,B,1,H,8,,BAO_0000219
687,,,,Expert,,13706,CHEMBL616270,105,,722.0,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,B,1,D,9,,BAO_0000219
688,,,,Autocuration,,15250,CHEMBL616271,51,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
689,,,,Autocuration,,17624,CHEMBL616272,51,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000219
690,,,,Expert,,6861,CHEMBL616273,51,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,B,1,H,8,,BAO_0000357
691,,,9606.0,Expert,Homo sapiens,17200,CHEMBL616274,51,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
692,,,,Autocuration,,17624,CHEMBL616275,51,,449.0,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,B,1,H,8,,BAO_0000219
693,,,,Autocuration,,17624,CHEMBL616276,51,,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,B,1,H,8,,BAO_0000219
694,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616277,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,F,1,U,0,,BAO_0000218
695,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616278,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,F,1,U,0,,BAO_0000218
696,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616279,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,F,1,U,0,,BAO_0000218
697,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616280,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,F,1,U,0,,BAO_0000218
698,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616281,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,F,1,U,0,,BAO_0000218
699,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616282,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,F,1,U,0,,BAO_0000218
700,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616283,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,F,1,U,0,,BAO_0000218
701,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616284,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,F,1,U,0,,BAO_0000218
702,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616285,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,F,1,U,0,,BAO_0000218
703,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616286,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,F,1,U,0,,BAO_0000218
704,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616287,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,F,1,U,0,,BAO_0000218
705,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616288,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,F,1,U,0,,BAO_0000218
706,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL616289,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,F,1,U,0,,BAO_0000218
707,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL615610,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,F,1,U,0,,BAO_0000218
708,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL615611,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,F,1,U,0,,BAO_0000218
709,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL615612,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,F,1,U,0,,BAO_0000218
710,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL615613,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,F,1,U,0,,BAO_0000218
711,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL615614,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,F,1,U,0,,BAO_0000218
712,,,10116.0,Autocuration,Rattus norvegicus,12058,CHEMBL615615,22226,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,F,1,U,0,,BAO_0000218
713,,,,Autocuration,,11440,CHEMBL615616,105093,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,B,1,H,4,,BAO_0000019
714,,1898.0,,Autocuration,,6238,CHEMBL615617,11923,,,Hypothalamus,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000249
715,,,,Autocuration,,10046,CHEMBL615618,10577,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,B,1,H,8,,BAO_0000019
716,,,,Autocuration,,10046,CHEMBL615619,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,B,1,H,8,,BAO_0000019
717,,,,Expert,,10046,CHEMBL615620,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,B,1,H,8,,BAO_0000019
718,,,,Autocuration,,167,CHEMBL615621,55,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,B,1,H,8,,BAO_0000357
719,,,,Autocuration,,167,CHEMBL615622,55,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,B,1,H,8,,BAO_0000357
720,,,,Autocuration,,11520,CHEMBL615623,12166,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,F,1,H,8,,BAO_0000019
721,,,,Autocuration,,11520,CHEMBL615624,12166,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,F,1,H,8,,BAO_0000019
722,,,,Autocuration,,11520,CHEMBL615625,12166,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,F,1,H,8,,BAO_0000019
723,,,,Autocuration,,11520,CHEMBL767045,12166,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,F,1,H,8,,BAO_0000019
724,,,10141.0,Autocuration,Cavia porcellus,135,CHEMBL615626,55,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,F,1,H,8,,BAO_0000019
725,,,10141.0,Autocuration,Cavia porcellus,135,CHEMBL615627,55,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,F,1,H,8,,BAO_0000019
726,,,10141.0,Autocuration,Cavia porcellus,11311,CHEMBL615628,55,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,B,1,H,8,,BAO_0000019
727,,,10141.0,Autocuration,Cavia porcellus,10193,CHEMBL615629,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,B,1,H,8,,BAO_0000357
728,,,9606.0,Expert,Homo sapiens,12281,CHEMBL615630,55,,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,B,1,D,9,,BAO_0000357
729,,,,Autocuration,,11311,CHEMBL615631,55,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,B,1,H,8,,BAO_0000219
730,,,,Autocuration,,12576,CHEMBL615632,17087,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,F,1,H,8,,BAO_0000218
731,,,,Autocuration,,12281,CHEMBL615633,17087,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,B,1,H,8,,BAO_0000357
732,,,,Autocuration,,12576,CHEMBL615634,17087,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,F,1,H,8,,BAO_0000218
733,,,9823.0,Expert,Sus scrofa,11089,CHEMBL615635,55,,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,B,1,H,8,,BAO_0000019
734,,,,Expert,,11006,CHEMBL615636,12166,,,,In vitro inhibition of rat 5-Lipoxygenase,,B,1,H,8,,BAO_0000357
735,,,10116.0,Expert,Rattus norvegicus,11481,CHEMBL615637,12166,,,,Inhibitory activity against 5-Lipoxygenase,,B,1,D,9,,BAO_0000357
736,,,,Expert,,10864,CHEMBL615638,12166,,702.0,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,B,1,H,8,,BAO_0000219
737,,,,Autocuration,,3595,CHEMBL615639,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,B,1,H,8,,BAO_0000219
738,,,,Autocuration,,11311,CHEMBL615640,12166,,702.0,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,B,1,H,8,,BAO_0000219
739,,,,Autocuration,,11311,CHEMBL615796,12166,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,B,1,H,8,,BAO_0000019
740,,,,Autocuration,,11311,CHEMBL615845,12166,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,B,1,H,8,,BAO_0000219
741,,,,Autocuration,,11006,CHEMBL615846,12166,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,B,1,H,8,,BAO_0000357
742,,,,Autocuration,,3595,CHEMBL615847,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,B,1,H,8,,BAO_0000219
743,,,,Autocuration,,11311,CHEMBL615848,12166,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,B,1,H,8,,BAO_0000357
744,,,10116.0,Autocuration,Rattus norvegicus,11481,CHEMBL615849,22226,,,,Ratio of IC50 against 5-LO and COX,,B,1,U,0,,BAO_0000019
745,,,,Autocuration,,11006,CHEMBL615850,12166,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,B,1,H,8,,BAO_0000357
746,,,,Autocuration,,11006,CHEMBL615851,12166,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,B,1,H,8,,BAO_0000357
747,,,,Autocuration,,11311,CHEMBL615852,12166,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,B,1,H,8,,BAO_0000219
748,,,,Autocuration,,11006,CHEMBL615853,12166,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,F,1,H,8,,BAO_0000019
749,,2367.0,,Autocuration,,4288,CHEMBL884527,120,,,Prostate gland,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,B,1,H,8,,BAO_0000357
750,,,8932.0,Autocuration,Columba livia,7587,CHEMBL872871,22226,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,B,1,U,0,,BAO_0000019
751,,,8932.0,Autocuration,Columba livia,7587,CHEMBL615854,22226,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,B,1,U,0,,BAO_0000019
752,,,8932.0,Autocuration,Columba livia,7587,CHEMBL767046,22226,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,B,1,U,0,,BAO_0000019
753,,,,Autocuration,,11249,CHEMBL615855,10732,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,B,1,H,8,,BAO_0000357
754,,,10116.0,Expert,Rattus norvegicus,8003,CHEMBL615856,12198,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,F,1,D,9,,BAO_0000019
755,,,10116.0,Expert,Rattus norvegicus,8003,CHEMBL615857,12198,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,F,1,D,9,,BAO_0000019
756,,,10116.0,Expert,Rattus norvegicus,8003,CHEMBL615858,12198,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,F,1,D,9,,BAO_0000019
757,,10000000.0,,Expert,,12416,CHEMBL615859,10576,,,Hippocampus,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,B,1,H,8,,BAO_0000221
758,,,,Autocuration,,16293,CHEMBL615860,51,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,B,1,H,8,,BAO_0000357
759,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL615861,22226,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,B,1,U,0,,BAO_0000019
760,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL615862,22226,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,B,1,U,0,,BAO_0000019
761,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL615863,22226,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,B,1,U,0,,BAO_0000019
762,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL615864,22226,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,B,1,U,0,,BAO_0000019
763,,10000000.0,,Autocuration,,10085,CHEMBL615865,104744,,,Hippocampus,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,B,1,H,4,,BAO_0000221
764,,10000000.0,,Autocuration,,10085,CHEMBL615866,104744,,,Hippocampus,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,B,1,H,4,,BAO_0000221
765,,10000000.0,,Autocuration,,10085,CHEMBL615867,104744,,,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,B,1,H,4,,BAO_0000221
766,Membranes,,,Autocuration,,9841,CHEMBL615868,104744,,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,B,1,H,4,,BAO_0000249
767,,,10116.0,Autocuration,Rattus norvegicus,8822,CHEMBL615869,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,B,1,D,5,,BAO_0000249
768,,,10116.0,Autocuration,Rattus norvegicus,9806,CHEMBL615870,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,B,1,D,5,,BAO_0000019
769,,,10116.0,Autocuration,Rattus norvegicus,9806,CHEMBL615871,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,B,1,D,5,,BAO_0000019
770,,,,Autocuration,,8868,CHEMBL615872,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,B,1,H,4,,BAO_0000224
771,,10000000.0,,Autocuration,,9036,CHEMBL833492,104744,,,Hippocampus,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,B,1,H,4,,BAO_0000221
772,,10000000.0,,Autocuration,,11374,CHEMBL615873,104744,,,Hippocampus,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,B,1,H,4,,BAO_0000221
773,,,,Autocuration,,10881,CHEMBL615479,104744,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,B,1,H,4,,BAO_0000224
774,,,,Autocuration,,8822,CHEMBL615480,104744,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,B,1,H,4,,BAO_0000019
775,,,10116.0,Autocuration,Rattus norvegicus,9806,CHEMBL615481,104744,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,B,1,D,5,,BAO_0000249
776,,,,Autocuration,,15463,CHEMBL872869,104744,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,B,1,H,4,,BAO_0000019
777,,,,Autocuration,,15463,CHEMBL615482,104744,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,B,1,H,4,,BAO_0000019
778,,955.0,,Autocuration,,14542,CHEMBL615483,104744,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,B,1,H,4,,BAO_0000221
779,,955.0,,Autocuration,,14542,CHEMBL615484,104744,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,B,1,H,4,,BAO_0000221
780,,,,Autocuration,,8569,CHEMBL615485,104744,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,B,1,H,4,,BAO_0000019
781,,,10116.0,Autocuration,Rattus norvegicus,10062,CHEMBL615486,104744,,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,B,1,D,5,,BAO_0000224
782,,,,Autocuration,,4771,CHEMBL615487,104744,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,B,1,H,4,,BAO_0000224
783,,,,Autocuration,,10062,CHEMBL615488,104744,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,B,1,H,4,,BAO_0000224
784,,,,Autocuration,,10062,CHEMBL615489,104744,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,B,1,H,4,,BAO_0000224
785,,,,Autocuration,,10062,CHEMBL615389,104744,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,B,1,H,4,,BAO_0000224
786,,,,Autocuration,,15463,CHEMBL615390,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,B,1,H,4,,BAO_0000019
787,,,,Autocuration,,15463,CHEMBL615391,104744,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,B,1,H,4,,BAO_0000019
788,,,,Autocuration,,9098,CHEMBL615392,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,B,1,H,4,,BAO_0000224
789,,,10116.0,Autocuration,Rattus norvegicus,3070,CHEMBL615393,22226,,,,Affinity for 5-hydroxytryptamine 1 receptor,,B,1,U,0,,BAO_0000019
790,,955.0,,Autocuration,,14542,CHEMBL615394,104744,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,B,1,H,4,,BAO_0000221
791,,955.0,,Autocuration,,14542,CHEMBL615395,104744,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,B,1,H,4,,BAO_0000221
792,,,,Autocuration,,6398,CHEMBL615396,104744,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,B,1,H,4,,BAO_0000224
793,,955.0,,Autocuration,,1344,CHEMBL615397,104744,,,Brain,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,B,1,H,4,,BAO_0000221
794,,,,Autocuration,,11963,CHEMBL615398,104744,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,B,1,H,4,,BAO_0000019
795,,,10116.0,Autocuration,Rattus norvegicus,8908,CHEMBL615399,22226,,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,B,1,U,0,,BAO_0000019
796,,,,Autocuration,,9098,CHEMBL615400,104744,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,B,1,H,4,,BAO_0000019
797,,,10116.0,Autocuration,Rattus norvegicus,8841,CHEMBL615401,104744,,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,B,1,D,5,,BAO_0000019
798,,,10116.0,Autocuration,Rattus norvegicus,8814,CHEMBL615402,22226,,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,B,1,U,0,,BAO_0000019
799,,,,Autocuration,,11752,CHEMBL615403,104744,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,B,1,H,4,,BAO_0000019
800,,955.0,,Autocuration,,11642,CHEMBL615404,104744,,,Brain,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,B,1,H,4,,BAO_0000221
801,,,,Autocuration,,11642,CHEMBL615781,104744,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,B,1,H,4,,BAO_0000019
802,,955.0,,Autocuration,,9231,CHEMBL615782,104744,,,Brain,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,B,1,H,4,,BAO_0000220
803,,955.0,,Autocuration,,11351,CHEMBL615783,104744,,,Brain,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,B,1,H,4,,BAO_0000221
804,,,,Autocuration,,4639,CHEMBL873481,22226,,,,Compound was tested for binding affinity against 5-HT1 receptor,,B,1,U,0,,BAO_0000019
805,,,,Autocuration,,1205,CHEMBL615784,22226,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,B,1,U,0,,BAO_0000019
806,,,,Expert,,10025,CHEMBL615785,10576,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,B,1,H,8,,BAO_0000357
807,,,,Autocuration,,13241,CHEMBL615786,10576,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,F,1,H,8,,BAO_0000249
808,,,,Autocuration,,16245,CHEMBL615787,10576,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,F,1,H,8,,BAO_0000218
809,,,,Autocuration,,16245,CHEMBL615788,10576,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,F,1,H,8,,BAO_0000218
810,,,,Autocuration,,12438,CHEMBL767044,10576,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000019
811,,,,Autocuration,,16245,CHEMBL615789,10576,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,F,1,H,8,,BAO_0000218
812,,,,Autocuration,,16245,CHEMBL615790,10576,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,F,1,H,8,,BAO_0000218
813,,,,Autocuration,,15740,CHEMBL615813,10576,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,F,1,H,8,,BAO_0000019
814,,,,Autocuration,,15535,CHEMBL615814,10576,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,F,1,H,8,,BAO_0000219
815,,,,Expert,,15535,CHEMBL615815,51,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,F,1,H,8,,BAO_0000219
816,,,,Autocuration,,15535,CHEMBL615816,10576,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,F,1,H,8,,BAO_0000219
817,,,,Expert,,9888,CHEMBL615817,10576,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,B,1,H,8,,BAO_0000249
818,,10000000.0,,Autocuration,,10085,CHEMBL615818,10576,,,Hippocampus,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000221
819,,10000000.0,,Autocuration,,10085,CHEMBL615819,10576,,,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000221
820,Membranes,,,Expert,,17331,CHEMBL615820,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,B,1,H,8,,BAO_0000249
821,,10000000.0,10116.0,Expert,Rattus norvegicus,10845,CHEMBL615821,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,B,1,D,9,,BAO_0000221
822,,10000000.0,10116.0,Expert,Rattus norvegicus,10845,CHEMBL615822,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,B,1,D,9,,BAO_0000221
823,,10000000.0,,Expert,,10845,CHEMBL615823,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
824,,10000000.0,10116.0,Expert,Rattus norvegicus,10845,CHEMBL615824,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,B,1,D,9,,BAO_0000221
825,,10000000.0,10116.0,Expert,Rattus norvegicus,10845,CHEMBL615825,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,B,1,D,9,,BAO_0000221
826,,,,Expert,,13730,CHEMBL615826,10576,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
827,,,,Expert,,13508,CHEMBL615827,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000249
828,,10000000.0,,Expert,,13508,CHEMBL615828,10576,,,Hippocampus,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000249
829,,10000000.0,,Expert,,12073,CHEMBL615829,10576,,,Hippocampus,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
830,,10000000.0,,Autocuration,,4671,CHEMBL615830,10576,,,Hippocampus,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
831,,10000000.0,,Expert,,13631,CHEMBL615831,10576,,,Hippocampus,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,B,1,H,8,,BAO_0000221
832,,,,Autocuration,,12438,CHEMBL615832,10576,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
833,,,,Autocuration,,10483,CHEMBL615833,10576,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,B,1,H,8,,BAO_0000019
834,,10000000.0,,Autocuration,,10483,CHEMBL615834,10576,,,Hippocampus,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,B,1,H,8,,BAO_0000221
835,,,,Intermediate,,12352,CHEMBL615835,10576,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,B,1,H,8,,BAO_0000249
836,,10000000.0,,Autocuration,,14732,CHEMBL615836,10576,,,Hippocampus,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,B,1,H,8,,BAO_0000249
837,,,10116.0,Expert,Rattus norvegicus,11049,CHEMBL615837,10576,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,B,1,D,9,,BAO_0000019
838,,,10116.0,Expert,Rattus norvegicus,11049,CHEMBL615838,10576,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,B,1,D,9,,BAO_0000019
839,,,,Expert,,13657,CHEMBL615839,10576,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,B,1,H,8,,BAO_0000249
840,,,,Autocuration,,11473,CHEMBL884525,10576,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000019
841,,,,Autocuration,,2014,CHEMBL615840,10576,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,B,1,H,8,,BAO_0000249
842,,10000000.0,,Expert,,3086,CHEMBL615405,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
843,,,,Expert,,15854,CHEMBL615406,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,B,1,H,8,,BAO_0000019
844,,10000000.0,,Expert,,10922,CHEMBL615900,10576,,,Hippocampus,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,B,1,H,8,,BAO_0000221
845,,10000000.0,,Expert,,13346,CHEMBL615901,10576,,,Hippocampus,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,B,1,H,8,,BAO_0000221
846,,,,Expert,,15311,CHEMBL615902,10576,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,B,1,H,8,,BAO_0000357
847,,10000000.0,,Autocuration,,10922,CHEMBL615903,10576,,,Hippocampus,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,B,1,H,8,,BAO_0000221
848,,,,Autocuration,,10025,CHEMBL615904,10576,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,B,1,H,8,,BAO_0000357
849,,,,Expert,,10025,CHEMBL615905,10576,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,B,1,H,8,,BAO_0000357
850,,,,Autocuration,,9742,CHEMBL615906,10576,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,B,1,H,8,,BAO_0000019
851,,,,Autocuration,,9742,CHEMBL615907,10576,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,F,1,H,8,,BAO_0000019
852,,,,Expert,,12304,CHEMBL615908,10576,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,B,1,H,8,,BAO_0000019
853,,10000000.0,,Autocuration,,15789,CHEMBL615909,10576,,,Hippocampus,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,B,1,H,8,,BAO_0000221
854,,,,Autocuration,,9912,CHEMBL615910,10576,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,B,1,H,8,,BAO_0000019
855,,,,Autocuration,,9912,CHEMBL615911,10576,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,B,1,H,8,,BAO_0000019
856,,,,Autocuration,,9912,CHEMBL615912,10576,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,B,1,H,8,,BAO_0000019
857,,,,Expert,,16693,CHEMBL615913,10576,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000019
858,,,,Expert,,13276,CHEMBL615914,10576,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000357
859,,10000000.0,,Autocuration,,12678,CHEMBL615915,10576,,,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,B,1,H,8,,BAO_0000221
860,,,,Autocuration,,11825,CHEMBL615916,10576,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,B,1,H,8,,BAO_0000357
861,,,,Expert,,12443,CHEMBL615917,10576,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,B,1,H,8,,BAO_0000357
862,,,,Expert,,13830,CHEMBL615918,10576,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
863,,10000000.0,,Expert,,14286,CHEMBL615919,10576,,,Hippocampus,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,B,1,H,8,,BAO_0000249
864,,10000000.0,10116.0,Expert,Rattus norvegicus,14356,CHEMBL615920,10576,,,Hippocampus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,B,1,D,9,,BAO_0000221
865,,,,Autocuration,,15306,CHEMBL615921,10576,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
866,,,,Expert,,15306,CHEMBL615922,10576,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,B,1,H,8,,BAO_0000357
867,,,10116.0,Expert,Rattus norvegicus,16616,CHEMBL881290,10576,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,F,1,D,9,,BAO_0000249
868,,10000000.0,,Autocuration,,3651,CHEMBL615923,10576,,,Hippocampus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,B,1,H,8,,BAO_0000221
869,,10000000.0,,Autocuration,,14331,CHEMBL615924,10576,,,Hippocampus,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,F,1,H,8,,BAO_0000221
870,,10000000.0,,Autocuration,,14331,CHEMBL615925,10576,,,Hippocampus,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,F,1,H,8,,BAO_0000221
871,,,10116.0,Expert,Rattus norvegicus,14178,CHEMBL615926,10576,,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
872,,,10116.0,Expert,Rattus norvegicus,10639,CHEMBL615927,10576,,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000019
873,,10000000.0,,Autocuration,,12306,CHEMBL615928,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,B,1,H,8,,BAO_0000221
874,,,10116.0,Expert,Rattus norvegicus,1348,CHEMBL615929,10576,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,B,1,D,9,,BAO_0000357
875,,10000000.0,,Autocuration,,13605,CHEMBL615930,10576,,,Hippocampus,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
876,,,,Autocuration,,17624,CHEMBL615931,51,,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,B,1,H,8,,BAO_0000219
877,,,,Autocuration,,17624,CHEMBL615932,51,,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000219
878,,,,Autocuration,,17624,CHEMBL615933,51,,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000219
879,,,,Autocuration,,15267,CHEMBL615934,51,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
880,,,,Autocuration,,16532,CHEMBL615935,51,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,B,1,H,8,,BAO_0000357
881,,,,Autocuration,,6563,CHEMBL615936,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,F,1,H,8,,BAO_0000019
882,,,,Autocuration,,4751,CHEMBL615937,51,,449.0,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,B,1,H,8,,BAO_0000219
883,,,,Autocuration,,15463,CHEMBL615938,51,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
884,,,,Autocuration,,3805,CHEMBL615797,51,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,B,1,H,8,,BAO_0000357
885,,,,Autocuration,,5640,CHEMBL615798,51,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
886,,,,Autocuration,,6563,CHEMBL872870,51,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,B,1,H,8,,BAO_0000357
887,,,,Autocuration,,5548,CHEMBL615799,51,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,B,1,H,8,,BAO_0000357
888,,,,Autocuration,,6347,CHEMBL615800,51,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
889,,,,Autocuration,,17296,CHEMBL615801,51,,722.0,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,F,1,H,8,,BAO_0000219
890,,,,Autocuration,,13047,CHEMBL615802,51,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,B,1,H,8,,BAO_0000019
891,,,,Autocuration,,15740,CHEMBL615803,51,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,B,1,H,8,,BAO_0000357
892,,,,Expert,,5640,CHEMBL835002,51,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,F,1,H,8,,BAO_0000019
893,,,,Autocuration,,5640,CHEMBL615804,51,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,F,1,H,8,,BAO_0000019
894,,,,Expert,,17211,CHEMBL615805,51,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000219
895,,,,Autocuration,,4751,CHEMBL615806,51,,449.0,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000219
896,,,9606.0,Expert,Homo sapiens,6491,CHEMBL615807,51,,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,B,1,D,9,,BAO_0000357
897,,,,Autocuration,,4707,CHEMBL615808,51,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,B,1,H,8,,BAO_0000357
898,,,9606.0,Expert,Homo sapiens,13910,CHEMBL615809,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
899,,,,Autocuration,,16190,CHEMBL615810,51,,308.0,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,B,1,H,8,,BAO_0000219
900,,,,Autocuration,,16633,CHEMBL615811,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
901,,,,Autocuration,,11898,CHEMBL615812,51,,449.0,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,B,1,H,8,,BAO_0000219
902,,,,Autocuration,,11898,CHEMBL615751,51,,449.0,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,B,1,H,8,,BAO_0000219
903,,,,Autocuration,,14331,CHEMBL615752,51,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
904,,,,Expert,,17624,CHEMBL615753,51,,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,B,1,H,8,,BAO_0000219
905,,,,Autocuration,,17624,CHEMBL615754,51,,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,B,1,H,8,,BAO_0000219
906,,,,Autocuration,,3307,CHEMBL615755,51,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
907,,,9606.0,Expert,Homo sapiens,6563,CHEMBL615756,51,,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
908,,,,Autocuration,,14165,CHEMBL615757,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000019
909,,,,Autocuration,,5732,CHEMBL615758,51,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,B,1,H,8,,BAO_0000357
910,,,,Expert,,13366,CHEMBL615759,51,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,B,1,H,8,,BAO_0000357
911,,,,Autocuration,,17626,CHEMBL615760,51,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
912,,,,Expert,,6588,CHEMBL615761,51,,308.0,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,B,1,H,8,,BAO_0000219
913,,,,Autocuration,,16209,CHEMBL872104,51,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,B,1,H,8,,BAO_0000357
914,,,,Autocuration,,15463,CHEMBL615762,51,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
915,,,,Autocuration,,15463,CHEMBL615763,51,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
916,,,,Autocuration,,14770,CHEMBL615764,51,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000357
917,,,,Autocuration,,16245,CHEMBL615765,51,,1167.0,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,B,1,H,8,,BAO_0000219
918,,,,Autocuration,,16245,CHEMBL615766,51,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,B,1,H,8,,BAO_0000019
919,,,,Autocuration,,5548,CHEMBL615767,51,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
920,,,,Expert,,5548,CHEMBL615768,51,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
921,,,,Autocuration,,5548,CHEMBL615769,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
922,,,,Expert,,6876,CHEMBL615770,51,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,B,1,H,8,,BAO_0000357
923,,,,Autocuration,,2598,CHEMBL615771,51,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
924,,,,Expert,,17785,CHEMBL615772,51,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,B,1,H,8,,BAO_0000357
925,,,,Autocuration,,6013,CHEMBL615773,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
926,,,,Expert,,5929,CHEMBL615774,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
927,,,,Autocuration,,16633,CHEMBL615775,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
928,,,,Autocuration,,1558,CHEMBL615776,51,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,B,1,H,8,,BAO_0000357
929,,,,Expert,,16026,CHEMBL615777,51,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
930,,,,Autocuration,,12469,CHEMBL615778,51,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,B,1,H,8,,BAO_0000219
931,,,9606.0,Expert,Homo sapiens,15874,CHEMBL615779,51,,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,B,1,D,9,,BAO_0000357
932,,,,Autocuration,,15874,CHEMBL615780,51,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000357
933,,,,Autocuration,,3935,CHEMBL616298,51,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
934,,,,Autocuration,,15818,CHEMBL616299,51,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
935,,,,Autocuration,,13706,CHEMBL616300,51,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,B,1,H,8,,BAO_0000219
936,,,,Expert,,13729,CHEMBL616301,51,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,F,1,H,8,,BAO_0000219
937,,,,Autocuration,,15413,CHEMBL616302,51,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000019
938,,,,Autocuration,,15413,CHEMBL616117,51,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,B,1,H,8,,BAO_0000019
939,,,,Autocuration,,15413,CHEMBL616118,51,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,B,1,H,8,,BAO_0000019
940,,,,Autocuration,,15413,CHEMBL616119,51,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,B,1,H,8,,BAO_0000019
941,,,9606.0,Expert,Homo sapiens,3445,CHEMBL616120,51,,308.0,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,B,1,D,9,,BAO_0000219
942,,,,Autocuration,,15740,CHEMBL616121,51,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
943,,,,Autocuration,,15740,CHEMBL616122,51,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,B,1,H,8,,BAO_0000357
944,,,,Autocuration,,17626,CHEMBL616123,51,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
945,,,9606.0,Expert,Homo sapiens,4234,CHEMBL616124,51,,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
946,,,,Expert,,5640,CHEMBL616125,51,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,B,1,H,8,,BAO_0000357
947,,,10116.0,Expert,Rattus norvegicus,5272,CHEMBL616126,51,,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000357
948,,,,Autocuration,,4622,CHEMBL616127,51,,449.0,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000219
949,,,,Expert,,17085,CHEMBL616128,51,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000019
950,,,,Autocuration,,3025,CHEMBL616129,51,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,B,1,H,8,,BAO_0000357
951,,,,Expert,,15315,CHEMBL616130,51,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
952,,,,Autocuration,,15267,CHEMBL616131,51,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,B,1,H,8,,BAO_0000357
953,,,,Autocuration,,17158,CHEMBL616132,51,,308.0,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,B,1,H,8,,BAO_0000219
954,,,9606.0,Expert,Homo sapiens,14214,CHEMBL616133,51,,308.0,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,B,1,D,9,,BAO_0000219
955,,,,Autocuration,,17133,CHEMBL616134,51,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
956,,,,Autocuration,,16532,CHEMBL616135,51,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,B,1,H,8,,BAO_0000357
957,,,9606.0,Expert,Homo sapiens,2391,CHEMBL616136,51,,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,B,1,D,9,,BAO_0000357
958,,,,Autocuration,,14447,CHEMBL616137,51,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,B,1,H,8,,BAO_0000019
959,,,,Autocuration,,14447,CHEMBL872105,51,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,B,1,H,8,,BAO_0000019
960,,,,Autocuration,,15086,CHEMBL616138,51,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,B,1,H,8,,BAO_0000357
961,,,9606.0,Expert,Homo sapiens,13051,CHEMBL616139,51,,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
962,,,,Autocuration,,16026,CHEMBL616140,51,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,F,1,H,8,,BAO_0000019
963,,,,Expert,,17085,CHEMBL616141,51,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,B,1,H,8,,BAO_0000019
964,,,,Autocuration,,17133,CHEMBL616142,51,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
965,,,,Autocuration,,17133,CHEMBL616143,51,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,B,1,H,8,,BAO_0000357
966,,,,Autocuration,,17211,CHEMBL616144,51,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,B,1,H,8,,BAO_0000219
967,,,,Autocuration,,17211,CHEMBL616145,51,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,B,1,H,8,,BAO_0000219
968,,,,Autocuration,,17211,CHEMBL616012,51,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,B,1,H,8,,BAO_0000219
969,,,,Autocuration,,17211,CHEMBL616013,51,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,B,1,H,8,,BAO_0000219
970,,,,Autocuration,,16394,CHEMBL616014,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,F,1,H,8,,BAO_0000019
971,,,,Autocuration,,16394,CHEMBL616015,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,F,1,H,8,,BAO_0000019
972,,,,Autocuration,,16394,CHEMBL616016,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,F,1,H,8,,BAO_0000019
973,,,,Autocuration,,16394,CHEMBL616017,51,,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,F,1,H,8,,BAO_0000218
974,,,,Autocuration,,16394,CHEMBL616018,51,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,B,1,H,8,,BAO_0000019
975,,,,Autocuration,,15740,CHEMBL616019,51,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,F,1,H,8,,BAO_0000019
976,,,,Autocuration,,15740,CHEMBL616020,51,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,F,1,H,8,,BAO_0000019
977,,,,Autocuration,,15740,CHEMBL858018,51,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
978,,,,Autocuration,,17296,CHEMBL616021,51,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,F,1,H,8,,BAO_0000219
979,,,,Expert,,5640,CHEMBL616022,51,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,F,1,H,8,,BAO_0000019
980,,,,Autocuration,,5640,CHEMBL616023,51,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,F,1,H,8,,BAO_0000019
981,,,,Autocuration,,5640,CHEMBL616024,51,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,F,1,H,8,,BAO_0000019
982,,,,Autocuration,,5640,CHEMBL616025,51,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,F,1,H,8,,BAO_0000019
983,,,,Autocuration,,2759,CHEMBL616026,51,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,F,1,H,8,,BAO_0000219
984,,,,Autocuration,,16394,CHEMBL616027,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,F,1,H,8,,BAO_0000019
985,,,9606.0,Expert,Homo sapiens,16394,CHEMBL616028,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,F,1,D,9,,BAO_0000019
986,,,9606.0,Expert,Homo sapiens,3445,CHEMBL616029,51,,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,F,1,D,9,,BAO_0000019
987,,,,Expert,,4316,CHEMBL616030,51,,449.0,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000219
988,,,,Expert,,4316,CHEMBL616031,51,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,B,1,H,8,,BAO_0000019
989,,,9606.0,Expert,Homo sapiens,15180,CHEMBL616032,51,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,F,1,D,9,,BAO_0000019
990,,,9606.0,Expert,Homo sapiens,15180,CHEMBL616033,51,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,F,1,D,9,,BAO_0000019
991,,,,Autocuration,,15042,CHEMBL616034,51,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,F,1,H,8,,BAO_0000019
992,,,,Autocuration,,15042,CHEMBL616035,51,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,F,1,H,8,,BAO_0000019
993,,,,Autocuration,,15042,CHEMBL616036,51,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000019
994,,,,Autocuration,,15042,CHEMBL616037,51,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,F,1,H,8,,BAO_0000019
995,,,,Autocuration,,15042,CHEMBL616038,51,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,F,1,H,8,,BAO_0000019
996,,,,Autocuration,,15042,CHEMBL616039,51,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,F,1,H,8,,BAO_0000019
997,,,,Autocuration,,15042,CHEMBL616040,51,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000019
998,,,9606.0,Expert,Homo sapiens,15180,CHEMBL616041,51,,308.0,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,F,1,D,9,,BAO_0000219
999,,,9606.0,Expert,Homo sapiens,15180,CHEMBL616042,51,,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,F,1,D,9,,BAO_0000219
1000,,,9606.0,Expert,Homo sapiens,15180,CHEMBL616043,51,,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,F,1,D,9,,BAO_0000219
1001,,,,Autocuration,,16245,CHEMBL616044,51,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,F,1,H,8,,BAO_0000019
1002,,,,Autocuration,,16026,CHEMBL616045,51,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,F,1,H,8,,BAO_0000019
1003,,,,Autocuration,,17296,CHEMBL616046,51,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,F,1,H,8,,BAO_0000219
1004,,,,Autocuration,,2759,CHEMBL616047,51,,449.0,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,F,1,H,8,,BAO_0000219
1005,,,,Autocuration,,2759,CHEMBL616048,51,,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,F,1,H,8,,BAO_0000219
1006,,,9606.0,Expert,Homo sapiens,2759,CHEMBL616049,51,,449.0,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,F,1,D,9,,BAO_0000219
1007,,,,Autocuration,,2759,CHEMBL616050,51,,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,F,1,H,8,,BAO_0000219
1008,,,,Expert,,15419,CHEMBL616051,51,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,F,1,H,8,,BAO_0000219
1009,,,,Autocuration,,15419,CHEMBL616212,51,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,F,1,H,8,,BAO_0000219
1010,,,,Autocuration,,16026,CHEMBL616213,51,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,F,1,H,8,,BAO_0000019
1011,,,,Expert,,1414,CHEMBL616214,51,,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,B,1,H,8,,BAO_0000219
1012,,,,Expert,,1414,CHEMBL616215,51,,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,B,1,H,8,,BAO_0000219
1013,,,,Autocuration,,12861,CHEMBL616216,51,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
1014,,,,Autocuration,,12861,CHEMBL616217,51,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,B,1,H,8,,BAO_0000019
1015,,,,Autocuration,,5104,CHEMBL616218,51,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1016,,,,Autocuration,,5105,CHEMBL616219,51,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1017,,,,Autocuration,,16312,CHEMBL616220,51,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1018,,,9606.0,Expert,Homo sapiens,15180,CHEMBL833493,51,,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1019,,,,Autocuration,,5033,CHEMBL616221,51,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1020,,,9606.0,Expert,Homo sapiens,16909,CHEMBL616222,51,,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,B,1,D,9,,BAO_0000219
1021,,,,Autocuration,,2590,CHEMBL616223,51,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000019
1022,,,,Autocuration,,2590,CHEMBL616224,51,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,F,1,H,8,,BAO_0000019
1023,,,,Expert,,16394,CHEMBL616225,51,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,B,1,H,8,,BAO_0000019
1024,,,9606.0,Expert,Homo sapiens,4540,CHEMBL616226,51,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,B,1,D,9,,BAO_0000219
1025,,,,Autocuration,,17296,CHEMBL616227,51,,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,B,1,H,8,,BAO_0000219
1026,,,,Autocuration,,17296,CHEMBL616228,51,,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000219
1027,,,,Autocuration,,15779,CHEMBL616229,51,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,B,1,H,8,,BAO_0000219
1028,,,,Autocuration,,15779,CHEMBL616230,51,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,B,1,H,8,,BAO_0000219
1029,,,,Autocuration,,15779,CHEMBL616231,51,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,B,1,H,8,,BAO_0000219
1030,,,,Autocuration,,6166,CHEMBL616232,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
1031,,,,Autocuration,,15779,CHEMBL616233,51,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,B,1,H,8,,BAO_0000219
1032,,,,Autocuration,,4199,CHEMBL857973,51,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,B,1,H,8,,BAO_0000219
1033,,,,Autocuration,,15316,CHEMBL616234,51,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,B,1,H,8,,BAO_0000219
1034,,,,Autocuration,,14875,CHEMBL616235,51,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1035,,,,Expert,,14727,CHEMBL616236,51,,308.0,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,B,1,H,8,,BAO_0000219
1036,,,,Expert,,14727,CHEMBL616237,51,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,B,1,H,8,,BAO_0000019
1037,,,,Autocuration,,15146,CHEMBL616238,51,,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000219
1038,,,,Autocuration,,5213,CHEMBL616239,51,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,B,1,H,8,,BAO_0000219
1039,,,,Autocuration,,16429,CHEMBL616240,51,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,B,1,H,8,,BAO_0000219
1040,,,9606.0,Expert,Homo sapiens,15042,CHEMBL616241,51,,308.0,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,B,1,D,9,,BAO_0000219
1041,,,,Autocuration,,14818,CHEMBL616242,51,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,B,1,H,8,,BAO_0000219
1042,,,,Autocuration,,4829,CHEMBL616243,51,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,B,1,H,8,,BAO_0000219
1043,,,,Expert,,17200,CHEMBL616244,51,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1044,,,9606.0,Autocuration,Homo sapiens,13051,CHEMBL616245,51,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1045,,,,Autocuration,,5486,CHEMBL616246,106,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,B,1,H,8,,BAO_0000357
1046,,,,Autocuration,,5254,CHEMBL616247,105,,,,Binding affinity against 5-HT1D receptor,,B,1,H,8,,BAO_0000357
1047,,,,Autocuration,,5254,CHEMBL616248,105,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1048,,,,Autocuration,,15331,CHEMBL616249,107,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,B,1,H,8,,BAO_0000357
1049,,,9606.0,Autocuration,Homo sapiens,13506,CHEMBL616250,10576,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,B,1,H,8,,BAO_0000357
1050,,,,Autocuration,,15267,CHEMBL616251,51,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1051,,,,Autocuration,,16616,CHEMBL616252,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,F,1,H,8,,BAO_0000218
1052,,,,Autocuration,,16616,CHEMBL616253,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,F,1,H,8,,BAO_0000218
1053,,,,Autocuration,,16616,CHEMBL616254,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,F,1,H,8,,BAO_0000218
1054,,,10090.0,Expert,Mus musculus,16616,CHEMBL616255,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,F,1,D,9,,BAO_0000218
1055,,,10090.0,Expert,Mus musculus,16616,CHEMBL832872,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,F,1,D,9,,BAO_0000218
1056,,,10090.0,Expert,Mus musculus,16616,CHEMBL616256,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,F,1,D,9,,BAO_0000218
1057,,,10090.0,Expert,Mus musculus,16616,CHEMBL616257,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,F,1,D,9,,BAO_0000218
1058,,,10090.0,Expert,Mus musculus,16616,CHEMBL616258,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,F,1,D,9,,BAO_0000218
1059,,,10090.0,Expert,Mus musculus,16616,CHEMBL616384,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,F,1,D,9,,BAO_0000218
1060,,10000000.0,,Autocuration,,10297,CHEMBL616385,11863,,,Hippocampus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,B,1,H,8,,BAO_0000221
1061,,,,Expert,,13704,CHEMBL616386,11863,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,B,1,H,8,,BAO_0000357
1062,,10000000.0,10090.0,Expert,Mus musculus,10297,CHEMBL616387,11863,,,Hippocampus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,B,1,D,9,,BAO_0000221
1063,,10000000.0,,Autocuration,,10297,CHEMBL616388,11863,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,B,1,H,8,,BAO_0000221
1064,,10000000.0,10090.0,Expert,Mus musculus,10297,CHEMBL616389,11863,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,B,1,D,9,,BAO_0000221
1065,,10000000.0,,Autocuration,,10297,CHEMBL616390,11863,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,B,1,H,8,,BAO_0000221
1066,,,,Autocuration,,217,CHEMBL616391,11863,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,B,1,H,8,,BAO_0000357
1067,,10000000.0,10090.0,Expert,Mus musculus,10297,CHEMBL616392,11863,,,Hippocampus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,B,1,D,9,,BAO_0000221
1068,,,9823.0,Autocuration,Sus scrofa,4921,CHEMBL616393,51,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1069,,,9823.0,Autocuration,Sus scrofa,4921,CHEMBL616394,51,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,B,1,H,8,,BAO_0000357
1070,,,9823.0,Autocuration,Sus scrofa,4996,CHEMBL616395,51,,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,B,1,H,8,,BAO_0000019
1071,,,9823.0,Autocuration,Sus scrofa,12918,CHEMBL616396,51,,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,B,1,H,8,,BAO_0000357
1072,,,9823.0,Autocuration,Sus scrofa,5333,CHEMBL872907,51,,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,B,1,H,8,,BAO_0000019
1073,,,9823.0,Autocuration,Sus scrofa,4437,CHEMBL616397,51,,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,B,1,H,8,,BAO_0000019
1074,,,9823.0,Autocuration,Sus scrofa,1742,CHEMBL616398,51,,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,B,1,H,8,,BAO_0000019
1075,,,9823.0,Expert,Sus scrofa,16688,CHEMBL616399,51,,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1076,,,9823.0,Autocuration,Sus scrofa,12861,CHEMBL857065,51,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
1077,,,9823.0,Expert,Sus scrofa,12861,CHEMBL616400,51,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,B,1,H,8,,BAO_0000019
1078,,,9823.0,Autocuration,Sus scrofa,12861,CHEMBL616401,51,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,B,1,H,8,,BAO_0000019
1079,,,,Expert,,12490,CHEMBL616402,10624,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,B,1,H,8,,BAO_0000019
1080,,,9823.0,Expert,Sus scrofa,11828,CHEMBL616403,51,,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000019
1081,,10000000.0,9823.0,Autocuration,Sus scrofa,11866,CHEMBL616404,51,,,Hippocampus,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000221
1082,,,9823.0,Autocuration,Sus scrofa,12827,CHEMBL616405,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,B,1,H,8,,BAO_0000249
1083,,,9823.0,Autocuration,Sus scrofa,12918,CHEMBL616406,51,,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,B,1,H,8,,BAO_0000019
1084,,,9823.0,Expert,Sus scrofa,12919,CHEMBL616407,51,,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,F,1,H,8,,BAO_0000019
1085,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL616408,51,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,B,1,H,8,,BAO_0000019
1086,,,10116.0,Expert,Rattus norvegicus,15796,CHEMBL616409,10576,,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,B,1,D,9,,BAO_0000249
1087,,10000000.0,10116.0,Expert,Rattus norvegicus,3651,CHEMBL616410,10576,,,Hippocampus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,B,1,D,9,,BAO_0000221
1088,,,,Autocuration,,188,CHEMBL616411,10576,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,B,1,H,8,,BAO_0000357
1089,Membranes,,10116.0,Expert,Rattus norvegicus,16616,CHEMBL616412,10576,,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,F,1,D,9,,BAO_0000249
1090,Membranes,10000000.0,10116.0,Expert,Rattus norvegicus,16616,CHEMBL616413,10576,,,Hippocampus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,F,1,D,9,,BAO_0000249
1091,,10000000.0,,Autocuration,,12306,CHEMBL616414,10576,,,Hippocampus,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,B,1,H,8,,BAO_0000221
1092,,10000000.0,10116.0,Expert,Rattus norvegicus,17167,CHEMBL616415,10576,,,Hippocampus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,B,1,D,9,,BAO_0000221
1093,,,,Autocuration,,14776,CHEMBL616416,10576,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,B,1,H,8,,BAO_0000019
1094,,,,Expert,,12158,CHEMBL616417,10576,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000357
1095,,,,Autocuration,,13481,CHEMBL616418,10576,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,B,1,H,8,,BAO_0000357
1096,,,,Autocuration,,13427,CHEMBL616419,10576,,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,B,1,H,8,,BAO_0000219
1097,,,,Autocuration,,10210,CHEMBL616420,10576,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000357
1098,Membranes,,,Autocuration,,10205,CHEMBL616421,10576,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,B,1,H,8,,BAO_0000249
1099,Membranes,,,Autocuration,,10205,CHEMBL616422,10576,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,B,1,H,8,,BAO_0000249
1100,Membranes,,,Expert,,10205,CHEMBL616423,10576,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,B,1,H,8,,BAO_0000249
1101,,,10116.0,Expert,Rattus norvegicus,12280,CHEMBL616424,10576,,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,B,1,D,9,,BAO_0000357
1102,,,,Expert,,17386,CHEMBL616425,10576,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1103,,,,Expert,,13654,CHEMBL616426,10576,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,B,1,H,8,,BAO_0000357
1104,,10000000.0,,Autocuration,,14423,CHEMBL616427,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,B,1,H,8,,BAO_0000221
1105,,10000000.0,,Autocuration,,15412,CHEMBL616428,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,B,1,H,8,,BAO_0000221
1106,,10000000.0,,Autocuration,,12073,CHEMBL616290,10576,,,Hippocampus,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
1107,,,10116.0,Expert,Rattus norvegicus,4101,CHEMBL616052,10576,,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1108,,,,Autocuration,,10062,CHEMBL616053,10576,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1109,,,,Autocuration,,6238,CHEMBL616054,10576,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000249
1110,,,,Autocuration,,16273,CHEMBL616055,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1111,,,,Autocuration,,11139,CHEMBL616056,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,B,1,H,8,,BAO_0000357
1112,,,,Expert,,16796,CHEMBL616057,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,B,1,H,8,,BAO_0000019
1113,,955.0,10116.0,Expert,Rattus norvegicus,9548,CHEMBL616058,10576,,,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,B,1,D,9,,BAO_0000221
1114,,955.0,,Autocuration,,10381,CHEMBL616059,10576,,,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,B,1,H,8,,BAO_0000221
1115,,,,Autocuration,,13408,CHEMBL616060,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000249
1116,,10000000.0,10116.0,Expert,Rattus norvegicus,13825,CHEMBL616061,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,B,1,D,9,,BAO_0000221
1117,,10000000.0,,Expert,,11147,CHEMBL616062,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,B,1,H,8,,BAO_0000221
1118,,,,Autocuration,,10552,CHEMBL616063,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000249
1119,,2435.0,,Autocuration,,10552,CHEMBL616064,10576,,,Striatum,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,B,1,H,8,,BAO_0000249
1120,Membranes,,10116.0,Expert,Rattus norvegicus,17136,CHEMBL616065,10576,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,B,1,D,9,,BAO_0000249
1121,Membranes,,10116.0,Expert,Rattus norvegicus,5778,CHEMBL616066,10576,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,B,1,D,9,,BAO_0000249
1122,,10000000.0,,Autocuration,,13481,CHEMBL616067,10576,,,Hippocampus,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1123,,10000000.0,,Autocuration,,13481,CHEMBL616068,10576,,,Hippocampus,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,B,1,H,8,,BAO_0000221
1124,,10000000.0,,Intermediate,,13630,CHEMBL616069,10576,,,Hippocampus,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1125,,,,Expert,,16245,CHEMBL616070,10576,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,B,1,H,8,,BAO_0000249
1126,,10000000.0,,Autocuration,,14509,CHEMBL616071,10576,,,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1127,,10000000.0,,Expert,,14509,CHEMBL616072,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000221
1128,,10000000.0,,Autocuration,,14509,CHEMBL616073,10576,,,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,B,1,H,8,,BAO_0000221
1129,,10000000.0,,Autocuration,,14509,CHEMBL616074,10576,,,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,B,1,H,8,,BAO_0000221
1130,,,,Expert,,14256,CHEMBL616075,10576,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,B,1,H,8,,BAO_0000019
1131,,,,Autocuration,,11139,CHEMBL616076,10576,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1132,,,10116.0,Expert,Rattus norvegicus,11047,CHEMBL616077,10576,,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,B,1,D,9,,BAO_0000019
1133,,,10116.0,Expert,Rattus norvegicus,11047,CHEMBL616078,10576,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,B,1,D,9,,BAO_0000019
1134,,,10116.0,Expert,Rattus norvegicus,11047,CHEMBL616079,10576,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,B,1,D,9,,BAO_0000019
1135,,,10116.0,Expert,Rattus norvegicus,2395,CHEMBL616080,10576,,485.0,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,B,1,D,9,,BAO_0000219
1136,,,,Autocuration,,9699,CHEMBL616081,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1137,,10000000.0,10116.0,Expert,Rattus norvegicus,12028,CHEMBL616082,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,B,1,D,9,,BAO_0000221
1138,,10000000.0,,Autocuration,,12028,CHEMBL616083,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,B,1,H,8,,BAO_0000221
1139,,,,Autocuration,,5815,CHEMBL616084,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,B,1,H,8,,BAO_0000019
1140,,,,Expert,,16616,CHEMBL616085,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,B,1,H,8,,BAO_0000019
1141,,,,Autocuration,,5815,CHEMBL616086,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,B,1,H,8,,BAO_0000019
1142,,10000000.0,,Autocuration,,2761,CHEMBL616087,10576,,,Hippocampus,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,B,1,H,8,,BAO_0000221
1143,,,,Expert,,13133,CHEMBL616088,10576,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,B,1,H,8,,BAO_0000357
1144,,,,Autocuration,,10444,CHEMBL616089,10576,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,B,1,H,8,,BAO_0000019
1145,,,10116.0,Expert,Rattus norvegicus,13278,CHEMBL616090,10576,,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,B,1,D,9,,BAO_0000357
1146,,,,Autocuration,,15874,CHEMBL616091,10576,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000357
1147,Membranes,2435.0,,Autocuration,,10552,CHEMBL616092,10576,,,Striatum,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,B,1,H,8,,BAO_0000249
1148,,,,Autocuration,,11130,CHEMBL616093,10576,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,B,1,H,8,,BAO_0000357
1149,,,,Autocuration,,11130,CHEMBL616094,10576,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,B,1,H,8,,BAO_0000218
1150,,955.0,,Autocuration,,14542,CHEMBL616095,10576,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,B,1,H,8,,BAO_0000221
1151,,,10116.0,Expert,Rattus norvegicus,13670,CHEMBL616096,10576,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1152,,,,Expert,,9888,CHEMBL616097,10576,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,B,1,H,8,,BAO_0000249
1153,Membranes,,10116.0,Expert,Rattus norvegicus,3678,CHEMBL616098,10576,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,B,1,D,9,,BAO_0000249
1154,,10000000.0,,Autocuration,,11332,CHEMBL616099,10576,,,Hippocampus,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1155,,10000000.0,,Autocuration,,11332,CHEMBL616100,10576,,,Hippocampus,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1156,,,,Expert,,1185,CHEMBL616101,10576,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1157,,,,Expert,,2014,CHEMBL616102,10576,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,B,1,H,8,,BAO_0000249
1158,,,,Autocuration,,1185,CHEMBL616103,10576,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1159,,,,Expert,,14429,CHEMBL616104,10576,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,B,1,H,8,,BAO_0000019
1160,,,,Expert,,16288,CHEMBL616105,10576,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,B,1,H,8,,BAO_0000019
1161,,,10116.0,Expert,Rattus norvegicus,5432,CHEMBL616106,10576,,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000019
1162,,,,Autocuration,,14429,CHEMBL616107,10576,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,B,1,H,8,,BAO_0000019
1163,,,,Expert,,13672,CHEMBL616108,10576,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,B,1,H,8,,BAO_0000357
1164,,10000000.0,,Expert,,11296,CHEMBL616109,10576,,,Hippocampus,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,B,1,H,8,,BAO_0000221
1165,,,,Autocuration,,11296,CHEMBL616110,10576,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,B,1,H,8,,BAO_0000357
1166,,,,Expert,,14749,CHEMBL616111,10576,,449.0,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,B,1,H,8,,BAO_0000219
1167,,,,Expert,,15086,CHEMBL616112,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000019
1168,,10000000.0,,Autocuration,,13462,CHEMBL616113,10576,,,Hippocampus,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,B,1,H,8,,BAO_0000221
1169,,,,Autocuration,,15363,CHEMBL616114,10576,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000019
1170,,,,Autocuration,,15363,CHEMBL616115,10576,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000019
1171,,,,Autocuration,,10796,CHEMBL616116,10576,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1172,,955.0,,Expert,,12816,CHEMBL615844,10576,,,Brain,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1173,,10000000.0,,Expert,,13542,CHEMBL615939,10576,,,Hippocampus,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000221
1174,,,,Expert,,13308,CHEMBL615940,10576,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,B,1,H,8,,BAO_0000019
1175,,10000000.0,,Expert,,13541,CHEMBL615941,10576,,,Hippocampus,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,B,1,H,8,,BAO_0000221
1176,,10000000.0,,Autocuration,,10058,CHEMBL615942,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,B,1,H,8,,BAO_0000221
1177,,10000000.0,,Autocuration,,10058,CHEMBL615943,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,B,1,H,8,,BAO_0000221
1178,,10000000.0,,Autocuration,,10058,CHEMBL615944,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,B,1,H,8,,BAO_0000221
1179,,10000000.0,,Autocuration,,10058,CHEMBL615945,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,B,1,H,8,,BAO_0000221
1180,,10000000.0,,Autocuration,,10058,CHEMBL615946,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,B,1,H,8,,BAO_0000221
1181,,10000000.0,,Autocuration,,10058,CHEMBL615947,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,B,1,H,8,,BAO_0000221
1182,,10000000.0,,Autocuration,,10058,CHEMBL615948,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,B,1,H,8,,BAO_0000221
1183,,10000000.0,,Autocuration,,10058,CHEMBL615949,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,B,1,H,8,,BAO_0000221
1184,,10000000.0,,Autocuration,,10058,CHEMBL615950,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,B,1,H,8,,BAO_0000221
1185,,10000000.0,,Autocuration,,10058,CHEMBL615951,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,B,1,H,8,,BAO_0000221
1186,,10000000.0,,Autocuration,,10058,CHEMBL615952,10576,,,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,B,1,H,8,,BAO_0000221
1187,,10000000.0,,Autocuration,,10058,CHEMBL615953,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,B,1,H,8,,BAO_0000221
1188,,10000000.0,,Autocuration,,10058,CHEMBL615954,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,B,1,H,8,,BAO_0000221
1189,,10000000.0,10116.0,Expert,Rattus norvegicus,10058,CHEMBL615955,10576,,,Hippocampus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,B,1,D,9,,BAO_0000221
1190,,10000000.0,,Autocuration,,10058,CHEMBL615956,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,B,1,H,8,,BAO_0000221
1191,,10000000.0,,Autocuration,,10058,CHEMBL615957,10576,,,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,B,1,H,8,,BAO_0000221
1192,,,,Expert,,12879,CHEMBL615958,10576,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,B,1,H,8,,BAO_0000019
1193,,,,Expert,,11964,CHEMBL615959,10576,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,B,1,H,8,,BAO_0000019
1194,,,,Autocuration,,11964,CHEMBL615960,10576,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,B,1,H,8,,BAO_0000019
1195,,,,Autocuration,,11964,CHEMBL615961,10576,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,B,1,H,8,,BAO_0000019
1196,,955.0,,Expert,,9548,CHEMBL615962,10576,,,Brain,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,B,1,H,8,,BAO_0000221
1197,,,,Expert,,9098,CHEMBL615963,10576,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,B,1,H,8,,BAO_0000019
1198,,,,Autocuration,,9098,CHEMBL615964,10576,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,B,1,H,8,,BAO_0000019
1199,,,,Autocuration,,9098,CHEMBL615965,10576,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,B,1,H,8,,BAO_0000019
1200,,,,Expert,,13248,CHEMBL615966,10576,,449.0,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,B,1,H,8,,BAO_0000219
1201,,,,Expert,,3147,CHEMBL615967,10576,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,B,1,H,8,,BAO_0000249
1202,,,,Expert,,13949,CHEMBL615968,10576,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000019
1203,,,,Autocuration,,11883,CHEMBL615969,10576,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,B,1,H,8,,BAO_0000218
1204,,,,Autocuration,,11883,CHEMBL615970,10576,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,B,1,H,8,,BAO_0000218
1205,,,10116.0,Expert,Rattus norvegicus,11883,CHEMBL615971,10576,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,B,1,D,9,,BAO_0000357
1206,Membranes,,,Expert,,15535,CHEMBL615972,10576,,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,B,1,H,8,,BAO_0000249
1207,,,,Autocuration,,15535,CHEMBL615973,10576,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,B,1,H,8,,BAO_0000249
1208,,,,Autocuration,,15535,CHEMBL615974,10576,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,B,1,H,8,,BAO_0000249
1209,,,9606.0,Expert,Homo sapiens,16372,CHEMBL615975,51,,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
1210,,,,Expert,,14608,CHEMBL615976,10576,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,B,1,H,8,,BAO_0000249
1211,,10000000.0,10116.0,Expert,Rattus norvegicus,4795,CHEMBL872106,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,B,1,D,9,,BAO_0000221
1212,,,,Autocuration,,13863,CHEMBL615977,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
1213,,,,Autocuration,,13863,CHEMBL615978,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,B,1,H,8,,BAO_0000357
1214,,,,Autocuration,,13863,CHEMBL616166,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,B,1,H,8,,BAO_0000357
1215,,,,Autocuration,,13863,CHEMBL616167,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,B,1,H,8,,BAO_0000357
1216,,,,Autocuration,,13863,CHEMBL616168,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,B,1,H,8,,BAO_0000357
1217,,,,Autocuration,,13863,CHEMBL616169,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,B,1,H,8,,BAO_0000357
1218,,,,Autocuration,,13863,CHEMBL616170,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,B,1,H,8,,BAO_0000357
1219,,,,Autocuration,,13863,CHEMBL616171,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,B,1,H,8,,BAO_0000357
1220,,,,Autocuration,,13863,CHEMBL616172,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,B,1,H,8,,BAO_0000357
1221,,,,Autocuration,,13863,CHEMBL616173,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,B,1,H,8,,BAO_0000357
1222,,,,Autocuration,,13863,CHEMBL616174,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,B,1,H,8,,BAO_0000357
1223,,,,Autocuration,,13863,CHEMBL616175,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,B,1,H,8,,BAO_0000357
1224,,,,Autocuration,,13863,CHEMBL616176,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,B,1,H,8,,BAO_0000357
1225,,,,Autocuration,,13863,CHEMBL616177,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,B,1,H,8,,BAO_0000357
1226,,,,Autocuration,,13863,CHEMBL616178,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,B,1,H,8,,BAO_0000357
1227,,,,Autocuration,,9742,CHEMBL616179,10576,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,B,1,H,8,,BAO_0000019
1228,,,,Autocuration,,12073,CHEMBL616180,10576,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1229,,,,Autocuration,,4101,CHEMBL616181,10576,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000357
1230,,,,Autocuration,,15360,CHEMBL616182,10576,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,B,1,H,8,,BAO_0000019
1231,,10000000.0,,Autocuration,,11576,CHEMBL616183,10576,,,Hippocampus,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000221
1232,,,,Expert,,5834,CHEMBL615874,10576,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,B,1,H,8,,BAO_0000019
1233,,,10116.0,Expert,Rattus norvegicus,2395,CHEMBL615875,10576,,485.0,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,B,1,D,9,,BAO_0000219
1234,,,,Autocuration,,1375,CHEMBL615876,10576,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,B,1,H,8,,BAO_0000019
1235,,,,Autocuration,,1375,CHEMBL615877,10576,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,B,1,H,8,,BAO_0000019
1236,,,,Autocuration,,3967,CHEMBL615878,10576,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,B,1,H,8,,BAO_0000357
1237,,,,Expert,,12884,CHEMBL615879,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,B,1,H,8,,BAO_0000357
1238,,,,Expert,,2343,CHEMBL615880,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,B,1,H,8,,BAO_0000357
1239,,,,Autocuration,,11511,CHEMBL615881,10576,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,B,1,H,8,,BAO_0000019
1240,,,10116.0,Expert,Rattus norvegicus,11511,CHEMBL615882,10576,,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,B,1,D,9,,BAO_0000019
1241,,,,Autocuration,,16394,CHEMBL615883,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,F,1,H,8,,BAO_0000218
1242,,,,Autocuration,,16394,CHEMBL615884,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,F,1,H,8,,BAO_0000218
1243,,,,Autocuration,,16394,CHEMBL615885,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,F,1,H,8,,BAO_0000218
1244,,,,Autocuration,,16394,CHEMBL615886,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,F,1,H,8,,BAO_0000218
1245,,,,Autocuration,,16394,CHEMBL615887,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,F,1,H,8,,BAO_0000218
1246,,,,Autocuration,,16394,CHEMBL615888,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,F,1,H,8,,BAO_0000218
1247,,,,Autocuration,,16394,CHEMBL615889,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,F,1,H,8,,BAO_0000218
1248,,,,Autocuration,,16394,CHEMBL615890,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,F,1,H,8,,BAO_0000218
1249,,,,Autocuration,,16394,CHEMBL615891,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,F,1,H,8,,BAO_0000218
1250,,,,Autocuration,,16394,CHEMBL615892,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,F,1,H,8,,BAO_0000218
1251,,,,Autocuration,,16394,CHEMBL615893,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,F,1,H,8,,BAO_0000218
1252,,,,Autocuration,,16394,CHEMBL615894,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,F,1,H,8,,BAO_0000218
1253,,,,Autocuration,,16394,CHEMBL615895,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,F,1,H,8,,BAO_0000218
1254,,,,Autocuration,,16394,CHEMBL615896,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,F,1,H,8,,BAO_0000218
1255,,,,Autocuration,,16394,CHEMBL615897,10576,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,F,1,H,8,,BAO_0000218
1256,Membranes,,10116.0,Expert,Rattus norvegicus,16616,CHEMBL615898,10576,,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,F,1,D,9,,BAO_0000249
1257,,,,Autocuration,,16796,CHEMBL615899,10576,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,B,1,H,8,,BAO_0000019
1258,,,,Autocuration,,16796,CHEMBL616291,10576,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,B,1,H,8,,BAO_0000019
1259,,,,Autocuration,,15629,CHEMBL616292,10576,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,B,1,H,8,,BAO_0000357
1260,,,,Autocuration,,13241,CHEMBL616293,10576,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,F,1,H,8,,BAO_0000249
1261,,10000000.0,,Expert,,12073,CHEMBL616294,10576,,,Hippocampus,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
1262,,10000000.0,,Autocuration,,14286,CHEMBL616295,10576,,,Hippocampus,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,B,1,H,8,,BAO_0000249
1263,,955.0,,Autocuration,,14542,CHEMBL616296,10576,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,B,1,H,8,,BAO_0000221
1264,,,,Autocuration,,13630,CHEMBL616297,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,F,1,H,8,,BAO_0000019
1265,,,,Autocuration,,13630,CHEMBL616605,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,F,1,H,8,,BAO_0000019
1266,,,,Autocuration,,13630,CHEMBL616606,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,F,1,H,8,,BAO_0000019
1267,,,,Autocuration,,13630,CHEMBL616607,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,F,1,H,8,,BAO_0000019
1268,,,,Expert,,13630,CHEMBL616608,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,F,1,H,8,,BAO_0000019
1269,,,,Autocuration,,13630,CHEMBL616609,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,F,1,H,8,,BAO_0000019
1270,,,10116.0,Expert,Rattus norvegicus,13630,CHEMBL616610,10576,,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,F,1,D,9,,BAO_0000019
1271,,,,Autocuration,,13630,CHEMBL616611,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,F,1,H,8,,BAO_0000019
1272,,,,Expert,,13630,CHEMBL616612,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,F,1,H,8,,BAO_0000019
1273,,,,Autocuration,,13630,CHEMBL616613,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,F,1,H,8,,BAO_0000019
1274,,,,Expert,,13630,CHEMBL616614,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,F,1,H,8,,BAO_0000019
1275,,,,Autocuration,,13630,CHEMBL616615,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,F,1,H,8,,BAO_0000019
1276,,,,Expert,,13630,CHEMBL616616,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,F,1,H,8,,BAO_0000019
1277,,,,Autocuration,,13630,CHEMBL616617,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,F,1,H,8,,BAO_0000019
1278,,,,Autocuration,,13630,CHEMBL616618,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,F,1,H,8,,BAO_0000019
1279,,,,Autocuration,,13630,CHEMBL616619,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,F,1,H,8,,BAO_0000019
1280,,,,Expert,,13630,CHEMBL616620,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,F,1,H,8,,BAO_0000019
1281,,,,Expert,,13630,CHEMBL616621,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,F,1,H,8,,BAO_0000019
1282,,,,Autocuration,,13630,CHEMBL616622,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,F,1,H,8,,BAO_0000019
1283,,,,Expert,,13630,CHEMBL616146,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,F,1,H,8,,BAO_0000019
1284,,,,Autocuration,,13630,CHEMBL832873,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,F,1,H,8,,BAO_0000019
1285,,,,Autocuration,,13630,CHEMBL616147,10576,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,F,1,H,8,,BAO_0000019
1286,,,,Autocuration,,13630,CHEMBL872872,10576,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,F,1,H,8,,BAO_0000019
1287,,,,Autocuration,,13630,CHEMBL616148,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,F,1,H,8,,BAO_0000019
1288,,10000000.0,,Autocuration,,9783,CHEMBL616149,10576,,,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,B,1,H,8,,BAO_0000221
1289,,10000000.0,,Expert,,9783,CHEMBL616150,10576,,,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,B,1,H,8,,BAO_0000221
1290,Membranes,,10116.0,Expert,Rattus norvegicus,14331,CHEMBL616151,10576,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,B,1,D,9,,BAO_0000249
1291,,10000000.0,,Expert,,15260,CHEMBL872873,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,B,1,H,8,,BAO_0000221
1292,,10000000.0,,Autocuration,,15260,CHEMBL616670,10576,,,Hippocampus,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,B,1,H,8,,BAO_0000221
1293,,10000000.0,,Autocuration,,15260,CHEMBL616671,10576,,,Hippocampus,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,B,1,H,8,,BAO_0000221
1294,,,10116.0,Expert,Rattus norvegicus,16616,CHEMBL884861,10576,,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,F,1,D,9,,BAO_0000249
1295,,,,Autocuration,,15629,CHEMBL616672,10576,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,B,1,H,8,,BAO_0000357
1296,,,,Autocuration,,15086,CHEMBL616673,10576,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,B,1,H,8,,BAO_0000019
1297,,,,Expert,,5717,CHEMBL616674,10576,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,F,1,H,8,,BAO_0000019
1298,,,,Autocuration,,12652,CHEMBL616675,10576,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,B,1,H,8,,BAO_0000357
1299,,10000000.0,,Autocuration,,14608,CHEMBL616676,10576,,,Hippocampus,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,B,1,H,8,,BAO_0000221
1300,,10000000.0,,Autocuration,,12306,CHEMBL616677,10576,,,Hippocampus,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,B,1,H,8,,BAO_0000221
1301,,10000000.0,,Autocuration,,12306,CHEMBL616678,10576,,,Hippocampus,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,B,1,H,8,,BAO_0000221
1302,,,10116.0,Expert,Rattus norvegicus,15247,CHEMBL616679,10576,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1303,,10000000.0,,Expert,,17529,CHEMBL616680,10576,,,Hippocampus,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,B,1,H,8,,BAO_0000221
1304,,10000000.0,,Autocuration,,14826,CHEMBL616681,10576,,,Hippocampus,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
1305,,10000000.0,,Autocuration,,14826,CHEMBL616682,10576,,,Hippocampus,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
1306,,10000000.0,,Autocuration,,13241,CHEMBL616683,10576,,,Hippocampus,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000221
1307,,10000000.0,,Autocuration,,14093,CHEMBL616684,10576,,,Hippocampus,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000221
1308,,10000000.0,,Autocuration,,14093,CHEMBL616685,10576,,,Hippocampus,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,B,1,H,8,,BAO_0000221
1309,,955.0,,Autocuration,,14442,CHEMBL616686,10576,,,Brain,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,B,1,H,8,,BAO_0000221
1310,,,,Autocuration,,9919,CHEMBL616687,10576,,,,Affinity for 5-hydroxytryptamine 1A receptor site,,B,1,H,8,,BAO_0000357
1311,,,,Autocuration,,9919,CHEMBL616688,10576,,,,Affinity for 5-hydroxytryptamine 1A receptor site,,B,1,H,8,,BAO_0000357
1312,,10000000.0,,Autocuration,,11440,CHEMBL616689,10576,,,Hippocampus,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,B,1,H,8,,BAO_0000221
1313,,,,Autocuration,,11257,CHEMBL616690,10576,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,B,1,H,8,,BAO_0000357
1314,,,,Expert,,10330,CHEMBL616691,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
1315,,10000000.0,10116.0,Expert,Rattus norvegicus,17331,CHEMBL616692,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,B,1,D,9,,BAO_0000221
1316,,,,Expert,,16567,CHEMBL616693,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,B,1,H,8,,BAO_0000249
1317,,,10116.0,Expert,Rattus norvegicus,12058,CHEMBL616694,10576,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,B,1,D,9,,BAO_0000019
1318,,10000000.0,,Autocuration,,9699,CHEMBL616695,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,B,1,H,8,,BAO_0000221
1319,,,,Autocuration,,9547,CHEMBL616696,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,B,1,H,8,,BAO_0000357
1320,,,,Autocuration,,10330,CHEMBL616697,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,B,1,H,8,,BAO_0000357
1321,,,,Autocuration,,14331,CHEMBL616698,10576,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1322,,,10116.0,Expert,Rattus norvegicus,14060,CHEMBL616949,10576,,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000019
1323,,10000000.0,,Autocuration,,14744,CHEMBL616950,10576,,,Hippocampus,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,B,1,H,8,,BAO_0000221
1324,,,,Autocuration,,13506,CHEMBL832875,10576,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,B,1,H,8,,BAO_0000357
1325,,955.0,,Expert,,10862,CHEMBL616951,10576,,,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,B,1,H,8,,BAO_0000221
1326,,955.0,,Expert,,10862,CHEMBL616952,10576,,,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,B,1,H,8,,BAO_0000221
1327,,,,Expert,,10062,CHEMBL616953,10576,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,B,1,H,8,,BAO_0000357
1328,,,,Autocuration,,12073,CHEMBL616954,10576,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,B,1,H,8,,BAO_0000357
1329,,,,Autocuration,,14875,CHEMBL616955,106,,,,GTPgammaS radioligand binding assay,,B,1,H,8,,BAO_0000357
1330,,,,Autocuration,,2391,CHEMBL616956,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,B,1,H,8,,BAO_0000357
1331,,,,Autocuration,,2391,CHEMBL616957,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,F,1,H,8,,BAO_0000019
1332,,,,Autocuration,,2391,CHEMBL616958,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,F,1,H,8,,BAO_0000019
1333,,,,Autocuration,,2391,CHEMBL616959,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1334,,,,Autocuration,,2391,CHEMBL616960,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,B,1,H,8,,BAO_0000357
1335,,,,Autocuration,,2391,CHEMBL616961,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,F,1,H,8,,BAO_0000019
1336,,,,Expert,,17211,CHEMBL616962,106,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000219
1337,,,,Autocuration,,17211,CHEMBL616963,106,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,B,1,H,8,,BAO_0000219
1338,,,9606.0,Expert,Homo sapiens,6491,CHEMBL616524,106,,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,B,1,D,9,,BAO_0000357
1339,,,,Autocuration,,16190,CHEMBL616525,106,,449.0,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000219
1340,,,,Autocuration,,14165,CHEMBL872908,106,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000019
1341,,,,Autocuration,,14165,CHEMBL616526,106,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,B,1,H,8,,BAO_0000019
1342,,,9606.0,Expert,Homo sapiens,4234,CHEMBL616527,106,,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1343,,,,Expert,,6328,CHEMBL616528,106,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,B,1,H,8,,BAO_0000219
1344,,,,Autocuration,,14770,CHEMBL616529,106,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000357
1345,,,,Autocuration,,2598,CHEMBL616530,106,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000357
1346,,,,Expert,,6897,CHEMBL616531,106,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1347,,,,Autocuration,,6897,CHEMBL616532,106,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1348,,,,Autocuration,,6013,CHEMBL616533,106,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1349,,,,Expert,,5843,CHEMBL616534,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1350,,,,Expert,,14454,CHEMBL616535,106,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,B,1,H,8,,BAO_0000357
1351,,,,Autocuration,,16209,CHEMBL616536,106,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,B,1,H,8,,BAO_0000357
1352,,,,Autocuration,,3935,CHEMBL616537,106,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1353,,,,Expert,,13729,CHEMBL616538,106,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,F,1,H,8,,BAO_0000219
1354,,,,Expert,,14251,CHEMBL616539,106,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,F,1,H,8,,BAO_0000019
1355,,,,Expert,,17085,CHEMBL616540,106,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000019
1356,,,,Autocuration,,3025,CHEMBL616429,106,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,B,1,H,8,,BAO_0000357
1357,,,,Expert,,15315,CHEMBL616430,106,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1358,,,9606.0,Expert,Homo sapiens,14214,CHEMBL616431,106,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,B,1,D,9,,BAO_0000219
1359,,,9606.0,Expert,Homo sapiens,3804,CHEMBL616432,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1360,,,9606.0,Expert,Homo sapiens,2391,CHEMBL616433,106,,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,B,1,D,9,,BAO_0000357
1361,,,9606.0,Expert,Homo sapiens,4175,CHEMBL616434,106,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1362,,,,Autocuration,,17296,CHEMBL616435,106,,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,B,1,H,8,,BAO_0000219
1363,,,,Expert,,17085,CHEMBL616436,106,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,B,1,H,8,,BAO_0000019
1364,,,,Autocuration,,17211,CHEMBL616437,106,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,B,1,H,8,,BAO_0000219
1365,,,,Autocuration,,17211,CHEMBL616438,106,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,B,1,H,8,,BAO_0000219
1366,,,,Autocuration,,17211,CHEMBL616439,106,,308.0,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,B,1,H,8,,BAO_0000219
1367,,,9606.0,Expert,Homo sapiens,15926,CHEMBL616440,106,,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,B,1,D,9,,BAO_0000357
1368,,,,Autocuration,,16312,CHEMBL616441,106,,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,B,1,H,8,,BAO_0000219
1369,,,,Expert,,5843,CHEMBL616442,106,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,B,1,H,8,,BAO_0000357
1370,,,,Autocuration,,5843,CHEMBL616443,106,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1371,,,,Expert,,16312,CHEMBL616444,106,,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000219
1372,,,9606.0,Expert,Homo sapiens,15926,CHEMBL616445,106,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1373,,,9606.0,Expert,Homo sapiens,15926,CHEMBL616446,106,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1374,,,9606.0,Expert,Homo sapiens,4540,CHEMBL616447,106,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,B,1,D,9,,BAO_0000219
1375,,,,Autocuration,,6166,CHEMBL616448,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,B,1,H,8,,BAO_0000357
1376,,,,Autocuration,,17296,CHEMBL616449,106,,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000219
1377,,,,Autocuration,,17296,CHEMBL616450,106,,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,B,1,H,8,,BAO_0000219
1378,,,,Autocuration,,17296,CHEMBL857974,106,,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000219
1379,,,,Autocuration,,15779,CHEMBL616451,106,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000219
1380,,,,Autocuration,,15779,CHEMBL616452,106,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000219
1381,,,,Autocuration,,15779,CHEMBL616453,106,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,B,1,H,8,,BAO_0000219
1382,,,,Autocuration,,4199,CHEMBL616454,106,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,B,1,H,8,,BAO_0000219
1383,,,9606.0,Expert,Homo sapiens,14875,CHEMBL616455,106,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1384,,,,Autocuration,,15146,CHEMBL616456,106,,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,B,1,H,8,,BAO_0000219
1385,,,,Autocuration,,5213,CHEMBL616457,106,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,B,1,H,8,,BAO_0000357
1386,,,,Autocuration,,14818,CHEMBL616458,106,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,B,1,H,8,,BAO_0000219
1387,,,,Autocuration,,4829,CHEMBL616459,106,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
1388,,,,Expert,,14454,CHEMBL616460,106,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,F,1,H,8,,BAO_0000019
1389,,,,Expert,,14454,CHEMBL616461,106,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,F,1,H,8,,BAO_0000019
1390,,,,Autocuration,,14875,CHEMBL616462,106,,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,F,1,H,8,,BAO_0000219
1391,,,,Autocuration,,14875,CHEMBL616463,106,,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,F,1,H,8,,BAO_0000219
1392,,,,Autocuration,,15250,CHEMBL616464,105,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,F,1,H,8,,BAO_0000019
1393,,,,Autocuration,,15250,CHEMBL616465,105,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,B,1,H,8,,BAO_0000219
1394,,,,Autocuration,,15086,CHEMBL832874,17105,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1395,,,9986.0,Autocuration,Oryctolagus cuniculus,3025,CHEMBL616184,106,,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,F,1,H,8,,BAO_0000019
1396,,,9986.0,Autocuration,Oryctolagus cuniculus,14998,CHEMBL616185,106,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,B,1,H,8,,BAO_0000019
1397,,,9986.0,Intermediate,Oryctolagus cuniculus,14998,CHEMBL616186,106,,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,B,1,H,8,,BAO_0000019
1398,,,9986.0,Autocuration,Oryctolagus cuniculus,14998,CHEMBL616187,106,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,B,1,H,8,,BAO_0000019
1399,,,,Expert,,13969,CHEMBL616188,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1400,,,,Intermediate,,13392,CHEMBL873475,10577,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1401,,2435.0,10116.0,Expert,Rattus norvegicus,3651,CHEMBL616189,10577,,,Striatum,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,B,1,D,9,,BAO_0000019
1402,,,,Expert,,10025,CHEMBL616190,10577,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,B,1,H,8,,BAO_0000357
1403,,,,Autocuration,,13863,CHEMBL616191,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,B,1,H,8,,BAO_0000357
1404,,,,Autocuration,,13863,CHEMBL616192,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,B,1,H,8,,BAO_0000357
1405,,,,Autocuration,,13863,CHEMBL616193,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,B,1,H,8,,BAO_0000357
1406,,,,Autocuration,,13863,CHEMBL616194,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,B,1,H,8,,BAO_0000357
1407,,,,Autocuration,,13863,CHEMBL616195,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,B,1,H,8,,BAO_0000357
1408,,,,Autocuration,,13863,CHEMBL616196,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,B,1,H,8,,BAO_0000357
1409,,10000000.0,,Autocuration,,4622,CHEMBL616197,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,B,1,H,8,,BAO_0000249
1410,,,,Intermediate,,14911,CHEMBL616198,10576,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000019
1411,,10000000.0,,Autocuration,,12678,CHEMBL616199,10576,,,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,B,1,H,8,,BAO_0000221
1412,,10000000.0,,Expert,,12678,CHEMBL616200,10576,,,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,B,1,H,8,,BAO_0000221
1413,,10000000.0,,Expert,,14235,CHEMBL616201,10576,,,Hippocampus,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1414,,10000000.0,,Expert,,14949,CHEMBL616202,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,B,1,H,8,,BAO_0000221
1415,,10000000.0,,Expert,,14949,CHEMBL616203,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,B,1,H,8,,BAO_0000221
1416,,10000000.0,,Expert,,14949,CHEMBL616204,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,B,1,H,8,,BAO_0000221
1417,,10000000.0,,Expert,,14949,CHEMBL616205,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,B,1,H,8,,BAO_0000221
1418,,10000000.0,,Expert,,14949,CHEMBL616206,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,B,1,H,8,,BAO_0000221
1419,,,,Expert,,16118,CHEMBL616207,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,B,1,H,8,,BAO_0000249
1420,,,,Autocuration,,3268,CHEMBL616208,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,B,1,H,8,,BAO_0000249
1421,,,,Autocuration,,3268,CHEMBL616209,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,B,1,H,8,,BAO_0000249
1422,,,,Expert,,16117,CHEMBL616210,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,B,1,H,8,,BAO_0000357
1423,,10000000.0,,Expert,,9783,CHEMBL616211,10576,,,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,B,1,H,8,,BAO_0000221
1424,,10000000.0,,Autocuration,,9783,CHEMBL616504,10576,,,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,B,1,H,8,,BAO_0000221
1425,,10000000.0,10116.0,Expert,Rattus norvegicus,14356,CHEMBL616505,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000221
1426,,,,Autocuration,,15740,CHEMBL616506,10576,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000019
1427,,10000000.0,,Autocuration,,12306,CHEMBL872107,10576,,,Hippocampus,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,B,1,H,8,,BAO_0000221
1428,,10000000.0,10116.0,Expert,Rattus norvegicus,13348,CHEMBL616507,10576,,,Hippocampus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,B,1,D,9,,BAO_0000221
1429,,,,Autocuration,,10394,CHEMBL616303,10576,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,B,1,H,8,,BAO_0000249
1430,,10000000.0,,Autocuration,,15260,CHEMBL616304,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,B,1,H,8,,BAO_0000221
1431,,10000000.0,,Expert,,10046,CHEMBL616305,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000221
1432,,10000000.0,,Intermediate,,15260,CHEMBL616306,10576,,,Hippocampus,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,F,1,H,8,,BAO_0000221
1433,,,,Autocuration,,12851,CHEMBL616307,10576,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1434,,10000000.0,10116.0,Expert,Rattus norvegicus,2148,CHEMBL881829,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,B,1,D,9,,BAO_0000221
1435,,,,Expert,,13134,CHEMBL616308,10576,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,B,1,H,8,,BAO_0000357
1436,,,,Autocuration,,12462,CHEMBL616309,10576,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,B,1,H,8,,BAO_0000019
1437,,,,Expert,,12462,CHEMBL616310,10576,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,B,1,H,8,,BAO_0000019
1438,,,,Autocuration,,12462,CHEMBL616311,10576,,449.0,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,B,1,H,8,,BAO_0000219
1439,,,,Expert,,11933,CHEMBL616312,10576,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
1440,,,,Autocuration,,11933,CHEMBL616313,10576,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,B,1,H,8,,BAO_0000357
1441,,10000000.0,10116.0,Expert,Rattus norvegicus,403,CHEMBL616314,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000221
1442,,10000000.0,,Autocuration,,15538,CHEMBL616315,10576,,,Hippocampus,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
1443,,10000000.0,,Autocuration,,15538,CHEMBL616567,10576,,,Hippocampus,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,B,1,H,8,,BAO_0000221
1444,,10000000.0,,Autocuration,,15538,CHEMBL616568,10576,,,Hippocampus,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,B,1,H,8,,BAO_0000221
1445,,,,Intermediate,,12464,CHEMBL616569,10576,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,B,1,H,8,,BAO_0000019
1446,,,,Expert,,1455,CHEMBL616570,10576,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,B,1,H,8,,BAO_0000357
1447,,,,Autocuration,,12652,CHEMBL616571,10576,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,B,1,H,8,,BAO_0000357
1448,,10000000.0,,Autocuration,,12639,CHEMBL616572,10576,,,Hippocampus,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,B,1,H,8,,BAO_0000221
1449,,,,Expert,,13949,CHEMBL616573,10576,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,B,1,H,8,,BAO_0000249
1450,,,10116.0,Expert,Rattus norvegicus,12463,CHEMBL616574,10576,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,B,1,D,9,,BAO_0000357
1451,,10000000.0,,Expert,,14829,CHEMBL616575,10576,,,Hippocampus,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,B,1,H,8,,BAO_0000221
1452,,10000000.0,,Autocuration,,14829,CHEMBL872108,10576,,,Hippocampus,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,B,1,H,8,,BAO_0000221
1453,,,,Autocuration,,12092,CHEMBL616576,10576,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000357
1454,,,,Autocuration,,403,CHEMBL616577,10576,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,B,1,H,8,,BAO_0000249
1455,,,,Autocuration,,403,CHEMBL616578,10576,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,B,1,H,8,,BAO_0000249
1456,,,,Expert,,3967,CHEMBL616579,10576,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,B,1,H,8,,BAO_0000357
1457,,,10116.0,Expert,Rattus norvegicus,12771,CHEMBL616580,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,B,1,D,9,,BAO_0000019
1458,,,,Autocuration,,15086,CHEMBL616581,10576,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,B,1,H,8,,BAO_0000019
1459,,10000000.0,,Autocuration,,14909,CHEMBL616582,10576,,,Hippocampus,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
1460,,10000000.0,,Expert,,14949,CHEMBL616583,10576,,,Hippocampus,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,B,1,H,8,,BAO_0000221
1461,,10000000.0,10116.0,Expert,Rattus norvegicus,2309,CHEMBL616584,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,B,1,D,9,,BAO_0000221
1462,,,,Expert,,4170,CHEMBL616585,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1463,,10000000.0,10116.0,Expert,Rattus norvegicus,11642,CHEMBL616586,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,B,1,D,9,,BAO_0000221
1464,,10000000.0,,Autocuration,,11642,CHEMBL616587,10576,,,Hippocampus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,B,1,H,8,,BAO_0000221
1465,,10000000.0,,Autocuration,,12953,CHEMBL616588,10576,,,Hippocampus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1466,,10000000.0,,Autocuration,,12953,CHEMBL616589,10576,,,Hippocampus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000221
1467,,10000000.0,,Expert,,12953,CHEMBL616590,10576,,,Hippocampus,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000221
1468,,,,Expert,,12903,CHEMBL616591,10576,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,B,1,H,8,,BAO_0000219
1469,,,,Expert,,12536,CHEMBL616592,10576,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1470,,,,Autocuration,,10058,CHEMBL616593,10576,,,,The inhibition activity of 5-HT1A at 1 uM,,B,1,H,8,,BAO_0000357
1471,,,,Expert,,12902,CHEMBL616594,10576,,485.0,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,B,1,H,8,,BAO_0000219
1472,,,,Expert,,14057,CHEMBL616595,10576,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,B,1,H,8,,BAO_0000249
1473,,,,Autocuration,,11296,CHEMBL616596,10576,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,B,1,H,8,,BAO_0000357
1474,,10000000.0,,Autocuration,,11296,CHEMBL616597,10576,,,Hippocampus,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,B,1,H,8,,BAO_0000221
1475,,10000000.0,,Expert,,11296,CHEMBL616598,10576,,,Hippocampus,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,B,1,H,8,,BAO_0000221
1476,Membranes,,10116.0,Expert,Rattus norvegicus,16616,CHEMBL616599,10576,,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,F,1,D,9,,BAO_0000249
1477,Membranes,10000000.0,10116.0,Expert,Rattus norvegicus,16616,CHEMBL616600,10576,,,Hippocampus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,F,1,D,9,,BAO_0000249
1478,,,,Autocuration,,16567,CHEMBL616601,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,B,1,H,8,,BAO_0000019
1479,,,,Autocuration,,16567,CHEMBL616602,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,B,1,H,8,,BAO_0000019
1480,,,,Autocuration,,16567,CHEMBL616603,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,B,1,H,8,,BAO_0000019
1481,,,,Autocuration,,16567,CHEMBL616604,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,B,1,H,8,,BAO_0000019
1482,,,,Autocuration,,17136,CHEMBL616316,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,B,1,H,8,,BAO_0000249
1483,,,,Autocuration,,17136,CHEMBL616317,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,B,1,H,8,,BAO_0000249
1484,,,10116.0,Expert,Rattus norvegicus,16616,CHEMBL616318,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,B,1,D,9,,BAO_0000019
1485,,10000000.0,,Autocuration,,17331,CHEMBL616319,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,B,1,H,8,,BAO_0000221
1486,,10000000.0,,Autocuration,,17331,CHEMBL616320,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,B,1,H,8,,BAO_0000221
1487,,10000000.0,10116.0,Expert,Rattus norvegicus,17167,CHEMBL616321,10576,,,Hippocampus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,B,1,D,9,,BAO_0000221
1488,,,,Autocuration,,15740,CHEMBL616322,10576,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,F,1,H,8,,BAO_0000019
1489,,,,Autocuration,,15740,CHEMBL616323,10576,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,F,1,H,8,,BAO_0000019
1490,,,,Autocuration,,4671,CHEMBL616324,10576,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,B,1,H,8,,BAO_0000357
1491,,10000000.0,,Autocuration,,10058,CHEMBL616325,10576,,,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,B,1,H,8,,BAO_0000221
1492,,10000000.0,,Autocuration,,10058,CHEMBL616326,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,B,1,H,8,,BAO_0000221
1493,,10000000.0,,Autocuration,,10058,CHEMBL616327,10576,,,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,B,1,H,8,,BAO_0000221
1494,,,,Autocuration,,12073,CHEMBL616328,10576,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1495,,,,Autocuration,,2759,CHEMBL858110,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,B,1,H,8,,BAO_0000249
1496,,,,Autocuration,,2759,CHEMBL616329,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,F,1,H,8,,BAO_0000249
1497,,,,Autocuration,,2759,CHEMBL616330,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,B,1,H,8,,BAO_0000249
1498,,,,Autocuration,,2759,CHEMBL616331,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,F,1,H,8,,BAO_0000249
1499,,,,Autocuration,,2759,CHEMBL616332,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,F,1,H,8,,BAO_0000249
1500,,955.0,,Autocuration,,9737,CHEMBL857063,10576,,,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,B,1,H,8,,BAO_0000249
1501,,,,Autocuration,,9737,CHEMBL616333,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,B,1,H,8,,BAO_0000019
1502,,,,Expert,,5717,CHEMBL616334,10576,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,F,1,H,8,,BAO_0000019
1503,,10000000.0,,Autocuration,,12253,CHEMBL616335,10576,,,Hippocampus,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,B,1,H,8,,BAO_0000221
1504,,,,Autocuration,,14025,CHEMBL616336,10576,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,B,1,H,8,,BAO_0000019
1505,,,,Expert,,10425,CHEMBL616337,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000249
1506,,,,Autocuration,,14998,CHEMBL616338,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,B,1,H,8,,BAO_0000019
1507,,10000000.0,,Autocuration,,13694,CHEMBL616339,10576,,,Hippocampus,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,B,1,H,8,,BAO_0000221
1508,,10000000.0,,Autocuration,,13694,CHEMBL616340,10576,,,Hippocampus,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,B,1,H,8,,BAO_0000221
1509,,,,Autocuration,,4342,CHEMBL616341,10576,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,B,1,H,8,,BAO_0000357
1510,,,10116.0,Expert,Rattus norvegicus,12936,CHEMBL616342,10576,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1511,,,10116.0,Expert,Rattus norvegicus,13144,CHEMBL616343,10576,,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,B,1,D,9,,BAO_0000019
1512,,,,Expert,,13343,CHEMBL616344,10576,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,B,1,H,8,,BAO_0000019
1513,,,,Expert,,12132,CHEMBL616345,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000357
1514,,,,Expert,,15419,CHEMBL616346,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,B,1,H,8,,BAO_0000019
1515,,10000000.0,,Autocuration,,1479,CHEMBL616347,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,B,1,H,8,,BAO_0000221
1516,,,,Expert,,14287,CHEMBL616348,10576,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,B,1,H,8,,BAO_0000019
1517,,,,Expert,,13116,CHEMBL616349,10576,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1518,Membranes,,10116.0,Expert,Rattus norvegicus,2759,CHEMBL616152,10576,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,B,1,D,9,,BAO_0000249
1519,,,,Autocuration,,2759,CHEMBL616153,10576,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,B,1,H,8,,BAO_0000249
1520,,,,Expert,,14748,CHEMBL616154,10576,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,B,1,H,8,,BAO_0000019
1521,,,,Autocuration,,12304,CHEMBL616155,10576,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,B,1,H,8,,BAO_0000019
1522,,10000000.0,10116.0,Expert,Rattus norvegicus,12409,CHEMBL616156,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,B,1,D,9,,BAO_0000221
1523,,10000000.0,10116.0,Expert,Rattus norvegicus,12409,CHEMBL616157,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,B,1,D,9,,BAO_0000221
1524,,10000000.0,,Autocuration,,13267,CHEMBL616158,10576,,,Hippocampus,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,B,1,H,8,,BAO_0000221
1525,,,,Autocuration,,15194,CHEMBL616159,10576,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000357
1526,,,,Expert,,14256,CHEMBL616160,10576,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,B,1,H,8,,BAO_0000357
1527,,,,Autocuration,,16567,CHEMBL616161,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,B,1,H,8,,BAO_0000019
1528,,,,Autocuration,,15740,CHEMBL616162,10576,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,F,1,H,8,,BAO_0000019
1529,,,10116.0,Expert,Rattus norvegicus,13278,CHEMBL616163,12687,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,B,1,D,9,,BAO_0000357
1530,Membranes,,,Expert,,1970,CHEMBL616164,10626,,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,B,1,H,8,,BAO_0000249
1531,,955.0,,Autocuration,,10034,CHEMBL616165,10576,,,Brain,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,B,1,H,8,,BAO_0000221
1532,,,10116.0,Autocuration,Rattus norvegicus,13348,CHEMBL616355,51,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,B,1,H,8,,BAO_0000019
1533,,,,Autocuration,,13630,CHEMBL616356,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,F,1,H,8,,BAO_0000019
1534,,955.0,,Autocuration,,10862,CHEMBL616357,10576,,,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,B,1,H,8,,BAO_0000221
1535,,,,Autocuration,,12058,CHEMBL616358,10576,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,B,1,H,8,,BAO_0000019
1536,,,,Autocuration,,4639,CHEMBL616359,51,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1537,,,,Expert,,15453,CHEMBL616360,51,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,B,1,H,8,,BAO_0000357
1538,,,,Expert,,4820,CHEMBL616361,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1539,,,,Autocuration,,1089,CHEMBL616362,51,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1540,Brain membranes,,,Autocuration,,386,CHEMBL616363,51,,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,B,1,H,8,,BAO_0000249
1541,,,,Autocuration,,6011,CHEMBL616364,51,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,B,1,H,8,,BAO_0000357
1542,,,,Autocuration,,5014,CHEMBL616365,51,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1543,,,,Expert,,4402,CHEMBL616366,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
1544,,,,Expert,,17066,CHEMBL872906,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1545,,,,Autocuration,,17515,CHEMBL616367,51,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,B,1,H,8,,BAO_0000357
1546,,,,Autocuration,,2474,CHEMBL616368,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1547,,,,Autocuration,,4775,CHEMBL616369,51,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,B,1,H,8,,BAO_0000357
1548,,,9606.0,Expert,Homo sapiens,14294,CHEMBL616370,51,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,B,1,D,9,,BAO_0000357
1549,,,9606.0,Expert,Homo sapiens,14294,CHEMBL616371,51,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,B,1,D,9,,BAO_0000357
1550,,,,Autocuration,,12249,CHEMBL616372,51,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,B,1,H,8,,BAO_0000219
1551,,,,Expert,,11376,CHEMBL616373,51,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,B,1,H,8,,BAO_0000219
1552,,,,Autocuration,,2474,CHEMBL616374,51,,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000218
1553,,10000000.0,,Autocuration,,13311,CHEMBL616375,51,,,Hippocampus,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,B,1,H,8,,BAO_0000221
1554,,,,Autocuration,,4373,CHEMBL616376,51,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,B,1,H,8,,BAO_0000357
1555,,,,Expert,,1633,CHEMBL857064,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,B,1,H,8,,BAO_0000357
1556,,,,Autocuration,,11866,CHEMBL616377,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,B,1,H,8,,BAO_0000357
1557,,,,Autocuration,,4373,CHEMBL616378,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,B,1,H,8,,BAO_0000357
1558,,,,Autocuration,,4687,CHEMBL616379,51,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1559,,,,Autocuration,,16946,CHEMBL616380,11863,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1560,,,,Autocuration,,13291,CHEMBL616381,11863,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,B,1,H,8,,BAO_0000357
1561,,,,Autocuration,,14159,CHEMBL616382,11863,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1562,,,,Autocuration,,10812,CHEMBL616383,11863,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,B,1,H,8,,BAO_0000357
1563,,,10090.0,Expert,Mus musculus,3032,CHEMBL616350,11863,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,B,1,D,9,,BAO_0000219
1564,,,,Autocuration,,16655,CHEMBL616351,11863,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1565,,,,Autocuration,,14532,CHEMBL616352,11863,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,B,1,H,8,,BAO_0000357
1566,,,,Autocuration,,13944,CHEMBL616353,11863,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1567,,,,Autocuration,,13033,CHEMBL616354,11863,,,,Binding affinity against serotonergic 5-HT1a receptor,,B,1,H,8,,BAO_0000357
1568,,,,Autocuration,,10321,CHEMBL616508,11863,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
1569,,,10090.0,Expert,Mus musculus,2968,CHEMBL616559,11863,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1570,,,,Autocuration,,13964,CHEMBL616560,11863,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1571,,,,Autocuration,,15527,CHEMBL616561,11863,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,B,1,H,8,,BAO_0000357
1572,,,,Autocuration,,12248,CHEMBL616562,11863,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,B,1,H,8,,BAO_0000219
1573,,,,Autocuration,,12249,CHEMBL616563,11863,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,B,1,H,8,,BAO_0000219
1574,,,,Autocuration,,15120,CHEMBL616564,11863,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1575,,,,Autocuration,,13313,CHEMBL616565,11863,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
1576,,,,Autocuration,,2613,CHEMBL616566,11863,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000218
1577,,,,Autocuration,,16700,CHEMBL616989,11863,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,B,1,H,8,,BAO_0000357
1578,,,,Autocuration,,2201,CHEMBL857975,11863,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1579,,,10090.0,Expert,Mus musculus,1274,CHEMBL616990,11863,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,D,9,,BAO_0000357
1580,,,,Autocuration,,1317,CHEMBL616991,11863,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,B,1,H,8,,BAO_0000357
1581,,,,Autocuration,,12146,CHEMBL616992,11863,,,,Tested against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1582,,,,Autocuration,,14059,CHEMBL616993,11863,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
1583,,,9986.0,Expert,Oryctolagus cuniculus,14025,CHEMBL616994,106,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,B,1,H,8,,BAO_0000019
1584,,,9986.0,Autocuration,Oryctolagus cuniculus,14025,CHEMBL616995,106,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,B,1,H,8,,BAO_0000019
1585,,,9593.0,Intermediate,Gorilla gorilla,14447,CHEMBL616996,105571,,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,B,1,D,9,,BAO_0000219
1586,,,10141.0,Autocuration,Cavia porcellus,3025,CHEMBL616997,106,,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,F,1,H,8,,BAO_0000218
1587,,,10141.0,Autocuration,Cavia porcellus,3025,CHEMBL616998,106,,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,F,1,H,8,,BAO_0000218
1588,,,10141.0,Autocuration,Cavia porcellus,15329,CHEMBL616999,106,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,F,1,H,8,,BAO_0000019
1589,,,10141.0,Autocuration,Cavia porcellus,15329,CHEMBL617000,106,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,F,1,H,8,,BAO_0000019
1590,,,10141.0,Autocuration,Cavia porcellus,15847,CHEMBL617001,106,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,F,1,H,8,,BAO_0000019
1591,,,10141.0,Autocuration,Cavia porcellus,15847,CHEMBL858111,106,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,F,1,H,8,,BAO_0000019
1592,,,,Autocuration,,14165,CHEMBL617002,106,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,F,1,H,8,,BAO_0000019
1593,,,,Autocuration,,14214,CHEMBL617003,106,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,F,1,H,8,,BAO_0000019
1594,,,,Autocuration,,14214,CHEMBL617004,106,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,F,1,H,8,,BAO_0000019
1595,,,9606.0,Expert,Homo sapiens,14214,CHEMBL617005,106,,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,F,1,D,9,,BAO_0000019
1596,,,9606.0,Expert,Homo sapiens,13729,CHEMBL616623,106,,485.0,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,F,1,D,9,,BAO_0000219
1597,,,,Autocuration,,3025,CHEMBL616624,106,,449.0,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,F,1,H,8,,BAO_0000219
1598,,,,Autocuration,,2391,CHEMBL883243,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1599,,,,Autocuration,,2391,CHEMBL616625,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,F,1,H,8,,BAO_0000019
1600,,,,Expert,,14956,CHEMBL616626,106,,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,F,1,H,8,,BAO_0000219
1601,,,,Autocuration,,2598,CHEMBL616627,106,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,F,1,H,8,,BAO_0000219
1602,,,,Autocuration,,2598,CHEMBL616628,106,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,F,1,H,8,,BAO_0000219
1603,,,,Autocuration,,2598,CHEMBL616629,106,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,F,1,H,8,,BAO_0000219
1604,,,,Autocuration,,2598,CHEMBL616630,106,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,F,1,H,8,,BAO_0000219
1605,,,,Expert,,14956,CHEMBL616631,106,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,F,1,H,8,,BAO_0000019
1606,,,,Autocuration,,14956,CHEMBL616632,106,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,F,1,H,8,,BAO_0000019
1607,,,9606.0,Expert,Homo sapiens,14214,CHEMBL616633,106,,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1608,,,,Expert,,3463,CHEMBL616634,106,,449.0,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,B,1,H,8,,BAO_0000219
1609,,,,Autocuration,,15331,CHEMBL616635,106,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,B,1,H,8,,BAO_0000357
1610,,,9606.0,Expert,Homo sapiens,16146,CHEMBL885358,106,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1611,,,9606.0,Expert,Homo sapiens,14159,CHEMBL616636,106,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
1612,,,,Expert,,14158,CHEMBL616637,106,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,B,1,H,8,,BAO_0000219
1613,,,,Autocuration,,14159,CHEMBL616638,106,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1614,,,,Expert,,15250,CHEMBL616639,106,,449.0,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
1615,,,,Expert,,15250,CHEMBL616640,106,,449.0,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,B,1,H,8,,BAO_0000219
1616,,,,Expert,,15331,CHEMBL616641,106,,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
1617,,,,Expert,,15332,CHEMBL616642,106,,449.0,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,B,1,H,8,,BAO_0000219
1618,,,,Expert,,14956,CHEMBL616643,106,,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,B,1,H,8,,BAO_0000219
1619,,,,Autocuration,,3805,CHEMBL616644,106,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,B,1,H,8,,BAO_0000357
1620,,,,Autocuration,,14875,CHEMBL616645,106,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,B,1,H,8,,BAO_0000357
1621,,,9986.0,Autocuration,Oryctolagus cuniculus,14454,CHEMBL616646,105,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,F,1,H,8,,BAO_0000019
1622,,,9986.0,Expert,Oryctolagus cuniculus,14454,CHEMBL616647,105,,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,F,1,H,8,,BAO_0000019
1623,,,,Autocuration,,16288,CHEMBL616509,105,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,B,1,H,8,,BAO_0000357
1624,,,,Autocuration,,16288,CHEMBL616510,105,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,B,1,H,8,,BAO_0000357
1625,,,,Autocuration,,16312,CHEMBL616511,105,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1626,,,9913.0,Expert,Bos taurus,1348,CHEMBL616512,105,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,B,1,H,8,,BAO_0000357
1627,,,9913.0,Autocuration,Bos taurus,5834,CHEMBL616513,105,,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,B,1,H,8,,BAO_0000357
1628,,2435.0,9913.0,Autocuration,Bos taurus,13366,CHEMBL616514,105,,,Striatum,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,B,1,H,8,,BAO_0000019
1629,,,9913.0,Expert,Bos taurus,1414,CHEMBL616515,105,,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,B,1,H,8,,BAO_0000357
1630,,,9913.0,Autocuration,Bos taurus,14998,CHEMBL616516,105,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,B,1,H,8,,BAO_0000019
1631,,,9913.0,Autocuration,Bos taurus,11473,CHEMBL616517,105,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,B,1,H,8,,BAO_0000357
1632,,,9913.0,Autocuration,Bos taurus,11473,CHEMBL616518,105,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,B,1,H,8,,BAO_0000357
1633,,,9913.0,Autocuration,Bos taurus,10639,CHEMBL616519,105,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,B,1,H,8,,BAO_0000357
1634,,,9913.0,Autocuration,Bos taurus,10639,CHEMBL616520,105,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,B,1,H,8,,BAO_0000357
1635,,,9913.0,Autocuration,Bos taurus,1375,CHEMBL616521,105,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,B,1,H,8,,BAO_0000357
1636,,,9913.0,Autocuration,Bos taurus,1375,CHEMBL616522,105,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,B,1,H,8,,BAO_0000357
1637,,,9913.0,Autocuration,Bos taurus,16532,CHEMBL884531,105,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,B,1,H,8,,BAO_0000357
1638,,,9913.0,Autocuration,Bos taurus,11147,CHEMBL616523,105,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1639,,2435.0,9913.0,Autocuration,Bos taurus,13366,CHEMBL616731,105,,,Striatum,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,B,1,H,8,,BAO_0000019
1640,,,9913.0,Autocuration,Bos taurus,10444,CHEMBL616732,105,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,B,1,H,8,,BAO_0000019
1641,,,9913.0,Autocuration,Bos taurus,16532,CHEMBL616733,105,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,B,1,H,8,,BAO_0000357
1642,,,9913.0,Autocuration,Bos taurus,16532,CHEMBL616734,105,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,B,1,H,8,,BAO_0000357
1643,,,9913.0,Autocuration,Bos taurus,12827,CHEMBL616735,105,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,B,1,H,8,,BAO_0000249
1644,,,9913.0,Autocuration,Bos taurus,12827,CHEMBL616736,105,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,B,1,H,8,,BAO_0000249
1645,,,9913.0,Expert,Bos taurus,12919,CHEMBL616737,105,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,F,1,H,8,,BAO_0000019
1646,,,9913.0,Autocuration,Bos taurus,14025,CHEMBL616738,105,,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,B,1,H,8,,BAO_0000019
1647,,,9913.0,Expert,Bos taurus,12919,CHEMBL616739,105,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,F,1,H,8,,BAO_0000019
1648,,,9913.0,Expert,Bos taurus,12919,CHEMBL616740,105,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,F,1,H,8,,BAO_0000019
1649,,,9913.0,Expert,Bos taurus,12919,CHEMBL616741,105,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,F,1,H,8,,BAO_0000019
1650,,,9593.0,Autocuration,Gorilla gorilla,14447,CHEMBL616742,105,,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,B,1,H,8,,BAO_0000219
1651,,,10141.0,Intermediate,Cavia porcellus,1375,CHEMBL616743,105570,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,B,1,D,9,,BAO_0000019
1652,,,10141.0,Intermediate,Cavia porcellus,1375,CHEMBL616744,105570,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,B,1,D,9,,BAO_0000019
1653,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616745,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,F,1,D,9,,BAO_0000019
1654,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616746,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,F,1,D,9,,BAO_0000019
1655,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616747,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,F,1,D,9,,BAO_0000019
1656,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616748,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,F,1,D,9,,BAO_0000019
1657,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616648,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,F,1,D,9,,BAO_0000019
1658,,,10141.0,Intermediate,Cavia porcellus,11574,CHEMBL616649,105570,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1659,,,10141.0,Intermediate,Cavia porcellus,1558,CHEMBL616650,105570,,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,B,1,D,9,,BAO_0000357
1660,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616651,105570,,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,F,1,D,9,,BAO_0000218
1661,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616652,105570,,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,F,1,D,9,,BAO_0000218
1662,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616653,105570,,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,F,1,D,9,,BAO_0000218
1663,,,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616654,105570,,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,F,1,D,9,,BAO_0000218
1664,,,10141.0,Intermediate,Cavia porcellus,12253,CHEMBL616655,105570,,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,B,1,D,9,,BAO_0000019
1665,,,10141.0,Intermediate,Cavia porcellus,12936,CHEMBL616656,105570,,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1666,,,10141.0,Autocuration,Cavia porcellus,13181,CHEMBL616657,105,,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,B,1,H,8,,BAO_0000019
1667,,2435.0,10141.0,Intermediate,Cavia porcellus,12409,CHEMBL616658,105570,,,Striatum,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,B,1,D,9,,BAO_0000357
1668,,,10141.0,Intermediate,Cavia porcellus,10639,CHEMBL616659,105570,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,B,1,D,9,,BAO_0000357
1669,,,,Autocuration,,5254,CHEMBL616660,51,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1670,,,,Autocuration,,13051,CHEMBL616661,106,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,B,1,H,8,,BAO_0000357
1671,,,,Expert,,3463,CHEMBL616662,105,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,F,1,H,8,,BAO_0000019
1672,,,,Autocuration,,15315,CHEMBL616663,105,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,F,1,H,8,,BAO_0000019
1673,,,,Autocuration,,6011,CHEMBL616664,105,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,F,1,H,8,,BAO_0000019
1674,,,9606.0,Expert,Homo sapiens,14159,CHEMBL881820,105,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,F,1,D,9,,BAO_0000219
1675,,,,Autocuration,,14159,CHEMBL616665,105,,449.0,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,F,1,H,8,,BAO_0000219
1676,,,,Expert,,15250,CHEMBL616666,105,,449.0,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000219
1677,,,,Autocuration,,15250,CHEMBL616667,105,,449.0,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000219
1678,,,,Expert,,15331,CHEMBL616668,105,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,F,1,H,8,,BAO_0000219
1679,,,9606.0,Expert,Homo sapiens,15332,CHEMBL616669,105,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,F,1,D,9,,BAO_0000219
1680,,,,Expert,,15332,CHEMBL617040,105,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,F,1,H,8,,BAO_0000219
1681,,,,Autocuration,,3294,CHEMBL617041,105,,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,F,1,H,8,,BAO_0000219
1682,,,,Expert,,14158,CHEMBL617042,105,,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,F,1,H,8,,BAO_0000219
1683,,,,Expert,,14956,CHEMBL617043,105,,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,F,1,H,8,,BAO_0000219
1684,,,,Autocuration,,12469,CHEMBL617044,105,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,F,1,H,8,,BAO_0000019
1685,,,,Expert,,3463,CHEMBL617045,105,,449.0,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,F,1,H,8,,BAO_0000219
1686,,,9606.0,Expert,Homo sapiens,15250,CHEMBL617046,105,,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,F,1,D,9,,BAO_0000219
1687,,,9606.0,Expert,Homo sapiens,15250,CHEMBL617047,105,,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,F,1,D,9,,BAO_0000219
1688,,,,Expert,,14956,CHEMBL617048,105,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,F,1,H,8,,BAO_0000019
1689,,,,Autocuration,,14159,CHEMBL616897,105,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,F,1,H,8,,BAO_0000019
1690,,,9606.0,Expert,Homo sapiens,14159,CHEMBL616898,105,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,F,1,D,9,,BAO_0000019
1691,,,9606.0,Expert,Homo sapiens,14499,CHEMBL858201,105,,449.0,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,F,1,D,9,,BAO_0000219
1692,,,,Autocuration,,15315,CHEMBL616899,105,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,F,1,H,8,,BAO_0000019
1693,,,,Autocuration,,3294,CHEMBL616900,105,,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,B,1,H,8,,BAO_0000219
1694,,,,Expert,,3463,CHEMBL616901,105,,449.0,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,B,1,H,8,,BAO_0000219
1695,,,,Autocuration,,15331,CHEMBL616902,105,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,B,1,H,8,,BAO_0000357
1696,,,9606.0,Expert,Homo sapiens,14159,CHEMBL616903,105,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
1697,,,,Expert,,14158,CHEMBL616904,105,,449.0,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,B,1,H,8,,BAO_0000219
1698,,,,Autocuration,,14159,CHEMBL616905,105,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1699,,,,Expert,,15250,CHEMBL616906,105,,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,B,1,H,8,,BAO_0000219
1700,,,,Expert,,15250,CHEMBL616907,105,,449.0,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
1701,,,,Expert,,15331,CHEMBL616908,105,,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
1702,,,9606.0,Expert,Homo sapiens,15332,CHEMBL616909,105,,449.0,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
1703,,,9606.0,Expert,Homo sapiens,14499,CHEMBL616910,105,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
1704,,,,Expert,,15332,CHEMBL616911,105,,449.0,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
1705,,,,Expert,,14956,CHEMBL616912,105,,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,B,1,H,8,,BAO_0000219
1706,,,,Autocuration,,3805,CHEMBL616913,105,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,B,1,H,8,,BAO_0000357
1707,,,9606.0,Expert,Homo sapiens,6011,CHEMBL616914,105,,449.0,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,B,1,D,9,,BAO_0000219
1708,,,,Autocuration,,16190,CHEMBL616915,105,,449.0,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000219
1709,,,,Autocuration,,14165,CHEMBL616916,105,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000019
1710,,,9606.0,Expert,Homo sapiens,4234,CHEMBL616917,105,,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1711,,,,Autocuration,,15527,CHEMBL616918,105,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,B,1,H,8,,BAO_0000357
1712,,,,Expert,,6328,CHEMBL616919,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,B,1,H,8,,BAO_0000219
1713,,,,Autocuration,,16209,CHEMBL616920,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1714,,,,Autocuration,,14770,CHEMBL872914,105,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000357
1715,,,,Autocuration,,2598,CHEMBL616921,105,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,B,1,H,8,,BAO_0000357
1716,,,,Expert,,6897,CHEMBL616922,105,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1717,,,,Autocuration,,6013,CHEMBL616923,105,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1718,,,,Expert,,5843,CHEMBL616924,105,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1719,,,,Expert,,14454,CHEMBL875909,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,B,1,H,8,,BAO_0000357
1720,,,,Autocuration,,14454,CHEMBL616925,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,B,1,H,8,,BAO_0000357
1721,,,,Autocuration,,14454,CHEMBL616926,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,B,1,H,8,,BAO_0000357
1722,,,,Autocuration,,15818,CHEMBL616927,105,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1723,,,,Expert,,13729,CHEMBL616928,105,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,F,1,H,8,,BAO_0000219
1724,,,9606.0,Expert,Homo sapiens,6011,CHEMBL616929,105,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,B,1,D,9,,BAO_0000219
1725,,,9606.0,Expert,Homo sapiens,4234,CHEMBL616930,105,,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1726,,,,Expert,,17085,CHEMBL616931,105,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000019
1727,,,,Autocuration,,3025,CHEMBL616932,105,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,B,1,H,8,,BAO_0000357
1728,,,,Expert,,15315,CHEMBL616933,105,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1729,,,9606.0,Expert,Homo sapiens,14214,CHEMBL616934,105,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,B,1,D,9,,BAO_0000219
1730,,,9606.0,Expert,Homo sapiens,3804,CHEMBL616935,105,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1731,,,,Autocuration,,16700,CHEMBL616936,105,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,B,1,H,8,,BAO_0000357
1732,,,9606.0,Expert,Homo sapiens,2391,CHEMBL616937,105,,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,B,1,D,9,,BAO_0000357
1733,,,9606.0,Expert,Homo sapiens,4175,CHEMBL616938,105,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1734,,,,Autocuration,,17085,CHEMBL616939,105,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000019
1735,,,,Expert,,17085,CHEMBL616940,105,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,B,1,H,8,,BAO_0000019
1736,,,9606.0,Expert,Homo sapiens,15926,CHEMBL616941,105,,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,B,1,D,9,,BAO_0000357
1737,,,,Autocuration,,16312,CHEMBL616942,105,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,B,1,H,8,,BAO_0000219
1738,,,,Autocuration,,16312,CHEMBL616943,105,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,B,1,H,8,,BAO_0000219
1739,,,,Autocuration,,14956,CHEMBL616944,104802,,449.0,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,B,1,H,4,,BAO_0000219
1740,,,,Autocuration,,3294,CHEMBL616945,105,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,F,1,H,8,,BAO_0000019
1741,,,,Autocuration,,12861,CHEMBL616946,105,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
1742,,,,Autocuration,,12861,CHEMBL616947,105,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,B,1,H,8,,BAO_0000019
1743,,,,Expert,,16312,CHEMBL616948,105,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000219
1744,,,,Autocuration,,5104,CHEMBL616851,105,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1745,,,,Autocuration,,5105,CHEMBL616852,105,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1746,,,,Autocuration,,14499,CHEMBL616853,105,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1747,,,9606.0,Expert,Homo sapiens,15926,CHEMBL616854,105,,,,Binding activity against human 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1748,,,9606.0,Expert,Homo sapiens,4540,CHEMBL616855,105,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,B,1,D,9,,BAO_0000219
1749,,,,Autocuration,,15779,CHEMBL616856,105,,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,B,1,H,8,,BAO_0000219
1750,,,,Autocuration,,15779,CHEMBL616857,105,,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000219
1751,,,,Autocuration,,6166,CHEMBL616858,105,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1752,,,,Autocuration,,15779,CHEMBL616859,105,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000219
1753,,,,Autocuration,,15779,CHEMBL616860,105,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,B,1,H,8,,BAO_0000219
1754,,,,Autocuration,,17451,CHEMBL616861,105,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000219
1755,,,,Autocuration,,17451,CHEMBL616541,105,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000219
1756,,,,Autocuration,,17451,CHEMBL616542,105,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,B,1,H,8,,BAO_0000219
1757,,,,Autocuration,,4199,CHEMBL616543,105,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,B,1,H,8,,BAO_0000219
1758,,,9606.0,Expert,Homo sapiens,14875,CHEMBL616544,105,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1759,,,,Autocuration,,15146,CHEMBL616545,105,,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,B,1,H,8,,BAO_0000219
1760,,,,Autocuration,,5213,CHEMBL616546,105,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,B,1,H,8,,BAO_0000357
1761,,,,Autocuration,,14818,CHEMBL616547,105,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,B,1,H,8,,BAO_0000219
1762,,,,Autocuration,,4829,CHEMBL616548,105,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
1763,,,,Expert,,14454,CHEMBL616549,105,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,F,1,H,8,,BAO_0000019
1764,,,,Expert,,14454,CHEMBL616550,105,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,F,1,H,8,,BAO_0000019
1765,,,,Autocuration,,5254,CHEMBL857066,108,,,,Binding affinity against 5-HT2C receptor,,B,1,H,8,,BAO_0000357
1766,,,,Autocuration,,5254,CHEMBL616551,108,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1767,,,,Autocuration,,10639,CHEMBL616552,10577,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,B,1,H,8,,BAO_0000357
1768,,,,Autocuration,,10639,CHEMBL832876,10577,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,F,1,H,8,,BAO_0000019
1769,,,,Expert,,12352,CHEMBL616553,10577,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,B,1,H,8,,BAO_0000019
1770,,,,Autocuration,,9098,CHEMBL616554,10577,,,,Binding affinity towards 5-HT1B was determined,,B,1,H,8,,BAO_0000357
1771,,,,Expert,,14430,CHEMBL616555,10577,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,B,1,H,8,,BAO_0000019
1772,,,,Expert,,13657,CHEMBL616556,10577,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,B,1,H,8,,BAO_0000019
1773,,,,Autocuration,,13657,CHEMBL616557,10577,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,B,1,H,8,,BAO_0000019
1774,,,,Expert,,15854,CHEMBL616558,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,B,1,H,8,,BAO_0000019
1775,,,10116.0,Expert,Rattus norvegicus,10639,CHEMBL616749,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,B,1,D,9,,BAO_0000019
1776,,,,Autocuration,,10025,CHEMBL616750,10577,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,B,1,H,8,,BAO_0000357
1777,,,,Autocuration,,10025,CHEMBL616751,10577,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,B,1,H,8,,BAO_0000357
1778,,,,Autocuration,,14286,CHEMBL616752,10577,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,B,1,H,8,,BAO_0000249
1779,,2435.0,,Autocuration,,3651,CHEMBL616753,10577,,,Striatum,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,B,1,H,8,,BAO_0000019
1780,,,10116.0,Expert,Rattus norvegicus,14178,CHEMBL616754,10577,,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1781,,,,Autocuration,,10639,CHEMBL616755,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,B,1,H,8,,BAO_0000019
1782,,2435.0,,Autocuration,,13605,CHEMBL616756,10577,,,Striatum,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,B,1,H,8,,BAO_0000019
1783,,2435.0,,Autocuration,,5834,CHEMBL616757,10577,,,Striatum,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,B,1,H,8,,BAO_0000019
1784,,2435.0,,Autocuration,,10922,CHEMBL616758,10577,,,Striatum,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,B,1,H,8,,BAO_0000357
1785,,,,Autocuration,,14286,CHEMBL616759,10577,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,B,1,H,8,,BAO_0000249
1786,,,,Autocuration,,11825,CHEMBL616760,10577,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,B,1,H,8,,BAO_0000357
1787,,2435.0,,Autocuration,,14826,CHEMBL616761,10577,,,Striatum,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,B,1,H,8,,BAO_0000019
1788,,2435.0,,Autocuration,,9699,CHEMBL616762,10577,,,Striatum,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,B,1,H,8,,BAO_0000019
1789,,,,Autocuration,,14423,CHEMBL616763,10577,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,B,1,H,8,,BAO_0000019
1790,,,,Expert,,10062,CHEMBL872909,10577,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,B,1,H,8,,BAO_0000357
1791,,,,Autocuration,,10062,CHEMBL616764,10577,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1792,,,10116.0,Expert,Rattus norvegicus,12280,CHEMBL616765,10577,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1793,,2435.0,,Autocuration,,15412,CHEMBL616766,10577,,,Striatum,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,B,1,H,8,,BAO_0000357
1794,,2435.0,,Autocuration,,15412,CHEMBL616767,10577,,,Striatum,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,B,1,H,8,,BAO_0000357
1795,,,,Autocuration,,10062,CHEMBL616768,10577,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1796,,,,Autocuration,,11147,CHEMBL616769,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1797,,,,Autocuration,,9547,CHEMBL616770,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,B,1,H,8,,BAO_0000019
1798,,,,Autocuration,,10444,CHEMBL616771,10577,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,B,1,H,8,,BAO_0000019
1799,,2435.0,,Autocuration,,12469,CHEMBL616772,10577,,,Striatum,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,B,1,H,8,,BAO_0000019
1800,,,,Expert,,9098,CHEMBL616773,10577,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,B,1,H,8,,BAO_0000019
1801,,,,Autocuration,,9098,CHEMBL616774,10577,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,B,1,H,8,,BAO_0000019
1802,,,,Autocuration,,9699,CHEMBL616775,10577,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1803,,,,Autocuration,,10394,CHEMBL616776,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,B,1,H,8,,BAO_0000249
1804,,,,Autocuration,,12092,CHEMBL616777,10577,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,B,1,H,8,,BAO_0000357
1805,,,,Autocuration,,16700,CHEMBL616778,10577,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,B,1,H,8,,BAO_0000357
1806,,,10116.0,Expert,Rattus norvegicus,403,CHEMBL616779,10577,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,B,1,D,9,,BAO_0000249
1807,,,10116.0,Expert,Rattus norvegicus,12771,CHEMBL616780,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,B,1,D,9,,BAO_0000357
1808,,,,Autocuration,,11642,CHEMBL616781,10577,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,B,1,H,8,,BAO_0000019
1809,,,,Autocuration,,12953,CHEMBL616782,10577,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1810,,,,Autocuration,,12953,CHEMBL616783,10577,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000357
1811,,2435.0,,Expert,,12953,CHEMBL616784,10577,,,Striatum,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000019
1812,,,,Autocuration,,12953,CHEMBL616785,10577,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,B,1,H,8,,BAO_0000357
1813,,955.0,,Autocuration,,9737,CHEMBL857067,10577,,,Brain,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,B,1,H,8,,BAO_0000249
1814,,,,Autocuration,,9737,CHEMBL616786,10577,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,B,1,H,8,,BAO_0000019
1815,,955.0,,Autocuration,,9737,CHEMBL616787,10577,,,Brain,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,B,1,H,8,,BAO_0000249
1816,,,,Autocuration,,12827,CHEMBL616788,10577,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,B,1,H,8,,BAO_0000357
1817,,,,Autocuration,,5033,CHEMBL616789,10577,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1818,,,10116.0,Expert,Rattus norvegicus,9786,CHEMBL616790,10577,,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,B,1,D,9,,BAO_0000019
1819,,,,Expert,,13116,CHEMBL616791,10577,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1820,,,,Autocuration,,16429,CHEMBL616792,10577,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,B,1,H,8,,BAO_0000019
1821,,,10116.0,Expert,Rattus norvegicus,12409,CHEMBL616793,10577,,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,B,1,D,9,,BAO_0000249
1822,,,,Autocuration,,15194,CHEMBL616794,10577,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1823,,,,Autocuration,,15194,CHEMBL616795,10577,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000357
1824,,,,Autocuration,,5486,CHEMBL616796,104686,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,B,1,H,4,,BAO_0000019
1825,,,,Autocuration,,4639,CHEMBL616797,106,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1826,Brain membranes,,,Autocuration,,386,CHEMBL616798,106,,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,B,1,H,8,,BAO_0000249
1827,,,,Autocuration,,2474,CHEMBL616799,106,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,B,1,H,8,,BAO_0000357
1828,,,,Autocuration,,6011,CHEMBL616800,106,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,B,1,H,8,,BAO_0000357
1829,,,,Autocuration,,5014,CHEMBL616801,106,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1830,,,,Autocuration,,17515,CHEMBL616802,106,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,B,1,H,8,,BAO_0000357
1831,,,,Autocuration,,4373,CHEMBL616803,106,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,B,1,H,8,,BAO_0000357
1832,,,,Expert,,1633,CHEMBL857068,106,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,B,1,H,8,,BAO_0000357
1833,,,,Autocuration,,1633,CHEMBL616804,106,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,B,1,H,8,,BAO_0000357
1834,,,,Autocuration,,4373,CHEMBL616805,106,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,B,1,H,8,,BAO_0000357
1835,,,,Autocuration,,4687,CHEMBL616806,106,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1836,,,,Autocuration,,11574,CHEMBL616807,106,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,B,1,H,8,,BAO_0000357
1837,,,,Autocuration,,10321,CHEMBL616808,106,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1838,,,,Autocuration,,15527,CHEMBL616809,106,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000357
1839,,,,Autocuration,,17200,CHEMBL616810,106,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,B,1,H,8,,BAO_0000357
1840,,,,Autocuration,,14423,CHEMBL616811,104802,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,B,1,H,4,,BAO_0000224
1841,,,9913.0,Autocuration,Bos taurus,5834,CHEMBL616812,108,,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,B,1,H,8,,BAO_0000357
1842,,,9823.0,Autocuration,Sus scrofa,11473,CHEMBL616813,108,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
1843,,,9823.0,Autocuration,Sus scrofa,11473,CHEMBL616814,108,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
1844,,,9823.0,Autocuration,Sus scrofa,10639,CHEMBL616815,108,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,B,1,H,8,,BAO_0000357
1845,,,9823.0,Autocuration,Sus scrofa,10639,CHEMBL616816,108,,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,B,1,H,8,,BAO_0000357
1846,,,9823.0,Autocuration,Sus scrofa,14331,CHEMBL616817,108,,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,B,1,H,8,,BAO_0000357
1847,,,9823.0,Autocuration,Sus scrofa,10796,CHEMBL616818,108,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,B,1,H,8,,BAO_0000357
1848,,,9823.0,Expert,Sus scrofa,9098,CHEMBL616819,108,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,B,1,H,8,,BAO_0000357
1849,,,9823.0,Expert,Sus scrofa,14331,CHEMBL616820,108,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,B,1,H,8,,BAO_0000357
1850,,,9823.0,Expert,Sus scrofa,11828,CHEMBL616821,108,,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,B,1,H,8,,BAO_0000019
1851,,,9823.0,Autocuration,Sus scrofa,11866,CHEMBL616822,108,,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,B,1,H,8,,BAO_0000357
1852,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL616823,108,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,B,1,H,8,,BAO_0000019
1853,,,10116.0,Autocuration,Rattus norvegicus,188,CHEMBL616824,12689,,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,B,1,D,9,,BAO_0000357
1854,,,10116.0,Autocuration,Rattus norvegicus,11825,CHEMBL616825,12689,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,B,1,D,9,,BAO_0000357
1855,,,10116.0,Autocuration,Rattus norvegicus,11825,CHEMBL616826,12689,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,B,1,D,9,,BAO_0000357
1856,,,10116.0,Expert,Rattus norvegicus,11624,CHEMBL616827,12689,,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,B,1,D,9,,BAO_0000019
1857,,,10116.0,Autocuration,Rattus norvegicus,11139,CHEMBL616828,12689,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,B,1,D,9,,BAO_0000357
1858,,,10116.0,Autocuration,Rattus norvegicus,11147,CHEMBL616829,12689,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,B,1,D,9,,BAO_0000357
1859,,,10116.0,Autocuration,Rattus norvegicus,10444,CHEMBL616830,12689,,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,B,1,D,9,,BAO_0000019
1860,,,10116.0,Expert,Rattus norvegicus,11624,CHEMBL616831,12689,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,B,1,D,9,,BAO_0000357
1861,,,10116.0,Autocuration,Rattus norvegicus,11662,CHEMBL616832,12689,,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,B,1,D,9,,BAO_0000019
1862,,,10116.0,Autocuration,Rattus norvegicus,11662,CHEMBL616833,12689,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,B,1,D,9,,BAO_0000019
1863,,,10116.0,Expert,Rattus norvegicus,11662,CHEMBL616834,12689,,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,B,1,D,9,,BAO_0000019
1864,,,10116.0,Autocuration,Rattus norvegicus,11662,CHEMBL829595,12689,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,B,1,D,9,,BAO_0000019
1865,,,10116.0,Autocuration,Rattus norvegicus,9098,CHEMBL616835,12689,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,B,1,D,9,,BAO_0000357
1866,,,10116.0,Autocuration,Rattus norvegicus,10394,CHEMBL872910,12689,,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,B,1,D,9,,BAO_0000249
1867,,,,Expert,,11933,CHEMBL616836,12689,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
1868,,,10116.0,Autocuration,Rattus norvegicus,12092,CHEMBL616837,12689,,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,B,1,D,9,,BAO_0000357
1869,,,10116.0,Autocuration,Rattus norvegicus,12253,CHEMBL616466,12689,,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,B,1,D,9,,BAO_0000019
1870,,,10116.0,Autocuration,Rattus norvegicus,12253,CHEMBL616467,12689,,722.0,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,B,1,D,9,,BAO_0000219
1871,,,,Autocuration,,1558,CHEMBL616468,108,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,B,1,H,8,,BAO_0000357
1872,,,,Autocuration,,2474,CHEMBL616469,108,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
1873,,,,Autocuration,,2474,CHEMBL616470,108,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
1874,,,,Autocuration,,11574,CHEMBL616471,12689,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,B,1,H,8,,BAO_0000357
1875,,,,Autocuration,,1558,CHEMBL616472,12689,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,B,1,H,8,,BAO_0000357
1876,,,,Autocuration,,13944,CHEMBL616473,12689,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,B,1,H,8,,BAO_0000357
1877,,,,Autocuration,,13033,CHEMBL616474,12689,,,,Binding affinity against serotonergic 5-HT1c receptor,,B,1,H,8,,BAO_0000357
1878,,,,Autocuration,,10321,CHEMBL616475,12689,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,B,1,H,8,,BAO_0000357
1879,,,,Autocuration,,11866,CHEMBL616476,12689,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,B,1,H,8,,BAO_0000357
1880,,,9986.0,Autocuration,Oryctolagus cuniculus,14454,CHEMBL616477,105,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,B,1,H,8,,BAO_0000019
1881,,,,Autocuration,,11574,CHEMBL616478,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,B,1,H,4,,BAO_0000224
1882,,,,Autocuration,,11574,CHEMBL616479,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,B,1,H,4,,BAO_0000224
1883,,,,Autocuration,,13631,CHEMBL616480,104686,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,B,1,H,4,,BAO_0000019
1884,,,10116.0,Autocuration,Rattus norvegicus,9630,CHEMBL616481,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,B,1,D,5,,BAO_0000019
1885,,,10116.0,Autocuration,Rattus norvegicus,8822,CHEMBL616482,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,B,1,D,5,,BAO_0000249
1886,,955.0,10116.0,Autocuration,Rattus norvegicus,9064,CHEMBL884713,104686,,,Brain,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,B,1,D,5,,BAO_0000221
1887,,,,Autocuration,,8868,CHEMBL616483,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,B,1,H,4,,BAO_0000224
1888,,,,Autocuration,,9064,CHEMBL616484,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,B,1,H,4,,BAO_0000224
1889,,,,Autocuration,,9806,CHEMBL616485,104686,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,B,1,H,4,,BAO_0000019
1890,,,,Autocuration,,9098,CHEMBL616486,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,B,1,H,4,,BAO_0000224
1891,,,,Autocuration,,8868,CHEMBL616487,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,B,1,H,4,,BAO_0000224
1892,,,,Autocuration,,12765,CHEMBL616488,104686,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,B,1,H,4,,BAO_0000224
1893,,,,Autocuration,,11049,CHEMBL616489,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,B,1,H,4,,BAO_0000019
1894,,,,Autocuration,,11049,CHEMBL616490,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,B,1,H,4,,BAO_0000019
1895,,,,Autocuration,,11049,CHEMBL616491,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,B,1,H,4,,BAO_0000019
1896,,,,Autocuration,,11049,CHEMBL616492,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,B,1,H,4,,BAO_0000019
1897,,,,Autocuration,,11049,CHEMBL616493,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,B,1,H,4,,BAO_0000019
1898,,,,Autocuration,,11473,CHEMBL616494,104686,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,B,1,H,4,,BAO_0000019
1899,,,,Autocuration,,11473,CHEMBL616495,104686,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,B,1,H,4,,BAO_0000019
1900,,,,Autocuration,,3086,CHEMBL616496,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,B,1,H,4,,BAO_0000019
1901,,,,Autocuration,,11049,CHEMBL616497,104686,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,B,1,H,4,,BAO_0000019
1902,,,,Autocuration,,11049,CHEMBL616498,104686,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,B,1,H,4,,BAO_0000019
1903,,,,Autocuration,,10639,CHEMBL616499,104686,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,B,1,H,4,,BAO_0000019
1904,,,,Autocuration,,10922,CHEMBL616500,104686,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,B,1,H,4,,BAO_0000019
1905,,955.0,10116.0,Autocuration,Rattus norvegicus,9064,CHEMBL616501,104686,,,Brain,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,B,1,D,5,,BAO_0000221
1906,,955.0,,Autocuration,,10748,CHEMBL616502,104686,,,Brain,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,B,1,H,4,,BAO_0000221
1907,Membranes,,,Autocuration,,11614,CHEMBL884529,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,B,1,H,4,,BAO_0000249
1908,Membranes,,,Autocuration,,11615,CHEMBL616503,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,B,1,H,4,,BAO_0000249
1909,,,,Autocuration,,11615,CHEMBL616964,104686,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
1910,Membranes,,,Autocuration,,11614,CHEMBL616965,104686,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,B,1,H,4,,BAO_0000249
1911,,,,Autocuration,,11702,CHEMBL616966,104686,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,B,1,H,4,,BAO_0000224
1912,,,,Autocuration,,11702,CHEMBL616967,104686,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,B,1,H,4,,BAO_0000224
1913,,,10116.0,Autocuration,Rattus norvegicus,11702,CHEMBL616968,104686,,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000224
1914,,,,Autocuration,,11702,CHEMBL616969,104686,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,B,1,H,4,,BAO_0000224
1915,,,,Autocuration,,13346,CHEMBL884530,104686,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,B,1,H,4,,BAO_0000019
1916,,,,Autocuration,,10025,CHEMBL616970,104686,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
1917,,,,Autocuration,,10025,CHEMBL616971,104686,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,B,1,H,4,,BAO_0000224
1918,,,,Autocuration,,10025,CHEMBL616972,104686,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,B,1,H,4,,BAO_0000224
1919,,,,Autocuration,,9036,CHEMBL616973,104686,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,B,1,H,4,,BAO_0000224
1920,,,,Autocuration,,9036,CHEMBL616974,104686,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,B,1,H,4,,BAO_0000224
1921,,,,Autocuration,,9161,CHEMBL616975,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,B,1,H,4,,BAO_0000019
1922,,,,Autocuration,,12304,CHEMBL616976,104686,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,B,1,H,4,,BAO_0000019
1923,,,,Autocuration,,13276,CHEMBL616977,104686,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,B,1,H,4,,BAO_0000224
1924,,,,Autocuration,,11825,CHEMBL616978,104686,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,B,1,H,4,,BAO_0000224
1925,,,,Autocuration,,12443,CHEMBL616979,104686,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,B,1,H,4,,BAO_0000224
1926,,,,Autocuration,,13830,CHEMBL616980,104686,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
1927,Membranes,,,Autocuration,,9592,CHEMBL616981,104686,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,B,1,H,4,,BAO_0000249
1928,Membranes,,,Autocuration,,9592,CHEMBL616982,104686,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,B,1,H,4,,BAO_0000249
1929,,,,Autocuration,,10881,CHEMBL616983,104686,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,B,1,H,4,,BAO_0000224
1930,,,,Autocuration,,13605,CHEMBL616984,104686,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,B,1,H,4,,BAO_0000019
1931,,,10116.0,Autocuration,Rattus norvegicus,11624,CHEMBL616985,104686,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000224
1932,,,,Autocuration,,4101,CHEMBL616986,104686,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,B,1,H,4,,BAO_0000224
1933,,,,Autocuration,,4101,CHEMBL616987,104686,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,B,1,H,4,,BAO_0000224
1934,,,,Autocuration,,15360,CHEMBL616988,104686,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,B,1,H,4,,BAO_0000019
1935,,,,Autocuration,,11576,CHEMBL617243,104686,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,B,1,H,4,,BAO_0000019
1936,,,,Autocuration,,5834,CHEMBL617244,104686,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,B,1,H,4,,BAO_0000019
1937,,,10116.0,Autocuration,Rattus norvegicus,2395,CHEMBL617245,104686,,485.0,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,B,1,D,5,,BAO_0000219
1938,Membranes,,,Autocuration,,11965,CHEMBL617246,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,B,1,H,4,,BAO_0000249
1939,,,,Autocuration,,3967,CHEMBL617546,104686,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,B,1,H,4,,BAO_0000224
1940,Brain membranes,,,Autocuration,,11130,CHEMBL617547,104686,,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,B,1,H,4,,BAO_0000249
1941,,,,Autocuration,,13427,CHEMBL617548,104686,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,B,1,H,4,,BAO_0000219
1942,,,,Autocuration,,9443,CHEMBL617549,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
1943,,,,Autocuration,,9443,CHEMBL617550,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,B,1,H,4,,BAO_0000224
1944,,,,Autocuration,,11825,CHEMBL617551,104686,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,B,1,H,4,,BAO_0000224
1945,Membranes,,,Autocuration,,12120,CHEMBL617552,104686,,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,B,1,H,4,,BAO_0000249
1946,Membranes,,,Autocuration,,12120,CHEMBL617553,104686,,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,B,1,H,4,,BAO_0000249
1947,,1515.0,,Autocuration,,11963,CHEMBL617554,104686,,,Thoracic aorta,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,F,1,H,4,,BAO_0000019
1948,,,,Autocuration,,9069,CHEMBL617555,104686,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000019
1949,,,,Autocuration,,8868,CHEMBL617556,104686,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,B,1,H,4,,BAO_0000224
1950,,,,Autocuration,,17200,CHEMBL617557,10624,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,B,1,H,8,,BAO_0000357
1951,,,,Autocuration,,17200,CHEMBL617558,10624,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,B,1,H,8,,BAO_0000357
1952,,,,Expert,,13969,CHEMBL617559,17106,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1953,,,,Expert,,13392,CHEMBL617560,17106,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1954,,,,Autocuration,,1742,CHEMBL617561,17106,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,B,1,H,8,,BAO_0000249
1955,,,,Autocuration,,1742,CHEMBL617562,17106,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,B,1,H,8,,BAO_0000249
1956,,2435.0,,Autocuration,,14331,CHEMBL617563,17106,,,Striatum,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,B,1,H,8,,BAO_0000357
1957,,,,Autocuration,,12861,CHEMBL617564,17106,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,F,1,H,8,,BAO_0000019
1958,,,,Expert,,12861,CHEMBL617565,17106,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000019
1959,,,,Autocuration,,12861,CHEMBL856076,17106,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
1960,,,,Autocuration,,12861,CHEMBL617566,17106,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000019
1961,,,,Expert,,12861,CHEMBL875911,17106,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,B,1,H,8,,BAO_0000019
1962,,,,Autocuration,,12861,CHEMBL617567,17106,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,B,1,H,8,,BAO_0000019
1963,,,,Autocuration,,675,CHEMBL617568,17106,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,B,1,H,8,,BAO_0000249
1964,,,,Expert,,12490,CHEMBL617569,17106,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,B,1,H,8,,BAO_0000019
1965,,,,Expert,,11828,CHEMBL617570,17106,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,B,1,H,8,,BAO_0000249
1966,,,,Autocuration,,11866,CHEMBL617571,17106,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,B,1,H,8,,BAO_0000357
1967,,,9823.0,Autocuration,Sus scrofa,773,CHEMBL617572,105,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,B,1,H,8,,BAO_0000357
1968,,,9986.0,Expert,Oryctolagus cuniculus,13047,CHEMBL617573,105,,,,The compound was tested for intrinsic activity against 5-HT1D receptor,,B,1,H,8,,BAO_0000357
1969,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL617574,105,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,B,1,H,8,,BAO_0000019
1970,,,9986.0,Expert,Oryctolagus cuniculus,13047,CHEMBL617575,105,,,,The compound was tested for binding affinity against 5-HT1D receptor,,B,1,H,8,,BAO_0000357
1971,,,,Autocuration,,188,CHEMBL617576,10578,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,B,1,H,8,,BAO_0000357
1972,,,,Autocuration,,10639,CHEMBL617577,10578,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,F,1,H,8,,BAO_0000019
1973,,,,Autocuration,,12438,CHEMBL617578,10578,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,F,1,H,8,,BAO_0000019
1974,,,,Autocuration,,12438,CHEMBL617579,10578,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1975,,,,Expert,,15854,CHEMBL617580,10578,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,B,1,H,8,,BAO_0000019
1976,,,,Autocuration,,10394,CHEMBL617581,10578,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,B,1,H,8,,BAO_0000249
1977,,,,Autocuration,,12092,CHEMBL617582,10578,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,B,1,H,8,,BAO_0000357
1978,,,,Expert,,3389,CHEMBL617583,10578,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,B,1,H,8,,BAO_0000019
1979,,,,Autocuration,,6011,CHEMBL617584,105,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,B,1,H,8,,BAO_0000357
1980,,,,Autocuration,,4639,CHEMBL617585,105,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1981,,,,Autocuration,,2474,CHEMBL875912,105,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1982,,,,Autocuration,,5014,CHEMBL617586,105,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1983,,,,Autocuration,,17515,CHEMBL617587,105,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,B,1,H,8,,BAO_0000357
1984,,,,Autocuration,,11866,CHEMBL617588,105,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,B,1,H,8,,BAO_0000357
1985,,,,Autocuration,,4687,CHEMBL857980,105,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1986,,,,Autocuration,,12146,CHEMBL617589,105,,,,Tested against 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
1987,,,,Autocuration,,10321,CHEMBL617590,105,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
1988,,,,Autocuration,,13267,CHEMBL617591,105,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000219
1989,,,9606.0,Expert,Homo sapiens,1274,CHEMBL617592,105,,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,B,1,D,9,,BAO_0000357
1990,,,,Autocuration,,15250,CHEMBL617593,105,,,,,,B,1,H,8,,BAO_0000357
1991,,,,Autocuration,,13706,CHEMBL617594,106,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,B,1,H,8,,BAO_0000219
1992,,,,Autocuration,,13706,CHEMBL617595,105,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,B,1,H,8,,BAO_0000219
1993,,,,Autocuration,,13706,CHEMBL617596,105,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,B,1,H,8,,BAO_0000219
1994,,,,Autocuration,,13706,CHEMBL617597,105,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,B,1,H,8,,BAO_0000219
1995,,,,Autocuration,,13047,CHEMBL617598,105,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,B,1,H,8,,BAO_0000019
1996,,,,Autocuration,,13366,CHEMBL872916,105,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,B,1,H,8,,BAO_0000357
1997,,,,Expert,,13366,CHEMBL617599,105,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,B,1,H,8,,BAO_0000357
1998,,,,Autocuration,,1558,CHEMBL617091,105,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,B,1,H,8,,BAO_0000357
1999,,,,Expert,,12902,CHEMBL617092,105,,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,B,1,H,8,,BAO_0000219
2000,,,,Autocuration,,13706,CHEMBL617093,105,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,B,1,H,8,,BAO_0000219
2001,,,,Autocuration,,13706,CHEMBL617094,105,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,F,1,H,8,,BAO_0000019
2002,,,,Autocuration,,13706,CHEMBL617095,105,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,F,1,H,8,,BAO_0000019
2003,,,,Autocuration,,14251,CHEMBL617096,105,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,F,1,H,8,,BAO_0000019
2004,,,,Autocuration,,14251,CHEMBL617097,105,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,F,1,H,8,,BAO_0000019
2005,,,,Autocuration,,14251,CHEMBL617098,105,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,F,1,H,8,,BAO_0000019
2006,,,,Autocuration,,13313,CHEMBL617301,105,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2007,,,,Autocuration,,13313,CHEMBL617302,105,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2008,,,,Autocuration,,13366,CHEMBL617303,105,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,B,1,H,8,,BAO_0000357
2009,,,,Expert,,13051,CHEMBL617304,105,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,B,1,H,8,,BAO_0000357
2010,,,,Expert,,12903,CHEMBL617305,105,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2011,,,9606.0,Autocuration,Homo sapiens,12469,CHEMBL617306,105,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,B,1,D,9,,BAO_0000219
2012,,,,Autocuration,,5619,CHEMBL617307,17106,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,B,1,H,8,,BAO_0000357
2013,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL617308,105,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,B,1,H,8,,BAO_0000019
2014,,,,Autocuration,,16633,CHEMBL617309,105,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,B,1,H,8,,BAO_0000357
2015,,,,Autocuration,,16633,CHEMBL617310,105,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,B,1,H,8,,BAO_0000357
2016,,,,Autocuration,,16633,CHEMBL617311,105,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,B,1,H,8,,BAO_0000357
2017,,,,Autocuration,,16633,CHEMBL617312,105,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
2018,,,,Autocuration,,3269,CHEMBL617313,105,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,B,1,H,8,,BAO_0000357
2019,,,,Expert,,12409,CHEMBL617314,105,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,B,1,H,8,,BAO_0000357
2020,,,,Autocuration,,13706,CHEMBL617315,106,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,F,1,H,8,,BAO_0000019
2021,,,,Autocuration,,13706,CHEMBL617316,106,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,B,1,H,8,,BAO_0000219
2022,,,,Autocuration,,13706,CHEMBL617317,106,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,B,1,H,8,,BAO_0000219
2023,,,,Autocuration,,12903,CHEMBL617318,106,,449.0,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2024,,,,Autocuration,,13047,CHEMBL617319,106,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,B,1,H,8,,BAO_0000019
2025,,,,Expert,,13366,CHEMBL617320,106,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,B,1,D,9,,BAO_0000357
2026,,,,Expert,,13366,CHEMBL617321,106,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,B,1,D,9,,BAO_0000357
2027,,,,Expert,,13366,CHEMBL617322,106,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,B,1,D,9,,BAO_0000357
2028,,,,Autocuration,,13366,CHEMBL616862,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
2029,,,,Autocuration,,13366,CHEMBL616863,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,B,1,H,8,,BAO_0000357
2030,,,,Autocuration,,12469,CHEMBL616864,106,,449.0,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,B,1,H,8,,BAO_0000219
2031,,,,Autocuration,,13706,CHEMBL616865,106,,485.0,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,B,1,H,8,,BAO_0000219
2032,,,,Autocuration,,13706,CHEMBL616866,106,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,B,1,H,8,,BAO_0000219
2033,,,,Autocuration,,13706,CHEMBL616867,106,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,F,1,H,8,,BAO_0000019
2034,,,,Expert,,12902,CHEMBL616868,106,,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,B,1,H,8,,BAO_0000219
2035,,,,Expert,,13051,CHEMBL616869,105,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,B,1,H,8,,BAO_0000357
2036,,,,Expert,,12903,CHEMBL616870,106,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2037,,,,Autocuration,,1558,CHEMBL616871,105,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,F,1,H,8,,BAO_0000219
2038,,,,Autocuration,,1558,CHEMBL616872,105,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,F,1,H,8,,BAO_0000219
2039,,,,Autocuration,,1558,CHEMBL616873,105,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,F,1,H,8,,BAO_0000219
2040,,,,Autocuration,,1558,CHEMBL616838,105,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,F,1,H,8,,BAO_0000219
2041,,,,Autocuration,,1558,CHEMBL616839,105,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,B,1,H,8,,BAO_0000357
2042,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL616840,106,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,B,1,H,8,,BAO_0000019
2043,,,,Autocuration,,13313,CHEMBL616841,105,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,B,1,H,8,,BAO_0000357
2044,,,,Autocuration,,13313,CHEMBL616842,105,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2045,,,,Expert,,12409,CHEMBL857976,105,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,B,1,H,8,,BAO_0000357
2046,,,,Autocuration,,15250,CHEMBL616843,10618,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2047,,,9606.0,Expert,Homo sapiens,1348,CHEMBL616844,10618,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,B,1,D,9,,BAO_0000357
2048,,,,Autocuration,,1348,CHEMBL616845,10618,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,B,1,H,8,,BAO_0000357
2049,,,9606.0,Expert,Homo sapiens,4234,CHEMBL616846,10618,,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,B,1,D,9,,BAO_0000357
2050,,,,Autocuration,,16209,CHEMBL616847,10618,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2051,,,,Autocuration,,10444,CHEMBL616848,10618,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,B,1,H,8,,BAO_0000019
2052,,,,Autocuration,,3935,CHEMBL616849,10618,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,B,1,H,8,,BAO_0000357
2053,,,,Autocuration,,15818,CHEMBL872911,10618,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,B,1,H,8,,BAO_0000357
2054,,,,Autocuration,,17085,CHEMBL616850,10618,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,B,1,H,8,,BAO_0000019
2055,,,9606.0,Expert,Homo sapiens,12936,CHEMBL616699,10618,,449.0,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
2056,,,,Autocuration,,6166,CHEMBL616700,10618,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,B,1,H,8,,BAO_0000357
2057,,,,Autocuration,,15779,CHEMBL616701,10618,,449.0,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000219
2058,,,,Autocuration,,15779,CHEMBL616702,10618,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000219
2059,,,,Autocuration,,15779,CHEMBL616703,10618,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,B,1,H,8,,BAO_0000219
2060,,,,Autocuration,,13181,CHEMBL616704,10618,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,B,1,H,8,,BAO_0000357
2061,,,,Autocuration,,4199,CHEMBL616705,10618,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,B,1,H,8,,BAO_0000219
2062,,,,Autocuration,,14875,CHEMBL616706,10618,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,B,1,H,8,,BAO_0000357
2063,,,,Autocuration,,15146,CHEMBL616707,10618,,449.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,B,1,H,8,,BAO_0000219
2064,,,,Autocuration,,5213,CHEMBL616708,10618,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,B,1,H,8,,BAO_0000357
2065,,,,Autocuration,,12146,CHEMBL616709,10618,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2066,,,,Autocuration,,13267,CHEMBL616710,10618,,449.0,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,B,1,H,8,,BAO_0000219
2067,,,,Autocuration,,14818,CHEMBL616711,10618,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,B,1,H,8,,BAO_0000219
2068,,,,Autocuration,,4829,CHEMBL616712,10618,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2069,,,,Autocuration,,4373,CHEMBL616713,10618,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,B,1,H,8,,BAO_0000357
2070,,,,Autocuration,,4373,CHEMBL616714,10618,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,B,1,H,8,,BAO_0000357
2071,,,,Autocuration,,14159,CHEMBL616715,10618,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,B,1,H,8,,BAO_0000357
2072,,,,Autocuration,,16633,CHEMBL616716,10618,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,B,1,H,8,,BAO_0000357
2073,,,,Autocuration,,17085,CHEMBL616717,279,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,F,1,H,8,,BAO_0000019
2074,,,,Expert,,17085,CHEMBL616718,279,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,F,1,H,8,,BAO_0000019
2075,,,,Autocuration,,16209,CHEMBL875905,279,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,F,1,H,8,,BAO_0000019
2076,,,,Autocuration,,16209,CHEMBL616719,279,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,F,1,H,8,,BAO_0000019
2077,,,,Expert,,17085,CHEMBL616720,279,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,F,1,H,8,,BAO_0000019
2078,,,,Autocuration,,14159,CHEMBL616721,279,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,B,1,H,8,,BAO_0000357
2079,,,,Autocuration,,15250,CHEMBL616722,279,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2080,,,,Autocuration,,3805,CHEMBL616723,279,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,B,1,H,8,,BAO_0000357
2081,,,,Autocuration,,16190,CHEMBL616724,279,,449.0,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,B,1,H,8,,BAO_0000219
2082,,,,Autocuration,,16190,CHEMBL616725,279,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,B,1,H,8,,BAO_0000357
2083,,,,Autocuration,,16209,CHEMBL616726,279,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,B,1,H,8,,BAO_0000357
2084,,,,Autocuration,,16209,CHEMBL616727,279,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,B,1,H,8,,BAO_0000357
2085,,,,Autocuration,,16209,CHEMBL616728,279,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,B,1,H,8,,BAO_0000357
2086,,,,Autocuration,,6866,CHEMBL616729,279,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,B,1,H,8,,BAO_0000357
2087,,,,Expert,,17085,CHEMBL616730,279,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,B,1,H,8,,BAO_0000019
2088,,,,Autocuration,,16312,CHEMBL617125,279,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,B,1,H,8,,BAO_0000357
2089,,,,Autocuration,,6166,CHEMBL857977,279,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,B,1,H,8,,BAO_0000357
2090,,,,Autocuration,,15779,CHEMBL617126,279,,449.0,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000219
2091,,,,Autocuration,,4199,CHEMBL617127,279,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,B,1,H,8,,BAO_0000219
2092,,,,Autocuration,,14875,CHEMBL617128,279,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,B,1,H,8,,BAO_0000357
2093,,,,Autocuration,,15146,CHEMBL617129,279,,449.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,B,1,H,8,,BAO_0000219
2094,,,,Autocuration,,5213,CHEMBL617130,279,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,B,1,H,8,,BAO_0000357
2095,,,,Autocuration,,14818,CHEMBL617131,279,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,B,1,H,8,,BAO_0000219
2096,,,,Autocuration,,4829,CHEMBL617132,279,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2097,,,,Autocuration,,4829,CHEMBL617133,279,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2098,,,,Autocuration,,4373,CHEMBL617134,279,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,B,1,H,8,,BAO_0000357
2099,,,,Autocuration,,4373,CHEMBL617135,279,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,B,1,H,8,,BAO_0000357
2100,,,,Autocuration,,5014,CHEMBL617136,279,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,B,1,H,8,,BAO_0000357
2101,,,,Autocuration,,11662,CHEMBL617137,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,B,1,H,4,,BAO_0000019
2102,,,,Autocuration,,11662,CHEMBL617138,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,B,1,H,4,,BAO_0000019
2103,,,,Autocuration,,11662,CHEMBL617139,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,B,1,H,4,,BAO_0000019
2104,,,,Autocuration,,14093,CHEMBL617140,12687,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000019
2105,,,,Autocuration,,11200,CHEMBL617141,104686,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,F,1,H,4,,BAO_0000218
2106,,,,Autocuration,,11200,CHEMBL858112,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,F,1,H,4,,BAO_0000019
2107,,,,Intermediate,,12352,CHEMBL617142,17005,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,B,1,H,8,,BAO_0000019
2108,,,9913.0,Autocuration,Bos taurus,13657,CHEMBL617143,22226,,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,B,1,U,0,,BAO_0000019
2109,,,9913.0,Autocuration,Bos taurus,14331,CHEMBL617144,22226,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,B,1,U,0,,BAO_0000019
2110,,,9913.0,Autocuration,Bos taurus,14331,CHEMBL617145,22226,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,B,1,U,0,,BAO_0000019
2111,,,,Autocuration,,14331,CHEMBL617146,22226,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,B,1,U,0,,BAO_0000019
2112,,,10141.0,Autocuration,Cavia porcellus,12685,CHEMBL617147,104784,,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,B,1,H,4,,BAO_0000019
2113,,,10141.0,Autocuration,Cavia porcellus,14389,CHEMBL617148,104784,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,B,1,H,4,,BAO_0000019
2114,,,10141.0,Autocuration,Cavia porcellus,14386,CHEMBL617149,104784,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,B,1,H,4,,BAO_0000019
2115,,,,Autocuration,,5732,CHEMBL617150,104784,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,B,1,H,4,,BAO_0000224
2116,,,,Autocuration,,16293,CHEMBL617151,104784,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,B,1,H,4,,BAO_0000224
2117,,,,Autocuration,,2078,CHEMBL617201,104784,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2118,,,,Autocuration,,5486,CHEMBL617202,10209,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,B,1,H,8,,BAO_0000357
2119,,,,Autocuration,,11820,CHEMBL617203,104826,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,B,1,H,4,,BAO_0000218
2120,,,,Autocuration,,10297,CHEMBL617204,104826,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,B,1,H,4,,BAO_0000019
2121,,,,Autocuration,,13704,CHEMBL617205,104826,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,B,1,H,4,,BAO_0000224
2122,,,10090.0,Autocuration,Mus musculus,10297,CHEMBL617206,104826,,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,B,1,D,5,,BAO_0000019
2123,,,,Autocuration,,11820,CHEMBL617207,104826,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,B,1,H,4,,BAO_0000218
2124,,,10090.0,Autocuration,Mus musculus,10297,CHEMBL617208,104826,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,B,1,D,5,,BAO_0000019
2125,,,,Autocuration,,11555,CHEMBL617209,104826,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2126,,,,Autocuration,,11555,CHEMBL617210,104826,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,B,1,H,4,,BAO_0000224
2127,,,,Autocuration,,11555,CHEMBL617211,104826,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,B,1,H,4,,BAO_0000224
2128,,,10090.0,Autocuration,Mus musculus,10297,CHEMBL617212,104826,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,B,1,D,5,,BAO_0000019
2129,,,9823.0,Autocuration,Sus scrofa,16688,CHEMBL617213,104784,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,B,1,H,4,,BAO_0000224
2130,,,9823.0,Autocuration,Sus scrofa,16688,CHEMBL617214,104784,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,B,1,H,4,,BAO_0000224
2131,,,,Autocuration,,5333,CHEMBL617215,22226,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,B,1,U,0,,BAO_0000221
2132,,,,Autocuration,,4437,CHEMBL617216,22226,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,B,1,U,0,,BAO_0000221
2133,,,9823.0,Autocuration,Sus scrofa,5033,CHEMBL617217,17005,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,B,1,H,8,,BAO_0000357
2134,,,,Autocuration,,15267,CHEMBL617218,104686,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000019
2135,,,,Autocuration,,15267,CHEMBL872913,104686,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000019
2136,,,,Autocuration,,11820,CHEMBL617219,104826,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,B,1,H,4,,BAO_0000019
2137,,,,Autocuration,,9069,CHEMBL873482,104686,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2138,,,10116.0,Autocuration,Rattus norvegicus,9162,CHEMBL617220,104686,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,B,1,D,5,,BAO_0000019
2139,,,,Autocuration,,9162,CHEMBL617221,104686,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,B,1,H,4,,BAO_0000019
2140,,,,Autocuration,,9162,CHEMBL617222,104686,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,B,1,H,4,,BAO_0000019
2141,,,,Autocuration,,10428,CHEMBL875906,104686,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,F,1,H,4,,BAO_0000019
2142,,,,Autocuration,,9628,CHEMBL617223,104686,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,B,1,H,4,,BAO_0000019
2143,,,,Autocuration,,12704,CHEMBL617224,104686,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2144,,,10116.0,Autocuration,Rattus norvegicus,15453,CHEMBL617225,104686,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,B,1,D,5,,BAO_0000224
2145,,,,Autocuration,,188,CHEMBL617226,104686,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,B,1,H,4,,BAO_0000224
2146,,,,Autocuration,,10349,CHEMBL617227,104686,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,B,1,H,4,,BAO_0000224
2147,,,,Autocuration,,10349,CHEMBL617228,104686,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,B,1,H,4,,BAO_0000224
2148,,,,Autocuration,,8868,CHEMBL617229,104686,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,B,1,H,4,,BAO_0000224
2149,,,,Autocuration,,10025,CHEMBL617230,104686,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,B,1,H,4,,BAO_0000224
2150,,,,Autocuration,,10025,CHEMBL617231,104686,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,B,1,H,4,,BAO_0000224
2151,,,,Autocuration,,11702,CHEMBL617232,104686,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,B,1,H,4,,BAO_0000224
2152,,,,Autocuration,,11702,CHEMBL617233,104686,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2153,,,,Autocuration,,11702,CHEMBL617234,104686,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,B,1,H,4,,BAO_0000224
2154,,,,Autocuration,,11702,CHEMBL617235,104686,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,F,1,H,4,,BAO_0000019
2155,,,,Autocuration,,11702,CHEMBL617236,104686,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,F,1,H,4,,BAO_0000019
2156,,10000000.0,,Autocuration,,10085,CHEMBL617237,104686,,,Hippocampus,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,B,1,H,4,,BAO_0000221
2157,,10000000.0,,Autocuration,,10085,CHEMBL617238,104686,,,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,B,1,H,4,,BAO_0000221
2158,,955.0,10116.0,Autocuration,Rattus norvegicus,9630,CHEMBL617239,104686,,,Brain,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,B,1,D,5,,BAO_0000221
2159,,,,Autocuration,,11070,CHEMBL617240,104686,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,B,1,H,4,,BAO_0000019
2160,Membranes,,,Autocuration,,9841,CHEMBL617241,104686,,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,B,1,H,4,,BAO_0000249
2161,Membranes,,,Autocuration,,9841,CHEMBL875907,104686,,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,B,1,H,4,,BAO_0000249
2162,,,,Autocuration,,13291,CHEMBL617242,104686,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,B,1,H,4,,BAO_0000019
2163,,,,Autocuration,,10590,CHEMBL617152,104686,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,F,1,H,4,,BAO_0000019
2164,,955.0,10116.0,Autocuration,Rattus norvegicus,9064,CHEMBL617153,104686,,,Brain,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,B,1,D,5,,BAO_0000221
2165,Membranes,,10116.0,Autocuration,Rattus norvegicus,12268,CHEMBL617154,104686,,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,B,1,D,5,,BAO_0000249
2166,,955.0,,Autocuration,,13508,CHEMBL617155,104686,,,Brain,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,B,1,H,4,,BAO_0000221
2167,,,,Autocuration,,11279,CHEMBL617156,104686,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,F,1,H,4,,BAO_0000019
2168,,,,Autocuration,,11200,CHEMBL617157,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,F,1,H,4,,BAO_0000019
2169,,,,Autocuration,,11200,CHEMBL617158,104686,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,F,1,H,4,,BAO_0000019
2170,,,,Autocuration,,11200,CHEMBL617159,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,F,1,H,4,,BAO_0000019
2171,,,,Autocuration,,11200,CHEMBL617160,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,F,1,H,4,,BAO_0000019
2172,,,,Autocuration,,11200,CHEMBL858113,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,F,1,H,4,,BAO_0000019
2173,,955.0,,Autocuration,,9231,CHEMBL617247,104686,,,Brain,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,B,1,H,4,,BAO_0000220
2174,,,,Autocuration,,9737,CHEMBL617248,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,B,1,H,4,,BAO_0000019
2175,,955.0,,Autocuration,,9737,CHEMBL617249,104686,,,Brain,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,B,1,H,4,,BAO_0000249
2176,,,,Autocuration,,9737,CHEMBL617250,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,B,1,H,4,,BAO_0000019
2177,,,,Autocuration,,9737,CHEMBL617251,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,B,1,H,4,,BAO_0000019
2178,,,10116.0,Autocuration,Rattus norvegicus,11828,CHEMBL617252,104686,,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000019
2179,,,,Autocuration,,12253,CHEMBL617006,104686,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,B,1,H,4,,BAO_0000019
2180,,,,Autocuration,,12253,CHEMBL617007,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,B,1,H,4,,BAO_0000019
2181,,,,Autocuration,,11279,CHEMBL617008,104686,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,F,1,H,4,,BAO_0000019
2182,,,,Autocuration,,11866,CHEMBL617009,104686,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,B,1,H,4,,BAO_0000019
2183,,,10116.0,Autocuration,Rattus norvegicus,14424,CHEMBL617010,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,B,1,D,5,,BAO_0000224
2184,,,10116.0,Autocuration,Rattus norvegicus,15180,CHEMBL857978,104686,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000019
2185,,,10116.0,Autocuration,Rattus norvegicus,15180,CHEMBL617011,104686,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000019
2186,,,10116.0,Autocuration,Rattus norvegicus,9786,CHEMBL617012,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,B,1,D,5,,BAO_0000019
2187,,,,Autocuration,,12132,CHEMBL617013,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,B,1,H,4,,BAO_0000224
2188,,,,Autocuration,,5486,CHEMBL617014,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,B,1,H,4,,BAO_0000249
2189,,,,Autocuration,,15316,CHEMBL617015,104686,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000019
2190,,,,Autocuration,,16429,CHEMBL617016,104686,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,B,1,H,4,,BAO_0000019
2191,,,,Autocuration,,14617,CHEMBL617017,104686,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,B,1,H,4,,BAO_0000224
2192,,955.0,,Autocuration,,11351,CHEMBL617018,104686,,,Brain,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,B,1,H,4,,BAO_0000221
2193,,,,Autocuration,,11279,CHEMBL617019,104686,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,F,1,H,4,,BAO_0000019
2194,,,,Autocuration,,9523,CHEMBL617020,105075,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,B,1,H,4,,BAO_0000019
2195,,,,Autocuration,,9523,CHEMBL617021,105075,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,B,1,H,4,,BAO_0000019
2196,,,,Autocuration,,9523,CHEMBL617022,105075,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,B,1,H,4,,BAO_0000019
2197,,,,Autocuration,,9523,CHEMBL617023,105075,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,B,1,H,4,,BAO_0000019
2198,,,,Autocuration,,9523,CHEMBL617024,105075,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,B,1,H,4,,BAO_0000019
2199,,,,Autocuration,,9523,CHEMBL617025,105075,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,B,1,H,4,,BAO_0000019
2200,,,,Autocuration,,9523,CHEMBL617026,105075,,,,Hill coefficient of compound was determined,,B,1,H,4,,BAO_0000224
2201,,,,Autocuration,,4771,CHEMBL617027,22226,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,B,1,U,0,,BAO_0000019
2202,,,10116.0,Autocuration,Rattus norvegicus,5033,CHEMBL617028,104686,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,B,1,D,5,,BAO_0000019
2203,,,,Expert,,10845,CHEMBL617029,12687,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,B,1,H,8,,BAO_0000019
2204,,,,Expert,,10845,CHEMBL875908,12687,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,B,1,H,8,,BAO_0000019
2205,,,,Autocuration,,16288,CHEMBL617030,12687,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,B,1,H,8,,BAO_0000357
2206,,,,Autocuration,,16288,CHEMBL617031,12687,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,B,1,H,8,,BAO_0000019
2207,,,,Autocuration,,16190,CHEMBL617032,12687,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,B,1,H,8,,BAO_0000019
2208,,,10116.0,Autocuration,Rattus norvegicus,12463,CHEMBL617033,104686,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,B,1,D,5,,BAO_0000224
2209,,,,Autocuration,,9699,CHEMBL617034,104686,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,B,1,H,4,,BAO_0000224
2210,,,,Autocuration,,9699,CHEMBL617035,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,B,1,H,4,,BAO_0000224
2211,,,,Autocuration,,11662,CHEMBL617036,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,B,1,H,4,,BAO_0000019
2212,,,,Autocuration,,1205,CHEMBL617037,104784,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2213,,,,Autocuration,,11376,CHEMBL617038,22226,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,B,1,U,0,,BAO_0000219
2214,,,,Autocuration,,11376,CHEMBL617039,104784,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,B,1,H,4,,BAO_0000219
2215,,,,Autocuration,,4639,CHEMBL617161,104784,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2216,,,,Autocuration,,2222,CHEMBL617162,104784,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2217,,,,Autocuration,,1558,CHEMBL617163,104784,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2218,,,,Autocuration,,1089,CHEMBL617164,104784,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2219,Brain membranes,,,Autocuration,,386,CHEMBL617165,104784,,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,B,1,H,4,,BAO_0000249
2220,,,,Autocuration,,2474,CHEMBL617166,104784,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,B,1,H,4,,BAO_0000224
2221,,,,Autocuration,,17066,CHEMBL617167,104784,,,,Binding affinity towards 5-HT2 receptor,,B,1,H,4,,BAO_0000224
2222,,,,Autocuration,,959,CHEMBL872912,104784,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2223,,,,Autocuration,,6398,CHEMBL617168,104784,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,B,1,H,4,,BAO_0000224
2224,,,,Autocuration,,11889,CHEMBL617169,104686,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,B,1,H,4,,BAO_0000224
2225,,,,Autocuration,,4221,CHEMBL617170,104784,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2226,,,,Autocuration,,11026,CHEMBL617171,104784,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,B,1,H,4,,BAO_0000224
2227,,,,Autocuration,,11866,CHEMBL617172,104784,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,B,1,H,4,,BAO_0000224
2228,,,,Autocuration,,4221,CHEMBL617173,104784,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2229,,,,Autocuration,,13950,CHEMBL617174,22226,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,B,1,U,0,,BAO_0000019
2230,,,,Autocuration,,1263,CHEMBL617175,104784,,,,5-hydroxytryptamine 2 receptor binding affinity,,B,1,H,4,,BAO_0000224
2231,,,,Autocuration,,13291,CHEMBL617176,17005,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,B,1,H,8,,BAO_0000357
2232,,,,Autocuration,,10812,CHEMBL617177,17005,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2233,,,,Autocuration,,13020,CHEMBL617178,104784,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,B,1,H,4,,BAO_0000224
2234,,,,Autocuration,,13021,CHEMBL617179,104784,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,B,1,H,4,,BAO_0000224
2235,,,,Autocuration,,13020,CHEMBL617180,104784,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,B,1,H,4,,BAO_0000224
2236,,,,Autocuration,,14532,CHEMBL617181,17005,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,B,1,H,8,,BAO_0000357
2237,,,,Autocuration,,13944,CHEMBL617182,17005,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,B,1,H,8,,BAO_0000357
2238,,,,Autocuration,,14331,CHEMBL617183,17005,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,B,1,H,8,,BAO_0000357
2239,,,,Autocuration,,14118,CHEMBL617184,17005,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2240,,,,Autocuration,,13033,CHEMBL617185,17005,,,,Binding affinity against serotonergic 5-HT2 receptor,,B,1,H,8,,BAO_0000357
2241,,,,Autocuration,,10321,CHEMBL617186,17005,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2242,,,,Autocuration,,12918,CHEMBL617187,17005,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,B,1,H,8,,BAO_0000357
2243,,,,Autocuration,,15120,CHEMBL617188,17005,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,B,1,H,8,,BAO_0000357
2244,,,,Autocuration,,2613,CHEMBL617189,17005,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,B,1,H,8,,BAO_0000218
2245,,,9606.0,Autocuration,Homo sapiens,13378,CHEMBL617190,104784,,,,Inhibitory activity against cloned human 5-HT2 receptor,,B,1,D,5,,BAO_0000224
2246,,,9606.0,Autocuration,Homo sapiens,2331,CHEMBL617191,104784,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,B,1,D,5,,BAO_0000219
2247,,,9606.0,Autocuration,Homo sapiens,2331,CHEMBL617192,104784,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,B,1,D,5,,BAO_0000219
2248,,,9606.0,Autocuration,Homo sapiens,2331,CHEMBL617193,104784,,449.0,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,B,1,D,5,,BAO_0000219
2249,,,9606.0,Autocuration,Homo sapiens,2331,CHEMBL617194,104784,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,B,1,D,5,,BAO_0000219
2250,,,,Autocuration,,4170,CHEMBL617195,104784,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2251,,,,Autocuration,,15453,CHEMBL881830,104784,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,B,1,H,4,,BAO_0000224
2252,,,,Autocuration,,1479,CHEMBL617196,17005,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,B,1,H,8,,BAO_0000357
2253,,,,Autocuration,,11139,CHEMBL617197,104686,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,B,1,H,4,,BAO_0000224
2254,,,,Expert,,13969,CHEMBL617198,17005,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2255,,,,Expert,,13392,CHEMBL873476,17005,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2256,,,,Expert,,14430,CHEMBL617199,17005,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,B,1,H,8,,BAO_0000019
2257,,,10141.0,Autocuration,Cavia porcellus,13181,CHEMBL617200,107,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2258,,,,Autocuration,,17200,CHEMBL617484,51,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,B,1,H,8,,BAO_0000357
2259,,,,Autocuration,,17200,CHEMBL617485,107,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,B,1,H,8,,BAO_0000357
2260,,,,Autocuration,,17200,CHEMBL617486,51,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,B,1,H,8,,BAO_0000357
2261,,,,Autocuration,,13463,CHEMBL858022,107,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2262,,,,Autocuration,,6347,CHEMBL617049,107,,449.0,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,B,1,H,8,,BAO_0000219
2263,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617050,107,,449.0,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,F,1,D,9,,BAO_0000219
2264,,,,Autocuration,,4176,CHEMBL617051,107,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,F,1,H,8,,BAO_0000219
2265,,,,Autocuration,,4176,CHEMBL617052,107,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,F,1,H,8,,BAO_0000219
2266,,,,Autocuration,,4176,CHEMBL617053,107,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,F,1,H,8,,BAO_0000219
2267,,,,Autocuration,,6347,CHEMBL617054,107,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,B,1,H,8,,BAO_0000219
2268,,,,Autocuration,,6347,CHEMBL617055,107,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,B,1,H,8,,BAO_0000219
2269,,,,Autocuration,,15331,CHEMBL882924,107,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,B,1,H,8,,BAO_0000357
2270,,,9606.0,Expert,Homo sapiens,16146,CHEMBL617056,107,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2271,,,,Autocuration,,15250,CHEMBL617057,107,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2272,,,,Expert,,13631,CHEMBL617058,107,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,B,1,H,8,,BAO_0000219
2273,,,,Autocuration,,3805,CHEMBL617059,107,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,B,1,H,8,,BAO_0000357
2274,,,,Autocuration,,4011,CHEMBL617060,107,,449.0,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,B,1,H,8,,BAO_0000219
2275,,,,Expert,,4012,CHEMBL617061,107,,449.0,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,B,1,H,8,,BAO_0000219
2276,,,,Expert,,6366,CHEMBL617062,107,,307.0,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,B,1,H,8,,BAO_0000219
2277,,,,Expert,,15949,CHEMBL617063,107,,449.0,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2278,,,,Autocuration,,14093,CHEMBL617064,107,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,F,1,H,8,,BAO_0000019
2279,,,,Autocuration,,13481,CHEMBL617065,107,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,F,1,H,8,,BAO_0000019
2280,,,,Autocuration,,6347,CHEMBL617066,107,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,B,1,H,8,,BAO_0000219
2281,,,,Autocuration,,6347,CHEMBL617067,107,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,B,1,H,8,,BAO_0000219
2282,,,,Autocuration,,14093,CHEMBL617068,107,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,F,1,H,8,,BAO_0000019
2283,,,,Autocuration,,14093,CHEMBL617069,107,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,F,1,H,8,,BAO_0000019
2284,,,,Autocuration,,13481,CHEMBL617070,107,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,F,1,H,8,,BAO_0000019
2285,,,,Autocuration,,14442,CHEMBL617071,107,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,B,1,H,8,,BAO_0000357
2286,,,,Autocuration,,14442,CHEMBL872915,107,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2287,,,,Autocuration,,14755,CHEMBL617072,107,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,B,1,H,8,,BAO_0000357
2288,,,,Autocuration,,16441,CHEMBL617073,107,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,B,1,H,8,,BAO_0000357
2289,,,,Autocuration,,14744,CHEMBL617074,107,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,B,1,H,8,,BAO_0000357
2290,,,,Expert,,16659,CHEMBL617075,107,,449.0,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2291,,,,Autocuration,,3307,CHEMBL617076,107,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2292,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617077,107,,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,B,1,D,9,,BAO_0000019
2293,,,,Expert,,5635,CHEMBL617078,107,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,B,1,H,8,,BAO_0000357
2294,,,9606.0,Expert,Homo sapiens,4234,CHEMBL617079,107,,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2295,,,,Autocuration,,15527,CHEMBL617080,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000357
2296,,,,Expert,,6588,CHEMBL617081,107,,449.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,B,1,H,8,,BAO_0000219
2297,,,,Expert,,13631,CHEMBL617082,107,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,,B,1,H,8,,BAO_0000219
2298,,,,Autocuration,,17723,CHEMBL617083,107,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2299,,,,Autocuration,,14770,CHEMBL617084,107,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000357
2300,,,9606.0,Expert,Homo sapiens,16293,CHEMBL617085,107,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2301,,,,Autocuration,,16209,CHEMBL617086,107,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,B,1,H,8,,BAO_0000357
2302,,,,Autocuration,,12469,CHEMBL617087,107,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,B,1,H,8,,BAO_0000219
2303,,,,Autocuration,,15363,CHEMBL617088,107,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2304,,,,Autocuration,,15363,CHEMBL617089,107,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2305,,,,Expert,,16441,CHEMBL617090,107,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,B,1,H,8,,BAO_0000019
2306,,,,Autocuration,,8,CHEMBL617513,107,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2307,,,,Autocuration,,4176,CHEMBL617514,107,,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000219
2308,,,,Autocuration,,17085,CHEMBL617515,107,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000019
2309,,,,Autocuration,,17200,CHEMBL617516,107,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,B,1,H,8,,BAO_0000357
2310,,,9606.0,Expert,Homo sapiens,17200,CHEMBL617517,107,,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,B,1,D,9,,BAO_0000357
2311,,,9606.0,Expert,Homo sapiens,4013,CHEMBL617518,107,,449.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
2312,,,,Autocuration,,5088,CHEMBL617519,107,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2313,,,9606.0,Expert,Homo sapiens,5088,CHEMBL617520,107,,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2314,,,,Autocuration,,5088,CHEMBL617521,107,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,B,1,H,8,,BAO_0000357
2315,,,9606.0,Expert,Homo sapiens,5088,CHEMBL617522,107,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2316,,,,Autocuration,,5088,CHEMBL617523,107,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2317,,,,Autocuration,,5088,CHEMBL617524,107,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,B,1,H,8,,BAO_0000357
2318,,,,Autocuration,,9786,CHEMBL617525,104686,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,B,1,H,4,,BAO_0000019
2319,,,10116.0,Autocuration,Rattus norvegicus,9205,CHEMBL617526,104686,,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,B,1,D,5,,BAO_0000019
2320,,,,Autocuration,,11257,CHEMBL617527,104686,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,B,1,H,4,,BAO_0000224
2321,,,,Autocuration,,9362,CHEMBL617528,104686,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,B,1,H,4,,BAO_0000019
2322,,,,Autocuration,,9362,CHEMBL617529,104686,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,B,1,H,4,,BAO_0000019
2323,,,,Autocuration,,10590,CHEMBL617530,104686,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,B,1,H,4,,BAO_0000224
2324,,,,Autocuration,,10468,CHEMBL617531,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,B,1,H,4,,BAO_0000019
2325,,,,Autocuration,,13050,CHEMBL617532,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,B,1,H,4,,BAO_0000019
2326,,,,Autocuration,,11624,CHEMBL617533,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,B,1,H,4,,BAO_0000019
2327,,,,Autocuration,,10468,CHEMBL617534,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,B,1,H,4,,BAO_0000019
2328,,,,Autocuration,,10330,CHEMBL617535,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,B,1,H,4,,BAO_0000224
2329,,,,Autocuration,,10062,CHEMBL617536,104686,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,B,1,H,4,,BAO_0000224
2330,,,,Autocuration,,11642,CHEMBL617537,104686,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2331,,,,Autocuration,,10062,CHEMBL617538,104686,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2332,,,,Autocuration,,13427,CHEMBL617539,104686,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,B,1,H,4,,BAO_0000219
2333,,,10116.0,Autocuration,Rattus norvegicus,12280,CHEMBL617540,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000224
2334,,,10116.0,Autocuration,Rattus norvegicus,4101,CHEMBL617541,104686,,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,B,1,D,5,,BAO_0000224
2335,,,,Autocuration,,10062,CHEMBL617542,104686,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2336,,,,Autocuration,,11147,CHEMBL617543,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,B,1,H,4,,BAO_0000224
2337,,,10116.0,Autocuration,Rattus norvegicus,2395,CHEMBL617544,104686,,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,B,1,D,5,,BAO_0000219
2338,,,10116.0,Autocuration,Rattus norvegicus,2395,CHEMBL617545,104686,,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,B,1,D,5,,BAO_0000219
2339,,,10116.0,Autocuration,Rattus norvegicus,9098,CHEMBL617413,104686,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,B,1,D,5,,BAO_0000019
2340,,,,Autocuration,,9098,CHEMBL617414,104686,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,B,1,H,4,,BAO_0000019
2341,,,10116.0,Autocuration,Rattus norvegicus,9098,CHEMBL617415,104686,,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,B,1,D,5,,BAO_0000019
2342,,,,Autocuration,,9443,CHEMBL617416,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2343,,,,Autocuration,,9443,CHEMBL617417,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,B,1,H,4,,BAO_0000224
2344,,,,Autocuration,,9699,CHEMBL617418,104686,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,B,1,H,4,,BAO_0000019
2345,,,,Autocuration,,9699,CHEMBL617419,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,B,1,H,4,,BAO_0000019
2346,,,,Autocuration,,9098,CHEMBL617420,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,B,1,H,4,,BAO_0000224
2347,,,10116.0,Autocuration,Rattus norvegicus,3070,CHEMBL617421,104686,,,,Affinity for 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000224
2348,,,,Autocuration,,9547,CHEMBL617422,104686,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,B,1,H,4,,BAO_0000224
2349,,,,Autocuration,,10444,CHEMBL617423,104686,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,B,1,H,4,,BAO_0000019
2350,,,,Autocuration,,14617,CHEMBL617424,104686,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,B,1,H,4,,BAO_0000019
2351,,,,Autocuration,,14617,CHEMBL617425,104686,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,B,1,H,4,,BAO_0000019
2352,,,,Autocuration,,11130,CHEMBL617426,104686,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,B,1,H,4,,BAO_0000224
2353,,,,Autocuration,,11130,CHEMBL617427,104686,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,B,1,H,4,,BAO_0000218
2354,,955.0,,Autocuration,,14542,CHEMBL617428,104686,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,B,1,H,4,,BAO_0000221
2355,,,,Autocuration,,2797,CHEMBL617429,104686,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,B,1,H,4,,BAO_0000224
2356,,,,Autocuration,,11332,CHEMBL617430,104686,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,B,1,H,4,,BAO_0000019
2357,,,,Autocuration,,11332,CHEMBL617431,104686,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,B,1,H,4,,BAO_0000019
2358,,1870.0,,Autocuration,,10752,CHEMBL617432,104686,,,Frontal cortex,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,B,1,H,4,,BAO_0000019
2359,,,,Autocuration,,1185,CHEMBL617433,104686,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2360,,,,Autocuration,,1185,CHEMBL617434,104686,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2361,,,10116.0,Autocuration,Rattus norvegicus,11624,CHEMBL617435,104686,,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,B,1,D,5,,BAO_0000224
2362,,,,Autocuration,,1344,CHEMBL617436,104686,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,B,1,H,4,,BAO_0000019
2363,,2435.0,10116.0,Autocuration,Rattus norvegicus,15453,CHEMBL617437,104686,,,Striatum,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,B,1,D,5,,BAO_0000019
2364,,,,Autocuration,,11662,CHEMBL617438,104686,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,B,1,H,4,,BAO_0000019
2365,,,,Autocuration,,11662,CHEMBL617439,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,B,1,H,4,,BAO_0000019
2366,,,,Autocuration,,10796,CHEMBL617440,104686,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2367,,,,Autocuration,,9069,CHEMBL617441,104686,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2368,,,10116.0,Autocuration,Rattus norvegicus,8814,CHEMBL872918,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,B,1,D,5,,BAO_0000019
2369,,,10116.0,Autocuration,Rattus norvegicus,8908,CHEMBL617442,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,B,1,D,5,,BAO_0000019
2370,,,,Autocuration,,9098,CHEMBL617443,104686,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,B,1,H,4,,BAO_0000019
2371,,,,Autocuration,,9098,CHEMBL617444,104686,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,B,1,H,4,,BAO_0000019
2372,,,,Autocuration,,9098,CHEMBL617445,104686,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,B,1,H,4,,BAO_0000019
2373,,,,Autocuration,,9098,CHEMBL617446,104686,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,B,1,H,4,,BAO_0000019
2374,,,,Autocuration,,9098,CHEMBL617447,104686,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,B,1,H,4,,BAO_0000249
2375,,,,Autocuration,,9098,CHEMBL617448,104686,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,B,1,H,4,,BAO_0000019
2376,,,,Autocuration,,9098,CHEMBL617449,104686,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,B,1,H,4,,BAO_0000019
2377,,,,Autocuration,,9161,CHEMBL617450,104686,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,B,1,H,4,,BAO_0000019
2378,,,,Autocuration,,9161,CHEMBL617451,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,B,1,H,4,,BAO_0000019
2379,,,,Autocuration,,9161,CHEMBL617452,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,B,1,H,4,,BAO_0000019
2380,,,,Autocuration,,9161,CHEMBL617453,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,B,1,H,4,,BAO_0000019
2381,,,,Autocuration,,9161,CHEMBL617660,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,B,1,H,4,,BAO_0000019
2382,,,,Autocuration,,9161,CHEMBL617661,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,B,1,H,4,,BAO_0000019
2383,,,,Autocuration,,9161,CHEMBL617662,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,B,1,H,4,,BAO_0000019
2384,,,,Autocuration,,9161,CHEMBL872919,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,B,1,H,4,,BAO_0000019
2385,,,,Autocuration,,9161,CHEMBL617663,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,B,1,H,4,,BAO_0000019
2386,,,,Autocuration,,9161,CHEMBL617664,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,B,1,H,4,,BAO_0000019
2387,,,,Autocuration,,9161,CHEMBL617665,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,B,1,H,4,,BAO_0000019
2388,,,,Autocuration,,9161,CHEMBL617666,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,B,1,H,4,,BAO_0000019
2389,,,,Autocuration,,12094,CHEMBL617667,104686,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,B,1,H,4,,BAO_0000019
2390,,,,Autocuration,,12018,CHEMBL617668,104686,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,B,1,H,4,,BAO_0000249
2391,,,,Autocuration,,10394,CHEMBL617669,104686,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,B,1,H,4,,BAO_0000249
2392,,,,Autocuration,,15260,CHEMBL617670,104686,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2393,,,10116.0,Autocuration,Rattus norvegicus,11624,CHEMBL617671,104686,,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000224
2394,,,,Autocuration,,13654,CHEMBL617672,104686,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2395,,,,Autocuration,,9541,CHEMBL617673,104686,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,B,1,H,4,,BAO_0000019
2396,,,,Autocuration,,11933,CHEMBL617674,104686,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,B,1,H,4,,BAO_0000224
2397,,,,Autocuration,,15538,CHEMBL617675,104686,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,B,1,H,4,,BAO_0000019
2398,,,,Autocuration,,15538,CHEMBL617676,104686,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,B,1,H,4,,BAO_0000019
2399,,,,Autocuration,,15538,CHEMBL617677,104686,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,B,1,H,4,,BAO_0000019
2400,,,,Autocuration,,8841,CHEMBL617678,104686,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000019
2401,,,,Autocuration,,1455,CHEMBL617679,104686,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,B,1,H,4,,BAO_0000224
2402,,,,Autocuration,,1455,CHEMBL617680,104686,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,B,1,H,4,,BAO_0000224
2403,,,,Autocuration,,11752,CHEMBL617681,104686,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,B,1,H,4,,BAO_0000019
2404,,955.0,,Autocuration,,11642,CHEMBL617682,104686,,,Brain,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,B,1,H,4,,BAO_0000221
2405,,,,Autocuration,,12092,CHEMBL617683,104686,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,B,1,H,4,,BAO_0000224
2406,,,,Autocuration,,3967,CHEMBL617684,104686,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,B,1,H,4,,BAO_0000224
2407,,,10116.0,Autocuration,Rattus norvegicus,12771,CHEMBL617685,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,B,1,D,5,,BAO_0000224
2408,,,,Autocuration,,11642,CHEMBL617686,104686,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,B,1,H,4,,BAO_0000019
2409,,,,Autocuration,,11628,CHEMBL617687,104686,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,B,1,H,4,,BAO_0000224
2410,,,,Autocuration,,13654,CHEMBL617688,104686,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,B,1,H,4,,BAO_0000224
2411,,,,Autocuration,,11200,CHEMBL617689,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,F,1,H,4,,BAO_0000019
2412,,,,Autocuration,,11200,CHEMBL617690,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,F,1,H,4,,BAO_0000019
2413,,,,Autocuration,,11200,CHEMBL617691,104686,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,F,1,H,4,,BAO_0000218
2414,,,,Autocuration,,11200,CHEMBL617692,104686,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,F,1,H,4,,BAO_0000218
2415,,,,Autocuration,,11200,CHEMBL617693,104686,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,F,1,H,4,,BAO_0000218
2416,,,,Autocuration,,11200,CHEMBL617694,104686,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,F,1,H,4,,BAO_0000218
2417,,955.0,,Expert,,15436,CHEMBL857985,12687,,,Brain,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,B,1,H,8,,BAO_0000221
2418,,,10116.0,Expert,Rattus norvegicus,15436,CHEMBL617695,12687,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,B,1,D,9,,BAO_0000019
2419,,,,Autocuration,,14025,CHEMBL617696,12687,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,B,1,H,8,,BAO_0000019
2420,,,,Autocuration,,4342,CHEMBL617697,12687,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,B,1,H,8,,BAO_0000357
2421,,,10116.0,Expert,Rattus norvegicus,13735,CHEMBL617257,12687,,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,B,1,D,9,,BAO_0000019
2422,,,10116.0,Expert,Rattus norvegicus,5816,CHEMBL617258,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,B,1,D,9,,BAO_0000357
2423,,,,Expert,,14287,CHEMBL617259,12687,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,B,1,H,8,,BAO_0000019
2424,,,,Autocuration,,15738,CHEMBL617260,12687,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,B,1,H,8,,BAO_0000357
2425,,,10116.0,Expert,Rattus norvegicus,15738,CHEMBL617261,12687,,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2426,,,,Autocuration,,15026,CHEMBL617262,12687,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,B,1,H,8,,BAO_0000019
2427,,,,Expert,,16647,CHEMBL617263,12687,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,B,1,H,8,,BAO_0000019
2428,,,,Autocuration,,16647,CHEMBL617264,12687,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,B,1,H,8,,BAO_0000019
2429,,,10116.0,Expert,Rattus norvegicus,13345,CHEMBL617265,12687,,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000019
2430,Membranes,,,Autocuration,,1543,CHEMBL617266,12687,,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000249
2431,,,,Autocuration,,12444,CHEMBL617267,12687,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,B,1,H,8,,BAO_0000019
2432,,,,Expert,,16404,CHEMBL617268,12687,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,B,1,H,8,,BAO_0000019
2433,,,,Autocuration,,16404,CHEMBL617269,12687,,449.0,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,B,1,H,8,,BAO_0000219
2434,,,,Expert,,15577,CHEMBL617323,12687,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,B,1,H,8,,BAO_0000357
2435,,,,Autocuration,,15577,CHEMBL617324,12687,,,,Serotonergic activity of the compound.,,B,1,H,8,,BAO_0000357
2436,,,,Autocuration,,2495,CHEMBL617325,12687,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,B,1,H,8,,BAO_0000249
2437,,,10116.0,Expert,Rattus norvegicus,15042,CHEMBL617326,12687,,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,B,1,D,9,,BAO_0000019
2438,,,,Expert,,15026,CHEMBL617327,12687,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,B,1,H,8,,BAO_0000249
2439,,,10116.0,Expert,Rattus norvegicus,12919,CHEMBL617328,12687,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,F,1,D,9,,BAO_0000019
2440,,,10116.0,Expert,Rattus norvegicus,12919,CHEMBL617329,12687,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,F,1,D,9,,BAO_0000019
2441,,,10116.0,Expert,Rattus norvegicus,12919,CHEMBL617330,12687,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,F,1,D,9,,BAO_0000019
2442,,,,Autocuration,,15194,CHEMBL617331,12687,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2443,,,,Autocuration,,15194,CHEMBL617332,12687,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,B,1,H,8,,BAO_0000357
2444,,,,Expert,,4820,CHEMBL617333,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2445,,,,Autocuration,,6736,CHEMBL617334,107,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,B,1,H,8,,BAO_0000357
2446,,,,Autocuration,,5163,CHEMBL617335,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,B,1,H,8,,BAO_0000357
2447,,,,Autocuration,,5163,CHEMBL617336,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,B,1,H,8,,BAO_0000357
2448,,,,Autocuration,,6011,CHEMBL617337,107,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,B,1,H,8,,BAO_0000357
2449,,,9606.0,Expert,Homo sapiens,14294,CHEMBL617338,107,,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,B,1,D,9,,BAO_0000357
2450,,,,Autocuration,,5014,CHEMBL617339,107,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2451,,,,Expert,,17066,CHEMBL617340,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2452,,,,Autocuration,,17515,CHEMBL617341,107,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,B,1,H,8,,BAO_0000357
2453,,,,Expert,,6736,CHEMBL617342,107,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2454,,,,Expert,,5163,CHEMBL617343,107,,,,Affinity for 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2455,,,,Expert,,16911,CHEMBL617344,107,,723.0,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,B,1,H,8,,BAO_0000219
2456,,,,Expert,,6841,CHEMBL617345,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,B,1,H,8,,BAO_0000357
2457,,,,Expert,,6119,CHEMBL617346,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,B,1,H,8,,BAO_0000357
2458,,,,Autocuration,,3962,CHEMBL617347,107,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2459,,,,Autocuration,,4373,CHEMBL617348,107,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,B,1,H,8,,BAO_0000357
2460,,,,Autocuration,,4373,CHEMBL617349,107,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,B,1,H,8,,BAO_0000357
2461,,,,Autocuration,,3962,CHEMBL617350,107,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,F,1,H,8,,BAO_0000019
2462,,,,Expert,,1633,CHEMBL872339,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,B,1,H,8,,BAO_0000357
2463,,,,Autocuration,,4373,CHEMBL617351,107,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,B,1,H,8,,BAO_0000357
2464,,,,Expert,,6576,CHEMBL617352,107,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2465,,,,Autocuration,,4687,CHEMBL617353,107,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2466,,,,Autocuration,,16946,CHEMBL617354,107,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2467,,,,Autocuration,,14159,CHEMBL617355,107,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2468,,,10090.0,Expert,Mus musculus,3032,CHEMBL617356,107,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,B,1,H,8,,BAO_0000219
2469,,,,Autocuration,,16655,CHEMBL617357,107,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2470,,,,Autocuration,,13964,CHEMBL617358,107,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2471,,,,Expert,,16989,CHEMBL617359,107,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2472,,,,Autocuration,,16117,CHEMBL617360,107,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,B,1,H,8,,BAO_0000357
2473,,,,Autocuration,,16700,CHEMBL875913,107,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,B,1,H,8,,BAO_0000357
2474,,,,Autocuration,,3269,CHEMBL617361,107,,,,Affinity against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2475,,,9606.0,Expert,Homo sapiens,1274,CHEMBL617362,107,,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2476,,,,Autocuration,,1317,CHEMBL617363,107,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,B,1,H,8,,BAO_0000357
2477,,,,Autocuration,,12146,CHEMBL617364,107,,,,Tested against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2478,,,,Autocuration,,12652,CHEMBL617365,105075,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,B,1,H,4,,BAO_0000224
2479,,,,Autocuration,,12652,CHEMBL617366,105075,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,B,1,H,4,,BAO_0000224
2480,,,,Autocuration,,12652,CHEMBL617367,105075,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,B,1,H,4,,BAO_0000224
2481,,,,Autocuration,,12652,CHEMBL617368,105075,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,B,1,H,4,,BAO_0000224
2482,,,,Autocuration,,16647,CHEMBL617369,107,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,B,1,H,8,,BAO_0000357
2483,,,9606.0,Expert,Homo sapiens,15851,CHEMBL617370,227,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,B,1,D,9,,BAO_0000219
2484,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617371,227,,449.0,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,F,1,D,9,,BAO_0000219
2485,,,,Autocuration,,3805,CHEMBL617372,227,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,B,1,H,8,,BAO_0000357
2486,,,9606.0,Expert,Homo sapiens,6491,CHEMBL617373,227,,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,B,1,D,9,,BAO_0000357
2487,,,,Autocuration,,14093,CHEMBL617374,227,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,F,1,H,8,,BAO_0000019
2488,,,,Autocuration,,13481,CHEMBL617375,227,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,F,1,H,8,,BAO_0000019
2489,,,,Autocuration,,14093,CHEMBL617376,227,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,F,1,H,8,,BAO_0000019
2490,,,,Autocuration,,14093,CHEMBL617377,227,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,F,1,H,8,,BAO_0000019
2491,,,,Autocuration,,14093,CHEMBL617378,227,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,F,1,H,8,,BAO_0000019
2492,,,,Autocuration,,13481,CHEMBL617379,227,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,F,1,H,8,,BAO_0000019
2493,,,,Autocuration,,14442,CHEMBL617380,227,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,B,1,H,8,,BAO_0000357
2494,,,,Autocuration,,14442,CHEMBL617381,227,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,B,1,H,8,,BAO_0000357
2495,,,,Autocuration,,14442,CHEMBL617382,227,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,B,1,H,8,,BAO_0000357
2496,,,,Autocuration,,12369,CHEMBL617383,107,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2497,,,,Expert,,12369,CHEMBL617384,107,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,B,1,H,8,,BAO_0000357
2498,,,,Expert,,12369,CHEMBL617385,107,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,B,1,H,8,,BAO_0000357
2499,,,,Autocuration,,14447,CHEMBL617386,107,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,B,1,H,8,,BAO_0000019
2500,,,,Autocuration,,14447,CHEMBL617387,107,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,B,1,H,8,,BAO_0000019
2501,,,,Autocuration,,17451,CHEMBL617388,107,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,B,1,H,8,,BAO_0000219
2502,,,,Autocuration,,6857,CHEMBL617389,107,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,F,1,H,8,,BAO_0000219
2503,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617390,107,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,F,1,D,9,,BAO_0000219
2504,,,,Autocuration,,5635,CHEMBL617391,104817,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,B,1,H,4,,BAO_0000224
2505,,,,Autocuration,,12861,CHEMBL617392,107,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
2506,,,,Autocuration,,12861,CHEMBL617393,107,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000019
2507,,,,Autocuration,,5105,CHEMBL617394,107,,307.0,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,B,1,H,8,,BAO_0000219
2508,,,,Expert,,5104,CHEMBL617395,107,,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,B,1,H,8,,BAO_0000219
2509,,,,Expert,,5105,CHEMBL617396,107,,307.0,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,B,1,H,8,,BAO_0000219
2510,,,,Autocuration,,5105,CHEMBL617397,107,,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,B,1,H,8,,BAO_0000219
2511,,,,Autocuration,,5254,CHEMBL617398,107,,,,Binding affinity against 5-HT2A receptor,,B,1,H,8,,BAO_0000357
2512,,,,Autocuration,,5254,CHEMBL617399,107,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2513,,,,Autocuration,,13267,CHEMBL617400,107,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000219
2514,,,,Autocuration,,13267,CHEMBL617401,107,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000219
2515,,,9606.0,Expert,Homo sapiens,14157,CHEMBL617402,107,,722.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,B,1,D,9,,BAO_0000219
2516,,,9606.0,Expert,Homo sapiens,12936,CHEMBL617403,107,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,B,1,D,9,,BAO_0000219
2517,,,,Expert,,14068,CHEMBL617404,107,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,B,1,H,8,,BAO_0000357
2518,,,9606.0,Expert,Homo sapiens,12936,CHEMBL857981,107,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,B,1,D,9,,BAO_0000219
2519,,,9606.0,Expert,Homo sapiens,12936,CHEMBL617405,107,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,B,1,D,9,,BAO_0000219
2520,,,9606.0,Expert,Homo sapiens,4540,CHEMBL617253,107,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,B,1,D,9,,BAO_0000219
2521,,,,Expert,,6166,CHEMBL617254,107,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,B,1,H,8,,BAO_0000357
2522,,,,Autocuration,,17296,CHEMBL617255,107,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000219
2523,,,,Autocuration,,17296,CHEMBL617256,107,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000219
2524,,,,Autocuration,,17296,CHEMBL616874,107,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000219
2525,,,9606.0,Expert,Homo sapiens,15779,CHEMBL616875,107,,722.0,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,B,1,D,9,,BAO_0000219
2526,,,,Expert,,14391,CHEMBL616876,107,,722.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000219
2527,,,,Expert,,15851,CHEMBL616877,107,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,B,1,H,8,,BAO_0000219
2528,,,9606.0,Expert,Homo sapiens,15851,CHEMBL616878,107,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,B,1,D,9,,BAO_0000219
2529,,,,Expert,,3832,CHEMBL616879,107,,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,B,1,H,8,,BAO_0000219
2530,,,,Expert,,3833,CHEMBL616880,107,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,B,1,H,8,,BAO_0000219
2531,,,9606.0,Expert,Homo sapiens,12936,CHEMBL616881,107,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,B,1,D,9,,BAO_0000219
2532,,,,Autocuration,,17451,CHEMBL616882,107,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000219
2533,,,,Autocuration,,17451,CHEMBL616883,107,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,B,1,H,8,,BAO_0000219
2534,,,,Autocuration,,17451,CHEMBL616884,107,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,B,1,H,8,,BAO_0000219
2535,,,,Autocuration,,4199,CHEMBL616885,107,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,B,1,H,8,,BAO_0000219
2536,,,,Autocuration,,1883,CHEMBL616886,107,,485.0,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,B,1,H,8,,BAO_0000219
2537,,,,Expert,,1883,CHEMBL616887,107,,485.0,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,B,1,H,8,,BAO_0000219
2538,,,9606.0,Expert,Homo sapiens,14875,CHEMBL616888,107,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2539,,,,Autocuration,,15146,CHEMBL616889,107,,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,B,1,H,8,,BAO_0000219
2540,,,,Autocuration,,5213,CHEMBL616890,107,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,B,1,H,8,,BAO_0000219
2541,,,9606.0,Expert,Homo sapiens,16404,CHEMBL616891,107,,449.0,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,B,1,D,9,,BAO_0000219
2542,,,,Autocuration,,14818,CHEMBL616892,107,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,B,1,H,8,,BAO_0000219
2543,,,,Autocuration,,4829,CHEMBL616893,107,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,B,1,H,8,,BAO_0000219
2544,,,,Autocuration,,12652,CHEMBL616894,10620,,723.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,F,1,H,8,,BAO_0000219
2545,,,,Expert,,4682,CHEMBL616895,107,,723.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,B,1,H,8,,BAO_0000219
2546,,,,Autocuration,,12652,CHEMBL616896,10620,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,F,1,H,8,,BAO_0000019
2547,,,,Autocuration,,4921,CHEMBL617099,10621,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2548,,,,Autocuration,,4921,CHEMBL617100,10621,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,B,1,H,8,,BAO_0000357
2549,,,9986.0,Autocuration,Oryctolagus cuniculus,16312,CHEMBL884532,107,,,,Binding affinity against rabbit aorta 5-HT2A receptor,,B,1,H,8,,BAO_0000357
2550,,,9986.0,Expert,Oryctolagus cuniculus,14998,CHEMBL617101,107,,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,B,1,H,8,,BAO_0000357
2551,,,9986.0,Expert,Oryctolagus cuniculus,14025,CHEMBL617102,107,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,B,1,H,8,,BAO_0000357
2552,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL617103,107,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,B,1,H,8,,BAO_0000019
2553,,,9986.0,Expert,Oryctolagus cuniculus,13047,CHEMBL617104,107,,,,The compound was tested for binding affinity against 5-HT2A receptor,,B,1,H,8,,BAO_0000357
2554,,,,Autocuration,,1883,CHEMBL857979,10576,,485.0,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,B,1,H,8,,BAO_0000219
2555,,,,Autocuration,,13463,CHEMBL857502,12687,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,B,1,H,8,,BAO_0000019
2556,,,,Autocuration,,13463,CHEMBL617105,12687,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,B,1,H,8,,BAO_0000019
2557,,945.0,,Autocuration,,13463,CHEMBL858021,12687,,,Stomach,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,B,1,H,8,,BAO_0000019
2558,,945.0,10116.0,Expert,Rattus norvegicus,13463,CHEMBL875910,12687,,,Stomach,Binding affinity for 5-HT 2A in rat stomach fundus,,B,1,D,9,,BAO_0000019
2559,,,,Autocuration,,13463,CHEMBL617106,12687,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,B,1,H,8,,BAO_0000019
2560,,,,Expert,,16326,CHEMBL617107,12687,,723.0,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000219
2561,,,,Autocuration,,14093,CHEMBL617108,12687,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,F,1,H,8,,BAO_0000019
2562,,,,Autocuration,,14093,CHEMBL617109,12687,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,F,1,H,8,,BAO_0000019
2563,,,,Autocuration,,15740,CHEMBL617110,12687,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2564,,,,Autocuration,,16633,CHEMBL617111,12687,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,B,1,H,8,,BAO_0000357
2565,,,10116.0,Expert,Rattus norvegicus,17200,CHEMBL617112,12687,,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,F,1,D,9,,BAO_0000019
2566,,,,Autocuration,,17133,CHEMBL617113,12687,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2567,,,,Autocuration,,17133,CHEMBL617114,12687,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2568,,,,Autocuration,,17133,CHEMBL617115,12687,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2569,,,,Autocuration,,17200,CHEMBL617116,12687,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,F,1,H,8,,BAO_0000219
2570,,,,Autocuration,,15363,CHEMBL617117,12687,,,,Efficacy at 5-hydroxytryptamine 2A receptor,,F,1,H,8,,BAO_0000019
2571,,,,Autocuration,,17200,CHEMBL617118,12687,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,B,1,H,8,,BAO_0000357
2572,,,10116.0,Expert,Rattus norvegicus,17200,CHEMBL617119,12687,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,B,1,D,9,,BAO_0000357
2573,,,10116.0,Expert,Rattus norvegicus,17200,CHEMBL617120,12687,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,B,1,D,9,,BAO_0000357
2574,,,10116.0,Expert,Rattus norvegicus,17200,CHEMBL617121,12687,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,F,1,D,9,,BAO_0000219
2575,,,,Autocuration,,17200,CHEMBL617122,12687,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,F,1,H,8,,BAO_0000219
2576,,,,Autocuration,,17211,CHEMBL617123,12687,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000019
2577,,,,Expert,,17331,CHEMBL617124,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,B,1,H,8,,BAO_0000019
2578,,,,Expert,,13565,CHEMBL617600,12687,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,B,1,H,8,,BAO_0000249
2579,,,,Expert,,13730,CHEMBL617601,12687,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2580,,,,Expert,,12416,CHEMBL882923,12687,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,B,1,H,8,,BAO_0000019
2581,,,,Autocuration,,15295,CHEMBL617602,12687,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2582,,,,Autocuration,,1742,CHEMBL617603,12687,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,B,1,H,8,,BAO_0000019
2583,,,,Autocuration,,15295,CHEMBL617604,12687,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2584,,,,Expert,,14970,CHEMBL617605,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000019
2585,,,,Expert,,16693,CHEMBL617606,12687,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000019
2586,,,10116.0,Expert,Rattus norvegicus,14776,CHEMBL617607,12687,,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000019
2587,,,,Autocuration,,14286,CHEMBL617455,12687,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,B,1,H,8,,BAO_0000249
2588,,,10116.0,Expert,Rattus norvegicus,17200,CHEMBL617456,12687,,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,B,1,D,9,,BAO_0000019
2589,,,,Expert,,15306,CHEMBL617457,12687,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,B,1,H,8,,BAO_0000357
2590,,,10116.0,Expert,Rattus norvegicus,14178,CHEMBL617458,12687,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2591,,,10116.0,Expert,Rattus norvegicus,14229,CHEMBL617459,12687,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,B,1,D,9,,BAO_0000019
2592,,,,Expert,,12884,CHEMBL617460,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,B,1,H,8,,BAO_0000357
2593,,,,Expert,,13149,CHEMBL617461,12687,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,B,1,H,8,,BAO_0000357
2594,,,10116.0,Expert,Rattus norvegicus,15295,CHEMBL617462,12687,,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,B,1,D,9,,BAO_0000019
2595,,,,Autocuration,,15740,CHEMBL617463,12687,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,B,1,H,8,,BAO_0000357
2596,,,,Autocuration,,15185,CHEMBL617464,12687,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,B,1,H,8,,BAO_0000019
2597,,,,Autocuration,,15185,CHEMBL617465,12687,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,B,1,H,8,,BAO_0000019
2598,,,,Expert,,17529,CHEMBL617466,12687,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,B,1,H,8,,BAO_0000019
2599,,,,Autocuration,,14826,CHEMBL617467,12687,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,B,1,H,8,,BAO_0000019
2600,,,,Expert,,17211,CHEMBL617468,12687,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,B,1,H,8,,BAO_0000019
2601,,,,Autocuration,,14826,CHEMBL617469,12687,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,B,1,H,8,,BAO_0000019
2602,,,,Autocuration,,14093,CHEMBL617470,12687,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000019
2603,,,,Autocuration,,14093,CHEMBL617471,12687,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,B,1,H,8,,BAO_0000019
2604,,,,Expert,,13246,CHEMBL617472,12687,,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,B,1,H,8,,BAO_0000219
2605,,,,Expert,,13246,CHEMBL617473,12687,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,B,1,H,8,,BAO_0000357
2606,,,10116.0,Expert,Rattus norvegicus,15436,CHEMBL617474,12687,,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,B,1,D,9,,BAO_0000019
2607,,,10116.0,Expert,Rattus norvegicus,15436,CHEMBL617475,12687,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,B,1,D,9,,BAO_0000019
2608,,955.0,,Autocuration,,14442,CHEMBL617476,12687,,,Brain,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,B,1,H,8,,BAO_0000221
2609,,,,Expert,,12457,CHEMBL617477,12687,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2610,,,,Expert,,12457,CHEMBL617478,12687,,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000219
2611,,,,Autocuration,,14755,CHEMBL617479,12687,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,F,1,H,8,,BAO_0000221
2612,,,,Autocuration,,4707,CHEMBL617480,12687,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,B,1,H,8,,BAO_0000357
2613,,,,Expert,,13297,CHEMBL617481,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2614,,,,Expert,,17331,CHEMBL617482,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,B,1,H,8,,BAO_0000019
2615,,,,Autocuration,,4664,CHEMBL617483,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000019
2616,,,,Autocuration,,16633,CHEMBL621528,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,B,1,H,8,,BAO_0000357
2617,,,10116.0,Expert,Rattus norvegicus,4664,CHEMBL621529,12687,,723.0,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,B,1,D,9,,BAO_0000219
2618,,,,Expert,,16133,CHEMBL621530,12687,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,B,1,H,8,,BAO_0000357
2619,,,,Expert,,16133,CHEMBL621531,12687,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2620,,,10116.0,Expert,Rattus norvegicus,14060,CHEMBL621532,12687,,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000019
2621,,,,Expert,,16326,CHEMBL621533,12687,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,B,1,H,8,,BAO_0000357
2622,,,,Expert,,16659,CHEMBL621534,12687,,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2623,,,,Autocuration,,14776,CHEMBL621535,12687,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,B,1,H,8,,BAO_0000019
2624,,,,Autocuration,,13481,CHEMBL621536,12687,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,B,1,H,8,,BAO_0000357
2625,,,,Autocuration,,17386,CHEMBL621537,12687,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2626,,,10116.0,Expert,Rattus norvegicus,6611,CHEMBL621538,12687,,,,Binding affinity for 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000357
2627,,,,Autocuration,,14423,CHEMBL621539,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,B,1,H,8,,BAO_0000019
2628,,,,Autocuration,,15412,CHEMBL621540,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,B,1,H,8,,BAO_0000019
2629,,,,Autocuration,,15412,CHEMBL621541,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,B,1,H,8,,BAO_0000019
2630,,,,Autocuration,,6238,CHEMBL621542,12687,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000019
2631,,,,Expert,,6648,CHEMBL621543,12687,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,B,1,H,8,,BAO_0000357
2632,,,,Expert,,5667,CHEMBL621544,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2633,,,10116.0,Expert,Rattus norvegicus,6611,CHEMBL621545,12687,,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,B,1,D,9,,BAO_0000357
2634,,,,Autocuration,,13481,CHEMBL621546,12687,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2635,,,,Autocuration,,13481,CHEMBL621547,12687,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,B,1,H,8,,BAO_0000357
2636,,,,Expert,,15558,CHEMBL618692,12687,,723.0,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000219
2637,,,,Autocuration,,6013,CHEMBL618693,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2638,,,,Autocuration,,16633,CHEMBL872922,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,B,1,H,8,,BAO_0000357
2639,,,,Autocuration,,6013,CHEMBL618694,12687,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2640,,,10116.0,Expert,Rattus norvegicus,6013,CHEMBL618695,12687,,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,B,1,D,9,,BAO_0000357
2641,,,,Autocuration,,6013,CHEMBL618696,12687,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,B,1,H,8,,BAO_0000357
2642,,,,Expert,,6013,CHEMBL618697,12687,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,B,1,H,8,,BAO_0000357
2643,,,,Autocuration,,6013,CHEMBL618892,12687,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,B,1,H,8,,BAO_0000357
2644,,,,Autocuration,,6013,CHEMBL618893,12687,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2645,,,,Autocuration,,16293,CHEMBL618894,12687,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2646,,,,Expert,,17175,CHEMBL618895,12687,,723.0,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000219
2647,,,10116.0,Expert,Rattus norvegicus,13278,CHEMBL618896,12687,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,B,1,D,9,,BAO_0000357
2648,,5383.0,,Autocuration,,3682,CHEMBL618897,12687,,,Caudate-putamen,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,B,1,H,8,,BAO_0000019
2649,,,,Autocuration,,2014,CHEMBL618898,12687,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,B,1,H,8,,BAO_0000357
2650,,,,Autocuration,,2014,CHEMBL618899,12687,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,B,1,H,8,,BAO_0000357
2651,,,,Autocuration,,4932,CHEMBL618900,12687,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,B,1,H,8,,BAO_0000357
2652,,,,Autocuration,,4932,CHEMBL618901,12687,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,B,1,H,8,,BAO_0000019
2653,,,,Autocuration,,3935,CHEMBL618902,12687,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2654,,10000000.0,10116.0,Expert,Rattus norvegicus,5432,CHEMBL618903,12687,,,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000221
2655,,,,Autocuration,,15818,CHEMBL618904,12687,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2656,,,,Autocuration,,13672,CHEMBL618905,12687,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,B,1,H,8,,BAO_0000357
2657,,,,Autocuration,,13672,CHEMBL618906,12687,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,B,1,H,8,,BAO_0000357
2658,,,,Expert,,14749,CHEMBL618907,12687,,723.0,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,B,1,H,8,,BAO_0000219
2659,,,,Autocuration,,13462,CHEMBL618908,12687,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,B,1,H,8,,BAO_0000019
2660,,,,Autocuration,,15740,CHEMBL617909,12687,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2661,,,,Expert,,16647,CHEMBL617910,12687,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,B,1,H,8,,BAO_0000019
2662,,955.0,,Autocuration,,13345,CHEMBL617911,12687,,,Brain,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,B,1,H,8,,BAO_0000221
2663,,,,Autocuration,,16740,CHEMBL872923,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,B,1,H,8,,BAO_0000249
2664,,,,Autocuration,,16740,CHEMBL617912,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,B,1,H,8,,BAO_0000249
2665,,,10116.0,Expert,Rattus norvegicus,15535,CHEMBL617913,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,B,1,D,9,,BAO_0000019
2666,,,,Expert,,16740,CHEMBL617914,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,B,1,H,8,,BAO_0000249
2667,,,,Autocuration,,16740,CHEMBL617915,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,B,1,H,8,,BAO_0000249
2668,,,,Autocuration,,16740,CHEMBL617916,12687,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,B,1,H,8,,BAO_0000249
2669,,,10116.0,Expert,Rattus norvegicus,4795,CHEMBL617917,12687,,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,B,1,D,9,,BAO_0000019
2670,,,,Expert,,8,CHEMBL617918,12687,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000019
2671,,,,Autocuration,,8,CHEMBL617919,12687,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,B,1,H,8,,BAO_0000019
2672,,,10116.0,Expert,Rattus norvegicus,17200,CHEMBL617920,12687,,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,B,1,D,9,,BAO_0000019
2673,,,10116.0,Expert,Rattus norvegicus,2148,CHEMBL617921,12687,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,B,1,D,9,,BAO_0000019
2674,,,10116.0,Expert,Rattus norvegicus,13345,CHEMBL617922,105102,,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,B,1,D,5,,BAO_0000224
2675,,,,Autocuration,,5088,CHEMBL617923,12687,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,B,1,H,8,,BAO_0000357
2676,,,,Autocuration,,5088,CHEMBL617924,12687,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,B,1,H,8,,BAO_0000357
2677,,,,Autocuration,,17133,CHEMBL617925,12687,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,B,1,H,8,,BAO_0000357
2678,,,10116.0,Expert,Rattus norvegicus,17133,CHEMBL617926,12687,,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,B,1,D,9,,BAO_0000357
2679,,,,Autocuration,,16532,CHEMBL617927,12687,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,B,1,H,8,,BAO_0000357
2680,,,,Autocuration,,15086,CHEMBL617928,12687,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,B,1,H,8,,BAO_0000357
2681,,,10116.0,Expert,Rattus norvegicus,2309,CHEMBL617929,12687,,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,B,1,D,9,,BAO_0000019
2682,,,,Expert,,12953,CHEMBL617930,12687,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,B,1,H,8,,BAO_0000019
2683,,,,Autocuration,,12953,CHEMBL617931,12687,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,B,1,H,8,,BAO_0000019
2684,,,,Autocuration,,12953,CHEMBL617932,12687,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,B,1,H,8,,BAO_0000019
2685,,,,Autocuration,,16659,CHEMBL617933,12687,,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,B,1,H,8,,BAO_0000219
2686,,,,Autocuration,,16740,CHEMBL617934,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,B,1,H,8,,BAO_0000019
2687,,,,Autocuration,,16740,CHEMBL617935,12687,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,B,1,H,8,,BAO_0000019
2688,,,,Autocuration,,17133,CHEMBL617936,12687,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,B,1,H,8,,BAO_0000357
2689,,,,Autocuration,,17211,CHEMBL617937,12687,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,B,1,H,8,,BAO_0000019
2690,,,,Autocuration,,17331,CHEMBL617938,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,B,1,H,8,,BAO_0000019
2691,,,,Autocuration,,16633,CHEMBL617939,12687,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,B,1,H,8,,BAO_0000218
2692,,,,Autocuration,,16633,CHEMBL617940,12687,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,B,1,H,8,,BAO_0000218
2693,,,,Autocuration,,16633,CHEMBL617941,12687,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,B,1,H,8,,BAO_0000218
2694,,,,Expert,,15026,CHEMBL617942,12687,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,B,1,H,8,,BAO_0000357
2695,,,,Expert,,15026,CHEMBL617943,12687,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,,B,1,H,8,,BAO_0000357
2696,,,,Expert,,16404,CHEMBL617944,105093,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,B,1,H,4,,BAO_0000224
2697,,,,Expert,,16404,CHEMBL617945,105093,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,B,1,H,4,,BAO_0000224
2698,,,,Expert,,16404,CHEMBL617946,105075,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,B,1,H,4,,BAO_0000224
2699,,,,Autocuration,,16404,CHEMBL617947,12687,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,B,1,H,8,,BAO_0000357
2700,,,,Expert,,16326,CHEMBL617948,12687,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,B,1,H,8,,BAO_0000357
2701,,,,Autocuration,,15847,CHEMBL858116,12687,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,F,1,H,8,,BAO_0000019
2702,,,,Autocuration,,15847,CHEMBL617949,12687,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,F,1,H,8,,BAO_0000019
2703,,,,Autocuration,,15329,CHEMBL617950,12687,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,F,1,H,8,,BAO_0000019
2704,,1515.0,,Expert,,16404,CHEMBL617951,12687,,,Thoracic aorta,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,F,1,H,8,,BAO_0000019
2705,,1515.0,,Expert,,16404,CHEMBL617952,12687,,,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,F,1,H,8,,BAO_0000019
2706,,1515.0,,Autocuration,,16404,CHEMBL617953,12687,,,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,F,1,H,8,,BAO_0000019
2707,,,,Autocuration,,12861,CHEMBL617954,12687,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
2708,,,,Expert,,12861,CHEMBL617955,12687,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000019
2709,,,,Autocuration,,12861,CHEMBL857071,12687,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,B,1,H,8,,BAO_0000019
2710,,,,Expert,,12490,CHEMBL617270,12687,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,B,1,H,8,,BAO_0000019
2711,,,,Autocuration,,12827,CHEMBL617271,12687,,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,B,1,H,8,,BAO_0000219
2712,,,,Autocuration,,12827,CHEMBL617272,12687,,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,B,1,H,8,,BAO_0000219
2713,,,,Autocuration,,12918,CHEMBL617273,12687,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,B,1,H,8,,BAO_0000019
2714,,,10116.0,Expert,Rattus norvegicus,12919,CHEMBL617274,12687,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,F,1,D,9,,BAO_0000019
2715,,,,Autocuration,,17723,CHEMBL617275,108,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2716,,,,Autocuration,,6013,CHEMBL617276,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2717,,,,Autocuration,,16293,CHEMBL617277,108,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2718,,,,Expert,,3857,CHEMBL617278,108,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000019
2719,,,,Expert,,3857,CHEMBL617279,108,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,B,1,H,8,,BAO_0000019
2720,,,,Expert,,3857,CHEMBL617280,108,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000019
2721,,,,Autocuration,,15363,CHEMBL617281,108,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2722,,,,Autocuration,,15363,CHEMBL617282,108,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2723,,,,Expert,,16441,CHEMBL617283,108,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,B,1,H,8,,BAO_0000019
2724,,,,Expert,,16441,CHEMBL617284,108,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,B,1,H,8,,BAO_0000019
2725,,,,Autocuration,,4176,CHEMBL617285,108,,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000219
2726,,,,Autocuration,,17085,CHEMBL617286,108,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000019
2727,,,9606.0,Expert,Homo sapiens,17200,CHEMBL617287,108,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,B,1,D,9,,BAO_0000357
2728,,,,Expert,,5088,CHEMBL617288,108,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,B,1,H,8,,BAO_0000357
2729,,,,Autocuration,,5088,CHEMBL617289,108,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,B,1,H,8,,BAO_0000357
2730,,,,Autocuration,,5088,CHEMBL872917,108,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2731,,,,Autocuration,,5088,CHEMBL617290,108,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2732,,,,Autocuration,,16659,CHEMBL617291,108,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2733,,,,Autocuration,,16659,CHEMBL617292,108,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,B,1,H,8,,BAO_0000219
2734,,,,Autocuration,,17451,CHEMBL617293,108,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,B,1,H,8,,BAO_0000219
2735,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617294,108,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,F,1,D,9,,BAO_0000219
2736,,,,Expert,,3857,CHEMBL617295,108,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,B,1,H,8,,BAO_0000019
2737,,,,Autocuration,,12861,CHEMBL617296,108,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
2738,,,,Autocuration,,12861,CHEMBL617297,108,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000019
2739,,,,Expert,,5104,CHEMBL617298,108,,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000219
2740,,,,Expert,,5105,CHEMBL617299,108,,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,B,1,H,8,,BAO_0000219
2741,,,,Autocuration,,5105,CHEMBL617300,108,,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,B,1,H,8,,BAO_0000219
2742,,,,Autocuration,,5254,CHEMBL617454,108,,,,Binding affinity against 5-HT2C receptor,,B,1,H,8,,BAO_0000357
2743,,,,Autocuration,,13267,CHEMBL617505,108,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000219
2744,,,9606.0,Expert,Homo sapiens,14157,CHEMBL617506,108,,722.0,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,B,1,D,9,,BAO_0000219
2745,,,9606.0,Expert,Homo sapiens,12936,CHEMBL617507,108,,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,B,1,D,9,,BAO_0000219
2746,,,,Expert,,14068,CHEMBL617508,108,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,B,1,H,8,,BAO_0000357
2747,,,9606.0,Expert,Homo sapiens,12936,CHEMBL857982,108,,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,B,1,D,9,,BAO_0000219
2748,,,9606.0,Expert,Homo sapiens,4540,CHEMBL617509,108,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,B,1,D,9,,BAO_0000219
2749,,,9606.0,Expert,Homo sapiens,4540,CHEMBL617510,108,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,B,1,D,9,,BAO_0000219
2750,,,,Autocuration,,6166,CHEMBL617511,108,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,B,1,H,8,,BAO_0000357
2751,,,,Autocuration,,17296,CHEMBL617512,108,,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000219
2752,,,,Autocuration,,17296,CHEMBL617749,108,,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000219
2753,,,,Autocuration,,15779,CHEMBL617750,108,,722.0,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000219
2754,,,,Autocuration,,15779,CHEMBL617751,108,,722.0,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000219
2755,,,,Expert,,14391,CHEMBL617752,108,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000219
2756,,,,Autocuration,,15779,CHEMBL617753,108,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,B,1,H,8,,BAO_0000219
2757,,,,Expert,,15851,CHEMBL617754,108,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,B,1,H,8,,BAO_0000219
2758,,,9606.0,Expert,Homo sapiens,15851,CHEMBL617755,108,,722.0,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,B,1,D,9,,BAO_0000219
2759,,,,Autocuration,,15779,CHEMBL617756,108,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,B,1,H,8,,BAO_0000219
2760,,,,Expert,,3832,CHEMBL617757,108,,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,B,1,H,8,,BAO_0000219
2761,,,,Expert,,3833,CHEMBL617758,108,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,B,1,H,8,,BAO_0000219
2762,,,,Autocuration,,17451,CHEMBL617759,108,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000219
2763,,,,Autocuration,,4199,CHEMBL617760,108,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,B,1,H,8,,BAO_0000219
2764,,,,Expert,,1883,CHEMBL617761,108,,485.0,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,B,1,H,8,,BAO_0000219
2765,,,9606.0,Expert,Homo sapiens,4321,CHEMBL617762,108,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,B,1,D,9,,BAO_0000357
2766,,,,Autocuration,,14875,CHEMBL617763,108,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2767,,,,Autocuration,,15146,CHEMBL857983,108,,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,B,1,H,8,,BAO_0000219
2768,,,,Autocuration,,5213,CHEMBL617764,108,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,B,1,H,8,,BAO_0000219
2769,,,,Autocuration,,16404,CHEMBL617765,108,,308.0,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,B,1,H,8,,BAO_0000219
2770,,,,Autocuration,,13267,CHEMBL617766,108,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,F,1,H,8,,BAO_0000019
2771,,10000000.0,,Autocuration,,13267,CHEMBL617767,108,,,Hippocampus,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,F,1,H,8,,BAO_0000221
2772,,,,Autocuration,,14818,CHEMBL617768,108,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,B,1,H,8,,BAO_0000219
2773,,,,Autocuration,,4829,CHEMBL617769,108,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,B,1,H,8,,BAO_0000219
2774,,,,Autocuration,,13463,CHEMBL858023,11864,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2775,,945.0,,Autocuration,,13463,CHEMBL617770,11864,,,Stomach,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,B,1,H,8,,BAO_0000019
2776,,945.0,,Autocuration,,13463,CHEMBL617771,11864,,,Stomach,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,B,1,H,8,,BAO_0000019
2777,,,,Autocuration,,12652,CHEMBL617772,11864,,625.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,F,1,H,8,,BAO_0000219
2778,,,,Autocuration,,4682,CHEMBL617773,11864,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,B,1,H,8,,BAO_0000219
2779,,,,Autocuration,,4682,CHEMBL617850,11864,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,B,1,H,8,,BAO_0000219
2780,,,,Autocuration,,4682,CHEMBL617851,11864,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,B,1,H,8,,BAO_0000219
2781,,,,Autocuration,,12652,CHEMBL617852,11864,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,F,1,H,8,,BAO_0000019
2782,,945.0,10090.0,Autocuration,Mus musculus,13463,CHEMBL858024,12689,,,Stomach,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,B,1,H,8,,BAO_0000019
2783,,945.0,10116.0,Expert,Rattus norvegicus,13463,CHEMBL617853,12689,,,Stomach,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,B,1,D,9,,BAO_0000019
2784,,,,Expert,,13969,CHEMBL617854,108,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2785,,,9823.0,Expert,Sus scrofa,13392,CHEMBL873477,108,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2786,,,,Expert,,13392,CHEMBL617855,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2787,,,,Expert,,14430,CHEMBL617856,108,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,B,1,H,8,,BAO_0000019
2788,,,,Autocuration,,1742,CHEMBL617857,108,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,B,1,H,8,,BAO_0000019
2789,,,,Autocuration,,14286,CHEMBL617858,108,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,B,1,H,8,,BAO_0000249
2790,,,,Autocuration,,5619,CHEMBL617859,108,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2791,,,,Autocuration,,15086,CHEMBL617860,108,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2792,,,,Autocuration,,12861,CHEMBL617861,108,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
2793,,,,Expert,,12861,CHEMBL617862,108,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000019
2794,,,,Autocuration,,12861,CHEMBL617863,108,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,B,1,H,8,,BAO_0000019
2795,,,,Autocuration,,12827,CHEMBL617864,108,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,B,1,H,8,,BAO_0000249
2796,,,,Autocuration,,12827,CHEMBL617649,108,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,B,1,H,8,,BAO_0000249
2797,,,9823.0,Expert,Sus scrofa,12919,CHEMBL617650,108,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,F,1,H,8,,BAO_0000019
2798,,,9823.0,Expert,Sus scrofa,12919,CHEMBL617651,108,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,F,1,H,8,,BAO_0000019
2799,,,9823.0,Autocuration,Sus scrofa,16429,CHEMBL617652,108,,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,B,1,H,8,,BAO_0000357
2800,,,9823.0,Autocuration,Sus scrofa,773,CHEMBL857072,108,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,B,1,H,8,,BAO_0000019
2801,,,9823.0,Autocuration,Sus scrofa,5033,CHEMBL617653,108,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2802,,,,Autocuration,,12861,CHEMBL617654,12687,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000019
2803,,,,Autocuration,,14093,CHEMBL617655,12689,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,F,1,H,8,,BAO_0000019
2804,,,,Expert,,14970,CHEMBL617656,12689,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2805,,,,Autocuration,,14970,CHEMBL617657,12689,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2806,,,,Autocuration,,14970,CHEMBL617658,12689,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,B,1,H,8,,BAO_0000357
2807,,,10116.0,Expert,Rattus norvegicus,14178,CHEMBL617659,12689,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,B,1,D,9,,BAO_0000357
2808,,,10116.0,Expert,Rattus norvegicus,14178,CHEMBL617838,12689,,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,B,1,D,9,,BAO_0000357
2809,Brain membranes,,10116.0,Expert,Rattus norvegicus,14229,CHEMBL617839,12689,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,B,1,D,9,,BAO_0000249
2810,,,,Autocuration,,16532,CHEMBL617840,12689,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,B,1,H,8,,BAO_0000357
2811,,,,Autocuration,,14826,CHEMBL617841,12689,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,B,1,H,8,,BAO_0000019
2812,,,,Autocuration,,17211,CHEMBL875915,12689,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,B,1,H,8,,BAO_0000019
2813,,,,Expert,,17211,CHEMBL617842,12689,,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,B,1,H,8,,BAO_0000219
2814,,,,Expert,,13246,CHEMBL617843,12689,,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,B,1,H,8,,BAO_0000219
2815,,,,Expert,,13246,CHEMBL617844,12689,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,B,1,H,8,,BAO_0000357
2816,,,,Expert,,12457,CHEMBL617845,12689,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2817,,,,Expert,,12457,CHEMBL617846,12689,,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000219
2818,,,,Autocuration,,4707,CHEMBL617847,12689,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,B,1,H,8,,BAO_0000357
2819,,,,Expert,,13297,CHEMBL617848,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2820,,,,Autocuration,,16633,CHEMBL617849,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,B,1,H,8,,BAO_0000357
2821,,,,Expert,,16133,CHEMBL621507,12689,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2822,,,,Expert,,16326,CHEMBL621508,12689,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,B,1,H,8,,BAO_0000357
2823,,,,Autocuration,,14423,CHEMBL621509,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,B,1,H,8,,BAO_0000019
2824,,,,Autocuration,,15412,CHEMBL621510,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,B,1,H,8,,BAO_0000019
2825,,,,Autocuration,,15412,CHEMBL621511,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,B,1,H,8,,BAO_0000019
2826,,,,Expert,,15558,CHEMBL621512,12689,,625.0,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000219
2827,,,,Autocuration,,16633,CHEMBL621513,12689,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,B,1,H,8,,BAO_0000357
2828,,,,Expert,,6013,CHEMBL621514,12689,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,B,1,H,8,,BAO_0000357
2829,,,,Expert,,17175,CHEMBL621515,12689,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000219
2830,,,,Autocuration,,12469,CHEMBL621516,12689,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,B,1,H,8,,BAO_0000219
2831,,5383.0,,Autocuration,,3682,CHEMBL621517,12689,,,Caudate-putamen,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,B,1,H,8,,BAO_0000019
2832,,,,Autocuration,,4932,CHEMBL621518,12689,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,B,1,H,8,,BAO_0000357
2833,,,,Autocuration,,4932,CHEMBL621519,12689,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,B,1,H,8,,BAO_0000019
2834,,,,Autocuration,,3935,CHEMBL621520,12689,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2835,,,,Autocuration,,15818,CHEMBL621521,12689,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2836,,,,Autocuration,,15818,CHEMBL621522,12689,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2837,,,,Expert,,14749,CHEMBL621523,12689,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,B,1,H,8,,BAO_0000219
2838,,,,Autocuration,,15740,CHEMBL621524,12689,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2839,,,10116.0,Expert,Rattus norvegicus,17133,CHEMBL621525,12689,,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,B,1,D,9,,BAO_0000357
2840,,,,Autocuration,,16532,CHEMBL872921,12689,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,B,1,H,8,,BAO_0000357
2841,,,,Autocuration,,12369,CHEMBL621526,12689,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2842,,,,Expert,,12369,CHEMBL621527,12689,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,B,1,H,8,,BAO_0000219
2843,,,10116.0,Expert,Rattus norvegicus,2309,CHEMBL617865,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,B,1,D,9,,BAO_0000019
2844,,,,Autocuration,,12953,CHEMBL617866,12689,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2845,,,,Autocuration,,12953,CHEMBL617867,12689,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,B,1,H,8,,BAO_0000019
2846,,,,Autocuration,,12953,CHEMBL617487,12689,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,B,1,H,8,,BAO_0000357
2847,,,,Expert,,12953,CHEMBL617488,12689,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2848,,,,Autocuration,,17133,CHEMBL617489,12689,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,B,1,H,8,,BAO_0000357
2849,,,,Autocuration,,17211,CHEMBL617490,12689,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,B,1,H,8,,BAO_0000019
2850,,,,Autocuration,,17211,CHEMBL617491,12689,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,B,1,H,8,,BAO_0000019
2851,,,,Autocuration,,14025,CHEMBL617492,12689,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,B,1,H,8,,BAO_0000019
2852,,,,Autocuration,,14998,CHEMBL617493,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,B,1,H,8,,BAO_0000019
2853,,,,Autocuration,,4342,CHEMBL617494,12689,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,B,1,H,8,,BAO_0000357
2854,,,10116.0,Expert,Rattus norvegicus,13735,CHEMBL617495,12689,,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,B,1,D,9,,BAO_0000019
2855,,,,Autocuration,,13181,CHEMBL617496,12689,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2856,,,,Autocuration,,1883,CHEMBL617497,12689,,485.0,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,B,1,H,8,,BAO_0000219
2857,,,,Autocuration,,15194,CHEMBL617498,12689,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2858,,,,Autocuration,,15194,CHEMBL617499,12689,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,B,1,H,8,,BAO_0000357
2859,,,,Autocuration,,14579,CHEMBL617500,12689,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,F,1,H,8,,BAO_0000019
2860,,,,Autocuration,,4639,CHEMBL617501,108,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2861,,,,Expert,,4820,CHEMBL617502,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2862,,,,Autocuration,,14442,CHEMBL617503,227,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,B,1,H,8,,BAO_0000357
2863,,,,Autocuration,,14755,CHEMBL617504,227,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,B,1,H,8,,BAO_0000357
2864,,,,Autocuration,,14744,CHEMBL617406,227,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,B,1,H,8,,BAO_0000357
2865,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617407,227,,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,B,1,D,9,,BAO_0000019
2866,,,,Autocuration,,16209,CHEMBL617408,227,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
2867,,,,Autocuration,,15363,CHEMBL617409,227,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,B,1,H,8,,BAO_0000357
2868,,,,Autocuration,,15363,CHEMBL617410,227,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,B,1,H,8,,BAO_0000357
2869,,,,Autocuration,,15363,CHEMBL617411,227,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,B,1,H,8,,BAO_0000357
2870,,,,Autocuration,,17085,CHEMBL617412,227,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,B,1,H,8,,BAO_0000019
2871,,,9606.0,Expert,Homo sapiens,17200,CHEMBL617774,227,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,B,1,D,9,,BAO_0000357
2872,,,9606.0,Expert,Homo sapiens,15851,CHEMBL617775,227,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,B,1,D,9,,BAO_0000219
2873,,,9606.0,Expert,Homo sapiens,15851,CHEMBL617776,227,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,B,1,D,9,,BAO_0000219
2874,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617777,227,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,F,1,D,9,,BAO_0000219
2875,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617778,227,,449.0,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,F,1,D,9,,BAO_0000219
2876,,,,Autocuration,,15779,CHEMBL617779,227,,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2877,,,,Expert,,15851,CHEMBL617780,227,,722.0,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000219
2878,,,,Autocuration,,15779,CHEMBL617781,227,,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,B,1,H,8,,BAO_0000219
2879,,,9606.0,Expert,Homo sapiens,14157,CHEMBL617782,227,,722.0,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,B,1,D,9,,BAO_0000219
2880,,,9606.0,Expert,Homo sapiens,4540,CHEMBL617783,227,,722.0,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,B,1,D,9,,BAO_0000219
2881,,,,Autocuration,,6166,CHEMBL617784,227,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,B,1,H,8,,BAO_0000357
2882,,,,Autocuration,,15779,CHEMBL617785,227,,722.0,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,B,1,H,8,,BAO_0000219
2883,,,,Expert,,14391,CHEMBL857984,227,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000219
2884,,,,Expert,,3832,CHEMBL617786,227,,722.0,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,B,1,H,8,,BAO_0000219
2885,,,,Expert,,3833,CHEMBL617787,227,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,B,1,H,8,,BAO_0000219
2886,,,9606.0,Expert,Homo sapiens,15851,CHEMBL617788,227,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,B,1,D,9,,BAO_0000219
2887,,,9606.0,Expert,Homo sapiens,15851,CHEMBL617789,227,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,B,1,D,9,,BAO_0000219
2888,,,,Autocuration,,4199,CHEMBL617790,227,,722.0,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,B,1,H,8,,BAO_0000219
2889,,,,Expert,,1883,CHEMBL617791,227,,485.0,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,B,1,H,8,,BAO_0000219
2890,,,,Expert,,4321,CHEMBL617608,227,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,,B,1,H,8,,BAO_0000357
2891,,,,Autocuration,,15146,CHEMBL617609,227,,722.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,B,1,H,8,,BAO_0000219
2892,,,,Autocuration,,5213,CHEMBL617610,227,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,B,1,H,8,,BAO_0000219
2893,,,,Autocuration,,14818,CHEMBL617611,227,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,B,1,H,8,,BAO_0000219
2894,,,,Autocuration,,4829,CHEMBL617612,227,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2895,,,,Autocuration,,4829,CHEMBL617613,227,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,B,1,H,8,,BAO_0000219
2896,,,9986.0,Autocuration,Oryctolagus cuniculus,14025,CHEMBL617614,227,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,B,1,H,8,,BAO_0000019
2897,,945.0,,Expert,,13463,CHEMBL617615,12688,,,Stomach,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,B,1,H,8,,BAO_0000019
2898,,945.0,,Expert,,7259,CHEMBL858114,12688,,,Stomach,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,B,1,H,8,,BAO_0000357
2899,,945.0,,Autocuration,,7259,CHEMBL617616,12688,,,Stomach,Affinity against serotonergic receptor in the isolated rat stomach fundus,,B,1,H,8,,BAO_0000357
2900,,945.0,10116.0,Expert,Rattus norvegicus,7185,CHEMBL617617,12688,,,Stomach,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,F,1,D,9,,BAO_0000019
2901,,,10116.0,Expert,Rattus norvegicus,7185,CHEMBL875914,12688,,,,Antagonistic against 5-hydroxytryptamine 2B receptor,,F,1,D,9,,BAO_0000019
2902,,945.0,,Autocuration,,13267,CHEMBL617618,12688,,,Stomach,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,F,1,H,8,,BAO_0000019
2903,,945.0,10116.0,Expert,Rattus norvegicus,13735,CHEMBL617619,12688,,,Stomach,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,B,1,D,9,,BAO_0000357
2904,,,,Autocuration,,15738,CHEMBL617620,12688,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,F,1,H,8,,BAO_0000019
2905,,,,Autocuration,,15738,CHEMBL617621,12688,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,F,1,H,8,,BAO_0000019
2906,,,,Autocuration,,15738,CHEMBL617622,12688,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,F,1,H,8,,BAO_0000019
2907,,945.0,10116.0,Expert,Rattus norvegicus,12936,CHEMBL617623,12688,,,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,B,1,D,9,,BAO_0000357
2908,,945.0,10116.0,Expert,Rattus norvegicus,12936,CHEMBL617624,12688,,,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,B,1,D,9,,BAO_0000357
2909,,945.0,10116.0,Expert,Rattus norvegicus,12936,CHEMBL617625,12688,,,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,B,1,D,9,,BAO_0000357
2910,,945.0,10116.0,Expert,Rattus norvegicus,12936,CHEMBL617626,12688,,,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,B,1,D,9,,BAO_0000357
2911,,945.0,,Autocuration,,16404,CHEMBL617627,12688,,,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,F,1,H,8,,BAO_0000019
2912,,945.0,,Expert,,16404,CHEMBL617628,12688,,,Stomach,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,F,1,H,8,,BAO_0000019
2913,,945.0,,Autocuration,,16404,CHEMBL617629,12688,,,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,F,1,H,8,,BAO_0000019
2914,,945.0,,Autocuration,,16404,CHEMBL858115,12688,,,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,F,1,H,8,,BAO_0000019
2915,,945.0,10116.0,Expert,Rattus norvegicus,16404,CHEMBL617630,12688,,,Stomach,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,F,1,D,9,,BAO_0000019
2916,,1515.0,,Autocuration,,16404,CHEMBL617631,12688,,,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,F,1,H,8,,BAO_0000019
2917,,,,Autocuration,,7483,CHEMBL617632,12688,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,B,1,H,8,,BAO_0000357
2918,,,,Expert,,7483,CHEMBL617633,12688,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,B,1,H,8,,BAO_0000357
2919,,,,Autocuration,,7483,CHEMBL617634,12688,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,B,1,H,8,,BAO_0000357
2920,,,,Autocuration,,7483,CHEMBL617635,12688,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,B,1,H,8,,BAO_0000357
2922,,945.0,10116.0,Autocuration,Rattus norvegicus,16404,CHEMBL617637,12688,,,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,F,1,D,9,,BAO_0000019
2923,,,,Autocuration,,6347,CHEMBL617638,227,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,B,1,H,8,,BAO_0000357
2924,,,,Autocuration,,4373,CHEMBL617639,227,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,B,1,H,8,,BAO_0000357
2925,,,,Autocuration,,4373,CHEMBL617640,227,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,B,1,H,8,,BAO_0000357
2926,,,,Autocuration,,4687,CHEMBL617641,227,,,,Evaluated for the binding affinity to 5-HT 2B receptor,,B,1,H,8,,BAO_0000357
2927,,,,Autocuration,,16946,CHEMBL617642,227,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,B,1,H,8,,BAO_0000357
2928,,,,Autocuration,,16633,CHEMBL617643,227,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,,B,1,H,8,,BAO_0000357
2929,,,,Autocuration,,16633,CHEMBL617644,227,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,B,1,H,8,,BAO_0000357
2930,,,,Autocuration,,16633,CHEMBL617645,227,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,B,1,H,8,,BAO_0000357
2931,,,,Expert,,15026,CHEMBL617646,108,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,B,1,H,8,,BAO_0000357
2932,,,9913.0,Autocuration,Bos taurus,15738,CHEMBL617647,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,B,1,H,8,,BAO_0000357
2933,,,9913.0,Autocuration,Bos taurus,15738,CHEMBL617648,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,B,1,H,8,,BAO_0000357
2934,,,9913.0,Autocuration,Bos taurus,15738,CHEMBL617875,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,B,1,H,8,,BAO_0000357
2935,,,9913.0,Autocuration,Bos taurus,15738,CHEMBL617876,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,B,1,H,8,,BAO_0000357
2936,,,9913.0,Expert,Bos taurus,16404,CHEMBL617877,108,,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,B,1,H,8,,BAO_0000357
2937,,,9913.0,Expert,Bos taurus,15026,CHEMBL617878,108,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,B,1,H,8,,BAO_0000357
2938,,,9913.0,Autocuration,Bos taurus,15738,CHEMBL617879,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,B,1,H,8,,BAO_0000357
2939,,,10141.0,Autocuration,Cavia porcellus,16312,CHEMBL617880,108,,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,B,1,H,8,,BAO_0000019
2940,,2435.0,10141.0,Intermediate,Cavia porcellus,5486,CHEMBL617881,20033,,,Striatum,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,B,1,D,9,,BAO_0000357
2941,,,,Autocuration,,5254,CHEMBL857073,51,,,,Binding affinity against 5-HT1A receptor,,B,1,H,8,,BAO_0000357
2942,,,,Expert,,3857,CHEMBL617882,108,,449.0,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,F,1,H,8,,BAO_0000219
2943,,,9606.0,Expert,Homo sapiens,6857,CHEMBL617883,108,,449.0,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,F,1,D,9,,BAO_0000219
2944,,,,Autocuration,,4176,CHEMBL617884,108,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,F,1,H,8,,BAO_0000219
2945,,,,Autocuration,,6347,CHEMBL617885,108,,449.0,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,B,1,H,8,,BAO_0000219
2946,,,,Autocuration,,6347,CHEMBL617886,108,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,B,1,H,8,,BAO_0000219
2947,,,9606.0,Expert,Homo sapiens,16146,CHEMBL617887,108,,,,Inhibition of human 5-hydroxytryptamine 2C receptor,,B,1,D,9,,BAO_0000357
2948,,,,Autocuration,,3805,CHEMBL617888,108,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,B,1,H,8,,BAO_0000357
2949,,,,Autocuration,,3857,CHEMBL617889,108,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,B,1,H,8,,BAO_0000019
2950,,,,Autocuration,,5635,CHEMBL617890,108,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
2951,,,,Autocuration,,5635,CHEMBL617891,108,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,B,1,H,8,,BAO_0000357
2952,,,,Autocuration,,5635,CHEMBL617892,108,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,B,1,H,8,,BAO_0000357
2953,,,,Expert,,4012,CHEMBL617893,108,,449.0,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,B,1,H,8,,BAO_0000219
2954,,,,Expert,,6366,CHEMBL617894,108,,449.0,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,B,1,H,8,,BAO_0000219
2955,,,,Expert,,15949,CHEMBL617895,108,,449.0,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2956,,,,Autocuration,,17211,CHEMBL617896,108,,449.0,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000219
2957,,,9606.0,Expert,Homo sapiens,6491,CHEMBL617897,108,,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,B,1,D,9,,BAO_0000357
2958,,,,Autocuration,,14093,CHEMBL617898,108,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,F,1,H,8,,BAO_0000019
2959,,,,Autocuration,,13481,CHEMBL617899,108,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,F,1,H,8,,BAO_0000019
2960,,,10116.0,Expert,Rattus norvegicus,6347,CHEMBL617900,108,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,B,1,H,8,,BAO_0000219
2961,,,,Autocuration,,14093,CHEMBL617901,108,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,F,1,H,8,,BAO_0000019
2962,,,,Autocuration,,14093,CHEMBL617902,108,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,F,1,H,8,,BAO_0000019
2963,,,,Autocuration,,13481,CHEMBL617903,108,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,F,1,H,8,,BAO_0000019
2964,,,,Autocuration,,14442,CHEMBL617904,108,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,B,1,H,8,,BAO_0000357
2965,,,,Autocuration,,14442,CHEMBL617905,108,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,B,1,H,8,,BAO_0000357
2966,,,,Autocuration,,14442,CHEMBL617906,108,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,B,1,H,8,,BAO_0000357
2967,,,,Autocuration,,14755,CHEMBL617907,108,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,B,1,H,8,,BAO_0000357
2968,,,,Autocuration,,14744,CHEMBL617908,108,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,B,1,H,8,,BAO_0000357
2969,,,,Expert,,16659,CHEMBL620617,108,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
2970,,,9606.0,Expert,Homo sapiens,6857,CHEMBL620618,108,,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,B,1,D,9,,BAO_0000019
2971,,,,Expert,,5635,CHEMBL620619,108,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,B,1,H,8,,BAO_0000357
2972,,,9606.0,Expert,Homo sapiens,4234,CHEMBL620620,108,,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,B,1,D,9,,BAO_0000357
2973,,,,Autocuration,,16209,CHEMBL620621,108,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,B,1,H,8,,BAO_0000357
2974,Membranes,,10116.0,Autocuration,Rattus norvegicus,5778,CHEMBL872920,104698,,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,B,1,D,7,,BAO_0000249
2975,,,,Autocuration,,5094,CHEMBL620622,104698,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,B,1,H,6,,BAO_0000223
2976,,,10116.0,Autocuration,Rattus norvegicus,809,CHEMBL620623,104698,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,B,1,D,7,,BAO_0000019
2977,,,,Autocuration,,1578,CHEMBL620624,104698,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,B,1,H,6,,BAO_0000019
2978,,,,Autocuration,,809,CHEMBL620625,104698,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,B,1,H,6,,BAO_0000019
2979,,,,Autocuration,,12469,CHEMBL620626,104698,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,B,1,H,6,,BAO_0000219
2980,,,,Autocuration,,14290,CHEMBL621307,104698,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,B,1,H,6,,BAO_0000019
2981,,,,Autocuration,,14290,CHEMBL621308,104698,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,B,1,H,6,,BAO_0000019
2982,,,,Autocuration,,10609,CHEMBL621309,104698,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,B,1,H,6,,BAO_0000223
2983,,,,Autocuration,,10609,CHEMBL621310,104698,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,B,1,H,6,,BAO_0000223
2984,,,,Autocuration,,10609,CHEMBL621311,104698,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,B,1,H,6,,BAO_0000223
2985,,,,Autocuration,,15253,CHEMBL621502,104698,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,B,1,H,6,,BAO_0000249
2986,,,,Autocuration,,15253,CHEMBL621503,104698,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,B,1,H,6,,BAO_0000249
2987,Membranes,,,Autocuration,,11683,CHEMBL621504,104698,,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,B,1,H,6,,BAO_0000249
2988,,,,Autocuration,,12092,CHEMBL621505,104698,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,B,1,H,6,,BAO_0000223
2989,,,,Autocuration,,1946,CHEMBL621506,104698,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,B,1,H,6,,BAO_0000019
2990,,,,Autocuration,,11623,CHEMBL619781,104698,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,B,1,H,6,,BAO_0000223
2991,,,,Autocuration,,11623,CHEMBL619782,104698,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,B,1,H,6,,BAO_0000223
2992,,,,Autocuration,,14788,CHEMBL619783,104698,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,B,1,H,6,,BAO_0000019
2993,,,10116.0,Autocuration,Rattus norvegicus,5432,CHEMBL619784,104698,,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,B,1,D,7,,BAO_0000019
2994,,,,Autocuration,,14826,CHEMBL619785,104698,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,B,1,H,6,,BAO_0000249
2995,,,,Autocuration,,2222,CHEMBL619786,104698,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,B,1,H,6,,BAO_0000223
2996,,,,Autocuration,,11963,CHEMBL619787,104698,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,B,1,H,6,,BAO_0000019
2997,,,,Autocuration,,14145,CHEMBL872925,104698,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,B,1,H,6,,BAO_0000019
2998,,,,Autocuration,,17819,CHEMBL619788,104698,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,B,1,H,6,,BAO_0000019
2999,,,,Autocuration,,10394,CHEMBL619789,104698,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,B,1,H,6,,BAO_0000249
3000,,,,Autocuration,,10394,CHEMBL619790,104698,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,B,1,H,6,,BAO_0000249
3001,,,,Autocuration,,15034,CHEMBL619791,104698,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,B,1,H,6,,BAO_0000019
3002,,,,Autocuration,,691,CHEMBL619792,104698,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,B,1,H,6,,BAO_0000019
3003,Membranes,,,Autocuration,,12092,CHEMBL619793,104698,,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,B,1,H,6,,BAO_0000249
3004,,,10116.0,Autocuration,Rattus norvegicus,11752,CHEMBL619794,104698,,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000223
3005,,955.0,,Autocuration,,11752,CHEMBL619795,104698,,,Brain,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,B,1,H,6,,BAO_0000221
3006,,,,Autocuration,,301,CHEMBL619796,104698,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,B,1,H,6,,BAO_0000019
3007,,,,Autocuration,,16532,CHEMBL620448,104698,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,B,1,H,6,,BAO_0000223
3008,,,,Autocuration,,16532,CHEMBL620449,104698,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,B,1,H,6,,BAO_0000223
3009,,,,Autocuration,,12092,CHEMBL620450,104698,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,B,1,H,6,,BAO_0000223
3010,,,,Autocuration,,11684,CHEMBL620451,104698,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,B,1,H,6,,BAO_0000223
3011,,,,Autocuration,,11684,CHEMBL620631,104698,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,B,1,H,6,,BAO_0000223
3012,,,,Autocuration,,12953,CHEMBL620632,104698,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,B,1,H,6,,BAO_0000019
3013,,,,Autocuration,,12953,CHEMBL620633,104698,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,B,1,H,6,,BAO_0000019
3014,,,,Autocuration,,12953,CHEMBL620634,104698,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,B,1,H,6,,BAO_0000223
3015,,,,Autocuration,,12861,CHEMBL620635,104698,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,B,1,H,6,,BAO_0000019
3016,,,,Autocuration,,11454,CHEMBL620636,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3017,,,,Autocuration,,11454,CHEMBL620637,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3018,,,,Autocuration,,11454,CHEMBL620638,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3019,,,,Autocuration,,11454,CHEMBL620639,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3020,,,,Autocuration,,11454,CHEMBL620640,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3021,,,,Autocuration,,11454,CHEMBL620641,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3022,,,,Autocuration,,11454,CHEMBL620642,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3023,,,,Autocuration,,11454,CHEMBL620643,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3024,,,,Autocuration,,11454,CHEMBL620644,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3025,,,,Autocuration,,11454,CHEMBL620645,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3026,,,,Autocuration,,11454,CHEMBL620646,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3027,,,,Autocuration,,11454,CHEMBL620647,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3028,,,,Autocuration,,11454,CHEMBL620648,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3029,,,,Autocuration,,11454,CHEMBL620649,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3030,,,,Autocuration,,11454,CHEMBL620650,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3031,,,,Autocuration,,11454,CHEMBL620651,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3032,,,,Autocuration,,11454,CHEMBL872875,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3033,,,,Autocuration,,11454,CHEMBL620652,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3034,,,,Autocuration,,10609,CHEMBL620653,104698,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,F,1,H,6,,BAO_0000019
3035,,,,Autocuration,,12861,CHEMBL857076,104698,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,B,1,H,6,,BAO_0000019
3036,,,10116.0,Autocuration,Rattus norvegicus,12861,CHEMBL620654,104698,,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000019
3037,,,,Autocuration,,12861,CHEMBL620655,104698,,,,Binding activity radioligand.,,B,1,H,6,,BAO_0000223
3038,Brain membranes,,,Autocuration,,10728,CHEMBL620656,104698,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,B,1,H,6,,BAO_0000249
3039,Brain membranes,,,Autocuration,,10728,CHEMBL620657,104698,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,B,1,H,6,,BAO_0000249
3040,,,,Autocuration,,5163,CHEMBL620658,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,B,1,H,8,,BAO_0000357
3041,,,,Autocuration,,5163,CHEMBL620659,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,B,1,H,8,,BAO_0000357
3042,,,,Autocuration,,6011,CHEMBL620660,108,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,B,1,H,8,,BAO_0000357
3043,,,,Autocuration,,5014,CHEMBL620661,108,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3044,,,,Autocuration,,5635,CHEMBL620662,108,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3045,,,,Expert,,5163,CHEMBL620663,108,,,,Affinity for 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3046,,,,Autocuration,,6841,CHEMBL620664,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,B,1,H,8,,BAO_0000357
3047,,,,Expert,,6119,CHEMBL620665,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,B,1,H,8,,BAO_0000357
3048,,,,Autocuration,,4373,CHEMBL620666,108,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,B,1,H,8,,BAO_0000357
3049,,,,Autocuration,,1633,CHEMBL620667,108,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,B,1,H,8,,BAO_0000357
3050,,,,Expert,,1633,CHEMBL620668,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,B,1,H,8,,BAO_0000357
3051,,,,Autocuration,,4373,CHEMBL620669,108,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,B,1,H,8,,BAO_0000357
3052,,,,Expert,,6576,CHEMBL620670,108,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3053,,,,Autocuration,,4687,CHEMBL620671,108,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3054,,,,Autocuration,,12146,CHEMBL620672,108,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,B,1,H,8,,BAO_0000357
3055,,,,Autocuration,,12146,CHEMBL620673,108,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,B,1,H,8,,BAO_0000357
3056,,,,Autocuration,,16946,CHEMBL620674,108,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3057,,,,Autocuration,,14159,CHEMBL620675,108,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3058,,,,Autocuration,,16700,CHEMBL620676,108,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,B,1,H,8,,BAO_0000357
3059,,,,Autocuration,,3269,CHEMBL621382,108,,,,Affinity against 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3060,,,9606.0,Expert,Homo sapiens,1274,CHEMBL621383,108,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,B,1,D,9,,BAO_0000357
3061,,,,Autocuration,,1317,CHEMBL621384,108,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,B,1,H,8,,BAO_0000357
3062,,,9913.0,Autocuration,Bos taurus,5834,CHEMBL621385,144,,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,B,1,H,8,,BAO_0000357
3063,,,9913.0,Autocuration,Bos taurus,11147,CHEMBL617989,144,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,B,1,H,8,,BAO_0000357
3064,,,10141.0,Expert,Cavia porcellus,14145,CHEMBL617990,104714,,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,F,1,H,4,,BAO_0000019
3065,,2116.0,10141.0,Autocuration,Cavia porcellus,10561,CHEMBL875085,104714,,,Ileum,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,B,1,H,4,,BAO_0000221
3066,,,10141.0,Autocuration,Cavia porcellus,15847,CHEMBL617991,104714,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,F,1,H,4,,BAO_0000019
3067,,,10141.0,Autocuration,Cavia porcellus,15847,CHEMBL617992,104714,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,F,1,H,4,,BAO_0000019
3068,,2116.0,10141.0,Autocuration,Cavia porcellus,10561,CHEMBL617993,104714,,,Ileum,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,B,1,H,4,,BAO_0000221
3069,,2116.0,10141.0,Autocuration,Cavia porcellus,11454,CHEMBL617994,104714,,,Ileum,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,B,1,H,4,,BAO_0000221
3070,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL617995,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,F,1,H,4,,BAO_0000019
3071,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL617996,104714,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,F,1,H,4,,BAO_0000019
3072,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL617997,104714,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,F,1,H,4,,BAO_0000019
3073,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL617998,104714,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,F,1,H,4,,BAO_0000019
3074,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL617999,104714,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,F,1,H,4,,BAO_0000019
3075,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL618000,104714,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,F,1,H,4,,BAO_0000019
3076,,2116.0,10141.0,Autocuration,Cavia porcellus,15253,CHEMBL617815,104714,,,Ileum,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,F,1,H,4,,BAO_0000221
3077,,2116.0,10141.0,Autocuration,Cavia porcellus,15253,CHEMBL617816,104714,,,Ileum,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,F,1,H,4,,BAO_0000221
3078,,2116.0,10141.0,Autocuration,Cavia porcellus,11963,CHEMBL617817,104714,,,Ileum,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,F,1,H,4,,BAO_0000221
3079,,2116.0,10141.0,Autocuration,Cavia porcellus,1946,CHEMBL617818,104714,,,Ileum,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,B,1,H,4,,BAO_0000221
3080,,2116.0,10141.0,Autocuration,Cavia porcellus,1946,CHEMBL617819,104714,,,Ileum,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,B,1,H,4,,BAO_0000221
3081,,,10141.0,Autocuration,Cavia porcellus,12045,CHEMBL617820,104714,,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,B,1,H,4,,BAO_0000223
3082,,2116.0,10141.0,Autocuration,Cavia porcellus,1559,CHEMBL617821,104714,,,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,B,1,H,4,,BAO_0000221
3083,,2116.0,10141.0,Autocuration,Cavia porcellus,273,CHEMBL617822,104714,,,Ileum,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,F,1,H,4,,BAO_0000221
3084,,2116.0,10141.0,Autocuration,Cavia porcellus,273,CHEMBL617823,104714,,,Ileum,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,F,1,H,4,,BAO_0000221
3085,,2116.0,10141.0,Autocuration,Cavia porcellus,188,CHEMBL617824,104714,,,Ileum,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,F,1,H,4,,BAO_0000221
3086,,2116.0,10141.0,Autocuration,Cavia porcellus,12919,CHEMBL617825,104714,,,Ileum,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,F,1,H,4,,BAO_0000221
3087,,2116.0,10141.0,Autocuration,Cavia porcellus,12918,CHEMBL617826,104714,,,Ileum,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,F,1,H,4,,BAO_0000221
3088,,2116.0,10141.0,Autocuration,Cavia porcellus,1559,CHEMBL617827,104714,,,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,B,1,H,4,,BAO_0000221
3089,,2116.0,10141.0,Autocuration,Cavia porcellus,273,CHEMBL617828,104714,,,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,F,1,H,4,,BAO_0000221
3090,,2116.0,10141.0,Autocuration,Cavia porcellus,1559,CHEMBL617829,104714,,,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,B,1,H,4,,BAO_0000221
3091,,2116.0,10141.0,Autocuration,Cavia porcellus,1559,CHEMBL617830,104714,,,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,B,1,H,4,,BAO_0000221
3092,,2116.0,10141.0,Autocuration,Cavia porcellus,1559,CHEMBL617831,104714,,,Ileum,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,B,1,H,4,,BAO_0000221
3093,,2116.0,10141.0,Autocuration,Cavia porcellus,14424,CHEMBL617832,104714,,,Ileum,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,B,1,H,4,,BAO_0000221
3094,,,10141.0,Autocuration,Cavia porcellus,13181,CHEMBL617833,22226,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,B,1,U,0,,BAO_0000019
3095,,,,Autocuration,,5486,CHEMBL617834,51,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,B,1,H,8,,BAO_0000357
3096,,,9606.0,Expert,Homo sapiens,6491,CHEMBL617835,104714,,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,B,1,D,5,,BAO_0000223
3097,,,,Autocuration,,6013,CHEMBL617836,104714,,,,Binding affinity towards 5-HT3 receptor,,B,1,H,4,,BAO_0000223
3098,,,,Autocuration,,12861,CHEMBL617837,104714,,,,Binding activity radioligand.,,B,1,H,4,,BAO_0000223
3099,,,,Autocuration,,12861,CHEMBL620392,104714,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,B,1,H,4,,BAO_0000019
3100,,,,Autocuration,,5104,CHEMBL620393,104714,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,B,1,H,4,,BAO_0000223
3101,,,,Autocuration,,5105,CHEMBL620394,104714,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,B,1,H,4,,BAO_0000223
3102,,,,Autocuration,,5104,CHEMBL620395,104714,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,B,1,H,4,,BAO_0000223
3103,,,,Autocuration,,3935,CHEMBL620396,22226,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,B,1,U,0,,BAO_0000019
3104,,,,Expert,,13657,CHEMBL620582,105030,,433.0,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,B,1,H,4,,BAO_0000219
3105,,,,Autocuration,,10369,CHEMBL620583,105030,,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,B,1,H,4,,BAO_0000218
3106,,,,Autocuration,,10369,CHEMBL620584,105030,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,B,1,H,4,,BAO_0000019
3107,,,,Autocuration,,12918,CHEMBL620585,105030,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,B,1,H,4,,BAO_0000224
3108,,,,Autocuration,,12918,CHEMBL620586,105030,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,B,1,H,4,,BAO_0000224
3109,,,,Autocuration,,10369,CHEMBL620587,105030,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,B,1,H,4,,BAO_0000019
3110,,,,Autocuration,,773,CHEMBL620588,105030,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,B,1,H,4,,BAO_0000019
3111,,,,Autocuration,,12918,CHEMBL620589,105030,,,,5-hydroxytryptamine 3 receptor agonism in mouse,,F,1,H,4,,BAO_0000218
3112,,,,Autocuration,,10561,CHEMBL620590,105030,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,B,1,H,4,,BAO_0000219
3113,,,,Autocuration,,12827,CHEMBL617956,105030,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,B,1,H,4,,BAO_0000019
3114,,,,Autocuration,,12827,CHEMBL617957,105030,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,B,1,H,4,,BAO_0000019
3115,,,,Autocuration,,12918,CHEMBL617958,105030,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,B,1,H,4,,BAO_0000224
3116,,,,Autocuration,,273,CHEMBL617959,105030,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,B,1,H,4,,BAO_0000219
3117,,,,Autocuration,,273,CHEMBL617960,105030,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,B,1,H,4,,BAO_0000219
3118,,,,Autocuration,,10561,CHEMBL617961,105030,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,B,1,H,4,,BAO_0000224
3119,,,,Autocuration,,5033,CHEMBL617962,105030,,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,B,1,H,4,,BAO_0000219
3120,,,,Autocuration,,16429,CHEMBL617963,105030,,339.0,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,B,1,H,4,,BAO_0000219
3121,,,,Autocuration,,10322,CHEMBL617964,11765,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,B,1,H,8,,BAO_0000019
3122,,,,Autocuration,,14331,CHEMBL617965,11765,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,B,1,H,8,,BAO_0000219
3123,,,10090.0,Autocuration,Mus musculus,13462,CHEMBL617966,10630,,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,B,1,D,9,,BAO_0000357
3124,,,,Autocuration,,12861,CHEMBL857074,17106,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,B,1,H,8,,BAO_0000019
3125,,,9823.0,Autocuration,Sus scrofa,15086,CHEMBL617967,144,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3126,,,9823.0,Autocuration,Sus scrofa,12861,CHEMBL617968,144,,,,Binding activity radioligand.,,B,1,H,8,,BAO_0000357
3127,,,9986.0,Autocuration,Oryctolagus cuniculus,10561,CHEMBL617969,104714,,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,B,1,H,4,,BAO_0000223
3128,,,9986.0,Autocuration,Oryctolagus cuniculus,10561,CHEMBL617970,104714,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,B,1,H,4,,BAO_0000223
3129,,,9986.0,Autocuration,Oryctolagus cuniculus,10561,CHEMBL617971,104714,,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,B,1,H,4,,BAO_0000223
3130,,,9986.0,Autocuration,Oryctolagus cuniculus,10561,CHEMBL617972,104714,,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,B,1,H,4,,BAO_0000019
3131,,,9986.0,Autocuration,Oryctolagus cuniculus,273,CHEMBL617973,104714,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,F,1,H,4,,BAO_0000019
3132,,,9986.0,Autocuration,Oryctolagus cuniculus,273,CHEMBL617974,104714,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,F,1,H,4,,BAO_0000019
3133,,2116.0,9986.0,Autocuration,Oryctolagus cuniculus,273,CHEMBL617975,104714,,,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,F,1,H,4,,BAO_0000221
3134,,,9986.0,Autocuration,Oryctolagus cuniculus,273,CHEMBL617976,104714,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,F,1,H,4,,BAO_0000019
3135,,,9986.0,Autocuration,Oryctolagus cuniculus,273,CHEMBL617977,104714,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,F,1,H,4,,BAO_0000019
3136,,,9986.0,Autocuration,Oryctolagus cuniculus,273,CHEMBL617978,104714,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,F,1,H,4,,BAO_0000019
3137,,,9986.0,Autocuration,Oryctolagus cuniculus,273,CHEMBL617979,104714,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,F,1,H,4,,BAO_0000019
3138,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL617980,104714,,449.0,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,B,1,H,4,,BAO_0000219
3139,,,10116.0,Autocuration,Rattus norvegicus,1650,CHEMBL617981,104698,,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000019
3140,,,,Autocuration,,16288,CHEMBL617982,12020,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,B,1,H,8,,BAO_0000019
3141,,,,Autocuration,,16288,CHEMBL617983,12020,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,B,1,H,8,,BAO_0000357
3142,,,10116.0,Autocuration,Rattus norvegicus,10254,CHEMBL617984,104698,,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,B,1,D,7,,BAO_0000019
3143,,,,Autocuration,,14532,CHEMBL617985,104698,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,B,1,H,6,,BAO_0000019
3144,,948.0,,Autocuration,,13392,CHEMBL617986,104698,,,Heart,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,F,1,H,6,,BAO_0000218
3145,,948.0,,Autocuration,,13392,CHEMBL617987,104698,,,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,F,1,H,6,,BAO_0000019
3146,,948.0,,Autocuration,,13392,CHEMBL617988,104698,,,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,F,1,H,6,,BAO_0000019
3147,,948.0,,Autocuration,,13392,CHEMBL617792,104698,,,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,F,1,H,6,,BAO_0000019
3148,,948.0,,Autocuration,,13392,CHEMBL617793,104698,,,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,F,1,H,6,,BAO_0000019
3149,,,,Autocuration,,13392,CHEMBL617794,104698,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,F,1,H,6,,BAO_0000019
3150,,,,Autocuration,,13392,CHEMBL617795,104698,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,F,1,H,6,,BAO_0000019
3151,,,,Autocuration,,13392,CHEMBL617796,104698,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,F,1,H,6,,BAO_0000019
3152,,,,Autocuration,,13392,CHEMBL617797,104698,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,F,1,H,6,,BAO_0000019
3153,,,10116.0,Autocuration,Rattus norvegicus,1089,CHEMBL617798,104698,,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,F,1,D,7,,BAO_0000218
3154,,,,Autocuration,,1089,CHEMBL617799,104698,,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,F,1,H,6,,BAO_0000218
3155,,,10116.0,Autocuration,Rattus norvegicus,11454,CHEMBL617800,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,F,1,D,7,,BAO_0000218
3156,,,10116.0,Autocuration,Rattus norvegicus,11454,CHEMBL617801,104698,,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,F,1,D,7,,BAO_0000019
3157,,,10116.0,Autocuration,Rattus norvegicus,12205,CHEMBL617802,104698,,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,F,1,D,7,,BAO_0000218
3158,,,10116.0,Autocuration,Rattus norvegicus,1089,CHEMBL617803,104698,,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,F,1,D,7,,BAO_0000019
3159,,,,Autocuration,,5094,CHEMBL617804,104698,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,B,1,H,6,,BAO_0000019
3160,,,10116.0,Autocuration,Rattus norvegicus,2622,CHEMBL617805,104698,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000019
3161,,,,Autocuration,,245,CHEMBL617806,104698,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,B,1,H,6,,BAO_0000223
3162,,,,Autocuration,,14788,CHEMBL617807,104698,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,B,1,H,6,,BAO_0000019
3163,,,,Autocuration,,14788,CHEMBL617808,104698,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,B,1,H,6,,BAO_0000019
3164,,,,Autocuration,,3020,CHEMBL617809,104698,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,B,1,H,6,,BAO_0000249
3165,,,,Autocuration,,1742,CHEMBL617810,104698,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,B,1,H,6,,BAO_0000019
3166,,955.0,,Autocuration,,17394,CHEMBL617811,104698,,,Brain,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,B,1,H,6,,BAO_0000249
3167,,955.0,,Autocuration,,17394,CHEMBL617812,104698,,,Brain,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,B,1,H,6,,BAO_0000221
3168,,,,Autocuration,,17394,CHEMBL617813,104698,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,B,1,H,6,,BAO_0000249
3169,,,,Autocuration,,14286,CHEMBL617814,104698,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,B,1,H,6,,BAO_0000249
3170,,,,Autocuration,,14178,CHEMBL617698,104698,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,B,1,H,6,,BAO_0000019
3171,,,10116.0,Autocuration,Rattus norvegicus,14178,CHEMBL617699,104698,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,B,1,D,7,,BAO_0000019
3172,,,10116.0,Autocuration,Rattus norvegicus,14178,CHEMBL617700,104698,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,B,1,D,7,,BAO_0000019
3173,,,10116.0,Autocuration,Rattus norvegicus,14178,CHEMBL617701,104698,,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000223
3174,,,,Autocuration,,15034,CHEMBL617702,104698,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,B,1,H,6,,BAO_0000019
3175,Membranes,,,Autocuration,,1089,CHEMBL617703,104698,,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,B,1,H,6,,BAO_0000249
3176,,,10116.0,Autocuration,Rattus norvegicus,1089,CHEMBL617704,104698,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,B,1,D,7,,BAO_0000019
3177,,,,Autocuration,,16532,CHEMBL617705,104698,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,B,1,H,6,,BAO_0000223
3178,,,10116.0,Autocuration,Rattus norvegicus,12801,CHEMBL617706,104698,,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000223
3179,,,,Autocuration,,15194,CHEMBL617707,104698,,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,B,1,H,6,,BAO_0000219
3180,,,,Autocuration,,15194,CHEMBL617708,104698,,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,B,1,H,6,,BAO_0000219
3181,,,,Autocuration,,15194,CHEMBL617709,104698,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,B,1,H,6,,BAO_0000019
3182,,,,Autocuration,,15194,CHEMBL617710,104698,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,B,1,H,6,,BAO_0000019
3183,,,,Autocuration,,15194,CHEMBL882925,104698,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,B,1,H,6,,BAO_0000019
3184,,,,Autocuration,,15194,CHEMBL617711,104698,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,B,1,H,6,,BAO_0000019
3185,,,,Autocuration,,10610,CHEMBL617712,104698,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,F,1,H,6,,BAO_0000019
3186,,,10116.0,Autocuration,Rattus norvegicus,10355,CHEMBL617713,104698,,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,F,1,D,7,,BAO_0000019
3187,,,,Autocuration,,691,CHEMBL617714,104698,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,F,1,H,6,,BAO_0000019
3188,,,,Autocuration,,10611,CHEMBL617715,104698,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,F,1,H,6,,BAO_0000218
3189,,,,Autocuration,,12801,CHEMBL617716,104698,,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,F,1,H,6,,BAO_0000218
3190,,,,Autocuration,,10609,CHEMBL617717,104698,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,F,1,H,6,,BAO_0000218
3191,,,,Autocuration,,11454,CHEMBL617718,104698,,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3192,,,,Autocuration,,11454,CHEMBL617719,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3193,,,,Autocuration,,11454,CHEMBL617720,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,F,1,H,6,,BAO_0000218
3194,,,10116.0,Autocuration,Rattus norvegicus,11454,CHEMBL617721,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,F,1,D,7,,BAO_0000218
3195,,,,Autocuration,,11454,CHEMBL617722,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3196,,,,Autocuration,,11454,CHEMBL617723,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,F,1,H,6,,BAO_0000218
3197,,,,Autocuration,,11454,CHEMBL617724,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3198,,,,Autocuration,,11454,CHEMBL617725,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3199,,,,Autocuration,,11454,CHEMBL617726,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3200,,,,Autocuration,,11454,CHEMBL617727,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3201,,,,Autocuration,,11454,CHEMBL617728,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3202,,,,Autocuration,,11454,CHEMBL617729,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3203,,,,Autocuration,,11454,CHEMBL617730,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3204,,,,Autocuration,,11454,CHEMBL617731,104698,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3205,,,,Autocuration,,11454,CHEMBL617732,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3206,,,,Autocuration,,11454,CHEMBL617733,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3207,,,,Autocuration,,11454,CHEMBL617734,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3208,,,,Autocuration,,11454,CHEMBL872874,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,F,1,H,6,,BAO_0000218
3209,,,,Autocuration,,11454,CHEMBL617735,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,F,1,H,6,,BAO_0000218
3210,,,,Autocuration,,11454,CHEMBL617736,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,F,1,H,6,,BAO_0000218
3211,,,,Autocuration,,11454,CHEMBL617737,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,F,1,H,6,,BAO_0000218
3212,,,,Autocuration,,11454,CHEMBL617738,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,F,1,H,6,,BAO_0000218
3213,,,,Autocuration,,11454,CHEMBL617739,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3214,,,,Autocuration,,11454,CHEMBL617740,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3215,,,,Autocuration,,11454,CHEMBL617741,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3216,,,,Autocuration,,11454,CHEMBL617742,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3217,,,,Autocuration,,11454,CHEMBL617743,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3218,,,,Autocuration,,11454,CHEMBL617744,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3219,,,,Autocuration,,11454,CHEMBL617745,104698,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,F,1,H,6,,BAO_0000218
3220,,,,Autocuration,,670,CHEMBL617746,104698,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,F,1,H,6,,BAO_0000218
3221,,,,Autocuration,,670,CHEMBL617747,104698,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,F,1,H,6,,BAO_0000218
3222,,,,Autocuration,,10321,CHEMBL617748,104698,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,F,1,H,6,,BAO_0000218
3223,,,,Autocuration,,10321,CHEMBL618909,104698,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,F,1,H,6,,BAO_0000218
3224,,,,Autocuration,,10321,CHEMBL618910,104698,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,F,1,H,6,,BAO_0000218
3225,,,,Autocuration,,10321,CHEMBL618911,104698,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,F,1,H,6,,BAO_0000218
3226,,,,Autocuration,,10321,CHEMBL618912,104698,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,F,1,H,6,,BAO_0000218
3227,,,,Autocuration,,10322,CHEMBL618913,104698,,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,F,1,H,6,,BAO_0000218
3228,,,,Autocuration,,15412,CHEMBL618914,104698,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,F,1,H,6,,BAO_0000019
3229,,,,Autocuration,,15412,CHEMBL618915,104698,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,F,1,H,6,,BAO_0000019
3230,,,10116.0,Autocuration,Rattus norvegicus,15412,CHEMBL618916,104698,,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000223
3231,,,,Autocuration,,15412,CHEMBL618917,104698,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,F,1,H,6,,BAO_0000019
3232,,10000000.0,,Intermediate,,15412,CHEMBL618918,104698,,,Hippocampus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,B,1,D,7,,BAO_0000221
3233,,,10116.0,Autocuration,Rattus norvegicus,15412,CHEMBL618919,104698,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,B,1,D,7,,BAO_0000019
3234,,,10116.0,Autocuration,Rattus norvegicus,17394,CHEMBL618920,104698,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000019
3235,,,,Autocuration,,12457,CHEMBL618921,104698,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,B,1,H,6,,BAO_0000223
3236,,,,Autocuration,,12457,CHEMBL618922,104698,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,B,1,H,6,,BAO_0000019
3237,,,,Autocuration,,12205,CHEMBL618923,104698,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,B,1,H,6,,BAO_0000019
3238,,,,Autocuration,,14532,CHEMBL618924,104698,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,B,1,H,6,,BAO_0000019
3239,,,,Autocuration,,1122,CHEMBL618925,104698,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,B,1,H,6,,BAO_0000019
3240,,,,Autocuration,,5094,CHEMBL618926,104698,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,B,1,H,6,,BAO_0000019
3241,,2116.0,10141.0,Intermediate,Cavia porcellus,809,CHEMBL618927,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,F,1,D,9,,BAO_0000221
3242,,2116.0,10141.0,Intermediate,Cavia porcellus,809,CHEMBL618928,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,F,1,D,9,,BAO_0000221
3243,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL618929,20033,,,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,F,1,D,9,,BAO_0000221
3244,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL618930,20033,,,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,F,1,D,9,,BAO_0000221
3245,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL618931,20033,,,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,F,1,D,9,,BAO_0000221
3246,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL619594,20033,,,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,F,1,D,9,,BAO_0000221
3247,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL619595,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,F,1,D,9,,BAO_0000221
3248,,2116.0,10141.0,Intermediate,Cavia porcellus,13961,CHEMBL619596,20033,,,Ileum,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,F,1,D,9,,BAO_0000221
3249,,2116.0,10141.0,Intermediate,Cavia porcellus,13961,CHEMBL619755,20033,,,Ileum,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,F,1,D,9,,BAO_0000221
3250,,2116.0,10141.0,Intermediate,Cavia porcellus,809,CHEMBL619756,20033,,,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,F,1,D,9,,BAO_0000221
3251,,2116.0,10141.0,Intermediate,Cavia porcellus,809,CHEMBL619757,20033,,,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,F,1,D,9,,BAO_0000221
3252,,2116.0,10141.0,Intermediate,Cavia porcellus,809,CHEMBL619758,20033,,,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,F,1,D,9,,BAO_0000221
3253,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL619759,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,F,1,D,9,,BAO_0000221
3254,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL619760,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,F,1,D,9,,BAO_0000221
3255,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL619761,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,F,1,D,9,,BAO_0000221
3256,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL619762,20033,,,Ileum,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,F,1,D,9,,BAO_0000221
3257,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL619763,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,F,1,D,9,,BAO_0000221
3258,,2116.0,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL617868,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,F,1,D,9,,BAO_0000221
3259,,,10141.0,Intermediate,Cavia porcellus,15034,CHEMBL617869,20033,,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,B,1,D,9,,BAO_0000357
3260,,2435.0,10141.0,Intermediate,Cavia porcellus,5094,CHEMBL882926,20033,,,Striatum,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,B,1,D,9,,BAO_0000249
3261,,2435.0,10141.0,Intermediate,Cavia porcellus,5094,CHEMBL617870,20033,,,Striatum,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,B,1,D,9,,BAO_0000249
3262,,2435.0,10141.0,Intermediate,Cavia porcellus,5399,CHEMBL617871,20033,,,Striatum,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,B,1,D,9,,BAO_0000357
3263,,2435.0,10141.0,Intermediate,Cavia porcellus,17394,CHEMBL617872,20033,,,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,B,1,D,9,,BAO_0000357
3264,,2435.0,10141.0,Intermediate,Cavia porcellus,17394,CHEMBL617873,20033,,,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,B,1,D,9,,BAO_0000357
3265,,2435.0,10141.0,Intermediate,Cavia porcellus,17394,CHEMBL617874,20033,,,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,B,1,D,9,,BAO_0000357
3266,,2116.0,10141.0,Intermediate,Cavia porcellus,13961,CHEMBL619067,20033,,,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,F,1,D,9,,BAO_0000221
3267,,2116.0,10141.0,Intermediate,Cavia porcellus,13961,CHEMBL619068,20033,,,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,F,1,D,9,,BAO_0000221
3268,,2116.0,10141.0,Intermediate,Cavia porcellus,13961,CHEMBL619069,20033,,,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,F,1,D,9,,BAO_0000221
3269,,,10141.0,Intermediate,Cavia porcellus,16946,CHEMBL619070,20033,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,B,1,D,9,,BAO_0000357
3270,,,10141.0,Intermediate,Cavia porcellus,16946,CHEMBL619071,20033,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,B,1,D,9,,BAO_0000357
3271,,,10141.0,Intermediate,Cavia porcellus,15034,CHEMBL619072,20033,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,F,1,D,9,,BAO_0000019
3272,,,10141.0,Intermediate,Cavia porcellus,15034,CHEMBL619073,20033,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,F,1,D,9,,BAO_0000019
3273,,,10141.0,Intermediate,Cavia porcellus,12918,CHEMBL619074,20033,,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,F,1,D,9,,BAO_0000019
3274,,,10141.0,Intermediate,Cavia porcellus,16946,CHEMBL619075,20033,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,B,1,D,9,,BAO_0000357
3275,,2435.0,10141.0,Intermediate,Cavia porcellus,17394,CHEMBL619076,20033,,,Striatum,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,B,1,D,9,,BAO_0000357
3276,,2435.0,10141.0,Intermediate,Cavia porcellus,15034,CHEMBL619077,20033,,,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,B,1,D,9,,BAO_0000357
3277,,2435.0,10141.0,Intermediate,Cavia porcellus,5094,CHEMBL619078,20033,,,Striatum,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,B,1,D,9,,BAO_0000249
3278,,2435.0,10141.0,Intermediate,Cavia porcellus,5094,CHEMBL619079,20033,,,Striatum,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,B,1,D,9,,BAO_0000249
3279,,2116.0,10141.0,Intermediate,Cavia porcellus,17358,CHEMBL619080,20033,,,Ileum,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,B,1,D,9,,BAO_0000221
3280,,,10141.0,Expert,Cavia porcellus,12953,CHEMBL619081,20033,,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,B,1,D,9,,BAO_0000357
3281,,,10141.0,Intermediate,Cavia porcellus,12953,CHEMBL619082,20033,,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,B,1,D,9,,BAO_0000357
3282,,,10141.0,Intermediate,Cavia porcellus,12953,CHEMBL619083,20033,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,B,1,D,9,,BAO_0000357
3283,,,10141.0,Intermediate,Cavia porcellus,12953,CHEMBL619084,20033,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,B,1,D,9,,BAO_0000357
3284,,2116.0,10141.0,Intermediate,Cavia porcellus,273,CHEMBL859397,20033,,,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,F,1,D,9,,BAO_0000221
3285,,2116.0,10141.0,Intermediate,Cavia porcellus,12918,CHEMBL619085,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,F,1,D,9,,BAO_0000221
3286,,2116.0,10141.0,Intermediate,Cavia porcellus,12919,CHEMBL619086,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,F,1,D,9,,BAO_0000221
3287,,2116.0,10141.0,Intermediate,Cavia porcellus,273,CHEMBL619087,20033,,,Ileum,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,F,1,D,9,,BAO_0000221
3288,,2116.0,10141.0,Intermediate,Cavia porcellus,273,CHEMBL619088,20033,,,Ileum,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,F,1,D,9,,BAO_0000221
3289,,,10141.0,Intermediate,Cavia porcellus,13181,CHEMBL619089,20033,,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,B,1,D,9,,BAO_0000357
3290,,,10141.0,Autocuration,Cavia porcellus,13181,CHEMBL619090,168,,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3291,,,10141.0,Intermediate,Cavia porcellus,15034,CHEMBL619091,20033,,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,F,1,D,9,,BAO_0000019
3292,,,10141.0,Intermediate,Cavia porcellus,5033,CHEMBL619092,20033,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,B,1,D,9,,BAO_0000357
3293,,,10141.0,Intermediate,Cavia porcellus,1980,CHEMBL619093,20033,,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,B,1,D,9,,BAO_0000019
3294,,,10141.0,Autocuration,Cavia porcellus,13181,CHEMBL619094,168,,722.0,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,B,1,H,8,,BAO_0000219
3295,,,10141.0,Intermediate,Cavia porcellus,14287,CHEMBL619095,20033,,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,B,1,D,9,,BAO_0000019
3296,,,10141.0,Intermediate,Cavia porcellus,1317,CHEMBL857988,20033,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,B,1,D,9,,BAO_0000357
3297,,,10141.0,Intermediate,Cavia porcellus,15316,CHEMBL619096,20033,,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,B,1,D,9,,BAO_0000357
3298,,2435.0,10141.0,Intermediate,Cavia porcellus,16429,CHEMBL619097,20033,,,Striatum,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,B,1,D,9,,BAO_0000357
3299,,10000000.0,10141.0,Intermediate,Cavia porcellus,14818,CHEMBL619098,20033,,,Hippocampus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,B,1,D,9,,BAO_0000221
3300,,,10141.0,Intermediate,Cavia porcellus,15194,CHEMBL619751,20033,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,B,1,D,9,,BAO_0000357
3301,,,10141.0,Intermediate,Cavia porcellus,15194,CHEMBL619752,20033,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,B,1,D,9,,BAO_0000357
3302,,2116.0,10141.0,Intermediate,Cavia porcellus,13961,CHEMBL875096,20033,,,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,F,1,D,9,,BAO_0000221
3303,,,,Autocuration,,5486,CHEMBL619004,108,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,B,1,H,8,,BAO_0000357
3304,,,,Autocuration,,16209,CHEMBL619005,168,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
3305,,,,Autocuration,,17085,CHEMBL619006,168,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000019
3306,,,,Autocuration,,4199,CHEMBL619007,168,,308.0,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,B,1,H,8,,BAO_0000219
3307,,,,Autocuration,,15146,CHEMBL619008,168,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3308,,,,Autocuration,,5213,CHEMBL619009,168,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3309,,,,Autocuration,,4829,CHEMBL619010,168,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,B,1,H,8,,BAO_0000219
3310,,,,Autocuration,,17358,CHEMBL619011,10622,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,B,1,H,8,,BAO_0000357
3311,,,,Autocuration,,17358,CHEMBL619012,10622,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,B,1,H,8,,BAO_0000357
3312,,,,Autocuration,,16946,CHEMBL619013,10622,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,B,1,H,8,,BAO_0000219
3313,,,,Autocuration,,17358,CHEMBL619014,10622,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,B,1,H,8,,BAO_0000357
3314,,2081.0,,Autocuration,,268,CHEMBL857503,11249,,,Cardiac atrium,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,F,1,H,8,,BAO_0000019
3315,,2081.0,,Autocuration,,268,CHEMBL619015,11249,,,Cardiac atrium,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,F,1,H,8,,BAO_0000019
3316,,,,Autocuration,,15086,CHEMBL619016,11249,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3317,,10000000.0,,Autocuration,,14875,CHEMBL619017,11249,,,Hippocampus,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000221
3318,,10000000.0,9823.0,Autocuration,Sus scrofa,13267,CHEMBL619018,168,,,Hippocampus,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,B,1,H,8,,BAO_0000221
3319,,,9986.0,Autocuration,Oryctolagus cuniculus,13047,CHEMBL619019,168,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,B,1,H,8,,BAO_0000019
3320,,,10116.0,Expert,Rattus norvegicus,1650,CHEMBL619020,10623,,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,B,1,D,9,,BAO_0000357
3321,,,,Autocuration,,567,CHEMBL619021,10623,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,F,1,H,8,,BAO_0000019
3322,,,,Autocuration,,17358,CHEMBL619022,10623,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,B,1,H,8,,BAO_0000357
3323,,,,Autocuration,,188,CHEMBL619023,10623,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,B,1,H,8,,BAO_0000357
3324,,,,Autocuration,,670,CHEMBL619024,10623,,,,lntrinsic activity relative to 5-HT receptor,,F,1,H,8,,BAO_0000019
3325,,,,Autocuration,,204,CHEMBL619025,10623,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,F,1,H,8,,BAO_0000019
3326,,,,Expert,,1946,CHEMBL619026,10623,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,F,1,H,8,,BAO_0000019
3327,,,,Autocuration,,6398,CHEMBL619027,10623,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,F,1,H,8,,BAO_0000019
3328,,,,Autocuration,,6398,CHEMBL619028,10623,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,F,1,H,8,,BAO_0000019
3329,,,,Autocuration,,17358,CHEMBL619029,10623,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,F,1,H,8,,BAO_0000019
3330,,,,Autocuration,,6398,CHEMBL619030,10623,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,F,1,H,8,,BAO_0000019
3331,,,,Expert,,11752,CHEMBL619031,10623,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,B,1,H,8,,BAO_0000357
3332,,,,Autocuration,,809,CHEMBL619032,10623,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,F,1,H,8,,BAO_0000019
3333,,,10116.0,Expert,Rattus norvegicus,14178,CHEMBL619033,10623,,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,B,1,D,9,,BAO_0000357
3334,,,,Autocuration,,567,CHEMBL619034,10623,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,B,1,H,8,,BAO_0000357
3335,,,,Autocuration,,1946,CHEMBL619035,10623,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,B,1,H,8,,BAO_0000357
3336,,,,Autocuration,,1946,CHEMBL619036,10623,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,B,1,H,8,,BAO_0000357
3337,,,10116.0,Expert,Rattus norvegicus,13961,CHEMBL619037,10623,,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,B,1,D,9,,BAO_0000019
3338,,2435.0,,Autocuration,,6238,CHEMBL619038,10623,,,Striatum,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,B,1,H,8,,BAO_0000249
3339,,,,Autocuration,,14290,CHEMBL619039,10623,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,B,1,H,8,,BAO_0000249
3340,,,,Expert,,14290,CHEMBL619040,10623,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,B,1,H,8,,BAO_0000249
3341,,2435.0,10116.0,Expert,Rattus norvegicus,809,CHEMBL619041,10623,,,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,B,1,D,9,,BAO_0000019
3342,,2435.0,,Autocuration,,1578,CHEMBL619042,10623,,,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,B,1,H,8,,BAO_0000019
3343,,2435.0,,Expert,,16709,CHEMBL619043,10623,,,Striatum,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,B,1,H,8,,BAO_0000249
3344,,2435.0,,Expert,,1946,CHEMBL619044,10623,,,Striatum,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,B,1,H,8,,BAO_0000019
3345,,2435.0,,Expert,,15253,CHEMBL619045,10623,,,Striatum,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,B,1,H,8,,BAO_0000249
3346,,2435.0,,Expert,,4535,CHEMBL619046,10623,,,Striatum,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,B,1,H,8,,BAO_0000249
3347,,,,Expert,,13961,CHEMBL619047,10623,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,B,1,H,8,,BAO_0000249
3348,,955.0,,Autocuration,,17358,CHEMBL619048,10623,,,Brain,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,F,1,H,8,,BAO_0000221
3349,,,,Autocuration,,15847,CHEMBL859398,10623,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,F,1,H,8,,BAO_0000019
3350,,,,Autocuration,,15847,CHEMBL619049,10623,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,F,1,H,8,,BAO_0000019
3351,,,,Autocuration,,670,CHEMBL857886,10623,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,F,1,H,8,,BAO_0000019
3352,,,,Autocuration,,670,CHEMBL619050,10623,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,F,1,H,8,,BAO_0000019
3353,,,,Autocuration,,1317,CHEMBL620591,10623,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,F,1,H,8,,BAO_0000019
3354,,,10116.0,Expert,Rattus norvegicus,12936,CHEMBL620592,10623,,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,B,1,D,9,,BAO_0000357
3355,,2435.0,,Expert,,4535,CHEMBL620593,10623,,,Striatum,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,B,1,H,8,,BAO_0000249
3356,,,10116.0,Expert,Rattus norvegicus,14424,CHEMBL620594,10623,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,F,1,D,9,,BAO_0000019
3357,,,,Expert,,14424,CHEMBL875079,10623,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,F,1,H,8,,BAO_0000019
3358,,,,Expert,,14424,CHEMBL620595,10623,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,F,1,H,8,,BAO_0000019
3359,,,10116.0,Expert,Rattus norvegicus,14424,CHEMBL620596,10623,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,F,1,D,9,,BAO_0000019
3360,,,,Autocuration,,14424,CHEMBL620597,10623,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,F,1,H,8,,BAO_0000019
3361,,,,Expert,,14424,CHEMBL620598,10623,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,F,1,H,8,,BAO_0000019
3362,,,,Expert,,14424,CHEMBL620599,10623,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,F,1,H,8,,BAO_0000218
3363,,,,Autocuration,,14424,CHEMBL620600,10623,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,F,1,H,8,,BAO_0000019
3364,,,10116.0,Autocuration,Rattus norvegicus,1980,CHEMBL620601,168,,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,F,1,H,8,,BAO_0000019
3365,,,,Autocuration,,4639,CHEMBL620602,168,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,F,1,H,8,,BAO_0000019
3366,,,,Autocuration,,17358,CHEMBL620603,168,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3367,,,,Autocuration,,17358,CHEMBL620604,168,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,B,1,H,8,,BAO_0000357
3368,,,,Autocuration,,17358,CHEMBL620605,168,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,B,1,H,8,,BAO_0000357
3369,,,,Autocuration,,1558,CHEMBL620606,168,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3370,,,,Autocuration,,17358,CHEMBL620607,168,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,F,1,H,8,,BAO_0000019
3371,,,,Autocuration,,16117,CHEMBL620608,168,,,,In vitro binding affinity towards 5-HT4 receptor was determined,,B,1,H,8,,BAO_0000357
3372,,,,Autocuration,,17358,CHEMBL620609,168,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,F,1,H,8,,BAO_0000019
3373,,,,Autocuration,,17358,CHEMBL620610,168,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,F,1,H,8,,BAO_0000019
3374,,,,Autocuration,,17358,CHEMBL620611,168,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3375,,,,Autocuration,,17358,CHEMBL620612,168,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,B,1,H,8,,BAO_0000357
3376,,,,Autocuration,,17358,CHEMBL620613,168,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,B,1,H,8,,BAO_0000357
3377,,,,Autocuration,,17358,CHEMBL620614,168,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,B,1,H,8,,BAO_0000357
3378,,,,Expert,,1274,CHEMBL620615,168,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3379,Brain membranes,,,Autocuration,,10728,CHEMBL857075,104698,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,B,1,H,6,,BAO_0000249
3380,Brain membranes,,,Autocuration,,11695,CHEMBL620616,104698,,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,B,1,H,6,,BAO_0000249
3381,Brain membranes,,,Autocuration,,11695,CHEMBL619411,104698,,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,B,1,H,6,,BAO_0000249
3382,,,,Autocuration,,12490,CHEMBL619412,104698,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,B,1,H,6,,BAO_0000019
3383,,,10116.0,Autocuration,Rattus norvegicus,11828,CHEMBL619413,104698,,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000019
3384,,10000000.0,,Autocuration,,12253,CHEMBL619414,104698,,,Hippocampus,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,B,1,H,6,,BAO_0000221
3385,,,,Autocuration,,10561,CHEMBL619415,104698,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,B,1,H,6,,BAO_0000019
3386,,,,Autocuration,,10561,CHEMBL619416,104698,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,B,1,H,6,,BAO_0000019
3387,,,,Autocuration,,14432,CHEMBL619417,104698,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,F,1,H,6,,BAO_0000019
3388,,,10116.0,Autocuration,Rattus norvegicus,12936,CHEMBL619418,104698,,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000223
3389,,,10116.0,Autocuration,Rattus norvegicus,1274,CHEMBL619419,104698,,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000223
3390,,,,Autocuration,,1980,CHEMBL619420,104698,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,B,1,H,6,,BAO_0000019
3391,,,,Autocuration,,670,CHEMBL619421,104698,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,B,1,H,6,,BAO_0000249
3392,,,10116.0,Autocuration,Rattus norvegicus,968,CHEMBL619422,104698,,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,B,1,D,7,,BAO_0000019
3393,,,,Autocuration,,14287,CHEMBL619423,104698,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,B,1,H,6,,BAO_0000019
3394,,,,Autocuration,,567,CHEMBL875080,104698,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,B,1,H,6,,BAO_0000019
3395,,,,Autocuration,,13267,CHEMBL619424,104698,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,B,1,H,6,,BAO_0000019
3396,,,,Autocuration,,14826,CHEMBL619425,104698,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,B,1,H,6,,BAO_0000249
3397,,,,Autocuration,,15194,CHEMBL619426,104698,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,B,1,H,6,,BAO_0000223
3398,,,,Autocuration,,15194,CHEMBL619427,104698,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,B,1,H,6,,BAO_0000223
3399,,,10116.0,Autocuration,Rattus norvegicus,10394,CHEMBL619645,104698,,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,B,1,D,7,,BAO_0000223
3400,,,,Expert,,13657,CHEMBL619646,10576,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,B,1,D,9,,BAO_0000249
3401,,955.0,,Autocuration,,1879,CHEMBL619647,12020,,,Brain,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,F,1,H,8,,BAO_0000221
3402,,,,Autocuration,,1879,CHEMBL619648,12020,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,F,1,H,8,,BAO_0000019
3403,,,,Autocuration,,1879,CHEMBL619165,12020,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,F,1,H,8,,BAO_0000019
3404,,,,Autocuration,,204,CHEMBL620719,12020,,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,F,1,H,8,,BAO_0000218
3405,,,,Autocuration,,1879,CHEMBL872924,12020,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,B,1,H,8,,BAO_0000019
3406,,,,Autocuration,,1879,CHEMBL620720,12020,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3407,,,,Autocuration,,1879,CHEMBL620721,12020,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,B,1,H,8,,BAO_0000019
3408,,,,Autocuration,,1879,CHEMBL620722,12020,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,B,1,H,8,,BAO_0000019
3409,,,,Autocuration,,10641,CHEMBL620723,104698,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,B,1,H,6,,BAO_0000019
3410,,,,Autocuration,,773,CHEMBL620724,12020,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,B,1,H,8,,BAO_0000019
3411,,,,Autocuration,,11952,CHEMBL620725,104698,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,B,1,H,6,,BAO_0000249
3412,,,10116.0,Autocuration,Rattus norvegicus,14145,CHEMBL620726,12020,,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,F,1,D,9,,BAO_0000019
3413,,,,Expert,,17066,CHEMBL620727,144,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3414,,,,Autocuration,,6398,CHEMBL620728,104714,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,B,1,H,4,,BAO_0000223
3415,,,,Autocuration,,10321,CHEMBL620729,22226,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,B,1,U,0,,BAO_0000019
3416,,,,Autocuration,,511,CHEMBL858288,104714,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,F,1,H,4,,BAO_0000019
3417,,,,Autocuration,,4639,CHEMBL620730,104714,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,4,,BAO_0000223
3418,,,,Autocuration,,4639,CHEMBL620731,104714,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,4,,BAO_0000223
3419,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL620732,104714,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,F,1,H,4,,BAO_0000019
3420,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL618042,104714,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,F,1,H,4,,BAO_0000019
3421,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL618043,104714,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,F,1,H,4,,BAO_0000019
3422,,,,Autocuration,,1558,CHEMBL618044,104714,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,4,,BAO_0000223
3423,,,,Autocuration,,268,CHEMBL618045,104714,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,F,1,H,4,,BAO_0000019
3424,,,,Autocuration,,2474,CHEMBL618046,104714,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,B,1,H,4,,BAO_0000223
3425,,,,Autocuration,,5067,CHEMBL618047,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,F,1,H,4,,BAO_0000019
3426,,,,Autocuration,,5067,CHEMBL875084,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,F,1,H,4,,BAO_0000019
3427,,,,Autocuration,,5067,CHEMBL618048,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,F,1,H,4,,BAO_0000019
3428,,,,Autocuration,,5067,CHEMBL618049,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,B,1,H,4,,BAO_0000223
3429,,,,Autocuration,,5067,CHEMBL619764,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,F,1,H,4,,BAO_0000019
3430,,,,Autocuration,,5067,CHEMBL619765,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,F,1,H,4,,BAO_0000019
3431,,,,Autocuration,,5067,CHEMBL619766,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,F,1,H,4,,BAO_0000019
3432,,,,Autocuration,,5067,CHEMBL619767,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,B,1,H,4,,BAO_0000223
3433,,,,Autocuration,,5067,CHEMBL619768,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,B,1,H,4,,BAO_0000223
3434,,,,Autocuration,,5067,CHEMBL619769,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,F,1,H,4,,BAO_0000019
3435,,,,Autocuration,,5067,CHEMBL619770,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,B,1,H,4,,BAO_0000223
3436,,,,Autocuration,,5067,CHEMBL619771,104714,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,4,,BAO_0000223
3437,,,,Autocuration,,14331,CHEMBL619772,104714,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,B,1,H,4,,BAO_0000219
3438,,,,Autocuration,,5067,CHEMBL619773,104714,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,B,1,H,4,,BAO_0000223
3439,,,,Autocuration,,6179,CHEMBL619774,104714,,433.0,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,B,1,H,4,,BAO_0000219
3440,,,,Autocuration,,4265,CHEMBL875083,104714,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,B,1,H,4,,BAO_0000019
3441,,,,Autocuration,,4265,CHEMBL620718,104714,,433.0,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,B,1,H,4,,BAO_0000219
3442,,,,Autocuration,,17358,CHEMBL618127,104714,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,B,1,H,4,,BAO_0000223
3443,,,,Autocuration,,17358,CHEMBL618128,104714,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,B,1,H,4,,BAO_0000223
3444,,,,Autocuration,,13628,CHEMBL618129,104714,,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,B,1,H,4,,BAO_0000219
3445,,,,Autocuration,,4612,CHEMBL618130,104714,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,B,1,H,4,,BAO_0000223
3446,,,,Autocuration,,17358,CHEMBL618131,104714,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,F,1,H,4,,BAO_0000019
3447,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL618132,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,F,1,H,4,,BAO_0000019
3448,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL618133,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,F,1,H,4,,BAO_0000019
3449,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL618134,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,F,1,H,4,,BAO_0000019
3450,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL618135,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,F,1,H,4,,BAO_0000019
3451,,,,Autocuration,,511,CHEMBL618136,104714,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,B,1,H,4,,BAO_0000223
3452,,,,Autocuration,,1479,CHEMBL618137,104714,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,4,,BAO_0000223
3453,,,,Autocuration,,1317,CHEMBL618138,104714,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,B,1,H,4,,BAO_0000223
3454,,,,Autocuration,,12146,CHEMBL618139,104714,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,B,1,H,4,,BAO_0000223
3455,,,,Autocuration,,12146,CHEMBL618140,104714,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,B,1,H,4,,BAO_0000223
3456,,,,Autocuration,,13969,CHEMBL618141,104714,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,B,1,H,4,,BAO_0000223
3457,,,,Expert,,13392,CHEMBL873478,108,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,B,1,H,8,,BAO_0000357
3458,,,,Autocuration,,13392,CHEMBL618142,104698,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,6,,BAO_0000223
3459,,,,Autocuration,,14159,CHEMBL618143,144,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3460,,,,Autocuration,,1558,CHEMBL618144,144,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3461,,,,Autocuration,,16655,CHEMBL618145,144,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3462,,,,Autocuration,,13020,CHEMBL618146,104714,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,B,1,H,4,,BAO_0000223
3463,,,,Autocuration,,13021,CHEMBL618147,104714,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,B,1,H,4,,BAO_0000223
3464,,,,Autocuration,,13020,CHEMBL618148,104714,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,B,1,H,4,,BAO_0000223
3465,,,,Autocuration,,10321,CHEMBL618149,144,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,B,1,H,8,,BAO_0000019
3466,,,,Autocuration,,15818,CHEMBL872927,144,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3467,,,,Autocuration,,15818,CHEMBL618150,144,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3468,,,,Autocuration,,17358,CHEMBL618151,144,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,B,1,H,8,,BAO_0000357
3469,,,,Autocuration,,2222,CHEMBL875094,144,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,B,1,H,8,,BAO_0000357
3470,,,,Autocuration,,10322,CHEMBL618152,144,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,B,1,H,8,,BAO_0000019
3471,,,,Autocuration,,16117,CHEMBL618153,144,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,B,1,H,8,,BAO_0000357
3472,,,,Autocuration,,17200,CHEMBL618888,144,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,B,1,H,8,,BAO_0000357
3473,,,,Autocuration,,17358,CHEMBL618889,144,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,F,1,H,8,,BAO_0000019
3474,,,,Autocuration,,16700,CHEMBL618890,144,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,B,1,H,8,,BAO_0000357
3475,,,,Autocuration,,1980,CHEMBL618891,144,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,B,1,H,8,,BAO_0000019
3476,,,,Autocuration,,1980,CHEMBL619054,144,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,B,1,H,8,,BAO_0000019
3477,,,,Autocuration,,12409,CHEMBL619055,104714,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,B,1,H,4,,BAO_0000223
3478,,,,Autocuration,,4365,CHEMBL619056,144,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,B,1,H,8,,BAO_0000357
3479,,,,Autocuration,,4365,CHEMBL619057,144,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,F,1,H,8,,BAO_0000019
3480,,,,Autocuration,,4365,CHEMBL619058,144,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,B,1,H,8,,BAO_0000357
3481,,,10116.0,Expert,Rattus norvegicus,6769,CHEMBL619059,12020,,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,F,1,D,9,,BAO_0000219
3482,,,10116.0,Expert,Rattus norvegicus,6769,CHEMBL619060,12020,,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,F,1,D,9,,BAO_0000219
3483,,,10116.0,Expert,Rattus norvegicus,6769,CHEMBL875095,12020,,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,F,1,D,9,,BAO_0000219
3484,,2116.0,10141.0,Intermediate,Cavia porcellus,809,CHEMBL619061,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,F,1,D,9,,BAO_0000221
3485,,2116.0,10141.0,Intermediate,Cavia porcellus,809,CHEMBL619062,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,F,1,D,9,,BAO_0000221
3486,,,10141.0,Intermediate,Cavia porcellus,14290,CHEMBL619063,20033,,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,F,1,D,9,,BAO_0000019
3487,,2116.0,10141.0,Intermediate,Cavia porcellus,17358,CHEMBL619064,20033,,,Ileum,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,B,1,D,9,,BAO_0000221
3488,,,10141.0,Intermediate,Cavia porcellus,17358,CHEMBL619065,20033,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,B,1,D,9,,BAO_0000357
3489,,2116.0,10141.0,Intermediate,Cavia porcellus,17358,CHEMBL619066,20033,,,Ileum,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,B,1,D,9,,BAO_0000221
3490,,2116.0,,Autocuration,,17386,CHEMBL619775,10209,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,B,1,H,8,,BAO_0000221
3491,,,,Autocuration,,3269,CHEMBL619776,10209,,,,Affinity against 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3492,,,10141.0,Autocuration,Cavia porcellus,7721,CHEMBL619777,104841,,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,B,1,H,4,,BAO_0000224
3493,,,10141.0,Autocuration,Cavia porcellus,7721,CHEMBL619778,104841,,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,B,1,H,4,,BAO_0000224
3494,,2116.0,10141.0,Autocuration,Cavia porcellus,9117,CHEMBL619779,104841,,,Ileum,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,B,1,H,4,,BAO_0000221
3495,,,10141.0,Autocuration,Cavia porcellus,7721,CHEMBL619780,104841,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,B,1,H,4,,BAO_0000224
3496,,,10141.0,Autocuration,Cavia porcellus,7721,CHEMBL619166,104841,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,B,1,H,4,,BAO_0000224
3497,,,10141.0,Autocuration,Cavia porcellus,15796,CHEMBL619167,104841,,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,F,1,H,4,,BAO_0000019
3498,,,10141.0,Autocuration,Cavia porcellus,15796,CHEMBL619168,104841,,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,F,1,H,4,,BAO_0000019
3499,,2081.0,9606.0,Expert,Homo sapiens,15650,CHEMBL619169,168,,,Cardiac atrium,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,B,1,D,9,,BAO_0000219
3500,,2081.0,9606.0,Expert,Homo sapiens,15650,CHEMBL619170,168,,,Cardiac atrium,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,B,1,D,9,,BAO_0000219
3501,,,9606.0,Autocuration,Homo sapiens,6866,CHEMBL619171,104841,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,F,1,D,5,,BAO_0000019
3502,,2081.0,9606.0,Expert,Homo sapiens,15650,CHEMBL619172,168,,,Cardiac atrium,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,F,1,D,9,,BAO_0000219
3503,,,10090.0,Autocuration,Mus musculus,10063,CHEMBL619173,22226,,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,B,1,U,0,,BAO_0000019
3504,,,10090.0,Autocuration,Mus musculus,12665,CHEMBL619174,22226,,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,B,1,U,0,,BAO_0000019
3505,,,,Autocuration,,7504,CHEMBL619175,104705,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,,B,1,H,4,,BAO_0000019
3506,,,,Autocuration,,7504,CHEMBL619176,104705,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,,B,1,H,4,,BAO_0000224
3507,,,,Autocuration,,7038,CHEMBL619177,104705,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,B,1,H,4,,BAO_0000019
3508,,,,Autocuration,,7626,CHEMBL619178,104705,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,B,1,H,4,,BAO_0000224
3509,,,,Autocuration,,7626,CHEMBL619179,104705,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,B,1,H,4,,BAO_0000224
3510,,945.0,,Autocuration,,7185,CHEMBL619180,104705,,,Stomach,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,F,1,H,4,,BAO_0000019
3511,,945.0,,Autocuration,,7185,CHEMBL619181,104705,,,Stomach,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,F,1,H,4,,BAO_0000019
3512,,,,Autocuration,,7185,CHEMBL619182,104705,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,F,1,H,4,,BAO_0000019
3513,,,,Autocuration,,6960,CHEMBL619183,104705,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,B,1,H,4,,BAO_0000224
3514,,,,Autocuration,,6960,CHEMBL619184,104705,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,B,1,H,4,,BAO_0000224
3515,,10000000.0,,Autocuration,,12416,CHEMBL619185,10576,,,Hippocampus,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,B,1,H,8,,BAO_0000221
3516,,,,Expert,,15753,CHEMBL619186,12198,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,,B,1,H,8,,BAO_0000357
3517,,,,Autocuration,,8062,CHEMBL619187,104705,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,B,1,H,4,,BAO_0000019
3518,,,10116.0,Autocuration,Rattus norvegicus,9036,CHEMBL619188,104705,,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,B,1,D,5,,BAO_0000019
3519,,,10116.0,Autocuration,Rattus norvegicus,15067,CHEMBL619189,104705,,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,B,1,D,5,,BAO_0000224
3520,,955.0,10116.0,Expert,Rattus norvegicus,15753,CHEMBL619190,12198,,,Brain,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,F,1,D,9,,BAO_0000019
3521,,2037.0,10116.0,Expert,Rattus norvegicus,15753,CHEMBL619191,12198,,,Cerebellum,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,F,1,D,9,,BAO_0000221
3522,,,10116.0,Autocuration,Rattus norvegicus,15295,CHEMBL619192,104705,,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,B,1,D,5,,BAO_0000019
3523,,,10116.0,Autocuration,Rattus norvegicus,6347,CHEMBL619193,104705,,,,Percent binding affinity against 5-hydroxytryptamine receptor,,B,1,D,5,,BAO_0000224
3524,,,,Autocuration,,6763,CHEMBL619194,22226,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,B,1,U,0,,BAO_0000019
3525,,,10116.0,Autocuration,Rattus norvegicus,12092,CHEMBL619195,104705,,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,B,1,D,5,,BAO_0000224
3526,,,10116.0,Autocuration,Rattus norvegicus,1579,CHEMBL619196,104705,,,,Affinity against 5-hydroxytryptamine receptor was determined,,B,1,D,5,,BAO_0000224
3527,,945.0,10116.0,Autocuration,Rattus norvegicus,1579,CHEMBL619197,104705,,,Stomach,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,B,1,D,5,,BAO_0000019
3528,,,9606.0,Expert,Homo sapiens,5963,CHEMBL619198,121,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,B,1,D,9,,BAO_0000219
3529,,,9606.0,Expert,Homo sapiens,5963,CHEMBL875081,121,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,B,1,D,9,,BAO_0000219
3530,,,,Autocuration,,5030,CHEMBL884712,18065,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,B,1,H,8,,BAO_0000357
3531,,,,Expert,,15796,CHEMBL884710,121,,,,Inhibition of 5-hydroxytryptamine reuptake,,B,1,H,8,,BAO_0000357
3532,,,,Autocuration,,15413,CHEMBL619199,18065,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,F,1,H,8,,BAO_0000019
3533,,,,Autocuration,,15413,CHEMBL619200,18065,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,F,1,H,8,,BAO_0000019
3534,,,,Autocuration,,15413,CHEMBL619201,18065,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,F,1,H,8,,BAO_0000019
3535,,,,Autocuration,,12409,CHEMBL619202,18065,,,,Tested for 5-hydroxytryptamine receptor uptake,,F,1,H,8,,BAO_0000019
3536,,,9606.0,Expert,Homo sapiens,16909,CHEMBL619203,51,,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,B,1,D,9,,BAO_0000219
3537,,,9606.0,Expert,Homo sapiens,16909,CHEMBL619204,51,,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,F,1,D,9,,BAO_0000019
3538,,,9606.0,Autocuration,Homo sapiens,15629,CHEMBL619205,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,B,1,H,8,,BAO_0000249
3539,,,,Autocuration,,15629,CHEMBL619206,10576,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,B,1,H,8,,BAO_0000357
3540,,,,Expert,,15629,CHEMBL619207,10576,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,B,1,H,8,,BAO_0000249
3541,,2435.0,,Autocuration,,10034,CHEMBL619208,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,F,1,H,8,,BAO_0000019
3542,,2435.0,,Autocuration,,10034,CHEMBL619209,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,F,1,H,8,,BAO_0000019
3543,,2435.0,,Autocuration,,10034,CHEMBL619210,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,F,1,H,8,,BAO_0000019
3544,,2435.0,,Autocuration,,10034,CHEMBL619211,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,F,1,H,8,,BAO_0000019
3545,,2435.0,,Autocuration,,10034,CHEMBL619212,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,F,1,H,8,,BAO_0000019
3546,,2435.0,,Autocuration,,10034,CHEMBL620681,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,F,1,H,8,,BAO_0000019
3547,,2435.0,,Autocuration,,10034,CHEMBL620682,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,F,1,H,8,,BAO_0000019
3548,,2435.0,,Autocuration,,10034,CHEMBL620683,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,F,1,H,8,,BAO_0000019
3549,,2435.0,,Autocuration,,10034,CHEMBL620684,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,F,1,H,8,,BAO_0000019
3550,,2435.0,,Autocuration,,10034,CHEMBL620685,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,F,1,H,8,,BAO_0000019
3551,,2435.0,,Autocuration,,10034,CHEMBL620686,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,F,1,H,8,,BAO_0000019
3552,,349.0,,Autocuration,,10034,CHEMBL620687,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,F,1,H,8,,BAO_0000019
3553,,349.0,,Autocuration,,10034,CHEMBL620688,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,F,1,H,8,,BAO_0000019
3554,,349.0,,Autocuration,,10034,CHEMBL620689,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,F,1,H,8,,BAO_0000019
3555,,349.0,,Autocuration,,10034,CHEMBL620690,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,F,1,H,8,,BAO_0000019
3556,,349.0,,Autocuration,,10034,CHEMBL620691,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,F,1,H,8,,BAO_0000019
3557,,349.0,,Autocuration,,10034,CHEMBL620692,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,F,1,H,8,,BAO_0000019
3558,,349.0,,Autocuration,,10034,CHEMBL620693,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,F,1,H,8,,BAO_0000019
3559,,,,Expert,,1274,CHEMBL620694,168,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3560,,,,Autocuration,,17358,CHEMBL857986,168,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,F,1,H,8,,BAO_0000019
3561,,,,Autocuration,,14532,CHEMBL620695,168,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,B,1,H,8,,BAO_0000357
3562,,,,Expert,,16989,CHEMBL620696,168,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3563,,,,Autocuration,,17200,CHEMBL620697,168,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,B,1,H,8,,BAO_0000357
3564,,,,Autocuration,,15779,CHEMBL620698,168,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,B,1,H,8,,BAO_0000357
3565,,,,Autocuration,,15779,CHEMBL620699,168,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,B,1,H,8,,BAO_0000357
3566,,,,Autocuration,,15779,CHEMBL620700,168,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,B,1,H,8,,BAO_0000357
3567,,,,Autocuration,,15650,CHEMBL620701,168,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,B,1,H,8,,BAO_0000219
3568,,,,Autocuration,,15650,CHEMBL875082,168,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,B,1,H,8,,BAO_0000219
3569,,,,Autocuration,,15650,CHEMBL620702,168,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,B,1,H,8,,BAO_0000219
3570,,,,Autocuration,,15650,CHEMBL620703,168,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,B,1,H,8,,BAO_0000219
3571,,,,Autocuration,,17046,CHEMBL620704,168,,673.0,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,B,1,H,8,,BAO_0000219
3572,,,,Expert,,17046,CHEMBL620705,168,,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,B,1,H,8,,BAO_0000219
3573,,,,Expert,,15650,CHEMBL620706,168,,673.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,B,1,H,8,,BAO_0000219
3574,,,,Expert,,17046,CHEMBL620707,168,,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,B,1,H,8,,BAO_0000219
3575,,,,Expert,,17066,CHEMBL620708,10624,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,B,1,H,8,,BAO_0000357
3576,,,,Autocuration,,17200,CHEMBL620709,105,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,B,1,H,8,,BAO_0000357
3577,,,9606.0,Expert,Homo sapiens,16146,CHEMBL620710,10624,,,,Binding affinity against 5-hydroxytryptamine 5A receptor,,B,1,D,9,,BAO_0000357
3578,,,,Autocuration,,15250,CHEMBL620711,10624,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
3579,,,9606.0,Expert,Homo sapiens,6491,CHEMBL620712,10624,,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,B,1,D,9,,BAO_0000357
3580,,,9606.0,Expert,Homo sapiens,17066,CHEMBL620713,10624,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,B,1,D,9,,BAO_0000357
3581,,,9606.0,Expert,Homo sapiens,17066,CHEMBL620714,10624,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,B,1,D,9,,BAO_0000357
3582,,,9606.0,Expert,Homo sapiens,4234,CHEMBL620715,10624,,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,B,1,D,9,,BAO_0000357
3583,,,,Autocuration,,6013,CHEMBL620716,10624,,,,Binding affinity towards 5-HT5A receptor,,B,1,H,8,,BAO_0000357
3584,,,,Expert,,17175,CHEMBL620717,10624,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,B,1,H,8,,BAO_0000357
3585,,,,Autocuration,,15818,CHEMBL618072,10624,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,B,1,H,8,,BAO_0000357
3586,,,,Autocuration,,6166,CHEMBL857987,10624,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,,B,1,H,8,,BAO_0000357
3587,,,,Autocuration,,15779,CHEMBL618073,10624,,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000219
3588,,,,Autocuration,,15779,CHEMBL618074,10624,,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,B,1,H,8,,BAO_0000219
3589,,,,Autocuration,,5213,CHEMBL618075,10624,,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,B,1,H,8,,BAO_0000219
3590,,,10090.0,Expert,Mus musculus,17066,CHEMBL618076,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,B,1,D,9,,BAO_0000357
3591,,,10090.0,Expert,Mus musculus,17066,CHEMBL618077,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,B,1,D,9,,BAO_0000357
3592,,,10090.0,Expert,Mus musculus,17066,CHEMBL618078,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,B,1,D,9,,BAO_0000357
3593,,,10090.0,Expert,Mus musculus,17066,CHEMBL881821,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,B,1,D,9,,BAO_0000357
3594,,,10090.0,Expert,Mus musculus,17066,CHEMBL618079,10625,,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,B,1,D,9,,BAO_0000357
3595,,,,Expert,,17175,CHEMBL618080,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,B,1,H,8,,BAO_0000357
3596,,,,Autocuration,,16190,CHEMBL618081,10576,,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000219
3597,,,,Autocuration,,16190,CHEMBL618082,10626,,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000219
3598,,,,Expert,,4820,CHEMBL618083,10624,,,,Binding affinity towards 5-HT5a receptor,,B,1,H,8,,BAO_0000357
3599,,,9606.0,Expert,Homo sapiens,17066,CHEMBL618084,10624,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,B,1,D,9,,BAO_0000357
3600,,,,Expert,,17066,CHEMBL618085,10624,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,B,1,H,8,,BAO_0000357
3601,,,,Expert,,17175,CHEMBL618086,10624,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,B,1,H,8,,BAO_0000357
3602,,,,Autocuration,,16633,CHEMBL875092,10624,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,,B,1,H,8,,BAO_0000357
3603,,,,Autocuration,,16633,CHEMBL618087,10624,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,B,1,H,8,,BAO_0000357
3604,,,,Autocuration,,16700,CHEMBL872926,10624,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,B,1,H,8,,BAO_0000357
3605,,,10141.0,Autocuration,Cavia porcellus,4639,CHEMBL618088,104714,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,F,1,H,4,,BAO_0000019
3606,,,,Autocuration,,5486,CHEMBL618089,104714,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,B,1,H,4,,BAO_0000223
3607,,,9606.0,Expert,Homo sapiens,16146,CHEMBL618090,10627,,,,Inhibition of human 5-hydroxytryptamine 6 receptor,,B,1,D,9,,BAO_0000357
3608,,,9606.0,Expert,Homo sapiens,17273,CHEMBL618091,10627,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,B,1,D,9,,BAO_0000357
3609,,,,Autocuration,,17687,CHEMBL618092,10627,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3610,,,9606.0,Expert,Homo sapiens,6491,CHEMBL618093,10627,,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,B,1,D,9,,BAO_0000357
3611,,,,Expert,,16190,CHEMBL618094,10627,,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,B,1,H,8,,BAO_0000219
3612,,,9606.0,Expert,Homo sapiens,17066,CHEMBL618095,10627,,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,B,1,D,9,,BAO_0000357
3613,,,9606.0,Expert,Homo sapiens,17066,CHEMBL875093,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,B,1,D,9,,BAO_0000357
3614,,,9606.0,Expert,Homo sapiens,17066,CHEMBL618096,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,B,1,D,9,,BAO_0000357
3615,,,9606.0,Expert,Homo sapiens,17066,CHEMBL618118,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,B,1,D,9,,BAO_0000357
3616,,,9606.0,Expert,Homo sapiens,3555,CHEMBL618119,10627,,,,Binding affinity against 5-hydroxytryptamine 6 receptor,,B,1,D,9,,BAO_0000357
3617,,,,Expert,,5808,CHEMBL618120,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3618,,,,Autocuration,,6013,CHEMBL618121,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3619,,,,Expert,,15818,CHEMBL618122,10627,,722.0,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,B,1,H,8,,BAO_0000219
3620,,,,Autocuration,,16209,CHEMBL618123,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000357
3621,,,,Expert,,3935,CHEMBL618124,10627,,722.0,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,B,1,H,8,,BAO_0000219
3622,,,,Autocuration,,15818,CHEMBL618125,10627,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3623,,,9606.0,Expert,Homo sapiens,3805,CHEMBL618126,10627,,722.0,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,B,1,D,9,,BAO_0000219
3624,,,,Expert,,16441,CHEMBL618236,10627,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,B,1,H,8,,BAO_0000019
3625,,,,Expert,,16441,CHEMBL618237,10627,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,B,1,H,8,,BAO_0000019
3626,,,,Expert,,6786,CHEMBL618238,10627,,643.0,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,B,1,H,8,,BAO_0000219
3627,,,9606.0,Expert,Homo sapiens,4234,CHEMBL618239,10627,,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,B,1,D,9,,BAO_0000357
3628,,,,Autocuration,,17085,CHEMBL618240,10627,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000019
3629,,,,Autocuration,,17200,CHEMBL618241,10627,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,B,1,H,8,,BAO_0000357
3630,,,,Autocuration,,17451,CHEMBL859399,10627,,722.0,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,B,1,H,8,,BAO_0000219
3631,,,,Autocuration,,3935,CHEMBL618242,10627,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,F,1,H,8,,BAO_0000019
3632,,,,Autocuration,,5033,CHEMBL857991,10627,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3633,,,,Expert,,4540,CHEMBL619951,10627,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3634,,,9606.0,Expert,Homo sapiens,4540,CHEMBL619952,10627,,308.0,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,B,1,D,9,,BAO_0000219
3635,,,9606.0,Expert,Homo sapiens,4540,CHEMBL619953,10627,,308.0,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,B,1,D,9,,BAO_0000219
3636,,,,Autocuration,,17296,CHEMBL619954,10627,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,B,1,H,8,,BAO_0000219
3637,,,,Autocuration,,17296,CHEMBL619955,10627,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000219
3638,,,,Autocuration,,17296,CHEMBL619956,10627,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000219
3639,,,,Autocuration,,15779,CHEMBL619957,10627,,449.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000219
3640,,,,Autocuration,,15779,CHEMBL619958,10627,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,B,1,H,8,,BAO_0000219
3641,,,,Autocuration,,15779,CHEMBL620627,10627,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,B,1,H,8,,BAO_0000219
3642,,,,Autocuration,,15779,CHEMBL620628,10627,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,B,1,H,8,,BAO_0000219
3643,,,,Autocuration,,15779,CHEMBL620629,10627,,308.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,B,1,H,8,,BAO_0000219
3644,,,,Autocuration,,6166,CHEMBL620630,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3645,,,,Autocuration,,17451,CHEMBL620782,10627,,308.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000219
3646,,,,Autocuration,,15316,CHEMBL620783,10627,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3647,,,,Expert,,4199,CHEMBL620784,10627,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3648,,,,Expert,,15146,CHEMBL620785,10627,,308.0,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,B,1,H,8,,BAO_0000219
3649,,,,Autocuration,,5213,CHEMBL857992,10627,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,B,1,H,8,,BAO_0000357
3650,,,,Autocuration,,16429,CHEMBL620786,10627,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,B,1,H,8,,BAO_0000219
3651,,,,Autocuration,,14818,CHEMBL620787,10627,,308.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,B,1,H,8,,BAO_0000219
3652,,,,Autocuration,,4829,CHEMBL620788,10627,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,B,1,H,8,,BAO_0000219
3653,,,,Autocuration,,4829,CHEMBL620789,10627,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,B,1,H,8,,BAO_0000219
3654,,,,Autocuration,,4829,CHEMBL620790,10627,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,B,1,H,8,,BAO_0000219
3655,,,,Autocuration,,15250,CHEMBL620791,10628,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
3656,,,,Autocuration,,14423,CHEMBL620792,10628,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,B,1,H,8,,BAO_0000019
3657,,,,Autocuration,,15086,CHEMBL620793,10628,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3658,,,,Autocuration,,4342,CHEMBL620794,10628,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,B,1,H,8,,BAO_0000357
3659,,,9606.0,Autocuration,Homo sapiens,16190,CHEMBL620795,10627,,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,B,1,D,9,,BAO_0000219
3660,,,,Expert,,4820,CHEMBL620796,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3661,,,,Autocuration,,4639,CHEMBL620797,10627,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,B,1,H,8,,BAO_0000357
3662,,,9606.0,Expert,Homo sapiens,17066,CHEMBL620798,10627,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,F,1,D,9,,BAO_0000019
3663,,,,Autocuration,,6011,CHEMBL620799,10627,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,B,1,H,8,,BAO_0000357
3664,,,,Expert,,17066,CHEMBL620800,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3665,,,,Autocuration,,17515,CHEMBL620801,10627,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,B,1,H,8,,BAO_0000357
3666,,,,Autocuration,,5014,CHEMBL875100,10627,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3667,,,,Autocuration,,4373,CHEMBL620802,10627,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,B,1,H,8,,BAO_0000357
3668,,,,Expert,,17066,CHEMBL620803,10627,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,F,1,H,8,,BAO_0000019
3669,,,,Expert,,17066,CHEMBL620804,10627,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,F,1,H,8,,BAO_0000019
3670,,,,Autocuration,,4373,CHEMBL620805,10627,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,B,1,H,8,,BAO_0000357
3671,,,,Autocuration,,4687,CHEMBL620806,10627,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3672,,,,Autocuration,,16946,CHEMBL620807,10627,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,B,1,H,8,,BAO_0000357
3673,,,,Autocuration,,16946,CHEMBL620808,10627,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,B,1,H,8,,BAO_0000357
3674,,,,Autocuration,,16633,CHEMBL620809,10627,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3675,,,,Autocuration,,16633,CHEMBL620810,10627,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3676,,,9606.0,Expert,Homo sapiens,17066,CHEMBL620811,10627,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,B,1,D,9,,BAO_0000357
3677,,,,Autocuration,,16700,CHEMBL620812,10627,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,B,1,H,8,,BAO_0000357
3678,,,,Autocuration,,3269,CHEMBL620813,10627,,,,Affinity against 5-hydroxytryptamine 6 receptor,,B,1,H,8,,BAO_0000357
3679,,,,Autocuration,,5486,CHEMBL620814,10627,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,B,1,H,8,,BAO_0000357
3680,,,9606.0,Expert,Homo sapiens,16146,CHEMBL620815,10209,,,,Inhibition of human 5-hydroxytryptamine 7 receptor,,B,1,D,9,,BAO_0000357
3681,,,,Autocuration,,5014,CHEMBL620816,10209,,722.0,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,B,1,H,8,,BAO_0000219
3682,,,,Autocuration,,15463,CHEMBL620817,10209,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3683,,,,Autocuration,,3805,CHEMBL620818,10209,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,B,1,H,8,,BAO_0000357
3684,,,,Expert,,5014,CHEMBL620819,10209,,722.0,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,B,1,H,8,,BAO_0000219
3685,,,9606.0,Expert,Homo sapiens,6491,CHEMBL620820,10209,,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,B,1,D,9,,BAO_0000357
3686,,,,Autocuration,,16190,CHEMBL620821,10209,,449.0,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,B,1,H,8,,BAO_0000219
3687,,,9606.0,Expert,Homo sapiens,17066,CHEMBL620822,10209,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,B,1,D,9,,BAO_0000357
3688,,,9606.0,Expert,Homo sapiens,17066,CHEMBL620823,10209,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,B,1,D,9,,BAO_0000357
3689,,,9606.0,Expert,Homo sapiens,3555,CHEMBL620824,10209,,,,Binding affinity against 5-hydroxytryptamine 7 receptor,,B,1,D,9,,BAO_0000357
3690,,,,Expert,,6588,CHEMBL620825,10209,,449.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,B,1,H,8,,BAO_0000219
3691,,,,Autocuration,,15463,CHEMBL872930,10209,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000357
3692,,,,Autocuration,,6013,CHEMBL620826,10209,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3693,,,,Autocuration,,16209,CHEMBL620827,10209,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
3694,,,,Autocuration,,3935,CHEMBL620828,10209,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3695,,,,Autocuration,,15818,CHEMBL620829,10209,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3696,,,,Expert,,5014,CHEMBL620830,10209,,722.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,B,1,H,8,,BAO_0000219
3697,,,,Expert,,16441,CHEMBL620831,10209,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,B,1,H,8,,BAO_0000019
3698,,,,Expert,,16441,CHEMBL620832,10209,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,B,1,H,8,,BAO_0000019
3699,,,9606.0,Expert,Homo sapiens,4234,CHEMBL621548,10209,,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,B,1,D,9,,BAO_0000357
3700,,,,Autocuration,,17085,CHEMBL621549,10209,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000019
3701,,,,Autocuration,,17200,CHEMBL621550,10209,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,B,1,H,8,,BAO_0000357
3702,,,,Autocuration,,17451,CHEMBL621551,10209,,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,B,1,H,8,,BAO_0000219
3703,,,,Autocuration,,17085,CHEMBL621552,10209,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,B,1,H,8,,BAO_0000019
3704,,,,Autocuration,,5104,CHEMBL857077,10209,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3705,,,,Autocuration,,5104,CHEMBL618158,10209,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,B,1,H,8,,BAO_0000357
3706,,,9606.0,Expert,Homo sapiens,5033,CHEMBL618159,10209,,643.0,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,B,1,D,9,,BAO_0000219
3707,,,,Autocuration,,5486,CHEMBL875101,10209,,643.0,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,B,1,H,8,,BAO_0000219
3708,,,9606.0,Expert,Homo sapiens,4540,CHEMBL618160,10209,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,B,1,D,9,,BAO_0000219
3709,,,,Expert,,6166,CHEMBL618161,10209,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,B,1,H,8,,BAO_0000357
3710,,,,Expert,,17342,CHEMBL618162,10209,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000219
3711,,,,Expert,,17342,CHEMBL618163,10209,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000357
3712,,,,Autocuration,,17296,CHEMBL618164,10209,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,B,1,H,8,,BAO_0000357
3713,,,,Expert,,16429,CHEMBL618165,10209,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,B,1,H,8,,BAO_0000219
3714,,,,Autocuration,,15779,CHEMBL618166,10209,,722.0,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,B,1,H,8,,BAO_0000219
3715,,,,Autocuration,,15779,CHEMBL857989,10209,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,B,1,H,8,,BAO_0000219
3716,,,,Autocuration,,15779,CHEMBL619888,10209,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,B,1,H,8,,BAO_0000219
3717,,,,Autocuration,,15779,CHEMBL619889,10209,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,B,1,H,8,,BAO_0000219
3718,,,,Autocuration,,15779,CHEMBL619890,10209,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,B,1,H,8,,BAO_0000219
3719,,,,Autocuration,,17451,CHEMBL619891,10209,,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,B,1,H,8,,BAO_0000219
3720,,,,Autocuration,,4199,CHEMBL619892,10209,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,B,1,H,8,,BAO_0000219
3721,,,,Expert,,4199,CHEMBL619893,10209,,722.0,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,B,1,D,9,,BAO_0000219
3722,,,,Autocuration,,4199,CHEMBL619894,10209,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,B,1,H,8,,BAO_0000219
3723,,,,Intermediate,,3680,CHEMBL619895,10209,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,B,1,D,9,,BAO_0000219
3724,,,,Intermediate,,3680,CHEMBL619896,10209,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,B,1,D,9,,BAO_0000357
3725,,,,Autocuration,,15316,CHEMBL619897,10209,,643.0,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,B,1,H,8,,BAO_0000219
3726,,,,Autocuration,,15146,CHEMBL619898,10209,,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,B,1,H,8,,BAO_0000219
3727,,,,Expert,,5213,CHEMBL619899,10209,,722.0,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,B,1,H,8,,BAO_0000219
3728,,,,Autocuration,,5213,CHEMBL619900,10209,,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,B,1,H,8,,BAO_0000219
3729,,,9606.0,Expert,Homo sapiens,14818,CHEMBL619901,10209,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,B,1,D,9,,BAO_0000219
3730,,,,Autocuration,,14818,CHEMBL620580,10209,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,B,1,H,8,,BAO_0000219
3731,,,,Autocuration,,14818,CHEMBL620581,10209,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,B,1,H,8,,BAO_0000219
3732,,,,Autocuration,,4829,CHEMBL620733,10209,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,B,1,H,8,,BAO_0000219
3733,,,9606.0,Autocuration,Homo sapiens,17200,CHEMBL620734,10209,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,B,1,D,9,,BAO_0000357
3734,,,10090.0,Expert,Mus musculus,17066,CHEMBL620735,10022,,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,B,1,D,9,,BAO_0000357
3735,,,9986.0,Autocuration,Oryctolagus cuniculus,14025,CHEMBL620736,10209,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,B,1,H,8,,BAO_0000019
3736,,,,Autocuration,,15250,CHEMBL620737,11923,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,B,1,H,8,,BAO_0000219
3737,,,,Autocuration,,16372,CHEMBL620738,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,B,1,H,8,,BAO_0000219
3738,,,,Autocuration,,16372,CHEMBL620739,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,B,1,H,8,,BAO_0000219
3739,,,,Autocuration,,16372,CHEMBL620740,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,B,1,H,8,,BAO_0000219
3740,,,,Autocuration,,16372,CHEMBL620741,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,B,1,H,8,,BAO_0000219
3741,,,,Autocuration,,16372,CHEMBL620742,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,B,1,H,8,,BAO_0000219
3742,,,,Autocuration,,16372,CHEMBL620743,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,B,1,H,8,,BAO_0000219
3743,,,,Autocuration,,16372,CHEMBL620744,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,B,1,H,8,,BAO_0000219
3744,,,,Autocuration,,16372,CHEMBL620745,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,B,1,H,8,,BAO_0000219
3745,,,,Autocuration,,16372,CHEMBL620746,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,B,1,H,8,,BAO_0000219
3746,,,,Autocuration,,16372,CHEMBL620747,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,B,1,H,8,,BAO_0000219
3747,,,,Autocuration,,16372,CHEMBL620748,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,B,1,H,8,,BAO_0000219
3748,,,,Autocuration,,16372,CHEMBL620749,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,B,1,H,8,,BAO_0000219
3749,,,,Expert,,17066,CHEMBL620750,11923,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3750,,,10116.0,Expert,Rattus norvegicus,17066,CHEMBL620751,11923,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,B,1,D,9,,BAO_0000357
3751,,,,Expert,,17386,CHEMBL620752,11923,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3752,,,,Autocuration,,14423,CHEMBL872929,11923,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,B,1,H,8,,BAO_0000019
3753,,,10116.0,Expert,Rattus norvegicus,15874,CHEMBL620753,11923,,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,B,1,D,9,,BAO_0000357
3754,,,10116.0,Expert,Rattus norvegicus,15874,CHEMBL620754,11923,,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,B,1,D,9,,BAO_0000357
3755,,,10116.0,Expert,Rattus norvegicus,16372,CHEMBL620755,11923,,449.0,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,B,1,D,9,,BAO_0000219
3756,,,,Autocuration,,4622,CHEMBL620756,11923,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
3757,,,,Autocuration,,15086,CHEMBL620757,11923,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3758,,,,Autocuration,,16372,CHEMBL620758,11923,,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,B,1,H,8,,BAO_0000219
3759,,,,Autocuration,,16372,CHEMBL620759,11923,,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,B,1,H,8,,BAO_0000219
3760,,,,Autocuration,,16372,CHEMBL620760,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,B,1,H,8,,BAO_0000219
3761,,,,Autocuration,,16372,CHEMBL620761,11923,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,B,1,H,8,,BAO_0000219
3762,,2116.0,,Autocuration,,17386,CHEMBL620762,11923,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,F,1,H,8,,BAO_0000221
3763,,2116.0,,Autocuration,,17386,CHEMBL620763,11923,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,F,1,H,8,,BAO_0000221
3764,,2116.0,,Autocuration,,17386,CHEMBL620764,11923,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,F,1,H,8,,BAO_0000221
3765,Membranes,,10116.0,Expert,Rattus norvegicus,5831,CHEMBL857990,11923,,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,B,1,D,9,,BAO_0000249
3766,,,,Autocuration,,4342,CHEMBL620765,11923,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,B,1,H,8,,BAO_0000357
3767,,,,Expert,,17319,CHEMBL620766,11923,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,B,1,H,8,,BAO_0000357
3768,,1898.0,,Expert,,17342,CHEMBL620767,11923,,,Hypothalamus,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,B,1,H,8,,BAO_0000019
3769,,,,Autocuration,,17342,CHEMBL620768,11923,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,B,1,H,8,,BAO_0000357
3770,,1898.0,,Expert,,3680,CHEMBL619051,11923,,,Hypothalamus,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,B,1,H,8,,BAO_0000249
3771,,,,Expert,,3680,CHEMBL619052,11923,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3772,,,10116.0,Expert,Rattus norvegicus,17319,CHEMBL619053,11923,,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,F,1,D,9,,BAO_0000219
3773,,,10116.0,Expert,Rattus norvegicus,17319,CHEMBL619703,11923,,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,F,1,D,9,,BAO_0000219
3774,,,10116.0,Autocuration,Rattus norvegicus,17319,CHEMBL619704,11923,,722.0,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,F,1,D,9,,BAO_0000219
3775,,,,Expert,,4820,CHEMBL619851,10209,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3776,,,,Autocuration,,4639,CHEMBL619852,10209,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,B,1,H,8,,BAO_0000357
3777,,,,Autocuration,,6011,CHEMBL619853,10209,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,B,1,H,8,,BAO_0000357
3778,,,9606.0,Expert,Homo sapiens,17066,CHEMBL619854,10209,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,B,1,D,9,,BAO_0000357
3779,,,,Expert,,17066,CHEMBL619855,10209,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3780,,,,Autocuration,,17515,CHEMBL619856,10209,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,B,1,H,8,,BAO_0000357
3781,,,,Autocuration,,4373,CHEMBL619857,10209,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,B,1,H,8,,BAO_0000357
3782,,,,Expert,,17066,CHEMBL619858,10209,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,F,1,H,8,,BAO_0000019
3783,,,,Autocuration,,4373,CHEMBL619859,10209,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,B,1,H,8,,BAO_0000357
3784,,,,Autocuration,,4373,CHEMBL619860,10209,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,B,1,H,8,,BAO_0000357
3785,,,,Autocuration,,4687,CHEMBL619861,10209,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3786,,,,Expert,,17342,CHEMBL619862,10209,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3787,,,,Autocuration,,16946,CHEMBL619863,10209,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,B,1,H,8,,BAO_0000357
3788,,,,Autocuration,,16946,CHEMBL619864,10209,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,B,1,H,8,,BAO_0000357
3789,,,,Autocuration,,16633,CHEMBL872928,10209,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3790,,,,Autocuration,,16633,CHEMBL619865,10209,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3791,,,,Expert,,17066,CHEMBL619866,10209,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,B,1,H,8,,BAO_0000357
3792,,,,Autocuration,,16700,CHEMBL619867,10209,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,B,1,H,8,,BAO_0000357
3793,,2116.0,,Autocuration,,17386,CHEMBL619868,10209,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,B,1,H,8,,BAO_0000221
3794,,,,Autocuration,,14080,CHEMBL619869,55,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,F,1,H,8,,BAO_0000019
3795,,,9606.0,Expert,Homo sapiens,14080,CHEMBL619870,55,,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,F,1,D,9,,BAO_0000019
3796,,,,Autocuration,,409,CHEMBL619871,55,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,B,1,H,8,,BAO_0000357
3797,,,,Autocuration,,409,CHEMBL619872,55,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,,B,1,H,8,,BAO_0000357
3798,,,,Autocuration,,409,CHEMBL619873,55,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,B,1,H,8,,BAO_0000357
3799,,178.0,,Expert,,11090,CHEMBL619874,55,,,Blood,Inhibition of 5-lipoxygenase in human whole blood.,,B,1,H,8,,BAO_0000357
3800,,178.0,,Expert,,11090,CHEMBL619875,55,,,Blood,Inhibition of 5-lipoxygenase in human whole blood.,,B,1,H,8,,BAO_0000357
3801,,,,Autocuration,,948,CHEMBL619876,55,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,B,1,H,8,,BAO_0000357
3802,,,,Autocuration,,948,CHEMBL619877,55,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,B,1,H,8,,BAO_0000357
3803,,,,Expert,,13622,CHEMBL619878,55,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,F,1,H,8,,BAO_0000219
3804,,178.0,,Autocuration,,13622,CHEMBL619879,55,,,Blood,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,F,1,H,8,,BAO_0000019
3805,,,,Autocuration,,9637,CHEMBL619880,55,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,B,1,H,8,,BAO_0000357
3806,,,,Autocuration,,11320,CHEMBL619881,55,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,B,1,H,8,,BAO_0000357
3807,,,,Expert,,11320,CHEMBL619882,55,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3808,,,,Autocuration,,6838,CHEMBL619883,55,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,B,1,H,8,,BAO_0000357
3809,,178.0,9606.0,Expert,Homo sapiens,17667,CHEMBL619884,55,,,Blood,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,B,1,D,9,,BAO_0000357
3810,,,,Autocuration,,12703,CHEMBL619885,55,,,,In vitro potency against human 5-Lipoxygenase,,B,1,H,8,,BAO_0000357
3811,,,9606.0,Expert,Homo sapiens,14312,CHEMBL619886,55,,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,F,1,D,9,,BAO_0000019
3812,,178.0,,Autocuration,,14312,CHEMBL619887,55,,,Blood,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,F,1,H,8,,BAO_0000019
3813,,,,Autocuration,,5364,CHEMBL875097,55,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,F,1,H,8,,BAO_0000019
3814,,,,Autocuration,,951,CHEMBL618001,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,B,1,H,8,,BAO_0000219
3815,,,,Autocuration,,951,CHEMBL618002,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,B,1,H,8,,BAO_0000219
3816,,,,Autocuration,,951,CHEMBL618003,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,B,1,H,8,,BAO_0000219
3817,,,,Autocuration,,951,CHEMBL618004,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,B,1,H,8,,BAO_0000219
3818,,,,Autocuration,,12365,CHEMBL618005,55,,,,Inhibition of human 5-lipoxygenase in human cells,,B,1,H,8,,BAO_0000219
3819,,,,Expert,,10603,CHEMBL618006,55,,,,Inhibition of human neutrophil 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3820,,,,Autocuration,,10501,CHEMBL875086,55,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,B,1,H,8,,BAO_0000019
3821,,178.0,,Expert,,12281,CHEMBL618007,55,,,Blood,Inhibition of 5-lipoxygenase from human whole blood,,B,1,H,8,,BAO_0000357
3822,,,,Autocuration,,2567,CHEMBL618008,55,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,B,1,H,8,,BAO_0000357
3823,,,,Autocuration,,2567,CHEMBL618009,55,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,B,1,H,8,,BAO_0000219
3824,,,,Expert,,10193,CHEMBL618010,55,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3825,,,,Autocuration,,10193,CHEMBL618011,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,B,1,H,8,,BAO_0000357
3826,,,,Expert,,13623,CHEMBL618012,55,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3827,,,,Autocuration,,12780,CHEMBL882927,55,,,,Tested against 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3828,,,,Autocuration,,12780,CHEMBL618013,55,,,,Tested for activity against 5-Lipoxygenase (5-LO),,B,1,H,8,,BAO_0000357
3829,,,,Autocuration,,12780,CHEMBL618014,55,,,,Tested for activity against 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3830,,,,Autocuration,,11966,CHEMBL618015,55,,,,Tested for inhibition of 5-HPETE production by human 5-LO,,B,1,H,8,,BAO_0000357
3831,,,,Autocuration,,5364,CHEMBL618016,55,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,F,1,H,8,,BAO_0000019
3832,,,,Expert,,13165,CHEMBL618017,55,,,,Inhibition of Human 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3833,,,,Autocuration,,5364,CHEMBL618018,55,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,B,1,H,8,,BAO_0000019
3834,,,,Autocuration,,11311,CHEMBL875087,55,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,B,1,H,8,,BAO_0000219
3835,,,,Autocuration,,11311,CHEMBL618019,55,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,B,1,H,8,,BAO_0000219
3836,,,,Autocuration,,14863,CHEMBL618020,55,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,B,1,H,8,,BAO_0000019
3837,,,,Autocuration,,14863,CHEMBL618021,55,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,B,1,H,8,,BAO_0000019
3838,,178.0,,Autocuration,,11087,CHEMBL618022,55,,,Blood,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,B,1,H,8,,BAO_0000357
3839,,,,Autocuration,,455,CHEMBL618023,55,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,B,1,H,8,,BAO_0000357
3840,,,,Autocuration,,13183,CHEMBL618024,55,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,B,1,H,8,,BAO_0000357
3841,,,,Expert,,10319,CHEMBL873950,55,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,B,1,H,8,,BAO_0000019
3842,,,,Autocuration,,10193,CHEMBL618025,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,B,1,H,8,,BAO_0000357
3843,,,,Autocuration,,951,CHEMBL618026,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,B,1,H,8,,BAO_0000219
3844,,,,Autocuration,,951,CHEMBL618027,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,B,1,H,8,,BAO_0000219
3845,,,,Autocuration,,951,CHEMBL618028,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,B,1,H,8,,BAO_0000219
3846,,,,Autocuration,,951,CHEMBL618029,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,B,1,H,8,,BAO_0000219
3847,,,,Expert,,9859,CHEMBL618030,55,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,B,1,H,8,,BAO_0000357
3848,,,,Expert,,9859,CHEMBL618031,55,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,B,1,H,8,,BAO_0000357
3849,,,,Autocuration,,9859,CHEMBL618032,55,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,B,1,H,8,,BAO_0000357
3850,,,,Autocuration,,2567,CHEMBL618033,55,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,B,1,H,8,,BAO_0000357
3851,,,,Autocuration,,10193,CHEMBL618034,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,B,1,H,8,,BAO_0000357
3852,,,,Autocuration,,10193,CHEMBL875088,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,B,1,H,8,,BAO_0000357
3853,,,,Autocuration,,949,CHEMBL618035,55,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,B,1,H,8,,BAO_0000019
3854,,,,Autocuration,,949,CHEMBL618036,55,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,B,1,H,8,,BAO_0000019
3855,,,,Expert,,10603,CHEMBL618037,55,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,B,1,H,8,,BAO_0000357
3856,,,,Expert,,10603,CHEMBL618038,55,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,B,1,H,8,,BAO_0000357
3857,,,,Autocuration,,10603,CHEMBL618761,55,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,F,1,H,8,,BAO_0000019
3858,,,,Expert,,10603,CHEMBL618762,55,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,B,1,H,8,,BAO_0000357
3859,,,,Expert,,10603,CHEMBL618763,55,,,,Inhibition of lipoxygenase at the concentration of 1 uM,,B,1,H,8,,BAO_0000357
3860,,,,Autocuration,,10193,CHEMBL618764,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,B,1,H,8,,BAO_0000357
3861,,,9606.0,Expert,Homo sapiens,14580,CHEMBL618765,55,,,,Inhibition of 5-Lipoxygenase (5-LOX),,B,1,D,9,,BAO_0000357
3862,,,,Expert,,11090,CHEMBL618766,17087,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,B,1,H,8,,BAO_0000357
3863,,,,Expert,,11090,CHEMBL618767,17087,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,B,1,H,8,,BAO_0000357
3864,,,,Autocuration,,6339,CHEMBL619380,17087,,,,Inhibitory activity against lipoxygenase-2 in mice,,B,1,H,8,,BAO_0000357
3865,,,,Expert,,6339,CHEMBL619381,17087,,,,Inhibitory activity against murine lipoxygenase-2.,,B,1,H,8,,BAO_0000357
3866,,,10090.0,Expert,Mus musculus,12281,CHEMBL619382,17087,,,,Inhibition of 5-lipoxygenase from mouse macrophage,,B,1,D,9,,BAO_0000357
3867,,,,Autocuration,,11311,CHEMBL619383,17087,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,B,1,H,8,,BAO_0000357
3868,,,9823.0,Autocuration,Sus scrofa,11089,CHEMBL619384,55,,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,B,1,H,8,,BAO_0000019
3869,,,9823.0,Autocuration,Sus scrofa,10091,CHEMBL619385,55,,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,B,1,H,8,,BAO_0000019
3870,,,9986.0,Autocuration,Oryctolagus cuniculus,14352,CHEMBL882928,55,,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,B,1,H,8,,BAO_0000019
3871,,,10116.0,Expert,Rattus norvegicus,13329,CHEMBL619386,12166,,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,B,1,D,9,,BAO_0000019
3872,,,,Autocuration,,13329,CHEMBL619387,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,B,1,H,8,,BAO_0000019
3873,,,,Autocuration,,13329,CHEMBL619388,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,B,1,H,8,,BAO_0000019
3874,,,,Autocuration,,13329,CHEMBL619389,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,B,1,H,8,,BAO_0000019
3875,,,,Expert,,13329,CHEMBL619390,12166,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,B,1,H,8,,BAO_0000019
3876,,,,Expert,,13329,CHEMBL619391,12166,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,B,1,H,8,,BAO_0000019
3877,,,,Autocuration,,13329,CHEMBL619392,12166,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,B,1,H,8,,BAO_0000019
3878,,,,Autocuration,,11311,CHEMBL619393,12166,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,B,1,H,8,,BAO_0000019
3879,,,,Autocuration,,11311,CHEMBL619394,12166,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,B,1,H,8,,BAO_0000019
3880,,,,Autocuration,,105,CHEMBL619395,12166,,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,B,1,H,8,,BAO_0000219
3881,,,,Autocuration,,105,CHEMBL619396,12166,,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,B,1,H,8,,BAO_0000219
3882,,,,Autocuration,,9138,CHEMBL619397,12166,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,B,1,H,8,,BAO_0000357
3883,,,,Autocuration,,9138,CHEMBL619398,12166,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,B,1,H,8,,BAO_0000357
3884,,,,Autocuration,,9138,CHEMBL619399,12166,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,B,1,H,8,,BAO_0000357
3885,,,,Autocuration,,14427,CHEMBL619400,12166,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,B,1,H,8,,BAO_0000357
3886,,,,Autocuration,,13329,CHEMBL619401,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,B,1,H,8,,BAO_0000019
3887,,,,Autocuration,,13329,CHEMBL619402,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,B,1,H,8,,BAO_0000019
3888,,,10116.0,Expert,Rattus norvegicus,14427,CHEMBL619403,12166,,663.0,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,B,1,D,9,,BAO_0000219
3889,,,,Autocuration,,14427,CHEMBL619404,12166,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,B,1,H,8,,BAO_0000357
3890,,,,Autocuration,,14427,CHEMBL619405,12166,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,B,1,H,8,,BAO_0000357
3891,,,,Expert,,10293,CHEMBL619406,12166,,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,B,1,H,8,,BAO_0000219
3892,,,10116.0,Expert,Rattus norvegicus,338,CHEMBL619407,12166,,702.0,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,B,1,D,9,,BAO_0000219
3893,,,,Autocuration,,303,CHEMBL619408,12166,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,B,1,H,8,,BAO_0000357
3894,,,,Autocuration,,303,CHEMBL619409,12166,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,B,1,H,8,,BAO_0000219
3895,,,,Expert,,9247,CHEMBL619410,12166,,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,B,1,H,8,,BAO_0000219
3896,,,,Autocuration,,9247,CHEMBL619753,12166,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,B,1,H,8,,BAO_0000219
3897,,,,Autocuration,,137,CHEMBL619754,12166,,702.0,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,B,1,H,8,,BAO_0000219
3898,,,,Expert,,11481,CHEMBL619903,12166,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3899,,,,Expert,,11481,CHEMBL619904,12166,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,B,1,H,8,,BAO_0000357
3900,,,,Expert,,9029,CHEMBL619905,12166,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,B,1,H,8,,BAO_0000357
3901,,,,Autocuration,,1701,CHEMBL619906,12166,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,B,1,H,8,,BAO_0000019
3902,,,,Autocuration,,1701,CHEMBL619907,12166,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,B,1,H,8,,BAO_0000019
3903,,,,Autocuration,,1701,CHEMBL619908,12166,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,B,1,H,8,,BAO_0000019
3904,,,,Autocuration,,1701,CHEMBL619909,12166,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,B,1,H,8,,BAO_0000019
3905,,,,Expert,,13358,CHEMBL619910,12166,,702.0,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,F,1,H,8,,BAO_0000219
3906,,,,Expert,,1175,CHEMBL882929,12166,,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,B,1,H,8,,BAO_0000219
3907,,,,Expert,,8797,CHEMBL619911,12166,,702.0,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,B,1,H,8,,BAO_0000219
3908,,,,Autocuration,,8797,CHEMBL619912,12166,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,B,1,H,8,,BAO_0000019
3909,,,10116.0,Expert,Rattus norvegicus,577,CHEMBL619913,12166,,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,B,1,D,9,,BAO_0000357
3910,,,,Expert,,9295,CHEMBL619914,12166,,702.0,,In vitro inhibitory activity against RBL-1 5-LO,,B,1,H,8,,BAO_0000219
3911,,,,Autocuration,,9295,CHEMBL619915,12166,,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,B,1,H,8,,BAO_0000219
3912,,,,Autocuration,,9295,CHEMBL619916,12166,,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,B,1,H,8,,BAO_0000219
3913,,,,Autocuration,,9295,CHEMBL619917,12166,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,B,1,H,8,,BAO_0000218
3914,,,,Autocuration,,9295,CHEMBL619918,12166,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,B,1,H,8,,BAO_0000357
3915,,,,Autocuration,,216,CHEMBL619919,12166,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,B,1,H,8,,BAO_0000218
3916,,,,Autocuration,,11090,CHEMBL883710,12166,,702.0,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,B,1,H,8,,BAO_0000219
3917,,178.0,,Autocuration,,11090,CHEMBL619920,12166,,,Blood,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,B,1,H,8,,BAO_0000019
3918,,,,Expert,,10091,CHEMBL619921,12166,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,B,1,H,8,,BAO_0000357
3919,,,,Autocuration,,10274,CHEMBL619922,12166,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,F,1,H,8,,BAO_0000019
3920,,,,Autocuration,,13622,CHEMBL619923,12166,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,F,1,H,8,,BAO_0000219
3921,,,,Expert,,12118,CHEMBL619924,12166,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,B,1,H,8,,BAO_0000219
3922,,,,Expert,,12576,CHEMBL619925,12166,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,B,1,H,8,,BAO_0000357
3923,,,,Expert,,9546,CHEMBL619926,12166,,702.0,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,B,1,H,8,,BAO_0000219
3924,,,,Autocuration,,9521,CHEMBL619927,12166,,702.0,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,B,1,H,8,,BAO_0000219
3925,,,,Expert,,10626,CHEMBL619928,12166,,702.0,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,B,1,H,8,,BAO_0000219
3926,,,,Autocuration,,9225,CHEMBL619929,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase,,B,1,H,8,,BAO_0000219
3927,,,,Autocuration,,9225,CHEMBL875089,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,B,1,H,8,,BAO_0000219
3928,,,,Autocuration,,9225,CHEMBL619930,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,B,1,H,8,,BAO_0000219
3929,,,,Autocuration,,9225,CHEMBL619931,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,B,1,H,8,,BAO_0000219
3930,,,,Autocuration,,9225,CHEMBL619932,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,B,1,H,8,,BAO_0000219
3931,,,,Autocuration,,9225,CHEMBL619933,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,B,1,H,8,,BAO_0000219
3932,,,,Autocuration,,9225,CHEMBL619934,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,B,1,H,8,,BAO_0000219
3933,,,,Autocuration,,9225,CHEMBL619935,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,B,1,H,8,,BAO_0000219
3934,,,,Autocuration,,9225,CHEMBL619936,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,B,1,H,8,,BAO_0000219
3935,,,,Autocuration,,9225,CHEMBL619937,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,B,1,H,8,,BAO_0000219
3936,,,,Autocuration,,9225,CHEMBL619938,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,B,1,H,8,,BAO_0000219
3937,,,,Autocuration,,9225,CHEMBL619939,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,B,1,H,8,,BAO_0000219
3938,,,,Autocuration,,9225,CHEMBL619940,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,B,1,H,8,,BAO_0000219
3939,,,,Autocuration,,9225,CHEMBL875090,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,B,1,H,8,,BAO_0000219
3940,,,,Autocuration,,9225,CHEMBL619941,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,B,1,H,8,,BAO_0000219
3941,,,,Autocuration,,9225,CHEMBL619942,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,B,1,H,8,,BAO_0000219
3942,,,,Autocuration,,9225,CHEMBL883711,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,B,1,H,8,,BAO_0000219
3943,,,,Autocuration,,9225,CHEMBL619943,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,B,1,H,8,,BAO_0000219
3944,,,,Autocuration,,9225,CHEMBL619944,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,B,1,H,8,,BAO_0000219
3945,,,,Autocuration,,9225,CHEMBL619945,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,B,1,H,8,,BAO_0000219
3946,,,,Autocuration,,9225,CHEMBL619946,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,B,1,H,8,,BAO_0000219
3947,,,,Autocuration,,9225,CHEMBL619947,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,B,1,H,8,,BAO_0000219
3948,,,,Autocuration,,9225,CHEMBL619948,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,B,1,H,8,,BAO_0000219
3949,,,,Autocuration,,9225,CHEMBL619949,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,B,1,H,8,,BAO_0000219
3950,,,,Expert,,9401,CHEMBL619950,12166,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,B,1,H,8,,BAO_0000019
3951,,,,Autocuration,,10325,CHEMBL618050,12166,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,B,1,H,8,,BAO_0000019
3952,,,,Expert,,1556,CHEMBL875091,12166,,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,F,1,H,8,,BAO_0000219
3953,,,,Expert,,1556,CHEMBL618051,12166,,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,F,1,H,8,,BAO_0000219
3954,,,10116.0,Expert,Rattus norvegicus,961,CHEMBL618052,12166,,702.0,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,B,1,D,9,,BAO_0000219
3955,,,,Autocuration,,6838,CHEMBL618053,12166,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,B,1,H,8,,BAO_0000019
3956,,,,Expert,,10325,CHEMBL618054,12166,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,B,1,H,8,,BAO_0000019
3957,,,10116.0,Expert,Rattus norvegicus,9209,CHEMBL618055,12166,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,B,1,D,9,,BAO_0000219
3958,,,,Expert,,11520,CHEMBL618056,12166,,702.0,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,B,1,H,8,,BAO_0000219
3959,,,,Autocuration,,137,CHEMBL618057,12166,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,,B,1,H,8,,BAO_0000357
3960,,,,Autocuration,,4717,CHEMBL618058,12166,,702.0,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,B,1,H,8,,BAO_0000219
3961,,,,Expert,,10636,CHEMBL618059,12166,,702.0,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,B,1,H,8,,BAO_0000219
3962,,,10116.0,Expert,Rattus norvegicus,14312,CHEMBL618060,12166,,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,F,1,D,9,,BAO_0000019
3963,,,,Autocuration,,1203,CHEMBL618061,12166,,702.0,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,B,1,H,8,,BAO_0000219
3964,,,,Autocuration,,1203,CHEMBL618062,12166,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,B,1,H,8,,BAO_0000019
3965,,,,Expert,,13622,CHEMBL618063,12166,,702.0,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,B,1,H,8,,BAO_0000219
3966,,,,Autocuration,,9793,CHEMBL618064,12166,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,B,1,H,8,,BAO_0000357
3967,,,10116.0,Expert,Rattus norvegicus,1143,CHEMBL618065,12166,,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,B,1,D,9,,BAO_0000219
3968,,,10116.0,Expert,Rattus norvegicus,11854,CHEMBL618066,12166,,702.0,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,B,1,D,9,,BAO_0000219
3969,,,,Autocuration,,3595,CHEMBL618067,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,B,1,H,8,,BAO_0000219
3970,,,,Autocuration,,3595,CHEMBL618068,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,B,1,H,8,,BAO_0000219
3971,,,10116.0,Expert,Rattus norvegicus,10501,CHEMBL618069,12166,,702.0,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,B,1,D,9,,BAO_0000219
3972,,,,Expert,,12526,CHEMBL618070,12166,,702.0,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,B,1,H,8,,BAO_0000219
3973,,349.0,,Autocuration,,10034,CHEMBL618071,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,F,1,H,8,,BAO_0000019
3974,,349.0,,Autocuration,,10034,CHEMBL619247,10825,,,Limbic system,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,F,1,H,8,,BAO_0000019
3975,,,,Autocuration,,10034,CHEMBL619248,10825,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,F,1,H,8,,BAO_0000019
3976,,10000000.0,,Autocuration,,10046,CHEMBL619249,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000221
3977,,10000000.0,,Autocuration,,10046,CHEMBL619250,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,B,1,H,8,,BAO_0000221
3978,,,,Autocuration,,10046,CHEMBL619251,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,B,1,H,8,,BAO_0000019
3979,,178.0,9615.0,Autocuration,Canis lupus familiaris,12079,CHEMBL619252,55,,,Blood,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,F,1,H,8,,BAO_0000019
3980,,178.0,,Autocuration,,12079,CHEMBL619253,55,,,Blood,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,F,1,H,8,,BAO_0000019
3981,,,,Autocuration,,11311,CHEMBL619254,12166,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,B,1,H,8,,BAO_0000219
3982,,,,Expert,,12338,CHEMBL619255,17140,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,B,1,H,8,,BAO_0000219
3983,,,,Expert,,12143,CHEMBL619256,17140,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,B,1,H,8,,BAO_0000219
3984,,,,Autocuration,,12143,CHEMBL875418,17140,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,B,1,H,8,,BAO_0000219
3985,,,,Expert,,12143,CHEMBL619257,17140,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,B,1,H,8,,BAO_0000219
3986,,,,Autocuration,,12143,CHEMBL619258,17140,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,B,1,H,8,,BAO_0000219
3987,,,,Expert,,12365,CHEMBL619259,17140,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,B,1,H,8,,BAO_0000357
3988,,,,Expert,,13500,CHEMBL619260,17140,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,B,1,H,8,,BAO_0000357
3989,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619261,55,,,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3990,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619263,55,,,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3991,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619264,55,,,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3992,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619265,55,,,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3993,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619266,55,,,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3994,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619902,55,,,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3995,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620058,55,,,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3996,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620059,55,,,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3997,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620060,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3998,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620061,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
3999,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620062,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,F,1,H,8,,BAO_0000218
4000,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620063,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4001,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620064,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,F,1,H,8,,BAO_0000218
4002,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620065,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4003,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620066,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,F,1,H,8,,BAO_0000218
4004,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620067,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4005,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620068,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,F,1,H,8,,BAO_0000218
4006,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620069,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4007,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620070,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,F,1,H,8,,BAO_0000218
4008,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620071,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4009,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620072,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,F,1,H,8,,BAO_0000218
4010,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620036,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4011,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL857702,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,F,1,H,8,,BAO_0000218
4012,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620037,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4013,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620038,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,F,1,H,8,,BAO_0000218
4014,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620039,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4015,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620040,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,F,1,H,8,,BAO_0000218
4016,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620041,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4017,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620042,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,F,1,H,8,,BAO_0000218
4018,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620043,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4019,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620044,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,F,1,H,8,,BAO_0000218
4020,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620045,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4021,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620046,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,F,1,H,8,,BAO_0000218
4022,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620047,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4023,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620048,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,F,1,H,8,,BAO_0000218
4024,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL857703,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4025,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620049,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,F,1,H,8,,BAO_0000218
4026,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620050,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4027,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL620051,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4028,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619213,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4029,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619214,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4030,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619804,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4031,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619805,55,,,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4032,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619806,55,,,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4033,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619807,55,,,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4034,,178.0,9615.0,Autocuration,Canis lupus familiaris,12832,CHEMBL619808,55,,,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,F,1,H,8,,BAO_0000218
4035,,,9615.0,Autocuration,Canis lupus familiaris,3595,CHEMBL619809,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,B,1,H,8,,BAO_0000218
4036,,,9615.0,Autocuration,Canis lupus familiaris,3595,CHEMBL619810,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,B,1,H,8,,BAO_0000218
4037,,,9615.0,Autocuration,Canis lupus familiaris,3595,CHEMBL619811,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,B,1,H,8,,BAO_0000218
4038,,,9615.0,Autocuration,Canis lupus familiaris,3595,CHEMBL620769,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,B,1,H,8,,BAO_0000218
4039,,,9615.0,Autocuration,Canis lupus familiaris,3595,CHEMBL620770,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,B,1,H,8,,BAO_0000218
4040,,,9615.0,Autocuration,Canis lupus familiaris,3595,CHEMBL620771,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,B,1,H,8,,BAO_0000218
4041,,,9615.0,Autocuration,Canis lupus familiaris,3595,CHEMBL620772,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,B,1,H,8,,BAO_0000218
4042,,,9615.0,Autocuration,Canis lupus familiaris,3595,CHEMBL620773,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,B,1,H,8,,BAO_0000218
4043,,,10141.0,Autocuration,Cavia porcellus,9203,CHEMBL620774,55,,,,Ability to inhibit 5-lipoxygenase in guinea pig,,B,1,H,8,,BAO_0000357
4044,,,10141.0,Expert,Cavia porcellus,82,CHEMBL620775,55,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,B,1,H,8,,BAO_0000357
4045,,,10141.0,Autocuration,Cavia porcellus,11090,CHEMBL620776,55,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,B,1,H,8,,BAO_0000357
4046,,178.0,10141.0,Autocuration,Cavia porcellus,12832,CHEMBL620777,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,B,1,H,8,,BAO_0000218
4047,,,10141.0,Autocuration,Cavia porcellus,1065,CHEMBL620778,55,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,B,1,H,8,,BAO_0000357
4048,,,10141.0,Autocuration,Cavia porcellus,1065,CHEMBL620779,55,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,B,1,H,8,,BAO_0000357
4049,,,10141.0,Expert,Cavia porcellus,12832,CHEMBL621500,55,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,B,1,H,8,,BAO_0000019
4050,,,10141.0,Expert,Cavia porcellus,12832,CHEMBL621501,55,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,B,1,H,8,,BAO_0000019
4051,,,10141.0,Autocuration,Cavia porcellus,12832,CHEMBL618098,55,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,B,1,H,8,,BAO_0000019
4052,,,10141.0,Autocuration,Cavia porcellus,10504,CHEMBL618099,55,,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,B,1,H,8,,BAO_0000019
4053,,,10141.0,Autocuration,Cavia porcellus,7788,CHEMBL618100,55,,,,Inhibitory activity against 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4054,,,10141.0,Autocuration,Cavia porcellus,10001,CHEMBL618101,55,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,B,1,H,8,,BAO_0000357
4055,,,10141.0,Autocuration,Cavia porcellus,10193,CHEMBL618102,55,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,B,1,H,8,,BAO_0000357
4056,,,10141.0,Autocuration,Cavia porcellus,13243,CHEMBL618103,55,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4057,,,10141.0,Autocuration,Cavia porcellus,13243,CHEMBL618104,55,,,,Inhibitory activity uM,,B,1,H,8,,BAO_0000357
4058,,,10141.0,Autocuration,Cavia porcellus,969,CHEMBL883712,55,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,B,1,H,8,,BAO_0000219
4059,,,10141.0,Autocuration,Cavia porcellus,10001,CHEMBL618105,55,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,,B,1,H,8,,BAO_0000357
4060,,,10141.0,Autocuration,Cavia porcellus,7788,CHEMBL618106,55,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,B,1,H,8,,BAO_0000357
4061,,,10141.0,Autocuration,Cavia porcellus,10001,CHEMBL618107,55,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,B,1,H,8,,BAO_0000357
4062,,,10141.0,Autocuration,Cavia porcellus,10193,CHEMBL618108,55,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,B,1,H,8,,BAO_0000357
4063,,,10141.0,Autocuration,Cavia porcellus,13243,CHEMBL618109,55,,,,Inhibitory activity uM,,B,1,H,8,,BAO_0000357
4064,,,10141.0,Autocuration,Cavia porcellus,13243,CHEMBL618110,55,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,B,1,H,8,,BAO_0000357
4065,,,10141.0,Expert,Cavia porcellus,13243,CHEMBL618111,55,,,,Inhibitory activity uM,,B,1,H,8,,BAO_0000357
4066,,,10141.0,Autocuration,Cavia porcellus,13243,CHEMBL618112,55,,,,Inhibitory activity uM,,F,1,H,8,,BAO_0000019
4067,,,10141.0,Autocuration,Cavia porcellus,10504,CHEMBL618113,55,,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,B,1,H,8,,BAO_0000019
4068,,,10141.0,Autocuration,Cavia porcellus,7788,CHEMBL618114,55,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,B,1,H,8,,BAO_0000357
4069,,2116.0,10141.0,Expert,Cavia porcellus,10546,CHEMBL620871,55,,,Ileum,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,F,1,H,8,,BAO_0000221
4070,,,,Autocuration,,13183,CHEMBL620872,55,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,B,1,H,8,,BAO_0000357
4071,,,,Autocuration,,13183,CHEMBL620873,55,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,B,1,H,8,,BAO_0000357
4072,,,,Autocuration,,2578,CHEMBL620874,55,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,B,1,H,8,,BAO_0000357
4073,,,,Expert,,12780,CHEMBL620875,55,,,,In vitro inhibition of human 5-Lipoxygenase.,,B,1,H,8,,BAO_0000357
4074,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620876,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,B,1,U,0,,BAO_0000251
4075,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620877,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,B,1,U,0,,BAO_0000251
4076,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL857854,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,B,1,U,0,,BAO_0000251
4077,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620878,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,B,1,U,0,,BAO_0000251
4078,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620879,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,B,1,U,0,,BAO_0000251
4079,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620880,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,B,1,U,0,,BAO_0000251
4080,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620881,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,B,1,U,0,,BAO_0000251
4081,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620882,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,B,1,U,0,,BAO_0000251
4082,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620883,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,B,1,U,0,,BAO_0000251
4083,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620884,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,B,1,U,0,,BAO_0000251
4084,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620885,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,B,1,U,0,,BAO_0000251
4085,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620886,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,B,1,U,0,,BAO_0000251
4086,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620887,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,B,1,U,0,,BAO_0000251
4087,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618039,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,B,1,U,0,,BAO_0000251
4088,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618040,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,B,1,U,0,,BAO_0000251
4089,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618041,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,B,1,U,0,,BAO_0000251
4090,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618216,22226,,,Liver,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,B,1,U,0,,BAO_0000251
4091,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618217,22226,,,Liver,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,B,1,U,0,,BAO_0000251
4092,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618218,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,B,1,U,0,,BAO_0000251
4093,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618219,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,B,1,U,0,,BAO_0000251
4094,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618220,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,B,1,U,0,,BAO_0000251
4095,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618221,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,B,1,U,0,,BAO_0000251
4096,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618222,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,B,1,U,0,,BAO_0000251
4097,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618223,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,B,1,U,0,,BAO_0000251
4098,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618224,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,B,1,U,0,,BAO_0000251
4099,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618225,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,B,1,U,0,,BAO_0000251
4100,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618226,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,B,1,U,0,,BAO_0000251
4101,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618227,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,B,1,U,0,,BAO_0000251
4102,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618228,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,B,1,U,0,,BAO_0000251
4103,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618229,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,B,1,U,0,,BAO_0000251
4104,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618230,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,B,1,U,0,,BAO_0000251
4105,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618231,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,B,1,U,0,,BAO_0000251
4106,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618232,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,B,1,U,0,,BAO_0000251
4107,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618233,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,B,1,U,0,,BAO_0000251
4108,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618234,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,B,1,U,0,,BAO_0000251
4109,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618235,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,B,1,U,0,,BAO_0000251
4110,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618115,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,B,1,U,0,,BAO_0000251
4111,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618116,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,B,1,U,0,,BAO_0000251
4112,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL618117,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,B,1,U,0,,BAO_0000251
4113,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619968,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,B,1,U,0,,BAO_0000251
4114,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619969,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,B,1,U,0,,BAO_0000251
4115,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619970,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,B,1,U,0,,BAO_0000251
4116,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619971,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,B,1,U,0,,BAO_0000251
4117,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619972,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,B,1,U,0,,BAO_0000251
4118,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619973,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,B,1,U,0,,BAO_0000251
4119,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619974,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,B,1,U,0,,BAO_0000251
4120,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619975,22226,,,Liver,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,B,1,U,0,,BAO_0000251
4121,Microsomes,,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619976,22226,,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,B,1,U,0,,BAO_0000251
4122,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619977,22226,,,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,B,1,U,0,,BAO_0000251
4123,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619978,22226,,,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,B,1,U,0,,BAO_0000251
4124,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619979,22226,,,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,B,1,U,0,,BAO_0000251
4125,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619980,22226,,,Liver,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,B,1,U,0,,BAO_0000251
4126,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619981,22226,,,Liver,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,B,1,U,0,,BAO_0000251
4127,,,9606.0,Intermediate,Homo sapiens,10797,CHEMBL619982,80433,,741.0,,In vitro inhibition of 7226/S myeloma cancer cell line,,F,1,N,1,,BAO_0000219
4128,,,9606.0,Intermediate,Homo sapiens,6881,CHEMBL619983,80698,,993.0,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,F,1,N,1,,BAO_0000219
4129,,,9606.0,Intermediate,Homo sapiens,3838,CHEMBL620031,80640,,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,F,1,N,1,,BAO_0000219
4130,,,9606.0,Intermediate,Homo sapiens,3838,CHEMBL620032,80640,,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,F,1,N,1,,BAO_0000219
4131,,,10029.0,Expert,Cricetulus griseus,12981,CHEMBL620033,81264,,505.0,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,F,1,N,1,,BAO_0000219
4132,,,10029.0,Expert,Cricetulus griseus,12981,CHEMBL620034,81264,,505.0,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,F,1,N,1,,BAO_0000219
4133,,,10116.0,Intermediate,Rattus norvegicus,7653,CHEMBL620035,80635,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,F,1,N,1,,BAO_0000219
4134,,,10116.0,Intermediate,Rattus norvegicus,7653,CHEMBL618318,80635,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,F,1,N,1,,BAO_0000219
4135,,,10116.0,Intermediate,Rattus norvegicus,7653,CHEMBL618319,80635,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,F,1,N,1,,BAO_0000219
4136,,,10116.0,Intermediate,Rattus norvegicus,7653,CHEMBL618320,80635,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,F,1,N,1,,BAO_0000219
4137,,,10116.0,Intermediate,Rattus norvegicus,7653,CHEMBL618321,80635,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,F,1,N,1,,BAO_0000219
4138,,,10116.0,Intermediate,Rattus norvegicus,7653,CHEMBL883118,80635,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,F,1,N,1,,BAO_0000219
4139,,,9606.0,Intermediate,Homo sapiens,17229,CHEMBL883795,80640,,391.0,,In vitro antitumor activity against renal 786-0 tumor cell lines,,F,1,N,1,,BAO_0000219
4140,,,9606.0,Intermediate,Homo sapiens,12858,CHEMBL618322,80640,,391.0,,Cytotoxic activity against 786-0 Renal cancer cell line,,F,1,N,1,,BAO_0000219
4141,,,9606.0,Intermediate,Homo sapiens,16325,CHEMBL618323,80640,,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,F,1,N,1,,BAO_0000219
4142,,,9606.0,Intermediate,Homo sapiens,16325,CHEMBL618324,80640,,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,F,1,N,1,,BAO_0000219
4143,,,9606.0,Intermediate,Homo sapiens,5858,CHEMBL618325,80640,,391.0,,In vitro antitumor activity against human renal 786-0 cell line,,F,1,N,1,,BAO_0000219
4144,,,9606.0,Intermediate,Homo sapiens,16325,CHEMBL875416,80640,,391.0,,Inhibition of Renal cancer in 786-0 cancer cell lines,,F,1,N,1,,BAO_0000219
4145,,,9606.0,Intermediate,Homo sapiens,14696,CHEMBL618326,80640,,391.0,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,F,1,N,1,,BAO_0000219
4146,,,9606.0,Intermediate,Homo sapiens,3786,CHEMBL618327,80640,,391.0,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,F,1,N,1,,BAO_0000219
4147,,,9606.0,Intermediate,Homo sapiens,14696,CHEMBL619215,80640,,391.0,,inhibition of the growth of renal cancer(786-0) cell line,,F,1,N,1,,BAO_0000219
4148,,,9606.0,Intermediate,Homo sapiens,14769,CHEMBL619216,80640,,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,F,1,N,1,,BAO_0000219
4149,,,9606.0,Intermediate,Homo sapiens,15354,CHEMBL619217,80640,,391.0,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,F,1,N,1,,BAO_0000219
4150,,,9606.0,Intermediate,Homo sapiens,14255,CHEMBL619218,80640,,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor,,F,1,N,1,,BAO_0000219
4151,,,9606.0,Intermediate,Homo sapiens,14255,CHEMBL619219,80640,,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,F,1,N,1,,BAO_0000219
4152,,,9606.0,Intermediate,Homo sapiens,14255,CHEMBL619220,80640,,391.0,,The IC50 value was measured on 786-0 cell line in renal tumor type.,,F,1,N,1,,BAO_0000219
4153,,,9606.0,Intermediate,Homo sapiens,14696,CHEMBL619221,80640,,391.0,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,F,1,N,1,,BAO_0000219
4154,,,9606.0,Intermediate,Homo sapiens,12016,CHEMBL619222,80640,,391.0,,Tested for cytotoxic activity against renal cancer 786-0 cell line,,F,1,N,1,,BAO_0000219
4155,,,9606.0,Intermediate,Homo sapiens,2597,CHEMBL857454,80640,,391.0,,Compound was tested for growth inhibitory activity against 786-0 cell line,,F,1,N,1,,BAO_0000219
4156,,,,Autocuration,,12526,CHEMBL619223,12166,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,B,1,H,8,,BAO_0000219
4157,,,,Autocuration,,12526,CHEMBL619224,12166,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,B,1,H,8,,BAO_0000219
4158,,,,Autocuration,,14799,CHEMBL619225,12166,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,B,1,H,8,,BAO_0000019
4159,,,,Expert,,3595,CHEMBL619226,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,B,1,H,8,,BAO_0000219
4160,,,,Expert,,3595,CHEMBL619227,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,B,1,H,8,,BAO_0000219
4161,,,,Autocuration,,12767,CHEMBL619228,12166,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4162,,,,Autocuration,,10997,CHEMBL619229,12166,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,B,1,H,8,,BAO_0000219
4163,,,,Autocuration,,11388,CHEMBL619230,12166,,702.0,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,B,1,H,8,,BAO_0000219
4164,,,,Autocuration,,167,CHEMBL619231,12166,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,B,1,H,8,,BAO_0000357
4165,,,,Autocuration,,167,CHEMBL619232,12166,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,B,1,H,8,,BAO_0000357
4166,,,,Expert,,13744,CHEMBL619233,12166,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,B,1,H,8,,BAO_0000357
4167,,,,Autocuration,,1630,CHEMBL619234,12166,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4168,,,,Autocuration,,1630,CHEMBL619235,12166,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,B,1,H,8,,BAO_0000357
4169,,,10116.0,Expert,Rattus norvegicus,969,CHEMBL619236,12166,,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,B,1,D,9,,BAO_0000019
4170,,,,Autocuration,,13621,CHEMBL619237,12166,,702.0,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,B,1,H,8,,BAO_0000219
4171,,,,Autocuration,,10089,CHEMBL619238,12166,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,B,1,H,8,,BAO_0000357
4172,,,,Expert,,10193,CHEMBL619239,12166,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4173,,,,Autocuration,,11966,CHEMBL619240,12166,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,B,1,H,8,,BAO_0000357
4174,,,,Autocuration,,12251,CHEMBL875417,12166,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,B,1,H,8,,BAO_0000019
4175,,,,Autocuration,,211,CHEMBL619241,12166,,702.0,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,B,1,H,8,,BAO_0000219
4176,,,,Expert,,12251,CHEMBL619242,12166,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,F,1,H,8,,BAO_0000019
4177,,,,Autocuration,,12495,CHEMBL883796,12166,,702.0,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,B,1,H,8,,BAO_0000219
4178,,,,Autocuration,,414,CHEMBL619243,12166,,,,Tested for its inhibitory activity against 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4179,,,,Autocuration,,414,CHEMBL619244,12166,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,B,1,H,8,,BAO_0000357
4180,,,,Expert,,10325,CHEMBL619245,12166,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,B,1,H,8,,BAO_0000019
4181,,,,Expert,,11966,CHEMBL619246,12166,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,B,1,H,8,,BAO_0000019
4182,,,,Expert,,165,CHEMBL619984,12166,,702.0,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,B,1,H,8,,BAO_0000219
4183,,,,Autocuration,,165,CHEMBL619985,12166,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,B,1,H,8,,BAO_0000219
4184,,,,Autocuration,,165,CHEMBL619986,12166,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,B,1,H,8,,BAO_0000219
4185,,,,Expert,,165,CHEMBL619987,12166,,702.0,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,B,1,H,8,,BAO_0000219
4186,,,,Autocuration,,11311,CHEMBL619988,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,B,1,H,8,,BAO_0000218
4187,,,,Autocuration,,11311,CHEMBL619989,12166,,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,B,1,H,8,,BAO_0000219
4188,,,,Autocuration,,11311,CHEMBL619990,12166,,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,B,1,H,8,,BAO_0000219
4189,,,,Autocuration,,11311,CHEMBL619991,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,B,1,H,8,,BAO_0000219
4190,,,,Autocuration,,11311,CHEMBL619992,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,B,1,H,8,,BAO_0000219
4191,,,,Autocuration,,11311,CHEMBL619993,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,B,1,H,8,,BAO_0000218
4192,,,,Autocuration,,11311,CHEMBL619994,12166,,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,F,1,H,8,,BAO_0000219
4193,,,,Autocuration,,11311,CHEMBL619995,12166,,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,F,1,H,8,,BAO_0000219
4194,,,,Autocuration,,11311,CHEMBL619996,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,B,1,H,8,,BAO_0000019
4195,,,,Autocuration,,11732,CHEMBL619997,12166,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,B,1,H,8,,BAO_0000019
4196,,,,Expert,,11732,CHEMBL619998,12166,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,B,1,H,8,,BAO_0000019
4197,,,,Expert,,11087,CHEMBL619999,12166,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,B,1,H,8,,BAO_0000019
4198,,,,Autocuration,,11087,CHEMBL620000,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,B,1,H,8,,BAO_0000019
4199,,,,Autocuration,,11087,CHEMBL620001,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,B,1,H,8,,BAO_0000219
4200,,,10116.0,Expert,Rattus norvegicus,11087,CHEMBL620002,12166,,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,B,1,D,9,,BAO_0000357
4201,,,,Autocuration,,496,CHEMBL620003,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,B,1,H,8,,BAO_0000219
4202,,,,Expert,,13986,CHEMBL620004,12166,,702.0,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,F,1,H,8,,BAO_0000219
4203,,,,Autocuration,,11520,CHEMBL874063,12166,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4204,,,,Autocuration,,10293,CHEMBL620005,12166,,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,B,1,H,8,,BAO_0000219
4205,,,,Autocuration,,303,CHEMBL620006,12166,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,B,1,H,8,,BAO_0000219
4206,,,,Autocuration,,303,CHEMBL620007,12166,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,B,1,H,8,,BAO_0000219
4207,,,,Autocuration,,9247,CHEMBL620008,12166,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,B,1,H,8,,BAO_0000219
4208,,,10116.0,Expert,Rattus norvegicus,9247,CHEMBL620009,12166,,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,B,1,D,9,,BAO_0000219
4209,,,,Autocuration,,9247,CHEMBL620010,12166,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,B,1,H,8,,BAO_0000219
4210,,,,Autocuration,,9247,CHEMBL620011,12166,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,B,1,H,8,,BAO_0000219
4211,,,,Autocuration,,9247,CHEMBL620677,12166,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,B,1,H,8,,BAO_0000219
4212,,,,Autocuration,,9247,CHEMBL620678,12166,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,B,1,H,8,,BAO_0000219
4213,,,,Autocuration,,9247,CHEMBL620679,12166,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,B,1,H,8,,BAO_0000219
4214,,,,Autocuration,,9247,CHEMBL620680,12166,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,B,1,H,8,,BAO_0000219
4215,,,10116.0,Expert,Rattus norvegicus,11481,CHEMBL620838,12166,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,,B,1,D,9,,BAO_0000357
4216,,,,Autocuration,,105,CHEMBL620839,12166,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,B,1,H,8,,BAO_0000357
4217,,,,Expert,,9029,CHEMBL620840,12166,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,B,1,H,8,,BAO_0000357
4218,,,,Expert,,1175,CHEMBL620841,12166,,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,B,1,H,8,,BAO_0000219
4219,,,,Autocuration,,12118,CHEMBL620842,12166,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,B,1,H,8,,BAO_0000219
4220,,,,Autocuration,,12118,CHEMBL620843,12166,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,B,1,H,8,,BAO_0000219
4221,,,,Autocuration,,12118,CHEMBL620844,12166,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,B,1,H,8,,BAO_0000219
4222,,,,Autocuration,,9225,CHEMBL620845,12166,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,B,1,H,8,,BAO_0000219
4223,,,,Autocuration,,9401,CHEMBL620846,12166,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,B,1,H,8,,BAO_0000019
4224,,,,Autocuration,,137,CHEMBL873951,12166,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,B,1,H,8,,BAO_0000357
4225,,,,Autocuration,,137,CHEMBL620847,12166,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,B,1,H,8,,BAO_0000357
4226,,,,Autocuration,,4717,CHEMBL620848,12166,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,B,1,H,8,,BAO_0000219
4227,,,,Autocuration,,3595,CHEMBL620849,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,B,1,H,8,,BAO_0000219
4228,,,,Autocuration,,10501,CHEMBL620850,12166,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,B,1,H,8,,BAO_0000219
4229,,,,Autocuration,,10501,CHEMBL620851,12166,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,B,1,H,8,,BAO_0000219
4230,,,,Autocuration,,10501,CHEMBL620852,12166,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,B,1,H,8,,BAO_0000219
4231,,,,Autocuration,,12526,CHEMBL875098,12166,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,B,1,H,8,,BAO_0000219
4232,,,10116.0,Expert,Rattus norvegicus,14799,CHEMBL620853,12166,,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,B,1,D,9,,BAO_0000219
4233,,,,Autocuration,,14799,CHEMBL620854,12166,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,B,1,H,8,,BAO_0000019
4234,,,,Autocuration,,3595,CHEMBL620855,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,B,1,H,8,,BAO_0000219
4235,,,,Expert,,3595,CHEMBL839884,12166,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,B,1,H,8,,BAO_0000219
4236,,,,Autocuration,,12526,CHEMBL620856,12166,,702.0,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,B,1,H,8,,BAO_0000219
4237,,,,Autocuration,,12526,CHEMBL620857,12166,,702.0,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,B,1,H,8,,BAO_0000219
4238,,,,Autocuration,,10193,CHEMBL620858,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,B,1,H,8,,BAO_0000019
4239,,,,Autocuration,,10193,CHEMBL620859,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,B,1,H,8,,BAO_0000019
4240,,,,Autocuration,,10193,CHEMBL620860,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,B,1,H,8,,BAO_0000019
4241,,,,Autocuration,,10193,CHEMBL620861,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,B,1,H,8,,BAO_0000019
4242,,,,Expert,,9138,CHEMBL620862,12166,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,B,1,H,8,,BAO_0000357
4243,,,,Autocuration,,9138,CHEMBL620863,12166,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,B,1,H,8,,BAO_0000357
4244,,,,Autocuration,,11966,CHEMBL620864,12166,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,B,1,H,8,,BAO_0000019
4245,,,,Autocuration,,165,CHEMBL620865,12166,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,B,1,H,8,,BAO_0000219
4246,,,,Autocuration,,165,CHEMBL620866,12166,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,B,1,H,8,,BAO_0000219
4247,,,,Autocuration,,11311,CHEMBL620867,12166,,663.0,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,B,1,H,8,,BAO_0000219
4248,,,,Autocuration,,11311,CHEMBL620868,12166,,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,B,1,H,8,,BAO_0000219
4249,,,,Autocuration,,11311,CHEMBL620869,12166,,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,F,1,H,8,,BAO_0000219
4250,,,,Autocuration,,11311,CHEMBL873952,12166,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,F,1,H,8,,BAO_0000019
4251,,,,Autocuration,,11311,CHEMBL875099,12166,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4252,,,,Autocuration,,11311,CHEMBL620870,12166,,663.0,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,F,1,H,8,,BAO_0000219
4253,,,,Autocuration,,11087,CHEMBL618261,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,B,1,H,8,,BAO_0000019
4254,,,,Autocuration,,11087,CHEMBL618262,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,B,1,H,8,,BAO_0000019
4255,,,,Autocuration,,11087,CHEMBL619428,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,B,1,H,8,,BAO_0000019
4256,,,,Autocuration,,11087,CHEMBL619429,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,B,1,H,8,,BAO_0000019
4257,,,,Autocuration,,11087,CHEMBL619430,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,B,1,H,8,,BAO_0000019
4258,,,,Autocuration,,496,CHEMBL620017,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,B,1,H,8,,BAO_0000219
4259,,,,Autocuration,,496,CHEMBL620018,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,B,1,H,8,,BAO_0000219
4260,,,,Autocuration,,13986,CHEMBL620019,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,F,1,H,8,,BAO_0000219
4261,,,,Autocuration,,13986,CHEMBL620020,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,F,1,H,8,,BAO_0000219
4262,,,,Autocuration,,13986,CHEMBL620021,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,F,1,H,8,,BAO_0000219
4263,,,,Autocuration,,13986,CHEMBL620022,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,F,1,H,8,,BAO_0000219
4264,,,,Autocuration,,13986,CHEMBL620023,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,F,1,H,8,,BAO_0000219
4265,,,,Autocuration,,13986,CHEMBL620024,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,F,1,H,8,,BAO_0000219
4266,,,,Autocuration,,13986,CHEMBL620025,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,F,1,H,8,,BAO_0000219
4267,,,,Autocuration,,13986,CHEMBL620026,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,F,1,H,8,,BAO_0000219
4268,,,,Autocuration,,13986,CHEMBL620027,12166,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,F,1,H,8,,BAO_0000219
4269,,,10116.0,Expert,Rattus norvegicus,13986,CHEMBL620028,12166,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,F,1,D,9,,BAO_0000019
4270,,,,Autocuration,,10193,CHEMBL620029,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4271,,,,Autocuration,,9295,CHEMBL620030,12166,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,B,1,H,8,,BAO_0000357
4272,,,,Autocuration,,4717,CHEMBL875415,12166,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,B,1,H,8,,BAO_0000219
4273,,,,Autocuration,,4717,CHEMBL618256,12166,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,B,1,H,8,,BAO_0000219
4274,,,,Autocuration,,11854,CHEMBL618257,12166,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,B,1,H,8,,BAO_0000219
4275,,,,Autocuration,,11854,CHEMBL618258,12166,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,B,1,H,8,,BAO_0000219
4276,,,,Autocuration,,11854,CHEMBL618259,12166,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,B,1,H,8,,BAO_0000219
4277,,,,Autocuration,,10193,CHEMBL618260,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,B,1,H,8,,BAO_0000019
4278,,,,Autocuration,,9295,CHEMBL618215,12166,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,B,1,H,8,,BAO_0000219
4279,,,,Autocuration,,9295,CHEMBL618390,12166,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,B,1,H,8,,BAO_0000219
4280,,,,Autocuration,,9295,CHEMBL618391,12166,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,B,1,H,8,,BAO_0000219
4281,,,,Autocuration,,9295,CHEMBL618392,12166,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,B,1,H,8,,BAO_0000219
4282,,,,Autocuration,,165,CHEMBL618393,12166,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,B,1,H,8,,BAO_0000219
4283,,,,Autocuration,,11311,CHEMBL618394,12166,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,B,1,H,8,,BAO_0000219
4284,,,9606.0,Expert,Homo sapiens,10489,CHEMBL618395,12166,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,B,1,H,8,,BAO_0000219
4285,,,10116.0,Expert,Rattus norvegicus,10489,CHEMBL618396,12166,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,B,1,D,9,,BAO_0000219
4286,,,10116.0,Expert,Rattus norvegicus,10489,CHEMBL858253,12166,,702.0,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,B,1,D,9,,BAO_0000219
4287,,,10116.0,Autocuration,Rattus norvegicus,14799,CHEMBL618397,12166,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,B,1,D,9,,BAO_0000019
4288,,,3847.0,Autocuration,Glycine max,9295,CHEMBL618398,12054,,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,B,1,H,8,,BAO_0000357
4289,,,,Autocuration,,16811,CHEMBL618399,22226,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,B,1,U,0,,BAO_0000019
4290,,,,Expert,,168,CHEMBL618400,55,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,B,1,H,8,,BAO_0000357
4291,,,,Autocuration,,6309,CHEMBL618401,55,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,B,1,H,8,,BAO_0000357
4292,,,,Autocuration,,6309,CHEMBL618402,55,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,B,1,H,8,,BAO_0000357
4293,,,,Autocuration,,3092,CHEMBL876400,55,,702.0,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,B,1,H,8,,BAO_0000219
4294,,,,Expert,,168,CHEMBL618403,55,,,,Inhibitory activity against 5-lipoxygenase.,,B,1,H,8,,BAO_0000357
4295,,,,Autocuration,,168,CHEMBL618404,55,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,B,1,H,8,,BAO_0000357
4296,,,,Autocuration,,168,CHEMBL618405,55,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,B,1,H,8,,BAO_0000357
4297,,,,Autocuration,,168,CHEMBL618406,55,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,B,1,H,8,,BAO_0000357
4298,,,,Expert,,12338,CHEMBL618407,55,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,F,1,H,8,,BAO_0000019
4299,,,,Autocuration,,4501,CHEMBL618408,55,,,,Tested for the inhibitory activity against 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4300,,,,Autocuration,,1132,CHEMBL618409,55,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,B,1,H,8,,BAO_0000357
4301,,,,Autocuration,,2117,CHEMBL618410,55,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,B,1,H,8,,BAO_0000357
4302,,,,Autocuration,,168,CHEMBL618411,55,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,B,1,H,8,,BAO_0000357
4303,,,,Autocuration,,168,CHEMBL618412,55,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,B,1,H,8,,BAO_0000357
4304,,,,Autocuration,,13575,CHEMBL618413,12166,,702.0,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,B,1,H,8,,BAO_0000219
4305,,,,Autocuration,,11089,CHEMBL618414,12166,,,,,,B,1,H,8,,BAO_0000357
4306,,,,Autocuration,,216,CHEMBL618415,10102,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,B,1,H,8,,BAO_0000357
4307,,,,Autocuration,,13165,CHEMBL618416,10102,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,B,1,H,8,,BAO_0000019
4308,,,,Autocuration,,3278,CHEMBL876401,10102,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,B,1,H,8,,BAO_0000357
4309,,,,Expert,,3278,CHEMBL618417,10102,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,B,1,H,8,,BAO_0000357
4310,,,,Autocuration,,11966,CHEMBL618418,10102,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,B,1,H,8,,BAO_0000357
4311,,,,Autocuration,,175,CHEMBL618419,10102,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,B,1,H,8,,BAO_0000357
4312,,,,Autocuration,,175,CHEMBL618420,10102,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,B,1,H,8,,BAO_0000357
4313,,,,Autocuration,,13449,CHEMBL618421,10102,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,B,1,H,8,,BAO_0000357
4314,,,,Autocuration,,12014,CHEMBL618422,11238,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,B,1,H,8,,BAO_0000019
4315,,,,Autocuration,,12014,CHEMBL618423,11238,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,B,1,H,8,,BAO_0000019
4316,,,,Autocuration,,12014,CHEMBL618424,11238,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,B,1,H,8,,BAO_0000019
4317,,,,Intermediate,,99,CHEMBL618425,100284,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,B,1,S,2,,BAO_0000220
4318,,,9606.0,Autocuration,Homo sapiens,4349,CHEMBL618426,22226,,,,The dark toxicity against 543 human galactophore carcinoma cells,,F,1,U,0,,BAO_0000019
4319,,,9606.0,Expert,Homo sapiens,4071,CHEMBL618427,80623,,390.0,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,F,1,N,1,,BAO_0000219
4320,,,9606.0,Expert,Homo sapiens,17589,CHEMBL618428,80008,,345.0,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,F,1,N,1,,BAO_0000219
4321,,,9606.0,Intermediate,Homo sapiens,15002,CHEMBL618429,80008,,345.0,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,F,1,N,1,,BAO_0000219
4322,,,9606.0,Intermediate,Homo sapiens,13958,CHEMBL618430,80008,,345.0,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,F,1,N,1,,BAO_0000219
4323,,,9606.0,Expert,Homo sapiens,17589,CHEMBL618431,80008,,345.0,,Growth inhibition against human 5637 cell lines,,F,1,N,1,,BAO_0000219
4324,,,9606.0,Expert,Homo sapiens,16748,CHEMBL883799,80008,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells.,,F,1,N,1,,BAO_0000219
4325,,,9606.0,Intermediate,Homo sapiens,16747,CHEMBL618432,80008,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,,F,1,N,1,,BAO_0000219
4326,,,9606.0,Intermediate,Homo sapiens,16747,CHEMBL618433,80008,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,,F,1,N,1,,BAO_0000219
4327,,,9913.0,Expert,Bos taurus,15285,CHEMBL618434,10443,,,,In vitro inhibition of bovine trypsin(Trp).,,B,1,D,9,,BAO_0000357
4328,,,9527.0,Expert,Cercopithecidae,3726,CHEMBL618435,240,,407.0,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,B,1,H,8,,BAO_0000219
4329,,,,Autocuration,,5033,CHEMBL876402,10577,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,B,1,H,8,,BAO_0000357
4330,,,,Autocuration,,11756,CHEMBL618436,104698,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,F,1,H,6,,BAO_0000019
4331,,,,Autocuration,,11953,CHEMBL618437,22226,,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,F,1,U,0,,BAO_0000218
4332,,,10141.0,Intermediate,Cavia porcellus,5033,CHEMBL618438,20033,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,B,1,D,9,,BAO_0000357
4333,Microsomes,,10116.0,Expert,Rattus norvegicus,11347,CHEMBL883800,17045,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,A,1,H,8,,BAO_0000251
4334,Microsomes,,10116.0,Expert,Rattus norvegicus,11347,CHEMBL618439,17045,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,A,1,H,8,,BAO_0000251
4335,,,,Intermediate,,1229,CHEMBL618440,22226,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,F,1,U,0,,BAO_0000019
4336,,,,Intermediate,,1229,CHEMBL618441,22226,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,F,1,U,0,,BAO_0000019
4337,,,5691.0,Expert,Trypanosoma brucei,17588,CHEMBL618442,11938,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,B,1,H,8,,BAO_0000019
4338,,,5691.0,Autocuration,Trypanosoma brucei,17588,CHEMBL618443,11938,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,B,1,H,8,,BAO_0000019
4339,,,9940.0,Expert,Ovis aries,17588,CHEMBL619158,11938,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,B,1,H,8,,BAO_0000019
4340,,,9940.0,Autocuration,Ovis aries,17588,CHEMBL620974,11938,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,B,1,H,8,,BAO_0000019
4341,,,,Autocuration,,16485,CHEMBL620975,11938,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,B,1,H,8,,BAO_0000357
4342,,,9606.0,Intermediate,Homo sapiens,4337,CHEMBL620976,22226,,,,Average inhibitory concentration against 60 human cell lines was reported,,F,1,U,0,,BAO_0000019
4343,,,9606.0,Expert,Homo sapiens,4112,CHEMBL620977,22226,,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,F,1,U,0,,BAO_0000019
4344,,,9606.0,Intermediate,Homo sapiens,16160,CHEMBL620978,80315,,542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,F,1,N,1,,BAO_0000219
4345,,,9606.0,Intermediate,Homo sapiens,16160,CHEMBL620979,80315,,542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,F,1,N,1,,BAO_0000219
4346,,,,Expert,,17376,CHEMBL620980,80315,,542.0,,In vitro mean growth inhibitory activity against 60-cell panel,,F,1,N,1,,BAO_0000219
4347,,,,Expert,,17376,CHEMBL620981,80315,,542.0,,In vitro mean growth lethal concentration against 60-cell panel,,F,1,N,1,,BAO_0000219
4348,,,,Expert,,17376,CHEMBL620982,80315,,542.0,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,F,1,N,1,,BAO_0000219
4349,,,,Expert,,17376,CHEMBL620983,80315,,542.0,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,F,1,N,1,,BAO_0000219
4350,,,,Autocuration,,3241,CHEMBL620984,104775,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,F,1,H,4,,BAO_0000019
4351,,,,Autocuration,,3241,CHEMBL620985,104775,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,F,1,H,4,,BAO_0000019
4352,,,,Expert,,3725,CHEMBL620986,275,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,B,1,H,8,,BAO_0000357
4353,,,5833.0,Expert,Plasmodium falciparum,10805,CHEMBL620987,50425,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,F,1,N,1,,BAO_0000218
4354,,,5833.0,Expert,Plasmodium falciparum,10805,CHEMBL620988,50425,,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,F,1,N,1,,BAO_0000218
4355,,,5833.0,Expert,Plasmodium falciparum,10805,CHEMBL620989,50425,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,F,1,N,1,,BAO_0000218
4356,,,5833.0,Expert,Plasmodium falciparum,10805,CHEMBL620990,50425,,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,F,1,N,1,,BAO_0000218
4357,,,5833.0,Intermediate,Plasmodium falciparum,10805,CHEMBL620991,50425,,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,F,1,N,1,,BAO_0000218
4358,,,10090.0,Intermediate,Mus musculus,10144,CHEMBL620992,80628,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,F,1,N,1,,BAO_0000218
4359,,,10090.0,Intermediate,Mus musculus,10144,CHEMBL620993,80628,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,F,1,N,1,,BAO_0000218
4360,,,10090.0,Intermediate,Mus musculus,10144,CHEMBL620994,80628,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,F,1,N,1,,BAO_0000218
4361,,,10090.0,Intermediate,Mus musculus,10144,CHEMBL620995,80628,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,F,1,N,1,,BAO_0000218
4362,,,10090.0,Intermediate,Mus musculus,10144,CHEMBL620996,80628,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,F,1,N,1,,BAO_0000218
4363,,,10090.0,Intermediate,Mus musculus,10144,CHEMBL875581,80628,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,F,1,N,1,,BAO_0000218
4364,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL620997,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,F,1,U,0,,BAO_0000218
4365,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL620998,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,F,1,U,0,,BAO_0000218
4366,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL620999,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,F,1,U,0,,BAO_0000218
4367,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL621000,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,F,1,U,0,,BAO_0000218
4368,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL621001,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,F,1,U,0,,BAO_0000218
4369,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL621002,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,F,1,U,0,,BAO_0000218
4370,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL621003,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,F,1,U,0,,BAO_0000218
4371,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL621004,22224,,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,F,1,U,0,,BAO_0000218
4372,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL621005,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,F,1,U,0,,BAO_0000218
4373,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL621006,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,F,1,U,0,,BAO_0000218
4374,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL621007,22224,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,F,1,U,0,,BAO_0000218
4375,,,10090.0,Autocuration,Mus musculus,10144,CHEMBL621008,22224,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,F,1,U,0,,BAO_0000218
4376,,,10090.0,Autocuration,Mus musculus,10144,CHEMBL621009,22224,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,F,1,U,0,,BAO_0000218
4377,,,10090.0,Autocuration,Mus musculus,10144,CHEMBL857705,22224,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,F,1,U,0,,BAO_0000218
4378,,,10090.0,Autocuration,Mus musculus,10144,CHEMBL619828,22224,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,F,1,U,0,,BAO_0000218
4379,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL619829,22224,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,F,1,U,0,,BAO_0000218
4380,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL619830,22224,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,F,1,U,0,,BAO_0000218
4381,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL619831,22224,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,F,1,U,0,,BAO_0000218
4382,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL619832,22224,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,F,1,U,0,,BAO_0000218
4383,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL619833,22224,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,A,1,U,0,,BAO_0000218
4384,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL619834,22224,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,A,1,U,0,,BAO_0000218
4385,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL619835,22224,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,A,1,U,0,,BAO_0000218
4386,,,10090.0,Autocuration,Mus musculus,10685,CHEMBL619836,22224,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,A,1,U,0,,BAO_0000218
4387,,,10090.0,Intermediate,Mus musculus,8831,CHEMBL619837,80628,,850.0,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,F,1,N,1,,BAO_0000218
4388,,,,Autocuration,,11704,CHEMBL619838,22224,,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,F,1,U,0,,BAO_0000218
4389,,,10090.0,Intermediate,Mus musculus,11704,CHEMBL619839,50594,,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,A,1,N,1,,BAO_0000218
4390,,,10090.0,Intermediate,Mus musculus,10685,CHEMBL619840,80628,,850.0,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,F,1,N,1,,BAO_0000218
4391,,,10090.0,Intermediate,Mus musculus,10685,CHEMBL619841,80628,,850.0,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,F,1,N,1,,BAO_0000218
4392,,,10090.0,Expert,Mus musculus,11368,CHEMBL857704,80628,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,F,1,N,1,,BAO_0000218
4393,,,10090.0,Intermediate,Mus musculus,11368,CHEMBL619842,80628,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,F,1,N,1,,BAO_0000218
4394,,,10090.0,Expert,Mus musculus,11368,CHEMBL619843,80628,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,F,1,N,1,,BAO_0000218
4395,,,1280.0,Autocuration,Staphylococcus aureus,17763,CHEMBL619844,22226,,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,B,1,U,0,,BAO_0000019
4396,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL857855,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,B,1,U,0,,BAO_0000251
4397,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619845,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,B,1,U,0,,BAO_0000251
4398,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619846,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,B,1,U,0,,BAO_0000251
4399,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619847,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,B,1,U,0,,BAO_0000251
4400,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL619848,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,B,1,U,0,,BAO_0000251
4401,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620893,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,B,1,U,0,,BAO_0000251
4402,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620894,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,B,1,U,0,,BAO_0000251
4403,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620895,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,B,1,U,0,,BAO_0000251
4404,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620896,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,B,1,U,0,,BAO_0000251
4405,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620897,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,B,1,U,0,,BAO_0000251
4406,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620898,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,B,1,U,0,,BAO_0000251
4407,Microsomes,2107.0,10116.0,Autocuration,Rattus norvegicus,7411,CHEMBL620899,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,B,1,U,0,,BAO_0000251
4408,,1969.0,9527.0,Autocuration,Cercopithecidae,347,CHEMBL620900,22224,,,Plasma,The apparent total plasma clearance in monkey,,A,1,U,0,,BAO_0000218
4409,,,9527.0,Autocuration,Cercopithecidae,3341,CHEMBL620901,22224,,,,Compound was evaluated for Hepatic clearance in monkey,,A,1,U,0,,BAO_0000218
4410,,,9527.0,Autocuration,Cercopithecidae,17853,CHEMBL620902,22224,,,,Lower clearance in monkey (i.v.) at 0.5 mpk,,A,1,U,0,,BAO_0000218
4411,,,9527.0,Autocuration,Cercopithecidae,4514,CHEMBL620903,22224,,,,Plasma clearance in rhesus monkey,,A,1,U,0,,BAO_0000218
4412,,,9527.0,Autocuration,Cercopithecidae,6062,CHEMBL620904,22224,,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
4413,,,9527.0,Autocuration,Cercopithecidae,6821,CHEMBL620905,22224,,,,Plasma clearance of compound was determined in monkey,,A,1,U,0,,BAO_0000218
4414,,,9527.0,Autocuration,Cercopithecidae,6057,CHEMBL620906,22224,,,,Plasma clearance was calculated in rhesus monkey,,A,1,U,0,,BAO_0000218
4415,,,9527.0,Autocuration,Cercopithecidae,5145,CHEMBL875420,22224,,,,Plasma clearance in rhesus monkey,,A,1,U,0,,BAO_0000218
4416,,,9527.0,Autocuration,Cercopithecidae,6641,CHEMBL620907,22224,,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,U,0,,BAO_0000218
4417,,,9527.0,Autocuration,Cercopithecidae,5472,CHEMBL620908,22224,,,,Plasma clearance was evaluated in rhesus,,A,1,U,0,,BAO_0000218
4418,,,9527.0,Autocuration,Cercopithecidae,4257,CHEMBL620909,22224,,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,A,1,U,0,,BAO_0000218
4419,,,9527.0,Autocuration,Cercopithecidae,5546,CHEMBL620910,22224,,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,A,1,U,0,,BAO_0000218
4420,,,9527.0,Autocuration,Cercopithecidae,5334,CHEMBL620911,22224,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,A,1,U,0,,BAO_0000218
4421,,,9527.0,Autocuration,Cercopithecidae,5334,CHEMBL620912,22224,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,A,1,U,0,,BAO_0000218
4422,,,9527.0,Autocuration,Cercopithecidae,17509,CHEMBL620913,22224,,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,A,1,U,0,,BAO_0000218
4423,,,9527.0,Autocuration,Cercopithecidae,6535,CHEMBL620914,22224,,,,Cmax in monkey after administration of 1 mg/kg iv,,A,1,U,0,,BAO_0000218
4424,,,9527.0,Autocuration,Cercopithecidae,5668,CHEMBL620915,22224,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,A,1,U,0,,BAO_0000218
4425,,,9527.0,Autocuration,Cercopithecidae,5922,CHEMBL620916,22224,,,,Cmax in cynomolgus monkey by iv administration,,A,1,U,0,,BAO_0000218
4426,,,9527.0,Autocuration,Cercopithecidae,5922,CHEMBL620917,22224,,,,Cmax in cynomolgus monkey by po administration,,A,1,U,0,,BAO_0000218
4427,,,9527.0,Autocuration,Cercopithecidae,6078,CHEMBL620918,22224,,,,Cmax value evaluated in monkey,,A,1,U,0,,BAO_0000218
4428,,,9527.0,Autocuration,Cercopithecidae,2661,CHEMBL620919,22224,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,A,1,U,0,,BAO_0000218
4429,,1969.0,9527.0,Autocuration,Cercopithecidae,3249,CHEMBL620920,22224,,,Plasma,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,A,1,U,0,,BAO_0000218
4430,,1969.0,9527.0,Autocuration,Cercopithecidae,3249,CHEMBL620921,22224,,,Plasma,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,A,1,U,0,,BAO_0000218
4431,,1969.0,9527.0,Autocuration,Cercopithecidae,5553,CHEMBL620922,22224,,,Plasma,Maximal plasma concentration in squirrel monkeys,,A,1,U,0,,BAO_0000218
4432,,,9527.0,Autocuration,Cercopithecidae,1916,CHEMBL620923,22224,,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,A,1,U,0,,BAO_0000218
4433,,1969.0,9527.0,Autocuration,Cercopithecidae,6227,CHEMBL620924,22224,,,Plasma,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,A,1,U,0,,BAO_0000218
4434,,,9527.0,Autocuration,Cercopithecidae,4809,CHEMBL620925,22224,,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,A,1,U,0,,BAO_0000218
4435,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL620926,22224,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,A,1,U,0,,BAO_0000218
4436,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL620927,22224,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,A,1,U,0,,BAO_0000218
4437,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL620928,22224,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,A,1,U,0,,BAO_0000218
4438,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL620929,22224,,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000218
4439,,1969.0,9527.0,Autocuration,Cercopithecidae,6221,CHEMBL620930,22224,,,Plasma,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,A,1,U,0,,BAO_0000218
4440,,,9527.0,Autocuration,Cercopithecidae,167,CHEMBL620931,22224,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,A,1,U,0,,BAO_0000218
4441,,,9527.0,Autocuration,Cercopithecidae,167,CHEMBL620932,22224,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,A,1,U,0,,BAO_0000218
4442,,,9443.0,Autocuration,monkey,4257,CHEMBL620933,22224,,,,Absolute bioavailability was evaluated in monkey,,A,1,U,0,,BAO_0000218
4443,,,9443.0,Autocuration,monkey,6221,CHEMBL620934,22224,,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,A,1,U,0,,BAO_0000218
4444,,,9443.0,Autocuration,monkey,17667,CHEMBL620935,22224,,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,A,1,U,0,,BAO_0000218
4445,,,9544.0,Autocuration,Macaca mulatta,17267,CHEMBL620936,22224,,,,Bioavailability of compound was determined in rhesus monkey,,A,1,U,0,,BAO_0000218
4446,,,38020.0,Autocuration,marmosets,4256,CHEMBL620937,22224,,,,Bioavailability determined after oral administration in marmoset,,A,1,U,0,,BAO_0000218
4447,,,9541.0,Autocuration,Macaca fascicularis,4256,CHEMBL620938,22224,,,,Oral bioavailability in cynomolgus monkey,,A,1,U,0,,BAO_0000218
4448,,,9443.0,Autocuration,monkey,17853,CHEMBL620939,22224,,,,Bioavailability in monkey (p.o.) at 2.0 mpk,,A,1,U,0,,BAO_0000218
4449,,,9443.0,Autocuration,monkey,16365,CHEMBL620940,22224,,,,Bioavailability was evaluated after oral administration in monkey,,A,1,U,0,,BAO_0000218
4450,,,9541.0,Autocuration,Macaca fascicularis,1916,CHEMBL620941,22224,,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,A,1,U,0,,BAO_0000218
4451,,,9544.0,Autocuration,Macaca mulatta,5334,CHEMBL620942,22224,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,A,1,U,0,,BAO_0000218
4452,,,9544.0,Autocuration,Macaca mulatta,5334,CHEMBL620943,22224,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,A,1,U,0,,BAO_0000218
4453,,,9443.0,Autocuration,monkey,17592,CHEMBL620944,22224,,,,Bioavailability of the compound was determined in monkey,,A,1,U,0,,BAO_0000218
4454,,,9521.0,Autocuration,Saimiri sciureus,1399,CHEMBL620945,22224,,,,Bioavailability in squirrel monkey (dose 5 mg/kg),,A,1,U,0,,BAO_0000218
4455,,,9443.0,Autocuration,monkey,4809,CHEMBL620946,22224,,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,A,1,U,0,,BAO_0000218
4456,,,9443.0,Autocuration,monkey,3341,CHEMBL620947,22224,,,,Oral bioavailability in monkey,,A,1,U,0,,BAO_0000218
4457,,,9521.0,Autocuration,Saimiri sciureus,64,CHEMBL620948,22224,,,,Compound was tested for bioavailability in squirrel monkey,,A,1,U,0,,BAO_0000218
4458,,,9544.0,Autocuration,Macaca mulatta,5005,CHEMBL620949,22224,,,,Oral bioavailability in Rhesus monkey,,A,1,U,0,,BAO_0000218
4459,,,9544.0,Autocuration,Macaca mulatta,5005,CHEMBL620950,22224,,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,A,1,U,0,,BAO_0000218
4460,,,9541.0,Autocuration,Macaca fascicularis,5237,CHEMBL620951,22224,,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,A,1,U,0,,BAO_0000218
4461,,,9541.0,Autocuration,Macaca fascicularis,5237,CHEMBL620952,22224,,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,A,1,U,0,,BAO_0000218
4462,,,9443.0,Autocuration,monkey,5302,CHEMBL875421,22224,,,,Oral bioavailability in monkey (dose 5 mg/kg),,A,1,U,0,,BAO_0000218
4463,,,9443.0,Autocuration,monkey,17667,CHEMBL620953,22224,,,,Oral bioavailability of compound at 5 mg/kg in monkey,,A,1,U,0,,BAO_0000218
4464,,,9615.0,Intermediate,Canis lupus familiaris,6161,CHEMBL873491,50588,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,A,1,N,1,,BAO_0000218
4465,,,9615.0,Intermediate,Canis lupus familiaris,6161,CHEMBL620954,50588,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,A,1,N,1,,BAO_0000218
4466,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3854,CHEMBL620955,50588,,,Plasma,Plasma half life determined,,A,1,N,1,,BAO_0000218
4467,,1969.0,9615.0,Intermediate,Canis lupus familiaris,993,CHEMBL618097,50588,,,Plasma,Plasma half life in dog,,A,1,N,1,,BAO_0000218
4468,,1969.0,9615.0,Intermediate,Canis lupus familiaris,4514,CHEMBL618268,50588,,,Plasma,Plasma half-life in Beagle dogs,,A,1,N,1,,BAO_0000218
4469,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5334,CHEMBL618269,50588,,,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,A,1,N,1,,BAO_0000218
4470,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5334,CHEMBL618270,50588,,,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,A,1,N,1,,BAO_0000218
4471,,,9615.0,Intermediate,Canis lupus familiaris,1466,CHEMBL618271,50588,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,A,1,N,1,,BAO_0000218
4472,,,9615.0,Intermediate,Canis lupus familiaris,1466,CHEMBL873493,50588,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,A,1,N,1,,BAO_0000218
4473,,,9615.0,Intermediate,Canis lupus familiaris,5313,CHEMBL621031,50588,,,,Tested for the half life period in dog,,A,1,N,1,,BAO_0000218
4474,,,9615.0,Intermediate,Canis lupus familiaris,5313,CHEMBL621032,50588,,,,Tested for the half life period in dog at dosage of 10 mpk,,A,1,N,1,,BAO_0000218
4475,,,9615.0,Intermediate,Canis lupus familiaris,3880,CHEMBL621033,50588,,,,The compound was tested for half life in dog,,A,1,N,1,,BAO_0000218
4476,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL621034,50588,,,Plasma,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,A,1,N,1,,BAO_0000218
4477,,,9615.0,Intermediate,Canis lupus familiaris,3880,CHEMBL621035,50588,,,,The half life was determined,,A,1,N,1,,BAO_0000218
4478,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3918,CHEMBL621036,50588,,,Plasma,The plasma half-life in dogs,,A,1,N,1,,BAO_0000218
4479,,1969.0,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL621037,50588,,,Plasma,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,A,1,N,1,,BAO_0000218
4480,,,9615.0,Intermediate,Canis lupus familiaris,17796,CHEMBL619812,50588,,,,Half life in dog,,A,1,N,1,,BAO_0000218
4481,,,9615.0,Intermediate,Canis lupus familiaris,5983,CHEMBL619813,50588,,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,A,1,N,1,,BAO_0000218
4482,,,9615.0,Intermediate,Canis lupus familiaris,1466,CHEMBL873335,50588,,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,A,1,N,1,,BAO_0000218
4483,,,9615.0,Intermediate,Canis lupus familiaris,16456,CHEMBL619814,50588,,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
4484,,,9669.0,Expert,Mustela putorius furo,6113,CHEMBL619815,50506,,,,Cmax in ferrets after 30 mg/kg oral dose,,A,1,N,1,,BAO_0000218
4485,,,9669.0,Expert,Mustela putorius furo,6113,CHEMBL619816,50506,,,,Emesis in ferrets at 30 mg/kg oral dose,,F,1,N,1,,BAO_0000218
4486,,,9541.0,Autocuration,Macaca fascicularis,17796,CHEMBL619817,22224,,,,Bioavailability in cynomolgus monkey,,A,1,U,0,,BAO_0000218
4487,,,9541.0,Intermediate,Macaca fascicularis,17796,CHEMBL619818,100710,,,,Volume of distribution in cynomolgus,,A,1,N,1,,BAO_0000218
4488,,1969.0,10141.0,Autocuration,Cavia porcellus,5308,CHEMBL619819,22224,,,Plasma,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,A,1,U,0,,BAO_0000218
4489,,,10141.0,Autocuration,Cavia porcellus,4877,CHEMBL619820,22224,,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,A,1,U,0,,BAO_0000218
4490,,,10141.0,Autocuration,Cavia porcellus,4876,CHEMBL875419,22224,,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,A,1,U,0,,BAO_0000218
4491,,1969.0,10141.0,Autocuration,Cavia porcellus,4878,CHEMBL619821,22224,,,Plasma,AUC in guinea pig after 3mg/kg oral dose,,A,1,U,0,,BAO_0000218
4492,,,10141.0,Autocuration,Cavia porcellus,5308,CHEMBL619822,22224,,,,Bioavailability in guinea pig was tested,,A,1,U,0,,BAO_0000218
4493,,,10141.0,Autocuration,Cavia porcellus,4877,CHEMBL619823,22224,,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,A,1,U,0,,BAO_0000218
4494,,,10141.0,Autocuration,Cavia porcellus,4876,CHEMBL619824,22224,,,,Tested for the oral bioavailability of the compound,,A,1,U,0,,BAO_0000218
4495,,,10141.0,Autocuration,Cavia porcellus,4876,CHEMBL619825,22224,,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,A,1,U,0,,BAO_0000218
4496,,,10141.0,Autocuration,Cavia porcellus,5308,CHEMBL619826,22224,,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,A,1,U,0,,BAO_0000218
4497,,2048.0,10141.0,Autocuration,Cavia porcellus,4877,CHEMBL619827,22224,,,Lung,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,A,1,U,0,,BAO_0000218
4498,,,10141.0,Autocuration,Cavia porcellus,4878,CHEMBL618167,22224,,,,Cmax in guinea pig after 3mg/kg oral dose,,A,1,U,0,,BAO_0000218
4499,,178.0,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL618168,22224,,,Blood,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,A,1,U,0,,BAO_0000019
4500,,955.0,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL618169,22224,,,Brain,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,A,1,U,0,,BAO_0000019
4501,,,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL618170,22224,,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,A,1,U,0,,BAO_0000019
4502,,160.0,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL618171,22224,,,Intestine,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,A,1,U,0,,BAO_0000019
4503,,2113.0,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL618172,22224,,,Kidney,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,A,1,U,0,,BAO_0000019
4504,,2107.0,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL618173,22224,,,Liver,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,A,1,U,0,,BAO_0000019
4505,,,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL618174,22224,,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,A,1,U,0,,BAO_0000019
4506,,2106.0,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL875408,22224,,,Spleen,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,A,1,U,0,,BAO_0000019
4507,,,10141.0,Autocuration,Cavia porcellus,14465,CHEMBL839827,22224,,,,Elimination T1/2 in Guinea pig (PO dose),,A,1,U,0,,BAO_0000218
4508,,,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL618175,22224,,,,Partition coefficient was measured as -log (counts per min ),,A,1,U,0,,BAO_0000019
4509,,,10141.0,Autocuration,Cavia porcellus,611,CHEMBL618176,22224,,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,A,1,U,0,,BAO_0000218
4510,,,10141.0,Autocuration,Cavia porcellus,611,CHEMBL618177,22224,,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,A,1,U,0,,BAO_0000218
4511,,,10141.0,Autocuration,Cavia porcellus,14465,CHEMBL618178,22224,,,,Elimination T1/2 in Guinea pig (PO dose),,A,1,U,0,,BAO_0000218
4512,,,10141.0,Autocuration,Cavia porcellus,4876,CHEMBL618179,22224,,,,"Tested for the half life period of the compound, intravenously",,A,1,U,0,,BAO_0000218
4513,,,10141.0,Autocuration,Cavia porcellus,5689,CHEMBL873489,22224,,,,Half-life was measured,,A,1,U,0,,BAO_0000019
4514,,,10141.0,Autocuration,Cavia porcellus,7515,CHEMBL618180,22224,,,,The time required for onset of inotropy after addition of a single dose of delta F75,,A,1,U,0,,BAO_0000019
4515,,,10141.0,Autocuration,Cavia porcellus,17667,CHEMBL618181,22224,,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,A,1,U,0,,BAO_0000218
4516,,,10141.0,Autocuration,Cavia porcellus,17667,CHEMBL618182,22224,,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,A,1,U,0,,BAO_0000218
4517,,,10029.0,Autocuration,Cricetulus griseus,4727,CHEMBL618183,22224,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,A,1,U,0,,BAO_0000218
4518,,,10090.0,Intermediate,Mus musculus,10107,CHEMBL618184,50594,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
4519,,,10090.0,Intermediate,Mus musculus,10107,CHEMBL618185,50594,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,A,1,N,1,,BAO_0000218
4520,,,10090.0,Intermediate,Mus musculus,10107,CHEMBL618186,50594,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
4521,,,10090.0,Intermediate,Mus musculus,10107,CHEMBL618187,50594,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
4522,,,10090.0,Intermediate,Mus musculus,10107,CHEMBL618188,50594,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,A,1,N,1,,BAO_0000218
4523,,,10090.0,Intermediate,Mus musculus,10107,CHEMBL875409,50594,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
4524,,,10090.0,Intermediate,Mus musculus,10107,CHEMBL618189,50594,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
4525,,178.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618190,50594,,,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4526,,178.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618191,50594,,,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4527,,178.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618192,50594,,,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4528,,10000001.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618193,50594,,,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4529,,10000001.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618194,50594,,,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4530,,10000001.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618195,50594,,,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4531,,955.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618196,50594,,,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4532,,955.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618197,50594,,,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4533,,955.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618198,50594,,,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4534,,948.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618199,50594,,,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4535,,948.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618200,50594,,,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4536,,948.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618201,50594,,,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4537,,160.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618202,50594,,,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4538,,160.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618203,50594,,,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4539,,160.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618204,50594,,,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4540,,2113.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618205,50594,,,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4541,,2113.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618206,50594,,,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4542,,2113.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618207,50594,,,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4543,,2107.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618208,50594,,,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4544,,2107.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618932,50594,,,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4545,,2107.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618933,50594,,,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4546,,2048.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618934,50594,,,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4547,,2048.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618935,50594,,,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4548,,2048.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618936,50594,,,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4549,,2385.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618937,50594,,,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4550,,2385.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL618938,50594,,,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4551,,2385.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL619104,50594,,,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4552,,2106.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL619105,50594,,,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4553,,2106.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL619106,50594,,,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4554,,2106.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL619107,50594,,,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4555,,945.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL875410,50594,,,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,A,1,N,1,,BAO_0000218
4556,,945.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL619108,50594,,,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,A,1,N,1,,BAO_0000218
4557,,945.0,10090.0,Intermediate,Mus musculus,3655,CHEMBL619109,50594,,,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,A,1,N,1,,BAO_0000218
4558,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL619110,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,A,1,N,1,,BAO_0000218
4559,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL619111,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,F,1,N,1,,BAO_0000218
4560,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL619112,50594,,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,A,1,N,1,,BAO_0000218
4561,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL619113,50594,,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,A,1,N,1,,BAO_0000218
4562,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL619114,50594,,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,A,1,N,1,,BAO_0000218
4563,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL619115,50594,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,F,1,N,1,,BAO_0000218
4564,,,9606.0,Intermediate,Homo sapiens,3830,CHEMBL619116,81034,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,F,1,N,1,,BAO_0000219
4565,,,9606.0,Intermediate,Homo sapiens,3829,CHEMBL619117,81034,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,F,1,N,1,,BAO_0000219
4566,,,9606.0,Intermediate,Homo sapiens,2040,CHEMBL619118,81034,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell lines.,,F,1,N,1,,BAO_0000219
4567,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619119,81034,,478.0,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,F,1,N,1,,BAO_0000219
4568,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619120,81034,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,F,1,N,1,,BAO_0000219
4569,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619121,81034,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,F,1,N,1,,BAO_0000219
4570,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619122,81034,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,F,1,N,1,,BAO_0000219
4571,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619123,81034,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,F,1,N,1,,BAO_0000219
4572,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619124,81034,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,F,1,N,1,,BAO_0000219
4573,,,9606.0,Intermediate,Homo sapiens,2859,CHEMBL619125,81034,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,,F,1,N,1,,BAO_0000219
4574,,,9606.0,Intermediate,Homo sapiens,5618,CHEMBL875411,81034,,478.0,,In vitro inhibitory activity against human tumor cell line A2780,,F,1,N,1,,BAO_0000219
4575,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619126,81034,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,F,1,N,1,,BAO_0000219
4576,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619127,81034,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,F,1,N,1,,BAO_0000219
4577,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619128,81034,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,F,1,N,1,,BAO_0000219
4578,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619129,81034,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,F,1,N,1,,BAO_0000219
4579,,,9606.0,Intermediate,Homo sapiens,2113,CHEMBL619130,81034,,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,F,1,N,1,,BAO_0000219
4580,,,9606.0,Intermediate,Homo sapiens,2113,CHEMBL619131,81034,,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,F,1,N,1,,BAO_0000219
4581,,,9606.0,Intermediate,Homo sapiens,16745,CHEMBL619132,81034,,478.0,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,F,1,N,1,,BAO_0000219
4582,,,9606.0,Expert,Homo sapiens,16597,CHEMBL619133,81034,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,F,1,N,1,,BAO_0000218
4583,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619134,81034,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,F,1,N,1,,BAO_0000219
4584,,,9606.0,Intermediate,Homo sapiens,15684,CHEMBL619135,81034,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,F,1,N,1,,BAO_0000219
4585,,,9606.0,Intermediate,Homo sapiens,2040,CHEMBL619136,81034,,478.0,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,F,1,N,1,,BAO_0000219
4586,,,9606.0,Intermediate,Homo sapiens,2040,CHEMBL619137,81034,,478.0,,Relative resistance factor in A2780 cisplatin-resistant line,,F,1,N,1,,BAO_0000219
4587,,,9606.0,Intermediate,Homo sapiens,16165,CHEMBL883713,81034,,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,F,1,N,1,,BAO_0000219
4588,,,9606.0,Intermediate,Homo sapiens,16165,CHEMBL875412,81034,,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,F,1,N,1,,BAO_0000219
4589,,,9606.0,Expert,Homo sapiens,16597,CHEMBL619138,81034,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,F,1,N,1,,BAO_0000218
4590,,,9606.0,Expert,Homo sapiens,16597,CHEMBL619262,81034,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,F,1,N,1,,BAO_0000218
4591,,,9606.0,Intermediate,Homo sapiens,3992,CHEMBL619139,81034,,478.0,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,F,1,N,1,,BAO_0000219
4592,,,9606.0,Intermediate,Homo sapiens,10553,CHEMBL619140,81034,,478.0,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,F,1,N,1,,BAO_0000219
4593,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL619141,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,F,1,N,1,,BAO_0000219
4594,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL619142,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,F,1,N,1,,BAO_0000219
4595,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL619143,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,F,1,N,1,,BAO_0000219
4596,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL619144,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,F,1,N,1,,BAO_0000219
4597,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL619145,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,F,1,N,1,,BAO_0000219
4598,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL619146,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,F,1,N,1,,BAO_0000219
4599,,,9606.0,Intermediate,Homo sapiens,15569,CHEMBL619147,81034,,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,F,1,N,1,,BAO_0000219
4600,,,9606.0,Intermediate,Homo sapiens,17420,CHEMBL619148,81034,,478.0,,Antiproliferative effect of compound on A2780/DX cell line,,F,1,N,1,,BAO_0000219
4601,,,9606.0,Intermediate,Homo sapiens,17420,CHEMBL619149,81034,,478.0,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,F,1,N,1,,BAO_0000219
4602,,,9606.0,Intermediate,Homo sapiens,15099,CHEMBL619150,81034,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,F,1,N,1,,BAO_0000219
4603,,,9606.0,Intermediate,Homo sapiens,15099,CHEMBL619151,81034,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,F,1,N,1,,BAO_0000219
4604,,,9606.0,Intermediate,Homo sapiens,17672,CHEMBL883794,81034,,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,F,1,N,1,,BAO_0000219
4605,,,9606.0,Intermediate,Homo sapiens,17672,CHEMBL619152,81034,,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,F,1,N,1,,BAO_0000219
4606,,,9606.0,Intermediate,Homo sapiens,17270,CHEMBL619153,81034,,478.0,,In vitro cytotoxicity against A2780ADR cell line,,F,1,N,1,,BAO_0000219
4607,,,9606.0,Intermediate,Homo sapiens,17270,CHEMBL619154,81034,,478.0,,In vitro cytotoxicity against A2780CIS cell line,,F,1,N,1,,BAO_0000219
4608,,,9606.0,Intermediate,Homo sapiens,5574,CHEMBL619155,81034,,478.0,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,F,1,N,1,,BAO_0000219
4609,,,9606.0,Intermediate,Homo sapiens,2113,CHEMBL619156,81034,,478.0,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,F,1,N,1,,BAO_0000219
4610,,,9606.0,Intermediate,Homo sapiens,16913,CHEMBL619157,81034,,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,F,1,N,1,,BAO_0000219
4611,,,9606.0,Intermediate,Homo sapiens,16913,CHEMBL619797,81034,,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,F,1,N,1,,BAO_0000219
4612,,,9544.0,Autocuration,Macaca mulatta,17839,CHEMBL619798,22224,,,,Oral bioavailability of compound in rhesus macaques,,A,1,U,0,,BAO_0000218
4613,,,9443.0,Autocuration,monkey,6821,CHEMBL619799,22224,,,,Oral bioavailability in monkey,,A,1,U,0,,BAO_0000218
4614,,,9443.0,Autocuration,monkey,6078,CHEMBL619800,22224,,,,Oral bioavailability evaluated in monkey,,A,1,U,0,,BAO_0000218
4615,,,9443.0,Autocuration,monkey,6535,CHEMBL619801,22224,,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,A,1,U,0,,BAO_0000218
4616,,,9544.0,Autocuration,Macaca mulatta,4449,CHEMBL619802,22224,,,,Oral bioavailability in Rhesus monkey,,A,1,U,0,,BAO_0000218
4617,,,9544.0,Autocuration,Macaca mulatta,6057,CHEMBL619803,22224,,,,Oral bioavailability was calculated in rhesus monkey,,A,1,U,0,,BAO_0000218
4618,,,9541.0,Autocuration,Macaca fascicularis,5922,CHEMBL619965,22224,,,,Oral bioavailability in cynomolgus monkey,,A,1,U,0,,BAO_0000218
4619,,,9443.0,Autocuration,monkey,5940,CHEMBL619966,22224,,,,Oral bioavailability in monkey,,A,1,U,0,,BAO_0000218
4620,,,9443.0,Autocuration,monkey,6265,CHEMBL619967,22224,,,,Oral bioavailability in monkey,,A,1,U,0,,BAO_0000218
4621,,,9443.0,Autocuration,monkey,6265,CHEMBL620073,22224,,,,Oral bioavailability in monkey (dose 1 mg/kg),,A,1,U,0,,BAO_0000218
4622,,,9443.0,Autocuration,monkey,6265,CHEMBL620074,22224,,,,Oral bioavailability in monkey (dose 5 mg/kg),,A,1,U,0,,BAO_0000218
4623,,,9443.0,Autocuration,monkey,5940,CHEMBL620075,22224,,,,Oral bioavailability in monkey,,A,1,U,0,,BAO_0000218
4624,,,9443.0,Autocuration,monkey,5940,CHEMBL620076,22224,,,,Oral bioavailability in monkey,,A,1,U,0,,BAO_0000218
4625,,,9544.0,Autocuration,Macaca mulatta,4514,CHEMBL620077,22224,,,,Oral bioavailability in rhesus monkey,,A,1,U,0,,BAO_0000218
4626,,,9544.0,Autocuration,Macaca mulatta,5546,CHEMBL620078,22224,,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,A,1,U,0,,BAO_0000218
4627,,,9521.0,Autocuration,Saimiri sciureus,5553,CHEMBL620079,22224,,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,A,1,U,0,,BAO_0000218
4628,,,9443.0,Autocuration,monkey,6641,CHEMBL620080,22224,,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,U,0,,BAO_0000218
4629,,,9544.0,Autocuration,Macaca mulatta,5472,CHEMBL620081,22224,,,,Oral bioavailability in Rhesus monkey,,A,1,U,0,,BAO_0000218
4630,,,9544.0,Autocuration,Macaca mulatta,5668,CHEMBL620082,22224,,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,A,1,U,0,,BAO_0000218
4631,,,9443.0,Autocuration,monkey,5711,CHEMBL620083,22224,,,,Oral bioavailability in monkey at 10 mg/kg of the compound,,A,1,U,0,,BAO_0000218
4632,,,9544.0,Autocuration,Macaca mulatta,5145,CHEMBL620084,22224,,,,Bioavailability in Rhesus monkey,,A,1,U,0,,BAO_0000218
4633,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL620085,22224,,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4634,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL874595,22224,,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4635,,,9527.0,Autocuration,Cercopithecidae,3249,CHEMBL873352,22224,,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,A,1,U,0,,BAO_0000218
4636,,,9527.0,Autocuration,Cercopithecidae,3249,CHEMBL620086,22224,,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,A,1,U,0,,BAO_0000218
4637,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL620087,22224,,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000218
4638,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL620088,22224,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,A,1,U,0,,BAO_0000218
4639,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL620089,22224,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,A,1,U,0,,BAO_0000218
4640,,,9527.0,Autocuration,Cercopithecidae,4809,CHEMBL620090,22224,,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,A,1,U,0,,BAO_0000218
4641,,,9527.0,Autocuration,Cercopithecidae,4809,CHEMBL620091,22224,,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,A,1,U,0,,BAO_0000218
4642,Microsomes,,9527.0,Autocuration,Cercopithecidae,14294,CHEMBL620092,22224,,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,A,1,U,0,,BAO_0000251
4643,Microsomes,,9527.0,Autocuration,Cercopithecidae,14294,CHEMBL620093,22224,,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,A,1,U,0,,BAO_0000251
4644,Microsomes,,9527.0,Autocuration,Cercopithecidae,14294,CHEMBL620094,22224,,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,A,1,U,0,,BAO_0000251
4645,Microsomes,,9527.0,Autocuration,Cercopithecidae,14294,CHEMBL620095,22224,,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,A,1,U,0,,BAO_0000251
4646,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL620096,22224,,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4647,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL620097,22224,,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4648,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL620098,22224,,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,A,1,U,0,,BAO_0000019
4649,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL620099,22224,,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4650,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL620100,22224,,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4651,,,9527.0,Autocuration,Cercopithecidae,6821,CHEMBL620101,22224,,,,Elimination Half-life of compound was determined in monkey,,A,1,U,0,,BAO_0000019
4652,,,9527.0,Autocuration,Cercopithecidae,17267,CHEMBL620102,22224,,,,Half life of compound was determined in rhesus monkey,,A,1,U,0,,BAO_0000019
4653,,1969.0,9527.0,Autocuration,Cercopithecidae,5819,CHEMBL620103,22224,,,Plasma,Half life in monkey plasma,,A,1,U,0,,BAO_0000366
4654,,1969.0,9527.0,Autocuration,Cercopithecidae,5819,CHEMBL620104,22224,,,Plasma,Half life in monkey plasma; Not detected,,A,1,U,0,,BAO_0000366
4655,,,9527.0,Autocuration,Cercopithecidae,1916,CHEMBL874596,22224,,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,A,1,U,0,,BAO_0000218
4656,,,9527.0,Autocuration,Cercopithecidae,17509,CHEMBL873490,22224,,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,A,1,U,0,,BAO_0000218
4657,,,9527.0,Autocuration,Cercopithecidae,1399,CHEMBL620105,22224,,,,Terminal half life of the compound.,,A,1,U,0,,BAO_0000019
4658,,,9527.0,Autocuration,Cercopithecidae,1916,CHEMBL620780,22224,,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,A,1,U,0,,BAO_0000218
4659,,,9527.0,Autocuration,Cercopithecidae,4809,CHEMBL620781,22224,,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,A,1,U,0,,BAO_0000218
4660,,,9527.0,Autocuration,Cercopithecidae,5546,CHEMBL620956,22224,,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,A,1,U,0,,BAO_0000218
4661,,1088.0,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL620957,22224,,,Urine,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4662,,1088.0,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL620958,22224,,,Urine,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4663,,,9527.0,Autocuration,Cercopithecidae,4257,CHEMBL620959,22224,,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,A,1,U,0,,BAO_0000218
4664,,,9527.0,Autocuration,Cercopithecidae,6221,CHEMBL620960,22224,,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,A,1,U,0,,BAO_0000218
4665,,,9527.0,Autocuration,Cercopithecidae,5472,CHEMBL620961,22224,,,,Volume of distribution was evaluated in rhesus,,A,1,U,0,,BAO_0000218
4666,,,10029.0,Autocuration,Cricetulus griseus,4727,CHEMBL620962,22224,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,A,1,U,0,,BAO_0000218
4667,,,10029.0,Autocuration,Cricetulus griseus,4727,CHEMBL620963,22224,,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,A,1,U,0,,BAO_0000218
4668,,,10029.0,Autocuration,Cricetulus griseus,4727,CHEMBL620964,22224,,,,Bioavailability in hamster was determined,,A,1,U,0,,BAO_0000218
4669,,,10029.0,Autocuration,Cricetulus griseus,4727,CHEMBL620965,22224,,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,A,1,U,0,,BAO_0000218
4670,,,10029.0,Autocuration,Cricetulus griseus,4727,CHEMBL620966,22224,,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,A,1,U,0,,BAO_0000218
4671,,178.0,10029.0,Autocuration,Cricetulus griseus,4727,CHEMBL620967,22224,,,Blood,Half life of compound was determined in hamster blood,,A,1,U,0,,BAO_0000221
4672,,,9823.0,Autocuration,Sus scrofa,1452,CHEMBL620968,22224,,,,Michaelis-Menten constant of the compound.,,A,1,U,0,,BAO_0000019
4673,,,9823.0,Autocuration,Sus scrofa,1452,CHEMBL874597,22224,,,,Vmax value was measured at 0 uM concentration of silyl ether.,,A,1,U,0,,BAO_0000019
4674,,,9823.0,Autocuration,Sus scrofa,1452,CHEMBL620969,22224,,,,Vmax value was measured at 10 uM concentration of silyl ether.,,A,1,U,0,,BAO_0000019
4675,,,9823.0,Autocuration,Sus scrofa,1452,CHEMBL620970,22224,,,,Vmax value was measured at 5 uM concentration of silyl ether.,,A,1,U,0,,BAO_0000019
4676,,,9606.0,Expert,Homo sapiens,11706,CHEMBL620971,235,,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,B,1,D,9,,BAO_0000357
4677,,,9606.0,Autocuration,Homo sapiens,1916,CHEMBL620972,22224,,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,A,1,U,0,,BAO_0000218
4678,,,9606.0,Autocuration,Homo sapiens,17791,CHEMBL620973,22224,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,A,1,U,0,,BAO_0000019
4679,,,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618243,22224,,,,Active metabolite of ifosfamide determined in humans; A-Active,,A,1,U,0,,BAO_0000019
4680,,,9606.0,Autocuration,Homo sapiens,6567,CHEMBL618244,22224,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,A,1,U,0,,BAO_0000019
4681,,,9606.0,Autocuration,Homo sapiens,6567,CHEMBL618245,22224,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,A,1,U,0,,BAO_0000019
4682,,,9606.0,Autocuration,Homo sapiens,6567,CHEMBL618246,22224,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,A,1,U,0,,BAO_0000019
4683,,,9606.0,Autocuration,Homo sapiens,6567,CHEMBL618247,22224,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,A,1,U,0,,BAO_0000019
4684,,,9606.0,Autocuration,Homo sapiens,17791,CHEMBL618248,22224,,,,Compound was evaluated for oral bioavailability in human,,A,1,U,0,,BAO_0000218
4685,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618249,22224,,,Urine,Metabolite of ifosfamide determined in urine; NF-Not found,,A,1,U,0,,BAO_0000019
4686,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL618250,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,A,1,U,0,,BAO_0000019
4687,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL874598,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,A,1,U,0,,BAO_0000019
4688,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL618251,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,A,1,U,0,,BAO_0000019
4689,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL618252,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,A,1,U,0,,BAO_0000019
4690,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL618253,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,A,1,U,0,,BAO_0000019
4691,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL618254,22224,,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,A,1,U,0,,BAO_0000019
4692,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL618255,22224,,,,Percent of compound in healthy individuals (Group D),,A,1,U,0,,BAO_0000019
4693,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,4397,CHEMBL618983,22224,,,Liver,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,A,1,U,0,,BAO_0000251
4694,,,9606.0,Autocuration,Homo sapiens,17409,CHEMBL618984,22224,,,,Binding towards human plasma protein at 10 uM,,A,1,U,0,,BAO_0000019
4695,,,9606.0,Autocuration,Homo sapiens,17409,CHEMBL618985,22224,,,,Binding towards human plasma protein at 100 uM,,A,1,U,0,,BAO_0000019
4696,,,9606.0,Autocuration,Homo sapiens,17176,CHEMBL618986,22224,,,,Human plasma protein binding activity was determined,,A,1,U,0,,BAO_0000019
4697,,,9606.0,Autocuration,Homo sapiens,15444,CHEMBL618987,22224,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,A,1,U,0,,BAO_0000019
4698,,,9606.0,Autocuration,Homo sapiens,17267,CHEMBL618988,22224,,,,Percent binding of compound towards human plasma protein was determined,,A,1,U,0,,BAO_0000019
4699,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5944,CHEMBL618989,22224,,,Liver,Plasma clearance in human liver microsomes,,A,1,U,0,,BAO_0000251
4700,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5668,CHEMBL618990,22224,,,Liver,In vitro intrinsic clearance in human liver microsome,,A,1,U,0,,BAO_0000251
4701,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5669,CHEMBL618991,22224,,,Liver,In vitro intrinsic clearance in human liver microsome,,A,1,U,0,,BAO_0000251
4702,Microsomes,,9606.0,Autocuration,Homo sapiens,5041,CHEMBL876725,22224,,,,In vitro microsome metabolism clearance in human was determined,,A,1,U,0,,BAO_0000251
4703,Microsomes,,9606.0,Autocuration,Homo sapiens,5041,CHEMBL618992,22224,,,,In vitro microsome metabolism clearance in human was determined; High,,A,1,U,0,,BAO_0000251
4704,Microsomes,,9606.0,Autocuration,Homo sapiens,5041,CHEMBL618993,22224,,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,A,1,U,0,,BAO_0000251
4705,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5676,CHEMBL618994,22224,,,Liver,Pharmacokinetic property (clearance) in human liver microsome,,A,1,U,0,,BAO_0000251
4706,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5944,CHEMBL618995,22224,,,Liver,Plasma clearance in human liver microsomes,,A,1,U,0,,BAO_0000251
4707,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,17538,CHEMBL618996,22224,,,Liver,In vitro clearance in human liver microsomes,,A,1,U,0,,BAO_0000251
4708,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,6331,CHEMBL618997,22224,,,Liver,Intrinsic clearance in human liver microsomes was determined,,A,1,U,0,,BAO_0000251
4709,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5948,CHEMBL618998,22224,,,Liver,Intrinsic clearance in human liver microsomes was determined,,A,1,U,0,,BAO_0000251
4710,,,9606.0,Autocuration,Homo sapiens,5965,CHEMBL618999,22224,,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,A,1,U,0,,BAO_0000218
4711,,,9606.0,Autocuration,Homo sapiens,1916,CHEMBL620223,22224,,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,A,1,U,0,,BAO_0000218
4712,,,9606.0,Autocuration,Homo sapiens,5965,CHEMBL620224,22224,,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,A,1,U,0,,BAO_0000218
4713,,,9606.0,Autocuration,Homo sapiens,1299,CHEMBL620225,22224,,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,A,1,U,0,,BAO_0000019
4714,,,9606.0,Autocuration,Homo sapiens,1299,CHEMBL620226,22224,,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,A,1,U,0,,BAO_0000019
4715,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL620227,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,A,1,U,0,,BAO_0000019
4716,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL876726,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,A,1,U,0,,BAO_0000019
4717,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL620228,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,A,1,U,0,,BAO_0000019
4718,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL620229,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,A,1,U,0,,BAO_0000019
4719,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620230,50594,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,F,1,N,1,,BAO_0000218
4720,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620231,50594,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,F,1,N,1,,BAO_0000218
4721,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620232,50594,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,F,1,N,1,,BAO_0000218
4722,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620233,50594,,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,F,1,N,1,,BAO_0000218
4723,,,10090.0,Intermediate,Mus musculus,14294,CHEMBL620234,50594,,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,A,1,N,1,,BAO_0000218
4724,,,10090.0,Intermediate,Mus musculus,14294,CHEMBL620235,50594,,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,A,1,N,1,,BAO_0000218
4725,,,10090.0,Intermediate,Mus musculus,14294,CHEMBL620236,50594,,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,A,1,N,1,,BAO_0000218
4726,,2107.0,10090.0,Intermediate,Mus musculus,6251,CHEMBL620237,50594,,,Liver,In vitro metabolic potential in mouse liver microsomes,,A,1,N,1,,BAO_0000218
4727,,,10090.0,Intermediate,Mus musculus,17582,CHEMBL620238,50594,,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,A,1,N,1,,BAO_0000218
4728,,2369.0,10090.0,Intermediate,Mus musculus,17811,CHEMBL620239,50594,,,Adrenal gland,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,A,1,N,1,,BAO_0000218
4729,,955.0,10090.0,Intermediate,Mus musculus,17811,CHEMBL620240,50594,,,Brain,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,A,1,N,1,,BAO_0000218
4730,,955.0,10090.0,Intermediate,Mus musculus,17811,CHEMBL620241,50594,,,Brain,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,A,1,N,1,,BAO_0000218
4731,,,10090.0,Intermediate,Mus musculus,17811,CHEMBL876727,50594,,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,A,1,N,1,,BAO_0000218
4732,,2113.0,10090.0,Intermediate,Mus musculus,17811,CHEMBL620242,50594,,,Kidney,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,A,1,N,1,,BAO_0000218
4733,,,10090.0,Intermediate,Mus musculus,17811,CHEMBL620243,50594,,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,A,1,N,1,,BAO_0000218
4734,,,10090.0,Intermediate,Mus musculus,5288,CHEMBL620244,50594,,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,A,1,N,1,,BAO_0000218
4735,,1977.0,10090.0,Intermediate,Mus musculus,2717,CHEMBL620245,50594,,,Serum,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,A,1,N,1,,BAO_0000218
4736,,1977.0,10090.0,Intermediate,Mus musculus,2717,CHEMBL620246,50594,,,Serum,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,A,1,N,1,,BAO_0000218
4737,,1977.0,10090.0,Intermediate,Mus musculus,2717,CHEMBL620247,50594,,,Serum,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,A,1,N,1,,BAO_0000218
4738,,1969.0,10090.0,Intermediate,Mus musculus,17753,CHEMBL620248,50594,,,Plasma,Half life of compound was determined in plasma of mice at 24 mg/Kg,,A,1,N,1,,BAO_0000218
4739,,1969.0,10090.0,Intermediate,Mus musculus,17753,CHEMBL873497,50594,,,Plasma,Half life of compound was determined in plasma of mice at 40 mg/Kg,,A,1,N,1,,BAO_0000218
4740,,1969.0,10090.0,Intermediate,Mus musculus,17753,CHEMBL620249,50594,,,Plasma,Half life of compound was determined in plasma of mice at 5 mg/Kg,,A,1,N,1,,BAO_0000218
4741,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620250,50594,,,,Half life after intraperitoneal administration in mice at 18 uM/kg,,F,1,N,1,,BAO_0000218
4742,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620251,50594,,,,Half life after intraperitoneal administration in mice at 23 uM/kg,,F,1,N,1,,BAO_0000218
4743,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620252,50594,,,,Half life after intraperitoneal administration in mice at 25 uM/kg,,F,1,N,1,,BAO_0000218
4744,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620253,50594,,,,Half life after intraperitoneal administration in mice at 26 uM/kg,,F,1,N,1,,BAO_0000218
4745,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620254,50594,,,,Half life after intravenous administration in mice at 23 uM/kg,,F,1,N,1,,BAO_0000218
4746,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620255,50594,,,,Half life after intravenous administration in mice at 24 uM/kg,,A,1,N,1,,BAO_0000218
4747,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL620256,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,A,1,N,1,,BAO_0000218
4748,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL876728,50594,,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,A,1,N,1,,BAO_0000218
4749,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL620257,50594,,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,A,1,N,1,,BAO_0000218
4750,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL620258,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,A,1,N,1,,BAO_0000218
4751,,,10090.0,Intermediate,Mus musculus,4890,CHEMBL620259,50594,,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,A,1,N,1,,BAO_0000218
4752,,,10090.0,Intermediate,Mus musculus,429,CHEMBL620260,50594,,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,A,1,N,1,,BAO_0000218
4753,,178.0,10090.0,Intermediate,Mus musculus,17837,CHEMBL620261,50594,,,Blood,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,A,1,N,1,,BAO_0000218
4754,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL620262,50594,,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,A,1,N,1,,BAO_0000218
4755,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL620263,50594,,,,Half life at a dose of 10 mg/kg peroral administration in mice.,,A,1,N,1,,BAO_0000218
4756,,,10090.0,Intermediate,Mus musculus,6619,CHEMBL620264,50594,,,,Half life in ob/ob mice,,A,1,N,1,,BAO_0000218
4757,,,10090.0,Intermediate,Mus musculus,4066,CHEMBL620265,50594,,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,A,1,N,1,,BAO_0000218
4758,,,10090.0,Intermediate,Mus musculus,4239,CHEMBL620266,50594,,,,Half-life was measured in mouse,,A,1,N,1,,BAO_0000218
4759,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL620267,50594,,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4760,,,10090.0,Intermediate,Mus musculus,8999,CHEMBL619364,50594,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,A,1,N,1,,BAO_0000218
4761,,,10090.0,Intermediate,Mus musculus,8999,CHEMBL619365,50594,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,A,1,N,1,,BAO_0000218
4762,,955.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL619366,50594,,,Brain,T2 in brain of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4763,,2113.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL619367,50594,,,Kidney,T2 in kidney of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4764,,2107.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL619368,50594,,,Liver,T2 in liver of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4765,,2048.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL619369,50594,,,Lung,T2 in lungs of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4766,,2106.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL876729,50594,,,Spleen,T2 in spleen of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4767,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL619370,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,A,1,N,1,,BAO_0000218
4768,,,10090.0,Intermediate,Mus musculus,4890,CHEMBL619371,50594,,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,A,1,N,1,,BAO_0000218
4769,,,10090.0,Intermediate,Mus musculus,429,CHEMBL619372,50594,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,A,1,N,1,,BAO_0000218
4770,,,10090.0,Intermediate,Mus musculus,429,CHEMBL620012,50594,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,A,1,N,1,,BAO_0000218
4771,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL620013,50594,,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,A,1,N,1,,BAO_0000218
4772,,,9606.0,Intermediate,Homo sapiens,16913,CHEMBL620014,81034,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,F,1,N,1,,BAO_0000219
4773,,,9606.0,Intermediate,Homo sapiens,16913,CHEMBL620015,81034,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,F,1,N,1,,BAO_0000219
4774,,,9606.0,Intermediate,Homo sapiens,16913,CHEMBL621010,81034,,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,F,1,N,1,,BAO_0000219
4775,,,9606.0,Intermediate,Homo sapiens,16913,CHEMBL621011,81034,,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,F,1,N,1,,BAO_0000219
4776,,,9606.0,Intermediate,Homo sapiens,16913,CHEMBL621012,81034,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,F,1,N,1,,BAO_0000219
4777,,,9606.0,Intermediate,Homo sapiens,16913,CHEMBL621013,81034,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,F,1,N,1,,BAO_0000219
4778,,,9606.0,Intermediate,Homo sapiens,17270,CHEMBL621014,81034,,478.0,,In vitro cytotoxicity against A2780TAX cell line,,F,1,N,1,,BAO_0000219
4779,,,9606.0,Intermediate,Homo sapiens,5618,CHEMBL618154,80017,,481.0,,In vitro inhibitory activity against human tumor cell line A2780cis,,F,1,N,1,,BAO_0000219
4780,,,9606.0,Expert,Homo sapiens,17777,CHEMBL618155,81034,,478.0,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,F,1,N,1,,BAO_0000219
4781,,,9606.0,Intermediate,Homo sapiens,16112,CHEMBL618156,80017,,481.0,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,F,1,N,1,,BAO_0000219
4782,,,9606.0,Intermediate,Homo sapiens,15748,CHEMBL618157,80017,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,F,1,N,1,,BAO_0000219
4783,,,9606.0,Intermediate,Homo sapiens,6633,CHEMBL618328,81034,,478.0,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,F,1,N,1,,BAO_0000219
4784,,,9606.0,Intermediate,Homo sapiens,16930,CHEMBL618329,81034,,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,F,1,N,1,,BAO_0000219
4785,,,9606.0,Intermediate,Homo sapiens,17496,CHEMBL618330,81034,,478.0,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,F,1,N,1,,BAO_0000219
4786,,,9606.0,Expert,Homo sapiens,12989,CHEMBL618331,81034,,478.0,,In vitro antitumor activity against A2780cisR cell line.,,F,1,N,1,,BAO_0000219
4787,,,9606.0,Intermediate,Homo sapiens,4840,CHEMBL618332,81034,,478.0,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,F,1,N,1,,BAO_0000219
4788,,,9606.0,Expert,Homo sapiens,12989,CHEMBL618333,81034,,478.0,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,F,1,N,1,,BAO_0000219
4789,,,9606.0,Intermediate,Homo sapiens,16745,CHEMBL618334,80017,,481.0,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,F,1,N,1,,BAO_0000219
4790,,,9606.0,Expert,Homo sapiens,16597,CHEMBL618335,81034,,478.0,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,F,1,N,1,,BAO_0000219
4791,,,10116.0,Expert,Rattus norvegicus,16547,CHEMBL618336,11736,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,B,1,D,9,,BAO_0000019
4792,,,,Expert,,16547,CHEMBL618337,11736,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,F,1,H,8,,BAO_0000019
4793,,,10116.0,Expert,Rattus norvegicus,16547,CHEMBL618338,11736,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,F,1,D,9,,BAO_0000019
4794,,,9606.0,Expert,Homo sapiens,15856,CHEMBL618339,278,,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,F,1,D,9,,BAO_0000219
4795,,,9606.0,Expert,Homo sapiens,15856,CHEMBL618340,278,,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,F,1,D,9,,BAO_0000219
4796,,,10090.0,Expert,Mus musculus,16547,CHEMBL618341,11831,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,B,1,D,9,,BAO_0000019
4797,,,,Expert,,16547,CHEMBL618342,11831,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,F,1,H,8,,BAO_0000019
4798,,,10090.0,Expert,Mus musculus,16547,CHEMBL618343,11831,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,F,1,D,9,,BAO_0000019
4799,,,,Expert,,17402,CHEMBL621038,280,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,B,1,H,8,,BAO_0000357
4800,,,9606.0,Autocuration,Homo sapiens,11746,CHEMBL621039,22226,,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,F,1,U,0,,BAO_0000219
4801,,,9606.0,Autocuration,Homo sapiens,11746,CHEMBL621040,22226,,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,F,1,U,0,,BAO_0000219
4802,,,9606.0,Intermediate,Homo sapiens,5455,CHEMBL621041,80018,,455.0,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,F,1,N,1,,BAO_0000219
4803,,,9606.0,Intermediate,Homo sapiens,2068,CHEMBL621042,80018,,455.0,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,F,1,N,1,,BAO_0000219
4804,,,9606.0,Intermediate,Homo sapiens,2683,CHEMBL621043,80018,,455.0,,In vitro antitumor activity against A375cell line extracted form melanoma,,F,1,N,1,,BAO_0000219
4805,,,9606.0,Expert,Homo sapiens,15313,CHEMBL621044,80018,,455.0,,Inhibition of cell growth in (A375) melan cell line,,F,1,N,1,,BAO_0000219
4806,,,9606.0,Intermediate,Homo sapiens,13739,CHEMBL621045,80018,,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,F,1,N,1,,BAO_0000219
4807,,,9606.0,Intermediate,Homo sapiens,13739,CHEMBL621046,80018,,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,F,1,N,1,,BAO_0000219
4808,,,9606.0,Intermediate,Homo sapiens,14750,CHEMBL621047,80018,,455.0,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,F,1,N,1,,BAO_0000219
4809,,,9606.0,Intermediate,Homo sapiens,14777,CHEMBL621048,80019,,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,,F,1,N,1,,BAO_0000219
4810,,,9606.0,Intermediate,Homo sapiens,14777,CHEMBL883798,80019,,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,,F,1,N,1,,BAO_0000219
4811,,,9606.0,Intermediate,Homo sapiens,17672,CHEMBL621049,80019,,797.0,,Cytotoxicity against lung carcinoma A427 tumor cell lines,,F,1,N,1,,BAO_0000219
4812,,,9606.0,Intermediate,Homo sapiens,14368,CHEMBL621050,80019,,797.0,,Inhibition of large cell lung carcinoma (A427),,F,1,N,1,,BAO_0000219
4813,,,9606.0,Intermediate,Homo sapiens,14368,CHEMBL621051,80019,,797.0,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,F,1,N,1,,BAO_0000219
4814,,,9606.0,Intermediate,Homo sapiens,13866,CHEMBL621052,80019,,797.0,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,F,1,N,1,,BAO_0000219
4815,,,9606.0,Intermediate,Homo sapiens,2545,CHEMBL621053,80019,,797.0,,Inhibitory concentration in human lung carcinoma A427 cell line,,F,1,N,1,,BAO_0000219
4816,,,9606.0,Intermediate,Homo sapiens,2545,CHEMBL621054,80019,,797.0,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,F,1,N,1,,BAO_0000219
4817,,,9527.0,Autocuration,Cercopithecidae,6062,CHEMBL621055,22224,,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
4818,,,9527.0,Autocuration,Cercopithecidae,4578,CHEMBL876398,22224,,,,Tested for volume of distribution upon iv administration to african green monkey,,A,1,U,0,,BAO_0000218
4819,,,9527.0,Autocuration,Cercopithecidae,17592,CHEMBL621056,22224,,,,Volume of distribution in monkey,,A,1,U,0,,BAO_0000218
4820,,,9544.0,Autocuration,Macaca mulatta,5005,CHEMBL621057,22224,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,A,1,U,0,,BAO_0000218
4821,,,9544.0,Autocuration,Macaca mulatta,5005,CHEMBL621058,22224,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,A,1,U,0,,BAO_0000218
4822,,,9527.0,Autocuration,Cercopithecidae,5922,CHEMBL621059,22224,,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,A,1,U,0,,BAO_0000218
4823,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL621060,22224,,,,The distribution volume after intravenous administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000218
4824,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL621061,22224,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,A,1,U,0,,BAO_0000218
4825,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL621062,22224,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,A,1,U,0,,BAO_0000218
4826,,,9527.0,Autocuration,Cercopithecidae,6057,CHEMBL621063,22224,,,,Volume displacement was calculated in rhesus monkey,,A,1,U,0,,BAO_0000218
4827,,,9527.0,Autocuration,Cercopithecidae,5145,CHEMBL621064,22224,,,,Volume of distribution in steady state was determined in rhesus monkey,,A,1,U,0,,BAO_0000218
4828,,,9527.0,Autocuration,Cercopithecidae,6821,CHEMBL621065,22224,,,,Volume of distribution of compound was determined in monkey,,A,1,U,0,,BAO_0000218
4829,,,9527.0,Autocuration,Cercopithecidae,5334,CHEMBL621066,22224,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,A,1,U,0,,BAO_0000218
4830,,,9527.0,Autocuration,Cercopithecidae,5334,CHEMBL621067,22224,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,A,1,U,0,,BAO_0000218
4831,,,9527.0,Autocuration,Cercopithecidae,6641,CHEMBL621068,22224,,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,U,0,,BAO_0000218
4832,,,9527.0,Autocuration,Cercopithecidae,2661,CHEMBL876399,22224,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,A,1,U,0,,BAO_0000218
4833,,,9527.0,Autocuration,Cercopithecidae,6535,CHEMBL621069,22224,,,,Volume distribution in monkey after administration of 1 mg/kg iv,,A,1,U,0,,BAO_0000218
4834,,,9527.0,Autocuration,Cercopithecidae,4809,CHEMBL621070,22224,,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,A,1,U,0,,BAO_0000218
4835,,,9527.0,Autocuration,Cercopithecidae,6062,CHEMBL621071,22224,,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
4836,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL621072,22224,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
4837,,,9527.0,Autocuration,Cercopithecidae,4578,CHEMBL618209,22224,,,,Oral systemic bioavailability upon iv administration to african green monkey,,A,1,U,0,,BAO_0000218
4838,,,9527.0,Autocuration,Cercopithecidae,4809,CHEMBL618210,22224,,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,A,1,U,0,,BAO_0000218
4839,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL618211,22224,,,,Baboon plasma free fraction. ,,A,1,U,0,,BAO_0000019
4840,,,9527.0,Autocuration,Cercopithecidae,6057,CHEMBL618212,22224,,,,Area under the curve was calculated in rhesus monkey after iv administration,,A,1,U,0,,BAO_0000218
4841,,,9527.0,Autocuration,Cercopithecidae,6057,CHEMBL618213,22224,,,,Area under the curve was calculated in rhesus monkey after peroral administration,,A,1,U,0,,BAO_0000019
4842,,,9527.0,Autocuration,Cercopithecidae,17853,CHEMBL618214,22224,,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,A,1,U,0,,BAO_0000019
4843,,,9527.0,Autocuration,Cercopithecidae,5302,CHEMBL873492,22224,,,,Half life period in monkey after 5 mg/kg dose,,A,1,U,0,,BAO_0000218
4844,,,9527.0,Autocuration,Cercopithecidae,4257,CHEMBL618272,22224,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,A,1,U,0,,BAO_0000218
4845,,,9527.0,Autocuration,Cercopithecidae,4257,CHEMBL618273,22224,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,A,1,U,0,,BAO_0000218
4846,,1969.0,9527.0,Autocuration,Cercopithecidae,13501,CHEMBL618274,22224,,,Plasma,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,A,1,U,0,,BAO_0000218
4847,,,9527.0,Autocuration,Cercopithecidae,5394,CHEMBL618275,22224,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,A,1,U,0,,BAO_0000218
4848,,,9527.0,Autocuration,Cercopithecidae,2661,CHEMBL618276,22224,,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,A,1,U,0,,BAO_0000218
4849,,,9527.0,Autocuration,Cercopithecidae,3341,CHEMBL618277,22224,,,,Compound was evaluated for terminal half life in monkey,,A,1,U,0,,BAO_0000019
4850,,,9527.0,Autocuration,Cercopithecidae,3045,CHEMBL618278,22224,,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,A,1,U,0,,BAO_0000218
4851,,1969.0,9544.0,Autocuration,Macaca mulatta,5005,CHEMBL618279,22224,,,Plasma,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,A,1,U,0,,BAO_0000218
4852,,,9527.0,Autocuration,Cercopithecidae,4847,CHEMBL618280,22224,,,,Half life of compound was determined in squirrel monkey,,A,1,U,0,,BAO_0000019
4853,,,9541.0,Autocuration,Macaca fascicularis,4256,CHEMBL618281,22224,,,,Half life after iv administration in cynomolgus monkey,,A,1,U,0,,BAO_0000218
4854,,1969.0,9527.0,Autocuration,Cercopithecidae,6535,CHEMBL618282,22224,,,Plasma,Half life in monkey plasma after administration of 1 mg/kg iv,,A,1,U,0,,BAO_0000218
4855,,,9527.0,Autocuration,Cercopithecidae,6057,CHEMBL618283,22224,,,,Half life was calculated in rhesus monkey,,A,1,U,0,,BAO_0000019
4856,,,9527.0,Autocuration,Cercopithecidae,17592,CHEMBL618284,22224,,,,Half life in monkey,,A,1,U,0,,BAO_0000019
4857,,,9527.0,Autocuration,Cercopithecidae,6641,CHEMBL618285,22224,,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,U,0,,BAO_0000218
4858,,,9527.0,Autocuration,Cercopithecidae,5472,CHEMBL618286,22224,,,,Half life was evaluated in rhesus,,A,1,U,0,,BAO_0000019
4859,,,9527.0,Autocuration,Cercopithecidae,6221,CHEMBL618287,22224,,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,A,1,U,0,,BAO_0000218
4860,,,9527.0,Autocuration,Cercopithecidae,5668,CHEMBL618288,22224,,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,A,1,U,0,,BAO_0000218
4861,,,9527.0,Autocuration,Cercopithecidae,4809,CHEMBL876393,22224,,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,A,1,U,0,,BAO_0000218
4862,,,9527.0,Autocuration,Cercopithecidae,5546,CHEMBL618289,22224,,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,A,1,U,0,,BAO_0000218
4863,,,9527.0,Autocuration,Cercopithecidae,5553,CHEMBL618290,22224,,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,A,1,U,0,,BAO_0000218
4864,,,9527.0,Autocuration,Cercopithecidae,6078,CHEMBL618291,22224,,,,Half-life was calculated in monkey,,A,1,U,0,,BAO_0000019
4865,,,9527.0,Autocuration,Cercopithecidae,5147,CHEMBL618292,22224,,,,Half-life in Squirrel monkey,,A,1,U,0,,BAO_0000019
4866,,,9527.0,Autocuration,Cercopithecidae,5145,CHEMBL618293,22224,,,,Half-life in rhesus monkey,,A,1,U,0,,BAO_0000019
4867,,,9527.0,Autocuration,Cercopithecidae,6062,CHEMBL618294,22224,,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
4868,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL618295,22224,,,,Half-life period after intravenous administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000218
4869,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL618296,22224,,,,Half-life period after oral administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000218
4870,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL618297,22224,,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,A,1,U,0,,BAO_0000218
4871,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618298,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,A,1,U,0,,BAO_0000019
4872,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618299,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,A,1,U,0,,BAO_0000019
4873,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618300,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,A,1,U,0,,BAO_0000019
4874,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618301,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,A,1,U,0,,BAO_0000019
4875,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618302,22224,,,Urine,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,A,1,U,0,,BAO_0000019
4876,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL876394,22224,,,Urine,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,A,1,U,0,,BAO_0000019
4877,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618303,22224,,,Urine,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,A,1,U,0,,BAO_0000019
4878,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618304,22224,,,Urine,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,A,1,U,0,,BAO_0000019
4879,,,9606.0,Autocuration,Homo sapiens,1916,CHEMBL618305,22224,,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,A,1,U,0,,BAO_0000218
4880,,,9606.0,Autocuration,Homo sapiens,16643,CHEMBL618306,22224,,,,Oral bioavailability in human,,A,1,U,0,,BAO_0000218
4881,,,9606.0,Autocuration,Homo sapiens,17248,CHEMBL618307,22224,,,,Compound was tested for human plasma protein binding,,A,1,U,0,,BAO_0000019
4882,,,9606.0,Autocuration,Homo sapiens,17248,CHEMBL618308,22224,,,,Compound was tested for human plasma protein binding; Not determined,,A,1,U,0,,BAO_0000019
4883,,,9606.0,Autocuration,Homo sapiens,6241,CHEMBL618309,22224,,,,Protein binding activity of compound in human plasma; % Free,,A,1,U,0,,BAO_0000019
4884,,,9606.0,Autocuration,Homo sapiens,17716,CHEMBL618310,22224,,,,Unbound fraction (plasma),,A,1,U,0,,BAO_0000019
4885,,1969.0,9606.0,Autocuration,Homo sapiens,17605,CHEMBL873353,22224,,,Plasma,Half life for the hydrolysis of compound in human blood serum,,A,1,U,0,,BAO_0000366
4886,,1969.0,9606.0,Autocuration,Homo sapiens,17625,CHEMBL618311,22224,,,Plasma,Half life period in human plasma using phosphate buffer (0.08 M),,A,1,U,0,,BAO_0000366
4887,,1969.0,9606.0,Autocuration,Homo sapiens,17625,CHEMBL618312,22224,,,Plasma,Half life period in human plasma using phosphate buffer (0.1 M),,A,1,U,0,,BAO_0000366
4888,,1969.0,9606.0,Autocuration,Homo sapiens,17747,CHEMBL618313,22224,,,Plasma,Half-life in human plasma was determined,,A,1,U,0,,BAO_0000366
4889,,,9606.0,Autocuration,Homo sapiens,15613,CHEMBL618314,22224,,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,A,1,U,0,,BAO_0000019
4890,,,9606.0,Autocuration,Homo sapiens,354,CHEMBL618315,22224,,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,A,1,U,0,,BAO_0000019
4891,,,9606.0,Autocuration,Homo sapiens,3741,CHEMBL618316,22224,,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,A,1,U,0,,BAO_0000019
4892,,,9606.0,Autocuration,Homo sapiens,3741,CHEMBL618317,22224,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,A,1,U,0,,BAO_0000019
4893,,,9606.0,Autocuration,Homo sapiens,3741,CHEMBL620138,22224,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,A,1,U,0,,BAO_0000019
4894,,,9606.0,Autocuration,Homo sapiens,17599,CHEMBL858280,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
4895,,,9606.0,Autocuration,Homo sapiens,5486,CHEMBL620139,22224,,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,A,1,U,0,,BAO_0000019
4896,Microsomes,,9606.0,Autocuration,Homo sapiens,5600,CHEMBL620140,22224,,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,A,1,U,0,,BAO_0000251
4897,,,9606.0,Autocuration,Homo sapiens,14294,CHEMBL620141,22224,,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,A,1,U,0,,BAO_0000019
4898,,,9606.0,Autocuration,Homo sapiens,14294,CHEMBL620142,22224,,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,A,1,U,0,,BAO_0000019
4899,,,9606.0,Autocuration,Homo sapiens,14294,CHEMBL620143,22224,,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,A,1,U,0,,BAO_0000019
4900,Microsomes,,9606.0,Autocuration,Homo sapiens,14294,CHEMBL620144,22224,,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,A,1,U,0,,BAO_0000251
4901,Microsomes,,9606.0,Autocuration,Homo sapiens,14294,CHEMBL620145,22224,,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,A,1,U,0,,BAO_0000251
4902,Microsomes,,9606.0,Autocuration,Homo sapiens,14294,CHEMBL620146,22224,,,,Metabolism of compound in human microsomes; Trace,,A,1,U,0,,BAO_0000251
4903,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,6260,CHEMBL620147,22224,,,Liver,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,A,1,U,0,,BAO_0000251
4904,Microsomes,,9606.0,Autocuration,Homo sapiens,6187,CHEMBL620148,22224,,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,A,1,U,0,,BAO_0000251
4905,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,6251,CHEMBL620149,22224,,,Liver,In vitro metabolic potential in human liver microsomes,,A,1,U,0,,BAO_0000251
4906,,,9606.0,Autocuration,Homo sapiens,3246,CHEMBL876412,22224,,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,A,1,U,0,,BAO_0000019
4907,,,9606.0,Autocuration,Homo sapiens,17313,CHEMBL619352,22224,,,,Tested for human plasma protein binding of the compound; Not tested,,A,1,U,0,,BAO_0000019
4908,,,9606.0,Autocuration,Homo sapiens,6227,CHEMBL619353,22224,,,,Compound was tested for percent protein binding (PB) in human,,A,1,U,0,,BAO_0000019
4909,,1969.0,9606.0,Autocuration,Homo sapiens,5530,CHEMBL619354,22224,,,Plasma,Protein binding in human plasma,,A,1,U,0,,BAO_0000019
4910,,,9606.0,Autocuration,Homo sapiens,6108,CHEMBL619355,22224,,,,Permeability coefficient (B to A) in Caco-2 cell,,A,1,U,0,,BAO_0000019
4911,,,9606.0,Autocuration,Homo sapiens,6108,CHEMBL619356,22224,,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,A,1,U,0,,BAO_0000019
4912,,,9606.0,Autocuration,Homo sapiens,2774,CHEMBL619357,22224,,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,A,1,U,0,,BAO_0000019
4913,,,9606.0,Autocuration,Homo sapiens,16643,CHEMBL619358,22224,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,,A,1,U,0,,BAO_0000019
4914,,,9606.0,Autocuration,Homo sapiens,17582,CHEMBL619359,22224,,495.0,,Cellular permeability of compound was determined in Caco-2 cells; High,,A,1,U,0,,BAO_0000219
4915,,,9606.0,Autocuration,Homo sapiens,6838,CHEMBL619360,22224,,495.0,,Permeability in Caco-2 cells of compound,,A,1,U,0,,BAO_0000219
4916,,,9606.0,Autocuration,Homo sapiens,6108,CHEMBL619361,22224,,,,Permeability coefficient (A to B) in Caco-2 cell,,A,1,U,0,,BAO_0000019
4917,,,9606.0,Autocuration,Homo sapiens,6108,CHEMBL619362,22224,,,,Permeability coefficient (B to A) in Caco-2 cell,,A,1,U,0,,BAO_0000019
4918,,,9606.0,Autocuration,Homo sapiens,6108,CHEMBL619363,22224,,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,A,1,U,0,,BAO_0000019
4919,,,9606.0,Autocuration,Homo sapiens,2146,CHEMBL618942,22224,,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,A,1,U,0,,BAO_0000019
4920,,,9606.0,Autocuration,Homo sapiens,4514,CHEMBL618943,22224,,,,Compound was tested for protein binding in human plasma,,A,1,U,0,,BAO_0000019
4921,,,9606.0,Autocuration,Homo sapiens,6108,CHEMBL618944,22224,,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,A,1,U,0,,BAO_0000019
4922,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL618945,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,A,1,U,0,,BAO_0000019
4923,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL618946,50594,,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4924,,,10090.0,Intermediate,Mus musculus,3277,CHEMBL876413,50594,,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,A,1,N,1,,BAO_0000218
4925,,,10090.0,Intermediate,Mus musculus,3802,CHEMBL618947,50594,,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,A,1,N,1,,BAO_0000218
4926,,1969.0,10090.0,Intermediate,Mus musculus,2862,CHEMBL618948,50594,,,Plasma,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,A,1,N,1,,BAO_0000218
4927,,1969.0,10090.0,Intermediate,Mus musculus,6348,CHEMBL618949,50594,,,Plasma,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
4928,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL618950,50594,,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,F,1,N,1,,BAO_0000218
4929,,,10090.0,Intermediate,Mus musculus,5781,CHEMBL618951,50594,,,,Tmax after oral administration at 30 mg/kg in ICR mouse,,A,1,N,1,,BAO_0000218
4930,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL618952,50594,,,,Tmax after peroral administration in mice at 2.4 uM/kg,,A,1,N,1,,BAO_0000218
4931,,,10090.0,Intermediate,Mus musculus,4066,CHEMBL618953,50594,,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,A,1,N,1,,BAO_0000218
4932,,955.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL618954,50594,,,Brain,Tmax in brain of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4933,,2113.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL618955,50594,,,Kidney,Tmax in kidney of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4934,,2107.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL618956,50594,,,Liver,Tmax in liver of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4935,,2048.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL618957,50594,,,Lung,Tmax in lungs of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4936,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL618958,50594,,,,Tmax in mice at 18 uM/kg i.p. administration,,F,1,N,1,,BAO_0000218
4937,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL618959,50594,,,,Tmax in mice at 23 uM/kg i.v. administration,,F,1,N,1,,BAO_0000218
4938,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL618960,50594,,,,Tmax in mice at 25 uM/kg i.p. administration,,F,1,N,1,,BAO_0000218
4939,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL876723,50594,,,,Tmax in mice at 26 uM/kg i.p. administration,,F,1,N,1,,BAO_0000218
4940,,2106.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL618961,50594,,,Spleen,Tmax in spleen of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4941,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL618962,50594,,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,A,1,N,1,,BAO_0000218
4942,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL618963,50594,,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,A,1,N,1,,BAO_0000218
4943,,,10090.0,Intermediate,Mus musculus,5951,CHEMBL618964,50594,,,,Tmax value in IRC mice,,A,1,N,1,,BAO_0000218
4944,,,10090.0,Intermediate,Mus musculus,5506,CHEMBL618965,50594,,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,A,1,N,1,,BAO_0000218
4945,,,10090.0,Intermediate,Mus musculus,5506,CHEMBL618966,50594,,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,A,1,N,1,,BAO_0000218
4946,,1088.0,10090.0,Intermediate,Mus musculus,429,CHEMBL618967,50594,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,A,1,N,1,,BAO_0000218
4947,,1088.0,10090.0,Intermediate,Mus musculus,429,CHEMBL618968,50594,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,A,1,N,1,,BAO_0000218
4948,,1088.0,10090.0,Intermediate,Mus musculus,4066,CHEMBL618969,50594,,,Urine,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,A,1,N,1,,BAO_0000218
4949,,,10090.0,Intermediate,Mus musculus,17734,CHEMBL618970,50594,,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,A,1,N,1,,BAO_0000218
4950,,,10090.0,Intermediate,Mus musculus,17734,CHEMBL618971,50594,,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,A,1,N,1,,BAO_0000218
4951,,,10090.0,Intermediate,Mus musculus,6062,CHEMBL618972,50594,,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
4952,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL618973,50594,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,A,1,N,1,,BAO_0000218
4953,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL618974,50594,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
4954,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL618975,50594,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,A,1,N,1,,BAO_0000218
4955,,,10090.0,Intermediate,Mus musculus,5980,CHEMBL618976,50594,,,,Vd in mice,,A,1,N,1,,BAO_0000218
4956,,,10090.0,Intermediate,Mus musculus,17592,CHEMBL618977,50594,,,,Volume of distribution in mouse,,A,1,N,1,,BAO_0000218
4957,,,10090.0,Intermediate,Mus musculus,6348,CHEMBL876724,50594,,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
4958,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL618978,50594,,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,A,1,N,1,,BAO_0000218
4959,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL618979,50594,,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,A,1,N,1,,BAO_0000218
4960,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL618980,50594,,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,A,1,N,1,,BAO_0000218
4961,,,10090.0,Intermediate,Mus musculus,4239,CHEMBL618981,50594,,,,Pharmacokinetic property (vdss) was measured in mouse,,A,1,N,1,,BAO_0000218
4962,,,10090.0,Intermediate,Mus musculus,2862,CHEMBL618982,50594,,,,Value distribution upon iv administration in mouse,,A,1,N,1,,BAO_0000218
4963,,,10090.0,Intermediate,Mus musculus,17734,CHEMBL620150,50594,,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,A,1,N,1,,BAO_0000218
4964,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL620151,50594,,,,Volume of distribution was evaluated in mice after intravenous administration,,A,1,N,1,,BAO_0000218
4965,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL620152,50594,,,,Volume of distribution was evaluated in mice after oral administration,,A,1,N,1,,BAO_0000218
4966,,,10090.0,Intermediate,Mus musculus,17837,CHEMBL620153,50594,,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,A,1,N,1,,BAO_0000218
4967,,,10090.0,Intermediate,Mus musculus,5727,CHEMBL876395,50594,,,,Steady state volume of distribution was determined in mice,,A,1,N,1,,BAO_0000218
4968,,,10090.0,Intermediate,Mus musculus,17852,CHEMBL620154,50594,,,,Volume distribution (steady state) of compound was determined in mouse,,A,1,N,1,,BAO_0000218
4969,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL620155,50594,,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,A,1,N,1,,BAO_0000218
4970,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL620156,50594,,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,A,1,N,1,,BAO_0000218
4971,,,10090.0,Intermediate,Mus musculus,6062,CHEMBL620157,50594,,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
4972,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL620158,50594,,,Kidney,Biodistribution of compound (oxidized form) in in kidney tissue,,A,1,N,1,,BAO_0000218
4973,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL620159,50594,,,Blood,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,A,1,N,1,,BAO_0000218
4974,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL620160,50594,,,Blood,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
4975,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL620161,50594,,,Blood,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
4976,,,9606.0,Intermediate,Homo sapiens,10708,CHEMBL620162,80019,,797.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,F,1,N,1,,BAO_0000219
4977,,,9606.0,Expert,Homo sapiens,16597,CHEMBL620163,80852,,500.0,,Inhibition of A431 human squamous cell carcinoma cell proliferation,,F,1,N,1,,BAO_0000219
4978,,,9606.0,Expert,Homo sapiens,16062,CHEMBL620833,80852,,500.0,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,F,1,N,1,,BAO_0000219
4979,,,9606.0,Expert,Homo sapiens,16062,CHEMBL876396,80852,,500.0,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,F,1,N,1,,BAO_0000219
4980,,,9606.0,Expert,Homo sapiens,16958,CHEMBL620834,80852,,500.0,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,F,1,N,1,,BAO_0000219
4981,,,9606.0,Expert,Homo sapiens,6700,CHEMBL620835,80852,,500.0,,Inhibition of A431 human carcinoma cell proliferation,,F,1,N,1,,BAO_0000219
4982,,,9606.0,Expert,Homo sapiens,17226,CHEMBL620836,80852,,500.0,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,F,1,N,1,,BAO_0000219
4983,,,9606.0,Intermediate,Homo sapiens,6828,CHEMBL620837,80852,,500.0,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,F,1,N,1,,BAO_0000219
4984,,,9606.0,Intermediate,Homo sapiens,12314,CHEMBL621017,80852,,500.0,,In vitro cytotoxicity against epidermoid carcinoma cell line,,F,1,N,1,,BAO_0000219
4985,,,9606.0,Expert,Homo sapiens,13412,CHEMBL621018,9,,500.0,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,F,1,D,9,,BAO_0000218
4986,,,9606.0,Intermediate,Homo sapiens,13299,CHEMBL621019,80852,,500.0,,Antiproliferative activity of compound was measured on human tumor cell line A431.,,F,1,N,1,,BAO_0000219
4987,,,9606.0,Intermediate,Homo sapiens,17420,CHEMBL621020,80852,,500.0,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,F,1,N,1,,BAO_0000219
4988,,,9606.0,Intermediate,Homo sapiens,13678,CHEMBL621021,80852,,500.0,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,F,1,N,1,,BAO_0000219
4989,,,,Expert,,14171,CHEMBL621022,9,,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,F,1,H,8,,BAO_0000219
4990,,,9606.0,Expert,Homo sapiens,6333,CHEMBL621023,80852,,500.0,,Tested for antiproliferative activity against human A431 cells,,F,1,N,1,,BAO_0000219
4991,,,9606.0,Expert,Homo sapiens,2356,CHEMBL621024,9,,500.0,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,F,1,D,9,,BAO_0000219
4992,,,9606.0,Expert,Homo sapiens,15578,CHEMBL621025,80852,,500.0,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,F,1,N,1,,BAO_0000219
4993,,,9606.0,Expert,Homo sapiens,5126,CHEMBL621026,80852,,500.0,,Inhibition of A431 cell proliferation,,F,1,N,1,,BAO_0000219
4994,,,9606.0,Expert,Homo sapiens,6844,CHEMBL621027,80852,,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells,,F,1,N,1,,BAO_0000219
4995,,,9606.0,Expert,Homo sapiens,6844,CHEMBL876397,80852,,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,F,1,N,1,,BAO_0000219
4996,,,9606.0,Intermediate,Homo sapiens,4925,CHEMBL883797,80852,,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,F,1,N,1,,BAO_0000219
4997,,,9606.0,Intermediate,Homo sapiens,4925,CHEMBL621028,80852,,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,F,1,N,1,,BAO_0000219
4998,,,9606.0,Intermediate,Homo sapiens,13978,CHEMBL621029,80852,,500.0,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,F,1,N,1,,BAO_0000219
4999,,,9606.0,Intermediate,Homo sapiens,16786,CHEMBL621030,80852,,500.0,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,F,1,N,1,,BAO_0000219
5000,,,,Expert,,13412,CHEMBL621147,9,,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,F,1,H,8,,BAO_0000219
5001,,,9606.0,Intermediate,Homo sapiens,17824,CHEMBL621148,80852,,500.0,,In vivo antiproliferative activity against A431 cell line,,F,1,N,1,,BAO_0000218
5002,,,9606.0,Expert,Homo sapiens,12751,CHEMBL621149,9,,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,F,1,D,9,,BAO_0000219
5003,,,9606.0,Expert,Homo sapiens,12380,CHEMBL621150,80852,,500.0,,Inhibition of A431 human epidermoid carcinoma cell proliferation,,F,1,N,1,,BAO_0000219
5004,,,9606.0,Expert,Homo sapiens,4959,CHEMBL621151,9,,500.0,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,F,1,D,9,,BAO_0000219
5005,,,9606.0,Intermediate,Homo sapiens,6333,CHEMBL621152,80852,,500.0,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,F,1,N,1,,BAO_0000219
5006,,,9606.0,Intermediate,Homo sapiens,6333,CHEMBL621153,80852,,500.0,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,F,1,N,1,,BAO_0000219
5007,,,9606.0,Intermediate,Homo sapiens,6333,CHEMBL884000,80852,,500.0,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,F,1,N,1,,BAO_0000219
5008,,,9606.0,Expert,Homo sapiens,5296,CHEMBL621154,9,,,,Inhibition of EGFR overexpressing A431 cell proliferation,,F,1,D,9,,BAO_0000019
5009,,,9606.0,Expert,Homo sapiens,12624,CHEMBL621155,80852,,500.0,,Inhibition of A431 cell proliferation,,F,1,N,1,,BAO_0000219
5010,,,9606.0,Expert,Homo sapiens,14926,CHEMBL621156,9,,500.0,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,F,1,D,9,,BAO_0000219
5011,,,9606.0,Expert,Homo sapiens,14926,CHEMBL621157,9,,500.0,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,F,1,D,9,,BAO_0000219
5012,,,,Expert,,14926,CHEMBL621158,9,,500.0,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,F,1,H,8,,BAO_0000219
5013,,,9606.0,Intermediate,Homo sapiens,15144,CHEMBL621159,80852,,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,F,1,N,1,,BAO_0000219
5014,,,9606.0,Intermediate,Homo sapiens,15144,CHEMBL621160,80852,,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,F,1,N,1,,BAO_0000219
5015,,,9606.0,Intermediate,Homo sapiens,5245,CHEMBL621161,80852,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,F,1,N,1,,BAO_0000219
5016,,,9606.0,Intermediate,Homo sapiens,5245,CHEMBL621162,80852,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,F,1,N,1,,BAO_0000219
5017,,,9606.0,Intermediate,Homo sapiens,5245,CHEMBL621163,80852,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,F,1,N,1,,BAO_0000219
5018,,,9606.0,Intermediate,Homo sapiens,5245,CHEMBL621164,80852,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,F,1,N,1,,BAO_0000219
5019,,,9606.0,Intermediate,Homo sapiens,5245,CHEMBL621165,80852,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,F,1,N,1,,BAO_0000219
5020,,,9527.0,Autocuration,Cercopithecidae,5922,CHEMBL619159,22224,,,,Half-life period in cynomolgus monkey,,A,1,U,0,,BAO_0000019
5021,,1969.0,9527.0,Autocuration,Cercopithecidae,1116,CHEMBL619160,22224,,,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,A,1,U,0,,BAO_0000366
5022,,,9527.0,Autocuration,Cercopithecidae,17853,CHEMBL619161,22224,,,,Longer half-life in monkey (i.v.) at 0.5 mpk,,A,1,U,0,,BAO_0000218
5023,,1969.0,9527.0,Autocuration,Cercopithecidae,993,CHEMBL619162,22224,,,Plasma,Plasma half life in monkey,,A,1,U,0,,BAO_0000366
5024,,1969.0,9527.0,Autocuration,Cercopithecidae,4514,CHEMBL619163,22224,,,Plasma,Plasma half-life in rhesus monkey,,A,1,U,0,,BAO_0000366
5025,,1969.0,9527.0,Autocuration,Cercopithecidae,5334,CHEMBL619164,22224,,,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,A,1,U,0,,BAO_0000218
5026,,1969.0,9527.0,Autocuration,Cercopithecidae,5334,CHEMBL619320,22224,,,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,A,1,U,0,,BAO_0000218
5027,,,9527.0,Autocuration,Cercopithecidae,4578,CHEMBL619321,22224,,,,Tested for half life upon iv administration to african green monkey,,A,1,U,0,,BAO_0000218
5028,,,9527.0,Autocuration,Cercopithecidae,2661,CHEMBL873336,22224,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,A,1,U,0,,BAO_0000218
5029,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL619322,22224,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,A,1,U,0,,BAO_0000218
5030,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL619323,22224,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,A,1,U,0,,BAO_0000218
5031,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL619324,22224,,,,The time for peak concentration value after oral administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000218
5032,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619325,22224,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,A,1,U,0,,BAO_0000019
5033,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL876411,22224,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,A,1,U,0,,BAO_0000019
5034,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619326,22224,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,A,1,U,0,,BAO_0000019
5035,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619327,22224,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,A,1,U,0,,BAO_0000019
5036,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619328,22224,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,A,1,U,0,,BAO_0000019
5037,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619329,22224,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,A,1,U,0,,BAO_0000019
5038,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619330,22224,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,A,1,U,0,,BAO_0000019
5039,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619331,22224,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,A,1,U,0,,BAO_0000019
5040,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619332,22224,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,A,1,U,0,,BAO_0000019
5041,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619333,22224,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,A,1,U,0,,BAO_0000019
5042,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619334,22224,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,A,1,U,0,,BAO_0000019
5043,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619335,22224,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,A,1,U,0,,BAO_0000019
5044,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619336,22224,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,A,1,U,0,,BAO_0000019
5045,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619337,22224,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,A,1,U,0,,BAO_0000019
5046,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619338,22224,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,A,1,U,0,,BAO_0000019
5047,,,9527.0,Autocuration,Cercopithecidae,11271,CHEMBL619339,22224,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,A,1,U,0,,BAO_0000019
5048,,,10116.0,Intermediate,Rattus norvegicus,5809,CHEMBL619340,50597,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
5049,,1969.0,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL873496,50597,,,Plasma,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,A,1,N,1,,BAO_0000218
5050,,1969.0,10116.0,Intermediate,Rattus norvegicus,3546,CHEMBL619341,50597,,,Plasma,AUC value in rat after IV administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5051,,1969.0,10116.0,Intermediate,Rattus norvegicus,3546,CHEMBL619342,50597,,,Plasma,AUC value in rat after oral administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5052,,,10116.0,Intermediate,Rattus norvegicus,3546,CHEMBL619343,50597,,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5053,,,10116.0,Intermediate,Rattus norvegicus,3546,CHEMBL619344,50597,,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5054,,,10116.0,Intermediate,Rattus norvegicus,3546,CHEMBL619345,50597,,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5055,,,10116.0,Intermediate,Rattus norvegicus,3546,CHEMBL619346,50597,,,,Vc value in rat after IV administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5056,,,10116.0,Intermediate,Rattus norvegicus,3546,CHEMBL619347,50597,,,,Half life period in rat after IV administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5057,,,9557.0,Autocuration,Papio hamadryas,10625,CHEMBL619348,22224,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,A,1,U,0,,BAO_0000019
5058,,,9557.0,Autocuration,Papio hamadryas,10625,CHEMBL619349,22224,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,A,1,U,0,,BAO_0000019
5059,,,9557.0,Autocuration,Papio hamadryas,10625,CHEMBL619350,22224,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,A,1,U,0,,BAO_0000019
5060,,,9557.0,Autocuration,Papio hamadryas,10625,CHEMBL619351,22224,,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,A,1,U,0,,BAO_0000019
5061,,,9557.0,Autocuration,Papio hamadryas,10625,CHEMBL875953,22224,,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,A,1,U,0,,BAO_0000019
5062,,,9557.0,Autocuration,Papio hamadryas,10625,CHEMBL621716,22224,,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,A,1,U,0,,BAO_0000019
5063,,,9557.0,Autocuration,Papio hamadryas,10625,CHEMBL621717,22224,,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,A,1,U,0,,BAO_0000019
5064,,,9557.0,Autocuration,Papio hamadryas,10625,CHEMBL621718,22224,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,A,1,U,0,,BAO_0000019
5065,,,9615.0,Autocuration,beagle,3510,CHEMBL621719,22224,,,,Area under curve after 1 mpk peroral administration to beagles,,A,1,U,0,,BAO_0000019
5066,,,9615.0,Autocuration,beagle,3510,CHEMBL621720,22224,,,,Area under curve after 2 mpk peroral administration to beagles,,A,1,U,0,,BAO_0000019
5067,,,9615.0,Autocuration,beagle,3510,CHEMBL621721,22224,,,,Cmax value after 1 mpk peroral administration to beagles,,A,1,U,0,,BAO_0000218
5068,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL621722,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,A,1,U,0,,BAO_0000019
5069,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL621723,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,A,1,U,0,,BAO_0000019
5070,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL621724,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,A,1,U,0,,BAO_0000019
5071,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL623443,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,A,1,U,0,,BAO_0000019
5072,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL623444,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,A,1,U,0,,BAO_0000019
5073,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL623445,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,A,1,U,0,,BAO_0000019
5074,,1088.0,9606.0,Autocuration,Homo sapiens,7766,CHEMBL623446,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,A,1,U,0,,BAO_0000019
5075,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,16643,CHEMBL623447,22224,,,Liver,Metabolic stability observed at 30 min after administration in human liver microsomes,,A,1,U,0,,BAO_0000251
5076,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL623448,22224,,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,A,1,U,0,,BAO_0000019
5077,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL623449,22224,,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,A,1,U,0,,BAO_0000019
5078,,,9606.0,Autocuration,Homo sapiens,6852,CHEMBL623450,22224,,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,A,1,U,0,,BAO_0000019
5079,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,6567,CHEMBL623451,22224,,,Liver,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,A,1,U,0,,BAO_0000251
5080,,,9606.0,Autocuration,Homo sapiens,6570,CHEMBL623452,22224,,,,Metabolic stability (% remaining at 30 mins) in human S9.,,A,1,U,0,,BAO_0000019
5081,,,9606.0,Autocuration,Homo sapiens,6570,CHEMBL623453,22224,,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,A,1,U,0,,BAO_0000019
5082,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5237,CHEMBL623454,22224,,,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes,,A,1,U,0,,BAO_0000251
5083,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5237,CHEMBL623455,22224,,,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,A,1,U,0,,BAO_0000251
5084,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5237,CHEMBL624371,22224,,,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,A,1,U,0,,BAO_0000251
5085,,,9606.0,Autocuration,Homo sapiens,5202,CHEMBL624372,22224,,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,A,1,U,0,,BAO_0000218
5086,,,9606.0,Autocuration,Homo sapiens,5481,CHEMBL624373,22224,,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,A,1,U,0,,BAO_0000019
5087,,,9606.0,Autocuration,Homo sapiens,5481,CHEMBL624374,22224,,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,A,1,U,0,,BAO_0000019
5088,,,9606.0,Autocuration,Homo sapiens,3956,CHEMBL624556,22224,,,,The percent remaining in human plasma after 30 min was determined,,A,1,U,0,,BAO_0000019
5089,,1969.0,9606.0,Autocuration,Homo sapiens,5074,CHEMBL624557,22224,,,Plasma,Conversion rate of the prodrug in human plasma,,A,1,U,0,,BAO_0000366
5090,,1969.0,9606.0,Autocuration,Homo sapiens,5074,CHEMBL624558,22224,,,Plasma,Conversion rate of the prodrug in human plasma; ND means no data,,A,1,U,0,,BAO_0000366
5091,,178.0,9606.0,Autocuration,Homo sapiens,4727,CHEMBL624559,22224,,,Blood,Half life of compound was determined in human blood,,A,1,U,0,,BAO_0000221
5092,,,9606.0,Autocuration,Homo sapiens,5965,CHEMBL624560,22224,,,,Half life of compound was determined in man with once daily dosing,,A,1,U,0,,BAO_0000019
5093,Microsomes,,9606.0,Autocuration,Homo sapiens,5732,CHEMBL624561,22224,,,,Half life in human microsomes,,A,1,U,0,,BAO_0000251
5094,,1969.0,9606.0,Autocuration,Homo sapiens,5819,CHEMBL624562,22224,,,Plasma,Half life in human plasma,,A,1,U,0,,BAO_0000366
5095,,1969.0,9606.0,Autocuration,Homo sapiens,5819,CHEMBL624563,22224,,,Plasma,Half life in human plasma; Not detected,,A,1,U,0,,BAO_0000366
5096,,,9606.0,Autocuration,Homo sapiens,1916,CHEMBL624564,22224,,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,A,1,U,0,,BAO_0000218
5097,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,6597,CHEMBL624565,22224,,,Liver,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,A,1,U,0,,BAO_0000251
5098,,1969.0,9606.0,Autocuration,Homo sapiens,5229,CHEMBL875152,22224,,,Plasma,Half-life in human plasma,,A,1,U,0,,BAO_0000366
5099,,1969.0,9606.0,Autocuration,Homo sapiens,5229,CHEMBL624566,22224,,,Plasma,Half-life of the parent prodrug in plasma,,A,1,U,0,,BAO_0000366
5100,,1969.0,9606.0,Autocuration,Homo sapiens,2192,CHEMBL873805,22224,,,Plasma,In vitro half life in human plasma was determined,,A,1,U,0,,BAO_0000366
5101,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,3032,CHEMBL624567,22224,,,Liver,The compound was tested In Vitro for half life in human liver microsomes.,,A,1,U,0,,BAO_0000251
5102,,,9606.0,Autocuration,Homo sapiens,1916,CHEMBL624568,22224,,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,A,1,U,0,,BAO_0000218
5103,,,9606.0,Autocuration,Homo sapiens,17716,CHEMBL624569,22224,,,,Observed volume of distribution,,A,1,U,0,,BAO_0000218
5104,,,9606.0,Autocuration,Homo sapiens,15778,CHEMBL624570,22224,,,,Oral bioavailability in human,,A,1,U,0,,BAO_0000218
5105,,,9606.0,Autocuration,Homo sapiens,17313,CHEMBL624571,22224,,,,Tested for human plasma protein binding of the compound,,A,1,U,0,,BAO_0000019
5106,,,9606.0,Autocuration,Homo sapiens,4231,CHEMBL624572,22224,,,,"First order rate constant, k was determined in human plasma",,A,1,U,0,,BAO_0000019
5107,,,9606.0,Autocuration,Homo sapiens,4755,CHEMBL624573,22224,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,A,1,U,0,,BAO_0000019
5108,,,9606.0,Autocuration,Homo sapiens,4755,CHEMBL875153,22224,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,A,1,U,0,,BAO_0000019
5109,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,16907,CHEMBL624574,22224,,,Liver,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,A,1,U,0,,BAO_0000251
5110,,,9606.0,Autocuration,Homo sapiens,10839,CHEMBL624575,22224,,,,The compound was tested for the plasma binding in human,,A,1,U,0,,BAO_0000019
5111,,,9606.0,Autocuration,Homo sapiens,10839,CHEMBL624576,22224,,,,Plasma protein binding (human),,A,1,U,0,,BAO_0000019
5112,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,3199,CHEMBL624577,22224,,,Liver,Compound was evaluated for half-life in human liver microsomes,,A,1,U,0,,BAO_0000251
5113,,178.0,9606.0,Autocuration,Homo sapiens,1345,CHEMBL624578,22224,,,Blood,Half life measured in vitro for its stability in human blood,,A,1,U,0,,BAO_0000221
5114,,1977.0,9606.0,Autocuration,Homo sapiens,4297,CHEMBL622796,22224,,,Serum,Half life in human serum,,A,1,U,0,,BAO_0000019
5115,,1977.0,9606.0,Autocuration,Homo sapiens,4297,CHEMBL622797,22224,,,Serum,Half life in human serum; ND=not determined,,A,1,U,0,,BAO_0000019
5116,,,9606.0,Autocuration,Homo sapiens,4297,CHEMBL622798,22224,,,,Half life were determined in CEM-SS cell extract in decomposition step 1,,A,1,U,0,,BAO_0000019
5117,,,9606.0,Autocuration,Homo sapiens,4297,CHEMBL622799,22224,,,,Half life were determined in CEM-SS cell extract in decomposition step 2,,A,1,U,0,,BAO_0000019
5118,,1969.0,9606.0,Autocuration,Homo sapiens,4231,CHEMBL622800,22224,,,Plasma,Half life of the in human plasma,,A,1,U,0,,BAO_0000366
5119,S9,,9606.0,Autocuration,Homo sapiens,5633,CHEMBL622801,22224,,,,Half life period in human hepatic S9 fraction was determined,,A,1,U,0,,BAO_0000220
5120,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,5633,CHEMBL622802,22224,,,Liver,Half life period in human liver microsome was determined,,A,1,U,0,,BAO_0000251
5121,,,9606.0,Autocuration,Homo sapiens,17791,CHEMBL622803,22224,,,,Half life period was determined; 6-7,,A,1,U,0,,BAO_0000019
5122,,,9606.0,Autocuration,Homo sapiens,17791,CHEMBL875154,22224,,,,Half life period was evaluated in human,,A,1,U,0,,BAO_0000019
5123,,1969.0,9606.0,Autocuration,Homo sapiens,3160,CHEMBL622804,22224,,,Plasma,Half life time in human plasma,,A,1,U,0,,BAO_0000366
5124,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622805,50594,,,Brain,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5125,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622611,50594,,,Heart,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5126,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622612,50594,,,Heart,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5127,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL875160,50594,,,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5128,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622613,50594,,,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5129,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622614,50594,,,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5130,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622615,50594,,,Liver,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5131,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622616,50594,,,Liver,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,A,1,N,1,,BAO_0000218
5132,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622617,50594,,,Liver,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5133,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622618,50594,,,Spleen,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,A,1,N,1,,BAO_0000218
5134,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622619,50594,,,Spleen,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5135,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622620,50594,,,Spleen,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5136,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622621,50594,,,Brain,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
5137,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622622,50594,,,Blood,Biodistribution of compound (oxidized form) in blood tissue,,A,1,N,1,,BAO_0000218
5138,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622623,50594,,,Blood,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5139,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622624,50594,,,Blood,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5140,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622625,50594,,,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
5141,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622626,50594,,,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5142,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622627,50594,,,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5143,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622628,50594,,,Brain,Biodistribution of compound (oxidized form) in brain tissue of mice,,A,1,N,1,,BAO_0000218
5144,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622629,50594,,,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5145,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622630,50594,,,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
5146,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622631,50594,,,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5147,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622632,50594,,,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5148,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622633,50594,,,Brain,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5149,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622634,50594,,,Heart,Biodistribution of compound (oxidized form) in heart tissue of mice,,A,1,N,1,,BAO_0000218
5150,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622635,50594,,,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5151,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL875161,50594,,,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5152,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622636,50594,,,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
5153,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623335,50594,,,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5154,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623336,50594,,,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5155,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623337,50594,,,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5156,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623338,50594,,,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5157,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623339,50594,,,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
5158,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623524,50594,,,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5159,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623525,50594,,,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
5160,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623526,50594,,,Liver,Biodistribution of compound (oxidized form) in liver tissue,,A,1,N,1,,BAO_0000218
5161,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623527,50594,,,Liver,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
5162,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL623528,50594,,,Liver,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
5163,,,9606.0,Intermediate,Homo sapiens,5245,CHEMBL624615,80852,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,F,1,N,1,,BAO_0000219
5164,,,9606.0,Intermediate,Homo sapiens,5245,CHEMBL621672,80852,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,F,1,N,1,,BAO_0000219
5165,,,,Expert,,16289,CHEMBL621673,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,F,1,N,1,,BAO_0000218
5166,,,,Expert,,16289,CHEMBL621674,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,F,1,N,1,,BAO_0000218
5167,,,9606.0,Expert,Homo sapiens,16093,CHEMBL884002,9,,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,F,1,D,9,,BAO_0000219
5168,,,9606.0,Intermediate,Homo sapiens,16825,CHEMBL621850,80852,,500.0,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,F,1,N,1,,BAO_0000219
5169,,,9606.0,Intermediate,Homo sapiens,4848,CHEMBL621851,80852,,500.0,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,F,1,N,1,,BAO_0000219
5170,,,9606.0,Expert,Homo sapiens,14827,CHEMBL621852,9,,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,F,1,D,9,,BAO_0000219
5171,,,9606.0,Expert,Homo sapiens,14827,CHEMBL621853,9,,500.0,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,F,1,D,9,,BAO_0000219
5172,,,,Expert,,16289,CHEMBL621854,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,F,1,N,1,,BAO_0000218
5173,,,,Expert,,16289,CHEMBL621855,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,F,1,N,1,,BAO_0000218
5174,,,,Expert,,16289,CHEMBL623724,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,F,1,N,1,,BAO_0000218
5175,,,,Expert,,16289,CHEMBL623725,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,F,1,N,1,,BAO_0000218
5176,,,,Expert,,16289,CHEMBL623726,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,F,1,N,1,,BAO_0000218
5177,,,9606.0,Expert,Homo sapiens,16289,CHEMBL623727,9,,500.0,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,F,1,D,9,,BAO_0000219
5178,,,,Expert,,16289,CHEMBL623728,9,,500.0,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,F,1,H,8,,BAO_0000219
5179,,,,Expert,,16289,CHEMBL623729,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,F,1,N,1,,BAO_0000218
5180,,,,Expert,,16289,CHEMBL623730,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,F,1,N,1,,BAO_0000218
5181,,,,Expert,,16289,CHEMBL623731,80852,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,F,1,N,1,,BAO_0000218
5182,,,10090.0,Expert,Mus musculus,14555,CHEMBL623732,80852,,500.0,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,F,1,N,1,,BAO_0000218
5183,,,10090.0,Expert,Mus musculus,14555,CHEMBL623733,80852,,500.0,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,F,1,N,1,,BAO_0000218
5184,,,10090.0,Expert,Mus musculus,14555,CHEMBL623734,80852,,500.0,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,F,1,N,1,,BAO_0000218
5185,,,10090.0,Expert,Mus musculus,14555,CHEMBL623735,80852,,500.0,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,F,1,N,1,,BAO_0000218
5186,,,9606.0,Expert,Homo sapiens,1937,CHEMBL623736,80852,,500.0,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,F,1,N,1,,BAO_0000219
5187,,,9606.0,Intermediate,Homo sapiens,13739,CHEMBL623737,80852,,500.0,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,F,1,N,1,,BAO_0000219
5188,,,9606.0,Intermediate,Homo sapiens,3558,CHEMBL623738,80852,,500.0,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,F,1,N,1,,BAO_0000219
5189,,,9606.0,Intermediate,Homo sapiens,3558,CHEMBL875168,80852,,500.0,,Dose giving a 50% decrease in the living cell number (A437 cells),,F,1,N,1,,BAO_0000219
5190,,,9606.0,Expert,Homo sapiens,17686,CHEMBL623739,80682,,646.0,,In vitro inhibitory concentration against proliferation of A459 cell line.,,F,1,N,1,,BAO_0000219
5191,,,9606.0,Intermediate,Homo sapiens,5305,CHEMBL623740,80682,,646.0,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,F,1,N,1,,BAO_0000219
5192,,,9606.0,Intermediate,Homo sapiens,3614,CHEMBL624424,80682,,646.0,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,F,1,N,1,,BAO_0000219
5193,,,9606.0,Intermediate,Homo sapiens,17229,CHEMBL624425,80021,,624.0,,In vitro antitumor activity against renal A498 tumor cell lines,,F,1,N,1,,BAO_0000219
5194,,,9606.0,Intermediate,Homo sapiens,15935,CHEMBL624426,80021,,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,F,1,N,1,,BAO_0000219
5195,,,9606.0,Intermediate,Homo sapiens,15935,CHEMBL624427,80021,,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,F,1,N,1,,BAO_0000219
5196,,,9606.0,Intermediate,Homo sapiens,15560,CHEMBL624428,80021,,624.0,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,F,1,N,1,,BAO_0000219
5197,,,9606.0,Intermediate,Homo sapiens,13891,CHEMBL624429,80021,,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,F,1,N,1,,BAO_0000219
5198,,,9606.0,Intermediate,Homo sapiens,13891,CHEMBL624620,80021,,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,F,1,N,1,,BAO_0000219
5199,,,9606.0,Intermediate,Homo sapiens,13788,CHEMBL624621,80021,,624.0,,Cytotoxicity on kidney carcinoma (A-498) cell line,,F,1,N,1,,BAO_0000219
5200,,,9606.0,Intermediate,Homo sapiens,15403,CHEMBL624622,80021,,624.0,,Compound was evaluated against Human cell line renal A498,,F,1,N,1,,BAO_0000219
5201,,,9606.0,Intermediate,Homo sapiens,1009,CHEMBL624623,80021,,624.0,,Compound was tested for inhibition of A498 human renal cancer cell line,,F,1,N,1,,BAO_0000219
5202,,,9606.0,Intermediate,Homo sapiens,1043,CHEMBL874365,80021,,624.0,,Growth inhibitory activity against A498 human cancer cell line,,F,1,N,1,,BAO_0000219
5203,,,9606.0,Intermediate,Homo sapiens,5858,CHEMBL624624,80021,,624.0,,In vitro antitumor activity against human renal A498 cell line,,F,1,N,1,,BAO_0000219
5204,,,9606.0,Intermediate,Homo sapiens,5958,CHEMBL624625,80021,,624.0,,In vitro cytotoxic activity against renal (A498) cell line,,F,1,N,1,,BAO_0000219
5205,,,9606.0,Intermediate,Homo sapiens,5506,CHEMBL624626,80021,,624.0,,In vitro cytotoxic activity against human renal cancer (A498) cell line,,F,1,N,1,,BAO_0000219
5206,,,9606.0,Intermediate,Homo sapiens,12781,CHEMBL624627,80021,,624.0,,Tested for cytostatic activity against renal A498 cell line,,F,1,N,1,,BAO_0000219
5207,,,9606.0,Intermediate,Homo sapiens,14399,CHEMBL883157,80021,,624.0,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,F,1,N,1,,BAO_0000219
5208,,,9606.0,Expert,Homo sapiens,5958,CHEMBL624628,80021,,624.0,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,F,1,N,1,,BAO_0000219
5209,,,9615.0,Autocuration,beagle,3510,CHEMBL624629,22224,,,,Cmax value after 2 mpk peroral administration to beagles,,A,1,U,0,,BAO_0000218
5210,,,9615.0,Autocuration,Canis lupus familiaris,3510,CHEMBL623551,22224,beagle,,,Bioavailability,,A,1,U,0,,BAO_0000218
5211,,,9615.0,Autocuration,Canis lupus familiaris,3510,CHEMBL623552,22224,beagle,,,Bioavailability after 1 mpk peroral administration to beagles,,A,1,U,0,,BAO_0000218
5212,,,9615.0,Autocuration,Canis lupus familiaris,3510,CHEMBL623553,22224,beagle,,,Bioavailability after 2 mpk peroral administration to beagles,,A,1,U,0,,BAO_0000218
5213,,,9913.0,Autocuration,Bos taurus,3085,CHEMBL623554,22224,,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,A,1,U,0,,BAO_0000019
5214,,,9913.0,Autocuration,Bos taurus,3085,CHEMBL623555,22224,,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,A,1,U,0,,BAO_0000019
5215,,,9913.0,Autocuration,Bos taurus,3085,CHEMBL623556,22224,,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,A,1,U,0,,BAO_0000019
5216,,,9913.0,Autocuration,Bos taurus,9372,CHEMBL623557,22224,,,,Solubility against bovine alpha-chymotrypsin,,A,1,U,0,,BAO_0000019
5217,,,9913.0,Autocuration,Bos taurus,3085,CHEMBL623558,22224,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,A,1,U,0,,BAO_0000019
5218,,,9913.0,Autocuration,Bos taurus,3085,CHEMBL623559,22224,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,A,1,U,0,,BAO_0000019
5219,,2106.0,9913.0,Autocuration,Bos taurus,1469,CHEMBL623560,22224,,,Spleen,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,A,1,U,0,,BAO_0000221
5220,,,9913.0,Autocuration,Bos taurus,4297,CHEMBL623561,22224,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,A,1,U,0,,BAO_0000019
5221,,,9913.0,Autocuration,Bos taurus,4297,CHEMBL623562,22224,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,A,1,U,0,,BAO_0000019
5222,,,9913.0,Autocuration,Bos taurus,17585,CHEMBL623563,22224,,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,A,1,U,0,,BAO_0000019
5223,,2106.0,9913.0,Autocuration,Bos taurus,1336,CHEMBL623564,22224,,,Spleen,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,A,1,U,0,,BAO_0000221
5224,,,9913.0,Autocuration,Bos taurus,3085,CHEMBL873806,22224,,,,Half life in presence of 2 mg/mL BSA at pH 8.8,,A,1,U,0,,BAO_0000019
5225,,,9913.0,Autocuration,Bos taurus,2857,CHEMBL623565,22224,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,A,1,U,0,,BAO_0000019
5226,,,9913.0,Autocuration,Bos taurus,2857,CHEMBL623566,22224,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,A,1,U,0,,BAO_0000019
5227,,,9913.0,Autocuration,Bos taurus,2857,CHEMBL623567,22224,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,A,1,U,0,,BAO_0000019
5228,,,9913.0,Autocuration,Bos taurus,1540,CHEMBL623568,22224,,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,A,1,U,0,,BAO_0000019
5229,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6316,CHEMBL623569,50588,,,Plasma,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
5230,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17594,CHEMBL623570,50588,,,Plasma,AUC after administration at 100 mg/kg/day in dogs,,A,1,N,1,,BAO_0000218
5231,,1969.0,9615.0,Intermediate,Canis lupus familiaris,4953,CHEMBL624254,50588,,,Plasma,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,A,1,N,1,,BAO_0000218
5232,,1969.0,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL624255,50588,,,Plasma,AUC value after 15 mg/kg iv dose in Dogs,,A,1,N,1,,BAO_0000218
5233,,1969.0,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL624256,50588,,,Plasma,AUC value after 30 mg/kg po dose in Dogs,,A,1,N,1,,BAO_0000218
5234,,1969.0,9615.0,Intermediate,Canis lupus familiaris,2959,CHEMBL624257,50588,,,Plasma,AUC value after administration of 4 mg/Kg oral dose in dog,,A,1,N,1,,BAO_0000218
5235,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17594,CHEMBL624258,50588,,,Plasma,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,A,1,N,1,,BAO_0000218
5236,,,9615.0,Intermediate,Canis lupus familiaris,5356,CHEMBL875277,50588,,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,A,1,N,1,,BAO_0000218
5237,,,9615.0,Intermediate,Canis lupus familiaris,16807,CHEMBL622667,50588,,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,A,1,N,1,,BAO_0000218
5238,,,9615.0,Intermediate,Canis lupus familiaris,4527,CHEMBL622668,50588,,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,A,1,N,1,,BAO_0000218
5239,,,9615.0,Intermediate,Canis lupus familiaris,4527,CHEMBL622669,50588,,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,A,1,N,1,,BAO_0000218
5240,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL622670,50588,,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,A,1,N,1,,BAO_0000218
5241,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL622671,50588,,,,Area under curve determined in dogs after oral administration of 10 mg/kg,,A,1,N,1,,BAO_0000218
5242,,,9615.0,Intermediate,Canis lupus familiaris,5802,CHEMBL622672,50588,,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,A,1,N,1,,BAO_0000218
5243,,,9615.0,Expert,Canis lupus familiaris,3598,CHEMBL622673,50588,,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5244,,,9615.0,Expert,Canis lupus familiaris,3598,CHEMBL622674,50588,,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5245,,,9615.0,Intermediate,Canis lupus familiaris,5944,CHEMBL622675,50588,,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,A,1,N,1,,BAO_0000218
5246,,,9615.0,Intermediate,Canis lupus familiaris,5944,CHEMBL622676,50588,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,A,1,N,1,,BAO_0000218
5247,,,9615.0,Intermediate,Canis lupus familiaris,5944,CHEMBL622677,50588,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,A,1,N,1,,BAO_0000218
5248,,,9615.0,Intermediate,Canis lupus familiaris,5944,CHEMBL622678,50588,,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,A,1,N,1,,BAO_0000218
5249,,,9615.0,Intermediate,Canis lupus familiaris,4186,CHEMBL622679,50588,,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,A,1,N,1,,BAO_0000218
5250,,,9615.0,Intermediate,Canis lupus familiaris,5007,CHEMBL622680,50588,,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,A,1,N,1,,BAO_0000218
5251,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL622681,50588,,,,Area under curve was determine after peroral administration at 10 mpk in dog,,A,1,N,1,,BAO_0000218
5252,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL875278,50588,,,,Area under curve was determine after peroral administration at 5 mpk in dog,,A,1,N,1,,BAO_0000218
5253,,,9615.0,Intermediate,Canis lupus familiaris,5006,CHEMBL622682,50588,,,,Area under curve was determined,,A,1,N,1,,BAO_0000218
5254,,,9615.0,Intermediate,Canis lupus familiaris,5006,CHEMBL622683,50588,,,,Area under curve in dogs,,A,1,N,1,,BAO_0000218
5255,,,9615.0,Intermediate,Canis lupus familiaris,3771,CHEMBL622684,50588,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,A,1,N,1,,BAO_0000218
5256,,,9615.0,Intermediate,Canis lupus familiaris,3771,CHEMBL622685,50588,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,A,1,N,1,,BAO_0000218
5257,,,9615.0,Intermediate,Canis lupus familiaris,3771,CHEMBL622686,50588,,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,A,1,N,1,,BAO_0000218
5258,,,9615.0,Intermediate,Canis lupus familiaris,1916,CHEMBL618344,50588,,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,A,1,N,1,,BAO_0000218
5259,,,9615.0,Intermediate,Canis lupus familiaris,5302,CHEMBL875582,50588,,,,Area under curve value in dog at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
5260,,,9615.0,Intermediate,Canis lupus familiaris,5600,CHEMBL618345,50588,,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,A,1,N,1,,BAO_0000218
5261,,,9615.0,Intermediate,Canis lupus familiaris,5600,CHEMBL618346,50588,,,,Area under curve was determined after 0.3 mg/kg po administration in dog,,A,1,N,1,,BAO_0000218
5262,,,9615.0,Intermediate,Canis lupus familiaris,17764,CHEMBL618347,50588,,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,A,1,N,1,,BAO_0000218
5263,,,9615.0,Intermediate,Canis lupus familiaris,4368,CHEMBL618348,50588,,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,A,1,N,1,,BAO_0000218
5264,,,9606.0,Autocuration,Homo sapiens,5318,CHEMBL618349,22224,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,A,1,U,0,,BAO_0000019
5265,,,9606.0,Autocuration,Homo sapiens,5318,CHEMBL618350,22224,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,A,1,U,0,,BAO_0000019
5266,,,9606.0,Autocuration,Homo sapiens,5318,CHEMBL618351,22224,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,A,1,U,0,,BAO_0000019
5267,,,9606.0,Autocuration,Homo sapiens,5318,CHEMBL618352,22224,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,A,1,U,0,,BAO_0000019
5268,,178.0,9606.0,Autocuration,Homo sapiens,14518,CHEMBL873494,22224,,,Blood,Time taken to reduce 50% of the concentration of compound in blood plasma,,A,1,U,0,,BAO_0000221
5269,,1969.0,9606.0,Autocuration,Homo sapiens,2209,CHEMBL618353,22224,,,Plasma,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,A,1,U,0,,BAO_0000366
5270,,1969.0,9606.0,Autocuration,Homo sapiens,6787,CHEMBL618354,22224,,,Plasma,Half life in human plasma,,A,1,U,0,,BAO_0000366
5271,,1969.0,9606.0,Autocuration,Homo sapiens,4898,CHEMBL875583,22224,,,Plasma,Half life in human plasma was reported,,A,1,U,0,,BAO_0000366
5272,,1977.0,9606.0,Autocuration,Homo sapiens,6072,CHEMBL618355,22224,,,Serum,Half life in human serum,,A,1,U,0,,BAO_0000019
5273,,1969.0,9606.0,Autocuration,Homo sapiens,16907,CHEMBL618356,22224,,,Plasma,Half life upon exposure to human plasma,,A,1,U,0,,BAO_0000366
5274,Microsomes,,9606.0,Autocuration,Homo sapiens,5656,CHEMBL618357,22224,,,,t1/2 in human microsomes,,A,1,U,0,,BAO_0000251
5275,,1969.0,9606.0,Autocuration,Homo sapiens,4755,CHEMBL618358,22224,,,Plasma,Half life period in 80% human plasma at 37 degree Centigrade,,A,1,U,0,,BAO_0000366
5276,,14.0,9606.0,Autocuration,Homo sapiens,17503,CHEMBL618359,22224,,,Zone of skin,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,A,1,U,0,,BAO_0000221
5277,,1969.0,9606.0,Autocuration,Homo sapiens,12357,CHEMBL618360,22224,,,Plasma,Half-life measured in in vitro Cathepsin B assay in human plasma,,A,1,U,0,,BAO_0000366
5278,,,9606.0,Autocuration,Homo sapiens,3076,CHEMBL618361,22224,,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,A,1,U,0,,BAO_0000019
5279,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,6410,CHEMBL618362,22224,,,Liver,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,A,1,U,0,,BAO_0000251
5280,,1969.0,9606.0,Autocuration,Homo sapiens,3741,CHEMBL618363,22224,,,Plasma,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,A,1,U,0,,BAO_0000366
5281,,1969.0,9606.0,Autocuration,Homo sapiens,3741,CHEMBL618364,22224,,,Plasma,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,A,1,U,0,,BAO_0000366
5282,,1969.0,9606.0,Autocuration,Homo sapiens,3741,CHEMBL875584,22224,,,Plasma,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,A,1,U,0,,BAO_0000366
5283,,,9606.0,Autocuration,Homo sapiens,1540,CHEMBL618365,22224,,,,Half-life in the CEM cell extracts,,A,1,U,0,,BAO_0000019
5284,,1969.0,9606.0,Autocuration,Homo sapiens,2905,CHEMBL873495,22224,,,Plasma,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,A,1,U,0,,BAO_0000366
5285,,1969.0,9606.0,Autocuration,Homo sapiens,2905,CHEMBL618366,22224,,,Plasma,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,A,1,U,0,,BAO_0000366
5286,,,9606.0,Autocuration,Homo sapiens,5523,CHEMBL618367,22224,,,,Half-life was determined,,A,1,U,0,,BAO_0000019
5287,,178.0,9606.0,Autocuration,Homo sapiens,1499,CHEMBL618368,22224,,,Blood,Half-life (human blood stability),,A,1,U,0,,BAO_0000221
5288,,178.0,9606.0,Autocuration,Homo sapiens,1499,CHEMBL618369,22224,,,Blood,Half-life (human blood stability); no data,,A,1,U,0,,BAO_0000221
5289,,1969.0,9606.0,Autocuration,Homo sapiens,17065,CHEMBL618370,22224,,,Plasma,Half-life in human plasma,,A,1,U,0,,BAO_0000366
5290,,,9606.0,Autocuration,Homo sapiens,6861,CHEMBL618371,22224,,,,CYP3A4 metabolism half-life (t1/2),,A,1,U,0,,BAO_0000019
5291,,178.0,9606.0,Autocuration,Homo sapiens,1499,CHEMBL618372,22224,,,Blood,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,A,1,U,0,,BAO_0000221
5292,,1969.0,9606.0,Autocuration,Homo sapiens,530,CHEMBL618373,22224,,,Plasma,In vitro half life in human plasma,,A,1,U,0,,BAO_0000366
5293,,1969.0,9606.0,Autocuration,Homo sapiens,1116,CHEMBL618374,22224,,,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,A,1,U,0,,BAO_0000366
5294,,1969.0,9606.0,Autocuration,Homo sapiens,6695,CHEMBL618375,22224,,,Plasma,In vitro hydrolysis in human plasma,,A,1,U,0,,BAO_0000366
5295,,1969.0,9606.0,Autocuration,Homo sapiens,6695,CHEMBL618376,22224,,,Plasma,In vitro hydrolysis in human plasma; no data,,A,1,U,0,,BAO_0000366
5296,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,10,CHEMBL618377,22224,,,Liver,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,A,1,U,0,,BAO_0000251
5297,,1969.0,9606.0,Autocuration,Homo sapiens,993,CHEMBL618378,22224,,,Plasma,Plasma half life in human,,A,1,U,0,,BAO_0000366
5298,,1969.0,9606.0,Autocuration,Homo sapiens,15429,CHEMBL618379,22224,,,Plasma,Stability after incubation with human plasma (at 37 degree C),,A,1,U,0,,BAO_0000366
5299,,1969.0,9606.0,Autocuration,Homo sapiens,1675,CHEMBL618380,22224,,,Plasma,T1/2 was evaluated in human plasma,,A,1,U,0,,BAO_0000366
5300,,1969.0,9606.0,Autocuration,Homo sapiens,2209,CHEMBL618381,22224,,,Plasma,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,A,1,U,0,,BAO_0000366
5301,,1969.0,9606.0,Autocuration,Homo sapiens,2209,CHEMBL618382,22224,,,Plasma,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,A,1,U,0,,BAO_0000366
5302,,,9606.0,Autocuration,Homo sapiens,5318,CHEMBL618383,22224,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,A,1,U,0,,BAO_0000019
5303,,,9606.0,Autocuration,Homo sapiens,2412,CHEMBL618384,22224,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,A,1,U,0,,BAO_0000019
5304,,,9606.0,Autocuration,Homo sapiens,2412,CHEMBL618385,22224,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,A,1,U,0,,BAO_0000019
5305,,1969.0,9606.0,Autocuration,Homo sapiens,2906,CHEMBL619099,22224,,,Plasma,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,A,1,U,0,,BAO_0000366
5306,,1969.0,9606.0,Autocuration,Homo sapiens,2906,CHEMBL619100,22224,,,Plasma,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,A,1,U,0,,BAO_0000366
5307,,,9606.0,Autocuration,Homo sapiens,5495,CHEMBL619101,22224,,,,Time taken for 50% to be consumed by serum PON1 was determined,,A,1,U,0,,BAO_0000019
5308,,,9606.0,Autocuration,Homo sapiens,5495,CHEMBL619102,22224,,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,A,1,U,0,,BAO_0000019
5309,Microsomes,2107.0,9606.0,Autocuration,Homo sapiens,4397,CHEMBL619103,22224,,,Liver,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,A,1,U,0,,BAO_0000251
5310,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL619268,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,A,1,U,0,,BAO_0000218
5311,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL619269,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5312,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL619270,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,A,1,U,0,,BAO_0000218
5313,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL619271,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5314,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL875585,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,A,1,U,0,,BAO_0000218
5315,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL619272,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,A,1,U,0,,BAO_0000218
5316,,,9606.0,Intermediate,Homo sapiens,6058,CHEMBL619273,80640,,391.0,,Compound tested for growth inhibition of renal cancer cell line 786-0,,F,1,N,1,,BAO_0000219
5317,,,9606.0,Intermediate,Homo sapiens,17708,CHEMBL619274,80640,,391.0,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,F,1,N,1,,BAO_0000219
5318,,,9606.0,Expert,Homo sapiens,14017,CHEMBL619275,80640,,391.0,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,F,1,N,1,,BAO_0000219
5319,,,9606.0,Intermediate,Homo sapiens,16818,CHEMBL619276,80640,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,F,1,N,1,,BAO_0000219
5320,,,9606.0,Intermediate,Homo sapiens,16818,CHEMBL619277,80640,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,F,1,N,1,,BAO_0000219
5321,,,9606.0,Intermediate,Homo sapiens,16818,CHEMBL619278,80640,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,F,1,N,1,,BAO_0000219
5322,,,9606.0,Intermediate,Homo sapiens,11970,CHEMBL619279,80640,,391.0,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,F,1,N,1,,BAO_0000219
5323,,,9606.0,Intermediate,Homo sapiens,12400,CHEMBL858458,80640,,391.0,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,F,1,N,1,,BAO_0000219
5324,,,9606.0,Expert,Homo sapiens,12888,CHEMBL619280,80640,,391.0,,Cytotoxic effect on renal cancer line 786-0,,F,1,N,1,,BAO_0000219
5325,,,9606.0,Intermediate,Homo sapiens,15300,CHEMBL619281,80640,,391.0,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,F,1,N,1,,BAO_0000219
5326,,,9606.0,Intermediate,Homo sapiens,14769,CHEMBL619282,80640,,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,F,1,N,1,,BAO_0000219
5327,,,9606.0,Intermediate,Homo sapiens,15895,CHEMBL619283,80640,,391.0,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,F,1,N,1,,BAO_0000219
5328,,,9606.0,Intermediate,Homo sapiens,17376,CHEMBL619284,80640,,391.0,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,F,1,N,1,,BAO_0000219
5329,,,9606.0,Intermediate,Homo sapiens,14882,CHEMBL619285,80640,,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,F,1,N,1,,BAO_0000219
5330,,,9606.0,Intermediate,Homo sapiens,14882,CHEMBL619286,80640,,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,F,1,N,1,,BAO_0000219
5331,,,9606.0,Intermediate,Homo sapiens,15176,CHEMBL619287,80640,,391.0,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,F,1,N,1,,BAO_0000219
5332,,,9606.0,Intermediate,Homo sapiens,12696,CHEMBL857455,80640,,391.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,F,1,N,1,,BAO_0000219
5333,,,9606.0,Intermediate,Homo sapiens,2496,CHEMBL883801,80640,,391.0,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,F,1,N,1,,BAO_0000219
5334,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619288,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,F,1,N,1,,BAO_0000219
5335,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619289,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,F,1,N,1,,BAO_0000219
5336,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619290,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,F,1,N,1,,BAO_0000219
5337,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619291,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,F,1,N,1,,BAO_0000219
5338,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619292,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,F,1,N,1,,BAO_0000219
5339,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619293,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,F,1,N,1,,BAO_0000219
5340,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619294,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,F,1,N,1,,BAO_0000219
5341,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619295,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,F,1,N,1,,BAO_0000219
5342,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619296,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,F,1,N,1,,BAO_0000219
5343,,,9606.0,Intermediate,Homo sapiens,11831,CHEMBL619297,80641,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,F,1,N,1,,BAO_0000219
5344,,,9606.0,Intermediate,Homo sapiens,12782,CHEMBL619298,80640,,391.0,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,F,1,N,1,,BAO_0000219
5345,,,,Intermediate,,1229,CHEMBL619299,22226,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,F,1,U,0,,BAO_0000019
5346,,,9606.0,Expert,Homo sapiens,15313,CHEMBL619300,80433,,741.0,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,F,1,N,1,,BAO_0000219
5347,,,9606.0,Expert,Homo sapiens,15313,CHEMBL619301,80433,,741.0,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,F,1,N,1,,BAO_0000219
5348,,,9606.0,Intermediate,Homo sapiens,11544,CHEMBL619302,80433,,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,F,1,N,1,,BAO_0000219
5349,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL619303,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,F,1,N,1,,BAO_0000219
5350,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL619304,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,F,1,N,1,,BAO_0000219
5351,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL857706,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5352,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL619305,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5353,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL619306,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5354,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL619307,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5355,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL619308,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5356,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL619309,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5357,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL619310,80433,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5358,,,9606.0,Intermediate,Homo sapiens,14769,CHEMBL619311,80021,,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,F,1,N,1,,BAO_0000219
5359,,,9606.0,Intermediate,Homo sapiens,15354,CHEMBL619312,80021,,624.0,,Compound was tested for the growth inhibition of A498 renal tumor cell line,,F,1,N,1,,BAO_0000219
5360,,,9606.0,Intermediate,Homo sapiens,17445,CHEMBL619313,80021,,624.0,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,F,1,N,1,,BAO_0000219
5361,,,9606.0,Intermediate,Homo sapiens,4337,CHEMBL619314,80021,,624.0,,In vitro inhibitory concentration against renal cancer cell line A498,,F,1,N,1,,BAO_0000219
5362,,,9606.0,Intermediate,Homo sapiens,15277,CHEMBL619959,80021,,624.0,,Cytotoxicity against A 498 tumor cell line,,F,1,N,1,,BAO_0000219
5363,,,9606.0,Intermediate,Homo sapiens,4812,CHEMBL619960,80021,,624.0,,In vitro antitumor activity against A498 human cancer cell line,,F,1,N,1,,BAO_0000219
5364,,,9606.0,Intermediate,Homo sapiens,4812,CHEMBL619961,80021,,624.0,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,F,1,N,1,,BAO_0000219
5365,,,9606.0,Intermediate,Homo sapiens,4995,CHEMBL619962,80021,,624.0,,Inhibitory dose required against A498 human tumor cell lines,,F,1,N,1,,BAO_0000219
5366,,,9606.0,Intermediate,Homo sapiens,5847,CHEMBL875586,80021,,624.0,,Anticancer activity against one renal cancer (A498 cell line),,F,1,N,1,,BAO_0000219
5367,,,9606.0,Intermediate,Homo sapiens,6557,CHEMBL619963,80021,,624.0,,In vitro cytotoxicity against melanoma A498 cell line,,F,1,N,1,,BAO_0000219
5368,,,9606.0,Intermediate,Homo sapiens,2597,CHEMBL619964,80021,,624.0,,Compound was tested for growth inhibitory activity against A498 cell line,,F,1,N,1,,BAO_0000219
5369,,,9606.0,Intermediate,Homo sapiens,6058,CHEMBL620108,80021,,624.0,,Compound tested for growth inhibition of renal cancer cell line A498,,F,1,N,1,,BAO_0000219
5370,,,9606.0,Intermediate,Homo sapiens,17708,CHEMBL620109,80021,,624.0,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,F,1,N,1,,BAO_0000219
5371,,,9606.0,Intermediate,Homo sapiens,15176,CHEMBL620110,80021,,624.0,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,F,1,N,1,,BAO_0000219
5372,,,9606.0,Intermediate,Homo sapiens,15300,CHEMBL620111,80021,,624.0,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,F,1,N,1,,BAO_0000219
5373,,,9606.0,Intermediate,Homo sapiens,11970,CHEMBL620112,80021,,624.0,,Tested for cytotoxicity against A498 cell lines in renal cancer,,F,1,N,1,,BAO_0000219
5374,,,9606.0,Intermediate,Homo sapiens,12400,CHEMBL620113,80021,,624.0,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,F,1,N,1,,BAO_0000219
5375,,,9606.0,Expert,Homo sapiens,12888,CHEMBL620114,80021,,624.0,,Cytotoxic effect on renal cancer lines A498,,F,1,N,1,,BAO_0000219
5376,,,9606.0,Intermediate,Homo sapiens,3030,CHEMBL620115,80021,,624.0,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,F,1,N,1,,BAO_0000219
5377,,,9606.0,Intermediate,Homo sapiens,14769,CHEMBL620116,80021,,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,F,1,N,1,,BAO_0000219
5378,,,9606.0,Intermediate,Homo sapiens,17376,CHEMBL620117,80021,,624.0,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,F,1,N,1,,BAO_0000219
5379,,,9606.0,Intermediate,Homo sapiens,16558,CHEMBL620118,80021,,624.0,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,F,1,N,1,,BAO_0000219
5380,,,9606.0,Intermediate,Homo sapiens,5194,CHEMBL620119,80021,,624.0,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,F,1,N,1,,BAO_0000219
5381,,,9606.0,Intermediate,Homo sapiens,10708,CHEMBL620120,80021,,624.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,F,1,N,1,,BAO_0000219
5382,,,9606.0,Expert,Homo sapiens,16880,CHEMBL620121,80682,,646.0,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
5383,,,9606.0,Intermediate,Homo sapiens,10196,CHEMBL620122,80682,,646.0,,Antitumor activity against A549 human lung carcinoma cell line,,F,1,N,1,,BAO_0000219
5384,,,9606.0,Intermediate,Homo sapiens,10196,CHEMBL620123,80682,,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,F,1,N,1,,BAO_0000219
5385,,,9606.0,Intermediate,Homo sapiens,10196,CHEMBL620124,80682,,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,F,1,N,1,,BAO_0000219
5386,,,9606.0,Intermediate,Homo sapiens,12083,CHEMBL620125,80682,,646.0,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,F,1,N,1,,BAO_0000219
5387,,,9606.0,Expert,Homo sapiens,16464,CHEMBL620126,80682,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,F,1,N,1,,BAO_0000219
5388,,,9606.0,Intermediate,Homo sapiens,16464,CHEMBL883027,80682,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,F,1,N,1,,BAO_0000219
5389,,,9606.0,Expert,Homo sapiens,16470,CHEMBL620127,80682,,646.0,,In vitro cytotoxic activity against human lung A549 cell line,,F,1,N,1,,BAO_0000219
5390,,,9606.0,Intermediate,Homo sapiens,16470,CHEMBL620128,80682,,646.0,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,F,1,N,1,,BAO_0000219
5391,,,9606.0,Intermediate,Homo sapiens,16470,CHEMBL620129,80682,,646.0,,In vitro cytotoxic activity against human lung A549 cell line),,F,1,N,1,,BAO_0000219
5392,,,9606.0,Intermediate,Homo sapiens,16470,CHEMBL620130,80682,,646.0,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,F,1,N,1,,BAO_0000219
5393,,,9606.0,Expert,Homo sapiens,16582,CHEMBL620131,80682,,646.0,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,F,1,N,1,,BAO_0000219
5394,,,9606.0,Intermediate,Homo sapiens,15935,CHEMBL620132,80682,,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,F,1,N,1,,BAO_0000219
5395,,,9606.0,Intermediate,Homo sapiens,15935,CHEMBL620133,80682,,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,F,1,N,1,,BAO_0000219
5396,,,9606.0,Expert,Homo sapiens,16597,CHEMBL620134,80682,,646.0,,Inhibition of A549 human lung carcinoma cell proliferation,,F,1,N,1,,BAO_0000219
5397,,,9606.0,Intermediate,Homo sapiens,17376,CHEMBL620135,80682,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,,F,1,N,1,,BAO_0000219
5398,,,9606.0,Intermediate,Homo sapiens,16496,CHEMBL620136,80682,,646.0,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,F,1,N,1,,BAO_0000219
5399,,,9606.0,Intermediate,Homo sapiens,16152,CHEMBL620137,80682,,646.0,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,F,1,N,1,,BAO_0000219
5400,,,9606.0,Intermediate,Homo sapiens,16152,CHEMBL620268,80682,,646.0,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,F,1,N,1,,BAO_0000219
5401,,,9606.0,Intermediate,Homo sapiens,16464,CHEMBL620269,80682,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,F,1,N,1,,BAO_0000219
5402,,,9606.0,Intermediate,Homo sapiens,2288,CHEMBL620270,80682,,646.0,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,F,1,N,1,,BAO_0000219
5403,,,9606.0,Intermediate,Homo sapiens,17350,CHEMBL620271,80682,,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,F,1,N,1,,BAO_0000219
5404,,,9606.0,Expert,Homo sapiens,4090,CHEMBL620272,80682,,646.0,,Inhibition of A549 cancer cell proliferation,,F,1,N,1,,BAO_0000219
5405,,,9606.0,Expert,Homo sapiens,4090,CHEMBL620273,80682,,646.0,,Inhibition of A549 cancer cell proliferation (Not tested),,F,1,N,1,,BAO_0000219
5406,,,9606.0,Intermediate,Homo sapiens,17350,CHEMBL620274,80682,,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,F,1,N,1,,BAO_0000219
5407,,,9606.0,Intermediate,Homo sapiens,4197,CHEMBL620275,80682,,646.0,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,F,1,N,1,,BAO_0000219
5408,,,9606.0,Intermediate,Homo sapiens,17072,CHEMBL620276,80682,,646.0,,Antiproliferative potency determined as inhibitory concentration against A549 cells,,F,1,N,1,,BAO_0000219
5409,,,9606.0,Intermediate,Homo sapiens,17072,CHEMBL620277,80682,,646.0,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,F,1,N,1,,BAO_0000219
5410,,,9606.0,Intermediate,Homo sapiens,5194,CHEMBL620278,80682,,646.0,,Cytotoxicity against Renal cell lines A549 was determined,,F,1,N,1,,BAO_0000219
5411,,,9615.0,Intermediate,Canis lupus familiaris,4257,CHEMBL620279,50588,,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,A,1,N,1,,BAO_0000218
5412,,,9615.0,Intermediate,Canis lupus familiaris,6123,CHEMBL620280,50588,,,,Area under curve was determined in dog after oral administration at 1 mg/kg,,A,1,N,1,,BAO_0000218
5413,,,9615.0,Intermediate,Canis lupus familiaris,1337,CHEMBL620281,50588,,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,A,1,N,1,,BAO_0000218
5414,,,9615.0,Intermediate,Canis lupus familiaris,1337,CHEMBL620282,50588,,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,A,1,N,1,,BAO_0000218
5415,,,9615.0,Intermediate,Canis lupus familiaris,8833,CHEMBL621134,50588,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,A,1,N,1,,BAO_0000218
5416,,,9615.0,Intermediate,Canis lupus familiaris,8833,CHEMBL621135,50588,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,A,1,N,1,,BAO_0000218
5417,,,9615.0,Intermediate,Canis lupus familiaris,8833,CHEMBL621136,50588,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,A,1,N,1,,BAO_0000218
5418,,,9615.0,Intermediate,Canis lupus familiaris,8833,CHEMBL621137,50588,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,A,1,N,1,,BAO_0000218
5419,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17657,CHEMBL621138,50588,,,Plasma,Area under plasma concentration time curve in dog upon oral administration,,A,1,N,1,,BAO_0000218
5420,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17650,CHEMBL875587,50588,,,Plasma,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,A,1,N,1,,BAO_0000218
5421,,,9615.0,Intermediate,Canis lupus familiaris,1977,CHEMBL621139,50588,,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,A,1,N,1,,BAO_0000218
5422,,,9615.0,Intermediate,Canis lupus familiaris,1977,CHEMBL621140,50588,,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,A,1,N,1,,BAO_0000218
5423,,,9615.0,Intermediate,Canis lupus familiaris,3132,CHEMBL621141,50588,,,,Area under the curve for the compound was obtained when tested in dog,,A,1,N,1,,BAO_0000218
5424,,,9615.0,Intermediate,Canis lupus familiaris,5473,CHEMBL621142,50588,,,,Area under the curve at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5425,,,9615.0,Intermediate,Canis lupus familiaris,5474,CHEMBL621143,50588,,,,Area under the curve at a dose of 1 mg/kg (oral),,A,1,N,1,,BAO_0000218
5426,,,9615.0,Intermediate,Canis lupus familiaris,5474,CHEMBL621144,50588,,,,Area under the curve at i.v. dose of 0.2 mg/kg,,A,1,N,1,,BAO_0000218
5427,,,9615.0,Intermediate,Canis lupus familiaris,6062,CHEMBL621145,50588,,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5428,,,9615.0,Intermediate,Canis lupus familiaris,4709,CHEMBL621146,50588,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
5429,,,9615.0,Intermediate,Canis lupus familiaris,2652,CHEMBL622567,50588,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,A,1,N,1,,BAO_0000218
5430,,,9615.0,Intermediate,Canis lupus familiaris,2652,CHEMBL622568,50588,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,A,1,N,1,,BAO_0000218
5431,,,9615.0,Intermediate,Canis lupus familiaris,2877,CHEMBL622569,50588,,,,Compound was evaluated for area under the curve in dog blood.,,A,1,N,1,,BAO_0000218
5432,,,9615.0,Intermediate,Canis lupus familiaris,5444,CHEMBL622570,50588,,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,A,1,N,1,,BAO_0000218
5433,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5130,CHEMBL622571,50588,,,Plasma,AUC in dog after oral dose (1 mg/kg),,A,1,N,1,,BAO_0000218
5434,,,9615.0,Intermediate,Canis lupus familiaris,6265,CHEMBL622572,50588,,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5435,,,9615.0,Intermediate,Canis lupus familiaris,4657,CHEMBL622573,50588,,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,A,1,N,1,,BAO_0000218
5436,,,9615.0,Intermediate,Canis lupus familiaris,16367,CHEMBL622574,50588,,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,A,1,N,1,,BAO_0000218
5437,,,9615.0,Intermediate,Canis lupus familiaris,16367,CHEMBL622575,50588,,,,Pharmacokinetic parameter AUC after oral administration to dogs,,A,1,N,1,,BAO_0000218
5438,,,9615.0,Intermediate,Canis lupus familiaris,9579,CHEMBL622576,50588,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,A,1,N,1,,BAO_0000218
5439,,,9615.0,Intermediate,Canis lupus familiaris,9579,CHEMBL622577,50588,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,A,1,N,1,,BAO_0000218
5440,,,9615.0,Intermediate,Canis lupus familiaris,5983,CHEMBL622578,50588,,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,A,1,N,1,,BAO_0000218
5441,,,9615.0,Intermediate,Canis lupus familiaris,6241,CHEMBL622579,50588,,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,A,1,N,1,,BAO_0000218
5442,,,9615.0,Intermediate,Canis lupus familiaris,5313,CHEMBL622580,50588,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,A,1,N,1,,BAO_0000218
5443,,,9615.0,Intermediate,Canis lupus familiaris,5313,CHEMBL622581,50588,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,A,1,N,1,,BAO_0000218
5444,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL622582,50588,,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,A,1,N,1,,BAO_0000218
5445,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL622583,50588,,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,A,1,N,1,,BAO_0000218
5446,,,9615.0,Intermediate,Canis lupus familiaris,6641,CHEMBL622584,50588,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,A,1,N,1,,BAO_0000218
5447,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL622585,50588,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,A,1,N,1,,BAO_0000218
5448,,,9615.0,Intermediate,Canis lupus familiaris,17791,CHEMBL622586,50588,,,,Compound was evaluated for oral bioavailability in dog; 90-100,,A,1,N,1,,BAO_0000218
5449,,,9615.0,Intermediate,Canis lupus familiaris,17655,CHEMBL623281,50588,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,A,1,N,1,,BAO_0000218
5450,,,9615.0,Intermediate,Canis lupus familiaris,17655,CHEMBL623282,50588,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,A,1,N,1,,BAO_0000218
5451,,,9615.0,Intermediate,Canis lupus familiaris,6596,CHEMBL623283,50588,,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,A,1,N,1,,BAO_0000218
5452,,,9615.0,Intermediate,Canis lupus familiaris,3880,CHEMBL623284,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
5453,,,9615.0,Intermediate,Canis lupus familiaris,16367,CHEMBL623285,50588,,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,A,1,N,1,,BAO_0000218
5454,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17409,CHEMBL623463,50588,,,Plasma,Plasma protein binding towards dog plasma at 10 uM,,A,1,N,1,,BAO_0000218
5455,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17409,CHEMBL875952,50588,,,Plasma,Plasma protein binding towards dog plasma at 100 uM,,A,1,N,1,,BAO_0000218
5456,,,9615.0,Intermediate,Canis lupus familiaris,2959,CHEMBL621705,50588,,,,Bioavailability in dog (dose 4 mg/kg p.o.),,A,1,N,1,,BAO_0000218
5457,,,9615.0,Intermediate,Canis lupus familiaris,13501,CHEMBL621706,50588,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,A,1,N,1,,BAO_0000218
5458,,,9615.0,Intermediate,Canis lupus familiaris,4527,CHEMBL621707,50588,,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,A,1,N,1,,BAO_0000218
5459,,,9615.0,Intermediate,Canis lupus familiaris,15145,CHEMBL621708,50588,,,,Bioavailability in dogs,,A,1,N,1,,BAO_0000218
5460,,,9615.0,Intermediate,Canis lupus familiaris,4219,CHEMBL621709,50588,,,,Bioavailability,,A,1,N,1,,BAO_0000218
5461,,,9615.0,Intermediate,Canis lupus familiaris,17538,CHEMBL621710,50588,,,,Oral bioavailability in dog (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
5462,,,9615.0,Intermediate,Canis lupus familiaris,17538,CHEMBL621711,50588,,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,A,1,N,1,,BAO_0000218
5463,,,9615.0,Intermediate,Canis lupus familiaris,1466,CHEMBL621712,50588,,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,A,1,N,1,,BAO_0000218
5464,,,9615.0,Intermediate,Canis lupus familiaris,17650,CHEMBL621713,50588,,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,A,1,N,1,,BAO_0000218
5465,,,9615.0,Intermediate,Canis lupus familiaris,3132,CHEMBL621714,50588,,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,A,1,N,1,,BAO_0000218
5466,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL621715,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5467,,2107.0,10095.0,Autocuration,Mus sp.,2413,CHEMBL623717,22224,,,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,A,1,U,0,,BAO_0000218
5468,,2107.0,10095.0,Autocuration,Mus sp.,2413,CHEMBL623718,22224,,,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,A,1,U,0,,BAO_0000218
5469,,2107.0,10095.0,Autocuration,Mus sp.,2413,CHEMBL623719,22224,,,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5470,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL623720,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,A,1,U,0,,BAO_0000218
5471,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL623721,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5472,,2385.0,10095.0,Autocuration,Mus sp.,2413,CHEMBL623722,22224,,,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,A,1,U,0,,BAO_0000218
5473,,2385.0,10095.0,Autocuration,Mus sp.,2413,CHEMBL623723,22224,,,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,A,1,U,0,,BAO_0000218
5474,,2385.0,10095.0,Autocuration,Mus sp.,2413,CHEMBL618543,22224,,,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5475,,2106.0,10095.0,Autocuration,Mus sp.,2413,CHEMBL618544,22224,,,Spleen,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,A,1,U,0,,BAO_0000218
5476,,2106.0,10095.0,Autocuration,Mus sp.,2413,CHEMBL875155,22224,,,Spleen,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5477,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL618545,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,A,1,U,0,,BAO_0000218
5478,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL618546,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,A,1,U,0,,BAO_0000218
5479,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL623529,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5480,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL623530,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,A,1,U,0,,BAO_0000218
5481,,,10095.0,Autocuration,Mus sp.,2413,CHEMBL621764,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,A,1,U,0,,BAO_0000218
5482,,,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621765,22224,,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5483,,2037.0,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621766,22224,,,Cerebellum,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5484,,1870.0,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621767,22224,,,Frontal cortex,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5485,,,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621768,22224,,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5486,,2435.0,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621769,22224,,,Striatum,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5487,,,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621770,22224,,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5488,,2037.0,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621771,22224,,,Cerebellum,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5489,,1870.0,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621772,22224,,,Frontal cortex,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5490,,,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621773,22224,,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5491,,2435.0,9527.0,Autocuration,Cercopithecidae,17827,CHEMBL621774,22224,,,Striatum,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,A,1,U,0,,BAO_0000019
5492,,,9527.0,Autocuration,Cercopithecidae,17791,CHEMBL621775,22224,,,,Compound was evaluated for oral bioavailability in rats,,A,1,U,0,,BAO_0000218
5493,,1969.0,9527.0,Autocuration,Cercopithecidae,17667,CHEMBL621776,22224,,,Plasma,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,A,1,U,0,,BAO_0000218
5494,,,9527.0,Autocuration,Cercopithecidae,17791,CHEMBL621777,22224,,,,Half life period was evaluated in monkey,,A,1,U,0,,BAO_0000019
5495,,,9527.0,Autocuration,Cercopithecidae,110,CHEMBL875162,22224,,,,Half-life in rhesus monkeys by intravenous administration of dose,,A,1,U,0,,BAO_0000218
5496,,1969.0,10090.0,Intermediate,Mus musculus,5781,CHEMBL621778,50594,,,Plasma,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,A,1,N,1,,BAO_0000218
5497,,1969.0,10090.0,Intermediate,Mus musculus,17734,CHEMBL621779,50594,,,Plasma,AUC after intraperitoneal administration of 100 mg/kg in mice,,A,1,N,1,,BAO_0000218
5498,,1969.0,10090.0,Intermediate,Mus musculus,17718,CHEMBL622479,50594,,,Plasma,AUC value was determined after oral administration,,A,1,N,1,,BAO_0000218
5499,,,10090.0,Intermediate,Mus musculus,4573,CHEMBL622480,50594,,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,A,1,N,1,,BAO_0000218
5500,,,10090.0,Intermediate,Mus musculus,3277,CHEMBL622481,50594,,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,A,1,N,1,,BAO_0000218
5501,,,10090.0,Intermediate,Mus musculus,2862,CHEMBL622482,50594,,,,Area under curve by ioral administration in mouse,,A,1,N,1,,BAO_0000218
5502,,,10090.0,Intermediate,Mus musculus,2862,CHEMBL622483,50594,,,,Area under curve by iv administration in mouse,,A,1,N,1,,BAO_0000218
5503,,,10090.0,Intermediate,Mus musculus,5951,CHEMBL622484,50594,,,,Area under curve at 0-8 hr in IRC mice after peroral administration,,A,1,N,1,,BAO_0000218
5504,,,10090.0,Intermediate,Mus musculus,17729,CHEMBL622641,50594,,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
5505,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL622642,50594,,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
5506,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL622643,50594,,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
5507,,,10090.0,Intermediate,Mus musculus,17729,CHEMBL622644,50594,,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
5508,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL622645,80433,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,F,1,N,1,,BAO_0000219
5509,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL622646,80433,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,F,1,N,1,,BAO_0000219
5510,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL621238,80433,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5511,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL621239,80433,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5512,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL621240,80433,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5513,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL621241,80433,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5514,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL621242,80433,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5515,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620350,80433,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5516,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620351,80433,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,F,1,N,1,,BAO_0000219
5517,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620352,80433,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,F,1,N,1,,BAO_0000219
5518,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620353,80433,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5519,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620354,80433,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5520,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620355,80433,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5521,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620356,80433,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5522,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620357,80433,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,F,1,N,1,,BAO_0000219
5523,,,9606.0,Intermediate,Homo sapiens,9424,CHEMBL620358,80433,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,F,1,N,1,,BAO_0000219
5524,,,9606.0,Expert,Homo sapiens,9424,CHEMBL620359,80433,,741.0,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,F,1,N,1,,BAO_0000219
5525,,,9606.0,Intermediate,Homo sapiens,11544,CHEMBL620360,80433,,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,F,1,N,1,,BAO_0000219
5526,,,9606.0,Intermediate,Homo sapiens,17378,CHEMBL620361,80433,,741.0,,Cytotoxicity of compound against 8226/DOX1V cells,,F,1,N,1,,BAO_0000219
5527,,,9606.0,Intermediate,Homo sapiens,17378,CHEMBL620362,80433,,741.0,,Cytotoxicity of compound against 8226/S cells,,F,1,N,1,,BAO_0000219
5528,,,9606.0,Intermediate,Homo sapiens,17079,CHEMBL620363,80433,,741.0,,Inhibitory concentration against 8226 myeloma cancer cell line,,F,1,N,1,,BAO_0000219
5529,,,9606.0,Intermediate,Homo sapiens,17079,CHEMBL620364,80433,,741.0,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,F,1,N,1,,BAO_0000219
5530,,,9606.0,Intermediate,Homo sapiens,13466,CHEMBL620365,80647,,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,F,1,N,1,,BAO_0000219
5531,,,9606.0,Intermediate,Homo sapiens,13466,CHEMBL620366,80647,,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,F,1,N,1,,BAO_0000219
5532,,,9606.0,Expert,Homo sapiens,2392,CHEMBL620367,80647,,854.0,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,F,1,N,1,,BAO_0000219
5533,,,9606.0,Intermediate,Homo sapiens,2392,CHEMBL620368,80647,,854.0,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,F,1,N,1,,BAO_0000219
5534,,,,Autocuration,,6608,CHEMBL620369,22226,,,,Inhibitory activity against caspase-1,,B,1,U,0,,BAO_0000019
5535,,,1351.0,Autocuration,Enterococcus faecalis,10199,CHEMBL620370,45,,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,B,1,H,8,,BAO_0000357
5536,,,9606.0,Intermediate,Homo sapiens,17749,CHEMBL620371,80648,,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,F,1,N,1,,BAO_0000219
5537,,,9606.0,Intermediate,Homo sapiens,17749,CHEMBL620372,80648,,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,F,1,N,1,,BAO_0000219
5538,,,,Intermediate,,1229,CHEMBL876492,22226,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,F,1,U,0,,BAO_0000019
5539,,,,Intermediate,,1229,CHEMBL620373,22226,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,F,1,U,0,,BAO_0000019
5540,,,,Intermediate,,1229,CHEMBL620374,22226,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,F,1,U,0,,BAO_0000019
5541,,,,Autocuration,,6390,CHEMBL620375,22226,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,B,1,U,0,,BAO_0000019
5542,,,1314.0,Autocuration,Streptococcus pyogenes,16219,CHEMBL857902,22226,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,F,1,U,0,,BAO_0000019
5543,,,1314.0,Autocuration,Streptococcus pyogenes,16219,CHEMBL620376,22226,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,F,1,U,0,,BAO_0000019
5544,,,,Autocuration,,17043,CHEMBL620377,11922,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,B,1,H,8,,BAO_0000357
5545,,,9606.0,Intermediate,Homo sapiens,6929,CHEMBL620378,81115,,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,F,1,N,1,,BAO_0000219
5546,,,9606.0,Intermediate,Homo sapiens,6929,CHEMBL620379,81115,,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,A,1,N,1,,BAO_0000219
5547,,,9606.0,Autocuration,Homo sapiens,7083,CHEMBL620380,22226,,,,In vitro cytotoxicity of compound was tested against 9KB cells.,,F,1,U,0,,BAO_0000219
5548,,,10116.0,Intermediate,Rattus norvegicus,12446,CHEMBL884006,80653,,392.0,,Cytotoxic concentration against 9L cells was determined on day 3,,F,1,N,1,,BAO_0000219
5549,,,10116.0,Expert,Rattus norvegicus,15345,CHEMBL620381,80653,,392.0,,Tested in vitro for anticancer activity against 9L cells,,F,1,N,1,,BAO_0000219
5550,,,10116.0,Expert,Rattus norvegicus,15345,CHEMBL620382,80653,,392.0,,Tested in vitro for anticancer activity against 9L cells; Not determined,,F,1,N,1,,BAO_0000219
5551,,,9606.0,Intermediate,Homo sapiens,6301,CHEMBL620383,80682,,646.0,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,F,1,N,1,,BAO_0000219
5552,,,9606.0,Intermediate,Homo sapiens,4833,CHEMBL876493,80682,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,F,1,N,1,,BAO_0000219
5553,,,9606.0,Intermediate,Homo sapiens,4833,CHEMBL620384,80682,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,F,1,N,1,,BAO_0000219
5554,,,9606.0,Intermediate,Homo sapiens,4833,CHEMBL620385,80682,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,F,1,N,1,,BAO_0000219
5555,,,9606.0,Expert,Homo sapiens,13330,CHEMBL620386,80682,,646.0,,Cytotoxicity against human lung carcinoma A549 cell line,,F,1,N,1,,BAO_0000219
5556,,,9606.0,Expert,Homo sapiens,17517,CHEMBL620387,25,,646.0,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,F,1,D,9,,BAO_0000219
5557,,,9606.0,Expert,Homo sapiens,17517,CHEMBL621404,25,,646.0,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,F,1,D,9,,BAO_0000219
5558,,,9606.0,Intermediate,Homo sapiens,14425,CHEMBL621405,80682,,646.0,,"In vitro growth inhibition of A549, lung carcinoma",,F,1,N,1,,BAO_0000219
5559,,,9606.0,Intermediate,Homo sapiens,14425,CHEMBL621406,80682,,646.0,,"In vitro growth inhibition of A549, lung carcinoma.",,F,1,N,1,,BAO_0000219
5560,,,9606.0,Expert,Homo sapiens,5228,CHEMBL621407,80682,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
5561,,,9606.0,Intermediate,Homo sapiens,5351,CHEMBL621408,80682,,646.0,,Cytotoxic activity against human lung cancer A549 cell line was determined,,F,1,N,1,,BAO_0000219
5562,,,9606.0,Expert,Homo sapiens,12198,CHEMBL885345,80682,,646.0,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,F,1,N,1,,BAO_0000219
5563,,,9606.0,Intermediate,Homo sapiens,13891,CHEMBL621409,80682,,646.0,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,F,1,N,1,,BAO_0000219
5564,,,9606.0,Expert,Homo sapiens,5677,CHEMBL876034,80682,,646.0,,Cytotoxicity in A549 (human carcinoma) cell line.,,F,1,N,1,,BAO_0000219
5565,,,9606.0,Intermediate,Homo sapiens,13788,CHEMBL621410,80682,,646.0,,Cytotoxicity on lung carcinoma (A-549) cell line,,F,1,N,1,,BAO_0000219
5566,,,9606.0,Expert,Homo sapiens,13384,CHEMBL621411,80682,,646.0,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,F,1,N,1,,BAO_0000219
5567,,,9606.0,Intermediate,Homo sapiens,6726,CHEMBL621412,80682,,646.0,,Effective dose of compound against replication of A549 cell line was evaluated,,F,1,N,1,,BAO_0000219
5568,,,9606.0,Expert,Homo sapiens,3455,CHEMBL621413,80682,,646.0,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,F,1,N,1,,BAO_0000219
5569,,,9606.0,Intermediate,Homo sapiens,5726,CHEMBL621414,80682,,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,F,1,N,1,,BAO_0000219
5570,,,9606.0,Intermediate,Homo sapiens,5726,CHEMBL621415,80682,,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,F,1,N,1,,BAO_0000219
5571,,,9606.0,Intermediate,Homo sapiens,3936,CHEMBL621416,80682,,646.0,,The compound was evaluated for antiproliferative activity against A549 cell line,,F,1,N,1,,BAO_0000219
5572,,,9606.0,Intermediate,Homo sapiens,14991,CHEMBL621417,80682,,646.0,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,F,1,N,1,,BAO_0000219
5573,,,9606.0,Intermediate,Homo sapiens,5243,CHEMBL621418,80682,,646.0,,Concentration required for growth inhibition of human lung carcinoma cell line A549,,F,1,N,1,,BAO_0000219
5574,,,9606.0,Intermediate,Homo sapiens,12858,CHEMBL621419,80682,,646.0,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,F,1,N,1,,BAO_0000219
5575,,,9606.0,Intermediate,Homo sapiens,6776,CHEMBL621420,80682,,646.0,,Growth inhibition against A549 cell line was evaluated,,F,1,N,1,,BAO_0000219
5576,,,9606.0,Intermediate,Homo sapiens,16558,CHEMBL875823,80682,,646.0,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,F,1,N,1,,BAO_0000219
5577,,,9606.0,Expert,Homo sapiens,4583,CHEMBL621421,80682,,646.0,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,F,1,N,1,,BAO_0000219
5578,,,9606.0,Intermediate,Homo sapiens,13514,CHEMBL621422,80682,,646.0,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,F,1,N,1,,BAO_0000219
5579,,,9606.0,Expert,Homo sapiens,15166,CHEMBL884014,80682,,646.0,,Chemosensitivity against DT-diaphorase rich A549 cell lines,,F,1,N,1,,BAO_0000219
5580,,,9606.0,Intermediate,Homo sapiens,13873,CHEMBL621423,80682,,646.0,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,F,1,N,1,,BAO_0000219
5581,,,9606.0,Expert,Homo sapiens,6447,CHEMBL621424,80682,,646.0,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,F,1,N,1,,BAO_0000219
5582,,,9606.0,Intermediate,Homo sapiens,2068,CHEMBL621425,80682,,646.0,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,F,1,N,1,,BAO_0000219
5583,,,9606.0,Expert,Homo sapiens,1863,CHEMBL621426,80682,,646.0,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,F,1,N,1,,BAO_0000219
5584,,,9606.0,Intermediate,Homo sapiens,13873,CHEMBL621427,80682,,646.0,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,F,1,N,1,,BAO_0000219
5585,,,9606.0,Intermediate,Homo sapiens,13873,CHEMBL621428,80682,,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,F,1,N,1,,BAO_0000219
5586,,,9606.0,Expert,Homo sapiens,13873,CHEMBL621429,80682,,646.0,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,F,1,N,1,,BAO_0000219
5587,,,9606.0,Intermediate,Homo sapiens,579,CHEMBL621430,80682,,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,F,1,N,1,,BAO_0000219
5588,,,9606.0,Intermediate,Homo sapiens,579,CHEMBL621431,80682,,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,F,1,N,1,,BAO_0000219
5589,,,9606.0,Intermediate,Homo sapiens,4584,CHEMBL621432,80682,,646.0,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,F,1,N,1,,BAO_0000219
5590,,,9606.0,Expert,Homo sapiens,5421,CHEMBL621433,80682,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,F,1,N,1,,BAO_0000219
5591,,,9606.0,Intermediate,Homo sapiens,5421,CHEMBL875824,80682,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,F,1,N,1,,BAO_0000219
5592,,,9606.0,Intermediate,Homo sapiens,5421,CHEMBL621434,80682,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,F,1,N,1,,BAO_0000219
5593,,,9606.0,Intermediate,Homo sapiens,5421,CHEMBL621435,80682,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,F,1,N,1,,BAO_0000219
5594,,,9606.0,Intermediate,Homo sapiens,14188,CHEMBL621436,80682,,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,F,1,N,1,,BAO_0000219
5595,,,9606.0,Intermediate,Homo sapiens,14188,CHEMBL621437,80682,,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,F,1,N,1,,BAO_0000219
5596,,,9606.0,Intermediate,Homo sapiens,15354,CHEMBL621438,80682,,646.0,,Compound was tested for the growth inhibition of A549 lung tumor cell line,,F,1,N,1,,BAO_0000219
5597,,,9606.0,Expert,Homo sapiens,14253,CHEMBL621439,80682,,646.0,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,F,1,N,1,,BAO_0000219
5598,,,9606.0,Intermediate,Homo sapiens,13873,CHEMBL621440,80682,,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,F,1,N,1,,BAO_0000219
5599,,,9615.0,Intermediate,Canis lupus familiaris,3043,CHEMBL621441,50588,,,,Oral bioavailability in dog (conscious),,A,1,N,1,,BAO_0000218
5600,,,9615.0,Intermediate,Canis lupus familiaris,3045,CHEMBL621442,50588,,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,A,1,N,1,,BAO_0000218
5601,,,9615.0,Intermediate,Canis lupus familiaris,3022,CHEMBL621443,50588,,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,A,1,N,1,,BAO_0000218
5602,,,9615.0,Intermediate,Canis lupus familiaris,4453,CHEMBL621444,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
5603,,,9615.0,Intermediate,Canis lupus familiaris,1696,CHEMBL625133,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
5604,,,9615.0,Intermediate,Canis lupus familiaris,5045,CHEMBL625134,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
5605,,,9615.0,Intermediate,Canis lupus familiaris,5356,CHEMBL625135,50588,,,,Oral bioavailability in dog (fasted),,A,1,N,1,,BAO_0000218
5606,,,9615.0,Intermediate,Canis lupus familiaris,17764,CHEMBL625136,50588,,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,A,1,N,1,,BAO_0000218
5607,,,9615.0,Intermediate,Canis lupus familiaris,6448,CHEMBL625137,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
5608,,,9615.0,Intermediate,Canis lupus familiaris,1475,CHEMBL625138,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
5609,,,9615.0,Intermediate,Canis lupus familiaris,3788,CHEMBL625139,50588,,,,Percent bioavailability in dog,,A,1,N,1,,BAO_0000218
5610,,,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL872264,50588,,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,A,1,N,1,,BAO_0000218
5611,,,9615.0,Intermediate,Canis lupus familiaris,13397,CHEMBL625140,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
5612,,,9615.0,Intermediate,Canis lupus familiaris,2137,CHEMBL624436,50588,,,,The compound was evaluated for bioavailability in dogs; 34-44,,A,1,N,1,,BAO_0000218
5613,,,9615.0,Intermediate,Canis lupus familiaris,2959,CHEMBL624437,50588,,,,Bioavailability in dog (dose 4 mg/kg p.o.),,A,1,N,1,,BAO_0000218
5614,,,9615.0,Intermediate,Canis lupus familiaris,6448,CHEMBL872261,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
5615,,,9615.0,Intermediate,Canis lupus familiaris,6084,CHEMBL624438,50588,,,,8 hour trough Blood level in dog was measured after administration of compound,,A,1,N,1,,BAO_0000218
5616,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL624439,50588,,,Plasma,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,A,1,N,1,,BAO_0000218
5617,,,9615.0,Intermediate,Canis lupus familiaris,6316,CHEMBL624440,50588,,,,C24 after oral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
5618,,,9615.0,Intermediate,Canis lupus familiaris,5238,CHEMBL624441,50588,,,,Clearance after oral and iv dosing in dogs,,A,1,N,1,,BAO_0000218
5619,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17796,CHEMBL624442,50588,,,Plasma,Clearance of the drug was measured in the plasma of dog,,A,1,N,1,,BAO_0000218
5620,,,9615.0,Intermediate,Canis lupus familiaris,2652,CHEMBL624443,50588,,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,A,1,N,1,,BAO_0000218
5621,,,9615.0,Intermediate,Canis lupus familiaris,5654,CHEMBL624444,50588,,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5622,,,9615.0,Intermediate,Canis lupus familiaris,6621,CHEMBL624445,50588,,,,Clearance of compound was determined in dogs,,A,1,N,1,,BAO_0000218
5623,,,9615.0,Intermediate,Canis lupus familiaris,6505,CHEMBL624446,50588,,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,A,1,N,1,,BAO_0000218
5624,,,9615.0,Intermediate,Canis lupus familiaris,5802,CHEMBL624447,50588,,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,A,1,N,1,,BAO_0000218
5625,,,9615.0,Intermediate,Canis lupus familiaris,17267,CHEMBL624448,50588,,,,Plasma clearance in dog was determined,,A,1,N,1,,BAO_0000218
5626,,,9615.0,Intermediate,Canis lupus familiaris,4521,CHEMBL624449,50588,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,A,1,N,1,,BAO_0000218
5627,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL624450,50588,,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,A,1,N,1,,BAO_0000218
5628,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL875942,50588,,,,Plasma clearance in dog after administration of 1 mg/kg iv,,A,1,N,1,,BAO_0000218
5629,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL624451,50588,,,,Plasma clearance in dogs,,A,1,N,1,,BAO_0000218
5630,,,9615.0,Intermediate,Canis lupus familiaris,5542,CHEMBL624452,50588,,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,A,1,N,1,,BAO_0000218
5631,,,9615.0,Intermediate,Canis lupus familiaris,5199,CHEMBL624453,50588,,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,A,1,N,1,,BAO_0000218
5632,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL624454,50588,,,,Plasma clearance after 15 mg/kg iv dose in Dogs,,A,1,N,1,,BAO_0000218
5633,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL624455,50588,,,,Plasma clearance after 30 mg/kg po dose in Dogs,,A,1,N,1,,BAO_0000218
5634,,,9615.0,Intermediate,Canis lupus familiaris,16367,CHEMBL624456,50588,,,,Plasma administration to dogs,,A,1,N,1,,BAO_0000218
5635,,,9615.0,Intermediate,Canis lupus familiaris,5505,CHEMBL624457,50588,,,,Plasma clearance was determined,,A,1,N,1,,BAO_0000218
5636,,,9615.0,Intermediate,Canis lupus familiaris,6215,CHEMBL624458,50588,,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
5637,,,9615.0,Intermediate,Canis lupus familiaris,1466,CHEMBL624459,50588,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,A,1,N,1,,BAO_0000218
5638,Microsomes,2107.0,9606.0,Intermediate,Homo sapiens,5007,CHEMBL624460,102164,,,Liver,Intrinsic clearance in human liver microsomes,,A,1,S,2,,BAO_0000251
5639,Microsomes,2107.0,9606.0,Intermediate,Homo sapiens,5007,CHEMBL624461,102164,,,Liver,Intrinsic clearance in human liver microsomes,,A,1,S,2,,BAO_0000251
5640,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL875943,50588,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,A,1,N,1,,BAO_0000218
5641,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL624462,50588,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,A,1,N,1,,BAO_0000218
5642,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL624463,50588,,,,Clearance in dog (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
5643,,,9615.0,Intermediate,Canis lupus familiaris,6221,CHEMBL624464,50588,,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,A,1,N,1,,BAO_0000218
5644,,,9615.0,Intermediate,Canis lupus familiaris,5007,CHEMBL624465,50588,,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,A,1,N,1,,BAO_0000218
5645,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL624466,50588,,,,Plasma clearance after peroral administration at 10 mpk in dog,,A,1,N,1,,BAO_0000218
5646,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL624467,50588,,,,Plasma clearance after peroral administration at 5 mpk in dog,,A,1,N,1,,BAO_0000218
5647,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL624468,50588,,,,Plasma clearance after peroral administration at 5 mg/kg in dog,,A,1,N,1,,BAO_0000218
5648,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL624469,50588,,,,Plasma clearance was measured in dog,,A,1,N,1,,BAO_0000218
5649,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL624470,50588,,,,Plasma clearance was measured in dog,,A,1,N,1,,BAO_0000218
5650,,,9615.0,Intermediate,Canis lupus familiaris,5983,CHEMBL624471,50588,,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,A,1,N,1,,BAO_0000218
5651,,,9615.0,Intermediate,Canis lupus familiaris,5600,CHEMBL624472,50588,,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,A,1,N,1,,BAO_0000218
5652,,,9615.0,Intermediate,Canis lupus familiaris,17764,CHEMBL622775,50588,,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,A,1,N,1,,BAO_0000218
5653,,,9615.0,Intermediate,Canis lupus familiaris,6039,CHEMBL622776,50588,,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,A,1,N,1,,BAO_0000218
5654,,,9615.0,Intermediate,Canis lupus familiaris,6039,CHEMBL622777,50588,,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,A,1,N,1,,BAO_0000218
5655,,,9615.0,Intermediate,Canis lupus familiaris,6039,CHEMBL622778,50588,,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,A,1,N,1,,BAO_0000218
5656,,,9615.0,Intermediate,Canis lupus familiaris,4368,CHEMBL622779,50588,,,,Clearance by intravenous administration of 1.2 mg/kg in dog,,A,1,N,1,,BAO_0000218
5657,,,9615.0,Intermediate,Canis lupus familiaris,4305,CHEMBL622780,50588,,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5658,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1918,CHEMBL622781,50588,,,Plasma,Clearance value was evaluated in dog plasma,,A,1,N,1,,BAO_0000218
5659,,,9615.0,Intermediate,Canis lupus familiaris,6005,CHEMBL622782,50588,,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5660,,1969.0,9615.0,Intermediate,Canis lupus familiaris,4839,CHEMBL622783,50588,,,Plasma,Compound was tested for plasma clearance in dog,,A,1,N,1,,BAO_0000218
5661,,,9615.0,Intermediate,Canis lupus familiaris,4239,CHEMBL622784,50588,,,,Pharmacokinetic property (Plasma clearance) was measured in dog,,A,1,N,1,,BAO_0000218
5662,,,10090.0,Intermediate,Mus musculus,17729,CHEMBL622785,50594,,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
5663,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL622786,50594,,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
5664,,,10090.0,Intermediate,Mus musculus,5302,CHEMBL622787,50594,,,,Area under curve value in mouse at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
5665,,,10090.0,Intermediate,Mus musculus,5506,CHEMBL875949,50594,,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,A,1,N,1,,BAO_0000218
5666,,,10090.0,Intermediate,Mus musculus,5506,CHEMBL622788,50594,,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,A,1,N,1,,BAO_0000218
5667,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL622789,50594,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,F,1,N,1,,BAO_0000218
5668,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL622790,50594,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,F,1,N,1,,BAO_0000218
5669,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL622791,50594,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,F,1,N,1,,BAO_0000218
5670,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL622792,50594,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,F,1,N,1,,BAO_0000218
5671,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL622793,50594,,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,A,1,N,1,,BAO_0000218
5672,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL622794,50594,,,,Area under curve was determined for the compound at 24 mg/Kg,,A,1,N,1,,BAO_0000218
5673,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL622795,50594,,,,Area under curve was determined for the compound at 40 mg/Kg,,A,1,N,1,,BAO_0000218
5674,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL621803,50594,,,,Area under curve was determined for the compound at 5 mg/Kg,,A,1,N,1,,BAO_0000218
5675,,,10090.0,Intermediate,Mus musculus,3132,CHEMBL621804,50594,,,,Area under the curve for the compound is obtained at dose 25 mg/kg,,A,1,N,1,,BAO_0000218
5676,,,10090.0,Intermediate,Mus musculus,3132,CHEMBL621805,50594,,,,Area under the curve for the compound was obtained when tested in mouse,,A,1,N,1,,BAO_0000218
5677,,,10090.0,Intermediate,Mus musculus,17837,CHEMBL621806,50594,,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,A,1,N,1,,BAO_0000218
5678,,,10090.0,Intermediate,Mus musculus,17837,CHEMBL621807,50594,,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,A,1,N,1,,BAO_0000218
5679,,,10090.0,Intermediate,Mus musculus,6062,CHEMBL621808,50594,,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5680,,,10090.0,Intermediate,Mus musculus,4066,CHEMBL621809,50594,,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,A,1,N,1,,BAO_0000218
5681,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL621810,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,A,1,N,1,,BAO_0000218
5682,,,10090.0,Intermediate,Mus musculus,14239,CHEMBL875164,50594,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,A,1,N,1,,BAO_0000218
5683,,,10090.0,Intermediate,Mus musculus,14239,CHEMBL621811,50594,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,A,1,N,1,,BAO_0000218
5684,,,10090.0,Intermediate,Mus musculus,4890,CHEMBL621812,50594,,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,A,1,N,1,,BAO_0000218
5685,,,10090.0,Intermediate,Mus musculus,429,CHEMBL621813,50594,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,A,1,N,1,,BAO_0000218
5686,,,10090.0,Intermediate,Mus musculus,429,CHEMBL621814,50594,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,A,1,N,1,,BAO_0000218
5687,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL621815,50594,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,A,1,N,1,,BAO_0000218
5688,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL621816,50594,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
5689,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL621817,50594,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,A,1,N,1,,BAO_0000218
5690,,,10090.0,Intermediate,Mus musculus,6091,CHEMBL621818,50594,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,A,1,N,1,,BAO_0000218
5691,,,10090.0,Intermediate,Mus musculus,6091,CHEMBL621819,50594,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,A,1,N,1,,BAO_0000218
5692,,,10090.0,Intermediate,Mus musculus,6091,CHEMBL621820,50594,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,A,1,N,1,,BAO_0000218
5693,,,10090.0,Intermediate,Mus musculus,6091,CHEMBL621821,50594,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,A,1,N,1,,BAO_0000218
5694,,,10090.0,Intermediate,Mus musculus,6178,CHEMBL621822,50594,,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,A,1,N,1,,BAO_0000218
5695,,,10090.0,Intermediate,Mus musculus,6178,CHEMBL619474,50594,,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,A,1,N,1,,BAO_0000218
5696,,,10090.0,Intermediate,Mus musculus,6619,CHEMBL619475,50594,,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,A,1,N,1,,BAO_0000218
5697,,,10090.0,Intermediate,Mus musculus,6619,CHEMBL619476,50594,,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,A,1,N,1,,BAO_0000218
5698,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL619477,50594,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,A,1,N,1,,BAO_0000218
5699,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL619478,50594,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,A,1,N,1,,BAO_0000218
5700,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL619479,50594,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,A,1,N,1,,BAO_0000218
5701,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL619480,50594,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,A,1,N,1,,BAO_0000218
5702,,,10090.0,Intermediate,Mus musculus,3192,CHEMBL619481,50594,,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,A,1,N,1,,BAO_0000218
5703,,,10090.0,Intermediate,Mus musculus,3192,CHEMBL619482,50594,,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,A,1,N,1,,BAO_0000218
5704,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL619483,50594,,,,Area under the curve was evaluated in mice after intravenous administration,,A,1,N,1,,BAO_0000218
5705,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL619484,50594,,,,Area under the curve was evaluated in mice after oral administration,,A,1,N,1,,BAO_0000218
5706,,1969.0,10090.0,Intermediate,Mus musculus,16597,CHEMBL619485,50594,,,Plasma,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,A,1,N,1,,BAO_0000218
5707,,1969.0,10090.0,Intermediate,Mus musculus,16597,CHEMBL619486,50594,,,Plasma,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,A,1,N,1,,BAO_0000218
5708,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL619487,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,A,1,N,1,,BAO_0000218
5709,,,10090.0,Intermediate,Mus musculus,17734,CHEMBL619488,50594,,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,A,1,N,1,,BAO_0000218
5710,,178.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL620106,50594,,,Blood,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5711,,,,Intermediate,,15345,CHEMBL620107,80653,,392.0,,The compound was tested in vitro for anticancer activity against 9L cells,,F,1,N,1,,BAO_0000219
5712,,,10116.0,Autocuration,Rattus norvegicus,2181,CHEMBL620283,22226,,,,Anti proliferation activity determined; Weak effect,,F,1,U,0,,BAO_0000019
5713,,,10116.0,Autocuration,Rattus norvegicus,2181,CHEMBL875176,22226,,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,F,1,U,0,,BAO_0000219
5714,,,10116.0,Autocuration,Rattus norvegicus,2181,CHEMBL620284,22226,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,F,1,U,0,,BAO_0000219
5715,,,10116.0,Autocuration,Rattus norvegicus,2181,CHEMBL623515,22226,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,F,1,U,0,,BAO_0000219
5716,,,10090.0,Autocuration,Mus musculus,10486,CHEMBL623516,22226,,,,The cytotoxic activity was in vitro tested by 9PS assay method,,F,1,U,0,,BAO_0000019
5717,,,10090.0,Autocuration,Mus musculus,10486,CHEMBL623517,22226,,,,The cytotoxic activity was in vitro tested by 9PS assay method.,,F,1,U,0,,BAO_0000019
5718,,,,Autocuration,,15508,CHEMBL857878,22224,,,,Partition coefficient (logD6.5),,A,1,U,0,,BAO_0000019
5719,,,9606.0,Expert,Homo sapiens,5242,CHEMBL623518,81034,,478.0,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,F,1,N,1,,BAO_0000219
5720,,,9606.0,Intermediate,Homo sapiens,16167,CHEMBL624195,80018,,455.0,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,F,1,N,1,,BAO_0000219
5721,,,9606.0,Expert,Homo sapiens,4782,CHEMBL624196,80852,,500.0,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,F,1,N,1,,BAO_0000219
5722,,,9606.0,Expert,Homo sapiens,16093,CHEMBL624197,9,,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,F,1,D,9,,BAO_0000219
5723,,,9606.0,Intermediate,Homo sapiens,2596,CHEMBL624198,80021,,624.0,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,F,1,N,1,,BAO_0000219
5724,,,9606.0,Intermediate,Homo sapiens,2596,CHEMBL621287,80021,,624.0,,in vitro cytotoxicity against A 498 cancer cell line,,F,1,N,1,,BAO_0000219
5725,,,9606.0,Intermediate,Homo sapiens,3239,CHEMBL621288,80021,,624.0,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,F,1,N,1,,BAO_0000219
5726,,,9606.0,Intermediate,Homo sapiens,1847,CHEMBL876496,80021,,624.0,,Cytotoxic activity against A 498 renal cancer cell lines.,,F,1,N,1,,BAO_0000219
5727,,,9606.0,Intermediate,Homo sapiens,10553,CHEMBL621289,80021,,624.0,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,F,1,N,1,,BAO_0000219
5728,,,1280.0,Autocuration,Staphylococcus aureus,16219,CHEMBL621290,22226,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,F,1,U,0,,BAO_0000019
5729,,,1280.0,Autocuration,Staphylococcus aureus,16219,CHEMBL621291,22226,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,F,1,U,0,,BAO_0000019
5730,,,1280.0,Autocuration,Staphylococcus aureus,16219,CHEMBL621292,22226,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,F,1,U,0,,BAO_0000019
5731,,,1280.0,Autocuration,Staphylococcus aureus,16219,CHEMBL621293,22226,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,F,1,U,0,,BAO_0000019
5732,,,9606.0,Intermediate,Homo sapiens,4782,CHEMBL621294,80682,,646.0,,Inhibitory concentration required against A 549 lung cancer cell line,,F,1,N,1,,BAO_0000219
5733,,,9606.0,Intermediate,Homo sapiens,11805,CHEMBL621295,80682,,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,F,1,N,1,,BAO_0000219
5734,,,9606.0,Intermediate,Homo sapiens,11805,CHEMBL884007,80682,,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,F,1,N,1,,BAO_0000219
5735,,,9606.0,Intermediate,Homo sapiens,2007,CHEMBL621296,80682,,646.0,,In vitro cytotoxicity against lung cancer A 549 cell lines,,F,1,N,1,,BAO_0000219
5736,,,9606.0,Intermediate,Homo sapiens,4594,CHEMBL621297,80682,,646.0,,Compound was tested for its cytotoxicity against A 549 cell line,,F,1,N,1,,BAO_0000219
5737,,,9606.0,Expert,Homo sapiens,6018,CHEMBL839828,80682,,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,F,1,N,1,,BAO_0000219
5738,,,9606.0,Intermediate,Homo sapiens,6018,CHEMBL620397,80682,,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,F,1,N,1,,BAO_0000219
5739,,,9606.0,Expert,Homo sapiens,3599,CHEMBL620398,80682,,646.0,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,F,1,N,1,,BAO_0000219
5740,,,9606.0,Intermediate,Homo sapiens,2551,CHEMBL620399,80682,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,F,1,N,1,,BAO_0000219
5741,,,9606.0,Expert,Homo sapiens,16132,CHEMBL620400,80682,,646.0,,In vitro inhibition of A549 (human lung cancer) cell growth.,,F,1,N,1,,BAO_0000219
5742,,,9606.0,Intermediate,Homo sapiens,16132,CHEMBL620401,80682,,646.0,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,F,1,N,1,,BAO_0000219
5743,,,9606.0,Expert,Homo sapiens,2551,CHEMBL620402,80682,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,F,1,N,1,,BAO_0000219
5744,,,9606.0,Expert,Homo sapiens,2551,CHEMBL620403,80682,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,F,1,N,1,,BAO_0000219
5745,,,,Autocuration,,11913,CHEMBL620404,22226,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,F,1,U,0,,BAO_0000218
5746,,,,Autocuration,,12621,CHEMBL620405,104694,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,F,1,H,4,,BAO_0000218
5747,,,,Autocuration,,12621,CHEMBL620406,104694,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,F,1,H,4,,BAO_0000218
5748,,,,Autocuration,,12621,CHEMBL620407,104694,,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,F,1,H,4,,BAO_0000218
5749,,,,Autocuration,,12621,CHEMBL620408,104694,,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,F,1,H,4,,BAO_0000218
5750,,,,Autocuration,,12621,CHEMBL620409,104694,,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,F,1,H,4,,BAO_0000218
5751,,,9606.0,Expert,Homo sapiens,3600,CHEMBL620410,80021,,624.0,,Inhibition of A-498 human Renal cell proliferation,,F,1,N,1,,BAO_0000219
5752,,,10116.0,Autocuration,Rattus norvegicus,1796,CHEMBL620411,22226,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,F,1,U,0,,BAO_0000019
5753,,,10116.0,Autocuration,Rattus norvegicus,1796,CHEMBL620412,22226,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,F,1,U,0,,BAO_0000019
5754,,,10116.0,Autocuration,Rattus norvegicus,1796,CHEMBL876596,22226,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,F,1,U,0,,BAO_0000019
5755,,,9606.0,Expert,Homo sapiens,16464,CHEMBL620413,80012,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,F,1,N,1,,BAO_0000219
5756,,,9606.0,Intermediate,Homo sapiens,16464,CHEMBL620414,80012,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,F,1,N,1,,BAO_0000219
5757,,,9606.0,Intermediate,Homo sapiens,16464,CHEMBL620415,80012,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,F,1,N,1,,BAO_0000219
5758,,,9606.0,Expert,Homo sapiens,13617,CHEMBL620416,80682,,646.0,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,F,1,N,1,,BAO_0000219
5759,,,9606.0,Intermediate,Homo sapiens,4584,CHEMBL620417,80682,,646.0,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,F,1,N,1,,BAO_0000219
5760,,,9606.0,Expert,Homo sapiens,13799,CHEMBL620418,80682,,646.0,,Cytotoxic activity evaluated against A549 tumor cells,,F,1,N,1,,BAO_0000219
5761,,,9606.0,Intermediate,Homo sapiens,16726,CHEMBL620419,80682,,646.0,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,F,1,N,1,,BAO_0000219
5762,,,9606.0,Intermediate,Homo sapiens,16109,CHEMBL620420,80682,,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,F,1,N,1,,BAO_0000219
5763,,,9606.0,Intermediate,Homo sapiens,16109,CHEMBL620421,80682,,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,F,1,N,1,,BAO_0000219
5764,,,9606.0,Intermediate,Homo sapiens,15474,CHEMBL620422,80682,,646.0,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,F,1,N,1,,BAO_0000219
5765,,,9606.0,Intermediate,Homo sapiens,6851,CHEMBL620423,80682,,646.0,,Cytotoxicity of compound against A549 cell line,,F,1,N,1,,BAO_0000219
5766,,,9606.0,Expert,Homo sapiens,17534,CHEMBL620424,80682,,646.0,,Cytotoxicity against human lung cell carcinoma A549 cell line,,F,1,N,1,,BAO_0000219
5767,,,9606.0,Intermediate,Homo sapiens,2621,CHEMBL620425,80682,,646.0,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,F,1,N,1,,BAO_0000219
5768,,,9606.0,Intermediate,Homo sapiens,830,CHEMBL620426,80682,,646.0,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,F,1,N,1,,BAO_0000219
5769,,,9606.0,Intermediate,Homo sapiens,14255,CHEMBL620427,80682,,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,F,1,N,1,,BAO_0000219
5770,,,9606.0,Intermediate,Homo sapiens,14255,CHEMBL620428,80682,,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,F,1,N,1,,BAO_0000219
5771,,,9606.0,Intermediate,Homo sapiens,1590,CHEMBL620429,80682,,646.0,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,F,1,N,1,,BAO_0000219
5772,,,9606.0,Expert,Homo sapiens,6146,CHEMBL620430,80682,,646.0,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,F,1,N,1,,BAO_0000219
5773,,,9606.0,Expert,Homo sapiens,17427,CHEMBL839887,80682,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
5774,,,9606.0,Intermediate,Homo sapiens,5280,CHEMBL620431,80682,,646.0,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,F,1,N,1,,BAO_0000219
5775,,,9606.0,Intermediate,Homo sapiens,16786,CHEMBL884010,80682,,646.0,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,F,1,N,1,,BAO_0000219
5776,,,9606.0,Intermediate,Homo sapiens,5895,CHEMBL620538,80682,,646.0,,In vitro cytotoxicity against A549 (human lung cancer),,F,1,N,1,,BAO_0000219
5777,,,9606.0,Expert,Homo sapiens,14297,CHEMBL620539,80682,,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
5778,,,9606.0,Intermediate,Homo sapiens,17824,CHEMBL623373,80682,,646.0,,In vivo antiproliferative activity against A549 cell line,,F,1,N,1,,BAO_0000218
5779,,,9606.0,Intermediate,Homo sapiens,14368,CHEMBL623374,80682,,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549),,F,1,N,1,,BAO_0000219
5780,,,9606.0,Intermediate,Homo sapiens,14368,CHEMBL623375,80682,,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,F,1,N,1,,BAO_0000219
5781,,,9606.0,Intermediate,Homo sapiens,14254,CHEMBL623376,80682,,646.0,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,F,1,N,1,,BAO_0000219
5782,,,9606.0,Intermediate,Homo sapiens,15897,CHEMBL623377,80682,,646.0,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,F,1,N,1,,BAO_0000219
5783,,,9606.0,Intermediate,Homo sapiens,13866,CHEMBL623378,80682,,646.0,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,F,1,N,1,,BAO_0000219
5784,,,9606.0,Intermediate,Homo sapiens,13370,CHEMBL623379,80682,,646.0,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,F,1,N,1,,BAO_0000219
5785,,,9606.0,Intermediate,Homo sapiens,4862,CHEMBL623380,80682,,646.0,,Inhibitory activity against A549 lung cancer cell line,,F,1,N,1,,BAO_0000219
5786,,,9606.0,Intermediate,Homo sapiens,4862,CHEMBL623381,80682,,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,F,1,N,1,,BAO_0000219
5787,,,9606.0,Intermediate,Homo sapiens,4862,CHEMBL623382,80682,,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,F,1,N,1,,BAO_0000219
5788,,,9606.0,Intermediate,Homo sapiens,15970,CHEMBL623383,80682,,646.0,,Inhibitory concentration against A549 (lung cancer) cell line,,F,1,N,1,,BAO_0000219
5789,,,9606.0,Expert,Homo sapiens,17713,CHEMBL623384,80682,,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
5790,,,9606.0,Intermediate,Homo sapiens,4833,CHEMBL623385,80682,,646.0,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,F,1,N,1,,BAO_0000219
5791,,,9606.0,Expert,Homo sapiens,13736,CHEMBL623386,80682,,646.0,,Activity against A549 cancer cell line.,,F,1,N,1,,BAO_0000219
5792,,,9606.0,Intermediate,Homo sapiens,4312,CHEMBL884105,80682,,646.0,,The compound was evaluated for cytotoxicity against A549 cell line,,F,1,N,1,,BAO_0000219
5793,,,9606.0,Intermediate,Homo sapiens,5421,CHEMBL623387,80682,,646.0,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,F,1,N,1,,BAO_0000219
5794,,,9606.0,Intermediate,Homo sapiens,5421,CHEMBL621568,80682,,646.0,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,F,1,N,1,,BAO_0000219
5795,,,9606.0,Intermediate,Homo sapiens,14717,CHEMBL621569,80682,,646.0,,Growth inhibitory activity was measured for human A549 tumor cell line.,,F,1,N,1,,BAO_0000219
5796,,,9606.0,Intermediate,Homo sapiens,4634,CHEMBL621570,80682,,646.0,,Inhibitory activity against A549 lung cancer cell line,,F,1,N,1,,BAO_0000219
5797,,,9606.0,Intermediate,Homo sapiens,1149,CHEMBL621571,80682,,646.0,,Inhibitory activity against A549 cell line; inactive,,F,1,N,1,,BAO_0000219
5798,,,9606.0,Expert,Homo sapiens,5421,CHEMBL621572,80682,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,F,1,N,1,,BAO_0000219
5799,,,9606.0,Expert,Homo sapiens,5421,CHEMBL621573,80682,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,F,1,N,1,,BAO_0000219
5800,,,9606.0,Intermediate,Homo sapiens,5421,CHEMBL621574,80682,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,F,1,N,1,,BAO_0000219
5801,,,9606.0,Intermediate,Homo sapiens,3320,CHEMBL621575,80682,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,F,1,N,1,,BAO_0000219
5802,,,9606.0,Intermediate,Homo sapiens,3320,CHEMBL621576,80682,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,F,1,N,1,,BAO_0000219
5803,,,9606.0,Intermediate,Homo sapiens,3320,CHEMBL621577,80682,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,F,1,N,1,,BAO_0000219
5804,,,9606.0,Intermediate,Homo sapiens,3320,CHEMBL621578,80682,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,F,1,N,1,,BAO_0000219
5805,,,9606.0,Intermediate,Homo sapiens,3320,CHEMBL621579,80682,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,F,1,N,1,,BAO_0000219
5806,,,9606.0,Intermediate,Homo sapiens,5726,CHEMBL621580,80682,,646.0,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,F,1,N,1,,BAO_0000219
5807,,,9615.0,Intermediate,Canis lupus familiaris,17800,CHEMBL621581,50588,,,,Plasma clearance (in vivo) in mongrel dogs was determined,,A,1,N,1,,BAO_0000218
5808,,,9615.0,Intermediate,Canis lupus familiaris,5985,CHEMBL621582,50588,,,,Plasma clearance was measured in dog,,A,1,N,1,,BAO_0000218
5809,,,9615.0,Intermediate,Canis lupus familiaris,5530,CHEMBL621583,50588,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,A,1,N,1,,BAO_0000218
5810,,,9615.0,Intermediate,Canis lupus familiaris,5530,CHEMBL621584,50588,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5811,,1969.0,9615.0,Intermediate,Canis lupus familiaris,4839,CHEMBL621585,50588,,,Plasma,Tested for plasma clearance in dog,,A,1,N,1,,BAO_0000218
5812,,,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL621586,50588,,,,The compound was tested for clearance in dog plasma.,,A,1,N,1,,BAO_0000218
5813,,,9615.0,Intermediate,Canis lupus familiaris,4838,CHEMBL875835,50588,,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,A,1,N,1,,BAO_0000218
5814,,,9615.0,Intermediate,Canis lupus familiaris,4137,CHEMBL621587,50588,,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,A,1,N,1,,BAO_0000218
5815,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5017,CHEMBL621588,50588,,,Plasma,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,A,1,N,1,,BAO_0000218
5816,Microsomes,2107.0,9615.0,Intermediate,Canis lupus familiaris,17538,CHEMBL621589,50588,,,Liver,In vitro clearance in dog liver microsomes,,A,1,N,1,,BAO_0000218
5817,,,9615.0,Intermediate,Canis lupus familiaris,6161,CHEMBL621590,50588,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,A,1,N,1,,BAO_0000218
5818,,,9615.0,Intermediate,Canis lupus familiaris,6161,CHEMBL621591,50588,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,A,1,N,1,,BAO_0000218
5819,,,9615.0,Intermediate,Canis lupus familiaris,1696,CHEMBL621592,50588,,,,Plasma clearance in dog,,A,1,N,1,,BAO_0000218
5820,,,9615.0,Intermediate,Canis lupus familiaris,6762,CHEMBL621593,50588,,,,Clearance rate in dog,,A,1,N,1,,BAO_0000218
5821,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5932,CHEMBL621594,50588,,,Plasma,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,A,1,N,1,,BAO_0000218
5822,,,9615.0,Intermediate,Canis lupus familiaris,6305,CHEMBL621595,50588,,,,Clearance in dogs,,A,1,N,1,,BAO_0000218
5823,,,9615.0,Intermediate,Canis lupus familiaris,4942,CHEMBL621596,50588,,,,Plasma clearance in dogs,,A,1,N,1,,BAO_0000218
5824,,,9615.0,Intermediate,Canis lupus familiaris,4219,CHEMBL621597,50588,,,,Plasma clearance was determined,,A,1,N,1,,BAO_0000218
5825,,,9615.0,Intermediate,Canis lupus familiaris,17853,CHEMBL621598,50588,,,,Lower clearance in dog (i.v.) at 0.5 mpk,,A,1,N,1,,BAO_0000218
5826,,,9615.0,Intermediate,Canis lupus familiaris,4514,CHEMBL621599,50588,,,,Plasma clearance in Beagle dogs,,A,1,N,1,,BAO_0000218
5827,,,9615.0,Intermediate,Canis lupus familiaris,6448,CHEMBL875836,50588,,,,Plasma clearance (Clp) in dog,,A,1,N,1,,BAO_0000218
5828,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL621600,50588,,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5829,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL621601,50588,,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,A,1,N,1,,BAO_0000218
5830,,,9615.0,Intermediate,Canis lupus familiaris,6062,CHEMBL618474,50588,,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
5831,,,9615.0,Intermediate,Canis lupus familiaris,6821,CHEMBL618475,50588,,,,Plasma clearance of compound was determined in dog,,A,1,N,1,,BAO_0000218
5832,,,9615.0,Intermediate,Canis lupus familiaris,4709,CHEMBL624524,50588,,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
5833,,,9615.0,Intermediate,Canis lupus familiaris,4521,CHEMBL624525,50588,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,A,1,N,1,,BAO_0000218
5834,,,9615.0,Intermediate,Canis lupus familiaris,5374,CHEMBL624526,50588,,,,Plasma clearance in dog was determined,,A,1,N,1,,BAO_0000218
5835,,,9615.0,Intermediate,Canis lupus familiaris,6057,CHEMBL624527,50588,,,,Plasma clearance was calculated in dog,,A,1,N,1,,BAO_0000218
5836,,,9615.0,Intermediate,Canis lupus familiaris,4727,CHEMBL624528,50588,,,,Plasma clearance at the dose of 2 mg/kg in dog,,A,1,N,1,,BAO_0000218
5837,,,9615.0,Intermediate,Canis lupus familiaris,5145,CHEMBL624529,50588,,,,Plasma clearance in dog,,A,1,N,1,,BAO_0000218
5838,,,9615.0,Intermediate,Canis lupus familiaris,17657,CHEMBL624530,50588,,,,Plasma clearance in dog,,A,1,N,1,,BAO_0000218
5839,,,9615.0,Intermediate,Canis lupus familiaris,17657,CHEMBL624531,50588,,,,Plasma clearance in dog; Unable to calculate,,A,1,N,1,,BAO_0000218
5840,,,9615.0,Intermediate,Canis lupus familiaris,5145,CHEMBL624532,50588,,,,Plasma clearance in rhesus monkey,,A,1,N,1,,BAO_0000218
5841,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL624533,50588,,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,A,1,N,1,,BAO_0000218
5842,,,9615.0,Intermediate,Canis lupus familiaris,6641,CHEMBL624534,50588,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,N,1,,BAO_0000218
5843,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL624535,50588,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,N,1,,BAO_0000218
5844,,,9615.0,Intermediate,Canis lupus familiaris,5472,CHEMBL624536,50588,,,,Plasma clearance was evaluated in dog,,A,1,N,1,,BAO_0000218
5845,,,9615.0,Intermediate,Canis lupus familiaris,5472,CHEMBL624537,50588,,,,Plasma clearance was evaluated in dog; Not tested,,A,1,N,1,,BAO_0000218
5846,,,9615.0,Intermediate,Canis lupus familiaris,5472,CHEMBL624538,50588,,,,Plasma clearance was evaluated in rhesus,,A,1,N,1,,BAO_0000218
5847,,,9615.0,Intermediate,Canis lupus familiaris,5472,CHEMBL624539,50588,,,,Plasma clearance was evaluated in rhesus; Not tested,,A,1,N,1,,BAO_0000218
5848,,,9615.0,Intermediate,Canis lupus familiaris,4257,CHEMBL624540,50588,,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,A,1,N,1,,BAO_0000218
5849,,,9615.0,Intermediate,Canis lupus familiaris,6679,CHEMBL624541,50588,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,A,1,N,1,,BAO_0000218
5850,,,9615.0,Intermediate,Canis lupus familiaris,5546,CHEMBL624542,50588,,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,A,1,N,1,,BAO_0000218
5851,,,9615.0,Intermediate,Canis lupus familiaris,6348,CHEMBL624543,50588,,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
5852,,,9615.0,Intermediate,Canis lupus familiaris,5474,CHEMBL624544,50588,,,,Clearance value at a dose of 0.2 mg/kg i.v.,,A,1,N,1,,BAO_0000218
5853,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6316,CHEMBL624545,50588,,,Plasma,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
5854,,,9615.0,Intermediate,Canis lupus familiaris,17594,CHEMBL624546,50588,,,,Cmax after oral dose of compound at 3 mg/kg in dogs,,A,1,N,1,,BAO_0000218
5855,,,9615.0,Intermediate,Canis lupus familiaris,17594,CHEMBL875957,50588,,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,A,1,N,1,,BAO_0000218
5856,,,9615.0,Intermediate,Canis lupus familiaris,5802,CHEMBL624547,50588,,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,A,1,N,1,,BAO_0000218
5857,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL624548,50588,,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,A,1,N,1,,BAO_0000218
5858,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL624549,50588,,,,Cmax in dog after administration of 1 mg/kg iv,,A,1,N,1,,BAO_0000218
5859,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1466,CHEMBL624550,50588,,,Plasma,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,A,1,N,1,,BAO_0000218
5860,,,9615.0,Intermediate,Canis lupus familiaris,6505,CHEMBL621613,50588,,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,A,1,N,1,,BAO_0000218
5861,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL621614,50588,,,,Cmax was determine after peroral administration at 10 mpk in dog,,A,1,N,1,,BAO_0000218
5862,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL623431,50588,,,,Cmax was determine after peroral administration at 5 mpk in dog,,A,1,N,1,,BAO_0000218
5863,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL623432,50588,,,,Cmax was determine after peroral administration at 5 mg/kg in dog,,A,1,N,1,,BAO_0000218
5864,,,9615.0,Intermediate,Canis lupus familiaris,5600,CHEMBL623433,50588,,,,Cmax after 0.3 mg/kg po administration in dog,,A,1,N,1,,BAO_0000218
5865,,,9615.0,Intermediate,Canis lupus familiaris,17764,CHEMBL623434,50588,,,,Cmax after peroral administration in dogs at 2.4 uM/kg,,A,1,N,1,,BAO_0000218
5866,,,9615.0,Intermediate,Canis lupus familiaris,6123,CHEMBL623435,50588,,,,Cmax in dog after oral administration at 1 mg/kg,,A,1,N,1,,BAO_0000218
5867,,,9615.0,Intermediate,Canis lupus familiaris,6123,CHEMBL623436,50588,,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,A,1,N,1,,BAO_0000218
5868,,,9615.0,Intermediate,Canis lupus familiaris,6757,CHEMBL875958,50588,,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,A,1,N,1,,BAO_0000218
5869,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL623437,50588,,,,Cmax value after 15 mg/kg iv dose in Dogs,,A,1,N,1,,BAO_0000218
5870,,178.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623438,50594,,,Blood,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5871,,178.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623439,50594,,,Blood,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5872,,10000001.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623440,50594,,,Bone,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5873,,10000001.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623441,50594,,,Bone,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5874,,10000001.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623442,50594,,,Bone,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5875,,,10090.0,Intermediate,Mus musculus,7767,CHEMBL623469,50594,,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5876,,,10090.0,Intermediate,Mus musculus,7767,CHEMBL623470,50594,,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5877,,,10090.0,Intermediate,Mus musculus,7767,CHEMBL623471,50594,,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5878,,948.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623472,50594,,,Heart,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5879,,948.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623473,50594,,,Heart,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5880,,948.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623474,50594,,,Heart,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5881,,2113.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623475,50594,,,Kidney,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5882,,2113.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623476,50594,,,Kidney,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5883,,2113.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL623477,50594,,,Kidney,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5884,,160.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL621896,50594,,,Intestine,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5885,,160.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL621897,50594,,,Intestine,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5886,,160.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL621898,50594,,,Intestine,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5887,,2107.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL621899,50594,,,Liver,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5888,,2107.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL621900,50594,,,Liver,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5889,,2107.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL621901,50594,,,Liver,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5890,,2048.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL621902,50594,,,Lung,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5891,,2048.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL621903,50594,,,Lung,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5892,,2048.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL622587,50594,,,Lung,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5893,,2385.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL620285,50594,,,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5894,,2385.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL875285,50594,,,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5895,,2385.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL620286,50594,,,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5896,,,10090.0,Intermediate,Mus musculus,7767,CHEMBL620287,50594,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5897,,,10090.0,Intermediate,Mus musculus,7767,CHEMBL620288,50594,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5898,,,10090.0,Intermediate,Mus musculus,7767,CHEMBL620289,50594,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5899,,160.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL620290,50594,,,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5900,,160.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL620291,50594,,,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5901,,160.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL620292,50594,,,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5902,,2106.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL620293,50594,,,Spleen,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5903,,2106.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL620294,50594,,,Spleen,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5904,,2106.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL618614,50594,,,Spleen,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5905,,945.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL618615,50594,,,Stomach,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5906,,945.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL618616,50594,,,Stomach,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
5907,,,9606.0,Expert,Homo sapiens,2036,CHEMBL618617,80012,,622.0,,Cytotoxicity against A-172 human tumor cell lines,,F,1,N,1,,BAO_0000219
5908,,,9606.0,Intermediate,Homo sapiens,2357,CHEMBL618618,80012,,622.0,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,F,1,N,1,,BAO_0000219
5909,,,9606.0,Intermediate,Homo sapiens,1457,CHEMBL618619,80014,,623.0,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,F,1,N,1,,BAO_0000219
5910,,,9606.0,Intermediate,Homo sapiens,4379,CHEMBL618620,81034,,478.0,,Tested for antiproliferative activity against A-2780 tumoral cell line,,F,1,N,1,,BAO_0000219
5911,,,9606.0,Intermediate,Homo sapiens,1093,CHEMBL618621,80018,,455.0,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,F,1,N,1,,BAO_0000219
5912,,,9606.0,Intermediate,Homo sapiens,12152,CHEMBL618622,80018,,455.0,,Tested in vitro against A-375 cell line human melanoma,,F,1,N,1,,BAO_0000219
5913,,,9606.0,Expert,Homo sapiens,16464,CHEMBL618623,80019,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,F,1,N,1,,BAO_0000219
5914,,,9606.0,Intermediate,Homo sapiens,16464,CHEMBL618624,80019,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,F,1,N,1,,BAO_0000219
5915,,,9606.0,Expert,Homo sapiens,16582,CHEMBL618625,80019,,797.0,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,F,1,N,1,,BAO_0000219
5916,,,9606.0,Intermediate,Homo sapiens,16464,CHEMBL618626,80019,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,F,1,N,1,,BAO_0000219
5917,,,9606.0,Intermediate,Homo sapiens,10413,CHEMBL618627,80019,,797.0,,Antitumor activity on A-427 lung carcinoma cell lines,,F,1,N,1,,BAO_0000219
5918,,,9606.0,Intermediate,Homo sapiens,6418,CHEMBL618628,80019,,797.0,,Cytotoxic activity against human A-427 lung tumor cell line,,F,1,N,1,,BAO_0000219
5919,,,9606.0,Expert,Homo sapiens,17134,CHEMBL618629,80019,,797.0,,In vitro antitumor effects against human A-427 cell lines.,,F,1,N,1,,BAO_0000219
5920,,,9606.0,Expert,Homo sapiens,16132,CHEMBL618630,80019,,797.0,,In vitro inhibition of A-427 (human lung cancer) cell growth.,,F,1,N,1,,BAO_0000219
5921,,,9606.0,Intermediate,Homo sapiens,16132,CHEMBL618631,80019,,797.0,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,F,1,N,1,,BAO_0000219
5922,,,9606.0,Intermediate,Homo sapiens,16780,CHEMBL618632,80019,,797.0,,Cytotoxic activity of compound against A-427 lung human tumor cell line,,F,1,N,1,,BAO_0000219
5923,,,9606.0,Expert,Homo sapiens,4085,CHEMBL618633,80852,,500.0,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,F,1,N,1,,BAO_0000219
5924,,,9606.0,Intermediate,Homo sapiens,1276,CHEMBL619315,80021,,624.0,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,F,1,N,1,,BAO_0000219
5925,,,9606.0,Expert,Homo sapiens,3498,CHEMBL619316,80021,,624.0,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,F,1,N,1,,BAO_0000219
5926,,,9606.0,Intermediate,Homo sapiens,1169,CHEMBL619317,80021,,624.0,,Cytotoxicity against human kidney carcinoma A-498cell lines,,F,1,N,1,,BAO_0000219
5927,,,9606.0,Intermediate,Homo sapiens,4450,CHEMBL619318,80021,,624.0,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,F,1,N,1,,BAO_0000219
5928,,,9606.0,Intermediate,Homo sapiens,3311,CHEMBL619319,80021,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,F,1,N,1,,BAO_0000219
5929,,,9606.0,Intermediate,Homo sapiens,4461,CHEMBL619739,80021,,624.0,,Antitumor cytotoxic activity against A-498 cell line was determined,,F,1,N,1,,BAO_0000219
5930,,,9606.0,Intermediate,Homo sapiens,3311,CHEMBL619740,80021,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,F,1,N,1,,BAO_0000219
5931,,,9606.0,Intermediate,Homo sapiens,3311,CHEMBL883158,80021,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,F,1,N,1,,BAO_0000219
5932,,,9606.0,Intermediate,Homo sapiens,1457,CHEMBL884012,80021,,624.0,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,F,1,N,1,,BAO_0000219
5933,,,9606.0,Intermediate,Homo sapiens,3664,CHEMBL619741,80021,,624.0,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,F,1,N,1,,BAO_0000219
5934,,,9606.0,Intermediate,Homo sapiens,15895,CHEMBL619742,80021,,624.0,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,F,1,N,1,,BAO_0000219
5935,,,9606.0,Intermediate,Homo sapiens,11843,CHEMBL876610,80682,,646.0,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,F,1,N,1,,BAO_0000219
5936,,,9606.0,Intermediate,Homo sapiens,11843,CHEMBL619743,80682,,646.0,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,F,1,N,1,,BAO_0000219
5937,,,9606.0,Intermediate,Homo sapiens,17705,CHEMBL619744,80682,,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line,,F,1,N,1,,BAO_0000219
5938,,,9606.0,Intermediate,Homo sapiens,17705,CHEMBL619745,80682,,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,F,1,N,1,,BAO_0000219
5939,,,9606.0,Intermediate,Homo sapiens,4369,CHEMBL619746,80682,,646.0,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,F,1,N,1,,BAO_0000219
5940,,,9606.0,Intermediate,Homo sapiens,4369,CHEMBL619747,80682,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,F,1,N,1,,BAO_0000219
5941,,,9606.0,Intermediate,Homo sapiens,4369,CHEMBL619748,80682,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,F,1,N,1,,BAO_0000219
5942,,,9606.0,Intermediate,Homo sapiens,4369,CHEMBL619749,80682,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,F,1,N,1,,BAO_0000219
5943,,,9606.0,Intermediate,Homo sapiens,4369,CHEMBL619750,80682,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,F,1,N,1,,BAO_0000219
5944,,,9606.0,Intermediate,Homo sapiens,4369,CHEMBL624014,80682,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,F,1,N,1,,BAO_0000219
5945,,,9606.0,Intermediate,Homo sapiens,4369,CHEMBL624015,80682,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,F,1,N,1,,BAO_0000219
5946,,,9606.0,Expert,Homo sapiens,4787,CHEMBL885344,80682,,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,F,1,N,1,,BAO_0000219
5947,,,9606.0,Intermediate,Homo sapiens,4787,CHEMBL623224,80682,,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,F,1,N,1,,BAO_0000219
5948,,,9606.0,Intermediate,Homo sapiens,6513,CHEMBL623225,80682,,646.0,,Cytotoxic activity against A-549 cell line,,F,1,N,1,,BAO_0000219
5949,,,9606.0,Intermediate,Homo sapiens,6690,CHEMBL622698,80682,,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,F,1,N,1,,BAO_0000219
5950,,,9606.0,Intermediate,Homo sapiens,6690,CHEMBL622699,80682,,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,F,1,N,1,,BAO_0000219
5951,,,9606.0,Expert,Homo sapiens,12263,CHEMBL622700,80682,,646.0,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,F,1,N,1,,BAO_0000219
5952,,,9606.0,Intermediate,Homo sapiens,1054,CHEMBL622701,80682,,646.0,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,F,1,N,1,,BAO_0000219
5953,,,9606.0,Intermediate,Homo sapiens,1359,CHEMBL622702,80682,,646.0,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,F,1,N,1,,BAO_0000219
5954,,,9606.0,Intermediate,Homo sapiens,3547,CHEMBL622703,80682,,646.0,,Cytotoxic activity against human lung carcinoma (A-549) cell line,,F,1,N,1,,BAO_0000219
5955,,,9606.0,Expert,Homo sapiens,5771,CHEMBL622704,80682,,646.0,,Cytotoxic activity towards A-549 cells,,F,1,N,1,,BAO_0000219
5956,,,9606.0,Intermediate,Homo sapiens,14425,CHEMBL622705,80682,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",,F,1,N,1,,BAO_0000219
5957,,,9606.0,Intermediate,Homo sapiens,14425,CHEMBL622706,80682,,646.0,,"In vitro percent inhibition of A549, lung carcinoma",,F,1,N,1,,BAO_0000219
5958,,,9606.0,Intermediate,Homo sapiens,14425,CHEMBL622707,80682,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",,F,1,N,1,,BAO_0000219
5959,,,9606.0,Intermediate,Homo sapiens,14425,CHEMBL622708,80682,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,F,1,N,1,,BAO_0000219
5960,,,9606.0,Intermediate,Homo sapiens,5280,CHEMBL622709,80682,,646.0,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,F,1,N,1,,BAO_0000219
5961,,,9606.0,Intermediate,Homo sapiens,15176,CHEMBL622710,80682,,646.0,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,F,1,N,1,,BAO_0000219
5962,,,9606.0,Intermediate,Homo sapiens,15300,CHEMBL622711,80682,,646.0,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,F,1,N,1,,BAO_0000219
5963,,,9606.0,Intermediate,Homo sapiens,17824,CHEMBL622712,80682,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,F,1,N,1,,BAO_0000218
5964,,,9606.0,Intermediate,Homo sapiens,17824,CHEMBL622713,80682,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,F,1,N,1,,BAO_0000218
5965,,,9606.0,Intermediate,Homo sapiens,17824,CHEMBL622714,80682,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,F,1,N,1,,BAO_0000218
5966,,,9606.0,Intermediate,Homo sapiens,17824,CHEMBL622715,80682,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,F,1,N,1,,BAO_0000218
5967,,,9606.0,Intermediate,Homo sapiens,17824,CHEMBL622716,80682,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,F,1,N,1,,BAO_0000218
5968,,,9606.0,Intermediate,Homo sapiens,17824,CHEMBL622717,80682,,646.0,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,F,1,N,1,,BAO_0000219
5969,,,9606.0,Intermediate,Homo sapiens,17528,CHEMBL622718,80682,,646.0,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,F,1,N,1,,BAO_0000218
5970,,,9606.0,Expert,Homo sapiens,6870,CHEMBL622719,80682,,646.0,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,F,1,N,1,,BAO_0000219
5971,,,9606.0,Intermediate,Homo sapiens,6870,CHEMBL622720,80682,,646.0,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,F,1,N,1,,BAO_0000219
5972,,,9606.0,Intermediate,Homo sapiens,6870,CHEMBL622721,80682,,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,F,1,N,1,,BAO_0000219
5973,,,9606.0,Intermediate,Homo sapiens,6870,CHEMBL622722,80682,,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,F,1,N,1,,BAO_0000219
5974,,,9606.0,Intermediate,Homo sapiens,16726,CHEMBL876030,80682,,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,F,1,N,1,,BAO_0000219
5975,,,9606.0,Intermediate,Homo sapiens,6170,CHEMBL620206,80682,,646.0,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,F,1,N,1,,BAO_0000219
5976,,,9606.0,Expert,Homo sapiens,6583,CHEMBL620207,80682,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,F,1,N,1,,BAO_0000219
5977,,,9606.0,Expert,Homo sapiens,6583,CHEMBL620208,80682,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,F,1,N,1,,BAO_0000219
5978,,,9606.0,Expert,Homo sapiens,6583,CHEMBL620209,80682,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,F,1,N,1,,BAO_0000219
5979,,,9606.0,Expert,Homo sapiens,6583,CHEMBL620210,80682,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,F,1,N,1,,BAO_0000219
5980,,,9606.0,Expert,Homo sapiens,6583,CHEMBL621639,80682,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,F,1,N,1,,BAO_0000219
5981,,,9606.0,Intermediate,Homo sapiens,17321,CHEMBL621640,80682,,646.0,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,F,1,N,1,,BAO_0000219
5982,,,9606.0,Expert,Homo sapiens,17528,CHEMBL621641,80682,,646.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,F,1,N,1,,BAO_0000219
5983,,,9606.0,Expert,Homo sapiens,12888,CHEMBL621642,80682,,646.0,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,F,1,N,1,,BAO_0000219
5984,,,9606.0,Intermediate,Homo sapiens,4312,CHEMBL621643,80682,,646.0,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,F,1,N,1,,BAO_0000219
5985,,,9606.0,Intermediate,Homo sapiens,4312,CHEMBL621644,80682,,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,F,1,N,1,,BAO_0000219
5986,,,9606.0,Intermediate,Homo sapiens,4312,CHEMBL621645,80682,,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,F,1,N,1,,BAO_0000219
5987,,,10090.0,Intermediate,Mus musculus,17737,CHEMBL621646,80682,,646.0,,In vitro antiproliferative activity against A549 cell line,,F,1,N,1,,BAO_0000219
5988,,,,Intermediate,,6630,CHEMBL621647,80682,,646.0,,Synergism with indomethacin in A549 cells,,F,1,N,1,,BAO_0000219
5989,,,,Intermediate,,6630,CHEMBL621648,80682,,646.0,,Synergism with tolmetin in A549 cells,,F,1,N,1,,BAO_0000219
5990,,,,Intermediate,,6630,CHEMBL621649,80682,,646.0,,Synergism with sulindac in A549 cells,,F,1,N,1,,BAO_0000219
5991,,,,Intermediate,,6630,CHEMBL621650,80682,,646.0,,Antagonism of indomethacin in A549 cells,,F,1,N,1,,BAO_0000219
5992,,,,Intermediate,,6630,CHEMBL621651,80682,,646.0,,Antagonism of sulindac in A549 cells,,F,1,N,1,,BAO_0000219
5993,,,,Intermediate,,6630,CHEMBL621652,80682,,646.0,,Antagonism of tolmetin in A549 cells,,F,1,N,1,,BAO_0000219
5994,,,,Intermediate,,6630,CHEMBL621653,80682,,646.0,,Synergism with indomethacin in A549 cells,,F,1,N,1,,BAO_0000219
5995,,,,Intermediate,,6630,CHEMBL621654,80682,,646.0,,Synergism with sulindac in A549 cells,,F,1,N,1,,BAO_0000219
5996,,,,Intermediate,,6630,CHEMBL621655,80682,,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,F,1,N,1,,BAO_0000219
5997,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL621656,50588,,,,Cmax value after 30 mg/kg po dose in Dogs,,A,1,N,1,,BAO_0000218
5998,,,9615.0,Intermediate,Canis lupus familiaris,5944,CHEMBL621657,50588,,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,A,1,N,1,,BAO_0000218
5999,,,9615.0,Intermediate,Canis lupus familiaris,5944,CHEMBL621658,50588,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,A,1,N,1,,BAO_0000218
6000,,,9615.0,Intermediate,Canis lupus familiaris,5944,CHEMBL621659,50588,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,A,1,N,1,,BAO_0000218
6001,,,9615.0,Intermediate,Canis lupus familiaris,5944,CHEMBL621660,50588,,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,A,1,N,1,,BAO_0000218
6002,,,9615.0,Intermediate,Canis lupus familiaris,2959,CHEMBL621661,50588,,,,Cmax value after administration of 4 mg/Kg oral dose in dog,,A,1,N,1,,BAO_0000218
6003,,,9615.0,Intermediate,Canis lupus familiaris,6241,CHEMBL621662,50588,,,,Cmax value in dog,,A,1,N,1,,BAO_0000218
6004,,,9615.0,Intermediate,Canis lupus familiaris,6241,CHEMBL621663,50588,,,,Cmax value in dogs after oral administration at 1 mg/kg,,A,1,N,1,,BAO_0000218
6005,,,9615.0,Intermediate,Canis lupus familiaris,2652,CHEMBL621664,50588,,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,A,1,N,1,,BAO_0000218
6006,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1806,CHEMBL621665,50588,,,Plasma,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,A,1,N,1,,BAO_0000218
6007,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1806,CHEMBL621666,50588,,,Plasma,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,A,1,N,1,,BAO_0000218
6008,,,9615.0,Intermediate,Canis lupus familiaris,1021,CHEMBL621667,50588,,,,Concentration maxima after oral dosing in dogs,,A,1,N,1,,BAO_0000218
6009,,,9615.0,Intermediate,Canis lupus familiaris,1021,CHEMBL876738,50588,,,,Concentration maxima after oral dosing in dogs; not available,,A,1,N,1,,BAO_0000218
6010,,,9615.0,Intermediate,Canis lupus familiaris,1021,CHEMBL621668,50588,,,,Concentration maxima after oral dosing in dogs; not available,,A,1,N,1,,BAO_0000218
6011,,,9615.0,Intermediate,Canis lupus familiaris,5444,CHEMBL621669,50588,,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,A,1,N,1,,BAO_0000218
6012,,,9615.0,Intermediate,Canis lupus familiaris,5444,CHEMBL621670,50588,,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,A,1,N,1,,BAO_0000218
6013,,,9615.0,Intermediate,Canis lupus familiaris,5444,CHEMBL621671,50588,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
6014,,,9615.0,Intermediate,Canis lupus familiaris,5444,CHEMBL622360,50588,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,A,1,N,1,,BAO_0000218
6015,,,9615.0,Intermediate,Canis lupus familiaris,5444,CHEMBL622361,50588,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,A,1,N,1,,BAO_0000218
6016,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5130,CHEMBL622362,50588,,,Plasma,Cmax in dog plasma after oral dose (1 mg/kg),,A,1,N,1,,BAO_0000218
6017,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3249,CHEMBL622363,50588,,,Plasma,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
6018,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5473,CHEMBL622364,50588,,,Plasma,Maximal plasma concentration at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
6019,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5474,CHEMBL622365,50588,,,Plasma,Maximal plasma concentration at a dose of 1 mg/kg (oral),,A,1,N,1,,BAO_0000218
6020,,1969.0,9615.0,Intermediate,Canis lupus familiaris,4657,CHEMBL622533,50588,,,Plasma,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,A,1,N,1,,BAO_0000218
6021,,,9615.0,Intermediate,Canis lupus familiaris,3031,CHEMBL622534,50588,,,,Maximum concentration of compound in dog was evaluated.,,A,1,N,1,,BAO_0000218
6022,,,9615.0,Intermediate,Canis lupus familiaris,4527,CHEMBL622535,50588,,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,A,1,N,1,,BAO_0000218
6023,,,9615.0,Intermediate,Canis lupus familiaris,4186,CHEMBL876739,50588,,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,A,1,N,1,,BAO_0000218
6024,,,9615.0,Intermediate,Canis lupus familiaris,5007,CHEMBL622536,50588,,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,A,1,N,1,,BAO_0000218
6025,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3132,CHEMBL622537,50588,,,Plasma,Maximum concentration obtained in dog plasma was determined,,A,1,N,1,,BAO_0000218
6026,,,9615.0,Intermediate,Canis lupus familiaris,5006,CHEMBL622538,50588,,,,Maximum concentration was determined,,A,1,N,1,,BAO_0000218
6027,,,9615.0,Intermediate,Canis lupus familiaris,4727,CHEMBL627867,50588,,,,Maximum concentration at the dose of 2 mg/kg in dog,,A,1,N,1,,BAO_0000218
6028,,,9615.0,Intermediate,Canis lupus familiaris,1916,CHEMBL627868,50588,,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,A,1,N,1,,BAO_0000218
6029,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1918,CHEMBL627869,50588,,,Plasma,Maximum concentration was evaluated in dog plasma,,A,1,N,1,,BAO_0000218
6030,,,9615.0,Intermediate,Canis lupus familiaris,3045,CHEMBL627870,50588,,,,Maximum concentration was evaluated after 75 min after administration in dog,,A,1,N,1,,BAO_0000218
6031,,1969.0,9615.0,Intermediate,Canis lupus familiaris,9579,CHEMBL627871,50588,,,Plasma,Maximum plasma concentration determined in dog after oral administration of 17b,,A,1,N,1,,BAO_0000218
6032,,1969.0,9615.0,Intermediate,Canis lupus familiaris,9579,CHEMBL627872,50588,,,Plasma,Maximum plasma concentration determined in dog after oral administration of 2b,,A,1,N,1,,BAO_0000218
6033,,1969.0,9615.0,Intermediate,Canis lupus familiaris,933,CHEMBL627873,50588,,,Plasma,Maximum plasma concentration in dog,,A,1,N,1,,BAO_0000218
6034,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL627874,50588,,,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,A,1,N,1,,BAO_0000218
6035,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL627875,50588,,,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,A,1,N,1,,BAO_0000218
6036,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL627876,50588,,,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,A,1,N,1,,BAO_0000218
6037,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL627877,50588,,,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,A,1,N,1,,BAO_0000218
6038,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6348,CHEMBL627878,50588,,,Plasma,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
6039,,1969.0,9615.0,Intermediate,Canis lupus familiaris,16367,CHEMBL627879,50588,,,Plasma,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
6040,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1337,CHEMBL875355,50588,,,Plasma,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,A,1,N,1,,BAO_0000218
6041,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1337,CHEMBL627880,50588,,,Plasma,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,A,1,N,1,,BAO_0000218
6042,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5199,CHEMBL627881,50588,,,Plasma,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,A,1,N,1,,BAO_0000218
6043,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17650,CHEMBL627882,50588,,,Plasma,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,A,1,N,1,,BAO_0000218
6044,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6679,CHEMBL627883,50588,,,Plasma,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
6045,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5356,CHEMBL628526,50588,,,Plasma,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,A,1,N,1,,BAO_0000218
6046,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5356,CHEMBL628527,50588,,,Plasma,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,A,1,N,1,,BAO_0000218
6047,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL628528,50588,,,Plasma,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
6048,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL628529,50588,,,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,A,1,N,1,,BAO_0000218
6049,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL628530,50588,,,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,A,1,N,1,,BAO_0000218
6050,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL625243,50588,,,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
6051,,1969.0,9615.0,Expert,Canis lupus familiaris,3598,CHEMBL625244,50588,,,Plasma,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
6052,,,9615.0,Intermediate,Canis lupus familiaris,4368,CHEMBL625245,50588,,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,A,1,N,1,,BAO_0000218
6053,,,9615.0,Intermediate,Canis lupus familiaris,6265,CHEMBL625246,50588,,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
6054,,945.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL625247,50594,,,Stomach,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
6055,,1088.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL625248,50594,,,Urine,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,A,1,N,1,,BAO_0000218
6056,,1088.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL625249,50594,,,Urine,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,A,1,N,1,,BAO_0000218
6057,,1088.0,10090.0,Intermediate,Mus musculus,7767,CHEMBL625250,50594,,,Urine,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,A,1,N,1,,BAO_0000218
6058,,,10090.0,Intermediate,Mus musculus,17811,CHEMBL625251,50594,,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,A,1,N,1,,BAO_0000218
6059,,,10090.0,Intermediate,Mus musculus,17811,CHEMBL875356,50594,,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,A,1,N,1,,BAO_0000218
6060,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL625252,50594,,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6061,,178.0,10090.0,Intermediate,Mus musculus,17827,CHEMBL625253,50594,,,Blood,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6062,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL625254,50594,,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6063,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL625255,50594,,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6064,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL625256,50594,,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6065,,178.0,10090.0,Intermediate,Mus musculus,17827,CHEMBL625257,50594,,,Blood,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6066,,178.0,10090.0,Intermediate,Mus musculus,17827,CHEMBL625258,50594,,,Blood,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6067,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL625259,50594,,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6068,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL625260,50594,,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,A,1,N,1,,BAO_0000218
6069,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL625261,50594,,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,A,1,N,1,,BAO_0000218
6070,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL625262,50594,,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,A,1,N,1,,BAO_0000218
6071,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL622639,50594,,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,A,1,N,1,,BAO_0000218
6072,,,10090.0,Intermediate,Mus musculus,17257,CHEMBL622640,50594,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,A,1,N,1,,BAO_0000218
6073,,,10090.0,Intermediate,Mus musculus,17257,CHEMBL622812,50594,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,A,1,N,1,,BAO_0000218
6074,,,10090.0,Intermediate,Mus musculus,17257,CHEMBL622813,50594,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,A,1,N,1,,BAO_0000218
6075,,,10090.0,Intermediate,Mus musculus,17257,CHEMBL622814,50594,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,A,1,N,1,,BAO_0000218
6076,,,10090.0,Intermediate,Mus musculus,17827,CHEMBL622815,50594,,,,Time at maximum activity in mice (Radiolabeled compound),,A,1,N,1,,BAO_0000218
6077,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL625342,50594,,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,A,1,N,1,,BAO_0000218
6078,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL625343,50594,,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,A,1,N,1,,BAO_0000218
6079,,,10090.0,Intermediate,Mus musculus,17409,CHEMBL877591,50594,,,,Binding towards mouse plasma protein at 10 uM,,A,1,N,1,,BAO_0000218
6080,,,10090.0,Intermediate,Mus musculus,17409,CHEMBL625344,50594,,,,Binding towards mouse plasma protein at 100 uM,,A,1,N,1,,BAO_0000218
6081,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL625345,50594,,,,Bioavailability was evaluated in mice after intravenous administration,,A,1,N,1,,BAO_0000218
6082,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL625346,50594,,,,Bioavailability was evaluated in mice after oral administration,,A,1,N,1,,BAO_0000218
6083,,,10090.0,Intermediate,Mus musculus,3132,CHEMBL625347,50594,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,A,1,N,1,,BAO_0000218
6084,,,10090.0,Intermediate,Mus musculus,3132,CHEMBL625348,50594,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,A,1,N,1,,BAO_0000218
6085,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL625349,50594,,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,A,1,N,1,,BAO_0000218
6086,,,10090.0,Intermediate,Mus musculus,2862,CHEMBL625350,50594,,,,Oral bioavailability in mouse,,A,1,N,1,,BAO_0000218
6087,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL882952,50594,,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,A,1,N,1,,BAO_0000218
6088,,955.0,10090.0,Intermediate,Mus musculus,846,CHEMBL625351,50594,,,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6089,,955.0,10090.0,Intermediate,Mus musculus,846,CHEMBL625352,50594,,,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6090,,955.0,10090.0,Intermediate,Mus musculus,846,CHEMBL877592,50594,,,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6091,,955.0,10090.0,Intermediate,Mus musculus,846,CHEMBL625353,50594,,,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6092,,955.0,10090.0,Intermediate,Mus musculus,846,CHEMBL625354,50594,,,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6093,,955.0,10090.0,Intermediate,Mus musculus,846,CHEMBL626019,50594,,,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6094,,948.0,10090.0,Intermediate,Mus musculus,846,CHEMBL626020,50594,,,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6095,,948.0,10090.0,Intermediate,Mus musculus,846,CHEMBL626021,50594,,,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6096,,948.0,10090.0,Intermediate,Mus musculus,846,CHEMBL626022,50594,,,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6097,,948.0,10090.0,Intermediate,Mus musculus,846,CHEMBL626192,50594,,,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6098,,,9606.0,Intermediate,Homo sapiens,1276,CHEMBL626193,80682,,646.0,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,F,1,N,1,,BAO_0000219
6099,,,9606.0,Expert,Homo sapiens,3498,CHEMBL626194,80682,,646.0,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,F,1,N,1,,BAO_0000219
6100,,,9606.0,Intermediate,Homo sapiens,1169,CHEMBL626195,80682,,646.0,,Cytotoxicity against human lung carcinoma A-549 cell lines,,F,1,N,1,,BAO_0000219
6101,,,9606.0,Intermediate,Homo sapiens,4450,CHEMBL626196,80682,,646.0,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,F,1,N,1,,BAO_0000219
6102,,,9606.0,Intermediate,Homo sapiens,358,CHEMBL626197,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549,,F,1,N,1,,BAO_0000219
6103,,,9606.0,Intermediate,Homo sapiens,358,CHEMBL626198,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,F,1,N,1,,BAO_0000219
6104,,,9606.0,Intermediate,Homo sapiens,358,CHEMBL626199,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,F,1,N,1,,BAO_0000219
6105,,,9606.0,Intermediate,Homo sapiens,358,CHEMBL626200,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,F,1,N,1,,BAO_0000219
6106,,,9606.0,Intermediate,Homo sapiens,358,CHEMBL626201,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,F,1,N,1,,BAO_0000219
6107,,,9606.0,Intermediate,Homo sapiens,358,CHEMBL626202,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,F,1,N,1,,BAO_0000219
6108,,,9606.0,Intermediate,Homo sapiens,358,CHEMBL626203,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,F,1,N,1,,BAO_0000219
6109,,,9606.0,Intermediate,Homo sapiens,15167,CHEMBL626204,80682,,646.0,,In vitro cytotoxicity against A-549 human lung cancer cells,,F,1,N,1,,BAO_0000219
6110,,,9606.0,Intermediate,Homo sapiens,4139,CHEMBL624701,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,F,1,N,1,,BAO_0000219
6111,,,9606.0,Intermediate,Homo sapiens,833,CHEMBL624702,80682,,646.0,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,F,1,N,1,,BAO_0000219
6112,,,9606.0,Expert,Homo sapiens,15718,CHEMBL624703,80682,,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,F,1,N,1,,BAO_0000219
6113,,,9606.0,Intermediate,Homo sapiens,12373,CHEMBL624704,80682,,646.0,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,F,1,N,1,,BAO_0000219
6114,,,9606.0,Intermediate,Homo sapiens,637,CHEMBL624705,80682,,646.0,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,F,1,N,1,,BAO_0000219
6115,,,9606.0,Expert,Homo sapiens,14867,CHEMBL624706,80682,,646.0,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,F,1,N,1,,BAO_0000219
6116,,,9606.0,Intermediate,Homo sapiens,4461,CHEMBL624707,80682,,646.0,,Antitumor cytotoxic activity against A-549 cell line was determined,,F,1,N,1,,BAO_0000219
6117,,,9606.0,Intermediate,Homo sapiens,5406,CHEMBL624708,80682,,646.0,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,F,1,N,1,,BAO_0000219
6118,,,9606.0,Intermediate,Homo sapiens,4457,CHEMBL624709,80682,,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,F,1,N,1,,BAO_0000219
6119,,,9606.0,Expert,Homo sapiens,1386,CHEMBL884107,80682,,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
6120,,,9606.0,Intermediate,Homo sapiens,3265,CHEMBL624710,80682,,646.0,,Antitumoral activity was assayed against A-549 cell line,,F,1,N,1,,BAO_0000219
6121,,,9606.0,Intermediate,Homo sapiens,2359,CHEMBL624711,80682,,646.0,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,F,1,N,1,,BAO_0000219
6122,,,9606.0,Intermediate,Homo sapiens,4457,CHEMBL624712,80682,,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,F,1,N,1,,BAO_0000219
6123,,,9606.0,Expert,Homo sapiens,12454,CHEMBL624713,80682,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
6124,,,9606.0,Intermediate,Homo sapiens,1481,CHEMBL624714,80682,,646.0,,Compound was tested for inhibition of cell growth of A-549 cells,,F,1,N,1,,BAO_0000219
6125,,,9606.0,Intermediate,Homo sapiens,1750,CHEMBL624715,80682,,646.0,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,F,1,N,1,,BAO_0000219
6126,,,9606.0,Intermediate,Homo sapiens,5065,CHEMBL624716,80682,,646.0,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,F,1,N,1,,BAO_0000219
6127,,,9606.0,Expert,Homo sapiens,808,CHEMBL619505,80682,,646.0,,In vitro cytotoxicity against A549-human lung carcinoma cells.,,F,1,N,1,,BAO_0000219
6128,,,9606.0,Expert,Homo sapiens,16364,CHEMBL619506,80682,,646.0,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,F,1,N,1,,BAO_0000219
6129,,,9606.0,Intermediate,Homo sapiens,1847,CHEMBL619507,80682,,646.0,,Cytotoxic activity against A-549 cell lines.,,F,1,N,1,,BAO_0000219
6130,,,9606.0,Expert,Homo sapiens,1747,CHEMBL619508,80682,,646.0,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,F,1,N,1,,BAO_0000219
6131,,,9606.0,Intermediate,Homo sapiens,1003,CHEMBL619509,80682,,646.0,,Cytotoxicity against human A549 non small cell lung cell lines,,F,1,N,1,,BAO_0000219
6132,,,9606.0,Expert,Homo sapiens,15313,CHEMBL619510,80682,,646.0,,Inhibition of cell growth in (A-549) lung cell line,,F,1,N,1,,BAO_0000219
6133,,,9606.0,Intermediate,Homo sapiens,3122,CHEMBL619511,80682,,646.0,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,F,1,N,1,,BAO_0000219
6134,,,9606.0,Intermediate,Homo sapiens,16049,CHEMBL619512,80682,,646.0,,In vitro antitumor activity against A-549 tumor cells.,,F,1,N,1,,BAO_0000219
6135,,,9606.0,Expert,Homo sapiens,17134,CHEMBL619513,80682,,646.0,,In vitro antitumor effects against human A-549 cell lines.,,F,1,N,1,,BAO_0000219
6136,,,9606.0,Intermediate,Homo sapiens,6406,CHEMBL619514,80682,,646.0,,In vitro cytotoxic activity of compound against A-549 cell line,,F,1,N,1,,BAO_0000219
6137,,,9606.0,Intermediate,Homo sapiens,627,CHEMBL619515,80682,,646.0,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,F,1,N,1,,BAO_0000219
6138,,,9606.0,Intermediate,Homo sapiens,12307,CHEMBL619516,80682,,646.0,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,F,1,N,1,,BAO_0000219
6139,,,9606.0,Intermediate,Homo sapiens,17861,CHEMBL884005,80682,,646.0,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,F,1,N,1,,BAO_0000219
6140,,,9606.0,Expert,Homo sapiens,6682,CHEMBL619517,80682,,646.0,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,F,1,N,1,,BAO_0000219
6141,,,9606.0,Intermediate,Homo sapiens,6663,CHEMBL619518,80682,,646.0,,Inhibitory concentration of compound against A-549 cell line,,F,1,N,1,,BAO_0000219
6142,,,9606.0,Intermediate,Homo sapiens,2454,CHEMBL619519,80682,,646.0,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,F,1,N,1,,BAO_0000219
6143,,,9606.0,Intermediate,Homo sapiens,14709,CHEMBL876489,80682,,646.0,,cytotoxic activity against leukemia (A-549) cancer cell line,,F,1,N,1,,BAO_0000219
6144,,,9606.0,Expert,Homo sapiens,15718,CHEMBL619520,80682,,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,F,1,N,1,,BAO_0000219
6145,,,9606.0,Intermediate,Homo sapiens,15718,CHEMBL619521,80682,,646.0,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,F,1,N,1,,BAO_0000219
6146,,,9606.0,Intermediate,Homo sapiens,17130,CHEMBL619522,80682,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,F,1,N,1,,BAO_0000219
6147,,,9606.0,Intermediate,Homo sapiens,17130,CHEMBL619523,80682,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,F,1,N,1,,BAO_0000219
6148,,,9606.0,Intermediate,Homo sapiens,17130,CHEMBL619524,80682,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,F,1,N,1,,BAO_0000219
6149,,,9606.0,Intermediate,Homo sapiens,17130,CHEMBL619525,80682,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,F,1,N,1,,BAO_0000219
6150,,,,Intermediate,,6630,CHEMBL619526,80682,,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,F,1,N,1,,BAO_0000219
6151,,,9606.0,Intermediate,Homo sapiens,16726,CHEMBL619527,80682,,646.0,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,F,1,N,1,,BAO_0000219
6152,,,9606.0,Intermediate,Homo sapiens,17846,CHEMBL619528,80682,,646.0,,Cytotoxicity against A549 cells; No cytotoxicity,,F,1,N,1,,BAO_0000219
6153,,,9606.0,Expert,Homo sapiens,3415,CHEMBL619529,80682,,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines,,F,1,N,1,,BAO_0000219
6154,,,9606.0,Expert,Homo sapiens,3415,CHEMBL619530,80682,,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,F,1,N,1,,BAO_0000219
6155,,,9606.0,Intermediate,Homo sapiens,5609,CHEMBL876490,80682,,646.0,,In vitro anticancer activity against human lung (A549) cell line,,F,1,N,1,,BAO_0000219
6156,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619531,80682,,646.0,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,F,1,N,1,,BAO_0000219
6157,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619532,80682,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6158,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619533,80682,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6159,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619534,80682,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6160,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL620164,80682,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6161,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL620165,80682,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6162,,,9606.0,Expert,Homo sapiens,16295,CHEMBL620166,80682,,646.0,,Inhibition of A549 human lung tumor cell proliferation,,F,1,N,1,,BAO_0000219
6163,,,9606.0,Intermediate,Homo sapiens,16825,CHEMBL620167,80682,,646.0,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,F,1,N,1,,BAO_0000219
6164,,,9606.0,Expert,Homo sapiens,3439,CHEMBL620168,80682,,646.0,,In vitro cytotoxicity against human tumor cell line A549,,F,1,N,1,,BAO_0000219
6165,,,9606.0,Intermediate,Homo sapiens,10870,CHEMBL620338,80682,,646.0,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,F,1,N,1,,BAO_0000219
6166,,,9606.0,Intermediate,Homo sapiens,4845,CHEMBL620339,80682,,646.0,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,F,1,N,1,,BAO_0000219
6167,,,9606.0,Intermediate,Homo sapiens,5822,CHEMBL620340,80682,,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,F,1,N,1,,BAO_0000219
6168,,,9606.0,Intermediate,Homo sapiens,5822,CHEMBL620341,80682,,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,F,1,N,1,,BAO_0000219
6169,,,9606.0,Intermediate,Homo sapiens,5822,CHEMBL876491,80682,,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,F,1,N,1,,BAO_0000219
6170,,,9606.0,Intermediate,Homo sapiens,16381,CHEMBL620342,80682,,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,F,1,N,1,,BAO_0000219
6171,,,9606.0,Intermediate,Homo sapiens,16381,CHEMBL620343,80682,,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,F,1,N,1,,BAO_0000219
6172,,,9606.0,Intermediate,Homo sapiens,16381,CHEMBL620344,80682,,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,F,1,N,1,,BAO_0000219
6173,,,9606.0,Intermediate,Homo sapiens,5609,CHEMBL620345,80682,,646.0,,In vitro anticancer activity against human lung (A549) cell line,,F,1,N,1,,BAO_0000219
6174,,,9606.0,Intermediate,Homo sapiens,4644,CHEMBL620346,80682,,646.0,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,F,1,N,1,,BAO_0000219
6175,,,9606.0,Intermediate,Homo sapiens,4644,CHEMBL620347,80682,,646.0,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,F,1,N,1,,BAO_0000219
6176,,,9606.0,Intermediate,Homo sapiens,4644,CHEMBL620348,80682,,646.0,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,F,1,N,1,,BAO_0000219
6177,,,9606.0,Intermediate,Homo sapiens,4644,CHEMBL620349,80682,,646.0,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,F,1,N,1,,BAO_0000219
6178,,,9606.0,Intermediate,Homo sapiens,5822,CHEMBL618667,80682,,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,F,1,N,1,,BAO_0000219
6179,,,9606.0,Expert,Homo sapiens,3415,CHEMBL618668,80682,,646.0,,Percentage inhibition of human lung carcinoma (A549) cell lines,,F,1,N,1,,BAO_0000219
6180,,,9606.0,Intermediate,Homo sapiens,16726,CHEMBL876031,80682,,646.0,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,F,1,N,1,,BAO_0000219
6181,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL618759,80682,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,F,1,N,1,,BAO_0000219
6182,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL618760,80682,,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,F,1,N,1,,BAO_0000219
6183,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619000,80682,,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,F,1,N,1,,BAO_0000219
6184,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619001,80682,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,F,1,N,1,,BAO_0000219
6185,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619002,80682,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,F,1,N,1,,BAO_0000219
6186,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619003,80682,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,F,1,N,1,,BAO_0000219
6187,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619597,80682,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,F,1,N,1,,BAO_0000219
6188,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619598,80682,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,F,1,N,1,,BAO_0000219
6189,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619599,80682,,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,F,1,N,1,,BAO_0000219
6190,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619600,80682,,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,F,1,N,1,,BAO_0000219
6191,,,9606.0,Intermediate,Homo sapiens,16726,CHEMBL619601,80682,,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,F,1,N,1,,BAO_0000219
6192,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619602,80682,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6193,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619603,80682,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6194,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619604,80682,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6195,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619605,80682,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6196,,,9615.0,Intermediate,Canis lupus familiaris,6084,CHEMBL619606,50588,,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
6197,,,9615.0,Intermediate,Canis lupus familiaris,6084,CHEMBL876032,50588,,,,Pharmacokinetic activity (Cmax) in dog,,A,1,N,1,,BAO_0000218
6198,,,9615.0,Intermediate,Canis lupus familiaris,4809,CHEMBL619607,50588,,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,A,1,N,1,,BAO_0000218
6199,,,9615.0,Intermediate,Canis lupus familiaris,5983,CHEMBL619608,50588,,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,A,1,N,1,,BAO_0000218
6200,,,9615.0,Intermediate,Canis lupus familiaris,6251,CHEMBL619609,50588,,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,A,1,N,1,,BAO_0000218
6201,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5932,CHEMBL619610,50588,,,Plasma,Cmax in dog plasma after 30mg/kg oral dose,,A,1,N,1,,BAO_0000218
6202,,178.0,9615.0,Intermediate,Canis lupus familiaris,4273,CHEMBL619611,50588,,,Blood,Tested for the peak blood level in dog,,A,1,N,1,,BAO_0000218
6203,,,9615.0,Intermediate,Canis lupus familiaris,5313,CHEMBL619612,50588,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,A,1,N,1,,BAO_0000218
6204,,,9615.0,Intermediate,Canis lupus familiaris,5313,CHEMBL619613,50588,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,A,1,N,1,,BAO_0000218
6205,,178.0,9615.0,Intermediate,Canis lupus familiaris,6221,CHEMBL619614,50588,,,Blood,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,A,1,N,1,,BAO_0000218
6206,,,9615.0,Intermediate,Canis lupus familiaris,4709,CHEMBL619615,50588,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
6207,,,9615.0,Intermediate,Canis lupus familiaris,167,CHEMBL619616,50588,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,A,1,N,1,,BAO_0000218
6208,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6241,CHEMBL619617,50588,,,Plasma,Final plasma concentration in dogs after oral administration at 1 mg/kg,,A,1,N,1,,BAO_0000218
6209,,,9615.0,Intermediate,Canis lupus familiaris,344,CHEMBL619618,50588,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,A,1,N,1,,BAO_0000218
6210,,,9615.0,Intermediate,Canis lupus familiaris,344,CHEMBL876033,50588,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,A,1,N,1,,BAO_0000218
6211,,,9615.0,Intermediate,Canis lupus familiaris,344,CHEMBL619619,50588,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,A,1,N,1,,BAO_0000218
6212,,,9615.0,Intermediate,Canis lupus familiaris,2189,CHEMBL619620,50588,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,A,1,N,1,,BAO_0000218
6213,,1088.0,9615.0,Intermediate,Canis lupus familiaris,2189,CHEMBL619621,50588,,,Urine,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,A,1,N,1,,BAO_0000218
6214,,1088.0,9615.0,Intermediate,Canis lupus familiaris,2189,CHEMBL619622,50588,,,Urine,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,A,1,N,1,,BAO_0000218
6215,,1088.0,9615.0,Intermediate,Canis lupus familiaris,2189,CHEMBL618874,50588,,,Urine,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,A,1,N,1,,BAO_0000218
6216,,,9615.0,Intermediate,Canis lupus familiaris,4257,CHEMBL618875,50588,,,,Absolute bioavailability was evaluated in dog,,A,1,N,1,,BAO_0000218
6217,,,9615.0,Intermediate,Canis lupus familiaris,6221,CHEMBL618876,50588,,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,A,1,N,1,,BAO_0000218
6218,,,9615.0,Intermediate,Canis lupus familiaris,6215,CHEMBL618877,50588,,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
6219,,,9615.0,Intermediate,Canis lupus familiaris,17267,CHEMBL618878,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6220,,,9615.0,Intermediate,Canis lupus familiaris,6621,CHEMBL618879,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6221,,,9615.0,Intermediate,Canis lupus familiaris,3854,CHEMBL618880,50588,,,,Bioavailability after intravenous administration in dogs,,A,1,N,1,,BAO_0000218
6222,,,9615.0,Intermediate,Canis lupus familiaris,3854,CHEMBL618881,50588,,,,Bioavailability after peroral administration in dogs,,A,1,N,1,,BAO_0000218
6223,,,9615.0,Intermediate,Canis lupus familiaris,5007,CHEMBL618882,50588,,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,A,1,N,1,,BAO_0000218
6224,,,9615.0,Intermediate,Canis lupus familiaris,4333,CHEMBL624226,50588,,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,A,1,N,1,,BAO_0000218
6225,,1969.0,9615.0,Intermediate,Canis lupus familiaris,4333,CHEMBL624227,50588,,,Plasma,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,A,1,N,1,,BAO_0000218
6226,,,9615.0,Intermediate,Canis lupus familiaris,5006,CHEMBL624228,50588,,,,Bioavailability,,A,1,N,1,,BAO_0000218
6227,,,9615.0,Intermediate,Canis lupus familiaris,5199,CHEMBL624229,50588,,,,Bioavailability,,A,1,N,1,,BAO_0000218
6228,,,9615.0,Intermediate,Canis lupus familiaris,4368,CHEMBL624230,50588,,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,A,1,N,1,,BAO_0000218
6229,,,9615.0,Intermediate,Canis lupus familiaris,3771,CHEMBL624231,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6230,,,9615.0,Intermediate,Canis lupus familiaris,4953,CHEMBL624232,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6231,,,9615.0,Intermediate,Canis lupus familiaris,5064,CHEMBL625127,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6232,,,9615.0,Intermediate,Canis lupus familiaris,17657,CHEMBL625128,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6233,,,9615.0,Intermediate,Canis lupus familiaris,17796,CHEMBL621675,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6234,,,9615.0,Intermediate,Canis lupus familiaris,17853,CHEMBL621676,50588,,,,Bioavailability in dog (p.o.) at 2.0 mpk,,A,1,N,1,,BAO_0000218
6235,,,9615.0,Intermediate,Canis lupus familiaris,4521,CHEMBL621677,50588,,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,A,1,N,1,,BAO_0000218
6236,,,9615.0,Intermediate,Canis lupus familiaris,4521,CHEMBL621678,50588,,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,A,1,N,1,,BAO_0000218
6237,,,9615.0,Intermediate,Canis lupus familiaris,5006,CHEMBL621679,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6238,,,9615.0,Intermediate,Canis lupus familiaris,16365,CHEMBL621680,50588,,,,Bioavailability was evaluated after oral administration in dog,,A,1,N,1,,BAO_0000218
6239,,,9615.0,Intermediate,Canis lupus familiaris,1916,CHEMBL621681,50588,,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,A,1,N,1,,BAO_0000218
6240,,,9615.0,Intermediate,Canis lupus familiaris,1918,CHEMBL876740,50588,,,,Bioavailability was evaluated in dog,,A,1,N,1,,BAO_0000218
6241,,,9615.0,Intermediate,Canis lupus familiaris,4239,CHEMBL621682,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6242,,,9615.0,Intermediate,Canis lupus familiaris,6505,CHEMBL621683,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6243,,,9615.0,Intermediate,Canis lupus familiaris,5334,CHEMBL621684,50588,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,A,1,N,1,,BAO_0000218
6244,,,9615.0,Intermediate,Canis lupus familiaris,5334,CHEMBL621685,50588,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,A,1,N,1,,BAO_0000218
6245,,,9615.0,Intermediate,Canis lupus familiaris,4809,CHEMBL621686,50588,,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,A,1,N,1,,BAO_0000218
6246,,,9615.0,Intermediate,Canis lupus familiaris,6348,CHEMBL621687,50588,,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
6247,,,9615.0,Intermediate,Canis lupus familiaris,6005,CHEMBL621688,50588,,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
6248,,,9615.0,Intermediate,Canis lupus familiaris,17804,CHEMBL621689,50588,,,,Bioavailability of compound in dog was determined after peroral administration,,A,1,N,1,,BAO_0000218
6249,,,9615.0,Intermediate,Canis lupus familiaris,3184,CHEMBL621690,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6250,,,9615.0,Intermediate,Canis lupus familiaris,1806,CHEMBL621691,50588,,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,A,1,N,1,,BAO_0000218
6251,,,9615.0,Intermediate,Canis lupus familiaris,1806,CHEMBL875941,50588,,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,A,1,N,1,,BAO_0000218
6252,,,9615.0,Intermediate,Canis lupus familiaris,1806,CHEMBL621692,50588,,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,A,1,N,1,,BAO_0000218
6253,,,9615.0,Intermediate,Canis lupus familiaris,4839,CHEMBL621693,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6254,,,9615.0,Intermediate,Canis lupus familiaris,5017,CHEMBL621694,50588,,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,A,1,N,1,,BAO_0000218
6255,,948.0,10090.0,Intermediate,Mus musculus,846,CHEMBL621695,50594,,,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6256,,948.0,10090.0,Intermediate,Mus musculus,846,CHEMBL621696,50594,,,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6257,,2113.0,10090.0,Intermediate,Mus musculus,846,CHEMBL621697,50594,,,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6258,,2113.0,10090.0,Intermediate,Mus musculus,846,CHEMBL621698,50594,,,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6259,,2113.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623420,50594,,,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6260,,2113.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623421,50594,,,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6261,,2113.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623422,50594,,,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6262,,2113.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623423,50594,,,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6263,,2107.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623424,50594,,,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6264,,2107.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623425,50594,,,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6265,,2107.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623426,50594,,,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6266,,2107.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623427,50594,,,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6267,,2107.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623428,50594,,,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6268,,2107.0,10090.0,Intermediate,Mus musculus,846,CHEMBL875947,50594,,,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6269,,2048.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623429,50594,,,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6270,,2048.0,10090.0,Intermediate,Mus musculus,846,CHEMBL623430,50594,,,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6271,,2048.0,10090.0,Intermediate,Mus musculus,846,CHEMBL622588,50594,,,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6272,,2048.0,10090.0,Intermediate,Mus musculus,846,CHEMBL622589,50594,,,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6273,,2048.0,10090.0,Intermediate,Mus musculus,846,CHEMBL622751,50594,,,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6274,,2048.0,10090.0,Intermediate,Mus musculus,846,CHEMBL622752,50594,,,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,A,1,N,1,,BAO_0000218
6275,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL622753,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6276,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL622647,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6277,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL875163,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6278,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL622648,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6279,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL622649,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6280,,955.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622650,50594,,42.0,Brain,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6281,,955.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622651,50594,,42.0,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6282,,955.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622652,50594,,42.0,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6283,,955.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622653,50594,,42.0,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6284,,955.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622654,50594,,42.0,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6285,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622655,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6286,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622656,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6287,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622657,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6288,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622658,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6289,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL622659,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6290,,2113.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624630,50594,,42.0,Kidney,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6291,,2113.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624631,50594,,42.0,Kidney,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6292,,2113.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624632,50594,,42.0,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6293,,,9606.0,Intermediate,Homo sapiens,17130,CHEMBL624633,80682,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,F,1,N,1,,BAO_0000219
6294,,,9606.0,Intermediate,Homo sapiens,17130,CHEMBL624634,80682,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,F,1,N,1,,BAO_0000219
6295,,,9606.0,Intermediate,Homo sapiens,17130,CHEMBL624635,80682,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,F,1,N,1,,BAO_0000219
6296,,,9606.0,Intermediate,Homo sapiens,17130,CHEMBL624636,80682,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,F,1,N,1,,BAO_0000219
6297,,,9606.0,Expert,Homo sapiens,3263,CHEMBL857055,80682,,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
6298,,,9606.0,Expert,Homo sapiens,6663,CHEMBL624637,80682,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,F,1,N,1,,BAO_0000219
6299,,,9606.0,Expert,Homo sapiens,6663,CHEMBL624638,80682,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,F,1,N,1,,BAO_0000219
6300,,,9606.0,Expert,Homo sapiens,6663,CHEMBL874366,80682,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,F,1,N,1,,BAO_0000219
6301,,,9606.0,Expert,Homo sapiens,6663,CHEMBL624639,80682,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,F,1,N,1,,BAO_0000219
6302,,,9606.0,Expert,Homo sapiens,6663,CHEMBL624640,80682,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,F,1,N,1,,BAO_0000219
6303,,,9606.0,Intermediate,Homo sapiens,6663,CHEMBL624641,80682,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,F,1,N,1,,BAO_0000219
6304,,,9606.0,Intermediate,Homo sapiens,6663,CHEMBL624642,80682,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,F,1,N,1,,BAO_0000219
6305,,,9606.0,Intermediate,Homo sapiens,6663,CHEMBL624643,80682,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,F,1,N,1,,BAO_0000219
6306,,,9606.0,Intermediate,Homo sapiens,6663,CHEMBL624644,80682,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,F,1,N,1,,BAO_0000219
6307,,,9606.0,Intermediate,Homo sapiens,6663,CHEMBL624645,80682,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,F,1,N,1,,BAO_0000219
6308,,,9606.0,Intermediate,Homo sapiens,3983,CHEMBL619445,80682,,646.0,,The compound was evaluated for its cytotoxic potency against A-549 cell line,,F,1,N,1,,BAO_0000219
6309,,,9606.0,Expert,Homo sapiens,11141,CHEMBL839886,80682,,646.0,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,F,1,N,1,,BAO_0000219
6310,,,9606.0,Intermediate,Homo sapiens,5076,CHEMBL619446,80682,,646.0,,Cytotoxic activity of compound against A-549 tumor cell line.,,F,1,N,1,,BAO_0000219
6311,,,9606.0,Intermediate,Homo sapiens,3311,CHEMBL619447,80682,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,F,1,N,1,,BAO_0000219
6312,,,9606.0,Intermediate,Homo sapiens,3311,CHEMBL619448,80682,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,F,1,N,1,,BAO_0000219
6313,,,9606.0,Intermediate,Homo sapiens,3311,CHEMBL619449,80682,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,F,1,N,1,,BAO_0000219
6314,,,9606.0,Intermediate,Homo sapiens,5076,CHEMBL619450,80682,,646.0,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,F,1,N,1,,BAO_0000219
6315,,,9606.0,Intermediate,Homo sapiens,4150,CHEMBL619451,80682,,646.0,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,F,1,N,1,,BAO_0000219
6316,,,9606.0,Expert,Homo sapiens,2150,CHEMBL619452,80682,,646.0,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,F,1,N,1,,BAO_0000219
6317,,,9606.0,Intermediate,Homo sapiens,4644,CHEMBL619453,80682,,646.0,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,F,1,N,1,,BAO_0000219
6318,,,9606.0,Intermediate,Homo sapiens,263,CHEMBL874367,80682,,646.0,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,F,1,N,1,,BAO_0000219
6319,,,9606.0,Intermediate,Homo sapiens,11333,CHEMBL619454,80682,,646.0,,Cytotoxic concentration against A-549 tumor cells.,,F,1,N,1,,BAO_0000219
6320,,,9606.0,Intermediate,Homo sapiens,11333,CHEMBL619455,80682,,646.0,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,F,1,N,1,,BAO_0000219
6321,,,9606.0,Intermediate,Homo sapiens,15895,CHEMBL619456,80682,,646.0,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,F,1,N,1,,BAO_0000219
6322,,,470.0,Expert,Acinetobacter baumannii,16677,CHEMBL619457,50191,,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,F,1,N,1,,BAO_0000218
6323,,,471.0,Intermediate,Acinetobacter calcoaceticus,10624,CHEMBL619458,50192,,,,Activity against Acinetobacter calcoaceticus (AC54),,F,1,N,1,,BAO_0000218
6324,,,5059.0,Expert,Aspergillus flavus,16717,CHEMBL619459,50274,,,,In vitro antifungal activity against Aspergillus flavus CM74,,F,1,N,1,,BAO_0000218
6325,,,5059.0,Expert,Aspergillus flavus,16717,CHEMBL619460,50274,,,,In vitro antifungal activity against Aspergillus flavus CM74,,F,1,N,1,,BAO_0000218
6326,,,746128.0,Intermediate,Aspergillus fumigatus,5513,CHEMBL619461,50416,,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,F,1,N,1,,BAO_0000218
6327,,,746128.0,Intermediate,Aspergillus fumigatus,15962,CHEMBL619462,50416,,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,F,1,N,1,,BAO_0000218
6328,,,746128.0,Intermediate,Aspergillus fumigatus,15962,CHEMBL620388,50416,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),,F,1,N,1,,BAO_0000218
6329,,,746128.0,Intermediate,Aspergillus fumigatus,15962,CHEMBL620389,50416,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),,F,1,N,1,,BAO_0000218
6330,,,746128.0,Intermediate,Aspergillus fumigatus,15962,CHEMBL620390,50416,,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,F,1,N,1,,BAO_0000218
6331,,,746128.0,Expert,Aspergillus fumigatus,16717,CHEMBL620391,50416,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,F,1,N,1,,BAO_0000218
6332,,,746128.0,Expert,Aspergillus fumigatus,16717,CHEMBL621073,50416,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,F,1,N,1,,BAO_0000218
6333,,,1655.0,Intermediate,Actinomyces naeslundii,8117,CHEMBL621074,50296,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,F,1,N,1,,BAO_0000218
6334,,,1656.0,Intermediate,Actinomyces viscosus,8117,CHEMBL621075,50366,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,F,1,N,1,,BAO_0000218
6335,,,6277.0,Intermediate,Acanthocheilonema viteae,15472,CHEMBL619554,50535,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,F,1,N,1,,BAO_0000218
6336,,,6277.0,Intermediate,Acanthocheilonema viteae,15472,CHEMBL619555,50535,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,F,1,N,1,,BAO_0000218
6337,,,714.0,Intermediate,Aggregatibacter actinomycetemcomitans,16443,CHEMBL619556,50169,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,F,1,N,1,,BAO_0000218
6338,,,714.0,Intermediate,Aggregatibacter actinomycetemcomitans,16443,CHEMBL619557,50169,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,F,1,N,1,,BAO_0000218
6339,,,714.0,Intermediate,Aggregatibacter actinomycetemcomitans,16443,CHEMBL619558,50169,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,F,1,N,1,,BAO_0000218
6340,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619559,80682,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6341,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619560,80682,,646.0,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6342,,,9606.0,Intermediate,Homo sapiens,16381,CHEMBL619561,80682,,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,F,1,N,1,,BAO_0000219
6343,,,9606.0,Intermediate,Homo sapiens,16381,CHEMBL619562,80682,,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,F,1,N,1,,BAO_0000219
6344,,,9606.0,Intermediate,Homo sapiens,16381,CHEMBL619563,80682,,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,F,1,N,1,,BAO_0000219
6345,,,9606.0,Intermediate,Homo sapiens,16381,CHEMBL857457,80682,,646.0,,GI values against A549 cells (lung cancer),,F,1,N,1,,BAO_0000219
6346,,,9606.0,Intermediate,Homo sapiens,17206,CHEMBL619564,80682,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,F,1,N,1,,BAO_0000219
6347,,,9606.0,Intermediate,Homo sapiens,16325,CHEMBL619565,80682,,646.0,,Inhibitory activity against A549 human adenocarcinoma,,F,1,N,1,,BAO_0000219
6348,,,9606.0,Intermediate,Homo sapiens,10708,CHEMBL619566,80682,,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,F,1,N,1,,BAO_0000218
6349,,,9606.0,Intermediate,Homo sapiens,10708,CHEMBL619567,80682,,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,F,1,N,1,,BAO_0000218
6350,,,9606.0,Intermediate,Homo sapiens,17376,CHEMBL619568,80682,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,,F,1,N,1,,BAO_0000219
6351,,,9606.0,Intermediate,Homo sapiens,17376,CHEMBL619569,80682,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,F,1,N,1,,BAO_0000219
6352,,,9606.0,Intermediate,Homo sapiens,17488,CHEMBL619570,80682,,646.0,,Cytotoxicity against human A549 lung cells,,F,1,N,1,,BAO_0000219
6353,,,9606.0,Intermediate,Homo sapiens,17404,CHEMBL619571,80682,,646.0,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,F,1,N,1,,BAO_0000218
6354,,,9606.0,Expert,Homo sapiens,10958,CHEMBL619572,80682,,646.0,,Growth inhibition of A549 (human lung carcinoma) cell line.,,F,1,N,1,,BAO_0000219
6355,,,9606.0,Expert,Homo sapiens,17099,CHEMBL619573,80682,,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line.,,F,1,N,1,,BAO_0000219
6356,,,9606.0,Intermediate,Homo sapiens,17099,CHEMBL619574,80682,,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,F,1,N,1,,BAO_0000219
6357,,,9606.0,Intermediate,Homo sapiens,4096,CHEMBL619575,80682,,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,F,1,N,1,,BAO_0000219
6358,,,9606.0,Expert,Homo sapiens,4096,CHEMBL619576,80682,,646.0,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,F,1,N,1,,BAO_0000219
6359,,,9606.0,Intermediate,Homo sapiens,4096,CHEMBL619577,80682,,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,F,1,N,1,,BAO_0000219
6360,,,9606.0,Intermediate,Homo sapiens,2525,CHEMBL619578,80682,,646.0,,In vitro inhibitory activity against A549 tumor cell culture,,F,1,N,1,,BAO_0000219
6361,,,9606.0,Intermediate,Homo sapiens,2525,CHEMBL884009,80682,,646.0,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,F,1,N,1,,BAO_0000219
6362,,,9606.0,Intermediate,Homo sapiens,5302,CHEMBL619579,80682,,646.0,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,F,1,N,1,,BAO_0000219
6363,,,9606.0,Intermediate,Homo sapiens,16325,CHEMBL619580,80682,,646.0,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,F,1,N,1,,BAO_0000219
6364,,,9606.0,Intermediate,Homo sapiens,16939,CHEMBL619581,80682,,646.0,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,F,1,N,1,,BAO_0000219
6365,,,9606.0,Intermediate,Homo sapiens,17229,CHEMBL619582,80682,,646.0,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,F,1,N,1,,BAO_0000219
6366,,,9606.0,Intermediate,Homo sapiens,17380,CHEMBL619583,80682,,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,F,1,N,1,,BAO_0000219
6367,,,9606.0,Intermediate,Homo sapiens,17380,CHEMBL876502,80682,,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,F,1,N,1,,BAO_0000219
6368,,,9606.0,Intermediate,Homo sapiens,1903,CHEMBL619584,80682,,646.0,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,F,1,N,1,,BAO_0000219
6369,,,9606.0,Intermediate,Homo sapiens,3838,CHEMBL619585,80682,,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,F,1,N,1,,BAO_0000219
6370,,,9606.0,Intermediate,Homo sapiens,14696,CHEMBL619586,80682,,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,F,1,N,1,,BAO_0000219
6371,,,9606.0,Intermediate,Homo sapiens,3838,CHEMBL619587,80682,,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,F,1,N,1,,BAO_0000219
6372,,,9606.0,Intermediate,Homo sapiens,1522,CHEMBL619588,80682,,646.0,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,F,1,N,1,,BAO_0000219
6373,,,9606.0,Intermediate,Homo sapiens,12400,CHEMBL619589,80682,,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,F,1,N,1,,BAO_0000219
6374,,,9606.0,Intermediate,Homo sapiens,14696,CHEMBL619590,80682,,646.0,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,F,1,N,1,,BAO_0000219
6375,,,9606.0,Intermediate,Homo sapiens,14769,CHEMBL619591,80682,,646.0,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,F,1,N,1,,BAO_0000219
6376,,,9606.0,Intermediate,Homo sapiens,14696,CHEMBL619592,80682,,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,F,1,N,1,,BAO_0000219
6377,,,9606.0,Intermediate,Homo sapiens,1888,CHEMBL619593,80682,,646.0,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,F,1,N,1,,BAO_0000219
6378,,,9606.0,Intermediate,Homo sapiens,12016,CHEMBL620217,80682,,646.0,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,F,1,N,1,,BAO_0000219
6379,,,9606.0,Intermediate,Homo sapiens,6058,CHEMBL620218,80682,,646.0,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,F,1,N,1,,BAO_0000219
6380,,,9606.0,Intermediate,Homo sapiens,17708,CHEMBL620219,80682,,646.0,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,F,1,N,1,,BAO_0000219
6381,,,9606.0,Intermediate,Homo sapiens,12301,CHEMBL620220,80682,,646.0,,Antitumor activity against A549/ATCC cell line,,F,1,N,1,,BAO_0000219
6382,,,9606.0,Intermediate,Homo sapiens,11970,CHEMBL625141,80682,,646.0,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,F,1,N,1,,BAO_0000219
6383,,,9606.0,Expert,Homo sapiens,11818,CHEMBL625142,80682,,646.0,,In vitro cytotoxicity against A549/ATCC cell line.,,F,1,N,1,,BAO_0000219
6384,,,9606.0,Intermediate,Homo sapiens,12400,CHEMBL625143,80682,,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,F,1,N,1,,BAO_0000219
6385,,,9606.0,Intermediate,Homo sapiens,3381,CHEMBL625144,80682,,646.0,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,F,1,N,1,,BAO_0000219
6386,,,9606.0,Intermediate,Homo sapiens,17376,CHEMBL622474,80682,,646.0,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,F,1,N,1,,BAO_0000219
6387,,,9606.0,Intermediate,Homo sapiens,10708,CHEMBL884104,80682,,646.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,F,1,N,1,,BAO_0000219
6388,,,9606.0,Autocuration,Homo sapiens,2964,CHEMBL622475,22226,,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,F,1,U,0,,BAO_0000219
6389,,,9615.0,Intermediate,Canis lupus familiaris,5005,CHEMBL622476,22224,,,,Compound was tested for oral bioavailability in dogs,,A,1,U,0,,BAO_0000218
6390,,,9615.0,Intermediate,Canis lupus familiaris,6229,CHEMBL875831,50588,,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,A,1,N,1,,BAO_0000218
6391,,,9615.0,Intermediate,Canis lupus familiaris,6229,CHEMBL622477,50588,,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,A,1,N,1,,BAO_0000218
6392,,,9615.0,Intermediate,Canis lupus familiaris,5374,CHEMBL622478,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6393,,,9615.0,Intermediate,Canis lupus familiaris,5374,CHEMBL623172,50588,,,,Compound was tested for the oral bioavailability in dog; No availability,,A,1,N,1,,BAO_0000218
6394,,,9615.0,Intermediate,Canis lupus familiaris,6265,CHEMBL623173,50588,,,,Oral bioavailability in dog (dose 5 mg/kg),,A,1,N,1,,BAO_0000218
6395,,,9615.0,Intermediate,Canis lupus familiaris,5654,CHEMBL623174,50588,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,A,1,N,1,,BAO_0000218
6396,,,9615.0,Intermediate,Canis lupus familiaris,5654,CHEMBL623175,50588,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,A,1,N,1,,BAO_0000218
6397,,,9615.0,Intermediate,Canis lupus familiaris,16456,CHEMBL623340,50588,,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,A,1,N,1,,BAO_0000218
6398,,,9615.0,Intermediate,Canis lupus familiaris,5302,CHEMBL623341,50588,,,,Oral bioavailability in dog (dose 5 mg/kg),,A,1,N,1,,BAO_0000218
6399,,,9615.0,Intermediate,Canis lupus familiaris,3624,CHEMBL623342,50588,,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,A,1,N,1,,BAO_0000218
6400,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL623343,50588,,,,Oral bioavailability of active FTIs in dogs,,A,1,N,1,,BAO_0000218
6401,,,9615.0,Intermediate,Canis lupus familiaris,5802,CHEMBL623344,50588,,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,A,1,N,1,,BAO_0000218
6402,,,9615.0,Expert,Canis lupus familiaris,3598,CHEMBL623345,50588,,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
6403,,,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL875832,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6404,,,9615.0,Intermediate,Canis lupus familiaris,6762,CHEMBL623346,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6405,,,9615.0,Intermediate,Canis lupus familiaris,6821,CHEMBL623347,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6406,,,9615.0,Intermediate,Canis lupus familiaris,6821,CHEMBL623348,50588,,,,Oral bioavailability of compound was determined in dog; Not tested,,A,1,N,1,,BAO_0000218
6407,,,9615.0,Intermediate,Canis lupus familiaris,5210,CHEMBL623349,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6408,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL623350,50588,,,,Oral bioavailability (10 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
6409,,,9615.0,Intermediate,Canis lupus familiaris,761,CHEMBL623351,50588,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
6410,,,9615.0,Intermediate,Canis lupus familiaris,761,CHEMBL623352,50588,,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,A,1,N,1,,BAO_0000218
6411,,,9615.0,Intermediate,Canis lupus familiaris,761,CHEMBL623353,50588,,,,Oral bioavailability administered in solution in rats,,A,1,N,1,,BAO_0000218
6412,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL875833,50588,,,,Oral bioavailability after 30 mg/kg po dose in Dogs,,A,1,N,1,,BAO_0000218
6413,,,9615.0,Intermediate,Canis lupus familiaris,5474,CHEMBL623354,50588,,,,Oral bioavailability at a dose of 1 mg/kg in dogs,,A,1,N,1,,BAO_0000218
6414,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL623355,50588,,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,A,1,N,1,,BAO_0000218
6415,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL623356,50588,,,,Oral bioavailability in Dog; ND = not determined,,A,1,N,1,,BAO_0000218
6416,,,9615.0,Intermediate,Canis lupus familiaris,3352,CHEMBL623357,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6417,,,9615.0,Intermediate,Canis lupus familiaris,6168,CHEMBL623358,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6418,,,9615.0,Intermediate,Canis lupus familiaris,5988,CHEMBL623359,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6419,,,9615.0,Intermediate,Canis lupus familiaris,4942,CHEMBL623360,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6420,,,9615.0,Intermediate,Canis lupus familiaris,4942,CHEMBL623361,50588,,,,Oral bioavailability in dogs; No data,,A,1,N,1,,BAO_0000218
6421,,,9615.0,Intermediate,Canis lupus familiaris,14541,CHEMBL623362,50588,,,,Oral bioavailability measured in dogs,,A,1,N,1,,BAO_0000218
6422,,,9615.0,Intermediate,Canis lupus familiaris,4449,CHEMBL623363,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6423,,,9615.0,Intermediate,Canis lupus familiaris,6057,CHEMBL623364,50588,,,,Oral bioavailability was calculated in dog,,A,1,N,1,,BAO_0000218
6424,,,9615.0,Intermediate,Canis lupus familiaris,5600,CHEMBL875834,50588,,,,Oral bioavailability after 0.3 mg/kg po administration in dog,,A,1,N,1,,BAO_0000218
6425,,,9615.0,Intermediate,Canis lupus familiaris,5542,CHEMBL623365,50588,,,,Oral bioavailability in dog (i.v. dosing),,A,1,N,1,,BAO_0000218
6426,,,9615.0,Intermediate,Canis lupus familiaris,5542,CHEMBL623366,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6427,,,9615.0,Intermediate,Canis lupus familiaris,5546,CHEMBL623367,50588,,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,A,1,N,1,,BAO_0000218
6428,,,9615.0,Intermediate,Canis lupus familiaris,4514,CHEMBL623368,50588,,,,Oral bioavailability in Beagle dogs,,A,1,N,1,,BAO_0000218
6429,,,9615.0,Intermediate,Canis lupus familiaris,3624,CHEMBL623369,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6430,,,9615.0,Intermediate,Canis lupus familiaris,3854,CHEMBL623370,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6431,,,9615.0,Intermediate,Canis lupus familiaris,5836,CHEMBL623371,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6432,,,9615.0,Intermediate,Canis lupus familiaris,5940,CHEMBL623372,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6433,,,9615.0,Intermediate,Canis lupus familiaris,6168,CHEMBL621351,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6434,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL621352,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6435,,,9615.0,Intermediate,Canis lupus familiaris,6251,CHEMBL621353,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6436,,,9615.0,Intermediate,Canis lupus familiaris,6448,CHEMBL621354,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6437,,,9615.0,Intermediate,Canis lupus familiaris,6647,CHEMBL621355,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6438,,,9615.0,Intermediate,Canis lupus familiaris,5940,CHEMBL621356,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6439,,,9615.0,Intermediate,Canis lupus familiaris,933,CHEMBL621357,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6440,,,9615.0,Intermediate,Canis lupus familiaris,5210,CHEMBL621358,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6441,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL621359,50588,,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,A,1,N,1,,BAO_0000218
6442,,,9615.0,Intermediate,Canis lupus familiaris,6641,CHEMBL621360,50588,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,A,1,N,1,,BAO_0000218
6443,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL621361,50588,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,A,1,N,1,,BAO_0000218
6444,,,9615.0,Intermediate,Canis lupus familiaris,5472,CHEMBL621362,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6445,,,9615.0,Intermediate,Canis lupus familiaris,5985,CHEMBL621363,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6446,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL621364,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6447,,,9615.0,Intermediate,Canis lupus familiaris,5530,CHEMBL621166,50588,,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,A,1,N,1,,BAO_0000218
6448,,,9615.0,Intermediate,Canis lupus familiaris,5530,CHEMBL621167,50588,,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
6449,,,9615.0,Intermediate,Canis lupus familiaris,6305,CHEMBL621168,50588,,,,Oral bioavailability (F) in dogs,,A,1,N,1,,BAO_0000218
6450,,,9615.0,Intermediate,Canis lupus familiaris,5210,CHEMBL621169,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6451,,,9615.0,Intermediate,Canis lupus familiaris,5238,CHEMBL875950,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6452,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL621170,50588,,,,Oral bioavailability in dog (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
6453,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL621171,50588,,,,Oral bioavailability after peroral administration at 5 mpk in Dog,,A,1,N,1,,BAO_0000218
6454,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL621172,50588,,,,Oral bioavailability in dog (dose 5 mg/kg),,A,1,N,1,,BAO_0000218
6455,,,9615.0,Intermediate,Canis lupus familiaris,6084,CHEMBL621173,50588,,,,Oral bioavailability in dog (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
6456,,2113.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621174,50594,,42.0,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6457,,2113.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621175,50594,,42.0,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6458,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621176,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6459,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621177,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6460,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621178,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6461,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621179,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6462,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621180,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6463,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL875951,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6464,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621181,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6465,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621182,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6466,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621183,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6467,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621184,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6468,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621185,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6469,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621186,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6470,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621187,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6471,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621188,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6472,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621189,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6473,,2106.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621190,50594,,42.0,Spleen,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6474,,2106.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL618520,50594,,42.0,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6475,,2106.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621739,50594,,42.0,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6476,,2106.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621740,50594,,42.0,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6477,,2106.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621741,50594,,42.0,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6478,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621742,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6479,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621743,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6480,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621744,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6481,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621745,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6482,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621746,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6483,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621747,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6484,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621748,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6485,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621749,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6486,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621750,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6487,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL621751,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6488,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621752,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6489,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621753,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6490,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL875955,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6491,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621754,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6492,,948.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621755,50594,,42.0,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6493,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL621756,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6494,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624199,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6495,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624200,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6496,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624375,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6497,,2107.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624376,50594,,42.0,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6498,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624377,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6499,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624378,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6500,,,107673.0,Intermediate,aeinetobacter anitrotap,12269,CHEMBL857901,50067,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,F,1,N,1,,BAO_0000218
6501,,,107673.0,Intermediate,Acinetobacter calcoaceticus subsp. anitratus,12269,CHEMBL875274,50067,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,F,1,N,1,,BAO_0000218
6502,,,107673.0,Intermediate,Acinetobacter calcoaceticus subsp. anitratus,12269,CHEMBL624379,50067,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,F,1,N,1,,BAO_0000218
6503,,,107673.0,Intermediate,aeinetobacter anitrotap,12269,CHEMBL624380,50067,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,F,1,N,1,,BAO_0000218
6504,,,471.0,Intermediate,Acinetobacter calcoaceticus,10624,CHEMBL624381,50192,,,,Activity against Acinetobacter calcoaceticus (AC54),,F,1,N,1,,BAO_0000218
6505,,,28377.0,Intermediate,Anolis carolinensis,17216,CHEMBL624382,50714,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,F,1,N,1,,BAO_0000218
6506,,,28377.0,Intermediate,Anolis carolinensis,17216,CHEMBL624383,50714,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,F,1,N,1,,BAO_0000218
6507,,,1655.0,Intermediate,Actinomyces naeslundii,9560,CHEMBL624384,50296,,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,F,1,N,1,,BAO_0000218
6508,,,1655.0,Intermediate,Actinomyces naeslundii,9560,CHEMBL624385,50296,,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,F,1,N,1,,BAO_0000218
6509,,,1655.0,Intermediate,Actinomyces naeslundii,9560,CHEMBL624386,50296,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,F,1,N,1,,BAO_0000218
6510,,,1655.0,Intermediate,Actinomyces naeslundii,9560,CHEMBL624387,50296,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,F,1,N,1,,BAO_0000218
6511,,,1655.0,Intermediate,Actinomyces naeslundii,9560,CHEMBL624388,50296,,,,Plaque bactericidal index against Actinomyces naeslundii 631,,F,1,N,1,,BAO_0000218
6512,,,1655.0,Intermediate,Actinomyces naeslundii,9560,CHEMBL624389,50296,,,,Plaque bactericidal index against Actinomyces naeslundii N/9,,F,1,N,1,,BAO_0000218
6513,,,1655.0,Intermediate,Actinomyces naeslundii,9560,CHEMBL624390,50296,,,,Plaque bactericidal index against Actinomyces naeslundii B74,,F,1,N,1,,BAO_0000218
6514,,,1655.0,Intermediate,Actinomyces naeslundii,9560,CHEMBL875275,50296,,,,Plaque bactericidal index against Actinomyces naeslundii N/3,,F,1,N,1,,BAO_0000218
6515,,,85549.0,Intermediate,Artemia salina,114,CHEMBL624391,50056,,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,F,1,N,1,,BAO_0000218
6516,,,85549.0,Intermediate,Artemia salina,114,CHEMBL623636,50056,,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,F,1,N,1,,BAO_0000218
6517,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623637,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,F,1,N,1,,BAO_0000218
6518,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623638,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,F,1,N,1,,BAO_0000218
6519,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623639,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,F,1,N,1,,BAO_0000218
6520,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623640,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,F,1,N,1,,BAO_0000218
6521,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623641,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,F,1,N,1,,BAO_0000218
6522,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623642,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,F,1,N,1,,BAO_0000218
6523,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623643,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,F,1,N,1,,BAO_0000218
6524,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623644,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,F,1,N,1,,BAO_0000218
6525,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623645,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,F,1,N,1,,BAO_0000218
6526,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623646,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,F,1,N,1,,BAO_0000218
6527,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623647,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,F,1,N,1,,BAO_0000218
6528,,,6253.0,Intermediate,Ascaris suum,10841,CHEMBL623648,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,F,1,N,1,,BAO_0000218
6529,,,1656.0,Intermediate,Actinomyces viscosus,8117,CHEMBL623649,50366,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,F,1,N,1,,BAO_0000218
6530,,,1656.0,Intermediate,Actinomyces viscosus,8117,CHEMBL623650,50366,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,F,1,N,1,,BAO_0000218
6531,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623651,50366,,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,F,1,N,1,,BAO_0000218
6532,,,1656.0,Expert,Actinomyces viscosus,9560,CHEMBL623652,50366,,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,F,1,N,1,,BAO_0000218
6533,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623653,50366,,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,F,1,N,1,,BAO_0000218
6534,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623654,50366,,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,F,1,N,1,,BAO_0000218
6535,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623655,50366,,,,Plaque bactericidal index against Actinomyces viscosus 8A06,,F,1,N,1,,BAO_0000218
6536,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623656,50366,,,,Plaque bactericidal index against Actinomyces viscosus M-100,,F,1,N,1,,BAO_0000218
6537,,,1656.0,Expert,Actinomyces viscosus,9560,CHEMBL623657,50366,,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,F,1,N,1,,BAO_0000218
6538,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623658,50366,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,F,1,N,1,,BAO_0000218
6539,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623659,50366,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,F,1,N,1,,BAO_0000218
6540,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623660,50366,,,,Plaque bactericidal index against Actinomyces viscosus 626,,F,1,N,1,,BAO_0000218
6541,,,1656.0,Intermediate,Actinomyces viscosus,9560,CHEMBL623661,50366,,,,Plaque bactericidal index against Actinomyces viscosus T14V,,F,1,N,1,,BAO_0000218
6542,,,6277.0,Intermediate,Acanthocheilonema viteae,10986,CHEMBL875281,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,F,1,N,1,,BAO_0000218
6543,,,6277.0,Intermediate,Acanthocheilonema viteae,10986,CHEMBL623662,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,F,1,N,1,,BAO_0000218
6544,,,6277.0,Intermediate,Acanthocheilonema viteae,10986,CHEMBL623663,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,F,1,N,1,,BAO_0000218
6545,,,6277.0,Intermediate,Acanthocheilonema viteae,10986,CHEMBL623664,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,F,1,N,1,,BAO_0000218
6546,,,6277.0,Intermediate,Acanthocheilonema viteae,10986,CHEMBL623665,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,F,1,N,1,,BAO_0000218
6547,,,9606.0,Intermediate,Homo sapiens,10708,CHEMBL621856,80023,,165.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,F,1,N,1,,BAO_0000219
6548,,,9606.0,Intermediate,Homo sapiens,10708,CHEMBL620432,80661,,645.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,F,1,N,1,,BAO_0000219
6549,,,10116.0,Autocuration,Rattus norvegicus,416,CHEMBL620433,22226,,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,F,1,U,0,,BAO_0000219
6550,,,10090.0,Intermediate,Mus musculus,14354,CHEMBL620434,80024,,625.0,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,F,1,N,1,,BAO_0000219
6551,,,10090.0,Intermediate,Mus musculus,14354,CHEMBL620435,80024,,625.0,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,F,1,N,1,,BAO_0000219
6552,,,9606.0,Intermediate,Homo sapiens,5116,CHEMBL620436,80024,,625.0,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,F,1,N,1,,BAO_0000219
6553,,,9606.0,Intermediate,Homo sapiens,5116,CHEMBL876597,80024,,625.0,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,F,1,N,1,,BAO_0000219
6554,,,9606.0,Expert,Homo sapiens,15694,CHEMBL620437,81037,,874.0,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,F,1,N,1,,BAO_0000219
6555,,,10090.0,Expert,Mus musculus,13038,CHEMBL620438,80024,,625.0,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,F,1,N,1,,BAO_0000219
6556,,,10090.0,Expert,Mus musculus,13038,CHEMBL620439,80024,,625.0,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,F,1,N,1,,BAO_0000219
6557,,,10090.0,Expert,Mus musculus,10923,CHEMBL619657,80024,,625.0,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,F,1,N,1,,BAO_0000219
6558,,,10090.0,Intermediate,Mus musculus,10923,CHEMBL619658,80024,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,F,1,N,1,,BAO_0000219
6559,,,10090.0,Intermediate,Mus musculus,10923,CHEMBL619659,80024,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,F,1,N,1,,BAO_0000219
6560,,,,Expert,,10923,CHEMBL619660,10649,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,F,1,H,8,,BAO_0000019
6561,,,10090.0,Intermediate,Mus musculus,10923,CHEMBL619661,80024,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,F,1,N,1,,BAO_0000219
6562,,,10090.0,Intermediate,Mus musculus,10923,CHEMBL619662,80024,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,F,1,N,1,,BAO_0000219
6563,,,10029.0,Intermediate,Cricetulus griseus,8158,CHEMBL619663,80663,,975.0,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,F,1,N,1,,BAO_0000219
6564,,,9606.0,Autocuration,Homo sapiens,15494,CHEMBL619664,22226,,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,F,1,U,0,,BAO_0000219
6565,,,9606.0,Autocuration,Homo sapiens,15494,CHEMBL619665,22226,,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,F,1,U,0,,BAO_0000219
6566,,,9606.0,Intermediate,Homo sapiens,12348,CHEMBL883244,80662,,974.0,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,F,1,N,1,,BAO_0000219
6567,,,9606.0,Intermediate,Homo sapiens,12348,CHEMBL884011,80662,,974.0,,Cytotoxicity was measured against AA5/HIV-1(IIIB),,F,1,N,1,,BAO_0000219
6568,,,9606.0,Intermediate,Homo sapiens,2726,CHEMBL619666,80662,,974.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,F,1,N,1,,BAO_0000219
6569,,,9606.0,Intermediate,Homo sapiens,2726,CHEMBL619667,80566,,379.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,F,1,N,1,,BAO_0000219
6570,,,10029.0,Intermediate,Cricetulus griseus,10747,CHEMBL619668,80578,,274.0,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,F,1,N,1,,BAO_0000219
6571,,,10029.0,Expert,Cricetulus griseus,11005,CHEMBL619669,80089,,185.0,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,F,1,N,1,,BAO_0000219
6572,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL876608,80089,,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6,,F,1,N,1,,BAO_0000219
6573,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL619670,80089,,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6.,,F,1,N,1,,BAO_0000219
6574,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL619671,80089,,185.0,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,F,1,N,1,,BAO_0000219
6575,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL619672,80089,,185.0,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,F,1,N,1,,BAO_0000219
6576,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL619673,80089,,185.0,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,F,1,N,1,,BAO_0000219
6577,,,10029.0,Intermediate,Cricetulus griseus,13436,CHEMBL619674,80089,,185.0,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,F,1,N,1,,BAO_0000219
6578,,,10029.0,Intermediate,Cricetulus griseus,13435,CHEMBL619675,80089,,185.0,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,F,1,N,1,,BAO_0000219
6579,,,10029.0,Intermediate,Cricetulus griseus,13302,CHEMBL619676,80089,,185.0,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,F,1,N,1,,BAO_0000219
6580,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL619677,80089,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,F,1,N,1,,BAO_0000219
6581,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL619678,80089,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,A,1,N,1,,BAO_0000219
6582,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL619679,80089,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,A,1,N,1,,BAO_0000219
6583,,,10029.0,Expert,Cricetulus griseus,12878,CHEMBL619680,80089,,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,A,1,N,1,,BAO_0000219
6584,,,10029.0,Intermediate,Cricetulus griseus,12878,CHEMBL621457,80089,,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,A,1,N,1,,BAO_0000219
6585,,,10029.0,Expert,Cricetulus griseus,14367,CHEMBL876609,80089,,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,F,1,N,1,,BAO_0000219
6586,,,10029.0,Intermediate,Cricetulus griseus,14367,CHEMBL621458,80089,,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,F,1,N,1,,BAO_0000219
6587,,,36483.0,Expert,hampster,12398,CHEMBL621459,80089,,185.0,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,F,1,N,1,,BAO_0000219
6588,,,10029.0,Expert,Cricetulus griseus,12878,CHEMBL621460,80089,,185.0,,Aerobic growth inhibition in Chinese hamster cell line AA8,,F,1,N,1,,BAO_0000219
6589,,,10029.0,Expert,Cricetulus griseus,13820,CHEMBL621461,80089,,185.0,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,F,1,N,1,,BAO_0000219
6590,,,10029.0,Expert,Cricetulus griseus,13436,CHEMBL621462,80089,,185.0,,Inhibition of growth under aerobic conditions in AA8 cells,,F,1,N,1,,BAO_0000219
6591,,,9615.0,Intermediate,Canis lupus familiaris,6084,CHEMBL621463,50588,,,,Oral bioavailability in dog (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
6592,,,9615.0,Intermediate,Canis lupus familiaris,5711,CHEMBL621464,50588,,,,Oral bioavailability in dog at 10 mg/kg of the compound,,A,1,N,1,,BAO_0000218
6593,,,9615.0,Intermediate,Canis lupus familiaris,4353,CHEMBL621465,50588,,,,Oral bioavailability in dog (dose 5 uM/kg),,A,1,N,1,,BAO_0000218
6594,,,9615.0,Intermediate,Canis lupus familiaris,4353,CHEMBL621466,50588,,,,Oral bioavailability in dog (dose 5 uM/kg),,A,1,N,1,,BAO_0000218
6595,,,9615.0,Intermediate,Canis lupus familiaris,17800,CHEMBL621467,50588,,,,Oral bioavailability in dog (mongrel),,A,1,N,1,,BAO_0000218
6596,,,9615.0,Intermediate,Canis lupus familiaris,3994,CHEMBL621468,50588,,,,Oral bioavailability in dog (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
6597,,,9615.0,Intermediate,Canis lupus familiaris,3994,CHEMBL876734,50588,,,,Oral bioavailability in dog (dose 10 mg/kg),,F,1,N,1,,BAO_0000218
6598,,,9615.0,Intermediate,Canis lupus familiaris,5145,CHEMBL618476,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6599,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL618477,50588,,,,Bioavailability in dog (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
6600,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL618478,50588,,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,A,1,N,1,,BAO_0000218
6601,,,9615.0,Intermediate,Canis lupus familiaris,5983,CHEMBL618479,50588,,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,A,1,N,1,,BAO_0000218
6602,,,9615.0,Intermediate,Canis lupus familiaris,4273,CHEMBL618480,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6603,,,9615.0,Intermediate,Canis lupus familiaris,12500,CHEMBL618481,50588,,,,Bioavailability in dog (dose 3-10 mg/kg),,A,1,N,1,,BAO_0000218
6604,,1969.0,9615.0,Intermediate,Canis lupus familiaris,12500,CHEMBL618482,50588,,,Plasma,The compound was tested for bioavailability of compound in plasma of dog; Complete,,A,1,N,1,,BAO_0000218
6605,,,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL618483,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6606,,,9615.0,Intermediate,Canis lupus familiaris,3880,CHEMBL618484,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6607,,,9615.0,Intermediate,Canis lupus familiaris,4838,CHEMBL618485,50588,,,,Bioavailability in dog,,A,1,N,1,,BAO_0000218
6608,,,9615.0,Intermediate,Canis lupus familiaris,15600,CHEMBL618486,50588,,,,oral bioavailability was measured in dogs,,A,1,N,1,,BAO_0000218
6609,,,9615.0,Intermediate,Canis lupus familiaris,17248,CHEMBL618487,50588,,,,Compound was tested for plasma protein binding in dog; Not determined,,A,1,N,1,,BAO_0000218
6610,,,9615.0,Intermediate,Canis lupus familiaris,17248,CHEMBL618488,50588,,,,Compound was tested for plasma protein binding of dog,,A,1,N,1,,BAO_0000218
6611,,,9615.0,Intermediate,Canis lupus familiaris,17248,CHEMBL876735,50588,,,,Compound was tested for plasma protein binding of dog; Not determined,,A,1,N,1,,BAO_0000218
6612,,,9615.0,Intermediate,Canis lupus familiaris,17443,CHEMBL618489,50588,,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,A,1,N,1,,BAO_0000218
6613,,,9615.0,Intermediate,Canis lupus familiaris,4186,CHEMBL618490,50588,,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,A,1,N,1,,BAO_0000218
6614,,,9615.0,Intermediate,Canis lupus familiaris,3749,CHEMBL618491,50588,,,,Half life was determined,,A,1,N,1,,BAO_0000218
6615,,,9615.0,Intermediate,Canis lupus familiaris,3249,CHEMBL618492,50588,,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
6616,,,9615.0,Intermediate,Canis lupus familiaris,3022,CHEMBL873354,50588,,,,Half life was evaluated in dog,,A,1,N,1,,BAO_0000218
6617,,,9615.0,Intermediate,Canis lupus familiaris,3749,CHEMBL618493,50588,,,,Half life was determined,,A,1,N,1,,BAO_0000218
6618,,,9615.0,Intermediate,Canis lupus familiaris,2517,CHEMBL618494,50588,,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,A,1,N,1,,BAO_0000218
6619,,948.0,9615.0,Intermediate,Canis lupus familiaris,2517,CHEMBL618495,50588,,,Heart,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,A,1,N,1,,BAO_0000218
6620,,2113.0,9615.0,Intermediate,Canis lupus familiaris,2517,CHEMBL618496,50588,,,Kidney,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,A,1,N,1,,BAO_0000218
6621,,2107.0,9615.0,Intermediate,Canis lupus familiaris,2517,CHEMBL618497,50588,,,Liver,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,A,1,N,1,,BAO_0000218
6622,,2048.0,9615.0,Intermediate,Canis lupus familiaris,2517,CHEMBL618498,50588,,,Lung,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,A,1,N,1,,BAO_0000218
6623,,2106.0,9615.0,Intermediate,Canis lupus familiaris,2517,CHEMBL618499,50588,,,Spleen,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,A,1,N,1,,BAO_0000218
6624,,,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL876736,50588,,,,LogP in dog,,A,1,N,1,,BAO_0000218
6625,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL618500,50588,,,,Partition coefficient (logP),,A,1,N,1,,BAO_0000218
6626,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL857831,50588,,,,Partition coefficient in dog,,A,1,N,1,,BAO_0000218
6627,,,9615.0,Intermediate,Canis lupus familiaris,17764,CHEMBL618501,50588,,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,A,1,N,1,,BAO_0000218
6628,,,9615.0,Intermediate,Canis lupus familiaris,4809,CHEMBL618502,50588,,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,A,1,N,1,,BAO_0000218
6629,,,9615.0,Intermediate,Canis lupus familiaris,5600,CHEMBL618503,50588,,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,A,1,N,1,,BAO_0000218
6630,,,9615.0,Intermediate,Canis lupus familiaris,14294,CHEMBL618504,50588,,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,A,1,N,1,,BAO_0000218
6631,,,9615.0,Intermediate,Canis lupus familiaris,14294,CHEMBL618505,50588,,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,A,1,N,1,,BAO_0000218
6632,,,9615.0,Intermediate,Canis lupus familiaris,14294,CHEMBL618506,50588,,,,Metabolism of compound in dog S9 microsomes; Trace,,A,1,N,1,,BAO_0000218
6633,,2107.0,9615.0,Intermediate,Canis lupus familiaris,6251,CHEMBL618507,50588,,,Liver,In vitro metabolic potential in dog liver microsomes,,A,1,N,1,,BAO_0000218
6634,,,9615.0,Intermediate,Canis lupus familiaris,3748,CHEMBL876737,50588,,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,A,1,N,1,,BAO_0000218
6635,,,9615.0,Intermediate,Canis lupus familiaris,2713,CHEMBL618508,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6636,,,9615.0,Intermediate,Canis lupus familiaris,6512,CHEMBL618509,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6637,,,9615.0,Intermediate,Canis lupus familiaris,6679,CHEMBL618510,50588,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,A,1,N,1,,BAO_0000218
6638,,,9615.0,Intermediate,Canis lupus familiaris,3749,CHEMBL618511,50588,,,,The compound was tested for bioavailability in dogs,,A,1,N,1,,BAO_0000218
6639,,,9615.0,Intermediate,Canis lupus familiaris,3749,CHEMBL618512,50588,,,,The compound was tested for oral bioavailability in dogs,,A,1,N,1,,BAO_0000218
6640,,,9615.0,Intermediate,Canis lupus familiaris,6742,CHEMBL618513,50588,,,,Oral bioavailability in dog,,A,1,N,1,,BAO_0000218
6641,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL618514,50588,,,,Compound was tested for percent protein binding (PB) in dog,,A,1,N,1,,BAO_0000218
6642,,,9615.0,Intermediate,Canis lupus familiaris,6874,CHEMBL620052,50588,,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,A,1,N,1,,BAO_0000218
6643,,1969.0,9615.0,Intermediate,Canis lupus familiaris,2877,CHEMBL620053,50588,,,Plasma,Compound was evaluated for plasma clearance.,,A,1,N,1,,BAO_0000218
6644,,1969.0,9615.0,Intermediate,Canis lupus familiaris,12500,CHEMBL620054,50588,,,Plasma,The compound was tested for plasma clearance in dog,,A,1,N,1,,BAO_0000218
6645,,1969.0,9615.0,Intermediate,Canis lupus familiaris,12500,CHEMBL620055,50588,,,Plasma,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,A,1,N,1,,BAO_0000218
6646,,,9615.0,Intermediate,Canis lupus familiaris,4709,CHEMBL620056,50588,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
6647,,2107.0,9615.0,Intermediate,Canis lupus familiaris,5542,CHEMBL620057,50588,,,Liver,In vitro relative rate of metabolism was determined in dog liver microsomes,,A,1,N,1,,BAO_0000218
6648,,,9615.0,Intermediate,Canis lupus familiaris,17594,CHEMBL618939,50588,,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,A,1,N,1,,BAO_0000218
6649,,,9615.0,Intermediate,Canis lupus familiaris,2652,CHEMBL618940,50588,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,A,1,N,1,,BAO_0000218
6650,,,9615.0,Intermediate,Canis lupus familiaris,17764,CHEMBL618941,50588,,,,Half life after intravenous administration in dogs at 1.2 uM/kg,,A,1,N,1,,BAO_0000218
6651,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624473,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6652,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624474,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6653,,2048.0,10090.0,Intermediate,Mus musculus,6599,CHEMBL624475,50594,,42.0,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6654,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL624476,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,A,1,N,1,,BAO_0000218
6655,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL623478,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,A,1,N,1,,BAO_0000218
6656,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL623479,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,A,1,N,1,,BAO_0000218
6657,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL623480,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,A,1,N,1,,BAO_0000218
6658,,,10090.0,Intermediate,Mus musculus,6599,CHEMBL623481,50594,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,A,1,N,1,,BAO_0000218
6659,,955.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623482,50594,,,Brain,C2 in brain of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6660,,2113.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623483,50594,,,Kidney,C2 in kidney of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6661,,2107.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623484,50594,,,Liver,C2 in liver of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6662,,2048.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623485,50594,,,Lung,C2 in lungs of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6663,,2106.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623486,50594,,,Spleen,C2 in spleen of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6664,,,10090.0,Intermediate,Mus musculus,17852,CHEMBL623487,50594,,,,Plasma clearance in mouse,,A,1,N,1,,BAO_0000218
6665,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL623488,50594,,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,A,1,N,1,,BAO_0000218
6666,,,10090.0,Intermediate,Mus musculus,17837,CHEMBL623489,50594,,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,A,1,N,1,,BAO_0000218
6667,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL875157,50594,,,,Clearance was evaluated in mice after intravenous administration,,A,1,N,1,,BAO_0000218
6668,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL623490,50594,,,,Clearance was evaluated in mice after oral administration,,A,1,N,1,,BAO_0000218
6669,,,10090.0,Intermediate,Mus musculus,4239,CHEMBL623491,50594,,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,A,1,N,1,,BAO_0000218
6670,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL623492,50594,,,,Plasma clearance of compound was determined at 40 mg/Kg,,A,1,N,1,,BAO_0000218
6671,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL623493,50594,,,,Plasma clearance of at 24 mg/Kg,,A,1,N,1,,BAO_0000218
6672,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL623494,50594,,,,Plasma clearance at 24 mg/Kg,,A,1,N,1,,BAO_0000218
6673,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL623495,50594,,,,Plasma clearance at 5 mg/Kg,,A,1,N,1,,BAO_0000218
6674,,,10090.0,Intermediate,Mus musculus,5727,CHEMBL623496,50594,,,,Plasma clearance in mice,,A,1,N,1,,BAO_0000218
6675,,,10090.0,Intermediate,Mus musculus,2862,CHEMBL623497,50594,,,,Plasma clearance value upon iv administration in mouse,,A,1,N,1,,BAO_0000218
6676,,1969.0,10090.0,Intermediate,Mus musculus,5980,CHEMBL623498,50594,,,Plasma,Total plasma clearance in mice,,A,1,N,1,,BAO_0000218
6677,,,10090.0,Intermediate,Mus musculus,17592,CHEMBL623499,50594,,,,Clearance in mouse,,A,1,N,1,,BAO_0000218
6678,,,10090.0,Intermediate,Mus musculus,17718,CHEMBL623500,50594,,,,Clearance value was determined,,A,1,N,1,,BAO_0000218
6679,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL623501,50594,,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,A,1,N,1,,BAO_0000218
6680,,,,Intermediate,,17384,CHEMBL875158,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
6681,,,10090.0,Intermediate,Mus musculus,6062,CHEMBL623502,50594,,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
6682,,,10090.0,Intermediate,Mus musculus,17734,CHEMBL623503,50594,,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,A,1,N,1,,BAO_0000218
6683,,,10090.0,Intermediate,Mus musculus,6348,CHEMBL623504,50594,,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
6684,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL623505,50594,,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,A,1,N,1,,BAO_0000218
6685,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL623506,50594,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6686,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL623507,50594,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,A,1,N,1,,BAO_0000218
6687,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL623508,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,A,1,N,1,,BAO_0000218
6688,,,10090.0,Intermediate,Mus musculus,5781,CHEMBL623509,50594,,,,Cmax after oral administration at 30 mg/kg in ICR mouse,,A,1,N,1,,BAO_0000218
6689,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL875159,50594,,,,Cmax after peroral administration in mice at 2.4 uM/kg,,A,1,N,1,,BAO_0000218
6690,,955.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623510,50594,,,Brain,Cmax in brain of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6691,,2113.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623511,50594,,,Kidney,Cmax in kidney of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6692,,2107.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623512,50594,,,Liver,Cmax in liver of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6693,,2048.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL623513,50594,,,Lung,Cmax in lungs of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6694,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL623514,50594,,,,Cmax in mice at 18 uM/kg i.p. administration,,F,1,N,1,,BAO_0000218
6695,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL622609,50594,,,,Cmax in mice at 23 uM/kg i.v. administration,,F,1,N,1,,BAO_0000218
6696,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL622610,50594,,,,Cmax in mice at 24 uM/kg i.p. administration,,F,1,N,1,,BAO_0000218
6697,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL621823,50594,,,,Cmax in mice at 25 uM/kg i.p. administration,,F,1,N,1,,BAO_0000218
6698,,,10090.0,Intermediate,Mus musculus,17764,CHEMBL621824,50594,,,,Cmax in mice at 26 uM/kg i.p. administration,,F,1,N,1,,BAO_0000218
6699,,2106.0,10090.0,Intermediate,Mus musculus,17641,CHEMBL621825,50594,,,Spleen,Cmax in spleen of mice at the oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6700,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL621826,50594,,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,A,1,N,1,,BAO_0000218
6701,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL621827,50594,,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,A,1,N,1,,BAO_0000218
6702,,,10090.0,Intermediate,Mus musculus,5727,CHEMBL621828,50594,,,,Cmax value was determined,,A,1,N,1,,BAO_0000218
6703,,,10090.0,Intermediate,Mus musculus,5951,CHEMBL621829,50594,,,,Cmax value in IRC mice,,A,1,N,1,,BAO_0000218
6704,,,10090.0,Intermediate,Mus musculus,5506,CHEMBL621830,50594,,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,A,1,N,1,,BAO_0000218
6705,,,10090.0,Intermediate,Mus musculus,5506,CHEMBL621831,50594,,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,A,1,N,1,,BAO_0000218
6706,,1969.0,10090.0,Intermediate,Mus musculus,14239,CHEMBL621832,50594,,,Plasma,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,A,1,N,1,,BAO_0000218
6707,,1969.0,10090.0,Intermediate,Mus musculus,4890,CHEMBL624579,50594,,,Plasma,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,A,1,N,1,,BAO_0000218
6708,,,10090.0,Intermediate,Mus musculus,429,CHEMBL624580,50594,,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,A,1,N,1,,BAO_0000218
6709,,,6277.0,Intermediate,Acanthocheilonema viteae,10986,CHEMBL624581,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,F,1,N,1,,BAO_0000218
6710,,,6277.0,Intermediate,Acanthocheilonema viteae,10986,CHEMBL624582,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,F,1,N,1,,BAO_0000218
6711,,,6277.0,Intermediate,Acanthocheilonema viteae,10986,CHEMBL624583,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,F,1,N,1,,BAO_0000218
6712,,,9606.0,Intermediate,Homo sapiens,13227,CHEMBL624584,80018,,455.0,,Inhibitory activity against human tumor cell line A0375 melanoma.,,F,1,N,1,,BAO_0000219
6713,Brain membranes,,10116.0,Expert,Rattus norvegicus,4481,CHEMBL624585,12512,,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,B,1,D,9,,BAO_0000249
6714,,,9606.0,Expert,Homo sapiens,16931,CHEMBL875165,114,,,,Forskolin-induced cAMP production at human A1 adenosine receptor,,F,1,D,9,,BAO_0000019
6715,,,,Autocuration,,3850,CHEMBL619490,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,F,1,H,8,,BAO_0000219
6716,,,,Autocuration,,3850,CHEMBL619491,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,F,1,H,8,,BAO_0000219
6717,,,,Expert,,3850,CHEMBL619492,114,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,F,1,H,8,,BAO_0000219
6718,,,,Expert,,3850,CHEMBL619493,114,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,F,1,H,8,,BAO_0000219
6719,,,,Autocuration,,3850,CHEMBL619494,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,F,1,H,8,,BAO_0000219
6720,,,,Autocuration,,3850,CHEMBL619495,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,F,1,H,8,,BAO_0000219
6721,,,,Autocuration,,3850,CHEMBL619496,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,F,1,H,8,,BAO_0000219
6722,,,9606.0,Expert,Homo sapiens,3850,CHEMBL619497,114,,449.0,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,F,1,D,9,,BAO_0000219
6723,,,,Autocuration,,3850,CHEMBL619498,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,F,1,H,8,,BAO_0000219
6724,,,,Autocuration,,3850,CHEMBL619499,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,F,1,H,8,,BAO_0000219
6725,,,,Expert,,3850,CHEMBL619500,114,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,F,1,H,8,,BAO_0000219
6726,,,,Autocuration,,3850,CHEMBL619501,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,F,1,H,8,,BAO_0000219
6727,,,,Expert,,3850,CHEMBL619502,114,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,F,1,H,8,,BAO_0000219
6728,,,,Autocuration,,3850,CHEMBL619503,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,F,1,H,8,,BAO_0000219
6729,,,,Autocuration,,3850,CHEMBL619504,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,F,1,H,8,,BAO_0000219
6730,,,,Autocuration,,3850,CHEMBL621298,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,F,1,H,8,,BAO_0000219
6731,,,,Expert,,3850,CHEMBL621299,114,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,F,1,H,8,,BAO_0000219
6732,,,,Autocuration,,3850,CHEMBL621300,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,F,1,H,8,,BAO_0000219
6733,,,,Autocuration,,3850,CHEMBL621301,114,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,F,1,H,8,,BAO_0000219
6734,,,,Expert,,3850,CHEMBL621302,114,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,F,1,H,8,,BAO_0000219
6735,,,9986.0,Intermediate,Oryctolagus cuniculus,12680,CHEMBL621303,80013,,164.0,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,F,1,N,1,,BAO_0000219
6736,,,10116.0,Autocuration,Rattus norvegicus,1313,CHEMBL621304,22226,,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,F,1,U,0,,BAO_0000219
6737,,,10116.0,Autocuration,Rattus norvegicus,1313,CHEMBL621305,22226,,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,F,1,U,0,,BAO_0000219
6738,,,10116.0,Intermediate,Rattus norvegicus,17567,CHEMBL621306,80013,,164.0,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,F,1,N,1,,BAO_0000219
6739,,,10116.0,Intermediate,Rattus norvegicus,17567,CHEMBL618444,80013,,164.0,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,F,1,N,1,,BAO_0000219
6740,,,10116.0,Intermediate,Rattus norvegicus,11819,CHEMBL618445,80013,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,F,1,N,1,,BAO_0000219
6741,,,10029.0,Intermediate,Cricetulus griseus,13436,CHEMBL618446,80089,,185.0,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,F,1,N,1,,BAO_0000219
6742,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL618447,80089,,185.0,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,F,1,N,1,,BAO_0000219
6743,,,10029.0,Intermediate,Cricetulus griseus,12651,CHEMBL618448,80089,,185.0,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,F,1,N,1,,BAO_0000219
6744,,,10029.0,Intermediate,Cricetulus griseus,13300,CHEMBL618449,80089,,185.0,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,F,1,N,1,,BAO_0000219
6745,,,10029.0,Intermediate,Cricetulus griseus,15296,CHEMBL618637,80089,,185.0,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,F,1,N,1,,BAO_0000219
6746,,,10029.0,Intermediate,Cricetulus griseus,15328,CHEMBL618638,80089,,185.0,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,F,1,N,1,,BAO_0000219
6747,,,10029.0,Intermediate,Cricetulus griseus,13302,CHEMBL618639,80089,,185.0,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,F,1,N,1,,BAO_0000219
6748,,,10029.0,Expert,Cricetulus griseus,14367,CHEMBL618640,80089,,185.0,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,F,1,N,1,,BAO_0000219
6749,,,10029.0,Expert,Cricetulus griseus,17002,CHEMBL618641,80089,,185.0,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,F,1,N,1,,BAO_0000219
6750,,,10029.0,Intermediate,Cricetulus griseus,13436,CHEMBL618642,80089,,185.0,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,F,1,N,1,,BAO_0000219
6751,,,10029.0,Intermediate,Cricetulus griseus,13435,CHEMBL618643,80089,,185.0,,Inhibitory activity against aerobic growth of AA8 cells.,,F,1,N,1,,BAO_0000219
6752,,,10029.0,Intermediate,Cricetulus griseus,10503,CHEMBL884013,80089,,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,A,1,N,1,,BAO_0000219
6753,,,10029.0,Expert,Cricetulus griseus,10503,CHEMBL622723,80089,,185.0,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,F,1,N,1,,BAO_0000219
6754,,,10029.0,Intermediate,Cricetulus griseus,10503,CHEMBL622724,80089,,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,F,1,N,1,,BAO_0000219
6755,,,10029.0,Expert,Cricetulus griseus,15090,CHEMBL622725,80089,,185.0,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,F,1,N,1,,BAO_0000219
6756,,,10029.0,Expert,Cricetulus griseus,10368,CHEMBL622726,80089,,185.0,,Cytotoxicity against AA8 cell line,,F,1,N,1,,BAO_0000219
6757,,,10029.0,Intermediate,Cricetulus griseus,12651,CHEMBL622727,80089,,185.0,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,F,1,N,1,,BAO_0000219
6758,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL622728,80089,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,A,1,N,1,,BAO_0000219
6759,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL622729,80089,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,F,1,N,1,,BAO_0000219
6760,,,10029.0,Intermediate,Cricetulus griseus,12687,CHEMBL622730,80089,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,A,1,N,1,,BAO_0000219
6761,,,10029.0,Intermediate,Cricetulus griseus,1890,CHEMBL622731,80089,,185.0,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,F,1,N,1,,BAO_0000219
6762,,,10029.0,Intermediate,Cricetulus griseus,10747,CHEMBL622732,80089,,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,F,1,N,1,,BAO_0000219
6763,,,10029.0,Intermediate,Cricetulus griseus,10747,CHEMBL622733,80089,,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,F,1,N,1,,BAO_0000219
6764,,,10029.0,Autocuration,Cricetulus griseus,11616,CHEMBL622734,22224,,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,F,1,U,0,,BAO_0000218
6765,,,10029.0,Expert,Cricetulus griseus,11616,CHEMBL622735,80089,,185.0,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,F,1,N,1,,BAO_0000219
6766,,,10029.0,Autocuration,Cricetulus griseus,3471,CHEMBL618746,22224,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,F,1,U,0,,BAO_0000219
6767,,,10029.0,Autocuration,Cricetulus griseus,3471,CHEMBL618747,22224,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,F,1,U,0,,BAO_0000219
6768,,,10029.0,Autocuration,Cricetulus griseus,3471,CHEMBL620540,22224,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,F,1,U,0,,BAO_0000219
6769,,,10029.0,Autocuration,Cricetulus griseus,3471,CHEMBL620541,22224,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,F,1,U,0,,BAO_0000219
6770,,,10029.0,Autocuration,Cricetulus griseus,3471,CHEMBL620542,22224,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,F,1,U,0,,BAO_0000219
6771,,,10029.0,Autocuration,Cricetulus griseus,3471,CHEMBL620543,22224,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,F,1,U,0,,BAO_0000219
6772,,,10029.0,Autocuration,Cricetulus griseus,3471,CHEMBL618832,22224,,185.0,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,F,1,U,0,,BAO_0000219
6773,,,10029.0,Expert,Cricetulus griseus,11616,CHEMBL618833,80089,,185.0,,Concentration required to reduce AA8 cell survival by 10%,,F,1,N,1,,BAO_0000219
6774,,,10029.0,Autocuration,Cricetulus griseus,2656,CHEMBL618834,22224,,185.0,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,F,1,U,0,,BAO_0000219
6775,,,10029.0,Autocuration,Cricetulus griseus,10518,CHEMBL618835,22224,,185.0,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,F,1,U,0,,BAO_0000219
6776,,,10029.0,Autocuration,Cricetulus griseus,10518,CHEMBL618836,22224,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,F,1,U,0,,BAO_0000219
6777,,,10029.0,Autocuration,Cricetulus griseus,10518,CHEMBL618837,22224,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,F,1,U,0,,BAO_0000219
6778,,,10029.0,Autocuration,Cricetulus griseus,10518,CHEMBL618838,22224,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,F,1,U,0,,BAO_0000219
6779,,,10029.0,Autocuration,Cricetulus griseus,16156,CHEMBL618839,22224,,185.0,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,F,1,U,0,,BAO_0000219
6780,,,10029.0,Autocuration,Cricetulus griseus,2656,CHEMBL618840,22224,,185.0,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,F,1,U,0,,BAO_0000219
6781,,,10029.0,Autocuration,Cricetulus griseus,11005,CHEMBL618841,22224,,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,F,1,U,0,,BAO_0000019
6782,,,10029.0,Autocuration,Cricetulus griseus,11942,CHEMBL618842,22224,,185.0,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,F,1,U,0,,BAO_0000219
6783,,,10029.0,Autocuration,Cricetulus griseus,2128,CHEMBL618843,22224,,185.0,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,F,1,U,0,,BAO_0000219
6784,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL618844,50588,,,,Half life period after 15 mg/kg iv dose in Dogs,,A,1,N,1,,BAO_0000218
6785,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL618845,50588,,,,Half life period after 30 mg/kg po dose in Dogs,,A,1,N,1,,BAO_0000218
6786,,,9615.0,Intermediate,Canis lupus familiaris,9579,CHEMBL618846,50588,,,,Half life was measured after oral 2b administration (tested in 6 dogs),,A,1,N,1,,BAO_0000218
6787,,,9615.0,Intermediate,Canis lupus familiaris,9579,CHEMBL618847,50588,,,,Half life was measured in dog after oral 17b administration,,A,1,N,1,,BAO_0000218
6788,,,9615.0,Intermediate,Canis lupus familiaris,9579,CHEMBL618848,50588,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,A,1,N,1,,BAO_0000218
6789,,,9615.0,Intermediate,Canis lupus familiaris,9579,CHEMBL618849,50588,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,A,1,N,1,,BAO_0000218
6790,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL618850,50588,,,,Tmax value after 15 mg/kg iv dose in Dogs,,A,1,N,1,,BAO_0000218
6791,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL618851,50588,,,,Tmax value after 30 mg/kg po dose in Dogs,,A,1,N,1,,BAO_0000218
6792,,,9615.0,Intermediate,Canis lupus familiaris,3184,CHEMBL873815,50588,,,,Compound was evaluated for its half life when administered intravenously in dog,,A,1,N,1,,BAO_0000218
6793,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5017,CHEMBL618852,50588,,,Plasma,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,A,1,N,1,,BAO_0000218
6794,,,9615.0,Intermediate,Canis lupus familiaris,6821,CHEMBL618853,50588,,,,Elimination Half-life of compound was determined in dog,,A,1,N,1,,BAO_0000218
6795,,,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL618854,50588,,,,Half life of compound in dog following oral administration,,A,1,N,1,,BAO_0000218
6796,,,9615.0,Intermediate,Canis lupus familiaris,17267,CHEMBL618855,50588,,,,Half life of compound was determined in dog,,A,1,N,1,,BAO_0000218
6797,,178.0,9615.0,Intermediate,Canis lupus familiaris,4727,CHEMBL618856,50588,,,Blood,Half life of compound was determined in dog blood,,A,1,N,1,,BAO_0000218
6798,,,9615.0,Intermediate,Canis lupus familiaris,5238,CHEMBL875827,50588,,,,Half life after oral and iv dosing in dogs,,A,1,N,1,,BAO_0000218
6799,,,9615.0,Intermediate,Canis lupus familiaris,4942,CHEMBL618857,50588,,,,Half life in dogs in hours,,A,1,N,1,,BAO_0000218
6800,,,9615.0,Intermediate,Canis lupus familiaris,6505,CHEMBL618858,50588,,,,Half life on i.v. administration of 2 mg/kg was measured in dog,,A,1,N,1,,BAO_0000218
6801,,,9615.0,Intermediate,Canis lupus familiaris,5130,CHEMBL618859,50588,,,,t1/2 in dog after oral dose (1 mg/kg),,A,1,N,1,,BAO_0000218
6802,,,9615.0,Intermediate,Canis lupus familiaris,1475,CHEMBL618860,50588,,,,Half life was evaluated in dog,,A,1,N,1,,BAO_0000218
6803,,,9615.0,Intermediate,Canis lupus familiaris,17804,CHEMBL618861,50588,,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,A,1,N,1,,BAO_0000218
6804,,,9615.0,Intermediate,Canis lupus familiaris,17804,CHEMBL622539,50588,,,,Half life period of compound was determined after peroral administration at 2 mg/kg,,A,1,N,1,,BAO_0000218
6805,,,9615.0,Intermediate,Canis lupus familiaris,6084,CHEMBL622540,50588,,,,Half life period (10 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
6806,,,9615.0,Intermediate,Canis lupus familiaris,6084,CHEMBL873803,50588,,,,Half life period (10 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
6807,,,9615.0,Intermediate,Canis lupus familiaris,5542,CHEMBL873804,50588,,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,A,1,N,1,,BAO_0000218
6808,,,9615.0,Intermediate,Canis lupus familiaris,5542,CHEMBL624311,50588,,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,A,1,N,1,,BAO_0000218
6809,,,9615.0,Intermediate,Canis lupus familiaris,6084,CHEMBL624312,50588,,,,Half life period in dog,,A,1,N,1,,BAO_0000218
6810,,,9615.0,Intermediate,Canis lupus familiaris,6241,CHEMBL624313,50588,,,,Half life period in dogs after oral administration at 1 mg/kg,,A,1,N,1,,BAO_0000218
6811,,,9615.0,Intermediate,Canis lupus familiaris,1916,CHEMBL624314,50588,,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,A,1,N,1,,BAO_0000218
6812,,,9615.0,Intermediate,Canis lupus familiaris,6621,CHEMBL624315,50588,,,,Half-life of compound was determined in dogs,,A,1,N,1,,BAO_0000218
6813,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1696,CHEMBL624316,50588,,,Plasma,Half-life in dog plasma,,A,1,N,1,,BAO_0000218
6814,,,9615.0,Intermediate,Canis lupus familiaris,17800,CHEMBL624317,50588,,,,Half-life in mongrel dogs was determined,,A,1,N,1,,BAO_0000218
6815,,,9615.0,Intermediate,Canis lupus familiaris,17657,CHEMBL624318,50588,,,,Half-life in dog upon oral administration,,A,1,N,1,,BAO_0000218
6816,,,9615.0,Intermediate,Canis lupus familiaris,17657,CHEMBL624319,50588,,,,Half-life in dog upon oral administration; Unable to calculate,,A,1,N,1,,BAO_0000218
6817,,,9615.0,Intermediate,Canis lupus familiaris,4239,CHEMBL624496,50588,,,,Half-life was measured in dog,,A,1,N,1,,BAO_0000218
6818,,,9615.0,Intermediate,Canis lupus familiaris,5985,CHEMBL624497,50588,,,,Half-life was measured in dog,,A,1,N,1,,BAO_0000218
6819,,,9615.0,Intermediate,Canis lupus familiaris,9932,CHEMBL624498,50588,,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,A,1,N,1,,BAO_0000218
6820,,,9615.0,Intermediate,Canis lupus familiaris,5199,CHEMBL624499,50588,,,,Oral half life was determined,,A,1,N,1,,BAO_0000218
6821,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5199,CHEMBL624500,50588,,,Plasma,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,A,1,N,1,,BAO_0000218
6822,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1475,CHEMBL624501,50588,,,Plasma,Plasma half life was evaluated,,A,1,N,1,,BAO_0000218
6823,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1475,CHEMBL623666,50588,,,Plasma,Plasma half life was evaluated in Dog,,A,1,N,1,,BAO_0000218
6824,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1475,CHEMBL623667,50588,,,Plasma,Plasma half life was evaluated in dog,,A,1,N,1,,BAO_0000218
6825,,,9615.0,Intermediate,Canis lupus familiaris,6316,CHEMBL623668,50588,,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
6826,,,9615.0,Intermediate,Canis lupus familiaris,4883,CHEMBL623669,50588,,,,Tested for the half life value in dog,,A,1,N,1,,BAO_0000218
6827,,,9615.0,Intermediate,Canis lupus familiaris,4727,CHEMBL623670,50588,,,,Maximum time at the dose of 2 mg/kg in dog,,A,1,N,1,,BAO_0000218
6828,,,9615.0,Intermediate,Canis lupus familiaris,1916,CHEMBL623671,50588,,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,A,1,N,1,,BAO_0000218
6829,,178.0,9615.0,Intermediate,Canis lupus familiaris,1337,CHEMBL875945,50588,,,Blood,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,A,1,N,1,,BAO_0000218
6830,,178.0,9615.0,Intermediate,Canis lupus familiaris,1337,CHEMBL623672,50588,,,Blood,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,A,1,N,1,,BAO_0000218
6831,,,9615.0,Intermediate,Canis lupus familiaris,6265,CHEMBL623673,50588,,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
6832,,,9615.0,Intermediate,Canis lupus familiaris,4809,CHEMBL623674,50588,,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,A,1,N,1,,BAO_0000218
6833,,,9615.0,Intermediate,Canis lupus familiaris,5983,CHEMBL623675,50588,,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,A,1,N,1,,BAO_0000218
6834,,,9615.0,Intermediate,Canis lupus familiaris,5313,CHEMBL872526,50588,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,A,1,N,1,,BAO_0000218
6835,,,9615.0,Intermediate,Canis lupus familiaris,5313,CHEMBL623676,50588,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,A,1,N,1,,BAO_0000218
6836,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17650,CHEMBL623677,50588,,,Plasma,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,A,1,N,1,,BAO_0000218
6837,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5199,CHEMBL623678,50588,,,Plasma,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,A,1,N,1,,BAO_0000218
6838,,1969.0,9615.0,Intermediate,Canis lupus familiaris,933,CHEMBL623679,50588,,,Plasma,Time taken for maximum plasma concentration in dog,,A,1,N,1,,BAO_0000218
6839,,,9615.0,Intermediate,Canis lupus familiaris,16367,CHEMBL623680,50588,,,,Time to reach Cmax after oral administration to dogs,,A,1,N,1,,BAO_0000218
6840,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6348,CHEMBL623681,50588,,,Plasma,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
6841,,,9615.0,Intermediate,Canis lupus familiaris,6316,CHEMBL623682,50588,,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
6842,,,9615.0,Intermediate,Canis lupus familiaris,6215,CHEMBL623683,50588,,,,Tmax after peroral administration (1 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
6843,,,9615.0,Expert,Canis lupus familiaris,3598,CHEMBL623684,50588,,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
6844,,,9615.0,Intermediate,Canis lupus familiaris,4527,CHEMBL622745,50588,,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,A,1,N,1,,BAO_0000218
6845,,,9615.0,Intermediate,Canis lupus familiaris,17764,CHEMBL622746,50588,,,,Tmax after peroral administration in dogs at 2.4 uM/kg,,A,1,N,1,,BAO_0000218
6846,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL622747,50594,,,,In vivo Cmax in mice at dose of 100 mg/kg,,A,1,N,1,,BAO_0000218
6847,,,10090.0,Intermediate,Mus musculus,5969,CHEMBL622748,50594,,,,In vivo Cmax in mice at dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6848,,,10090.0,Intermediate,Mus musculus,4573,CHEMBL622749,50594,,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,A,1,N,1,,BAO_0000218
6849,,1969.0,10090.0,Intermediate,Mus musculus,3277,CHEMBL622750,50594,,,Plasma,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,A,1,N,1,,BAO_0000218
6850,,1969.0,10090.0,Intermediate,Mus musculus,17734,CHEMBL623411,50594,,,Plasma,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,A,1,N,1,,BAO_0000218
6851,,1969.0,10090.0,Intermediate,Mus musculus,3132,CHEMBL875946,50594,,,Plasma,Maximum concentration obtained in mouse plasma was determined,,A,1,N,1,,BAO_0000218
6852,,1969.0,10090.0,Intermediate,Mus musculus,3132,CHEMBL623412,50594,,,Plasma,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,A,1,N,1,,BAO_0000218
6853,,1969.0,10090.0,Intermediate,Mus musculus,6348,CHEMBL623413,50594,,,Plasma,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
6854,,1969.0,10090.0,Intermediate,Mus musculus,17729,CHEMBL623414,50594,,,Plasma,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6855,,1969.0,10090.0,Intermediate,Mus musculus,17729,CHEMBL623415,50594,,,Plasma,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
6856,,1969.0,10090.0,Intermediate,Mus musculus,17729,CHEMBL623416,50594,,,Plasma,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
6857,,1969.0,10090.0,Intermediate,Mus musculus,17728,CHEMBL623417,50594,,,Plasma,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,A,1,N,1,,BAO_0000218
6858,,1969.0,10090.0,Intermediate,Mus musculus,17728,CHEMBL623418,50594,,,Plasma,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,A,1,N,1,,BAO_0000218
6859,,1969.0,10090.0,Intermediate,Mus musculus,17728,CHEMBL623419,50594,,,Plasma,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,A,1,N,1,,BAO_0000218
6860,,,10090.0,Intermediate,Mus musculus,4066,CHEMBL622816,50594,,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,A,1,N,1,,BAO_0000218
6861,,,10090.0,Intermediate,Mus musculus,6178,CHEMBL623313,50594,,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,A,1,N,1,,BAO_0000218
6862,,,10090.0,Intermediate,Mus musculus,6178,CHEMBL623314,50594,,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,A,1,N,1,,BAO_0000218
6863,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL876788,50594,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,A,1,N,1,,BAO_0000218
6864,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL623315,50594,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,A,1,N,1,,BAO_0000218
6865,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL623316,50594,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,A,1,N,1,,BAO_0000218
6866,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL623317,50594,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,A,1,N,1,,BAO_0000218
6868,,,10090.0,Intermediate,Mus musculus,5961,CHEMBL623319,50594,,,,Cmax in male mice after 2 mg/kg oral dose,,A,1,N,1,,BAO_0000218
6869,,,10090.0,Intermediate,Mus musculus,6137,CHEMBL623320,50594,,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,A,1,N,1,,BAO_0000218
6870,,,10090.0,Intermediate,Mus musculus,3802,CHEMBL623321,50594,,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,A,1,N,1,,BAO_0000218
6871,,,10090.0,Intermediate,Mus musculus,3535,CHEMBL623322,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,A,1,N,1,,BAO_0000218
6872,,,10090.0,Intermediate,Mus musculus,3535,CHEMBL623323,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,A,1,N,1,,BAO_0000218
6873,,,10090.0,Intermediate,Mus musculus,3535,CHEMBL623324,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,A,1,N,1,,BAO_0000218
6874,,,10090.0,Intermediate,Mus musculus,3535,CHEMBL623325,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,A,1,N,1,,BAO_0000218
6875,,,10090.0,Intermediate,Mus musculus,3535,CHEMBL623326,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,A,1,N,1,,BAO_0000218
6876,,,10090.0,Intermediate,Mus musculus,3535,CHEMBL623327,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,A,1,N,1,,BAO_0000218
6877,,1969.0,10090.0,Intermediate,Mus musculus,2862,CHEMBL623328,50594,,,Plasma,Maximum concentration in plasma upon oral administration in mouse,,A,1,N,1,,BAO_0000218
6878,,1969.0,10090.0,Intermediate,Mus musculus,2675,CHEMBL623329,50594,,,Plasma,Maximum plasma concentration was evaluated in mice after oral administration,,A,1,N,1,,BAO_0000218
6879,,1969.0,10090.0,Intermediate,Mus musculus,2675,CHEMBL623330,50594,,,Plasma,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,A,1,N,1,,BAO_0000218
6880,,,10090.0,Intermediate,Mus musculus,5399,CHEMBL876789,50594,,,,Dose at which the compound induced fecal excretion in mice,,A,1,N,1,,BAO_0000218
6893,,,10116.0,Expert,Rattus norvegicus,11819,CHEMBL623333,80013,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,F,1,N,1,,BAO_0000219
6894,,,10116.0,Expert,Rattus norvegicus,11819,CHEMBL623334,80013,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,F,1,N,1,,BAO_0000219
6895,,,10116.0,Expert,Rattus norvegicus,11819,CHEMBL627536,80013,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,F,1,N,1,,BAO_0000219
6896,,,10116.0,Expert,Rattus norvegicus,11819,CHEMBL627537,80013,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,F,1,N,1,,BAO_0000219
6897,,,10116.0,Intermediate,Rattus norvegicus,16361,CHEMBL627538,80013,,164.0,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,F,1,N,1,,BAO_0000219
6898,,,9606.0,Intermediate,Homo sapiens,2288,CHEMBL884106,80655,,393.0,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,F,1,N,1,,BAO_0000219
6899,,,9606.0,Intermediate,Homo sapiens,10404,CHEMBL625294,80655,,393.0,,Anticancer activity against human ovarian carcinoma A121 cells,,F,1,N,1,,BAO_0000219
6900,,,9606.0,Intermediate,Homo sapiens,14790,CHEMBL625295,80655,,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,F,1,N,1,,BAO_0000219
6901,,,9606.0,Intermediate,Homo sapiens,14790,CHEMBL625296,80655,,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,F,1,N,1,,BAO_0000219
6902,,,9606.0,Expert,Homo sapiens,14253,CHEMBL625297,80655,,393.0,,Growth inhibition of human ovarian carcinoma (A121) cell line,,F,1,N,1,,BAO_0000219
6903,,,9606.0,Expert,Homo sapiens,13617,CHEMBL625298,80655,,393.0,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,F,1,N,1,,BAO_0000219
6904,,,9606.0,Intermediate,Homo sapiens,1003,CHEMBL625960,80655,,393.0,,Cytotoxicity against human A121 ovarian cells,,F,1,N,1,,BAO_0000219
6905,,,9606.0,Intermediate,Homo sapiens,830,CHEMBL625961,80655,,393.0,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,F,1,N,1,,BAO_0000219
6906,,,9606.0,Intermediate,Homo sapiens,12307,CHEMBL625962,80655,,393.0,,In vitro cytotoxicity against human ovarian carcinoma A21,,F,1,N,1,,BAO_0000219
6907,,,9606.0,Intermediate,Homo sapiens,14254,CHEMBL624717,80655,,393.0,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,F,1,N,1,,BAO_0000219
6908,,,9606.0,Intermediate,Homo sapiens,13370,CHEMBL624718,80655,,393.0,,Inhibitory activity of compound against human A121 ovarian cell line.,,F,1,N,1,,BAO_0000219
6909,,,9606.0,Intermediate,Homo sapiens,14790,CHEMBL624719,80655,,393.0,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,F,1,N,1,,BAO_0000219
6910,,,9606.0,Intermediate,Homo sapiens,3614,CHEMBL624720,80655,,393.0,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,F,1,N,1,,BAO_0000219
6911,,,9606.0,Intermediate,Homo sapiens,2664,CHEMBL624721,80012,,622.0,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,F,1,N,1,,BAO_0000219
6912,,,9606.0,Expert,Homo sapiens,2037,CHEMBL624722,80012,,622.0,,In vitro cytotoxicity against A172 human tumor cell lines.,,F,1,N,1,,BAO_0000219
6913,,,9606.0,Intermediate,Homo sapiens,14539,CHEMBL877597,80012,,622.0,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,F,1,N,1,,BAO_0000219
6914,,,9606.0,Intermediate,Homo sapiens,2836,CHEMBL624723,80012,,622.0,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,F,1,N,1,,BAO_0000219
6915,,,9606.0,Intermediate,Homo sapiens,10708,CHEMBL624724,80012,,622.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,F,1,N,1,,BAO_0000219
6916,,,9615.0,Autocuration,Canis lupus familiaris,8975,CHEMBL624725,104729,,,,Association constant against A2 adenosine receptor,,B,1,H,4,,BAO_0000224
6917,,,,Intermediate,fish,7645,CHEMBL624726,80656,,1085.0,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,F,1,N,1,,BAO_0000219
6918,,,10116.0,Autocuration,Rattus norvegicus,11377,CHEMBL857535,104713,,,,Ratio of Ki for adenosine A2 and A1 receptor binding,,B,1,D,5,,BAO_0000224
6919,,,9606.0,Expert,Homo sapiens,13528,CHEMBL624727,80014,,623.0,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,F,1,N,1,,BAO_0000219
6920,,,9606.0,Expert,Homo sapiens,10160,CHEMBL624728,80014,,623.0,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,F,1,N,1,,BAO_0000219
6921,,,9606.0,Intermediate,Homo sapiens,15144,CHEMBL624729,80015,,404.0,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,F,1,N,1,,BAO_0000219
6922,,,9606.0,Intermediate,Homo sapiens,13160,CHEMBL624730,80657,,973.0,,Growth inhibition against Human squamous cell line(A 253),,F,1,N,1,,BAO_0000219
6923,,,9606.0,Intermediate,Homo sapiens,12898,CHEMBL624731,80657,,973.0,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,F,1,N,1,,BAO_0000219
6924,,,9606.0,Intermediate,Homo sapiens,13069,CHEMBL624732,80657,,973.0,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,F,1,N,1,,BAO_0000219
6925,,,9606.0,Intermediate,Homo sapiens,15984,CHEMBL883245,80657,,973.0,,Growth inhibition of A253 cell lines.,,F,1,N,1,,BAO_0000219
6926,,,9606.0,Intermediate,Homo sapiens,15564,CHEMBL624733,80657,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,F,1,N,1,,BAO_0000219
6927,,,9606.0,Intermediate,Homo sapiens,15564,CHEMBL624734,80657,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,F,1,N,1,,BAO_0000219
6928,,,9606.0,Intermediate,Homo sapiens,15564,CHEMBL624735,80657,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,F,1,N,1,,BAO_0000219
6929,,,9606.0,Intermediate,Homo sapiens,4720,CHEMBL621780,81034,,478.0,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,F,1,N,1,,BAO_0000219
6930,,,9606.0,Intermediate,Homo sapiens,16112,CHEMBL877598,81034,,478.0,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,F,1,N,1,,BAO_0000219
6931,,,9606.0,Expert,Homo sapiens,16597,CHEMBL621781,81034,,478.0,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,F,1,N,1,,BAO_0000219
6932,,,9606.0,Intermediate,Homo sapiens,16378,CHEMBL621782,81034,,478.0,,Cytotoxicity against human cancer cell lines A2780 (ovarian),,F,1,N,1,,BAO_0000219
6933,,,9606.0,Expert,Homo sapiens,16085,CHEMBL621783,81034,,478.0,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,F,1,N,1,,BAO_0000219
6934,,,9606.0,Intermediate,Homo sapiens,16317,CHEMBL621784,81034,,478.0,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,F,1,N,1,,BAO_0000219
6935,,,9606.0,Intermediate,Homo sapiens,15748,CHEMBL621785,81034,,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,F,1,N,1,,BAO_0000219
6936,,,9606.0,Expert,Homo sapiens,16597,CHEMBL621968,81034,,478.0,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,F,1,N,1,,BAO_0000219
6937,,,9606.0,Expert,Homo sapiens,16597,CHEMBL621969,81034,,478.0,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,F,1,N,1,,BAO_0000219
6938,,,9606.0,Expert,Homo sapiens,16597,CHEMBL621970,81034,,478.0,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,F,1,N,1,,BAO_0000219
6939,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL621971,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,F,1,N,1,,BAO_0000219
6940,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL621972,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,F,1,N,1,,BAO_0000219
6941,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL884108,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,F,1,N,1,,BAO_0000219
6942,,,10029.0,Autocuration,Cricetulus griseus,15296,CHEMBL623826,22224,,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,F,1,U,0,,BAO_0000019
6943,,,10029.0,Autocuration,Cricetulus griseus,10251,CHEMBL623827,22224,,185.0,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,A,1,U,0,,BAO_0000219
6944,,,10029.0,Autocuration,Cricetulus griseus,10251,CHEMBL623828,22224,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,F,1,U,0,,BAO_0000219
6945,,,10029.0,Autocuration,Cricetulus griseus,10251,CHEMBL623829,22224,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,F,1,U,0,,BAO_0000219
6946,,,10029.0,Autocuration,Cricetulus griseus,10251,CHEMBL623830,22224,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,F,1,U,0,,BAO_0000219
6947,,,10029.0,Autocuration,Cricetulus griseus,11858,CHEMBL623831,22224,,,,Growth inhibition against CHO-derived cell line AA8,,F,1,U,0,,BAO_0000019
6948,,,10029.0,Autocuration,Cricetulus griseus,11858,CHEMBL623832,22224,,185.0,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,F,1,U,0,,BAO_0000219
6949,,,36483.0,Expert,hampster,11616,CHEMBL623833,80089,,185.0,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,F,1,N,1,,BAO_0000219
6950,,,10029.0,Expert,Cricetulus griseus,11616,CHEMBL623834,80089,,185.0,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,F,1,N,1,,BAO_0000219
6951,,,10029.0,Autocuration,Cricetulus griseus,10518,CHEMBL623835,22224,,185.0,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,F,1,U,0,,BAO_0000219
6952,,,10029.0,Autocuration,Cricetulus griseus,11396,CHEMBL623836,22224,,185.0,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,F,1,U,0,,BAO_0000219
6953,,,10029.0,Autocuration,Cricetulus griseus,10518,CHEMBL623837,22224,,185.0,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,F,1,U,0,,BAO_0000219
6954,,,10029.0,Expert,Cricetulus griseus,11616,CHEMBL623838,80089,,185.0,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,F,1,N,1,,BAO_0000219
6955,,,,Autocuration,,14837,CHEMBL623839,12675,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,F,1,H,8,,BAO_0000019
6956,,,,Autocuration,,14837,CHEMBL623840,12675,,,,Number of binding sites (n) of isolated serum protein AAG,,F,1,H,8,,BAO_0000019
6957,,,,Intermediate,,16037,CHEMBL623841,22222,,,,Association constant for binding to AATT duplex,,B,1,M,3,,BAO_0000225
6958,,,9606.0,Expert,Homo sapiens,16597,CHEMBL623842,100090,,416.0,,Inhibition of ABAE human fibroblast cell proliferation,,F,1,N,1,,BAO_0000219
6959,,,10090.0,Intermediate,Mus musculus,8831,CHEMBL623843,80668,,1064.0,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,F,1,N,1,,BAO_0000218
6960,,,9986.0,Expert,Oryctolagus cuniculus,13419,CHEMBL618669,102444,,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,F,1,D,9,,BAO_0000218
6961,,,9986.0,Expert,Oryctolagus cuniculus,13419,CHEMBL618670,102444,,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,F,1,D,9,,BAO_0000218
6962,,,,Autocuration,,15778,CHEMBL618671,69,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,B,1,H,8,,BAO_0000357
6963,,,,Autocuration,,15778,CHEMBL618672,69,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,B,1,H,8,,BAO_0000357
6964,,,9606.0,Intermediate,Homo sapiens,12988,CHEMBL618673,80669,,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,F,1,N,1,,BAO_0000219
6965,,,9606.0,Intermediate,Homo sapiens,12988,CHEMBL618674,80669,,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,F,1,N,1,,BAO_0000219
6966,,,11676.0,Autocuration,Human immunodeficiency virus 1,12988,CHEMBL618675,22224,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,F,1,U,0,,BAO_0000219
6967,,,11676.0,Autocuration,Human immunodeficiency virus 1,12988,CHEMBL618676,22224,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,F,1,U,0,,BAO_0000219
6968,,,11676.0,Autocuration,Human immunodeficiency virus 1,12988,CHEMBL618677,22224,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,F,1,U,0,,BAO_0000219
6969,,,9606.0,Intermediate,Homo sapiens,11843,CHEMBL618678,80025,,626.0,,Inhibition of growth of renal cancer ACHN cell line,,F,1,N,1,,BAO_0000219
6970,,,9606.0,Intermediate,Homo sapiens,16939,CHEMBL618679,80025,,626.0,,Inhibition of growth of ACHN renal cancer cell line,,F,1,N,1,,BAO_0000219
6971,,,9606.0,Intermediate,Homo sapiens,4782,CHEMBL618680,80025,,626.0,,Inhibitory concentration required against ACHN renal cancer cell line,,F,1,N,1,,BAO_0000219
6972,,,9606.0,Expert,Homo sapiens,6310,CHEMBL618681,80025,,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line,,F,1,N,1,,BAO_0000219
6973,,,9606.0,Intermediate,Homo sapiens,6310,CHEMBL618682,80025,,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,F,1,N,1,,BAO_0000219
6974,,,9606.0,Intermediate,Homo sapiens,12858,CHEMBL618683,80025,,626.0,,Cytotoxic activity against ACHN Renal cancer cell line,,F,1,N,1,,BAO_0000219
6975,,,9606.0,Intermediate,Homo sapiens,17380,CHEMBL618684,80025,,626.0,,Cytotoxicity evaluation against ACHN renal cancer cells,,F,1,N,1,,BAO_0000219
6976,,,9606.0,Intermediate,Homo sapiens,5858,CHEMBL618685,80025,,626.0,,In vitro antitumor activity against human renal ACHN cell line,,F,1,N,1,,BAO_0000219
6977,,,9606.0,Intermediate,Homo sapiens,3838,CHEMBL876499,80025,,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,F,1,N,1,,BAO_0000219
6978,,,9606.0,Intermediate,Homo sapiens,3838,CHEMBL618686,80025,,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,F,1,N,1,,BAO_0000219
6979,,,9606.0,Intermediate,Homo sapiens,5406,CHEMBL618687,80025,,626.0,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,F,1,N,1,,BAO_0000219
6980,,,9606.0,Intermediate,Homo sapiens,4071,CHEMBL618688,80025,,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,F,1,N,1,,BAO_0000219
6981,,,9606.0,Expert,Homo sapiens,4071,CHEMBL618689,80025,,626.0,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,F,1,N,1,,BAO_0000219
6982,,,9606.0,Intermediate,Homo sapiens,4071,CHEMBL618690,80025,,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,F,1,N,1,,BAO_0000219
6983,,,9606.0,Intermediate,Homo sapiens,15002,CHEMBL618691,80025,,626.0,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,F,1,N,1,,BAO_0000219
6984,,,9606.0,Intermediate,Homo sapiens,14769,CHEMBL619373,80025,,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,F,1,N,1,,BAO_0000219
6985,,,9606.0,Intermediate,Homo sapiens,13958,CHEMBL884008,80025,,626.0,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,F,1,N,1,,BAO_0000219
6986,,,9606.0,Intermediate,Homo sapiens,1665,CHEMBL619374,80025,,626.0,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,F,1,N,1,,BAO_0000219
6987,,,9606.0,Intermediate,Homo sapiens,15354,CHEMBL619375,80025,,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,F,1,N,1,,BAO_0000219
6988,,,9606.0,Intermediate,Homo sapiens,15354,CHEMBL619376,80025,,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,F,1,N,1,,BAO_0000219
6989,,,9606.0,Intermediate,Homo sapiens,13978,CHEMBL619377,80025,,626.0,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,F,1,N,1,,BAO_0000219
6990,,,9606.0,Intermediate,Homo sapiens,6798,CHEMBL619378,80025,,626.0,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,F,1,N,1,,BAO_0000219
6991,,,9615.0,Intermediate,Canis lupus familiaris,2959,CHEMBL872527,50588,,,,Tmax value after administration of 4 mg/Kg oral dose in dog,,A,1,N,1,,BAO_0000218
6992,,,9615.0,Intermediate,Canis lupus familiaris,9932,CHEMBL876500,50588,,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,A,1,N,1,,BAO_0000218
6993,,,9615.0,Intermediate,Canis lupus familiaris,5546,CHEMBL619379,50588,,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,A,1,N,1,,BAO_0000218
6994,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL619538,50588,,,,Volume distribution after 15 mg/kg iv dose in Dogs,,A,1,N,1,,BAO_0000218
6995,,,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL619539,50588,,,,Volume distribution after 30 mg/kg po dose in Dogs,,A,1,N,1,,BAO_0000218
6996,,,9615.0,Intermediate,Canis lupus familiaris,4257,CHEMBL619540,50588,,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,A,1,N,1,,BAO_0000218
6997,,,9615.0,Intermediate,Canis lupus familiaris,4305,CHEMBL619541,50588,,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
6998,,,9615.0,Intermediate,Canis lupus familiaris,5472,CHEMBL619542,50588,,,,Volume of distribution was evaluated in dog,,A,1,N,1,,BAO_0000218
6999,,,9615.0,Intermediate,Canis lupus familiaris,6062,CHEMBL619543,50588,,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7000,,,9615.0,Expert,Canis lupus familiaris,3598,CHEMBL619544,50588,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
7001,,,9615.0,Intermediate,Canis lupus familiaris,12500,CHEMBL619545,50588,,,,The compound was tested for volume of distribution in dog,,A,1,N,1,,BAO_0000218
7002,,,9615.0,Intermediate,Canis lupus familiaris,12500,CHEMBL619546,50588,,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,A,1,N,1,,BAO_0000218
7003,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL619547,50588,,,,Vd (1 mg/kg) was determined in dog (in vivo),,A,1,N,1,,BAO_0000218
7004,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL619548,50588,,,,Vd in dog,,A,1,N,1,,BAO_0000218
7005,,,9615.0,Intermediate,Canis lupus familiaris,4219,CHEMBL619549,50588,,,,Volume distribution was determined,,A,1,N,1,,BAO_0000218
7006,,,9615.0,Intermediate,Canis lupus familiaris,1696,CHEMBL619550,50588,,,,Volume of distribution in dog,,A,1,N,1,,BAO_0000218
7007,,,9615.0,Intermediate,Canis lupus familiaris,5542,CHEMBL876501,50588,,,,Volume of distribution by as 4 fold increase by iv administration in dogs,,A,1,N,1,,BAO_0000218
7008,,,9615.0,Intermediate,Canis lupus familiaris,5199,CHEMBL619551,50588,,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,A,1,N,1,,BAO_0000218
7009,,,9615.0,Intermediate,Canis lupus familiaris,6348,CHEMBL619552,50588,,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
7010,,,9615.0,Intermediate,Canis lupus familiaris,4727,CHEMBL619553,50588,,,,Volume distribution at the dose of 2 mg/kg in dog,,A,1,N,1,,BAO_0000218
7011,,,9615.0,Intermediate,Canis lupus familiaris,16367,CHEMBL618722,50588,,,,Steady state volume of distribution was determined,,A,1,N,1,,BAO_0000218
7012,,,9615.0,Intermediate,Canis lupus familiaris,2652,CHEMBL618723,50588,,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,A,1,N,1,,BAO_0000218
7013,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL618724,50588,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,A,1,N,1,,BAO_0000218
7014,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL618725,50588,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,A,1,N,1,,BAO_0000218
7015,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL618726,50588,,,,Bioavailability in dog (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
7016,,,9615.0,Intermediate,Canis lupus familiaris,5334,CHEMBL618727,50588,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,A,1,N,1,,BAO_0000218
7017,,,9615.0,Intermediate,Canis lupus familiaris,4239,CHEMBL624233,50588,,,,Pharmacokinetic property (vdss) was measured in dog,,A,1,N,1,,BAO_0000218
7018,,,9615.0,Intermediate,Canis lupus familiaris,4709,CHEMBL624234,50588,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
7019,,,9615.0,Intermediate,Canis lupus familiaris,5600,CHEMBL624235,50588,,,,Vdss was determined after iv 0.1 mg/kg administration in dog,,A,1,N,1,,BAO_0000218
7020,,,9615.0,Intermediate,Canis lupus familiaris,6057,CHEMBL624236,50588,,,,Volume displacement was calculated in dog,,A,1,N,1,,BAO_0000218
7021,,,9615.0,Intermediate,Canis lupus familiaris,5654,CHEMBL624237,50588,,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7022,,,9615.0,Intermediate,Canis lupus familiaris,5505,CHEMBL624238,50588,,,,Volume distribution constant was determined,,A,1,N,1,,BAO_0000218
7023,,,9615.0,Intermediate,Canis lupus familiaris,4527,CHEMBL624239,50588,,,,Volume distribution at a dose of 1 uM/kg in dog was determined,,A,1,N,1,,BAO_0000218
7024,,,9615.0,Intermediate,Canis lupus familiaris,4521,CHEMBL875829,50588,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,A,1,N,1,,BAO_0000218
7025,,,9615.0,Intermediate,Canis lupus familiaris,4521,CHEMBL624240,50588,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,A,1,N,1,,BAO_0000218
7026,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL624241,50588,,,,Volume distribution (Vdss) was measured in dog,,A,1,N,1,,BAO_0000218
7027,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL624242,50588,,,,Volume distribution (Vdss) was measured in dog,,A,1,N,1,,BAO_0000218
7028,,,9615.0,Intermediate,Canis lupus familiaris,6679,CHEMBL624243,50588,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,A,1,N,1,,BAO_0000218
7029,,,9615.0,Intermediate,Canis lupus familiaris,5145,CHEMBL624244,50588,,,,Volume of distribution in steady state was determined in dog,,A,1,N,1,,BAO_0000218
7030,,,9615.0,Intermediate,Canis lupus familiaris,6821,CHEMBL624245,50588,,,,Volume of distribution of compound was determined in dog,,A,1,N,1,,BAO_0000218
7031,,,9615.0,Intermediate,Canis lupus familiaris,4137,CHEMBL624246,50588,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,A,1,N,1,,BAO_0000218
7032,,,9615.0,Intermediate,Canis lupus familiaris,5334,CHEMBL624247,50588,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,A,1,N,1,,BAO_0000218
7033,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL624248,50588,,,,Volume of distribution (Vdss) was measured in dog,,A,1,N,1,,BAO_0000218
7034,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL624249,50588,,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,A,1,N,1,,BAO_0000218
7035,,,9615.0,Intermediate,Canis lupus familiaris,6641,CHEMBL624250,50588,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,N,1,,BAO_0000218
7036,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL624251,50588,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,N,1,,BAO_0000218
7037,,,9615.0,Intermediate,Canis lupus familiaris,11659,CHEMBL624252,50588,,,,Maximum rate of depolarization of the upstroke of the action potential,,A,1,N,1,,BAO_0000218
7038,,,9615.0,Intermediate,Canis lupus familiaris,6448,CHEMBL624253,50588,,,,Steady state volume distribution in dog,,A,1,N,1,,BAO_0000218
7039,,,9615.0,Intermediate,Canis lupus familiaris,5474,CHEMBL624950,50588,,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,A,1,N,1,,BAO_0000218
7040,,,9615.0,Intermediate,Canis lupus familiaris,1466,CHEMBL624951,50588,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,A,1,N,1,,BAO_0000218
7041,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL875830,50588,,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,A,1,N,1,,BAO_0000218
7042,,,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL624952,50588,,,,Volume distribution in dog after administration of 1 mg/kg iv,,A,1,N,1,,BAO_0000218
7043,,,9615.0,Intermediate,Canis lupus familiaris,17764,CHEMBL624953,50588,,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,A,1,N,1,,BAO_0000218
7044,,,9615.0,Intermediate,Canis lupus familiaris,6215,CHEMBL624954,50588,,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
7045,,,9615.0,Intermediate,Canis lupus familiaris,6505,CHEMBL624955,50588,,,,Vss on i.v. administration of 2 mg/kg was measured in dog,,A,1,N,1,,BAO_0000218
7046,,,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL624956,50588,,,,Vss was determined,,A,1,N,1,,BAO_0000218
7047,,,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL625129,50588,,,,Vss in dog,,A,1,N,1,,BAO_0000218
7048,,,9615.0,Intermediate,Canis lupus familiaris,6062,CHEMBL625130,50588,,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7049,,,9615.0,Intermediate,Canis lupus familiaris,4942,CHEMBL625131,50588,,,,Volume distribution in dogs,,A,1,N,1,,BAO_0000218
7050,,,9615.0,Intermediate,Canis lupus familiaris,17796,CHEMBL625132,50588,,,,Volume of distribution in dog,,A,1,N,1,,BAO_0000218
7051,,,9615.0,Intermediate,Canis lupus familiaris,4883,CHEMBL872263,50588,,,,Tested for the oral bioavailability in dog,,A,1,N,1,,BAO_0000218
7060,,,10090.0,Intermediate,Mus musculus,17837,CHEMBL624336,50594,,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,A,1,N,1,,BAO_0000218
7061,,,10090.0,Intermediate,Mus musculus,17729,CHEMBL624337,50594,,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,A,1,N,1,,BAO_0000218
7062,,,10090.0,Intermediate,Mus musculus,17729,CHEMBL624338,50594,,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,A,1,N,1,,BAO_0000218
7063,,,10090.0,Intermediate,Mus musculus,4239,CHEMBL624339,50594,,,,Bioavailability was measured in mouse,,A,1,N,1,,BAO_0000218
7064,,,10090.0,Intermediate,Mus musculus,17592,CHEMBL624340,50594,,,,Bioavailability in mouse,,A,1,N,1,,BAO_0000218
7065,,,10090.0,Intermediate,Mus musculus,6348,CHEMBL624341,50594,,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
7066,,,10090.0,Intermediate,Mus musculus,2801,CHEMBL624342,50594,,,,Bioavailability in mouse,,A,1,N,1,,BAO_0000218
7067,,,10090.0,Intermediate,Mus musculus,2801,CHEMBL624343,50594,,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7068,,,10090.0,Intermediate,Mus musculus,17718,CHEMBL624344,50594,,,,Oral bioavailability in mouse,,A,1,N,1,,BAO_0000218
7069,,,10090.0,Intermediate,Mus musculus,5727,CHEMBL624345,50594,,,,Oral availability at 50 mg/kg po in male mice,,A,1,N,1,,BAO_0000218
7070,,,10090.0,Intermediate,Mus musculus,5302,CHEMBL624346,50594,,,,Oral bioavailability in mouse (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
7071,,,10090.0,Expert,Mus musculus,3598,CHEMBL624347,50594,,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
7072,,,10090.0,Intermediate,Mus musculus,5961,CHEMBL624348,50594,,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,A,1,N,1,,BAO_0000218
7074,,,10090.0,Intermediate,Mus musculus,6091,CHEMBL622754,50594,,,,Oral bioavailability in mouse,,A,1,N,1,,BAO_0000218
7075,,,10090.0,Intermediate,Mus musculus,6091,CHEMBL622755,50594,,,,Oral bioavailability in vivo in mice;ND=Not determined,,A,1,N,1,,BAO_0000218
7076,,,10090.0,Intermediate,Mus musculus,5711,CHEMBL622756,50594,,,,Oral bioavailability in mouse at 10 mg/kg of the compound,,A,1,N,1,,BAO_0000218
7077,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL622757,50594,,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,A,1,N,1,,BAO_0000218
7078,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL622758,50594,,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,A,1,N,1,,BAO_0000218
7079,,,10090.0,Intermediate,Mus musculus,3802,CHEMBL622759,50594,,,,Tested for bioavailability of the compound,,A,1,N,1,,BAO_0000218
7080,,,10090.0,Intermediate,Mus musculus,3802,CHEMBL622760,50594,,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,A,1,N,1,,BAO_0000218
7081,,1969.0,10090.0,Intermediate,Mus musculus,14029,CHEMBL622761,50594,,,Plasma,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,A,1,N,1,,BAO_0000218
7082,,1969.0,10090.0,Intermediate,Mus musculus,14029,CHEMBL622762,50594,,,Plasma,The plasma half life of compound was determined on heparin prepared by human plasma. ,,A,1,N,1,,BAO_0000218
7083,,1969.0,10090.0,Intermediate,Mus musculus,14029,CHEMBL622763,50594,,,Plasma,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,A,1,N,1,,BAO_0000218
7084,,1969.0,10090.0,Intermediate,Mus musculus,14029,CHEMBL622764,50594,,,Plasma,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,A,1,N,1,,BAO_0000218
7085,,1969.0,10090.0,Intermediate,Mus musculus,14029,CHEMBL622765,50594,,,Plasma,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,A,1,N,1,,BAO_0000218
7086,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL622766,50594,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,F,1,N,1,,BAO_0000218
7087,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL622767,50594,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,A,1,N,1,,BAO_0000218
7088,,,10090.0,Intermediate,Mus musculus,17753,CHEMBL622768,50594,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,A,1,N,1,,BAO_0000218
7089,,178.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL875948,50594,,,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7090,,178.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL622769,50594,,,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,A,1,N,1,,BAO_0000218
7091,,178.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL622770,50594,,,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7092,,178.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL622771,50594,,,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7093,,178.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL622772,50594,,,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7094,,178.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL622773,50594,,,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7095,,178.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL622774,50594,,,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7096,,10000001.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621725,50594,,,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7097,,10000001.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621726,50594,,,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,A,1,N,1,,BAO_0000218
7098,,,9606.0,Intermediate,Homo sapiens,15608,CHEMBL621727,81034,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,F,1,N,1,,BAO_0000219
7099,,,9606.0,Expert,Homo sapiens,3290,CHEMBL622413,81034,,478.0,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,F,1,N,1,,BAO_0000219
7100,,,9606.0,Intermediate,Homo sapiens,2859,CHEMBL622414,81034,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,,F,1,N,1,,BAO_0000219
7101,,,9606.0,Expert,Homo sapiens,15688,CHEMBL622415,81034,,478.0,,Inhibition of A2780 cell clonogenic assay,,F,1,N,1,,BAO_0000219
7102,,,9606.0,Expert,Homo sapiens,5642,CHEMBL884001,81034,,478.0,,Cytotoxic effect on ovarian cancer cell line (A2780),,F,1,N,1,,BAO_0000219
7103,,,9606.0,Intermediate,Homo sapiens,6633,CHEMBL622416,81034,,478.0,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,F,1,N,1,,BAO_0000219
7104,,,9606.0,Intermediate,Homo sapiens,3906,CHEMBL622417,81034,,478.0,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,F,1,N,1,,BAO_0000219
7105,,,9606.0,Expert,Homo sapiens,6788,CHEMBL622590,81034,,478.0,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,F,1,N,1,,BAO_0000219
7106,,,9606.0,Expert,Homo sapiens,17582,CHEMBL622591,81034,,478.0,,Antiproliferative activity against human A2780 cells,,F,1,N,1,,BAO_0000219
7107,,,9606.0,Expert,Homo sapiens,17764,CHEMBL622592,81034,,478.0,,Inhibition of human A2780 cell proliferation,,F,1,N,1,,BAO_0000219
7108,,,9606.0,Expert,Homo sapiens,17764,CHEMBL622593,81034,,478.0,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,F,1,N,1,,BAO_0000219
7109,,,9606.0,Expert,Homo sapiens,17764,CHEMBL622594,81034,,478.0,,Inhibition of human A2780 cell proliferation (No data),,F,1,N,1,,BAO_0000219
7110,,,9606.0,Intermediate,Homo sapiens,2815,CHEMBL622595,81034,,478.0,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,F,1,N,1,,BAO_0000219
7111,,,9606.0,Intermediate,Homo sapiens,16930,CHEMBL622596,81034,,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780,,F,1,N,1,,BAO_0000219
7112,,,9606.0,Expert,Homo sapiens,17777,CHEMBL622597,81034,,478.0,,Growth inhibition against A2780 wild-type ovarian cell lines,,F,1,N,1,,BAO_0000219
7113,,,9606.0,Intermediate,Homo sapiens,17777,CHEMBL622598,81034,,478.0,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,F,1,N,1,,BAO_0000219
7114,,,9606.0,Autocuration,Homo sapiens,16936,CHEMBL622599,104766,,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,F,1,D,5,,BAO_0000019
7115,,,9606.0,Intermediate,Homo sapiens,13759,CHEMBL622600,81034,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,F,1,N,1,,BAO_0000219
7116,,,9606.0,Intermediate,Homo sapiens,13759,CHEMBL622601,81034,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,F,1,N,1,,BAO_0000219
7117,,,9606.0,Intermediate,Homo sapiens,13759,CHEMBL622602,81034,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,F,1,N,1,,BAO_0000219
7118,,,9606.0,Intermediate,Homo sapiens,13759,CHEMBL622603,81034,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,F,1,N,1,,BAO_0000219
7119,,,9606.0,Intermediate,Homo sapiens,15292,CHEMBL622604,81034,,478.0,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,F,1,N,1,,BAO_0000219
7120,,,9606.0,Intermediate,Homo sapiens,15292,CHEMBL622605,81034,,478.0,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,F,1,N,1,,BAO_0000219
7121,,,9606.0,Expert,Homo sapiens,15069,CHEMBL622606,81034,,478.0,,In vitro inhibition of human ovarian cell line A2780,,F,1,N,1,,BAO_0000219
7122,,,9606.0,Expert,Homo sapiens,15069,CHEMBL619463,81034,,478.0,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,F,1,N,1,,BAO_0000219
7123,,,9606.0,Intermediate,Homo sapiens,14073,CHEMBL619464,81034,,478.0,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,F,1,N,1,,BAO_0000219
7124,,,9606.0,Expert,Homo sapiens,14553,CHEMBL619465,81034,,478.0,,Concentration required to inhibit A2780-cell growth by 50%,,F,1,N,1,,BAO_0000219
7125,,,9606.0,Expert,Homo sapiens,13040,CHEMBL619466,81034,,478.0,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,F,1,N,1,,BAO_0000219
7126,,,9606.0,Expert,Homo sapiens,6891,CHEMBL619467,81034,,478.0,,Cytotoxic effect on human ovarian (A2780) cancer cell line,,F,1,N,1,,BAO_0000219
7127,,,9606.0,Intermediate,Homo sapiens,15569,CHEMBL619468,81034,,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,F,1,N,1,,BAO_0000219
7128,,,9606.0,Expert,Homo sapiens,14190,CHEMBL619469,81034,,478.0,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,F,1,N,1,,BAO_0000219
7129,,,9606.0,Expert,Homo sapiens,15014,CHEMBL619470,81034,,478.0,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,F,1,N,1,,BAO_0000219
7130,,,9606.0,Intermediate,Homo sapiens,15014,CHEMBL619471,81034,,478.0,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,F,1,N,1,,BAO_0000219
7131,,,9606.0,Intermediate,Homo sapiens,17496,CHEMBL619472,81034,,478.0,,Cytotoxicity against human ovarian carcinoma A2780 cell line,,F,1,N,1,,BAO_0000219
7132,,,9606.0,Intermediate,Homo sapiens,13617,CHEMBL619473,81034,,478.0,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,F,1,N,1,,BAO_0000219
7133,,,9606.0,Intermediate,Homo sapiens,13617,CHEMBL874368,81034,,478.0,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,F,1,N,1,,BAO_0000219
7134,,,9606.0,Intermediate,Homo sapiens,13617,CHEMBL884003,81034,,478.0,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,F,1,N,1,,BAO_0000219
7135,,,9606.0,Intermediate,Homo sapiens,13617,CHEMBL622690,81034,,478.0,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,F,1,N,1,,BAO_0000219
7136,,,9606.0,Intermediate,Homo sapiens,17672,CHEMBL622691,81034,,478.0,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,F,1,N,1,,BAO_0000219
7137,,,9606.0,Intermediate,Homo sapiens,4544,CHEMBL622692,81034,,478.0,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,F,1,N,1,,BAO_0000219
7138,,,9606.0,Intermediate,Homo sapiens,4544,CHEMBL623406,81034,,478.0,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,F,1,N,1,,BAO_0000219
7139,,,9606.0,Intermediate,Homo sapiens,16317,CHEMBL884004,81034,,478.0,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,F,1,N,1,,BAO_0000219
7140,,,9606.0,Intermediate,Homo sapiens,15099,CHEMBL623407,81034,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,F,1,N,1,,BAO_0000219
7141,,,9606.0,Intermediate,Homo sapiens,13978,CHEMBL623408,81034,,478.0,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,F,1,N,1,,BAO_0000219
7142,,,9606.0,Expert,Homo sapiens,12989,CHEMBL623409,81034,,478.0,,In vitro antitumor activity against A2780 cell line.,,F,1,N,1,,BAO_0000219
7143,,,9606.0,Intermediate,Homo sapiens,5574,CHEMBL623410,81034,,478.0,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,F,1,N,1,,BAO_0000219
7144,,,9606.0,Expert,Homo sapiens,13528,CHEMBL623576,81034,,478.0,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,F,1,N,1,,BAO_0000219
7145,,,9606.0,Intermediate,Homo sapiens,12782,CHEMBL623577,80025,,626.0,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,F,1,N,1,,BAO_0000219
7146,,,9606.0,Intermediate,Homo sapiens,14255,CHEMBL623578,80025,,626.0,,The IC50 value was measured on ACHN cell line in renal tumor type.,,F,1,N,1,,BAO_0000219
7147,,,9606.0,Intermediate,Homo sapiens,16364,CHEMBL623579,80025,,626.0,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,F,1,N,1,,BAO_0000219
7148,,,9606.0,Expert,Homo sapiens,17376,CHEMBL623580,80025,,626.0,,In vitro lethal concentration against most sensitive ACHN cell line,,F,1,N,1,,BAO_0000219
7149,,,9606.0,Intermediate,Homo sapiens,12016,CHEMBL623581,80025,,626.0,,Tested for cytotoxic activity against renal cancer ACHN cell line,,F,1,N,1,,BAO_0000219
7150,,,9606.0,Intermediate,Homo sapiens,6058,CHEMBL857456,80025,,626.0,,Compound tested for growth inhibition of renal cancer cell line ACHN,,F,1,N,1,,BAO_0000219
7151,,,9606.0,Intermediate,Homo sapiens,17708,CHEMBL623582,80025,,626.0,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,F,1,N,1,,BAO_0000219
7152,,,9606.0,Intermediate,Homo sapiens,15176,CHEMBL623583,80025,,626.0,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,F,1,N,1,,BAO_0000219
7153,,,9606.0,Intermediate,Homo sapiens,2806,CHEMBL623584,80025,,626.0,,In vitro anticancer activity against ACHN renal cancer cell line,,F,1,N,1,,BAO_0000219
7154,,,9606.0,Intermediate,Homo sapiens,15300,CHEMBL623585,80025,,626.0,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,F,1,N,1,,BAO_0000219
7155,,,9606.0,Intermediate,Homo sapiens,16364,CHEMBL623586,80025,,626.0,,Percent selectivity was evaluated in renal ACHN cell lines,,F,1,N,1,,BAO_0000219
7156,,,9606.0,Intermediate,Homo sapiens,13859,CHEMBL623587,80025,,626.0,,In vitro inhibitory activity against renal ACHN cancer cell line,,F,1,N,1,,BAO_0000219
7157,,,9606.0,Intermediate,Homo sapiens,11970,CHEMBL875279,80025,,626.0,,Tested for cytotoxicity against ACHN cell lines in renal cancer,,F,1,N,1,,BAO_0000219
7158,,,9606.0,Intermediate,Homo sapiens,2450,CHEMBL623588,80025,,626.0,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,F,1,N,1,,BAO_0000219
7159,,,9606.0,Intermediate,Homo sapiens,12696,CHEMBL623589,80025,,626.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,F,1,N,1,,BAO_0000219
7160,,,9606.0,Intermediate,Homo sapiens,12400,CHEMBL623590,80025,,626.0,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,F,1,N,1,,BAO_0000219
7161,,,9606.0,Expert,Homo sapiens,12888,CHEMBL623591,80025,,626.0,,Cytotoxic effect on renal cancer line ACHN,,F,1,N,1,,BAO_0000219
7162,,,9606.0,Intermediate,Homo sapiens,3156,CHEMBL623592,80025,,626.0,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,F,1,N,1,,BAO_0000219
7163,,,9606.0,Intermediate,Homo sapiens,3381,CHEMBL623593,80025,,626.0,,In vitro inhibition of Renal Cancer ACHN cell lines,,F,1,N,1,,BAO_0000219
7164,,,9606.0,Intermediate,Homo sapiens,16747,CHEMBL623594,80025,,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells,,F,1,N,1,,BAO_0000219
7165,,,9606.0,Expert,Homo sapiens,16748,CHEMBL621833,80025,,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells.,,F,1,N,1,,BAO_0000219
7166,,,9606.0,Intermediate,Homo sapiens,12062,CHEMBL621834,80025,,626.0,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,F,1,N,1,,BAO_0000219
7167,,,9606.0,Intermediate,Homo sapiens,14769,CHEMBL621835,80025,,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,F,1,N,1,,BAO_0000219
7168,,,9606.0,Intermediate,Homo sapiens,15895,CHEMBL621836,80025,,626.0,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,F,1,N,1,,BAO_0000219
7169,,,9606.0,Intermediate,Homo sapiens,17376,CHEMBL621837,80025,,626.0,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,F,1,N,1,,BAO_0000219
7170,,,9606.0,Intermediate,Homo sapiens,14882,CHEMBL875280,80025,,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,F,1,N,1,,BAO_0000219
7171,,,9606.0,Intermediate,Homo sapiens,14882,CHEMBL621838,80025,,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,F,1,N,1,,BAO_0000219
7172,,,9606.0,Intermediate,Homo sapiens,15661,CHEMBL621839,80025,,626.0,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,F,1,N,1,,BAO_0000219
7173,,,,Autocuration,,9680,CHEMBL621840,22224,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,A,1,U,0,,BAO_0000019
7174,,,,Autocuration,,14579,CHEMBL621841,10647,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,F,1,H,8,,BAO_0000019
7175,,,10358.0,Expert,Cytomegalovirus,17290,CHEMBL622979,50529,,468.0,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,F,1,N,1,,BAO_0000218
7176,,,10358.0,Intermediate,Cytomegalovirus,17290,CHEMBL876595,50529,,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,F,1,N,1,,BAO_0000218
7177,,,,Autocuration,,15891,CHEMBL620221,12159,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,B,1,H,8,,BAO_0000357
7178,,,,Autocuration,,15890,CHEMBL620222,12159,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,B,1,H,8,,BAO_0000357
7179,,,9913.0,Intermediate,Bos taurus,3801,CHEMBL620506,80670,,979.0,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,F,1,N,1,,BAO_0000219
7180,,,10090.0,Intermediate,Mus musculus,9222,CHEMBL620507,80671,,980.0,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,F,1,N,1,,BAO_0000219
7181,,,10090.0,Intermediate,Mus musculus,9222,CHEMBL620508,80671,,980.0,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,F,1,N,1,,BAO_0000219
7182,,,10090.0,Intermediate,Mus musculus,7257,CHEMBL620509,80671,,980.0,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,F,1,N,1,,BAO_0000219
7183,,,10090.0,Intermediate,Mus musculus,7257,CHEMBL620510,80671,,980.0,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,F,1,N,1,,BAO_0000219
7184,,,10090.0,Intermediate,Mus musculus,7257,CHEMBL620511,80671,,980.0,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,A,1,N,1,,BAO_0000219
7185,,,10090.0,Intermediate,Mus musculus,8084,CHEMBL620512,80671,,980.0,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,F,1,N,1,,BAO_0000219
7186,,,10090.0,Autocuration,Mus musculus,14943,CHEMBL620513,22224,,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,F,1,U,0,,BAO_0000019
7187,,,10090.0,Autocuration,Mus musculus,14943,CHEMBL620514,22224,,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,F,1,U,0,,BAO_0000019
7188,,,10090.0,Autocuration,Mus musculus,14943,CHEMBL620515,22224,,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,F,1,U,0,,BAO_0000019
7189,,,1423.0,Autocuration,Bacillus subtilis,10524,CHEMBL620516,22224,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,A,1,U,0,,BAO_0000218
7190,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3546,CHEMBL620517,50588,,,Plasma,AUC value in dog after IV administration at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7191,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3546,CHEMBL620518,50588,,,Plasma,AUC value in dog after oral administration at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7192,,,9615.0,Intermediate,Canis lupus familiaris,3546,CHEMBL620519,50588,,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7193,,,9615.0,Intermediate,Canis lupus familiaris,3546,CHEMBL621386,50588,,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7194,,,9615.0,Intermediate,Canis lupus familiaris,3546,CHEMBL621387,50588,,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7195,,,9615.0,Intermediate,Canis lupus familiaris,3184,CHEMBL621388,50588,,,,Compound was evaluated for its clearance when administered intravenously in dog,,A,1,N,1,,BAO_0000218
7196,,,9615.0,Intermediate,Canis lupus familiaris,16456,CHEMBL621389,50588,,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
7197,,,9615.0,Intermediate,Canis lupus familiaris,4809,CHEMBL621390,50588,,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,A,1,N,1,,BAO_0000218
7198,,,,Intermediate,,4219,CHEMBL621391,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
7199,,,9615.0,Intermediate,Canis lupus familiaris,3748,CHEMBL621392,50588,,,,Half life in dog,,A,1,N,1,,BAO_0000218
7200,,,9615.0,Intermediate,Canis lupus familiaris,3132,CHEMBL621393,50588,,,,Time taken for EC90 was determined when tested in dog,,A,1,N,1,,BAO_0000218
7201,,,9615.0,Intermediate,Canis lupus familiaris,4219,CHEMBL621394,50588,,,,Half life (iv) was determined,,A,1,N,1,,BAO_0000218
7202,,2107.0,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL621395,50588,,,Liver,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,A,1,N,1,,BAO_0000218
7203,,,9615.0,Intermediate,Canis lupus familiaris,6057,CHEMBL621396,50588,,,,Area under the curve was calculated in dog after iv administration,,A,1,N,1,,BAO_0000218
7204,,,9615.0,Intermediate,Canis lupus familiaris,6057,CHEMBL621397,50588,,,,Area under the curve was calculated in dog after peroral administration,,A,1,N,1,,BAO_0000218
7205,,,9615.0,Intermediate,Canis lupus familiaris,17853,CHEMBL621398,50588,,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,A,1,N,1,,BAO_0000218
7206,,,9615.0,Intermediate,Canis lupus familiaris,3639,CHEMBL618818,50588,,,,pKa was evaluated in dog,,A,1,N,1,,BAO_0000218
7207,,,9615.0,Intermediate,Canis lupus familiaris,14541,CHEMBL618819,50588,,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,A,1,N,1,,BAO_0000218
7208,,,9615.0,Intermediate,Canis lupus familiaris,16456,CHEMBL618820,50588,,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
7209,,,9615.0,Intermediate,Canis lupus familiaris,16456,CHEMBL873810,50588,,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
7210,,,9615.0,Intermediate,Canis lupus familiaris,2652,CHEMBL876606,50588,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,A,1,N,1,,BAO_0000218
7211,,,9615.0,Intermediate,Canis lupus familiaris,3624,CHEMBL618821,50588,,,,Compound was evaluated for the half-life (t 1/2) in hours,,A,1,N,1,,BAO_0000218
7212,,178.0,9615.0,Intermediate,Canis lupus familiaris,1337,CHEMBL618822,50588,,,Blood,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,A,1,N,1,,BAO_0000218
7213,,178.0,9615.0,Intermediate,Canis lupus familiaris,1337,CHEMBL618823,50588,,,Blood,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,A,1,N,1,,BAO_0000218
7214,,,9615.0,Intermediate,Canis lupus familiaris,4709,CHEMBL618824,50588,,,,Half life after intravenous administration of 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
7215,,,9615.0,Intermediate,Canis lupus familiaris,15660,CHEMBL618825,50588,,,,Half life was measured in dog,,A,1,N,1,,BAO_0000218
7216,,,9615.0,Intermediate,Canis lupus familiaris,5302,CHEMBL618826,50588,,,,Half life period in dog after 5 mg/kg dose,,A,1,N,1,,BAO_0000218
7217,,,9615.0,Intermediate,Canis lupus familiaris,17791,CHEMBL618827,50588,,,,Half life period was evaluated in dog; 4-4.8,,A,1,N,1,,BAO_0000218
7218,,,9615.0,Intermediate,Canis lupus familiaris,6348,CHEMBL618828,50588,,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
7219,,,9615.0,Intermediate,Canis lupus familiaris,4257,CHEMBL618829,50588,,,,Half-life was determined in dog after a3 mg/kg of iv dose,,A,1,N,1,,BAO_0000218
7220,,,9615.0,Intermediate,Canis lupus familiaris,3771,CHEMBL618830,50588,,,,Half-life was determined,,A,1,N,1,,BAO_0000218
7221,,,9615.0,Intermediate,Canis lupus familiaris,6305,CHEMBL618831,50588,,,,Half life in dogs,,A,1,N,1,,BAO_0000218
7222,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13501,CHEMBL619489,50588,,,Plasma,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,A,1,N,1,,BAO_0000218
7223,,,9615.0,Intermediate,Canis lupus familiaris,17594,CHEMBL619649,50588,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,A,1,N,1,,BAO_0000218
7224,,,9615.0,Intermediate,Canis lupus familiaris,3045,CHEMBL876607,50588,,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,A,1,N,1,,BAO_0000218
7225,,,9615.0,Intermediate,Canis lupus familiaris,3043,CHEMBL619650,50588,,,,Compound was evaluated for the half life period after oral administration in conscious dog.,,A,1,N,1,,BAO_0000218
7226,,,9615.0,Intermediate,Canis lupus familiaris,4839,CHEMBL619651,50588,,,,Compound was tested for half life in dog,,A,1,N,1,,BAO_0000218
7227,,,9615.0,Intermediate,Canis lupus familiaris,4839,CHEMBL619652,50588,,,,Compound was tested for its half life in dog,,A,1,N,1,,BAO_0000218
7228,,,9615.0,Intermediate,Canis lupus familiaris,5802,CHEMBL619653,50588,,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,A,1,N,1,,BAO_0000218
7229,,,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL619654,50588,,,,Half life of compound in dog was determined,,A,1,N,1,,BAO_0000218
7230,,,9615.0,Intermediate,Canis lupus familiaris,4219,CHEMBL619655,50588,,,,Half life (iv) was determined,,A,1,N,1,,BAO_0000218
7231,,178.0,9615.0,Intermediate,Canis lupus familiaris,13966,CHEMBL619656,50588,,,Blood,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,A,1,N,1,,BAO_0000218
7232,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3994,CHEMBL873812,50588,,,Plasma,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,A,1,N,1,,BAO_0000218
7233,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3994,CHEMBL621365,50588,,,Plasma,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,F,1,N,1,,BAO_0000218
7234,,,9615.0,Intermediate,Canis lupus familiaris,4453,CHEMBL621366,50588,,,,Half life in dog,,A,1,N,1,,BAO_0000218
7235,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL621367,50588,,,Plasma,Half life in dog plasma,,A,1,N,1,,BAO_0000218
7236,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL621368,50588,,,Plasma,Half life in dog plasma after administration of 0.25 mg/kg iv,,A,1,N,1,,BAO_0000218
7237,,1969.0,9615.0,Intermediate,Canis lupus familiaris,6535,CHEMBL621369,50588,,,Plasma,Half life in dog plasma after administration of 1 mg/kg iv,,A,1,N,1,,BAO_0000218
7238,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3132,CHEMBL621370,50588,,,Plasma,Half life in dog plasma was determined at dose 10 mg/kg,,A,1,N,1,,BAO_0000218
7239,,,9615.0,Intermediate,Canis lupus familiaris,5374,CHEMBL621371,50588,,,,Half life in dog was determined,,A,1,N,1,,BAO_0000218
7240,,,9615.0,Intermediate,Canis lupus familiaris,5007,CHEMBL621372,50588,,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,A,1,N,1,,BAO_0000218
7241,,1969.0,9615.0,Intermediate,Canis lupus familiaris,16907,CHEMBL621373,50588,,,Plasma,Half life upon exposure to human plasma,,A,1,N,1,,BAO_0000218
7242,,,9615.0,Intermediate,Canis lupus familiaris,6057,CHEMBL621374,50588,,,,Half life was calculated in dog,,A,1,N,1,,BAO_0000218
7243,,,9615.0,Intermediate,Canis lupus familiaris,5006,CHEMBL621375,50588,,,,Half life was determined,,A,1,N,1,,BAO_0000218
7244,,,9615.0,Intermediate,Canis lupus familiaris,5473,CHEMBL621376,50588,,,,Half life was determined,,A,1,N,1,,BAO_0000218
7245,,,9615.0,Intermediate,Canis lupus familiaris,4368,CHEMBL619624,50588,,,,Half life by intravenous administration of 1.2 mg/kg in dog,,A,1,N,1,,BAO_0000218
7246,,,9615.0,Intermediate,Canis lupus familiaris,6448,CHEMBL875840,50588,,,,Half life in dog,,A,1,N,1,,BAO_0000218
7247,,,9615.0,Intermediate,Canis lupus familiaris,4353,CHEMBL619625,50588,,,,Half life in dog after intra venous administration of the compound,,A,1,N,1,,BAO_0000218
7248,,,9615.0,Intermediate,Canis lupus familiaris,4353,CHEMBL619626,50588,,,,Half life in dog after intra venous administration of the compound; ND means Not determined,,A,1,N,1,,BAO_0000218
7249,,,9615.0,Intermediate,Canis lupus familiaris,4353,CHEMBL619627,50588,,,,Half life in dog after po administration of the compound,,A,1,N,1,,BAO_0000218
7250,,,9615.0,Intermediate,Canis lupus familiaris,4353,CHEMBL873817,50588,,,,Half life in dog after po administration of the compound; ND means Not determined,,A,1,N,1,,BAO_0000218
7251,,,9615.0,Intermediate,Canis lupus familiaris,6265,CHEMBL619628,50588,,,,Half life in dog at the single oral dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7252,,,9615.0,Intermediate,Canis lupus familiaris,5006,CHEMBL619629,50588,,,,Half life in dogs,,A,1,N,1,,BAO_0000218
7253,,,9615.0,Intermediate,Canis lupus familiaris,5356,CHEMBL619630,50588,,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,A,1,N,1,,BAO_0000218
7254,,,9615.0,Intermediate,Canis lupus familiaris,405,CHEMBL619631,50588,,,,Half life in rat,,A,1,N,1,,BAO_0000218
7255,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL619632,50588,,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,A,1,N,1,,BAO_0000218
7256,,10000001.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619633,50594,,,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7257,,10000001.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL875841,50594,,,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7258,,10000001.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619634,50594,,,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7259,,10000001.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619635,50594,,,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7260,,10000001.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619636,50594,,,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7261,,10000004.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619637,50594,,,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7262,,10000004.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619638,50594,,,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,A,1,N,1,,BAO_0000218
7263,,10000004.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619639,50594,,,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7264,,10000004.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619640,50594,,,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7265,,10000004.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619641,50594,,,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7266,,10000004.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619642,50594,,,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7267,,10000004.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619643,50594,,,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7268,,948.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL619644,50594,,,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7269,,948.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621112,50594,,,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,A,1,N,1,,BAO_0000218
7270,,948.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621113,50594,,,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7271,,948.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621114,50594,,,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7272,,948.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621115,50594,,,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7273,,948.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621116,50594,,,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7274,,948.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621117,50594,,,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7275,,2113.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621118,50594,,,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7276,,2113.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621119,50594,,,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,A,1,N,1,,BAO_0000218
7277,,2113.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621120,50594,,,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7278,,2113.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621757,50594,,,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7279,,2113.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621758,50594,,,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7280,,2113.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621759,50594,,,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7281,,2113.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621760,50594,,,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7282,,2107.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621761,50594,,,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7283,,2107.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621762,50594,,,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,A,1,N,1,,BAO_0000218
7284,,2107.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL621763,50594,,,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7285,,2107.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624502,50594,,,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7286,,2107.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624503,50594,,,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7287,,2107.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624504,50594,,,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7288,,2107.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624505,50594,,,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7289,,2048.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624506,50594,,,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7290,,,9606.0,Intermediate,Homo sapiens,5895,CHEMBL624507,81034,,478.0,,In vitro cytotoxicity against A2780 (human ovarian cancer),,F,1,N,1,,BAO_0000219
7291,,,9606.0,Intermediate,Homo sapiens,6338,CHEMBL624508,81034,,478.0,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,F,1,N,1,,BAO_0000219
7292,,,9606.0,Intermediate,Homo sapiens,15163,CHEMBL624509,81034,,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,F,1,N,1,,BAO_0000219
7293,,,9606.0,Intermediate,Homo sapiens,15163,CHEMBL624510,81034,,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,F,1,N,1,,BAO_0000219
7294,,,9606.0,Expert,Homo sapiens,15000,CHEMBL875956,81034,,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,F,1,N,1,,BAO_0000219
7295,,,9606.0,Expert,Homo sapiens,15000,CHEMBL839885,81034,,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,F,1,N,1,,BAO_0000219
7296,,,9606.0,Expert,Homo sapiens,14729,CHEMBL624511,81034,,478.0,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,F,1,N,1,,BAO_0000219
7297,,,9606.0,Intermediate,Homo sapiens,17270,CHEMBL624512,81034,,478.0,,In vitro cytotoxicity against A2780 cell line,,F,1,N,1,,BAO_0000219
7298,,,9606.0,Intermediate,Homo sapiens,5685,CHEMBL624513,81034,,478.0,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,F,1,N,1,,BAO_0000219
7299,,,9606.0,Intermediate,Homo sapiens,3563,CHEMBL624514,81034,,478.0,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,F,1,N,1,,BAO_0000219
7300,,,9606.0,Intermediate,Homo sapiens,17753,CHEMBL618547,81034,,478.0,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,F,1,N,1,,BAO_0000218
7301,,,9606.0,Intermediate,Homo sapiens,16317,CHEMBL618548,81034,,478.0,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,F,1,N,1,,BAO_0000219
7302,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL618549,81034,,478.0,,Inhibition of tubulin polymerization in analogy of ca.,,F,1,N,1,,BAO_0000219
7303,,,9606.0,Intermediate,Homo sapiens,3801,CHEMBL618550,81034,,478.0,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,F,1,N,1,,BAO_0000219
7304,,,9606.0,Expert,Homo sapiens,6181,CHEMBL618551,81034,,478.0,,Cytotoxic effect in ovarian cancer cell line (A2780),,F,1,N,1,,BAO_0000219
7305,,,9606.0,Intermediate,Homo sapiens,5318,CHEMBL618552,81034,,478.0,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,F,1,N,1,,BAO_0000219
7306,,,9606.0,Intermediate,Homo sapiens,4840,CHEMBL618553,81034,,478.0,,Tested for the cytotoxicity in A2780 ovarian cell line,,F,1,N,1,,BAO_0000219
7307,,,9606.0,Intermediate,Homo sapiens,15748,CHEMBL618554,81034,,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,F,1,N,1,,BAO_0000219
7308,,,9606.0,Intermediate,Homo sapiens,15748,CHEMBL618555,81034,,478.0,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,F,1,N,1,,BAO_0000219
7309,,,,Intermediate,,15748,CHEMBL618556,80017,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,F,1,N,1,,BAO_0000219
7310,,,,Intermediate,,15748,CHEMBL618557,80017,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,F,1,N,1,,BAO_0000219
7311,,,,Intermediate,,15748,CHEMBL618558,80017,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,F,1,N,1,,BAO_0000219
7312,,,,Intermediate,,15748,CHEMBL618559,80017,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,F,1,N,1,,BAO_0000219
7313,,,9606.0,Intermediate,Homo sapiens,17753,CHEMBL618560,81034,,478.0,,In vivo log of cells killed after administration of compound in A2780 cell line,,F,1,N,1,,BAO_0000218
7314,,,9606.0,Intermediate,Homo sapiens,17753,CHEMBL618561,81034,,478.0,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,F,1,N,1,,BAO_0000218
7315,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL618562,81034,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,F,1,N,1,,BAO_0000219
7316,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL618563,81034,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,F,1,N,1,,BAO_0000219
7317,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL618564,81034,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,F,1,N,1,,BAO_0000219
7318,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL618565,81034,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,F,1,N,1,,BAO_0000219
7319,,,9606.0,Intermediate,Homo sapiens,17528,CHEMBL618566,81034,,478.0,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,F,1,N,1,,BAO_0000218
7320,,,9606.0,Intermediate,Homo sapiens,6633,CHEMBL618567,81034,,478.0,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,F,1,N,1,,BAO_0000219
7321,,,9606.0,Expert,Homo sapiens,15000,CHEMBL618568,81034,,478.0,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,F,1,N,1,,BAO_0000219
7322,,,9606.0,Expert,Homo sapiens,17528,CHEMBL618569,81034,,478.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,F,1,N,1,,BAO_0000219
7323,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL621857,81034,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,F,1,N,1,,BAO_0000219
7324,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL621858,81034,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,F,1,N,1,,BAO_0000219
7325,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL621859,81034,,478.0,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,F,1,N,1,,BAO_0000219
7326,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL621860,81034,,478.0,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,F,1,N,1,,BAO_0000219
7327,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL621861,81034,,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,F,1,N,1,,BAO_0000219
7328,,,9606.0,Expert,Homo sapiens,16936,CHEMBL621862,81034,,478.0,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,F,1,N,1,,BAO_0000219
7329,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL621863,81034,,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,F,1,N,1,,BAO_0000219
7330,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL621864,81034,,478.0,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,F,1,N,1,,BAO_0000219
7331,,,9606.0,Intermediate,Homo sapiens,16936,CHEMBL621865,81034,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,F,1,N,1,,BAO_0000219
7332,,,10090.0,Intermediate,Mus musculus,17737,CHEMBL621866,81034,,478.0,,In vitro antiproliferative activity against A2780 cell line,,F,1,N,1,,BAO_0000219
7333,,,10090.0,Expert,Mus musculus,17764,CHEMBL621867,81034,,478.0,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,F,1,N,1,,BAO_0000219
7334,,,9606.0,Intermediate,Homo sapiens,3830,CHEMBL621868,81034,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,F,1,N,1,,BAO_0000219
7335,,,9606.0,Intermediate,Homo sapiens,3829,CHEMBL875282,81034,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,F,1,N,1,,BAO_0000219
7336,,,9615.0,Intermediate,Canis lupus familiaris,3546,CHEMBL621869,50588,,,,Vc value in dog after IV administration at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7337,,,9615.0,Intermediate,Canis lupus familiaris,3546,CHEMBL621870,50588,,,,Half life period in dog after IV administration at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7338,,,9527.0,Autocuration,Cercopithecidae,5668,CHEMBL621871,22224,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,A,1,U,0,,BAO_0000019
7339,,1969.0,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL621243,22224,,,Plasma,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
7340,,1969.0,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL621244,22224,,,Plasma,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
7341,,,9541.0,Autocuration,Macaca fascicularis,4256,CHEMBL621245,22224,,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,A,1,U,0,,BAO_0000218
7342,,,9541.0,Autocuration,Macaca fascicularis,4256,CHEMBL621246,22224,,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,A,1,U,0,,BAO_0000218
7343,,,9541.0,Autocuration,Macaca fascicularis,4256,CHEMBL621247,22224,,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,A,1,U,0,,BAO_0000218
7344,,,10116.0,Autocuration,Rattus norvegicus,4256,CHEMBL618386,22224,,,,Oral Bioavailability in rat,,A,1,U,0,,BAO_0000218
7345,,,9527.0,Autocuration,Cercopithecidae,1916,CHEMBL618387,22224,,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,A,1,U,0,,BAO_0000218
7346,,,9527.0,Autocuration,Cercopithecidae,5302,CHEMBL618388,22224,,,,Area under curve value in monkey at a dose of 5 mg/kg,,A,1,U,0,,BAO_0000218
7347,,,9527.0,Autocuration,Cercopithecidae,4257,CHEMBL618389,22224,,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,A,1,U,0,,BAO_0000218
7348,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL618574,22224,,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000019
7349,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL618575,22224,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000019
7350,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL618576,22224,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,A,1,U,0,,BAO_0000019
7351,,,9527.0,Autocuration,Cercopithecidae,6078,CHEMBL618577,22224,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,A,1,U,0,,BAO_0000218
7352,,,9527.0,Autocuration,Cercopithecidae,6078,CHEMBL876487,22224,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,A,1,U,0,,BAO_0000218
7353,,,9527.0,Autocuration,Cercopithecidae,6062,CHEMBL618578,22224,,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
7354,,,9527.0,Autocuration,Cercopithecidae,2661,CHEMBL618579,22224,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,A,1,U,0,,BAO_0000218
7355,,,9527.0,Autocuration,Cercopithecidae,2661,CHEMBL618580,22224,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,A,1,U,0,,BAO_0000019
7356,,,9527.0,Autocuration,Cercopithecidae,5394,CHEMBL618581,22224,,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,A,1,U,0,,BAO_0000218
7357,,,9527.0,Autocuration,Cercopithecidae,4397,CHEMBL618582,22224,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,A,1,U,0,,BAO_0000218
7358,,,9527.0,Autocuration,Cercopithecidae,17509,CHEMBL618583,22224,,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,A,1,U,0,,BAO_0000218
7359,,,9527.0,Autocuration,Cercopithecidae,17509,CHEMBL618584,22224,,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,A,1,U,0,,BAO_0000218
7360,,,9527.0,Autocuration,Cercopithecidae,6641,CHEMBL618585,22224,,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,A,1,U,0,,BAO_0000218
7361,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL618586,22224,,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,A,1,U,0,,BAO_0000218
7362,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL618587,22224,,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
7363,,,9527.0,Autocuration,Cercopithecidae,3443,CHEMBL618588,22224,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,A,1,U,0,,BAO_0000218
7364,,,9527.0,Autocuration,Cercopithecidae,17409,CHEMBL618589,22224,,,,Binding towards monkey plasma protein at 10 uM,,A,1,U,0,,BAO_0000019
7365,,,9527.0,Autocuration,Cercopithecidae,17409,CHEMBL618590,22224,,,,Binding towards monkey plasma protein at 100 uM,,A,1,U,0,,BAO_0000019
7366,,,9527.0,Autocuration,Cercopithecidae,1052,CHEMBL872262,22224,,,,Apparent bioavailability in squirrel monkey was determined,,A,1,U,0,,BAO_0000218
7367,,,9527.0,Autocuration,Cercopithecidae,13501,CHEMBL618591,22224,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,A,1,U,0,,BAO_0000218
7368,,,9443.0,Autocuration,monkey,17509,CHEMBL618592,22224,,,,Bioavailability in monkey (dose 2 mg/kg),,A,1,U,0,,BAO_0000218
7369,,,9527.0,Autocuration,Cercopithecidae,5394,CHEMBL876488,22224,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,A,1,U,0,,BAO_0000218
7370,,,9527.0,Autocuration,Cercopithecidae,2661,CHEMBL618593,22224,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,A,1,U,0,,BAO_0000218
7371,,,9443.0,Autocuration,monkey,11219,CHEMBL618594,22224,,,,Bioavailability in monkey (i.d. dosing),,A,1,U,0,,BAO_0000218
7372,,,9527.0,Autocuration,Cercopithecidae,3045,CHEMBL618595,22224,,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,A,1,U,0,,BAO_0000218
7373,,,9527.0,Autocuration,Cercopithecidae,17796,CHEMBL621469,22224,,,,Clearance of the drug was measured in cynomolgus,,A,1,U,0,,BAO_0000019
7374,,,9527.0,Autocuration,Cercopithecidae,1399,CHEMBL621470,22224,,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,A,1,U,0,,BAO_0000218
7375,,,9527.0,Autocuration,Cercopithecidae,2661,CHEMBL621471,22224,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,A,1,U,0,,BAO_0000218
7376,,1969.0,9544.0,Autocuration,Macaca mulatta,5005,CHEMBL621472,22224,,,Plasma,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,A,1,U,0,,BAO_0000218
7377,,,9527.0,Autocuration,Cercopithecidae,17267,CHEMBL621473,22224,,,,Plasma clearance in rhesus monkey was determined,,A,1,U,0,,BAO_0000218
7378,,,9527.0,Autocuration,Cercopithecidae,6535,CHEMBL621474,22224,,,,Plasma clearance in monkey after administration of 1 mg/kg iv,,A,1,U,0,,BAO_0000218
7379,,,9527.0,Autocuration,Cercopithecidae,5922,CHEMBL621475,22224,,,,Plasma clearance in cynomolgus monkey,,A,1,U,0,,BAO_0000218
7380,,,9527.0,Autocuration,Cercopithecidae,6221,CHEMBL621476,22224,,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,A,1,U,0,,BAO_0000218
7381,,,9527.0,Autocuration,Cercopithecidae,5668,CHEMBL624290,22224,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,A,1,U,0,,BAO_0000218
7382,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL624291,22224,,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,A,1,U,0,,BAO_0000218
7383,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL624292,22224,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,A,1,U,0,,BAO_0000218
7384,,,9527.0,Autocuration,Cercopithecidae,5355,CHEMBL624293,22224,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,A,1,U,0,,BAO_0000218
7385,,,9527.0,Autocuration,Cercopithecidae,4578,CHEMBL624294,22224,,,,Tested for Clearance upon iv administration to african green monkey,,A,1,U,0,,BAO_0000218
7386,,,9527.0,Autocuration,Cercopithecidae,17592,CHEMBL624295,22224,,,,Clearance in monkey,,A,1,U,0,,BAO_0000218
7387,,,9615.0,Intermediate,Canis lupus familiaris,6641,CHEMBL624296,50588,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,N,1,,BAO_0000218
7388,,,9615.0,Intermediate,Canis lupus familiaris,6642,CHEMBL624297,50588,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,A,1,N,1,,BAO_0000218
7389,,,9615.0,Intermediate,Canis lupus familiaris,16367,CHEMBL624298,50588,,,,Half life was evaluated after intravenous administration to dogs,,A,1,N,1,,BAO_0000218
7390,,,9615.0,Intermediate,Canis lupus familiaris,5472,CHEMBL624299,50588,,,,Half life was evaluated in dog,,A,1,N,1,,BAO_0000218
7391,,,9615.0,Intermediate,Canis lupus familiaris,5474,CHEMBL624300,50588,,,,Half life was evaluated in dog,,A,1,N,1,,BAO_0000218
7392,,,9615.0,Intermediate,Canis lupus familiaris,5654,CHEMBL624301,50588,,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7393,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL624302,50588,,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,A,1,N,1,,BAO_0000218
7394,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL876026,50588,,,,Half life period after intravenous administration in dog,,A,1,N,1,,BAO_0000218
7395,,,9615.0,Intermediate,Canis lupus familiaris,6221,CHEMBL624303,50588,,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,A,1,N,1,,BAO_0000218
7396,,,9615.0,Intermediate,Canis lupus familiaris,4527,CHEMBL624304,50588,,,,Half life period at a dose of 1 uM/kg in dog was determined,,A,1,N,1,,BAO_0000218
7397,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL624305,50588,,,,Half life period was determine after peroral administration at 10 mpk in dog,,A,1,N,1,,BAO_0000218
7398,,,9615.0,Intermediate,Canis lupus familiaris,5668,CHEMBL624306,50588,,,,Half life period was determine after peroral administration at 5 mpk in dog,,A,1,N,1,,BAO_0000218
7399,,,9615.0,Intermediate,Canis lupus familiaris,3854,CHEMBL624307,50588,,,,Half life period was determined,,A,1,N,1,,BAO_0000218
7400,,,9615.0,Intermediate,Canis lupus familiaris,5505,CHEMBL624308,50588,,,,Half life period was determined,,A,1,N,1,,BAO_0000218
7401,,,9615.0,Intermediate,Canis lupus familiaris,6251,CHEMBL624309,50588,,,,Half life period by iv administration in dog at a dose of 6 mg/kg,,A,1,N,1,,BAO_0000218
7402,,,9615.0,Intermediate,Canis lupus familiaris,1918,CHEMBL624310,50588,,,,Half life period was evaluated in dog,,A,1,N,1,,BAO_0000218
7403,,,9615.0,Intermediate,Canis lupus familiaris,5546,CHEMBL625003,50588,,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,A,1,N,1,,BAO_0000218
7404,,,9615.0,Intermediate,Canis lupus familiaris,4809,CHEMBL625004,50588,,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,A,1,N,1,,BAO_0000218
7405,,,9615.0,Intermediate,Canis lupus familiaris,6215,CHEMBL625005,50588,,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,A,1,N,1,,BAO_0000218
7406,,,9615.0,Intermediate,Canis lupus familiaris,4527,CHEMBL873813,50588,,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,A,1,N,1,,BAO_0000218
7407,,,9615.0,Intermediate,Canis lupus familiaris,17594,CHEMBL625006,50588,,,,Half-life after oral dose of compound at 3 mg/kg in dogs,,A,1,N,1,,BAO_0000218
7408,,,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL625007,50588,,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,A,1,N,1,,BAO_0000218
7409,,,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL876027,50588,,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,A,1,N,1,,BAO_0000218
7410,,,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL625008,50588,,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,A,1,N,1,,BAO_0000218
7411,,,9615.0,Intermediate,Canis lupus familiaris,17839,CHEMBL625009,50588,,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,A,1,N,1,,BAO_0000218
7412,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5210,CHEMBL625010,50588,,,Plasma,Half-life of compound in plasma of dog was determined,,A,1,N,1,,BAO_0000218
7413,,,9615.0,Intermediate,Canis lupus familiaris,5210,CHEMBL625011,50588,,,,Half-life of compound was determined in dogs,,A,1,N,1,,BAO_0000218
7414,,,9615.0,Intermediate,Canis lupus familiaris,2959,CHEMBL621553,50588,,,,Half-life after administration of 4 mg/Kg oral dose in dog,,A,1,N,1,,BAO_0000218
7415,,,9615.0,Intermediate,Canis lupus familiaris,4137,CHEMBL621554,50588,,,,Half-life after intravenous administration of 1 mg/kg/h in dog,,A,1,N,1,,BAO_0000218
7416,,,9615.0,Intermediate,Canis lupus familiaris,5064,CHEMBL621555,50588,,,,Half-life in Dog,,A,1,N,1,,BAO_0000218
7417,,,9615.0,Intermediate,Canis lupus familiaris,5147,CHEMBL621556,50588,,,,Half-life in Dog,,A,1,N,1,,BAO_0000218
7418,,,9615.0,Intermediate,Canis lupus familiaris,5145,CHEMBL621557,50588,,,,Half-life in dog,,A,1,N,1,,BAO_0000218
7419,,,9615.0,Intermediate,Canis lupus familiaris,6123,CHEMBL621558,50588,,,,Half-life in dog after oral administration at 1 mg/kg,,A,1,N,1,,BAO_0000218
7420,,,9615.0,Intermediate,Canis lupus familiaris,6123,CHEMBL621559,50588,,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,A,1,N,1,,BAO_0000218
7421,,,9615.0,Intermediate,Canis lupus familiaris,4333,CHEMBL621560,50588,,,,Half-life in dogs,,A,1,N,1,,BAO_0000218
7422,,,9615.0,Intermediate,Canis lupus familiaris,4333,CHEMBL876028,50588,,,,Half-life in dogs; ND indicates not determined,,A,1,N,1,,BAO_0000218
7423,,1969.0,9615.0,Intermediate,Canis lupus familiaris,12500,CHEMBL621561,50588,,,Plasma,Half-life in plasma of dog,,A,1,N,1,,BAO_0000218
7424,,1969.0,9615.0,Intermediate,Canis lupus familiaris,12500,CHEMBL621562,50588,,,Plasma,Half-life in plasma of dog at dose of 3-10 mgkg,,A,1,N,1,,BAO_0000218
7425,,,9615.0,Intermediate,Canis lupus familiaris,6005,CHEMBL621563,50588,,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7426,,,9615.0,Intermediate,Canis lupus familiaris,6062,CHEMBL621564,50588,,,,Half-life was measured in dog after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7427,,,9615.0,Intermediate,Canis lupus familiaris,17650,CHEMBL621565,50588,,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,A,1,N,1,,BAO_0000218
7428,,,9615.0,Intermediate,Canis lupus familiaris,5530,CHEMBL621566,50588,,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,A,1,N,1,,BAO_0000218
7429,,,9615.0,Intermediate,Canis lupus familiaris,5530,CHEMBL621567,50588,,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
7430,,,9615.0,Intermediate,Canis lupus familiaris,5600,CHEMBL622978,50588,,,,Half-life of the compound after 0.3 mg/kg po administration in dog,,A,1,N,1,,BAO_0000218
7431,,,9615.0,Intermediate,Canis lupus familiaris,6039,CHEMBL873814,50588,,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,A,1,N,1,,BAO_0000218
7432,,,9615.0,Intermediate,Canis lupus familiaris,6039,CHEMBL623219,50588,,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,A,1,N,1,,BAO_0000218
7433,,,9615.0,Intermediate,Canis lupus familiaris,6039,CHEMBL624477,50588,,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,A,1,N,1,,BAO_0000218
7434,,,9615.0,Intermediate,Canis lupus familiaris,6227,CHEMBL624478,50588,,,,t1/2 in dog,,A,1,N,1,,BAO_0000218
7435,,,9615.0,Intermediate,Canis lupus familiaris,14541,CHEMBL624479,50588,,,,Half-life period measured in dogs,,A,1,N,1,,BAO_0000218
7436,,,9615.0,Intermediate,Canis lupus familiaris,4521,CHEMBL624480,50588,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,A,1,N,1,,BAO_0000218
7437,,,9615.0,Intermediate,Canis lupus familiaris,4521,CHEMBL623595,50588,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,A,1,N,1,,BAO_0000218
7438,,,9615.0,Intermediate,Canis lupus familiaris,6679,CHEMBL623596,50588,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,A,1,N,1,,BAO_0000218
7439,,1969.0,9615.0,Intermediate,Canis lupus familiaris,1116,CHEMBL623597,50588,,,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,A,1,N,1,,BAO_0000218
7440,,,9615.0,Intermediate,Canis lupus familiaris,5444,CHEMBL623598,50588,,,,In vivo half life period was calculated at 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
7441,,,9615.0,Intermediate,Canis lupus familiaris,5444,CHEMBL623599,50588,,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,A,1,N,1,,BAO_0000218
7442,,,9615.0,Intermediate,Canis lupus familiaris,17853,CHEMBL623600,50588,,,,Longer half-life in dog (i.v.) at 0.5 mpk,,A,1,N,1,,BAO_0000218
7443,,,9615.0,Intermediate,Canis lupus familiaris,4353,CHEMBL623601,50588,,,,Oral bioavailability in dog (dose 5 uM/kg),,A,1,N,1,,BAO_0000218
7444,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL623602,50588,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,A,1,N,1,,BAO_0000218
7445,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL623603,50588,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,A,1,N,1,,BAO_0000218
7446,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL623604,50588,,,,Bioavailability in dog (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
7447,,2048.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623605,50594,,,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,A,1,N,1,,BAO_0000218
7448,,2048.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623606,50594,,,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7449,,2048.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623607,50594,,,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7450,,2048.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623608,50594,,,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7451,,2048.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623609,50594,,,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7452,,2048.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623610,50594,,,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7453,,2385.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623611,50594,,,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7454,,2385.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623612,50594,,,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,A,1,N,1,,BAO_0000218
7455,,2385.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623613,50594,,,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7456,,2385.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623614,50594,,,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7457,,2385.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623615,50594,,,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7458,,2385.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623616,50594,,,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7459,,2385.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623617,50594,,,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7460,,14.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL875944,50594,,,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7461,,14.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623618,50594,,,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,A,1,N,1,,BAO_0000218
7462,,14.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623619,50594,,,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7463,,14.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623620,50594,,,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7464,,14.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623621,50594,,,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7465,,14.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623622,50594,,,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7466,,14.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623623,50594,,,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7467,,2106.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL623624,50594,,,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7468,,2106.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL618521,50594,,,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,A,1,N,1,,BAO_0000218
7469,,2106.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL618522,50594,,,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7470,,2106.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL618523,50594,,,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7471,,2106.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL618524,50594,,,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7472,,2106.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL618525,50594,,,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7473,,2106.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624586,50594,,,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7474,,945.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624587,50594,,,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,A,1,N,1,,BAO_0000218
7475,,945.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624588,50594,,,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,A,1,N,1,,BAO_0000218
7476,,945.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624589,50594,,,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,A,1,N,1,,BAO_0000218
7477,,945.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624590,50594,,,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,A,1,N,1,,BAO_0000218
7478,,945.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624591,50594,,,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,A,1,N,1,,BAO_0000218
7479,,945.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624592,50594,,,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,A,1,N,1,,BAO_0000218
7480,,945.0,10090.0,Intermediate,Mus musculus,10107,CHEMBL624593,50594,,,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,A,1,N,1,,BAO_0000218
7481,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL624594,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
7482,,,10116.0,Intermediate,Rattus norvegicus,4950,CHEMBL624595,50597,,,,Tested for the bioavailability in rat,,A,1,N,1,,BAO_0000218
7483,,,10116.0,Intermediate,Rattus norvegicus,5328,CHEMBL624596,50597,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,A,1,N,1,,BAO_0000218
7484,,,10116.0,Intermediate,Rattus norvegicus,406,CHEMBL624597,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
7485,,,10116.0,Intermediate,Rattus norvegicus,12500,CHEMBL624598,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
7486,,,10116.0,Intermediate,Rattus norvegicus,12500,CHEMBL624599,50597,,,,Bioavailability in rat (dose 3-10 mg/kg),,A,1,N,1,,BAO_0000218
7487,,,10116.0,Intermediate,Rattus norvegicus,5247,CHEMBL875166,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
7488,,1969.0,10116.0,Intermediate,Rattus norvegicus,4186,CHEMBL624600,50597,,,Plasma,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,A,1,N,1,,BAO_0000218
7489,,1969.0,10116.0,Intermediate,Rattus norvegicus,4186,CHEMBL624601,50597,,,Plasma,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,A,1,N,1,,BAO_0000218
7490,,,10116.0,Intermediate,Rattus norvegicus,6647,CHEMBL624602,50597,,,,Half life after oral administration was determined in rats at 6 mg/kg,,A,1,N,1,,BAO_0000218
7491,,,10116.0,Intermediate,Rattus norvegicus,6484,CHEMBL624603,50597,,,,Half life was determined,,A,1,N,1,,BAO_0000218
7492,,,10116.0,Intermediate,Rattus norvegicus,3249,CHEMBL624604,50597,,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
7493,,1969.0,10116.0,Intermediate,Rattus norvegicus,6281,CHEMBL624605,50597,,,Plasma,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,A,1,N,1,,BAO_0000218
7494,,,10116.0,Intermediate,Rattus norvegicus,3307,CHEMBL624606,50597,,,,Half life in rats,,A,1,N,1,,BAO_0000218
7495,,178.0,10116.0,Intermediate,Rattus norvegicus,12058,CHEMBL624607,50597,,,Blood,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,A,1,N,1,,BAO_0000218
7496,,,10116.0,Intermediate,Rattus norvegicus,8833,CHEMBL624608,50597,,,,Hill coefficient of the compound,,A,1,N,1,,BAO_0000218
7497,,178.0,10116.0,Intermediate,Rattus norvegicus,3193,CHEMBL624609,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,A,1,N,1,,BAO_0000218
7498,,178.0,10116.0,Intermediate,Rattus norvegicus,3193,CHEMBL624610,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,A,1,N,1,,BAO_0000218
7499,,178.0,10116.0,Intermediate,Rattus norvegicus,3193,CHEMBL624611,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,A,1,N,1,,BAO_0000218
7500,,178.0,10116.0,Intermediate,Rattus norvegicus,3193,CHEMBL624612,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,A,1,N,1,,BAO_0000218
7501,,178.0,10116.0,Intermediate,Rattus norvegicus,3193,CHEMBL875167,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,A,1,N,1,,BAO_0000218
7502,,178.0,10116.0,Intermediate,Rattus norvegicus,3193,CHEMBL624613,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,A,1,N,1,,BAO_0000218
7503,,178.0,10116.0,Intermediate,Rattus norvegicus,3193,CHEMBL624614,50597,,,Blood,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,A,1,N,1,,BAO_0000218
7504,,,10116.0,Intermediate,Rattus norvegicus,5960,CHEMBL624392,50597,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,A,1,N,1,,BAO_0000218
7505,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624393,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7506,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624394,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7507,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624395,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7508,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624396,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7509,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624397,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7510,,2046.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624398,50597,,,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7511,,2046.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624399,50597,,,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7512,,2046.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624400,50597,,,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7513,,2046.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624401,50597,,,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7514,,2046.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624402,50597,,,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,A,1,N,1,,BAO_0000218
7515,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL624403,50597,,,Blood,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7516,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL624404,50597,,,Blood,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,A,1,N,1,,BAO_0000218
7517,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL624405,50597,,,Blood,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7518,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL624406,50597,,,Bone,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7519,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL624407,50597,,,Bone,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,A,1,N,1,,BAO_0000218
7520,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL624408,50597,,,Bone,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7521,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618644,50597,,,Heart,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7522,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618645,50597,,,Heart,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,A,1,N,1,,BAO_0000218
7523,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618646,50597,,,Heart,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7524,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618647,50597,,,Kidney,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7525,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618648,50597,,,Kidney,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,A,1,N,1,,BAO_0000218
7526,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618649,50597,,,Kidney,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7527,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618650,50597,,,Liver,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7528,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618651,50597,,,Liver,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,A,1,N,1,,BAO_0000218
7529,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876497,50597,,,Liver,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7530,,2048.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618652,50597,,,Lung,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7531,,2048.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618653,50597,,,Lung,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,A,1,N,1,,BAO_0000218
7532,,2048.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618654,50597,,,Lung,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7533,,,10116.0,Intermediate,Rattus norvegicus,6351,CHEMBL618655,50597,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,A,1,N,1,,BAO_0000218
7534,,,10116.0,Intermediate,Rattus norvegicus,1465,CHEMBL618656,50597,,,,Compound was tested for solubility in water,,A,1,N,1,,BAO_0000218
7535,,,,Intermediate,,5182,CHEMBL618657,22229,,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,P,1,U,0,,BAO_0000100
7536,,,10116.0,Intermediate,Rattus norvegicus,17847,CHEMBL618658,50597,,,,Solubility was determined,,A,1,N,1,,BAO_0000218
7537,,,10116.0,Intermediate,Rattus norvegicus,15339,CHEMBL618659,50597,,,,solubility in water (ug/mL) at 37 degree C.,,A,1,N,1,,BAO_0000218
7538,,,10116.0,Intermediate,Rattus norvegicus,5202,CHEMBL618660,50597,,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,A,1,N,1,,BAO_0000218
7539,,,10116.0,Intermediate,Rattus norvegicus,1088,CHEMBL618661,50597,,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,A,1,N,1,,BAO_0000218
7540,,,10116.0,Intermediate,Rattus norvegicus,3169,CHEMBL873807,50597,,,,Half life in rats,,A,1,N,1,,BAO_0000218
7541,,,10116.0,Intermediate,Rattus norvegicus,5353,CHEMBL618662,50597,,,,Half life in Dawley rat,,A,1,N,1,,BAO_0000218
7542,,,10116.0,Intermediate,Rattus norvegicus,2864,CHEMBL618663,50597,,,,Half life period after 3 mg/kg iv administration,,A,1,N,1,,BAO_0000218
7543,,,10116.0,Intermediate,Rattus norvegicus,2864,CHEMBL618664,50597,,,,Half life period after 3 mg/kg iv administration in rat,,A,1,N,1,,BAO_0000218
7544,,,10116.0,Intermediate,Rattus norvegicus,2864,CHEMBL618665,50597,,,,Half life period after 3 mg/kg iv administration in the rat,,A,1,N,1,,BAO_0000218
7545,,,10116.0,Intermediate,Rattus norvegicus,6362,CHEMBL876498,50597,,,,Half life period in female Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
7546,,,10116.0,Intermediate,Rattus norvegicus,6249,CHEMBL618666,50597,,,,Half life period in rat,,A,1,N,1,,BAO_0000218
7547,,,10116.0,Intermediate,Rattus norvegicus,3169,CHEMBL620440,50597,,,,Half-life in rats was determined,,A,1,N,1,,BAO_0000218
7548,,,10116.0,Intermediate,Rattus norvegicus,3169,CHEMBL620441,50597,,,,Half-life in rats with metabolic oxidation,,A,1,N,1,,BAO_0000218
7549,,,10116.0,Intermediate,Rattus norvegicus,3169,CHEMBL620442,50597,,,,Half-life in rats,,A,1,N,1,,BAO_0000218
7550,,,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL620443,50597,,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
7551,,,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL620444,50597,,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
7552,,,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL620445,50597,,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
7553,,,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL620446,50597,,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
7554,,1969.0,10116.0,Intermediate,Rattus norvegicus,2879,CHEMBL620447,50597,,,Plasma,Biological half-life measured in plasma of rat,,A,1,N,1,,BAO_0000218
7555,,1969.0,10116.0,Intermediate,Rattus norvegicus,2879,CHEMBL621129,50597,,,Plasma,Biological half-life measured in plasma of rat; 22-25,,A,1,N,1,,BAO_0000218
7556,,1969.0,10116.0,Intermediate,Rattus norvegicus,2879,CHEMBL621130,50597,,,Plasma,Biological half-life measured in plasma of rat; 9-16,,A,1,N,1,,BAO_0000218
7557,,,10116.0,Intermediate,Rattus norvegicus,3184,CHEMBL873808,50597,,,,Compound was evaluated for its half life when administered intravenously in rat,,A,1,N,1,,BAO_0000218
7558,,,10116.0,Intermediate,Rattus norvegicus,4891,CHEMBL876598,50597,,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,A,1,N,1,,BAO_0000218
7559,,,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL621131,50597,,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,A,1,N,1,,BAO_0000218
7560,,,10116.0,Intermediate,Rattus norvegicus,5656,CHEMBL621132,50597,,,,Half life (T1/2) after oral administration in rat,,A,1,N,1,,BAO_0000218
7561,,,10116.0,Intermediate,Rattus norvegicus,4413,CHEMBL621133,50597,,,,Half life of compound after iv administration of 20 mg/kg dose in rat,,A,1,N,1,,BAO_0000218
7562,,,10116.0,Expert,Rattus norvegicus,3598,CHEMBL621312,50597,,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
7563,,,10116.0,Intermediate,Rattus norvegicus,17267,CHEMBL621313,50597,,,,Half life of compound was determined in rat,,A,1,N,1,,BAO_0000218
7564,,178.0,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL621314,50597,,,Blood,Half life of compound was determined in rat blood,,A,1,N,1,,BAO_0000218
7565,,,10116.0,Intermediate,Rattus norvegicus,17651,CHEMBL621315,50597,,,,Half life at 1 mg/kg was determined in rat,,A,1,N,1,,BAO_0000218
7566,,,10116.0,Intermediate,Rattus norvegicus,17651,CHEMBL621316,50597,,,,Half life at 10 mg/kg was determined in rat,,A,1,N,1,,BAO_0000218
7567,,,10116.0,Intermediate,Rattus norvegicus,401,CHEMBL621317,50597,,,,Half life in rats,,A,1,N,1,,BAO_0000218
7568,,,10116.0,Intermediate,Rattus norvegicus,4942,CHEMBL621318,50597,,,,Half life in rats in hours,,A,1,N,1,,BAO_0000218
7569,,,10116.0,Intermediate,Rattus norvegicus,17735,CHEMBL621319,50597,,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,A,1,N,1,,BAO_0000218
7570,,,10116.0,Intermediate,Rattus norvegicus,6056,CHEMBL621377,50597,,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,A,1,N,1,,BAO_0000218
7571,,,10116.0,Intermediate,Rattus norvegicus,5213,CHEMBL621378,50597,,,,Half life was determined,,A,1,N,1,,BAO_0000218
7572,,,10116.0,Intermediate,Rattus norvegicus,6616,CHEMBL876599,50597,,,,Half life after i.v. administration,,A,1,N,1,,BAO_0000218
7573,,,10116.0,Intermediate,Rattus norvegicus,5937,CHEMBL621379,50597,,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,A,1,N,1,,BAO_0000218
7574,,1969.0,10116.0,Intermediate,Rattus norvegicus,5819,CHEMBL621380,50597,,,Plasma,Half life in rat plasma,,A,1,N,1,,BAO_0000218
7575,,1969.0,10116.0,Intermediate,Rattus norvegicus,5819,CHEMBL621381,50597,,,Plasma,Half life in rat plasma; Not detected,,A,1,N,1,,BAO_0000218
7576,,,10116.0,Intermediate,Rattus norvegicus,6803,CHEMBL618515,50597,,,,Half life in rats,,A,1,N,1,,BAO_0000218
7577,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL618516,50597,,,,Half life period of compound was determined after peroral administration,,A,1,N,1,,BAO_0000218
7578,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL618517,50597,,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,A,1,N,1,,BAO_0000218
7579,,,10116.0,Intermediate,Rattus norvegicus,5948,CHEMBL618518,50597,,,,Half life period in rat,,A,1,N,1,,BAO_0000218
7580,,,10116.0,Intermediate,Rattus norvegicus,1916,CHEMBL618519,50597,,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,A,1,N,1,,BAO_0000218
7581,,,10116.0,Intermediate,Rattus norvegicus,1916,CHEMBL618698,50597,,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,A,1,N,1,,BAO_0000218
7582,,,10116.0,Intermediate,Rattus norvegicus,1916,CHEMBL618862,50597,,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,A,1,N,1,,BAO_0000218
7583,,,10116.0,Intermediate,Rattus norvegicus,4890,CHEMBL618863,50597,,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
7584,,,10116.0,Intermediate,Rattus norvegicus,17764,CHEMBL618864,50597,,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,A,1,N,1,,BAO_0000218
7585,,,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL618865,50597,,,,Half life time in rat the dose of 2 mg/kg,,A,1,N,1,,BAO_0000218
7586,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL618866,50597,,,,Half-life 24 hr after 10 mg/kg iv administration in rats,,A,1,N,1,,BAO_0000218
7587,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL618867,50597,,,,Half-life 24 hr after 2 mg/kg iv administration in rats,,A,1,N,1,,BAO_0000218
7588,,,10116.0,Intermediate,Rattus norvegicus,6597,CHEMBL875828,50597,,,,Half-life consistent with the observed metabolic steady state in rats,,A,1,N,1,,BAO_0000218
7589,,,10116.0,Intermediate,Rattus norvegicus,17735,CHEMBL618868,50597,,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,A,1,N,1,,BAO_0000218
7590,,,10116.0,Intermediate,Rattus norvegicus,6597,CHEMBL618869,50597,,,,Half-life for oxidative metabolic stability was determined using male human,,A,1,N,1,,BAO_0000218
7591,,,10116.0,Intermediate,Rattus norvegicus,17670,CHEMBL618870,50597,,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,A,1,N,1,,BAO_0000218
7592,,1969.0,10116.0,Intermediate,Rattus norvegicus,1696,CHEMBL618871,50597,,,Plasma,Half-life in rat plasma,,A,1,N,1,,BAO_0000218
7593,,1969.0,10116.0,Intermediate,Rattus norvegicus,1742,CHEMBL618872,50597,,,Plasma,Half-life in rat plasma was determined,,A,1,N,1,,BAO_0000218
7594,,,10116.0,Intermediate,Rattus norvegicus,17800,CHEMBL873816,50597,,,,Half-life in rats was determined,,A,1,N,1,,BAO_0000218
7595,,,,Autocuration,,12923,CHEMBL618873,22224,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,A,1,U,0,,BAO_0000218
7596,,,,Autocuration,,11954,CHEMBL621602,22224,,,,Area under curve after oral dose of 0.1 mg//kg,,A,1,U,0,,BAO_0000019
7597,,,,Autocuration,,11954,CHEMBL621603,22224,,,,Area under curve after oral dose of 0.3 mg/kg,,A,1,U,0,,BAO_0000218
7598,,,,Autocuration,,11954,CHEMBL621604,22224,,,,Area under curve after oral dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
7599,,,,Autocuration,,11954,CHEMBL621605,22224,,,,Area under curve after oral dose of 10 mg/kg,,A,1,U,0,,BAO_0000218
7600,,,,Autocuration,,11954,CHEMBL621606,22224,,,,Area under curve after oral dose of 23.4 mg/kg,,A,1,U,0,,BAO_0000218
7601,,,,Autocuration,,11954,CHEMBL621607,22224,,,,Area under curve after oral dose of 3 mg/kg,,A,1,U,0,,BAO_0000218
7602,,,,Autocuration,,11954,CHEMBL621608,22224,,,,Area under curve after oral dose of 3.87 mg/kg,,A,1,U,0,,BAO_0000218
7603,,,,Autocuration,,5237,CHEMBL621609,22224,,,,Area under curve was determined,,A,1,U,0,,BAO_0000019
7604,,,,Autocuration,,4026,CHEMBL621610,22224,,,,Area under curve at a dose of 10 mg/kg,,A,1,U,0,,BAO_0000218
7605,,,10116.0,Intermediate,Rattus norvegicus,5237,CHEMBL621611,50597,,,,Area under curve was determined; ND=No data,,A,1,N,1,,BAO_0000218
7606,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL621612,50597,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,A,1,N,1,,BAO_0000218
7607,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622308,50597,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,A,1,N,1,,BAO_0000218
7608,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622309,50597,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,A,1,N,1,,BAO_0000218
7609,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622310,50597,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,A,1,N,1,,BAO_0000218
7610,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622311,50597,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,A,1,N,1,,BAO_0000218
7611,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622312,50597,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,A,1,N,1,,BAO_0000218
7612,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622931,50597,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,A,1,N,1,,BAO_0000218
7613,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622932,50597,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,A,1,N,1,,BAO_0000218
7614,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622736,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,A,1,N,1,,BAO_0000218
7615,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622737,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,A,1,N,1,,BAO_0000218
7616,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622738,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,A,1,N,1,,BAO_0000218
7617,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622739,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,A,1,N,1,,BAO_0000218
7618,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622740,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,A,1,N,1,,BAO_0000218
7619,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622741,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,A,1,N,1,,BAO_0000218
7620,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622742,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,A,1,N,1,,BAO_0000218
7621,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL622743,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,A,1,N,1,,BAO_0000218
7622,,1969.0,10090.0,Intermediate,Mus musculus,11637,CHEMBL622744,50594,,,Plasma,AUC in mice,,A,1,N,1,,BAO_0000218
7623,,,,Autocuration,,11149,CHEMBL624134,22224,,,,Area under curve was measured from the graph obtained from concentration Vs time,,A,1,U,0,,BAO_0000019
7624,,,,Autocuration,,10016,CHEMBL624135,22224,,,,Area under curve value of compound per hour after oral administration,,A,1,U,0,,BAO_0000019
7625,,,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL624136,50597,,,,Area under curve was determined after oral administration in rats,,A,1,N,1,,BAO_0000218
7626,,,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL624137,50597,,,,Area under curve was determined after oral administration in rats; No data,,A,1,N,1,,BAO_0000218
7627,,,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL624320,50597,,,,Area under curve was determined after oral administration in rats;No data,,A,1,N,1,,BAO_0000218
7628,,,9615.0,Intermediate,Canis lupus familiaris,12923,CHEMBL624321,50588,,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,A,1,N,1,,BAO_0000218
7629,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL624322,50597,,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,A,1,N,1,,BAO_0000218
7630,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL624323,50597,,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,,A,1,N,1,,BAO_0000218
7631,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL624324,50597,,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,A,1,N,1,,BAO_0000218
7632,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL624325,50597,,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,A,1,N,1,,BAO_0000218
7633,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL624326,50597,,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,A,1,N,1,,BAO_0000218
7634,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL624327,50597,,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,A,1,N,1,,BAO_0000218
7635,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL624328,50597,,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,A,1,N,1,,BAO_0000218
7636,,,9615.0,Intermediate,Canis lupus familiaris,14169,CHEMBL627848,50588,,,,Area under curve was determined in Dogs after peroral administration,,A,1,N,1,,BAO_0000218
7637,,,10116.0,Intermediate,Rattus norvegicus,14169,CHEMBL627849,50597,,,,Area under curve was determined in Rats after peroral administration,,A,1,N,1,,BAO_0000218
7638,,,10116.0,Intermediate,Rattus norvegicus,14258,CHEMBL627850,50597,,,,Area under curve was determined in carotid blood of rat when administered intradermally,,A,1,N,1,,BAO_0000218
7639,,,10116.0,Intermediate,Rattus norvegicus,14258,CHEMBL627851,50597,,,,Area under curve was determined in portal blood of rat when administered intradermally,,A,1,N,1,,BAO_0000218
7640,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627852,50594,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
7641,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627853,50594,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
7642,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627854,50594,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,A,1,N,1,,BAO_0000218
7643,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627855,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
7644,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627856,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,A,1,N,1,,BAO_0000218
7645,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL875339,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
7646,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627857,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,A,1,N,1,,BAO_0000218
7647,,2106.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL627858,50597,,,Spleen,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
7648,,178.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627859,50597,,,Blood,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7649,,955.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627860,50597,,,Brain,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7650,,948.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627019,50597,,,Heart,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7651,,2107.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627020,50597,,,Liver,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7652,,2048.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627021,50597,,,Lung,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7653,,2385.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627022,50597,,,Muscle tissue,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7654,,,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627023,50597,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7655,,2106.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627024,50597,,,Spleen,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7656,,2046.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627025,50597,,,Thyroid gland,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7657,,2113.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627026,50597,,,Kidney,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7658,,178.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627027,50597,,,Blood,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7659,,955.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627028,50597,,,Brain,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7660,,948.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627029,50597,,,Heart,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7661,,2113.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627030,50597,,,Kidney,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7662,,2107.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627031,50597,,,Liver,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7663,,2048.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627032,50597,,,Lung,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7664,,2385.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627033,50597,,,Muscle tissue,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7665,,,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627034,50597,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7666,,2106.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627035,50597,,,Spleen,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7667,,2046.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627036,50597,,,Thyroid gland,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7668,,178.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL875340,50597,,,Blood,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7669,,948.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627037,50597,,,Heart,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7670,,2113.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627038,50597,,,Kidney,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7671,,2107.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627039,50597,,,Liver,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7672,,2385.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL627040,50597,,,Muscle tissue,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7673,,2106.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL624663,50597,,,Spleen,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7674,,2046.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL625963,50597,,,Thyroid gland,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7675,,955.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL876799,50597,,,Brain,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7676,,2048.0,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL626133,50597,,,Lung,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7677,,,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL626134,50597,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,A,1,N,1,,BAO_0000218
7678,,,10116.0,Intermediate,Rattus norvegicus,6295,CHEMBL626135,50597,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
7679,,,10116.0,Intermediate,Rattus norvegicus,6296,CHEMBL626136,50597,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
7680,,,10116.0,Intermediate,Rattus norvegicus,6296,CHEMBL626137,50597,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,A,1,N,1,,BAO_0000218
7681,,,10116.0,Intermediate,Rattus norvegicus,6295,CHEMBL626138,50597,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
7682,,,10116.0,Intermediate,Rattus norvegicus,6296,CHEMBL626139,50597,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
7683,,,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL626140,50597,,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
7684,,,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL626141,50597,,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
7685,,,10116.0,Intermediate,Rattus norvegicus,17686,CHEMBL626142,50597,,,,C24h in rat p.o. at 20 mg/kg concentration,,A,1,N,1,,BAO_0000218
7686,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627930,50597,,,Muscle tissue,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7687,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627931,50597,,,Muscle tissue,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,A,1,N,1,,BAO_0000218
7688,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627932,50597,,,Muscle tissue,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7689,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627933,50597,,,Spleen,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7690,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627934,50597,,,Spleen,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,A,1,N,1,,BAO_0000218
7691,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627935,50597,,,Spleen,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,A,1,N,1,,BAO_0000218
7692,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627936,50597,,,Blood,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7693,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627937,50597,,,Blood,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7694,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627938,50597,,,Blood,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7695,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627939,50597,,,Blood,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,A,1,N,1,,BAO_0000218
7696,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627940,50597,,,Blood,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7697,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627941,50597,,,Blood,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7698,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876800,50597,,,Blood,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7699,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627942,50597,,,Blood,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7700,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627943,50597,,,Blood,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7701,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627944,50597,,,Blood,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,A,1,N,1,,BAO_0000218
7702,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627945,50597,,,Blood,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,A,1,N,1,,BAO_0000218
7703,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL628584,50597,,,Blood,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,A,1,N,1,,BAO_0000218
7704,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL628585,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,A,1,N,1,,BAO_0000218
7705,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL628586,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,A,1,N,1,,BAO_0000218
7706,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL628587,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,A,1,N,1,,BAO_0000218
7707,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL628588,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,A,1,N,1,,BAO_0000218
7708,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL628589,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,A,1,N,1,,BAO_0000218
7709,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL625304,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,A,1,N,1,,BAO_0000218
7710,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL625305,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,A,1,N,1,,BAO_0000218
7711,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL625306,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,A,1,N,1,,BAO_0000218
7712,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL625307,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,A,1,N,1,,BAO_0000218
7713,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL625308,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,A,1,N,1,,BAO_0000218
7714,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627740,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,A,1,N,1,,BAO_0000218
7715,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627741,50597,,,Blood,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,A,1,N,1,,BAO_0000218
7716,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627742,50597,,,Blood,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7717,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627743,50597,,,Blood,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,A,1,N,1,,BAO_0000218
7718,,178.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627744,50597,,,Blood,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,A,1,N,1,,BAO_0000218
7719,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627745,50597,,,Bone,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7720,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627746,50597,,,Bone,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7721,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627747,50597,,,Bone,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7722,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876810,50597,,,Bone,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,A,1,N,1,,BAO_0000218
7723,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627748,50597,,,Bone,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7724,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627749,50597,,,Bone,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7725,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL627750,50597,,,Bone,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7726,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618728,50597,,,Bone,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7727,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618729,50597,,,Bone,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7728,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618730,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,A,1,N,1,,BAO_0000218
7729,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618731,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,A,1,N,1,,BAO_0000218
7730,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618732,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,A,1,N,1,,BAO_0000218
7731,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618733,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,A,1,N,1,,BAO_0000218
7732,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618734,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,A,1,N,1,,BAO_0000218
7733,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618735,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,A,1,N,1,,BAO_0000218
7734,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876602,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,A,1,N,1,,BAO_0000218
7735,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618736,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,A,1,N,1,,BAO_0000218
7736,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618737,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,A,1,N,1,,BAO_0000218
7737,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618738,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,A,1,N,1,,BAO_0000218
7738,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618739,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,A,1,N,1,,BAO_0000218
7739,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618740,50597,,,Bone,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,A,1,N,1,,BAO_0000218
7740,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618741,50597,,,Bone,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7741,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618742,50597,,,Bone,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,A,1,N,1,,BAO_0000218
7742,,10000001.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL618743,50597,,,Bone,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,A,1,N,1,,BAO_0000218
7743,,1969.0,10116.0,Intermediate,Rattus norvegicus,17752,CHEMBL618744,50597,,,Plasma,Half-life from rat plasma at a single oral dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
7744,,,10116.0,Intermediate,Rattus norvegicus,5610,CHEMBL618745,50597,,,,Half-life in male rat,,A,1,N,1,,BAO_0000218
7745,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL620479,50597,,,,Half-life in rat after peroral administration at 10 mg/kg concentration,,A,1,N,1,,BAO_0000218
7746,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL620480,50597,,,,Half-life in rat after peroral administration at 5 mg/kg concentration,,A,1,N,1,,BAO_0000218
7747,,,10116.0,Intermediate,Rattus norvegicus,17771,CHEMBL620481,50597,,,,Half-life in rat at a dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
7748,,,10116.0,Intermediate,Rattus norvegicus,1974,CHEMBL620482,50597,,,,Half-life was evaluated in rats,,A,1,N,1,,BAO_0000218
7749,,,10116.0,Intermediate,Rattus norvegicus,4239,CHEMBL876603,50597,,,,Half-life was measured in rat,,A,1,N,1,,BAO_0000218
7750,,,10116.0,Intermediate,Rattus norvegicus,6681,CHEMBL620483,50597,,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,,A,1,N,1,,BAO_0000218
7751,,,10116.0,Intermediate,Rattus norvegicus,17752,CHEMBL620484,50597,,,,Half-life period in rats after intravenous administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
7752,,,10116.0,Intermediate,Rattus norvegicus,6046,CHEMBL620485,50597,,,,Half-life period in rat at 10 mg/kg,,A,1,N,1,,BAO_0000218
7753,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL620486,50597,,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
7754,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL620487,50597,,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,A,1,N,1,,BAO_0000218
7755,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL620488,50597,,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,A,1,N,1,,BAO_0000218
7756,,,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL620489,50597,,,,Half-life time in rat the dose of 2 mg/kg,,A,1,N,1,,BAO_0000218
7757,,,10116.0,Intermediate,Rattus norvegicus,1088,CHEMBL620490,50597,,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,A,1,N,1,,BAO_0000218
7758,,,10116.0,Intermediate,Rattus norvegicus,5610,CHEMBL620491,50597,,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,A,1,N,1,,BAO_0000218
7759,,1969.0,10116.0,Intermediate,Rattus norvegicus,3032,CHEMBL876604,50597,,,Plasma,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,A,1,N,1,,BAO_0000218
7760,,,10116.0,Intermediate,Rattus norvegicus,5199,CHEMBL620492,50597,,,,Oral half life was determined,,A,1,N,1,,BAO_0000218
7761,,,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL620493,50597,,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,A,1,N,1,,BAO_0000218
7762,,,10116.0,Intermediate,Rattus norvegicus,4408,CHEMBL620494,50597,,,,Pharmacokinetic property (t1/2) in rat,,A,1,N,1,,BAO_0000218
7763,,1969.0,10116.0,Intermediate,Rattus norvegicus,2552,CHEMBL620495,50597,,,Plasma,Plasma elimination half-life was determined,,A,1,N,1,,BAO_0000218
7764,,1969.0,10116.0,Intermediate,Rattus norvegicus,5199,CHEMBL620496,50597,,,Plasma,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,A,1,N,1,,BAO_0000218
7765,,1969.0,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL620497,50597,,,Plasma,Plasma half life was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
7766,,1969.0,10116.0,Intermediate,Rattus norvegicus,1465,CHEMBL620498,50597,,,Plasma,Plasma half-life was determined,,A,1,N,1,,BAO_0000218
7767,,1969.0,10116.0,Intermediate,Rattus norvegicus,1446,CHEMBL620499,50597,,,Plasma,Plasma half-life following oral administration in Fisher rats,,A,1,N,1,,BAO_0000218
7768,,1969.0,10116.0,Intermediate,Rattus norvegicus,6824,CHEMBL620500,50597,,,Plasma,Plasma half-life in rat,,A,1,N,1,,BAO_0000218
7769,,1969.0,10116.0,Intermediate,Rattus norvegicus,17533,CHEMBL873809,50597,,,Plasma,Plasmatic Half-life after intravenous administration to rat,,A,1,N,1,,BAO_0000218
7770,,,10116.0,Intermediate,Rattus norvegicus,5979,CHEMBL620501,50597,,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,A,1,N,1,,BAO_0000218
7771,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL620502,50597,,,,Terminal half life after intravenous administration (1 mg/kg) in rat,,A,1,N,1,,BAO_0000218
7772,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL620503,50597,,,,Terminal half life in Rat at a oral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7773,,,10116.0,Intermediate,Rattus norvegicus,2463,CHEMBL620504,50597,,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,A,1,N,1,,BAO_0000218
7774,,,10116.0,Intermediate,Rattus norvegicus,4883,CHEMBL876605,50597,,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,A,1,N,1,,BAO_0000218
7775,,,10116.0,Intermediate,Rattus norvegicus,4883,CHEMBL620505,50597,,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,A,1,N,1,,BAO_0000218
7776,,1969.0,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL873811,50597,,,Plasma,plasma half life was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
7777,,,10116.0,Expert,Rattus norvegicus,3598,CHEMBL624016,50597,,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
7778,,,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL624017,50597,,,,Half life of compound determined in rat,,A,1,N,1,,BAO_0000218
7779,,,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL624018,50597,,,,Mean residence time determined in rat,,A,1,N,1,,BAO_0000218
7780,,,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL624019,50597,,,,Plasma half life determined in rat,,A,1,N,1,,BAO_0000218
7781,,955.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL624020,50597,,,Brain,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,A,1,N,1,,BAO_0000218
7782,,,10116.0,Intermediate,Rattus norvegicus,4891,CHEMBL624201,50597,,,,Compound was evaluated for pharmacokinetic parameter maximum time period,,A,1,N,1,,BAO_0000218
7783,,,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL872528,50597,,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,A,1,N,1,,BAO_0000218
7784,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL624202,50597,,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
7785,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL624203,50597,,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
7786,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL624350,50597,,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
7787,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL621320,50597,,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
7788,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL621321,50597,,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,A,1,N,1,,BAO_0000218
7789,,,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL621322,50597,,,,Maximum time (Tmax) required to reach Cmax in rats,,A,1,N,1,,BAO_0000218
7790,,,10116.0,Intermediate,Rattus norvegicus,4890,CHEMBL621323,50597,,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
7791,,,10116.0,Intermediate,Rattus norvegicus,6571,CHEMBL621324,50597,,,,Maximum time of clearance of compound in rats after peroral administration,,A,1,N,1,,BAO_0000218
7792,,,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL621325,50597,,,,Maximum time at the dose of 2 mg/kg in rat,,A,1,N,1,,BAO_0000218
7793,,1969.0,10116.0,Intermediate,Rattus norvegicus,17651,CHEMBL875837,50597,,,Plasma,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,A,1,N,1,,BAO_0000218
7794,,1969.0,10116.0,Intermediate,Rattus norvegicus,17651,CHEMBL621326,50597,,,Plasma,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,A,1,N,1,,BAO_0000218
7795,,,10116.0,Intermediate,Rattus norvegicus,14465,CHEMBL621327,50597,,,,Tmax in Guinea pig (PO dose),,A,1,N,1,,BAO_0000218
7796,,,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL621328,50597,,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,A,1,N,1,,BAO_0000218
7797,,,10116.0,Intermediate,Rattus norvegicus,5960,CHEMBL621329,50597,,,,Pharmacokinetic parameter (Tmax) in rat,,A,1,N,1,,BAO_0000218
7798,,,10116.0,Intermediate,Rattus norvegicus,5022,CHEMBL621330,50597,,,,Pharmacokinetic parameter (Tmax) was estimated,,A,1,N,1,,BAO_0000218
7799,,,10116.0,Intermediate,Rattus norvegicus,4408,CHEMBL621331,50597,,,,Pharmacokinetic property (Tmax) in rat,,A,1,N,1,,BAO_0000218
7800,,,10116.0,Intermediate,Rattus norvegicus,5983,CHEMBL621332,50597,,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,A,1,N,1,,BAO_0000218
7801,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL621333,50597,,,,T max in Rat at a oral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
7802,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL621334,50597,,,,T max was determined at 10 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
7803,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL621335,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,A,1,N,1,,BAO_0000218
7804,,,9615.0,Intermediate,Canis lupus familiaris,14180,CHEMBL621336,50588,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,A,1,N,1,,BAO_0000218
7805,,,10116.0,Intermediate,Rattus norvegicus,14180,CHEMBL621337,50597,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,A,1,N,1,,BAO_0000218
7806,,,9615.0,Intermediate,Canis lupus familiaris,14599,CHEMBL621338,50588,,,,Area under curve was measured after i.v. administration into Beagle dog.,,A,1,N,1,,BAO_0000218
7807,,,9615.0,Intermediate,Canis lupus familiaris,14599,CHEMBL875838,50588,,,,Area under curve was measured after iv administration into Beagle dog,,A,1,N,1,,BAO_0000218
7808,,,9615.0,Intermediate,Canis lupus familiaris,14599,CHEMBL621339,50588,,,,Area under curve was measured after po administration into Beagle dog,,A,1,N,1,,BAO_0000218
7809,,,9615.0,Intermediate,Canis lupus familiaris,14599,CHEMBL621340,50588,,,,Area under curve was measured after po administration into Beagle dog.,,A,1,N,1,,BAO_0000218
7810,,,,Autocuration,,15675,CHEMBL621341,22224,,,,Area under curve was measured at peroral dose of 3 mg/kg,,A,1,U,0,,BAO_0000218
7811,,,,Autocuration,,12706,CHEMBL621342,22224,,,,Area under curve was measured by using concentration Vs time,,A,1,U,0,,BAO_0000019
7812,,,,Autocuration,,12706,CHEMBL621343,22224,,,,Area under curve was measured by using concentration Vs time; not tested,,A,1,U,0,,BAO_0000019
7813,,,10090.0,Intermediate,Mus musculus,9750,CHEMBL621344,50594,,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,A,1,N,1,,BAO_0000218
7814,,,10090.0,Intermediate,Mus musculus,9750,CHEMBL621345,50594,,,,Area under curve(AUC) was measured in mice after oral administration.,,A,1,N,1,,BAO_0000218
7815,,,,Autocuration,,14691,CHEMBL621346,22224,,,,Area under curve(AUC) value of the compound,,A,1,U,0,,BAO_0000019
7816,,,,Autocuration,,14691,CHEMBL621347,22224,,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,A,1,U,0,,BAO_0000218
7817,,,9615.0,Intermediate,Canis lupus familiaris,14691,CHEMBL621348,50588,,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,A,1,N,1,,BAO_0000218
7818,,178.0,,Autocuration,,2939,CHEMBL621349,22224,,,Blood,Area under curve(carotid artery) was determined by the availability in blood,,A,1,U,0,,BAO_0000019
7819,,178.0,,Autocuration,,2939,CHEMBL621350,22224,,,Blood,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,A,1,U,0,,BAO_0000019
7820,,178.0,,Autocuration,,2939,CHEMBL875839,22224,,,Blood,Area under curve(carotid artery) was determined by the availability in blood; No data,,A,1,U,0,,BAO_0000019
7821,,178.0,,Autocuration,,2939,CHEMBL620211,22224,,,Blood,Area under curve(portal vein) was determined by the availability in blood,,A,1,U,0,,BAO_0000019
7822,,178.0,,Autocuration,,2939,CHEMBL620212,22224,,,Blood,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,A,1,U,0,,BAO_0000019
7823,,178.0,,Autocuration,,2939,CHEMBL620213,22224,,,Blood,Area under curve(portal vein) was determined by the availability in blood; No data,,A,1,U,0,,BAO_0000019
7824,,1969.0,9544.0,Intermediate,Macaca mulatta,9552,CHEMBL620214,50797,,,Plasma,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,A,1,N,1,,BAO_0000218
7825,,1969.0,9544.0,Intermediate,Macaca mulatta,9552,CHEMBL620215,50797,,,Plasma,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,A,1,N,1,,BAO_0000218
7826,,1969.0,9544.0,Intermediate,Macaca mulatta,9552,CHEMBL620216,50797,,,Plasma,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,A,1,N,1,,BAO_0000218
7827,,1969.0,9615.0,Intermediate,Canis lupus familiaris,9552,CHEMBL620888,50588,,,Plasma,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,A,1,N,1,,BAO_0000218
7828,,1969.0,9615.0,Intermediate,Canis lupus familiaris,9552,CHEMBL620889,50588,,,Plasma,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,A,1,N,1,,BAO_0000218
7829,,1969.0,,Autocuration,,9552,CHEMBL620890,22224,,,Plasma,Area under plasma concentration vs time curve observed in rats for 0-3 h,,A,1,U,0,,BAO_0000019
7830,,1969.0,10116.0,Intermediate,Rattus norvegicus,11911,CHEMBL620891,50597,,,Plasma,Area under plasma time curve determined in male rat,,A,1,N,1,,BAO_0000218
7831,,,,Autocuration,,16618,CHEMBL620892,22224,,,,Area under the MAP curve measured over 5 min.,,A,1,U,0,,BAO_0000019
7832,,,10090.0,Intermediate,Mus musculus,14387,CHEMBL621079,50594,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,A,1,N,1,,BAO_0000218
7833,,,10090.0,Intermediate,Mus musculus,14387,CHEMBL621080,50594,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,A,1,N,1,,BAO_0000218
7834,,,9615.0,Intermediate,Canis lupus familiaris,12836,CHEMBL621081,50588,,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
7835,,,10026.0,Intermediate,Cricetinae,12836,CHEMBL621082,100712,,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
7836,,,10116.0,Intermediate,Rattus norvegicus,12836,CHEMBL621083,50597,,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
7837,,,9615.0,Intermediate,Canis lupus familiaris,14339,CHEMBL621084,50588,,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,A,1,N,1,,BAO_0000218
7838,,,9615.0,Intermediate,Canis lupus familiaris,14339,CHEMBL621085,50588,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,A,1,N,1,,BAO_0000218
7839,,,9615.0,Intermediate,Canis lupus familiaris,14339,CHEMBL621086,50588,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,A,1,N,1,,BAO_0000218
7840,,,9615.0,Intermediate,Canis lupus familiaris,10524,CHEMBL621087,50588,,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,A,1,N,1,,BAO_0000218
7841,,,9615.0,Intermediate,Canis lupus familiaris,9994,CHEMBL622607,50588,,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,A,1,N,1,,BAO_0000218
7842,,,9615.0,Intermediate,Canis lupus familiaris,11325,CHEMBL622608,50588,,,,Serum AUC in marmosets (IV dose),,A,1,N,1,,BAO_0000218
7843,,,,Autocuration,,12536,CHEMBL624481,22224,,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,,A,1,U,0,,BAO_0000019
7844,,,,Autocuration,,12536,CHEMBL624482,22224,,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,,A,1,U,0,,BAO_0000019
7845,,,,Autocuration,,12536,CHEMBL624483,22224,,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,,A,1,U,0,,BAO_0000019
7846,,,,Autocuration,,12536,CHEMBL624484,22224,,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,,A,1,U,0,,BAO_0000019
7847,,,,Autocuration,,12536,CHEMBL624485,22224,,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,,A,1,U,0,,BAO_0000019
7848,,,10116.0,Intermediate,Rattus norvegicus,15556,CHEMBL624486,50597,,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,,A,1,N,1,,BAO_0000218
7849,,,,Autocuration,,2809,CHEMBL624487,22224,,,,Area under the curve for the compound was calculated.,,A,1,U,0,,BAO_0000019
7850,,,,Autocuration,,9511,CHEMBL624488,22224,,,,Area under the curve in concentration/ time,,A,1,U,0,,BAO_0000019
7851,,,10116.0,Intermediate,Rattus norvegicus,12818,CHEMBL624489,50597,,,,Area under the curve administered intraintestinal in rats.,,A,1,N,1,,BAO_0000218
7852,,,10116.0,Intermediate,Rattus norvegicus,12818,CHEMBL625184,50597,,,,Area under the curve administered intravenously in rats.,,A,1,N,1,,BAO_0000218
7853,,,,Autocuration,,15118,CHEMBL625185,22224,,,,Area under the curve during intravenous administration,,A,1,U,0,,BAO_0000019
7854,,,,Autocuration,,15118,CHEMBL875954,22224,,,,Area under the curve during intravenous administration; Not determined,,A,1,U,0,,BAO_0000019
7855,,,,Autocuration,,15118,CHEMBL625186,22224,,,,Area under the curve during systemic administration,,A,1,U,0,,BAO_0000019
7856,,,,Autocuration,,15118,CHEMBL625187,22224,,,,Area under the curve during systemic administration; Not determined,,A,1,U,0,,BAO_0000019
7857,,,,Autocuration,,2632,CHEMBL625188,22224,,,,Area under the curve was calculated for the compound.,,A,1,U,0,,BAO_0000019
7858,,,9615.0,Intermediate,Canis lupus familiaris,14346,CHEMBL625189,50588,,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,A,1,N,1,,BAO_0000218
7859,,,9615.0,Intermediate,Canis lupus familiaris,14346,CHEMBL625190,50588,,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,A,1,N,1,,BAO_0000218
7860,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL621733,50597,,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,A,1,N,1,,BAO_0000218
7861,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL621734,50597,,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,A,1,N,1,,BAO_0000218
7862,,,10116.0,Intermediate,Rattus norvegicus,11149,CHEMBL621735,50597,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,A,1,N,1,,BAO_0000218
7863,,1969.0,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL621736,50597,,,Plasma,Clearance of the drug was measured in the plasma of rat; No data,,A,1,N,1,,BAO_0000218
7864,,1969.0,10116.0,Intermediate,Rattus norvegicus,5247,CHEMBL621737,50597,,,Plasma,The pharmacokinetic parameter plasma clearance in vivo in rats,,A,1,N,1,,BAO_0000218
7865,,,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL621738,50597,,,,Plasma clearance at the dose of 2 mg/kg in rat,,A,1,N,1,,BAO_0000218
7866,,,10116.0,Intermediate,Rattus norvegicus,5654,CHEMBL622806,50597,,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
7867,,,10116.0,Intermediate,Rattus norvegicus,5654,CHEMBL623519,50597,,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
7868,,,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL623520,50597,,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
7869,,,10116.0,Intermediate,Rattus norvegicus,17065,CHEMBL623521,50597,,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,A,1,N,1,,BAO_0000218
7870,,,10116.0,Intermediate,Rattus norvegicus,17671,CHEMBL623522,50597,,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,A,1,N,1,,BAO_0000218
7871,,,10116.0,Intermediate,Rattus norvegicus,6672,CHEMBL623523,50597,,,,Clearance rate in rat,,A,1,N,1,,BAO_0000218
7872,,,10116.0,Intermediate,Rattus norvegicus,6673,CHEMBL623690,50597,,,,Clearance rate in rat,,A,1,N,1,,BAO_0000218
7873,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623691,50597,,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
7874,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623692,50597,,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
7875,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623693,50597,,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
7876,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623694,50597,,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
7877,,,10116.0,Intermediate,Rattus norvegicus,4413,CHEMBL623695,50597,,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,,A,1,N,1,,BAO_0000218
7878,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL623696,50597,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,A,1,N,1,,BAO_0000218
7879,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL623697,50597,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,A,1,N,1,,BAO_0000218
7880,,1969.0,9544.0,Intermediate,Macaca mulatta,5005,CHEMBL623698,22224,,,Plasma,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,A,1,U,0,,BAO_0000218
7881,,1969.0,10116.0,Intermediate,Rattus norvegicus,5005,CHEMBL623699,22224,,,Plasma,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,A,1,U,0,,BAO_0000218
7882,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL623700,50597,,,,Mean (%CV) PK parameters for CL(mL/min/kg).,,A,1,N,1,,BAO_0000218
7883,,,10116.0,Intermediate,Rattus norvegicus,3747,CHEMBL623701,50597,,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,A,1,N,1,,BAO_0000218
7884,,1969.0,10116.0,Intermediate,Rattus norvegicus,16366,CHEMBL623702,50597,,,Plasma,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,A,1,N,1,,BAO_0000218
7885,,,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL623703,50597,,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,A,1,N,1,,BAO_0000218
7886,,,10116.0,Intermediate,Rattus norvegicus,17267,CHEMBL623704,50597,,,,Plasma clearance in rat was determined,,A,1,N,1,,BAO_0000218
7887,,,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL623705,50597,,,,Plasma clearance in rat after administration of 2 mg/kg iv,,A,1,N,1,,BAO_0000218
7888,,,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL623706,50597,,,,Plasma clearance in rat after administration of 2 mg/kg iv,,A,1,N,1,,BAO_0000218
7889,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL623707,50597,,,,Plasma clearance was determined,,A,1,N,1,,BAO_0000218
7890,,,10116.0,Intermediate,Rattus norvegicus,5960,CHEMBL623708,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
7891,,,10116.0,Intermediate,Rattus norvegicus,5937,CHEMBL623709,50597,,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,A,1,N,1,,BAO_0000218
7892,,,10116.0,Intermediate,Rattus norvegicus,5871,CHEMBL623710,50597,,,,Plasma clearance in rat by iv administration,,A,1,N,1,,BAO_0000218
7893,,,10116.0,Intermediate,Rattus norvegicus,5874,CHEMBL623711,50597,,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
7894,,,10116.0,Intermediate,Rattus norvegicus,6504,CHEMBL623712,50597,,,,Plasma clearance in rat p.o.,,A,1,N,1,,BAO_0000218
7895,,,10116.0,Intermediate,Rattus norvegicus,6803,CHEMBL623713,50597,,,,Plasma clearance in rats,,A,1,N,1,,BAO_0000218
7896,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL623714,50597,,,,Plasma clearance was determined; ND denotes no data,,A,1,N,1,,BAO_0000218
7897,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL623715,50597,,,,Plasma clearance was determined; ND denotes not determined,,A,1,N,1,,BAO_0000218
7898,,,10116.0,Intermediate,Rattus norvegicus,1916,CHEMBL623716,50597,,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,A,1,N,1,,BAO_0000218
7899,,,10116.0,Intermediate,Rattus norvegicus,5199,CHEMBL622980,50597,,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,A,1,N,1,,BAO_0000218
7900,,,10116.0,Intermediate,Rattus norvegicus,16367,CHEMBL622981,50597,,,,Plasma administration to rats,,A,1,N,1,,BAO_0000218
7901,,,10116.0,Intermediate,Rattus norvegicus,6362,CHEMBL622982,50597,,,,Plasma clearance of the compound in female Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
7902,,,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL622983,50597,,,,Plasma clearance was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
7903,,,10116.0,Intermediate,Rattus norvegicus,6215,CHEMBL622984,50597,,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,A,1,N,1,,BAO_0000218
7904,,,10116.0,Intermediate,Rattus norvegicus,1466,CHEMBL622985,50597,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,A,1,N,1,,BAO_0000218
7905,,1969.0,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL623631,50597,,,Plasma,plasma clearance was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
7906,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL623632,50597,,,,In vivo CL/F determined,,A,1,N,1,,BAO_0000218
7907,,1969.0,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL623633,50597,,,Plasma,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,A,1,N,1,,BAO_0000218
7908,,1969.0,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL623634,50597,,,Plasma,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,A,1,N,1,,BAO_0000218
7909,,,10116.0,Intermediate,Rattus norvegicus,5213,CHEMBL623635,50597,,,,Compound was tested for the lower blood clearance in rat,,A,1,N,1,,BAO_0000218
7910,,,10116.0,Intermediate,Rattus norvegicus,4687,CHEMBL621195,50597,,,,Evaluated for the low clearance in rat (in vivo),,A,1,N,1,,BAO_0000218
7911,,,10116.0,Intermediate,Rattus norvegicus,3371,CHEMBL621196,50597,,,,Pharmacokinetic property (CLb)of the compound was determined in rat,,A,1,N,1,,BAO_0000218
7912,,,10116.0,Intermediate,Rattus norvegicus,4690,CHEMBL875287,50597,,,,Rapid clearance after intravenous administration in rat was determined,,A,1,N,1,,BAO_0000218
7913,,,10116.0,Intermediate,Rattus norvegicus,5702,CHEMBL621197,50597,,,,Clearance measured in rat,,A,1,N,1,,BAO_0000218
7914,,1969.0,10116.0,Intermediate,Rattus norvegicus,740,CHEMBL621198,50597,,,Plasma,Compound was evaluated for plasma clearance in rat,,A,1,N,1,,BAO_0000218
7915,,1969.0,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL621199,50597,,,Plasma,Low plasma clearance was calculated in rat,,A,1,N,1,,BAO_0000218
7916,,,10116.0,Intermediate,Rattus norvegicus,5789,CHEMBL621200,50597,,,,Pharmacokinetic property (Clp) in rat,,A,1,N,1,,BAO_0000218
7917,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL621201,50597,,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
7918,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL621202,50597,,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
7919,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL621203,50597,,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,A,1,N,1,,BAO_0000218
7920,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL621204,50597,,,,Plasma clearance after IV dosing at 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
7921,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621205,50597,,,Heart,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7922,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621206,50597,,,Heart,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7923,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621207,50597,,,Heart,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7924,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621208,50597,,,Heart,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7925,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621209,50597,,,Heart,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,A,1,N,1,,BAO_0000218
7926,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876484,50597,,,Heart,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7927,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621210,50597,,,Heart,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7928,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621211,50597,,,Heart,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7929,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621212,50597,,,Heart,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7930,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621213,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,A,1,N,1,,BAO_0000218
7931,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621214,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,A,1,N,1,,BAO_0000218
7932,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621215,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,A,1,N,1,,BAO_0000218
7933,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621216,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,A,1,N,1,,BAO_0000218
7934,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621217,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,A,1,N,1,,BAO_0000218
7935,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621218,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,A,1,N,1,,BAO_0000218
7936,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621219,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,A,1,N,1,,BAO_0000218
7937,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621220,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,A,1,N,1,,BAO_0000218
7938,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621221,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,A,1,N,1,,BAO_0000218
7939,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621222,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,A,1,N,1,,BAO_0000218
7940,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621223,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,A,1,N,1,,BAO_0000218
7941,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876485,50597,,,Heart,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,A,1,N,1,,BAO_0000218
7942,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621224,50597,,,Heart,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7943,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621225,50597,,,Heart,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,A,1,N,1,,BAO_0000218
7944,,948.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621226,50597,,,Heart,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,A,1,N,1,,BAO_0000218
7945,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621227,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7946,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621228,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7947,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621229,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7948,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621230,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,A,1,N,1,,BAO_0000218
7949,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621231,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,A,1,N,1,,BAO_0000218
7950,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621232,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7951,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621233,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7952,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621234,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7953,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621235,50597,,,Kidney,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,A,1,N,1,,BAO_0000218
7954,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621236,50597,,,Kidney,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7955,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621237,50597,,,Kidney,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,A,1,N,1,,BAO_0000218
7956,,2113.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876486,50597,,,Kidney,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,A,1,N,1,,BAO_0000218
7957,,160.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622436,50597,,,Intestine,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,A,1,N,1,,BAO_0000218
7958,,160.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622437,50597,,,Intestine,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,A,1,N,1,,BAO_0000218
7959,,160.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622438,50597,,,Intestine,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,A,1,N,1,,BAO_0000218
7960,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622439,50597,,,Liver,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,A,1,N,1,,BAO_0000218
7961,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622440,50597,,,Liver,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,A,1,N,1,,BAO_0000218
7962,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622441,50597,,,Liver,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,A,1,N,1,,BAO_0000218
7963,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622442,50597,,,Liver,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7964,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622443,50597,,,Liver,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7965,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622444,50597,,,Liver,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7966,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622445,50597,,,Liver,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7967,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622446,50597,,,Liver,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,A,1,N,1,,BAO_0000218
7968,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622447,50597,,,Liver,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
7969,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622448,50597,,,Liver,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
7970,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622449,50597,,,Liver,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,A,1,N,1,,BAO_0000218
7971,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622450,50597,,,Liver,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,A,1,N,1,,BAO_0000218
7972,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622451,50597,,,Liver,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,A,1,N,1,,BAO_0000218
7973,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622452,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,A,1,N,1,,BAO_0000218
7974,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622453,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,A,1,N,1,,BAO_0000218
7975,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622454,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,A,1,N,1,,BAO_0000218
7976,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL622455,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,A,1,N,1,,BAO_0000218
7977,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876024,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,A,1,N,1,,BAO_0000218
7978,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL622456,50597,,,,T max was determined at 3 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
7979,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL622457,50597,,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
7980,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL622458,50597,,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
7981,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL622459,50597,,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,A,1,N,1,,BAO_0000218
7982,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL873343,50597,,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,A,1,N,1,,BAO_0000218
7983,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL622460,50597,,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,A,1,N,1,,BAO_0000218
7984,,1969.0,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL622461,50597,,,Plasma,Time for maximum plasma concentration determined in rat,,A,1,N,1,,BAO_0000218
7985,,1969.0,10116.0,Intermediate,Rattus norvegicus,6681,CHEMBL622462,50597,,,Plasma,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,A,1,N,1,,BAO_0000218
7986,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL622463,50597,,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
7987,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL622464,50597,,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
7988,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL622465,50597,,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
7989,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL622466,50597,,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
7990,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL622467,50597,,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
7991,,1969.0,10116.0,Intermediate,Rattus norvegicus,6824,CHEMBL622468,50597,,,Plasma,Time of maximum plasma concentration in rat,,A,1,N,1,,BAO_0000218
7992,,1969.0,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL876025,50597,,,Plasma,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
7993,,1969.0,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622469,50597,,,Plasma,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,A,1,N,1,,BAO_0000218
7994,,1969.0,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622470,50597,,,Plasma,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,A,1,N,1,,BAO_0000218
7995,,,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL622471,50597,,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,,A,1,N,1,,BAO_0000218
7996,,1969.0,10116.0,Intermediate,Rattus norvegicus,1742,CHEMBL622472,50597,,,Plasma,Time required to reach maximum concentration in rat plasma,,A,1,N,1,,BAO_0000218
7997,,1969.0,10116.0,Intermediate,Rattus norvegicus,2774,CHEMBL622473,50597,,,Plasma,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,A,1,N,1,,BAO_0000218
7998,,1969.0,10116.0,Intermediate,Rattus norvegicus,5199,CHEMBL624282,50597,,,Plasma,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
7999,,1969.0,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL624283,50597,,,Plasma,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
8000,,1969.0,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL624284,50597,,,Plasma,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
8001,,1969.0,10116.0,Intermediate,Rattus norvegicus,1916,CHEMBL624285,50597,,,Plasma,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,A,1,N,1,,BAO_0000218
8002,,,10116.0,Intermediate,Rattus norvegicus,16367,CHEMBL624286,50597,,,,Time to reach Cmax after oral administration to rats,,A,1,N,1,,BAO_0000218
8003,,,10116.0,Intermediate,Rattus norvegicus,16366,CHEMBL624287,50597,,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,A,1,N,1,,BAO_0000218
8004,,,10116.0,Intermediate,Rattus norvegicus,216,CHEMBL624288,50597,,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,A,1,N,1,,BAO_0000218
8005,,1969.0,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL624289,50597,,,Plasma,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,A,1,N,1,,BAO_0000218
8006,,1969.0,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL873344,50597,,,Plasma,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
8007,,,10116.0,Intermediate,Rattus norvegicus,6215,CHEMBL619623,50597,,,,Tmax after peroral administration (10 mg/kg) was determined in rat,,A,1,N,1,,BAO_0000218
8008,,,10116.0,Expert,Rattus norvegicus,3598,CHEMBL621399,50597,,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
8009,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL621400,50597,,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
8010,,,10116.0,Intermediate,Rattus norvegicus,17670,CHEMBL621401,50597,,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,A,1,N,1,,BAO_0000218
8011,,,10116.0,Intermediate,Rattus norvegicus,1465,CHEMBL621402,50597,,,,Tmax was determined,,A,1,N,1,,BAO_0000218
8012,,,10116.0,Intermediate,Rattus norvegicus,2552,CHEMBL621403,50597,,,,Tmax was determined,,A,1,N,1,,BAO_0000218
8013,,,10116.0,Intermediate,Rattus norvegicus,5656,CHEMBL621121,50597,,,,Tmax after oral administration in rat,,A,1,N,1,,BAO_0000218
8014,,,10116.0,Intermediate,Rattus norvegicus,17764,CHEMBL872525,50597,,,,Tmax after peroral administration in rats at 2.4 uM/kg,,A,1,N,1,,BAO_0000218
8015,,,10116.0,Intermediate,Rattus norvegicus,5610,CHEMBL621122,50597,,,,Tmax in male rat,,A,1,N,1,,BAO_0000218
8016,,,10116.0,Intermediate,Rattus norvegicus,6046,CHEMBL621123,50597,,,,Tmax in rat at 10 mg/kg,,A,1,N,1,,BAO_0000218
8017,,,10116.0,Intermediate,Rattus norvegicus,5874,CHEMBL621124,50597,,,,Tmax in rat by po administration at a dose of 40 mg/kg,,A,1,N,1,,BAO_0000218
8018,,,10116.0,Intermediate,Rattus norvegicus,17596,CHEMBL621125,50597,,,,Tmax in rats,,A,1,N,1,,BAO_0000218
8019,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL621126,50597,,,,Tmax was measured in rats after peroral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
8020,,,10116.0,Intermediate,Rattus norvegicus,1908,CHEMBL621127,50597,,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,A,1,N,1,,BAO_0000218
8021,,,10116.0,Intermediate,Rattus norvegicus,2959,CHEMBL621128,50597,,,,Tmax value after administration of 20 mg/Kg oral dose in rat,,A,1,N,1,,BAO_0000218
8022,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL618263,50597,,,,Tmax value at a dose of 10 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
8023,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL618264,50597,,,,Tmax value at a dose of 100 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
8024,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL618265,50597,,,,Tmax value at a dose of 50 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
8025,,1969.0,10116.0,Intermediate,Rattus norvegicus,4186,CHEMBL618266,50597,,,Plasma,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,A,1,N,1,,BAO_0000218
8026,,,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL618267,50597,,,,time required to reach maximum concentration (Cmax) after oral administration in rat,,A,1,N,1,,BAO_0000218
8027,,1088.0,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL618450,50597,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,A,1,N,1,,BAO_0000218
8028,,1088.0,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL618451,50597,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,A,1,N,1,,BAO_0000218
8029,,,10116.0,Intermediate,Rattus norvegicus,5546,CHEMBL618452,50597,,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,A,1,N,1,,BAO_0000218
8030,,1088.0,10116.0,Intermediate,Rattus norvegicus,3173,CHEMBL618453,50597,,,Urine,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,A,1,N,1,,BAO_0000218
8031,,1088.0,10116.0,Intermediate,Rattus norvegicus,3173,CHEMBL618454,50597,,,Urine,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,A,1,N,1,,BAO_0000218
8032,,1088.0,10116.0,Intermediate,Rattus norvegicus,3173,CHEMBL618455,50597,,,Urine,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,A,1,N,1,,BAO_0000218
8033,,,10116.0,Intermediate,Rattus norvegicus,4257,CHEMBL618456,50597,,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,A,1,N,1,,BAO_0000218
8034,,,10116.0,Intermediate,Rattus norvegicus,6011,CHEMBL618457,50597,,,,Compound distribution in rat tissues was determined,,A,1,N,1,,BAO_0000218
8035,,,10116.0,Intermediate,Rattus norvegicus,5472,CHEMBL618458,50597,,,,Volume of distribution was evaluated in rat,,A,1,N,1,,BAO_0000218
8036,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL618459,50597,,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,A,1,N,1,,BAO_0000218
8037,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL876733,50597,,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,A,1,N,1,,BAO_0000218
8038,,,9615.0,Intermediate,Canis lupus familiaris,14346,CHEMBL618460,50588,,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,A,1,N,1,,BAO_0000218
8039,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL618461,50597,,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,A,1,N,1,,BAO_0000218
8040,,,,Autocuration,,15469,CHEMBL618462,22224,,,,Area under the curve was determined after oral administration (300 uM/Kg),,A,1,U,0,,BAO_0000019
8041,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL618463,50597,,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,A,1,N,1,,BAO_0000218
8042,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL618464,50597,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,A,1,N,1,,BAO_0000218
8043,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL618465,50597,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,A,1,N,1,,BAO_0000218
8044,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL618466,50597,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,A,1,N,1,,BAO_0000218
8045,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL618467,50597,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,A,1,N,1,,BAO_0000218
8046,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL618468,50597,,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,A,1,N,1,,BAO_0000218
8047,,1969.0,9615.0,Intermediate,Canis lupus familiaris,12935,CHEMBL618469,50588,,,Plasma,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,A,1,N,1,,BAO_0000218
8048,,1969.0,9615.0,Intermediate,Canis lupus familiaris,12935,CHEMBL618470,50588,,,Plasma,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,A,1,N,1,,BAO_0000218
8049,,,,Autocuration,,14813,CHEMBL618471,22224,,,,Plasma drug AUC in rat (PO dose),,A,1,U,0,,BAO_0000218
8050,,,10090.0,Intermediate,Mus musculus,15792,CHEMBL618472,50594,,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,A,1,N,1,,BAO_0000218
8051,,,,Autocuration,,3579,CHEMBL618473,22224,,,,Area under was determined at a dose of 30 mg/kg,,A,1,U,0,,BAO_0000218
8052,,,9669.0,Intermediate,Mustela putorius furo,12487,CHEMBL621699,50506,,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,A,1,N,1,,BAO_0000218
8053,,,10116.0,Intermediate,Rattus norvegicus,12487,CHEMBL621700,50597,,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,A,1,N,1,,BAO_0000218
8054,,,10116.0,Intermediate,Rattus norvegicus,12487,CHEMBL621701,50597,,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,A,1,N,1,,BAO_0000218
8055,,,9669.0,Intermediate,Mustela putorius furo,12487,CHEMBL621702,50506,,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,A,1,N,1,,BAO_0000218
8056,,,9615.0,Intermediate,Canis lupus familiaris,12487,CHEMBL621703,50588,,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,A,1,N,1,,BAO_0000218
8057,,,9615.0,Intermediate,Canis lupus familiaris,12487,CHEMBL621704,50588,,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,A,1,N,1,,BAO_0000218
8058,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL624259,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,A,1,N,1,,BAO_0000218
8059,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL624260,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,A,1,N,1,,BAO_0000218
8060,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL624430,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,A,1,N,1,,BAO_0000218
8061,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL624431,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,A,1,N,1,,BAO_0000218
8062,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL624432,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,A,1,N,1,,BAO_0000218
8063,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL624433,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,A,1,N,1,,BAO_0000218
8064,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL624434,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,A,1,N,1,,BAO_0000218
8065,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL624435,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,A,1,N,1,,BAO_0000218
8066,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL618570,50594,,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,A,1,N,1,,BAO_0000218
8067,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL618571,50594,,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,A,1,N,1,,BAO_0000218
8068,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL618572,50594,,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,A,1,N,1,,BAO_0000218
8069,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL618573,50594,,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,A,1,N,1,,BAO_0000218
8070,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL619267,50594,,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,A,1,N,1,,BAO_0000218
8071,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL619431,50594,,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,A,1,N,1,,BAO_0000218
8072,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL619432,50594,,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,A,1,N,1,,BAO_0000218
8073,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL619433,50594,,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,A,1,N,1,,BAO_0000218
8074,,1969.0,,Autocuration,,13298,CHEMBL619434,22224,,,Plasma,AUC in mice after oral dose (50 mg/kg),,A,1,U,0,,BAO_0000218
8075,,1977.0,10090.0,Intermediate,Mus musculus,12226,CHEMBL619435,50594,,,Serum,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,A,1,N,1,,BAO_0000218
8076,,1969.0,,Autocuration,,12634,CHEMBL619436,22224,,,Plasma,AUC (0-4 hr) ug/ml/h,,A,1,U,0,,BAO_0000019
8077,,,10116.0,Intermediate,Rattus norvegicus,14810,CHEMBL619437,50597,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,A,1,N,1,,BAO_0000218
8078,,,,Autocuration,,13889,CHEMBL619438,22224,,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,A,1,U,0,,BAO_0000218
8079,,,10090.0,Intermediate,Mus musculus,10018,CHEMBL619439,50594,,,,Compound was evaluated for Area under curve in mice,,A,1,N,1,,BAO_0000218
8080,,,10116.0,Intermediate,Rattus norvegicus,8758,CHEMBL619440,50597,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,A,1,N,1,,BAO_0000218
8081,,,,Autocuration,,8758,CHEMBL619441,22224,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,F,1,U,0,,BAO_0000218
8082,,,10116.0,Intermediate,Rattus norvegicus,8758,CHEMBL619442,50597,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,A,1,N,1,,BAO_0000218
8083,,,,Autocuration,,2249,CHEMBL875156,22224,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,A,1,U,0,,BAO_0000019
8084,,,,Autocuration,,2249,CHEMBL619443,22224,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,A,1,U,0,,BAO_0000019
8085,,,,Autocuration,,2249,CHEMBL619444,22224,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,A,1,U,0,,BAO_0000019
8086,,,,Autocuration,,2249,CHEMBL623464,22224,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,A,1,U,0,,BAO_0000019
8087,,,10090.0,Intermediate,Mus musculus,15115,CHEMBL623465,50594,,,,Compound was evaluated for area under curve when administered through oral route in mouse,,A,1,N,1,,BAO_0000218
8088,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL623466,50597,,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,A,1,N,1,,BAO_0000218
8089,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL623467,50597,,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,A,1,N,1,,BAO_0000218
8090,,,10116.0,Intermediate,Rattus norvegicus,6249,CHEMBL623468,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
8091,,,10116.0,Intermediate,Rattus norvegicus,2463,CHEMBL622660,50597,,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,A,1,N,1,,BAO_0000218
8092,,,10116.0,Intermediate,Rattus norvegicus,4969,CHEMBL622661,50597,,,,Plasma clearance rate in Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8093,,,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL622662,50597,,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,F,1,N,1,,BAO_0000218
8094,,,10116.0,Intermediate,Rattus norvegicus,3457,CHEMBL622663,50597,,,,Pharmacokinetic property (total body clearance) in rat,,A,1,N,1,,BAO_0000218
8095,,,10116.0,Intermediate,Rattus norvegicus,5983,CHEMBL622664,50597,,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,A,1,N,1,,BAO_0000218
8096,,,10116.0,Intermediate,Rattus norvegicus,6295,CHEMBL622665,50597,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
8097,,,10116.0,Intermediate,Rattus norvegicus,6296,CHEMBL622666,50597,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
8098,,,10116.0,Intermediate,Rattus norvegicus,17686,CHEMBL621615,50597,,,,Cl in rat i.v. at 2 mg/kg concentration,,A,1,N,1,,BAO_0000218
8099,,,10116.0,Intermediate,Rattus norvegicus,17764,CHEMBL621616,50597,,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,,A,1,N,1,,BAO_0000218
8100,,,10116.0,Intermediate,Rattus norvegicus,5503,CHEMBL621617,50597,,,,Clearance was determined,,A,1,N,1,,BAO_0000218
8101,,,10116.0,Intermediate,Rattus norvegicus,4368,CHEMBL621618,50597,,,,Clearance by intravenous administration of 3.4 mg/kg in rat,,A,1,N,1,,BAO_0000218
8102,,,10116.0,Intermediate,Rattus norvegicus,6005,CHEMBL621619,50597,,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
8103,,,10116.0,Intermediate,Rattus norvegicus,5031,CHEMBL621620,50597,,,,Clearance rate after i.v. administration in rats,,A,1,N,1,,BAO_0000218
8104,,,10116.0,Intermediate,Rattus norvegicus,4890,CHEMBL621786,50597,,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8105,,,10116.0,Intermediate,Rattus norvegicus,5182,CHEMBL621787,50597,,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,A,1,N,1,,BAO_0000218
8106,,,10116.0,Intermediate,Rattus norvegicus,5979,CHEMBL621788,50597,,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,A,1,N,1,,BAO_0000218
8107,,,10116.0,Intermediate,Rattus norvegicus,5656,CHEMBL621789,50597,,,,Clearance (Cl) after oral administration in rat,,A,1,N,1,,BAO_0000218
8108,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL621790,50597,,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,A,1,N,1,,BAO_0000218
8109,,1969.0,10116.0,Intermediate,Rattus norvegicus,4839,CHEMBL621791,50597,,,Plasma,Compound was tested for plasma clearance in rat,,A,1,N,1,,BAO_0000218
8110,Microsomes,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL621792,50597,,,,In vitro microsome metabolism clearance in rat was determined,,A,1,N,1,,BAO_0000218
8111,Microsomes,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL621793,50597,,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,A,1,N,1,,BAO_0000218
8112,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL621794,50597,,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8113,,1969.0,10116.0,Intermediate,Rattus norvegicus,5496,CHEMBL621795,50597,,,Plasma,In vivo plasma clearance was determined,,A,1,N,1,,BAO_0000218
8114,,,10116.0,Intermediate,Rattus norvegicus,5739,CHEMBL621796,50597,,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,A,1,N,1,,BAO_0000218
8115,,2107.0,10116.0,Intermediate,Rattus norvegicus,5676,CHEMBL621797,50597,,401.0,Liver,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,A,1,N,1,,BAO_0000218
8116,,,10116.0,Intermediate,Rattus norvegicus,4239,CHEMBL621798,50597,,,,Pharmacokinetic property (Plasma clearance) was measured in rat,,A,1,N,1,,BAO_0000218
8117,,,10116.0,Intermediate,Rattus norvegicus,5676,CHEMBL621799,50597,,,,Pharmacokinetic property (clearance) in rat i.v.,,A,1,N,1,,BAO_0000218
8118,,,10116.0,Intermediate,Rattus norvegicus,1918,CHEMBL621800,50597,,,,"Plasma Clearance was evaluated in rats, iv",,A,1,N,1,,BAO_0000218
8119,,,10116.0,Intermediate,Rattus norvegicus,17800,CHEMBL621801,50597,,,,Plasma clearance (in vivo) in rats was determined,,A,1,N,1,,BAO_0000218
8120,,,10116.0,Intermediate,Rattus norvegicus,6056,CHEMBL621802,50597,,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,A,1,N,1,,BAO_0000218
8121,,,10116.0,Intermediate,Rattus norvegicus,5496,CHEMBL618596,50597,,,,Plasma clearance was determined,,A,1,N,1,,BAO_0000218
8122,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL618597,50597,,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,A,1,N,1,,BAO_0000218
8123,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL618598,50597,,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,A,1,N,1,,BAO_0000218
8124,,,10116.0,Intermediate,Rattus norvegicus,17752,CHEMBL618599,50597,,,,Plasma clearance in rats,,A,1,N,1,,BAO_0000218
8125,,,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL618600,50597,,,,Plasma clearance rate determined in rat,,A,1,N,1,,BAO_0000218
8126,,,10116.0,Intermediate,Rattus norvegicus,6011,CHEMBL618601,50597,,,,Plasma clearance was determined in rat,,A,1,N,1,,BAO_0000218
8127,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL618602,50597,,,,Plasma clearance was determined,,A,1,N,1,,BAO_0000218
8128,,,10116.0,Intermediate,Rattus norvegicus,5948,CHEMBL618603,50597,,,,Plasma clearance value in rat,,A,1,N,1,,BAO_0000218
8129,,2107.0,10116.0,Intermediate,Rattus norvegicus,6125,CHEMBL618604,50597,,,Liver,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,A,1,N,1,,BAO_0000218
8130,,,10116.0,Intermediate,Rattus norvegicus,4839,CHEMBL618605,50597,,,,Clearance in rat,,A,1,N,1,,BAO_0000218
8131,,,10116.0,Intermediate,Rattus norvegicus,17686,CHEMBL618606,50597,,,,Total body clearance in rat i.v. at 2 mg/kg concentration,,A,1,N,1,,BAO_0000218
8132,,,10116.0,Intermediate,Rattus norvegicus,6571,CHEMBL618607,50597,,,,Clearance of compound in rats after intravenous administration,,A,1,N,1,,BAO_0000218
8133,,,10116.0,Intermediate,Rattus norvegicus,3364,CHEMBL618608,50597,,,,Clearance after iv administration to rats,,A,1,N,1,,BAO_0000218
8134,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618609,50597,,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,A,1,N,1,,BAO_0000218
8135,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618610,50597,,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,A,1,N,1,,BAO_0000218
8136,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618611,50597,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,A,1,N,1,,BAO_0000218
8137,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618612,50597,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,A,1,N,1,,BAO_0000218
8138,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618613,50597,,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,A,1,N,1,,BAO_0000218
8139,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL621076,50597,,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,A,1,N,1,,BAO_0000218
8140,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL621077,50597,,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,A,1,N,1,,BAO_0000218
8141,,,10116.0,Intermediate,Rattus norvegicus,17670,CHEMBL621078,50597,,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,A,1,N,1,,BAO_0000218
8142,,,10116.0,Intermediate,Rattus norvegicus,5970,CHEMBL621251,50597,,,,Clearance in rat,,A,1,N,1,,BAO_0000218
8143,,,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL621252,50597,,,,Clearance in rat after oral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
8144,,,10116.0,Intermediate,Rattus norvegicus,4590,CHEMBL621253,50597,,,,Clearance in rat.,,A,1,N,1,,BAO_0000218
8145,,,10116.0,Intermediate,Rattus norvegicus,6193,CHEMBL621254,50597,,,,Clearance rate following an oral dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
8146,,,10116.0,Intermediate,Rattus norvegicus,2832,CHEMBL621255,50597,,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,A,1,N,1,,BAO_0000218
8147,,1969.0,10116.0,Intermediate,Rattus norvegicus,1052,CHEMBL621256,50597,,,Plasma,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,A,1,N,1,,BAO_0000218
8148,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621257,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,A,1,N,1,,BAO_0000218
8149,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621258,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,A,1,N,1,,BAO_0000218
8150,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621259,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,A,1,N,1,,BAO_0000218
8151,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621260,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,A,1,N,1,,BAO_0000218
8152,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876494,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,A,1,N,1,,BAO_0000218
8153,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621261,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,A,1,N,1,,BAO_0000218
8154,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621262,50597,,,Liver,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,A,1,N,1,,BAO_0000218
8155,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621263,50597,,,Liver,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,A,1,N,1,,BAO_0000218
8156,,2107.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621264,50597,,,Liver,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,A,1,N,1,,BAO_0000218
8157,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621265,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
8158,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621266,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,A,1,N,1,,BAO_0000218
8159,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621267,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
8160,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621268,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
8161,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621269,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,A,1,N,1,,BAO_0000218
8162,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621270,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,A,1,N,1,,BAO_0000218
8163,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621271,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,A,1,N,1,,BAO_0000218
8164,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621272,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,A,1,N,1,,BAO_0000218
8165,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621273,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,A,1,N,1,,BAO_0000218
8166,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621274,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,A,1,N,1,,BAO_0000218
8167,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876495,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,A,1,N,1,,BAO_0000218
8168,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621275,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,A,1,N,1,,BAO_0000218
8169,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621276,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,A,1,N,1,,BAO_0000218
8170,,2385.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621277,50597,,,Muscle tissue,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,A,1,N,1,,BAO_0000218
8171,,160.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621278,50597,,,Intestine,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,A,1,N,1,,BAO_0000218
8172,,160.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621279,50597,,,Intestine,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,A,1,N,1,,BAO_0000218
8173,,160.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621280,50597,,,Intestine,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,A,1,N,1,,BAO_0000218
8174,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621281,50597,,,Spleen,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
8175,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621282,50597,,,Spleen,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,A,1,N,1,,BAO_0000218
8176,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621283,50597,,,Spleen,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,A,1,N,1,,BAO_0000218
8177,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621284,50597,,,Spleen,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,A,1,N,1,,BAO_0000218
8178,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621285,50597,,,Spleen,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,A,1,N,1,,BAO_0000218
8179,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621286,50597,,,Spleen,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,A,1,N,1,,BAO_0000218
8180,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL623220,50597,,,Spleen,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,A,1,N,1,,BAO_0000218
8181,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL623221,50597,,,Spleen,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,A,1,N,1,,BAO_0000218
8182,,2106.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL876029,50597,,,Spleen,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,A,1,N,1,,BAO_0000218
8183,,945.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL623222,50597,,,Stomach,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,A,1,N,1,,BAO_0000218
8184,,945.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL623223,50597,,,Stomach,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,A,1,N,1,,BAO_0000218
8185,,945.0,10116.0,Intermediate,Rattus norvegicus,9866,CHEMBL621445,50597,,,Stomach,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,A,1,N,1,,BAO_0000218
8186,,178.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621446,50597,,,Blood,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8187,,178.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621447,50597,,,Blood,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8188,,178.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619681,50597,,,Blood,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8189,,178.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619682,50597,,,Blood,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8190,,178.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619683,50597,,,Blood,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8191,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619684,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8192,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619685,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8193,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619686,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8194,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619687,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8195,,955.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619688,50597,,,Brain,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8196,,948.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619689,50597,,,Heart,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8197,,948.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619690,50597,,,Heart,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8198,,948.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619691,50597,,,Heart,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8199,,,10116.0,Intermediate,Rattus norvegicus,6062,CHEMBL619692,50597,,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
8200,,,10116.0,Expert,Rattus norvegicus,3598,CHEMBL619693,50597,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
8201,,,10116.0,Intermediate,Rattus norvegicus,1908,CHEMBL619694,50597,,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,,A,1,N,1,,BAO_0000218
8202,,,10116.0,Intermediate,Rattus norvegicus,17596,CHEMBL619695,50597,,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,A,1,N,1,,BAO_0000218
8203,,,10116.0,Intermediate,Rattus norvegicus,4891,CHEMBL619696,50597,,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,,A,1,N,1,,BAO_0000218
8204,,,10116.0,Intermediate,Rattus norvegicus,740,CHEMBL619697,50597,,,,Compound was evaluated for volume of distribution in rat,,A,1,N,1,,BAO_0000218
8205,,,10116.0,Intermediate,Rattus norvegicus,16366,CHEMBL619698,50597,,,,Steady state volume distribution was determined; steady state(ss),,A,1,N,1,,BAO_0000218
8206,,,10116.0,Intermediate,Rattus norvegicus,3364,CHEMBL619699,50597,,,,Steady state volume of distribution after iv administration to rats,,A,1,N,1,,BAO_0000218
8207,,,10116.0,Intermediate,Rattus norvegicus,2552,CHEMBL619700,50597,,,,Steady state volume of distribution dosing at 3 mg/kg iv,,A,1,N,1,,BAO_0000218
8208,,,10116.0,Intermediate,Rattus norvegicus,406,CHEMBL619701,50597,,,,The compound was evaluated for volume of distribution in rat,,A,1,N,1,,BAO_0000218
8209,,,10116.0,Intermediate,Rattus norvegicus,12500,CHEMBL619702,50597,,,,The compound was tested for volume of distribution in rat,,A,1,N,1,,BAO_0000218
8210,,,10116.0,Intermediate,Rattus norvegicus,12500,CHEMBL620335,50597,,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,A,1,N,1,,BAO_0000218
8211,,,10116.0,Intermediate,Rattus norvegicus,5656,CHEMBL620336,50597,,,,Volume distribution (VD) after oral administration in rat,,A,1,N,1,,BAO_0000218
8212,,,10116.0,Intermediate,Rattus norvegicus,17671,CHEMBL620337,50597,,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,A,1,N,1,,BAO_0000218
8213,,,10116.0,Intermediate,Rattus norvegicus,1094,CHEMBL620520,50597,,,,Volume distribution in rat,,A,1,N,1,,BAO_0000218
8214,,,10116.0,Intermediate,Rattus norvegicus,5833,CHEMBL620521,50597,,,,Volume distribution in rat,,A,1,N,1,,BAO_0000218
8215,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL875825,50597,,,,Volume distribution in rat after peroral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
8216,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL620522,50597,,,,Volume distribution in rat after peroral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
8217,,,10116.0,Intermediate,Rattus norvegicus,6005,CHEMBL620523,50597,,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
8218,,,10116.0,Intermediate,Rattus norvegicus,1696,CHEMBL620524,50597,,,,Volume of distribution in rat.,,A,1,N,1,,BAO_0000218
8219,,,10116.0,Intermediate,Rattus norvegicus,6672,CHEMBL620525,50597,,,,Volume of distribution in rat,,A,1,N,1,,BAO_0000218
8220,,,10116.0,Intermediate,Rattus norvegicus,6673,CHEMBL620526,50597,,,,Volume of distribution in rat,,A,1,N,1,,BAO_0000218
8221,,,10116.0,Intermediate,Rattus norvegicus,5871,CHEMBL620527,50597,,,,Volume of distribution in rat by iv administration,,A,1,N,1,,BAO_0000218
8222,,,10116.0,Intermediate,Rattus norvegicus,6803,CHEMBL620528,50597,,,,Volume of distribution in rats,,A,1,N,1,,BAO_0000218
8223,,,10116.0,Intermediate,Rattus norvegicus,5199,CHEMBL620529,50597,,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,A,1,N,1,,BAO_0000218
8224,,,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL620530,50597,,,,Volume distribution at the dose of 2 mg/kg in rat,,A,1,N,1,,BAO_0000218
8225,,,10116.0,Intermediate,Rattus norvegicus,16367,CHEMBL620531,50597,,,,Steady state volume of distribution was determined,,A,1,N,1,,BAO_0000218
8226,,,9544.0,Intermediate,Macaca mulatta,5005,CHEMBL620532,22224,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,A,1,U,0,,BAO_0000218
8227,,,10116.0,Intermediate,Rattus norvegicus,5005,CHEMBL620533,22224,,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,A,1,U,0,,BAO_0000218
8228,,,10116.0,Intermediate,Rattus norvegicus,5005,CHEMBL620534,22224,,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,A,1,U,0,,BAO_0000218
8229,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL620535,50597,,,,Mean (%CV) PK parameters for Vdss(mL/kg).,,A,1,N,1,,BAO_0000218
8230,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL875826,50597,,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,A,1,N,1,,BAO_0000218
8231,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL620536,50597,,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,A,1,N,1,,BAO_0000218
8232,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL620537,50597,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8233,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL618526,50597,,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,A,1,N,1,,BAO_0000218
8234,,,10116.0,Intermediate,Rattus norvegicus,5739,CHEMBL618527,50597,,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,A,1,N,1,,BAO_0000218
8235,,,10116.0,Intermediate,Rattus norvegicus,5789,CHEMBL618528,50597,,,,Pharmacokinetic property (Vdss) in rat,,A,1,N,1,,BAO_0000218
8236,,,10116.0,Intermediate,Rattus norvegicus,4239,CHEMBL618529,50597,,,,Pharmacokinetic property (vdss) was measured in rat,,A,1,N,1,,BAO_0000218
8237,,,10116.0,Intermediate,Rattus norvegicus,4709,CHEMBL618530,50597,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
8238,,,10116.0,Intermediate,Rattus norvegicus,6642,CHEMBL618531,50597,,,,Volume of distribution in rat,,A,1,N,1,,BAO_0000218
8239,,,10116.0,Intermediate,Rattus norvegicus,5247,CHEMBL618532,50597,,,,The pharmacokinetic parameter volume of distribution in vivo in rats,,A,1,N,1,,BAO_0000218
8240,,,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL618533,50597,,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,F,1,N,1,,BAO_0000218
8241,,,10116.0,Intermediate,Rattus norvegicus,17686,CHEMBL618534,50597,,,,Vdss in rat i.v. at 2 mg/kg concentration,,A,1,N,1,,BAO_0000218
8242,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL618535,50597,,,,Volume distribution after intravenous administration (1 mg/kg) in rat,,A,1,N,1,,BAO_0000218
8243,,,10116.0,Intermediate,Rattus norvegicus,5654,CHEMBL618536,50597,,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
8244,,,10116.0,Intermediate,Rattus norvegicus,5654,CHEMBL618537,50597,,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
8245,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL618538,50597,,,,Volume distribution at a dose of 10 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
8246,,,10116.0,Intermediate,Rattus norvegicus,4521,CHEMBL618539,50597,,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,A,1,N,1,,BAO_0000218
8247,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL618540,50597,,,,Volume distribution was calculated in rat,,A,1,N,1,,BAO_0000218
8248,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL618541,50597,,,,Volume distribution was determined,,A,1,N,1,,BAO_0000218
8249,,,10116.0,Intermediate,Rattus norvegicus,2938,CHEMBL618542,50597,,,,Volume of distribution after intravenous administration was evaluated in rat,,A,1,N,1,,BAO_0000218
8250,,,10116.0,Intermediate,Rattus norvegicus,6679,CHEMBL622544,50597,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,A,1,N,1,,BAO_0000218
8251,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622545,50597,,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,A,1,N,1,,BAO_0000218
8252,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622546,50597,,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,A,1,N,1,,BAO_0000218
8253,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622547,50597,,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,A,1,N,1,,BAO_0000218
8254,,,10116.0,Intermediate,Rattus norvegicus,5145,CHEMBL622548,50597,,,,Volume of distribution in steady state was determined in rat,,A,1,N,1,,BAO_0000218
8255,,,10116.0,Intermediate,Rattus norvegicus,6467,CHEMBL622549,50597,,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,A,1,N,1,,BAO_0000218
8256,,,10116.0,Intermediate,Rattus norvegicus,6467,CHEMBL622550,50597,,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,A,1,N,1,,BAO_0000218
8257,,,10090.0,Intermediate,Mus musculus,15115,CHEMBL622551,50594,,,,Compound was evaluated for area under curve when administered through oral route to mouse,,A,1,N,1,,BAO_0000218
8258,,,10116.0,Intermediate,Rattus norvegicus,8758,CHEMBL622552,50597,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,A,1,N,1,,BAO_0000218
8259,,,10116.0,Intermediate,Rattus norvegicus,8758,CHEMBL622553,50597,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,A,1,N,1,,BAO_0000218
8260,,,,Autocuration,,8267,CHEMBL622554,22224,,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,F,1,U,0,,BAO_0000218
8261,,,9615.0,Intermediate,Canis lupus familiaris,8267,CHEMBL622555,50588,,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,A,1,N,1,,BAO_0000218
8262,,,10090.0,Intermediate,Mus musculus,14239,CHEMBL622556,50594,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,A,1,N,1,,BAO_0000218
8263,,,10090.0,Intermediate,Mus musculus,14239,CHEMBL622557,50594,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,A,1,N,1,,BAO_0000218
8264,,178.0,10090.0,Intermediate,Mus musculus,10754,CHEMBL622558,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,A,1,N,1,,BAO_0000218
8265,,178.0,10090.0,Intermediate,Mus musculus,10754,CHEMBL622559,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,A,1,N,1,,BAO_0000218
8266,,,9615.0,Intermediate,Canis lupus familiaris,10754,CHEMBL622560,50588,,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,A,1,N,1,,BAO_0000218
8267,,,10116.0,Intermediate,Rattus norvegicus,14681,CHEMBL622561,50597,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,A,1,N,1,,BAO_0000218
8268,,,10116.0,Intermediate,Rattus norvegicus,14681,CHEMBL622562,50597,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,A,1,N,1,,BAO_0000218
8269,,,10116.0,Intermediate,Rattus norvegicus,14681,CHEMBL622563,50597,,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,A,1,N,1,,BAO_0000218
8270,,,,Autocuration,,13118,CHEMBL622564,22224,,,,Concentration of compound in Central nervous system,,A,1,U,0,,BAO_0000019
8271,,,,Autocuration,,13118,CHEMBL622565,22224,,,,Concentration of compound in Central nervous system; Not detectable,,A,1,U,0,,BAO_0000019
8272,,,10090.0,Intermediate,Mus musculus,13318,CHEMBL622566,50594,,,,"Concentration of diester in the blood, following oral administration in mice",,A,1,N,1,,BAO_0000218
8273,,,10090.0,Intermediate,Mus musculus,13318,CHEMBL624515,50594,,,,"Concentration of monoester in the blood, following oral administration in mice",,A,1,N,1,,BAO_0000218
8274,,,10090.0,Intermediate,Mus musculus,13318,CHEMBL624516,50594,,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,A,1,N,1,,BAO_0000218
8275,,,,Autocuration,,15692,CHEMBL624517,22224,,,,Evaluated for Pharmacokinetic property: Area under the curve,,A,1,U,0,,BAO_0000019
8276,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL624518,50594,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,A,1,N,1,,BAO_0000218
8277,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL624519,100710,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,A,1,N,1,,BAO_0000218
8278,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL624520,100710,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8279,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL624521,100710,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8280,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL624522,100710,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8281,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL624523,100710,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8282,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL624409,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,A,1,N,1,,BAO_0000218
8283,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL624410,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,A,1,N,1,,BAO_0000218
8284,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL624411,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,A,1,N,1,,BAO_0000218
8285,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL623531,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,A,1,N,1,,BAO_0000218
8286,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL623532,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,A,1,N,1,,BAO_0000218
8287,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL623533,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,A,1,N,1,,BAO_0000218
8288,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL623534,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,A,1,N,1,,BAO_0000218
8289,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623535,50594,,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8290,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623536,50594,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8291,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623537,50594,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8292,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623538,50594,,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8293,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623539,50594,,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8294,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623540,50594,,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,A,1,N,1,,BAO_0000218
8295,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623541,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,A,1,N,1,,BAO_0000218
8296,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623542,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,A,1,N,1,,BAO_0000218
8297,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623543,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,A,1,N,1,,BAO_0000218
8298,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623544,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,A,1,N,1,,BAO_0000218
8299,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623545,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,A,1,N,1,,BAO_0000218
8300,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623546,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,A,1,N,1,,BAO_0000218
8301,,1969.0,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL623547,50597,,,Plasma,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8302,,,10116.0,Intermediate,Rattus norvegicus,6827,CHEMBL623548,50597,,,,High i.v. clearance in Dawley rats,,A,1,N,1,,BAO_0000218
8303,Microsomes,2107.0,10116.0,Intermediate,Rattus norvegicus,17538,CHEMBL623549,50597,,,Liver,In vitro clearance in rat liver microsomes,,A,1,N,1,,BAO_0000218
8304,Microsomes,2107.0,10116.0,Intermediate,Rattus norvegicus,6331,CHEMBL623550,50597,,,Liver,Intrinsic clearance in rat liver microsomes was determined,,A,1,N,1,,BAO_0000218
8305,,2107.0,10116.0,Intermediate,Rattus norvegicus,5948,CHEMBL875276,50597,,401.0,Liver,Intrinsic clearance in rat hepatocytes was determined,,A,1,N,1,,BAO_0000218
8306,,,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL621872,50597,,,,Plasma Clearance was determined,,A,1,N,1,,BAO_0000218
8307,,,10116.0,Intermediate,Rattus norvegicus,6647,CHEMBL621873,50597,,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,A,1,N,1,,BAO_0000218
8308,,,10116.0,Intermediate,Rattus norvegicus,1696,CHEMBL621874,50597,,,,Plasma clearance in rat.,,A,1,N,1,,BAO_0000218
8309,,,10116.0,Intermediate,Rattus norvegicus,6597,CHEMBL621875,50597,,,,Plasma clearance in rats,,A,1,N,1,,BAO_0000218
8310,,,10116.0,Intermediate,Rattus norvegicus,347,CHEMBL621876,50597,,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,A,1,N,1,,BAO_0000218
8311,,,10116.0,Intermediate,Rattus norvegicus,16423,CHEMBL621877,50597,,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,A,1,N,1,,BAO_0000218
8312,,,10116.0,Intermediate,Rattus norvegicus,2879,CHEMBL621878,50597,,,,Plasma clearance was measured in rat,,A,1,N,1,,BAO_0000218
8313,,,10116.0,Intermediate,Rattus norvegicus,4883,CHEMBL621879,50597,,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,A,1,N,1,,BAO_0000218
8314,,1969.0,10116.0,Intermediate,Rattus norvegicus,5328,CHEMBL621880,50597,,,Plasma,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,A,1,N,1,,BAO_0000218
8315,,,10116.0,Intermediate,Rattus norvegicus,5160,CHEMBL621881,50597,,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
8316,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL621882,50597,,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,A,1,N,1,,BAO_0000218
8317,,,10116.0,Intermediate,Rattus norvegicus,17651,CHEMBL875283,50597,,,,Total clearance at 1 mg/kg was determined in rat,,A,1,N,1,,BAO_0000218
8318,,,10116.0,Intermediate,Rattus norvegicus,17651,CHEMBL621883,50597,,,,Total clearance at 10 mg/kg was determined in rat,,A,1,N,1,,BAO_0000218
8319,,,10116.0,Intermediate,Rattus norvegicus,6596,CHEMBL621884,50597,,,,Clearance in rat,,A,1,N,1,,BAO_0000218
8320,,,10116.0,Intermediate,Rattus norvegicus,4796,CHEMBL621885,50597,,,,Plasma clearance rate determined in rats,,A,1,N,1,,BAO_0000218
8321,,,10116.0,Intermediate,Rattus norvegicus,6850,CHEMBL621886,50597,,,,Clearance of compound in rat was evaluated,,A,1,N,1,,BAO_0000218
8322,,1969.0,10116.0,Intermediate,Rattus norvegicus,5932,CHEMBL621887,50597,,,Plasma,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,A,1,N,1,,BAO_0000218
8323,,,10116.0,Intermediate,Rattus norvegicus,3371,CHEMBL621888,50597,,,,Pharmacokinetic property (blood clearance) in rat,,A,1,N,1,,BAO_0000218
8324,,,10116.0,Intermediate,Rattus norvegicus,2083,CHEMBL621889,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
8325,,,10116.0,Intermediate,Rattus norvegicus,4942,CHEMBL621890,50597,,,,Plasma clearance in rats,,A,1,N,1,,BAO_0000218
8326,Microsomes,2107.0,10116.0,Intermediate,Rattus norvegicus,6838,CHEMBL621891,50597,,,Liver,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,A,1,N,1,,BAO_0000218
8327,,,10116.0,Intermediate,Rattus norvegicus,5353,CHEMBL621892,50597,,,,Clearance in Dawley rat,,A,1,N,1,,BAO_0000218
8328,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL621893,50597,,,,Clearance rat,,A,1,N,1,,BAO_0000218
8329,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL621894,50597,,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,A,1,N,1,,BAO_0000218
8330,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL621895,50597,,,,Clearance rat; Not determined,,A,1,N,1,,BAO_0000218
8331,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL875284,50597,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,A,1,N,1,,BAO_0000218
8332,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL618699,50597,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,A,1,N,1,,BAO_0000218
8333,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL618700,50597,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,A,1,N,1,,BAO_0000218
8334,,,10116.0,Intermediate,Rattus norvegicus,6211,CHEMBL618701,50597,,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8335,,1969.0,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL876600,50597,,,Plasma,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,A,1,N,1,,BAO_0000218
8336,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL618702,50597,,,,Clearance of compound in rat after 1 mg/kg i.v. administration,,A,1,N,1,,BAO_0000218
8337,,,10116.0,Intermediate,Rattus norvegicus,3341,CHEMBL618703,50597,,,,Compound was evaluated for Hepatic clearance in rat,,A,1,N,1,,BAO_0000218
8338,,,10116.0,Intermediate,Rattus norvegicus,4891,CHEMBL618704,50597,,,,In vivo clearance after 5 mg/kg dose,,A,1,N,1,,BAO_0000218
8339,,1969.0,10116.0,Intermediate,Rattus norvegicus,1094,CHEMBL618705,50597,,,Plasma,Compound was tested for plasma clearance in rats,,A,1,N,1,,BAO_0000218
8340,,,10116.0,Intermediate,Rattus norvegicus,2938,CHEMBL618706,50597,,,,Hepatic clearance after intravenous administration was evaluated in rat,,A,1,N,1,,BAO_0000218
8341,,,10116.0,Intermediate,Rattus norvegicus,17853,CHEMBL618707,50597,,,,Lower clearance in rat (i.v.) at 0.5 mpk,,A,1,N,1,,BAO_0000218
8342,,1969.0,10116.0,Intermediate,Rattus norvegicus,6049,CHEMBL618708,50597,,,Plasma,Pharmacokinetic parameter expressed as plasma clearance in rat,,A,1,N,1,,BAO_0000218
8343,,,10116.0,Intermediate,Rattus norvegicus,5789,CHEMBL618709,50597,,,,Pharmacokinetic property (Clp) in rat,,A,1,N,1,,BAO_0000218
8344,,,10116.0,Intermediate,Rattus norvegicus,4514,CHEMBL618710,50597,,,,Plasma clearance in Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8345,,,10116.0,Intermediate,Rattus norvegicus,6448,CHEMBL618711,50597,,,,Plasma clearance (Clp) in rat,,A,1,N,1,,BAO_0000218
8346,,,10116.0,Intermediate,Rattus norvegicus,6062,CHEMBL618712,50597,,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
8347,,,10116.0,Intermediate,Rattus norvegicus,5710,CHEMBL618713,50597,,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,A,1,N,1,,BAO_0000218
8348,,,10116.0,Intermediate,Rattus norvegicus,4709,CHEMBL618714,50597,,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
8349,,,10116.0,Intermediate,Rattus norvegicus,4521,CHEMBL618715,50597,,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,A,1,N,1,,BAO_0000218
8350,,,10116.0,Intermediate,Rattus norvegicus,1742,CHEMBL618716,50597,,,,Plasma clearance in rat was determined,,A,1,N,1,,BAO_0000218
8351,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL876601,50597,,,,Plasma clearance measured in rat,,A,1,N,1,,BAO_0000218
8352,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL618717,50597,,,,Plasma clearance was calculated in rat,,A,1,N,1,,BAO_0000218
8353,,,10116.0,Intermediate,Rattus norvegicus,5145,CHEMBL618718,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
8354,,,10116.0,Intermediate,Rattus norvegicus,5833,CHEMBL618719,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
8355,,,10116.0,Intermediate,Rattus norvegicus,6453,CHEMBL618720,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
8356,,,10116.0,Intermediate,Rattus norvegicus,6640,CHEMBL618721,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
8357,,,10116.0,Intermediate,Rattus norvegicus,6305,CHEMBL621477,50597,,,,Plasma clearance in rats,,A,1,N,1,,BAO_0000218
8358,,,10116.0,Intermediate,Rattus norvegicus,6642,CHEMBL621478,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
8359,,,10116.0,Intermediate,Rattus norvegicus,5472,CHEMBL621479,50597,,,,Plasma clearance was evaluated in rat,,A,1,N,1,,BAO_0000218
8360,,,10116.0,Intermediate,Rattus norvegicus,5472,CHEMBL621480,50597,,,,Plasma clearance was evaluated in rat; Not tested,,A,1,N,1,,BAO_0000218
8361,,,10116.0,Intermediate,Rattus norvegicus,5144,CHEMBL621481,50597,,,,Plasma clearance rate was determined for the compound in rat,,A,1,N,1,,BAO_0000218
8362,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL621482,50597,,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,A,1,N,1,,BAO_0000218
8363,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL621483,50597,,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,A,1,N,1,,BAO_0000218
8364,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL621484,50597,,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,A,1,N,1,,BAO_0000218
8365,,948.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621485,50597,,,Heart,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8366,,948.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621486,50597,,,Heart,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8367,,160.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621487,50597,,,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8368,,160.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621488,50597,,,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8369,,160.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621489,50597,,,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8370,,160.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621490,50597,,,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8371,,160.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621491,50597,,,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8372,,2113.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621492,50597,,,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8373,,2113.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621493,50597,,,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8374,,2113.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621494,50597,,,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8375,,2113.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621495,50597,,,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8376,,2113.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621496,50597,,,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8377,,2107.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621497,50597,,,Liver,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8378,,2107.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621498,50597,,,Liver,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8379,,2107.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL621499,50597,,,Liver,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8380,,2107.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL618634,50597,,,Liver,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8381,,2107.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL618635,50597,,,Liver,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8382,,2048.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL618636,50597,,,Lung,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8383,,2048.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619737,50597,,,Lung,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8384,,2048.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL619738,50597,,,Lung,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8385,,2048.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624329,50597,,,Lung,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8386,,2048.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624330,50597,,,Lung,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8387,,2385.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624331,50597,,,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8388,,2385.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624332,50597,,,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8389,,2385.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624333,50597,,,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8390,,2385.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624334,50597,,,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8391,,2385.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL624335,50597,,,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8392,,2106.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620016,50597,,,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8393,,2106.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620169,50597,,,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8394,,2106.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620170,50597,,,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8395,,2106.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620171,50597,,,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8396,,2106.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620172,50597,,,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8397,,945.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620173,50597,,,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8398,,945.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620174,50597,,,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8399,,945.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620175,50597,,,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8400,,945.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620176,50597,,,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8401,,945.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620177,50597,,,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8402,,2037.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620178,50597,,,Cerebellum,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8403,,2037.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620179,50597,,,Cerebellum,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8404,,,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620180,50597,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8405,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL620181,50597,,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,A,1,N,1,,BAO_0000218
8406,,,10116.0,Intermediate,Rattus norvegicus,6571,CHEMBL620182,50597,,,,Volume of distribution of compound in rats after intravenous administration,,A,1,N,1,,BAO_0000218
8407,,,10116.0,Intermediate,Rattus norvegicus,6453,CHEMBL620183,50597,,,,Volume of distribution in rat,,A,1,N,1,,BAO_0000218
8408,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL620184,50597,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,A,1,N,1,,BAO_0000218
8409,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL620185,50597,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,A,1,N,1,,BAO_0000218
8410,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL620186,50597,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,A,1,N,1,,BAO_0000218
8411,,,10116.0,Intermediate,Rattus norvegicus,5353,CHEMBL620187,50597,,,,Volume of distribution was determined in Dawley rat,,A,1,N,1,,BAO_0000218
8412,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL620188,50597,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8413,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL620189,50597,,,,Volume of distribution was reported in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8414,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL620190,50597,,,,Volumes of distribution in rat after peroral administration,,A,1,N,1,,BAO_0000218
8415,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL620191,50597,,,,Volumes of distribution in rat after po administration,,A,1,N,1,,BAO_0000218
8416,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL620192,50597,,,,Volumes of distribution in rat after po administration; Not determined,,A,1,N,1,,BAO_0000218
8417,,,10116.0,Intermediate,Rattus norvegicus,5676,CHEMBL620193,50597,,,,Pharmacokinetic property (Volume) in rat i.v.,,A,1,N,1,,BAO_0000218
8418,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL620194,50597,,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,A,1,N,1,,BAO_0000218
8419,,,10116.0,Intermediate,Rattus norvegicus,17670,CHEMBL876730,50597,,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,A,1,N,1,,BAO_0000218
8420,,,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL620195,50597,,,,Volume distribution in rat after oral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
8421,,,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL620196,50597,,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8422,,,10116.0,Intermediate,Rattus norvegicus,4883,CHEMBL620197,50597,,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,A,1,N,1,,BAO_0000218
8423,,,10116.0,Intermediate,Rattus norvegicus,6647,CHEMBL620198,50597,,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,A,1,N,1,,BAO_0000218
8424,,,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL620199,50597,,,,Volume of distribution in rats,,A,1,N,1,,BAO_0000218
8425,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL620200,50597,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,A,1,N,1,,BAO_0000218
8426,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL620201,50597,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,A,1,N,1,,BAO_0000218
8427,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL620202,50597,,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8428,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL620203,50597,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8429,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL620204,50597,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,A,1,N,1,,BAO_0000218
8430,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL620205,50597,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8431,,,10116.0,Intermediate,Rattus norvegicus,5960,CHEMBL624664,50597,,,,Pharmacokinetic parameter (Vss) in rat,,A,1,N,1,,BAO_0000218
8432,,,10116.0,Intermediate,Rattus norvegicus,5676,CHEMBL624665,50597,,,,Pharmacokinetic property (Volume) in rat i.v.,,A,1,N,1,,BAO_0000218
8433,,,10116.0,Intermediate,Rattus norvegicus,5948,CHEMBL624666,50597,,,,Pharmacokinetic property (Vss) in rat,,A,1,N,1,,BAO_0000218
8434,,,10116.0,Intermediate,Rattus norvegicus,5979,CHEMBL624667,50597,,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,A,1,N,1,,BAO_0000218
8435,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL624668,50597,,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8436,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL624669,50597,,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8437,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL624670,50597,,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8438,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL624671,50597,,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8439,,,10116.0,Intermediate,Rattus norvegicus,6448,CHEMBL624672,50597,,,,Steady state volume distribution in rat,,A,1,N,1,,BAO_0000218
8440,,1969.0,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL624673,50597,,,Plasma,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,A,1,N,1,,BAO_0000218
8441,,,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL624674,50597,,,,Steady state volume of distribution determined in rat,,A,1,N,1,,BAO_0000218
8442,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL624675,50597,,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,A,1,N,1,,BAO_0000218
8443,,,10116.0,Intermediate,Rattus norvegicus,1466,CHEMBL621728,50597,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,A,1,N,1,,BAO_0000218
8444,,,10116.0,Intermediate,Rattus norvegicus,5182,CHEMBL621729,50597,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,A,1,N,1,,BAO_0000218
8445,,,10116.0,Intermediate,Rattus norvegicus,5182,CHEMBL621730,50597,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,A,1,N,1,,BAO_0000218
8446,,,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL621731,50597,,,,Volume distribution in rat after administration of 2 mg/kg iv,,A,1,N,1,,BAO_0000218
8447,,,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL621732,50597,,,,Volume distribution in rat after administration of 2 mg/kg iv,,A,1,N,1,,BAO_0000218
8448,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL621908,50597,,,,Volume in steady state distribution value was determined,,A,1,N,1,,BAO_0000218
8449,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL875347,50597,,,,Volume in steady state distribution value was determined; ND denotes no data,,A,1,N,1,,BAO_0000218
8450,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL621909,50597,,,,Volume in steady state distribution value was determined; ND denotes not determined,,A,1,N,1,,BAO_0000218
8451,,,10116.0,Intermediate,Rattus norvegicus,17065,CHEMBL621910,50597,,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,A,1,N,1,,BAO_0000218
8452,,,10116.0,Intermediate,Rattus norvegicus,6597,CHEMBL621911,50597,,,,Volume of distribution at steady state was evaluated in rats,,A,1,N,1,,BAO_0000218
8453,,,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL621912,50597,,,,Volume of distribution at steady state was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
8454,,,10116.0,Intermediate,Rattus norvegicus,6485,CHEMBL621913,50597,,,,Volume of distribution in steady state was determined in rat,,A,1,N,1,,BAO_0000218
8455,,,10116.0,Intermediate,Rattus norvegicus,17655,CHEMBL621914,50597,,,,Volume of distribution in steady state was determined in rat,,A,1,N,1,,BAO_0000218
8456,,,10116.0,Intermediate,Rattus norvegicus,6616,CHEMBL621915,50597,,,,Volume of distribution after i.v. administration,,A,1,N,1,,BAO_0000218
8457,,,10116.0,Intermediate,Rattus norvegicus,1916,CHEMBL621916,50597,,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,A,1,N,1,,BAO_0000218
8458,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL621917,50594,,,Liver,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
8459,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL621918,50594,,,Liver,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
8460,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL621919,50594,,,Spleen,Biodistribution of compound (oxidized form) in spleen tissue,,A,1,N,1,,BAO_0000218
8461,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL621920,50594,,,Spleen,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
8462,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL621921,50594,,,Spleen,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
8463,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622401,50594,,,Spleen,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8464,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL875348,50594,,,Spleen,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,A,1,N,1,,BAO_0000218
8465,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622402,50594,,,Spleen,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,A,1,N,1,,BAO_0000218
8466,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622403,50594,,,Blood,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,A,1,N,1,,BAO_0000218
8467,,178.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622404,50594,,,Blood,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8468,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622405,50594,,,Brain,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,A,1,N,1,,BAO_0000218
8469,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622406,50594,,,Brain,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8470,,955.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622407,50594,,,Brain,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8471,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622408,50594,,,Heart,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,A,1,N,1,,BAO_0000218
8472,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622409,50594,,,Heart,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8473,,948.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622410,50594,,,Heart,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8474,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL622411,50594,,,Kidney,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,A,1,N,1,,BAO_0000218
8475,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL627864,50594,,,Kidney,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,A,1,N,1,,BAO_0000218
8476,,2113.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL627865,50594,,,Kidney,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8477,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL627866,50594,,,Liver,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,A,1,N,1,,BAO_0000218
8478,,2107.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL627751,50594,,,Liver,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8479,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL627752,50594,,,Spleen,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,A,1,N,1,,BAO_0000218
8480,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL627753,50594,,,Spleen,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,A,1,N,1,,BAO_0000218
8481,,2106.0,10090.0,Intermediate,Mus musculus,16438,CHEMBL627754,50594,,,Spleen,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,A,1,N,1,,BAO_0000218
8482,,,10090.0,Intermediate,Mus musculus,12467,CHEMBL627755,50594,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,A,1,N,1,,BAO_0000218
8483,,955.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627756,50594,,,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8484,,955.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627757,50594,,,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8485,,955.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627758,50594,,,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8486,,955.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627759,50594,,,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8487,,955.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627760,50594,,,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8488,,955.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627761,50594,,,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8489,,948.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL876811,50594,,,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8490,,948.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627762,50594,,,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8491,,948.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627763,50594,,,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8492,,948.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627764,50594,,,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8493,,948.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627765,50594,,,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8494,,948.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627766,50594,,,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8495,,2113.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627767,50594,,,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8496,,2113.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627768,50594,,,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8497,,2113.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL628422,50594,,,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8498,,2113.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL628423,50594,,,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8499,,,10116.0,Intermediate,Rattus norvegicus,5089,CHEMBL628424,50597,,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,A,1,N,1,,BAO_0000218
8500,,,10116.0,Intermediate,Rattus norvegicus,5089,CHEMBL628425,50597,,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,A,1,N,1,,BAO_0000218
8501,,,10116.0,Intermediate,Rattus norvegicus,4257,CHEMBL628426,50597,,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,A,1,N,1,,BAO_0000218
8502,,,10116.0,Intermediate,Rattus norvegicus,6679,CHEMBL628427,50597,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,A,1,N,1,,BAO_0000218
8503,,,10116.0,Intermediate,Rattus norvegicus,5546,CHEMBL626938,50597,,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,A,1,N,1,,BAO_0000218
8504,,,10116.0,Intermediate,Rattus norvegicus,6141,CHEMBL626939,50597,,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8505,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL626940,50597,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8506,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL626941,50597,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8507,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL626942,50597,,,,Plasma clearance was reported in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8508,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL876812,50597,,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,,A,1,N,1,,BAO_0000218
8509,,,10116.0,Intermediate,Rattus norvegicus,6848,CHEMBL626943,50597,,,,Plasma clearance of compound in rats was evaluated,,A,1,N,1,,BAO_0000218
8510,,,10116.0,Intermediate,Rattus norvegicus,6848,CHEMBL626944,50597,,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,A,1,N,1,,BAO_0000218
8511,,,10116.0,Intermediate,Rattus norvegicus,6467,CHEMBL626945,50597,,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,A,1,N,1,,BAO_0000218
8512,,,10116.0,Intermediate,Rattus norvegicus,6467,CHEMBL626946,50597,,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,A,1,N,1,,BAO_0000218
8513,,,10116.0,Intermediate,Rattus norvegicus,4956,CHEMBL626856,50597,,,,Plasma clearance rate in Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8514,,,10116.0,Intermediate,Rattus norvegicus,5529,CHEMBL626857,50597,,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,A,1,N,1,,BAO_0000218
8515,,1969.0,10116.0,Intermediate,Rattus norvegicus,406,CHEMBL626858,50597,,,Plasma,The compound was evaluated for plasma clearance in rat,,A,1,N,1,,BAO_0000218
8516,,1969.0,10116.0,Intermediate,Rattus norvegicus,17655,CHEMBL627018,50597,,,Plasma,Total plasma clearance in rat,,A,1,N,1,,BAO_0000218
8517,,178.0,10116.0,Intermediate,Rattus norvegicus,3293,CHEMBL625331,50597,,,Blood,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,A,1,N,1,,BAO_0000218
8518,,178.0,10116.0,Intermediate,Rattus norvegicus,4075,CHEMBL625332,50597,,,Blood,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,A,1,N,1,,BAO_0000218
8519,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL877590,50597,,,,C max was determined at 10 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
8520,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL625333,50597,,,,C max was determined at 3 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
8521,,,10116.0,Intermediate,Rattus norvegicus,17594,CHEMBL625334,50597,,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,A,1,N,1,,BAO_0000218
8522,,,10116.0,Intermediate,Rattus norvegicus,17594,CHEMBL625335,50597,,,,Cmax after single intravenous bolus of 1 mg/kg in rats,,A,1,N,1,,BAO_0000218
8523,,,10116.0,Intermediate,Rattus norvegicus,4762,CHEMBL625336,50597,,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,,A,1,N,1,,BAO_0000218
8524,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL625337,50597,,,,Cmax 24 hr after 10 mg/kg oral administration in rats,,A,1,N,1,,BAO_0000218
8525,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL625338,50597,,,,Cmax 24 hr after 2 mg/kg oral administration in rats,,A,1,N,1,,BAO_0000218
8526,,1969.0,10116.0,Intermediate,Rattus norvegicus,1466,CHEMBL625339,50597,,,Plasma,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,A,1,N,1,,BAO_0000218
8527,,,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL625340,50597,,,,Cmax in rat after administration of 2 mg/kg iv,,A,1,N,1,,BAO_0000218
8528,,,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL625341,50597,,,,Cmax in rat after administration of 2 mg/kg iv,,A,1,N,1,,BAO_0000218
8529,,,10116.0,Intermediate,Rattus norvegicus,3169,CHEMBL622687,50597,,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,A,1,N,1,,BAO_0000218
8530,,1969.0,10116.0,Intermediate,Rattus norvegicus,6515,CHEMBL622688,50597,,,Plasma,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,A,1,N,1,,BAO_0000218
8531,,178.0,10116.0,Intermediate,Rattus norvegicus,11149,CHEMBL622689,50597,,,Blood,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,A,1,N,1,,BAO_0000218
8532,,178.0,10116.0,Intermediate,Rattus norvegicus,11149,CHEMBL620295,50597,,,Blood,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,A,1,N,1,,BAO_0000218
8533,,,10116.0,Intermediate,Rattus norvegicus,17858,CHEMBL620296,50597,,,,Cmax after 10 mg/kg oral administration in rat,,A,1,N,1,,BAO_0000218
8534,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL620297,50597,,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,A,1,N,1,,BAO_0000218
8535,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL620298,50597,,,,Cmax after IV dosing at 1 mg/kg in rat; no data,,A,1,N,1,,BAO_0000218
8536,,,10116.0,Intermediate,Rattus norvegicus,4426,CHEMBL620299,50597,,,,Cmax after oral administration at 20 mpk in rats,,A,1,N,1,,BAO_0000218
8537,,,10116.0,Intermediate,Rattus norvegicus,4426,CHEMBL620300,50597,,,,Cmax after oral administration at 20 mpk in rats; Not performed.,,A,1,N,1,,BAO_0000218
8538,,,10116.0,Intermediate,Rattus norvegicus,4426,CHEMBL620301,50597,,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,,A,1,N,1,,BAO_0000218
8539,,,10116.0,Intermediate,Rattus norvegicus,5656,CHEMBL620302,50597,,,,Cmax after oral administration in rat,,A,1,N,1,,BAO_0000218
8540,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL620303,50597,,,,Cmax after oral administration at a dose of 2 mg/kg in rat,,A,1,N,1,,BAO_0000218
8541,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL620304,50597,,,,Cmax after oral administration at a dose of 4 mg/kg in rat,,A,1,N,1,,BAO_0000218
8542,,,10116.0,Intermediate,Rattus norvegicus,6113,CHEMBL620305,50597,,,,Cmax in rats after 20 mg/kg oral dose,,A,1,N,1,,BAO_0000218
8543,,,10116.0,Intermediate,Rattus norvegicus,17764,CHEMBL620306,50597,,,,Cmax after peroral administration in rats at 2.4 uM/kg,,A,1,N,1,,BAO_0000218
8544,,,10116.0,Intermediate,Rattus norvegicus,4756,CHEMBL620307,50597,,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,,A,1,N,1,,BAO_0000218
8545,,,10116.0,Intermediate,Rattus norvegicus,4756,CHEMBL620308,50597,,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,,A,1,N,1,,BAO_0000218
8546,,,10116.0,Intermediate,Rattus norvegicus,6402,CHEMBL620309,50597,,,,Cmax by administering at 20 mg/kg p.o. in rats,,A,1,N,1,,BAO_0000218
8547,,,10116.0,Intermediate,Rattus norvegicus,5610,CHEMBL620310,50597,,,,Cmax in male rat,,A,1,N,1,,BAO_0000218
8548,,,10116.0,Intermediate,Rattus norvegicus,5207,CHEMBL620311,50597,,,,Cmax in rat,,A,1,N,1,,BAO_0000218
8549,,,10116.0,Intermediate,Rattus norvegicus,6011,CHEMBL620312,50597,,,,Cmax in rat,,A,1,N,1,,BAO_0000218
8550,,,10116.0,Intermediate,Rattus norvegicus,6504,CHEMBL620313,50597,,,,Cmax in rat,,A,1,N,1,,BAO_0000218
8551,,,10116.0,Intermediate,Rattus norvegicus,6046,CHEMBL620314,50597,,,,Cmax in rat at 10 mg/kg,,A,1,N,1,,BAO_0000218
8552,,,10116.0,Intermediate,Rattus norvegicus,6504,CHEMBL620315,50597,,,,Cmax in rat at the dose of 1 mg/kg i.v.,,A,1,N,1,,BAO_0000218
8553,,,10116.0,Intermediate,Rattus norvegicus,5874,CHEMBL620316,50597,,,,Cmax in rat by po administration at a dose of 40 mg/kg,,A,1,N,1,,BAO_0000218
8554,,,10116.0,Intermediate,Rattus norvegicus,17686,CHEMBL620317,50597,,,,Cmax in rat p.o. at 20 mg/kg concentration,,A,1,N,1,,BAO_0000218
8555,,,10116.0,Intermediate,Rattus norvegicus,5836,CHEMBL620318,50597,,,,Cmax in rats,,A,1,N,1,,BAO_0000218
8556,,,10116.0,Intermediate,Rattus norvegicus,17596,CHEMBL620319,50597,,,,Cmax in rats,,A,1,N,1,,BAO_0000218
8557,,,10116.0,Intermediate,Rattus norvegicus,16423,CHEMBL620320,50597,,,,Cmax was evaluated after 20 uM/kg of peroral administration,,A,1,N,1,,BAO_0000218
8558,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL620321,50597,,,,Cmax was measured in rats after peroral administration at 3 mg/kg,,A,1,N,1,,BAO_0000218
8559,,,10116.0,Intermediate,Rattus norvegicus,1908,CHEMBL620322,50597,,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,A,1,N,1,,BAO_0000218
8560,,,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620323,50597,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8561,,1870.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620324,50597,,,Frontal cortex,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8562,,1870.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620325,50597,,,Frontal cortex,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8563,,10000000.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620326,50597,,,Hippocampus,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8564,,10000000.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620327,50597,,,Hippocampus,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8565,,,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620328,50597,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8566,,,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620329,50597,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8567,,1891.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620330,50597,,,Midbrain,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8568,,1891.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL875286,50597,,,Midbrain,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8569,,,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620331,50597,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8570,,,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620332,50597,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8571,,2435.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620333,50597,,,Striatum,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8572,,2435.0,10116.0,Intermediate,Rattus norvegicus,13950,CHEMBL620334,50597,,,Striatum,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,A,1,N,1,,BAO_0000218
8573,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621015,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8574,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621016,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8575,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621191,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8576,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621192,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8577,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621193,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8578,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621194,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8579,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624204,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8580,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624205,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8581,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624206,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8582,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624207,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8583,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624208,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8584,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624209,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8585,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624210,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8586,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624211,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8587,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624212,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8588,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624213,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8589,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL876611,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
8590,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624214,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
8591,,178.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624215,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
8592,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624216,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8593,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624217,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
8594,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624218,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
8595,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624219,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8596,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624220,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
8597,,178.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624221,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
8598,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624222,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8599,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624223,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8600,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624224,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8601,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624225,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8602,,,10116.0,Intermediate,Rattus norvegicus,17764,CHEMBL622420,50597,,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,A,1,N,1,,BAO_0000218
8603,,,10116.0,Intermediate,Rattus norvegicus,5031,CHEMBL622421,50597,,,,Volume of steady state distribution after i.v. administration in rats,,A,1,N,1,,BAO_0000218
8604,,,10116.0,Intermediate,Rattus norvegicus,6215,CHEMBL622422,50597,,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,A,1,N,1,,BAO_0000218
8605,,,10116.0,Intermediate,Rattus norvegicus,17671,CHEMBL622423,50597,,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,A,1,N,1,,BAO_0000218
8606,,,10116.0,Intermediate,Rattus norvegicus,17752,CHEMBL622424,50597,,,,Vss was determined,,A,1,N,1,,BAO_0000218
8607,,,10116.0,Intermediate,Rattus norvegicus,6596,CHEMBL622425,50597,,,,Vss in rat,,A,1,N,1,,BAO_0000218
8608,,,10116.0,Intermediate,Rattus norvegicus,16423,CHEMBL876612,50597,,,,Vss was evaluated after 10 uM/kg of intra arterial administration,,A,1,N,1,,BAO_0000218
8609,,,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL622426,50597,,,,volume of distribution at steady state was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
8610,,,10116.0,Intermediate,Rattus norvegicus,6062,CHEMBL622427,50597,,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
8611,,,10116.0,Intermediate,Rattus norvegicus,5874,CHEMBL622428,50597,,,,Pharmacokinetic (PK) parameter Vz in rat,,A,1,N,1,,BAO_0000218
8612,,,10116.0,Intermediate,Rattus norvegicus,4942,CHEMBL622429,50597,,,,Volume distribution in rats,,A,1,N,1,,BAO_0000218
8613,,,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL622430,50597,,,,Volume of distribution in rat; No data,,A,1,N,1,,BAO_0000218
8614,,,10116.0,Intermediate,Rattus norvegicus,4890,CHEMBL622431,50597,,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8615,,2116.0,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL622432,50597,,,Ileum,% absorption predicted from in vitro rat ileum transport studies,,A,1,N,1,,BAO_0000218
8616,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL622433,50597,,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,A,1,N,1,,BAO_0000218
8617,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL622434,50597,,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,A,1,N,1,,BAO_0000218
8618,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL622435,50597,,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,A,1,N,1,,BAO_0000218
8619,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618748,50597,,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,A,1,N,1,,BAO_0000218
8620,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618749,50597,,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,A,1,N,1,,BAO_0000218
8621,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618750,50597,,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,A,1,N,1,,BAO_0000218
8622,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618751,50597,,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,A,1,N,1,,BAO_0000218
8623,,,10116.0,Intermediate,Rattus norvegicus,13569,CHEMBL618752,50597,,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,A,1,N,1,,BAO_0000218
8624,,,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL618753,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
8625,,1969.0,10116.0,Intermediate,Rattus norvegicus,750,CHEMBL618754,50597,,,Plasma,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,A,1,N,1,,BAO_0000218
8626,,,10116.0,Intermediate,Rattus norvegicus,750,CHEMBL618755,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
8627,,,10116.0,Intermediate,Rattus norvegicus,4590,CHEMBL618756,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
8628,,,10116.0,Intermediate,Rattus norvegicus,1716,CHEMBL618757,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
8629,,,10116.0,Intermediate,Rattus norvegicus,1974,CHEMBL618758,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
8630,,,10116.0,Intermediate,Rattus norvegicus,4502,CHEMBL621088,50597,,,,Oral bioavailability in rat (dose 30 mg/kg),,A,1,N,1,,BAO_0000218
8631,,,10116.0,Intermediate,Rattus norvegicus,3371,CHEMBL621089,50597,,,,Pharmacokinetic property (cLogP) in rat,,A,1,N,1,,BAO_0000218
8632,,178.0,10116.0,Intermediate,Rattus norvegicus,9099,CHEMBL621090,50597,,,Blood,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,F,1,N,1,,BAO_0000218
8633,,178.0,10116.0,Intermediate,Rattus norvegicus,9099,CHEMBL621091,50597,,,Blood,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,F,1,N,1,,BAO_0000218
8634,,,10116.0,Intermediate,Rattus norvegicus,4590,CHEMBL876731,50597,,,,Clearance in rat.,,A,1,N,1,,BAO_0000218
8635,,,10116.0,Intermediate,Rattus norvegicus,3184,CHEMBL621092,50597,,,,Compound was evaluated for its clearance when administered intravenously in rat,,A,1,N,1,,BAO_0000218
8636,,,10116.0,Intermediate,Rattus norvegicus,16456,CHEMBL621093,50597,,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
8637,,,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL621094,50597,,,,Blood: Brain distribution ratio is determined in rat,,A,1,N,1,,BAO_0000218
8638,,,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL621095,50597,,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,A,1,N,1,,BAO_0000218
8639,,,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL621096,50597,,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,A,1,N,1,,BAO_0000218
8640,,2113.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL621097,50597,,,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
8641,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL621098,50597,,,,Percent dose excreted in 0-48 hours administered ip to male rat,,F,1,N,1,,BAO_0000218
8642,,2037.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621099,50597,,,Cerebellum,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8643,,2037.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621100,50597,,,Cerebellum,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8644,,2037.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621101,50597,,,Cerebellum,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8645,,2037.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621102,50597,,,Cerebellum,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8646,,2037.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL876732,50597,,,Cerebellum,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8647,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621103,50597,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8648,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621104,50597,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8649,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621105,50597,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8650,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621106,50597,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8651,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621107,50597,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8652,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621108,50597,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8653,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621109,50597,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8654,,2113.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL621110,50594,,,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8655,,2113.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL621111,50594,,,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8656,,2107.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL622541,50594,,,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8657,,2107.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL622542,50594,,,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8658,,2107.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL622543,50594,,,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8659,,2107.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624412,50594,,,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8660,,2107.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624413,50594,,,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8661,,2107.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624414,50594,,,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8662,,2048.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624415,50594,,,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8663,,2048.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624416,50594,,,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8664,,2048.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624417,50594,,,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8665,,2048.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624418,50594,,,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8666,,2048.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624419,50594,,,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8667,,2048.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624420,50594,,,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8668,,2385.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624421,50594,,,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8669,,2385.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624422,50594,,,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8670,,2385.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL624423,50594,,,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8671,,2385.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL625123,50594,,,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8672,,2385.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL625124,50594,,,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8673,,2385.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL625125,50594,,,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8674,,14.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL625126,50594,,,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8675,,14.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626947,50594,,,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8676,,14.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626948,50594,,,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8677,,14.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626949,50594,,,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8678,,14.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626950,50594,,,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8679,,14.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626951,50594,,,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8680,,2106.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626952,50594,,,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8681,,2106.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626953,50594,,,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8682,,2106.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626954,50594,,,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8683,,2106.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626955,50594,,,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8684,,2106.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626956,50594,,,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8685,,2106.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626957,50594,,,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8686,,178.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626958,50594,,,Blood,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8687,,178.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626959,50594,,,Blood,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8688,,178.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626960,50594,,,Blood,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8689,,178.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL626961,50594,,,Blood,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8690,,178.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627589,50594,,,Blood,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8691,,178.0,10090.0,Intermediate,Mus musculus,17208,CHEMBL627590,50594,,,Blood,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,A,1,N,1,,BAO_0000218
8692,,,10090.0,Intermediate,Mus musculus,3132,CHEMBL627591,50594,,,,Time taken for EC90 was determined when tested in mouse,,A,1,N,1,,BAO_0000218
8693,,,10090.0,Intermediate,Mus musculus,3132,CHEMBL627592,50594,,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,A,1,N,1,,BAO_0000218
8694,,,10090.0,Intermediate,Mus musculus,16597,CHEMBL627593,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,A,1,N,1,,BAO_0000218
8695,,,10090.0,Intermediate,Mus musculus,5727,CHEMBL627594,50594,,,,Half life in mice,,A,1,N,1,,BAO_0000218
8696,,,10090.0,Intermediate,Mus musculus,5302,CHEMBL876813,50594,,,,Half life period in mouse after 10 mg/Kg dose,,A,1,N,1,,BAO_0000218
8697,,,10090.0,Intermediate,Mus musculus,5302,CHEMBL627595,50594,,,,Half life period in mouse after 10 mg/kg dose,,A,1,N,1,,BAO_0000218
8698,,,10090.0,Intermediate,Mus musculus,6348,CHEMBL627596,50594,,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
8699,,,10116.0,Intermediate,Rattus norvegicus,5964,CHEMBL627597,50597,,,,Cmax value at 5 mg/kg po was determined in rat,,A,1,N,1,,BAO_0000218
8700,,,10116.0,Intermediate,Rattus norvegicus,6078,CHEMBL627598,50597,,,,Cmax value evaluated in rat,,A,1,N,1,,BAO_0000218
8701,,955.0,10116.0,Intermediate,Rattus norvegicus,5206,CHEMBL627599,50597,,,Brain,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,A,1,N,1,,BAO_0000218
8702,,,10116.0,Intermediate,Rattus norvegicus,2959,CHEMBL627600,50597,,,,Cmax value after administration of 20 mg/Kg oral dose in rat,,A,1,N,1,,BAO_0000218
8703,,,10116.0,Intermediate,Rattus norvegicus,5964,CHEMBL627601,50597,,,,Cmax value at 1 mg/kg po in rat,,A,1,N,1,,BAO_0000218
8704,,,10116.0,Intermediate,Rattus norvegicus,5964,CHEMBL627776,50597,,,,Cmax value at 5 mg/kg po in rat,,A,1,N,1,,BAO_0000218
8705,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL627777,50597,,,,Cmax value at a dose of 10 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
8706,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL627778,50597,,,,Cmax value at a dose of 100 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
8707,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL627779,50597,,,,Cmax value at a dose of 50 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
8708,,,10116.0,Intermediate,Rattus norvegicus,17617,CHEMBL876814,50597,,,,Cmax value in rats at 10 mg/kg,,A,1,N,1,,BAO_0000218
8709,,,10116.0,Intermediate,Rattus norvegicus,1445,CHEMBL627780,50597,,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
8710,,,10116.0,Intermediate,Rattus norvegicus,6082,CHEMBL627781,50597,,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,,A,1,N,1,,BAO_0000218
8711,,,10116.0,Intermediate,Rattus norvegicus,1446,CHEMBL627782,50597,,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,A,1,N,1,,BAO_0000218
8712,,1969.0,10116.0,Intermediate,Rattus norvegicus,5407,CHEMBL627783,50597,,,Plasma,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,A,1,N,1,,BAO_0000218
8713,,1969.0,10116.0,Intermediate,Rattus norvegicus,2690,CHEMBL627784,50597,,,Plasma,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,A,1,N,1,,BAO_0000218
8714,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL627785,50597,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,A,1,N,1,,BAO_0000218
8715,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL627786,50597,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,A,1,N,1,,BAO_0000218
8716,,1969.0,10116.0,Intermediate,Rattus norvegicus,4891,CHEMBL627787,50597,,,Plasma,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,A,1,N,1,,BAO_0000218
8717,,1969.0,10116.0,Intermediate,Rattus norvegicus,2807,CHEMBL627788,50597,,,Plasma,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,A,1,N,1,,BAO_0000218
8718,,1969.0,10116.0,Intermediate,Rattus norvegicus,2807,CHEMBL626579,50597,,,Plasma,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,A,1,N,1,,BAO_0000218
8719,,1969.0,10116.0,Intermediate,Rattus norvegicus,2807,CHEMBL626580,50597,,,Plasma,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,A,1,N,1,,BAO_0000218
8720,,,10116.0,Intermediate,Rattus norvegicus,3634,CHEMBL876815,50597,,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
8721,,1969.0,10116.0,Intermediate,Rattus norvegicus,1881,CHEMBL626581,50597,,,Plasma,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,A,1,N,1,,BAO_0000218
8722,,1969.0,10116.0,Intermediate,Rattus norvegicus,1881,CHEMBL626582,50597,,,Plasma,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,A,1,N,1,,BAO_0000218
8723,,,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL626583,50597,,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,A,1,N,1,,BAO_0000218
8724,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL626205,50597,,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8725,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL626206,50597,,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8726,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL626207,50597,,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8727,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL623882,50597,,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8728,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL623883,50597,,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,A,1,N,1,,BAO_0000218
8729,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL623884,50597,,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
8730,,1969.0,10116.0,Intermediate,Rattus norvegicus,3032,CHEMBL623885,50597,,,Plasma,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,A,1,N,1,,BAO_0000218
8731,,1969.0,10116.0,Intermediate,Rattus norvegicus,6295,CHEMBL623886,50597,,,Plasma,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
8732,,,10116.0,Intermediate,Rattus norvegicus,6619,CHEMBL623887,50597,,,,Maximal concentration in rat was determined,,A,1,N,1,,BAO_0000218
8733,,,10116.0,Intermediate,Rattus norvegicus,6616,CHEMBL623888,50597,,,,Maximal concentration after i.v. administration,,A,1,N,1,,BAO_0000218
8734,,1969.0,10116.0,Intermediate,Rattus norvegicus,3249,CHEMBL623889,50597,,,Plasma,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
8735,,1969.0,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL623890,50597,,,Plasma,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,A,1,N,1,,BAO_0000218
8736,,1969.0,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL623891,50597,,,Plasma,Cmax in rat plasma after oral dose (50 mg/Kg),,A,1,N,1,,BAO_0000218
8737,,1969.0,10116.0,Intermediate,Rattus norvegicus,1360,CHEMBL623892,50597,,,Plasma,Maximal plasma concentration was determined.,,A,1,N,1,,BAO_0000218
8738,,1969.0,10116.0,Intermediate,Rattus norvegicus,2552,CHEMBL623893,50597,,,Plasma,Maximal plasma drug concentration was determined,,A,1,N,1,,BAO_0000218
8739,,,10116.0,Intermediate,Rattus norvegicus,6571,CHEMBL877616,50597,,,,Maximal concentration in rats after peroral administration,,A,1,N,1,,BAO_0000218
8740,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL623894,50597,,,,Maximum concentration in rat after 2 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
8741,,1969.0,10116.0,Intermediate,Rattus norvegicus,6567,CHEMBL623895,50597,,,Plasma,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,A,1,N,1,,BAO_0000218
8742,,,10116.0,Intermediate,Rattus norvegicus,3031,CHEMBL623896,50597,,,,Maximum concentration of compound in rat was evaluated.,,A,1,N,1,,BAO_0000218
8743,,,10116.0,Intermediate,Rattus norvegicus,3436,CHEMBL623897,50597,,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
8744,,,10116.0,Intermediate,Rattus norvegicus,3436,CHEMBL623898,50597,,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
8745,,,10116.0,Intermediate,Rattus norvegicus,2083,CHEMBL623899,50597,,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,A,1,N,1,,BAO_0000218
8746,,,10116.0,Intermediate,Rattus norvegicus,3436,CHEMBL623900,50597,,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
8747,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL623901,50597,,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
8748,,,10116.0,Intermediate,Rattus norvegicus,1974,CHEMBL623902,50597,,,,Maximum concentration was evaluated in rats,,A,1,N,1,,BAO_0000218
8749,,1359.0,10116.0,Intermediate,Rattus norvegicus,3307,CHEMBL623903,50597,,,Cerebrospinal fluid,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,A,1,N,1,,BAO_0000218
8750,,1969.0,10116.0,Intermediate,Rattus norvegicus,3307,CHEMBL623904,50597,,,Plasma,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,A,1,N,1,,BAO_0000218
8751,,1969.0,10116.0,Intermediate,Rattus norvegicus,1916,CHEMBL877617,50597,,,Plasma,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,A,1,N,1,,BAO_0000218
8752,,,10116.0,Intermediate,Rattus norvegicus,1500,CHEMBL623905,50597,,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,A,1,N,1,,BAO_0000218
8753,,,10116.0,Intermediate,Rattus norvegicus,1500,CHEMBL623906,50597,,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
8754,,1969.0,10116.0,Intermediate,Rattus norvegicus,4186,CHEMBL623907,50597,,,Plasma,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,A,1,N,1,,BAO_0000218
8755,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623908,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8756,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623909,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8757,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623910,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8758,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623911,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8759,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623912,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8760,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624616,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8761,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624617,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8762,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624618,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8763,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624619,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8764,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624794,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8765,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624795,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8766,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623921,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8767,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623922,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
8768,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623923,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
8769,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623924,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
8770,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623925,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8771,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623926,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
8772,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623927,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
8773,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623928,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8774,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623929,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
8775,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623930,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
8776,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623931,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8777,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622165,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8778,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621249,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8779,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621250,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8780,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621448,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8781,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621449,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8782,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621450,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8783,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621451,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8784,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621452,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8785,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621453,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8786,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621454,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8787,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621455,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8788,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621456,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8789,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625145,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8790,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL875847,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8791,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625146,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8792,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625147,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
8793,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625148,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
8794,,955.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625149,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
8795,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625150,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8796,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625151,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
8797,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625152,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
8798,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625153,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
8799,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625154,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
8800,,955.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625155,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8801,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625156,50597,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8802,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624354,50597,,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8803,,10000000.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624355,50597,,,Hippocampus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8804,,10000000.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624356,50597,,,Hippocampus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8805,,10000000.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624357,50597,,,Hippocampus,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8806,,10000000.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624358,50597,,,Hippocampus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8807,,2435.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624359,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8808,,2435.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624360,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8809,,2435.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624361,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8810,,2435.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624362,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8811,,2435.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624363,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8812,,178.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624364,50597,,,Blood,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8813,,178.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624365,50597,,,Blood,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8814,,178.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624366,50597,,,Blood,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8815,,178.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624367,50597,,,Blood,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8816,,955.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624368,50597,,,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8817,,955.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624369,50597,,,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8818,,955.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624370,50597,,,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8819,,955.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625069,50597,,,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8820,,955.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625070,50597,,,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8821,,948.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626051,50597,,,Heart,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8822,,948.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626052,50597,,,Heart,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8823,,948.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626053,50597,,,Heart,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8824,,948.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626054,50597,,,Heart,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8825,,948.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626055,50597,,,Heart,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8826,,2113.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626056,50597,,,Kidney,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8827,,2113.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626057,50597,,,Kidney,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8828,,2113.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625193,50597,,,Kidney,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8829,,2113.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625194,50597,,,Kidney,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8830,,2107.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625195,50597,,,Liver,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8831,,2107.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625196,50597,,,Liver,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8832,,2107.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625197,50597,,,Liver,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8833,,2107.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625198,50597,,,Liver,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8834,,2107.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL627929,50597,,,Liver,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8835,,2048.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL627074,50597,,,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8836,,2048.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL627075,50597,,,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8837,,2048.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL627076,50597,,,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8838,,2048.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL627077,50597,,,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8839,,2048.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL627078,50597,,,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8840,,2385.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL627079,50597,,,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8841,,,10090.0,Intermediate,Mus musculus,4573,CHEMBL873824,50594,,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,A,1,N,1,,BAO_0000218
8842,,1969.0,10090.0,Intermediate,Mus musculus,3132,CHEMBL627080,50594,,,Plasma,Half life in mouse plasma was determined at dose 25 mg/kg,,A,1,N,1,,BAO_0000218
8843,,,10090.0,Intermediate,Mus musculus,17718,CHEMBL627081,50594,,,,Half life was determined,,A,1,N,1,,BAO_0000218
8844,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL627082,50594,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,A,1,N,1,,BAO_0000218
8845,,,10090.0,Intermediate,Mus musculus,5961,CHEMBL627083,50594,,,,Half-life in male mice after 1 mg/kg intravenous dose,,A,1,N,1,,BAO_0000218
8847,,1969.0,10090.0,Intermediate,Mus musculus,17731,CHEMBL627085,50594,,,Plasma,Half life in mice plasma,,A,1,N,1,,BAO_0000218
8848,,,10090.0,Intermediate,Mus musculus,17592,CHEMBL627086,50594,,,,Half life in mouse,,A,1,N,1,,BAO_0000218
8849,,1969.0,10090.0,Intermediate,Mus musculus,3132,CHEMBL627087,50594,,,Plasma,Half life in mouse plasma at dose 25 mg/kg,,A,1,N,1,,BAO_0000218
8850,,,10090.0,Intermediate,Mus musculus,17729,CHEMBL627088,50594,,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,A,1,N,1,,BAO_0000218
8851,,,10090.0,Intermediate,Mus musculus,17729,CHEMBL627089,50594,,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,A,1,N,1,,BAO_0000218
8852,,,10090.0,Intermediate,Mus musculus,17729,CHEMBL627090,50594,,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,A,1,N,1,,BAO_0000218
8853,,,10090.0,Intermediate,Mus musculus,3277,CHEMBL627091,50594,,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,A,1,N,1,,BAO_0000218
8854,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL627092,50594,,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,A,1,N,1,,BAO_0000218
8855,,,10090.0,Intermediate,Mus musculus,3760,CHEMBL876785,50594,,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,A,1,N,1,,BAO_0000218
8856,,,10090.0,Intermediate,Mus musculus,2862,CHEMBL627093,50594,,,,Half-life by iv administration in mouse,,A,1,N,1,,BAO_0000218
8857,,,10090.0,Intermediate,Mus musculus,2862,CHEMBL627094,50594,,,,Half-life by oral administration in mouse,,A,1,N,1,,BAO_0000218
8858,,,10090.0,Intermediate,Mus musculus,5980,CHEMBL627095,50594,,,,Half-life in mice,,A,1,N,1,,BAO_0000218
8859,,955.0,10090.0,Intermediate,Mus musculus,6159,CHEMBL627096,50594,,,Brain,Half-life using mouse brain homogenate,,A,1,N,1,,BAO_0000218
8860,,,10090.0,Intermediate,Mus musculus,6254,CHEMBL627097,50594,,,,Half-life was measured in mice,,A,1,N,1,,BAO_0000218
8861,,,10090.0,Intermediate,Mus musculus,6062,CHEMBL627098,50594,,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
8862,,178.0,10090.0,Intermediate,Mus musculus,1574,CHEMBL627099,50594,,,Blood,Half-life period was determined in mouse blood,,A,1,N,1,,BAO_0000218
8863,,955.0,10090.0,Intermediate,Mus musculus,56,CHEMBL627100,50594,,,Brain,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,A,1,N,1,,BAO_0000218
8864,,1969.0,10090.0,Intermediate,Mus musculus,993,CHEMBL627101,50594,,,Plasma,Plasma half life in mouse,,A,1,N,1,,BAO_0000218
8865,,,10090.0,Intermediate,Mus musculus,6652,CHEMBL627102,50594,,,,Stability of the peptide in the presence of mouse serum,,A,1,N,1,,BAO_0000218
8866,,,10090.0,Intermediate,Mus musculus,17852,CHEMBL627103,50594,,,,Terminal half life of compound was determined in mouse,,A,1,N,1,,BAO_0000218
8867,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL627104,50594,,,,Terminal half life was evaluated in mice after intravenous administration,,A,1,N,1,,BAO_0000218
8868,,,10090.0,Intermediate,Mus musculus,2675,CHEMBL627105,50594,,,,Terminal half life was evaluated in mice after oral administration,,A,1,N,1,,BAO_0000218
8869,,,10090.0,Intermediate,Mus musculus,499,CHEMBL876786,50594,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,A,1,N,1,,BAO_0000218
8870,,,10090.0,Intermediate,Mus musculus,499,CHEMBL873825,50594,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,A,1,N,1,,BAO_0000218
8871,,,10090.0,Intermediate,Mus musculus,499,CHEMBL627106,50594,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,A,1,N,1,,BAO_0000218
8872,,,10090.0,Intermediate,Mus musculus,14239,CHEMBL626336,50594,,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,A,1,N,1,,BAO_0000218
8873,,,10090.0,Intermediate,Mus musculus,5506,CHEMBL877462,50594,,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,A,1,N,1,,BAO_0000218
8874,,,10090.0,Intermediate,Mus musculus,5506,CHEMBL626337,50594,,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,A,1,N,1,,BAO_0000218
8875,,,10090.0,Intermediate,Mus musculus,17734,CHEMBL626338,50594,,,,Half life after intraperitoneal administration of 100 mg/kg in mice,,A,1,N,1,,BAO_0000218
8876,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL626339,50594,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,A,1,N,1,,BAO_0000218
8877,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL626340,50594,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,A,1,N,1,,BAO_0000218
8878,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL625377,50594,,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,A,1,N,1,,BAO_0000218
8879,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL625378,50594,,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,A,1,N,1,,BAO_0000218
8880,,,10090.0,Intermediate,Mus musculus,17728,CHEMBL625379,50594,,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,A,1,N,1,,BAO_0000218
8881,Microsomes,,9823.0,Autocuration,Sus scrofa,14294,CHEMBL625380,22224,,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,A,1,U,0,,BAO_0000251
8882,Microsomes,,9823.0,Autocuration,Sus scrofa,14294,CHEMBL625381,22224,,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,A,1,U,0,,BAO_0000251
8883,,,9823.0,Autocuration,Sus scrofa,6056,CHEMBL625382,22224,,,,Stability to porcine renal DHP-I,,A,1,U,0,,BAO_0000019
8884,,,9823.0,Autocuration,Sus scrofa,1317,CHEMBL873828,22224,,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,A,1,U,0,,BAO_0000218
8885,,,9823.0,Autocuration,Sus scrofa,1317,CHEMBL625383,22224,,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,A,1,U,0,,BAO_0000218
8886,,,9823.0,Autocuration,Sus scrofa,5229,CHEMBL625384,22224,,,,Half-life of the parent prodrug in porcine esterase solution,,A,1,U,0,,BAO_0000019
8887,,,9823.0,Autocuration,Sus scrofa,4231,CHEMBL625385,22224,,,,"First order rate constant, k was determined in in pig liver Esterase",,A,1,U,0,,BAO_0000019
8888,,2107.0,9823.0,Autocuration,Sus scrofa,4231,CHEMBL625386,22224,,,Liver,Half life of the in pig liver Esterase,,A,1,U,0,,BAO_0000221
8889,,2107.0,9823.0,Autocuration,Sus scrofa,5318,CHEMBL623571,22224,,,Liver,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,A,1,U,0,,BAO_0000221
8890,,2107.0,9823.0,Autocuration,Sus scrofa,5318,CHEMBL623572,22224,,,Liver,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,A,1,U,0,,BAO_0000221
8891,,2107.0,9823.0,Autocuration,Sus scrofa,5318,CHEMBL623573,22224,,,Liver,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,A,1,U,0,,BAO_0000221
8892,,2107.0,9823.0,Autocuration,Sus scrofa,3305,CHEMBL623574,22224,,,Liver,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,A,1,U,0,,BAO_0000221
8893,,2107.0,9823.0,Autocuration,Sus scrofa,3305,CHEMBL623575,22224,,,Liver,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,A,1,U,0,,BAO_0000221
8894,,2107.0,9823.0,Autocuration,Sus scrofa,2842,CHEMBL623749,22224,,,Liver,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,A,1,U,0,,BAO_0000221
8895,,2107.0,9823.0,Autocuration,Sus scrofa,2842,CHEMBL623750,22224,,,Liver,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,A,1,U,0,,BAO_0000221
8896,,2107.0,9823.0,Autocuration,Sus scrofa,889,CHEMBL623751,22224,,,Liver,Half-life in vitro in pig liver,,A,1,U,0,,BAO_0000221
8897,,2107.0,9823.0,Autocuration,Sus scrofa,1904,CHEMBL623752,22224,,,Liver,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,A,1,U,0,,BAO_0000221
8898,,1969.0,10116.0,Intermediate,Rattus norvegicus,4186,CHEMBL623753,50597,,,Plasma,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,A,1,N,1,,BAO_0000218
8899,,1969.0,10116.0,Intermediate,Rattus norvegicus,2774,CHEMBL623754,50597,,,Plasma,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,A,1,N,1,,BAO_0000218
8900,,1969.0,10116.0,Intermediate,Rattus norvegicus,1742,CHEMBL623755,50597,,,Plasma,Maximum concentration in rat plasma was determined,,A,1,N,1,,BAO_0000218
8901,,,10116.0,Intermediate,Rattus norvegicus,3169,CHEMBL623756,50597,,,,Maximum concentration in rats,,A,1,N,1,,BAO_0000218
8902,,,10116.0,Intermediate,Rattus norvegicus,3169,CHEMBL623757,50597,,,,Maximum concentration in rats at 1-2 hours,,A,1,N,1,,BAO_0000218
8903,,,10116.0,Intermediate,Rattus norvegicus,2081,CHEMBL623758,50597,,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,A,1,N,1,,BAO_0000218
8904,,955.0,10116.0,Intermediate,Rattus norvegicus,3307,CHEMBL623759,50597,,,Brain,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,A,1,N,1,,BAO_0000218
8905,,,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL623760,50597,,,,Maximum concentration at the dose of 2 mg/kg in rat,,A,1,N,1,,BAO_0000218
8906,,,10116.0,Intermediate,Rattus norvegicus,6597,CHEMBL623761,50597,,,,Maximum concentration was evaluated in rats,,A,1,N,1,,BAO_0000218
8907,,1969.0,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL623762,50597,,,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
8908,,1969.0,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL877594,50597,,,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
8909,,1969.0,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL623763,50597,,,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
8910,,1969.0,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL623764,50597,,,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
8911,,1969.0,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL623765,50597,,,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
8912,,178.0,10116.0,Intermediate,Rattus norvegicus,2591,CHEMBL623766,50597,,,Blood,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,A,1,N,1,,BAO_0000218
8913,,178.0,10116.0,Intermediate,Rattus norvegicus,2591,CHEMBL623767,50597,,,Blood,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,A,1,N,1,,BAO_0000218
8914,,178.0,10116.0,Intermediate,Rattus norvegicus,2591,CHEMBL623768,50597,,,Blood,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,A,1,N,1,,BAO_0000218
8915,,1969.0,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623769,50597,,,Plasma,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8916,,1969.0,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623770,50597,,,Plasma,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8917,,1969.0,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623771,50597,,,Plasma,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8918,,1969.0,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623772,50597,,,Plasma,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8919,,1969.0,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623773,50597,,,Plasma,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8920,,1969.0,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623774,50597,,,Plasma,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8921,,1969.0,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL623775,50597,,,Plasma,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
8922,,,10116.0,Intermediate,Rattus norvegicus,14465,CHEMBL623776,50597,,,,Cmax in rat (PO dose),,A,1,N,1,,BAO_0000218
8923,,1969.0,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL622191,50597,,,Plasma,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
8924,,1969.0,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL622192,50597,,,Plasma,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
8925,,1969.0,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL622193,50597,,,Plasma,Maximum plasma concentration determined in rat,,A,1,N,1,,BAO_0000218
8926,,1969.0,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL622194,50597,,,Plasma,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
8927,,1969.0,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL622195,50597,,,Plasma,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
8928,,1969.0,10116.0,Intermediate,Rattus norvegicus,6824,CHEMBL622196,50597,,,Plasma,Maximum plasma concentration in rat,,A,1,N,1,,BAO_0000218
8929,,1969.0,10116.0,Intermediate,Rattus norvegicus,17065,CHEMBL622197,50597,,,Plasma,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,A,1,N,1,,BAO_0000218
8930,,1969.0,10116.0,Intermediate,Rattus norvegicus,2932,CHEMBL622198,50597,,,Plasma,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,A,1,N,1,,BAO_0000218
8931,,1969.0,10116.0,Intermediate,Rattus norvegicus,2932,CHEMBL622199,50597,,,Plasma,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,A,1,N,1,,BAO_0000218
8932,,1969.0,10116.0,Intermediate,Rattus norvegicus,2879,CHEMBL622200,50597,,,Plasma,Maximum plasma concentration of compound was measured in rat,,A,1,N,1,,BAO_0000218
8933,,1969.0,10116.0,Intermediate,Rattus norvegicus,2864,CHEMBL622201,50597,,,Plasma,Maximum plasma concentration after 20 mg/kg oral administration in rat,,A,1,N,1,,BAO_0000218
8934,,1969.0,10116.0,Intermediate,Rattus norvegicus,16367,CHEMBL623990,50597,,,Plasma,Maximum plasma concentration after oral administration to rats,,A,1,N,1,,BAO_0000218
8935,,1969.0,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL623991,50597,,,Plasma,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,A,1,N,1,,BAO_0000218
8936,,1969.0,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL623992,50597,,,Plasma,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,A,1,N,1,,BAO_0000218
8937,,1969.0,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL623993,50597,,,Plasma,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,A,1,N,1,,BAO_0000218
8938,,1969.0,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL623994,50597,,,Plasma,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,A,1,N,1,,BAO_0000218
8939,,1969.0,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL623995,50597,,,Plasma,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,F,1,N,1,,BAO_0000218
8940,,1969.0,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL623996,50597,,,Plasma,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,F,1,N,1,,BAO_0000218
8941,,1969.0,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL623997,50597,,,Plasma,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,F,1,N,1,,BAO_0000218
8942,,1969.0,10116.0,Intermediate,Rattus norvegicus,4516,CHEMBL623998,50597,,,Plasma,Maximum plasma concentration dosed orally in rats,,A,1,N,1,,BAO_0000218
8943,,1969.0,10116.0,Intermediate,Rattus norvegicus,4516,CHEMBL623999,50597,,,Plasma,Maximum plasma concentration dosed orally in rats after 6 hours,,A,1,N,1,,BAO_0000218
8944,,1969.0,10116.0,Intermediate,Rattus norvegicus,4516,CHEMBL624000,50597,,,Plasma,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,A,1,N,1,,BAO_0000218
8945,,1969.0,10116.0,Intermediate,Rattus norvegicus,5199,CHEMBL624001,50597,,,Plasma,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
8946,,1969.0,10116.0,Intermediate,Rattus norvegicus,17538,CHEMBL624002,50597,,,Plasma,Maximum plasma concentration in rat after po administration,,A,1,N,1,,BAO_0000218
8947,,1969.0,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL624003,50597,,,Plasma,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
8948,,1969.0,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL624004,50597,,,Plasma,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,A,1,N,1,,BAO_0000218
8949,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624005,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8950,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624006,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8951,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624007,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8952,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624008,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8953,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624009,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8954,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL874387,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8955,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624010,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8956,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624011,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8957,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624012,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8958,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624013,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8959,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624736,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8960,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624737,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8961,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624738,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
8962,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624739,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
8963,,948.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL624740,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
8964,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624896,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8965,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624897,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
8966,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624108,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
8967,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624109,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8968,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624110,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
8969,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624111,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
8970,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624112,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8971,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL624113,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8972,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619709,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8973,,948.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619710,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8974,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619711,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8975,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619712,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8976,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619713,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8977,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619714,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8978,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619715,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
8979,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619716,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
8980,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619717,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
8981,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619718,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
8982,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619719,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8983,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL875329,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8984,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619720,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8985,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619721,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8986,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619722,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
8987,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619723,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
8988,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619724,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
8989,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619725,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
8990,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619726,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
8991,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619727,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
8992,,2113.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL619728,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
8993,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL619729,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
8994,,2385.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL619730,50597,,,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8995,,2385.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL619731,50597,,,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8996,,2385.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL619732,50597,,,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
8997,,2385.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL619733,50597,,,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8998,,2385.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL619734,50597,,,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
8999,,14.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL619735,50597,,,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9000,,14.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL875330,50597,,,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9001,,14.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL628465,50597,,,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
9002,,14.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL628466,50597,,,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9003,,14.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL628467,50597,,,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9004,,2106.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL628468,50597,,,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9005,,2106.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL628469,50597,,,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9006,,2106.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL628470,50597,,,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
9007,,2106.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL628471,50597,,,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9008,,2106.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL628472,50597,,,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9009,,2046.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625191,50597,,,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9010,,2046.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL625192,50597,,,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9011,,2046.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL875337,50597,,,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,A,1,N,1,,BAO_0000218
9012,,2046.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626341,50597,,,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9013,,2046.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL626342,50597,,,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9014,,2107.0,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL621943,50597,,,Liver,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,A,1,N,1,,BAO_0000218
9015,,,10116.0,Intermediate,Rattus norvegicus,3748,CHEMBL621944,50597,,,,Half life in rats,,A,1,N,1,,BAO_0000218
9016,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL621945,50597,,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,A,1,N,1,,BAO_0000218
9017,,,10116.0,Intermediate,Rattus norvegicus,4871,CHEMBL621946,50597,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,A,1,N,1,,BAO_0000218
9018,,,10116.0,Intermediate,Rattus norvegicus,4871,CHEMBL621947,50597,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,A,1,N,1,,BAO_0000218
9019,,,10116.0,Intermediate,Rattus norvegicus,4872,CHEMBL621948,50597,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,A,1,N,1,,BAO_0000218
9020,,,10116.0,Intermediate,Rattus norvegicus,4872,CHEMBL621949,50597,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,A,1,N,1,,BAO_0000218
9021,,,10116.0,Intermediate,Rattus norvegicus,5413,CHEMBL621950,50597,,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,A,1,N,1,,BAO_0000218
9022,,,10116.0,Intermediate,Rattus norvegicus,5413,CHEMBL621951,50597,,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,A,1,N,1,,BAO_0000218
9023,,178.0,10116.0,Intermediate,Rattus norvegicus,15272,CHEMBL621952,50597,,,Blood,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,A,1,N,1,,BAO_0000218
9024,,2107.0,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL621953,50597,,,Liver,Stability (%) in rat liver microsomes,,A,1,N,1,,BAO_0000218
9025,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL621954,50597,,,,Area under curve was calculated after intravenous administration,,A,1,N,1,,BAO_0000218
9026,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL621955,50597,,,,Area under the curve was calculated after iv administration in rat,,A,1,N,1,,BAO_0000218
9027,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL621956,50597,,,,Area under the curve was calculated in rat after peroral administration,,A,1,N,1,,BAO_0000218
9028,,,10116.0,Intermediate,Rattus norvegicus,6211,CHEMBL621957,50597,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
9029,,,10116.0,Intermediate,Rattus norvegicus,5710,CHEMBL621958,50597,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,A,1,N,1,,BAO_0000218
9030,,,10116.0,Intermediate,Rattus norvegicus,5710,CHEMBL621959,50597,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,A,1,N,1,,BAO_0000218
9031,,,10116.0,Intermediate,Rattus norvegicus,17853,CHEMBL621960,50597,,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,A,1,N,1,,BAO_0000218
9032,,,10116.0,Intermediate,Rattus norvegicus,17853,CHEMBL621961,50597,,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,A,1,N,1,,BAO_0000218
9033,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL621962,50597,,,,p value of the compound,,A,1,N,1,,BAO_0000218
9034,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL876787,50597,,,,p value of the compound,,F,1,N,1,,BAO_0000218
9035,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL621963,50597,,,,p value of the compound,,A,1,N,1,,BAO_0000218
9036,,945.0,10116.0,Intermediate,Rattus norvegicus,6175,CHEMBL622637,50597,,,Stomach,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,A,1,N,1,,BAO_0000218
9037,,945.0,10116.0,Intermediate,Rattus norvegicus,6175,CHEMBL622638,50597,,,Stomach,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,A,1,N,1,,BAO_0000218
9038,,945.0,10116.0,Intermediate,Rattus norvegicus,6175,CHEMBL626561,50597,,,Stomach,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,A,1,N,1,,BAO_0000218
9039,,,9986.0,Autocuration,Oryctolagus cuniculus,7991,CHEMBL626562,22224,,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,F,1,U,0,,BAO_0000019
9040,,,9986.0,Autocuration,Oryctolagus cuniculus,429,CHEMBL626563,22224,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,A,1,U,0,,BAO_0000218
9041,,,9986.0,Autocuration,Oryctolagus cuniculus,429,CHEMBL626564,22224,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,A,1,U,0,,BAO_0000218
9042,,,9986.0,Autocuration,Oryctolagus cuniculus,6253,CHEMBL626565,22224,,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,A,1,U,0,,BAO_0000218
9043,,,9986.0,Autocuration,Oryctolagus cuniculus,6253,CHEMBL626566,22224,,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,A,1,U,0,,BAO_0000218
9044,,,9986.0,Autocuration,Oryctolagus cuniculus,3615,CHEMBL626567,22224,,,,Clearance rate in rabbits,,A,1,U,0,,BAO_0000218
9045,,,9986.0,Autocuration,Oryctolagus cuniculus,4059,CHEMBL626568,22224,,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,A,1,U,0,,BAO_0000218
9046,,,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL626569,22224,,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,A,1,U,0,,BAO_0000218
9047,,,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL626570,22224,,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,A,1,U,0,,BAO_0000218
9048,,,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL626571,22224,,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,A,1,U,0,,BAO_0000218
9049,,,9986.0,Autocuration,Oryctolagus cuniculus,429,CHEMBL626572,22224,,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,A,1,U,0,,BAO_0000218
9050,,1969.0,9986.0,Autocuration,Oryctolagus cuniculus,4059,CHEMBL626573,22224,,,Plasma,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,A,1,U,0,,BAO_0000218
9051,Microsomes,2107.0,9986.0,Autocuration,Oryctolagus cuniculus,9659,CHEMBL626574,22224,,,Liver,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,A,1,U,0,,BAO_0000251
9052,Microsomes,2107.0,9986.0,Autocuration,Oryctolagus cuniculus,9659,CHEMBL626575,22224,,,Liver,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,A,1,U,0,,BAO_0000251
9053,,,9986.0,Autocuration,Oryctolagus cuniculus,3639,CHEMBL626576,22224,,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,A,1,U,0,,BAO_0000218
9054,,,9986.0,Autocuration,Oryctolagus cuniculus,3639,CHEMBL626577,22224,,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,,A,1,U,0,,BAO_0000218
9055,,,9986.0,Autocuration,Oryctolagus cuniculus,3639,CHEMBL626578,22224,,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,,A,1,U,0,,BAO_0000218
9056,,,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL625263,22224,,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,A,1,U,0,,BAO_0000218
9057,,,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL625264,22224,,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,A,1,U,0,,BAO_0000218
9058,,,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL625265,22224,,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,A,1,U,0,,BAO_0000218
9059,Microsomes,,9986.0,Autocuration,Oryctolagus cuniculus,14294,CHEMBL625266,22224,,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,A,1,U,0,,BAO_0000251
9060,Microsomes,,9986.0,Autocuration,Oryctolagus cuniculus,14294,CHEMBL876796,22224,,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,A,1,U,0,,BAO_0000251
9061,,,9986.0,Autocuration,Oryctolagus cuniculus,429,CHEMBL625267,22224,,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,A,1,U,0,,BAO_0000218
9062,,1969.0,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL625268,22224,,,Plasma,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,A,1,U,0,,BAO_0000218
9063,,1969.0,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL625269,22224,,,Plasma,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,A,1,U,0,,BAO_0000218
9064,,1969.0,9986.0,Autocuration,Oryctolagus cuniculus,5124,CHEMBL624689,22224,,,Plasma,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,A,1,U,0,,BAO_0000218
9065,,,9986.0,Autocuration,Oryctolagus cuniculus,429,CHEMBL624690,22224,,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,A,1,U,0,,BAO_0000218
9066,,1088.0,9986.0,Autocuration,Oryctolagus cuniculus,429,CHEMBL624691,22224,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,A,1,U,0,,BAO_0000218
9067,,1088.0,9986.0,Autocuration,Oryctolagus cuniculus,429,CHEMBL624692,22224,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,A,1,U,0,,BAO_0000218
9068,,,9986.0,Autocuration,Oryctolagus cuniculus,4059,CHEMBL624693,22224,,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,A,1,U,0,,BAO_0000218
9069,,,9986.0,Autocuration,Oryctolagus cuniculus,4137,CHEMBL624694,22224,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,A,1,U,0,,BAO_0000218
9070,,,9986.0,Autocuration,Oryctolagus cuniculus,11672,CHEMBL877596,22224,,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,A,1,U,0,,BAO_0000221
9071,,,9986.0,Autocuration,Oryctolagus cuniculus,12886,CHEMBL624695,22224,,,,Time within which only 10% of the drug was degraded,,A,1,U,0,,BAO_0000019
9072,,2107.0,9986.0,Autocuration,Oryctolagus cuniculus,3853,CHEMBL624696,22224,,,Liver,Half life period in rabbit liver homogenate,,A,1,U,0,,BAO_0000221
9073,,,9986.0,Autocuration,Oryctolagus cuniculus,3615,CHEMBL624697,22224,,,,Half life value in rabbits,,A,1,U,0,,BAO_0000019
9074,,178.0,9986.0,Autocuration,Oryctolagus cuniculus,6253,CHEMBL624698,22224,,,Blood,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,A,1,U,0,,BAO_0000218
9075,,178.0,9986.0,Autocuration,Oryctolagus cuniculus,6253,CHEMBL624699,22224,,,Blood,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,A,1,U,0,,BAO_0000218
9076,,,9986.0,Autocuration,Oryctolagus cuniculus,6077,CHEMBL624700,22224,,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,,A,1,U,0,,BAO_0000218
9077,,1969.0,10116.0,Intermediate,Rattus norvegicus,17617,CHEMBL622903,50597,,,Plasma,AUC 0-8 hr value in rats at 10 mg/kg,,A,1,N,1,,BAO_0000218
9078,,1969.0,10116.0,Intermediate,Rattus norvegicus,17594,CHEMBL622904,50597,,,Plasma,AUC after administration at 2000 mg/kg/day in rats,,A,1,N,1,,BAO_0000218
9079,,1969.0,10116.0,Intermediate,Rattus norvegicus,6149,CHEMBL622905,50597,,,Plasma,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,A,1,N,1,,BAO_0000218
9080,,1969.0,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL622906,50597,,,Plasma,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
9081,,1969.0,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL622907,50597,,,Plasma,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
9082,,1969.0,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL622908,50597,,,Plasma,AUC in rat after oral administration at 10.5 mg/kg dose,,A,1,N,1,,BAO_0000218
9083,,1969.0,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL622909,50597,,,Plasma,AUC in rat after oral administration at 11.2 mg/kg dose,,A,1,N,1,,BAO_0000218
9084,,1969.0,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL622910,50597,,,Plasma,AUC in rat after oral administration at 9.7 mg/kg dose,,A,1,N,1,,BAO_0000218
9085,,955.0,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL622911,50597,,,Brain,AUC in rat brain after oral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
9086,,1969.0,10116.0,Intermediate,Rattus norvegicus,6504,CHEMBL622912,50597,,,Plasma,AUC in rat p.o.,,A,1,N,1,,BAO_0000218
9087,,1969.0,10116.0,Intermediate,Rattus norvegicus,17686,CHEMBL622913,50597,,,Plasma,AUC in rat p.o. at 20 mg/kg concentration,,A,1,N,1,,BAO_0000218
9088,,1969.0,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL622914,50597,,,Plasma,AUC in rat plasma after oral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
9089,,1969.0,10116.0,Intermediate,Rattus norvegicus,216,CHEMBL622915,50597,,,Plasma,AUC in rats,,A,1,N,1,,BAO_0000218
9090,,1969.0,10116.0,Intermediate,Rattus norvegicus,1908,CHEMBL622916,50597,,,Plasma,AUC value after IV dose at a dose of 5 mg/kg in rats.,,A,1,N,1,,BAO_0000218
9091,,1969.0,10116.0,Intermediate,Rattus norvegicus,1908,CHEMBL622917,50597,,,Plasma,AUC value after oral dose at a dose of 10 mg/kg in rats.,,A,1,N,1,,BAO_0000218
9092,,1969.0,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622918,50597,,,Plasma,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,A,1,N,1,,BAO_0000218
9093,,1969.0,10116.0,Intermediate,Rattus norvegicus,216,CHEMBL622919,50597,,,Plasma,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,A,1,N,1,,BAO_0000218
9094,,1969.0,10116.0,Intermediate,Rattus norvegicus,6049,CHEMBL622920,50597,,,Plasma,Maximum plasma concentration was evaluated in rat,,A,1,N,1,,BAO_0000218
9095,,1969.0,10116.0,Intermediate,Rattus norvegicus,2463,CHEMBL622921,50597,,,Plasma,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,A,1,N,1,,BAO_0000218
9096,,1969.0,10116.0,Intermediate,Rattus norvegicus,6679,CHEMBL622922,50597,,,Plasma,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,A,1,N,1,,BAO_0000218
9097,,1969.0,10116.0,Intermediate,Rattus norvegicus,6681,CHEMBL622923,50597,,,Plasma,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,A,1,N,1,,BAO_0000218
9098,,1969.0,10116.0,Intermediate,Rattus norvegicus,4890,CHEMBL877604,50597,,,Plasma,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
9099,,1969.0,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL622924,50597,,,Plasma,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
9100,,1969.0,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL622925,50597,,,Plasma,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
9101,,1969.0,10116.0,Intermediate,Rattus norvegicus,16366,CHEMBL622926,50597,,,Plasma,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,A,1,N,1,,BAO_0000218
9102,,1969.0,10116.0,Intermediate,Rattus norvegicus,6227,CHEMBL623625,50597,,,Plasma,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9103,,1969.0,10116.0,Expert,Rattus norvegicus,3598,CHEMBL623626,50597,,,Plasma,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9104,,1969.0,10116.0,Intermediate,Rattus norvegicus,1465,CHEMBL623627,50597,,,Plasma,Maximum plasma drug concentration was determined,,A,1,N,1,,BAO_0000218
9105,,,10116.0,Intermediate,Rattus norvegicus,4368,CHEMBL623628,50597,,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,A,1,N,1,,BAO_0000218
9106,,1969.0,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL623629,50597,,,Plasma,Mean peak plasma concentration was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
9107,,1969.0,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL623630,50597,,,Plasma,Mean peak plasma concentration was observed after oral administration in rat,,A,1,N,1,,BAO_0000218
9108,,,10116.0,Intermediate,Rattus norvegicus,5355,CHEMBL623804,50597,,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,A,1,N,1,,BAO_0000218
9109,,,10116.0,Intermediate,Rattus norvegicus,5355,CHEMBL623805,50597,,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
9110,,1969.0,10116.0,Intermediate,Rattus norvegicus,1567,CHEMBL623806,50597,,,Plasma,Peak oral plasma concentration was determined in rats by oral administration,,A,1,N,1,,BAO_0000218
9111,,1969.0,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL623807,50597,,,Plasma,Peak plasma concentration (Cmax) was determined,,A,1,N,1,,BAO_0000218
9112,,1969.0,10116.0,Intermediate,Rattus norvegicus,6193,CHEMBL623808,50597,,,Plasma,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
9113,,1969.0,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL623809,50597,,,Plasma,Peak plasma concentration (Cmax) in rats,,A,1,N,1,,BAO_0000218
9114,,1969.0,10116.0,Intermediate,Rattus norvegicus,6485,CHEMBL623810,50597,,,Plasma,Peak plasma concentration at 1 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
9115,,1969.0,10116.0,Intermediate,Rattus norvegicus,17655,CHEMBL623811,50597,,,Plasma,Peak plasma concentration in rat,,A,1,N,1,,BAO_0000218
9116,,1969.0,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL623812,50597,,,Plasma,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,A,1,N,1,,BAO_0000218
9117,,,10116.0,Intermediate,Rattus norvegicus,5394,CHEMBL877605,50597,,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,A,1,N,1,,BAO_0000218
9118,,,10116.0,Intermediate,Rattus norvegicus,4408,CHEMBL623813,50597,,,,Pharmacokinetic property (Cmax) in rat,,A,1,N,1,,BAO_0000218
9119,,,10116.0,Intermediate,Rattus norvegicus,5983,CHEMBL623814,50597,,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,A,1,N,1,,BAO_0000218
9120,,,10116.0,Intermediate,Rattus norvegicus,4878,CHEMBL623815,50597,,,,Cmax in rat after 3mg/kg oral dose,,A,1,N,1,,BAO_0000218
9121,,,10116.0,Intermediate,Rattus norvegicus,5862,CHEMBL623816,50597,Sprague-Dawley,,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,A,1,N,1,,BAO_0000218
9122,,,10116.0,Intermediate,Rattus norvegicus,4517,CHEMBL623145,50597,,,,Cmax in rats after 20 mg/kg oral dose,,A,1,N,1,,BAO_0000218
9123,,1969.0,10116.0,Intermediate,Rattus norvegicus,5932,CHEMBL623146,50597,,,Plasma,Cmax in rat plasma after 30mg/kg oral dose,,A,1,N,1,,BAO_0000218
9124,,1969.0,10116.0,Intermediate,Rattus norvegicus,5436,CHEMBL623147,50597,,,Plasma,Plasma concentration after oral administration of 100 mg/kg to rats,,A,1,N,1,,BAO_0000218
9125,,955.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL623042,50597,,,Brain,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9126,,,10116.0,Intermediate,Rattus norvegicus,4950,CHEMBL623043,50597,,,,Tested for the Cmax in rat at 10 mg/kg per orally,,A,1,N,1,,BAO_0000218
9127,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL623044,50597,,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9128,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL623045,50597,,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9129,,,10116.0,Intermediate,Rattus norvegicus,3360,CHEMBL623046,50597,,,,Bioavailability as oral Cmax in rats at 30 mins,,A,1,N,1,,BAO_0000218
9130,,,10116.0,Intermediate,Rattus norvegicus,3360,CHEMBL623226,50597,,,,Bioavailability as oral Cmax in rats at 6hr,,A,1,N,1,,BAO_0000218
9131,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL623227,50597,,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,,A,1,N,1,,BAO_0000218
9132,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL623228,50597,,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,,A,1,N,1,,BAO_0000218
9133,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL623229,50597,,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,,A,1,N,1,,BAO_0000218
9134,,1969.0,10116.0,Intermediate,Rattus norvegicus,5160,CHEMBL623230,50597,,,Plasma,The maximum plasma levels for the compounds were determined by LC-MS.,,A,1,N,1,,BAO_0000218
9135,,1969.0,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL623231,50597,,,Plasma,mean peak plasma concentration was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
9136,,1969.0,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL623232,50597,,,Plasma,mean peak plasma concentration was observed after oral administration in rat,,A,1,N,1,,BAO_0000218
9137,,,10116.0,Intermediate,Rattus norvegicus,4709,CHEMBL623233,50597,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
9138,,,10116.0,Intermediate,Rattus norvegicus,3535,CHEMBL623234,50597,,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,A,1,N,1,,BAO_0000218
9139,,,10116.0,Intermediate,Rattus norvegicus,3535,CHEMBL623235,50597,,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,,A,1,N,1,,BAO_0000218
9140,,,10116.0,Intermediate,Rattus norvegicus,3535,CHEMBL623236,50597,,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,,A,1,N,1,,BAO_0000218
9141,,,10116.0,Intermediate,Rattus norvegicus,3535,CHEMBL623237,50597,,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,A,1,N,1,,BAO_0000218
9142,,,10116.0,Intermediate,Rattus norvegicus,3535,CHEMBL623238,50597,,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,A,1,N,1,,BAO_0000218
9143,,,10116.0,Intermediate,Rattus norvegicus,3535,CHEMBL623239,50597,,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,A,1,N,1,,BAO_0000218
9144,,1969.0,10116.0,Intermediate,Rattus norvegicus,5005,CHEMBL623240,22224,,,Plasma,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,A,1,U,0,,BAO_0000218
9145,,1898.0,10116.0,Intermediate,Rattus norvegicus,6326,CHEMBL623241,50597,,,Hypothalamus,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,A,1,N,1,,BAO_0000218
9146,,1898.0,10116.0,Intermediate,Rattus norvegicus,6326,CHEMBL623242,50597,,,Hypothalamus,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,A,1,N,1,,BAO_0000218
9147,,,10116.0,Intermediate,Rattus norvegicus,6326,CHEMBL874394,50597,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,A,1,N,1,,BAO_0000218
9148,,,10116.0,Intermediate,Rattus norvegicus,6326,CHEMBL623243,50597,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,A,1,N,1,,BAO_0000218
9149,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL623244,50597,,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9150,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623245,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9151,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623246,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9152,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623247,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9153,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623248,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9154,,2113.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623249,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9155,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625072,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9156,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625073,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9157,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625074,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9158,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625075,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9159,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625076,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9160,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625077,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9161,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625078,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9162,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL874395,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9163,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625079,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9164,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625080,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9165,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625081,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9166,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625082,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9167,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625083,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9168,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625084,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9169,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625085,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9170,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL625086,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9171,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625087,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
9172,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625088,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
9173,,2107.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622205,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
9174,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622206,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9175,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622207,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9176,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622366,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9177,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622367,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9178,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL875331,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9179,,2107.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622368,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9180,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622369,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9181,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622370,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9182,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622371,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9183,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622372,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9184,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622373,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9185,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622374,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9186,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622375,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9187,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622376,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9188,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622377,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9189,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622378,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9190,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622379,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9191,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622380,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9192,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622381,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9193,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622382,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9194,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622383,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
9195,,945.0,10116.0,Intermediate,Rattus norvegicus,6175,CHEMBL875332,50597,,,Stomach,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,A,1,N,1,,BAO_0000218
9196,,945.0,10116.0,Intermediate,Rattus norvegicus,6175,CHEMBL622384,50597,,,Stomach,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,A,1,N,1,,BAO_0000218
9197,,945.0,10116.0,Intermediate,Rattus norvegicus,6175,CHEMBL622385,50597,,,Stomach,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,A,1,N,1,,BAO_0000218
9198,,945.0,10116.0,Intermediate,Rattus norvegicus,6175,CHEMBL622386,50597,,,Stomach,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,A,1,N,1,,BAO_0000218
9199,,,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL622387,50597,,,,The compound was tested for the plasma binding in rat,,A,1,N,1,,BAO_0000218
9200,,,10116.0,Intermediate,Rattus norvegicus,16459,CHEMBL622388,50597,,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,A,1,N,1,,BAO_0000218
9201,,,10116.0,Intermediate,Rattus norvegicus,16459,CHEMBL622389,50597,,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,A,1,N,1,,BAO_0000218
9202,,,10116.0,Intermediate,Rattus norvegicus,16459,CHEMBL622390,50597,,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,A,1,N,1,,BAO_0000218
9203,,,10116.0,Intermediate,Rattus norvegicus,16459,CHEMBL622391,50597,,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,A,1,N,1,,BAO_0000218
9204,,,10116.0,Intermediate,Rattus norvegicus,16459,CHEMBL622392,50597,,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,A,1,N,1,,BAO_0000218
9205,,,10116.0,Intermediate,Rattus norvegicus,16459,CHEMBL622393,50597,,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,A,1,N,1,,BAO_0000218
9206,,,10116.0,Intermediate,Rattus norvegicus,3278,CHEMBL622394,50597,,,,Plasma level at 2 hr after administration of the compound,,A,1,N,1,,BAO_0000218
9207,,,10116.0,Intermediate,Rattus norvegicus,3278,CHEMBL622395,50597,,,,plasma level at 2 hr after administration of the compound,,A,1,N,1,,BAO_0000218
9208,,1977.0,10116.0,Intermediate,Rattus norvegicus,4684,CHEMBL622396,50597,,,Serum,Stability in rat serum measured as % recovery at 1 min,,A,1,N,1,,BAO_0000218
9209,,1977.0,10116.0,Intermediate,Rattus norvegicus,4684,CHEMBL624894,50597,,,Serum,Stability in rat serum measured as % recovery at 10 min,,A,1,N,1,,BAO_0000218
9210,,1977.0,10116.0,Intermediate,Rattus norvegicus,4684,CHEMBL624895,50597,,,Serum,Stability in rat serum measured as % recovery at 10 mins,,A,1,N,1,,BAO_0000218
9211,,1977.0,10116.0,Intermediate,Rattus norvegicus,4684,CHEMBL624058,50597,,,Serum,Stability in rat serum measured as % recovery at 2 hr,,A,1,N,1,,BAO_0000218
9212,,1977.0,10116.0,Intermediate,Rattus norvegicus,4684,CHEMBL624059,50597,,,Serum,Stability in rat serum measured as % recovery at 3 min,,A,1,N,1,,BAO_0000218
9213,,1977.0,10116.0,Intermediate,Rattus norvegicus,4684,CHEMBL624060,50597,,,Serum,Stability in rat serum measured as % recovery at 3 mins,,A,1,N,1,,BAO_0000218
9214,,1977.0,10116.0,Intermediate,Rattus norvegicus,4684,CHEMBL624061,50597,,,Serum,Stability in rat serum measured as % recovery at 5 min,,A,1,N,1,,BAO_0000218
9215,,1977.0,10116.0,Intermediate,Rattus norvegicus,4684,CHEMBL624062,50597,,,Serum,Stability in rat serum measured as % recovery at 5 mins,,A,1,N,1,,BAO_0000218
9216,,,10116.0,Intermediate,Rattus norvegicus,16456,CHEMBL624063,50597,,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9217,,,10116.0,Intermediate,Rattus norvegicus,16456,CHEMBL624064,50597,,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9218,,1969.0,10116.0,Intermediate,Rattus norvegicus,723,CHEMBL624065,50597,,,Plasma,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,A,1,N,1,,BAO_0000218
9219,,1969.0,10116.0,Intermediate,Rattus norvegicus,723,CHEMBL624066,50597,,,Plasma,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,A,1,N,1,,BAO_0000218
9220,,,10116.0,Intermediate,Rattus norvegicus,5160,CHEMBL877490,50597,,,,Half life tested in mature male rat at a dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
9221,,,10116.0,Intermediate,Rattus norvegicus,4709,CHEMBL874442,50597,,,,Half life after intravenous administration of 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
9222,,,10116.0,Intermediate,Rattus norvegicus,5633,CHEMBL626890,50597,,,,Half life period after administration (30 mg/kg) in rat,,A,1,N,1,,BAO_0000218
9223,,,10116.0,Intermediate,Rattus norvegicus,5302,CHEMBL626891,50597,,,,Half life period in rat after 5 mg/Kg dose,,A,1,N,1,,BAO_0000218
9224,,,10116.0,Intermediate,Rattus norvegicus,5302,CHEMBL626892,50597,,,,Half life period in rat after 5 mg/kg dose,,A,1,N,1,,BAO_0000218
9225,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL626893,50597,,,,Half life period was determined,,A,1,N,1,,BAO_0000218
9226,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL626894,50597,,,,Half life period was evaluated in rat,,A,1,N,1,,BAO_0000218
9227,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL626895,50597,,,,Half life period was evaluated in rat; 0.5-1.0,,A,1,N,1,,BAO_0000218
9228,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL626896,50597,,,,Half life period was evaluated in rat; 5.9-7.5,,A,1,N,1,,BAO_0000218
9229,,1969.0,10116.0,Intermediate,Rattus norvegicus,14512,CHEMBL626897,50597,,,Plasma,Half-life in rat plasma,,A,1,N,1,,BAO_0000218
9230,,,10116.0,Intermediate,Rattus norvegicus,6230,CHEMBL626898,50597,,,,Half-life time in rat was determined,,A,1,N,1,,BAO_0000218
9231,,,10116.0,Intermediate,Rattus norvegicus,3364,CHEMBL626899,50597,,,,Terminal half-life after iv administration to rats,,A,1,N,1,,BAO_0000218
9232,,,10116.0,Intermediate,Rattus norvegicus,6874,CHEMBL626900,50597,,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,A,1,N,1,,BAO_0000218
9233,,,10116.0,Intermediate,Rattus norvegicus,857,CHEMBL626901,50597,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,A,1,N,1,,BAO_0000218
9234,,,10116.0,Intermediate,Rattus norvegicus,858,CHEMBL626902,50597,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,A,1,N,1,,BAO_0000218
9235,,,10116.0,Intermediate,Rattus norvegicus,858,CHEMBL626903,50597,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,A,1,N,1,,BAO_0000218
9236,,,10116.0,Intermediate,Rattus norvegicus,5355,CHEMBL874443,50597,,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,A,1,N,1,,BAO_0000218
9237,,,10116.0,Intermediate,Rattus norvegicus,5355,CHEMBL626904,50597,,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
9238,,,10116.0,Intermediate,Rattus norvegicus,6305,CHEMBL626905,50597,,,,Half life in rats,,A,1,N,1,,BAO_0000218
9239,,1969.0,10116.0,Intermediate,Rattus norvegicus,13501,CHEMBL873830,50597,,,Plasma,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,A,1,N,1,,BAO_0000218
9240,,,10116.0,Intermediate,Rattus norvegicus,17594,CHEMBL626906,50597,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,A,1,N,1,,BAO_0000218
9241,,1969.0,10116.0,Intermediate,Rattus norvegicus,4186,CHEMBL631076,50597,,,Plasma,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,A,1,N,1,,BAO_0000218
9242,,1969.0,10116.0,Intermediate,Rattus norvegicus,2932,CHEMBL631077,50597,,,Plasma,Biological half-life was measured in plasma of rats,,A,1,N,1,,BAO_0000218
9243,,,10116.0,Intermediate,Rattus norvegicus,17065,CHEMBL631078,50597,,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,A,1,N,1,,BAO_0000218
9244,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL631079,50597,,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,A,1,N,1,,BAO_0000218
9245,,,10116.0,Intermediate,Rattus norvegicus,2713,CHEMBL631080,50597,,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,A,1,N,1,,BAO_0000218
9246,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL631081,50597,,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,A,1,N,1,,BAO_0000218
9247,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL631239,50597,,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,A,1,N,1,,BAO_0000218
9248,,1969.0,10116.0,Intermediate,Rattus norvegicus,740,CHEMBL631240,50597,,,Plasma,Compound was evaluated for plasma half life in rat,,A,1,N,1,,BAO_0000218
9249,,1969.0,10116.0,Intermediate,Rattus norvegicus,6597,CHEMBL631241,50597,,,Plasma,AUC value at a dose of 5 mg/kg (p.o.) in rats,,A,1,N,1,,BAO_0000218
9250,,1969.0,10116.0,Intermediate,Rattus norvegicus,2959,CHEMBL631242,50597,,,Plasma,AUC value after administration of 20 mg/Kg oral dose in rat,,A,1,N,1,,BAO_0000218
9251,,1969.0,10116.0,Intermediate,Rattus norvegicus,17594,CHEMBL631243,50597,,,Plasma,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,A,1,N,1,,BAO_0000218
9252,,1969.0,10116.0,Intermediate,Rattus norvegicus,17596,CHEMBL874444,50597,,,Plasma,AUC0-96 after administration at 50 mg/kg,,A,1,N,1,,BAO_0000218
9253,,1969.0,10116.0,Intermediate,Rattus norvegicus,17594,CHEMBL631244,50597,,,Plasma,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,A,1,N,1,,BAO_0000218
9254,,,10116.0,Intermediate,Rattus norvegicus,3293,CHEMBL631245,50597,,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,A,1,N,1,,BAO_0000218
9255,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL627162,50597,,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
9256,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL627163,50597,,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
9257,,,10116.0,Intermediate,Rattus norvegicus,6757,CHEMBL627164,50597,,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,A,1,N,1,,BAO_0000218
9258,,2113.0,10116.0,Intermediate,Rattus norvegicus,5979,CHEMBL627165,50597,,,Kidney,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,A,1,N,1,,BAO_0000218
9259,,,10116.0,Intermediate,Rattus norvegicus,5979,CHEMBL627166,50597,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,A,1,N,1,,BAO_0000218
9260,,,10116.0,Intermediate,Rattus norvegicus,5979,CHEMBL627167,50597,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,A,1,N,1,,BAO_0000218
9261,,,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL627822,50597,,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,,A,1,N,1,,BAO_0000218
9262,,,10116.0,Intermediate,Rattus norvegicus,5355,CHEMBL627823,50597,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
9263,,,10116.0,Intermediate,Rattus norvegicus,5355,CHEMBL627824,50597,,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,A,1,N,1,,BAO_0000218
9264,,,10116.0,Intermediate,Rattus norvegicus,5355,CHEMBL627825,50597,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
9265,,,10116.0,Intermediate,Rattus norvegicus,5633,CHEMBL627826,50597,,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,A,1,N,1,,BAO_0000218
9266,,,10116.0,Intermediate,Rattus norvegicus,1716,CHEMBL627827,50597,,,,Area under curve (Pharmacokinetic property) was determined,,A,1,N,1,,BAO_0000218
9267,,,10116.0,Intermediate,Rattus norvegicus,1716,CHEMBL627828,50597,,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,,A,1,N,1,,BAO_0000218
9268,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL627829,50597,,,,Area under curve after intravenous administration (1 mg/kg) in rat,,A,1,N,1,,BAO_0000218
9269,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL627830,50597,,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
9270,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL627831,50597,,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
9271,,,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL627832,50597,,,,Area under curve in male SD rats was observed after oral administration in rat,,A,1,N,1,,BAO_0000218
9272,,,10116.0,Intermediate,Rattus norvegicus,4413,CHEMBL627833,50597,,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,A,1,N,1,,BAO_0000218
9273,,,10116.0,Expert,Rattus norvegicus,3598,CHEMBL627834,50597,,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9274,,,10116.0,Expert,Rattus norvegicus,3598,CHEMBL628004,50597,,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9275,,,10116.0,Intermediate,Rattus norvegicus,5964,CHEMBL628005,50597,,,,Area under curve at 5 mg/kg po was determined in rat,,A,1,N,1,,BAO_0000218
9276,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL628006,50597,,,,Area under curve in Rat at a oral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
9277,,,10116.0,Intermediate,Rattus norvegicus,4186,CHEMBL628007,50597,,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,A,1,N,1,,BAO_0000218
9278,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL625676,50597,,,,Area under curve was determined,,A,1,N,1,,BAO_0000218
9279,,,10116.0,Intermediate,Rattus norvegicus,17858,CHEMBL631309,50597,,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,A,1,N,1,,BAO_0000218
9280,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL631310,50597,,,,Area under curve after intravenous administration at 3 mg/kg,,A,1,N,1,,BAO_0000218
9281,,,10116.0,Intermediate,Rattus norvegicus,6106,CHEMBL631311,50597,,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,A,1,N,1,,BAO_0000218
9282,,,10116.0,Intermediate,Rattus norvegicus,5964,CHEMBL631312,50597,,,,Area under curve at 4 hr in rat,,A,1,N,1,,BAO_0000218
9283,,,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL631313,50597,,,,Area under curve at a dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
9284,,,10116.0,Intermediate,Rattus norvegicus,4756,CHEMBL631314,50597,,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,A,1,N,1,,BAO_0000218
9285,,,10116.0,Intermediate,Rattus norvegicus,4756,CHEMBL631315,50597,,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,A,1,N,1,,BAO_0000218
9286,,,10116.0,Intermediate,Rattus norvegicus,5862,CHEMBL631316,50597,,,,Area under curve for a 2-mpk po dose in SD rats,,A,1,N,1,,BAO_0000218
9287,,,10116.0,Intermediate,Rattus norvegicus,5862,CHEMBL631317,50597,,,,Area under curve in SD rats,,A,1,N,1,,BAO_0000218
9288,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL874471,50597,,,,Area under curve in rat after oral administration at 13 mg/kg dose,,A,1,N,1,,BAO_0000218
9289,,,10116.0,Intermediate,Rattus norvegicus,5871,CHEMBL631318,50597,,,,Area under curve in rat by po administration at 0-24 hr,,A,1,N,1,,BAO_0000218
9290,,1969.0,10116.0,Intermediate,Rattus norvegicus,5919,CHEMBL631319,50597,,,Plasma,Area under curve in rat plasma,,A,1,N,1,,BAO_0000218
9291,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL631320,50597,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
9292,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL631321,50597,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
9293,,,10116.0,Intermediate,Rattus norvegicus,10,CHEMBL631322,50597,,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,A,1,N,1,,BAO_0000218
9294,,,10116.0,Intermediate,Rattus norvegicus,11149,CHEMBL631323,50597,,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,A,1,N,1,,BAO_0000218
9295,,,10116.0,Intermediate,Rattus norvegicus,5302,CHEMBL631324,50597,,,,Area under curve value in rat at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
9296,,,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL631325,50597,,,,Area under curve was determined after oral administration in rats,,A,1,N,1,,BAO_0000218
9297,,,10116.0,Intermediate,Rattus norvegicus,4890,CHEMBL631326,50597,,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
9298,,,10116.0,Intermediate,Rattus norvegicus,6011,CHEMBL631327,50597,,,,Area under curve was determined after peroral administration in rat,,A,1,N,1,,BAO_0000218
9299,,,10116.0,Intermediate,Rattus norvegicus,5375,CHEMBL631328,50597,,,,Area under curve was determined at a dose 30 mpk administered orally.,,A,1,N,1,,BAO_0000218
9300,,,10116.0,Intermediate,Rattus norvegicus,17764,CHEMBL631329,50597,,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,A,1,N,1,,BAO_0000218
9301,,,10116.0,Intermediate,Rattus norvegicus,4368,CHEMBL627217,50597,,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,A,1,N,1,,BAO_0000218
9302,,,10116.0,Intermediate,Rattus norvegicus,5610,CHEMBL626352,50597,,,,Area under curve was determined in male rat,,A,1,N,1,,BAO_0000218
9303,,,10116.0,Intermediate,Rattus norvegicus,5833,CHEMBL626353,50597,,,,Area under curve was determined in rat after PO administration,,A,1,N,1,,BAO_0000218
9304,,,10116.0,Intermediate,Rattus norvegicus,4257,CHEMBL626354,50597,,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,,A,1,N,1,,BAO_0000218
9305,,,10116.0,Intermediate,Rattus norvegicus,5937,CHEMBL626355,50597,,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,A,1,N,1,,BAO_0000218
9306,,,10116.0,Intermediate,Rattus norvegicus,5932,CHEMBL626356,50597,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,A,1,N,1,,BAO_0000218
9307,,,10116.0,Intermediate,Rattus norvegicus,5932,CHEMBL626357,50597,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,A,1,N,1,,BAO_0000218
9308,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL626358,50597,,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9309,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL626359,50597,,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9310,,1969.0,10116.0,Intermediate,Rattus norvegicus,17771,CHEMBL626360,50597,,,Plasma,Peak plasma concentration in rat at a dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
9311,,,10116.0,Intermediate,Rattus norvegicus,1628,CHEMBL626361,50597,,,,Plasma concentration at 2 hr in rats was evaluated.,,A,1,N,1,,BAO_0000218
9312,,,10116.0,Intermediate,Rattus norvegicus,1628,CHEMBL626362,50597,,,,Plasma concentration at 2 hr in rats was evaluated; Not available,,A,1,N,1,,BAO_0000218
9313,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL626363,50597,,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9314,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL626970,50597,,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9315,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL626971,50597,,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9316,,1969.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL626972,50597,,,Plasma,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9317,,1969.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL626973,50597,,,Plasma,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9318,,1969.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL626974,50597,,,Plasma,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9319,,1969.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL874592,50597,,,Plasma,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9320,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL626975,50597,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,A,1,N,1,,BAO_0000218
9321,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL626976,50597,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,A,1,N,1,,BAO_0000218
9322,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL626977,50597,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,A,1,N,1,,BAO_0000218
9323,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL626978,50597,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,A,1,N,1,,BAO_0000218
9324,,,10116.0,Intermediate,Rattus norvegicus,16427,CHEMBL626979,50597,,,,PK study was carried to determine the relative absorption ranking in rat.,,A,1,N,1,,BAO_0000218
9325,,1969.0,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL626980,50597,,,Plasma,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
9326,,178.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL626981,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,A,1,N,1,,BAO_0000218
9327,,178.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL626982,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,A,1,N,1,,BAO_0000218
9328,,178.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL626983,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,A,1,N,1,,BAO_0000218
9329,,178.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622522,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,A,1,N,1,,BAO_0000218
9330,,178.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622523,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,A,1,N,1,,BAO_0000218
9331,,178.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622524,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,A,1,N,1,,BAO_0000218
9332,,955.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622525,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,A,1,N,1,,BAO_0000218
9333,,955.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622526,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,A,1,N,1,,BAO_0000218
9334,,955.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL619849,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,A,1,N,1,,BAO_0000218
9335,,955.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL619850,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,A,1,N,1,,BAO_0000218
9336,,955.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL623864,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,A,1,N,1,,BAO_0000218
9337,,955.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL623865,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,A,1,N,1,,BAO_0000218
9338,,948.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL623866,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,A,1,N,1,,BAO_0000218
9339,,948.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL623867,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,A,1,N,1,,BAO_0000218
9340,,948.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL877615,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,A,1,N,1,,BAO_0000218
9341,,948.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL623868,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,A,1,N,1,,BAO_0000218
9342,,948.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL623869,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,A,1,N,1,,BAO_0000218
9343,,948.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL623870,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,A,1,N,1,,BAO_0000218
9344,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623871,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
9345,,2048.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623872,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
9346,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622129,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9347,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622130,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9348,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622131,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9349,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622132,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9350,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622133,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9351,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622134,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9352,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622135,50597,,,Lung,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9353,,2048.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622136,50597,,,Lung,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9354,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622137,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9355,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622138,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9356,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623017,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9357,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623018,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9358,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623019,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9359,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623020,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9360,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623021,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9361,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623022,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9362,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623023,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9363,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623024,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9364,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623025,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9365,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620545,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9366,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620546,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9367,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620547,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9368,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620548,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9369,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620549,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9370,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL620550,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
9371,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL620551,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
9372,,2385.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL620552,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
9373,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620553,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9374,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620554,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9375,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL875845,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9376,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620555,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9377,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620556,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9378,,2385.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL620557,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9379,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL620558,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9380,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL620559,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9381,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622939,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9382,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622940,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9383,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622941,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9384,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622942,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9385,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622943,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9386,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622944,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9387,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622945,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9388,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622946,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9389,,,10116.0,Intermediate,Rattus norvegicus,3341,CHEMBL622947,50597,,,,Compound was evaluated for terminal half life in rat,,A,1,N,1,,BAO_0000218
9390,,1969.0,10116.0,Intermediate,Rattus norvegicus,3634,CHEMBL622948,50597,,,Plasma,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,A,1,N,1,,BAO_0000218
9391,,1969.0,10116.0,Intermediate,Rattus norvegicus,3634,CHEMBL622949,50597,,,Plasma,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,A,1,N,1,,BAO_0000218
9392,,,10116.0,Intermediate,Rattus norvegicus,4839,CHEMBL622950,50597,,,,Compound was tested for its half life in rat,,A,1,N,1,,BAO_0000218
9393,,1969.0,9544.0,Intermediate,Macaca mulatta,5005,CHEMBL622951,22224,,,Plasma,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,A,1,U,0,,BAO_0000218
9394,,1969.0,10116.0,Intermediate,Rattus norvegicus,5005,CHEMBL622952,22224,,,Plasma,Compound was tested for its plasma half life in Sprague Dawley rats,,A,1,U,0,,BAO_0000366
9395,,1969.0,10116.0,Intermediate,Rattus norvegicus,5005,CHEMBL622953,22224,,,Plasma,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,A,1,U,0,,BAO_0000366
9396,,1969.0,10116.0,Intermediate,Rattus norvegicus,1094,CHEMBL873818,50597,,,Plasma,Compound was tested for plasma half-life period in rat,,A,1,N,1,,BAO_0000218
9397,,,10116.0,Intermediate,Rattus norvegicus,5031,CHEMBL622954,50597,,,,Elimination half life after i.v. administration of compound in rats,,A,1,N,1,,BAO_0000218
9398,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL622955,50597,,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,A,1,N,1,,BAO_0000218
9399,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL875229,50597,,,,Elimination half-life after IV dosing at 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
9400,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL622956,50597,,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,A,1,N,1,,BAO_0000218
9401,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL622957,50597,,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,A,1,N,1,,BAO_0000218
9402,,955.0,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL622958,50597,,,Brain,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,A,1,N,1,,BAO_0000218
9403,,1969.0,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL622959,50597,,,Plasma,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,A,1,N,1,,BAO_0000218
9404,,955.0,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL622960,50597,,,Brain,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,A,1,N,1,,BAO_0000218
9405,,1969.0,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL622961,50597,,,Plasma,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,A,1,N,1,,BAO_0000218
9406,,,10116.0,Intermediate,Rattus norvegicus,4687,CHEMBL622962,50597,,,,Evaluated for the half life in rat (in vivo),,A,1,N,1,,BAO_0000218
9407,,,10116.0,Intermediate,Rattus norvegicus,6640,CHEMBL622963,50597,,,,Hafl life in rat,,A,1,N,1,,BAO_0000218
9408,,,10116.0,Intermediate,Rattus norvegicus,6640,CHEMBL622964,50597,,,,Hafl life rat,,A,1,N,1,,BAO_0000218
9409,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL622965,50597,,,,Hafl life rat,,A,1,N,1,,BAO_0000218
9410,,,10116.0,Intermediate,Rattus norvegicus,6640,CHEMBL622966,50597,,,,Hafl life rat; Not determined,,A,1,N,1,,BAO_0000218
9411,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL622967,50597,,,,Hafl life rat; Not determined,,A,1,N,1,,BAO_0000218
9412,,2113.0,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL622968,50597,,,Kidney,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9413,,2107.0,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL622969,50597,,,Liver,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9414,,2048.0,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL875327,50597,,,Lung,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9415,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL628638,50597,,,,Half life in rat after 1 mg/kg i.v. administration,,A,1,N,1,,BAO_0000218
9416,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL628639,50597,,,,Half life in rat after 2 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
9417,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL625840,50597,,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9418,,,10116.0,Intermediate,Rattus norvegicus,4722,CHEMBL625841,50597,,,,Half life of 10 mg/kg oral dose determined in rats,,A,1,N,1,,BAO_0000218
9419,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL625842,50597,,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9420,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL625843,50597,,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9421,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL625844,50597,,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9422,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL873822,50597,,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9423,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL625845,50597,,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9424,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL627059,50597,,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9425,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL627060,50597,,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9426,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL627061,50597,,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9427,,,10116.0,Intermediate,Rattus norvegicus,4762,CHEMBL627709,50597,,,,Half life of compound at 5 mg/kg after po administration was determined in rat,,A,1,N,1,,BAO_0000218
9428,,,10116.0,Intermediate,Rattus norvegicus,5327,CHEMBL627710,50597,,,,Half life of compound determined after intravenous administration to rat,,A,1,N,1,,BAO_0000218
9429,,,10116.0,Intermediate,Rattus norvegicus,4847,CHEMBL627711,50597,,,,Half life of compound was determined in rat,,A,1,N,1,,BAO_0000218
9430,,1969.0,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL627712,50597,,,Plasma,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,A,1,N,1,,BAO_0000218
9431,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL627713,50597,,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
9432,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL627714,50597,,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
9433,,,9541.0,Intermediate,Macaca fascicularis,4256,CHEMBL627889,22224,,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,A,1,U,0,,BAO_0000218
9434,,,10116.0,Intermediate,Rattus norvegicus,4256,CHEMBL627890,22224,,,,Half life determined in rat by intravenous administration,,A,1,U,0,,BAO_0000218
9435,,,10116.0,Intermediate,Rattus norvegicus,4722,CHEMBL627891,50597,,,,Half life determined in rats after iv administration,,A,1,N,1,,BAO_0000218
9436,,1969.0,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL627892,50597,,,Plasma,Half life in rat plasma after administration of 2 mg/kg iv,,A,1,N,1,,BAO_0000218
9437,,1969.0,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL627893,50597,,,Plasma,Half life in rat plasma after administration of 2 mg/kg iv,,A,1,N,1,,BAO_0000218
9438,,1969.0,10116.0,Intermediate,Rattus norvegicus,1435,CHEMBL627894,50597,,,Plasma,Half life in rat plasma was determined,,A,1,N,1,,BAO_0000218
9439,,1969.0,10116.0,Intermediate,Rattus norvegicus,1435,CHEMBL627895,50597,,,Plasma,Half life in rat plasma was determined; NA means not applicable,,A,1,N,1,,BAO_0000218
9440,,,10116.0,Intermediate,Rattus norvegicus,5206,CHEMBL627896,50597,,,,Half life in rat was tested,,A,1,N,1,,BAO_0000218
9441,,1969.0,10116.0,Intermediate,Rattus norvegicus,6080,CHEMBL627897,50597,,,Plasma,Half life measured in rat plasma,,A,1,N,1,,BAO_0000218
9442,,,10116.0,Intermediate,Rattus norvegicus,4449,CHEMBL627898,50597,,,,Half life recorded in rats,,A,1,N,1,,BAO_0000218
9443,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL627899,50597,,,,Half life was calculated,,A,1,N,1,,BAO_0000218
9444,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL873823,50597,,,,Half life was calculated in rat,,A,1,N,1,,BAO_0000218
9445,,,10116.0,Intermediate,Rattus norvegicus,3747,CHEMBL627900,50597,,,,Half life was determined,,A,1,N,1,,BAO_0000218
9446,,,10116.0,Intermediate,Rattus norvegicus,17858,CHEMBL627901,50597,,,,Half life after 10 mg/kg oral administration in rat,,A,1,N,1,,BAO_0000218
9447,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL627902,50597,,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
9448,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL627903,50597,,,,Half life after administering orally a dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
9449,,,10116.0,Intermediate,Rattus norvegicus,5031,CHEMBL627904,50597,,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,A,1,N,1,,BAO_0000218
9450,,,10116.0,Intermediate,Rattus norvegicus,4722,CHEMBL627905,50597,,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,A,1,N,1,,BAO_0000218
9451,,,10116.0,Intermediate,Rattus norvegicus,6078,CHEMBL627906,50597,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,A,1,N,1,,BAO_0000218
9452,,,10116.0,Intermediate,Rattus norvegicus,6078,CHEMBL627907,50597,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,A,1,N,1,,BAO_0000218
9453,,,10116.0,Intermediate,Rattus norvegicus,6078,CHEMBL876783,50597,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9454,,,10116.0,Intermediate,Rattus norvegicus,6078,CHEMBL627908,50597,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,A,1,N,1,,BAO_0000218
9455,,,10116.0,Intermediate,Rattus norvegicus,17065,CHEMBL627909,50597,,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,A,1,N,1,,BAO_0000218
9456,,,10116.0,Intermediate,Rattus norvegicus,1353,CHEMBL627910,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,A,1,N,1,,BAO_0000218
9457,,,10116.0,Intermediate,Rattus norvegicus,1353,CHEMBL627911,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,A,1,N,1,,BAO_0000218
9458,,,10116.0,Intermediate,Rattus norvegicus,1353,CHEMBL627912,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,A,1,N,1,,BAO_0000218
9459,,,10116.0,Intermediate,Rattus norvegicus,1353,CHEMBL627913,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,A,1,N,1,,BAO_0000218
9460,,,10116.0,Intermediate,Rattus norvegicus,1353,CHEMBL627914,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,A,1,N,1,,BAO_0000218
9461,,,10116.0,Intermediate,Rattus norvegicus,16423,CHEMBL627915,50597,,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,A,1,N,1,,BAO_0000218
9462,,,10116.0,Intermediate,Rattus norvegicus,16423,CHEMBL627916,50597,,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,,A,1,N,1,,BAO_0000218
9463,,,10116.0,Intermediate,Rattus norvegicus,6062,CHEMBL627917,50597,,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
9464,,,10116.0,Intermediate,Rattus norvegicus,6056,CHEMBL627918,50597,,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,A,1,N,1,,BAO_0000218
9465,,,10116.0,Intermediate,Rattus norvegicus,5182,CHEMBL627919,50597,,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,A,1,N,1,,BAO_0000218
9466,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL627920,50597,,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
9467,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL627921,50597,,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
9468,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL627922,50597,,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
9469,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL876784,50597,,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
9470,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL627923,50597,,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
9471,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL626208,50597,,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
9472,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL626209,50597,,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
9473,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL626210,50597,,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
9474,,1969.0,10116.0,Intermediate,Rattus norvegicus,2463,CHEMBL627994,50597,,,Plasma,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,A,1,N,1,,BAO_0000218
9475,,,10116.0,Intermediate,Rattus norvegicus,4709,CHEMBL627995,50597,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
9476,,,10116.0,Intermediate,Rattus norvegicus,4075,CHEMBL627996,50597,,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,A,1,N,1,,BAO_0000218
9477,,,10116.0,Intermediate,Rattus norvegicus,5394,CHEMBL627997,50597,,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,A,1,N,1,,BAO_0000218
9478,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL627998,50597,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,A,1,N,1,,BAO_0000218
9479,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL628640,50597,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,A,1,N,1,,BAO_0000218
9480,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL628641,50597,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,A,1,N,1,,BAO_0000218
9481,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL628642,50597,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,A,1,N,1,,BAO_0000218
9482,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL628643,50597,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,A,1,N,1,,BAO_0000218
9483,,,10116.0,Intermediate,Rattus norvegicus,2591,CHEMBL628644,50597,,,,Compound was tested for area under curve in rat,,A,1,N,1,,BAO_0000218
9484,,,10116.0,Intermediate,Rattus norvegicus,6567,CHEMBL628645,50597,,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,A,1,N,1,,BAO_0000218
9485,,,10116.0,Intermediate,Rattus norvegicus,6211,CHEMBL628646,50597,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
9486,,,10116.0,Intermediate,Rattus norvegicus,5529,CHEMBL628647,50597,,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,A,1,N,1,,BAO_0000218
9487,,,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL628648,50597,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,A,1,N,1,,BAO_0000218
9488,,,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL625358,50597,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,A,1,N,1,,BAO_0000218
9489,,,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL625359,50597,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,A,1,N,1,,BAO_0000218
9490,,,10116.0,Intermediate,Rattus norvegicus,5408,CHEMBL625360,50597,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,A,1,N,1,,BAO_0000218
9491,,,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL625361,50597,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,A,1,N,1,,BAO_0000218
9492,,,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL625362,50597,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,A,1,N,1,,BAO_0000218
9493,,,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL625363,50597,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,A,1,N,1,,BAO_0000218
9494,,,10116.0,Intermediate,Rattus norvegicus,4796,CHEMBL625364,50597,,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,A,1,N,1,,BAO_0000218
9495,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL625365,50597,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9496,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL625366,50597,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9497,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL625367,50597,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9498,,2113.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625368,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,A,1,N,1,,BAO_0000218
9499,,2113.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625369,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,A,1,N,1,,BAO_0000218
9500,,2113.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625370,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,A,1,N,1,,BAO_0000218
9501,,2113.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625371,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,A,1,N,1,,BAO_0000218
9502,,2113.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625372,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,A,1,N,1,,BAO_0000218
9503,,2113.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625373,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,A,1,N,1,,BAO_0000218
9504,,2107.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625374,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,A,1,N,1,,BAO_0000218
9505,,2107.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL877593,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,A,1,N,1,,BAO_0000218
9506,,2107.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625375,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,A,1,N,1,,BAO_0000218
9507,,2107.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL625376,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,A,1,N,1,,BAO_0000218
9508,,2107.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL621973,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,A,1,N,1,,BAO_0000218
9509,,2107.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL621974,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,A,1,N,1,,BAO_0000218
9510,,2048.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL621975,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,A,1,N,1,,BAO_0000218
9511,,2048.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622166,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,A,1,N,1,,BAO_0000218
9512,,2048.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622167,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,A,1,N,1,,BAO_0000218
9513,,2048.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622168,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,A,1,N,1,,BAO_0000218
9514,,2048.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622169,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,A,1,N,1,,BAO_0000218
9515,,2048.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622170,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,A,1,N,1,,BAO_0000218
9516,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622171,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,A,1,N,1,,BAO_0000218
9517,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622172,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,A,1,N,1,,BAO_0000218
9518,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622173,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,A,1,N,1,,BAO_0000218
9519,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622174,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,A,1,N,1,,BAO_0000218
9520,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622175,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,A,1,N,1,,BAO_0000218
9521,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622176,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,A,1,N,1,,BAO_0000218
9522,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622177,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,A,1,N,1,,BAO_0000218
9523,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622178,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,A,1,N,1,,BAO_0000218
9524,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622179,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,A,1,N,1,,BAO_0000218
9525,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622180,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,A,1,N,1,,BAO_0000218
9526,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622181,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9527,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622182,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9528,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622183,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9529,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622184,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9530,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622185,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9531,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622186,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9532,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622187,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
9533,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625002,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
9534,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622090,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
9535,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622091,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9536,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622092,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9537,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622093,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9538,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622094,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9539,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622095,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9540,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622264,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9541,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622265,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9542,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622266,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9543,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622267,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9544,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622268,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9545,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622269,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9546,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL625071,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9547,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621621,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9548,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621622,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9549,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621623,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9550,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621624,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9551,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621625,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9552,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621626,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9553,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621627,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9554,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621628,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9555,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL875328,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9556,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621629,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9557,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621630,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
9558,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621631,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
9559,,2106.0,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL621632,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
9560,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621633,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9561,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621634,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9562,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621635,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9563,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621636,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9564,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621637,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9565,,2106.0,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL621638,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9566,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL618883,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9567,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL618884,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9568,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL628627,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9569,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL628628,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9570,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL628629,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9571,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL628630,50597,,,,Half life after administering orally a dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
9572,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL628631,50597,,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
9573,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL628632,50597,,,,Half life after administering intravenously a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
9574,,,10116.0,Intermediate,Rattus norvegicus,526,CHEMBL628633,50597,,,,Half life after oral dosing in rats,,A,1,N,1,,BAO_0000218
9575,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL628634,50597,,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,A,1,N,1,,BAO_0000218
9576,,,10116.0,Intermediate,Rattus norvegicus,4368,CHEMBL627789,50597,,,,Half life by intravenous administration of 3.4 mg/kg in rat,,A,1,N,1,,BAO_0000218
9577,,,10116.0,Intermediate,Rattus norvegicus,3371,CHEMBL627790,50597,,,,Half life in rat,,A,1,N,1,,BAO_0000218
9578,,,10116.0,Intermediate,Rattus norvegicus,6448,CHEMBL627791,50597,,,,Half life in rat,,A,1,N,1,,BAO_0000218
9579,,,10116.0,Intermediate,Rattus norvegicus,6453,CHEMBL627792,50597,,,,Half life in rat,,A,1,N,1,,BAO_0000218
9580,,,10116.0,Intermediate,Rattus norvegicus,4353,CHEMBL627793,50597,,,,Half life in rat after intravenous administration of the compound,,A,1,N,1,,BAO_0000218
9581,,1969.0,10116.0,Intermediate,Rattus norvegicus,4353,CHEMBL627794,50597,,,Plasma,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,A,1,N,1,,BAO_0000218
9582,,,10116.0,Intermediate,Rattus norvegicus,4353,CHEMBL627795,50597,,,,Half life in rat after po administration of the compound,,A,1,N,1,,BAO_0000218
9583,,,10116.0,Intermediate,Rattus norvegicus,4353,CHEMBL627796,50597,,,,Half life in rat after po administration of the compound; ND means Not determined,,A,1,N,1,,BAO_0000218
9584,,1969.0,10116.0,Intermediate,Rattus norvegicus,4353,CHEMBL875335,50597,,,Plasma,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,A,1,N,1,,BAO_0000218
9585,,1969.0,10116.0,Intermediate,Rattus norvegicus,4353,CHEMBL627797,50597,,,Plasma,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,A,1,N,1,,BAO_0000218
9586,,,10116.0,Intermediate,Rattus norvegicus,5789,CHEMBL627798,50597,,,,Half life in rat i.v.,,A,1,N,1,,BAO_0000218
9587,,,10116.0,Intermediate,Rattus norvegicus,17686,CHEMBL627799,50597,,,,Half life in rat i.v. at 2 mg/kg concentration,,A,1,N,1,,BAO_0000218
9588,,,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL627800,50597,,,,Half life in rats,,A,1,N,1,,BAO_0000218
9589,,,10116.0,Intermediate,Rattus norvegicus,484,CHEMBL627801,50597,,,,Half life in rats after intravenous administration,,A,1,N,1,,BAO_0000218
9590,,,10116.0,Intermediate,Rattus norvegicus,6467,CHEMBL627802,50597,,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,,A,1,N,1,,BAO_0000218
9591,,,10116.0,Expert,Rattus norvegicus,6642,CHEMBL627803,50597,,,,Half life in rat,,A,1,N,1,,BAO_0000218
9592,,,10116.0,Intermediate,Rattus norvegicus,16367,CHEMBL873820,50597,,,,Half life was evaluated after intravenous administration to rats,,A,1,N,1,,BAO_0000218
9593,,,10116.0,Intermediate,Rattus norvegicus,1369,CHEMBL627804,50597,,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,A,1,N,1,,BAO_0000218
9594,,,10116.0,Intermediate,Rattus norvegicus,5472,CHEMBL627805,50597,,,,Half life was evaluated in rat,,A,1,N,1,,BAO_0000218
9595,,,10116.0,Intermediate,Rattus norvegicus,6049,CHEMBL627806,50597,,,,Half life was evaluated in rat,,A,1,N,1,,BAO_0000218
9596,,,10116.0,Intermediate,Rattus norvegicus,5472,CHEMBL627107,50597,,,,Half life was evaluated in rat; Not tested,,A,1,N,1,,BAO_0000218
9597,,,10116.0,Intermediate,Rattus norvegicus,16366,CHEMBL627108,50597,,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,A,1,N,1,,BAO_0000218
9598,,,10116.0,Intermediate,Rattus norvegicus,11149,CHEMBL627109,50597,,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,A,1,N,1,,BAO_0000218
9599,,178.0,10116.0,Intermediate,Rattus norvegicus,11149,CHEMBL627110,50597,,,Blood,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,A,1,N,1,,BAO_0000218
9600,,,9443.0,Intermediate,Primates,2891,CHEMBL627111,22224,,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,A,1,U,0,,BAO_0000218
9601,,,9443.0,Intermediate,Primates,2891,CHEMBL627112,22224,,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,A,1,U,0,,BAO_0000218
9602,,,10116.0,Intermediate,Rattus norvegicus,2891,CHEMBL627113,22224,,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,,A,1,U,0,,BAO_0000218
9603,,,10116.0,Intermediate,Rattus norvegicus,2891,CHEMBL627114,22224,,,,Half life was measured in rat at dose of 30 mg/kg by po administration,,A,1,U,0,,BAO_0000218
9604,,,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL627115,50597,,,,Half life (t1/2) was determined,,A,1,N,1,,BAO_0000218
9605,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL627116,50597,,,,Half life period at a dose of 10 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
9606,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL627117,50597,,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,A,1,N,1,,BAO_0000218
9607,,,10116.0,Intermediate,Rattus norvegicus,5503,CHEMBL627118,50597,,,,Half life period was determined,,A,1,N,1,,BAO_0000218
9608,,,10116.0,Intermediate,Rattus norvegicus,4426,CHEMBL627119,50597,,,,Half life period after intravenous administration at 20 mpk in rats,,A,1,N,1,,BAO_0000218
9609,,,10116.0,Intermediate,Rattus norvegicus,4426,CHEMBL627120,50597,,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,A,1,N,1,,BAO_0000218
9610,,,10116.0,Intermediate,Rattus norvegicus,6109,CHEMBL626922,50597,,,,Half life period after intravenous administration in rat,,A,1,N,1,,BAO_0000218
9611,,,10116.0,Intermediate,Rattus norvegicus,5654,CHEMBL626923,50597,,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
9612,,,10116.0,Intermediate,Rattus norvegicus,5654,CHEMBL626924,50597,,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
9613,,1969.0,10116.0,Intermediate,Rattus norvegicus,4755,CHEMBL626925,50597,,,Plasma,Half life period in 80% rat plasma at 37 degree Centigrade,,A,1,N,1,,BAO_0000218
9614,,,10116.0,Intermediate,Rattus norvegicus,5862,CHEMBL626926,50597,,,,Half life period in SD rats,,A,1,N,1,,BAO_0000218
9615,,1969.0,10116.0,Intermediate,Rattus norvegicus,1515,CHEMBL626927,50597,,,Plasma,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,A,1,N,1,,BAO_0000218
9616,,1969.0,10116.0,Intermediate,Rattus norvegicus,1515,CHEMBL626928,50597,,,Plasma,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,A,1,N,1,,BAO_0000218
9617,,1969.0,10116.0,Intermediate,Rattus norvegicus,1515,CHEMBL626929,50597,,,Plasma,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,A,1,N,1,,BAO_0000218
9618,,1969.0,10116.0,Intermediate,Rattus norvegicus,1515,CHEMBL626930,50597,,,Plasma,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,A,1,N,1,,BAO_0000218
9619,,,10116.0,Intermediate,Rattus norvegicus,5960,CHEMBL626931,50597,,,,Half life period in rat,,A,1,N,1,,BAO_0000218
9620,,,10116.0,Intermediate,Rattus norvegicus,6103,CHEMBL626932,50597,,,,Half life period in rat,,A,1,N,1,,BAO_0000218
9621,,,10116.0,Intermediate,Rattus norvegicus,6317,CHEMBL626933,50597,,,,Half life period in rat,,A,1,N,1,,BAO_0000218
9622,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL873826,50597,,,,Half life period in rat after oral administration at 10.5 mg/kg dose,,A,1,N,1,,BAO_0000218
9623,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL626934,50597,,,,Half life period in rat after oral administration at 11.2 mg/kg dose,,A,1,N,1,,BAO_0000218
9624,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL626935,50597,,,,Half life period in rat after oral administration at 13 mg/kg dose,,A,1,N,1,,BAO_0000218
9625,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL626936,50597,,,,Half life period in rat after oral administration at 9.7 mg/kg dose,,A,1,N,1,,BAO_0000218
9626,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL626937,50597,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
9627,,,10116.0,Intermediate,Rattus norvegicus,6295,CHEMBL625906,50597,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
9628,,,10116.0,Intermediate,Rattus norvegicus,6296,CHEMBL625907,50597,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,A,1,N,1,,BAO_0000218
9629,,,10116.0,Intermediate,Rattus norvegicus,16427,CHEMBL625908,50597,,,,PK study was carried to determine AUC (area under curve) value in rat,,A,1,N,1,,BAO_0000218
9630,,,10116.0,Intermediate,Rattus norvegicus,16367,CHEMBL625909,50597,,,,Pharmacokinetic parameter AUC after intravenous administration to rats,,A,1,N,1,,BAO_0000218
9631,,,10116.0,Intermediate,Rattus norvegicus,16367,CHEMBL625910,50597,,,,Pharmacokinetic parameter AUC after oral administration to rats,,A,1,N,1,,BAO_0000218
9632,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL625911,50597,,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,A,1,N,1,,BAO_0000218
9633,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL625912,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,A,1,N,1,,BAO_0000218
9634,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL626538,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,A,1,N,1,,BAO_0000218
9635,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL876794,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,A,1,N,1,,BAO_0000218
9636,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL626539,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,A,1,N,1,,BAO_0000218
9637,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL626540,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,A,1,N,1,,BAO_0000218
9638,,,10116.0,Intermediate,Rattus norvegicus,5394,CHEMBL626541,50597,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,A,1,N,1,,BAO_0000218
9639,,,10116.0,Intermediate,Rattus norvegicus,5394,CHEMBL626542,50597,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,A,1,N,1,,BAO_0000218
9640,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL626543,50597,,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
9641,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL626544,50597,,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,A,1,N,1,,BAO_0000218
9642,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL626545,50597,,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
9643,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL626546,50597,,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,A,1,N,1,,BAO_0000218
9644,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL626547,50597,,,,Pharmacokinetic parameter area under curve was reported,,A,1,N,1,,BAO_0000218
9645,,,10116.0,Intermediate,Rattus norvegicus,4408,CHEMBL626548,50597,,,,Pharmacokinetic property (AUC) in rat,,A,1,N,1,,BAO_0000218
9646,,,10116.0,Intermediate,Rattus norvegicus,5983,CHEMBL626549,50597,,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,A,1,N,1,,BAO_0000218
9647,,,10116.0,Intermediate,Rattus norvegicus,4397,CHEMBL626550,50597,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,A,1,N,1,,BAO_0000218
9648,,,10116.0,Intermediate,Rattus norvegicus,4397,CHEMBL626551,50597,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,A,1,N,1,,BAO_0000218
9649,,,10116.0,Intermediate,Rattus norvegicus,5491,CHEMBL623777,50597,,,,Pharmacokinetic property was determined,,A,1,N,1,,BAO_0000218
9650,,,10116.0,Intermediate,Rattus norvegicus,5491,CHEMBL623778,50597,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,A,1,N,1,,BAO_0000218
9651,,,10116.0,Intermediate,Rattus norvegicus,5491,CHEMBL623779,50597,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,A,1,N,1,,BAO_0000218
9652,,1969.0,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL623780,50597,,,Plasma,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,A,1,N,1,,BAO_0000218
9653,,1969.0,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL622015,50597,,,Plasma,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,A,1,N,1,,BAO_0000218
9654,,1969.0,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL622016,50597,,,Plasma,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,A,1,N,1,,BAO_0000218
9655,,,10116.0,Intermediate,Rattus norvegicus,5173,CHEMBL622017,50597,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,A,1,N,1,,BAO_0000218
9656,,,10116.0,Intermediate,Rattus norvegicus,5173,CHEMBL622018,50597,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,A,1,N,1,,BAO_0000218
9657,,,10116.0,Intermediate,Rattus norvegicus,5173,CHEMBL622019,50597,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,A,1,N,1,,BAO_0000218
9658,,,10116.0,Intermediate,Rattus norvegicus,5173,CHEMBL622020,50597,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,A,1,N,1,,BAO_0000218
9659,,,10116.0,Intermediate,Rattus norvegicus,16366,CHEMBL622021,50597,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,A,1,N,1,,BAO_0000218
9660,,,10116.0,Intermediate,Rattus norvegicus,16366,CHEMBL622022,50597,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,A,1,N,1,,BAO_0000218
9661,,,10116.0,Intermediate,Rattus norvegicus,5327,CHEMBL622023,50597,,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,A,1,N,1,,BAO_0000218
9662,,,10116.0,Intermediate,Rattus norvegicus,6681,CHEMBL622024,50597,,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,A,1,N,1,,BAO_0000218
9663,,,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL622693,50597,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,A,1,N,1,,BAO_0000218
9664,,,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL622694,50597,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,A,1,N,1,,BAO_0000218
9665,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622695,50597,,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9666,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622696,50597,,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,A,1,N,1,,BAO_0000218
9667,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL622697,50597,,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,A,1,N,1,,BAO_0000218
9668,,,10116.0,Intermediate,Rattus norvegicus,6619,CHEMBL622874,50597,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,A,1,N,1,,BAO_0000218
9669,,,10116.0,Intermediate,Rattus norvegicus,6619,CHEMBL622875,50597,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,A,1,N,1,,BAO_0000218
9670,,,10116.0,Intermediate,Rattus norvegicus,10363,CHEMBL622876,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,A,1,N,1,,BAO_0000218
9671,,,10116.0,Intermediate,Rattus norvegicus,4796,CHEMBL622877,50597,,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,A,1,N,1,,BAO_0000218
9672,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL622878,50597,,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9673,,1969.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL622879,50597,,,Plasma,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9674,,,10116.0,Intermediate,Rattus norvegicus,4839,CHEMBL877602,50597,,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,A,1,N,1,,BAO_0000218
9675,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL622880,50597,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9676,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL622881,50597,,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9677,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL622882,50597,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9678,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL622883,50597,,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9679,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622884,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,A,1,N,1,,BAO_0000218
9680,,2046.0,10116.0,Intermediate,Rattus norvegicus,11450,CHEMBL622885,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,A,1,N,1,,BAO_0000218
9681,,,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL622886,50597,,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,A,1,N,1,,BAO_0000218
9682,,,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL622887,50597,,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,A,1,N,1,,BAO_0000218
9683,,1088.0,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL622888,50597,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,A,1,N,1,,BAO_0000218
9684,,178.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622889,50597,,,Blood,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9685,,178.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622890,50597,,,Blood,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9686,,178.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622891,50597,,,Blood,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9687,,178.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL877603,50597,,,Blood,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9688,,955.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622892,50597,,,Brain,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9689,,955.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622893,50597,,,Brain,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9690,,955.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622894,50597,,,Brain,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9691,,955.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622895,50597,,,Brain,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9692,,955.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622896,50597,,,Brain,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,A,1,N,1,,BAO_0000218
9693,,948.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622897,50597,,,Heart,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9694,,948.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622898,50597,,,Heart,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9695,,948.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622899,50597,,,Heart,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9696,,2113.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622900,50597,,,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9697,,2113.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624114,50597,,,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9698,,2113.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624115,50597,,,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9699,,2113.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624116,50597,,,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9700,,2107.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624117,50597,,,Liver,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9701,,2107.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624118,50597,,,Liver,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9702,,2107.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624119,50597,,,Liver,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9703,,2107.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624120,50597,,,Liver,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9704,,2048.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624121,50597,,,Lung,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9705,,2048.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624122,50597,,,Lung,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9706,,2048.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624123,50597,,,Lung,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9707,,2048.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624124,50597,,,Lung,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9708,,2385.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624125,50597,,,Muscle tissue,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9709,,2385.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624126,50597,,,Muscle tissue,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9710,,2385.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624127,50597,,,Muscle tissue,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9711,,2385.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624128,50597,,,Muscle tissue,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9712,,14.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624129,50597,,,Zone of skin,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9713,,14.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL624130,50597,,,Zone of skin,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9714,,14.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622340,50597,,,Zone of skin,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9715,,14.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622341,50597,,,Zone of skin,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9716,,160.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622342,50597,,,Intestine,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9717,,160.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622343,50597,,,Intestine,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9718,,160.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622344,50597,,,Intestine,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9719,,160.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622345,50597,,,Intestine,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9720,,2106.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622346,50597,,,Spleen,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9721,,2106.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622347,50597,,,Spleen,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9722,,2106.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622348,50597,,,Spleen,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9723,,2106.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622349,50597,,,Spleen,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9724,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622350,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,A,1,N,1,,BAO_0000218
9725,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622351,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9726,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622352,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9727,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622353,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9728,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622354,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9729,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622355,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9730,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622356,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9731,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622357,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,A,1,N,1,,BAO_0000218
9732,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622358,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,A,1,N,1,,BAO_0000218
9733,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL622359,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,A,1,N,1,,BAO_0000218
9734,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL874393,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,A,1,N,1,,BAO_0000218
9735,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622872,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
9736,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL622873,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
9737,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL623047,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
9738,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623048,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9739,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623049,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9740,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623050,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9741,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623051,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,A,1,N,1,,BAO_0000218
9742,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL623052,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9743,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL626343,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9744,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL626344,50597,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,A,1,N,1,,BAO_0000218
9745,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL626345,50597,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,A,1,N,1,,BAO_0000218
9746,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL626346,50597,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,A,1,N,1,,BAO_0000218
9747,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL626347,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,A,1,N,1,,BAO_0000218
9748,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL626348,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,A,1,N,1,,BAO_0000218
9749,,,10116.0,Intermediate,Rattus norvegicus,16434,CHEMBL626349,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,A,1,N,1,,BAO_0000218
9750,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL626350,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,F,1,N,1,,BAO_0000218
9751,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL626351,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9752,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL627650,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9753,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL627651,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,F,1,N,1,,BAO_0000218
9754,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL627652,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,A,1,N,1,,BAO_0000218
9755,,,10116.0,Intermediate,Rattus norvegicus,16435,CHEMBL627653,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,A,1,N,1,,BAO_0000218
9756,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627654,50597,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9757,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627835,50597,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9758,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627836,50597,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,A,1,N,1,,BAO_0000218
9759,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627837,50597,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,A,1,N,1,,BAO_0000218
9760,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627838,50597,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9761,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL875338,50597,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9762,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627839,50597,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,A,1,N,1,,BAO_0000218
9763,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627840,50597,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,A,1,N,1,,BAO_0000218
9764,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627841,50597,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9765,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627842,50597,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9766,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627843,50597,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,A,1,N,1,,BAO_0000218
9767,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627844,50597,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,A,1,N,1,,BAO_0000218
9768,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL627845,50597,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9769,,,10116.0,Intermediate,Rattus norvegicus,5874,CHEMBL627846,50597,,,,Half life period in rat by iv administration at a dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
9770,,1969.0,10116.0,Intermediate,Rattus norvegicus,1515,CHEMBL627847,50597,,,Plasma,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,A,1,N,1,,BAO_0000218
9771,,1969.0,10116.0,Intermediate,Rattus norvegicus,1515,CHEMBL873821,50597,,,Plasma,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,A,1,N,1,,BAO_0000218
9772,,1969.0,10116.0,Intermediate,Rattus norvegicus,1515,CHEMBL626079,50597,,,Plasma,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,A,1,N,1,,BAO_0000218
9773,,1969.0,10116.0,Intermediate,Rattus norvegicus,1515,CHEMBL626080,50597,,,Plasma,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,A,1,N,1,,BAO_0000218
9774,,1969.0,10116.0,Intermediate,Rattus norvegicus,5491,CHEMBL626081,50597,,,Plasma,Half life period was evaluated in rat plasma,,A,1,N,1,,BAO_0000218
9775,,1969.0,10116.0,Intermediate,Rattus norvegicus,5491,CHEMBL875344,50597,,,Plasma,Half life period was evaluated in rat plasma; Not tested,,A,1,N,1,,BAO_0000218
9776,,,10116.0,Intermediate,Rattus norvegicus,1918,CHEMBL626082,50597,,,,Half life period was evaluated in rats,,A,1,N,1,,BAO_0000218
9777,,,10116.0,Intermediate,Rattus norvegicus,1918,CHEMBL626250,50597,,,,"Half life period was evaluated in rats, iv",,A,1,N,1,,BAO_0000218
9778,,,10116.0,Intermediate,Rattus norvegicus,6113,CHEMBL626251,50597,,,,Half life period after intravenous administration at 5 mg/kg in rat,,A,1,N,1,,BAO_0000218
9779,,,10116.0,Intermediate,Rattus norvegicus,5546,CHEMBL626252,50597,,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,A,1,N,1,,BAO_0000218
9780,,,10116.0,Intermediate,Rattus norvegicus,5553,CHEMBL626253,50597,,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
9781,,1969.0,10116.0,Intermediate,Rattus norvegicus,4188,CHEMBL626254,50597,,,Plasma,Half life stability of compound was evaluated in rat plasma,,A,1,N,1,,BAO_0000218
9782,,,10116.0,Intermediate,Rattus norvegicus,6215,CHEMBL626255,50597,,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,A,1,N,1,,BAO_0000218
9783,,,10116.0,Intermediate,Rattus norvegicus,6141,CHEMBL626256,50597,,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
9784,,,10116.0,Intermediate,Rattus norvegicus,5182,CHEMBL626257,50597,,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,A,1,N,1,,BAO_0000218
9785,,,10116.0,Intermediate,Rattus norvegicus,5182,CHEMBL626258,50597,,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,A,1,N,1,,BAO_0000218
9786,,,10116.0,Intermediate,Rattus norvegicus,5710,CHEMBL626259,50597,,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,A,1,N,1,,BAO_0000218
9787,,,10116.0,Intermediate,Rattus norvegicus,5789,CHEMBL626260,50597,,,,Half in rat i.v.,,A,1,N,1,,BAO_0000218
9788,,,10116.0,Intermediate,Rattus norvegicus,6011,CHEMBL875345,50597,,,,Half period in rat after intravenous administration,,A,1,N,1,,BAO_0000218
9789,,,10116.0,Intermediate,Rattus norvegicus,17594,CHEMBL626261,50597,,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,A,1,N,1,,BAO_0000218
9790,,2107.0,10116.0,Intermediate,Rattus norvegicus,12357,CHEMBL626262,50597,,,Liver,Half-life measured in in vitro Cathepsin B assay in rat liver,,A,1,N,1,,BAO_0000218
9791,,,10116.0,Intermediate,Rattus norvegicus,5210,CHEMBL626263,50597,,,,Half-life of compound was determined in rats,,A,1,N,1,,BAO_0000218
9792,,,10116.0,Intermediate,Rattus norvegicus,17596,CHEMBL625270,50597,,,,Half-life at 10 mg/kg in rat upon intravenous administration,,A,1,N,1,,BAO_0000218
9793,,,10116.0,Intermediate,Rattus norvegicus,6672,CHEMBL625271,50597,,,,Half-life determined in rat,,A,1,N,1,,BAO_0000218
9794,,,10116.0,Intermediate,Rattus norvegicus,6673,CHEMBL625272,50597,,,,Half-life determined in rat,,A,1,N,1,,BAO_0000218
9795,,955.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL625273,50597,,,Brain,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9796,,1969.0,10116.0,Intermediate,Rattus norvegicus,3741,CHEMBL625274,50597,,,Plasma,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,A,1,N,1,,BAO_0000218
9797,,,10116.0,Intermediate,Rattus norvegicus,17671,CHEMBL625275,50597,,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,A,1,N,1,,BAO_0000218
9798,,1969.0,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL625276,50597,,,Plasma,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
9799,,1969.0,10116.0,Intermediate,Rattus norvegicus,17537,CHEMBL625277,50597,,,Plasma,Half-life in rat plasma,,A,1,N,1,,BAO_0000218
9800,,1969.0,10116.0,Intermediate,Rattus norvegicus,4965,CHEMBL625278,50597,,,Plasma,Half-life in rat plasma was determined,,A,1,N,1,,BAO_0000218
9801,,1969.0,10116.0,Intermediate,Rattus norvegicus,17537,CHEMBL625279,50597,,,Plasma,Half-life in rat plasma; Not tested,,A,1,N,1,,BAO_0000218
9802,,1977.0,10116.0,Intermediate,Rattus norvegicus,6124,CHEMBL625280,50597,,,Serum,Half-life in rat serum,,A,1,N,1,,BAO_0000218
9803,,1977.0,10116.0,Intermediate,Rattus norvegicus,6124,CHEMBL876797,50597,,,Serum,Half-life in rat serum; na is not available,,A,1,N,1,,BAO_0000218
9804,,,10116.0,Intermediate,Rattus norvegicus,6078,CHEMBL625281,50597,,,,Half-life was calculated in rat,,A,1,N,1,,BAO_0000218
9805,,1969.0,10116.0,Intermediate,Rattus norvegicus,17668,CHEMBL873827,50597,,,Plasma,Half-life was calculated in rat plasma,,A,1,N,1,,BAO_0000218
9806,,,10116.0,Intermediate,Rattus norvegicus,3185,CHEMBL625282,50597,,,,Half-life was determined,,A,1,N,1,,BAO_0000218
9807,,,10116.0,Intermediate,Rattus norvegicus,4883,CHEMBL625283,50597,,,,Half-life was determined,,A,1,N,1,,BAO_0000218
9808,,,10116.0,Intermediate,Rattus norvegicus,2959,CHEMBL625284,50597,,,,Half-life after administration of 20 mg/Kg oral dose in rat,,A,1,N,1,,BAO_0000218
9809,,,10116.0,Intermediate,Rattus norvegicus,4029,CHEMBL625285,50597,,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,,A,1,N,1,,BAO_0000218
9810,,,10116.0,Intermediate,Rattus norvegicus,4029,CHEMBL625286,50597,,,,Half-life after intravenous administration in female rat,,A,1,N,1,,BAO_0000218
9811,,,10116.0,Intermediate,Rattus norvegicus,4029,CHEMBL625287,50597,,,,Half-life after intravenous administration in male rat,,A,1,N,1,,BAO_0000218
9812,,,10116.0,Intermediate,Rattus norvegicus,6180,CHEMBL625288,50597,,,,Half-life after intravenous dose in rat,,A,1,N,1,,BAO_0000218
9813,,2107.0,10116.0,Intermediate,Rattus norvegicus,1557,CHEMBL625289,50597,,,Liver,Half-life in a rat liver homogenate preparation,,A,1,N,1,,BAO_0000218
9814,,1969.0,10116.0,Intermediate,Rattus norvegicus,12500,CHEMBL625290,50597,,,Plasma,Half-life in plasma of rat,,A,1,N,1,,BAO_0000218
9815,,1969.0,10116.0,Intermediate,Rattus norvegicus,12500,CHEMBL876798,50597,,,Plasma,Half-life in plasma of rat at dose of 3-10 mgkg,,A,1,N,1,,BAO_0000218
9816,,,10116.0,Intermediate,Rattus norvegicus,5064,CHEMBL625291,50597,,,,Half-life in rat,,A,1,N,1,,BAO_0000218
9817,,,10116.0,Intermediate,Rattus norvegicus,5145,CHEMBL625292,50597,,,,Half-life in rat,,A,1,N,1,,BAO_0000218
9818,,,10116.0,Intermediate,Rattus norvegicus,5147,CHEMBL625293,50597,,,,Half-life in rat,,A,1,N,1,,BAO_0000218
9819,,,10116.0,Intermediate,Rattus norvegicus,5833,CHEMBL622832,50597,,,,Half-life in rat,,A,1,N,1,,BAO_0000218
9820,,,10116.0,Intermediate,Rattus norvegicus,6596,CHEMBL622833,50597,,,,Half-life in rat,,A,1,N,1,,BAO_0000218
9821,,,10116.0,Intermediate,Rattus norvegicus,17655,CHEMBL622834,50597,,,,Half-life in rat,,A,1,N,1,,BAO_0000218
9822,,,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL622835,50597,,,,Half-life in rat after oral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
9823,,,10116.0,Intermediate,Rattus norvegicus,17538,CHEMBL622836,50597,,,,Half-life in rat after po administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9824,,,10116.0,Intermediate,Rattus norvegicus,17538,CHEMBL622837,50597,,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,A,1,N,1,,BAO_0000218
9825,,,10116.0,Intermediate,Rattus norvegicus,10,CHEMBL622838,50597,,,,Half-life in rat at 3 mg/kg dose administered intravenously,,A,1,N,1,,BAO_0000218
9826,,955.0,10116.0,Intermediate,Rattus norvegicus,17669,CHEMBL622839,50597,,,Brain,Half-life in rat brain homogenate,,A,1,N,1,,BAO_0000218
9827,,1969.0,10116.0,Intermediate,Rattus norvegicus,17065,CHEMBL622840,50597,,,Plasma,Half-life in rat plasma,,A,1,N,1,,BAO_0000218
9828,,,10116.0,Intermediate,Rattus norvegicus,4333,CHEMBL622841,50597,,,,Half-life in rats,,A,1,N,1,,BAO_0000218
9829,,,10116.0,Intermediate,Rattus norvegicus,6827,CHEMBL622842,50597,,,,Half-life in Dawley rats,,A,1,N,1,,BAO_0000218
9830,,1969.0,10116.0,Intermediate,Rattus norvegicus,889,CHEMBL622843,50597,,,Plasma,Half-life in vitro in rat plasma,,A,1,N,1,,BAO_0000218
9831,,1969.0,10116.0,Intermediate,Rattus norvegicus,889,CHEMBL622844,50597,,,Plasma,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,A,1,N,1,,BAO_0000218
9832,,,10116.0,Intermediate,Rattus norvegicus,3747,CHEMBL622845,50597,,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,A,1,N,1,,BAO_0000218
9833,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL622846,50597,,,,The area under the curve of compound was measured at the dose of 100 umol/kg,,A,1,N,1,,BAO_0000218
9834,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL622847,50597,,,,The area under the curve of compound was measured at the dose of 300 umol/kg,,A,1,N,1,,BAO_0000218
9835,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL622848,50597,,,,The area under the curve of compound was measured at the dose of 30 umol/kg,,A,1,N,1,,BAO_0000218
9836,,,10116.0,Intermediate,Rattus norvegicus,3360,CHEMBL622849,50597,,,,Bioavailability as oral AUC in rats,,A,1,N,1,,BAO_0000218
9837,,1969.0,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL622850,50597,,,Plasma,The plasma concentration versus time curve (AUC) was determined,,A,1,N,1,,BAO_0000218
9838,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL876807,50597,,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9839,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL622851,50597,,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9840,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL622852,50597,,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9841,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL622853,50597,,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,A,1,N,1,,BAO_0000218
9842,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL622854,50597,,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,A,1,N,1,,BAO_0000218
9843,,,10116.0,Intermediate,Rattus norvegicus,17411,CHEMBL622855,50597,,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,A,1,N,1,,BAO_0000218
9844,,1969.0,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL622856,50597,,,Plasma,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,A,1,N,1,,BAO_0000218
9845,,1969.0,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL622857,50597,,,Plasma,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,A,1,N,1,,BAO_0000218
9846,,1969.0,10116.0,Intermediate,Rattus norvegicus,17538,CHEMBL622858,50597,,,Plasma,AUC in rat after po administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
9847,,1969.0,10116.0,Intermediate,Rattus norvegicus,17752,CHEMBL622859,50597,,,Plasma,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,A,1,N,1,,BAO_0000218
9848,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL622860,50597,,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,A,1,N,1,,BAO_0000218
9849,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL622861,50597,,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,A,1,N,1,,BAO_0000218
9850,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL622862,50597,,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,A,1,N,1,,BAO_0000218
9851,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL622863,50597,,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,A,1,N,1,,BAO_0000218
9852,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL623817,50597,,,,Area under curve value 6 hr after po administration in rat,,A,1,N,1,,BAO_0000218
9853,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL623818,50597,,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,A,1,N,1,,BAO_0000218
9854,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL623819,50597,,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,A,1,N,1,,BAO_0000218
9855,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL623820,50597,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,A,1,N,1,,BAO_0000218
9856,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL623821,50597,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,A,1,N,1,,BAO_0000218
9857,,1969.0,10116.0,Intermediate,Rattus norvegicus,6642,CHEMBL623822,50597,,,Plasma,AUC normalized for dose (AUCN) in rat,,A,1,N,1,,BAO_0000218
9858,,,10116.0,Intermediate,Rattus norvegicus,6640,CHEMBL623823,50597,,,,Area under curve in rat after p.o. administration,,A,1,N,1,,BAO_0000218
9859,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL623824,50597,,,,Area under curve in rat after p.o. administration,,A,1,N,1,,BAO_0000218
9860,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL623825,50597,,,,Area under curve in rat after p.o. administration; Not determined,,A,1,N,1,,BAO_0000218
9861,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL622070,50597,,,,Area under curve in rat after peroral administration,,A,1,N,1,,BAO_0000218
9862,,,10116.0,Intermediate,Rattus norvegicus,3603,CHEMBL622071,50597,,,,Area under curve (carotid artery) value of the compound,,A,1,N,1,,BAO_0000218
9863,,,10116.0,Intermediate,Rattus norvegicus,3550,CHEMBL622072,50597,,,,Bioavailability expressed as the area under curve of rat carotid artery,,A,1,N,1,,BAO_0000218
9864,,,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL622073,50597,,,,Area under curve in male SD rats was observed after intravenous administration in rat,,A,1,N,1,,BAO_0000218
9865,,,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL622074,50597,,,,Area under curve of the compound was determined,,A,1,N,1,,BAO_0000218
9866,,,10116.0,Intermediate,Rattus norvegicus,5407,CHEMBL622075,50597,,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,A,1,N,1,,BAO_0000218
9867,,1969.0,10116.0,Intermediate,Rattus norvegicus,17752,CHEMBL622076,50597,,,Plasma,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,A,1,N,1,,BAO_0000218
9868,,1969.0,10116.0,Intermediate,Rattus norvegicus,17752,CHEMBL622077,50597,,,Plasma,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,A,1,N,1,,BAO_0000218
9869,,,10116.0,Intermediate,Rattus norvegicus,3603,CHEMBL622078,50597,,,,Area under curve (portal vein) value of the compound,,A,1,N,1,,BAO_0000218
9870,,,10116.0,Intermediate,Rattus norvegicus,3550,CHEMBL622079,50597,,,,Bioavailability expressed as the area under curve of rat portal vein,,A,1,N,1,,BAO_0000218
9871,,1969.0,10116.0,Intermediate,Rattus norvegicus,17655,CHEMBL622080,50597,,,Plasma,Area Under plasma concentration time curve in rat upon peroral administration,,A,1,N,1,,BAO_0000218
9872,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL877612,50597,,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,A,1,N,1,,BAO_0000218
9873,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL622081,50597,,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,A,1,N,1,,BAO_0000218
9874,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL622082,50597,,,,Compound was evaluated for oral bioavailability in rats,,A,1,N,1,,BAO_0000218
9875,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL622083,50597,,,,Compound was evaluated for oral bioavailability in rats after iv administration,,A,1,N,1,,BAO_0000218
9876,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL622084,50597,,,,Compound was evaluated for oral bioavailability in rats; 30-80,,A,1,N,1,,BAO_0000218
9877,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL622085,50597,,,,Compound was evaluated for oral bioavailability in rats; 50-60,,A,1,N,1,,BAO_0000218
9878,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL622086,50597,,,,Compound was evaluated for oral bioavailability in rats; no data,,A,1,N,1,,BAO_0000218
9879,,,10116.0,Intermediate,Rattus norvegicus,17791,CHEMBL622087,50597,,,,Compound was evaluated for oral bioavailability in rats; peptide,,A,1,N,1,,BAO_0000218
9880,,178.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL622088,50597,,,Blood,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,A,1,N,1,,BAO_0000218
9881,,178.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL622089,50597,,,Blood,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,A,1,N,1,,BAO_0000218
9882,,178.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL623685,50597,,,Blood,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,A,1,N,1,,BAO_0000218
9883,,178.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL623686,50597,,,Blood,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,A,1,N,1,,BAO_0000218
9884,,945.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL623687,50597,,,Stomach,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9885,,945.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL623688,50597,,,Stomach,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9886,,945.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL623689,50597,,,Stomach,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9887,,945.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622485,50597,,,Stomach,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9888,,2046.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622486,50597,,,Thyroid gland,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9889,,2046.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL877613,50597,,,Thyroid gland,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9890,,2046.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622487,50597,,,Thyroid gland,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9891,,2046.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622488,50597,,,Thyroid gland,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9892,,948.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622489,50597,,,Heart,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,A,1,N,1,,BAO_0000218
9893,,1088.0,10116.0,Intermediate,Rattus norvegicus,6899,CHEMBL622490,50597,,,Urine,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,A,1,N,1,,BAO_0000218
9894,,1088.0,10116.0,Intermediate,Rattus norvegicus,6899,CHEMBL622491,50597,,,Urine,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,A,1,N,1,,BAO_0000218
9895,,2107.0,10116.0,Intermediate,Rattus norvegicus,6899,CHEMBL622492,50597,,,Liver,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,A,1,N,1,,BAO_0000218
9896,,1088.0,10116.0,Intermediate,Rattus norvegicus,6899,CHEMBL622493,50597,,,Urine,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,A,1,N,1,,BAO_0000218
9897,,1088.0,10116.0,Intermediate,Rattus norvegicus,6899,CHEMBL622494,50597,,,Urine,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,A,1,N,1,,BAO_0000218
9898,,2385.0,10116.0,Intermediate,Rattus norvegicus,8677,CHEMBL622495,50597,,,Muscle tissue,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,A,1,N,1,,BAO_0000218
9899,,,10116.0,Intermediate,Rattus norvegicus,6899,CHEMBL622496,50597,,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,A,1,N,1,,BAO_0000218
9900,,1088.0,10116.0,Intermediate,Rattus norvegicus,6899,CHEMBL622497,50597,,,Urine,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,A,1,N,1,,BAO_0000218
9901,,,10116.0,Intermediate,Rattus norvegicus,2189,CHEMBL622498,50597,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,A,1,N,1,,BAO_0000218
9902,,1088.0,10116.0,Intermediate,Rattus norvegicus,2189,CHEMBL624918,50597,,,Urine,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,A,1,N,1,,BAO_0000218
9903,,1088.0,10116.0,Intermediate,Rattus norvegicus,2189,CHEMBL624919,50597,,,Urine,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,A,1,N,1,,BAO_0000218
9904,,178.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624920,50597,,,Blood,Biodistribution of compound in rat blood after 5 min of administration,,A,1,N,1,,BAO_0000218
9905,,178.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624921,50597,,,Blood,Biodistribution of compound in rat blood after 5 min of administration.,,A,1,N,1,,BAO_0000218
9906,,955.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624922,50597,,,Brain,Biodistribution of compound in rat brain after 5 min of administration,,A,1,N,1,,BAO_0000218
9907,,948.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624923,50597,,,Heart,Biodistribution of compound in rat heart after 5 min of administration,,A,1,N,1,,BAO_0000218
9908,,948.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624924,50597,,,Heart,Biodistribution of compound in rat heart after 5 min of administration.,,A,1,N,1,,BAO_0000218
9909,,2113.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624925,50597,,,Kidney,Biodistribution of compound in rat kidney after 5 min of administration,,A,1,N,1,,BAO_0000218
9910,,2113.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624926,50597,,,Kidney,Biodistribution of compound in rat kidney after 5 min of administration.,,A,1,N,1,,BAO_0000218
9911,,2107.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624927,50597,,,Liver,Biodistribution of compound in rat liver after 5 min of administration,,A,1,N,1,,BAO_0000218
9912,,2107.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL874402,50597,,,Liver,Biodistribution of compound in rat liver after 5 min of administration.,,A,1,N,1,,BAO_0000218
9913,,2048.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624928,50597,,,Lung,Biodistribution of compound in rat lung after 5 min of administration,,A,1,N,1,,BAO_0000218
9914,,2048.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624929,50597,,,Lung,Biodistribution of compound in rat lung after 5 min of administration.,,A,1,N,1,,BAO_0000218
9915,,2385.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624930,50597,,,Muscle tissue,Biodistribution of compound in rat muscle after 5 min of administration,,A,1,N,1,,BAO_0000218
9916,,2385.0,10116.0,Intermediate,Rattus norvegicus,10839,CHEMBL624931,50597,,,Muscle tissue,Biodistribution of compound in rat muscle after 5 min of administration.,,A,1,N,1,,BAO_0000218
9917,,948.0,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624932,50597,,,Heart,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9918,,948.0,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624933,50597,,,Heart,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9919,,2107.0,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624934,50597,,,Liver,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9920,,2107.0,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624935,50597,,,Liver,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9921,,,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624936,50597,,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9922,,,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624937,50597,,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9923,,2106.0,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624938,50597,,,Spleen,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9924,,2106.0,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624939,50597,,,Spleen,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9925,,,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL624940,50597,,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9926,,,10116.0,Intermediate,Rattus norvegicus,4043,CHEMBL874403,50597,,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,A,1,N,1,,BAO_0000218
9927,,,10116.0,Intermediate,Rattus norvegicus,1446,CHEMBL624941,50597,,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,A,1,N,1,,BAO_0000218
9928,,1088.0,10116.0,Intermediate,Rattus norvegicus,9971,CHEMBL624942,50597,,,Urine,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,A,1,N,1,,BAO_0000218
9929,,1088.0,10116.0,Intermediate,Rattus norvegicus,9971,CHEMBL624943,50597,,,Urine,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,A,1,N,1,,BAO_0000218
9930,,,10116.0,Intermediate,Rattus norvegicus,5765,CHEMBL624944,50597,,,,% Bioavailability after 1 day of the drug administration in rats,,A,1,N,1,,BAO_0000218
9931,,,10116.0,Intermediate,Rattus norvegicus,5765,CHEMBL624945,50597,,,,% Bioavailability after 4 day of the drug administration in rats,,A,1,N,1,,BAO_0000218
9932,,,10116.0,Intermediate,Rattus norvegicus,4257,CHEMBL624946,50597,,,,Absolute bioavailability was evaluated in rat,,A,1,N,1,,BAO_0000218
9933,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624947,50597,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9934,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624948,50597,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,A,1,N,1,,BAO_0000218
9935,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624949,50597,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,A,1,N,1,,BAO_0000218
9936,,2113.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622025,50597,,,Kidney,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9937,,2113.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622026,50597,,,Kidney,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9938,,2113.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622027,50597,,,Kidney,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,A,1,N,1,,BAO_0000218
9939,,2113.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622028,50597,,,Kidney,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,A,1,N,1,,BAO_0000218
9940,,2107.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622029,50597,,,Liver,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9941,,2107.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622208,50597,,,Liver,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9942,,2107.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622209,50597,,,Liver,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,A,1,N,1,,BAO_0000218
9943,,2107.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622210,50597,,,Liver,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,A,1,N,1,,BAO_0000218
9944,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622211,50597,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9945,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622212,50597,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9946,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL622213,50597,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,A,1,N,1,,BAO_0000218
9947,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL874404,50597,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,A,1,N,1,,BAO_0000218
9948,,2385.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL620452,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9949,,2385.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL620453,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9950,,2385.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL620454,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,A,1,N,1,,BAO_0000218
9951,,2385.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624067,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,A,1,N,1,,BAO_0000218
9952,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624068,50597,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9953,,992.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624069,50597,,,Female gonad,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9954,,992.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624070,50597,,,Female gonad,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,A,1,N,1,,BAO_0000218
9955,,992.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624071,50597,,,Female gonad,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,A,1,N,1,,BAO_0000218
9956,,995.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624072,50597,,,Uterus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9957,,995.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624073,50597,,,Uterus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9958,,995.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624788,50597,,,Uterus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,A,1,N,1,,BAO_0000218
9959,,995.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624789,50597,,,Uterus,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,A,1,N,1,,BAO_0000218
9960,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624790,50597,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9961,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624791,50597,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9962,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624792,50597,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,A,1,N,1,,BAO_0000218
9963,,,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624793,50597,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,A,1,N,1,,BAO_0000218
9964,,2385.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL877491,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,A,1,N,1,,BAO_0000218
9965,,2385.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624957,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,A,1,N,1,,BAO_0000218
9966,,2385.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624958,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,A,1,N,1,,BAO_0000218
9967,,2385.0,10116.0,Intermediate,Rattus norvegicus,13091,CHEMBL624959,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,A,1,N,1,,BAO_0000218
9968,,,10116.0,Intermediate,Rattus norvegicus,11977,CHEMBL624960,50597,,,,Dissociation constant was determined,,A,1,N,1,,BAO_0000218
9969,,,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL624961,50597,,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,A,1,N,1,,BAO_0000218
9970,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL624962,50597,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9971,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL624963,50597,,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
9972,,,10116.0,Intermediate,Rattus norvegicus,4755,CHEMBL624964,50597,,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,A,1,N,1,,BAO_0000218
9973,,,10116.0,Intermediate,Rattus norvegicus,589,CHEMBL624965,50597,,,,LogP value was evaluated in the in situ rat gut perfusion assay,,A,1,N,1,,BAO_0000218
9974,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL624966,50597,,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,A,1,N,1,,BAO_0000218
9975,,,10116.0,Intermediate,Rattus norvegicus,5031,CHEMBL624967,50597,,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,A,1,N,1,,BAO_0000218
9976,,,10116.0,Intermediate,Rattus norvegicus,17764,CHEMBL624968,50597,,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,A,1,N,1,,BAO_0000218
9977,,,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL624969,50597,,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,A,1,N,1,,BAO_0000218
9978,,,10116.0,Expert,Rattus norvegicus,2862,CHEMBL624970,50597,,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,F,1,N,1,,BAO_0000218
9979,,,10116.0,Intermediate,Rattus norvegicus,16423,CHEMBL624971,50597,,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,,A,1,N,1,,BAO_0000218
9980,,,10116.0,Intermediate,Rattus norvegicus,16423,CHEMBL624972,50597,,,,Half-life was evaluated after 20 uM/kg of peroral administration,,A,1,N,1,,BAO_0000218
9981,,,10116.0,Intermediate,Rattus norvegicus,6005,CHEMBL624973,50597,,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
9982,,1969.0,10116.0,Intermediate,Rattus norvegicus,2938,CHEMBL624974,50597,,,Plasma,Half-life was evaluated in plasma of rat,,A,1,N,1,,BAO_0000218
9983,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL624975,50597,,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
9984,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL877492,50597,,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
9985,,,10116.0,Intermediate,Rattus norvegicus,6062,CHEMBL624976,50597,,,,Half-life was measured in rat after an iv dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
9986,,,10116.0,Intermediate,Rattus norvegicus,6571,CHEMBL624977,50597,,,,Half-life period of compound in rats after peroral administration,,A,1,N,1,,BAO_0000218
9987,,1969.0,10116.0,Intermediate,Rattus norvegicus,3136,CHEMBL626848,50597,,,Plasma,Half-life period of compound was measured in rat plasma.,,A,1,N,1,,BAO_0000218
9988,,1969.0,10116.0,Intermediate,Rattus norvegicus,3136,CHEMBL626849,50597,,,Plasma,Half-life period of compound was measured in rat plasma; ND is not determined,,A,1,N,1,,BAO_0000218
9989,,1969.0,10116.0,Intermediate,Rattus norvegicus,3136,CHEMBL626850,50597,,,Plasma,Half-life period of compound was measured in rat plasma; not determined,,A,1,N,1,,BAO_0000218
9990,,,10116.0,Intermediate,Rattus norvegicus,4521,CHEMBL626851,50597,,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,A,1,N,1,,BAO_0000218
9991,,,10116.0,Intermediate,Rattus norvegicus,5871,CHEMBL626852,50597,,,,Half-life period in rat by iv administration,,A,1,N,1,,BAO_0000218
9992,,,10116.0,Intermediate,Rattus norvegicus,6077,CHEMBL626853,50597,,,,Half-life period in rats following intravenous administration at 2 mg/kg,,A,1,N,1,,BAO_0000218
9993,,,10116.0,Intermediate,Rattus norvegicus,6679,CHEMBL626854,50597,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,A,1,N,1,,BAO_0000218
9994,,,10116.0,Intermediate,Rattus norvegicus,5144,CHEMBL627486,50597,,,,Half-life period was determined for the compound in rat,,A,1,N,1,,BAO_0000218
9995,,,10116.0,Intermediate,Rattus norvegicus,4498,CHEMBL627487,50597,,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,A,1,N,1,,BAO_0000218
9996,,,10116.0,Intermediate,Rattus norvegicus,4498,CHEMBL627488,50597,,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,A,1,N,1,,BAO_0000218
9997,,,10116.0,Intermediate,Rattus norvegicus,1908,CHEMBL627489,50597,,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,A,1,N,1,,BAO_0000218
9998,,,10116.0,Intermediate,Rattus norvegicus,6211,CHEMBL627490,50597,,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
9999,,,10116.0,Intermediate,Rattus norvegicus,5529,CHEMBL873829,50597,,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,A,1,N,1,,BAO_0000218
10000,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL627655,50597,,,,Half-life was determined in rat at a dose of 1 mpk i.v.,,A,1,N,1,,BAO_0000218
10001,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL625994,50597,,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,A,1,N,1,,BAO_0000218
10002,,,10116.0,Intermediate,Rattus norvegicus,6444,CHEMBL625995,50597,,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,A,1,N,1,,BAO_0000218
10003,,,10116.0,Intermediate,Rattus norvegicus,5207,CHEMBL625996,50597,,,,Half-life in rat,,A,1,N,1,,BAO_0000218
10004,,1969.0,10116.0,Intermediate,Rattus norvegicus,530,CHEMBL625850,50597,,,Plasma,In vitro half life in rat plasma,,A,1,N,1,,BAO_0000218
10005,,1969.0,10116.0,Intermediate,Rattus norvegicus,1116,CHEMBL625851,50597,,,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,A,1,N,1,,BAO_0000218
10006,,,10116.0,Intermediate,Rattus norvegicus,3219,CHEMBL625852,50597,,,,In vitro half life in rat,,A,1,N,1,,BAO_0000218
10007,,,10116.0,Intermediate,Rattus norvegicus,6109,CHEMBL625853,50597,,,,In vivo half life period after intravenous administration in rat,,A,1,N,1,,BAO_0000218
10008,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL625854,50597,,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,A,1,N,1,,BAO_0000218
10009,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL874450,50597,,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,A,1,N,1,,BAO_0000218
10010,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL625855,50597,,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10011,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL625856,50597,,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10012,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL625857,50597,,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10013,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL873831,50597,,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10014,,,10116.0,Intermediate,Rattus norvegicus,17853,CHEMBL625858,50597,,,,Longer half-life in rat (i.v.) at 0.5 mpk,,A,1,N,1,,BAO_0000218
10015,,,10116.0,Intermediate,Rattus norvegicus,17853,CHEMBL625859,50597,,,,Longer half-life in rat (p.o.) at 2.0 mpk,,A,1,N,1,,BAO_0000218
10016,,,10116.0,Intermediate,Rattus norvegicus,3457,CHEMBL625860,50597,,,,Pharmacokinetic property (half life) in rat,,A,1,N,1,,BAO_0000218
10017,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL625861,50597,,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
10018,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL625862,50597,,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,A,1,N,1,,BAO_0000218
10019,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL625863,50597,,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
10020,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL625864,50597,,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,A,1,N,1,,BAO_0000218
10021,,,10116.0,Intermediate,Rattus norvegicus,5739,CHEMBL625865,50597,,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,A,1,N,1,,BAO_0000218
10022,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL625866,50597,,,,Pharmacokinetic half time was determined intravenously in rats.,,A,1,N,1,,BAO_0000218
10023,,1969.0,10116.0,Intermediate,Rattus norvegicus,6567,CHEMBL625867,50597,,,Plasma,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,A,1,N,1,,BAO_0000218
10024,,1969.0,10116.0,Intermediate,Rattus norvegicus,2448,CHEMBL625868,50597,,,Plasma,Plasma half life of hydrolysis of the compound,,A,1,N,1,,BAO_0000218
10025,,1969.0,10116.0,Intermediate,Rattus norvegicus,5423,CHEMBL625869,50597,,,Plasma,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,A,1,N,1,,BAO_0000218
10026,,1969.0,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL874451,50597,,,Plasma,Plasma half life period was calculated in rat,,A,1,N,1,,BAO_0000218
10027,,1969.0,10116.0,Intermediate,Rattus norvegicus,4514,CHEMBL625870,50597,,,Plasma,Plasma half-life in Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
10028,,1969.0,10116.0,Intermediate,Rattus norvegicus,4514,CHEMBL625871,50597,,,Plasma,Plasma half-life in Sprague-Dawley rats; Not determined,,A,1,N,1,,BAO_0000218
10029,,1969.0,10116.0,Intermediate,Rattus norvegicus,1500,CHEMBL625872,50597,,,Plasma,Plasma half-life in rats,,A,1,N,1,,BAO_0000218
10030,,1969.0,10116.0,Intermediate,Rattus norvegicus,1500,CHEMBL625873,50597,,,Plasma,Plasma half-life in rats; <MQL,,A,1,N,1,,BAO_0000218
10031,,1969.0,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL625874,50597,,,Plasma,Plasma half-life period (0-8 h) was determined,,A,1,N,1,,BAO_0000218
10032,,1969.0,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL625875,50597,,,Plasma,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10033,,1969.0,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL625876,50597,,,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10034,,1969.0,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL631258,50597,,,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10035,,1969.0,10116.0,Intermediate,Rattus norvegicus,4956,CHEMBL631259,50597,,,Plasma,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,A,1,N,1,,BAO_0000218
10036,,1969.0,10116.0,Intermediate,Rattus norvegicus,4956,CHEMBL631260,50597,,,Plasma,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,A,1,N,1,,BAO_0000218
10037,,178.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631261,50597,,,Blood,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,A,1,N,1,,BAO_0000218
10038,,178.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631262,50597,,,Blood,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,A,1,N,1,,BAO_0000218
10039,,178.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631263,50597,,,Blood,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,A,1,N,1,,BAO_0000218
10040,,,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631264,50597,,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,A,1,N,1,,BAO_0000218
10041,,,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631265,50597,,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,A,1,N,1,,BAO_0000218
10042,,,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631266,50597,,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,A,1,N,1,,BAO_0000218
10043,,,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631267,50597,,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,A,1,N,1,,BAO_0000218
10044,,,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631268,50597,,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,A,1,N,1,,BAO_0000218
10045,,,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631269,50597,,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,A,1,N,1,,BAO_0000218
10046,,,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631270,50597,,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,A,1,N,1,,BAO_0000218
10047,,948.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631271,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,A,1,N,1,,BAO_0000218
10048,,948.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631272,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,A,1,N,1,,BAO_0000218
10049,,948.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631273,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,A,1,N,1,,BAO_0000218
10050,,948.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631274,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,A,1,N,1,,BAO_0000218
10051,,948.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL631275,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,A,1,N,1,,BAO_0000218
10052,,948.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626984,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,A,1,N,1,,BAO_0000218
10053,,948.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626985,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,A,1,N,1,,BAO_0000218
10054,,2107.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626986,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,A,1,N,1,,BAO_0000218
10055,,2107.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626987,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,A,1,N,1,,BAO_0000218
10056,,2107.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626988,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,A,1,N,1,,BAO_0000218
10057,,2107.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626989,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,A,1,N,1,,BAO_0000218
10058,,2107.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626990,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,A,1,N,1,,BAO_0000218
10059,,2107.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626991,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,A,1,N,1,,BAO_0000218
10060,,2107.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626992,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,A,1,N,1,,BAO_0000218
10061,,2048.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626993,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,A,1,N,1,,BAO_0000218
10062,,2048.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL874593,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,A,1,N,1,,BAO_0000218
10063,,2048.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626994,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,A,1,N,1,,BAO_0000218
10064,,2048.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626995,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,A,1,N,1,,BAO_0000218
10065,,2048.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626190,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,A,1,N,1,,BAO_0000218
10066,,2048.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626191,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,A,1,N,1,,BAO_0000218
10067,,2048.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626364,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,A,1,N,1,,BAO_0000218
10068,,2046.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626365,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,A,1,N,1,,BAO_0000218
10069,,2046.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626366,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,A,1,N,1,,BAO_0000218
10070,,2046.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626367,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,A,1,N,1,,BAO_0000218
10071,,2046.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626368,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,A,1,N,1,,BAO_0000218
10072,,2046.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626369,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,A,1,N,1,,BAO_0000218
10073,,2046.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626370,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,A,1,N,1,,BAO_0000218
10074,,,10116.0,Intermediate,Rattus norvegicus,4498,CHEMBL626371,50597,,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,A,1,N,1,,BAO_0000218
10075,,,10116.0,Intermediate,Rattus norvegicus,4498,CHEMBL626372,50597,,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,A,1,N,1,,BAO_0000218
10076,,,10116.0,Intermediate,Rattus norvegicus,3603,CHEMBL626373,50597,,,,Bioavailability after a dose of 10 mg/kg p.o.,,A,1,N,1,,BAO_0000218
10077,,,10116.0,Intermediate,Rattus norvegicus,6215,CHEMBL626374,50597,,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,A,1,N,1,,BAO_0000218
10078,,,10116.0,Intermediate,Rattus norvegicus,5710,CHEMBL626375,50597,,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,A,1,N,1,,BAO_0000218
10079,,,10116.0,Intermediate,Rattus norvegicus,5710,CHEMBL626376,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
10080,,,10116.0,Intermediate,Rattus norvegicus,5676,CHEMBL626377,50597,,,,Bioavailability in rat po was determined,,A,1,N,1,,BAO_0000218
10081,,,10116.0,Intermediate,Rattus norvegicus,17667,CHEMBL626378,50597,,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,,A,1,N,1,,BAO_0000218
10082,,,10116.0,Intermediate,Rattus norvegicus,17667,CHEMBL626379,50597,,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,A,1,N,1,,BAO_0000218
10083,,,10116.0,Intermediate,Rattus norvegicus,6848,CHEMBL626380,50597,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10084,,,10116.0,Intermediate,Rattus norvegicus,6848,CHEMBL626381,50597,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10085,,,10116.0,Intermediate,Rattus norvegicus,17267,CHEMBL626382,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10086,,,10116.0,Intermediate,Rattus norvegicus,6362,CHEMBL626383,50597,,,,Bioavailability in rat (Sprague-Dawley) (female),,A,1,N,1,,BAO_0000218
10087,,,10116.0,Intermediate,Rattus norvegicus,17671,CHEMBL874652,50597,,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,A,1,N,1,,BAO_0000218
10088,,,10116.0,Intermediate,Rattus norvegicus,17671,CHEMBL626384,50597,,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,A,1,N,1,,BAO_0000218
10089,,,10116.0,Intermediate,Rattus norvegicus,4333,CHEMBL626385,50597,,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,A,1,N,1,,BAO_0000218
10090,,,10116.0,Intermediate,Rattus norvegicus,6077,CHEMBL626386,50597,,,,Bioavailability in rat at an oral dose of 2 mg/kg,,A,1,N,1,,BAO_0000218
10091,,,10116.0,Intermediate,Rattus norvegicus,3278,CHEMBL626387,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10092,,,10116.0,Intermediate,Rattus norvegicus,5964,CHEMBL626388,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10093,,,10116.0,Intermediate,Rattus norvegicus,4884,CHEMBL626389,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10094,,,10116.0,Intermediate,Rattus norvegicus,4905,CHEMBL626390,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10095,,,10116.0,Intermediate,Rattus norvegicus,4884,CHEMBL626391,50597,,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,A,1,N,1,,BAO_0000218
10096,,,10116.0,Intermediate,Rattus norvegicus,6850,CHEMBL626392,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10097,,,10116.0,Intermediate,Rattus norvegicus,2864,CHEMBL626393,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10098,,,10116.0,Intermediate,Rattus norvegicus,5780,CHEMBL623026,50597,,,,Bioavailability was determined in rat,,A,1,N,1,,BAO_0000218
10099,,,10116.0,Intermediate,Rattus norvegicus,1465,CHEMBL623027,50597,,,,Bioavailability,,A,1,N,1,,BAO_0000218
10100,,,10116.0,Intermediate,Rattus norvegicus,5199,CHEMBL623028,50597,,,,Bioavailability,,A,1,N,1,,BAO_0000218
10101,,,10116.0,Intermediate,Rattus norvegicus,5765,CHEMBL623029,50597,,,,Bioavailability in rat after 1 day dosing,,A,1,N,1,,BAO_0000218
10102,,,10116.0,Intermediate,Rattus norvegicus,5765,CHEMBL623030,50597,,,,Bioavailability in rat after 4 day dosing,,A,1,N,1,,BAO_0000218
10103,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL623031,50597,,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,A,1,N,1,,BAO_0000218
10104,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL623032,50597,,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,A,1,N,1,,BAO_0000218
10105,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL623033,50597,,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,A,1,N,1,,BAO_0000218
10106,,,10116.0,Intermediate,Rattus norvegicus,6518,CHEMBL623034,50597,,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,A,1,N,1,,BAO_0000218
10107,,,10116.0,Intermediate,Rattus norvegicus,2083,CHEMBL623035,50597,,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,A,1,N,1,,BAO_0000218
10108,,,10116.0,Intermediate,Rattus norvegicus,17260,CHEMBL623036,50597,,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,A,1,N,1,,BAO_0000218
10109,,,10116.0,Intermediate,Rattus norvegicus,4956,CHEMBL623037,50597,,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10110,,,10116.0,Intermediate,Rattus norvegicus,4368,CHEMBL623038,50597,,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,A,1,N,1,,BAO_0000218
10111,,1969.0,10116.0,Intermediate,Rattus norvegicus,17752,CHEMBL874385,50597,,,Plasma,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
10112,,,10116.0,Intermediate,Rattus norvegicus,1446,CHEMBL623039,50597,,,,Bioavailability in rat (Fisher) (fasted),,A,1,N,1,,BAO_0000218
10113,,,9443.0,Intermediate,Primates,2891,CHEMBL623040,22224,,,,Bioavailability in monkey after po administration of 10 mg/kg dose,,A,1,U,0,,BAO_0000218
10114,,,9443.0,Intermediate,Primates,2891,CHEMBL623041,22224,,,,Oral bioavailability in monkey (dose 10 mg/kg),,A,1,U,0,,BAO_0000218
10115,,,10116.0,Intermediate,Rattus norvegicus,6672,CHEMBL623741,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10116,,,10116.0,Intermediate,Rattus norvegicus,6673,CHEMBL623742,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10117,,,10116.0,Intermediate,Rattus norvegicus,17655,CHEMBL623743,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10118,,,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL623744,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10119,,,10116.0,Intermediate,Rattus norvegicus,17853,CHEMBL623745,50597,,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10120,,,10116.0,Intermediate,Rattus norvegicus,4521,CHEMBL623746,50597,,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10121,,,10116.0,Intermediate,Rattus norvegicus,4940,CHEMBL623747,50597,,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10122,,,10116.0,Intermediate,Rattus norvegicus,2891,CHEMBL623748,22224,,,,Bioavailability in rat after po administration of 30 mg/kg dose,,A,1,U,0,,BAO_0000218
10123,,,10116.0,Intermediate,Rattus norvegicus,2891,CHEMBL623916,22224,,,,Bioavailability in rat after po administration of 30 mg/kg dose,,A,1,U,0,,BAO_0000218
10124,,,10116.0,Intermediate,Rattus norvegicus,4521,CHEMBL623917,50597,,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,A,1,N,1,,BAO_0000218
10125,,,10116.0,Intermediate,Rattus norvegicus,17686,CHEMBL623918,50597,,,,Bioavailability in rat (dose 2 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10126,,,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL874386,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10127,,1969.0,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL623919,50597,,,Plasma,Bioavailability in rat; Only traces detected in rat plasma,,A,1,N,1,,BAO_0000218
10128,,,10116.0,Intermediate,Rattus norvegicus,5064,CHEMBL623920,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10129,,,10116.0,Intermediate,Rattus norvegicus,5147,CHEMBL623148,50597,,,,Bioavailability upon oral administration of compound,,A,1,N,1,,BAO_0000218
10130,,,10116.0,Intermediate,Rattus norvegicus,1916,CHEMBL623149,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,A,1,N,1,,BAO_0000218
10131,,,10116.0,Intermediate,Rattus norvegicus,6049,CHEMBL623150,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10132,,,10116.0,Intermediate,Rattus norvegicus,1445,CHEMBL623151,50597,,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,A,1,N,1,,BAO_0000218
10133,,,10116.0,Intermediate,Rattus norvegicus,1445,CHEMBL623152,50597,,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,A,1,N,1,,BAO_0000218
10134,,,10116.0,Expert,Rattus norvegicus,2862,CHEMBL623153,50597,,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,F,1,N,1,,BAO_0000218
10135,,,10116.0,Expert,Rattus norvegicus,2862,CHEMBL623154,50597,,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,F,1,N,1,,BAO_0000218
10136,,,10116.0,Intermediate,Rattus norvegicus,4194,CHEMBL623155,50597,,,,In vitro and metabolic stability was determined,,A,1,N,1,,BAO_0000218
10137,,,10116.0,Intermediate,Rattus norvegicus,4194,CHEMBL623156,50597,,,,In vitro metabolic stability in rat hepatocytes,,A,1,N,1,,BAO_0000218
10138,,,10116.0,Intermediate,Rattus norvegicus,5486,CHEMBL623157,50597,,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,A,1,N,1,,BAO_0000218
10139,,2107.0,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL623158,50597,,401.0,Liver,Metabolic rate for compound was observed in rat hepatocytes,,A,1,N,1,,BAO_0000218
10140,,,10116.0,Intermediate,Rattus norvegicus,5600,CHEMBL623159,50597,,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,A,1,N,1,,BAO_0000218
10141,,,10116.0,Intermediate,Rattus norvegicus,14294,CHEMBL874390,50597,,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,A,1,N,1,,BAO_0000218
10142,,,10116.0,Intermediate,Rattus norvegicus,14294,CHEMBL623160,50597,,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,A,1,N,1,,BAO_0000218
10143,,,10116.0,Intermediate,Rattus norvegicus,14294,CHEMBL623161,50597,,,,Metabolism of compound in rat S9 microsomes; Trace,,A,1,N,1,,BAO_0000218
10144,,,10116.0,Intermediate,Rattus norvegicus,17847,CHEMBL623162,50597,,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,A,1,N,1,,BAO_0000218
10145,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623163,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,A,1,N,1,,BAO_0000218
10146,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623164,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,A,1,N,1,,BAO_0000218
10147,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623165,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,A,1,N,1,,BAO_0000218
10148,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623166,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,A,1,N,1,,BAO_0000218
10149,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL624983,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,A,1,N,1,,BAO_0000218
10150,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL624984,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,A,1,N,1,,BAO_0000218
10151,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL624985,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,A,1,N,1,,BAO_0000218
10152,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622970,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,A,1,N,1,,BAO_0000218
10153,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622971,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,A,1,N,1,,BAO_0000218
10154,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622972,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,A,1,N,1,,BAO_0000218
10155,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622973,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,A,1,N,1,,BAO_0000218
10156,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622974,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,A,1,N,1,,BAO_0000218
10157,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622975,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,A,1,N,1,,BAO_0000218
10158,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622976,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,A,1,N,1,,BAO_0000218
10159,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622977,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,A,1,N,1,,BAO_0000218
10160,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL624351,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,A,1,N,1,,BAO_0000218
10161,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL624352,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,A,1,N,1,,BAO_0000218
10162,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL624353,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,A,1,N,1,,BAO_0000218
10163,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622397,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,A,1,N,1,,BAO_0000218
10164,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622398,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,A,1,N,1,,BAO_0000218
10165,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622399,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,A,1,N,1,,BAO_0000218
10166,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL622400,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,A,1,N,1,,BAO_0000218
10167,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL628428,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,A,1,N,1,,BAO_0000218
10168,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL628590,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,A,1,N,1,,BAO_0000218
10169,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL628591,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,A,1,N,1,,BAO_0000218
10170,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL628592,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,A,1,N,1,,BAO_0000218
10171,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL628593,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,A,1,N,1,,BAO_0000218
10172,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL875333,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,A,1,N,1,,BAO_0000218
10173,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL628594,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,A,1,N,1,,BAO_0000218
10174,,1969.0,10116.0,Intermediate,Rattus norvegicus,4969,CHEMBL628595,50597,,,Plasma,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,A,1,N,1,,BAO_0000218
10175,,1969.0,10116.0,Intermediate,Rattus norvegicus,6737,CHEMBL628596,50597,,,Plasma,Stability in rat plasma was determined,,A,1,N,1,,BAO_0000218
10176,,1969.0,10116.0,Intermediate,Rattus norvegicus,6737,CHEMBL628597,50597,,,Plasma,Stability in rat plasma was determined; ND= no data,,A,1,N,1,,BAO_0000218
10177,,1969.0,10116.0,Intermediate,Rattus norvegicus,5089,CHEMBL628598,50597,,,Plasma,Tested for plasma half life period in rat (0-8 hr),,A,1,N,1,,BAO_0000218
10178,,1969.0,10116.0,Intermediate,Rattus norvegicus,5089,CHEMBL628599,50597,,,Plasma,Tested for plasma half life period in rat (0-8 hr); Not determined,,A,1,N,1,,BAO_0000218
10179,,,10116.0,Intermediate,Rattus norvegicus,1466,CHEMBL628600,50597,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,A,1,N,1,,BAO_0000218
10180,,,10116.0,Intermediate,Rattus norvegicus,1466,CHEMBL628601,50597,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,A,1,N,1,,BAO_0000218
10181,,,10116.0,Intermediate,Rattus norvegicus,4950,CHEMBL628602,50597,,,,Tested for the half life in rat,,A,1,N,1,,BAO_0000218
10182,,,10116.0,Intermediate,Rattus norvegicus,2412,CHEMBL628603,50597,,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,A,1,N,1,,BAO_0000218
10183,,,10116.0,Intermediate,Rattus norvegicus,2412,CHEMBL628604,50597,,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,A,1,N,1,,BAO_0000218
10184,,,10116.0,Intermediate,Rattus norvegicus,2412,CHEMBL628605,50597,,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,A,1,N,1,,BAO_0000218
10185,,,10116.0,Intermediate,Rattus norvegicus,2412,CHEMBL628606,50597,,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,A,1,N,1,,BAO_0000218
10186,,,10116.0,Intermediate,Rattus norvegicus,2412,CHEMBL628607,50597,,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,A,1,N,1,,BAO_0000218
10187,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL628608,50597,,,,The biological half life the compound was measured at the dose of 100 umol/kg,,A,1,N,1,,BAO_0000218
10188,,,10116.0,Intermediate,Rattus norvegicus,15022,CHEMBL628609,50597,,,,The biological half life the compound was measured at the dose of 30 umol/kg,,A,1,N,1,,BAO_0000218
10189,,1969.0,10116.0,Intermediate,Rattus norvegicus,406,CHEMBL628610,50597,,,Plasma,The compound was evaluated for plasma half life period in rat,,A,1,N,1,,BAO_0000218
10190,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL873819,50597,,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
10191,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL628611,50597,,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
10192,,,10116.0,Intermediate,Rattus norvegicus,5247,CHEMBL628612,50597,,,,The pharmacokinetic parameter half-life period in vivo in rats,,A,1,N,1,,BAO_0000218
10193,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL628613,50597,,,,"The pharmacokinetic property, Half-life was determined",,A,1,N,1,,BAO_0000218
10194,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL628614,50597,,,,"The pharmacokinetic property, Half-life in rat in vivo",,A,1,N,1,,BAO_0000218
10195,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL628615,50597,,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,A,1,N,1,,BAO_0000218
10196,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL628616,50597,,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,A,1,N,1,,BAO_0000218
10197,,1969.0,10116.0,Intermediate,Rattus norvegicus,3918,CHEMBL627924,50597,,,Plasma,The plasma half life period in rats,,A,1,N,1,,BAO_0000218
10198,,2107.0,10116.0,Intermediate,Rattus norvegicus,2906,CHEMBL627925,50597,,,Liver,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,A,1,N,1,,BAO_0000218
10199,,,10116.0,Intermediate,Rattus norvegicus,6467,CHEMBL627926,50597,,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,A,1,N,1,,BAO_0000218
10200,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL627927,50597,,,,t1/2 (apparent elimination)of the compound was determined,,A,1,N,1,,BAO_0000218
10201,,,10116.0,Intermediate,Rattus norvegicus,3788,CHEMBL627928,50597,,,,t1/2 value in rat,,A,1,N,1,,BAO_0000218
10202,,,10116.0,Intermediate,Rattus norvegicus,17796,CHEMBL627539,50597,,,,Half life in rat,,A,1,N,1,,BAO_0000218
10203,,1969.0,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL876790,50597,,,Plasma,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,A,1,N,1,,BAO_0000218
10204,,,10116.0,Intermediate,Rattus norvegicus,5983,CHEMBL858186,50597,,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,A,1,N,1,,BAO_0000218
10205,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL627540,50597,,,,Half-life period in fasted rats,,A,1,N,1,,BAO_0000218
10206,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL627541,50597,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,A,1,N,1,,BAO_0000218
10207,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL627715,50597,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,A,1,N,1,,BAO_0000218
10208,,,10116.0,Intermediate,Rattus norvegicus,429,CHEMBL627716,50597,,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,A,1,N,1,,BAO_0000218
10209,,,10116.0,Intermediate,Rattus norvegicus,17655,CHEMBL627717,50597,,,,Maximum time required to achieve Cmax was determined in rat,,A,1,N,1,,BAO_0000218
10210,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL627718,50597,,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,A,1,N,1,,BAO_0000218
10211,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL627719,50597,,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,A,1,N,1,,BAO_0000218
10212,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL627720,50597,,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,A,1,N,1,,BAO_0000218
10213,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL627721,50597,,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
10214,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL627722,50597,,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,A,1,N,1,,BAO_0000218
10215,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL627723,50597,,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10216,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL626058,50597,,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10217,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL626059,50597,,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10218,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL626060,50597,,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10219,,1969.0,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL626061,50597,,,Plasma,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,A,1,N,1,,BAO_0000218
10220,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL876791,50597,,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
10221,,,10116.0,Intermediate,Rattus norvegicus,4723,CHEMBL626062,50597,,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,A,1,N,1,,BAO_0000218
10222,,,10116.0,Intermediate,Rattus norvegicus,4756,CHEMBL626063,50597,,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,,A,1,N,1,,BAO_0000218
10223,,,10116.0,Intermediate,Rattus norvegicus,4756,CHEMBL626064,50597,,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,,A,1,N,1,,BAO_0000218
10224,,1969.0,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL626065,50597,,,Plasma,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,A,1,N,1,,BAO_0000218
10225,,1969.0,10116.0,Intermediate,Rattus norvegicus,17720,CHEMBL626066,50597,,,Plasma,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,A,1,N,1,,BAO_0000218
10226,,,10116.0,Intermediate,Rattus norvegicus,1466,CHEMBL626067,50597,,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,A,1,N,1,,BAO_0000218
10227,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL626068,50597,,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,F,1,N,1,,BAO_0000218
10228,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL626069,50597,,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,F,1,N,1,,BAO_0000218
10229,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL626070,50597,,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,,F,1,N,1,,BAO_0000218
10230,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL626071,50597,,,,Percent total excretion of N-methoxyacetaminophen glucuronide,,F,1,N,1,,BAO_0000218
10231,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL626072,50597,,,,Percent total excretion of N-methoxyacetaminophen sulfate,,F,1,N,1,,BAO_0000218
10232,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL626073,50597,,,,Percent total excretion of acetaminophen,,F,1,N,1,,BAO_0000218
10233,,2046.0,10116.0,Intermediate,Rattus norvegicus,7768,CHEMBL626741,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,A,1,N,1,,BAO_0000218
10234,,,10116.0,Intermediate,Rattus norvegicus,17655,CHEMBL626742,50597,,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,A,1,N,1,,BAO_0000218
10235,,,10116.0,Intermediate,Rattus norvegicus,17735,CHEMBL626743,50597,,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,A,1,N,1,,BAO_0000218
10236,,,10116.0,Intermediate,Rattus norvegicus,5960,CHEMBL876792,50597,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,A,1,N,1,,BAO_0000218
10237,,,10116.0,Intermediate,Rattus norvegicus,17735,CHEMBL626744,50597,,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,A,1,N,1,,BAO_0000218
10238,,,10116.0,Intermediate,Rattus norvegicus,7116,CHEMBL626745,50597,,,,Compound was tested for antidiuretic activity in rats,,A,1,N,1,,BAO_0000218
10239,,1969.0,10116.0,Intermediate,Rattus norvegicus,4878,CHEMBL626746,50597,,,Plasma,AUC in rat after 3mg/kg oral dose,,A,1,N,1,,BAO_0000218
10240,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL626747,50597,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
10241,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL626748,50597,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
10242,,,10116.0,Intermediate,Rattus norvegicus,16367,CHEMBL626749,50597,,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,,A,1,N,1,,BAO_0000218
10243,,,10116.0,Intermediate,Rattus norvegicus,16366,CHEMBL626750,50597,,,,Oral Bioavailability was determined,,A,1,N,1,,BAO_0000218
10244,,,10116.0,Intermediate,Rattus norvegicus,4426,CHEMBL626751,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10245,,,10116.0,Intermediate,Rattus norvegicus,4426,CHEMBL626913,50597,,,,Oral bioavailability in rat; Not performed.,,A,1,N,1,,BAO_0000218
10246,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL626914,50597,,,,Bioavailability,,A,1,N,1,,BAO_0000218
10247,,,10116.0,Intermediate,Rattus norvegicus,5041,CHEMBL626915,50597,,,,Bioavailability was determined; ND denotes no data,,A,1,N,1,,BAO_0000218
10248,,,10116.0,Intermediate,Rattus norvegicus,1500,CHEMBL626916,50597,,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,A,1,N,1,,BAO_0000218
10249,,,10116.0,Intermediate,Rattus norvegicus,1500,CHEMBL626917,50597,,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,A,1,N,1,,BAO_0000218
10250,,,10116.0,Intermediate,Rattus norvegicus,17409,CHEMBL626918,50597,,,,Binding towards rat plasma protein at 10 uM,,A,1,N,1,,BAO_0000218
10251,,,10116.0,Intermediate,Rattus norvegicus,17409,CHEMBL626919,50597,,,,Binding towards rat plasma protein at 100 uM,,A,1,N,1,,BAO_0000218
10252,,,10116.0,Intermediate,Rattus norvegicus,2959,CHEMBL626920,50597,,,,Bioavailability in rat (dose 20 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10253,,,10116.0,Intermediate,Rattus norvegicus,13501,CHEMBL621976,50597,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,A,1,N,1,,BAO_0000218
10254,,,10116.0,Intermediate,Rattus norvegicus,6567,CHEMBL877599,50597,,,,Bioavailability in rat after 5 mg/kg oral gavage,,A,1,N,1,,BAO_0000218
10255,,,10116.0,Intermediate,Rattus norvegicus,6571,CHEMBL621977,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10256,,,10116.0,Intermediate,Rattus norvegicus,6715,CHEMBL621978,50597,,,,Bioavailability in rat (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10257,,,10116.0,Intermediate,Rattus norvegicus,6715,CHEMBL621979,50597,,,,Bioavailability in rat (dose 3 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10258,,,10116.0,Intermediate,Rattus norvegicus,2932,CHEMBL621980,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10259,,,10116.0,Intermediate,Rattus norvegicus,4171,CHEMBL621981,50597,,,,Bioavailability of the compound in rats after administration of 30 mg/kg,,A,1,N,1,,BAO_0000218
10260,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL621982,50597,,,,Bioavailability after administration of 10 mg/kg in rats,,A,1,N,1,,BAO_0000218
10261,,,10116.0,Intermediate,Rattus norvegicus,17509,CHEMBL882953,50597,,,,Bioavailability after administration of 2 mg/kg in rats,,A,1,N,1,,BAO_0000218
10262,,,10116.0,Intermediate,Rattus norvegicus,4527,CHEMBL621983,50597,,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,A,1,N,1,,BAO_0000218
10263,,,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL621984,50597,,,,Bioavailability in dogs was determined; high,,A,1,N,1,,BAO_0000218
10264,,,10116.0,Intermediate,Rattus norvegicus,6659,CHEMBL621985,50597,,,,Bioavailability in monkey after intravenous administration at 1 mpk,,A,1,N,1,,BAO_0000218
10265,,,10116.0,Intermediate,Rattus norvegicus,6659,CHEMBL621986,50597,,,,Bioavailability in monkey after peroral administration at 10 mpk,,A,1,N,1,,BAO_0000218
10266,,,10116.0,Intermediate,Rattus norvegicus,6659,CHEMBL621987,50597,,,,Bioavailability in rat after intravenous administration at 1 mpk,,A,1,N,1,,BAO_0000218
10267,,,10116.0,Intermediate,Rattus norvegicus,6659,CHEMBL877600,50597,,,,Bioavailability in rat after intravenous administration at 2 mpk,,F,1,N,1,,BAO_0000218
10268,,,10116.0,Intermediate,Rattus norvegicus,6659,CHEMBL621988,50597,,,,Bioavailability in rat after peroral administration at 30 mpk,,A,1,N,1,,BAO_0000218
10269,,,10116.0,Intermediate,Rattus norvegicus,6659,CHEMBL621989,50597,,,,Bioavailability in rat after peroral administration at at 100 mpk,,F,1,N,1,,BAO_0000218
10270,,,10116.0,Intermediate,Rattus norvegicus,6597,CHEMBL621990,50597,,,,Bioavailability in rats was evaluated,,A,1,N,1,,BAO_0000218
10271,,,10116.0,Intermediate,Rattus norvegicus,1202,CHEMBL621991,50597,,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,A,1,N,1,,BAO_0000218
10272,,,10116.0,Intermediate,Rattus norvegicus,1202,CHEMBL621992,50597,,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,A,1,N,1,,BAO_0000218
10273,,,10116.0,Intermediate,Rattus norvegicus,1202,CHEMBL621993,50597,,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,A,1,N,1,,BAO_0000218
10274,,,10116.0,Intermediate,Rattus norvegicus,1202,CHEMBL621994,50597,,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,A,1,N,1,,BAO_0000218
10275,,,10116.0,Intermediate,Rattus norvegicus,5207,CHEMBL621995,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10276,,,10116.0,Intermediate,Rattus norvegicus,5970,CHEMBL621996,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10277,,,10116.0,Intermediate,Rattus norvegicus,17538,CHEMBL621997,50597,,,,Oral bioavailability in rat (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
10278,,,10116.0,Intermediate,Rattus norvegicus,17538,CHEMBL621998,50597,,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,A,1,N,1,,BAO_0000218
10279,,,10116.0,Intermediate,Rattus norvegicus,1466,CHEMBL621999,50597,,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,A,1,N,1,,BAO_0000218
10280,,,10116.0,Intermediate,Rattus norvegicus,2879,CHEMBL622000,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10281,,,10116.0,Intermediate,Rattus norvegicus,2879,CHEMBL622001,50597,,,,Bioavailability was measured in rat after oral administration; 2-4,,A,1,N,1,,BAO_0000218
10282,,,10116.0,Intermediate,Rattus norvegicus,2879,CHEMBL622002,50597,,,,Bioavailability was measured in rat after oral administration; 3-7,,A,1,N,1,,BAO_0000218
10283,,,10116.0,Intermediate,Rattus norvegicus,3777,CHEMBL622003,50597,,,,Bioavailability in rat (intraduodenal administration),,A,1,N,1,,BAO_0000218
10284,,,10116.0,Intermediate,Rattus norvegicus,3777,CHEMBL877601,50597,,,,Bioavailability in rat (intraduodenal administration),,A,1,N,1,,BAO_0000218
10285,,,10116.0,Intermediate,Rattus norvegicus,3777,CHEMBL624871,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10286,,,10116.0,Intermediate,Rattus norvegicus,3777,CHEMBL622004,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10287,,,10116.0,Intermediate,Rattus norvegicus,5423,CHEMBL882954,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10288,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL622005,50597,,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,A,1,N,1,,BAO_0000218
10289,,,10116.0,Intermediate,Rattus norvegicus,16365,CHEMBL622006,50597,,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,A,1,N,1,,BAO_0000218
10290,,,10116.0,Intermediate,Rattus norvegicus,4239,CHEMBL622007,50597,,,,Bioavailability was measured in rat,,A,1,N,1,,BAO_0000218
10291,,,10116.0,Intermediate,Rattus norvegicus,5438,CHEMBL622008,50597,,,,Bioavailability was reported,,A,1,N,1,,BAO_0000218
10292,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL622009,50597,,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10293,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL622010,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
10294,,,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL622011,50597,,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,A,1,N,1,,BAO_0000218
10295,,,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL622012,50597,,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,A,1,N,1,,BAO_0000218
10296,,,10116.0,Intermediate,Rattus norvegicus,4199,CHEMBL622013,50597,,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,A,1,N,1,,BAO_0000218
10297,,,10116.0,Intermediate,Rattus norvegicus,4890,CHEMBL622014,50597,,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
10298,,,10116.0,Intermediate,Rattus norvegicus,2792,CHEMBL624749,50597,,,,Bioavailability was determined at 3 mg/kg po dose in rats,,A,1,N,1,,BAO_0000218
10299,,,10116.0,Intermediate,Rattus norvegicus,5529,CHEMBL624750,50597,,,,Oral bioavailability in rat (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
10300,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL624751,50597,,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
10301,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL624752,50597,,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,A,1,N,1,,BAO_0000218
10302,,,10116.0,Intermediate,Rattus norvegicus,6685,CHEMBL624753,50597,,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,A,1,N,1,,BAO_0000218
10303,,,10116.0,Intermediate,Rattus norvegicus,6005,CHEMBL624754,50597,,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
10304,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL624755,50597,,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,A,1,N,1,,BAO_0000218
10305,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL624756,50597,,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
10306,,,10116.0,Intermediate,Rattus norvegicus,6103,CHEMBL624757,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10307,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL624758,50597,,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,A,1,N,1,,BAO_0000218
10308,,,10116.0,Intermediate,Rattus norvegicus,6410,CHEMBL622270,50597,,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
10309,,,10116.0,Intermediate,Rattus norvegicus,5353,CHEMBL622271,50597,,,,Bioavailability in rat (Sprague-Dawley),,A,1,N,1,,BAO_0000218
10310,,,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL622272,50597,,,,Bioavailability in rat at the dose of 2 mg/kg,,A,1,N,1,,BAO_0000218
10311,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL622273,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10312,,,10116.0,Intermediate,Rattus norvegicus,5809,CHEMBL622274,50597,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
10313,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL622275,50597,,,,Bioavailability value of compound in rats was determined after peroral administration,,A,1,N,1,,BAO_0000218
10314,,,10116.0,Intermediate,Rattus norvegicus,3634,CHEMBL622276,50597,,,,Oral bioavailability in rat (dose 20 mg/kg),,A,1,N,1,,BAO_0000218
10315,,,10116.0,Intermediate,Rattus norvegicus,3341,CHEMBL622277,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10316,,,10116.0,Intermediate,Rattus norvegicus,2690,CHEMBL622278,50597,,,,Oral bioavailability in rat (dose 5 mg/kg),,A,1,N,1,,BAO_0000218
10317,,,10116.0,Intermediate,Rattus norvegicus,3184,CHEMBL622279,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10318,,,10116.0,Intermediate,Rattus norvegicus,740,CHEMBL622280,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10319,,,10116.0,Intermediate,Rattus norvegicus,1806,CHEMBL624083,50597,,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,,A,1,N,1,,BAO_0000218
10320,,,10116.0,Intermediate,Rattus norvegicus,4891,CHEMBL624084,50597,,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,A,1,N,1,,BAO_0000218
10321,,,10116.0,Intermediate,Rattus norvegicus,3634,CHEMBL624085,50597,,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,A,1,N,1,,BAO_0000218
10322,,,10116.0,Intermediate,Rattus norvegicus,64,CHEMBL624086,50597,,,,Compound was tested for bioavailability in rats,,A,1,N,1,,BAO_0000218
10323,,,10116.0,Intermediate,Rattus norvegicus,4839,CHEMBL624087,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10324,,,10116.0,Intermediate,Rattus norvegicus,1094,CHEMBL624088,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10325,,,9544.0,Intermediate,Macaca mulatta,5005,CHEMBL624089,22224,,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,A,1,U,0,,BAO_0000218
10326,,,10116.0,Intermediate,Rattus norvegicus,5005,CHEMBL624090,22224,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,A,1,U,0,,BAO_0000218
10327,,,10116.0,Intermediate,Rattus norvegicus,4687,CHEMBL624091,50597,,,,Evaluated for the bioavailability in rat (in vivo),,A,1,N,1,,BAO_0000218
10328,,,10116.0,Intermediate,Rattus norvegicus,17804,CHEMBL624092,50597,,,,F value of compound in rats was determined after peroral administration,,A,1,N,1,,BAO_0000218
10329,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL624093,50597,,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10330,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL624094,50597,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10331,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL624095,50597,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10332,,,10116.0,Intermediate,Rattus norvegicus,5974,CHEMBL624096,50597,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10333,,,10116.0,Intermediate,Rattus norvegicus,1088,CHEMBL624097,50597,,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,A,1,N,1,,BAO_0000218
10334,,,10116.0,Intermediate,Rattus norvegicus,1742,CHEMBL624098,50597,,,,Maximum fall in carotid flow in rat,,A,1,N,1,,BAO_0000218
10335,,,10116.0,Intermediate,Rattus norvegicus,4689,CHEMBL874392,50597,,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,A,1,N,1,,BAO_0000218
10336,,,10116.0,Intermediate,Rattus norvegicus,2463,CHEMBL624099,50597,,,,Oral bioavailability in rat (dose 5 mg/kg),,A,1,N,1,,BAO_0000218
10337,,,10116.0,Intermediate,Rattus norvegicus,5654,CHEMBL624100,50597,,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
10338,,,10116.0,Intermediate,Rattus norvegicus,5654,CHEMBL624101,50597,,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,A,1,N,1,,BAO_0000218
10339,,,10116.0,Intermediate,Rattus norvegicus,6874,CHEMBL624102,50597,,,,Oral bioavailability in rat (male Wistar),,A,1,N,1,,BAO_0000218
10340,,,10116.0,Intermediate,Rattus norvegicus,5633,CHEMBL624103,50597,,,,Oral bioavailability after administration (30 mg/kg) in rat; good,,A,1,N,1,,BAO_0000218
10341,,,10116.0,Intermediate,Rattus norvegicus,5496,CHEMBL624104,50597,,,,Oral bioavailability at the dose of 2 mg/kg in rat,,A,1,N,1,,BAO_0000218
10342,,,10116.0,Intermediate,Rattus norvegicus,2358,CHEMBL624105,50597,,,,Oral bioavailability determined in rats,,A,1,N,1,,BAO_0000218
10343,,,10116.0,Intermediate,Rattus norvegicus,16456,CHEMBL624106,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10344,,,10116.0,Intermediate,Rattus norvegicus,5302,CHEMBL624107,50597,,,,Oral bioavailability in rat (dose single 10 mg/kg),,A,1,N,1,,BAO_0000218
10345,,,10116.0,Intermediate,Rattus norvegicus,5302,CHEMBL623943,50597,,,,Oral bioavailability in rat (dose single 10 mg/kg),,A,1,N,1,,BAO_0000218
10346,,,10116.0,Intermediate,Rattus norvegicus,5302,CHEMBL623944,50597,,,,Oral bioavailability in rat (dose 5 mg/kg,,A,1,N,1,,BAO_0000218
10347,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623945,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,A,1,N,1,,BAO_0000218
10348,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623946,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,A,1,N,1,,BAO_0000218
10349,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623947,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,A,1,N,1,,BAO_0000218
10350,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623948,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,A,1,N,1,,BAO_0000218
10351,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623949,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,A,1,N,1,,BAO_0000218
10352,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623950,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,A,1,N,1,,BAO_0000218
10353,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL874398,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,A,1,N,1,,BAO_0000218
10354,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623951,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,A,1,N,1,,BAO_0000218
10355,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623952,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,A,1,N,1,,BAO_0000218
10356,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623953,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,A,1,N,1,,BAO_0000218
10357,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623954,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,A,1,N,1,,BAO_0000218
10358,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623955,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,A,1,N,1,,BAO_0000218
10359,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL623956,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,A,1,N,1,,BAO_0000218
10360,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627807,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,A,1,N,1,,BAO_0000218
10361,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627808,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,A,1,N,1,,BAO_0000218
10362,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627809,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,A,1,N,1,,BAO_0000218
10363,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627810,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,A,1,N,1,,BAO_0000218
10364,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627811,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,A,1,N,1,,BAO_0000218
10365,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627812,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,A,1,N,1,,BAO_0000218
10366,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627813,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,A,1,N,1,,BAO_0000218
10367,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627814,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,A,1,N,1,,BAO_0000218
10368,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL875336,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,A,1,N,1,,BAO_0000218
10369,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627815,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,A,1,N,1,,BAO_0000218
10370,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627816,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,A,1,N,1,,BAO_0000218
10371,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627817,50597,,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,A,1,N,1,,BAO_0000218
10372,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627818,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,A,1,N,1,,BAO_0000218
10373,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627819,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,A,1,N,1,,BAO_0000218
10374,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627820,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,A,1,N,1,,BAO_0000218
10375,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL627821,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,A,1,N,1,,BAO_0000218
10376,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL628464,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,A,1,N,1,,BAO_0000218
10377,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626239,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,A,1,N,1,,BAO_0000218
10378,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626240,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,A,1,N,1,,BAO_0000218
10379,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626241,50597,,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,A,1,N,1,,BAO_0000218
10380,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626242,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,A,1,N,1,,BAO_0000218
10381,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626243,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,A,1,N,1,,BAO_0000218
10382,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626244,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,A,1,N,1,,BAO_0000218
10383,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626907,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,A,1,N,1,,BAO_0000218
10384,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626908,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,A,1,N,1,,BAO_0000218
10385,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626909,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,A,1,N,1,,BAO_0000218
10386,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL626910,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,A,1,N,1,,BAO_0000218
10387,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL875342,50597,,,,Percent total excretion of acetaminophen cysteine conjugate,,F,1,N,1,,BAO_0000218
10388,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL626911,50597,,,,Percent total excretion of acetaminophen glucuronide,,F,1,N,1,,BAO_0000218
10389,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL626912,50597,,,,Percent total excretion of acetaminophen sulfate,,F,1,N,1,,BAO_0000218
10390,,,10116.0,Intermediate,Rattus norvegicus,7449,CHEMBL627065,50597,,,,Percent total excretion of acetaminophen-mercapturic acid,,F,1,N,1,,BAO_0000218
10391,,1088.0,10116.0,Intermediate,Rattus norvegicus,3172,CHEMBL627066,50597,,,Urine,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,A,1,N,1,,BAO_0000218
10392,,,10116.0,Intermediate,Rattus norvegicus,16456,CHEMBL627067,50597,,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
10393,,2385.0,8656.0,Autocuration,ratrat,10839,CHEMBL627068,22224,,,Muscle tissue,Biodistribution of compound in rat muscle after 5 min of administration,,A,1,U,0,,BAO_0000218
10394,,2385.0,8656.0,Autocuration,ratrat,10839,CHEMBL627069,22224,,,Muscle tissue,Biodistribution of compound in rat muscle after 5 min of administration.,,A,1,U,0,,BAO_0000218
10395,,,9940.0,Autocuration,Ovis aries,5334,CHEMBL627070,22224,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,A,1,U,0,,BAO_0000218
10396,,,9940.0,Autocuration,Ovis aries,5334,CHEMBL627071,22224,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,A,1,U,0,,BAO_0000218
10397,,,9940.0,Autocuration,Ovis aries,5334,CHEMBL627072,22224,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,A,1,U,0,,BAO_0000218
10398,,,9940.0,Autocuration,Ovis aries,5334,CHEMBL627073,22224,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,A,1,U,0,,BAO_0000218
10399,,,9940.0,Autocuration,Ovis aries,5334,CHEMBL625387,22224,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,A,1,U,0,,BAO_0000218
10400,,,9940.0,Autocuration,Ovis aries,5334,CHEMBL625388,22224,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,A,1,U,0,,BAO_0000218
10401,,1969.0,9940.0,Autocuration,Ovis aries,5334,CHEMBL625389,22224,,,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,A,1,U,0,,BAO_0000218
10402,,1969.0,9940.0,Autocuration,Ovis aries,5334,CHEMBL875343,22224,,,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,A,1,U,0,,BAO_0000218
10403,,,8570.0,Intermediate,Serpentes,1735,CHEMBL876795,50497,,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,A,1,N,1,,BAO_0000218
10404,,,8570.0,Intermediate,Serpentes,1469,CHEMBL626552,50497,,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,A,1,N,1,,BAO_0000218
10405,,,8570.0,Intermediate,Serpentes,1336,CHEMBL626553,50497,,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,A,1,N,1,,BAO_0000218
10406,,1969.0,9606.0,Autocuration,Homo sapiens,12403,CHEMBL626554,22224,,,Plasma,The human biological plasma half life of the compound,,A,1,U,0,,BAO_0000366
10407,,1088.0,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL626555,50597,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,A,1,N,1,,BAO_0000218
10408,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL626556,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,A,1,N,1,,BAO_0000218
10409,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL626557,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,A,1,N,1,,BAO_0000218
10410,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL626558,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,A,1,N,1,,BAO_0000218
10411,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL626559,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10412,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL626560,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10413,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL876803,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10414,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627964,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,A,1,N,1,,BAO_0000218
10415,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627965,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10416,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627966,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,A,1,N,1,,BAO_0000218
10417,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627967,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10418,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627968,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10419,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627969,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10420,,,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627970,50597,,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10421,,178.0,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627971,50597,,,Blood,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10422,,178.0,10116.0,Intermediate,Rattus norvegicus,8004,CHEMBL627972,50597,,,Blood,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,A,1,N,1,,BAO_0000218
10423,,,9606.0,Expert,Homo sapiens,15917,CHEMBL856029,180,,,,Dissociation constant against binding to human cyclophilin A,,B,1,D,9,,BAO_0000357
10424,,,9913.0,Expert,Bos taurus,12396,CHEMBL627973,11591,,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,B,1,H,8,,BAO_0000019
10425,,,,Autocuration,,7065,CHEMBL627974,22224,,,,-Log C was determined by performing the electroshock minimum test,,A,1,U,0,,BAO_0000019
10426,,,,Autocuration,,7065,CHEMBL627975,22224,,,,-Log C was determined by performing the foot shock test,,A,1,U,0,,BAO_0000019
10427,,,,Autocuration,,7065,CHEMBL627976,22224,,,,-Log C was determined by performing the incl screen test,,A,1,U,0,,BAO_0000019
10428,,,,Autocuration,,7065,CHEMBL627977,22224,,,,-Log C was determined by performing the maximum electroshock test,,A,1,U,0,,BAO_0000019
10429,,,,Autocuration,,7065,CHEMBL627978,22224,,,,-Log C was determined by performing the pentylenetetrazole test,,A,1,U,0,,BAO_0000019
10430,,,,Autocuration,,12415,CHEMBL627979,22224,,,,Tested for experimental arotinoid inhibitory dose,,A,1,U,0,,BAO_0000019
10431,,,,Autocuration,,10256,CHEMBL876804,22224,,,,Negative log transformed activity,,A,1,U,0,,BAO_0000019
10432,,,,Autocuration,,7991,CHEMBL627980,22224,,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,A,1,U,0,,BAO_0000019
10433,,,10141.0,Intermediate,Cavia porcellus,14342,CHEMBL627981,50512,,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,A,1,N,1,,BAO_0000218
10434,,,10141.0,Intermediate,Cavia porcellus,14342,CHEMBL627982,50512,,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,A,1,N,1,,BAO_0000218
10435,,,10141.0,Intermediate,Cavia porcellus,14342,CHEMBL627983,50512,,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,A,1,N,1,,BAO_0000218
10436,,2116.0,10141.0,Intermediate,Cavia porcellus,14342,CHEMBL627984,50512,,,Ileum,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,A,1,N,1,,BAO_0000218
10437,,,,Autocuration,,6047,CHEMBL627985,22229,,,,Solubility in water was determined; values expressed as -log,,P,1,U,0,,BAO_0000100
10438,,,,Autocuration,,17269,CHEMBL627986,22224,,,,Ratio of Kcat to that of Km was determined,,A,1,U,0,,BAO_0000019
10439,,,,Autocuration,,10026,CHEMBL627987,22224,,,,Observed first order rate constant,,A,1,U,0,,BAO_0000019
10440,,,,Autocuration,,14583,CHEMBL627988,22224,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,A,1,U,0,,BAO_0000019
10441,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL627989,50597,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,A,1,N,1,,BAO_0000218
10442,,,10116.0,Intermediate,Rattus norvegicus,2661,CHEMBL627990,50597,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,A,1,N,1,,BAO_0000218
10443,,,10116.0,Intermediate,Rattus norvegicus,4029,CHEMBL876805,50597,,,,Oral Bioavailability after administration of 10 mg/kg in male rat,,A,1,N,1,,BAO_0000218
10444,,,10116.0,Intermediate,Rattus norvegicus,17735,CHEMBL627991,50597,,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10445,,,10116.0,Intermediate,Rattus norvegicus,4576,CHEMBL627992,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10446,,,10116.0,Intermediate,Rattus norvegicus,17582,CHEMBL627993,50597,,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,A,1,N,1,,BAO_0000218
10447,,,10116.0,Intermediate,Rattus norvegicus,17651,CHEMBL622817,50597,,,,Oral bioavailability at 1 mg/kg was determined in rat,,A,1,N,1,,BAO_0000218
10448,,,10116.0,Intermediate,Rattus norvegicus,17651,CHEMBL622818,50597,,,,Oral bioavailability at 10 mg/kg was determined in rat,,A,1,N,1,,BAO_0000218
10449,,,10116.0,Intermediate,Rattus norvegicus,17670,CHEMBL622819,50597,,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,A,1,N,1,,BAO_0000218
10450,,,10116.0,Intermediate,Rattus norvegicus,5045,CHEMBL872267,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10451,,,10116.0,Intermediate,Rattus norvegicus,1696,CHEMBL622820,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10452,,,10116.0,Intermediate,Rattus norvegicus,17764,CHEMBL622821,50597,,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,A,1,N,1,,BAO_0000218
10453,,,10116.0,Intermediate,Rattus norvegicus,6448,CHEMBL622822,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10454,,,10116.0,Intermediate,Rattus norvegicus,6596,CHEMBL622823,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10455,,,10116.0,Intermediate,Rattus norvegicus,17547,CHEMBL622824,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10456,,,10116.0,Intermediate,Rattus norvegicus,17771,CHEMBL622825,50597,,,,Oral bioavailability in rat at a dose of 3 mg/kg,,A,1,N,1,,BAO_0000218
10457,,,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL622901,50597,,,,Oral bioavailability in rat after oral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
10458,,,10116.0,Intermediate,Rattus norvegicus,4558,CHEMBL622902,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10459,,,10116.0,Intermediate,Rattus norvegicus,17596,CHEMBL621844,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10460,,,10116.0,Intermediate,Rattus norvegicus,6827,CHEMBL621845,50597,,,,Oral bioavailability in Dawley rats,,A,1,N,1,,BAO_0000218
10461,,,10116.0,Intermediate,Rattus norvegicus,4026,CHEMBL621846,50597,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
10462,,,10116.0,Intermediate,Rattus norvegicus,10,CHEMBL621847,50597,,,,Oral bioavailability in rat (dose 30 mg/kg),,A,1,N,1,,BAO_0000218
10463,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL877609,50597,,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,A,1,N,1,,BAO_0000218
10464,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL621848,50597,,,,Bioavailability in rat (dose 3 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10465,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL621849,50597,,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,A,1,N,1,,BAO_0000218
10466,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL622030,50597,,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10467,,,10116.0,Intermediate,Rattus norvegicus,4796,CHEMBL622031,50597,,,,Percent oral bioavailability determined in rats,,A,1,N,1,,BAO_0000218
10468,,,10116.0,Intermediate,Rattus norvegicus,4883,CHEMBL622032,50597,,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,A,1,N,1,,BAO_0000218
10469,,,10116.0,Intermediate,Rattus norvegicus,2137,CHEMBL622033,50597,,,,The compound was evaluated for bioavailability in rats; 32-51,,A,1,N,1,,BAO_0000218
10470,,,10116.0,Intermediate,Rattus norvegicus,2959,CHEMBL622034,50597,,,,Bioavailability in rat (dose 20 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10471,,,10116.0,Intermediate,Rattus norvegicus,1361,CHEMBL622035,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10472,,,10116.0,Intermediate,Rattus norvegicus,4727,CHEMBL882966,50597,,,,Bioavailability percent in rat at the dose of 2 mg/kg,,A,1,N,1,,BAO_0000218
10473,,,10116.0,Intermediate,Rattus norvegicus,16423,CHEMBL622036,50597,,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,,A,1,N,1,,BAO_0000218
10474,,,10116.0,Intermediate,Rattus norvegicus,5206,CHEMBL622037,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10475,,,10116.0,Intermediate,Rattus norvegicus,6448,CHEMBL622038,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10476,,,10116.0,Intermediate,Rattus norvegicus,17723,CHEMBL622039,50597,,,,Bioavailability in rats,,A,1,N,1,,BAO_0000218
10477,,178.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622040,50597,,,Blood,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10478,,178.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622041,50597,,,Blood,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10479,,178.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622042,50597,,,Blood,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10480,,178.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622043,50597,,,Blood,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10481,,178.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622044,50597,,,Blood,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10482,,10000001.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622045,50597,,,Bone,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10483,,10000001.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622046,50597,,,Bone,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10484,,10000001.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622047,50597,,,Bone,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10485,,10000001.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL877610,50597,,,Bone,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10486,,955.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622048,50597,,,Brain,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10487,,955.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622049,50597,,,Brain,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10488,,955.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622050,50597,,,Brain,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10489,,955.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622051,50597,,,Brain,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10490,,,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622052,50597,,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10491,,,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622053,50597,,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10492,,,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622054,50597,,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10493,,,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622055,50597,,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10494,,,10116.0,Intermediate,Rattus norvegicus,5237,CHEMBL622056,50597,,,,Oral bioavailability in rats was determined; High,,A,1,N,1,,BAO_0000218
10495,,,10116.0,Intermediate,Rattus norvegicus,5503,CHEMBL622057,50597,,,,Oral bioavailability in the rat was determined,,A,1,N,1,,BAO_0000218
10496,,,10116.0,Intermediate,Rattus norvegicus,15765,CHEMBL628008,50597,,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,A,1,N,1,,BAO_0000218
10497,,,10116.0,Intermediate,Rattus norvegicus,15660,CHEMBL622058,50597,,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10498,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL622059,50597,,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10499,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL622060,50597,,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10500,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL622061,50597,,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10501,,,10116.0,Intermediate,Rattus norvegicus,5978,CHEMBL622062,50597,,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,A,1,N,1,,BAO_0000218
10502,,,10116.0,Intermediate,Rattus norvegicus,5656,CHEMBL622063,50597,,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,A,1,N,1,,BAO_0000218
10503,,,10116.0,Expert,Rattus norvegicus,3598,CHEMBL877611,50597,,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
10504,,,10116.0,Intermediate,Rattus norvegicus,4216,CHEMBL622064,50597,,,,Oral bioavailability of compound in Sprague Dawley rats,,A,1,N,1,,BAO_0000218
10505,,,10116.0,Intermediate,Rattus norvegicus,17839,CHEMBL622065,50597,,,,Oral bioavailability of compound in rat,,A,1,N,1,,BAO_0000218
10506,,,10116.0,Intermediate,Rattus norvegicus,6570,CHEMBL622066,50597,,,,Oral bioavailability in rat (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
10507,,,10116.0,Intermediate,Rattus norvegicus,5334,CHEMBL622067,50597,,,,Oral bioavailability of compound in rat was determined,,A,1,N,1,,BAO_0000218
10508,,,10116.0,Intermediate,Rattus norvegicus,6886,CHEMBL622068,50597,,,,Oral bioavailability of compound in rats,,A,1,N,1,,BAO_0000218
10509,,,10116.0,Intermediate,Rattus norvegicus,5210,CHEMBL622069,50597,,,,Oral bioavailability of compound was determined in rats,,A,1,N,1,,BAO_0000218
10510,,,10116.0,Intermediate,Rattus norvegicus,4170,CHEMBL624796,50597,,,,Oral bioavailability at a dose of 30 mg/kg in rats,,A,1,N,1,,BAO_0000218
10511,,,10116.0,Intermediate,Rattus norvegicus,6028,CHEMBL624797,50597,,,,Oral bioavailability in rat (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
10512,,,10116.0,Intermediate,Rattus norvegicus,6028,CHEMBL623053,50597,,,,Oral bioavailability in rat (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
10513,,,10116.0,Intermediate,Rattus norvegicus,6078,CHEMBL623054,50597,,,,Oral bioavailability evaluated in rat,,A,1,N,1,,BAO_0000218
10514,,,10116.0,Intermediate,Rattus norvegicus,6168,CHEMBL623055,50597,,,,Oral bioavailability in fasted rat,,A,1,N,1,,BAO_0000218
10515,,,10116.0,Intermediate,Rattus norvegicus,6168,CHEMBL623056,50597,,,,Oral bioavailability in fed rat,,A,1,N,1,,BAO_0000218
10516,,,10116.0,Intermediate,Rattus norvegicus,5160,CHEMBL623057,50597,,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,A,1,N,1,,BAO_0000218
10517,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL623058,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10518,,,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL623059,50597,,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10519,,,10116.0,Intermediate,Rattus norvegicus,6535,CHEMBL623060,50597,,,,Oral bioavailability in rat after administration of 10 mg/kg po,,A,1,N,1,,BAO_0000218
10520,,,10116.0,Intermediate,Rattus norvegicus,4194,CHEMBL623061,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10521,,,10116.0,Intermediate,Rattus norvegicus,6230,CHEMBL623062,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10522,,,10116.0,Intermediate,Rattus norvegicus,6619,CHEMBL623063,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10523,,,10116.0,Intermediate,Rattus norvegicus,17607,CHEMBL623064,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10524,,,10116.0,Intermediate,Rattus norvegicus,4942,CHEMBL623065,50597,,,,Oral bioavailability in ratrs,,A,1,N,1,,BAO_0000218
10525,,,10116.0,Intermediate,Rattus norvegicus,4942,CHEMBL623066,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10526,,,10116.0,Intermediate,Rattus norvegicus,6646,CHEMBL623067,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10527,,,10116.0,Intermediate,Rattus norvegicus,5237,CHEMBL623068,50597,,,,Oral bioavailability in rats was determined; High,,A,1,N,1,,BAO_0000218
10528,,,10116.0,Intermediate,Rattus norvegicus,6646,CHEMBL623069,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10529,,,10116.0,Intermediate,Rattus norvegicus,4449,CHEMBL623070,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10530,,,10116.0,Intermediate,Rattus norvegicus,6057,CHEMBL623071,50597,,,,Oral bioavailability was calculated in rat,,A,1,N,1,,BAO_0000218
10531,,,10116.0,Intermediate,Rattus norvegicus,2552,CHEMBL623072,50597,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
10532,,,10116.0,Intermediate,Rattus norvegicus,5496,CHEMBL623073,50597,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
10533,,,10116.0,Intermediate,Rattus norvegicus,6484,CHEMBL623074,50597,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
10534,,,10116.0,Intermediate,Rattus norvegicus,6485,CHEMBL623075,50597,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
10535,,,10116.0,Intermediate,Rattus norvegicus,6616,CHEMBL623076,50597,,,,Oral bioavailability after i.v. administration,,A,1,N,1,,BAO_0000218
10536,,,10116.0,Intermediate,Rattus norvegicus,4969,CHEMBL623077,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10537,,,10116.0,Intermediate,Rattus norvegicus,5862,CHEMBL623078,50597,,,,Oral bioavailability in rat (Sprague-Dawley),,A,1,N,1,,BAO_0000218
10538,,,10116.0,Intermediate,Rattus norvegicus,4514,CHEMBL623079,50597,,,,Oral bioavailability in Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
10539,,,10116.0,Intermediate,Rattus norvegicus,4514,CHEMBL623080,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10540,,,10116.0,Intermediate,Rattus norvegicus,4514,CHEMBL623081,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
10541,,,10116.0,Intermediate,Rattus norvegicus,5546,CHEMBL623082,50597,,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,A,1,N,1,,BAO_0000218
10542,,,10116.0,Intermediate,Rattus norvegicus,6168,CHEMBL874400,50597,,,,Oral bioavailability in fasted rat,,A,1,N,1,,BAO_0000218
10543,,,10116.0,Intermediate,Rattus norvegicus,6168,CHEMBL623083,50597,,,,Oral bioavailability in fed rat,,A,1,N,1,,BAO_0000218
10544,,,10116.0,Intermediate,Rattus norvegicus,3624,CHEMBL623084,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10545,,,10116.0,Intermediate,Rattus norvegicus,5213,CHEMBL623085,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10546,,,10116.0,Intermediate,Rattus norvegicus,5496,CHEMBL623086,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10547,,,10116.0,Intermediate,Rattus norvegicus,5553,CHEMBL623087,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10548,,,10116.0,Intermediate,Rattus norvegicus,5833,CHEMBL623088,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10549,,,10116.0,Intermediate,Rattus norvegicus,5836,CHEMBL623089,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10550,,,10116.0,Intermediate,Rattus norvegicus,5865,CHEMBL623090,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10551,,,10116.0,Intermediate,Rattus norvegicus,5960,CHEMBL623091,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10552,,,10116.0,Intermediate,Rattus norvegicus,6249,CHEMBL623092,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10553,,,10116.0,Intermediate,Rattus norvegicus,6448,CHEMBL623093,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10554,,,10116.0,Intermediate,Rattus norvegicus,6453,CHEMBL874401,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10555,,,10116.0,Intermediate,Rattus norvegicus,6640,CHEMBL623094,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10556,,,10116.0,Intermediate,Rattus norvegicus,17607,CHEMBL623095,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10557,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL623096,50597,,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
10558,,,10116.0,Intermediate,Rattus norvegicus,5939,CHEMBL624913,50597,,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,,A,1,N,1,,BAO_0000218
10559,,,10116.0,Intermediate,Rattus norvegicus,6281,CHEMBL624914,50597,,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10560,,,10116.0,Intermediate,Rattus norvegicus,5874,CHEMBL624915,50597,,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,A,1,N,1,,BAO_0000218
10561,,,10116.0,Intermediate,Rattus norvegicus,5213,CHEMBL624916,50597,,,,Oral bioavailability in rat; Not measured,,A,1,N,1,,BAO_0000218
10562,,,10116.0,Intermediate,Rattus norvegicus,4964,CHEMBL624917,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10563,,,10116.0,Intermediate,Rattus norvegicus,11020,CHEMBL625157,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,A,1,N,1,,BAO_0000218
10564,,2107.0,10116.0,Intermediate,Rattus norvegicus,6251,CHEMBL625158,50597,,,Liver,In vitro metabolic potential in rat liver microsomes,,A,1,N,1,,BAO_0000218
10565,,,10116.0,Intermediate,Rattus norvegicus,1568,CHEMBL625159,50597,,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,A,1,N,1,,BAO_0000218
10566,,,10116.0,Intermediate,Rattus norvegicus,3032,CHEMBL625160,50597,,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,A,1,N,1,,BAO_0000218
10567,,,10116.0,Intermediate,Rattus norvegicus,3748,CHEMBL625161,50597,,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,A,1,N,1,,BAO_0000218
10568,,,10116.0,Intermediate,Rattus norvegicus,401,CHEMBL625162,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10569,,,10116.0,Intermediate,Rattus norvegicus,6512,CHEMBL625163,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10570,,,10116.0,Intermediate,Rattus norvegicus,17617,CHEMBL625164,50597,,,,Oral bioavailability in rats at 10 mg/kg,,A,1,N,1,,BAO_0000218
10571,,,10116.0,Intermediate,Rattus norvegicus,6679,CHEMBL625165,50597,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,A,1,N,1,,BAO_0000218
10572,,,10116.0,Intermediate,Rattus norvegicus,6742,CHEMBL625166,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10573,,,10116.0,Intermediate,Rattus norvegicus,589,CHEMBL625167,50597,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,A,1,N,1,,BAO_0000218
10574,,,10116.0,Intermediate,Rattus norvegicus,589,CHEMBL625168,50597,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,A,1,N,1,,BAO_0000218
10575,,,10116.0,Intermediate,Rattus norvegicus,3185,CHEMBL625169,50597,,,,Plasma clearance of the compound,,A,1,N,1,,BAO_0000218
10576,,,10116.0,Intermediate,Rattus norvegicus,17596,CHEMBL626264,50597,,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,A,1,N,1,,BAO_0000218
10577,,,10116.0,Intermediate,Rattus norvegicus,2713,CHEMBL626265,50597,,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,A,1,N,1,,BAO_0000218
10578,,1969.0,10116.0,Intermediate,Rattus norvegicus,12500,CHEMBL626266,50597,,,Plasma,The compound was tested for plasma clearance in rat,,A,1,N,1,,BAO_0000218
10579,,1969.0,10116.0,Intermediate,Rattus norvegicus,12500,CHEMBL626267,50597,,,Plasma,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,A,1,N,1,,BAO_0000218
10580,,,10116.0,Intermediate,Rattus norvegicus,2713,CHEMBL626268,50597,,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,,A,1,N,1,,BAO_0000218
10581,,,10116.0,Intermediate,Rattus norvegicus,1446,CHEMBL626269,50597,,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,A,1,N,1,,BAO_0000218
10582,,,10116.0,Intermediate,Rattus norvegicus,6227,CHEMBL626270,50597,,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,A,1,N,1,,BAO_0000218
10583,,,10116.0,Intermediate,Rattus norvegicus,4709,CHEMBL626271,50597,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
10584,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL626272,50597,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,A,1,N,1,,BAO_0000218
10585,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL626273,50597,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,A,1,N,1,,BAO_0000218
10586,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL875346,50597,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,A,1,N,1,,BAO_0000218
10587,,,10116.0,Intermediate,Rattus norvegicus,5510,CHEMBL626274,50597,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,A,1,N,1,,BAO_0000218
10588,,,10116.0,Intermediate,Rattus norvegicus,4514,CHEMBL626275,50597,,,,Compound was tested for protein binding in rat plasma,,A,1,N,1,,BAO_0000218
10589,,,10116.0,Intermediate,Rattus norvegicus,2713,CHEMBL624646,50597,,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,A,1,N,1,,BAO_0000218
10590,,,10116.0,Intermediate,Rattus norvegicus,2713,CHEMBL624647,50597,,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,A,1,N,1,,BAO_0000218
10591,,2107.0,10116.0,Intermediate,Rattus norvegicus,5340,CHEMBL624648,50597,,,Liver,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,A,1,N,1,,BAO_0000218
10592,,,10116.0,Intermediate,Rattus norvegicus,12058,CHEMBL624649,50597,,,,Area under curve ratio was determined (po/iv) in rat,,A,1,N,1,,BAO_0000218
10593,,,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL624650,50597,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10594,,,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL624651,50597,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10595,,,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL624652,50597,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10596,,,10116.0,Intermediate,Rattus norvegicus,6495,CHEMBL624653,50597,,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,A,1,N,1,,BAO_0000218
10597,,,10116.0,Intermediate,Rattus norvegicus,6078,CHEMBL624654,50597,,,,Ratio of AUCbrain to AUCplasma,,A,1,N,1,,BAO_0000218
10598,,,10116.0,Intermediate,Rattus norvegicus,5656,CHEMBL624655,50597,,,,Ratio of brain to plasma,,A,1,N,1,,BAO_0000218
10599,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL624656,50597,,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,A,1,N,1,,BAO_0000218
10600,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL624657,50597,,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,A,1,N,1,,BAO_0000218
10601,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL624658,50597,,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,A,1,N,1,,BAO_0000218
10602,,,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL624659,50597,,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,A,1,N,1,,BAO_0000218
10603,,,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL624660,50597,,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,A,1,N,1,,BAO_0000218
10604,,,10116.0,Intermediate,Rattus norvegicus,10130,CHEMBL624661,50597,,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,A,1,N,1,,BAO_0000218
10605,,,10116.0,Intermediate,Rattus norvegicus,5213,CHEMBL624662,50597,,,,Steady state brain :blood ratio was determined,,A,1,N,1,,BAO_0000218
10606,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL625199,50597,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
10607,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL625200,50597,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,A,1,N,1,,BAO_0000218
10608,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL625201,50597,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,A,1,N,1,,BAO_0000218
10609,,,10116.0,Intermediate,Rattus norvegicus,4910,CHEMBL625202,50597,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,A,1,N,1,,BAO_0000218
10610,,,10116.0,Intermediate,Rattus norvegicus,2083,CHEMBL625203,50597,,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,,A,1,N,1,,BAO_0000218
10611,,,10116.0,Intermediate,Rattus norvegicus,2082,CHEMBL625204,50597,,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,A,1,N,1,,BAO_0000218
10612,,,10116.0,Intermediate,Rattus norvegicus,2082,CHEMBL625205,50597,,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,A,1,N,1,,BAO_0000218
10613,,,10116.0,Intermediate,Rattus norvegicus,6351,CHEMBL625206,50597,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,A,1,N,1,,BAO_0000218
10614,,,,Autocuration,,14583,CHEMBL625207,22224,,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,A,1,U,0,,BAO_0000019
10615,,,,Autocuration,,14583,CHEMBL625208,22224,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,A,1,U,0,,BAO_0000019
10616,,,9606.0,Intermediate,Homo sapiens,4608,CHEMBL625209,50587,,495.0,,In vivo absorption in Caco-2 cell line monolayers was determined,,A,1,N,1,,BAO_0000218
10617,,,,Autocuration,,13668,CHEMBL625210,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
10618,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL625211,50597,,,,Area under curve was determine after peroral administration at 10 mpk in Rat,,A,1,N,1,,BAO_0000218
10619,,,9544.0,Intermediate,Macaca mulatta,5669,CHEMBL625212,50797,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,A,1,N,1,,BAO_0000218
10620,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL625213,50597,,,,Area under curve was determine after peroral administration at 160 mpk in Rat,,A,1,N,1,,BAO_0000218
10621,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL625214,50597,,,,Area under curve was determine after peroral administration at 20 mpk in Rat,,A,1,N,1,,BAO_0000218
10622,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL874542,50597,,,,Area under curve was determine after peroral administration at 50 mpk in Rat,,A,1,N,1,,BAO_0000218
10623,,,,Autocuration,,6472,CHEMBL625215,22229,,,,Calculated partition coefficient (clogP) (AlogP),,P,1,U,0,,BAO_0000100
10624,,,,Autocuration,,15106,CHEMBL625216,22224,,,,Activated partial thromboplastin time measured,,A,1,U,0,,BAO_0000019
10625,,,,Autocuration,,15207,CHEMBL625217,22224,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,P,1,U,0,,BAO_0000100
10626,,,,Autocuration,,15207,CHEMBL625218,22224,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,P,1,U,0,,BAO_0000100
10627,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13941,CHEMBL622864,50588,,,Plasma,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
10628,,1969.0,10116.0,Intermediate,Rattus norvegicus,13941,CHEMBL622865,50597,,,Plasma,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,A,1,N,1,,BAO_0000218
10629,,1969.0,10116.0,Intermediate,Rattus norvegicus,13941,CHEMBL622866,50597,,,Plasma,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,A,1,N,1,,BAO_0000218
10630,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13941,CHEMBL622867,50588,,,Plasma,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,A,1,N,1,,BAO_0000218
10631,,1969.0,10141.0,Intermediate,Cavia porcellus,15240,CHEMBL876808,50512,,,Plasma,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,A,1,N,1,,BAO_0000218
10632,,955.0,,Autocuration,,10655,CHEMBL627725,22224,,,Brain,AUC in brain,,A,1,U,0,,BAO_0000019
10633,,1977.0,,Autocuration,,10655,CHEMBL627726,22224,,,Serum,AUC in serum,,A,1,U,0,,BAO_0000019
10634,,1969.0,,Autocuration,,6504,CHEMBL627727,22224,,,Plasma,AUC was determined,,A,1,U,0,,BAO_0000019
10635,,1969.0,,Autocuration,,10615,CHEMBL627728,22224,,,Plasma,AUC of the compound.,,A,1,U,0,,BAO_0000019
10636,,1969.0,,Autocuration,,10353,CHEMBL627729,22224,,,Plasma,AUC value (0-4 hr),,A,1,U,0,,BAO_0000019
10637,,1969.0,,Autocuration,,14907,CHEMBL627730,22224,,,Plasma,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,A,1,U,0,,BAO_0000019
10638,,1969.0,,Autocuration,,14907,CHEMBL627731,22224,,,Plasma,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,A,1,U,0,,BAO_0000019
10639,,1969.0,,Autocuration,,14907,CHEMBL627732,22224,,,Plasma,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,A,1,U,0,,BAO_0000019
10640,,1969.0,,Autocuration,,14907,CHEMBL627733,22224,,,Plasma,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,A,1,U,0,,BAO_0000019
10641,,1969.0,10116.0,Intermediate,Rattus norvegicus,16359,CHEMBL627734,50597,,,Plasma,AUC(area under curve) was determined after intravenous administration in rats,,A,1,N,1,,BAO_0000218
10642,,1969.0,10116.0,Intermediate,Rattus norvegicus,16359,CHEMBL627735,50597,,,Plasma,AUC(area under curve) was determined after oral administration in rats,,A,1,N,1,,BAO_0000218
10643,,1969.0,10141.0,Intermediate,Cavia porcellus,15240,CHEMBL627736,50512,,,Plasma,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,A,1,N,1,,BAO_0000218
10644,,1969.0,10116.0,Intermediate,Rattus norvegicus,15240,CHEMBL876809,50597,,,Plasma,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,A,1,N,1,,BAO_0000218
10645,,,,Autocuration,,15469,CHEMBL627737,22224,,,,Area Under Curve after oral dosing of 100 uM/Kg,,A,1,U,0,,BAO_0000019
10646,,,,Autocuration,,15469,CHEMBL627738,22224,,,,Area Under Curve after oral dosing of 30 uM/Kg,,A,1,U,0,,BAO_0000019
10647,,,,Autocuration,,13520,CHEMBL627739,22224,,,,Area Under Curve was measured by ploting the graph between concentration verses time,,A,1,U,0,,BAO_0000019
10648,,,9615.0,Intermediate,Canis lupus familiaris,17025,CHEMBL626143,50588,,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,A,1,N,1,,BAO_0000218
10649,,,314293.0,Autocuration,Simiiformes,17025,CHEMBL626144,22224,,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,A,1,U,0,,BAO_0000218
10650,,,9986.0,Intermediate,Oryctolagus cuniculus,17025,CHEMBL626145,50592,,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,A,1,N,1,,BAO_0000218
10651,,,10116.0,Intermediate,Rattus norvegicus,17025,CHEMBL626146,50597,,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,A,1,N,1,,BAO_0000218
10652,,178.0,10116.0,Intermediate,Rattus norvegicus,12032,CHEMBL626147,50597,,,Blood,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,A,1,N,1,,BAO_0000218
10653,,,,Autocuration,,10291,CHEMBL626148,22224,,,,Area under curve (AUC) was determined,,A,1,U,0,,BAO_0000019
10654,,,,Autocuration,,5767,CHEMBL626149,22224,,,,Area under curve (AUC) following ip administration at 1 mg/kg,,A,1,U,0,,BAO_0000218
10655,,,,Autocuration,,1434,CHEMBL626150,22224,,,,Area under curve (AUC) was determined; ND is Not determined,,A,1,U,0,,BAO_0000019
10656,,,9615.0,Intermediate,Canis lupus familiaris,14925,CHEMBL626151,50588,,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,A,1,N,1,,BAO_0000218
10657,,,9615.0,Intermediate,Canis lupus familiaris,14925,CHEMBL626152,50588,,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,A,1,N,1,,BAO_0000218
10658,,,9615.0,Intermediate,Canis lupus familiaris,14925,CHEMBL626153,50588,,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,A,1,N,1,,BAO_0000218
10659,,,,Autocuration,,1434,CHEMBL626154,22224,,,,Area under curve (AUR) was determined,,A,1,U,0,,BAO_0000019
10660,,,,Autocuration,,11883,CHEMBL626155,22224,,,,Area under curve at 1 uM/dg administered intravenously,,A,1,U,0,,BAO_0000019
10661,,,,Autocuration,,11883,CHEMBL626156,22224,,,,Area under curve at 10 uM/dg administered perorally,,A,1,U,0,,BAO_0000019
10662,,,,Autocuration,,11883,CHEMBL626157,22224,,,,Area under curve at 2 uM/dg administered intravenously,,A,1,U,0,,BAO_0000019
10663,,,,Autocuration,,11883,CHEMBL626158,22224,,,,Area under curve at 20 uM/dg administered perorally,,A,1,U,0,,BAO_0000019
10664,,,9615.0,Intermediate,Canis lupus familiaris,15233,CHEMBL626159,50588,,,,Area under curve at a peroral dose of 3 mg/kg in dog,,A,1,N,1,,BAO_0000218
10665,,,10116.0,Intermediate,Rattus norvegicus,15233,CHEMBL626160,50597,,,,Area under curve at a peroral dose of 3 mg/kg in rat,,A,1,N,1,,BAO_0000218
10666,,,9615.0,Intermediate,Canis lupus familiaris,15233,CHEMBL626161,50588,,,,Area under curve at an iv dose of 1 mg/kg in dog,,A,1,N,1,,BAO_0000218
10667,,,10116.0,Intermediate,Rattus norvegicus,15233,CHEMBL626162,50597,,,,Area under curve at an iv dose of 1 mg/kg in rat,,A,1,N,1,,BAO_0000218
10668,,,,Autocuration,,12978,CHEMBL626163,22224,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,A,1,U,0,,BAO_0000019
10669,,,,Autocuration,,12978,CHEMBL626164,22224,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,A,1,U,0,,BAO_0000019
10670,,,10090.0,Intermediate,Mus musculus,11355,CHEMBL626165,50594,,,,Area under curve measured as conc vs time after intravenous administration to mice.,,A,1,N,1,,BAO_0000218
10671,,,10090.0,Intermediate,Mus musculus,11355,CHEMBL626166,50594,,,,Area under curve measured as conc vs time after peroral administration to mice.,,A,1,N,1,,BAO_0000218
10672,,,9615.0,Intermediate,Canis lupus familiaris,12923,CHEMBL626167,50588,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,A,1,N,1,,BAO_0000218
10673,,,9615.0,Intermediate,Canis lupus familiaris,12923,CHEMBL626168,50588,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,A,1,N,1,,BAO_0000218
10674,,,9615.0,Intermediate,Canis lupus familiaris,12923,CHEMBL877463,50588,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,A,1,N,1,,BAO_0000218
10675,,,9615.0,Intermediate,Canis lupus familiaris,12923,CHEMBL626169,50588,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,A,1,N,1,,BAO_0000218
10676,,948.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL626170,50597,,,Heart,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10677,,948.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL626171,50597,,,Heart,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10678,,948.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL626172,50597,,,Heart,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10679,,948.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL626173,50597,,,Heart,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10680,,2113.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL626174,50597,,,Kidney,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10681,,2113.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL626175,50597,,,Kidney,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10682,,2113.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL626176,50597,,,Kidney,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10683,,2113.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL626177,50597,,,Kidney,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10684,,2113.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622499,50597,,,Kidney,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10685,,2107.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622500,50597,,,Liver,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10686,,2107.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622501,50597,,,Liver,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10687,,2107.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622502,50597,,,Liver,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10688,,2107.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL622503,50597,,,Liver,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10689,,2107.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL877614,50597,,,Liver,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10690,,2048.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL624839,50597,,,Lung,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10691,,2048.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL624840,50597,,,Lung,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10692,,2048.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL624841,50597,,,Lung,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10693,,2048.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL624842,50597,,,Lung,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10694,,2385.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL624843,50597,,,Muscle tissue,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10695,,2385.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL624844,50597,,,Muscle tissue,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10696,,2385.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL624845,50597,,,Muscle tissue,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10697,,2385.0,10116.0,Intermediate,Rattus norvegicus,17738,CHEMBL621904,50597,,,Muscle tissue,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,A,1,N,1,,BAO_0000218
10698,,178.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL621905,50597,,,Blood,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10699,,178.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL874382,50597,,,Blood,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10700,,178.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL621906,50597,,,Blood,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10701,,955.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL621907,50597,,,Brain,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10702,,955.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622096,50597,,,Brain,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10703,,955.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622097,50597,,,Brain,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10704,,948.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622098,50597,,,Heart,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10705,,948.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622099,50597,,,Heart,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10706,,948.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622100,50597,,,Heart,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10707,,2113.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622101,50597,,,Kidney,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10708,,2113.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622102,50597,,,Kidney,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10709,,2113.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622103,50597,,,Kidney,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10710,,2107.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622104,50597,,,Liver,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10711,,2107.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622105,50597,,,Liver,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10712,,2107.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622106,50597,,,Liver,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10713,,2048.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622107,50597,,,Lung,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10714,,2048.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622108,50597,,,Lung,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10715,,2048.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622109,50597,,,Lung,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10716,,2385.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622110,50597,,,Muscle tissue,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10717,,2385.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622111,50597,,,Muscle tissue,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10718,,2385.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL874383,50597,,,Muscle tissue,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10719,,14.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622112,50597,,,Zone of skin,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10720,,14.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622113,50597,,,Zone of skin,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10721,,14.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622114,50597,,,Zone of skin,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10722,,2106.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622115,50597,,,Spleen,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10723,,2106.0,10116.0,Intermediate,Rattus norvegicus,11195,CHEMBL622116,50597,,,Spleen,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,A,1,N,1,,BAO_0000218
10724,,,10116.0,Intermediate,Rattus norvegicus,6193,CHEMBL622117,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10725,,,10116.0,Intermediate,Rattus norvegicus,6803,CHEMBL622118,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10726,,,10116.0,Intermediate,Rattus norvegicus,6647,CHEMBL622119,50597,,,,Oral bioavailability in rats at 6 mg/kg,,A,1,N,1,,BAO_0000218
10727,,,10116.0,Intermediate,Rattus norvegicus,6647,CHEMBL622120,50597,,,,Oral bioavailability in rat (dose 6 mg/kg),,A,1,N,1,,BAO_0000218
10728,,,10116.0,Intermediate,Rattus norvegicus,6647,CHEMBL622121,50597,,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,A,1,N,1,,BAO_0000218
10729,,,10116.0,Intermediate,Rattus norvegicus,6640,CHEMBL622122,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10730,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL622123,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10731,,,10116.0,Intermediate,Rattus norvegicus,6641,CHEMBL622124,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10732,,,10116.0,Intermediate,Rattus norvegicus,6642,CHEMBL622125,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10733,,,10116.0,Intermediate,Rattus norvegicus,5472,CHEMBL622126,50597,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
10734,,,10116.0,Intermediate,Rattus norvegicus,6141,CHEMBL620455,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
10735,,,10116.0,Intermediate,Rattus norvegicus,4390,CHEMBL620456,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10736,,,10116.0,Intermediate,Rattus norvegicus,5472,CHEMBL620457,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10737,,,10116.0,Intermediate,Rattus norvegicus,5472,CHEMBL620458,50597,,,,Oral bioavailability was evaluated; Not tested,,A,1,N,1,,BAO_0000218
10738,,,10116.0,Intermediate,Rattus norvegicus,5438,CHEMBL620459,50597,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
10739,,,10116.0,Intermediate,Rattus norvegicus,4883,CHEMBL620460,50597,,,,Oral bioavailability in rat by oral dosing,,A,1,N,1,,BAO_0000218
10740,,,10116.0,Intermediate,Rattus norvegicus,1908,CHEMBL620461,50597,,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10741,,,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL620462,50597,,,,Oral bioavailability in rat (Sprague-Dawley),,A,1,N,1,,BAO_0000218
10742,,,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL620463,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10743,,,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL620464,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10744,,,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL620465,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,A,1,N,1,,BAO_0000218
10745,,,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL620466,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10746,,,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL620467,50597,,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,A,1,N,1,,BAO_0000218
10747,,,10116.0,Intermediate,Rattus norvegicus,4853,CHEMBL620468,50597,,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,A,1,N,1,,BAO_0000218
10748,,,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL620469,50597,,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,A,1,N,1,,BAO_0000218
10749,,,10116.0,Intermediate,Rattus norvegicus,12873,CHEMBL620470,50597,,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,A,1,N,1,,BAO_0000218
10750,,,10116.0,Intermediate,Rattus norvegicus,3169,CHEMBL620471,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10751,,,10116.0,Intermediate,Rattus norvegicus,6305,CHEMBL620472,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10752,,,10116.0,Intermediate,Rattus norvegicus,4762,CHEMBL620473,50597,,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,A,1,N,1,,BAO_0000218
10753,,,10116.0,Intermediate,Rattus norvegicus,17847,CHEMBL620474,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10754,,,10116.0,Intermediate,Rattus norvegicus,6211,CHEMBL620475,50597,,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,A,1,N,1,,BAO_0000218
10755,,,10116.0,Intermediate,Rattus norvegicus,6011,CHEMBL620476,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10756,,,10116.0,Intermediate,Rattus norvegicus,6317,CHEMBL620477,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10757,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL620478,50597,,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,A,1,N,1,,BAO_0000218
10758,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL618768,50597,,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,A,1,N,1,,BAO_0000218
10759,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL618769,50597,,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,A,1,N,1,,BAO_0000218
10760,,,10116.0,Intermediate,Rattus norvegicus,6644,CHEMBL618770,50597,,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,A,1,N,1,,BAO_0000218
10761,,,10116.0,Intermediate,Rattus norvegicus,6113,CHEMBL618771,50597,,,,Oral bioavailability (dose 20 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10762,,,10116.0,Intermediate,Rattus norvegicus,5937,CHEMBL618772,50597,,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,A,1,N,1,,BAO_0000218
10763,,,10116.0,Intermediate,Rattus norvegicus,5711,CHEMBL618773,50597,,,,Oral bioavailability in rat at 10 mg/kg of the compound,,A,1,N,1,,BAO_0000218
10764,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL875842,50597,,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,A,1,N,1,,BAO_0000218
10765,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL618774,50597,,,,Bioavailability in rat (dose 3 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10766,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL618775,50597,,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,A,1,N,1,,BAO_0000218
10767,,,10116.0,Intermediate,Rattus norvegicus,17717,CHEMBL618776,50597,,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10768,,,10116.0,Intermediate,Rattus norvegicus,4722,CHEMBL618777,50597,,,,Percent bioavailability (F) in rats after iv administration,,A,1,N,1,,BAO_0000218
10769,,,10116.0,Intermediate,Rattus norvegicus,4722,CHEMBL618778,50597,,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
10770,,,10116.0,Intermediate,Rattus norvegicus,4353,CHEMBL618779,50597,,,,Bioavailability in rat (dose 5 uM/kg p.o.),,A,1,N,1,,BAO_0000218
10771,,,10116.0,Intermediate,Rattus norvegicus,15662,CHEMBL618780,50597,,,,Oral bioavailability,,A,1,N,1,,BAO_0000218
10772,,,10116.0,Intermediate,Rattus norvegicus,4756,CHEMBL618781,50597,,,,Bioavailability in rat (dose 2 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10773,,,10116.0,Intermediate,Rattus norvegicus,4756,CHEMBL618782,50597,,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,A,1,N,1,,BAO_0000218
10774,,,10116.0,Intermediate,Rattus norvegicus,3436,CHEMBL618783,50597,,,,Oral bioavailability in rat (dose 20 mg/kg),,A,1,N,1,,BAO_0000218
10775,,,10116.0,Intermediate,Rattus norvegicus,17800,CHEMBL618784,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10776,,,10116.0,Intermediate,Rattus norvegicus,15762,CHEMBL618785,50597,,,,Percent oral bioavailability evaluated in rat,,A,1,N,1,,BAO_0000218
10777,,,10116.0,Intermediate,Rattus norvegicus,5089,CHEMBL618786,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10778,,,10116.0,Intermediate,Rattus norvegicus,5089,CHEMBL618787,50597,,,,Percent oral bioavailability in rat; Not determined,,A,1,N,1,,BAO_0000218
10779,,,10116.0,Intermediate,Rattus norvegicus,3185,CHEMBL618788,50597,,,,Oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10780,,,10116.0,Intermediate,Rattus norvegicus,5145,CHEMBL618789,50597,,,,Bioavailability in rat,,A,1,N,1,,BAO_0000218
10781,,,10116.0,Intermediate,Rattus norvegicus,3457,CHEMBL618790,50597,,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,A,1,N,1,,BAO_0000218
10782,,,10116.0,Intermediate,Rattus norvegicus,3457,CHEMBL618791,50597,,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,A,1,N,1,,BAO_0000218
10783,,,10116.0,Intermediate,Rattus norvegicus,5983,CHEMBL875843,50597,,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,A,1,N,1,,BAO_0000218
10784,,,10116.0,Intermediate,Rattus norvegicus,5739,CHEMBL618792,50597,,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),,A,1,N,1,,BAO_0000218
10785,,,10116.0,Intermediate,Rattus norvegicus,3579,CHEMBL623395,50597,,,,Cmax at a dose of 30 mg/kg in rat,,A,1,N,1,,BAO_0000218
10786,,,314293.0,Autocuration,Simiiformes,17788,CHEMBL623396,22224,,,,Cmax in monkeys at a dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
10787,,,10116.0,Intermediate,Rattus norvegicus,14956,CHEMBL623397,50597,,,,Cmax in rat,,A,1,N,1,,BAO_0000218
10788,,,10116.0,Intermediate,Rattus norvegicus,17788,CHEMBL623398,50597,,,,Cmax in rats at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
10789,,,10090.0,Intermediate,Mus musculus,9750,CHEMBL623399,50594,,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,,A,1,N,1,,BAO_0000218
10790,,,,Autocuration,,12767,CHEMBL623400,22224,,,,"Cmax value at a dose of 12.7 uM/kg, po",,A,1,U,0,,BAO_0000218
10791,,,,Autocuration,,12767,CHEMBL623401,22224,,,,"Cmax value at a dose of 6.3 uM/kg, iv",,A,1,U,0,,BAO_0000218
10792,,,,Autocuration,,12767,CHEMBL623402,22224,,,,"Cmax value at a dose of 7.1 uM/kg, iv",,A,1,U,0,,BAO_0000218
10793,,,,Autocuration,,12703,CHEMBL623403,22224,,,,Cmax value of compound was determined after 1 hr,,A,1,U,0,,BAO_0000218
10794,,,,Autocuration,,15778,CHEMBL623404,22224,,,,Cmax value of the compound,,A,1,U,0,,BAO_0000218
10795,,,10116.0,Intermediate,Rattus norvegicus,12818,CHEMBL625997,50597,,,,Cmax value administered intraintestinal in rats.,,A,1,N,1,,BAO_0000218
10796,,,10116.0,Intermediate,Rattus norvegicus,14964,CHEMBL625998,50597,,,,Cmax value administered perorally was determined in rat; Not determined,,A,1,N,1,,BAO_0000218
10797,,,,Autocuration,,15808,CHEMBL625999,22224,,,,Cmax value at the dose of 2.3 mg/kg,,A,1,U,0,,BAO_0000218
10798,,,,Autocuration,,15808,CHEMBL626000,22224,,,,Cmax value at the dose of 5 mg/kg,,A,1,U,0,,BAO_0000218
10799,,,,Autocuration,,15778,CHEMBL626001,22224,,,,Cmax value in the period of 8 hr after dosing. ,,A,1,U,0,,BAO_0000218
10800,,,,Autocuration,,3715,CHEMBL626002,22224,,,,Cmax value at a oral dose of 20 mg/kg; Not tested,,A,1,U,0,,BAO_0000218
10801,,,,Autocuration,,3715,CHEMBL626003,22224,,,,Cmax value at a oral dose of 20 mg/kg,,A,1,U,0,,BAO_0000218
10802,,,10116.0,Intermediate,Rattus norvegicus,1446,CHEMBL626004,50597,,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,A,1,N,1,,BAO_0000218
10803,,,10141.0,Intermediate,Cavia porcellus,15240,CHEMBL626005,50512,,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,A,1,N,1,,BAO_0000218
10804,,,10116.0,Intermediate,Rattus norvegicus,15240,CHEMBL626006,50597,,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,A,1,N,1,,BAO_0000218
10805,,1969.0,10116.0,Intermediate,Rattus norvegicus,14810,CHEMBL626007,50597,,,Plasma,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,A,1,N,1,,BAO_0000218
10806,,1969.0,10090.0,Intermediate,Mus musculus,14239,CHEMBL626008,50594,,,Plasma,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,A,1,N,1,,BAO_0000218
10807,,2107.0,9615.0,Intermediate,Canis lupus familiaris,12555,CHEMBL626009,50588,,,Liver,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,A,1,N,1,,BAO_0000218
10808,,,9615.0,Intermediate,Canis lupus familiaris,10754,CHEMBL626010,50588,,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,A,1,N,1,,BAO_0000218
10809,,178.0,10090.0,Intermediate,Mus musculus,10754,CHEMBL626011,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,A,1,N,1,,BAO_0000218
10810,,178.0,10090.0,Intermediate,Mus musculus,10754,CHEMBL626012,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,A,1,N,1,,BAO_0000218
10811,,178.0,10090.0,Intermediate,Mus musculus,10754,CHEMBL626013,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,A,1,N,1,,BAO_0000218
10812,,178.0,10090.0,Intermediate,Mus musculus,10754,CHEMBL626014,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,A,1,N,1,,BAO_0000218
10813,,178.0,10090.0,Intermediate,Mus musculus,10754,CHEMBL877496,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,A,1,N,1,,BAO_0000218
10814,,,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626015,50588,,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,F,1,N,1,,BAO_0000218
10815,,,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626016,50588,,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,F,1,N,1,,BAO_0000218
10816,,,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626017,50588,,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,F,1,N,1,,BAO_0000218
10817,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13543,CHEMBL626018,50588,,,Plasma,Bioavailability as maximal plasma concentration in dogs,,A,1,N,1,,BAO_0000218
10818,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13543,CHEMBL626692,50588,,,Plasma,Bioavailability as maximal plasma concentration in dogs,,A,1,N,1,,BAO_0000218
10819,,1969.0,10116.0,Intermediate,Rattus norvegicus,13543,CHEMBL626693,50597,,,Plasma,Bioavailability as maximal plasma concentration in rats,,A,1,N,1,,BAO_0000218
10820,,1969.0,10116.0,Autocuration,Rattus norvegicus,13543,CHEMBL626694,22224,,,Plasma,Bioavailability as maximal plasma concentration in rats,,A,1,U,0,,BAO_0000218
10821,,178.0,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626695,50588,,,Blood,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,A,1,N,1,,BAO_0000218
10822,,178.0,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626696,50588,,,Blood,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,A,1,N,1,,BAO_0000218
10823,,178.0,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626697,50588,,,Blood,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,A,1,N,1,,BAO_0000218
10824,,178.0,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626859,50588,,,Blood,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,A,1,N,1,,BAO_0000218
10825,,178.0,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626860,50588,,,Blood,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,A,1,N,1,,BAO_0000218
10826,,178.0,9615.0,Intermediate,Canis lupus familiaris,14600,CHEMBL626861,50588,,,Blood,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,A,1,N,1,,BAO_0000218
10827,,,10116.0,Intermediate,Rattus norvegicus,14681,CHEMBL626296,50597,,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,A,1,N,1,,BAO_0000218
10828,,,,Autocuration,,15905,CHEMBL626297,22224,,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,A,1,U,0,,BAO_0000218
10829,,1969.0,,Autocuration,,15905,CHEMBL626298,22224,,,Plasma,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,A,1,U,0,,BAO_0000218
10830,,1969.0,10116.0,Intermediate,Rattus norvegicus,13304,CHEMBL626299,50597,,,Plasma,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,A,1,N,1,,BAO_0000218
10831,,1969.0,10116.0,Intermediate,Rattus norvegicus,15137,CHEMBL626300,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,A,1,N,1,,BAO_0000218
10832,,1969.0,10116.0,Intermediate,Rattus norvegicus,15137,CHEMBL626301,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,A,1,N,1,,BAO_0000218
10833,,1969.0,10116.0,Intermediate,Rattus norvegicus,15137,CHEMBL626962,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,A,1,N,1,,BAO_0000218
10834,,1969.0,10116.0,Intermediate,Rattus norvegicus,15137,CHEMBL626963,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,A,1,N,1,,BAO_0000218
10835,,1969.0,10116.0,Intermediate,Rattus norvegicus,15137,CHEMBL626964,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,A,1,N,1,,BAO_0000218
10836,,1969.0,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL626965,100710,,,Plasma,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,A,1,N,1,,BAO_0000218
10837,,1969.0,10090.0,Intermediate,Mus musculus,14839,CHEMBL626966,50594,,,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,A,1,N,1,,BAO_0000218
10838,,1969.0,10090.0,Intermediate,Mus musculus,14839,CHEMBL626967,50594,,,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,A,1,N,1,,BAO_0000218
10839,,1969.0,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL626968,100710,,,Plasma,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,A,1,N,1,,BAO_0000218
10840,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626969,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,A,1,N,1,,BAO_0000218
10841,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627126,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,A,1,N,1,,BAO_0000218
10842,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631276,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,A,1,N,1,,BAO_0000218
10843,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631277,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,A,1,N,1,,BAO_0000218
10844,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631278,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,A,1,N,1,,BAO_0000218
10845,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL874457,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,A,1,N,1,,BAO_0000218
10846,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631279,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,A,1,N,1,,BAO_0000218
10847,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631280,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,A,1,N,1,,BAO_0000218
10848,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631281,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,A,1,N,1,,BAO_0000218
10849,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631968,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,A,1,N,1,,BAO_0000218
10850,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631969,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,A,1,N,1,,BAO_0000218
10851,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631970,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,A,1,N,1,,BAO_0000218
10852,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631971,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,A,1,N,1,,BAO_0000218
10853,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631972,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,A,1,N,1,,BAO_0000218
10854,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630435,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,A,1,N,1,,BAO_0000218
10855,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630436,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,A,1,N,1,,BAO_0000218
10856,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630437,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,A,1,N,1,,BAO_0000218
10857,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630438,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,A,1,N,1,,BAO_0000218
10858,,948.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630439,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,A,1,N,1,,BAO_0000218
10859,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630440,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,A,1,N,1,,BAO_0000218
10860,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630441,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,A,1,N,1,,BAO_0000218
10861,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630442,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,A,1,N,1,,BAO_0000218
10862,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625234,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,A,1,N,1,,BAO_0000218
10863,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625235,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,A,1,N,1,,BAO_0000218
10864,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625236,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,A,1,N,1,,BAO_0000218
10865,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625237,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,A,1,N,1,,BAO_0000218
10866,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626125,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,A,1,N,1,,BAO_0000218
10867,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626126,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,A,1,N,1,,BAO_0000218
10868,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626127,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,A,1,N,1,,BAO_0000218
10869,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626128,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,A,1,N,1,,BAO_0000218
10870,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626129,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,A,1,N,1,,BAO_0000218
10871,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626130,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,A,1,N,1,,BAO_0000218
10872,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626131,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,A,1,N,1,,BAO_0000218
10873,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626132,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,A,1,N,1,,BAO_0000218
10874,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626752,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,A,1,N,1,,BAO_0000218
10875,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626753,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,A,1,N,1,,BAO_0000218
10876,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626754,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,A,1,N,1,,BAO_0000218
10877,,2113.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626755,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,A,1,N,1,,BAO_0000218
10878,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626756,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,A,1,N,1,,BAO_0000218
10879,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626757,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,A,1,N,1,,BAO_0000218
10880,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626758,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,A,1,N,1,,BAO_0000218
10881,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626759,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,A,1,N,1,,BAO_0000218
10882,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL626760,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,A,1,N,1,,BAO_0000218
10883,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL626394,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
10884,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL626395,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
10885,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL626396,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
10886,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL626397,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
10887,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL626398,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,A,1,N,1,,BAO_0000218
10888,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL626399,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
10889,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL874653,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
10890,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL626400,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
10891,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL626401,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
10892,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL626402,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
10893,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL626403,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
10894,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL626404,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
10895,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL626405,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
10896,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625529,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
10897,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625530,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
10898,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625531,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
10899,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625532,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
10900,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625533,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
10901,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL875474,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
10902,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625534,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
10903,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625535,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
10904,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625536,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
10905,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625537,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
10906,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625538,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
10907,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625539,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
10908,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625540,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
10909,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625541,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
10910,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625542,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
10911,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625543,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
10912,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625544,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
10913,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625545,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
10914,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625546,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
10915,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625547,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
10916,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625548,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
10917,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625549,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
10918,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625550,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
10919,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625551,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
10920,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL875475,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
10921,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625552,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
10922,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625553,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
10923,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625554,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
10924,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625555,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,A,1,N,1,,BAO_0000218
10925,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL625556,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
10926,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624986,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
10927,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624987,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
10928,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624988,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
10929,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624989,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,A,1,N,1,,BAO_0000218
10930,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624990,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,A,1,N,1,,BAO_0000218
10931,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL874391,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,A,1,N,1,,BAO_0000218
10932,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624991,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,A,1,N,1,,BAO_0000218
10933,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624992,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,A,1,N,1,,BAO_0000218
10934,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624993,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,A,1,N,1,,BAO_0000218
10935,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624994,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,A,1,N,1,,BAO_0000218
10936,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624995,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,A,1,N,1,,BAO_0000218
10937,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624996,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,A,1,N,1,,BAO_0000218
10938,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624997,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,A,1,N,1,,BAO_0000218
10939,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624998,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,A,1,N,1,,BAO_0000218
10940,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624999,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,A,1,N,1,,BAO_0000218
10941,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL882955,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,A,1,N,1,,BAO_0000218
10942,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625000,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,A,1,N,1,,BAO_0000218
10943,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625001,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,A,1,N,1,,BAO_0000218
10944,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625089,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,A,1,N,1,,BAO_0000218
10945,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625090,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,A,1,N,1,,BAO_0000218
10946,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625091,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,A,1,N,1,,BAO_0000218
10947,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625092,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,A,1,N,1,,BAO_0000218
10948,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625093,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,A,1,N,1,,BAO_0000218
10949,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625094,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,A,1,N,1,,BAO_0000218
10950,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625095,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,A,1,N,1,,BAO_0000218
10951,,,9615.0,Intermediate,Canis lupus familiaris,2249,CHEMBL625096,50588,,,,Compound was evaluated for its bioavailability in the dogs,,A,1,N,1,,BAO_0000218
10952,,,10116.0,Intermediate,Rattus norvegicus,2249,CHEMBL625097,50597,,,,Compound was evaluated for its bioavailability in the rats,,A,1,N,1,,BAO_0000218
10953,,,,Autocuration,,17515,CHEMBL882956,22224,,,,Compound was evaluated for oral bioavailability,,A,1,U,0,,BAO_0000218
10954,,,10116.0,Intermediate,Rattus norvegicus,14541,CHEMBL625098,50597,,,,Compound was evaluated for percentage of Oral bioavailability in rats,,A,1,N,1,,BAO_0000218
10955,,,10141.0,Autocuration,Cavia porcellus,12797,CHEMBL625099,22224,,,,Bioavailability in guinea pig,,A,1,U,0,,BAO_0000218
10956,,,10116.0,Intermediate,Rattus norvegicus,12797,CHEMBL625100,50597,,,,Compound was evaluated for the oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10957,,,9615.0,Intermediate,Canis lupus familiaris,12797,CHEMBL625101,50588,,,,Compound was evaluated for the oral bioavailability in dog,,A,1,N,1,,BAO_0000218
10958,,,10116.0,Intermediate,Rattus norvegicus,12797,CHEMBL874396,50597,,,,Compound was evaluated for the oral bioavailability in rat,,A,1,N,1,,BAO_0000218
10959,,,9615.0,Autocuration,Canis lupus familiaris,11727,CHEMBL625102,22224,,,,Bioavailability in dog (dosed i.v.),,F,1,U,0,,BAO_0000218
10960,,,9615.0,Intermediate,Canis lupus familiaris,13249,CHEMBL625103,50588,,,,Compound was tested for in vivo bioavailability in dog,,A,1,N,1,,BAO_0000218
10961,,,10026.0,Intermediate,Cricetinae,13249,CHEMBL625104,100712,,,,Compound was tested for in vivo bioavailability in hamsters,,A,1,N,1,,BAO_0000218
10962,,,314293.0,Autocuration,Simiiformes,13249,CHEMBL625105,22224,,,,Compound was tested for in vivo bioavailability in monkey,,A,1,U,0,,BAO_0000218
10963,,,10116.0,Intermediate,Rattus norvegicus,13249,CHEMBL625106,50597,,,,Compound was tested for in vivo bioavailability in rat,,A,1,N,1,,BAO_0000218
10964,,,10090.0,Autocuration,Mus musculus,9552,CHEMBL625107,22224,,,,Oral bioavailability in mouse,,A,1,U,0,,BAO_0000218
10965,,,10090.0,Intermediate,Mus musculus,9552,CHEMBL625108,50594,,,,Compound was tested for percent of oral bioavailability in mice; 56-74,,A,1,N,1,,BAO_0000218
10966,,,10090.0,Autocuration,Mus musculus,14839,CHEMBL625109,22224,,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,A,1,U,0,,BAO_0000218
10967,,,9541.0,Autocuration,Macaca fascicularis,14839,CHEMBL625110,22224,,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,A,1,U,0,,BAO_0000218
10968,,,9541.0,Autocuration,Macaca fascicularis,14839,CHEMBL625111,22224,,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,A,1,U,0,,BAO_0000218
10969,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL625112,50594,,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,A,1,N,1,,BAO_0000218
10970,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL875334,50594,,,,Oral bioavailability in nude mice,,A,1,N,1,,BAO_0000218
10971,,,9443.0,Autocuration,Primates,11219,CHEMBL628617,22224,,,,Bioavailability in monkey (i.d. dosing),,A,1,U,0,,BAO_0000218
10972,,,10116.0,Autocuration,Rattus norvegicus,9552,CHEMBL628618,22224,,,,Bioavailability in rat,,A,1,U,0,,BAO_0000218
10973,,,,Autocuration,,11732,CHEMBL628619,22224,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,A,1,U,0,,BAO_0000218
10974,,,,Autocuration,,11732,CHEMBL628620,22224,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,A,1,U,0,,BAO_0000218
10975,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL628621,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,A,1,N,1,,BAO_0000218
10976,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL628622,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,A,1,N,1,,BAO_0000218
10977,,,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL628623,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,A,1,N,1,,BAO_0000218
10978,,1969.0,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL628624,100710,,,Plasma,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
10979,,1969.0,10090.0,Intermediate,Mus musculus,14839,CHEMBL628625,50594,,,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,A,1,N,1,,BAO_0000218
10980,,1969.0,9541.0,Intermediate,Macaca fascicularis,14839,CHEMBL628626,100710,,,Plasma,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,A,1,N,1,,BAO_0000218
10981,,1969.0,10090.0,Intermediate,Mus musculus,14839,CHEMBL627041,50594,,,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,A,1,N,1,,BAO_0000218
10982,,1969.0,10090.0,Intermediate,Mus musculus,14839,CHEMBL627042,50594,,,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,A,1,N,1,,BAO_0000218
10983,,1969.0,10090.0,Intermediate,Mus musculus,14839,CHEMBL627043,50594,,,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,A,1,N,1,,BAO_0000218
10984,,1969.0,,Autocuration,,13932,CHEMBL627044,22224,,,Plasma,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,A,1,U,0,,BAO_0000218
10985,,1969.0,10090.0,Intermediate,Mus musculus,11637,CHEMBL627045,50594,,,Plasma,Cmax in mouse plasma,,A,1,N,1,,BAO_0000218
10986,,1969.0,,Autocuration,,11637,CHEMBL627046,22224,,,Plasma,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,A,1,U,0,,BAO_0000218
10987,,1969.0,10116.0,Intermediate,Rattus norvegicus,13960,CHEMBL627047,50597,,,Plasma,Maximal plasma concentration in rat,,A,1,N,1,,BAO_0000218
10988,,1969.0,10116.0,Intermediate,Rattus norvegicus,15905,CHEMBL627048,50597,,,Plasma,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,A,1,N,1,,BAO_0000218
10989,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL627049,50597,,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,A,1,N,1,,BAO_0000218
10990,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL627050,50597,,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,A,1,N,1,,BAO_0000218
10991,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL627051,50597,,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,A,1,N,1,,BAO_0000218
10992,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL627052,50597,,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,A,1,N,1,,BAO_0000218
10993,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL627053,50597,,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,A,1,N,1,,BAO_0000218
10994,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL627054,50597,,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,A,1,N,1,,BAO_0000218
10995,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627055,50594,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
10996,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627056,50594,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
10997,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627057,50594,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,A,1,N,1,,BAO_0000218
10998,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL627058,50594,,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
10999,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL626211,50594,,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,A,1,N,1,,BAO_0000218
11000,,,,Autocuration,,10291,CHEMBL626212,22224,,,,Maximum Concentration of the compound.,,A,1,U,0,,BAO_0000218
11001,,,9615.0,Intermediate,Canis lupus familiaris,14599,CHEMBL626213,50588,,,,Maximum Concentration was measured after iv administration into Beagle dog,,A,1,N,1,,BAO_0000218
11002,,,9615.0,Intermediate,Canis lupus familiaris,14599,CHEMBL626214,50588,,,,Maximum Concentration was measured after iv administration into Beagle dog.,,A,1,N,1,,BAO_0000218
11003,,,9615.0,Intermediate,Canis lupus familiaris,14599,CHEMBL626215,50588,,,,Maximum Concentration was measured after po administration into Beagle dog,,A,1,N,1,,BAO_0000218
11004,,,9615.0,Intermediate,Canis lupus familiaris,14599,CHEMBL626216,50588,,,,Maximum Concentration was measured after po administration into Beagle dog.,,A,1,N,1,,BAO_0000218
11005,,178.0,,Autocuration,,12767,CHEMBL626217,22224,,,Blood,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,A,1,U,0,,BAO_0000218
11006,,178.0,,Autocuration,,12767,CHEMBL626218,22224,,,Blood,Maximum blood level reached after an iv dose of 12.2 uM/kg,,A,1,U,0,,BAO_0000218
11007,,178.0,,Autocuration,,12767,CHEMBL626219,22224,,,Blood,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,A,1,U,0,,BAO_0000218
11008,,178.0,,Autocuration,,12767,CHEMBL626220,22224,,,Blood,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,A,1,U,0,,BAO_0000218
11009,,178.0,,Autocuration,,12767,CHEMBL626221,22224,,,Blood,Maximum blood level reached after an oral dose of 5.0 mg/kg,,A,1,U,0,,BAO_0000218
11010,,178.0,,Autocuration,,12767,CHEMBL626222,22224,,,Blood,Maximum blood level reached at dose of 10.6 uM/kg orally,,A,1,U,0,,BAO_0000218
11011,,,10141.0,Intermediate,Cavia porcellus,14706,CHEMBL626223,50512,,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,A,1,N,1,,BAO_0000218
11012,,,10141.0,Intermediate,Cavia porcellus,14706,CHEMBL626224,50512,,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,A,1,N,1,,BAO_0000218
11013,,955.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL626225,50597,,,Brain,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
11014,,955.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL626226,50597,,,Brain,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
11015,,955.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL626227,50597,,,Brain,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,A,1,N,1,,BAO_0000218
11016,,955.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL626228,50597,,,Brain,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
11017,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL626229,50597,,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
11018,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL626921,50597,,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
11019,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL876793,50597,,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,A,1,N,1,,BAO_0000218
11020,,,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL625309,50597,,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
11021,,,1423.0,Intermediate,Bacillus subtilis,10524,CHEMBL625310,50278,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,A,1,N,1,,BAO_0000218
11022,,,314293.0,Autocuration,Simiiformes,11871,CHEMBL625311,22224,,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,A,1,U,0,,BAO_0000218
11023,,,10116.0,Intermediate,Rattus norvegicus,11871,CHEMBL625312,50597,,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,A,1,N,1,,BAO_0000218
11024,,,,Autocuration,,3437,CHEMBL625313,22224,,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,A,1,U,0,,BAO_0000218
11025,,,10090.0,Intermediate,Mus musculus,12038,CHEMBL625314,50594,,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,A,1,N,1,,BAO_0000218
11026,,,10116.0,Intermediate,Rattus norvegicus,12038,CHEMBL625315,50597,,,,Maximum concentration in male rats after iv administration of 20 mg/kg,,A,1,N,1,,BAO_0000218
11027,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625316,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,A,1,N,1,,BAO_0000218
11028,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625317,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,A,1,N,1,,BAO_0000218
11029,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625318,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,A,1,N,1,,BAO_0000218
11030,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625319,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,A,1,N,1,,BAO_0000218
11031,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625320,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,A,1,N,1,,BAO_0000218
11032,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625321,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,A,1,N,1,,BAO_0000218
11033,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625322,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,A,1,N,1,,BAO_0000218
11034,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL876801,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,A,1,N,1,,BAO_0000218
11035,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625323,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,A,1,N,1,,BAO_0000218
11036,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625324,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,A,1,N,1,,BAO_0000218
11037,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625325,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,A,1,N,1,,BAO_0000218
11038,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625326,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,A,1,N,1,,BAO_0000218
11039,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625327,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,A,1,N,1,,BAO_0000218
11040,,2107.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625328,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,A,1,N,1,,BAO_0000218
11041,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625329,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,A,1,N,1,,BAO_0000218
11042,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL625330,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,A,1,N,1,,BAO_0000218
11043,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627774,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,A,1,N,1,,BAO_0000218
11044,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627775,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,A,1,N,1,,BAO_0000218
11045,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627949,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,A,1,N,1,,BAO_0000218
11046,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627950,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,A,1,N,1,,BAO_0000218
11047,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627951,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,A,1,N,1,,BAO_0000218
11048,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627952,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,A,1,N,1,,BAO_0000218
11049,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627953,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,A,1,N,1,,BAO_0000218
11050,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627954,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,A,1,N,1,,BAO_0000218
11051,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627955,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,A,1,N,1,,BAO_0000218
11052,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627956,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,A,1,N,1,,BAO_0000218
11053,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL876802,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,A,1,N,1,,BAO_0000218
11054,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627957,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,A,1,N,1,,BAO_0000218
11055,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627958,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,A,1,N,1,,BAO_0000218
11056,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627959,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,A,1,N,1,,BAO_0000218
11057,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627960,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,A,1,N,1,,BAO_0000218
11058,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627961,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,A,1,N,1,,BAO_0000218
11059,,2048.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL627962,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,A,1,N,1,,BAO_0000218
11060,,,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL627963,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11061,,,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL624759,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11062,,,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL624760,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11063,,,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL624761,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11064,,,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL877607,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11065,,2107.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL624762,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11066,,2107.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL624763,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11067,,2107.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL624764,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11068,,2107.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL624765,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11069,,2107.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL624766,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11070,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624767,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11071,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624768,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11072,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624769,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
11073,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624770,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
11074,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624771,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,A,1,N,1,,BAO_0000218
11075,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624772,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11076,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624773,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11077,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624774,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
11078,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624775,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
11079,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624776,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
11080,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624777,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
11081,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624778,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
11082,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624779,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11083,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624780,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
11084,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624781,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
11085,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL877608,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
11086,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624782,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
11087,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624783,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
11088,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624784,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11089,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624785,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
11090,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624786,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
11091,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL624787,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
11092,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL628676,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
11093,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL621842,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11094,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL621843,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
11095,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL623873,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
11096,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL623874,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
11097,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL623875,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
11098,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL623876,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
11099,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623877,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11100,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623878,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
11101,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623879,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11102,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623880,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11103,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623881,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11104,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623957,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
11105,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623958,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11106,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623959,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11107,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623960,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11108,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623961,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
11109,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL623962,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
11110,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624676,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,A,1,N,1,,BAO_0000218
11111,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624677,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11112,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624678,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11113,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624679,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
11114,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624680,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
11115,,,,Autocuration,,11732,CHEMBL624849,22224,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,A,1,U,0,,BAO_0000218
11116,,,,Autocuration,,11732,CHEMBL624850,22224,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,A,1,U,0,,BAO_0000218
11117,,,,Autocuration,,11732,CHEMBL874399,22224,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,A,1,U,0,,BAO_0000218
11118,,,,Autocuration,,11732,CHEMBL624851,22224,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,A,1,U,0,,BAO_0000218
11119,,,,Autocuration,,11732,CHEMBL624852,22224,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,A,1,U,0,,BAO_0000218
11120,,,10116.0,Autocuration,Rattus norvegicus,13359,CHEMBL624853,22224,,,,Oral bioavailability in rat (dose 10 mg/kg),,A,1,U,0,,BAO_0000218
11121,,,10116.0,Autocuration,Rattus norvegicus,16618,CHEMBL624854,22224,,,,Oral bioavailability in rat (Sprague-Dawley),,A,1,U,0,,BAO_0000218
11122,,,10116.0,Autocuration,Rattus norvegicus,13960,CHEMBL624855,22224,,,,Oral bioavailability in rat,,A,1,U,0,,BAO_0000218
11123,,,10116.0,Autocuration,Rattus norvegicus,13917,CHEMBL624856,22224,,,,Oral bioavailability in rats was determined in vivo,,A,1,U,0,,BAO_0000218
11124,,,9615.0,Autocuration,Canis lupus familiaris,14266,CHEMBL882957,22224,,,,Oral bioavailability in dog,,A,1,U,0,,BAO_0000218
11125,,,314293.0,Autocuration,Simiiformes,12359,CHEMBL624857,22224,,,,Oral bioavailability of compound in monkey,,A,1,U,0,,BAO_0000218
11126,,,10116.0,Intermediate,Rattus norvegicus,12359,CHEMBL622202,50597,,,,Oral bioavailability of compound in rat,,A,1,N,1,,BAO_0000218
11127,,,10116.0,Autocuration,Rattus norvegicus,12359,CHEMBL622203,22224,,,,Bioavailability in rat of PMEA prodrug,,A,1,U,0,,BAO_0000218
11128,,,10116.0,Intermediate,Rattus norvegicus,12359,CHEMBL625522,50597,,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,A,1,N,1,,BAO_0000218
11129,,,9544.0,Autocuration,Macaca mulatta,10791,CHEMBL622868,22224,,,,Serum conc at 3 hours following 25 mg/kg dose,,A,1,U,0,,BAO_0000218
11130,,1088.0,9544.0,Autocuration,Macaca mulatta,10791,CHEMBL622869,22224,,,Urine,Urine conc 0-5 hours following 25 mg/kg dose,,A,1,U,0,,BAO_0000218
11131,,1088.0,9544.0,Autocuration,Macaca mulatta,10791,CHEMBL622870,22224,,,Urine,Urine conc 0-24 hours following 25 mg/kg dose,,A,1,U,0,,BAO_0000218
11132,,,9534.0,Autocuration,Chlorocebus aethiops,138,CHEMBL622871,22224,,,,Oral bioavailability in African green monkeys; 20-25,,A,1,U,0,,BAO_0000218
11133,,,9541.0,Intermediate,Macaca fascicularis,14521,CHEMBL620560,100710,,,,Oral bioavailability in cynomolgus monkey.,,A,1,N,1,,BAO_0000218
11134,,,9615.0,Autocuration,Canis lupus familiaris,13953,CHEMBL620561,22224,,,,Oral bioavailability in dog,,A,1,U,0,,BAO_0000218
11135,,,9615.0,Intermediate,Canis lupus familiaris,12836,CHEMBL620562,50588,,,,Oral bioavailability in dog at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11136,,,10026.0,Intermediate,Cricetinae,12836,CHEMBL620563,100712,,,,Oral bioavailability in hamster at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11137,,,10116.0,Intermediate,Rattus norvegicus,12836,CHEMBL620564,50597,,,,Oral bioavailability in rat at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11138,,,10116.0,Autocuration,Rattus norvegicus,14521,CHEMBL872265,22224,,,,Oral bioavailability in rat,,A,1,U,0,,BAO_0000218
11139,,,10116.0,Autocuration,Rattus norvegicus,13953,CHEMBL620565,22224,,,,Oral bioavailability in rat,,A,1,U,0,,BAO_0000218
11140,,,9347.0,Autocuration,Eutheria,6799,CHEMBL620566,22224,,,,Oral bioavailability,,A,1,U,0,,BAO_0000218
11141,,,,Autocuration,,11311,CHEMBL620567,22224,,,,Oral bioavailability was determined; range 49-102%,,A,1,U,0,,BAO_0000218
11142,,,9615.0,Intermediate,Canis lupus familiaris,4013,CHEMBL620568,50588,,,,Oral bioavailability was determined in dogs,,A,1,N,1,,BAO_0000218
11143,,,10116.0,Autocuration,Rattus norvegicus,4013,CHEMBL620569,22224,,,,Oral bioavailability in rat,,A,1,U,0,,BAO_0000218
11144,,,9347.0,Autocuration,Eutheria,17591,CHEMBL620570,22224,,,,Oral bioavailability,,A,1,U,0,,BAO_0000218
11145,,,,Autocuration,,17591,CHEMBL620571,22224,,,,Oral bioavailability was determined; Not orally available,,A,1,U,0,,BAO_0000218
11146,,,10090.0,Intermediate,Mus musculus,15011,CHEMBL620572,50594,,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,A,1,N,1,,BAO_0000218
11147,,,10090.0,Autocuration,Mus musculus,15011,CHEMBL620573,22224,,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,A,1,U,0,,BAO_0000218
11148,,,10090.0,Autocuration,Mus musculus,15011,CHEMBL620574,22224,,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,A,1,U,0,,BAO_0000218
11149,,,9544.0,Autocuration,Macaca mulatta,9552,CHEMBL620575,22224,,,,Oral bioavailability in Rhesus monkey,,A,1,U,0,,BAO_0000218
11150,,,9615.0,Autocuration,Canis lupus familiaris,9552,CHEMBL620576,22224,,,,Oral bioavailability in dog (female mongrel),,A,1,U,0,,BAO_0000218
11151,,,,Autocuration,,3639,CHEMBL875846,22224,,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,A,1,U,0,,BAO_0000218
11152,,,9615.0,Autocuration,Canis lupus familiaris,13397,CHEMBL620577,22224,,,,Oral bioavailability in dog,,A,1,U,0,,BAO_0000218
11153,,,,Autocuration,,3031,CHEMBL620578,22224,,,,Percentage Bioavailability was evaluated.,,A,1,U,0,,BAO_0000218
11154,,,10116.0,Autocuration,Rattus norvegicus,12818,CHEMBL620579,22224,,,,Bioavailability in rat administered i.d.,,A,1,U,0,,BAO_0000218
11155,,,9347.0,Autocuration,Eutheria,4847,CHEMBL621248,22224,,,,Bioavailability,,A,1,U,0,,BAO_0000218
11156,,,9615.0,Autocuration,Canis lupus familiaris,12421,CHEMBL625390,22224,,,,Bioavailability in dog (male Beagle) i.v. administration,,A,1,U,0,,BAO_0000218
11157,,,10116.0,Autocuration,Rattus norvegicus,11966,CHEMBL625391,22224,,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,A,1,U,0,,BAO_0000218
11158,,,9443.0,Autocuration,Primates,11218,CHEMBL872266,22224,,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,A,1,U,0,,BAO_0000218
11159,,,10116.0,Autocuration,Rattus norvegicus,13129,CHEMBL625392,22224,,,,Oral bioavailability in rat (Sprague-Dawley) (male),,A,1,U,0,,BAO_0000218
11160,,,10116.0,Intermediate,Rattus norvegicus,12350,CHEMBL625393,50597,,,,The oral bioavailability was measured on rats after oral administration,,A,1,N,1,,BAO_0000218
11161,,,10116.0,Intermediate,Rattus norvegicus,2231,CHEMBL625394,50597,,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
11162,,,9544.0,Intermediate,Macaca mulatta,2231,CHEMBL625395,50797,,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
11163,,,10116.0,Autocuration,Rattus norvegicus,12187,CHEMBL625396,22224,,,,Bioavailability in rat (dose 10 mg/kg i.d.),,A,1,U,0,,BAO_0000218
11164,,,9615.0,Autocuration,Canis lupus familiaris,12421,CHEMBL625397,22224,,,,Bioavailability in dog (male Beagle) i.v. administration,,A,1,U,0,,BAO_0000218
11165,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL625398,50594,,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11166,,178.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL625399,50594,,,Blood,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11167,,2037.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL626074,50594,,,Cerebellum,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11168,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL626075,50594,,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11169,,1969.0,10116.0,Intermediate,Rattus norvegicus,2231,CHEMBL626076,50597,,,Plasma,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
11170,,1969.0,9544.0,Intermediate,Macaca mulatta,2231,CHEMBL626077,50797,,,Plasma,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
11171,,178.0,10116.0,Intermediate,Rattus norvegicus,12178,CHEMBL626078,50597,,,Blood,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,A,1,N,1,,BAO_0000218
11172,,178.0,,Autocuration,,12178,CHEMBL625846,22224,,,Blood,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,A,1,U,0,,BAO_0000218
11173,,178.0,,Autocuration,,12178,CHEMBL625847,22224,,,Blood,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,A,1,U,0,,BAO_0000218
11174,,,10116.0,Expert,Rattus norvegicus,15633,CHEMBL625848,50597,,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,A,1,N,1,,BAO_0000218
11175,,1969.0,10116.0,Intermediate,Rattus norvegicus,14258,CHEMBL625849,50597,,,Plasma,Maximum concentration of compound in plasma administered orally to rats,,A,1,N,1,,BAO_0000218
11176,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14224,CHEMBL626023,50588,,,Plasma,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,A,1,N,1,,BAO_0000218
11177,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14224,CHEMBL626024,50588,,,Plasma,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,A,1,N,1,,BAO_0000218
11178,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14224,CHEMBL626025,50588,,,Plasma,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,A,1,N,1,,BAO_0000218
11179,,,,Autocuration,,5566,CHEMBL626026,22224,,,,Maximum concentration after 10 mg/kg by oral administration,,A,1,U,0,,BAO_0000218
11180,,,,Autocuration,,16935,CHEMBL626027,22224,,,,Maximum concentration at a dose of 1.5 mg/kg,,A,1,U,0,,BAO_0000218
11181,,,,Autocuration,,16935,CHEMBL626028,22224,,,,Maximum concentration at a dose of 2.0 mg/kg,,A,1,U,0,,BAO_0000218
11182,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14224,CHEMBL626029,50588,,,Plasma,Maximum concentration in dog plasma,,A,1,N,1,,BAO_0000218
11183,,1969.0,,Autocuration,,12536,CHEMBL626030,22224,,,Plasma,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,A,1,U,0,,BAO_0000218
11184,,1969.0,,Autocuration,,12536,CHEMBL626031,22224,,,Plasma,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,A,1,U,0,,BAO_0000218
11185,,1969.0,,Autocuration,,12536,CHEMBL626032,22224,,,Plasma,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,A,1,U,0,,BAO_0000218
11186,,1969.0,,Autocuration,,12536,CHEMBL626033,22224,,,Plasma,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,A,1,U,0,,BAO_0000218
11187,,1969.0,,Autocuration,,12536,CHEMBL626034,22224,,,Plasma,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,A,1,U,0,,BAO_0000218
11188,,1969.0,9615.0,Intermediate,Canis lupus familiaris,9994,CHEMBL626035,50588,,,Plasma,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,A,1,N,1,,BAO_0000218
11189,,1969.0,,Autocuration,,1434,CHEMBL626036,22224,,,Plasma,Maximum concentration in plasma at Tmax,,A,1,U,0,,BAO_0000218
11190,,1969.0,9615.0,Expert,Canis lupus familiaris,12836,CHEMBL626037,50588,,,Plasma,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11191,,1969.0,10026.0,Intermediate,Cricetinae,12836,CHEMBL626038,100712,,,Plasma,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11192,,1969.0,10116.0,Intermediate,Rattus norvegicus,12836,CHEMBL626039,50597,,,Plasma,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11193,,1969.0,10116.0,Intermediate,Rattus norvegicus,12545,CHEMBL626040,50597,,,Plasma,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,A,1,N,1,,BAO_0000218
11194,,1969.0,9986.0,Intermediate,Oryctolagus cuniculus,13856,CHEMBL626041,50592,,,Plasma,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,A,1,N,1,,BAO_0000218
11195,,,,Autocuration,,3550,CHEMBL626042,22224,,,,Maximum concentration was calculated,,A,1,U,0,,BAO_0000218
11196,,,,Autocuration,,2632,CHEMBL626043,22224,,,,Maximum concentration was calculated.,,A,1,U,0,,BAO_0000218
11197,,,,Autocuration,,5566,CHEMBL626044,22224,,,,Maximum concentration at a peroral dose of 10 mg/kg,,A,1,U,0,,BAO_0000218
11198,,,,Autocuration,,11883,CHEMBL626045,22224,,,,Maximum concentration of the drug at 10 uM/dg administered perorally,,A,1,U,0,,BAO_0000218
11199,,,,Autocuration,,11883,CHEMBL626046,22224,,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,,A,1,U,0,,BAO_0000218
11200,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14122,CHEMBL626047,50588,,,Plasma,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,A,1,N,1,,BAO_0000218
11201,,1969.0,10026.0,Intermediate,Cricetinae,14122,CHEMBL626048,100712,,,Plasma,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,A,1,N,1,,BAO_0000218
11202,,1969.0,10116.0,Intermediate,Rattus norvegicus,14122,CHEMBL626049,50597,,,Plasma,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,A,1,N,1,,BAO_0000218
11203,,1969.0,10116.0,Intermediate,Rattus norvegicus,12542,CHEMBL626050,50597,,,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11204,,1969.0,9615.0,Intermediate,Canis lupus familiaris,12542,CHEMBL874541,50588,,,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11205,,1969.0,10026.0,Intermediate,Cricetinae,12542,CHEMBL622826,100712,,,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11206,,1969.0,10026.0,Intermediate,Cricetinae,12542,CHEMBL622827,100712,,,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11207,,1969.0,10116.0,Intermediate,Rattus norvegicus,12542,CHEMBL622828,50597,,,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11208,,1969.0,10116.0,Intermediate,Rattus norvegicus,14080,CHEMBL622829,50597,,,Plasma,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,A,1,N,1,,BAO_0000218
11209,,,10116.0,Intermediate,Rattus norvegicus,11911,CHEMBL876806,50597,,,,Maximum concentration reached following intravenous administration in male rat,,A,1,N,1,,BAO_0000218
11210,,,9615.0,Intermediate,Canis lupus familiaris,13204,CHEMBL622830,50588,,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,A,1,N,1,,BAO_0000218
11211,,,10116.0,Intermediate,Rattus norvegicus,13204,CHEMBL622831,50597,,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,A,1,N,1,,BAO_0000218
11212,,,9615.0,Intermediate,Canis lupus familiaris,14346,CHEMBL626794,50588,,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,A,1,N,1,,BAO_0000218
11213,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL626795,50597,,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,A,1,N,1,,BAO_0000218
11214,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL626796,50597,,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,A,1,N,1,,BAO_0000218
11215,,,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL626797,50597,,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,A,1,N,1,,BAO_0000218
11216,,,10116.0,Intermediate,Rattus norvegicus,14127,CHEMBL626798,50597,,,,Maximum drug concentration is determined after oral dosing in rats.,,A,1,N,1,,BAO_0000218
11217,,,9615.0,Intermediate,Canis lupus familiaris,14339,CHEMBL626799,50588,,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,A,1,N,1,,BAO_0000218
11218,,,9615.0,Intermediate,Canis lupus familiaris,14339,CHEMBL626800,50588,,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,,A,1,N,1,,BAO_0000218
11219,,1969.0,,Autocuration,,13494,CHEMBL626801,22224,,,Plasma,Maximum plasma concentration,,A,1,U,0,,BAO_0000218
11220,,1969.0,10116.0,Intermediate,Rattus norvegicus,14925,CHEMBL876816,50597,,,Plasma,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,A,1,N,1,,BAO_0000218
11221,,1969.0,10116.0,Intermediate,Rattus norvegicus,14474,CHEMBL626802,50597,,,Plasma,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,A,1,N,1,,BAO_0000218
11222,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14474,CHEMBL626803,50588,,,Plasma,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,A,1,N,1,,BAO_0000218
11223,,1969.0,,Autocuration,,13917,CHEMBL626804,22224,,,Plasma,Maximum plasma concentration following oral administration of 30 umol/kg,,A,1,U,0,,BAO_0000218
11224,,1969.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626805,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,A,1,N,1,,BAO_0000218
11225,,1969.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626309,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11226,,1969.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626310,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11227,,1969.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626311,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11228,,1969.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626312,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11229,,995.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626313,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11230,,995.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626314,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11231,,995.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626315,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11232,,995.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626316,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11233,,995.0,10116.0,Intermediate,Rattus norvegicus,9796,CHEMBL626317,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,A,1,N,1,,BAO_0000218
11234,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626318,50597,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,A,1,N,1,,BAO_0000218
11235,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626319,50597,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,A,1,N,1,,BAO_0000218
11236,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626320,50597,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,A,1,N,1,,BAO_0000218
11237,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL875053,50597,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,A,1,N,1,,BAO_0000218
11238,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626321,50597,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,A,1,N,1,,BAO_0000218
11239,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626322,50597,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,A,1,N,1,,BAO_0000218
11240,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626323,50597,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,A,1,N,1,,BAO_0000218
11241,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626324,50597,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,A,1,N,1,,BAO_0000218
11242,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626325,50597,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,A,1,N,1,,BAO_0000218
11243,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626326,50597,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,A,1,N,1,,BAO_0000218
11244,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626327,50597,,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,A,1,N,1,,BAO_0000218
11245,,,10116.0,Intermediate,Rattus norvegicus,8363,CHEMBL626328,50597,,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,A,1,N,1,,BAO_0000218
11246,,178.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL626329,50597,,,Blood,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11247,,178.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL626330,50597,,,Blood,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11248,,178.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL626331,50597,,,Blood,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11249,,178.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL626332,50597,,,Blood,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11250,,178.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL626333,50597,,,Blood,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11251,,178.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL626334,50597,,,Blood,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11252,,178.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL626335,50597,,,Blood,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11253,,178.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624798,50597,,,Blood,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11254,,955.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624799,50597,,,Brain,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,A,1,N,1,,BAO_0000218
11255,,955.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624800,50597,,,Brain,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,A,1,N,1,,BAO_0000218
11256,,955.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624801,50597,,,Brain,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,A,1,N,1,,BAO_0000218
11257,,955.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624802,50597,,,Brain,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,A,1,N,1,,BAO_0000218
11258,,955.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624803,50597,,,Brain,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,A,1,N,1,,BAO_0000218
11259,,955.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624804,50597,,,Brain,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,A,1,N,1,,BAO_0000218
11260,,955.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624805,50597,,,Brain,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,A,1,N,1,,BAO_0000218
11261,,955.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624806,50597,,,Brain,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,A,1,N,1,,BAO_0000218
11262,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624807,50597,,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11263,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624808,50597,,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11264,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624809,50597,,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11265,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624810,50597,,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11266,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL877618,50597,,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11267,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624811,50597,,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11268,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624812,50597,,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11269,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624813,50597,,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11270,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624814,50597,,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11271,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624815,50597,,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11272,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624816,50597,,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11273,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624817,50597,,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11274,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624818,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11275,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624819,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
11276,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624820,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
11277,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624821,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
11278,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624822,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,A,1,N,1,,BAO_0000218
11279,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624823,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
11280,,,562.0,Intermediate,Escherichia coli,15599,CHEMBL624824,50212,,,,Observed diffusion coefficient in organic solvent for Escherichia coli,,A,1,N,1,,BAO_0000218
11281,,178.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624825,50597,,,Blood,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,A,1,N,1,,BAO_0000218
11282,,178.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624826,50597,,,Blood,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,A,1,N,1,,BAO_0000218
11283,,2081.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL876817,50597,,,Cardiac atrium,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,A,1,N,1,,BAO_0000218
11284,,2081.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624827,50597,,,Cardiac atrium,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,A,1,N,1,,BAO_0000218
11285,,,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624828,50597,,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,A,1,N,1,,BAO_0000218
11286,,,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624829,50597,,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,A,1,N,1,,BAO_0000218
11287,,2107.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624830,50597,,,Liver,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,A,1,N,1,,BAO_0000218
11288,,2107.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624831,50597,,,Liver,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,A,1,N,1,,BAO_0000218
11289,,2081.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624832,50597,,,Cardiac atrium,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,A,1,N,1,,BAO_0000218
11290,,2081.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624833,50597,,,Cardiac atrium,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,A,1,N,1,,BAO_0000218
11291,,,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624834,50597,,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,A,1,N,1,,BAO_0000218
11292,,,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624835,50597,,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,A,1,N,1,,BAO_0000218
11293,,2106.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624836,50597,,,Spleen,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,A,1,N,1,,BAO_0000218
11294,,2106.0,10116.0,Intermediate,Rattus norvegicus,9614,CHEMBL624837,50597,,,Spleen,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,A,1,N,1,,BAO_0000218
11295,,178.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL624838,50597,,,Blood,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11296,,178.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL622188,50597,,,Blood,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11297,,948.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL622189,50597,,,Heart,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11298,,948.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL622190,50597,,,Heart,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,A,1,N,1,,BAO_0000218
11299,,948.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625170,50597,,,Heart,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11300,,2113.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625171,50597,,,Kidney,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11301,,2113.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625172,50597,,,Kidney,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11302,,2113.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625173,50597,,,Kidney,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11303,,2107.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625174,50597,,,Liver,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11304,,2107.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625175,50597,,,Liver,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11305,,2107.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625176,50597,,,Liver,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,A,1,N,1,,BAO_0000218
11306,,2048.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625177,50597,,,Lung,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11307,,2048.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625178,50597,,,Lung,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11308,,2048.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625179,50597,,,Lung,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,A,1,N,1,,BAO_0000218
11309,,2048.0,10116.0,Intermediate,Rattus norvegicus,9071,CHEMBL625180,50597,,,Lung,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,A,1,N,1,,BAO_0000218
11310,,,,Autocuration,,10677,CHEMBL625181,22224,,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,A,1,U,0,,BAO_0000218
11311,,1088.0,10090.0,Intermediate,Mus musculus,9750,CHEMBL625182,50594,,,Urine,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,A,1,N,1,,BAO_0000218
11312,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL625183,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11313,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL875848,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11314,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL622260,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11315,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL622261,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11316,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL622262,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11317,,2113.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL622263,50597,,,Kidney,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11318,,2113.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL622418,50597,,,Kidney,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11319,,2107.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL622419,50597,,,Liver,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11320,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL623388,50594,,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11321,,2107.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL623389,50594,,,Liver,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11322,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL623390,50594,,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11323,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL623391,50594,,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11324,,178.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL623392,50594,,,Blood,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11325,,2037.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL623393,50594,,,Cerebellum,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11326,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL623394,50594,,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11327,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL618885,50594,,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11328,,2107.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL618886,50594,,,Liver,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11329,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL618887,50594,,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11330,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL619535,50594,,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11331,,178.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL619536,50594,,,Blood,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11332,,2037.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL619537,50594,,,Cerebellum,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11333,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL619705,50594,,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11334,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL619706,50594,,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11335,,2107.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL619707,50594,,,Liver,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11336,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL619708,50594,,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11337,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL625219,50594,,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11338,,178.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL625220,50594,,,Blood,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11339,,2037.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL625221,50594,,,Cerebellum,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11340,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL625222,50594,,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11341,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL625223,50594,,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11342,,2107.0,10090.0,Intermediate,Mus musculus,13256,CHEMBL625224,50594,,,Liver,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11343,,,10090.0,Intermediate,Mus musculus,13256,CHEMBL625225,50594,,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,A,1,N,1,,BAO_0000218
11344,,178.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625226,50597,,,Blood,Biodistribution in Rat blood after 24 hours of iv administration,,A,1,N,1,,BAO_0000218
11345,,178.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625227,50597,,,Blood,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11346,,178.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625228,50597,,,Blood,Biodistribution in Rat blood after 30 minutes of iv administration,,A,1,N,1,,BAO_0000218
11347,,178.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL875354,50597,,,Blood,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11348,,178.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625229,50597,,,Blood,Biodistribution in Rat blood after 5 minutes of iv administration,,A,1,N,1,,BAO_0000218
11349,,178.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625230,50597,,,Blood,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11350,,948.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625231,50597,,,Heart,Biodistribution in Rat heart after 24 hours of iv administration,,A,1,N,1,,BAO_0000218
11351,,948.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625900,50597,,,Heart,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11352,,948.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625901,50597,,,Heart,Biodistribution in Rat heart after 30 minutes of iv administration,,A,1,N,1,,BAO_0000218
11353,,948.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625902,50597,,,Heart,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11354,,948.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625903,50597,,,Heart,Biodistribution in Rat heart after 5 minutes of iv administration,,A,1,N,1,,BAO_0000218
11355,,948.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625904,50597,,,Heart,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11356,,2107.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625905,50597,,,Liver,Biodistribution in Rat liver after 24 hours of iv administration,,A,1,N,1,,BAO_0000218
11357,,2107.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL627861,50597,,,Liver,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11358,,2107.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL627862,50597,,,Liver,Biodistribution in Rat liver after 30 minutes of iv administration,,A,1,N,1,,BAO_0000218
11359,,2107.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL627863,50597,,,Liver,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11360,,2107.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL627769,50597,,,Liver,Biodistribution in Rat liver after 30 minutes of iv administration,,A,1,N,1,,BAO_0000218
11361,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13249,CHEMBL627770,50588,,,Plasma,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,A,1,N,1,,BAO_0000218
11362,,,9541.0,Intermediate,Macaca fascicularis,13622,CHEMBL627771,100710,,,,Cmax in cynomolgus monkey (PO dose),,A,1,N,1,,BAO_0000218
11363,,,10116.0,Intermediate,Rattus norvegicus,13622,CHEMBL627772,50597,,,,Cmax in rat (PO dose),,A,1,N,1,,BAO_0000218
11364,,,10116.0,Intermediate,Rattus norvegicus,13622,CHEMBL627773,50597,,,,Cmax in rat (PO dose),,A,1,N,1,,BAO_0000218
11365,,1969.0,10116.0,Intermediate,Rattus norvegicus,13494,CHEMBL621922,50597,,,Plasma,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
11366,,1969.0,10116.0,Intermediate,Rattus norvegicus,12170,CHEMBL621923,50597,,,Plasma,Cmax in rat plasma after oral dose (10 mg/kg),,A,1,N,1,,BAO_0000218
11367,,1969.0,,Autocuration,,12170,CHEMBL621924,22224,,,Plasma,Cmax in plasma after oral dose (10 mg/kg),,A,1,U,0,,BAO_0000218
11368,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17025,CHEMBL621925,50588,,,Plasma,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,A,1,N,1,,BAO_0000218
11369,,1969.0,314293.0,Autocuration,Simiiformes,17025,CHEMBL621926,22224,,,Plasma,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,A,1,U,0,,BAO_0000218
11370,,1969.0,9986.0,Intermediate,Oryctolagus cuniculus,17025,CHEMBL621927,50592,,,Plasma,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,A,1,N,1,,BAO_0000218
11371,,1969.0,10116.0,Intermediate,Rattus norvegicus,17025,CHEMBL621928,50597,,,Plasma,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,A,1,N,1,,BAO_0000218
11372,,1969.0,10116.0,Intermediate,Rattus norvegicus,14187,CHEMBL621929,50597,,,Plasma,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,A,1,N,1,,BAO_0000218
11373,,1969.0,10090.0,Intermediate,Mus musculus,14816,CHEMBL621930,50594,,,Plasma,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,A,1,N,1,,BAO_0000218
11374,,1969.0,10116.0,Intermediate,Rattus norvegicus,17820,CHEMBL621931,50597,,,Plasma,Maximum plasma concentration after oral dosing in rat,,A,1,N,1,,BAO_0000218
11375,,1969.0,,Autocuration,,14380,CHEMBL621932,22224,,,Plasma,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11376,,1969.0,,Autocuration,,14380,CHEMBL621933,22224,,,Plasma,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11377,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14691,CHEMBL621934,50588,,,Plasma,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,A,1,N,1,,BAO_0000218
11378,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14691,CHEMBL621935,50588,,,Plasma,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,A,1,N,1,,BAO_0000218
11379,,1969.0,10116.0,Intermediate,Rattus norvegicus,13375,CHEMBL621936,50597,,,Plasma,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,A,1,N,1,,BAO_0000218
11380,,1969.0,,Autocuration,,6236,CHEMBL621937,22224,,,Plasma,Maximum plasma concentration was determined,,A,1,U,0,,BAO_0000218
11381,,1969.0,,Autocuration,,14380,CHEMBL621938,22224,,,Plasma,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11382,,1969.0,,Autocuration,,14380,CHEMBL621939,22224,,,Plasma,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11383,,1969.0,,Autocuration,,14380,CHEMBL621940,22224,,,Plasma,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11384,,1969.0,,Autocuration,,14380,CHEMBL621941,22224,,,Plasma,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11385,,1969.0,,Autocuration,,14380,CHEMBL621942,22224,,,Plasma,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11386,,1969.0,,Autocuration,,14380,CHEMBL626178,22224,,,Plasma,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11387,,1969.0,,Autocuration,,14380,CHEMBL626179,22224,,,Plasma,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11388,,1969.0,,Autocuration,,14380,CHEMBL626180,22224,,,Plasma,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11389,,1969.0,10116.0,Intermediate,Rattus norvegicus,13622,CHEMBL626181,50597,,,Plasma,Plasma Cmax in rat (PO dose),,A,1,N,1,,BAO_0000218
11390,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL626182,50597,,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,A,1,N,1,,BAO_0000218
11391,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL626183,50597,,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,A,1,N,1,,BAO_0000218
11392,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL626184,50597,,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,A,1,N,1,,BAO_0000218
11393,,,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL626185,50597,,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,A,1,N,1,,BAO_0000218
11394,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14925,CHEMBL626186,50588,,,Plasma,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,A,1,N,1,,BAO_0000218
11395,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14925,CHEMBL877589,50588,,,Plasma,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,A,1,N,1,,BAO_0000218
11396,,,,Autocuration,,11883,CHEMBL626187,22224,,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,,A,1,U,0,,BAO_0000218
11397,,,,Autocuration,,11883,CHEMBL626188,22224,,,,Maximum concentration of the drug at 20 uM/dg administered perorally,,A,1,U,0,,BAO_0000218
11398,,,,Autocuration,,13391,CHEMBL626189,22224,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,A,1,U,0,,BAO_0000218
11399,,178.0,,Autocuration,,13391,CHEMBL626855,22224,,,Blood,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,A,1,U,0,,BAO_0000218
11400,,178.0,,Autocuration,,13391,CHEMBL623781,22224,,,Blood,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,A,1,U,0,,BAO_0000218
11401,,178.0,,Autocuration,,13391,CHEMBL623782,22224,,,Blood,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,A,1,U,0,,BAO_0000218
11402,,1969.0,10116.0,Intermediate,Rattus norvegicus,16360,CHEMBL623783,50597,,,Plasma,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,A,1,N,1,,BAO_0000218
11403,,1969.0,9615.0,Intermediate,Canis lupus familiaris,3673,CHEMBL623784,50588,,,Plasma,Cmax in dog plasma after 1mg/kg oral dose,,A,1,N,1,,BAO_0000218
11404,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14431,CHEMBL623785,50588,,,Plasma,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11405,,1969.0,10116.0,Intermediate,Rattus norvegicus,14431,CHEMBL623786,50597,,,Plasma,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,A,1,N,1,,BAO_0000218
11406,,,10116.0,Intermediate,Rattus norvegicus,14964,CHEMBL623787,50597,,,,Oral maximum concentration in rat,,A,1,N,1,,BAO_0000218
11407,,,10116.0,Intermediate,Rattus norvegicus,14964,CHEMBL623788,50597,,,,Oral maximum concentration in rat,,A,1,N,1,,BAO_0000218
11408,,1969.0,10090.0,Intermediate,Mus musculus,14209,CHEMBL623789,50594,,,Plasma,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,A,1,N,1,,BAO_0000218
11409,,178.0,10090.0,Intermediate,Mus musculus,11355,CHEMBL623790,50594,,,Blood,Peak concentration in blood after intravenous administration to mice,,A,1,N,1,,BAO_0000218
11410,,178.0,10090.0,Intermediate,Mus musculus,11355,CHEMBL623791,50594,,,Blood,Peak concentration in blood after peroral administration to mice,,A,1,N,1,,BAO_0000218
11411,,1969.0,10116.0,Intermediate,Rattus norvegicus,11966,CHEMBL623792,50597,,,Plasma,Peak concentration in rat plasma was determined,,A,1,N,1,,BAO_0000218
11412,,1969.0,314293.0,Autocuration,Simiiformes,8918,CHEMBL623793,22224,,,Plasma,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,A,1,U,0,,BAO_0000218
11413,,1969.0,10090.0,Intermediate,Mus musculus,8918,CHEMBL623794,50594,,,Plasma,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,A,1,N,1,,BAO_0000218
11414,,1969.0,10116.0,Intermediate,Rattus norvegicus,8918,CHEMBL623795,50597,,,Plasma,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,A,1,N,1,,BAO_0000218
11415,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623796,50597,,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11416,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623797,50597,,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11417,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623798,50597,,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11418,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623799,50597,,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11419,,160.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624490,50597,,,Intestine,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11420,,160.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624491,50597,,,Intestine,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11421,,160.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624492,50597,,,Intestine,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11422,,160.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624493,50597,,,Intestine,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11423,,160.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL877595,50597,,,Intestine,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11424,,160.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624494,50597,,,Intestine,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11425,,160.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624495,50597,,,Intestine,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11426,,160.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624681,50597,,,Intestine,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11427,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624682,50597,,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11428,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624683,50597,,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11429,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624684,50597,,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11430,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624685,50597,,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11431,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624686,50597,,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11432,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624687,50597,,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11433,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624688,50597,,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11434,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL627161,50597,,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11435,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL622127,50597,,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11436,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL622128,50597,,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11437,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL874384,50597,,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11438,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624898,50597,,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11439,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624899,50597,,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11440,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624900,50597,,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11441,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624901,50597,,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11442,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624902,50597,,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11443,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624903,50597,,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11444,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624904,50597,,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11445,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624905,50597,,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11446,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624906,50597,,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11447,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624907,50597,,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11448,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624908,50597,,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11449,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624909,50597,,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11450,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624910,50597,,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11451,,2385.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624911,50597,,,Muscle tissue,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11452,,2385.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL874388,50597,,,Muscle tissue,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11453,,2385.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL624912,50597,,,Muscle tissue,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11454,,2385.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL622930,50597,,,Muscle tissue,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11455,,2385.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623121,50597,,,Muscle tissue,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11456,,2385.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623122,50597,,,Muscle tissue,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11457,,2385.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623123,50597,,,Muscle tissue,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11458,,2385.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623124,50597,,,Muscle tissue,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11459,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623125,50597,,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11460,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623126,50597,,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11461,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623127,50597,,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11462,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623128,50597,,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11463,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623129,50597,,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11464,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623130,50597,,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11465,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623131,50597,,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11466,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL623132,50597,,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11467,,2107.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623133,50597,,,Liver,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11468,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623134,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11469,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL874389,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11470,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623135,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11471,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623136,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11472,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623137,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11473,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623138,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11474,,2113.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623139,50597,,,Kidney,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11475,,2113.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623140,50597,,,Kidney,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11476,,2107.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623141,50597,,,Liver,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11477,,2107.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623142,50597,,,Liver,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11478,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL623143,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11479,,1088.0,10090.0,Intermediate,Mus musculus,14571,CHEMBL623144,50594,,,Urine,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,A,1,N,1,,BAO_0000218
11480,,1088.0,10116.0,Intermediate,Rattus norvegicus,14571,CHEMBL623405,50597,,,Urine,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,A,1,N,1,,BAO_0000218
11481,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624074,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11482,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624075,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11483,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624076,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11484,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624077,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11485,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624078,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11486,,2113.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624079,50597,,,Kidney,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11487,,2113.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624261,50597,,,Kidney,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11488,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624262,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11489,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624263,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11490,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624264,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11491,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624265,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11492,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624266,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11493,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624267,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11494,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624268,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11495,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL875227,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11496,,2113.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624269,50597,,,Kidney,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11497,,2113.0,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624270,50597,,,Kidney,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11498,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624271,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,A,1,N,1,,BAO_0000218
11499,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624272,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11500,,,10116.0,Intermediate,Rattus norvegicus,8319,CHEMBL624273,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,A,1,N,1,,BAO_0000218
11501,,1088.0,10116.0,Intermediate,Rattus norvegicus,12064,CHEMBL624274,50597,,,Urine,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,A,1,N,1,,BAO_0000218
11502,,1088.0,10116.0,Intermediate,Rattus norvegicus,12064,CHEMBL624275,50597,,,Urine,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,A,1,N,1,,BAO_0000218
11503,,1088.0,10116.0,Intermediate,Rattus norvegicus,12064,CHEMBL624276,50597,,,Urine,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,A,1,N,1,,BAO_0000218
11504,,1088.0,10116.0,Intermediate,Rattus norvegicus,12038,CHEMBL624277,50597,,,Urine,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,A,1,N,1,,BAO_0000218
11505,,,,Autocuration,,14314,CHEMBL624278,22224,,,,% dose converted to 2-amino-5-chlorophenyl sulfate,,A,1,U,0,,BAO_0000019
11506,,,,Autocuration,,14314,CHEMBL624279,22224,,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,A,1,U,0,,BAO_0000019
11507,,1988.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL624280,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,A,1,N,1,,BAO_0000218
11508,,1988.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL624281,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,A,1,N,1,,BAO_0000218
11509,,1988.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL622933,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,A,1,N,1,,BAO_0000218
11510,,1988.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL622934,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,A,1,N,1,,BAO_0000218
11511,,2107.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL622935,50597,,,Liver,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11512,,2107.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL622936,50597,,,Liver,Biodistribution in Rat liver after 5 minutes of iv administration,,A,1,N,1,,BAO_0000218
11513,,2107.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL875228,50597,,,Liver,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11514,,2048.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL622937,50597,,,Lung,Biodistribution in Rat lung after 24 hours of iv administration,,A,1,N,1,,BAO_0000218
11515,,2048.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL622938,50597,,,Lung,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11516,,2048.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL619736,50597,,,Lung,Biodistribution in Rat lung after 30 minutes of iv administration,,A,1,N,1,,BAO_0000218
11517,,2048.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625117,50597,,,Lung,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11518,,2048.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625118,50597,,,Lung,Biodistribution in Rat lung after 5 minutes of iv administration,,A,1,N,1,,BAO_0000218
11519,,2048.0,10116.0,Intermediate,Rattus norvegicus,8829,CHEMBL625119,50597,,,Lung,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,A,1,N,1,,BAO_0000218
11520,,2037.0,10116.0,Intermediate,Rattus norvegicus,14972,CHEMBL625120,50597,,,Cerebellum,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,A,1,N,1,,BAO_0000218
11521,,,10116.0,Intermediate,Rattus norvegicus,14972,CHEMBL625121,50597,,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,A,1,N,1,,BAO_0000218
11522,,10000006.0,10116.0,Intermediate,Rattus norvegicus,14972,CHEMBL625122,50597,,,Thalamus,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,A,1,N,1,,BAO_0000218
11523,,178.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL622204,50597,,,Blood,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11524,,178.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL877503,50597,,,Blood,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11525,,178.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL627127,50597,,,Blood,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11526,,10000000.0,,Autocuration,,14608,CHEMBL627128,22224,,,Hippocampus,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,U,0,,BAO_0000218
11527,,10000000.0,,Autocuration,,14608,CHEMBL627129,22224,,,Hippocampus,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,U,0,,BAO_0000218
11528,,10000000.0,,Autocuration,,14608,CHEMBL627130,22224,,,Hippocampus,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,U,0,,BAO_0000218
11529,,955.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL627131,50597,,,Brain,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11530,,955.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL627132,50597,,,Brain,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11531,,955.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL627133,50597,,,Brain,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11532,,2037.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL627134,50597,,,Cerebellum,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11533,,2037.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL627135,50597,,,Cerebellum,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11534,,2037.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL627136,50597,,,Cerebellum,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11535,,,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628435,50597,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11536,,,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628436,50597,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11537,,,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628437,50597,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11538,,948.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628438,50597,,,Heart,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11539,,948.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628439,50597,,,Heart,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11540,,948.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628440,50597,,,Heart,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11541,,10000000.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628441,50597,,,Hippocampus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11542,,10000000.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628442,50597,,,Hippocampus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11543,,10000000.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628443,50597,,,Hippocampus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11544,,2113.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628444,50597,,,Kidney,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11545,,2113.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628445,50597,,,Kidney,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11546,,2113.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL877504,50597,,,Kidney,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11547,,2107.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL628446,50597,,,Liver,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11548,,2107.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL626874,50597,,,Liver,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11549,,2107.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL626875,50597,,,Liver,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11550,,2048.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL626876,50597,,,Lung,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11551,,2048.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL626877,50597,,,Lung,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11552,,2048.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL626878,50597,,,Lung,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11553,,2385.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL626879,50597,,,Muscle tissue,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11554,,1969.0,314293.0,Autocuration,Simiiformes,8918,CHEMBL626880,22224,,,Plasma,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,A,1,U,0,,BAO_0000218
11555,,1969.0,10090.0,Intermediate,Mus musculus,8918,CHEMBL626881,50594,,,Plasma,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,A,1,N,1,,BAO_0000218
11556,,1969.0,10116.0,Intermediate,Rattus norvegicus,8918,CHEMBL626882,50597,,,Plasma,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,A,1,N,1,,BAO_0000218
11557,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14470,CHEMBL626883,50588,,,Plasma,Peak plasma concentration was measured in dogs,,A,1,N,1,,BAO_0000218
11558,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL626884,50597,,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,A,1,N,1,,BAO_0000218
11559,,,10116.0,Intermediate,Rattus norvegicus,14886,CHEMBL626885,50597,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,A,1,N,1,,BAO_0000218
11560,,,10116.0,Intermediate,Rattus norvegicus,14886,CHEMBL626886,50597,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,A,1,N,1,,BAO_0000218
11561,,,10116.0,Intermediate,Rattus norvegicus,14886,CHEMBL626887,50597,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,A,1,N,1,,BAO_0000218
11562,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL626888,50597,,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,A,1,N,1,,BAO_0000218
11563,,,9615.0,Intermediate,Canis lupus familiaris,13465,CHEMBL626889,50588,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,A,1,N,1,,BAO_0000218
11564,,,314293.0,Autocuration,Simiiformes,13465,CHEMBL626761,22224,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,A,1,U,0,,BAO_0000218
11565,,,9615.0,Intermediate,Canis lupus familiaris,13465,CHEMBL626762,50588,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,A,1,N,1,,BAO_0000218
11566,,,9615.0,Intermediate,Canis lupus familiaris,13465,CHEMBL626763,50588,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,A,1,N,1,,BAO_0000218
11567,,,10116.0,Intermediate,Rattus norvegicus,13465,CHEMBL626764,50597,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,A,1,N,1,,BAO_0000218
11568,,,10116.0,Intermediate,Rattus norvegicus,13465,CHEMBL626765,50597,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,A,1,N,1,,BAO_0000218
11569,,,9615.0,Intermediate,Canis lupus familiaris,13465,CHEMBL626766,50588,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,A,1,N,1,,BAO_0000218
11570,,,10116.0,Intermediate,Rattus norvegicus,13465,CHEMBL626767,50597,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,A,1,N,1,,BAO_0000218
11571,,,10116.0,Intermediate,Rattus norvegicus,13465,CHEMBL626768,50597,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,A,1,N,1,,BAO_0000218
11572,,,9615.0,Intermediate,Canis lupus familiaris,13465,CHEMBL626769,50588,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,A,1,N,1,,BAO_0000218
11573,,,9615.0,Intermediate,Canis lupus familiaris,13465,CHEMBL874463,50588,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,A,1,N,1,,BAO_0000218
11574,,,314293.0,Autocuration,Simiiformes,13465,CHEMBL626770,22224,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,A,1,U,0,,BAO_0000218
11575,,,314293.0,Autocuration,Simiiformes,13465,CHEMBL626771,22224,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,A,1,U,0,,BAO_0000218
11576,,,10116.0,Intermediate,Rattus norvegicus,13465,CHEMBL626772,50597,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,A,1,N,1,,BAO_0000218
11577,,,9541.0,Intermediate,Macaca fascicularis,14731,CHEMBL626773,100710,,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,A,1,N,1,,BAO_0000218
11578,,,10090.0,Intermediate,Mus musculus,14731,CHEMBL626774,50594,,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,A,1,N,1,,BAO_0000218
11579,,,9615.0,Intermediate,Canis lupus familiaris,13376,CHEMBL626775,50588,,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,A,1,N,1,,BAO_0000218
11580,,,9615.0,Intermediate,Canis lupus familiaris,13376,CHEMBL626776,50588,,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,A,1,N,1,,BAO_0000218
11581,,,10116.0,Intermediate,Rattus norvegicus,14443,CHEMBL626777,50597,,,,Maximum concentration (Cmax) in rat when administered orally,,A,1,N,1,,BAO_0000218
11582,,1969.0,314293.0,Autocuration,Simiiformes,13465,CHEMBL626778,22224,,,Plasma,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,A,1,U,0,,BAO_0000218
11583,,,10116.0,Autocuration,Rattus norvegicus,16359,CHEMBL626779,22224,,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,A,1,U,0,,BAO_0000218
11584,,,10116.0,Autocuration,Rattus norvegicus,16359,CHEMBL626780,22224,,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,A,1,U,0,,BAO_0000218
11585,,1969.0,,Autocuration,,15618,CHEMBL626781,22224,,,Plasma,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,A,1,U,0,,BAO_0000218
11586,,,10116.0,Intermediate,Rattus norvegicus,14554,CHEMBL632164,50597,,,,Pharmacokinetic profile Cmax was evaluated in rats,,A,1,N,1,,BAO_0000218
11587,,,9615.0,Intermediate,Canis lupus familiaris,11537,CHEMBL632165,50588,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,A,1,N,1,,BAO_0000218
11588,,,10090.0,Intermediate,Mus musculus,11537,CHEMBL632166,50594,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,A,1,N,1,,BAO_0000218
11589,,,9615.0,Intermediate,Canis lupus familiaris,11537,CHEMBL632167,50588,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,A,1,N,1,,BAO_0000218
11590,,,10090.0,Intermediate,Mus musculus,11537,CHEMBL632168,50594,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,A,1,N,1,,BAO_0000218
11591,,1969.0,10116.0,Autocuration,Rattus norvegicus,2021,CHEMBL632169,22224,,,Plasma,Cmax in rat plasma,,A,1,U,0,,BAO_0000218
11592,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5932,CHEMBL632170,50588,,,Plasma,Cmax in dog plasma after 30mg/kg oral dose,,A,1,N,1,,BAO_0000218
11593,,1969.0,10116.0,Intermediate,Rattus norvegicus,5932,CHEMBL632171,50597,,,Plasma,Cmax in rat plasma after 30mg/kg oral dose,,A,1,N,1,,BAO_0000218
11594,,1969.0,10116.0,Intermediate,Rattus norvegicus,17320,CHEMBL632172,50597,,,Plasma,Plasma level in rats at 30 mg/kg,,A,1,N,1,,BAO_0000218
11595,,1969.0,10090.0,Intermediate,Mus musculus,15831,CHEMBL632173,50594,,,Plasma,Tested for maximum plasma concentration in mice,,A,1,N,1,,BAO_0000218
11596,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL632174,50597,,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
11597,,,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL632175,50597,,,,The Cmax values in female wistar rats.,,A,1,N,1,,BAO_0000218
11598,,1969.0,9615.0,Intermediate,Canis lupus familiaris,15343,CHEMBL632176,50588,,,Plasma,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,A,1,N,1,,BAO_0000218
11599,,1969.0,10116.0,Intermediate,Rattus norvegicus,15343,CHEMBL632177,50597,,,Plasma,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,A,1,N,1,,BAO_0000218
11600,,1969.0,10116.0,Intermediate,Rattus norvegicus,14856,CHEMBL632178,50597,,,Plasma,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,A,1,N,1,,BAO_0000218
11601,,,10116.0,Intermediate,Rattus norvegicus,13129,CHEMBL632179,50597,,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,A,1,N,1,,BAO_0000218
11602,,178.0,10116.0,Intermediate,Rattus norvegicus,13098,CHEMBL632180,50597,,,Blood,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,A,1,N,1,,BAO_0000218
11603,,178.0,10116.0,Intermediate,Rattus norvegicus,13098,CHEMBL632181,50597,,,Blood,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,A,1,N,1,,BAO_0000218
11604,,178.0,10116.0,Intermediate,Rattus norvegicus,13098,CHEMBL632182,50597,,,Blood,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,A,1,N,1,,BAO_0000218
11605,,178.0,10090.0,Autocuration,Mus musculus,15478,CHEMBL632183,22224,,,Blood,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,A,1,U,0,,BAO_0000218
11606,,,9615.0,Intermediate,Canis lupus familiaris,15341,CHEMBL632184,50588,,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,A,1,N,1,,BAO_0000218
11607,,,10116.0,Intermediate,Rattus norvegicus,15341,CHEMBL874470,50597,,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,A,1,N,1,,BAO_0000218
11608,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL631302,50597,,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11609,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL631303,50597,,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11610,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL631304,50597,,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11611,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL631305,50597,,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11612,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL631306,50597,,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11613,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL631307,50597,,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11614,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL631308,50597,,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11615,,,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625557,50597,,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11616,,2106.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625558,50597,,,Spleen,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11617,,2106.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625559,50597,,,Spleen,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11618,,2106.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625560,50597,,,Spleen,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11619,,2106.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625561,50597,,,Spleen,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11620,,2106.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625562,50597,,,Spleen,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11621,,2106.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL875320,50597,,,Spleen,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11622,,2106.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625563,50597,,,Spleen,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11623,,2106.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625564,50597,,,Spleen,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11624,,995.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625565,50597,,,Uterus,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11625,,995.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625566,50597,,,Uterus,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11626,,995.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625567,50597,,,Uterus,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11627,,995.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL625568,50597,,,Uterus,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11628,,995.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL628217,50597,,,Uterus,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11629,,995.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL628218,50597,,,Uterus,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11630,,995.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL628219,50597,,,Uterus,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11631,,995.0,10116.0,Intermediate,Rattus norvegicus,8684,CHEMBL628220,50597,,,Uterus,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,A,1,N,1,,BAO_0000218
11632,,,,Autocuration,,8926,CHEMBL628221,22224,,,,Distribution in the blood after 120 min of intravenous administration,,A,1,U,0,,BAO_0000019
11633,,,,Autocuration,,8926,CHEMBL628222,22224,,,,Distribution in the blood after 15 min of intravenous administration,,A,1,U,0,,BAO_0000019
11634,,,,Autocuration,,8926,CHEMBL628223,22224,,,,Distribution in the blood after 30 min of intravenous administration,,A,1,U,0,,BAO_0000019
11635,,,,Autocuration,,8926,CHEMBL628224,22224,,,,Distribution in the blood after 5 min of intravenous administration,,A,1,U,0,,BAO_0000019
11636,,,,Autocuration,,8926,CHEMBL628225,22224,,,,Distribution in the blood after 60 min of intravenous administration,,A,1,U,0,,BAO_0000019
11637,,,,Autocuration,,8926,CHEMBL628226,22224,,,,Distribution in the blood after 90 min of intravenous administration,,A,1,U,0,,BAO_0000019
11638,,,,Autocuration,,8926,CHEMBL628227,22224,,,,Distribution in the bone after 120 min of intravenous administration,,A,1,U,0,,BAO_0000019
11639,,,,Autocuration,,8926,CHEMBL875481,22224,,,,Distribution in the bone after 15 min of intravenous administration,,A,1,U,0,,BAO_0000019
11640,,,,Autocuration,,8926,CHEMBL628228,22224,,,,Distribution in the bone after 30 min of intravenous administration,,A,1,U,0,,BAO_0000019
11641,,,,Autocuration,,8926,CHEMBL628229,22224,,,,Distribution in the bone after 5 min of intravenous administration,,A,1,U,0,,BAO_0000019
11642,,,,Autocuration,,8926,CHEMBL628230,22224,,,,Distribution in the bone after 60 min of intravenous administration,,A,1,U,0,,BAO_0000019
11643,,,,Autocuration,,8926,CHEMBL628231,22224,,,,Distribution in the bone after 90 min of intravenous administration,,A,1,U,0,,BAO_0000019
11644,,,,Autocuration,,8926,CHEMBL628232,22224,,,,Distribution in the heart after 120 min of intravenous administration,,A,1,U,0,,BAO_0000019
11645,,,,Autocuration,,8926,CHEMBL628233,22224,,,,Distribution in the heart after 15 min of intravenous administration,,A,1,U,0,,BAO_0000019
11646,,,,Autocuration,,8926,CHEMBL628234,22224,,,,Distribution in the heart after 30 min of intravenous administration,,A,1,U,0,,BAO_0000019
11647,,,,Autocuration,,8926,CHEMBL628235,22224,,,,Distribution in the heart after 5 min of intravenous administration,,A,1,U,0,,BAO_0000019
11648,,,,Autocuration,,8926,CHEMBL628236,22224,,,,Distribution in the heart after 60 min of intravenous administration,,A,1,U,0,,BAO_0000019
11649,,,,Autocuration,,8926,CHEMBL628237,22224,,,,Distribution in the heart after 90 min of intravenous administration,,A,1,U,0,,BAO_0000019
11650,,,,Autocuration,,8926,CHEMBL628238,22224,,,,Distribution in the kidneys after 120 min of intravenous administration,,A,1,U,0,,BAO_0000019
11651,,,,Autocuration,,8926,CHEMBL628239,22224,,,,Distribution in the kidneys after 15 min of intravenous administration,,A,1,U,0,,BAO_0000019
11652,,,,Autocuration,,8926,CHEMBL628240,22224,,,,Distribution in the kidneys after 30 min of intravenous administration,,A,1,U,0,,BAO_0000019
11653,,,,Autocuration,,8926,CHEMBL628241,22224,,,,Distribution in the kidneys after 5 min of intravenous administration,,A,1,U,0,,BAO_0000019
11654,,,,Autocuration,,8926,CHEMBL628242,22224,,,,Distribution in the kidneys after 60 min of intravenous administration,,A,1,U,0,,BAO_0000019
11655,,,,Autocuration,,8926,CHEMBL875482,22224,,,,Distribution in the kidneys after 90 min of intravenous administration,,A,1,U,0,,BAO_0000019
11656,,,,Autocuration,,8926,CHEMBL628243,22224,,,,Distribution in the liver after 120 min of intravenous administration,,A,1,U,0,,BAO_0000019
11657,,,,Autocuration,,8926,CHEMBL628244,22224,,,,Distribution in the liver after 15 min of intravenous administration,,A,1,U,0,,BAO_0000019
11658,,,,Autocuration,,8926,CHEMBL628245,22224,,,,Distribution in the liver after 30 min of intravenous administration,,A,1,U,0,,BAO_0000019
11659,,,,Autocuration,,8926,CHEMBL628246,22224,,,,Distribution in the liver after 5 min of intravenous administration,,A,1,U,0,,BAO_0000019
11660,,,,Autocuration,,8926,CHEMBL628247,22224,,,,Distribution in the liver after 60 min of intravenous administration,,A,1,U,0,,BAO_0000019
11661,,,,Autocuration,,8926,CHEMBL628248,22224,,,,Distribution in the liver after 90 min of intravenous administration,,A,1,U,0,,BAO_0000019
11662,,,,Autocuration,,8926,CHEMBL628249,22224,,,,Distribution in the lung after 120 min of intravenous administration,,A,1,U,0,,BAO_0000019
11663,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL625452,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,A,1,N,1,,BAO_0000218
11664,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL625453,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,A,1,N,1,,BAO_0000218
11665,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL625454,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,A,1,N,1,,BAO_0000218
11666,,,10090.0,Intermediate,Mus musculus,14839,CHEMBL623844,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,A,1,N,1,,BAO_0000218
11667,,,10116.0,Intermediate,Rattus norvegicus,12178,CHEMBL623845,50597,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,A,1,N,1,,BAO_0000218
11668,,,10116.0,Intermediate,Rattus norvegicus,12178,CHEMBL623846,50597,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,A,1,N,1,,BAO_0000218
11669,,,,Autocuration,,12178,CHEMBL623847,22224,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,A,1,U,0,,BAO_0000218
11670,,,9541.0,Intermediate,Macaca fascicularis,12186,CHEMBL623848,100710,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,A,1,N,1,,BAO_0000218
11671,,,9541.0,Intermediate,Macaca fascicularis,12186,CHEMBL623849,100710,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,A,1,N,1,,BAO_0000218
11672,,,9541.0,Intermediate,Macaca fascicularis,12186,CHEMBL623850,100710,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,A,1,N,1,,BAO_0000218
11673,,,9541.0,Intermediate,Macaca fascicularis,12186,CHEMBL623851,100710,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,A,1,N,1,,BAO_0000218
11674,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL623852,22224,,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,A,1,U,0,,BAO_0000218
11675,,,9669.0,Intermediate,Mustela putorius furo,12187,CHEMBL624551,50506,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,A,1,N,1,,BAO_0000218
11676,,,9669.0,Intermediate,Mustela putorius furo,12187,CHEMBL624552,50506,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,A,1,N,1,,BAO_0000218
11677,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL624553,22224,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,A,1,U,0,,BAO_0000218
11678,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL624554,22224,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,A,1,U,0,,BAO_0000218
11679,,,10116.0,Intermediate,Rattus norvegicus,12187,CHEMBL624555,50597,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,A,1,N,1,,BAO_0000218
11680,,,10116.0,Intermediate,Rattus norvegicus,12187,CHEMBL624741,50597,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,A,1,N,1,,BAO_0000218
11681,,,9615.0,Intermediate,Canis lupus familiaris,14122,CHEMBL624742,50588,,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,A,1,N,1,,BAO_0000218
11682,,,10026.0,Intermediate,Cricetinae,14122,CHEMBL624743,100712,,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,A,1,N,1,,BAO_0000218
11683,,,10116.0,Intermediate,Rattus norvegicus,14122,CHEMBL877606,50597,,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,A,1,N,1,,BAO_0000218
11684,,,,Autocuration,,13391,CHEMBL624744,22224,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,A,1,U,0,,BAO_0000218
11685,,178.0,,Autocuration,,13391,CHEMBL624745,22224,,,Blood,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,A,1,U,0,,BAO_0000218
11686,,178.0,,Autocuration,,13391,CHEMBL624746,22224,,,Blood,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,A,1,U,0,,BAO_0000218
11687,,178.0,,Autocuration,,13391,CHEMBL624747,22224,,,Blood,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,A,1,U,0,,BAO_0000218
11688,,,,Autocuration,,16360,CHEMBL624748,22224,,,,Oral absorption expressed as Area under curve was determined,,A,1,U,0,,BAO_0000019
11689,,,9615.0,Intermediate,Canis lupus familiaris,3673,CHEMBL622504,50588,,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,A,1,N,1,,BAO_0000218
11690,,,9615.0,Intermediate,Canis lupus familiaris,14122,CHEMBL622505,50588,,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,A,1,N,1,,BAO_0000218
11691,,,10026.0,Intermediate,Cricetinae,14122,CHEMBL622506,100712,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,A,1,N,1,,BAO_0000218
11692,,,10026.0,Intermediate,Cricetinae,14122,CHEMBL622507,100712,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,A,1,N,1,,BAO_0000218
11693,,,10116.0,Intermediate,Rattus norvegicus,14122,CHEMBL622508,50597,,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,A,1,N,1,,BAO_0000218
11694,,,,Autocuration,,13889,CHEMBL622509,22224,,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,A,1,U,0,,BAO_0000019
11695,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL622510,50597,,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,A,1,N,1,,BAO_0000218
11696,,,10116.0,Intermediate,Rattus norvegicus,17279,CHEMBL622511,50597,,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,A,1,N,1,,BAO_0000218
11697,,,9541.0,Intermediate,Macaca fascicularis,14548,CHEMBL622512,100710,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,A,1,N,1,,BAO_0000218
11698,,,9541.0,Intermediate,Macaca fascicularis,14548,CHEMBL622513,100710,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,A,1,N,1,,BAO_0000218
11699,,,9541.0,Intermediate,Macaca fascicularis,14548,CHEMBL622514,100710,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,A,1,N,1,,BAO_0000218
11700,,,9615.0,Intermediate,Canis lupus familiaris,14548,CHEMBL622515,50588,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,A,1,N,1,,BAO_0000218
11701,,,9615.0,Intermediate,Canis lupus familiaris,14548,CHEMBL622516,50588,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,A,1,N,1,,BAO_0000218
11702,,,10116.0,Intermediate,Rattus norvegicus,14548,CHEMBL622517,50597,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,A,1,N,1,,BAO_0000218
11703,,,10116.0,Intermediate,Rattus norvegicus,14548,CHEMBL622518,50597,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,A,1,N,1,,BAO_0000218
11704,,,10116.0,Intermediate,Rattus norvegicus,14548,CHEMBL622519,50597,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,A,1,N,1,,BAO_0000218
11705,,2385.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL622520,50597,,,Muscle tissue,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11706,,2385.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL622521,50597,,,Muscle tissue,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11707,,14.0,10090.0,Intermediate,Mus musculus,14608,CHEMBL625113,50594,,,Zone of skin,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11708,,14.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL625114,50597,,,Zone of skin,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11709,,14.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL874397,50597,,,Zone of skin,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11710,,2106.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL625115,50597,,,Spleen,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11711,,2106.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL625116,50597,,,Spleen,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11712,,2106.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL623932,50597,,,Spleen,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11713,,2435.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL623933,50597,,,Striatum,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11714,,2435.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL623934,50597,,,Striatum,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11715,,2435.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL623935,50597,,,Striatum,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11716,,2046.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL623936,50597,,,Thyroid gland,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,A,1,N,1,,BAO_0000218
11717,,2046.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL623937,50597,,,Thyroid gland,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,A,1,N,1,,BAO_0000218
11718,,2046.0,10116.0,Intermediate,Rattus norvegicus,14608,CHEMBL623938,50597,,,Thyroid gland,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,A,1,N,1,,BAO_0000218
11719,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL623939,50594,,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,A,1,N,1,,BAO_0000218
11720,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL623940,50594,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,A,1,N,1,,BAO_0000218
11721,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL623941,50594,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,A,1,N,1,,BAO_0000218
11722,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL627216,50594,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11723,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL623942,50594,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11724,,955.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618793,50594,,,Brain,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,A,1,N,1,,BAO_0000218
11725,,955.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618794,50594,,,Brain,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11726,,955.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618795,50594,,,Brain,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11727,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL618796,50594,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11728,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL618797,50594,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11729,,2113.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618798,50594,,,Kidney,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,A,1,N,1,,BAO_0000218
11730,,2113.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618799,50594,,,Kidney,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,A,1,N,1,,BAO_0000218
11731,,2113.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618800,50594,,,Kidney,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,A,1,N,1,,BAO_0000218
11732,,2113.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618801,50594,,,Kidney,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,A,1,N,1,,BAO_0000218
11733,,2113.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618802,50594,,,Kidney,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11734,,2113.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618803,50594,,,Kidney,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11735,,2107.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618804,50594,,,Liver,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,A,1,N,1,,BAO_0000218
11736,,2107.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618805,50594,,,Liver,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,A,1,N,1,,BAO_0000218
11737,,2107.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618806,50594,,,Liver,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,A,1,N,1,,BAO_0000218
11738,,2107.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618807,50594,,,Liver,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,A,1,N,1,,BAO_0000218
11739,,2107.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618808,50594,,,Liver,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11740,,2107.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618809,50594,,,Liver,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11741,,2385.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618810,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,A,1,N,1,,BAO_0000218
11742,,2385.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618811,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,A,1,N,1,,BAO_0000218
11743,,2385.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL875844,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,A,1,N,1,,BAO_0000218
11744,,2385.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618812,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11745,,2385.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL618813,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11746,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL618814,50594,,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,A,1,N,1,,BAO_0000218
11747,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL618815,50594,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11748,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL618816,50594,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11749,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL618817,50594,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11750,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL620544,50594,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11751,,,10116.0,Intermediate,Rattus norvegicus,15341,CHEMBL626230,50597,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,A,1,N,1,,BAO_0000218
11752,,,10116.0,Intermediate,Rattus norvegicus,15341,CHEMBL626231,50597,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,A,1,N,1,,BAO_0000218
11753,,,10116.0,Intermediate,Rattus norvegicus,15341,CHEMBL626232,50597,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,A,1,N,1,,BAO_0000218
11754,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14906,CHEMBL626233,50588,,,Plasma,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,A,1,N,1,,BAO_0000218
11755,,1969.0,10116.0,Intermediate,Rattus norvegicus,14906,CHEMBL626234,50597,,,Plasma,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,A,1,N,1,,BAO_0000218
11756,,1969.0,10116.0,Intermediate,Rattus norvegicus,14906,CHEMBL875341,50597,,,Plasma,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,A,1,N,1,,BAO_0000218
11757,,1969.0,9606.0,Intermediate,Homo sapiens,14215,CHEMBL626235,50587,,,Plasma,The maximum plasma concentration (100 mg/kg) administered orally in human,,A,1,N,1,,BAO_0000218
11758,,1969.0,9481.0,Autocuration,Callithrix,14215,CHEMBL626236,22224,,,Plasma,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,A,1,U,0,,BAO_0000218
11759,,1969.0,314293.0,Autocuration,Simiiformes,14215,CHEMBL626237,22224,,,Plasma,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,A,1,U,0,,BAO_0000218
11760,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14215,CHEMBL626238,50588,,,Plasma,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,A,1,N,1,,BAO_0000218
11761,,1969.0,9606.0,Intermediate,Homo sapiens,14215,CHEMBL622412,50587,,,Plasma,The maximum plasma concentration (200 mg/kg) administered orally in human,,A,1,N,1,,BAO_0000218
11762,,1969.0,10116.0,Intermediate,Rattus norvegicus,14215,CHEMBL623114,50597,,,Plasma,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,A,1,N,1,,BAO_0000218
11763,,1969.0,9481.0,Autocuration,Callithrix,14215,CHEMBL623115,22224,,,Plasma,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,A,1,U,0,,BAO_0000218
11764,,1969.0,314293.0,Autocuration,Simiiformes,14215,CHEMBL623116,22224,,,Plasma,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,A,1,U,0,,BAO_0000218
11765,,1969.0,9615.0,Autocuration,Canis lupus familiaris,14215,CHEMBL623117,22224,,,Plasma,The maximum plasma concentration (30 mg/kg) administered orally in dog,,A,1,U,0,,BAO_0000218
11766,,1969.0,9606.0,Intermediate,Homo sapiens,14215,CHEMBL623118,50587,,,Plasma,The maximum plasma concentration (400 mg/kg) administered orally in human,,A,1,N,1,,BAO_0000218
11767,,1969.0,10116.0,Intermediate,Rattus norvegicus,14215,CHEMBL623119,50597,,,Plasma,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,A,1,N,1,,BAO_0000218
11768,,1969.0,10116.0,Intermediate,Rattus norvegicus,14215,CHEMBL623120,50597,,,Plasma,The maximum plasma concentration (50 mg/kg) administered orally in rat,,A,1,N,1,,BAO_0000218
11769,,1969.0,9606.0,Intermediate,Homo sapiens,14215,CHEMBL623286,50587,,,Plasma,The maximum plasma concentration (800 mg/kg) administered orally in human,,A,1,N,1,,BAO_0000218
11770,,1969.0,10116.0,Intermediate,Rattus norvegicus,14067,CHEMBL623287,50597,,,Plasma,The maximum plasma concentration was measured on rats,,A,1,N,1,,BAO_0000218
11771,,1969.0,10116.0,Intermediate,Rattus norvegicus,12350,CHEMBL623288,50597,,,Plasma,The maximum plasma concentration was measured on rats after oral administration,,A,1,N,1,,BAO_0000218
11772,,1969.0,10116.0,Intermediate,Rattus norvegicus,14813,CHEMBL623289,50597,,,Plasma,Plasma drug Cmax in rat (PO dose),,A,1,N,1,,BAO_0000218
11773,,,,Autocuration,,12536,CHEMBL623290,22224,,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,A,1,U,0,,BAO_0000218
11774,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14169,CHEMBL623291,50588,,,Plasma,maximum Plasma concentration in Dog was determined after Peroral administration,,A,1,N,1,,BAO_0000218
11775,,1969.0,10116.0,Intermediate,Rattus norvegicus,14169,CHEMBL623292,50597,,,Plasma,maximum Plasma concentration in Rats was determined after Peroral administration,,A,1,N,1,,BAO_0000218
11776,,1969.0,9615.0,Intermediate,Canis lupus familiaris,15604,CHEMBL623293,50588,,,Plasma,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,A,1,N,1,,BAO_0000218
11777,,1969.0,314293.0,Autocuration,Simiiformes,15604,CHEMBL623294,22224,,,Plasma,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,A,1,U,0,,BAO_0000218
11778,,1969.0,10116.0,Intermediate,Rattus norvegicus,15604,CHEMBL623295,50597,,,Plasma,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,A,1,N,1,,BAO_0000218
11779,,,10090.0,Intermediate,Mus musculus,14387,CHEMBL623296,50594,,,,maximum concentration was measured when administered through oral route in mice,,A,1,N,1,,BAO_0000218
11780,,,10090.0,Intermediate,Mus musculus,15115,CHEMBL875349,50594,,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,A,1,N,1,,BAO_0000218
11781,,,314293.0,Autocuration,Simiiformes,15115,CHEMBL623297,22224,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,A,1,U,0,,BAO_0000019
11782,,,314293.0,Autocuration,Simiiformes,15115,CHEMBL623298,22224,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,A,1,U,0,,BAO_0000019
11783,,,314293.0,Autocuration,Simiiformes,15115,CHEMBL623299,22224,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,A,1,U,0,,BAO_0000019
11784,,,10116.0,Intermediate,Rattus norvegicus,16359,CHEMBL623300,50597,,,,Pharmacokinetic parameter was evaluated in rats,,A,1,N,1,,BAO_0000218
11785,,,10090.0,Intermediate,Mus musculus,12829,CHEMBL623301,50594,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,A,1,N,1,,BAO_0000218
11786,,,10090.0,Intermediate,Mus musculus,12829,CHEMBL623302,50594,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,A,1,N,1,,BAO_0000218
11787,,,10090.0,Intermediate,Mus musculus,12829,CHEMBL623303,50594,,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,A,1,N,1,,BAO_0000218
11788,,,10090.0,Intermediate,Mus musculus,12829,CHEMBL623304,50594,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,A,1,N,1,,BAO_0000218
11789,,,10090.0,Intermediate,Mus musculus,12829,CHEMBL623305,50594,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,A,1,N,1,,BAO_0000218
11790,,1969.0,10116.0,Intermediate,Rattus norvegicus,15137,CHEMBL623306,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,A,1,N,1,,BAO_0000218
11791,,1969.0,10116.0,Intermediate,Rattus norvegicus,15137,CHEMBL623307,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,A,1,N,1,,BAO_0000218
11792,,1969.0,10116.0,Intermediate,Rattus norvegicus,15137,CHEMBL623308,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,A,1,N,1,,BAO_0000218
11793,,1969.0,10090.0,Intermediate,Mus musculus,15137,CHEMBL623309,50594,,,Plasma,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,A,1,N,1,,BAO_0000218
11794,,,10090.0,Intermediate,Mus musculus,13509,CHEMBL623310,50594,,,,Plasma Concentration after 120 min of oral administration to mice,,A,1,N,1,,BAO_0000218
11795,,,10090.0,Intermediate,Mus musculus,13509,CHEMBL623311,50594,,,,Plasma Concentration after 30 min of oral administration to mice,,A,1,N,1,,BAO_0000218
11796,,,9541.0,Intermediate,Macaca fascicularis,13509,CHEMBL623312,100710,,,,Plasma Concentration after 60 min of oral administration to mice,,A,1,N,1,,BAO_0000218
11797,,,10090.0,Intermediate,Mus musculus,13509,CHEMBL875350,50594,,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,,A,1,N,1,,BAO_0000218
11798,,,10090.0,Intermediate,Mus musculus,13509,CHEMBL628635,50594,,,,Plasma Concentration after 90 min of oral administration to mice,,A,1,N,1,,BAO_0000218
11799,,,10116.0,Intermediate,Rattus norvegicus,12064,CHEMBL628636,50597,,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,A,1,N,1,,BAO_0000218
11800,,,10116.0,Intermediate,Rattus norvegicus,12064,CHEMBL628637,50597,,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,A,1,N,1,,BAO_0000218
11801,,,10116.0,Intermediate,Rattus norvegicus,12064,CHEMBL628058,50597,,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,A,1,N,1,,BAO_0000218
11802,,,10116.0,Intermediate,Rattus norvegicus,10677,CHEMBL628059,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,A,1,N,1,,BAO_0000218
11803,,,10116.0,Intermediate,Rattus norvegicus,10677,CHEMBL628060,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,A,1,N,1,,BAO_0000218
11804,,,,Autocuration,,8926,CHEMBL628061,22224,,,,Distribution in the lung after 15 min of intravenous administration,,A,1,U,0,,BAO_0000019
11805,,,,Autocuration,,8926,CHEMBL628062,22224,,,,Distribution in the lung after 30 min of intravenous administration,,A,1,U,0,,BAO_0000019
11806,,,,Autocuration,,8926,CHEMBL628063,22224,,,,Distribution in the lung after 5 min of intravenous administration,,A,1,U,0,,BAO_0000019
11807,,,,Autocuration,,8926,CHEMBL628064,22224,,,,Distribution in the lung after 60 min of intravenous administration,,A,1,U,0,,BAO_0000019
11808,,,,Autocuration,,8926,CHEMBL628065,22224,,,,Distribution in the lung after 90 min of intravenous administration,,A,1,U,0,,BAO_0000019
11809,,2385.0,,Autocuration,,8926,CHEMBL628066,22224,,,Muscle tissue,Distribution in the muscle after 120 min of intravenous administration,,A,1,U,0,,BAO_0000019
11810,,2385.0,,Autocuration,,8926,CHEMBL628067,22224,,,Muscle tissue,Distribution in the muscle after 15 min of intravenous administration,,A,1,U,0,,BAO_0000019
11811,,2385.0,10090.0,Intermediate,Mus musculus,8926,CHEMBL874646,50594,,,Muscle tissue,Distribution in the muscle after 30 min of intravenous administration,,A,1,N,1,,BAO_0000218
11812,,2385.0,,Autocuration,,8926,CHEMBL628068,22224,,,Muscle tissue,Distribution in the muscle after 5 min of intravenous administration,,A,1,U,0,,BAO_0000019
11813,,2385.0,,Autocuration,,8926,CHEMBL628069,22224,,,Muscle tissue,Distribution in the muscle after 60 min of intravenous administration,,A,1,U,0,,BAO_0000019
11814,,2385.0,,Autocuration,,8926,CHEMBL628070,22224,,,Muscle tissue,Distribution in the muscle after 90 min of intravenous administration,,A,1,U,0,,BAO_0000019
11815,,2106.0,,Autocuration,,8926,CHEMBL628071,22224,,,Spleen,Distribution in the spleen after 120 min of intravenous administration,,A,1,U,0,,BAO_0000019
11816,,2106.0,,Autocuration,,8926,CHEMBL628072,22224,,,Spleen,Distribution in the spleen after 15 min of intravenous administration,,A,1,U,0,,BAO_0000019
11817,,2106.0,,Autocuration,,8926,CHEMBL628073,22224,,,Spleen,Distribution in the spleen after 30 min of intravenous administration,,A,1,U,0,,BAO_0000019
11818,,2106.0,,Autocuration,,8926,CHEMBL628074,22224,,,Spleen,Distribution in the spleen after 5 min of intravenous administration,,A,1,U,0,,BAO_0000019
11819,,2106.0,,Autocuration,,8926,CHEMBL628075,22224,,,Spleen,Distribution in the spleen after 60 min of intravenous administration,,A,1,U,0,,BAO_0000019
11820,,2106.0,,Autocuration,,8926,CHEMBL628076,22224,,,Spleen,Distribution in the spleen after 90 min of intravenous administration,,A,1,U,0,,BAO_0000019
11821,,1235.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL628077,50597,,,Adrenal cortex,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11822,,178.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL628078,50597,,,Blood,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11823,,2107.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL628079,50597,,,Liver,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11824,,992.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL628080,50597,,,Female gonad,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11825,,2046.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL628081,50597,,,Thyroid gland,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11826,,1235.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL628082,50597,,,Adrenal cortex,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11827,,178.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL874647,50597,,,Blood,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11828,,2107.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL626406,50597,,,Liver,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11829,,992.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL626407,50597,,,Female gonad,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11830,,2046.0,10116.0,Intermediate,Rattus norvegicus,7570,CHEMBL626408,50597,,,Thyroid gland,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,A,1,N,1,,BAO_0000218
11831,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626409,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,A,1,N,1,,BAO_0000218
11832,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626410,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,A,1,N,1,,BAO_0000218
11833,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626411,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,A,1,N,1,,BAO_0000218
11834,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626412,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,A,1,N,1,,BAO_0000218
11835,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626413,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,A,1,N,1,,BAO_0000218
11836,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626414,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,A,1,N,1,,BAO_0000218
11837,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626415,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,A,1,N,1,,BAO_0000218
11838,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626416,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,A,1,N,1,,BAO_0000218
11839,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627062,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,A,1,N,1,,BAO_0000218
11840,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627063,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,A,1,N,1,,BAO_0000218
11841,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627064,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,A,1,N,1,,BAO_0000218
11842,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627227,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,A,1,N,1,,BAO_0000218
11843,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627228,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,A,1,N,1,,BAO_0000218
11844,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627229,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,A,1,N,1,,BAO_0000218
11845,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL625792,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,A,1,N,1,,BAO_0000218
11846,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL625793,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,A,1,N,1,,BAO_0000218
11847,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL625794,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,A,1,N,1,,BAO_0000218
11848,,178.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL625795,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,A,1,N,1,,BAO_0000218
11849,,,10090.0,Intermediate,Mus musculus,13792,CHEMBL625796,50594,,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,A,1,N,1,,BAO_0000218
11850,,,9615.0,Intermediate,Canis lupus familiaris,13376,CHEMBL625797,50588,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,A,1,N,1,,BAO_0000218
11851,,,9615.0,Intermediate,Canis lupus familiaris,13376,CHEMBL625798,50588,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,A,1,N,1,,BAO_0000218
11852,,,,Autocuration,,14380,CHEMBL875613,22224,,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11853,,,,Autocuration,,14380,CHEMBL625799,22224,,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11854,,,,Autocuration,,14380,CHEMBL625800,22224,,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11855,,,,Autocuration,,14380,CHEMBL625801,22224,,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11856,,,,Autocuration,,14380,CHEMBL625802,22224,,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11857,,,,Autocuration,,14380,CHEMBL625803,22224,,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11858,,,,Autocuration,,14380,CHEMBL625804,22224,,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,A,1,U,0,,BAO_0000019
11859,,,,Autocuration,,14380,CHEMBL622530,22224,,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,A,1,U,0,,BAO_0000218
11860,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL622531,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,A,1,N,1,,BAO_0000218
11861,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL622532,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,A,1,N,1,,BAO_0000218
11862,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL623176,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11863,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL623177,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,A,1,N,1,,BAO_0000218
11864,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL623178,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,A,1,N,1,,BAO_0000218
11865,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL623179,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,A,1,N,1,,BAO_0000218
11866,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL623180,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,A,1,N,1,,BAO_0000218
11867,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL623181,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11868,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL624131,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11869,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL624132,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,A,1,N,1,,BAO_0000218
11870,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL624133,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11871,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL624846,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,A,1,N,1,,BAO_0000218
11872,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL624847,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11873,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL624848,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11874,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625012,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,A,1,N,1,,BAO_0000218
11875,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625013,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11876,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625014,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,A,1,N,1,,BAO_0000218
11877,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625015,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,A,1,N,1,,BAO_0000218
11878,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625016,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11879,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625017,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,A,1,N,1,,BAO_0000218
11880,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625018,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11881,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625019,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11882,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625020,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
11883,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL625021,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,A,1,N,1,,BAO_0000218
11884,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL625022,50597,,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,A,1,N,1,,BAO_0000218
11885,,,10090.0,Intermediate,Mus musculus,14731,CHEMBL625023,50594,,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,A,1,N,1,,BAO_0000218
11886,,,9541.0,Intermediate,Macaca fascicularis,14731,CHEMBL625024,100710,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,A,1,N,1,,BAO_0000218
11887,,,9541.0,Intermediate,Macaca fascicularis,14731,CHEMBL627626,100710,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,A,1,N,1,,BAO_0000218
11888,,955.0,,Autocuration,,13758,CHEMBL627627,22224,,,Brain,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,A,1,U,0,,BAO_0000218
11889,,1977.0,,Autocuration,,13758,CHEMBL627628,22224,,,Serum,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,A,1,U,0,,BAO_0000218
11890,,955.0,,Autocuration,,13758,CHEMBL627629,22224,,,Brain,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,A,1,U,0,,BAO_0000218
11891,,1977.0,,Autocuration,,13758,CHEMBL627630,22224,,,Serum,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,A,1,U,0,,BAO_0000218
11892,,,,Autocuration,,16359,CHEMBL627631,22224,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,A,1,U,0,,BAO_0000019
11893,,,,Autocuration,,16359,CHEMBL629515,22224,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,A,1,U,0,,BAO_0000218
11894,,2106.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL629516,50594,,,Spleen,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,A,1,N,1,,BAO_0000218
11895,,2106.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL629517,50594,,,Spleen,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11896,,2106.0,10090.0,Intermediate,Mus musculus,15383,CHEMBL629518,50594,,,Spleen,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11897,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL877499,50594,,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,A,1,N,1,,BAO_0000218
11898,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL629519,50594,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,A,1,N,1,,BAO_0000218
11899,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL629520,50594,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,A,1,N,1,,BAO_0000218
11900,,,10090.0,Intermediate,Mus musculus,15383,CHEMBL629521,50594,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,A,1,N,1,,BAO_0000218
11901,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629522,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,A,1,N,1,,BAO_0000218
11902,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629523,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,A,1,N,1,,BAO_0000218
11903,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629524,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,A,1,N,1,,BAO_0000218
11904,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629525,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,A,1,N,1,,BAO_0000218
11905,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629526,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,A,1,N,1,,BAO_0000218
11906,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629527,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,A,1,N,1,,BAO_0000218
11907,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629528,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,A,1,N,1,,BAO_0000218
11908,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629529,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,A,1,N,1,,BAO_0000218
11909,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629530,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,A,1,N,1,,BAO_0000218
11910,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL629531,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,A,1,N,1,,BAO_0000218
11911,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628656,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,A,1,N,1,,BAO_0000218
11912,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628657,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,A,1,N,1,,BAO_0000218
11913,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628658,50597,,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11914,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628659,50597,,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11915,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL877500,50597,,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11916,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628660,50597,,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11917,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628661,50597,,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11918,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628662,50597,,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11919,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628663,50597,,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11920,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628664,50597,,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11921,,178.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628665,50597,,,Blood,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11922,,178.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628666,50597,,,Blood,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11923,,178.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628667,50597,,,Blood,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11924,,178.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628668,50597,,,Blood,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11925,,178.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628669,50597,,,Blood,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11926,,178.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628670,50597,,,Blood,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11927,,178.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628671,50597,,,Blood,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11928,,10000001.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL628672,50597,,,Bone,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11929,,10000001.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL630300,50597,,,Bone,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11930,,10000001.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629787,50597,,,Bone,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11931,,10000001.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629788,50597,,,Bone,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11932,,955.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629789,50597,,,Brain,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11933,,955.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629790,50597,,,Brain,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11934,,955.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629791,50597,,,Brain,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11935,,955.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629792,50597,,,Brain,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11936,,955.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629793,50597,,,Brain,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11937,,955.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629794,50597,,,Brain,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
11938,,,10116.0,Intermediate,Rattus norvegicus,10677,CHEMBL874459,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,A,1,N,1,,BAO_0000218
11939,,,10116.0,Intermediate,Rattus norvegicus,10677,CHEMBL629795,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,A,1,N,1,,BAO_0000218
11940,,,10116.0,Intermediate,Rattus norvegicus,10677,CHEMBL629796,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,A,1,N,1,,BAO_0000218
11941,,,10116.0,Intermediate,Rattus norvegicus,10677,CHEMBL629797,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,A,1,N,1,,BAO_0000218
11942,,,10116.0,Intermediate,Rattus norvegicus,10677,CHEMBL629798,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,A,1,N,1,,BAO_0000218
11943,,2369.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629799,50597,,,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11944,,2369.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629800,50597,,,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11945,,2369.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629801,50597,,,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11946,,2369.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629802,50597,,,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,A,1,N,1,,BAO_0000218
11947,,2369.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629803,50597,,,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11948,,178.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629804,50597,,,Blood,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11949,,178.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629805,50597,,,Blood,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11950,,178.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629806,50597,,,Blood,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11951,,178.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629807,50597,,,Blood,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11952,,178.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629808,50597,,,Blood,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11953,,955.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629809,50597,,,Brain,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11954,,955.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629810,50597,,,Brain,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11955,,955.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629811,50597,,,Brain,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11956,,955.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629812,50597,,,Brain,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11957,,955.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629813,50597,,,Brain,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11958,,955.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL874460,50597,,,Brain,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11959,,,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629814,50597,,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11960,,,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629815,50597,,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11961,,,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629816,50597,,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11962,,,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL629817,50597,,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11963,,2113.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL626643,50597,,,Kidney,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11964,,2113.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL626644,50597,,,Kidney,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11965,,2113.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL626806,50597,,,Kidney,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11966,,2113.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL626807,50597,,,Kidney,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11967,,2107.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627261,50597,,,Liver,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11968,,2107.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627262,50597,,,Liver,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11969,,2107.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627263,50597,,,Liver,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11970,,2107.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627264,50597,,,Liver,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11971,,2048.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627265,50597,,,Lung,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11972,,2048.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627266,50597,,,Lung,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11973,,2048.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627267,50597,,,Lung,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11974,,2048.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627268,50597,,,Lung,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11975,,2385.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627269,50597,,,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11976,,2385.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627270,50597,,,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
11977,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627271,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,A,1,N,1,,BAO_0000218
11978,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627946,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,A,1,N,1,,BAO_0000218
11979,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL875472,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,A,1,N,1,,BAO_0000218
11980,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627947,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,A,1,N,1,,BAO_0000218
11981,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627948,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,A,1,N,1,,BAO_0000218
11982,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628113,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,A,1,N,1,,BAO_0000218
11983,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628114,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,A,1,N,1,,BAO_0000218
11984,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628115,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,A,1,N,1,,BAO_0000218
11985,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628116,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,A,1,N,1,,BAO_0000218
11986,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628117,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,A,1,N,1,,BAO_0000218
11987,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628118,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,A,1,N,1,,BAO_0000218
11988,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628119,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,A,1,N,1,,BAO_0000218
11989,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628120,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,A,1,N,1,,BAO_0000218
11990,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628121,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,A,1,N,1,,BAO_0000218
11991,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628122,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,A,1,N,1,,BAO_0000218
11992,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627297,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,A,1,N,1,,BAO_0000218
11993,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627298,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,A,1,N,1,,BAO_0000218
11994,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627299,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,A,1,N,1,,BAO_0000218
11995,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627300,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,A,1,N,1,,BAO_0000218
11996,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627301,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,A,1,N,1,,BAO_0000218
11997,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627302,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,A,1,N,1,,BAO_0000218
11998,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627303,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,A,1,N,1,,BAO_0000218
11999,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627304,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,A,1,N,1,,BAO_0000218
12000,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627305,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,A,1,N,1,,BAO_0000218
12001,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627306,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,A,1,N,1,,BAO_0000218
12002,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623982,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,A,1,N,1,,BAO_0000218
12003,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623983,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,A,1,N,1,,BAO_0000218
12004,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623984,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,A,1,N,1,,BAO_0000218
12005,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623985,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,A,1,N,1,,BAO_0000218
12006,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623986,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,A,1,N,1,,BAO_0000218
12007,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623987,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,A,1,N,1,,BAO_0000218
12008,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623988,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,A,1,N,1,,BAO_0000218
12009,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623989,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,A,1,N,1,,BAO_0000218
12010,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL622215,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,A,1,N,1,,BAO_0000218
12011,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL622216,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,A,1,N,1,,BAO_0000218
12012,,,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL877481,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,A,1,N,1,,BAO_0000218
12013,,,,Autocuration,,16359,CHEMBL622217,22224,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,A,1,U,0,,BAO_0000218
12014,,,10090.0,Intermediate,Mus musculus,13701,CHEMBL622218,50594,,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,A,1,N,1,,BAO_0000218
12015,,,10116.0,Intermediate,Rattus norvegicus,14554,CHEMBL622219,50597,,,,Pharmacokinetic profile AUC was evaluated in rats,,A,1,N,1,,BAO_0000218
12016,,,,Autocuration,,6241,CHEMBL622220,22224,,,,Pharmacokinetic property (Area under curve),,A,1,U,0,,BAO_0000019
12017,,,9615.0,Intermediate,Canis lupus familiaris,11537,CHEMBL622221,50588,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,A,1,N,1,,BAO_0000218
12018,,,10090.0,Intermediate,Mus musculus,11537,CHEMBL622222,50594,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,A,1,N,1,,BAO_0000218
12019,,,9615.0,Intermediate,Canis lupus familiaris,11537,CHEMBL622223,50588,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,A,1,N,1,,BAO_0000218
12020,,,10090.0,Intermediate,Mus musculus,11537,CHEMBL622224,50594,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,A,1,N,1,,BAO_0000218
12021,,,,Autocuration,,13118,CHEMBL622225,22224,,,,Plasma concentration (AUC) was determined,,A,1,U,0,,BAO_0000019
12022,,,,Autocuration,,13118,CHEMBL622226,22224,,,,Plasma concentration (AUC) was determined; Not detectable,,A,1,U,0,,BAO_0000019
12023,,,10141.0,Intermediate,Cavia porcellus,9562,CHEMBL624154,50512,,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,A,1,N,1,,BAO_0000218
12024,,,10116.0,Intermediate,Rattus norvegicus,10363,CHEMBL624155,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,A,1,N,1,,BAO_0000218
12025,,,10116.0,Intermediate,Rattus norvegicus,10363,CHEMBL624156,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,A,1,N,1,,BAO_0000218
12026,,,10116.0,Intermediate,Rattus norvegicus,10363,CHEMBL624157,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,A,1,N,1,,BAO_0000218
12027,,,10116.0,Intermediate,Rattus norvegicus,10363,CHEMBL624158,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,A,1,N,1,,BAO_0000218
12028,,,10116.0,Intermediate,Rattus norvegicus,12504,CHEMBL624159,50597,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,A,1,N,1,,BAO_0000218
12029,,,10116.0,Intermediate,Rattus norvegicus,12504,CHEMBL624160,50597,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,A,1,N,1,,BAO_0000218
12030,,,10116.0,Intermediate,Rattus norvegicus,12504,CHEMBL624161,50597,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,A,1,N,1,,BAO_0000218
12031,,,10116.0,Intermediate,Rattus norvegicus,12504,CHEMBL624162,50597,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,A,1,N,1,,BAO_0000218
12032,,,9615.0,Intermediate,Canis lupus familiaris,13317,CHEMBL624163,50588,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,A,1,N,1,,BAO_0000218
12033,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL624164,50597,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
12034,,,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL624165,50597,,,,The AUC(0-infinity) values in female wistar rats.,,A,1,N,1,,BAO_0000218
12035,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL624166,50597,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
12036,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL624167,50597,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,A,1,N,1,,BAO_0000218
12037,,,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL624168,50597,,,,The AUC(0-t)values in female wistar rats.,,A,1,N,1,,BAO_0000218
12038,,,10116.0,Intermediate,Rattus norvegicus,14067,CHEMBL624169,50597,,,,The Area under the concentration time curve of compound was measured on rats,,A,1,N,1,,BAO_0000218
12039,,,9606.0,Intermediate,Homo sapiens,14215,CHEMBL624170,50587,,,,The area under curve (100 mg/kg) administered orally in humans,,A,1,N,1,,BAO_0000218
12040,,,9481.0,Autocuration,Callithrix,14215,CHEMBL624171,22224,,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,A,1,U,0,,BAO_0000218
12041,,,314293.0,Autocuration,Simiiformes,14215,CHEMBL624172,22224,,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,,A,1,U,0,,BAO_0000218
12042,,,9615.0,Intermediate,Canis lupus familiaris,14215,CHEMBL624173,50588,,,,The area under curve (15 mg/kg) administered intravenously in dog,,A,1,N,1,,BAO_0000218
12043,,,9606.0,Intermediate,Homo sapiens,14215,CHEMBL877488,50587,,,,The area under curve (200 mg/kg) administered orally in humans,,A,1,N,1,,BAO_0000218
12044,,,10116.0,Intermediate,Rattus norvegicus,14215,CHEMBL624174,50597,,,,The area under curve (25 mg/kg) administered intravenously in rat,,A,1,N,1,,BAO_0000218
12045,,,9481.0,Autocuration,Callithrix,14215,CHEMBL624175,22224,,,,The area under curve (25 mg/kg) administered orally in marmoset,,A,1,U,0,,BAO_0000218
12046,,,314293.0,Autocuration,Simiiformes,14215,CHEMBL624176,22224,,,,The area under curve (25 mg/kg) administered orally in monkey,,A,1,U,0,,BAO_0000218
12047,,,9615.0,Intermediate,Canis lupus familiaris,14215,CHEMBL624177,50588,,,,The area under curve (30 mg/kg) administered orally in dog,,A,1,N,1,,BAO_0000218
12048,,,9606.0,Intermediate,Homo sapiens,14215,CHEMBL624178,50587,,,,The area under curve (400 mg/kg) administered orally in humans,,A,1,N,1,,BAO_0000218
12049,,,10116.0,Intermediate,Rattus norvegicus,14215,CHEMBL624179,50597,,,,The area under curve (50 mg/kg) administered orally in fasted rat,,A,1,N,1,,BAO_0000218
12050,,,10116.0,Intermediate,Rattus norvegicus,14215,CHEMBL627689,50597,,,,The area under curve (50 mg/kg) administered orally in rat,,A,1,N,1,,BAO_0000218
12051,,,9606.0,Intermediate,Homo sapiens,14215,CHEMBL627690,50587,,,,The area under curve (800 mg/kg) administered orally in humans,,A,1,N,1,,BAO_0000218
12052,,,,Autocuration,,11324,CHEMBL627691,22224,,,,The compound was evaluated for area under the curve,,A,1,U,0,,BAO_0000019
12053,,,9481.0,Autocuration,Callithrix,11324,CHEMBL627692,22224,,,,The compound was evaluated for area under the curve in marmosets,,A,1,U,0,,BAO_0000019
12054,,,9481.0,Autocuration,Callithrix,11324,CHEMBL627693,22224,,,,The compound was evaluated for area under the curve in marmosets,,A,1,U,0,,BAO_0000019
12055,,,10116.0,Intermediate,Rattus norvegicus,13875,CHEMBL627694,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,A,1,N,1,,BAO_0000218
12056,,,10116.0,Intermediate,Rattus norvegicus,13875,CHEMBL627695,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,A,1,N,1,,BAO_0000218
12057,,,,Autocuration,,13875,CHEMBL627696,22224,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,A,1,U,0,,BAO_0000218
12058,,,10116.0,Intermediate,Rattus norvegicus,13875,CHEMBL627697,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,A,1,N,1,,BAO_0000218
12059,,,10116.0,Intermediate,Rattus norvegicus,13875,CHEMBL627698,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,A,1,N,1,,BAO_0000218
12060,,,10116.0,Intermediate,Rattus norvegicus,13875,CHEMBL627699,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,A,1,N,1,,BAO_0000218
12061,,,10116.0,Intermediate,Rattus norvegicus,13807,CHEMBL627700,50597,,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,A,1,N,1,,BAO_0000218
12062,,,10116.0,Intermediate,Rattus norvegicus,14127,CHEMBL627701,50597,,,,Total drug exposure is determined after oral dosing in rats.,,A,1,N,1,,BAO_0000218
12063,,,,Autocuration,,15116,CHEMBL627702,22224,,,,Total drug exposure (5 mg/kg) when administered intravenously,,A,1,U,0,,BAO_0000218
12064,,,,Autocuration,,15116,CHEMBL627703,22224,,,,Total drug exposure (5 mg/kg) when administered orally,,A,1,U,0,,BAO_0000218
12065,,,314293.0,Autocuration,Simiiformes,15604,CHEMBL626873,22224,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,A,1,U,0,,BAO_0000218
12066,,,10116.0,Intermediate,Rattus norvegicus,15604,CHEMBL629583,50597,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,A,1,N,1,,BAO_0000218
12067,,,9615.0,Intermediate,Canis lupus familiaris,15604,CHEMBL629584,50588,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,A,1,N,1,,BAO_0000218
12068,,,9615.0,Intermediate,Canis lupus familiaris,15604,CHEMBL629585,50588,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,A,1,N,1,,BAO_0000218
12069,,955.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629586,50597,,,Brain,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12070,,955.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629587,50597,,,Brain,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12071,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629588,50597,,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12072,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629589,50597,,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12073,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629590,50597,,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12074,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629591,50597,,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12075,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629592,50597,,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12076,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629593,50597,,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12077,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629594,50597,,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12078,,948.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL629595,50597,,,Heart,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12079,,948.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL630290,50597,,,Heart,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12080,,948.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627137,50597,,,Heart,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12081,,948.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627138,50597,,,Heart,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12082,,948.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627139,50597,,,Heart,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12083,,948.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627140,50597,,,Heart,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12084,,948.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627141,50597,,,Heart,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12085,,2113.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627142,50597,,,Kidney,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12086,,2113.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627143,50597,,,Kidney,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12087,,2113.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL874449,50597,,,Kidney,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12088,,2113.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627144,50597,,,Kidney,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12089,,2113.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627145,50597,,,Kidney,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12090,,2113.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627146,50597,,,Kidney,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12091,,2113.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627147,50597,,,Kidney,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12092,,2107.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627148,50597,,,Liver,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12093,,2048.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627149,50597,,,Lung,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12094,,2048.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL632160,50597,,,Lung,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12095,,2048.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL632161,50597,,,Lung,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12096,,2048.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL632162,50597,,,Lung,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12097,,2048.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL632163,50597,,,Lung,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12098,,2048.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL874469,50597,,,Lung,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12099,,2048.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627182,50597,,,Lung,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12100,,2385.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627183,50597,,,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12101,,2385.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627184,50597,,,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12102,,2385.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627185,50597,,,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12103,,2385.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627186,50597,,,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12104,,2385.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627187,50597,,,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12105,,2385.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627188,50597,,,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12106,,2385.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627189,50597,,,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12107,,,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627190,50597,,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12108,,2107.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627191,50597,,,Liver,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12109,,2107.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627192,50597,,,Liver,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12110,,2107.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL627193,50597,,,Liver,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12111,,2385.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL874590,50597,,,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12112,,2385.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627194,50597,,,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12113,,2385.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627195,50597,,,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12114,,992.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627196,50597,,,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12115,,992.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627197,50597,,,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12116,,992.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627198,50597,,,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12117,,992.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627199,50597,,,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,A,1,N,1,,BAO_0000218
12118,,992.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627200,50597,,,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12119,,1969.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627201,50597,,,Plasma,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12120,,1969.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627202,50597,,,Plasma,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12121,,1969.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627203,50597,,,Plasma,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12122,,1969.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627204,50597,,,Plasma,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12123,,2106.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627205,50597,,,Spleen,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12124,,2106.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627206,50597,,,Spleen,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12125,,2106.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627207,50597,,,Spleen,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12126,,2106.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627208,50597,,,Spleen,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12127,,2046.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627209,50597,,,Thyroid gland,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12128,,2046.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627210,50597,,,Thyroid gland,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12129,,2046.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627211,50597,,,Thyroid gland,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12130,,2046.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627212,50597,,,Thyroid gland,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12131,,995.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL627213,50597,,,Uterus,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12132,,995.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL626599,50597,,,Uterus,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12133,,995.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL626600,50597,,,Uterus,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12134,,995.0,10116.0,Intermediate,Rattus norvegicus,10911,CHEMBL626601,50597,,,Uterus,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,A,1,N,1,,BAO_0000218
12135,,,,Autocuration,,8081,CHEMBL627484,22224,,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,A,1,U,0,,BAO_0000019
12136,,1969.0,9541.0,Intermediate,Macaca fascicularis,17248,CHEMBL627485,100710,,,Plasma,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,A,1,N,1,,BAO_0000218
12137,,1969.0,9541.0,Intermediate,Macaca fascicularis,17248,CHEMBL628147,100710,,,Plasma,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,A,1,N,1,,BAO_0000218
12138,,1969.0,9541.0,Intermediate,Macaca fascicularis,17248,CHEMBL628148,100710,,,Plasma,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,A,1,N,1,,BAO_0000218
12139,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17248,CHEMBL628149,50588,,,Plasma,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,A,1,N,1,,BAO_0000218
12140,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17248,CHEMBL628150,50588,,,Plasma,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,A,1,N,1,,BAO_0000218
12141,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17248,CHEMBL628318,50588,,,Plasma,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,A,1,N,1,,BAO_0000218
12142,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17248,CHEMBL628319,50588,,,Plasma,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,A,1,N,1,,BAO_0000218
12143,,,9615.0,Intermediate,Canis lupus familiaris,15592,CHEMBL875609,50588,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,A,1,N,1,,BAO_0000218
12144,,,,Autocuration,,7040,CHEMBL628320,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,A,1,U,0,,BAO_0000019
12145,,,,Autocuration,,7040,CHEMBL628321,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,A,1,U,0,,BAO_0000019
12146,,,,Autocuration,,7040,CHEMBL628322,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,A,1,U,0,,BAO_0000019
12147,,,,Autocuration,,7040,CHEMBL628323,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,A,1,U,0,,BAO_0000019
12148,,,,Autocuration,,7040,CHEMBL628324,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,A,1,U,0,,BAO_0000019
12149,,,,Autocuration,,7040,CHEMBL628325,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,A,1,U,0,,BAO_0000019
12150,,,,Autocuration,,7040,CHEMBL628326,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,A,1,U,0,,BAO_0000019
12151,,1236.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL628327,50588,,,Adrenal medulla,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,A,1,N,1,,BAO_0000218
12152,,1236.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL628328,50588,,,Adrenal medulla,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,A,1,N,1,,BAO_0000218
12153,,178.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL628329,50588,,,Blood,"Concentration of compound in blood of dog 1, after administering intravenously",,A,1,N,1,,BAO_0000218
12154,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628330,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,A,1,N,1,,BAO_0000218
12155,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628331,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,A,1,N,1,,BAO_0000218
12156,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628332,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,A,1,N,1,,BAO_0000218
12157,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628333,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,A,1,N,1,,BAO_0000218
12158,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628334,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,A,1,N,1,,BAO_0000218
12159,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628335,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,A,1,N,1,,BAO_0000218
12160,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628336,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,A,1,N,1,,BAO_0000218
12161,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628337,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,A,1,N,1,,BAO_0000218
12162,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628338,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,A,1,N,1,,BAO_0000218
12163,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL875610,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,A,1,N,1,,BAO_0000218
12164,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628339,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,A,1,N,1,,BAO_0000218
12165,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628340,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,A,1,N,1,,BAO_0000218
12166,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL628341,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,A,1,N,1,,BAO_0000218
12167,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL622214,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,A,1,N,1,,BAO_0000218
12168,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623167,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,A,1,N,1,,BAO_0000218
12169,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623168,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,A,1,N,1,,BAO_0000218
12170,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623169,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,A,1,N,1,,BAO_0000218
12171,,2107.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL623170,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,A,1,N,1,,BAO_0000218
12172,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627224,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,A,1,N,1,,BAO_0000218
12173,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL875634,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,A,1,N,1,,BAO_0000218
12174,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627225,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,A,1,N,1,,BAO_0000218
12175,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627226,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,A,1,N,1,,BAO_0000218
12176,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626083,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,A,1,N,1,,BAO_0000218
12177,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626084,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,A,1,N,1,,BAO_0000218
12178,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626085,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,A,1,N,1,,BAO_0000218
12179,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626086,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,A,1,N,1,,BAO_0000218
12180,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626087,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,A,1,N,1,,BAO_0000218
12181,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626088,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,A,1,N,1,,BAO_0000218
12182,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626089,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,A,1,N,1,,BAO_0000218
12183,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626090,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,A,1,N,1,,BAO_0000218
12184,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626091,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,A,1,N,1,,BAO_0000218
12185,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626092,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,A,1,N,1,,BAO_0000218
12186,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626093,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,A,1,N,1,,BAO_0000218
12187,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626094,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,A,1,N,1,,BAO_0000218
12188,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626095,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,A,1,N,1,,BAO_0000218
12189,,2048.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626096,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,A,1,N,1,,BAO_0000218
12190,,,314293.0,Autocuration,Simiiformes,15604,CHEMBL626097,22224,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,A,1,U,0,,BAO_0000218
12191,,,10116.0,Intermediate,Rattus norvegicus,15604,CHEMBL626098,50597,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,A,1,N,1,,BAO_0000218
12192,,1969.0,,Autocuration,,1806,CHEMBL626099,22224,,,Plasma,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,A,1,U,0,,BAO_0000218
12193,,1969.0,,Autocuration,,1806,CHEMBL626100,22224,,,Plasma,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,A,1,U,0,,BAO_0000218
12194,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17237,CHEMBL626101,50588,,,Plasma,AUC 0-inf in dog,,A,1,N,1,,BAO_0000218
12195,,1969.0,10141.0,Intermediate,Cavia porcellus,17237,CHEMBL626102,50512,,,Plasma,AUC 0-inf in guinea pig,,A,1,N,1,,BAO_0000218
12196,,1969.0,9615.0,Intermediate,Canis lupus familiaris,17237,CHEMBL626103,50588,,,Plasma,AUC 0-t in dog,,A,1,N,1,,BAO_0000218
12197,,1969.0,10141.0,Intermediate,Cavia porcellus,17237,CHEMBL628391,50512,,,Plasma,AUC 0-t in guinea pig,,A,1,N,1,,BAO_0000218
12198,,,10116.0,Intermediate,Rattus norvegicus,15194,CHEMBL628392,50597,,,,The compound was tested for brain to plasma partition in rat,,A,1,N,1,,BAO_0000218
12199,,,10116.0,Intermediate,Rattus norvegicus,15194,CHEMBL628393,50597,,,,The compound was tested for brain to plasma partition in rat.,,A,1,N,1,,BAO_0000218
12200,,178.0,,Autocuration,,8787,CHEMBL628394,22224,,,Blood,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,A,1,U,0,,BAO_0000019
12201,,,9615.0,Intermediate,Canis lupus familiaris,17025,CHEMBL628395,50588,,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12202,,,314293.0,Autocuration,Simiiformes,17025,CHEMBL628396,22224,,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,A,1,U,0,,BAO_0000218
12203,,,9986.0,Intermediate,Oryctolagus cuniculus,17025,CHEMBL628397,50592,,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12204,,,10116.0,Intermediate,Rattus norvegicus,17025,CHEMBL628398,50597,,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12205,,,9544.0,Intermediate,Macaca mulatta,4236,CHEMBL628399,50797,,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,A,1,N,1,,BAO_0000218
12206,,,9615.0,Intermediate,Canis lupus familiaris,15343,CHEMBL628400,50588,,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,A,1,N,1,,BAO_0000218
12207,,,10116.0,Intermediate,Rattus norvegicus,15343,CHEMBL874907,50597,,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,A,1,N,1,,BAO_0000218
12208,,,,Autocuration,,17720,CHEMBL628401,22224,,,,Area under curve of the compound was determined,,A,1,U,0,,BAO_0000019
12209,,1969.0,314293.0,Autocuration,Simiiformes,17788,CHEMBL628402,22224,,,Plasma,AUC in monkeys at a dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
12210,,1969.0,10116.0,Intermediate,Rattus norvegicus,17788,CHEMBL628403,50597,,,Plasma,AUC in rats at a dose of 1 mg/kg,,A,1,N,1,,BAO_0000218
12211,,,,Autocuration,,8778,CHEMBL628404,22224,,,,Compound was evaluated for the overall absorbance loss at pH of 2,,A,1,U,0,,BAO_0000019
12212,,,,Autocuration,,8778,CHEMBL628405,22224,,,,Compound was evaluated for the overall absorbance loss at pH of 4,,A,1,U,0,,BAO_0000019
12213,,,,Autocuration,,8778,CHEMBL628406,22224,,,,Compound was evaluated for the overall absorbance loss at pH of 7,,A,1,U,0,,BAO_0000019
12214,,,10116.0,Intermediate,Rattus norvegicus,2249,CHEMBL628407,50597,,,,Compound was evaluated for its absorption in the rats,,A,1,N,1,,BAO_0000218
12215,,1088.0,10116.0,Intermediate,Rattus norvegicus,8881,CHEMBL628408,50597,,,Urine,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,A,1,N,1,,BAO_0000218
12216,,1088.0,10116.0,Intermediate,Rattus norvegicus,8881,CHEMBL629171,50597,,,Urine,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,A,1,N,1,,BAO_0000218
12217,,1088.0,10116.0,Intermediate,Rattus norvegicus,8881,CHEMBL629172,50597,,,Urine,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,A,1,N,1,,BAO_0000218
12218,,1088.0,10116.0,Intermediate,Rattus norvegicus,8881,CHEMBL629173,50597,,,Urine,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,A,1,N,1,,BAO_0000218
12219,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL629174,50597,,,,In vitro percent permeability into rat ileum,,A,1,N,1,,BAO_0000218
12220,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL629175,50597,,,,In vitro percent permeability into rat ileum; Range is 10-17,,A,1,N,1,,BAO_0000218
12221,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL629176,50597,,,,In vitro percent permeability into rat ileum; Range is 10-18,,A,1,N,1,,BAO_0000218
12222,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL629177,50597,,,,In vitro percent permeability into rat ileum; Range is 10-19,,A,1,N,1,,BAO_0000218
12223,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL629178,50597,,,,In vitro percent permeability into rat ileum; Range is 12-15,,A,1,N,1,,BAO_0000218
12224,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631869,50597,,,,In vitro percent permeability into rat ileum; Range is 13-19,,A,1,N,1,,BAO_0000218
12225,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631870,50597,,,,In vitro percent permeability into rat ileum; Range is 14-17,,A,1,N,1,,BAO_0000218
12226,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631871,50597,,,,In vitro percent permeability into rat ileum; Range is 15-18,,A,1,N,1,,BAO_0000218
12227,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631872,50597,,,,In vitro percent permeability into rat ileum; Range is 2-5,,A,1,N,1,,BAO_0000218
12228,,2116.0,,Autocuration,,15286,CHEMBL875775,22224,,,Ileum,In vitro percent permeability into rat ileum; Range is 23-42,,A,1,U,0,,BAO_0000221
12229,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631873,50597,,,,In vitro percent permeability into rat ileum; Range is 28-36,,A,1,N,1,,BAO_0000218
12230,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631874,50597,,,,In vitro percent permeability into rat ileum; Range is 29-35,,A,1,N,1,,BAO_0000218
12231,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631875,50597,,,,In vitro percent permeability into rat ileum; Range is 46-66,,A,1,N,1,,BAO_0000218
12232,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631876,50597,,,,In vitro percent permeability into rat ileum; Range is 50-68,,A,1,N,1,,BAO_0000218
12233,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631877,50597,,,,In vitro percent permeability into rat ileum; Range is 78-81,,A,1,N,1,,BAO_0000218
12234,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631878,50597,,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,A,1,N,1,,BAO_0000218
12235,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631879,50597,,,,In vitro percent permeability into rat ileum; nd indicates not detected,,A,1,N,1,,BAO_0000218
12236,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631880,50597,,,,In vitro percent permeability into rat ileum; nt indicates not detected,,A,1,N,1,,BAO_0000218
12237,,,10116.0,Intermediate,Rattus norvegicus,15286,CHEMBL631881,50597,,,,In vitro percent permeability into rat ileum; nt indicates not tested,,A,1,N,1,,BAO_0000218
12238,,,10116.0,Intermediate,Rattus norvegicus,13770,CHEMBL631882,50597,,,,Compound was tested for oral absorption in bile-duct cannulated rats,,A,1,N,1,,BAO_0000218
12239,,,10116.0,Intermediate,Rattus norvegicus,13770,CHEMBL630749,50597,,,,Compound was tested for oral absorption in bile-duct cannulated rats.,,A,1,N,1,,BAO_0000218
12240,,,9606.0,Intermediate,Homo sapiens,5202,CHEMBL630750,50587,,,,Oral absorption using Caco-2 cell monolayers.,,A,1,N,1,,BAO_0000218
12241,,,9606.0,Intermediate,Homo sapiens,14920,CHEMBL630253,50587,,,,Percent of the drug absorbed after administration to humans was determined,,A,1,N,1,,BAO_0000218
12242,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL630254,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,A,1,N,1,,BAO_0000218
12243,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL630255,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,A,1,N,1,,BAO_0000218
12244,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL630256,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,A,1,N,1,,BAO_0000218
12245,,2107.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL875781,50597,,,Liver,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12246,,2107.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL630257,50597,,,Liver,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12247,,2107.0,10116.0,Intermediate,Rattus norvegicus,13751,CHEMBL630258,50597,,,Liver,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,A,1,N,1,,BAO_0000218
12248,,,10116.0,Intermediate,Rattus norvegicus,15807,CHEMBL630259,50597,,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,A,1,N,1,,BAO_0000218
12249,,2435.0,10116.0,Intermediate,Rattus norvegicus,15807,CHEMBL630260,50597,,,Striatum,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,A,1,N,1,,BAO_0000218
12250,,2435.0,10116.0,Intermediate,Rattus norvegicus,15807,CHEMBL630261,50597,,,Striatum,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,A,1,N,1,,BAO_0000218
12251,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630262,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,A,1,N,1,,BAO_0000218
12252,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630263,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,A,1,N,1,,BAO_0000218
12253,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630264,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,A,1,N,1,,BAO_0000218
12254,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630265,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,A,1,N,1,,BAO_0000218
12255,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630266,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,A,1,N,1,,BAO_0000218
12256,,2113.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630267,50597,,,Kidney,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,A,1,N,1,,BAO_0000218
12257,,2113.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630268,50597,,,Kidney,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,A,1,N,1,,BAO_0000218
12258,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630269,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,A,1,N,1,,BAO_0000218
12259,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630270,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,A,1,N,1,,BAO_0000218
12260,,2048.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630141,50597,,,Lung,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,A,1,N,1,,BAO_0000218
12261,,2048.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630142,50597,,,Lung,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,A,1,N,1,,BAO_0000218
12262,,2385.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630143,50597,,,Muscle tissue,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,A,1,N,1,,BAO_0000218
12263,,2385.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630144,50597,,,Muscle tissue,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,A,1,N,1,,BAO_0000218
12264,,2367.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630145,50597,,,Prostate gland,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,A,1,N,1,,BAO_0000218
12265,,2367.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630146,50597,,,Prostate gland,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,A,1,N,1,,BAO_0000218
12266,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630147,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,A,1,N,1,,BAO_0000218
12267,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630148,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,A,1,N,1,,BAO_0000218
12268,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630149,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,A,1,N,1,,BAO_0000218
12269,,2106.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630150,50597,,,Spleen,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,A,1,N,1,,BAO_0000218
12270,,2106.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL630151,50597,,,Spleen,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,A,1,N,1,,BAO_0000218
12271,,2046.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL632031,50597,,,Thyroid gland,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,A,1,N,1,,BAO_0000218
12272,,2046.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL632032,50597,,,Thyroid gland,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,A,1,N,1,,BAO_0000218
12273,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL632033,50597,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,A,1,N,1,,BAO_0000218
12274,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL632034,50597,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,A,1,N,1,,BAO_0000218
12275,,2385.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL632035,50597,,,Muscle tissue,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,A,1,N,1,,BAO_0000218
12276,,,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL632036,50597,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,A,1,N,1,,BAO_0000218
12277,,2046.0,10116.0,Intermediate,Rattus norvegicus,14950,CHEMBL632037,50597,,,Thyroid gland,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,A,1,N,1,,BAO_0000218
12278,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL632038,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,A,1,N,1,,BAO_0000218
12279,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL632039,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,A,1,N,1,,BAO_0000218
12280,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL632040,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,A,1,N,1,,BAO_0000218
12281,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL632041,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,A,1,N,1,,BAO_0000218
12282,,178.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632042,50588,,,Blood,"Concentration of compound in blood of dog 2, after administering intravenously",,A,1,N,1,,BAO_0000218
12283,,,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632043,50588,,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,A,1,N,1,,BAO_0000218
12284,,,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632044,50588,,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,A,1,N,1,,BAO_0000218
12285,,2107.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632045,50588,,,Liver,"Concentration of compound in liver of dog 1, after administering intravenously",,A,1,N,1,,BAO_0000218
12286,,2107.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632046,50588,,,Liver,"Concentration of compound in liver of dog 2, after administering intravenously",,A,1,N,1,,BAO_0000218
12287,,2048.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632047,50588,,,Lung,"Concentration of compound in lung of dog 1, after administering intravenously",,A,1,N,1,,BAO_0000218
12288,,2048.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632048,50588,,,Lung,"Concentration of compound in lung of dog 2, after administering intravenously",,A,1,N,1,,BAO_0000218
12289,,2385.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632049,50588,,,Muscle tissue,"Concentration of compound in muscle of dog 1, after administering intravenously",,A,1,N,1,,BAO_0000218
12290,,2385.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL876418,50588,,,Muscle tissue,"Concentration of compound in muscle of dog 2, after administering intravenously",,A,1,N,1,,BAO_0000218
12291,,2106.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632050,50588,,,Spleen,"Concentration of compound in spleen of dog 1,after administering intravenously",,A,1,N,1,,BAO_0000218
12292,,2106.0,9615.0,Intermediate,Canis lupus familiaris,9614,CHEMBL632051,50588,,,Spleen,"Concentration of compound in spleen of dog 2, after administering intravenously",,A,1,N,1,,BAO_0000218
12293,,,,Autocuration,,10353,CHEMBL632052,22224,,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,F,1,U,0,,BAO_0000218
12294,,,,Autocuration,,10353,CHEMBL632053,22224,,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,F,1,U,0,,BAO_0000218
12295,,,,Autocuration,,10353,CHEMBL632054,22224,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,A,1,U,0,,BAO_0000218
12296,,,,Autocuration,,10353,CHEMBL632055,22224,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,F,1,U,0,,BAO_0000218
12297,,,,Autocuration,,10353,CHEMBL631181,22224,,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,F,1,U,0,,BAO_0000218
12298,,,,Autocuration,,9196,CHEMBL631182,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,A,1,U,0,,BAO_0000218
12299,,,,Autocuration,,9196,CHEMBL631183,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,A,1,U,0,,BAO_0000218
12300,,,,Autocuration,,9196,CHEMBL631184,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,A,1,U,0,,BAO_0000218
12301,,,,Autocuration,,9196,CHEMBL629774,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,A,1,U,0,,BAO_0000218
12302,,,,Autocuration,,9196,CHEMBL629775,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,A,1,U,0,,BAO_0000218
12303,,,,Autocuration,,9196,CHEMBL876549,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,A,1,U,0,,BAO_0000218
12304,,,,Autocuration,,9196,CHEMBL628172,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,A,1,U,0,,BAO_0000218
12305,,,,Autocuration,,9196,CHEMBL628173,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,A,1,U,0,,BAO_0000218
12306,,,,Autocuration,,9196,CHEMBL628174,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,A,1,U,0,,BAO_0000218
12307,,,,Autocuration,,9196,CHEMBL628175,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,A,1,U,0,,BAO_0000218
12308,,,,Autocuration,,9196,CHEMBL628176,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,A,1,U,0,,BAO_0000218
12309,,,,Autocuration,,9196,CHEMBL628177,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,A,1,U,0,,BAO_0000218
12310,,,,Autocuration,,9196,CHEMBL628178,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,A,1,U,0,,BAO_0000218
12311,,,,Autocuration,,9196,CHEMBL628179,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,A,1,U,0,,BAO_0000218
12312,,,,Autocuration,,9196,CHEMBL628180,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,A,1,U,0,,BAO_0000218
12313,,,,Autocuration,,9196,CHEMBL628181,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,A,1,U,0,,BAO_0000218
12314,,,,Autocuration,,9196,CHEMBL628182,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,A,1,U,0,,BAO_0000218
12315,,,,Autocuration,,9196,CHEMBL628183,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,A,1,U,0,,BAO_0000218
12316,,,,Autocuration,,9196,CHEMBL628184,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,A,1,U,0,,BAO_0000218
12317,,,,Autocuration,,9196,CHEMBL628185,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,A,1,U,0,,BAO_0000218
12318,,,,Autocuration,,9196,CHEMBL875617,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,A,1,U,0,,BAO_0000218
12319,,,,Autocuration,,9196,CHEMBL628186,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,A,1,U,0,,BAO_0000218
12320,,,,Autocuration,,9196,CHEMBL628187,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,A,1,U,0,,BAO_0000218
12321,,,,Autocuration,,9196,CHEMBL628188,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,A,1,U,0,,BAO_0000218
12322,,,,Autocuration,,9196,CHEMBL628189,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,A,1,U,0,,BAO_0000218
12323,,,,Autocuration,,9196,CHEMBL628190,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,A,1,U,0,,BAO_0000218
12324,,,,Autocuration,,9196,CHEMBL628191,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,A,1,U,0,,BAO_0000218
12325,,,,Autocuration,,9196,CHEMBL626513,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,A,1,U,0,,BAO_0000218
12326,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626514,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,A,1,N,1,,BAO_0000218
12327,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626515,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,A,1,N,1,,BAO_0000218
12328,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626516,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,A,1,N,1,,BAO_0000218
12329,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626517,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,A,1,N,1,,BAO_0000218
12330,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626518,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,A,1,N,1,,BAO_0000218
12331,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626519,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,A,1,N,1,,BAO_0000218
12332,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626520,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,A,1,N,1,,BAO_0000218
12333,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626521,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,A,1,N,1,,BAO_0000218
12334,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626522,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,A,1,N,1,,BAO_0000218
12335,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626523,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,A,1,N,1,,BAO_0000218
12336,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626524,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,A,1,N,1,,BAO_0000218
12337,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626688,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,A,1,N,1,,BAO_0000218
12338,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626689,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,A,1,N,1,,BAO_0000218
12339,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626690,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,A,1,N,1,,BAO_0000218
12340,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL626691,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,A,1,N,1,,BAO_0000218
12341,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL627319,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,A,1,N,1,,BAO_0000218
12342,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL624052,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,A,1,N,1,,BAO_0000218
12343,,2046.0,10116.0,Intermediate,Rattus norvegicus,8608,CHEMBL624053,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,A,1,N,1,,BAO_0000218
12344,,,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL624054,50597,,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12345,,,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL624055,50597,,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12346,,,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL624056,50597,,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12347,,995.0,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL624057,50597,,,Uterus,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12348,,995.0,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL622281,50597,,,Uterus,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12349,,995.0,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL622282,50597,,,Uterus,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12350,,995.0,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL622283,50597,,,Uterus,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12351,,995.0,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL622284,50597,,,Uterus,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12352,,995.0,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL622285,50597,,,Uterus,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12353,,995.0,10116.0,Intermediate,Rattus norvegicus,8085,CHEMBL622286,50597,,,Uterus,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,A,1,N,1,,BAO_0000218
12354,,,,Autocuration,,7657,CHEMBL622287,22224,,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,P,1,U,0,,BAO_0000100
12355,,,10090.0,Intermediate,Mus musculus,8935,CHEMBL622288,50594,,,,Partition coefficient (logD7.4),,A,1,N,1,,BAO_0000218
12356,,,10090.0,Intermediate,Mus musculus,13792,CHEMBL622289,50594,,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,A,1,N,1,,BAO_0000218
12357,,955.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL622290,50594,,,Brain,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,A,1,N,1,,BAO_0000218
12358,,,10090.0,Intermediate,Mus musculus,13792,CHEMBL622291,50594,,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,A,1,N,1,,BAO_0000218
12359,,955.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL622292,50594,,,Brain,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,A,1,N,1,,BAO_0000218
12360,,,10090.0,Intermediate,Mus musculus,13792,CHEMBL622293,50594,,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,A,1,N,1,,BAO_0000218
12361,,955.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL622294,50594,,,Brain,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,A,1,N,1,,BAO_0000218
12362,,,10090.0,Intermediate,Mus musculus,13792,CHEMBL622295,50594,,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,A,1,N,1,,BAO_0000218
12363,,955.0,10116.0,Intermediate,Rattus norvegicus,13792,CHEMBL622296,50597,,,Brain,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,A,1,N,1,,BAO_0000218
12364,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL874409,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,A,1,N,1,,BAO_0000218
12365,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622297,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,A,1,N,1,,BAO_0000218
12366,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622298,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,A,1,N,1,,BAO_0000218
12367,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622299,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,A,1,N,1,,BAO_0000218
12368,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622300,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,A,1,N,1,,BAO_0000218
12369,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622301,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,A,1,N,1,,BAO_0000218
12370,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622302,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,A,1,N,1,,BAO_0000218
12371,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622303,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,A,1,N,1,,BAO_0000218
12372,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622304,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,A,1,N,1,,BAO_0000218
12373,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622305,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,A,1,N,1,,BAO_0000218
12374,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL622306,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,A,1,N,1,,BAO_0000218
12375,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626864,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,A,1,N,1,,BAO_0000218
12376,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626865,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,A,1,N,1,,BAO_0000218
12377,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626866,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,A,1,N,1,,BAO_0000218
12378,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626867,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,A,1,N,1,,BAO_0000218
12379,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626868,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,A,1,N,1,,BAO_0000218
12380,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626869,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,A,1,N,1,,BAO_0000218
12381,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626870,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,A,1,N,1,,BAO_0000218
12382,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626871,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,A,1,N,1,,BAO_0000218
12383,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL626872,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,A,1,N,1,,BAO_0000218
12384,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL632185,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,A,1,N,1,,BAO_0000218
12385,,1969.0,10116.0,Intermediate,Rattus norvegicus,14103,CHEMBL632186,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,A,1,N,1,,BAO_0000218
12386,,,,Autocuration,,12904,CHEMBL629310,22224,,,,Amount of acetic acid produced by the compound,,A,1,U,0,,BAO_0000019
12387,,,,Autocuration,,12904,CHEMBL629311,22224,,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,A,1,U,0,,BAO_0000019
12388,,,10116.0,Intermediate,Rattus norvegicus,9663,CHEMBL629312,50597,,,,Log of (Cbrain/Cblood) in rats,,A,1,N,1,,BAO_0000218
12389,,,,Autocuration,,7652,CHEMBL629313,22224,,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000221
12390,,,,Autocuration,,7652,CHEMBL629314,22224,,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000221
12391,,,,Autocuration,,7652,CHEMBL629315,22224,,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000221
12392,,,,Autocuration,,7652,CHEMBL629316,22224,,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,B,1,U,0,,BAO_0000219
12393,,,,Autocuration,,7652,CHEMBL629317,22224,,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000221
12394,,,,Autocuration,,7652,CHEMBL629318,22224,,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12395,,,,Autocuration,,7652,CHEMBL877497,22224,,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12396,,,,Autocuration,,7652,CHEMBL629319,22224,,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12397,,,,Autocuration,,7652,CHEMBL629320,22224,,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12398,,,,Autocuration,,7652,CHEMBL629496,22224,,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12399,,,,Autocuration,,7652,CHEMBL629497,22224,,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12400,,,,Autocuration,,7652,CHEMBL629498,22224,,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12401,,,,Autocuration,,7652,CHEMBL629499,22224,,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12402,,,,Autocuration,,7652,CHEMBL629500,22224,,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12403,,,,Autocuration,,7652,CHEMBL629501,22224,,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12404,,,,Autocuration,,7652,CHEMBL629502,22224,,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,A,1,U,0,,BAO_0000019
12405,,,,Autocuration,,8267,CHEMBL629503,22224,,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,F,1,U,0,,BAO_0000218
12406,,,9615.0,Intermediate,Canis lupus familiaris,8267,CHEMBL629504,50588,,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,A,1,N,1,,BAO_0000218
12407,,,,Autocuration,,14479,CHEMBL629505,22224,,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,A,1,U,0,,BAO_0000019
12408,,,,Autocuration,,17515,CHEMBL629506,22224,,,,Compound was evaluated for total body clearance,,A,1,U,0,,BAO_0000019
12409,,,,Autocuration,,17515,CHEMBL629507,22224,,,,Compound was evaluated for volume of distribution at steady state,,A,1,U,0,,BAO_0000019
12410,,,,Autocuration,,8142,CHEMBL877498,22224,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,A,1,U,0,,BAO_0000019
12411,,,,Autocuration,,14849,CHEMBL629508,22224,,,,Percentage of the diamine which is monoprotonated at pH 7.4,,A,1,U,0,,BAO_0000019
12412,,,,Autocuration,,7653,CHEMBL629509,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,A,1,U,0,,BAO_0000019
12413,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL629510,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,A,1,N,1,,BAO_0000218
12414,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL629511,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,A,1,N,1,,BAO_0000218
12415,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL629512,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,A,1,N,1,,BAO_0000218
12416,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL629513,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,A,1,N,1,,BAO_0000218
12417,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL629514,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,A,1,N,1,,BAO_0000218
12418,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL628447,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,A,1,N,1,,BAO_0000218
12419,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL628448,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,A,1,N,1,,BAO_0000218
12420,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL628449,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,A,1,N,1,,BAO_0000218
12421,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631119,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,A,1,N,1,,BAO_0000218
12422,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631120,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,A,1,N,1,,BAO_0000218
12423,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631121,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,A,1,N,1,,BAO_0000218
12424,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL874458,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,A,1,N,1,,BAO_0000218
12425,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631122,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,A,1,N,1,,BAO_0000218
12426,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631123,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,A,1,N,1,,BAO_0000218
12427,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631124,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,A,1,N,1,,BAO_0000218
12428,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631125,50597,,,Blood,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,A,1,N,1,,BAO_0000218
12429,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631290,50597,,,Blood,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,A,1,N,1,,BAO_0000218
12430,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631291,50597,,,Blood,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,A,1,N,1,,BAO_0000218
12431,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631292,50597,,,Blood,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,A,1,N,1,,BAO_0000218
12432,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631293,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,A,1,N,1,,BAO_0000218
12433,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631294,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,A,1,N,1,,BAO_0000218
12434,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631295,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,A,1,N,1,,BAO_0000218
12435,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631296,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,A,1,N,1,,BAO_0000218
12436,,178.0,10116.0,Intermediate,Rattus norvegicus,8631,CHEMBL631297,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,A,1,N,1,,BAO_0000218
12437,,,,Autocuration,,10263,CHEMBL631298,22224,,,,Maximum biodistribution (Bmax) was determined.,,A,1,U,0,,BAO_0000218
12438,,,10090.0,Intermediate,Mus musculus,12364,CHEMBL631299,50594,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,A,1,N,1,,BAO_0000218
12439,,,10090.0,Intermediate,Mus musculus,12364,CHEMBL631300,50594,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,A,1,N,1,,BAO_0000218
12440,,,10090.0,Intermediate,Mus musculus,12364,CHEMBL631301,50594,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,A,1,N,1,,BAO_0000218
12441,,,10090.0,Intermediate,Mus musculus,12364,CHEMBL630291,50594,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,A,1,N,1,,BAO_0000218
12442,,,,Autocuration,,14793,CHEMBL630292,22224,,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,A,1,U,0,,BAO_0000218
12443,,,,Autocuration,,14793,CHEMBL630293,22224,,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,A,1,U,0,,BAO_0000218
12444,,,,Autocuration,,14793,CHEMBL630294,22224,,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12445,,,,Autocuration,,14793,CHEMBL630295,22224,,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,A,1,U,0,,BAO_0000218
12446,,,,Autocuration,,14793,CHEMBL630296,22224,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,A,1,U,0,,BAO_0000218
12447,,,,Autocuration,,14793,CHEMBL626782,22224,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12448,,,,Autocuration,,14793,CHEMBL626783,22224,,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12449,,,,Autocuration,,14793,CHEMBL626784,22224,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,A,1,U,0,,BAO_0000218
12450,,,,Autocuration,,14793,CHEMBL626785,22224,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,A,1,U,0,,BAO_0000218
12451,,,,Autocuration,,14793,CHEMBL626786,22224,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12452,,,,Autocuration,,9196,CHEMBL626787,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,A,1,U,0,,BAO_0000218
12453,,,,Autocuration,,9196,CHEMBL626788,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,A,1,U,0,,BAO_0000218
12454,,,,Autocuration,,9196,CHEMBL625927,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,A,1,U,0,,BAO_0000218
12455,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625928,50597,,,Blood,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12456,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625929,50597,,,Blood,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,A,1,N,1,,BAO_0000218
12457,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625930,50597,,,Blood,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,A,1,N,1,,BAO_0000218
12458,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625931,50597,,,Blood,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,A,1,N,1,,BAO_0000218
12459,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627230,50597,,,Blood,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,A,1,N,1,,BAO_0000218
12460,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627231,50597,,,Blood,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12461,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627232,50597,,,Blood,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,A,1,N,1,,BAO_0000218
12462,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627233,50597,,,Blood,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,A,1,N,1,,BAO_0000218
12463,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL875470,50597,,,Blood,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12464,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627234,50597,,,Blood,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12465,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627235,50597,,,Blood,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12466,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627236,50597,,,Blood,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12467,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627237,50597,,,Blood,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12468,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627238,50597,,,Blood,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12469,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627239,50597,,,Blood,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12470,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627240,50597,,,Blood,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12471,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627241,50597,,,Blood,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12472,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627242,50597,,,Blood,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12473,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627243,50597,,,Blood,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,A,1,N,1,,BAO_0000218
12474,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627244,50597,,,Blood,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,A,1,N,1,,BAO_0000218
12475,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627245,50597,,,Blood,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12476,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627246,50597,,,Blood,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12477,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627247,50597,,,Blood,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12478,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627248,50597,,,Blood,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12479,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627249,50597,,,Blood,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12480,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625569,50597,,,Blood,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12481,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625570,50597,,,Blood,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12482,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625571,50597,,,Blood,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12483,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625572,50597,,,Blood,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,A,1,N,1,,BAO_0000218
12484,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625573,50597,,,Blood,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,A,1,N,1,,BAO_0000218
12485,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL625574,50597,,,Blood,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,A,1,N,1,,BAO_0000218
12486,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL626245,50597,,,Blood,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,A,1,N,1,,BAO_0000218
12487,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL626246,50597,,,Blood,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12488,,,,Autocuration,,9196,CHEMBL626247,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,A,1,U,0,,BAO_0000218
12489,,,,Autocuration,,9196,CHEMBL626248,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,A,1,U,0,,BAO_0000218
12490,,,,Autocuration,,9196,CHEMBL626249,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,A,1,U,0,,BAO_0000218
12491,,,,Autocuration,,9196,CHEMBL626420,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,A,1,U,0,,BAO_0000218
12492,,,,Autocuration,,9196,CHEMBL626421,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,A,1,U,0,,BAO_0000218
12493,,,,Autocuration,,9196,CHEMBL626422,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,A,1,U,0,,BAO_0000218
12494,,,,Autocuration,,9196,CHEMBL626423,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,A,1,U,0,,BAO_0000218
12495,,,,Autocuration,,9196,CHEMBL626424,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,A,1,U,0,,BAO_0000218
12496,,,9615.0,Intermediate,Canis lupus familiaris,12023,CHEMBL626425,50588,,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,A,1,N,1,,BAO_0000218
12497,,,10116.0,Intermediate,Rattus norvegicus,12023,CHEMBL875476,50597,,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,A,1,N,1,,BAO_0000218
12498,,,9541.0,Intermediate,Macaca fascicularis,12023,CHEMBL626426,100710,,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,A,1,N,1,,BAO_0000218
12499,,,,Autocuration,,10580,CHEMBL626427,22224,,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,P,1,U,0,,BAO_0000100
12500,,,,Autocuration,,10580,CHEMBL626428,22224,,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,P,1,U,0,,BAO_0000100
12501,,,,Autocuration,,16032,CHEMBL626429,22224,,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,A,1,U,0,,BAO_0000019
12502,,1088.0,,Autocuration,,16032,CHEMBL625025,22224,,,Urine,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,A,1,U,0,,BAO_0000019
12503,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625026,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12504,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625027,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12505,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL874410,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12506,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625028,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12507,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625029,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12508,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625030,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12509,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625031,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12510,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625032,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12511,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625033,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12512,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL625034,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12513,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624872,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12514,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624873,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12515,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624874,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12516,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624875,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12517,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624876,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12518,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624877,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12519,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624878,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12520,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624879,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12521,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624880,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12522,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624881,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12523,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624882,50597,,,Heart,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,A,1,N,1,,BAO_0000218
12524,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624883,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12525,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624884,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12526,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624885,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12527,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624886,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12528,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624887,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12529,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624888,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12530,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624889,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12531,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624890,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12532,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL621964,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12533,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL621965,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12534,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL621966,50597,,,Liver,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12535,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL621967,50597,,,Liver,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12536,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL622164,50597,,,Liver,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12537,,,,Autocuration,,7653,CHEMBL623097,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,A,1,U,0,,BAO_0000019
12538,,,,Autocuration,,7653,CHEMBL623098,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,A,1,U,0,,BAO_0000019
12539,,,,Autocuration,,7653,CHEMBL623099,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,A,1,U,0,,BAO_0000019
12540,,,,Autocuration,,7653,CHEMBL623100,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,A,1,U,0,,BAO_0000019
12541,,,10116.0,Intermediate,Rattus norvegicus,9104,CHEMBL628673,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,A,1,N,1,,BAO_0000218
12542,,,10116.0,Intermediate,Rattus norvegicus,9104,CHEMBL628674,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,A,1,N,1,,BAO_0000218
12543,,,10116.0,Intermediate,Rattus norvegicus,9104,CHEMBL628675,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,A,1,N,1,,BAO_0000218
12544,,,10116.0,Intermediate,Rattus norvegicus,9104,CHEMBL627644,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,A,1,N,1,,BAO_0000218
12545,,,10116.0,Intermediate,Rattus norvegicus,9104,CHEMBL627645,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,A,1,N,1,,BAO_0000218
12546,,,10116.0,Intermediate,Rattus norvegicus,9104,CHEMBL627646,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,A,1,N,1,,BAO_0000218
12547,,,10116.0,Intermediate,Rattus norvegicus,9104,CHEMBL627647,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,A,1,N,1,,BAO_0000218
12548,,,10116.0,Intermediate,Rattus norvegicus,9104,CHEMBL627648,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,A,1,N,1,,BAO_0000218
12549,,,10116.0,Intermediate,Rattus norvegicus,12902,CHEMBL627649,50597,,,,Free level in rat plasma,,A,1,N,1,,BAO_0000218
12550,,,,Autocuration,,6614,CHEMBL628313,22224,,,,Level reaching in blood plasma of rat or human was determined,,A,1,U,0,,BAO_0000019
12551,,,10116.0,Intermediate,Rattus norvegicus,9663,CHEMBL628314,50597,,,,Log (Cbrain/Cblood) in rats,,A,1,N,1,,BAO_0000218
12552,,,,Autocuration,,17658,CHEMBL628315,22224,,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,A,1,U,0,,BAO_0000019
12553,,,,Autocuration,,17658,CHEMBL628316,22224,,,,Mean percentage of compound transport through membrane; expressed as membrane transport,,A,1,U,0,,BAO_0000019
12554,,,,Autocuration,,14314,CHEMBL628317,22224,,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,A,1,U,0,,BAO_0000218
12555,,,,Autocuration,,7385,CHEMBL628473,22224,,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,A,1,U,0,,BAO_0000019
12556,,,,Autocuration,,7385,CHEMBL628474,22224,,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,A,1,U,0,,BAO_0000019
12557,,,,Autocuration,,7385,CHEMBL628475,22224,,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,A,1,U,0,,BAO_0000019
12558,,,,Autocuration,,1329,CHEMBL628476,22224,,,,Net water uptake by a carrier mediated transport (%cm) mechanism,,A,1,U,0,,BAO_0000019
12559,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL628477,22224,,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,A,1,U,0,,BAO_0000218
12560,,,9669.0,Intermediate,Mustela putorius furo,12187,CHEMBL628478,50506,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,A,1,N,1,,BAO_0000218
12561,,,9669.0,Intermediate,Mustela putorius furo,12187,CHEMBL628479,50506,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,A,1,N,1,,BAO_0000218
12562,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL628480,22224,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,A,1,U,0,,BAO_0000218
12563,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL628481,22224,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,A,1,U,0,,BAO_0000218
12564,,,10116.0,Intermediate,Rattus norvegicus,12187,CHEMBL628482,50597,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,A,1,N,1,,BAO_0000218
12565,,,10116.0,Intermediate,Rattus norvegicus,12187,CHEMBL628483,50597,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,A,1,N,1,,BAO_0000218
12566,,1969.0,10116.0,Intermediate,Rattus norvegicus,9278,CHEMBL628484,50597,,,Plasma,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,A,1,N,1,,BAO_0000218
12567,,1969.0,10116.0,Intermediate,Rattus norvegicus,9278,CHEMBL628485,50597,,,Plasma,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,A,1,N,1,,BAO_0000218
12568,,1969.0,9541.0,Intermediate,Macaca fascicularis,9278,CHEMBL628486,100710,,,Plasma,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,A,1,N,1,,BAO_0000218
12569,,1969.0,9606.0,Intermediate,Homo sapiens,9278,CHEMBL628487,50587,,,Plasma,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,A,1,N,1,,BAO_0000218
12570,,1969.0,10116.0,Intermediate,Rattus norvegicus,9278,CHEMBL628488,50597,,,Plasma,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,A,1,N,1,,BAO_0000218
12571,,1969.0,10116.0,Intermediate,Rattus norvegicus,9278,CHEMBL628489,50597,,,Plasma,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,A,1,N,1,,BAO_0000218
12572,,1969.0,10116.0,Intermediate,Rattus norvegicus,9278,CHEMBL628490,50597,,,Plasma,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,A,1,N,1,,BAO_0000218
12573,,,9541.0,Intermediate,Macaca fascicularis,12186,CHEMBL628491,100710,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,A,1,N,1,,BAO_0000218
12574,,,9541.0,Intermediate,Macaca fascicularis,12186,CHEMBL877507,100710,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,A,1,N,1,,BAO_0000218
12575,,,,Autocuration,,12186,CHEMBL628492,22224,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,A,1,U,0,,BAO_0000218
12576,,,314293.0,Autocuration,Simiiformes,12041,CHEMBL628493,22224,,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,A,1,U,0,,BAO_0000019
12577,,,314293.0,Autocuration,Simiiformes,12041,CHEMBL628494,22224,,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,A,1,U,0,,BAO_0000019
12578,,,314293.0,Autocuration,Simiiformes,12041,CHEMBL628495,22224,,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,A,1,U,0,,BAO_0000019
12579,,,9606.0,Intermediate,Homo sapiens,6737,CHEMBL628496,50587,,,,Permeability in Caco-2 assay at 10E-6,,A,1,N,1,,BAO_0000218
12580,,955.0,,Autocuration,,13758,CHEMBL628497,22224,,,Brain,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,A,1,U,0,,BAO_0000218
12581,,955.0,,Autocuration,,13758,CHEMBL628498,22224,,,Brain,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,A,1,U,0,,BAO_0000218
12582,,,,Autocuration,,5676,CHEMBL628499,22224,,,,Plasma protein binding was determined,,A,1,U,0,,BAO_0000019
12583,,,,Autocuration,,14793,CHEMBL627656,22224,,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12584,,,,Autocuration,,14793,CHEMBL627657,22224,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,A,1,U,0,,BAO_0000218
12585,,,,Autocuration,,14793,CHEMBL626808,22224,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,A,1,U,0,,BAO_0000218
12586,,,,Autocuration,,14793,CHEMBL626809,22224,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12587,,,,Autocuration,,14793,CHEMBL626810,22224,,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12588,,,,Autocuration,,14793,CHEMBL626811,22224,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,A,1,U,0,,BAO_0000218
12589,,,,Autocuration,,14793,CHEMBL874465,22224,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,A,1,U,0,,BAO_0000218
12590,,,,Autocuration,,14793,CHEMBL626812,22224,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12591,,,,Autocuration,,14793,CHEMBL626813,22224,,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12592,,,,Autocuration,,14793,CHEMBL626814,22224,,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,A,1,U,0,,BAO_0000218
12593,,,,Autocuration,,14000,CHEMBL626815,22224,,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,A,1,U,0,,BAO_0000019
12594,,,,Autocuration,,5948,CHEMBL628566,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
12595,,,,Autocuration,,13824,CHEMBL628567,22229,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,P,1,U,0,,BAO_0000100
12596,,,,Autocuration,,10778,CHEMBL628568,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12597,,,9615.0,Intermediate,Canis lupus familiaris,17237,CHEMBL628569,50588,,,,C max in dog,,A,1,N,1,,BAO_0000218
12598,,,10141.0,Intermediate,Cavia porcellus,17237,CHEMBL628570,50512,,,,C max in guinea pig,,A,1,N,1,,BAO_0000218
12599,,,,Autocuration,,2809,CHEMBL628571,22224,,,,C max value was evaluated,,A,1,U,0,,BAO_0000218
12600,,,,Autocuration,,11954,CHEMBL628572,22224,,,,Cmax value after oral dose of 0.1 mg//kg,,A,1,U,0,,BAO_0000218
12601,,,,Autocuration,,11954,CHEMBL628573,22224,,,,Cmax value after oral dose of 0.3 mg/kg,,A,1,U,0,,BAO_0000218
12602,,,,Autocuration,,11954,CHEMBL628574,22224,,,,Cmax value after oral dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
12603,,,,Autocuration,,11954,CHEMBL628575,22224,,,,Cmax value after oral dose of 10 mg/kg,,A,1,U,0,,BAO_0000218
12604,,,,Autocuration,,11954,CHEMBL628576,22224,,,,Cmax value after oral dose of 23.4 mg/kg,,A,1,U,0,,BAO_0000218
12605,,,,Autocuration,,11954,CHEMBL628577,22224,,,,Cmax value after oral dose of 3 mg/kg,,A,1,U,0,,BAO_0000218
12606,,,,Autocuration,,11954,CHEMBL628578,22224,,,,Cmax value after oral dose of 3.87 mg/kg,,A,1,U,0,,BAO_0000218
12607,,,9615.0,Intermediate,Canis lupus familiaris,12768,CHEMBL874466,50588,,,,Cmax value in female Beagle dogs,,A,1,N,1,,BAO_0000218
12608,,,10116.0,Intermediate,Rattus norvegicus,12768,CHEMBL628579,50597,,,,Cmax value in male rats,,A,1,N,1,,BAO_0000218
12609,,1969.0,10116.0,Intermediate,Rattus norvegicus,12780,CHEMBL628580,50597,,,Plasma,Cmax value in rat plasma when administered 20 mg/kg perorally,,A,1,N,1,,BAO_0000218
12610,,1969.0,9615.0,Intermediate,Canis lupus familiaris,15592,CHEMBL628581,50588,,,Plasma,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,A,1,N,1,,BAO_0000218
12611,,1969.0,9615.0,Intermediate,Canis lupus familiaris,15592,CHEMBL628582,50588,,,Plasma,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,A,1,N,1,,BAO_0000218
12612,,,9615.0,Intermediate,Canis lupus familiaris,17025,CHEMBL628583,50588,,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12613,,,314293.0,Autocuration,Simiiformes,17025,CHEMBL625782,22224,,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,A,1,U,0,,BAO_0000218
12614,,,9986.0,Intermediate,Oryctolagus cuniculus,17025,CHEMBL625783,50592,,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12615,,,10116.0,Intermediate,Rattus norvegicus,17025,CHEMBL625784,50597,,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12616,,1969.0,9544.0,Intermediate,Macaca mulatta,4236,CHEMBL625785,50797,,,Plasma,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,A,1,N,1,,BAO_0000218
12617,,,10116.0,Intermediate,Rattus norvegicus,15791,CHEMBL625786,50597,,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
12618,,,,Autocuration,,11149,CHEMBL874467,22224,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,A,1,U,0,,BAO_0000019
12619,,,9615.0,Intermediate,Canis lupus familiaris,15592,CHEMBL625787,50588,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,A,1,N,1,,BAO_0000218
12620,,,12721.0,Intermediate,Human immunodeficiency virus,15778,CHEMBL625964,50677,,,,cytotoxicity against HIV protease enzyme.,,A,1,N,1,,BAO_0000218
12621,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL625965,50594,,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,A,1,N,1,,BAO_0000218
12622,,,10090.0,Intermediate,Mus musculus,12745,CHEMBL625966,50594,,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,A,1,N,1,,BAO_0000218
12623,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13941,CHEMBL625967,50588,,,Plasma,The plasma clearance in dog.,,A,1,N,1,,BAO_0000218
12624,,1969.0,10116.0,Intermediate,Rattus norvegicus,13941,CHEMBL625968,50597,,,Plasma,The plasma clearance in rat.,,A,1,N,1,,BAO_0000218
12625,,1969.0,10116.0,Intermediate,Rattus norvegicus,16449,CHEMBL625969,50597,,,Plasma,Clearance from plasma in male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
12626,,1969.0,9541.0,Intermediate,Macaca fascicularis,16449,CHEMBL625970,100710,,,Plasma,Clearance from plasma in male cynomolgus monkeys,,A,1,N,1,,BAO_0000218
12627,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14224,CHEMBL625971,50588,,,Plasma,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,A,1,N,1,,BAO_0000218
12628,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14224,CHEMBL625972,50588,,,Plasma,Clearance of compound in dog plasma,,A,1,N,1,,BAO_0000218
12629,,1969.0,9606.0,Intermediate,Homo sapiens,14224,CHEMBL625973,50587,,,Plasma,Clearance of compound in human plasma,,A,1,N,1,,BAO_0000218
12630,,,9615.0,Intermediate,Canis lupus familiaris,14317,CHEMBL625974,50588,,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,A,1,N,1,,BAO_0000218
12631,,,9615.0,Intermediate,Canis lupus familiaris,14317,CHEMBL625975,50588,,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,,A,1,N,1,,BAO_0000218
12632,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14224,CHEMBL625976,50588,,,Plasma,"Clearance (10 mg/kg, intravenously) in dog plasma",,A,1,N,1,,BAO_0000218
12633,,,9615.0,Intermediate,Canis lupus familiaris,17237,CHEMBL625977,50588,,,,Clearance value in dog,,A,1,N,1,,BAO_0000218
12634,,,10141.0,Intermediate,Cavia porcellus,17237,CHEMBL625978,50512,,,,Clearance value in guinea pig,,A,1,N,1,,BAO_0000218
12635,,,10116.0,Intermediate,Rattus norvegicus,14187,CHEMBL874468,50597,,,,Clearance values in rats after iv administration.,,A,1,N,1,,BAO_0000218
12636,,1969.0,,Autocuration,,4806,CHEMBL625421,22224,,,Plasma,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,A,1,U,0,,BAO_0000218
12637,,,9986.0,Intermediate,Oryctolagus cuniculus,15025,CHEMBL625422,50592,,,,In vivo clearance (5 mg/kg) was determined in rabbits,,A,1,N,1,,BAO_0000218
12638,,,10116.0,Intermediate,Rattus norvegicus,13197,CHEMBL625423,50597,,,,Plasma Clearance rate was determined for the compound in rats,,A,1,N,1,,BAO_0000218
12639,,,9520.0,Autocuration,Saimiri,13197,CHEMBL625424,22224,,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,,A,1,U,0,,BAO_0000218
12640,,,10116.0,Intermediate,Rattus norvegicus,13960,CHEMBL625425,50597,,,,Plasma clearance in rat,,A,1,N,1,,BAO_0000218
12641,,,,Autocuration,,17820,CHEMBL625426,22224,,,,Plasma clearance of the compound,,A,1,U,0,,BAO_0000218
12642,,,10141.0,Intermediate,Cavia porcellus,14706,CHEMBL625427,50512,,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,A,1,N,1,,BAO_0000218
12643,,,10141.0,Intermediate,Cavia porcellus,14706,CHEMBL625428,50512,,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,A,1,N,1,,BAO_0000218
12644,,,,Autocuration,,6504,CHEMBL625429,22224,,,,Plasma clearance was determined,,A,1,U,0,,BAO_0000218
12645,,,9615.0,Intermediate,Canis lupus familiaris,14925,CHEMBL625430,50588,,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,A,1,N,1,,BAO_0000218
12646,,,10116.0,Intermediate,Rattus norvegicus,13197,CHEMBL625431,50597,,,,Plasma clearance rate was determined for the compound in rats,,A,1,N,1,,BAO_0000218
12647,,,9520.0,Autocuration,Saimiri,13197,CHEMBL627307,22224,,,,Plasma clearance rate was determined for the compound in squirrel monkeys,,A,1,U,0,,BAO_0000218
12648,,,,Autocuration,,3437,CHEMBL627308,22224,,,,Slow clearance (CL) was determined,,A,1,U,0,,BAO_0000218
12649,,,,Autocuration,,9196,CHEMBL627309,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,A,1,U,0,,BAO_0000218
12650,,,,Autocuration,,9196,CHEMBL627310,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,A,1,U,0,,BAO_0000218
12651,,,,Autocuration,,9196,CHEMBL627311,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,A,1,U,0,,BAO_0000218
12652,,,,Autocuration,,9196,CHEMBL627312,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,A,1,U,0,,BAO_0000218
12653,,,,Autocuration,,9196,CHEMBL627313,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,A,1,U,0,,BAO_0000218
12654,,,,Autocuration,,9196,CHEMBL627314,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,A,1,U,0,,BAO_0000218
12655,,,,Autocuration,,9196,CHEMBL627315,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,A,1,U,0,,BAO_0000218
12656,,,,Autocuration,,9196,CHEMBL627316,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,A,1,U,0,,BAO_0000218
12657,,,,Autocuration,,9196,CHEMBL627317,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,A,1,U,0,,BAO_0000218
12658,,,,Autocuration,,9196,CHEMBL627318,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,A,1,U,0,,BAO_0000218
12659,,,,Autocuration,,9196,CHEMBL627999,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,A,1,U,0,,BAO_0000218
12660,,,,Autocuration,,9196,CHEMBL628000,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,A,1,U,0,,BAO_0000218
12661,,,,Autocuration,,9196,CHEMBL628001,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,A,1,U,0,,BAO_0000218
12662,,,,Autocuration,,9196,CHEMBL628002,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,A,1,U,0,,BAO_0000218
12663,,,,Autocuration,,9196,CHEMBL625610,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,A,1,U,0,,BAO_0000218
12664,,,,Autocuration,,9196,CHEMBL625611,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,A,1,U,0,,BAO_0000218
12665,,,,Autocuration,,9196,CHEMBL625612,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,A,1,U,0,,BAO_0000218
12666,,,,Autocuration,,9196,CHEMBL625613,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,A,1,U,0,,BAO_0000218
12667,,,,Autocuration,,9196,CHEMBL875479,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,A,1,U,0,,BAO_0000218
12668,,,,Autocuration,,9196,CHEMBL625614,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,A,1,U,0,,BAO_0000218
12669,,,,Autocuration,,9196,CHEMBL625615,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,A,1,U,0,,BAO_0000218
12670,,,,Autocuration,,9196,CHEMBL626302,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,A,1,U,0,,BAO_0000218
12671,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL626303,50597,,,Blood,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12672,,178.0,10116.0,Intermediate,Rattus norvegicus,8374,CHEMBL627420,50597,,,Blood,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,A,1,N,1,,BAO_0000218
12673,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL627421,50597,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,A,1,N,1,,BAO_0000218
12674,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL625695,50597,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,A,1,N,1,,BAO_0000218
12675,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL625696,50597,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,A,1,N,1,,BAO_0000218
12676,,955.0,10090.0,Intermediate,Mus musculus,10009,CHEMBL875606,50594,,,Brain,Distribution of compound in mice brain was measured after 1 hr,,A,1,N,1,,BAO_0000218
12677,,955.0,10090.0,Intermediate,Mus musculus,10009,CHEMBL625697,50594,,,Brain,Distribution of compound in mice brain was measured after 24 hr r,,A,1,N,1,,BAO_0000218
12678,,955.0,10090.0,Intermediate,Mus musculus,10009,CHEMBL625698,50594,,,Brain,Distribution of compound in mice brain was measured after 2 hr,,A,1,N,1,,BAO_0000218
12679,,955.0,10090.0,Intermediate,Mus musculus,10009,CHEMBL625699,50594,,,Brain,Distribution of compound in mice brain was measured after 3 hr,,A,1,N,1,,BAO_0000218
12680,,955.0,10090.0,Intermediate,Mus musculus,10009,CHEMBL625700,50594,,,Brain,Distribution of compound in mice brain was measured after 6 hr,,A,1,N,1,,BAO_0000218
12681,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL625701,50594,,,,Distribution of compound in mice liver was measured after 1 hr,,A,1,N,1,,BAO_0000218
12682,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL625702,50594,,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,A,1,N,1,,BAO_0000218
12683,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL625703,50594,,,,Distribution of compound in mice liver was measured after 2 hr,,A,1,N,1,,BAO_0000218
12684,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL625704,50594,,,,Distribution of compound in mice liver was measured after 3 hr,,A,1,N,1,,BAO_0000218
12685,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL625705,50594,,,,Distribution of compound in mice liver was measured after 6 hr,,A,1,N,1,,BAO_0000218
12686,,1236.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL625706,50588,,,Adrenal medulla,Distribution in dog adrenal medulla 30 min after administration.,,A,1,N,1,,BAO_0000218
12687,,1236.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL625707,50588,,,Adrenal medulla,Distribution in dog adrenal medulla 72 hours after administration.,,A,1,N,1,,BAO_0000218
12688,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL625708,50588,,,,Distribution in female dog Ovary 24 hours after administration.,,A,1,N,1,,BAO_0000218
12689,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL625709,50588,,,,Distribution in female dog Ovary 72 hours after administration.,,A,1,N,1,,BAO_0000218
12690,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624180,50588,,,,Distribution in female dog adipose 24 hours after administration.,,A,1,N,1,,BAO_0000218
12691,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624181,50588,,,,Distribution in female dog adipose 72 hours after administration.,,A,1,N,1,,BAO_0000218
12692,,1235.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624182,50588,,,Adrenal cortex,Distribution in female dog adrenal cortex 72 hours after administration.,,A,1,N,1,,BAO_0000218
12693,,1235.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624183,50588,,,Adrenal cortex,Distribution in female dog adrenal cortex 72 hours after administration.,,A,1,N,1,,BAO_0000218
12694,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624184,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12695,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL877489,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12696,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624185,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12697,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624186,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12698,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624187,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12699,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624188,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12700,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624189,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12701,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624190,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12702,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624191,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12703,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624192,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12704,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624193,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12705,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624194,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12706,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624891,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12707,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624892,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12708,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL624893,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12709,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627632,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12710,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627633,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12711,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627634,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12712,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627635,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12713,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627636,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12714,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626816,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12715,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626817,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12716,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626818,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12717,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626819,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12718,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626820,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12719,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626821,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12720,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626822,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12721,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626823,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12722,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626824,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12723,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626825,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12724,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626826,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12725,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626827,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12726,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626828,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12727,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626829,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12728,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626830,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12729,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627150,50597,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12730,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627151,50597,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12731,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627152,50597,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,A,1,N,1,,BAO_0000218
12732,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL627153,50597,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12733,,,,Autocuration,,12904,CHEMBL627154,22224,,,,Rate of acetate production by the compound was determined,,A,1,U,0,,BAO_0000019
12734,,,,Autocuration,,12904,CHEMBL627155,22224,,,,Rate of acetate production by the compound was determined; Not determined,,A,1,U,0,,BAO_0000019
12735,,,,Autocuration,,3730,CHEMBL627156,22224,,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,A,1,U,0,,BAO_0000019
12736,,,,Autocuration,,3627,CHEMBL627157,22224,,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,A,1,U,0,,BAO_0000019
12737,,,9986.0,Intermediate,Oryctolagus cuniculus,13799,CHEMBL627158,50592,,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,A,1,N,1,,BAO_0000218
12738,,1969.0,9986.0,Intermediate,Oryctolagus cuniculus,13799,CHEMBL627159,50592,,,Plasma,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,A,1,N,1,,BAO_0000218
12739,,,10090.0,Intermediate,Mus musculus,13799,CHEMBL627160,50594,,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,A,1,N,1,,BAO_0000218
12740,,,10116.0,Intermediate,Rattus norvegicus,13799,CHEMBL628540,50597,,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,A,1,N,1,,BAO_0000218
12741,,1969.0,10116.0,Intermediate,Rattus norvegicus,13799,CHEMBL628541,50597,,,Plasma,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,A,1,N,1,,BAO_0000218
12742,,1969.0,10116.0,Intermediate,Rattus norvegicus,13799,CHEMBL628542,50597,,,Plasma,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,A,1,N,1,,BAO_0000218
12743,,,,Autocuration,,6629,CHEMBL628543,22229,,,,Solubility after at a pH 1.2,,P,1,U,0,,BAO_0000100
12744,,,,Autocuration,,6629,CHEMBL628544,22229,,,,Solubility after at pH 1.2,,P,1,U,0,,BAO_0000100
12745,,,,Autocuration,,6629,CHEMBL628545,22229,,,,Solubility after injection of water,,P,1,U,0,,BAO_0000100
12746,,,,Autocuration,,14000,CHEMBL628546,22224,,,,Statistical significance of IC 50 values; Expressed as R value,,A,1,U,0,,BAO_0000019
12747,,,,Autocuration,,8267,CHEMBL874455,22224,,,,Systemic availability with respect to methyldopa was determined,,A,1,U,0,,BAO_0000019
12748,,,10116.0,Intermediate,Rattus norvegicus,13799,CHEMBL628547,50597,,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,A,1,N,1,,BAO_0000218
12749,,1969.0,10116.0,Intermediate,Rattus norvegicus,13799,CHEMBL628548,50597,,,Plasma,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,A,1,N,1,,BAO_0000218
12750,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628549,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,A,1,N,1,,BAO_0000218
12751,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628550,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,A,1,N,1,,BAO_0000218
12752,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628551,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,A,1,N,1,,BAO_0000218
12753,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628552,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,A,1,N,1,,BAO_0000218
12754,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628553,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,A,1,N,1,,BAO_0000218
12755,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628554,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,A,1,N,1,,BAO_0000218
12756,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628555,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,A,1,N,1,,BAO_0000218
12757,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628556,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,A,1,N,1,,BAO_0000218
12758,,2113.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628557,50592,,,Kidney,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,A,1,N,1,,BAO_0000218
12759,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628558,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,A,1,N,1,,BAO_0000218
12760,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628559,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,A,1,N,1,,BAO_0000218
12761,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628560,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,A,1,N,1,,BAO_0000218
12762,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL874456,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,A,1,N,1,,BAO_0000218
12763,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628561,50592,,,Feces,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,A,1,N,1,,BAO_0000218
12764,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628562,50592,,,Feces,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,A,1,N,1,,BAO_0000218
12765,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628563,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,A,1,N,1,,BAO_0000218
12766,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628564,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,A,1,N,1,,BAO_0000218
12767,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL628565,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,A,1,N,1,,BAO_0000218
12768,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL631248,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,A,1,N,1,,BAO_0000218
12769,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL631249,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,A,1,N,1,,BAO_0000218
12770,,2113.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL627214,50592,,,Kidney,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,A,1,N,1,,BAO_0000218
12771,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL874591,50592,,,Feces,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,A,1,N,1,,BAO_0000218
12772,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL627215,50592,,,Feces,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,A,1,N,1,,BAO_0000218
12773,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL625471,50592,,,Feces,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,A,1,N,1,,BAO_0000218
12774,,,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL625472,50592,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,A,1,N,1,,BAO_0000218
12775,,,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL625473,50592,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,A,1,N,1,,BAO_0000218
12776,,,9615.0,Intermediate,Canis lupus familiaris,13317,CHEMBL625474,50588,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,A,1,N,1,,BAO_0000218
12777,,,9615.0,Intermediate,Canis lupus familiaris,15341,CHEMBL625475,50588,,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,A,1,N,1,,BAO_0000218
12778,,,10116.0,Intermediate,Rattus norvegicus,15341,CHEMBL625476,50597,,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,A,1,N,1,,BAO_0000218
12779,,,10116.0,Intermediate,Rattus norvegicus,15341,CHEMBL625477,50597,,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,A,1,N,1,,BAO_0000218
12780,,,10116.0,Intermediate,Rattus norvegicus,15341,CHEMBL625478,50597,,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,A,1,N,1,,BAO_0000218
12781,,,10116.0,Intermediate,Rattus norvegicus,12801,CHEMBL625479,50597,,,esophageal tunica muscularis mucosae,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,A,1,N,1,,BAO_0000218
12782,,,10116.0,Intermediate,Rattus norvegicus,12801,CHEMBL625480,50597,,,esophageal tunica muscularis mucosae,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,A,1,N,1,,BAO_0000218
12783,,1969.0,10116.0,Intermediate,Rattus norvegicus,14856,CHEMBL625481,50597,,,Plasma,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,A,1,N,1,,BAO_0000218
12784,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL625482,50597,,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,A,1,N,1,,BAO_0000218
12785,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL625483,50597,,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,A,1,N,1,,BAO_0000218
12786,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL625484,50597,,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,A,1,N,1,,BAO_0000218
12787,,,10116.0,Intermediate,Rattus norvegicus,14062,CHEMBL625485,50597,,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,A,1,N,1,,BAO_0000218
12788,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14346,CHEMBL625486,50588,,,Plasma,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,A,1,N,1,,BAO_0000218
12789,,1969.0,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL625487,50597,,,Plasma,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,A,1,N,1,,BAO_0000218
12790,,1969.0,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL625488,50597,,,Plasma,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,A,1,N,1,,BAO_0000218
12791,,1969.0,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL625489,50597,,,Plasma,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,A,1,N,1,,BAO_0000218
12792,,1969.0,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL625490,50597,,,Plasma,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,A,1,N,1,,BAO_0000218
12793,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14346,CHEMBL625491,50588,,,Plasma,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,A,1,N,1,,BAO_0000218
12794,,1969.0,10116.0,Intermediate,Rattus norvegicus,14346,CHEMBL625492,50597,,,Plasma,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,A,1,N,1,,BAO_0000218
12795,,1969.0,9606.0,Intermediate,Homo sapiens,15711,CHEMBL625493,50587,,,Plasma,plasma clearance in human,,A,1,N,1,,BAO_0000218
12796,,,10116.0,Intermediate,Rattus norvegicus,14886,CHEMBL625494,50597,,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,A,1,N,1,,BAO_0000218
12797,,,10116.0,Intermediate,Rattus norvegicus,14886,CHEMBL625495,50597,,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,A,1,N,1,,BAO_0000218
12798,,,10116.0,Intermediate,Rattus norvegicus,14886,CHEMBL625496,50597,,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,A,1,N,1,,BAO_0000218
12799,,,,Autocuration,,4115,CHEMBL625497,22229,,,,1-Octanol/water partition coefficient measured at 7.4,,P,1,U,0,,BAO_0000100
12800,,,,Autocuration,,13733,CHEMBL625498,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12801,,,,Autocuration,,12102,CHEMBL625499,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
12802,,,,Autocuration,,12676,CHEMBL625500,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12803,,,,Autocuration,,13733,CHEMBL625501,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12804,,,,Autocuration,,13740,CHEMBL625502,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12805,,,,Autocuration,,12766,CHEMBL625503,22229,,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),,P,1,U,0,,BAO_0000100
12806,,,,Autocuration,,2764,CHEMBL625504,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12807,,,,Autocuration,,12355,CHEMBL625505,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12808,,,,Autocuration,,11314,CHEMBL625506,22229,,,,Calculated partition coefficient of the compound,,P,1,U,0,,BAO_0000100
12809,,,,Autocuration,,12706,CHEMBL625507,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
12810,,,,Autocuration,,12645,CHEMBL625508,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12811,,,,Autocuration,,13668,CHEMBL625509,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12812,,,,Autocuration,,12819,CHEMBL625510,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12813,,,,Autocuration,,13668,CHEMBL883125,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12814,,,,Autocuration,,13017,CHEMBL625511,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12815,,,,Autocuration,,2448,CHEMBL874650,22224,,,,Partition coefficient of the compound,,A,1,U,0,,BAO_0000019
12816,,,,Autocuration,,11526,CHEMBL625512,22224,,,,Partition coefficient of the compound,,A,1,U,0,,BAO_0000019
12817,,,,Autocuration,,12426,CHEMBL625513,22224,,,,Partition coefficient of compound was determined,,A,1,U,0,,BAO_0000019
12818,,,,Autocuration,,2448,CHEMBL625514,22224,,,,Partition coefficient was determined,,A,1,U,0,,BAO_0000019
12819,,,,Autocuration,,12001,CHEMBL625515,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12820,,,,Autocuration,,12426,CHEMBL625516,22229,,,,partition coefficient of compound was determined,,P,1,U,0,,BAO_0000100
12821,,,9615.0,Intermediate,Canis lupus familiaris,13204,CHEMBL625517,50588,,,,The total body administered intravenously in dog,,A,1,N,1,,BAO_0000218
12822,,,10116.0,Intermediate,Rattus norvegicus,13204,CHEMBL625518,50597,,,,The total body administered intravenously in rats,,A,1,N,1,,BAO_0000218
12823,,,10090.0,Intermediate,Mus musculus,13889,CHEMBL625519,50594,,,,Time taken for the administration to female NIH mice weighing 25-30 g.,,A,1,N,1,,BAO_0000218
12824,,,,Autocuration,,13889,CHEMBL625520,22224,,,,Time taken for the administration,,A,1,U,0,,BAO_0000019
12825,,,9615.0,Intermediate,Canis lupus familiaris,17025,CHEMBL874651,50588,,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12826,,,314293.0,Autocuration,Simiiformes,17025,CHEMBL625521,22224,,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,A,1,U,0,,BAO_0000218
12827,,,9986.0,Intermediate,Oryctolagus cuniculus,17025,CHEMBL623171,50592,,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12828,,,10116.0,Intermediate,Rattus norvegicus,17025,CHEMBL623853,50597,,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,A,1,N,1,,BAO_0000218
12829,,,,Autocuration,,15067,CHEMBL623854,22224,,,,Plasma clearance for the compound was determined.,,A,1,U,0,,BAO_0000019
12830,,,,Autocuration,,3091,CHEMBL874405,22224,,,,CLog P value of the compound,,P,1,U,0,,BAO_0000100
12831,,,,Autocuration,,15592,CHEMBL623855,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12832,,,,Autocuration,,14738,CHEMBL623856,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12833,,,,Autocuration,,14738,CHEMBL623857,22224,,,,ClogP value of the compound; nd ='no data',,P,1,U,0,,BAO_0000100
12834,,,,Autocuration,,14738,CHEMBL623858,22224,,,,ClogP value of the compound; nd ='not determined',,P,1,U,0,,BAO_0000100
12835,,,,Autocuration,,6076,CHEMBL623859,22224,,,,CLog P was determined,,P,1,U,0,,BAO_0000100
12836,,,,Autocuration,,17840,CHEMBL839829,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12837,,,,Autocuration,,13589,CHEMBL623860,22224,,,,CLogP was calculated,,A,1,U,0,,BAO_0000019
12838,,,,Autocuration,,17655,CHEMBL623861,22224,,,,CLogP value was determined,,A,1,U,0,,BAO_0000019
12839,,,,Autocuration,,5867,CHEMBL623862,22224,,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,A,1,U,0,,BAO_0000019
12840,,,,Autocuration,,5867,CHEMBL874406,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12841,,,,Autocuration,,10783,CHEMBL623863,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12842,,,,Autocuration,,14849,CHEMBL624021,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12843,,1236.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624022,50588,,,Adrenal medulla,Distribution in female dog adrenal medulla 24 hours after administration.,,A,1,N,1,,BAO_0000218
12844,,1236.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624023,50588,,,Adrenal medulla,Distribution in female dog adrenal medulla 72 hours after administration.,,A,1,N,1,,BAO_0000218
12845,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624024,50588,,,,Distribution in female dog bile 24 hours after administration.,,A,1,N,1,,BAO_0000218
12846,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624025,50588,,,,Distribution in female dog bile 72 hr after administration.,,A,1,N,1,,BAO_0000218
12847,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624026,50588,,,,Distribution in female dog blood 24 hours after administration.,,A,1,N,1,,BAO_0000218
12848,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624027,50588,,,,Distribution in female dog blood 72 hours after administration.,,A,1,N,1,,BAO_0000218
12849,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624028,50588,,,,Distribution in female dog heart 24 hours after administration.,,A,1,N,1,,BAO_0000218
12850,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624029,50588,,,,Distribution in female dog heart 72 hours after administration.,,A,1,N,1,,BAO_0000218
12851,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624030,50588,,,,Distribution in female dog kidney 24 hours after administration.,,A,1,N,1,,BAO_0000218
12852,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624031,50588,,,,Distribution in female dog kidney 72 hours after administration.,,A,1,N,1,,BAO_0000218
12853,,160.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624032,50588,,,Intestine,Distribution in female dog large intestine 24 hours after administration.,,A,1,N,1,,BAO_0000218
12854,,160.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL874407,50588,,,Intestine,Distribution in female dog large intestine 72 hours after administration.,,A,1,N,1,,BAO_0000218
12855,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624033,50588,,,,Distribution in female dog liver 24 hours after administration.,,A,1,N,1,,BAO_0000218
12856,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624034,50588,,,,Distribution in female dog liver 72 hours after administration.,,A,1,N,1,,BAO_0000218
12857,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624035,50588,,,,Distribution in female dog lung 24 hours after administration.,,A,1,N,1,,BAO_0000218
12858,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624036,50588,,,,Distribution in female dog lung 72 hours after administration.,,A,1,N,1,,BAO_0000218
12859,,2385.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624037,50588,,,Muscle tissue,Distribution in female dog muscle 24 hours after administration.,,A,1,N,1,,BAO_0000218
12860,,2385.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624038,50588,,,Muscle tissue,Distribution in female dog muscle 72 hours after administration.,,A,1,N,1,,BAO_0000218
12861,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624039,50588,,,,Distribution in female dog pancreas 24 hours after administration.,,A,1,N,1,,BAO_0000218
12862,,,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624040,50588,,,,Distribution in female dog pancreas 72 hours after administration.,,A,1,N,1,,BAO_0000218
12863,,160.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624041,50588,,,Intestine,Distribution in female dog small intestine 24 hours after administration.,,A,1,N,1,,BAO_0000218
12864,,160.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624042,50588,,,Intestine,Distribution in female dog small intestine 72 hours after administration.,,A,1,N,1,,BAO_0000218
12865,,2106.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624043,50588,,,Spleen,Distribution in female dog spleen 24 hours after administration.,,A,1,N,1,,BAO_0000218
12866,,2106.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624044,50588,,,Spleen,Distribution in female dog spleen 72 hours after administration.,,A,1,N,1,,BAO_0000218
12867,,945.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624045,50588,,,Stomach,Distribution in female dog stomach 24 hours after administration.,,A,1,N,1,,BAO_0000218
12868,,945.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624046,50588,,,Stomach,Distribution in female dog stomach 72 hours after administration.,,A,1,N,1,,BAO_0000218
12869,,2046.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624047,50588,,,Thyroid gland,Distribution in female dog thyroid 24 hours after administration.,,A,1,N,1,,BAO_0000218
12870,,2046.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624048,50588,,,Thyroid gland,Distribution in female dog thyroid 72 hours after administration.,,A,1,N,1,,BAO_0000218
12871,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL874408,50588,,,Urine,Distribution in female dog urine 24 hours after administration.,,A,1,N,1,,BAO_0000218
12872,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8170,CHEMBL624049,50588,,,Urine,Distribution in female dog urine 72 hr after administration.,,A,1,N,1,,BAO_0000218
12873,,1969.0,,Autocuration,,14283,CHEMBL624050,22224,,,Plasma,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,A,1,U,0,,BAO_0000218
12874,,,,Autocuration,,5623,CHEMBL624051,22224,,,,Plasma concentration at 7 hr after intravenous dosing,,A,1,U,0,,BAO_0000019
12875,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623278,50597,,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,A,1,N,1,,BAO_0000218
12876,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623279,50597,,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,A,1,N,1,,BAO_0000218
12877,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623280,50597,,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,A,1,N,1,,BAO_0000218
12878,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623963,50597,,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,A,1,N,1,,BAO_0000218
12879,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623964,50597,,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,A,1,N,1,,BAO_0000218
12880,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623965,50597,,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,A,1,N,1,,BAO_0000218
12881,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623966,50597,,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,A,1,N,1,,BAO_0000218
12882,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL874415,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,A,1,N,1,,BAO_0000218
12883,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623967,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,A,1,N,1,,BAO_0000218
12884,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623968,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,A,1,N,1,,BAO_0000218
12885,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL623969,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,A,1,N,1,,BAO_0000218
12886,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL628409,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,A,1,N,1,,BAO_0000218
12887,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL628410,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,A,1,N,1,,BAO_0000218
12888,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL628411,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,A,1,N,1,,BAO_0000218
12889,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL628412,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,A,1,N,1,,BAO_0000218
12890,,,,Autocuration,,12553,CHEMBL628413,22224,,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,A,1,U,0,,BAO_0000019
12891,,1969.0,,Autocuration,,14548,CHEMBL628414,22224,,,Plasma,The concentration in plasmat; Not determined,,A,1,U,0,,BAO_0000019
12892,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL628415,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in blood,,A,1,N,1,,BAO_0000218
12893,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL628416,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,A,1,N,1,,BAO_0000218
12894,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL628417,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in heart,,A,1,N,1,,BAO_0000218
12895,,2107.0,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL874908,50597,,,Liver,Tissue level at 10 mg/kg/po in wistar rats in liver,,A,1,N,1,,BAO_0000218
12896,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL628418,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,,A,1,N,1,,BAO_0000218
12897,,2385.0,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL628419,50597,,,Muscle tissue,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,A,1,N,1,,BAO_0000218
12898,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL628420,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,A,1,N,1,,BAO_0000218
12899,,,,Autocuration,,1629,CHEMBL628421,22224,,,,Water solubility at 37 degree C.,,A,1,U,0,,BAO_0000019
12900,,,,Autocuration,,8194,CHEMBL626726,22229,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,P,1,U,0,,BAO_0000100
12901,,,,Autocuration,,8194,CHEMBL626727,22229,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,P,1,U,0,,BAO_0000100
12902,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626728,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12903,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626729,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12904,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626730,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12905,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626731,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12906,,178.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626732,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12907,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626733,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12908,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626734,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12909,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626735,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12910,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL874909,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12911,,948.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626736,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12912,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL626737,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12913,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630999,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12914,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631000,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12915,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631001,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12916,,2113.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631002,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12917,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631003,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12918,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631004,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12919,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631005,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12920,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631006,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12921,,2107.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631007,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12922,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631008,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12923,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631009,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12924,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631010,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12925,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631011,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12926,,2048.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL631012,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12927,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630271,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12928,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630272,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12929,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630273,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12930,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630274,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12931,,2046.0,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630275,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12932,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL875782,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12933,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630276,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12934,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630277,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12935,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630278,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12936,,,10116.0,Intermediate,Rattus norvegicus,8594,CHEMBL630279,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,A,1,N,1,,BAO_0000218
12937,,,,Autocuration,,8151,CHEMBL630280,22224,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,A,1,U,0,,BAO_0000019
12938,,,,Autocuration,,8151,CHEMBL630281,22224,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,A,1,U,0,,BAO_0000019
12939,,,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630282,50592,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,A,1,N,1,,BAO_0000218
12940,,,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630283,50592,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,A,1,N,1,,BAO_0000218
12941,,,,Autocuration,,5797,CHEMBL630284,22224,,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,A,1,U,0,,BAO_0000019
12942,,,,Autocuration,,7849,CHEMBL630285,22224,,,,Alkylating activity was determined,,A,1,U,0,,BAO_0000019
12943,Microsomes,,,Autocuration,,14220,CHEMBL630286,22224,,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,A,1,U,0,,BAO_0000251
12944,,,9986.0,Intermediate,Oryctolagus cuniculus,8650,CHEMBL630069,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,A,1,N,1,,BAO_0000218
12945,,,9986.0,Intermediate,Oryctolagus cuniculus,8650,CHEMBL630070,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,A,1,N,1,,BAO_0000218
12946,,,9986.0,Intermediate,Oryctolagus cuniculus,8650,CHEMBL630071,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,A,1,N,1,,BAO_0000218
12947,,,9986.0,Intermediate,Oryctolagus cuniculus,8650,CHEMBL630072,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,A,1,N,1,,BAO_0000218
12948,,,9986.0,Intermediate,Oryctolagus cuniculus,8650,CHEMBL875110,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,A,1,N,1,,BAO_0000218
12949,,,10116.0,Intermediate,Rattus norvegicus,7116,CHEMBL630073,50597,,,,Compound was tested for antidiuretic activity in rats,,A,1,N,1,,BAO_0000218
12950,,,,Autocuration,,14131,CHEMBL630074,22224,,,,Compound was tested for inactivation kinetic values,,A,1,U,0,,BAO_0000019
12951,,,,Autocuration,,7415,CHEMBL630075,22224,,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,A,1,U,0,,BAO_0000218
12952,,,,Autocuration,,13178,CHEMBL630076,22224,,,,Dissociation rate calculated from the first-order equation using the t1/2 value,,A,1,U,0,,BAO_0000019
12953,,,,Autocuration,,8815,CHEMBL630077,22229,,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,P,1,U,0,,BAO_0000100
12954,,,,Autocuration,,1450,CHEMBL630078,22229,,,,Aqueous solubility was measured,,P,1,U,0,,BAO_0000100
12955,,,,Autocuration,,1450,CHEMBL630079,22229,,,,Aqueous solubility was measured at a pH 4,,P,1,U,0,,BAO_0000100
12956,,,,Autocuration,,1450,CHEMBL630080,22229,,,,Aqueous solubility (pH 7),,P,1,U,0,,BAO_0000100
12957,,,,Autocuration,,1450,CHEMBL630081,22229,,,,Aqueous solubility was measured at a pH 9,,P,1,U,0,,BAO_0000100
12958,,,,Autocuration,,12711,CHEMBL630082,22224,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,A,1,U,0,,BAO_0000019
12959,,,,Autocuration,,12711,CHEMBL630083,22224,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,A,1,U,0,,BAO_0000019
12960,,,,Autocuration,,12711,CHEMBL630084,22224,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,A,1,U,0,,BAO_0000019
12961,,,,Autocuration,,15032,CHEMBL629198,22229,,,,Aqueous solubility of the compound,,P,1,U,0,,BAO_0000100
12962,,,,Autocuration,,9964,CHEMBL629199,22229,,,,Aqueous solubility at 37 degree Celsius at pH 7.38,,P,1,U,0,,BAO_0000100
12963,,,,Autocuration,,14962,CHEMBL629200,22229,,,,Aqueous solubility in pH 7.4 phosphate buffer,,P,1,U,0,,BAO_0000100
12964,,,9615.0,Intermediate,Canis lupus familiaris,12487,CHEMBL629201,50588,,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,A,1,N,1,,BAO_0000218
12965,,,9615.0,Intermediate,Canis lupus familiaris,12487,CHEMBL629202,50588,,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,A,1,N,1,,BAO_0000218
12966,,,9606.0,Intermediate,Homo sapiens,10026,CHEMBL875111,50587,,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,A,1,N,1,,BAO_0000218
12967,,,9606.0,Intermediate,Homo sapiens,10026,CHEMBL629203,50587,,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,A,1,N,1,,BAO_0000218
12968,,,9606.0,Intermediate,Homo sapiens,10026,CHEMBL629204,50587,,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,A,1,N,1,,BAO_0000218
12969,,,9606.0,Intermediate,Homo sapiens,10026,CHEMBL629205,50587,,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,A,1,N,1,,BAO_0000218
12970,,,9606.0,Intermediate,Homo sapiens,10026,CHEMBL629206,50587,,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,A,1,N,1,,BAO_0000218
12971,,,,Autocuration,,10026,CHEMBL631185,22224,,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,A,1,U,0,,BAO_0000019
12972,,,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL631186,50597,,,,Compound was evaluated for the average bile flow rat in rats,,A,1,N,1,,BAO_0000218
12973,,,9986.0,Intermediate,Oryctolagus cuniculus,17025,CHEMBL631187,50592,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,A,1,N,1,,BAO_0000218
12974,,,9986.0,Intermediate,Oryctolagus cuniculus,17025,CHEMBL631188,50592,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,A,1,N,1,,BAO_0000218
12975,,,,Autocuration,,10184,CHEMBL876419,22224,,,,Average half life period was determined,,A,1,U,0,,BAO_0000019
12976,,,,Autocuration,,10184,CHEMBL631189,22224,,,,Average half life period was determined,,A,1,U,0,,BAO_0000019
12977,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL631190,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,A,1,N,1,,BAO_0000218
12978,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL631191,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,A,1,N,1,,BAO_0000218
12979,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL631192,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,A,1,N,1,,BAO_0000218
12980,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL632400,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,A,1,N,1,,BAO_0000218
12981,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL630564,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,A,1,N,1,,BAO_0000218
12982,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL630565,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,A,1,N,1,,BAO_0000218
12983,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL630566,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,A,1,N,1,,BAO_0000218
12984,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL631229,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,A,1,N,1,,BAO_0000218
12985,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL631230,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,A,1,N,1,,BAO_0000218
12986,,,,Autocuration,,6030,CHEMBL876428,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12987,,,,Autocuration,,6147,CHEMBL631231,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12988,,,,Autocuration,,14556,CHEMBL631232,22229,,,,Calculated partition coefficient (clogP) (MacLogP),,P,1,U,0,,BAO_0000100
12989,,,,Autocuration,,768,CHEMBL631233,22224,,,,Hydrophilicity was determined,,A,1,U,0,,BAO_0000019
12990,,,,Autocuration,,14452,CHEMBL631234,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12991,,,,Autocuration,,5237,CHEMBL883126,22224,,,,Increased absorption was determined,,A,1,U,0,,BAO_0000019
12992,,,,Autocuration,,14378,CHEMBL631235,22224,,,,Lipophilicity value was evaluated,,P,1,U,0,,BAO_0000100
12993,,,,Autocuration,,14418,CHEMBL631236,22224,,,,Log P value of the compound.,,P,1,U,0,,BAO_0000100
12994,,,,Autocuration,,5249,CHEMBL631237,22224,,,,Partition coefficient of compound was determined,,A,1,U,0,,BAO_0000019
12995,,,,Autocuration,,14621,CHEMBL631238,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12996,,,,Autocuration,,12542,CHEMBL876429,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
12997,,,,Autocuration,,12542,CHEMBL631414,22224,,,,Partition coefficient was measured by medchem software; Not calculated,,A,1,U,0,,BAO_0000019
12998,,,,Autocuration,,12542,CHEMBL631415,22224,,,,Partition coefficient was measured by octanol-water using standard shake-flask method,,P,1,U,0,,BAO_0000100
12999,,,,Autocuration,,15462,CHEMBL631416,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13000,,,,Autocuration,,14884,CHEMBL631417,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
13001,,,,Autocuration,,16526,CHEMBL631418,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13002,,,,Autocuration,,13693,CHEMBL631419,22229,,,,The Octanol/Water partition coefficient CLogP,,P,1,U,0,,BAO_0000100
13003,,,,Autocuration,,13693,CHEMBL631420,22224,,,,The pharmacokinetic parameter C Log p was reported,,A,1,U,0,,BAO_0000019
13004,,,,Autocuration,,13779,CHEMBL631421,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13005,,,,Autocuration,,14772,CHEMBL631422,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13006,,,,Autocuration,,14393,CHEMBL631423,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13007,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL876430,50597,,,Plasma,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
13008,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL631424,50597,,,Plasma,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
13009,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13744,CHEMBL631425,50588,,,Plasma,Compound was administered intravenously in dog to evaluate plasma clearance values,,A,1,N,1,,BAO_0000218
13010,,1969.0,314293.0,Autocuration,Simiiformes,13744,CHEMBL631426,22224,,,Plasma,Compound was administered intravenously in monkey to evaluate plasma clearance values,,A,1,U,0,,BAO_0000218
13011,,1969.0,10090.0,Intermediate,Mus musculus,13744,CHEMBL631427,50594,,,Plasma,Compound was administered intravenously in mouse to evaluate plasma clearance values,,A,1,N,1,,BAO_0000218
13012,,1969.0,9615.0,Intermediate,Canis lupus familiaris,13207,CHEMBL631428,50588,,,Plasma,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,A,1,N,1,,BAO_0000218
13013,Microsomes,2107.0,9544.0,Intermediate,Macaca mulatta,5669,CHEMBL631429,50797,,,Liver,Intrinsic clearance in Rhesus liver microsome,,A,1,N,1,,BAO_0000218
13014,Microsomes,2107.0,9615.0,Intermediate,Canis lupus familiaris,5669,CHEMBL631430,50588,,,Liver,Intrinsic clearance in dog liver microsome,,A,1,N,1,,BAO_0000218
13015,Microsomes,2107.0,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL631431,50597,,,Liver,Intrinsic clearance in rat liver microsome,,A,1,N,1,,BAO_0000218
13016,,1969.0,9544.0,Intermediate,Macaca mulatta,4853,CHEMBL631432,50797,,,Plasma,Low plasma clearance was calculated in rhesus monkey,,A,1,N,1,,BAO_0000218
13017,,,9615.0,Intermediate,Canis lupus familiaris,16452,CHEMBL631433,50588,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,A,1,N,1,,BAO_0000218
13018,,,,Autocuration,,11954,CHEMBL631434,22224,,,,Plasma clearance after intravenous dose of 0.3 mg/kg,,A,1,U,0,,BAO_0000218
13019,,,,Autocuration,,11954,CHEMBL631435,22224,,,,Plasma clearance after intravenous dose of 1 mg/kg,,A,1,U,0,,BAO_0000218
13020,,,,Autocuration,,11954,CHEMBL631436,22224,,,,Plasma clearance after intravenous dose of 3 mg/kg,,A,1,U,0,,BAO_0000218
13021,,,,Autocuration,,11954,CHEMBL631437,22224,,,,Plasma clearance after intravenous dose of 3.87 mg/kg,,A,1,U,0,,BAO_0000218
13022,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL631438,50597,,,,Plasma clearance after peroral administration at 10 mpk in Rat,,A,1,N,1,,BAO_0000218
13023,,,9544.0,Intermediate,Macaca mulatta,5669,CHEMBL876431,50797,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,A,1,N,1,,BAO_0000218
13024,,,9615.0,Intermediate,Canis lupus familiaris,5669,CHEMBL631439,50588,,,,Plasma clearance after peroral administration at 10 mpk in dog,,A,1,N,1,,BAO_0000218
13025,,,10116.0,Intermediate,Rattus norvegicus,13662,CHEMBL631440,50597,,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,A,1,N,1,,BAO_0000218
13026,,,,Autocuration,,8272,CHEMBL631441,22224,,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,A,1,U,0,,BAO_0000019
13027,,,,Autocuration,,13410,CHEMBL631442,22224,,,,Critical Micellar concentration was determined,,A,1,U,0,,BAO_0000019
13028,,,,Autocuration,,13410,CHEMBL626525,22224,,,,Critical Micellar concentration of the compound. was determined,,A,1,U,0,,BAO_0000019
13029,,,,Autocuration,,12628,CHEMBL627168,22224,,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,A,1,U,0,,BAO_0000019
13030,,,,Autocuration,,9675,CHEMBL875618,22224,,,,Critical micellar concentration was measured in water by the dye solubilization method,,A,1,U,0,,BAO_0000019
13031,,,,Autocuration,,12628,CHEMBL626612,22224,,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,B,1,U,0,,BAO_0000019
13032,,,,Autocuration,,12766,CHEMBL626613,22224,,,,CMR value (relative to BAY K 8644),,A,1,U,0,,BAO_0000019
13033,,,,Autocuration,,7849,CHEMBL626614,22224,,,,Carbamoylating activity was determined,,A,1,U,0,,BAO_0000019
13034,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL626615,22224,,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,A,1,U,0,,BAO_0000218
13035,,,,Autocuration,,2040,CHEMBL626616,22224,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,A,1,U,0,,BAO_0000019
13036,,,,Autocuration,,2040,CHEMBL626617,22224,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,A,1,U,0,,BAO_0000019
13037,,1969.0,9615.0,Intermediate,Canis lupus familiaris,14180,CHEMBL626618,50588,,,Plasma,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,A,1,N,1,,BAO_0000218
13038,,1969.0,10116.0,Intermediate,Rattus norvegicus,14180,CHEMBL626619,50597,,,Plasma,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,A,1,N,1,,BAO_0000218
13039,,,9615.0,Intermediate,Canis lupus familiaris,14474,CHEMBL626620,50588,,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",,A,1,N,1,,BAO_0000218
13040,,,10116.0,Intermediate,Rattus norvegicus,14474,CHEMBL626621,50597,,,,"Clearance rate at 5.5 mg/kg, iv, in rat",,A,1,N,1,,BAO_0000218
13041,,,9541.0,Intermediate,Macaca fascicularis,14548,CHEMBL626622,100710,,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,A,1,N,1,,BAO_0000218
13042,,,9541.0,Intermediate,Macaca fascicularis,14548,CHEMBL626623,100710,,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,A,1,N,1,,BAO_0000218
13043,,,9615.0,Intermediate,Canis lupus familiaris,14548,CHEMBL626624,50588,,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,A,1,N,1,,BAO_0000218
13044,,,10116.0,Intermediate,Rattus norvegicus,14548,CHEMBL626625,50597,,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,A,1,N,1,,BAO_0000218
13045,,2107.0,10116.0,Intermediate,Rattus norvegicus,6125,CHEMBL626626,50597,,,Liver,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,A,1,N,1,,BAO_0000218
13046,,,,Autocuration,,6874,CHEMBL626627,22224,,,,Tested for the total clearance of the compound,,A,1,U,0,,BAO_0000218
13047,,,9615.0,Intermediate,Canis lupus familiaris,15343,CHEMBL626628,50588,,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,A,1,N,1,,BAO_0000218
13048,,,,Autocuration,,6236,CHEMBL626629,22224,,,,Total body clearance was determined,,A,1,U,0,,BAO_0000218
13049,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626630,50597,,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,A,1,N,1,,BAO_0000218
13050,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626631,50597,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,A,1,N,1,,BAO_0000218
13051,,,,Autocuration,,8194,CHEMBL626632,22229,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,P,1,U,0,,BAO_0000100
13052,,,,Autocuration,,8194,CHEMBL626633,22229,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,P,1,U,0,,BAO_0000100
13053,,,,Autocuration,,8194,CHEMBL626634,22229,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,P,1,U,0,,BAO_0000100
13054,,,,Autocuration,,8194,CHEMBL626635,22229,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,P,1,U,0,,BAO_0000100
13055,,,,Autocuration,,8194,CHEMBL626636,22229,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,P,1,U,0,,BAO_0000100
13056,,,,Autocuration,,8194,CHEMBL626637,22229,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,P,1,U,0,,BAO_0000100
13057,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL626638,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,A,1,N,1,,BAO_0000218
13058,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL626639,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,A,1,N,1,,BAO_0000218
13059,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL626640,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,A,1,N,1,,BAO_0000218
13060,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL626641,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,A,1,N,1,,BAO_0000218
13061,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL627272,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,A,1,N,1,,BAO_0000218
13062,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL627273,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,A,1,N,1,,BAO_0000218
13063,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL627441,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,A,1,N,1,,BAO_0000218
13064,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL628355,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,A,1,N,1,,BAO_0000218
13065,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL628356,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,A,1,N,1,,BAO_0000218
13066,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL628357,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,A,1,N,1,,BAO_0000218
13067,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL628358,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,A,1,N,1,,BAO_0000218
13068,,,4754.0,Intermediate,Pneumocystis carinii,13273,CHEMBL622307,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,A,1,N,1,,BAO_0000218
13069,,,,Autocuration,,13118,CHEMBL622527,22224,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,A,1,U,0,,BAO_0000019
13070,,,,Autocuration,,13118,CHEMBL622528,22224,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,A,1,U,0,,BAO_0000019
13071,,,,Autocuration,,13118,CHEMBL622529,22224,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,A,1,U,0,,BAO_0000019
13072,,,,Autocuration,,13118,CHEMBL622992,22224,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,A,1,U,0,,BAO_0000019
13073,,,,Autocuration,,13118,CHEMBL622993,22224,,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,A,1,U,0,,BAO_0000019
13074,,,,Autocuration,,13118,CHEMBL622994,22224,,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,A,1,U,0,,BAO_0000019
13075,,,10116.0,Intermediate,Rattus norvegicus,10633,CHEMBL622995,50597,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,A,1,N,1,,BAO_0000218
13076,,,10116.0,Intermediate,Rattus norvegicus,10633,CHEMBL622996,50597,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,A,1,N,1,,BAO_0000218
13077,,,10116.0,Intermediate,Rattus norvegicus,10633,CHEMBL622997,50597,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,A,1,N,1,,BAO_0000218
13078,,,10116.0,Intermediate,Rattus norvegicus,10633,CHEMBL622998,50597,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,A,1,N,1,,BAO_0000218
13079,,,,Autocuration,,5767,CHEMBL622999,22224,,,,Cp max following ip administration at 1 mg/kg,,A,1,U,0,,BAO_0000218
13080,,1969.0,,Autocuration,,3302,CHEMBL623000,22224,,,Plasma,Maximum concentration in plasma was reported at 0.5 hour,,A,1,U,0,,BAO_0000218
13081,,1969.0,,Autocuration,,3302,CHEMBL623001,22224,,,Plasma,Maximum concentration in plasma was reported at 2 hour,,A,1,U,0,,BAO_0000218
13082,,,10090.0,Intermediate,Mus musculus,12467,CHEMBL623002,50594,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,A,1,N,1,,BAO_0000218
13083,,,,Autocuration,,11778,CHEMBL623003,22229,,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,P,1,U,0,,BAO_0000100
13084,,,,Autocuration,,4321,CHEMBL623004,22224,,,,Steady state concentration was evaluated,,A,1,U,0,,BAO_0000019
13085,,,,Autocuration,,14884,CHEMBL623005,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
13086,,,,Autocuration,,15234,CHEMBL623006,22224,,,,Partition coefficient (logD7.4),,A,1,U,0,,BAO_0000019
13087,,2107.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623007,50597,,,Liver,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,A,1,N,1,,BAO_0000218
13088,,10000001.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623008,50597,,,Bone,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,A,1,N,1,,BAO_0000218
13089,,2037.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL876654,50597,,,Cerebellum,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,A,1,N,1,,BAO_0000218
13090,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623009,50597,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,A,1,N,1,,BAO_0000218
13091,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623010,50597,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,A,1,N,1,,BAO_0000218
13092,,948.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623011,50597,,,Heart,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,A,1,N,1,,BAO_0000218
13093,,160.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623012,50597,,,Intestine,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,A,1,N,1,,BAO_0000218
13094,,,,Autocuration,,8151,CHEMBL623013,22224,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,A,1,U,0,,BAO_0000019
13095,,,,Autocuration,,8151,CHEMBL623014,22224,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,A,1,U,0,,BAO_0000019
13096,,1088.0,,Autocuration,,8151,CHEMBL623015,22224,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,A,1,U,0,,BAO_0000019
13097,,1088.0,,Autocuration,,8151,CHEMBL623016,22224,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,A,1,U,0,,BAO_0000019
13098,,1088.0,,Autocuration,,8151,CHEMBL624858,22224,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,A,1,U,0,,BAO_0000019
13099,,,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL624859,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,A,1,N,1,,BAO_0000218
13100,,,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL624860,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,A,1,N,1,,BAO_0000218
13101,,,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL624861,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,A,1,N,1,,BAO_0000218
13102,,,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL624862,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,A,1,N,1,,BAO_0000218
13103,,,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL624863,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,A,1,N,1,,BAO_0000218
13104,,,10116.0,Intermediate,Rattus norvegicus,8151,CHEMBL876655,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,A,1,N,1,,BAO_0000218
13105,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624864,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,A,1,N,1,,BAO_0000218
13106,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624865,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,A,1,N,1,,BAO_0000218
13107,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624866,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,A,1,N,1,,BAO_0000218
13108,,,9615.0,Expert,Canis lupus familiaris,6996,CHEMBL624867,50588,,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,F,1,N,1,,BAO_0000218
13109,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL624868,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,A,1,N,1,,BAO_0000218
13110,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628450,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,A,1,N,1,,BAO_0000218
13111,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628451,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,A,1,N,1,,BAO_0000218
13112,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628452,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,A,1,N,1,,BAO_0000218
13113,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628453,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,A,1,N,1,,BAO_0000218
13114,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628454,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,A,1,N,1,,BAO_0000218
13115,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628455,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,A,1,N,1,,BAO_0000218
13116,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628456,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,A,1,N,1,,BAO_0000218
13117,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628457,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,A,1,N,1,,BAO_0000218
13118,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL877505,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,A,1,N,1,,BAO_0000218
13119,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628458,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,A,1,N,1,,BAO_0000218
13120,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628459,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,A,1,N,1,,BAO_0000218
13121,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628460,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,A,1,N,1,,BAO_0000218
13122,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628461,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,A,1,N,1,,BAO_0000218
13123,,,,Autocuration,,6996,CHEMBL628462,22224,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,B,1,U,0,,BAO_0000218
13124,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL628463,50588,,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,A,1,N,1,,BAO_0000218
13125,,,10116.0,Expert,Rattus norvegicus,6996,CHEMBL625666,50597,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,F,1,N,1,,BAO_0000218
13126,,,,Autocuration,,6996,CHEMBL625667,22224,,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,B,1,U,0,,BAO_0000218
13127,,,10116.0,Expert,Rattus norvegicus,6996,CHEMBL625668,50597,,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,A,1,N,1,,BAO_0000218
13128,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL625669,50597,,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,A,1,N,1,,BAO_0000218
13129,,,,Autocuration,,7114,CHEMBL625670,22224,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,A,1,U,0,,BAO_0000019
13130,,,10116.0,Intermediate,Rattus norvegicus,7114,CHEMBL625671,50597,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,A,1,N,1,,BAO_0000218
13131,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL625672,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,A,1,N,1,,BAO_0000218
13132,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL625673,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,A,1,N,1,,BAO_0000218
13133,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL625674,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,A,1,N,1,,BAO_0000218
13134,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL625675,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,A,1,N,1,,BAO_0000218
13135,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL627637,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,A,1,N,1,,BAO_0000218
13136,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL627638,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,A,1,N,1,,BAO_0000218
13137,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL627639,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,A,1,N,1,,BAO_0000218
13138,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL627640,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,A,1,N,1,,BAO_0000218
13139,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL627641,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,A,1,N,1,,BAO_0000218
13140,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL627642,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,A,1,N,1,,BAO_0000218
13141,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL877506,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,A,1,N,1,,BAO_0000218
13142,,,10090.0,Intermediate,Mus musculus,8613,CHEMBL627275,50594,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,A,1,N,1,,BAO_0000218
13143,,,9669.0,Intermediate,Mustela putorius furo,11219,CHEMBL627643,50506,,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,A,1,N,1,,BAO_0000218
13144,,,9669.0,Intermediate,Mustela putorius furo,11219,CHEMBL631246,50506,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,A,1,N,1,,BAO_0000218
13145,,,9669.0,Intermediate,Mustela putorius furo,11219,CHEMBL631247,50506,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,A,1,N,1,,BAO_0000218
13146,,,9669.0,Intermediate,Mustela putorius furo,11219,CHEMBL629532,50506,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,A,1,N,1,,BAO_0000218
13147,,,9669.0,Intermediate,Mustela putorius furo,11219,CHEMBL629533,50506,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,A,1,N,1,,BAO_0000218
13148,,,9669.0,Intermediate,Mustela putorius furo,11219,CHEMBL629534,50506,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,A,1,N,1,,BAO_0000218
13149,,,9669.0,Intermediate,Mustela putorius furo,11219,CHEMBL629535,50506,,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,A,1,N,1,,BAO_0000218
13150,,,,Autocuration,,14837,CHEMBL625932,22224,,,,Pharmacokinetic parameter :drug bound to plasma was reported,,A,1,U,0,,BAO_0000019
13151,,,,Autocuration,,14837,CHEMBL625933,22224,,,,compound was evaluated for drug bound in plasma,,A,1,U,0,,BAO_0000019
13152,,,10116.0,Intermediate,Rattus norvegicus,15343,CHEMBL625934,50597,,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,A,1,N,1,,BAO_0000218
13153,,,9347.0,Autocuration,Eutheria,13761,CHEMBL625935,22224,,,,Bioavailability,,A,1,U,0,,BAO_0000218
13154,,,10116.0,Intermediate,Rattus norvegicus,14810,CHEMBL625936,50597,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,A,1,N,1,,BAO_0000218
13155,,,10116.0,Intermediate,Rattus norvegicus,14810,CHEMBL625937,50597,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,A,1,N,1,,BAO_0000218
13156,,,9615.0,Intermediate,Canis lupus familiaris,13249,CHEMBL625938,50588,,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,A,1,N,1,,BAO_0000218
13157,,1970.0,10116.0,Intermediate,Rattus norvegicus,9267,CHEMBL625939,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,A,1,N,1,,BAO_0000218
13158,,1970.0,10116.0,Intermediate,Rattus norvegicus,9267,CHEMBL625940,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,A,1,N,1,,BAO_0000218
13159,,1970.0,10116.0,Intermediate,Rattus norvegicus,9267,CHEMBL874464,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,A,1,N,1,,BAO_0000218
13160,,1970.0,10116.0,Intermediate,Rattus norvegicus,9267,CHEMBL625941,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,A,1,N,1,,BAO_0000218
13161,,1970.0,10116.0,Intermediate,Rattus norvegicus,9267,CHEMBL625942,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,A,1,N,1,,BAO_0000218
13162,,1970.0,10116.0,Intermediate,Rattus norvegicus,9267,CHEMBL625943,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,A,1,N,1,,BAO_0000218
13163,,1977.0,9606.0,Intermediate,Homo sapiens,15549,CHEMBL625944,50587,,,Serum,In vitro protein binding in human serum at 5 ug/ml,,A,1,N,1,,BAO_0000218
13164,,,,Autocuration,,10929,CHEMBL625945,22224,,,,Serum protein binding ability was measured,,A,1,U,0,,BAO_0000019
13165,,,,Autocuration,,15444,CHEMBL625946,22224,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,A,1,U,0,,BAO_0000019
13166,,,9615.0,Autocuration,Canis lupus familiaris,12860,CHEMBL625947,22224,,,,Oral bioavailability in dog,,A,1,U,0,,BAO_0000218
13167,,,10116.0,Intermediate,Rattus norvegicus,12170,CHEMBL625948,50597,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,A,1,N,1,,BAO_0000218
13168,,,,Autocuration,,15173,CHEMBL625949,22224,,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,,A,1,U,0,,BAO_0000218
13169,,,,Autocuration,,15173,CHEMBL625950,22224,,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,A,1,U,0,,BAO_0000218
13170,,,9347.0,Autocuration,Eutheria,15173,CHEMBL625951,22224,,,,Oral bioavailability (dose 15 mg/kg i.v.),,A,1,U,0,,BAO_0000218
13171,,,,Autocuration,,15173,CHEMBL625952,22224,,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,A,1,U,0,,BAO_0000218
13172,,,,Autocuration,,15173,CHEMBL625953,22224,,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,A,1,U,0,,BAO_0000218
13173,,,,Autocuration,,15173,CHEMBL625954,22224,,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,A,1,U,0,,BAO_0000218
13174,,,,Autocuration,,15173,CHEMBL882959,22224,,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,A,1,U,0,,BAO_0000218
13175,,,9615.0,Intermediate,Canis lupus familiaris,11767,CHEMBL625955,50588,,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,A,1,N,1,,BAO_0000218
13176,,,9669.0,Autocuration,Mustela putorius furo,11219,CHEMBL625956,22224,,,,Bioavailability in ferret,,A,1,U,0,,BAO_0000218
13177,,,9541.0,Intermediate,Macaca fascicularis,12186,CHEMBL625957,100710,,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,A,1,N,1,,BAO_0000218
13178,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL625958,50597,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,A,1,N,1,,BAO_0000218
13179,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL625959,50597,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,A,1,N,1,,BAO_0000218
13180,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626642,50597,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,A,1,N,1,,BAO_0000218
13181,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL631330,50597,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,A,1,N,1,,BAO_0000218
13182,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL631331,50597,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,A,1,N,1,,BAO_0000218
13183,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL631332,50597,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,A,1,N,1,,BAO_0000218
13184,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL631333,50597,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,A,1,N,1,,BAO_0000218
13185,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632018,50597,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,A,1,N,1,,BAO_0000218
13186,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632019,50597,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,A,1,N,1,,BAO_0000218
13187,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632020,50597,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,A,1,N,1,,BAO_0000218
13188,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632021,50597,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,A,1,N,1,,BAO_0000218
13189,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632022,50597,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,A,1,N,1,,BAO_0000218
13190,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632023,50597,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,A,1,N,1,,BAO_0000218
13191,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632024,50597,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,A,1,N,1,,BAO_0000218
13192,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL874472,50597,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,A,1,N,1,,BAO_0000218
13193,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632025,50597,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,A,1,N,1,,BAO_0000218
13194,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632026,50597,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,A,1,N,1,,BAO_0000218
13195,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632027,50597,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,A,1,N,1,,BAO_0000218
13196,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL632028,50597,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,A,1,N,1,,BAO_0000218
13197,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626430,50597,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,A,1,N,1,,BAO_0000218
13198,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626431,50597,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,A,1,N,1,,BAO_0000218
13199,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626432,50597,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,A,1,N,1,,BAO_0000218
13200,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626433,50597,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,A,1,N,1,,BAO_0000218
13201,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626434,50597,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,A,1,N,1,,BAO_0000218
13202,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627280,50597,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,A,1,N,1,,BAO_0000218
13203,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627281,50597,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,A,1,N,1,,BAO_0000218
13204,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627282,50597,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,A,1,N,1,,BAO_0000218
13205,,,,Autocuration,,7199,CHEMBL627283,22224,,,,Total body clearance was measured at given dose,,A,1,U,0,,BAO_0000019
13206,,,,Autocuration,,7199,CHEMBL627284,22224,,,,Total body clearance was measured at given dose.,,A,1,U,0,,BAO_0000218
13207,,,10116.0,Intermediate,Rattus norvegicus,7095,CHEMBL627285,50597,,,,Metabolic clearance from the body in rat,,A,1,N,1,,BAO_0000218
13208,,,,Autocuration,,7095,CHEMBL627286,22224,,,,Renal clearance from the body,,A,1,U,0,,BAO_0000218
13209,,,10116.0,Intermediate,Rattus norvegicus,7095,CHEMBL875477,50597,,,,Renal clearance from the body in rat,,A,1,N,1,,BAO_0000218
13210,,,10116.0,Intermediate,Rattus norvegicus,12528,CHEMBL627287,50597,,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,A,1,N,1,,BAO_0000218
13211,,,9615.0,Intermediate,Canis lupus familiaris,12528,CHEMBL627288,50588,,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,A,1,N,1,,BAO_0000218
13212,,,10116.0,Intermediate,Rattus norvegicus,7095,CHEMBL627289,50597,,,,Total clearance from the body in rat,,A,1,N,1,,BAO_0000218
13213,,1969.0,10116.0,Intermediate,Rattus norvegicus,14223,CHEMBL627290,50597,,,Plasma,Clearance into cortex from rat plasma or PBS,,A,1,N,1,,BAO_0000218
13214,,,,Autocuration,,13569,CHEMBL627291,22224,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,A,1,U,0,,BAO_0000218
13215,,,,Autocuration,,13569,CHEMBL627292,22224,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,A,1,U,0,,BAO_0000218
13216,,,,Autocuration,,13569,CHEMBL627293,22224,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,A,1,U,0,,BAO_0000218
13217,,,,Autocuration,,13569,CHEMBL627294,22224,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,A,1,U,0,,BAO_0000218
13218,,,,Autocuration,,13569,CHEMBL875478,22224,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,A,1,U,0,,BAO_0000218
13219,,,,Autocuration,,13979,CHEMBL627295,22224,,,,Clearance was determined,,A,1,U,0,,BAO_0000218
13220,,,10090.0,Intermediate,Mus musculus,14315,CHEMBL627296,50594,,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,A,1,N,1,,BAO_0000218
13221,,,9986.0,Intermediate,Oryctolagus cuniculus,14315,CHEMBL626119,50592,,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,A,1,N,1,,BAO_0000218
13222,,,10116.0,Intermediate,Rattus norvegicus,14315,CHEMBL626120,50597,,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,A,1,N,1,,BAO_0000218
13223,,,10116.0,Intermediate,Rattus norvegicus,12174,CHEMBL626121,50597,,,,Clearance in rat after iv dose (100 ug/kg),,A,1,N,1,,BAO_0000218
13224,,,10141.0,Autocuration,Cavia porcellus,12797,CHEMBL626122,22224,,,,Clearance in guinea pig,,A,1,U,0,,BAO_0000218
13225,,,10116.0,Intermediate,Rattus norvegicus,12797,CHEMBL626123,50597,,,,Compound was evaluated for clearance in rat,,A,1,N,1,,BAO_0000218
13226,,,9615.0,Intermediate,Canis lupus familiaris,12797,CHEMBL623456,50588,,,,Compound was evaluated for the clearance in dog,,A,1,N,1,,BAO_0000218
13227,,,10116.0,Intermediate,Rattus norvegicus,12797,CHEMBL623457,50597,,,,Compound was evaluated for the clearance in rat,,A,1,N,1,,BAO_0000218
13228,,,10116.0,Intermediate,Rattus norvegicus,11500,CHEMBL623458,50597,,,,Compound was tested in vivo for clearance after iv administration in the rat,,A,1,N,1,,BAO_0000218
13229,,,,Autocuration,,15173,CHEMBL623459,22224,,,,IV clearance determined at an iv dose of 14 mg/kg,,A,1,U,0,,BAO_0000218
13230,,,,Autocuration,,15173,CHEMBL875484,22224,,,,IV clearance determined at an iv dose of 15.2 mg/kg,,A,1,U,0,,BAO_0000218
13231,,,,Autocuration,,15173,CHEMBL623460,22224,,,,IV clearance determined at an iv dose of 15 mg/kg,,A,1,U,0,,BAO_0000218
13232,,,,Autocuration,,15173,CHEMBL623461,22224,,,,IV clearance determined at an peroral dose of 30 mg/kg.,,A,1,U,0,,BAO_0000218
13233,,,,Autocuration,,15173,CHEMBL623462,22224,,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,,A,1,U,0,,BAO_0000218
13234,,,,Autocuration,,15173,CHEMBL627386,22224,,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,,A,1,U,0,,BAO_0000218
13235,,2113.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627387,50597,,,Kidney,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,A,1,N,1,,BAO_0000218
13236,,2107.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627388,50597,,,Liver,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,A,1,N,1,,BAO_0000218
13237,,2048.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627389,50597,,,Lung,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,A,1,N,1,,BAO_0000218
13238,,2385.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627390,50597,,,Muscle tissue,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,A,1,N,1,,BAO_0000218
13239,,1969.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627391,50597,,,Plasma,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,A,1,N,1,,BAO_0000218
13240,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627392,50597,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,A,1,N,1,,BAO_0000218
13241,,2106.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627393,50597,,,Spleen,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,A,1,N,1,,BAO_0000218
13242,,3126.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627394,50597,,,Trachea,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,A,1,N,1,,BAO_0000218
13243,,10000001.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627395,50597,,,Bone,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,A,1,N,1,,BAO_0000218
13244,,2037.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL875485,50597,,,Cerebellum,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,A,1,N,1,,BAO_0000218
13245,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627396,50597,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,A,1,N,1,,BAO_0000218
13246,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627397,50597,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,A,1,N,1,,BAO_0000218
13247,,948.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627398,50597,,,Heart,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,A,1,N,1,,BAO_0000218
13248,,10000001.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627399,50597,,,Bone,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,A,1,N,1,,BAO_0000218
13249,,2113.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627400,50597,,,Kidney,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,A,1,N,1,,BAO_0000218
13250,,2107.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627401,50597,,,Liver,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,A,1,N,1,,BAO_0000218
13251,,2048.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627402,50597,,,Lung,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,A,1,N,1,,BAO_0000218
13252,,2385.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627403,50597,,,Muscle tissue,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,A,1,N,1,,BAO_0000218
13253,,1969.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL627404,50597,,,Plasma,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,A,1,N,1,,BAO_0000218
13254,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623101,50597,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,A,1,N,1,,BAO_0000218
13255,,2106.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL877480,50597,,,Spleen,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,A,1,N,1,,BAO_0000218
13256,,3126.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623102,50597,,,Trachea,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,A,1,N,1,,BAO_0000218
13257,,10000001.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623103,50597,,,Bone,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,A,1,N,1,,BAO_0000218
13258,,2037.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623104,50597,,,Cerebellum,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,A,1,N,1,,BAO_0000218
13259,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623105,50597,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,A,1,N,1,,BAO_0000218
13260,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623106,50597,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,A,1,N,1,,BAO_0000218
13261,,948.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623107,50597,,,Heart,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,A,1,N,1,,BAO_0000218
13262,,160.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623108,50597,,,Intestine,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,A,1,N,1,,BAO_0000218
13263,,2113.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623109,50597,,,Kidney,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,A,1,N,1,,BAO_0000218
13264,,2107.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623110,50597,,,Liver,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,A,1,N,1,,BAO_0000218
13265,,2048.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL623111,50597,,,Lung,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,A,1,N,1,,BAO_0000218
13266,,2385.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625060,50597,,,Muscle tissue,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,A,1,N,1,,BAO_0000218
13267,,1969.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625061,50597,,,Plasma,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,A,1,N,1,,BAO_0000218
13268,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625062,50597,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,A,1,N,1,,BAO_0000218
13269,,2106.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625063,50597,,,Spleen,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,A,1,N,1,,BAO_0000218
13270,,3126.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625064,50597,,,Trachea,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,A,1,N,1,,BAO_0000218
13271,,10000001.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625065,50597,,,Bone,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,A,1,N,1,,BAO_0000218
13272,,2037.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625066,50597,,,Cerebellum,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,A,1,N,1,,BAO_0000218
13273,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625067,50597,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,A,1,N,1,,BAO_0000218
13274,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL625068,50597,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,A,1,N,1,,BAO_0000218
13275,,948.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622159,50597,,,Heart,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,A,1,N,1,,BAO_0000218
13276,,160.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622160,50597,,,Intestine,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,A,1,N,1,,BAO_0000218
13277,,2113.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622161,50597,,,Kidney,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,A,1,N,1,,BAO_0000218
13278,,2048.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622162,50597,,,Lung,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,A,1,N,1,,BAO_0000218
13279,,2385.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622163,50597,,,Muscle tissue,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,A,1,N,1,,BAO_0000218
13280,,1969.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622313,50597,,,Plasma,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,A,1,N,1,,BAO_0000218
13281,,,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622314,50597,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,A,1,N,1,,BAO_0000218
13282,,2106.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622315,50597,,,Spleen,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,A,1,N,1,,BAO_0000218
13283,,3126.0,10116.0,Intermediate,Rattus norvegicus,14198,CHEMBL622316,50597,,,Trachea,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,A,1,N,1,,BAO_0000218
13284,,,562.0,Intermediate,Escherichia coli,15599,CHEMBL877486,50212,,,,Normal diffusion coefficient in water for Escherichia coli,,A,1,N,1,,BAO_0000218
13285,,,,Autocuration,,8204,CHEMBL622317,22224,,,,Average max percent decrease in RVR (renal vascular resistance) was determined,,A,1,U,0,,BAO_0000019
13286,,,,Autocuration,,8204,CHEMBL622318,22224,,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,,A,1,U,0,,BAO_0000019
13287,,,,Autocuration,,6154,CHEMBL622319,22224,,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,A,1,U,0,,BAO_0000019
13288,,,,Autocuration,,6154,CHEMBL622320,22224,,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,A,1,U,0,,BAO_0000019
13289,,,,Autocuration,,6154,CHEMBL622321,22224,,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,A,1,U,0,,BAO_0000019
13290,,,,Autocuration,,6154,CHEMBL622322,22224,,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,A,1,U,0,,BAO_0000019
13291,,,,Autocuration,,7114,CHEMBL622323,22224,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,A,1,U,0,,BAO_0000019
13292,,,10116.0,Intermediate,Rattus norvegicus,7114,CHEMBL622324,50597,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,A,1,N,1,,BAO_0000218
13293,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622325,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,A,1,N,1,,BAO_0000218
13294,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622326,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13295,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL877487,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13296,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622327,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,A,1,N,1,,BAO_0000218
13297,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622328,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13298,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622329,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,A,1,N,1,,BAO_0000218
13299,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622330,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,A,1,N,1,,BAO_0000218
13300,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622331,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,A,1,N,1,,BAO_0000218
13301,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622332,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,A,1,N,1,,BAO_0000218
13302,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL622333,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,A,1,N,1,,BAO_0000218
13303,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL627658,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,A,1,U,0,,BAO_0000218
13304,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL630428,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,A,1,U,0,,BAO_0000218
13305,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL630429,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,A,1,U,0,,BAO_0000218
13306,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL630430,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,A,1,U,0,,BAO_0000218
13307,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL630431,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,A,1,U,0,,BAO_0000218
13308,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL630432,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,A,1,N,1,,BAO_0000218
13309,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL630433,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,A,1,N,1,,BAO_0000218
13310,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL630434,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,A,1,N,1,,BAO_0000218
13311,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629372,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,A,1,N,1,,BAO_0000218
13312,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629553,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,A,1,N,1,,BAO_0000218
13313,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629554,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,A,1,N,1,,BAO_0000218
13314,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL874447,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,A,1,N,1,,BAO_0000218
13315,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629555,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,A,1,N,1,,BAO_0000218
13316,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629556,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,A,1,N,1,,BAO_0000218
13317,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629557,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13318,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629558,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,A,1,N,1,,BAO_0000218
13319,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629559,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,A,1,N,1,,BAO_0000218
13320,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629560,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,A,1,N,1,,BAO_0000218
13321,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629561,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,A,1,N,1,,BAO_0000218
13322,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629562,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,A,1,N,1,,BAO_0000218
13323,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629563,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,A,1,N,1,,BAO_0000218
13324,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629564,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13325,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629565,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,A,1,N,1,,BAO_0000218
13326,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629566,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,A,1,N,1,,BAO_0000218
13327,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629567,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,A,1,N,1,,BAO_0000218
13328,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629568,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,A,1,N,1,,BAO_0000218
13329,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629569,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,A,1,N,1,,BAO_0000218
13330,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL629570,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,A,1,N,1,,BAO_0000218
13331,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL629571,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,A,1,U,0,,BAO_0000218
13332,,,10116.0,Autocuration,Rattus norvegicus,12170,CHEMBL629572,22224,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,A,1,U,0,,BAO_0000218
13333,,,10116.0,Autocuration,Rattus norvegicus,12170,CHEMBL629573,22224,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,A,1,U,0,,BAO_0000218
13334,,,9347.0,Autocuration,Eutheria,4985,CHEMBL629574,22224,,,,Bioavailability (dose 20 mg/kg),,A,1,U,0,,BAO_0000218
13335,,,9615.0,Autocuration,Canis lupus familiaris,15145,CHEMBL629575,22224,,,,Bioavailability in dog,,A,1,U,0,,BAO_0000218
13336,,,10116.0,Autocuration,Rattus norvegicus,14080,CHEMBL874448,22224,,,,Bioavailability in rat (Sprague-Dawley) (male),,A,1,U,0,,BAO_0000218
13337,,,9443.0,Autocuration,Primates,11219,CHEMBL629576,22224,,,,Bioavailability in monkey (dose 10 mg/kg i.d.),,A,1,U,0,,BAO_0000218
13338,,,10116.0,Autocuration,Rattus norvegicus,15145,CHEMBL629577,22224,,,,Bioavailability in rat,,A,1,U,0,,BAO_0000218
13339,,,10116.0,Autocuration,Rattus norvegicus,15145,CHEMBL629578,22224,,,,Bioavailability in rat,,A,1,U,0,,BAO_0000218
13340,,,9615.0,Autocuration,Canis lupus familiaris,1202,CHEMBL629579,22224,,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),,A,1,U,0,,BAO_0000218
13341,,,9615.0,Autocuration,Canis lupus familiaris,1202,CHEMBL882958,22224,,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,A,1,U,0,,BAO_0000218
13342,,,9598.0,Intermediate,Pan troglodytes,1202,CHEMBL629580,50505,,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,A,1,N,1,,BAO_0000218
13343,,,9347.0,Autocuration,Eutheria,4026,CHEMBL629581,22224,,,,Bioavailability,,A,1,U,0,,BAO_0000218
13344,,,9520.0,Autocuration,Saimiri,1492,CHEMBL629582,22224,,,,Bioavailability in squirrel monkey,,A,1,U,0,,BAO_0000218
13345,,,9615.0,Intermediate,Canis lupus familiaris,12793,CHEMBL628522,50588,,,,Bioavailability was evaluated in dog,,A,1,N,1,,BAO_0000218
13346,,,10026.0,Intermediate,Cricetinae,12793,CHEMBL625432,100712,,,,Bioavailability was evaluated in hamster,,A,1,N,1,,BAO_0000218
13347,,,10116.0,Autocuration,Rattus norvegicus,12793,CHEMBL625433,22224,,,,Bioavailability in rat,,A,1,U,0,,BAO_0000218
13348,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL625434,50597,,,Plasma,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
13349,,1969.0,10116.0,Intermediate,Rattus norvegicus,14793,CHEMBL625435,50597,,,Plasma,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,A,1,N,1,,BAO_0000218
13350,,,10116.0,Autocuration,Rattus norvegicus,14793,CHEMBL625436,22224,,,,Bioavailability in rat (dose 10 mg/kg p.o.),,A,1,U,0,,BAO_0000218
13351,,,9541.0,Intermediate,Macaca fascicularis,14731,CHEMBL874588,100710,,,,Bioavailability was measured in cynomolgus monkeys.,,A,1,N,1,,BAO_0000218
13352,,,10090.0,Intermediate,Mus musculus,14731,CHEMBL625437,50594,,,,Bioavailability was measured in nude mice.,,A,1,N,1,,BAO_0000218
13353,,,9669.0,Autocuration,Mustela putorius furo,12187,CHEMBL625438,22224,,,,Bioavailability in ferret (dose 10 mg/kg i.d.),,A,1,U,0,,BAO_0000218
13354,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL625439,22224,,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,A,1,U,0,,BAO_0000218
13355,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL625440,22224,,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,A,1,U,0,,BAO_0000218
13356,,,314293.0,Autocuration,Simiiformes,12187,CHEMBL625441,22224,,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,A,1,U,0,,BAO_0000218
13357,,,10116.0,Autocuration,Rattus norvegicus,12187,CHEMBL625442,22224,,,,Bioavailability in rat (dose 10 mg/kg i.d.),,A,1,U,0,,BAO_0000218
13358,,,10116.0,Intermediate,Rattus norvegicus,12187,CHEMBL625443,50597,,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,A,1,N,1,,BAO_0000218
13359,,,,Autocuration,,17431,CHEMBL625444,22224,,,,Bioavailability was determined; extremely poor,,A,1,U,0,,BAO_0000218
13360,,,10090.0,Intermediate,Mus musculus,13318,CHEMBL625445,50594,,,,% bioavailability in mice after oral administration of prodrug,,A,1,N,1,,BAO_0000218
13361,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625446,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,A,1,N,1,,BAO_0000218
13362,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL882960,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,A,1,N,1,,BAO_0000218
13363,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625447,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,A,1,N,1,,BAO_0000218
13364,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625448,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,A,1,N,1,,BAO_0000218
13365,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625449,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,A,1,N,1,,BAO_0000218
13366,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL874589,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,A,1,N,1,,BAO_0000218
13367,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625450,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,A,1,N,1,,BAO_0000218
13368,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625451,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,A,1,N,1,,BAO_0000218
13369,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL626584,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,A,1,N,1,,BAO_0000218
13370,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL626585,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,A,1,N,1,,BAO_0000218
13371,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL626586,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,A,1,N,1,,BAO_0000218
13372,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL626587,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,A,1,N,1,,BAO_0000218
13373,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL626588,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,A,1,N,1,,BAO_0000218
13374,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL626589,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,A,1,N,1,,BAO_0000218
13375,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL626590,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,A,1,N,1,,BAO_0000218
13376,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL626591,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,A,1,N,1,,BAO_0000218
13377,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL627181,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,A,1,N,1,,BAO_0000218
13378,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628083,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,A,1,N,1,,BAO_0000218
13379,,,,Autocuration,,15173,CHEMBL628084,22224,,,,IV clearance determined at an peroral dose of 15 mg/kg.,,A,1,U,0,,BAO_0000218
13380,,,102285.0,Expert,Hymenolepis nana,7732,CHEMBL628085,50064,,,,Mouse oral clearance was measured against Hymenolepiasis nana.,,F,1,N,1,,BAO_0000218
13381,,,6339.0,Expert,Heligmosomoides polygyrus,7732,CHEMBL628086,50545,,,,Mouse oral clearance was measured against Nematospiroides dubius,,F,1,N,1,,BAO_0000218
13382,,,,Autocuration,,7732,CHEMBL628087,22224,,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,F,1,U,0,,BAO_0000218
13383,,,10090.0,Intermediate,Mus musculus,7732,CHEMBL628088,50594,,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,A,1,N,1,,BAO_0000218
13384,,,,Autocuration,,7732,CHEMBL628089,22224,,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,B,1,U,0,,BAO_0000218
13385,,,,Autocuration,,8328,CHEMBL628090,22224,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13386,,,,Autocuration,,8328,CHEMBL628091,22224,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13387,,,,Autocuration,,8328,CHEMBL628092,22224,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13388,,,,Autocuration,,8328,CHEMBL628093,22224,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13389,,,,Autocuration,,8328,CHEMBL875607,22224,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13390,,,,Autocuration,,8328,CHEMBL625710,22224,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13391,,,,Autocuration,,8328,CHEMBL625711,22224,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13392,,,,Autocuration,,8328,CHEMBL625712,22224,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13393,,,,Autocuration,,8328,CHEMBL625713,22224,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,A,1,U,0,,BAO_0000218
13394,,,9615.0,Intermediate,Canis lupus familiaris,13376,CHEMBL625714,50588,,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,A,1,N,1,,BAO_0000218
13395,,,9544.0,Intermediate,Macaca mulatta,13477,CHEMBL625715,50797,,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,A,1,N,1,,BAO_0000218
13396,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL625716,50597,,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,A,1,N,1,,BAO_0000218
13397,,,10116.0,Intermediate,Rattus norvegicus,13477,CHEMBL625717,50597,,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,A,1,N,1,,BAO_0000218
13398,,,10116.0,Intermediate,Rattus norvegicus,13313,CHEMBL625718,50597,,,,Plasma clearance was determined for the compound in rats,,A,1,N,1,,BAO_0000218
13399,,,10116.0,Intermediate,Rattus norvegicus,12504,CHEMBL625719,50597,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,A,1,N,1,,BAO_0000218
13400,,,10116.0,Intermediate,Rattus norvegicus,12504,CHEMBL625720,50597,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,A,1,N,1,,BAO_0000218
13401,,,10116.0,Intermediate,Rattus norvegicus,12504,CHEMBL625721,50597,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,A,1,N,1,,BAO_0000218
13402,,,10116.0,Intermediate,Rattus norvegicus,12504,CHEMBL625722,50597,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,A,1,N,1,,BAO_0000218
13403,,,10116.0,Intermediate,Rattus norvegicus,13129,CHEMBL625723,50597,,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,A,1,N,1,,BAO_0000218
13404,,,6339.0,Intermediate,Heligmosomoides polygyrus,7732,CHEMBL625724,50545,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,A,1,N,1,,BAO_0000218
13405,,,6339.0,Intermediate,Heligmosomoides polygyrus,7732,CHEMBL625725,50545,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,A,1,N,1,,BAO_0000218
13406,,,6339.0,Intermediate,Heligmosomoides polygyrus,7732,CHEMBL625726,50545,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,A,1,N,1,,BAO_0000218
13407,,,6339.0,Intermediate,Heligmosomoides polygyrus,7732,CHEMBL875608,50545,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,A,1,N,1,,BAO_0000218
13408,,,6339.0,Intermediate,Heligmosomoides polygyrus,7732,CHEMBL625727,50545,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,A,1,N,1,,BAO_0000218
13409,,1088.0,10116.0,Autocuration,Rattus norvegicus,9278,CHEMBL625728,22224,,,Urine,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,A,1,U,0,,BAO_0000218
13410,,,10116.0,Autocuration,Rattus norvegicus,9278,CHEMBL625729,22224,,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,A,1,U,0,,BAO_0000218
13411,,,10116.0,Autocuration,Rattus norvegicus,9278,CHEMBL625730,22224,,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,A,1,U,0,,BAO_0000218
13412,,1088.0,10116.0,Autocuration,Rattus norvegicus,9278,CHEMBL625731,22224,,,Urine,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,A,1,U,0,,BAO_0000218
13413,,1088.0,10116.0,Autocuration,Rattus norvegicus,9278,CHEMBL626417,22224,,,Urine,Urinary clearance was determined in rat at 25 mg/kg os dosage,,A,1,U,0,,BAO_0000218
13414,,1088.0,9606.0,Intermediate,Homo sapiens,9278,CHEMBL626418,50587,,,Urine,Urinary clearance was determined at 100 mg/kg oral dosage in human,,A,1,N,1,,BAO_0000218
13415,,1088.0,9615.0,Intermediate,Canis lupus familiaris,9278,CHEMBL626419,50588,,,Urine,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,A,1,N,1,,BAO_0000218
13416,,1969.0,9615.0,Intermediate,Canis lupus familiaris,5932,CHEMBL626592,50588,,,Plasma,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,A,1,N,1,,BAO_0000218
13417,,1969.0,10116.0,Intermediate,Rattus norvegicus,5932,CHEMBL626593,50597,,,Plasma,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,A,1,N,1,,BAO_0000218
13418,,,10116.0,Intermediate,Rattus norvegicus,5182,CHEMBL626594,50597,,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,A,1,N,1,,BAO_0000218
13419,,,9615.0,Intermediate,Canis lupus familiaris,10499,CHEMBL625035,50588,,,,Clearance rate in dogs,,A,1,N,1,,BAO_0000218
13420,,,,Autocuration,,6051,CHEMBL625036,22224,,,,Compound was measured for intrinsic clearance,,A,1,U,0,,BAO_0000019
13421,,,,Autocuration,,17508,CHEMBL625037,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13422,,,,Autocuration,,6228,CHEMBL625038,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13423,,,,Autocuration,,6231,CHEMBL625039,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13424,,,,Autocuration,,17740,CHEMBL625040,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13425,,,,Autocuration,,6495,CHEMBL625041,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13426,,,,Autocuration,,2171,CHEMBL625042,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13427,,,,Autocuration,,3255,CHEMBL874411,22224,,,,Partition coefficient of the compound,,A,1,U,0,,BAO_0000019
13428,,,,Autocuration,,6821,CHEMBL625043,22224,,,,Permeability,,A,1,U,0,,BAO_0000019
13429,,,,Autocuration,,2685,CHEMBL625044,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13430,,,,Autocuration,,17584,CHEMBL625045,22224,,,,Partition coefficient (logD),,A,1,U,0,,BAO_0000019
13431,,,,Autocuration,,13824,CHEMBL625046,22229,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,P,1,U,0,,BAO_0000100
13432,,,,Autocuration,,13824,CHEMBL625047,22229,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,P,1,U,0,,BAO_0000100
13433,,,,Autocuration,,16479,CHEMBL625048,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13434,,,,Autocuration,,11997,CHEMBL625049,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13435,,,,Autocuration,,2988,CHEMBL625050,22229,,,,Calculated logarithm of partition coefficient (P) was determined,,P,1,U,0,,BAO_0000100
13436,,,,Autocuration,,931,CHEMBL625051,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13437,,,,Autocuration,,4381,CHEMBL874412,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13438,,,,Autocuration,,4397,CHEMBL625052,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13439,,,,Autocuration,,5889,CHEMBL625053,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13440,,,,Autocuration,,6154,CHEMBL623250,22224,,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,A,1,U,0,,BAO_0000019
13441,,,,Autocuration,,6154,CHEMBL623251,22224,,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,A,1,U,0,,BAO_0000019
13442,,,,Autocuration,,6154,CHEMBL623252,22224,,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,A,1,U,0,,BAO_0000019
13443,,,,Autocuration,,6154,CHEMBL623253,22224,,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,A,1,U,0,,BAO_0000019
13444,,,,Autocuration,,6154,CHEMBL623254,22224,,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,A,1,U,0,,BAO_0000019
13445,,,,Autocuration,,6154,CHEMBL623255,22224,,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,A,1,U,0,,BAO_0000019
13446,,,,Autocuration,,6887,CHEMBL626831,22224,,,,Percent degradation of compound at a pH of 1 over a 18 hr period,,A,1,U,0,,BAO_0000019
13447,,,,Autocuration,,6887,CHEMBL877494,22224,,,,Percent degradation of compound at pH of 1 over an 18 hr period,,A,1,U,0,,BAO_0000019
13448,,,,Autocuration,,14116,CHEMBL626832,22224,,,,Delta Logarithm of Partition Coefficient value was determined.,,A,1,U,0,,BAO_0000019
13449,,,,Autocuration,,11137,CHEMBL626833,22224,,,,Delta logPoct-cyc,,A,1,U,0,,BAO_0000019
13450,,,,Autocuration,,7230,CHEMBL626834,22224,,,,Lipophilicity estimated on reversed phase TLC,,P,1,U,0,,BAO_0000100
13451,,,,Autocuration,,15741,CHEMBL626835,22224,,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,A,1,U,0,,BAO_0000019
13452,,,,Autocuration,,9663,CHEMBL626836,22224,,,,Delta logPoct-cyc,,A,1,U,0,,BAO_0000019
13453,,,,Autocuration,,9663,CHEMBL626837,22229,,,,Change in logarithm of partition coefficient of the compound,,P,1,U,0,,BAO_0000100
13454,,,,Autocuration,,13807,CHEMBL626838,22224,,,,Delta logD (pH 6.5),,A,1,U,0,,BAO_0000019
13455,,,,Autocuration,,13807,CHEMBL626839,22224,,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,P,1,U,0,,BAO_0000100
13456,,,,Autocuration,,17425,CHEMBL626840,22224,,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,A,1,U,0,,BAO_0000019
13457,,,,Autocuration,,12143,CHEMBL626841,22224,,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,A,1,U,0,,BAO_0000019
13458,,,,Autocuration,,12608,CHEMBL626842,22224,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,A,1,U,0,,BAO_0000219
13459,,,,Autocuration,,12608,CHEMBL626843,22224,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,A,1,U,0,,BAO_0000219
13460,,,10116.0,Intermediate,Rattus norvegicus,8649,CHEMBL626844,50597,,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,A,1,N,1,,BAO_0000218
13461,,,10116.0,Intermediate,Rattus norvegicus,8649,CHEMBL877495,50597,,,,Amount of deuterium retained was reported after normal workup in rats,,A,1,N,1,,BAO_0000218
13462,,,10116.0,Intermediate,Rattus norvegicus,8649,CHEMBL626845,50597,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,A,1,N,1,,BAO_0000218
13463,,,10116.0,Intermediate,Rattus norvegicus,8649,CHEMBL626846,50597,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,A,1,N,1,,BAO_0000218
13464,,,10116.0,Intermediate,Rattus norvegicus,8649,CHEMBL626847,50597,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,A,1,N,1,,BAO_0000218
13465,,,10116.0,Intermediate,Rattus norvegicus,8649,CHEMBL628677,50597,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,A,1,N,1,,BAO_0000218
13466,,,10116.0,Intermediate,Rattus norvegicus,8649,CHEMBL628678,50597,,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,A,1,N,1,,BAO_0000218
13467,,,,Autocuration,,9659,CHEMBL628679,22224,,,,Compound was subjected to electrochemical oxidation,,A,1,U,0,,BAO_0000019
13468,,,,Autocuration,,9659,CHEMBL628680,22224,,,,Compound was subjected to photochemical oxidation,,A,1,U,0,,BAO_0000019
13469,,,,Autocuration,,9659,CHEMBL628681,22224,,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,A,1,U,0,,BAO_0000019
13470,,,,Autocuration,,9659,CHEMBL628682,22224,,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,A,1,U,0,,BAO_0000019
13471,,,,Autocuration,,9659,CHEMBL628683,22224,,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,,A,1,U,0,,BAO_0000019
13472,,,10116.0,Intermediate,Rattus norvegicus,9607,CHEMBL628684,50597,,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,,A,1,N,1,,BAO_0000218
13473,,,,Autocuration,,7057,CHEMBL877501,22229,,,,Dissociation constant (pKa),,P,1,U,0,,BAO_0000100
13474,,,,Autocuration,,7057,CHEMBL628685,22224,,,,Dissociation constant value of the compound; ND means not determined.,,P,1,U,0,,BAO_0000100
13475,,178.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL628686,50597,,,Blood,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,A,1,N,1,,BAO_0000218
13476,,178.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL628687,50597,,,Blood,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,A,1,N,1,,BAO_0000218
13477,,,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL628688,50597,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,A,1,N,1,,BAO_0000218
13478,,,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL628689,50597,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,A,1,N,1,,BAO_0000218
13479,,2107.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL628690,50597,,,Liver,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,A,1,N,1,,BAO_0000218
13480,,2107.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL629363,50597,,,Liver,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,A,1,N,1,,BAO_0000218
13481,,2106.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL629364,50597,,,Spleen,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,A,1,N,1,,BAO_0000218
13482,,2106.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL629365,50597,,,Spleen,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,A,1,N,1,,BAO_0000218
13483,,,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL629366,50597,,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,A,1,N,1,,BAO_0000218
13484,,1088.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL629367,50597,,,Urine,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,A,1,N,1,,BAO_0000218
13485,,1988.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL629368,50597,,,Feces,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,A,1,N,1,,BAO_0000218
13486,,1088.0,10116.0,Intermediate,Rattus norvegicus,7911,CHEMBL877502,50597,,,Urine,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,A,1,N,1,,BAO_0000218
13487,,2037.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL629369,50594,,,Cerebellum,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,A,1,N,1,,BAO_0000218
13488,,955.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL629370,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,A,1,N,1,,BAO_0000218
13489,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL629371,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,A,1,U,0,,BAO_0000218
13490,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL626276,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,A,1,U,0,,BAO_0000218
13491,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL626277,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,A,1,U,0,,BAO_0000218
13492,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL631250,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,A,1,U,0,,BAO_0000218
13493,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL631251,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,A,1,N,1,,BAO_0000218
13494,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL631252,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,A,1,N,1,,BAO_0000218
13495,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL631253,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13496,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL631254,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,A,1,N,1,,BAO_0000218
13497,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL631255,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13498,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL631256,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,A,1,N,1,,BAO_0000218
13499,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL631257,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,A,1,N,1,,BAO_0000218
13500,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628009,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,A,1,N,1,,BAO_0000218
13501,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628010,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,A,1,N,1,,BAO_0000218
13502,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628011,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,A,1,N,1,,BAO_0000218
13503,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628012,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,A,1,N,1,,BAO_0000218
13504,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628013,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,A,1,N,1,,BAO_0000218
13505,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628014,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,A,1,N,1,,BAO_0000218
13506,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628015,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,A,1,N,1,,BAO_0000218
13507,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628016,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,A,1,N,1,,BAO_0000218
13508,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL874461,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,A,1,N,1,,BAO_0000218
13509,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628017,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13510,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628018,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,A,1,N,1,,BAO_0000218
13511,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628019,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,A,1,N,1,,BAO_0000218
13512,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628020,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,A,1,N,1,,BAO_0000218
13513,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628021,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,A,1,N,1,,BAO_0000218
13514,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628022,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,A,1,N,1,,BAO_0000218
13515,,1088.0,9615.0,Intermediate,Canis lupus familiaris,8133,CHEMBL628023,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,A,1,N,1,,BAO_0000218
13516,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL628024,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,A,1,U,0,,BAO_0000218
13517,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL628025,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,A,1,U,0,,BAO_0000218
13518,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL628026,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,A,1,U,0,,BAO_0000218
13519,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL628027,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,A,1,U,0,,BAO_0000218
13520,,1088.0,314293.0,Autocuration,Simiiformes,8133,CHEMBL628028,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,A,1,U,0,,BAO_0000218
13521,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628029,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,A,1,N,1,,BAO_0000218
13522,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628030,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,A,1,N,1,,BAO_0000218
13523,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628031,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,A,1,N,1,,BAO_0000218
13524,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628032,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13525,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628033,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13526,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628034,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,A,1,N,1,,BAO_0000218
13527,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628035,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,A,1,N,1,,BAO_0000218
13528,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL628036,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,A,1,N,1,,BAO_0000218
13529,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL874462,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,A,1,N,1,,BAO_0000218
13530,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628037,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,A,1,N,1,,BAO_0000218
13531,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628123,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,A,1,N,1,,BAO_0000218
13532,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628124,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,A,1,N,1,,BAO_0000218
13533,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628125,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,A,1,N,1,,BAO_0000218
13534,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628126,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,A,1,N,1,,BAO_0000218
13535,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628127,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,A,1,N,1,,BAO_0000218
13536,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628128,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,A,1,N,1,,BAO_0000218
13537,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628129,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,A,1,N,1,,BAO_0000218
13538,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628130,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,A,1,N,1,,BAO_0000218
13539,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628131,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,A,1,N,1,,BAO_0000218
13540,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628132,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,A,1,N,1,,BAO_0000218
13541,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628133,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,A,1,N,1,,BAO_0000218
13542,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628134,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,A,1,N,1,,BAO_0000218
13543,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628135,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,A,1,N,1,,BAO_0000218
13544,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628136,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,A,1,N,1,,BAO_0000218
13545,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628137,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,A,1,N,1,,BAO_0000218
13546,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628138,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,A,1,N,1,,BAO_0000218
13547,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628139,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,A,1,N,1,,BAO_0000218
13548,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628140,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,A,1,N,1,,BAO_0000218
13549,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628141,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,A,1,N,1,,BAO_0000218
13550,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628142,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,A,1,N,1,,BAO_0000218
13551,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628143,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,A,1,N,1,,BAO_0000218
13552,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628144,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,A,1,N,1,,BAO_0000218
13553,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628145,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,A,1,N,1,,BAO_0000218
13554,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL628146,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,A,1,N,1,,BAO_0000218
13555,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625355,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,A,1,N,1,,BAO_0000218
13556,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625356,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,A,1,N,1,,BAO_0000218
13557,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625357,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,A,1,N,1,,BAO_0000218
13558,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625527,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,A,1,N,1,,BAO_0000218
13559,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL875473,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,A,1,N,1,,BAO_0000218
13560,,,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL625528,50588,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,A,1,N,1,,BAO_0000218
13561,,,10116.0,Intermediate,Rattus norvegicus,9025,CHEMBL626304,50597,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,A,1,N,1,,BAO_0000218
13562,,1637.0,9615.0,Intermediate,Canis lupus familiaris,9025,CHEMBL624138,50588,,,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,A,1,N,1,,BAO_0000218
13563,,,,Autocuration,,6448,CHEMBL624139,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13564,,,,Autocuration,,17221,CHEMBL624140,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13565,,,,Autocuration,,6545,CHEMBL624141,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13566,,,,Autocuration,,577,CHEMBL624142,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13567,,,,Autocuration,,6285,CHEMBL624143,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13568,,,,Autocuration,,6500,CHEMBL624144,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13569,,,,Autocuration,,6716,CHEMBL624145,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13570,,,,Autocuration,,13658,CHEMBL624146,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13571,,,,Autocuration,,6549,CHEMBL624147,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13572,,,,Autocuration,,14685,CHEMBL883123,22229,,,,Calculated partition coefficient (clogP) (MacLogP),,P,1,U,0,,BAO_0000100
13573,,,,Autocuration,,6893,CHEMBL624148,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
13574,,,,Autocuration,,3687,CHEMBL874416,22224,,,,Kinetic parameter was determined,,A,1,U,0,,BAO_0000019
13575,,,,Autocuration,,4207,CHEMBL624149,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13576,,,,Autocuration,,4626,CHEMBL624150,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13577,,,,Autocuration,,1021,CHEMBL624151,22224,,,,Lipophilicity was determined,,P,1,U,0,,BAO_0000100
13578,,,,Autocuration,,3777,CHEMBL624152,22224,,,,Lipophilicity was determined,,P,1,U,0,,BAO_0000100
13579,,,,Autocuration,,17533,CHEMBL622139,22224,,,,Lipophilicity was determined,,P,1,U,0,,BAO_0000100
13580,,,,Autocuration,,6524,CHEMBL622140,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13581,,,,Autocuration,,17533,CHEMBL622141,22224,,,,Lipophilicity was determined,,P,1,U,0,,BAO_0000100
13582,,,,Autocuration,,6480,CHEMBL622142,22224,,,,Lipophilicity in octanol-water,,P,1,U,0,,BAO_0000100
13583,,,,Autocuration,,17606,CHEMBL622143,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13584,,,,Autocuration,,6863,CHEMBL622144,22229,,,,Octanol-water partition coefficient was determined,,P,1,U,0,,BAO_0000100
13585,,,,Autocuration,,1356,CHEMBL877473,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
13586,,,,Autocuration,,3326,CHEMBL622145,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13587,,,,Autocuration,,1356,CHEMBL622146,22224,,,,Partition coefficient was determined; ND means not determined,,A,1,U,0,,BAO_0000019
13588,,,,Autocuration,,12984,CHEMBL622147,22229,,,,Calculated partition coefficient (clogP),,P,1,U,0,,BAO_0000100
13589,,,,Autocuration,,17363,CHEMBL622148,22224,,,,Partition coefficient of the compound,,A,1,U,0,,BAO_0000019
13590,,,,Autocuration,,6827,CHEMBL883124,22224,,,,Permeability was determined,,A,1,U,0,,BAO_0000019
13591,,,,Autocuration,,261,CHEMBL622149,22229,,,,The compound was evaluated for the partition coefficient,,P,1,U,0,,BAO_0000100
13592,,,,Autocuration,,2685,CHEMBL622150,22224,,,,Partition coefficient (logP),,A,1,U,0,,BAO_0000019
13593,,,,Autocuration,,414,CHEMBL622151,22224,,,,The lipophilicity was reported,,P,1,U,0,,BAO_0000100
13594,,,,Autocuration,,15769,CHEMBL622152,22229,,,,logarithm of the octanol-water partition coefficient for the compound,,P,1,U,0,,BAO_0000100
13595,,,,Autocuration,,17248,CHEMBL622153,22224,,,,Clogp value was determined,,A,1,U,0,,BAO_0000019
13596,,,,Autocuration,,16935,CHEMBL877474,22224,,,,Clp at a dose of 1.5 mg/kg,,A,1,U,0,,BAO_0000218
13597,,,,Autocuration,,16935,CHEMBL622154,22224,,,,Clp at a dose of 2.0 mg/kg,,A,1,U,0,,BAO_0000218
13598,,1969.0,,Autocuration,,14832,CHEMBL622155,22224,,,Plasma,"Clp, plasma clearance at a dose of 10 mg/kg",,A,1,U,0,,BAO_0000218
13599,,1969.0,,Autocuration,,14832,CHEMBL622156,22224,,,Plasma,"Clp, plasma clearance at a dose of 50 mg/kg",,A,1,U,0,,BAO_0000218
13600,,1969.0,10116.0,Intermediate,Rattus norvegicus,2399,CHEMBL622157,50597,,,Plasma,Compound was tested for plasma clearance in rat,,A,1,N,1,,BAO_0000218
13601,,1969.0,10116.0,Intermediate,Rattus norvegicus,2399,CHEMBL622158,50597,,,Plasma,Compound was tested for plasma clearance in rat; Not determined,,A,1,N,1,,BAO_0000218
13602,,,10116.0,Intermediate,Rattus norvegicus,6227,CHEMBL622807,50597,,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,A,1,N,1,,BAO_0000218
13603,,,9544.0,Intermediate,Macaca mulatta,6227,CHEMBL622808,50797,,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,A,1,N,1,,BAO_0000218
13604,,,,Autocuration,,5623,CHEMBL622809,22224,,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,,A,1,U,0,,BAO_0000218
13605,,,,Autocuration,,4854,CHEMBL622810,22224,,,,Plasma clearance determined,,A,1,U,0,,BAO_0000218
13606,,,10026.0,Intermediate,Cricetinae,4493,CHEMBL876653,100712,,,,Plasma clearance after iv administration at 3 mg/kg in hamster,,A,1,N,1,,BAO_0000218
13607,,,10026.0,Intermediate,Cricetinae,4493,CHEMBL622811,100712,,,,Plasma clearance after iv administration at 4 mg/kg in hamster,,A,1,N,1,,BAO_0000218
13608,,,10116.0,Intermediate,Rattus norvegicus,14956,CHEMBL622986,50597,,,,Rate of clearance in rat was determined,,A,1,N,1,,BAO_0000218
13609,,1969.0,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL622987,50597,,,Plasma,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,A,1,N,1,,BAO_0000218
13610,,1969.0,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL622988,50597,,,Plasma,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,A,1,N,1,,BAO_0000218
13611,,1969.0,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL622989,50597,,,Plasma,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,A,1,N,1,,BAO_0000218
13612,,1969.0,10116.0,Intermediate,Rattus norvegicus,15372,CHEMBL622990,50597,,,Plasma,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,A,1,N,1,,BAO_0000218
13613,,1969.0,314293.0,Autocuration,Simiiformes,15604,CHEMBL622991,22224,,,Plasma,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,A,1,U,0,,BAO_0000218
13614,,1969.0,10116.0,Intermediate,Rattus norvegicus,15604,CHEMBL622227,50597,,,Plasma,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,A,1,N,1,,BAO_0000218
13615,,1969.0,9615.0,Intermediate,Canis lupus familiaris,15604,CHEMBL622228,50588,,,Plasma,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,A,1,N,1,,BAO_0000218
13616,,,10116.0,Intermediate,Rattus norvegicus,14964,CHEMBL622229,50597,,,,Clpl value in rat,,A,1,N,1,,BAO_0000218
13617,,,10141.0,Intermediate,Cavia porcellus,15240,CHEMBL622230,50512,,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,A,1,N,1,,BAO_0000218
13618,,,10116.0,Intermediate,Rattus norvegicus,16449,CHEMBL622231,50597,,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,A,1,N,1,,BAO_0000218
13619,,,9541.0,Intermediate,Macaca fascicularis,16449,CHEMBL622232,100710,,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,A,1,N,1,,BAO_0000218
13620,,,,Autocuration,,12902,CHEMBL622233,22224,,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,A,1,U,0,,BAO_0000218
13621,,,,Autocuration,,12902,CHEMBL622234,22224,,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,A,1,U,0,,BAO_0000218
13622,,,,Autocuration,,12902,CHEMBL622235,22224,,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,A,1,U,0,,BAO_0000218
13623,,,,Autocuration,,12902,CHEMBL622236,22224,,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,A,1,U,0,,BAO_0000218
13624,,,,Autocuration,,12902,CHEMBL622237,22224,,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,A,1,U,0,,BAO_0000218
13625,,,,Autocuration,,12902,CHEMBL877482,22224,,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,A,1,U,0,,BAO_0000218
13626,,,,Autocuration,,12902,CHEMBL622238,22224,,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,A,1,U,0,,BAO_0000218
13627,,,,Autocuration,,12902,CHEMBL622239,22224,,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,A,1,U,0,,BAO_0000218
13628,,178.0,,Autocuration,,11149,CHEMBL622240,22224,,,Blood,Cmax was calculated as maximum concentration reached in the blood,,A,1,U,0,,BAO_0000218
13629,,178.0,,Autocuration,,11149,CHEMBL622241,22224,,,Blood,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,A,1,U,0,,BAO_0000218
13630,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL631013,50597,,,,Cmax was determine after peroral administration at 10 mpk in Rat,,A,1,N,1,,BAO_0000218
13631,,,9544.0,Intermediate,Macaca mulatta,5669,CHEMBL631014,50797,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,A,1,N,1,,BAO_0000218
13632,,,9615.0,Intermediate,Canis lupus familiaris,5669,CHEMBL631015,50588,,,,Cmax was determine after peroral administration at 10 mpk in dog,,A,1,N,1,,BAO_0000218
13633,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL631016,50597,,,,Cmax was determine after peroral administration at 160 mpk in Rat,,A,1,N,1,,BAO_0000218
13634,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL631017,50597,,,,Cmax was determine after peroral administration at 20 mpk in Rat,,A,1,N,1,,BAO_0000218
13635,,,10116.0,Intermediate,Rattus norvegicus,5669,CHEMBL631018,50597,,,,Cmax was determine after peroral administration at 50 mpk in Rat,,A,1,N,1,,BAO_0000218
13636,,,,Autocuration,,4236,CHEMBL631019,22224,,,,Cmax was determined,,A,1,U,0,,BAO_0000218
13637,,955.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL875761,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,A,1,N,1,,BAO_0000218
13638,,955.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL631020,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,A,1,N,1,,BAO_0000218
13639,,955.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL631669,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,A,1,N,1,,BAO_0000218
13640,,955.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL631670,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,A,1,N,1,,BAO_0000218
13641,,2435.0,10090.0,Intermediate,Mus musculus,13792,CHEMBL631671,50594,,,Striatum,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,A,1,N,1,,BAO_0000218
13642,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631672,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,A,1,N,1,,BAO_0000218
13643,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631673,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,A,1,N,1,,BAO_0000218
13644,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631856,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,A,1,N,1,,BAO_0000218
13645,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631857,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,A,1,N,1,,BAO_0000218
13646,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631858,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,A,1,N,1,,BAO_0000218
13647,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631859,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,A,1,N,1,,BAO_0000218
13648,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631860,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,A,1,N,1,,BAO_0000218
13649,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631861,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,A,1,N,1,,BAO_0000218
13650,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631862,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,A,1,N,1,,BAO_0000218
13651,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631863,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,A,1,N,1,,BAO_0000218
13652,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631864,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,A,1,N,1,,BAO_0000218
13653,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631865,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,A,1,N,1,,BAO_0000218
13654,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL631866,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,A,1,N,1,,BAO_0000218
13655,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629360,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,A,1,N,1,,BAO_0000218
13656,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629361,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,A,1,N,1,,BAO_0000218
13657,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629362,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,A,1,N,1,,BAO_0000218
13658,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630740,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,A,1,N,1,,BAO_0000218
13659,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630741,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,A,1,N,1,,BAO_0000218
13660,,178.0,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630742,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,A,1,N,1,,BAO_0000218
13661,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630743,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,A,1,N,1,,BAO_0000218
13662,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630744,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,A,1,N,1,,BAO_0000218
13663,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630745,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,A,1,N,1,,BAO_0000218
13664,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630746,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,A,1,N,1,,BAO_0000218
13665,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630747,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,A,1,N,1,,BAO_0000218
13666,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL630748,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,A,1,N,1,,BAO_0000218
13667,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL632056,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,A,1,N,1,,BAO_0000218
13668,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL632057,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,A,1,N,1,,BAO_0000218
13669,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL632058,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,A,1,N,1,,BAO_0000218
13670,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL632059,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,A,1,N,1,,BAO_0000218
13671,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL632060,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,A,1,N,1,,BAO_0000218
13672,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL632061,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,A,1,N,1,,BAO_0000218
13673,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629207,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,A,1,N,1,,BAO_0000218
13674,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629208,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,A,1,N,1,,BAO_0000218
13675,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629209,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,A,1,N,1,,BAO_0000218
13676,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629210,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,A,1,N,1,,BAO_0000218
13677,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629211,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,A,1,N,1,,BAO_0000218
13678,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629212,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,A,1,N,1,,BAO_0000218
13679,,,10116.0,Intermediate,Rattus norvegicus,8418,CHEMBL629213,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,A,1,N,1,,BAO_0000218
13680,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629214,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,A,1,N,1,,BAO_0000218
13681,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL629215,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,A,1,N,1,,BAO_0000218
13682,,1088.0,10116.0,Intermediate,Rattus norvegicus,8133,CHEMBL635154,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,A,1,N,1,,BAO_0000218
13683,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL629216,50597,,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
13684,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL629217,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
13685,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL629218,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
13686,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL629219,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
13687,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL629220,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
13688,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL629221,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
13689,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631127,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
13690,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631128,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
13691,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631129,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
13692,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631130,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
13693,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631131,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
13694,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631132,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
13695,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631133,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
13696,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631134,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
13697,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL875120,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
13698,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631135,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
13699,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631136,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
13700,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631137,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
13701,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631138,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
13702,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631139,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
13703,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631140,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
13704,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631141,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,A,1,N,1,,BAO_0000218
13705,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631142,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,A,1,N,1,,BAO_0000218
13706,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631143,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,A,1,N,1,,BAO_0000218
13707,,,10116.0,Intermediate,Rattus norvegicus,6996,CHEMBL631144,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,A,1,N,1,,BAO_0000218
13708,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631145,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
13709,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631146,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
13710,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631147,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
13711,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631148,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
13712,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631149,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
13713,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631150,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
13714,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631151,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
13715,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631152,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
13716,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631443,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
13717,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631444,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
13718,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631445,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
13719,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631446,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,A,1,N,1,,BAO_0000218
13720,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631447,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
13721,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631448,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,A,1,N,1,,BAO_0000218
13722,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631449,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,A,1,N,1,,BAO_0000218
13723,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL631450,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,A,1,N,1,,BAO_0000218
13724,,,9615.0,Intermediate,Canis lupus familiaris,6996,CHEMBL629724,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,A,1,N,1,,BAO_0000218
13725,,14.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL629725,50594,,,Zone of skin,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13726,,14.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL629726,50594,,,Zone of skin,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13727,,2106.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL629727,50594,,,Spleen,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13728,,2106.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL630404,50594,,,Spleen,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13729,,2106.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL630405,50594,,,Spleen,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13730,,2106.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL630406,50594,,,Spleen,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13731,,945.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL630407,50594,,,Stomach,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13732,,945.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL630573,50594,,,Stomach,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13733,,945.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL630574,50594,,,Stomach,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13734,,945.0,10090.0,Intermediate,Mus musculus,9716,CHEMBL630575,50594,,,Stomach,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13735,,,10090.0,Intermediate,Mus musculus,9716,CHEMBL630576,50594,,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13736,,,10090.0,Intermediate,Mus musculus,9716,CHEMBL630577,50594,,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13737,,,10090.0,Intermediate,Mus musculus,9716,CHEMBL630578,50594,,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13738,,,10090.0,Intermediate,Mus musculus,9716,CHEMBL630579,50594,,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,A,1,N,1,,BAO_0000218
13739,,2113.0,10090.0,Intermediate,Mus musculus,12192,CHEMBL630580,50594,,,Kidney,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,A,1,N,1,,BAO_0000218
13740,,2113.0,10090.0,Intermediate,Mus musculus,12192,CHEMBL630581,50594,,,Kidney,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,A,1,N,1,,BAO_0000218
13741,,2113.0,10090.0,Intermediate,Mus musculus,12192,CHEMBL630582,50594,,,Kidney,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,A,1,N,1,,BAO_0000218
13742,,,10090.0,Intermediate,Mus musculus,12192,CHEMBL630583,50594,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,A,1,N,1,,BAO_0000218
13743,,,10090.0,Intermediate,Mus musculus,12192,CHEMBL630584,50594,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,A,1,N,1,,BAO_0000218
13744,,,10090.0,Intermediate,Mus musculus,12192,CHEMBL630585,50594,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,A,1,N,1,,BAO_0000218
13745,,,10090.0,Intermediate,Mus musculus,12192,CHEMBL630586,50594,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,A,1,N,1,,BAO_0000218
13746,,,10090.0,Intermediate,Mus musculus,12192,CHEMBL630587,50594,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,A,1,N,1,,BAO_0000218
13747,,,10090.0,Intermediate,Mus musculus,12192,CHEMBL630588,50594,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,A,1,N,1,,BAO_0000218
13748,,,10090.0,Intermediate,Mus musculus,12192,CHEMBL630589,50594,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,A,1,N,1,,BAO_0000218
13749,,,10090.0,Intermediate,Mus musculus,12192,CHEMBL630590,50594,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,A,1,N,1,,BAO_0000218
13750,,1988.0,,Autocuration,,12192,CHEMBL630591,22224,,,Feces,Removal of 238-Plutonium(IV) in feces at 24 h,,A,1,U,0,,BAO_0000019
13751,,1988.0,,Autocuration,,12192,CHEMBL630592,22224,,,Feces,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,A,1,U,0,,BAO_0000019
13752,,,,Autocuration,,12192,CHEMBL630593,22224,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,A,1,U,0,,BAO_0000019
13753,,,,Autocuration,,12192,CHEMBL630594,22224,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,A,1,U,0,,BAO_0000019
13754,,1088.0,,Autocuration,,12192,CHEMBL630595,22224,,,Urine,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,A,1,U,0,,BAO_0000019
13755,,1088.0,,Autocuration,,12192,CHEMBL630596,22224,,,Urine,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,A,1,U,0,,BAO_0000019
13756,,1088.0,,Autocuration,,12192,CHEMBL630597,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 0-24 h,,A,1,U,0,,BAO_0000019
13757,,1088.0,,Autocuration,,12192,CHEMBL630598,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,A,1,U,0,,BAO_0000019
13758,,1088.0,,Autocuration,,12192,CHEMBL630599,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 0-4 h,,A,1,U,0,,BAO_0000019
13759,,1088.0,,Autocuration,,12192,CHEMBL630600,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,A,1,U,0,,BAO_0000019
13760,,1088.0,,Autocuration,,12192,CHEMBL630601,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 4-24 h,,A,1,U,0,,BAO_0000019
13761,,1088.0,,Autocuration,,12192,CHEMBL630602,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,A,1,U,0,,BAO_0000019
13762,,1088.0,,Autocuration,,12192,CHEMBL630603,22224,,,Urine,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,A,1,U,0,,BAO_0000019
13763,,1088.0,,Autocuration,,12192,CHEMBL630604,22224,,,Urine,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,A,1,U,0,,BAO_0000019
13764,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL624869,50597,,,Blood,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13765,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL624870,50597,,,Blood,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13766,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623189,50597,,,Blood,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13767,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623190,50597,,,Blood,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13768,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623191,50597,,,Blood,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13769,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623192,50597,,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13770,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623193,50597,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13771,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623194,50597,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13772,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623195,50597,,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13773,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623196,50597,,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13774,,,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623197,50597,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,A,1,N,1,,BAO_0000218
13775,,,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623198,50597,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13776,,,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623199,50597,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,A,1,N,1,,BAO_0000218
13777,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623200,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13778,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623201,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13779,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623202,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13780,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623203,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13781,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623204,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13782,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623205,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,A,1,N,1,,BAO_0000218
13783,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623206,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13784,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623207,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,A,1,N,1,,BAO_0000218
13785,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623208,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,A,1,N,1,,BAO_0000218
13786,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623209,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13787,,2385.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623210,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,A,1,N,1,,BAO_0000218
13788,,,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623211,50597,,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13789,,995.0,10116.0,Intermediate,Rattus norvegicus,11836,CHEMBL623212,50597,,,Uterus,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,A,1,N,1,,BAO_0000218
13790,,,,Autocuration,,12640,CHEMBL623213,22224,,,,Tested in vitro for intrinsic activity relative to quinpirole,,A,1,U,0,,BAO_0000019
13791,,,,Autocuration,,14218,CHEMBL623214,22224,,,,"Relative ion enhancement, determined in pulsed ultrafiltration",,A,1,U,0,,BAO_0000019
13792,,,,Autocuration,,11296,CHEMBL623215,22224,,,,% ionization at the pH 7.4 at 37 degree Centigrade,,A,1,U,0,,BAO_0000019
13793,,,,Autocuration,,10929,CHEMBL623216,22224,,,,Percentage ionization was measured,,A,1,U,0,,BAO_0000019
13794,,,9913.0,Intermediate,Bos taurus,13841,CHEMBL623217,50591,,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,A,1,N,1,,BAO_0000218
13795,,,,Autocuration,,10431,CHEMBL623218,22224,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,A,1,U,0,,BAO_0000019
13796,,,,Autocuration,,10431,CHEMBL623913,22224,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,A,1,U,0,,BAO_0000019
13797,,,,Autocuration,,10431,CHEMBL623914,22224,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,A,1,U,0,,BAO_0000019
13798,,,,Autocuration,,8826,CHEMBL623915,22229,,,,Compound was evaluated for the partition coefficient in octanol/water,,P,1,U,0,,BAO_0000100
13799,,,,Autocuration,,8826,CHEMBL624080,22229,,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,P,1,U,0,,BAO_0000100
13800,,,,Autocuration,,9884,CHEMBL624081,22224,,,,Equilibrium constant measured by the pulse radiolysis at pH 7,,A,1,U,0,,BAO_0000019
13801,,,9606.0,Intermediate,Homo sapiens,9827,CHEMBL624082,50587,,,,In vitro hydrolytic rate constant determined in human blood,,A,1,N,1,,BAO_0000218
13802,,,9606.0,Intermediate,Homo sapiens,10009,CHEMBL625054,50587,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,A,1,N,1,,BAO_0000218
13803,,,,Autocuration,,10009,CHEMBL877485,22224,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,A,1,U,0,,BAO_0000019
13804,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL625055,50594,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,A,1,N,1,,BAO_0000218
13805,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL625056,50594,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,A,1,N,1,,BAO_0000218
13806,,,9606.0,Intermediate,Homo sapiens,10009,CHEMBL625057,50587,,,,In vitro oxidation of compound in presence of human plasma,,A,1,N,1,,BAO_0000218
13807,,,,Autocuration,,10009,CHEMBL625058,22224,,,,In vitro oxidation of compound in presence of hydrogen peroxide,,A,1,U,0,,BAO_0000019
13808,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL625059,50594,,,,In vitro oxidation of compound in presence of mouse brain homogenate,,A,1,N,1,,BAO_0000218
13809,,,10090.0,Intermediate,Mus musculus,10009,CHEMBL629536,50594,,,,In vitro oxidation of compound in presence of mouse liver homogenate,,A,1,N,1,,BAO_0000218
13810,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629537,50597,,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,A,1,N,1,,BAO_0000218
13811,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629538,50597,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,A,1,N,1,,BAO_0000218
13812,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629539,50597,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,A,1,N,1,,BAO_0000218
13813,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL874445,50597,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,A,1,N,1,,BAO_0000218
13814,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629540,50597,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,A,1,N,1,,BAO_0000218
13815,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629541,50597,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,A,1,N,1,,BAO_0000218
13816,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629542,50597,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,A,1,N,1,,BAO_0000218
13817,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630243,50597,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,A,1,N,1,,BAO_0000218
13818,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630244,50597,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,A,1,N,1,,BAO_0000218
13819,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630245,50597,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,A,1,N,1,,BAO_0000218
13820,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630246,50597,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,A,1,N,1,,BAO_0000218
13821,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630247,50597,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,A,1,N,1,,BAO_0000218
13822,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630248,50597,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,A,1,N,1,,BAO_0000218
13823,,178.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630249,50597,,,Blood,Biodistribution in rat blood at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13824,,178.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630250,50597,,,Blood,Biodistribution in rat blood at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13825,,178.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630251,50597,,,Blood,Biodistribution in rat blood at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13826,,178.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630252,50597,,,Blood,Biodistribution in rat blood at 3 hr after dose administration.,,A,1,N,1,,BAO_0000218
13827,,178.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630408,50597,,,Blood,Biodistribution in rat blood at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13828,,2037.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630409,50597,,,Cerebellum,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13829,,2037.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL874446,50597,,,Cerebellum,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13830,,2037.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630410,50597,,,Cerebellum,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13831,,2037.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630411,50597,,,Cerebellum,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13832,,2037.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630412,50597,,,Cerebellum,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13833,,2037.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630413,50597,,,Cerebellum,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13834,,2037.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630414,50597,,,Cerebellum,Biodistribution in rat cerebellum at 3 hr after dose administration.,,A,1,N,1,,BAO_0000218
13835,,2037.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630415,50597,,,Cerebellum,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13836,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630416,50597,,,,Biodistribution in rat cortex at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13837,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630417,50597,,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13838,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630418,50597,,,,Biodistribution in rat cortex at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13839,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630419,50597,,,,Biodistribution in rat cortex at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13840,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630420,50597,,,,Biodistribution in rat cortex at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13841,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630421,50597,,,,Biodistribution in rat cortex at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13842,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630422,50597,,,,Biodistribution in rat cortex at 3 hr after dose administration.,,A,1,N,1,,BAO_0000218
13843,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630423,50597,,,,Biodistribution in rat cortex at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13844,,948.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630424,50597,,,Heart,Biodistribution in rat heart at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13845,,948.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630425,50597,,,Heart,Biodistribution in rat heart at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13846,,948.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL629462,50597,,,Heart,Biodistribution in rat heart at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13847,,948.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630426,50597,,,Heart,Biodistribution in rat heart at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13848,,948.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630427,50597,,,Heart,Biodistribution in rat heart at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13849,,948.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625877,50597,,,Heart,Biodistribution in rat heart at 3 hr after dose administration.,,A,1,N,1,,BAO_0000218
13850,,948.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625878,50597,,,Heart,Biodistribution in rat heart at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13851,,10000000.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625879,50597,,,Hippocampus,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13852,,10000000.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625880,50597,,,Hippocampus,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13853,,10000000.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625881,50597,,,Hippocampus,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13854,,10000000.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625882,50597,,,Hippocampus,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13855,,10000000.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625883,50597,,,Hippocampus,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13856,,2113.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625884,50597,,,Kidney,Biodistribution in rat kidney at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13857,,2113.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625885,50597,,,Kidney,Biodistribution in rat kidney at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13858,,2113.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628649,50597,,,Kidney,Biodistribution in rat kidney at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13859,,2113.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628650,50597,,,Kidney,Biodistribution in rat kidney at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13860,,2113.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628651,50597,,,Kidney,Biodistribution in rat kidney at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13861,,2113.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628652,50597,,,Kidney,Biodistribution in rat kidney at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13862,,2113.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628653,50597,,,Kidney,Biodistribution in rat kidney at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13863,,2107.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628654,50597,,,Liver,Biodistribution in rat liver at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13864,,2107.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628655,50597,,,Liver,Biodistribution in rat liver at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13865,,2107.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625238,50597,,,Liver,Biodistribution in rat liver at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13866,,2107.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625239,50597,,,Liver,Biodistribution in rat liver at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13867,,2107.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625240,50597,,,Liver,Biodistribution in rat liver at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13868,,2107.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625241,50597,,,Liver,Biodistribution in rat liver at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13869,,2107.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625242,50597,,,Liver,Biodistribution in rat liver at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13870,,2048.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL874587,50597,,,Lung,Biodistribution in rat lung at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13871,,2048.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625405,50597,,,Lung,Biodistribution in rat lung at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13872,,2048.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625406,50597,,,Lung,Biodistribution in rat lung at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13873,,2048.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625407,50597,,,Lung,Biodistribution in rat lung at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13874,,2048.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625408,50597,,,Lung,Biodistribution in rat lung at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13875,,2048.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL625409,50597,,,Lung,Biodistribution in rat lung at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
13876,,1515.0,10116.0,Intermediate,Rattus norvegicus,12361,CHEMBL625410,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,A,1,N,1,,BAO_0000218
13877,,1515.0,10116.0,Intermediate,Rattus norvegicus,12361,CHEMBL625411,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,A,1,N,1,,BAO_0000218
13878,,1515.0,10116.0,Intermediate,Rattus norvegicus,12361,CHEMBL625412,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,A,1,N,1,,BAO_0000218
13879,,1515.0,10116.0,Intermediate,Rattus norvegicus,12361,CHEMBL625413,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,A,1,N,1,,BAO_0000218
13880,,1515.0,10116.0,Intermediate,Rattus norvegicus,12361,CHEMBL625414,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,A,1,N,1,,BAO_0000218
13881,,1515.0,10116.0,Intermediate,Rattus norvegicus,12361,CHEMBL625415,50597,,,Thoracic aorta,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,A,1,N,1,,BAO_0000218
13882,,1515.0,10116.0,Intermediate,Rattus norvegicus,12361,CHEMBL625416,50597,,,Thoracic aorta,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,A,1,N,1,,BAO_0000218
13883,,1088.0,10116.0,Intermediate,Rattus norvegicus,12712,CHEMBL625417,50597,,,Urine,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,A,1,N,1,,BAO_0000218
13884,,1988.0,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL625418,50597,,,Feces,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,A,1,N,1,,BAO_0000218
13885,,1088.0,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL625419,50597,,,Urine,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,A,1,N,1,,BAO_0000218
13886,,,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL625420,50597,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,A,1,N,1,,BAO_0000218
13887,,,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL626996,50597,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,A,1,N,1,,BAO_0000218
13888,,1988.0,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL626997,50597,,,Feces,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,A,1,N,1,,BAO_0000218
13889,,1088.0,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL626998,50597,,,Urine,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,A,1,N,1,,BAO_0000218
13890,,,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL626999,50597,,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,A,1,N,1,,BAO_0000218
13891,,,10090.0,Intermediate,Mus musculus,8050,CHEMBL627000,50594,,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,A,1,N,1,,BAO_0000218
13892,,,10090.0,Intermediate,Mus musculus,8050,CHEMBL627001,50594,,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,A,1,N,1,,BAO_0000218
13893,,,10090.0,Intermediate,Mus musculus,8050,CHEMBL627002,50594,,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,A,1,N,1,,BAO_0000218
13894,,,10090.0,Intermediate,Mus musculus,8050,CHEMBL627003,50594,,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,A,1,N,1,,BAO_0000218
13895,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627004,50594,,,Urine,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,A,1,N,1,,BAO_0000218
13896,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627005,50594,,,Urine,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,A,1,N,1,,BAO_0000218
13897,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL874594,50594,,,Urine,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,A,1,N,1,,BAO_0000218
13898,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627006,50594,,,Urine,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,A,1,N,1,,BAO_0000218
13899,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627007,50594,,,Urine,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,A,1,N,1,,BAO_0000218
13900,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627884,50594,,,Urine,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,A,1,N,1,,BAO_0000218
13901,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627885,50594,,,Urine,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,A,1,N,1,,BAO_0000218
13902,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627886,50594,,,Urine,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,A,1,N,1,,BAO_0000218
13903,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627887,50594,,,Urine,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,A,1,N,1,,BAO_0000218
13904,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627888,50594,,,Urine,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,A,1,N,1,,BAO_0000218
13905,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL628057,50594,,,Urine,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,A,1,N,1,,BAO_0000218
13906,,1088.0,10090.0,Intermediate,Mus musculus,8050,CHEMBL627405,50594,,,Urine,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,A,1,N,1,,BAO_0000218
13907,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627406,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13908,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627407,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13909,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627408,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13910,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627409,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13911,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL875486,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13912,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627410,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13913,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627411,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13914,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627412,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13915,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627413,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13916,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627414,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13917,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627415,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13918,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627416,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13919,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627417,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13920,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627418,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13921,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627419,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13922,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627320,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13923,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627321,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
13924,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627322,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13925,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627323,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13926,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627491,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13927,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627492,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13928,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627493,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13929,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627494,50597,,,Liver,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13930,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627495,50597,,,Liver,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13931,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627496,50597,,,Liver,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13932,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627497,50597,,,Liver,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13933,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627498,50597,,,Liver,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13934,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627499,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13935,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627500,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13936,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL627501,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13937,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625616,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13938,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625617,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13939,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625618,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13940,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625619,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13941,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625620,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13942,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625621,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13943,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625622,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13944,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625788,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13945,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625789,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13946,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625790,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13947,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL625791,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13948,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL622334,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13949,,2046.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL622335,50597,,,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13950,,2046.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL622336,50597,,,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13951,,2046.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL622337,50597,,,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13952,,2046.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL622338,50597,,,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13953,,2046.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL622339,50597,,,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13954,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL624153,50597,,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13955,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL628430,50597,,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13956,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL628431,50597,,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
13957,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL628432,50597,,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13958,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL628433,50597,,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
13959,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL628434,50597,,,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,A,1,N,1,,BAO_0000218
13960,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL626789,50597,,,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,A,1,N,1,,BAO_0000218
13961,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL626790,50597,,,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,A,1,N,1,,BAO_0000218
13962,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL626791,50597,,,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,A,1,N,1,,BAO_0000218
13963,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL626792,50597,,,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,A,1,N,1,,BAO_0000218
13964,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL626793,50597,,,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,A,1,N,1,,BAO_0000218
13965,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627436,50597,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,A,1,N,1,,BAO_0000218
13966,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627437,50597,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,A,1,N,1,,BAO_0000218
13967,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627438,50597,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,A,1,N,1,,BAO_0000218
13968,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627439,50597,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,A,1,N,1,,BAO_0000218
13969,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627440,50597,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,A,1,N,1,,BAO_0000218
13970,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627602,50597,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,A,1,N,1,,BAO_0000218
13971,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627603,50597,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,A,1,N,1,,BAO_0000218
13972,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627604,50597,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,A,1,N,1,,BAO_0000218
13973,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627605,50597,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,A,1,N,1,,BAO_0000218
13974,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627606,50597,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,A,1,N,1,,BAO_0000218
13975,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627607,50597,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,A,1,N,1,,BAO_0000218
13976,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627608,50597,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,A,1,N,1,,BAO_0000218
13977,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627609,50597,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,A,1,N,1,,BAO_0000218
13978,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627610,50597,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,A,1,N,1,,BAO_0000218
13979,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627611,50597,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,A,1,N,1,,BAO_0000218
13980,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL627612,50597,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,A,1,N,1,,BAO_0000218
13981,,,,Autocuration,,8362,CHEMBL627613,22229,,,,Octanol:water partition coefficient is evaluated,,P,1,U,0,,BAO_0000100
13982,,,,Autocuration,,8257,CHEMBL627614,22224,,,,Partition coefficient in 1-octanol/water system,,P,1,U,0,,BAO_0000100
13983,,,,Autocuration,,8257,CHEMBL627615,22224,,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,,P,1,U,0,,BAO_0000100
13984,,,,Autocuration,,9468,CHEMBL627616,22224,,,,Partition coefficient in octanol/water system was determined,,P,1,U,0,,BAO_0000100
13985,,,,Autocuration,,9468,CHEMBL627617,22224,,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,P,1,U,0,,BAO_0000100
13986,,,,Autocuration,,10568,CHEMBL627618,22224,,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,A,1,U,0,,BAO_0000019
13987,,,,Autocuration,,10568,CHEMBL627619,22224,,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,A,1,U,0,,BAO_0000019
13988,,,,Autocuration,,15359,CHEMBL627620,22224,,,,Pseudo-first-order rate constant of the compound,,A,1,U,0,,BAO_0000019
13989,,,,Autocuration,,15359,CHEMBL627621,22224,,,,Pseudo-first-order rate constant with 1-min time point,,A,1,U,0,,BAO_0000019
13990,,,,Autocuration,,15359,CHEMBL627622,22224,,,,Pseudo-first-order rate constant without 1-min time point,,A,1,U,0,,BAO_0000019
13991,,,,Autocuration,,10431,CHEMBL627623,22224,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,A,1,U,0,,BAO_0000019
13992,,,,Autocuration,,10431,CHEMBL627624,22224,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,A,1,U,0,,BAO_0000019
13993,,,,Autocuration,,10431,CHEMBL627625,22224,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,A,1,U,0,,BAO_0000019
13994,,,,Autocuration,,15704,CHEMBL628523,22224,,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,A,1,U,0,,BAO_0000019
13995,,,,Autocuration,,15287,CHEMBL628524,22224,,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,,A,1,U,0,,BAO_0000019
13996,,,,Autocuration,,7516,CHEMBL628525,22224,,,,The efflux rate constant of the compound,,A,1,U,0,,BAO_0000019
13997,,,,Autocuration,,12973,CHEMBL625732,22224,,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,A,1,U,0,,BAO_0000019
13998,,,,Autocuration,,12973,CHEMBL625733,22224,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,A,1,U,0,,BAO_0000019
13999,,,,Autocuration,,12973,CHEMBL625734,22224,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,F,1,U,0,,BAO_0000019
14000,,,,Autocuration,,12973,CHEMBL625913,22224,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,A,1,U,0,,BAO_0000019
14001,,,,Autocuration,,8696,CHEMBL625914,22224,,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,A,1,U,0,,BAO_0000019
14002,,,,Autocuration,,15052,CHEMBL625915,22224,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,A,1,U,0,,BAO_0000019
14003,,,,Autocuration,,15052,CHEMBL625916,22224,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,A,1,U,0,,BAO_0000019
14004,,,,Autocuration,,10503,CHEMBL625917,22224,,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,A,1,U,0,,BAO_0000019
14005,,,,Autocuration,,8354,CHEMBL625918,22224,,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14006,,,,Autocuration,,8354,CHEMBL625919,22224,,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14007,,,,Autocuration,,8354,CHEMBL625920,22224,,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14008,,,,Autocuration,,8354,CHEMBL874453,22224,,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14009,,,,Autocuration,,8354,CHEMBL625921,22224,,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14010,,,,Autocuration,,10503,CHEMBL625922,22224,,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,A,1,U,0,,BAO_0000019
14011,,,,Autocuration,,8354,CHEMBL625923,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14012,,,,Autocuration,,8354,CHEMBL625924,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14013,,,,Autocuration,,8354,CHEMBL625925,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14014,,,,Autocuration,,8354,CHEMBL625926,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14015,,2048.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL627704,50597,,,Lung,Biodistribution in rat lung at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14016,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL627705,50597,,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14017,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL627706,50597,,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14018,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL627707,50597,,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14019,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL627708,50597,,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14020,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628361,50597,,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14021,,,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628362,50597,,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14022,,2435.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628363,50597,,,Striatum,Biodistribution in rat striatum at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14023,,2435.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628364,50597,,,Striatum,Biodistribution in rat striatum at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14024,,2435.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628365,50597,,,Striatum,Biodistribution in rat striatum at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14025,,2435.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL874454,50597,,,Striatum,Biodistribution in rat striatum at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14026,,2435.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628531,50597,,,Striatum,Biodistribution in rat striatum at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14027,,2435.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628532,50597,,,Striatum,Biodistribution in rat striatum at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14028,,2435.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628533,50597,,,Striatum,Biodistribution in rat striatum at 3 hr after dose administration.,,A,1,N,1,,BAO_0000218
14029,,2435.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628534,50597,,,Striatum,Biodistribution in rat striatum at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14030,,2046.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628535,50597,,,Thyroid gland,Biodistribution in rat thyroid at 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14031,,2046.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628536,50597,,,Thyroid gland,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14032,,2046.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628537,50597,,,Thyroid gland,Biodistribution in rat thyroid at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14033,,2046.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628538,50597,,,Thyroid gland,Biodistribution in rat thyroid at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14034,,2046.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628539,50597,,,Thyroid gland,Biodistribution in rat thyroid at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14035,,2046.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630297,50597,,,Thyroid gland,Biodistribution in rat thyroid at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14036,,2046.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630298,50597,,,Thyroid gland,Biodistribution in rat thyroid at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14037,,955.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL630299,50597,,,Brain,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14038,,955.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628094,50597,,,Brain,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14039,,955.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628095,50597,,,Brain,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14040,,955.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL874648,50597,,,Brain,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14041,,955.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628096,50597,,,Brain,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14042,,955.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628097,50597,,,Brain,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14043,,955.0,10116.0,Intermediate,Rattus norvegicus,13100,CHEMBL628098,50597,,,Brain,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,A,1,N,1,,BAO_0000218
14044,,,,Autocuration,,13331,CHEMBL628099,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,A,1,U,0,,BAO_0000019
14045,,,,Autocuration,,13331,CHEMBL628100,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,A,1,U,0,,BAO_0000019
14046,,,,Autocuration,,13331,CHEMBL628101,22224,,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,A,1,U,0,,BAO_0000019
14047,,,,Autocuration,,13331,CHEMBL628102,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,A,1,U,0,,BAO_0000019
14048,,,,Autocuration,,13331,CHEMBL628103,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,A,1,U,0,,BAO_0000019
14049,,,,Autocuration,,13331,CHEMBL628104,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,A,1,U,0,,BAO_0000019
14050,,,,Autocuration,,13331,CHEMBL628105,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,A,1,U,0,,BAO_0000019
14051,,,,Autocuration,,13331,CHEMBL628106,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,A,1,U,0,,BAO_0000019
14052,,1088.0,10116.0,Intermediate,Rattus norvegicus,10086,CHEMBL628107,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,A,1,N,1,,BAO_0000218
14053,,1088.0,,Autocuration,,10086,CHEMBL628108,22224,,,Urine,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,F,1,U,0,,BAO_0000218
14054,,1088.0,10116.0,Intermediate,Rattus norvegicus,10086,CHEMBL628109,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,A,1,N,1,,BAO_0000218
14055,,1088.0,,Autocuration,,10086,CHEMBL625299,22224,,,Urine,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,F,1,U,0,,BAO_0000218
14056,,1088.0,10116.0,Intermediate,Rattus norvegicus,10086,CHEMBL625300,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,A,1,N,1,,BAO_0000218
14057,,1088.0,10116.0,Intermediate,Rattus norvegicus,10086,CHEMBL625301,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,A,1,N,1,,BAO_0000218
14058,,1088.0,10116.0,Intermediate,Rattus norvegicus,10086,CHEMBL625302,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,A,1,N,1,,BAO_0000218
14059,,1088.0,10116.0,Intermediate,Rattus norvegicus,10086,CHEMBL874649,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,A,1,N,1,,BAO_0000218
14060,,,10116.0,Intermediate,Rattus norvegicus,13248,CHEMBL625303,50597,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,A,1,N,1,,BAO_0000218
14061,,,10116.0,Intermediate,Rattus norvegicus,13248,CHEMBL625463,50597,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,A,1,N,1,,BAO_0000218
14062,,2107.0,9606.0,Intermediate,Homo sapiens,14527,CHEMBL625464,50587,,,Liver,In vitro metabolism in human liver microsomes,,A,1,N,1,,BAO_0000218
14063,,,9606.0,Intermediate,Homo sapiens,3008,CHEMBL625465,50587,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,A,1,N,1,,BAO_0000218
14064,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625466,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14065,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625467,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14066,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625468,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14067,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625469,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14068,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625470,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14069,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL632418,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14070,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627250,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14071,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627251,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14072,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627252,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14073,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627253,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14074,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627254,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14075,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL875471,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14076,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627255,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14077,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627256,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14078,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627257,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14079,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627258,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14080,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627259,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14081,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627260,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14082,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623256,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14083,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL874413,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14084,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623257,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14085,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623258,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14086,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623259,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14087,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623260,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14088,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623261,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14089,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623262,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14090,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623263,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14091,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623264,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14092,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623265,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14093,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623266,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14094,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623267,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14095,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623268,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14096,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623269,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14097,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623270,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14098,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623271,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14099,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623272,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14100,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623273,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14101,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623274,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14102,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL874414,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14103,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623275,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14104,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL629150,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14105,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623276,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14106,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623277,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14107,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623112,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14108,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623113,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14109,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623800,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14110,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623801,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14111,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623802,50597,,,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,A,1,N,1,,BAO_0000218
14112,,995.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623803,50597,,,Uterus,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14113,,995.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623970,50597,,,Uterus,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14114,,995.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL623971,50597,,,Uterus,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14115,,178.0,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623972,50597,,,Blood,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14116,,178.0,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623973,50597,,,Blood,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14117,,178.0,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623974,50597,,,Blood,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14118,,178.0,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623975,50597,,,Blood,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14119,,955.0,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623976,50597,,,Brain,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14120,,955.0,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623977,50597,,,Brain,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14121,,955.0,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623978,50597,,,Brain,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14122,,955.0,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623979,50597,,,Brain,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14123,,,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623980,50597,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14124,,,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL623981,50597,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14125,,,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL626278,50597,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14126,,,10116.0,Intermediate,Rattus norvegicus,14045,CHEMBL626279,50597,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,A,1,N,1,,BAO_0000218
14127,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL626280,50594,,,,Biodistribution in mice bladder plus excreted urine was determined,,A,1,N,1,,BAO_0000218
14128,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL626281,50594,,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",,A,1,N,1,,BAO_0000218
14129,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL626282,50594,,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",,A,1,N,1,,BAO_0000218
14130,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL626283,50594,,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",,A,1,N,1,,BAO_0000218
14131,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL626284,50594,,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",,A,1,N,1,,BAO_0000218
14132,,955.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL626285,50594,,,Brain,"Percentage biodistribution in mouse brain, 10 minutes post injection",,A,1,N,1,,BAO_0000218
14133,,955.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL626286,50594,,,Brain,"Percentage biodistribution in mouse brain, 30 minutes post injection",,A,1,N,1,,BAO_0000218
14134,,955.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL626287,50594,,,Brain,"Percentage biodistribution in mouse brain, 5 minutes post injection",,A,1,N,1,,BAO_0000218
14135,,955.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL626288,50594,,,Brain,"Percentage biodistribution in mouse brain, 60 minutes post injection",,A,1,N,1,,BAO_0000218
14136,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL626289,50594,,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",,A,1,N,1,,BAO_0000218
14137,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL626290,50594,,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",,A,1,N,1,,BAO_0000218
14138,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL626291,50594,,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",,A,1,N,1,,BAO_0000218
14139,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL839888,50594,,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",,A,1,N,1,,BAO_0000218
14140,,160.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL626292,50594,,,Intestine,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,A,1,N,1,,BAO_0000218
14141,,160.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL626293,50594,,,Intestine,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,A,1,N,1,,BAO_0000218
14142,,160.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL626294,50594,,,Intestine,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,A,1,N,1,,BAO_0000218
14143,,160.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL626295,50594,,,Intestine,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,A,1,N,1,,BAO_0000218
14144,,2107.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL627659,50594,,,Liver,"Percentage biodistribution in mouse liver, 10 minutes post injection",,A,1,N,1,,BAO_0000218
14145,,2107.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL627660,50594,,,Liver,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,A,1,N,1,,BAO_0000218
14146,,2107.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL627661,50594,,,Liver,"Percentage biodistribution in mouse liver, 5 minutes post injection",,A,1,N,1,,BAO_0000218
14147,,2107.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL627662,50594,,,Liver,Biodistribution in mice liver at 60 minutes of post injection,,A,1,N,1,,BAO_0000218
14148,,2048.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL627663,50594,,,Lung,Biodistribution in mice lungs at 10 min of post injection,,A,1,N,1,,BAO_0000218
14149,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL627664,50594,,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",,A,1,N,1,,BAO_0000218
14150,,,10090.0,Intermediate,Mus musculus,14045,CHEMBL627665,50594,,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",,A,1,N,1,,BAO_0000218
14151,,2048.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL627666,50594,,,Lung,Biodistribution in mice lungs at 60 min of post injection,,A,1,N,1,,BAO_0000218
14152,,2106.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL627667,50594,,,Spleen,Percentage biodistribution in mouse spleen,,A,1,N,1,,BAO_0000218
14153,,945.0,10090.0,Intermediate,Mus musculus,14045,CHEMBL627668,50594,,,Stomach,Percentage biodistribution in mouse stomach,,A,1,N,1,,BAO_0000218
14154,,1088.0,10090.0,Intermediate,Mus musculus,11745,CHEMBL627669,50594,,,Urine,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,A,1,N,1,,BAO_0000218
14155,,1255.0,,Autocuration,,13257,CHEMBL627670,22224,,,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,A,1,U,0,,BAO_0000218
14156,,178.0,,Autocuration,,13257,CHEMBL627671,22224,,,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,A,1,U,0,,BAO_0000218
14157,,1474.0,,Autocuration,,13257,CHEMBL627672,22224,,,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,A,1,U,0,,BAO_0000218
14158,,,,Autocuration,,13257,CHEMBL627673,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,A,1,U,0,,BAO_0000218
14159,,2113.0,,Autocuration,,13257,CHEMBL627674,22224,,,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,A,1,U,0,,BAO_0000218
14160,,2107.0,,Autocuration,,13257,CHEMBL627675,22224,,,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,A,1,U,0,,BAO_0000218
14161,,2048.0,,Autocuration,,13257,CHEMBL627676,22224,,,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,A,1,U,0,,BAO_0000218
14162,,2385.0,,Autocuration,,13257,CHEMBL627677,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,A,1,U,0,,BAO_0000218
14163,,,,Autocuration,,8354,CHEMBL627678,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
14164,,1977.0,10116.0,Intermediate,Rattus norvegicus,7095,CHEMBL627679,50597,,,Serum,Affinity for protein binding expressed as association constant in fresh rat serum,,A,1,N,1,,BAO_0000218
14165,,,,Autocuration,,12185,CHEMBL627680,22224,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,A,1,U,0,,BAO_0000019
14166,,,,Autocuration,,12185,CHEMBL627681,22224,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,A,1,U,0,,BAO_0000019
14167,,,,Autocuration,,12185,CHEMBL627682,22224,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,A,1,U,0,,BAO_0000019
14168,,,,Autocuration,,12185,CHEMBL627683,22224,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,A,1,U,0,,BAO_0000019
14169,,,,Autocuration,,12686,CHEMBL627684,22224,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,A,1,U,0,,BAO_0000019
14170,,,,Autocuration,,12686,CHEMBL874441,22224,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,A,1,U,0,,BAO_0000019
14171,,,,Autocuration,,12686,CHEMBL627685,22224,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,A,1,U,0,,BAO_0000019
14172,,,,Autocuration,,12686,CHEMBL627686,22224,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,A,1,U,0,,BAO_0000019
14173,,,,Autocuration,,8057,CHEMBL627687,22224,,,,Apparent rate constant Koff for inactivation of dTMP synthase.,,A,1,U,0,,BAO_0000019
14174,,,,Autocuration,,15778,CHEMBL627688,22224,,,,The irreversible inhibitor activity by second order rate equation.,,A,1,U,0,,BAO_0000019
14175,,,10116.0,Intermediate,Rattus norvegicus,12375,CHEMBL628038,50597,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,A,1,N,1,,BAO_0000218
14176,,,10116.0,Intermediate,Rattus norvegicus,12375,CHEMBL628039,50597,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,A,1,N,1,,BAO_0000218
14177,,,10116.0,Intermediate,Rattus norvegicus,12375,CHEMBL628040,50597,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,A,1,N,1,,BAO_0000218
14178,,,,Autocuration,,13588,CHEMBL628041,22224,,,,Dissociation rate calculated from the first-order equation using t1/2 value,,A,1,U,0,,BAO_0000019
14179,,,,Autocuration,,15039,CHEMBL630226,22224,,,,The compound was tested for Binding constant against DNA,,A,1,U,0,,BAO_0000019
14180,,,,Autocuration,,9500,CHEMBL628042,22224,,,,First order rate constant for cyclization of the compound,,A,1,U,0,,BAO_0000019
14181,,,,Autocuration,,10014,CHEMBL625232,22224,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,A,1,U,0,,BAO_0000019
14182,,,,Autocuration,,10014,CHEMBL625233,22224,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,A,1,U,0,,BAO_0000019
14183,,,,Autocuration,,568,CHEMBL625979,22224,,,,Hydrolysis rate constant was determined,,A,1,U,0,,BAO_0000019
14184,,,,Autocuration,,10026,CHEMBL625980,22224,,,,Observed first order rate constant,,A,1,U,0,,BAO_0000019
14185,,,,Autocuration,,10281,CHEMBL625981,22224,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,A,1,U,0,,BAO_0000019
14186,,,,Autocuration,,10281,CHEMBL625982,22224,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,A,1,U,0,,BAO_0000019
14187,,,,Autocuration,,9680,CHEMBL625983,22224,,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,A,1,U,0,,BAO_0000019
14188,,,,Autocuration,,13028,CHEMBL625984,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14189,,,,Autocuration,,13028,CHEMBL625985,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14190,,,,Autocuration,,13028,CHEMBL625986,22224,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14191,,,,Autocuration,,13028,CHEMBL625987,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14192,,,,Autocuration,,13028,CHEMBL625988,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14193,,,,Autocuration,,13028,CHEMBL625989,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14194,,,,Autocuration,,13028,CHEMBL625990,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14195,,,,Autocuration,,13028,CHEMBL625991,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14196,,,,Autocuration,,13028,CHEMBL625992,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14197,,,,Autocuration,,13028,CHEMBL625993,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14198,,,,Autocuration,,13028,CHEMBL631973,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14199,,,,Autocuration,,13028,CHEMBL632143,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14200,,,,Autocuration,,13028,CHEMBL632144,22224,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14201,,,,Autocuration,,13028,CHEMBL632145,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14202,,,,Autocuration,,13028,CHEMBL632146,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14203,,,,Autocuration,,13028,CHEMBL632147,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14204,,,,Autocuration,,13028,CHEMBL632148,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14205,,,,Autocuration,,13028,CHEMBL632149,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14206,,,,Autocuration,,13028,CHEMBL632150,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14207,,,,Autocuration,,13028,CHEMBL632151,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14208,,,9606.0,Intermediate,Homo sapiens,3008,CHEMBL632152,50587,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,A,1,N,1,,BAO_0000218
14209,,,9606.0,Intermediate,Homo sapiens,4509,CHEMBL632153,50587,,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,A,1,N,1,,BAO_0000218
14210,,,9606.0,Intermediate,Homo sapiens,4509,CHEMBL632154,50587,,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,A,1,N,1,,BAO_0000218
14211,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL632155,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,A,1,N,1,,BAO_0000218
14212,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL632156,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,A,1,N,1,,BAO_0000218
14213,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL632157,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,A,1,N,1,,BAO_0000218
14214,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL632158,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,A,1,N,1,,BAO_0000218
14215,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL632159,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,A,1,N,1,,BAO_0000218
14216,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL626305,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,A,1,N,1,,BAO_0000218
14217,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL626306,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,A,1,N,1,,BAO_0000218
14218,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL626307,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,A,1,N,1,,BAO_0000218
14219,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL626308,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,A,1,N,1,,BAO_0000218
14220,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL626479,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,A,1,N,1,,BAO_0000218
14221,,,10298.0,Intermediate,Human herpesvirus 1,8613,CHEMBL626480,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,A,1,N,1,,BAO_0000218
14222,,,,Autocuration,,6021,CHEMBL626481,22229,,,,Calculated partition coefficient (clogP) (MlogP),,P,1,U,0,,BAO_0000100
14223,,,,Autocuration,,9348,CHEMBL626482,22224,,,,Equipotent potent ratio relative to carbachol (nicotinic activity),,A,1,U,0,,BAO_0000019
14224,,,9615.0,Intermediate,Canis lupus familiaris,15592,CHEMBL626483,50588,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,A,1,N,1,,BAO_0000218
14225,,,9615.0,Intermediate,Canis lupus familiaris,15592,CHEMBL626484,50588,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,A,1,N,1,,BAO_0000218
14226,,,,Autocuration,,15592,CHEMBL626485,22229,,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,,P,1,U,0,,BAO_0000100
14227,,,,Autocuration,,15592,CHEMBL626486,22229,,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,P,1,U,0,,BAO_0000100
14228,,,,Autocuration,,15592,CHEMBL626487,22229,,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,,P,1,U,0,,BAO_0000100
14229,,1969.0,9615.0,Intermediate,Canis lupus familiaris,15592,CHEMBL626488,50588,,,Plasma,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,A,1,N,1,,BAO_0000218
14230,,1977.0,10116.0,Intermediate,Rattus norvegicus,7095,CHEMBL626489,50597,,,Serum,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,A,1,N,1,,BAO_0000218
14231,,,,Autocuration,,16618,CHEMBL626490,22224,,,,Area under the MAP curve measured over 5 min; ND means Not determined,,A,1,U,0,,BAO_0000019
14232,,,,Autocuration,,16835,CHEMBL626491,22224,,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,P,1,U,0,,BAO_0000100
14233,,,,Autocuration,,15284,CHEMBL626492,22229,,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,P,1,U,0,,BAO_0000100
14234,,,,Autocuration,,15750,CHEMBL626493,22224,,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,A,1,U,0,,BAO_0000019
14235,,,10116.0,Intermediate,Rattus norvegicus,16618,CHEMBL626494,50597,,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,A,1,N,1,,BAO_0000218
14236,,,,Autocuration,,16618,CHEMBL626495,22224,,,,Half life after oral tested,,A,1,U,0,,BAO_0000218
14237,,1969.0,10116.0,Intermediate,Rattus norvegicus,15812,CHEMBL626496,50597,,,Plasma,Half life was determined in plasma of rat; NT indicates not tested,,A,1,N,1,,BAO_0000218
14238,,,10116.0,Intermediate,Rattus norvegicus,16618,CHEMBL626497,50597,,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,A,1,N,1,,BAO_0000218
14239,,,,Autocuration,,16618,CHEMBL626498,22224,,,,Oral bioavailability after oral tested,,A,1,U,0,,BAO_0000218
14240,,,10116.0,Intermediate,Rattus norvegicus,13098,CHEMBL626499,50597,,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,A,1,N,1,,BAO_0000218
14241,,,10116.0,Intermediate,Rattus norvegicus,13098,CHEMBL626500,50597,,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,A,1,N,1,,BAO_0000218
14242,,1969.0,10116.0,Intermediate,Rattus norvegicus,15812,CHEMBL626501,50597,,,Plasma,half life was determined in plasma of rat; NT indicates not tested,,A,1,N,1,,BAO_0000218
14243,,1969.0,10116.0,Intermediate,Rattus norvegicus,15812,CHEMBL626502,50597,,,Plasma,half life was determined in plasma of rat; NT means not tested,,A,1,N,1,,BAO_0000218
14244,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626503,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,A,1,N,1,,BAO_0000218
14245,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626504,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,A,1,N,1,,BAO_0000218
14246,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626505,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,A,1,N,1,,BAO_0000218
14247,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626506,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,A,1,N,1,,BAO_0000218
14248,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626507,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,A,1,N,1,,BAO_0000218
14249,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626508,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,A,1,N,1,,BAO_0000218
14250,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626509,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,A,1,N,1,,BAO_0000218
14251,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL875480,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,A,1,N,1,,BAO_0000218
14252,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626510,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,A,1,N,1,,BAO_0000218
14253,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626511,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,A,1,N,1,,BAO_0000218
14254,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL626512,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,A,1,N,1,,BAO_0000218
14255,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL628208,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,A,1,N,1,,BAO_0000218
14256,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL628209,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,A,1,N,1,,BAO_0000218
14257,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL628210,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,A,1,N,1,,BAO_0000218
14258,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL628211,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,A,1,N,1,,BAO_0000218
14259,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL628212,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,A,1,N,1,,BAO_0000218
14260,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL628213,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,A,1,N,1,,BAO_0000218
14261,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628214,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14262,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628215,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14263,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628216,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14264,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626595,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14265,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626596,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14266,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626597,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14267,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626598,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14268,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL622242,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14269,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL622243,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14270,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL622244,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14271,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL622245,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14272,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL622246,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14273,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL622247,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14274,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL622248,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14275,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL877483,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14276,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL622249,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14277,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622250,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14278,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622251,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14279,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622252,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14280,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622253,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14281,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622254,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14282,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622255,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14283,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622256,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14284,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622257,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14285,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622258,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14286,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622259,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14287,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622927,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14288,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622928,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14289,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL622929,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14290,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL623182,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14291,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL623183,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14292,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623184,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14293,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623185,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14294,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL877484,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14295,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL627274,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14296,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623186,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14297,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623187,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14298,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL623188,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14299,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628055,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14300,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628056,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14301,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628200,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14302,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628201,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14303,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628202,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14304,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628203,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14305,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628204,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14306,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628205,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14307,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628206,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14308,,2367.0,,Autocuration,,13257,CHEMBL628207,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,A,1,U,0,,BAO_0000218
14309,,2367.0,,Autocuration,,13257,CHEMBL627220,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,A,1,U,0,,BAO_0000218
14310,,2385.0,,Autocuration,,13257,CHEMBL627221,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,A,1,U,0,,BAO_0000218
14311,,2367.0,,Autocuration,,13257,CHEMBL627222,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,A,1,U,0,,BAO_0000218
14312,,,,Autocuration,,13257,CHEMBL627223,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,A,1,U,0,,BAO_0000218
14313,,2385.0,,Autocuration,,13257,CHEMBL632062,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,A,1,U,0,,BAO_0000218
14314,,2106.0,,Autocuration,,13257,CHEMBL632063,22224,,,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,A,1,U,0,,BAO_0000218
14315,,1255.0,,Autocuration,,13257,CHEMBL632064,22224,,,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,A,1,U,0,,BAO_0000218
14316,,178.0,,Autocuration,,13257,CHEMBL632065,22224,,,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,A,1,U,0,,BAO_0000218
14317,,1474.0,,Autocuration,,13257,CHEMBL632066,22224,,,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,A,1,U,0,,BAO_0000218
14318,,,,Autocuration,,13257,CHEMBL632067,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,A,1,U,0,,BAO_0000218
14319,,2113.0,,Autocuration,,13257,CHEMBL629188,22224,,,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,A,1,U,0,,BAO_0000218
14320,,2107.0,,Autocuration,,13257,CHEMBL629189,22224,,,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,A,1,U,0,,BAO_0000218
14321,,2048.0,,Autocuration,,13257,CHEMBL629190,22224,,,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,A,1,U,0,,BAO_0000218
14322,,2385.0,,Autocuration,,13257,CHEMBL629191,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,A,1,U,0,,BAO_0000218
14323,,2367.0,,Autocuration,,13257,CHEMBL629192,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,A,1,U,0,,BAO_0000218
14324,,2385.0,,Autocuration,,13257,CHEMBL629193,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,A,1,U,0,,BAO_0000218
14325,,2367.0,,Autocuration,,13257,CHEMBL629194,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,A,1,U,0,,BAO_0000218
14326,,,,Autocuration,,13257,CHEMBL629195,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,A,1,U,0,,BAO_0000218
14327,,2385.0,,Autocuration,,13257,CHEMBL629373,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,A,1,U,0,,BAO_0000218
14328,,2106.0,,Autocuration,,13257,CHEMBL629374,22224,,,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,A,1,U,0,,BAO_0000218
14329,,2367.0,,Autocuration,,13257,CHEMBL629375,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,A,1,U,0,,BAO_0000218
14330,,1255.0,,Autocuration,,13257,CHEMBL629376,22224,,,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,A,1,U,0,,BAO_0000218
14331,,178.0,,Autocuration,,13257,CHEMBL629377,22224,,,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,A,1,U,0,,BAO_0000218
14332,,1474.0,,Autocuration,,13257,CHEMBL629378,22224,,,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,A,1,U,0,,BAO_0000218
14333,,,,Autocuration,,13257,CHEMBL629379,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,A,1,U,0,,BAO_0000218
14334,,2113.0,,Autocuration,,13257,CHEMBL629151,22224,,,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,A,1,U,0,,BAO_0000218
14335,,2107.0,,Autocuration,,13257,CHEMBL629152,22224,,,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,A,1,U,0,,BAO_0000218
14336,,2048.0,,Autocuration,,13257,CHEMBL629153,22224,,,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,A,1,U,0,,BAO_0000218
14337,,2385.0,,Autocuration,,13257,CHEMBL629154,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,A,1,U,0,,BAO_0000218
14338,,2367.0,,Autocuration,,13257,CHEMBL629155,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,A,1,U,0,,BAO_0000218
14339,,2367.0,,Autocuration,,13257,CHEMBL629156,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,A,1,U,0,,BAO_0000218
14340,,2385.0,,Autocuration,,13257,CHEMBL629157,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,A,1,U,0,,BAO_0000218
14341,,2367.0,,Autocuration,,13257,CHEMBL629158,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,A,1,U,0,,BAO_0000218
14342,,,,Autocuration,,13257,CHEMBL629159,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,A,1,U,0,,BAO_0000218
14343,,2385.0,,Autocuration,,13257,CHEMBL629160,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,A,1,U,0,,BAO_0000218
14344,,2106.0,,Autocuration,,13257,CHEMBL629161,22224,,,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,A,1,U,0,,BAO_0000218
14345,,1255.0,,Autocuration,,13257,CHEMBL629162,22224,,,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,A,1,U,0,,BAO_0000218
14346,,178.0,,Autocuration,,13257,CHEMBL629163,22224,,,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,A,1,U,0,,BAO_0000218
14347,,1474.0,,Autocuration,,13257,CHEMBL629164,22224,,,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,A,1,U,0,,BAO_0000218
14348,,,,Autocuration,,13257,CHEMBL629165,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,A,1,U,0,,BAO_0000218
14349,,2107.0,,Autocuration,,13257,CHEMBL629166,22224,,,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,A,1,U,0,,BAO_0000218
14350,,2048.0,,Autocuration,,13257,CHEMBL629167,22224,,,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,A,1,U,0,,BAO_0000218
14351,,2385.0,,Autocuration,,13257,CHEMBL629168,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,A,1,U,0,,BAO_0000218
14352,,,,Autocuration,,2193,CHEMBL629169,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,A,1,U,0,,BAO_0000019
14353,,,,Autocuration,,2193,CHEMBL629170,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,A,1,U,0,,BAO_0000019
14354,,,,Autocuration,,2193,CHEMBL631153,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,A,1,U,0,,BAO_0000019
14355,,,,Autocuration,,2193,CHEMBL875121,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,A,1,U,0,,BAO_0000019
14356,,,,Autocuration,,2193,CHEMBL631154,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,A,1,U,0,,BAO_0000019
14357,,,,Autocuration,,2193,CHEMBL631155,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,A,1,U,0,,BAO_0000019
14358,,,,Autocuration,,568,CHEMBL631156,22224,,,,Hydrolysis rate constant was determined,,A,1,U,0,,BAO_0000019
14359,,,,Autocuration,,9680,CHEMBL631157,22224,,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,A,1,U,0,,BAO_0000019
14360,,,,Autocuration,,9680,CHEMBL631158,22224,,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,A,1,U,0,,BAO_0000019
14361,,,,Autocuration,,9680,CHEMBL631159,22224,,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,A,1,U,0,,BAO_0000019
14362,,,,Autocuration,,10026,CHEMBL631160,22224,,,,Observed second order rate constant,,A,1,U,0,,BAO_0000019
14363,,,,Autocuration,,10281,CHEMBL631161,22224,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,A,1,U,0,,BAO_0000019
14364,,,,Autocuration,,10014,CHEMBL631162,22224,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,A,1,U,0,,BAO_0000019
14365,,,,Autocuration,,10014,CHEMBL630313,22224,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,A,1,U,0,,BAO_0000019
14366,,,,Autocuration,,9680,CHEMBL630314,22224,,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,A,1,U,0,,BAO_0000019
14367,,,,Autocuration,,9680,CHEMBL630315,22224,,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,A,1,U,0,,BAO_0000019
14368,,,,Autocuration,,13028,CHEMBL630316,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14369,,,,Autocuration,,13028,CHEMBL630986,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14370,,,,Autocuration,,13028,CHEMBL630987,22224,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14371,,,,Autocuration,,13028,CHEMBL630988,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14372,,,,Autocuration,,13028,CHEMBL630989,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14373,,,,Autocuration,,13028,CHEMBL630990,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14374,,,,Autocuration,,13028,CHEMBL630991,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14375,,,,Autocuration,,13028,CHEMBL630992,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14376,,,,Autocuration,,13028,CHEMBL630993,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14377,,,,Autocuration,,13028,CHEMBL630994,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,A,1,U,0,,BAO_0000019
14378,,,10116.0,Intermediate,Rattus norvegicus,10014,CHEMBL630995,50597,,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,A,1,N,1,,BAO_0000218
14379,,,,Autocuration,,9962,CHEMBL629252,22224,,,,Association constant for compound at 31 degree C was determined,,A,1,U,0,,BAO_0000019
14380,,,,Autocuration,,12029,CHEMBL629253,22224,,,,Calculated antagonist equilibrium dissociation constant of the compound,,A,1,U,0,,BAO_0000019
14381,,,,Autocuration,,12029,CHEMBL629944,22224,,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,A,1,U,0,,BAO_0000019
14382,,3126.0,10141.0,Intermediate,Cavia porcellus,10583,CHEMBL629945,50512,,,Trachea,Dissociation constants vs LTE4 on guinea pig trachea,,A,1,N,1,,BAO_0000218
14383,,,,Autocuration,,568,CHEMBL629946,22224,,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,A,1,U,0,,BAO_0000019
14384,,,,Autocuration,,568,CHEMBL629947,22224,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,A,1,U,0,,BAO_0000019
14385,,,,Autocuration,,568,CHEMBL629948,22224,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,A,1,U,0,,BAO_0000019
14386,,,,Autocuration,,568,CHEMBL856024,22224,,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,A,1,U,0,,BAO_0000019
14387,,,,Autocuration,,7493,CHEMBL629949,22224,,,,Affinity constant KD value was derived from TMP,,A,1,U,0,,BAO_0000019
14388,,,,Autocuration,,8371,CHEMBL629950,22224,,,,Apparent dissociation (binding) rate constant was evaluated,,A,1,U,0,,BAO_0000019
14389,,,,Autocuration,,13114,CHEMBL630127,22224,,,,Dissociation constant (KD) of the compound,,P,1,U,0,,BAO_0000100
14390,,,,Autocuration,,15515,CHEMBL630128,22224,,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,P,1,U,0,,BAO_0000100
14391,,,,Autocuration,,522,CHEMBL630129,22224,,,,Dissociation constant from ESR titration experiments,,P,1,U,0,,BAO_0000100
14392,,,,Autocuration,,13888,CHEMBL630130,22224,,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,1,U,0,,BAO_0000019
14393,,,,Autocuration,,2616,CHEMBL875234,22224,,,,Dissociation constant was evaluated.,,P,1,U,0,,BAO_0000100
14394,,,,Autocuration,,3798,CHEMBL630131,22224,,,,Dissociation constant was reported,,P,1,U,0,,BAO_0000100
14395,,,10116.0,Intermediate,Rattus norvegicus,8731,CHEMBL630132,50597,,,,Dissociation constant was determined in rat pituitary cells.,,A,1,N,1,,BAO_0000218
14396,,,,Autocuration,,11892,CHEMBL630133,22224,,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,A,1,U,0,,BAO_0000019
14397,,,,Autocuration,,11892,CHEMBL630134,22224,,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,A,1,U,0,,BAO_0000019
14398,,,,Autocuration,,2582,CHEMBL630135,22224,,,,Equilibrium dissociation constant of the compound,,A,1,U,0,,BAO_0000019
14399,,,,Autocuration,,11892,CHEMBL630136,22224,,,,Equilibrium dissociation constant was determined,,A,1,U,0,,BAO_0000019
14400,,,,Autocuration,,13396,CHEMBL630137,22224,,,,Kinetic constant KD was evaluated,,A,1,U,0,,BAO_0000019
14401,,,,Autocuration,,603,CHEMBL630138,22224,,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,A,1,U,0,,BAO_0000019
14402,,,,Autocuration,,15673,CHEMBL630139,22224,,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,A,1,U,0,,BAO_0000019
14403,,,,Autocuration,,10368,CHEMBL630140,22224,,,,Rate constant for hydrolysis in aqueous acetone.,,A,1,U,0,,BAO_0000019
14404,,,,Autocuration,,14228,CHEMBL875235,22224,,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,A,1,U,0,,BAO_0000019
14405,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL876439,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,A,1,N,1,,BAO_0000218
14406,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630605,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,A,1,N,1,,BAO_0000218
14407,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630606,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,A,1,N,1,,BAO_0000218
14408,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630607,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,A,1,N,1,,BAO_0000218
14409,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630608,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,A,1,N,1,,BAO_0000218
14410,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630609,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,A,1,N,1,,BAO_0000218
14411,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630610,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,A,1,N,1,,BAO_0000218
14412,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL630611,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,A,1,N,1,,BAO_0000218
14413,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629552,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,A,1,N,1,,BAO_0000218
14414,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629733,50597,,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,A,1,N,1,,BAO_0000218
14415,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629734,50597,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,A,1,N,1,,BAO_0000218
14416,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629735,50597,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,A,1,N,1,,BAO_0000218
14417,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629736,50597,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,A,1,N,1,,BAO_0000218
14418,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629737,50597,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,A,1,N,1,,BAO_0000218
14419,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629738,50597,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,A,1,N,1,,BAO_0000218
14420,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629739,50597,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,A,1,N,1,,BAO_0000218
14421,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629740,50597,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,A,1,N,1,,BAO_0000218
14422,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629741,50597,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,A,1,N,1,,BAO_0000218
14423,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629742,50597,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,A,1,N,1,,BAO_0000218
14424,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629743,50597,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,A,1,N,1,,BAO_0000218
14425,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629744,50597,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,A,1,N,1,,BAO_0000218
14426,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629745,50597,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,A,1,N,1,,BAO_0000218
14427,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629746,50597,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,A,1,N,1,,BAO_0000218
14428,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629747,50597,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,A,1,N,1,,BAO_0000218
14429,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629748,50597,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,A,1,N,1,,BAO_0000218
14430,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629749,50597,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,A,1,N,1,,BAO_0000218
14431,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629750,50597,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,A,1,N,1,,BAO_0000218
14432,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629751,50597,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,A,1,N,1,,BAO_0000218
14433,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629752,50597,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,A,1,N,1,,BAO_0000218
14434,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629753,50597,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,A,1,N,1,,BAO_0000218
14435,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629754,50597,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,A,1,N,1,,BAO_0000218
14436,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629755,50597,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,A,1,N,1,,BAO_0000218
14437,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629756,50597,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,A,1,N,1,,BAO_0000218
14438,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629757,50597,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,A,1,N,1,,BAO_0000218
14439,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629758,50597,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,A,1,N,1,,BAO_0000218
14440,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629759,50597,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,A,1,N,1,,BAO_0000218
14441,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL629760,50597,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,A,1,N,1,,BAO_0000218
14442,,,10116.0,Intermediate,Rattus norvegicus,11510,CHEMBL876443,50597,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,A,1,N,1,,BAO_0000218
14443,,,9615.0,Intermediate,Canis lupus familiaris,8310,CHEMBL629761,50588,,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,A,1,N,1,,BAO_0000218
14444,,,9615.0,Intermediate,Canis lupus familiaris,8310,CHEMBL629762,50588,,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,A,1,N,1,,BAO_0000218
14445,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL629763,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,A,1,N,1,,BAO_0000218
14446,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL629764,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,A,1,N,1,,BAO_0000218
14447,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL629765,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,A,1,N,1,,BAO_0000218
14448,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL629766,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,A,1,N,1,,BAO_0000218
14449,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL629767,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,A,1,N,1,,BAO_0000218
14450,,,9615.0,Intermediate,Canis lupus familiaris,8310,CHEMBL629768,50588,,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,A,1,N,1,,BAO_0000218
14451,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL629769,50594,,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,A,1,N,1,,BAO_0000218
14452,,,9615.0,Intermediate,Canis lupus familiaris,8310,CHEMBL629770,50588,,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,A,1,N,1,,BAO_0000218
14453,,,9615.0,Intermediate,Canis lupus familiaris,8310,CHEMBL629771,50588,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,A,1,N,1,,BAO_0000218
14454,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL629772,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,A,1,N,1,,BAO_0000218
14455,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL629773,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,A,1,N,1,,BAO_0000218
14456,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL625455,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,A,1,N,1,,BAO_0000218
14457,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL625456,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,A,1,N,1,,BAO_0000218
14458,,,10090.0,Intermediate,Mus musculus,8310,CHEMBL625457,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,A,1,N,1,,BAO_0000218
14459,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625458,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14460,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625459,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14461,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL875483,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14462,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL634779,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14463,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625460,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14464,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626117,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14465,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626118,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14466,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628342,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14467,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628343,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14468,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628344,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14469,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628345,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14470,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628346,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14471,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628347,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14472,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628348,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14473,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628349,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14474,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL875611,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14475,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628350,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14476,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628351,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14477,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628352,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14478,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628353,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14479,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628354,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14480,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626667,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14481,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626668,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14482,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626669,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14483,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626670,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14484,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626671,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14485,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626672,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14486,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626673,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14487,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626674,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14488,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626675,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14489,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626676,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14490,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626677,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14491,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626678,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14492,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626679,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14493,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL875612,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14494,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626680,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14495,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626681,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14496,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626682,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14497,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626683,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14498,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626684,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14499,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626685,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14500,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626686,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14501,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626687,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14502,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL624978,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14503,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL624979,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14504,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL624980,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14505,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL624981,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14506,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL624982,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14507,,2367.0,,Autocuration,,13257,CHEMBL627564,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,A,1,U,0,,BAO_0000218
14508,,2367.0,,Autocuration,,13257,CHEMBL627565,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,A,1,U,0,,BAO_0000218
14509,,,,Autocuration,,13257,CHEMBL627566,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,A,1,U,0,,BAO_0000218
14510,,2385.0,,Autocuration,,13257,CHEMBL627567,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,A,1,U,0,,BAO_0000218
14511,,2106.0,,Autocuration,,13257,CHEMBL627568,22224,,,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,A,1,U,0,,BAO_0000218
14512,,2113.0,,Autocuration,,13257,CHEMBL627569,22224,,,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,A,1,U,0,,BAO_0000218
14513,,1255.0,,Autocuration,,13257,CHEMBL627570,22224,,,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,A,1,U,0,,BAO_0000218
14514,,178.0,,Autocuration,,13257,CHEMBL627571,22224,,,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,A,1,U,0,,BAO_0000218
14515,,1474.0,,Autocuration,,13257,CHEMBL627572,22224,,,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,A,1,U,0,,BAO_0000218
14516,,,,Autocuration,,13257,CHEMBL627573,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,A,1,U,0,,BAO_0000218
14517,,2113.0,,Autocuration,,13257,CHEMBL627574,22224,,,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,A,1,U,0,,BAO_0000218
14518,,2107.0,,Autocuration,,13257,CHEMBL627575,22224,,,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,A,1,U,0,,BAO_0000218
14519,,2048.0,,Autocuration,,13257,CHEMBL627576,22224,,,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,A,1,U,0,,BAO_0000218
14520,,2385.0,,Autocuration,,13257,CHEMBL627577,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,A,1,U,0,,BAO_0000218
14521,,2367.0,,Autocuration,,13257,CHEMBL627578,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,A,1,U,0,,BAO_0000218
14522,,2367.0,,Autocuration,,13257,CHEMBL627579,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,A,1,U,0,,BAO_0000218
14523,,2385.0,,Autocuration,,13257,CHEMBL627580,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,A,1,U,0,,BAO_0000218
14524,,2367.0,,Autocuration,,13257,CHEMBL627581,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,A,1,U,0,,BAO_0000218
14525,,,,Autocuration,,13257,CHEMBL627582,22224,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,A,1,U,0,,BAO_0000218
14526,,2385.0,,Autocuration,,13257,CHEMBL627583,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,A,1,U,0,,BAO_0000218
14527,,2106.0,,Autocuration,,13257,CHEMBL627584,22224,,,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,A,1,U,0,,BAO_0000218
14528,,2367.0,,Autocuration,,13257,CHEMBL627585,22224,,,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,A,1,U,0,,BAO_0000218
14529,,2385.0,,Autocuration,,13257,CHEMBL627586,22224,,,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,A,1,U,0,,BAO_0000218
14530,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL627587,50597,,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14531,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL627588,50597,,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14532,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628250,50597,,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14533,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628251,50597,,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14534,,10000000.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628252,50597,,,Hippocampus,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14535,,10000000.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628253,50597,,,Hippocampus,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14536,,1898.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628254,50597,,,Hypothalamus,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14537,,1898.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL877493,50597,,,Hypothalamus,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14538,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628255,50597,,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14539,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628256,50597,,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14540,,10000000.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628257,50597,,,Hippocampus,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14541,,1898.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628258,50597,,,Hypothalamus,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14542,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628259,50597,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14543,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL628429,50597,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14544,,10000000.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL626862,50597,,,Hippocampus,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,A,1,N,1,,BAO_0000218
14545,,1898.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL626863,50597,,,Hypothalamus,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,A,1,N,1,,BAO_0000218
14546,,2037.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625886,50597,,,Cerebellum,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,A,1,N,1,,BAO_0000218
14547,,2037.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625887,50597,,,Cerebellum,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,A,1,N,1,,BAO_0000218
14548,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625888,50597,,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,A,1,N,1,,BAO_0000218
14549,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625889,50597,,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,A,1,N,1,,BAO_0000218
14550,,10000000.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625890,50597,,,Hippocampus,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,A,1,N,1,,BAO_0000218
14551,,10000000.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625891,50597,,,Hippocampus,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,A,1,N,1,,BAO_0000218
14552,,1898.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625892,50597,,,Hypothalamus,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,A,1,N,1,,BAO_0000218
14553,,1898.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625893,50597,,,Hypothalamus,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,A,1,N,1,,BAO_0000218
14554,,2037.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625894,50597,,,Cerebellum,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,A,1,N,1,,BAO_0000218
14555,,,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL625895,50597,,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,A,1,N,1,,BAO_0000218
14556,,,,Autocuration,,12404,CHEMBL625896,22224,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,A,1,U,0,,BAO_0000019
14557,,,,Autocuration,,568,CHEMBL625897,22224,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,A,1,U,0,,BAO_0000019
14558,,,,Autocuration,,568,CHEMBL625898,22224,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,A,1,U,0,,BAO_0000019
14559,,,,Autocuration,,568,CHEMBL625899,22224,,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,A,1,U,0,,BAO_0000019
14560,,,,Autocuration,,12404,CHEMBL626124,22224,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,A,1,U,0,,BAO_0000019
14561,,,562.0,Intermediate,Escherichia coli,7624,CHEMBL628500,50212,,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,A,1,N,1,,BAO_0000218
14562,,,10116.0,Intermediate,Rattus norvegicus,7624,CHEMBL857856,50597,,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,A,1,N,1,,BAO_0000218
14563,,,10116.0,Intermediate,Rattus norvegicus,7624,CHEMBL628501,50597,,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,A,1,N,1,,BAO_0000218
14564,,,,Autocuration,,4643,CHEMBL628502,22224,,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,A,1,U,0,,BAO_0000019
14565,,,,Autocuration,,11532,CHEMBL628503,22224,,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,A,1,U,0,,BAO_0000019
14566,,,,Autocuration,,11018,CHEMBL628504,22224,,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,A,1,U,0,,BAO_0000019
14567,,,,Autocuration,,2276,CHEMBL628505,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,A,1,U,0,,BAO_0000019
14568,,,,Autocuration,,2276,CHEMBL874452,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,A,1,U,0,,BAO_0000019
14569,,,,Autocuration,,2276,CHEMBL628506,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,A,1,U,0,,BAO_0000019
14570,,,,Autocuration,,2276,CHEMBL628507,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,A,1,U,0,,BAO_0000019
14571,,,,Autocuration,,2276,CHEMBL628508,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,A,1,U,0,,BAO_0000019
14572,,,,Autocuration,,8949,CHEMBL628509,22224,,,,Michaelis constant (KM) was evaluated,,A,1,U,0,,BAO_0000019
14573,,,,Autocuration,,12404,CHEMBL628510,22224,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,A,1,U,0,,BAO_0000019
14574,,,,Autocuration,,7625,CHEMBL628511,22224,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,B,1,U,0,,BAO_0000019
14575,,,,Autocuration,,7625,CHEMBL628512,22224,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,B,1,U,0,,BAO_0000019
14576,,,,Autocuration,,7625,CHEMBL628513,22224,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,B,1,U,0,,BAO_0000019
14577,,,,Autocuration,,7625,CHEMBL628514,22224,,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,B,1,U,0,,BAO_0000019
14578,,,,Autocuration,,12908,CHEMBL628515,22224,,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,A,1,U,0,,BAO_0000019
14579,,,,Autocuration,,10368,CHEMBL628516,22224,,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,A,1,U,0,,BAO_0000019
14580,,,,Autocuration,,13108,CHEMBL628517,22224,,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,A,1,U,0,,BAO_0000019
14581,,,,Autocuration,,13108,CHEMBL628518,22224,,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,A,1,U,0,,BAO_0000019
14582,,,,Autocuration,,15217,CHEMBL628519,22224,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,A,1,U,0,,BAO_0000019
14583,,,,Autocuration,,15217,CHEMBL628520,22224,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,A,1,U,0,,BAO_0000019
14584,,,,Autocuration,,10933,CHEMBL628521,22224,,,,Binding constant was determined,,A,1,U,0,,BAO_0000019
14585,,,,Autocuration,,2363,CHEMBL630443,22224,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,A,1,U,0,,BAO_0000019
14586,,,,Autocuration,,2363,CHEMBL630444,22224,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,A,1,U,0,,BAO_0000019
14587,,,,Autocuration,,2276,CHEMBL857732,22224,,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,A,1,U,0,,BAO_0000019
14588,,,,Autocuration,,14915,CHEMBL630445,22224,,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,P,1,U,0,,BAO_0000100
14589,,,,Autocuration,,8847,CHEMBL630446,22224,,,,Catalytic rate constant of the compound,,A,1,U,0,,BAO_0000019
14590,,,,Autocuration,,15357,CHEMBL630447,22224,,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,B,1,U,0,,BAO_0000019
14591,,,,Autocuration,,2869,CHEMBL630448,22224,,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,A,1,U,0,,BAO_0000019
14592,,,,Autocuration,,3484,CHEMBL630449,22224,,,,Catalytic rate constant against phospholipase A2 was determined,,A,1,U,0,,BAO_0000019
14593,,,,Autocuration,,1373,CHEMBL630450,22224,,,,"Compound was evaluated for catalytic constant, Kcat",,A,1,U,0,,BAO_0000019
14594,,,,Autocuration,,8142,CHEMBL630451,22224,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,A,1,U,0,,BAO_0000019
14595,,,,Autocuration,,14131,CHEMBL630452,22224,,,,Kcat calculated from 0.693/T1/2,,A,1,U,0,,BAO_0000019
14596,,,,Autocuration,,17269,CHEMBL630453,22224,,,,Kcat was determined,,A,1,U,0,,BAO_0000019
14597,,,,Autocuration,,3485,CHEMBL630454,22224,,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,A,1,U,0,,BAO_0000019
14598,,,,Autocuration,,3485,CHEMBL630455,22224,,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,A,1,U,0,,BAO_0000019
14599,,,,Autocuration,,3485,CHEMBL631487,22224,,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,A,1,U,0,,BAO_0000019
14600,,,,Autocuration,,5962,CHEMBL631488,22224,,,,Kcat value was determined,,A,1,U,0,,BAO_0000019
14601,,,,Autocuration,,3133,CHEMBL876440,22224,,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,A,1,U,0,,BAO_0000019
14602,,,,Autocuration,,3133,CHEMBL631489,22224,,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,A,1,U,0,,BAO_0000019
14603,,,,Autocuration,,2276,CHEMBL857742,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,A,1,U,0,,BAO_0000019
14604,,,,Autocuration,,2276,CHEMBL631490,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,A,1,U,0,,BAO_0000019
14605,,,,Autocuration,,2276,CHEMBL631491,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,A,1,U,0,,BAO_0000019
14606,,,,Autocuration,,2276,CHEMBL631492,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,A,1,U,0,,BAO_0000019
14607,,,,Autocuration,,2276,CHEMBL631493,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,A,1,U,0,,BAO_0000019
14608,,,,Autocuration,,4892,CHEMBL631494,22224,,,,Kinetic parameter for rate of conversion to PABA was determined,,A,1,U,0,,BAO_0000019
14609,,,,Autocuration,,3133,CHEMBL631495,22224,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,A,1,U,0,,BAO_0000019
14610,,1988.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL631496,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,A,1,N,1,,BAO_0000218
14611,,1088.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL631497,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,A,1,N,1,,BAO_0000218
14612,,1088.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL631498,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,A,1,N,1,,BAO_0000218
14613,,1088.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL629776,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,A,1,N,1,,BAO_0000218
14614,,1088.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL629777,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,A,1,N,1,,BAO_0000218
14615,,1088.0,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL629778,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,A,1,N,1,,BAO_0000218
14616,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630456,50597,,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,A,1,N,1,,BAO_0000218
14617,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630457,50597,,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,A,1,N,1,,BAO_0000218
14618,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630458,50597,,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,A,1,N,1,,BAO_0000218
14619,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630459,50597,,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,A,1,N,1,,BAO_0000218
14620,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630460,50597,,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,A,1,N,1,,BAO_0000218
14621,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL876550,50597,,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,A,1,N,1,,BAO_0000218
14622,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630461,50597,,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,A,1,N,1,,BAO_0000218
14623,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630462,50597,,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,A,1,N,1,,BAO_0000218
14624,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630463,50597,,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,A,1,N,1,,BAO_0000218
14625,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630464,50597,,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,A,1,N,1,,BAO_0000218
14626,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630465,50597,,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,A,1,N,1,,BAO_0000218
14627,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630466,50597,,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,A,1,N,1,,BAO_0000218
14628,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630467,50597,,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,A,1,N,1,,BAO_0000218
14629,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630633,50597,,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,A,1,N,1,,BAO_0000218
14630,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630634,50597,,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,A,1,N,1,,BAO_0000218
14631,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630635,50597,,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,A,1,N,1,,BAO_0000218
14632,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630636,50597,,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,A,1,N,1,,BAO_0000218
14633,,,10116.0,Intermediate,Rattus norvegicus,11488,CHEMBL630637,50597,,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,A,1,N,1,,BAO_0000218
14634,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630638,50592,,,Feces,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,A,1,N,1,,BAO_0000218
14635,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630639,50592,,,Feces,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,A,1,N,1,,BAO_0000218
14636,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630640,50592,,,Feces,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,A,1,N,1,,BAO_0000218
14637,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL876551,50592,,,Feces,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,A,1,N,1,,BAO_0000218
14638,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630641,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,A,1,N,1,,BAO_0000218
14639,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630642,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,A,1,N,1,,BAO_0000218
14640,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630643,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,A,1,N,1,,BAO_0000218
14641,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630644,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,A,1,N,1,,BAO_0000218
14642,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL630645,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,A,1,N,1,,BAO_0000218
14643,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL625599,50592,,,Feces,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,A,1,N,1,,BAO_0000218
14644,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL625600,50592,,,Feces,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,A,1,N,1,,BAO_0000218
14645,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL625601,50592,,,Feces,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,A,1,N,1,,BAO_0000218
14646,,1988.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL625602,50592,,,Feces,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,A,1,N,1,,BAO_0000218
14647,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL627470,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,A,1,N,1,,BAO_0000218
14648,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL627471,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,A,1,N,1,,BAO_0000218
14649,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL627472,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,A,1,N,1,,BAO_0000218
14650,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL627473,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,A,1,N,1,,BAO_0000218
14651,,1088.0,9986.0,Intermediate,Oryctolagus cuniculus,7132,CHEMBL627474,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,A,1,N,1,,BAO_0000218
14652,,178.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL627475,50597,,,Blood,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14653,,178.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL627476,50597,,,Blood,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14654,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627477,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14655,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627478,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14656,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627479,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14657,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627480,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14658,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627481,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14659,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627482,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14660,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL627483,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14661,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL875636,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14662,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625764,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14663,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625765,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14664,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625766,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14665,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625767,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14666,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625768,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14667,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625769,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14668,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625770,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14669,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625771,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14670,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625772,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14671,,1088.0,9615.0,Intermediate,Canis lupus familiaris,12582,CHEMBL625773,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14672,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625774,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14673,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625775,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14674,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625776,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14675,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625777,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14676,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625778,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14677,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625779,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14678,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625780,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14679,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL625781,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14680,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL875637,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14681,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626473,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14682,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626474,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14683,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626475,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14684,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626476,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14685,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL634397,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14686,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL626477,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14687,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631069,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14688,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631070,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14689,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631071,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14690,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631072,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14691,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631073,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14692,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631074,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14693,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631075,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14694,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631725,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14695,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631726,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14696,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631727,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14697,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631728,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14698,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631729,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14699,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631730,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14700,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631731,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14701,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631910,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14702,,10000000.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL631911,50597,,,Hippocampus,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,A,1,N,1,,BAO_0000218
14703,,1898.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL631912,50597,,,Hypothalamus,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,A,1,N,1,,BAO_0000218
14704,,1898.0,10116.0,Intermediate,Rattus norvegicus,15413,CHEMBL631913,50597,,,Hypothalamus,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,A,1,N,1,,BAO_0000218
14705,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631914,50597,,,Blood,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14706,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631915,50597,,,Blood,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14707,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL875778,50597,,,Blood,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14708,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631916,50597,,,Blood,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14709,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631917,50597,,,Blood,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14710,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631918,50597,,,Blood,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14711,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631919,50597,,,Blood,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14712,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631920,50597,,,Blood,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14713,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631921,50597,,,Blood,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14714,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631922,50597,,,Blood,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14715,,178.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631923,50597,,,Blood,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14716,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631924,50597,,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14717,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630234,50597,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14718,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630235,50597,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14719,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630236,50597,,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14720,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630237,50597,,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14721,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630238,50597,,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14722,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630239,50597,,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14723,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630303,50597,,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14724,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630304,50597,,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14725,,,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630305,50597,,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14726,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630306,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14727,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630307,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14728,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630308,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14729,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630309,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14730,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL629309,50597,,,Kidney,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14731,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL629993,50597,,,Kidney,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14732,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL629994,50597,,,Kidney,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14733,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL629995,50597,,,Kidney,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14734,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631993,50597,,,Kidney,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14735,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631994,50597,,,Kidney,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14736,,2113.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631995,50597,,,Kidney,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14737,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631996,50597,,,Liver,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14738,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631997,50597,,,Liver,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14739,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631998,50597,,,Liver,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14740,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631999,50597,,,Liver,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14741,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL632000,50597,,,Liver,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14742,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL632001,50597,,,Liver,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14743,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL874424,50597,,,Liver,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14744,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL632002,50597,,,Liver,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14745,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL632003,50597,,,Liver,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14746,,,,Autocuration,,3133,CHEMBL632004,22224,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,A,1,U,0,,BAO_0000019
14747,,,,Autocuration,,2742,CHEMBL632005,22224,,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,A,1,U,0,,BAO_0000019
14748,,,,Autocuration,,2742,CHEMBL632006,22224,,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,,A,1,U,0,,BAO_0000019
14749,,,,Autocuration,,2742,CHEMBL632007,22224,,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,A,1,U,0,,BAO_0000019
14750,,,,Autocuration,,2742,CHEMBL632008,22224,,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,,A,1,U,0,,BAO_0000019
14751,,,,Autocuration,,2742,CHEMBL632009,22224,,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,A,1,U,0,,BAO_0000019
14752,,,,Autocuration,,2742,CHEMBL632010,22224,,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,,A,1,U,0,,BAO_0000019
14753,,,,Autocuration,,2742,CHEMBL857750,22224,,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,A,1,U,0,,BAO_0000019
14754,,,,Autocuration,,2742,CHEMBL632011,22224,,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,,A,1,U,0,,BAO_0000019
14755,,,,Autocuration,,2276,CHEMBL632012,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,A,1,U,0,,BAO_0000019
14756,,,,Autocuration,,2276,CHEMBL632013,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,A,1,U,0,,BAO_0000019
14757,,,,Autocuration,,2276,CHEMBL632014,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,A,1,U,0,,BAO_0000019
14758,,,,Autocuration,,2276,CHEMBL629622,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,A,1,U,0,,BAO_0000019
14759,,,,Autocuration,,2276,CHEMBL629623,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,A,1,U,0,,BAO_0000019
14760,,,,Autocuration,,2276,CHEMBL629624,22224,,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,A,1,U,0,,BAO_0000019
14761,,,,Autocuration,,17269,CHEMBL629625,22224,,,,Ratio of Kcat to that of Km was determined,,A,1,U,0,,BAO_0000019
14762,,,,Autocuration,,2276,CHEMBL629626,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,A,1,U,0,,BAO_0000019
14763,,,,Autocuration,,2276,CHEMBL629627,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,A,1,U,0,,BAO_0000019
14764,,,,Autocuration,,15917,CHEMBL629628,22224,,,,"Compound was evaluated for constant, Kd",,A,1,U,0,,BAO_0000019
14765,,,,Autocuration,,10933,CHEMBL629629,22224,,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,A,1,U,0,,BAO_0000019
14766,,,,Autocuration,,10933,CHEMBL629630,22224,,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,A,1,U,0,,BAO_0000019
14767,,,,Autocuration,,14293,CHEMBL856030,22224,,,,Dissociation Constant of compound determined,,A,1,U,0,,BAO_0000019
14768,,,,Autocuration,,6698,CHEMBL629631,22224,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,B,1,U,0,,BAO_0000019
14769,,,,Autocuration,,6698,CHEMBL629632,22224,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,B,1,U,0,,BAO_0000019
14770,,,,Autocuration,,4318,CHEMBL629633,22224,,,,Dissociation constant of compound with Fructose was determined,,P,1,U,0,,BAO_0000100
14771,,,,Autocuration,,4318,CHEMBL629634,22224,,,,Dissociation constant of compound with Fructose was determined; Not determined,,P,1,U,0,,BAO_0000100
14772,,,,Autocuration,,4318,CHEMBL629635,22224,,,,Dissociation constant of compound with Lactulose was determined,,P,1,U,0,,BAO_0000100
14773,,,,Autocuration,,4318,CHEMBL629636,22224,,,,Dissociation constant of compound with Lactulose was determined; Not determined,,P,1,U,0,,BAO_0000100
14774,,,,Autocuration,,14959,CHEMBL629637,22224,,,,Dissociation constant of the Compound,,P,1,U,0,,BAO_0000100
14775,,,,Autocuration,,5913,CHEMBL629638,22224,,,,Dissociation constant by non-linear regression analysis,,P,1,U,0,,BAO_0000100
14776,,,,Autocuration,,14218,CHEMBL629639,22224,,,,Dissociation constant was determined,,P,1,U,0,,BAO_0000100
14777,,,,Autocuration,,10689,CHEMBL629640,22224,,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,P,1,U,0,,BAO_0000100
14778,,,,Autocuration,,13925,CHEMBL629641,22224,,,,Dissociation constant was determined,,P,1,U,0,,BAO_0000100
14779,,,,Autocuration,,16359,CHEMBL631344,22224,,,,Dissociation constant was determined,,P,1,U,0,,BAO_0000100
14780,,2385.0,10116.0,Intermediate,Rattus norvegicus,10944,CHEMBL631345,50597,,,Muscle tissue,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,A,1,N,1,,BAO_0000218
14781,,,,Autocuration,,11080,CHEMBL631346,22224,,,,The dissociation constant determined by fluorescence displacement assay,,A,1,U,0,,BAO_0000019
14782,,,,Autocuration,,17805,CHEMBL631524,22224,,,,kd value surface plasmon resonance (SPR) method,,A,1,U,0,,BAO_0000019
14783,,2385.0,10116.0,Intermediate,Rattus norvegicus,10944,CHEMBL631525,50597,,,Muscle tissue,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,A,1,N,1,,BAO_0000218
14784,,,,Autocuration,,16645,CHEMBL631526,22224,,,,First dissociation constant of the binding of compound to V30M TTR,,F,1,U,0,,BAO_0000019
14785,,,,Autocuration,,16645,CHEMBL631527,22224,,,,Second dissociation constant of the binding of compound to V30M TTR,,F,1,U,0,,BAO_0000019
14786,,,,Autocuration,,7793,CHEMBL631528,22224,,,,"Compound was evaluated for equilibrium constant, Ke",,A,1,U,0,,BAO_0000019
14787,,1898.0,,Autocuration,,12199,CHEMBL631529,22224,,,Hypothalamus,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,A,1,U,0,,BAO_0000019
14788,,1898.0,,Autocuration,,12199,CHEMBL631530,22224,,,Hypothalamus,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,A,1,U,0,,BAO_0000019
14789,,,,Autocuration,,9680,CHEMBL631531,22224,,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,A,1,U,0,,BAO_0000019
14790,,,,Autocuration,,9680,CHEMBL631532,22224,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,A,1,U,0,,BAO_0000019
14791,,,,Autocuration,,9680,CHEMBL631533,22224,,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,A,1,U,0,,BAO_0000019
14792,,,10090.0,Intermediate,Mus musculus,13758,CHEMBL876552,50594,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,A,1,N,1,,BAO_0000218
14793,,,10090.0,Intermediate,Mus musculus,13758,CHEMBL631534,50594,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,A,1,N,1,,BAO_0000218
14794,,,10090.0,Intermediate,Mus musculus,13758,CHEMBL631535,50594,,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,A,1,N,1,,BAO_0000218
14795,,,10090.0,Intermediate,Mus musculus,13758,CHEMBL631536,50594,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,A,1,N,1,,BAO_0000218
14796,,,10090.0,Intermediate,Mus musculus,13758,CHEMBL631537,50594,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,A,1,N,1,,BAO_0000218
14797,,,10090.0,Intermediate,Mus musculus,13758,CHEMBL631538,50594,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,A,1,N,1,,BAO_0000218
14798,,,10090.0,Intermediate,Mus musculus,13758,CHEMBL631539,50594,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,A,1,N,1,,BAO_0000218
14799,,,10090.0,Intermediate,Mus musculus,13758,CHEMBL631540,50594,,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,A,1,N,1,,BAO_0000218
14800,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL625637,50597,,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,A,1,N,1,,BAO_0000218
14801,,,10116.0,Intermediate,Rattus norvegicus,14393,CHEMBL625638,50597,,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,A,1,N,1,,BAO_0000218
14802,,,10116.0,Intermediate,Rattus norvegicus,15078,CHEMBL625639,50597,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,A,1,N,1,,BAO_0000218
14803,,955.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625640,50597,,,Brain,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14804,,955.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625641,50597,,,Brain,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14805,,948.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625642,50597,,,Heart,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14806,,948.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625643,50597,,,Heart,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14807,,2113.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625644,50597,,,Kidney,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14808,,2113.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625645,50597,,,Kidney,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14809,,2107.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625646,50597,,,Liver,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14810,,2107.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625647,50597,,,Liver,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14811,,2048.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625648,50597,,,Lung,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14812,,2048.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625649,50597,,,Lung,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14813,,2385.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625650,50597,,,Muscle tissue,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14814,,2385.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625651,50597,,,Muscle tissue,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14815,,14.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625652,50597,,,Zone of skin,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14816,,14.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625653,50597,,,Zone of skin,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14817,,2106.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625654,50597,,,Spleen,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14818,,2106.0,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL625655,50597,,,Spleen,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,A,1,N,1,,BAO_0000218
14819,,178.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL625656,50597,,,Blood,Biodistribution of Compound in rat blood after 15 minutes of administration,,A,1,N,1,,BAO_0000218
14820,,178.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL625657,50597,,,Blood,Biodistribution of Compound in rat blood after 2 minutes of administration,,A,1,N,1,,BAO_0000218
14821,,955.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL625658,50597,,,Brain,Biodistribution of Compound in rat brain after 15 minutes of administration,,A,1,N,1,,BAO_0000218
14822,,955.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL625659,50597,,,Brain,Biodistribution of Compound in rat brain after 2 minutes of administration,,A,1,N,1,,BAO_0000218
14823,,948.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL625660,50597,,,Heart,Biodistribution of Compound in rat heart after 15 minutes of administration,,A,1,N,1,,BAO_0000218
14824,,948.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL625661,50597,,,Heart,Biodistribution of Compound in rat heart after 2 minutes of administration,,A,1,N,1,,BAO_0000218
14825,,2107.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL625662,50597,,,Liver,Biodistribution of Compound in rat liver after 15 minutes of administration,,A,1,N,1,,BAO_0000218
14826,,2107.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL625663,50597,,,Liver,Biodistribution of Compound in rat liver after 2 minutes of administration,,A,1,N,1,,BAO_0000218
14827,,2048.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL875621,50597,,,Lung,Biodistribution of Compound in rat lung after 15 minutes of administration,,A,1,N,1,,BAO_0000218
14828,,2048.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL628382,50597,,,Lung,Biodistribution of Compound in rat lung after 2 minutes of administration,,A,1,N,1,,BAO_0000218
14829,,2385.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL628383,50597,,,Muscle tissue,Biodistribution of Compound in rat muscle after 15 minutes of administration,,A,1,N,1,,BAO_0000218
14830,,2385.0,10116.0,Intermediate,Rattus norvegicus,9712,CHEMBL628384,50597,,,Muscle tissue,Biodistribution of Compound in rat muscle after 2 minutes of administration,,A,1,N,1,,BAO_0000218
14831,,,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL628385,50597,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,A,1,N,1,,BAO_0000218
14832,,,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL875753,50597,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,A,1,N,1,,BAO_0000218
14833,,,10116.0,Intermediate,Rattus norvegicus,13925,CHEMBL628386,50597,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,A,1,N,1,,BAO_0000218
14834,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL628387,50597,,,,Organ distribution in rat blood 2 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14835,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL628388,50597,,,,Organ distribution in rat blood 2 hr after intravenous injection,,A,1,N,1,,BAO_0000218
14836,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL628389,50597,,,,Organ distribution in rat blood 30 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14837,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL632756,50597,,,,Organ distribution in rat blood 30 min after intravenous injection,,A,1,N,1,,BAO_0000218
14838,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL628390,50597,,,,Organ distribution in rat brain 2 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14839,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631811,50597,,,,Organ distribution in rat brain 2 hr after intravenous injection,,A,1,N,1,,BAO_0000218
14840,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631812,50597,,,,Organ distribution in rat brain 30 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14841,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631813,50597,,,,Organ distribution in rat heart 2 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14842,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631814,50597,,,,Organ distribution in rat heart 2 hr after intravenous injection,,A,1,N,1,,BAO_0000218
14843,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631815,50597,,,,Organ distribution in rat heart 30 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14844,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631816,50597,,,,Organ distribution in rat kidney 2 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14845,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL875758,50597,,,,Organ distribution in rat kidney 2 hr after intravenous injection,,A,1,N,1,,BAO_0000218
14846,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631817,50597,,,,Organ distribution in rat kidney 30 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14847,,2107.0,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631818,50597,,,Liver,Organ distribution in rat liver 2 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14848,,2107.0,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631819,50597,,,Liver,Organ distribution in rat liver 2 hr after intravenous injection,,A,1,N,1,,BAO_0000218
14849,,2107.0,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631820,50597,,,Liver,Organ distribution in rat liver 30 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14850,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631821,50597,,,,Organ distribution in rat lung 2 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14851,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631822,50597,,,,Organ distribution in rat lung 2 hr after intravenous injection,,A,1,N,1,,BAO_0000218
14852,,,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631823,50597,,,,Organ distribution in rat lung 30 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14853,,2385.0,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631824,50597,,,Muscle tissue,Organ distribution in rat muscle 2 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14854,,2385.0,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631825,50597,,,Muscle tissue,Organ distribution in rat muscle 2 hr after intravenous injection,,A,1,N,1,,BAO_0000218
14855,,2385.0,10116.0,Intermediate,Rattus norvegicus,6941,CHEMBL631826,50597,,,Muscle tissue,Organ distribution in rat muscle 30 minutes after intravenous injection,,A,1,N,1,,BAO_0000218
14856,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL631827,50594,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,A,1,N,1,,BAO_0000218
14857,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL631828,50594,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,A,1,N,1,,BAO_0000218
14858,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL631829,50594,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,A,1,N,1,,BAO_0000218
14859,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL875759,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14860,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631830,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14861,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631831,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14862,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631832,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14863,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631833,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14864,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631834,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14865,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631835,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14866,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631836,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14867,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631837,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14868,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631838,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14869,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631839,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14870,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631840,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14871,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631841,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14872,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631842,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14873,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631843,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14874,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631844,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14875,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631845,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14876,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631846,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14877,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL875760,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14878,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL632199,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14879,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631847,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14880,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL631848,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14881,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628707,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14882,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628708,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14883,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628709,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14884,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628710,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14885,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628711,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14886,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628712,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14887,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628713,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14888,,1088.0,10116.0,Intermediate,Rattus norvegicus,12582,CHEMBL628714,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,A,1,N,1,,BAO_0000218
14889,,,10116.0,Intermediate,Rattus norvegicus,7415,CHEMBL628715,50597,,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,A,1,N,1,,BAO_0000218
14890,,,,Autocuration,,7313,CHEMBL629179,22224,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,A,1,U,0,,BAO_0000019
14891,,,,Autocuration,,7313,CHEMBL629180,22224,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,A,1,U,0,,BAO_0000019
14892,,,,Autocuration,,7313,CHEMBL875108,22224,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,A,1,U,0,,BAO_0000019
14893,,1235.0,,Autocuration,,7570,CHEMBL629181,22224,,,Adrenal cortex,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14894,,1235.0,,Autocuration,,7570,CHEMBL629182,22224,,,Adrenal cortex,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14895,,,,Autocuration,,7570,CHEMBL629183,22224,,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14896,,,,Autocuration,,7570,CHEMBL629184,22224,,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14897,,1235.0,,Autocuration,,7570,CHEMBL629185,22224,,,Adrenal cortex,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14898,,1235.0,,Autocuration,,7570,CHEMBL629186,22224,,,Adrenal cortex,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14899,,,,Autocuration,,7570,CHEMBL629187,22224,,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14900,,,,Autocuration,,7570,CHEMBL629887,22224,,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14901,,,,Autocuration,,7570,CHEMBL629888,22224,,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14902,,,,Autocuration,,7570,CHEMBL629889,22224,,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14903,,1235.0,,Autocuration,,7570,CHEMBL629890,22224,,,Adrenal cortex,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14904,,,,Autocuration,,7570,CHEMBL629891,22224,,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14905,,,,Autocuration,,7570,CHEMBL629892,22224,,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14906,,1235.0,,Autocuration,,7570,CHEMBL629893,22224,,,Adrenal cortex,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14907,,,,Autocuration,,7570,CHEMBL629894,22224,,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14908,,,,Autocuration,,7570,CHEMBL629895,22224,,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,A,1,U,0,,BAO_0000019
14909,,,9615.0,Autocuration,Canis lupus familiaris,14122,CHEMBL875109,22224,,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,A,1,U,0,,BAO_0000218
14910,,,9541.0,Autocuration,Macaca fascicularis,16449,CHEMBL629896,22224,,,,Absolute bioavailability in male cynomolgus monkeys,,A,1,U,0,,BAO_0000218
14911,,,10116.0,Autocuration,Rattus norvegicus,16449,CHEMBL629897,22224,,,,Absolute bioavailability in maleSprague-Dawley rats,,A,1,U,0,,BAO_0000218
14912,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL629898,50597,,,Liver,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14913,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630057,50597,,,Liver,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14914,,2107.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630058,50597,,,Liver,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14915,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630059,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14916,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630060,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14917,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630061,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14918,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630062,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14919,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630063,50597,,,Lung,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14920,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630064,50597,,,Lung,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14921,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630065,50597,,,Lung,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14922,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630066,50597,,,Lung,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14923,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630067,50597,,,Lung,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14924,,2048.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630068,50597,,,Lung,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14925,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631113,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14926,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631114,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14927,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631115,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14928,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL631116,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14929,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630528,50597,,,Muscle tissue,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14930,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630529,50597,,,Muscle tissue,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14931,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630530,50597,,,Muscle tissue,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14932,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630531,50597,,,Muscle tissue,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14933,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630532,50597,,,Muscle tissue,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14934,,2385.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630533,50597,,,Muscle tissue,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14935,,178.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630534,50594,,,Blood,Biodistribution in normal mice blood after 120 hr,,A,1,N,1,,BAO_0000218
14936,,178.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630535,50594,,,Blood,Biodistribution in normal mice blood after 24 hr,,A,1,N,1,,BAO_0000218
14937,,178.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630536,50594,,,Blood,Biodistribution in normal mice blood after 4 hr,,A,1,N,1,,BAO_0000218
14938,,10000001.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630537,50594,,,Bone,Biodistribution in normal mice bone after 120 hr,,A,1,N,1,,BAO_0000218
14939,,10000001.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630538,50594,,,Bone,Biodistribution in normal mice bone after 24 hr,,A,1,N,1,,BAO_0000218
14940,,10000001.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630539,50594,,,Bone,Biodistribution in normal mice bone after 4 hr,,A,1,N,1,,BAO_0000218
14941,,948.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630540,50594,,,Heart,Biodistribution in normal mice heart after 120 hr,,A,1,N,1,,BAO_0000218
14942,,948.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630541,50594,,,Heart,Biodistribution in normal mice heart after 24 hr,,A,1,N,1,,BAO_0000218
14943,,948.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630542,50594,,,Heart,Biodistribution in normal mice heart after 4 hr,,A,1,N,1,,BAO_0000218
14944,,2113.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630543,50594,,,Kidney,Biodistribution in normal mice kidney after 120 hr,,A,1,N,1,,BAO_0000218
14945,,2113.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630544,50594,,,Kidney,Biodistribution in normal mice kidney after 24 hr,,A,1,N,1,,BAO_0000218
14946,,2113.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630545,50594,,,Kidney,Biodistribution in normal mice kidney after 4 hr,,A,1,N,1,,BAO_0000218
14947,,2107.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630546,50594,,,Liver,Biodistribution in normal mice liver after 120 hr,,A,1,N,1,,BAO_0000218
14948,,2107.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630547,50594,,,Liver,Biodistribution in normal mice liver after 24 hr,,A,1,N,1,,BAO_0000218
14949,,2107.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630548,50594,,,Liver,Biodistribution in normal mice liver after 4 hr,,A,1,N,1,,BAO_0000218
14950,,2106.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630549,50594,,,Spleen,Biodistribution in normal mice spleen after 120 hr,,A,1,N,1,,BAO_0000218
14951,,2106.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL630550,50594,,,Spleen,Biodistribution in normal mice spleen after 24 hr,,A,1,N,1,,BAO_0000218
14952,,2106.0,10090.0,Intermediate,Mus musculus,15045,CHEMBL876426,50594,,,Spleen,Biodistribution in normal mice spleen after 4 hr,,A,1,N,1,,BAO_0000218
14953,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630551,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14954,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630552,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14955,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630553,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14956,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630554,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14957,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630555,50597,,,Spleen,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14958,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630556,50597,,,Spleen,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14959,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630557,50597,,,Spleen,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14960,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630558,50597,,,Spleen,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,A,1,N,1,,BAO_0000218
14961,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630559,50597,,,Spleen,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14962,,2106.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL630560,50597,,,Spleen,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14963,,2046.0,10116.0,Intermediate,Rattus norvegicus,12017,CHEMBL876427,50597,,,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,A,1,N,1,,BAO_0000218
14964,,,10116.0,Intermediate,Rattus norvegicus,14941,CHEMBL630561,50597,,,,The Kel values in female wistar rats.,,A,1,N,1,,BAO_0000218
14965,,,,Autocuration,,4646,CHEMBL630562,22224,,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,A,1,U,0,,BAO_0000019
14966,,,,Autocuration,,8847,CHEMBL630563,22224,,,,Hydrolysis rate constant of the compound,,A,1,U,0,,BAO_0000019
14967,,,,Autocuration,,11778,CHEMBL629673,22229,,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,P,1,U,0,,BAO_0000100
14968,,,,Autocuration,,2363,CHEMBL629674,22224,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,A,1,U,0,,BAO_0000019
14969,,,,Autocuration,,2363,CHEMBL629675,22224,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,A,1,U,0,,BAO_0000019
14970,,,,Autocuration,,2363,CHEMBL629676,22224,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,A,1,U,0,,BAO_0000019
14971,,,,Autocuration,,2363,CHEMBL629677,22224,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,A,1,U,0,,BAO_0000019
14972,,,,Autocuration,,8371,CHEMBL629678,22224,,,,Apparent inactivation rate constant was evaluated,,A,1,U,0,,BAO_0000019
14973,,,,Autocuration,,14883,CHEMBL629679,22224,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,A,1,U,0,,BAO_0000019
14974,,,,Autocuration,,14883,CHEMBL629680,22224,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,A,1,U,0,,BAO_0000019
14975,,,,Autocuration,,4643,CHEMBL629681,22224,,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,A,1,U,0,,BAO_0000019
14976,,,,Autocuration,,3519,CHEMBL629682,22224,,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,A,1,U,0,,BAO_0000019
14977,,,,Autocuration,,10600,CHEMBL629683,22224,,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,A,1,U,0,,BAO_0000019
14978,,,,Autocuration,,8501,CHEMBL629684,22224,,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,F,1,U,0,,BAO_0000019
14979,,,,Autocuration,,8505,CHEMBL629685,22224,,,,Dissociation constant was determined,,P,1,U,0,,BAO_0000100
14980,,,,Autocuration,,9778,CHEMBL629686,22224,,,,Dissociation constant was determined,,P,1,U,0,,BAO_0000100
14981,,,,Autocuration,,9778,CHEMBL872932,22224,,,,Dissociation constant at pH 7.4,,P,1,U,0,,BAO_0000100
14982,,,,Autocuration,,9778,CHEMBL629687,22224,,,,Dissociation constant in presence of 1 mM dithiothreitol,,P,1,U,0,,BAO_0000100
14983,,,,Autocuration,,13007,CHEMBL872931,22224,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,A,1,U,0,,BAO_0000019
14984,,,,Autocuration,,13007,CHEMBL628151,22224,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,A,1,U,0,,BAO_0000019
14985,,,,Autocuration,,13007,CHEMBL628152,22224,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,A,1,U,0,,BAO_0000019
14986,,,,Autocuration,,13007,CHEMBL628153,22224,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,A,1,U,0,,BAO_0000019
14987,,,,Autocuration,,11482,CHEMBL628154,22224,,,,Kinetic constant for aromatization of androstenedione,,A,1,U,0,,BAO_0000019
14988,,,,Autocuration,,11482,CHEMBL628155,22224,,,,Kinetic constant for aromatization of testosterone,,A,1,U,0,,BAO_0000019
14989,,,,Autocuration,,2303,CHEMBL628156,22224,,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,A,1,U,0,,BAO_0000019
14990,,,,Autocuration,,11964,CHEMBL628157,22224,,,,Local inhibition constant was determined,,A,1,U,0,,BAO_0000019
14991,,,4932.0,Intermediate,Saccharomyces cerevisiae,3140,CHEMBL857533,50347,,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,A,1,N,1,,BAO_0000218
14992,,,,Autocuration,,10650,CHEMBL628158,22224,,,,Dissociation constant value of the compound,,P,1,U,0,,BAO_0000100
14993,,964.0,,Autocuration,,4667,CHEMBL628159,22224,,,Cornea,In vitro permeability through cornea without epithelium,,A,1,U,0,,BAO_0000019
14994,,964.0,,Autocuration,,4667,CHEMBL875616,22224,,,Cornea,In vitro permeability through intact cornea,,A,1,U,0,,BAO_0000019
14995,,964.0,9986.0,Intermediate,Oryctolagus cuniculus,9199,CHEMBL628160,50592,,,Cornea,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,A,1,N,1,,BAO_0000218
14996,,,,Autocuration,,11966,CHEMBL628161,22224,,,,Rate of enzyme inactivation for the compound was determined,,A,1,U,0,,BAO_0000019
14997,,964.0,,Autocuration,,4667,CHEMBL628162,22224,,,Cornea,In vitro permeability through cornea without epithelium,,A,1,U,0,,BAO_0000019
14998,,964.0,,Autocuration,,4667,CHEMBL628163,22224,,,Cornea,In vitro permeability through intact cornea,,A,1,U,0,,BAO_0000019
14999,,,,Autocuration,,8354,CHEMBL628164,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15000,,,,Autocuration,,8354,CHEMBL628165,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15001,,,,Autocuration,,8354,CHEMBL628166,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15002,,,,Autocuration,,8354,CHEMBL628167,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15003,,,,Autocuration,,8354,CHEMBL628168,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15004,,,,Autocuration,,8354,CHEMBL628169,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15005,,,,Autocuration,,8354,CHEMBL628170,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15006,,,,Autocuration,,8354,CHEMBL628171,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15007,,,,Autocuration,,8354,CHEMBL627434,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15008,,,,Autocuration,,8354,CHEMBL627435,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15009,,,,Autocuration,,8354,CHEMBL628110,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15010,,,,Autocuration,,8354,CHEMBL628111,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15011,,,,Autocuration,,8354,CHEMBL628112,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15012,,,,Autocuration,,8354,CHEMBL628260,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15013,,,,Autocuration,,8354,CHEMBL628261,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,A,1,U,0,,BAO_0000019
15014,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628262,50594,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,A,1,N,1,,BAO_0000218
15015,,,9606.0,Intermediate,Homo sapiens,14439,CHEMBL628263,50587,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,A,1,N,1,,BAO_0000218
15016,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628264,50594,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,A,1,N,1,,BAO_0000218
15017,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628265,50594,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,A,1,N,1,,BAO_0000218
15018,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628266,50594,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,A,1,N,1,,BAO_0000218
15019,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628267,50594,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,A,1,N,1,,BAO_0000218
15020,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628268,50594,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,A,1,N,1,,BAO_0000218
15021,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628269,50594,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,A,1,N,1,,BAO_0000218
15022,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628270,50594,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,A,1,N,1,,BAO_0000218
15023,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628271,50594,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,A,1,N,1,,BAO_0000218
15024,,,10090.0,Intermediate,Mus musculus,14439,CHEMBL628272,50594,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,A,1,N,1,,BAO_0000218
